levodopa has been researched along with Parkinson Disease in 8575 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1665 (19.42) | 18.7374 |
| 1990's | 1593 (18.58) | 18.2507 |
| 2000's | 2051 (23.92) | 29.6817 |
| 2010's | 2308 (26.92) | 24.3611 |
| 2020's | 958 (11.17) | 2.80 |
| Authors | Studies |
|---|---|
| Cacciatore, I; Cantalamessa, F; Cerasa, LS; Cornacchia, C; Di Stefano, A; Falcioni, ML; Gabbianelli, R; Iannitelli, A; Nasuti, C; Pinnen, F; Sekar, D; Sozio, P | 1 |
| Ahmed, MA; Alkskas, IA; Azam, F | 1 |
| Cerasa, LS; Chiavaroli, A; Claudi, F; Di Stefano, A; Ferrante, C; Giorgioni, G; Glennon, RA; Orlando, G; Palmieri, GF; Ricciutelli, M; Ruggieri, S; Sozio, P | 1 |
| Campbell, B; Hider, RC; Hobbs, CJ; Jairaj, M; Jenner, P; Rose, S; Syme, A; Tayarani-Binazir, KA; Zhou, T | 1 |
| Beauchamp, DA; Boulet, J; Branum, S; Bullington, JL; Chakravarty, D; Damon, S; Davis, S; Demarest, K; Hall, D; Hansen, K; Heintzelman, GR; Jackson, PF; Li, X; Osborne, MC; Palmer, D; Rassnick, S; Reyes, M; Rhodes, K; Rupert, KC; Russell, R; Shook, BC; Tang, Y; Wells, KM; Westover, L; Youells, S | 1 |
| Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
| Bajpai, M; Banerjee, A; Bhateja, DK; Gandhi, MN; Gharat, LA; Gudi, GS; Gullapalli, S; Gupta, PK; Khairatkar-Joshi, N; Patil, S; Pawar, MY; Sangana, RR | 1 |
| Ahn, J; Chung, KS; Han, HS; Huh, E; Lee, HH; Lee, JY; Lee, KT; Moon, GH; Oh, MS; Woo, J; Yang, S | 1 |
| Algar, S; Ballesteros, JA; Benhamú, B; Brea, J; Cincilla, G; García-Cárceles, J; Ladron de Guevara-Miranda, D; López-Rodríguez, ML; Loza, MI; Roberts, RS; Rodríguez de Fonseca, F; Sánchez-Martínez, M; Sánchez-Merino, A; Teresa de Los Frailes, M; Vázquez-Villa, H | 1 |
| Alekseenko, PV; Ismailova, SB; Mosaleva, EI; Pokhabov, DV; Prokopenko, SV; Zhumzhanov, IM | 1 |
| Chen, L; Chen, Z; Guo, H; He, L; Ji, L; Li, X; Ma, Y; Shirakawa, M; Xiong, Y; Yuan, C; Zhang, X; Zhao, H | 1 |
| Fernandez, H; Hattori, N; Hauser, RA; Isaacson, SH; LeWitt, P; Li, J; Mochizuki, H; Mori, A; Nakajima, Y; Rascol, O; Ristuccia, R; Stocchi, F | 1 |
| Adar, L; Arkadir, D; Case, R; Ebersbach, G; Ellenbogen, AL; Espay, AJ; Fuchs Orenbach, S; Giladi, N; Isaacson, SH; Kieburtz, K; LeWitt, P; Olanow, CW; Oren, S; Poewe, W; Rosenfeld, O; Sasson, N; Simuni, T; Stocchi, F; Thomas, A; Yardeni, T; Zlotogorski, A | 1 |
| Cilia, R; Devigili, G; Eleopra, R; Elia, AE; Franzini, AA; Golfrè Andreasi, N; Levi, V; Messina, G; Novelli, A; Rinaldo, S; Romito, LM; Telese, R; Tringali, G | 1 |
| Ando, R; Hosokawa, Y; Miyaue, N; Nagai, M; Tada, S; Yabe, H; Yamanishi, Y; Yoshida, A | 1 |
| Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Ferreira, JJ; Jenner, P; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Borsek, M; Jeleňová, B; Necpál, J | 1 |
| Bartlett, MJ; Falk, T; Morrison, HW; Pottenger, AE; Sherman, SJ | 1 |
| Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 2 |
| Conrad, R; Fois, AF; Hampe, T | 1 |
| Bezard, E; Friedman, E; Kottmann, AH; Li, Q; Malave, L; Qin, C; Rebholz, H; Starikov, L; Uribe-Cano, S; Zuelke, DR | 1 |
| Rovno, HDS | 1 |
| Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T | 1 |
| Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y | 1 |
| Annesi, G; Blankenburg, H; Ciullo, M; Domingues, FS; Esposito, T; Gialluisi, A; Hicks, AA; König, E; Melotti, R; Modugno, N; Nicoletti, A; Pattaro, C; Picard, A; Pichler, I; Pramstaller, PP; Schwienbacher, C; Zappia, M | 1 |
| Abdollahi, M; Boutet, A; Cohn, M; Elias, GJB; Fasano, A; Gan-Or, Z; Germann, J; Ghani, M; Hodaie, M; Kakhki, EG; Kalia, SK; Lang, AE; Lozano, AM; Moreno, D; Munhoz, R; Naghibzadeh, M; Naranian, T; Poon, YY; Rajalingam, R; Rogaeva, E; Sato, C; Statucka, M; Visanji, NP; Yu, E | 1 |
| Constantinescu, M; Nassar, M; Schlesinger, I; Sinai, A; Sprecher, E; Zaaroor, M | 1 |
| Dusek, P; Novotny, M; Rusz, J; Ruzicka, E; Sonka, K; Tykalova, T; Zogala, D | 1 |
| Adar, L; Caraco, Y; Case, R; Djaldetti, R; Giladi, N; Gurevich, T; Leibman-Barak, S; Sasson, N | 1 |
| Anan, C; Bhidayasiri, R; Chaudhuri, KR; Phimpha, A; Phokaewvarangkul, O; van Laar, T | 1 |
| Chen, LG; Chen, SY; Huang, LC; Lin, SZ; Pang, CY; Tsai, ST; Wu, PA | 1 |
| Feldman, M; Margolesky, J; Marmol, S; Singer, C | 1 |
| Liu, L; Xie, ZY; Zhao, Y; Zhao, YT | 1 |
| Dal, S; Fung, VSC; Morales-Briceno, H; Ong, TL; Williams, LJ | 1 |
| Bariotto-Dos-Santos, K; Guimarães, RP; Padovan-Neto, FE; Ribeiro, DL | 1 |
| Bai, Y; Gao, D; Guo, Z; Hu, W; Li, Z; Liu, C; Mo, J; Wang, X; Wang, Y; Yang, B; Zhang, C; Zhang, J; Zhang, K; Zhang, X; Zhao, B; Zhao, X; Zou, L | 1 |
| Fabbri, M; Poewe, W; Rascol, O | 1 |
| Pitakpatapee, Y; Sangpeamsook, T; Srikajon, J; Srivanitchapoom, P | 1 |
| Merello, M; Perez-Lloret, S; Rossi, M | 1 |
| Maruyama, H; Matsumoto, Y; Nakamura, M; Tsuboi, Y | 1 |
| Duan, J; Fan, H; Liu, D; Lu, G; Wu, X; Yin, Z; Zhang, B; Zheng, Z; Zhou, D; Zhou, Y | 1 |
| Caulfield, ME; Stancati, JA; Steece-Collier, K | 1 |
| Krüger-Zechlin, C; Stock, L; Timmermann, L; Waldthaler, J | 1 |
| Boca, M; Kobylecki, C; Michou, E; Shiderova, I | 1 |
| Hasantabar, V; Lakouraj, MM; Rezaei, M | 1 |
| Larson, D; Simuni, T | 1 |
| Ávila de Oliveira, J; Bazán, PR; Bernardo, C; Carvalho, MJ; Coelho, DB; de Lima-Pardini, AC; de Oliveira, CEN; de Oliveira, LDS; Hondo, SM; Los Angeles, E; Treza, RC | 1 |
| Eerola-Rautio, J; Koivu, M; Pauls, KAM; Pekkonen, E; Toppila, J; Udd, M | 1 |
| Pérez-Torre, P | 1 |
| Baik, K; Chung, SJ; Jeong, SH; Jeong, Y; Jung, JH; Kim, YJ; Lee, HS; Lee, PH; Lee, YG; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Harrison, DJ; Hills, R; Lane, EL; Lelos, MJ; Ramos-Varas, E; Turner, S | 1 |
| Armstrong, MJ; Billinghurst, L; Cothros, N; Day, GS; de Bie, RMA; Espay, AJ; Fitts, MS; Gronseth, G; Gurwell, JA; Hagerbrant, L; Hall, DA; Hastings, T; Hauser, RA; Lang, AE; Licking, N; Martello, JP; Miyasaki, JM; O'Brien, MD; Pringsheim, T; Rae-Grant, A; Rafferty, M; Roze, E; Silsbee, H; Smith, DB; Sullivan, K | 1 |
| Agnieszka, W; Małgorzata, K; Paweł, P | 1 |
| Alcock, L; Araújo-Silva, F; Barbieri, FA; Felipe I Imaizumi, L; Santinelli, FB; Silveira, APB; Vieira, LHP | 1 |
| Belvisi, D; Berardelli, A; Borraccino, A; Bruno, G; Canevelli, M; Costanzo, M; Fabbrini, A; Fabbrini, G; Giangrosso, M | 1 |
| Arlotti, M; Averna, A; Bocci, T; Locatelli, M; Marceglia, S; Priori, A; Rampini, P | 1 |
| Fukasawa, M; Gemba, R; Irie, T; Murae, M; Noguchi, K; Ogawa, M; Saijo, M; Shimojima, M | 1 |
| Leitinger, G; Maurer, C; Radulović, S; Sunkara, S | 1 |
| Hirata, Y; Ishikawa, H; Kato, N; Matsuura, K; Matsuyama, H; Narita, Y; Niwa, A; Tomimoto, H | 2 |
| Emanuele, R; Lettieri, M; Minunni, M; Palladino, P; Scarano, S | 1 |
| Acera, M; Ayala, U; Carmona, M; Del Pino, R; Fernández, M; Fernández, T; Gabilondo, I; Gómez-Esteban, JC; Murueta-Goyena, A; Tijero, B | 1 |
| Chen, H; Feng, T; Kou, W; Liu, G; Ma, H; Su, D; Wang, D; Wang, X; Wang, Z; Zhang, Z; Zhao, J | 1 |
| Bortolanza, M; Del-Bel, EA; Faccioli, LH; Gardinassi, LG; Peti, APF; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V | 1 |
| Bergman, H; Deffains, M; Eitan, R; Fonar, G; Iskhakova, L; Israel, Z; Marmor, O; Paz, R; Rappel, P | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Lu, CS; Wang, Y | 1 |
| Bojorges-Valdez, E; Pardo-Rodriguez, M; Yanez-Suarez, O | 1 |
| Chen, Y; Cui, C; Cui, G; Xiao, Q; Xu, C; Zhang, W; Zu, J | 1 |
| Abril-Jaramillo, J; Almeida, F; Bermejo, P; Borrue, C; Caballol, N; Campins-Romeu, M; Clavero, P; García-Caldentey, J; Gómez-Mayordomo, V; Labandeira, C; López-Ariztegui, N; Martí-Andrés, G; Martínez-Castrillo, JC; Martinez-Poles, J; Mata-Alvarez Santullano, M; Muñoz, T; Rico-Villademoros, F; Rojo, R; Salom, JM; Sarasa, P; Tegel, I; Valderrama-Martín, C; Vinagre-Aragón, A | 1 |
| Barbir, R; Frkanec, R; Hall, CR; Kalčec, N; Peranić, N; Sani, MA; Separovic, F; Smith, TA; Vinković Vrček, I | 1 |
| Chung, SJ; Hwang, YS; Jeon, SR; Jo, S; Kim, MS; Lee, J; Lee, SH; Park, KW | 1 |
| Müller, T | 14 |
| Ito, H; Kajimoto, Y; Koh, J; Mori, A; Shimokawa, T; Takahashi, M; Takeshima, T; Yamashita, H | 1 |
| Ito, E; Sugiura, Y; Tokimura, R; Ugawa, Y | 1 |
| Hosokawa, Y; Miyaue, N; Yabe, H | 1 |
| Agan, K; Gunal, DI; Jafarova, S; Oner, OG; Seker, A; Sunter, G | 1 |
| Bhidayasiri, R; Phokaewvarangkul, O; Virameteekul, S | 1 |
| Alachkar, A; Alhassen, S; Senel, M | 1 |
| Batalhão, ME; Bortolanza, M; Capellari-Carnio, E; Del-Bel, EA; Pimentel, ÂV; Pinheiro, LC; Santos-Lobato, BL; Tumas, V | 1 |
| Dagda, R; Dagda, RK; Grigoruta, M; Martinez, B; Vazquez-Mayorga, E | 1 |
| Clarke, CE; Gray, A; Gray, R; Ives, N; Jenkinson, C; McIntosh, E; Muzerengi, S; Patel, S; Rick, C; Wheatley, K; Williams, A; Woolley, R | 1 |
| Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL | 1 |
| Bhanu, C; Nimmons, D; Orlu, M; Schrag, A; Walters, K | 1 |
| Bai, X; Chen, J; Gao, T; Gu, L; Gu, Q; Guan, X; Guo, T; Huang, P; Liu, X; Pu, J; Song, Z; Wen, J; Wu, H; Wu, J; Xu, X; Xuan, M; Zhang, B; Zhang, M; Zhou, C | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Gao, T; Iansek, R; Kovács, N; Kukreja, P; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Chen, X; Cheng, O; Han, Y; Liu, J; Peng, J; Shen, Y; Wang, A; Wang, J; Wei, M; Wu, X; Zou, D | 1 |
| Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Hong, PK; Leey, TC; Ling, TC; Semilan, SLA; Sivanandy, P; Wey Han, SA; Xiang, TC | 1 |
| Abosch, A; Branco, L; Ince, NF; Velasco, S | 1 |
| Cappelletti, G; Castellani, D; Filidei, M; Gaggiotti, M; Nigro, P; Paolini Paoletti, F; Parnetti, L; Simoni, S; Tambasco, N | 1 |
| Cossu, G; Di Fonzo, A; Falla, M | 1 |
| Bove, F; Calabresi, P | 1 |
| Annarumma, S; Hansen, CA; Khoshbouei, H; Miller, DR; Ramirez-Zamora, A; Rusch, CT | 1 |
| Buhmann, C; Classen, J; Eggert, K; Jost, WH; Kohl, Z; Outeiro, T; Reichmann, H; Tönges, L; Woitalla, D | 1 |
| Slavin, KV | 1 |
| Gaburo, K; Kirson, N; Mehta, D; Pappert, E; Thach, A; Williams, GR; Yang, K; Zichlin, ML | 1 |
| Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Domingos, J; Femia, S; Jalundhwala, YJ; Jimenez-Shahed, J; Jones, S; Kandukuri, PL; Lee, MY; Lindvall, S; Malaty, IA; Martinez-Martin, P; Odin, P; Onuk, K; Skorvanek, M; Soileau, MJ; Wright, J | 1 |
| Bullock, A; El Aidy, S; van Dijk, G; van Kessel, SP | 1 |
| A'raaf Sirojan Kusuma, M; Akbar, M; Bintang, AK; Faridwazdi, DAN; Florentia, SW; Gustaf, A; Herawangsa, S; Raisa, N; Sativa, MO; Shodry, S; Soraya, GV; Ulhaq, ZS | 1 |
| Azizi, G; Hossein-Khannazer, N; Mousavi, MA; Salahi, S; Vosough, M | 1 |
| Jost, WH | 4 |
| Iguchi, Y; Murakami, H; Omoto, S; Shiraishi, T; Umehara, T | 1 |
| Beckmann, CF; Bloem, BR; Buitelaar, JK; Faber, M; Haak, KV; Helmich, RC; Huertas, I; Llera, A; Marquand, AF; Oldehinkel, M | 1 |
| Iwamuro, H; Nakajima, A; Odo, M; Shimo, Y; Tokugawa, J | 1 |
| Garg, A; Sinha, S | 1 |
| Gultekin, M; Tufekcioglu, Z | 1 |
| Fang, B; Fang, J; Gao, L; Jin, Z; Liu, A; Meng, D; Qi, L; Su, Y; Wang, R; Wang, Y | 1 |
| Assadnejad, T; Aygun, D; Kocabicak, E; Nassehi, B; Yildiz, O | 1 |
| Kocabicak, E; Ozturk, S; Taskin, O; Temel, Y; Yildiz, O | 1 |
| Chen, B; Feng, ST; Hu, D; Wang, XL; Wang, ZZ; Zhang, Y | 1 |
| Kim, MS; Park, DG; Yoon, JH | 1 |
| Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K | 1 |
| Araujo, SM; Bortolotto, VC; Janner, DE; La Rosa Novo, D; Meichtry, LB; Mesko, MF; Musachio, EAS; Poetini, MR; Prigol, M; Ramborger, BP; Roehrs, R; Silva, NC | 1 |
| Kang, HY; Kwak, N; Lee, H; Lee, MJ; Park, J; Suh, JK | 1 |
| Di Battista, V; Hey-Hawkins, E | 1 |
| Balás, I; Harmat, M; Janszky, J; Járdaházi, E; Juhász, A; Kovács, N; Makó, T; Pintér, D | 1 |
| Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY | 1 |
| Cubo, E; Miranda, J | 1 |
| Cai, Y; Fang, L; Li, L; Liang, B; Mao, X; Ren, H; Xu, S; Ye, X; Zhang, S; Zhang, Y | 1 |
| Bourque, M; Di Paolo, T; Morissette, M; Tremblay, MÈ | 1 |
| Chagraoui, A; De Deurwaerdère, P; Di Giovanni, G | 1 |
| Baviera-Muñoz, R; Campins-Romeu, M; Losada-López, M; Martínez-Torres, I; Morata-Martínez, C; Pérez-García, J; Pons-Beltrán, V; Sastre-Bataller, I | 1 |
| Fabbri, M; Ferreira, JJ; Rascol, O | 1 |
| Baayen, C; Medori, R; Meulien, D; Rascol, O; Such, P | 1 |
| Baldermann, JC; Barbe, MT; Dafsari, HS; Dembek, TA; Fink, GR; Jergas, H; Petry-Schmelzer, JN; Visser-Vandewalle, V | 1 |
| Barbieri, S; Borellini, L; Cogiamanian, F; Dini, M; Ferrucci, R; Fiore, G; Locatelli, M; Maiorana, N; Mameli, F; Marceglia, S; Pirola, E; Poletti, B; Prenassi, M; Priori, A; Reitano, MR; Remore, LG; Ruggiero, F | 1 |
| deVries, T; Jacobs, D; Jaros, M; Quartel, A; Rascol, O; Tönges, L | 1 |
| Fukae, J; Hatano, T; Hirano, S; Joki, H; Kano, O; Kimura, K; Matsukawa, MK; Mukai, Y; Murakami, H; Nagayama, H; Nishikawa, N; Nomura, K; Ogaki, K; Seki, M; Sengoku, R; Shimura, H; Suzuki, K; Takahashi, K; Tashiro, J; Terashi, H; Tsuboi, Y; Uchiyama, T; Yamamoto, T; Yanagisawa, N; Yoritaka, A; Yoshida, N | 1 |
| Li, K; Ning, P; Ren, H; Xu, Y; Yang, H; Yang, X | 1 |
| Glover, A; Kemp, AS; Larson-Prior, LJ; Lotia, M; Pillai, L; Spencer, H; Syeda, HB; Virmani, T | 1 |
| Brotchie, J; Friedman, H; Giladi, N; Hauser, RA; Litman, P; Oren, S; Poewe, W | 1 |
| Shen, W; Surmeier, DJ; Zhai, S | 1 |
| Ghasemzadeh Rahbardar, M; Hosseinzadeh, H; Mohammadzadeh, L; Razavi, BM | 1 |
| Atlas, D; Wiesen, T | 1 |
| Alcock, L; Brooks, DJ; Burn, DJ; Colloby, SJ; Firbank, MJ; Galna, B; Lawson, RA; Lord, S; O'Brien, JT; Pavese, N; Rochester, L; Sigurdsson, HP; Taylor, JP; Yarnall, AJ | 1 |
| Farashi, S; Khazaei, M | 1 |
| Ceballos-Baumann, A | 3 |
| Cenci, MA; Odin, P; Skovgård, K | 1 |
| Akcan, O; Dimiou, S; Huang, H; Kubajewska, I; Lopes, RM; Mellor, RD; Schätzlein, AG; Schlosser, CS; Shet, MS; Uchegbu, IF; Whiteside, GT | 1 |
| Bai, Y; Gu, R; Jiang, X; Jiang, Y; Pan, Y; Shen, B; Wang, Y; Yan, J; Zhang, L; Zhong, M; Zhu, J; Zhu, S | 1 |
| Bartsch, RP; Hassin-Baer, S; Inzelberg, R; Katzir, Z; Koren, O; Plotnik, M; Rosenblum, U | 1 |
| Habet, S | 1 |
| Akbari, M; Eslami, S; Ghafouri-Fard, S; Gholipour, M; Hussen, BM; Sayad, A; Taheri, M | 1 |
| Choi, JH; Choi, JW; Kim, E; Kim, J; Lee, J; Rah, JC | 1 |
| Alobaidi, A; Bao, Y; Chaudhuri, KR; Jalundhwala, YJ; Jones, G; Kandukuri, PL; Madin-Warburton, M; Najle-Rahim, S; Oddsdottir, J; Pickard, AS; Ridley, C; Schrag, A; Sus, J; Xu, W | 1 |
| Carroll, C; Chaudhuri, KR; Evans, J; Foltynie, T; Lees, A; Pavese, N; Reichmann, H; Schofield, C; Sharma, JC; Soares-da-Silva, P; Zurowska, L | 1 |
| Calabresi, P; Campanelli, F; Ghiglieri, V; Marino, G; Natale, G | 1 |
| Errico, V; Giannini, F; Lazzaro, GD; Pisani, A; Ricci, M; Saggio, G | 1 |
| Kumar, P; Yadav, D | 1 |
| Facheris, MF; Liu, W; Rosebraugh, M; Stodtmann, S | 1 |
| Alonso-Cánovas, A; Baena-Álvarez, B; Beltrán-Corbellini, Á; Chico-García, JL; López-Sendón, JL; Martínez-Castrillo, JC; Pagonabarraga, J; Pareés, I; Parra-Díaz, P; Pérez-Torre, P; Rodríguez-Jorge, F | 1 |
| Eggert, K; Kemmer, M; Lees, AJ; Oehlwein, C; Reichmann, H; Soares-da-Silva, P; Warnecke, T | 1 |
| Boccuni, L; Broeder, S; Meesen, R; Nieuwboer, A; Vandendoorent, B; Verheyden, G | 1 |
| Fan, JQ; Feng, WC; Lu, WJ; Tan, WQ; Zhuang, LX | 1 |
| Klivényi, P; Salamon, A; Szpisjak, L; Vécsei, L; Zádori, D | 3 |
| Feng, T; Ma, H; Wan, Z; Wang, X; Wang, Z | 1 |
| Buskens, E; Moes, HR; van Laar, T | 1 |
| Branković, M; Dragašević-Mišković, NT; Jančić, I; Kostić, VS; Marjanović, A; Milićević, O; Milovanović, A; Petrović, I; Radojević, B; Savić, MM; Stanisavljević, D; Svetel, M | 1 |
| Eggers, C; Feis, DL; Melzer, C; Pelzer, EA; Scharge, M; Schwartz, F; Stürmer, S; Timmermann, L; Tittgemeyer, M | 1 |
| Bianchini, E; Ceriello, F; De Carolis, L; Pontieri, FE; Rinaldi, D | 1 |
| Bin, Q; Hantao, S; JiYi, X; Lijiao, Z | 1 |
| Flisar, D; Kojović, M; Kolmančič, K; Kramberger, MG; Pirtošek, Z; Trošt, M; Zupančič, NK | 1 |
| Chen, H; Chen, J; Chen, S; Li, Q; Liu, J; Lu, Y; Shao, F; Tang, M; Wu, W; Xu, Z; Yang, D; Zhai, L | 1 |
| Radad, K; Rausch, WD; Wang, F | 1 |
| Fernandez, HH; Mata, IF; Salles, PA | 1 |
| Kochoian, BA; Leventhal, L; Masilamoni, GJ; McRiner, AJ; Papa, SM; Singh, A; Sinon, CG | 1 |
| Baba, Y; Futamura, A; Kinno, R; Nabeshima, Y; Nomoto, S; Osakabe, Y; Shoji, D; Takahashi, S; Yasumoto, T | 1 |
| Fu, SC; Hsieh, YC; Lee, CH; Lin, SH; Wang, H; Wu, PH | 1 |
| Chen, J; Cheng, XY; Gu, HY; Jin, H; Li, K; Liu, CF; Liu, MH; Mao, CJ; Xiong, YT; Zhang, JR | 1 |
| Drummond, N; Elabi, OF; Kirkeby, A; Kunath, T; Lane, EL; Nolbrant, S; Parmar, M; Pass, R; Sormonta, I | 1 |
| García-Cano Lizcano, J; Gil Rojas, S; González Martínez, F; López Moreno, MB; Martínez Blanco, P; Olcina Domínguez, P | 1 |
| Isogai, Z; Kato, M; Matsumoto, H; Mizokami, F; Takeda, A | 1 |
| Athanasakis, E; Avgoustaki, A; Boura, I; Koulentaki, M; Orfanoudaki, E; Spanaki, C | 1 |
| Chen, L; Chen, Y; Cheng, O; Guo, J; Hu, S; Huang, W; Lei, L; Li, B; Li, J; Liao, W; Liu, W; Liu, Y; Liu, Z; Pan, H; Shen, Y; Sun, Q; Tan, H; Tang, B; Tang, J; Wang, C; Wang, P; Wang, Q; Wang, T; Wang, X; Wu, H; Wu, X; Xiang, Y; Xie, Y; Xu, P; Xu, Q; Xue, Z; Yan, X; Ye, M; You, Y; Yuan, K; Zhang, Z; Zhao, Y; Zhou, X; Zhou, Z; Zhu, J | 1 |
| Ann Natividad, J; Chaudhuri, KR; Chung-Faye, G; Lau, YH; Leta, V; Metta, V; Parry, M; Rukavina, K | 1 |
| Bakker, M; Corre, L; Johnson, JL; Johnson, ME; Li, X; Mill, DN; Woodman, RJ | 1 |
| Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E | 1 |
| Baviera-Muñoz, R; Buigues-Lafuente, A; Campins-Romeu, M; Garcés-Sánchez, M; Martinez-Torres, I | 1 |
| Langer, K; Rose, O; Weitzel, J | 1 |
| Bui, BV; Finkelstein, DI; Hoang, A; Lim, JKH; Nguyen, CTO; Shahandeh, A; Tran, KKN; Wong, VHY | 1 |
| Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C | 1 |
| Liparoti, M; Manzo, V; Minino, R; Sorrentino, G; Sorrentino, P; Tafuri, D; Troisi Lopez, E | 1 |
| Antoniades, CA; Bloem, BR; Bogdanovic, M; Buchanan, T; FitzGerald, JJ; Gavine, B; Green, AL; Patel, S; Sarangmat, N; Su, ZH | 1 |
| Müller, T; Schlegel, E; Thiede, HM; Zingler, S | 1 |
| Appel, JM; Borsali, R; Cardoso, MA; da Rosa, NN; de Carvalho, KAT; de Oliveira, NB; Dziedzic, DSM; Halila, S; Irioda, AC; Mogharbel, BF; Perussolo, MC; Saçaki, CS; Slompo, RC; Stricker, PEF; Travelet, C | 1 |
| Ando, M; Hatano, T; Hattori, N; Honda, T; Komatsu, N; Tsutsui, M; Yasuda, H | 1 |
| Frouni, I; Huot, P | 1 |
| Kajiyama, Y; Mochizuki, H | 1 |
| Takeda, A | 3 |
| Chen, YH; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Brys, I; Dias, CMV; Leal, DAB | 1 |
| Chaurasia, RN; Dwivedi, A; Dwivedi, N; Joshi, D; Kumar, A; Mishra, VN; Mohanty, S; Pathak, A; Singh, VK | 1 |
| Daneault, JF; Duval, C; Lee, SI; Liu, Y; Oubre, B | 1 |
| Alobaidi, A; Bergmann, L; Elibol, B; Fasano, A; Fung, VSC; Onuk, K; Parra, JC; Pirtosek, Z; Seppi, K; Takáts, A | 1 |
| MacDonald, S; Shah, AS; Tousi, B | 1 |
| Doerhoff, S; Glover, A; Landes, RD; Pillai, L; Virmani, T | 1 |
| Bell, JS; Ilomäki, J; Koivisto, AM; Koponen, M; Lalic, S; Watson, R | 1 |
| Fernandez, HH; Liao, J; Mata, IF; Salles, PA; Shuaib, U | 1 |
| Artusi, CA; Imbalzano, G; Ledda, C; Lopiano, L; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Combes, A; Coutant, B; Degos, B; Frontera, JL; Léna, C; Mailhes-Hamon, C; Menardy, F; Perez, S; Perrin, E; Popa, D; Tarpin, T; Venance, L | 1 |
| Kotagiri, YG; Litvan, I; Longardner, K; Mahato, K; Moon, JM; Podhajny, T; Sempionatto, JR; Tehrani, F; Teymourian, H; Wang, J | 1 |
| Cerquera-Cleves, C; Dulski, J; Koziorowski, D; Kwiatek-Majkusiak, J; Milanowski, L; Pentela-Nowicka, J; Ross, OA; Sławek, J; Wszolek, ZK | 1 |
| Bahroo, L; Di Maria, G; Jankovic, J; Lamotte, G; Lenka, A | 1 |
| Kubo, M; Miyaue, N; Nagai, M | 1 |
| Jiang, R; Mei, S; Yang, J; Zhao, Z | 1 |
| Blaise, AS; Carrière, N; Cuvelier, E; Defebvre, L; Devos, D; Moreau, F; Mutez, E | 1 |
| Byran, G; Gangadharappa, HV; Garikapati, KK; Krishnamurthy, PT; Kumari, M; Sola, P | 1 |
| Far, R; Girgis, F; Ovruchesky, E; Saez, I; Sardo, A; Shahlaie, K; Sperry, L; Zhang, L | 1 |
| Ahlskog, JE; Ali, F; Botha, H; Carlos, AF; Clark, HM; Coon, EA; Dickson, DW; Josephs, KA; Koga, S; Lowe, V; Pham, NTT; Sekiya, H; Trejo-Lopez, JA; Whitwell, JL | 1 |
| Gažová, A; Košutzká, Z; Minár, M; Stanková, S; Straka, I | 1 |
| Brzostek, T; Kawalec, P; Śladowska, K; Żegleń, M | 1 |
| Bellumori, M; Grenet, D; Howard, SL; Knight, CA | 1 |
| Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L | 1 |
| Lang, AE; Lizárraga, KJ | 1 |
| Corrá, M; Maetzler, W; Maia, LF; Sardoeira, A; Sousa, AP; Vila-Chã, N | 1 |
| Hikita, E; Hotozuka, S; Shirota, M; Yasu, T | 1 |
| Hu, BL; Huang, JF; Huang, SS; Liu, RP; Wang, JY; Zhang, X; Zhu, JH; Zhu, SG | 1 |
| Djoukhadar, I; Jabbari, E; Kobylecki, C; Lally, I; Leahy, CB; Morris, HR; Robinson, AC; Roncaroli, F | 1 |
| Aigbogun, OP; Nwabufo, CK | 1 |
| Chan, J; Goetz, CG; Luo, S; Macklin, EA; Oakes, D; Schwarzschild, MA; Simuni, T; Stebbins, GT; Zou, H | 1 |
| Di Luca, DG; Fox, SH; Reyes, NGD | 1 |
| Lezzi, P; Lezzi, T; Lupo, R; Vitale, E | 1 |
| Garg, K; Rajan, R; Singh, M; Srivastava, AK | 1 |
| Bardinet, E; Benatru, I; Betrouni, N; Brefel, C; Carrière, N; Chupin, M; Corvol, JC; Defebvre, L; Devos, D; Drapier, S; Durif, F; Eusebio, A; Giordana, C; Guehl, D; Hainque, E; Hopes, L; Hubsch, C; Jarraya, B; Kuchcinski, G; Lopes, R; Maltête, D; Moreau, C; Rascol, O; Rolland, AS; Rouaud, T; Thobois, S; Tir, M; Tranchant, C; Viard, R | 1 |
| Katsuno, M; Komori, S; Nakamura, T; Suzuki, M; Tsuboi, T | 1 |
| Antonini, A; Biundo, R; Calandrella, D; Carecchio, M; Carrer, T; Del Sorbo, F; Farinati, F; Garrì, F; Mainardi, M; Pezzoli, G; Pistonesi, F; Russo, FP; Sandre, M; Savarino, E; Soliveri, P; Weis, L; Zecchinelli, AL | 1 |
| Chung, SJ; Lee, EC; Lee, PH; Seong, JK; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á | 1 |
| Anderson, S; Burchiel, KJ; Holland, MT; Jiao, J; Mantovani, A; Mitchell, KA; Safarpour, D | 1 |
| Kramberger, MG; Križnar, NZ; Ocepek, L; Pirtošek, Z; Premzl, M; Rajnar, R; Rus, T; Trošt, M | 1 |
| Chen, G; Chen, Z; Cheng, W; Tao, X; Wang, W; Wang, Z; Yan, Z; Zuo, G | 1 |
| Castillo-Torres, SA; Merello, M; Rossi, M | 1 |
| Fung, VS; Griffith, J; Qiu, J; Tsui, D; Waller, S; Williams, L | 1 |
| Bartels, RHMA; Bloem, BR; Esselink, RAJ; Geerlings, M; Georgiev, D; Selvaraj, AK; Vinke, RS | 1 |
| Anand, A; Bellows, S; Dang, H; Gadot, R; Horn, A; Jankovic, J; Najera, RA; Sheth, SA; Shofty, B; Taneff, LY; Tarakad, A; Vanegas Arroyave, N; Viswanathan, A | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Dijkgraaf, MGW; Munts, A; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A | 1 |
| Bankiewicz, K; Christine, CW; Fine, EM; Khwaja, OS; Larson, PS; Liang, GS; Meier, A; Richardson, RM; Roberts, EW | 1 |
| Bankiewicz, K; Christine, CW; Fine, EM; Khwaja, OS; Larson, PS; Liang, GS; Richardson, RM; Van Laar, A | 1 |
| Palma, JA | 1 |
| Kang, UJ; Nakamura, K; Zhuang, X | 1 |
| El-Masri, S; Evans, A; Malpas, CB; Walterfang, M | 1 |
| Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
| Chung, SJ; Jeong, SH; Lee, HS; Lee, PH; Sohn, YH | 1 |
| Della Morte, D; Geusa, L; Giannella, E; Grillo, P; Mascioli, D; Mercuri, NB; Sancesario, GM; Schirinzi, T; Zenuni, H | 1 |
| Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Hegde, S; Odin, P; Pahwa, R; Parra, JC; Snedecor, SJ; Standaert, DG; Thakkar, S; Titova, N; Zadikoff, C | 1 |
| Arena, M; Brumbach, BH; Diamond, S; Nutt, JG; Pfeiffer, R; Quinn, J; Safarpour, D | 1 |
| Barbosa, ER; Barbosa, PM; Chien, HF; Limongi, JCP; Torres, MRC | 1 |
| Chung, SJ; Jeong, Y; Kim, YJ; Lee, HS; Lee, PH; Park, CW; Shin, HW; Sohn, YH; Yun, M | 1 |
| Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M | 1 |
| Bubb, VJ; Kõks, S; Pfaff, AL; Quinn, JP; Singleton, LM | 1 |
| Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Asakawa, T; Chen, W; Jia, X; Qin, W; Shi, Y | 1 |
| Bergmann, L; Fasano, A; Femia, S; Gurevich, T; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Vela-Desojo, L | 1 |
| Chung, J; Chung, SJ; Min, S; Ryu, HS; Yoon, W | 1 |
| Bruno, V; Chang, A; Fox, SH; Freitas, ME; Lang, AE; Rajalingam, R; Ruiz-Lopez, M; Terroba-Chambi, C | 1 |
| Djaldetti, R; Hadad, B; Kharash, BA; Lerner, B; Reiner, J | 1 |
| Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B | 1 |
| Amami, P; Bocchi, E; Bonvegna, S; Bruzzone, MG; Ciceri, EFM; Cilia, R; Devigili, G; Eleopra, R; Elia, AE; Gasparini, V; Ghielmetti, F; Golfrè Andreasi, N; Grisoli, M; Levi, V; Messina, G; Novelli, A; Piacentini, SHMJ; Prioni, S; Rinaldo, S; Romito, LM; Stanziano, M; Straccia, G; Tringali, G | 1 |
| Abrigo, J; Chan, A; Chan, D; Chan, DYC; Cheung, T; Lau, C; Ma, K; Mok, V; Poon, WS; Tang, V; Yeung, J; Zhu, XL | 1 |
| Airas, L; Helin, S; Joutsa, J; Parkkola, R; Rinne, JO; Rissanen, E; Tuisku, J; Waggan, I | 1 |
| Antonini, A; Ferreira, JJ; Guimarães, B; Moreira, J; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P; Stocchi, F | 1 |
| Fasano, A; Gomez, CCR; Lang, AE; Munhoz, RP; Olszewska, DA | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Chen, Y; Du, T; Ma, R; Yuan, T; Zhang, J; Zhang, X; Zhu, G | 1 |
| Burke, JF; Chung, JE; Han, KJ; Larson, PS; Lee, AT; Martin, AJ; Nichols, N; Ostrem, JL; Starr, PA; Sudhakar, VR; Volz, MM; Wang, DD; Wozny, TA | 1 |
| Angelopoulou, E; Antonelou, R; Bozi, M; Geronikolou, S; Koros, C; Maniati, M; Michalopoulos, I; Papagiannakis, N; Poula, D; Scarmeas, N; Simitsi, AM; Stamelou, M; Stefanis, L; Vassilatis, DK | 1 |
| Averna, A; Bianchi, AM; Coelli, S; Ferrara, R; Priori, A | 1 |
| Arlt, C; Ebersbach, G; Eggert, K; Fritz, B; Möller, JC; Schwarz, J; Sensken, SC; Weiss, D | 1 |
| Amato, F; Artusi, CA; Calandra-Buonaura, G; Contin, M; Cortelli, P; Giannini, G; Imbalzano, G; Ledda, C; Lopiano, L; Olmo, G; Rinaldi, D; Romagnolo, A; Sambati, L; Zibetti, M | 1 |
| Bellezza, I; Cacciatore, I; Cornacchia, C; De Filippis, B; Di Biase, G; Di Rienzo, A; Di Stefano, A; Dimmito, MP; Mardinoglu, A; Marinelli, L; Serra, F; Turkez, H | 1 |
| Jing, XZ; Taximaimaiti, R; Wang, XP; Yang, HJ | 1 |
| McCarter, SJ; Savica, R | 1 |
| Klein, S; Wollmer, E | 2 |
| Liu, X; Ming, D; Moussian, B; Pang, M; Peng, R; Su, Y; Wang, P; Wang, Y; Zhu, Y | 1 |
| Jahanshahi, M; Leimbach, F; Rawji, V | 1 |
| Adekunle, AO; Alananzeh, WA; Amali, MO; Ayipo, YO; Badeggi, UM; Lawal, BA; Mordi, MN | 1 |
| Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| Fung, VSC; Griffith, J; Qiu, J; Tsui, D; Waller, S; Williams, L | 1 |
| Bartels, EM; Celicanin, M; Danneskiold-Samsøe, B; Harrison, AP; Ilic, T; Korbo, L; Løkkegård, A; Olsen, JK; Petersen, CB; Siebner, HR | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Chung, SJ; Jeon, SR; Jo, S; Kim, JW; Kim, M; Kim, MS; Lee, J; Lee, SH | 1 |
| McConvey, V; Miyasaki, J; Ray Chaudhuri, K; Rukavina, K | 1 |
| Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF | 1 |
| Abusrair, AH; Bohlega, S; Elsekaily, W | 1 |
| Aballéa, S; Bebrysz, M; Fujimura, K; Fujioka, S; Migita, H; Mishima, T; Nomoto, M; Tsuboi, Y; Yamaguchi, J; Yamazaki, T | 1 |
| Boura, I; Chaudhuri, KR; Espay, AJ; Jenner, P; Leta, V; Odin, P; Rota, S; Urso, D; van Wamelen, DJ | 1 |
| Cao, X; Gan, C; Si, Q; Sun, H; Wang, L; Wang, M; Yuan, Y; Zhang, H; Zhang, K | 1 |
| He, X; Lai, Y; Li, J; Liu, X; Mo, C; Qian, Y; Xiao, Q; Xu, S; Yan, Z; Yang, X; Zhang, Y | 1 |
| Atri, A; Moreno, AM; Paquette, C; Potvin-Desrochers, A | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijk, JM; Dijkgraaf, MGW; Frequin, HL; Lang, A; Munts, AG; Post, B; Schouten, J; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Asghar, M; Fattahi, AJ; Henriksson, AE; Khosousi, S; Miglar, A; Odeh, A; Svenningsson, P | 1 |
| Sheng, S; Xu, K; Zhang, F | 1 |
| Kovrov, GV; Nodel, MR; Shevtsova, KV | 1 |
| Correia, MAS; Gallardo, E; Gonçalves, AM; Oliveira, AE; Oliveira, DM; Passarinha, LA; Pedro, AQ; Queiroz, JA; Romão, MJ; Santos, MFA | 1 |
| Ellmén, J; Kuoppamäki, M; Rouru, J; Sjöstedt, N; Tuunainen, J; Vahteristo, M; Yliperttula, M | 1 |
| Kulisevsky, J | 3 |
| Azulay, JP; Carron, R; Eusebio, A; Grimaldi, S; Regis, JM; Velly, L; Witjas, T | 1 |
| Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P | 1 |
| Bhuvanendran, S; Magalingam, KB; Radhakrishnan, AK; Ramdas, P; Selvaduray, KR; Somanath, SD | 1 |
| Belotti, LMB; Calandra-Buonaura, G; Contin, M; Cortelli, P; Galletti, M; Lopane, G | 1 |
| Fujimaki, M; Hattori, N; Igami, E; Ishiguro, Y; Kodama, T; Noda, K; Okuma, Y; Shimizu, M | 1 |
| Chen, FF; Chen, XT; Wen, SY; Zhang, Q; Zhou, CQ | 1 |
| Asci, F; Berardelli, A; Bologna, M; D'Onofrio, V; Fabbrini, G; Ferreri, F; Guerra, A | 1 |
| Harker, G; Horak, FB; Kelly, VE; Martini, DN; Morris, R; Nutt, JG | 1 |
| Horiguchi, S; Ito, S; Takahashi, M; Tsuji, Y | 1 |
| Fox, SH | 2 |
| Aldred, J; Budur, K; Facheris, MF; Fisseha, N; Fung, VS; Hauser, RA; Jeong, A; Kimber, TE; Klos, K; Litvan, I; O'Neill, D; Robieson, WZ; Soileau, MJ; Spindler, MA; Standaert, DG; Talapala, S; Vaou, EO; Zheng, H | 1 |
| Isonishi, A; Kawabe, Y; Nakahara, K; Okuda, H; Tanaka, T; Tatsumi, K; Wanaka, A | 1 |
| Chen, L; Shang, H; Stromberg, K; Sun, B; Wang, J; Wang, X; Woods, J; Zhang, Y | 1 |
| Kim, YJ; Kostal, E; Matylitskaya, V; Park, S; Partel, S; Ryu, W | 1 |
| Casado-Polanco, R; Castela, I; Costa, RM; da Silva, JA; Hernandez, LF; Marquez, R; Moratalla, R; Obeso, J; Pro, B; Redgrave, P; Rubio, YV | 1 |
| Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Isaacson, SH; Kandukuri, PL; Merola, A; Odin, P; Pahwa, R; Parra, JC; Wang, L; Yan, CH; Zadikoff, C | 1 |
| Chen, L; Dai, C; Du, J; Liang, Y; Liu, G; Liu, H; Liu, X; Mo, L; Tan, C; Zhao, L; Zhong, Y; Zhou, X | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Gu, SC; Shi, R; Wang, CD; Wu, Y; Yang, YW; Ye, Q; Yuan, CX; Zhang, Y | 1 |
| Pilipovich, AA; Vorob'eva, OV | 2 |
| Ayton, S; Behnke, S; Berg, D; Bloem, BR; Bordet, R; Bush, AI; Cabantchik, I; Carpentier, J; Chupin, M; Coelho, MVS; Compta, Y; Corvol, JC; de Bie, RMA; Defebvre, L; Deplanque, D; Devedjian, JC; Devos, D; Dexter, DT; Dodel, R; Duce, JA; Duhamel, A; Dušek, P; Eusebio, A; Ferreira, J; Fradette, C; Gago, M; Garçon, G; Guyon Delannoy, P; Habert, MO; Januario, C; Kuchcinski, G; Kulisevsky, J; Labreuche, J; Leclercq, C; Lehericy, S; Lopes, R; Maetzler, W; Mangin, JF; Marques, AR; Meissner, WG; Moreau, C; Nyholm, D; Ory-Magne, F; Otto, M; Ouk, T; Pavese, N; Pigny, P; Poewe, W; Post, B; Potey, C; Pruvo, JP; Rascol, O; Rolland, AS; Růžička, E; Scherfler, C; Seppi, K; Simonin, O; Spino, M; Thobois, S; Tranchant, C; Tricta, F; Viard, R; Vilas, D; Walter, U; Worth, P | 1 |
| Fu, JF; Klyuzhin, IS; Mannheim, JG; McKeown, MJ; Sossi, V; Stoessl, AJ; Wegener, T | 1 |
| Chen, J; Ge, YL; Jin, H; Li, D; Li, K; Li, W; Liu, CF; Mao, CJ; Wang, F; Wang, PZ; Yan, JH; Yang, YP; Zhang, JR; Zhang, YC | 1 |
| Han, XM; Li, YP; Liu, BP; Wang, RF; Wang, Z; Xu, SS; Zhang, HY | 1 |
| Chung, SJ; Hwang, YS; Jeon, SR; Jo, S; Kim, MS; Kim, N; Lee, SH | 1 |
| Blandini, F; Cerri, S; Cesaroni, V | 1 |
| Antonoglou, A; Bougea, A; Efthymiopoulou, E; Loupo, B | 1 |
| Ko, HS; Kwatra, M; Kwon, DK; Wang, J | 1 |
| Cao, X; Gan, C; Ji, M; Sun, H; Wang, L; Yuan, Y; Zhang, H; Zhang, K | 1 |
| Farokhniaee, A; Lowery, MM; Marceglia, S; Priori, A | 1 |
| Tang, D; Yu, Z | 1 |
| Bishop, C; Centner, A; Cohen, S; Glinski, J; Lipari, N; Manfredsson, FP | 1 |
| Baló, B; Botz, K; Györfi, B; Jost, WH | 1 |
| Ayala-Torres, JD; Calvo-Torres, F; Gaviria-Mendoza, A; Machado-Alba, JE; Valencia-Vásquez, A | 1 |
| De Venuto, D; Mezzina, G | 1 |
| Jones-Tabah, J | 1 |
| Ahn, JH; Cho, JW; Kim, M; Kwon, J; Moon, SH; Mun, JK; Park, H; Won, JH; Youn, J | 1 |
| Kataoka, H; Sugie, K | 1 |
| Cannard, KR; Charles, D; Davis, TL; Fan, R; Hacker, ML; Harper, K; Konrad, PE; Meystedt, JC; Turchan, M; Ye, F | 1 |
| Ghaedian, T; Hossein-Tehrani, MR; Kalhor, L; Ostovan, VR; Rakhsha, A; Razmkon, A; Rezaei, R; Yousefi, O | 1 |
| Christofoletti, G; Müller, PT; Oliveira, RT; Ramos, AG; Santos, FMD; Seki, KLM | 1 |
| Chen, Y; Liu, JS; Pu, JL; Shi, DD; Zhang, BR | 1 |
| Caulfield, ME; Manfredsson, FP; Steece-Collier, K | 1 |
| Morelli, M; Parekh, P; Pinna, A | 1 |
| Baggen, RJ; Bouche, K; De Letter, M; Herssens, N; Lefeber, N; Leroy, T; Maes, L; Santens, P; Van Bladel, A | 1 |
| Comoglu, S; Onder, H | 1 |
| Dulski, J; Piekarski, R; Roszmann, A; Sławek, J | 2 |
| Moro, E; Romito, LM | 1 |
| Franco, R; Labandeira-García, JL; Lillo, A; Lillo, J; Muñoz, A; Navarro, G; Raïch, I; Rivas-Santisteban, R; Rodríguez-Pérez, AI | 1 |
| Aguado-Carrillo, G; Armas-Salazar, A; Beltrán, JQ; Carrillo-Ruiz, JD; Jiménez-Ponce, F; Navarro-Olvera, JL; Velasco-Campos, F | 1 |
| Álvarez Carriles, JC; Álvarez Martínez, V; Blázquez Estrada, M; García Fernández, C; González Álvarez, L; Lozano Aragoneses, B; Prendes Fernández, P; Saiz Ayala, A; Santamarta Liébana, E; Sol Álvarez, J; Suárez San Martín, E | 1 |
| Funayama, M; Hattori, N; Li, Y; Nishioka, K; Peng, H; Shimizu, M; Yoshino, H | 1 |
| Berg, D; Leplow, B; Liepelt-Scarfone, I; Maetzler, W; Michaelis, K; Renftle, D; Solbrig, S; Thomas, M | 1 |
| Goetz, CG; Kaasinen, V; Luo, S; Martinez-Martin, P; Stebbins, GT | 1 |
| Belozertseva, IV; Dorotenko, A; Efimova, EV; Fesenko, Z; Gainetdinov, RR; Mor, MS; Savchenko, A; Sotnikova, TD; Sukhanov, I | 1 |
| Chiu, R; Frank, C; Lee, J | 2 |
| Cao, L; Zhao, G; Zheng, Z | 1 |
| Kähkölä, J; Katisko, J; Keinänen, T; Lahtinen, M | 1 |
| Cibulka, M; Cierny, D; Grendar, M; Grofik, M; Kolisek, M; Kurca, E; Nosal, V; Oleksakova, J; Ruzinak, R; Sivak, S; Tatarkova, Z | 1 |
| Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H | 1 |
| Ashkan, K; Baig, F; Benjaber, M; Bertaina, I; Denison, T; Duchet, B; Hasegawa, H; He, S; Morgante, F; Pereira, EA; Pogosyan, A; Tan, H; Torrecillos, F; Wiest, C | 1 |
| Kaminska, M; Lafontaine, AL; Scanga, A | 1 |
| Andrade, RS; Andrade, SM; Costa, TDC; Costa-Ribeiro, A; Lemos Segundo, RP; Lindquist, ARR; Machado, CBDS; Machado, DGDS; Morya, E; Rosa, MRD; Silva, ACT; Silva, JPDS; Smaili, SM | 1 |
| Guo, X; He, L; Wang, F; Zhao, H | 1 |
| Antonini, A; Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Atasie, NH; Babalola, RM; Ibrahim, A; Ipinloju, N; Muhammad, SA; Oyeneyin, OE | 1 |
| Chen, F; Chen, J; Fu, Y; Ge, R; Huo, Y; Ren, A; Wang, H; Wang, M | 1 |
| Gordon, E; Graham, L; Hughes, E; Monaghan, AS; Morris, R; Peterson, DS | 1 |
| Aureli, F; Bhidayasiri, R; Campagnolo, M; Chung-Faye, G; Falup-Pecurariu, C; Jenner, P; Klingelhoefer, L; Leta, V; Levent, HÇ; Longardner, K; Metta, V; Ray Chaudhuri, K; Stocchi, F; Warnecke, T | 1 |
| Liu, X; Yang, G; Zhao, Y | 1 |
| Gil, YE; Kim, MS; Park, DG; Shin, IJ; Yoon, JH | 1 |
| Cao, X; Lian, P; Wu, Y; Xu, Y; Yuan, Y; Zhang, X | 1 |
| Cui, Y; Feng, T; Gan, Y; Jing, J; Liu, Z; Sossi, V; Stoessl, AJ; Su, D; Wang, Z; Wu, T; Zhang, Z; Zhou, J | 1 |
| Bergmann, L; Fasano, A; García-Ramos, R; Gurevich, T; Jech, R; Parra, JC; Sanchez-Soliño, O; Simu, M | 1 |
| Barker, RA; Björklund, A | 1 |
| Colon-Semenza, C; Earp, JE; LoBuono, DL | 1 |
| Duckworth-Mothes, B; Grund, KE; Jost, WH; Zipfel, A | 1 |
| Chen, J; Ge, YL; Jin, H; Li, D; Li, K; Li, W; Liu, CF; Mao, CJ; Wang, F; Wang, PZ; Yan, JH; Zhang, JR | 1 |
| Factor, SA; Goldstein, FC; McKay, JL; Nye, J; Smith, Y; Sommerfeld, B; Weinshenker, D | 1 |
| Chen, Q; Hallett, M; Hattori, T; Hirakawa, A; Hirata, K; Kina, S; Matsubayashi, T; Ohara, M; Shimano, K; Yokota, T | 1 |
| Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Kim, SJ; Lee, PH; Lee, YH; Na, HK; Sohn, YH; Yoo, HS | 1 |
| Angelopoulou, E; Bougea, A; Chrysovitsanou, C; Koros, C; Panagiotounakou, E; Papagiannakis, N; Simitsi, AM; Stefanis, L | 1 |
| Kobtrakul, K; Vilairat, C; Vimolmangkang, S | 1 |
| Disilvestro, I; Donzuso, G; Mostile, G; Nicoletti, A; Sciacca, G; Zappia, M | 1 |
| Alonso-Canovas, A; Bloem, BR; Gifford, L; Lees, AJ; Thomas, O; Voeten, J | 1 |
| Hallett, M; Katzenschlager, R; Pirker, W; Poewe, W | 1 |
| Bernhard, D; Clifford, GD; Esper, CD; Factor, SA; Genias, I; Kwon, H; McKay, JL | 1 |
| Amato, F; Asci, F; Calculli, A; Cesarini, V; Costantini, G; Di Leo, P; Pisani, A; Saggio, G; Suppa, A | 1 |
| Farhadi, K; Hosseini, N; Mehrabi, S; Mohtasham Kia, Y; Noori, A | 1 |
| Bouillot, R; Delabrousse-Mayoux, JP; Leblanc, A; Patat, M; Pouyet, A; Sogni, L; Vérin, M; Viakhireva-Dovganyuk, I; Zagnoli, F; Ziegler, M | 1 |
| Chan, P; Chhetri, JK; Su, D; Su, Y; Xu, B | 1 |
| Braccagni, G; Carta, M; Caruso, D; Cioffi, L; Corsi, S; Diviccaro, S; Fanni, S; Frau, R; Gambarana, C; Gentile, M; Melcangi, RC; Pardu, A; Scheggi, S; Stancampiano, R | 1 |
| Chen, YH; Choi, HI; Greig, NH; Hoffer, BJ; Huang, EY; Jung, J; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Almeida, RMM; Artigas, NR; Dutra, ACL; Krimberg, JS; Monticelli, BE; Pereira, GM; Rieder, CRM; Schumacher-Schuh, AF; Soares, NM | 1 |
| Ahlskog, JE | 9 |
| Torres, V; Valldeoriola, F | 1 |
| Artusi, CA; Bianchini, E; De Carolis, L; Galli, S; Imbalzano, G; Ledda, C; Lopiano, L; Pontieri, FE; Rinaldi, D; Zibetti, M | 1 |
| Buskens, E; Lunter, G; Moes, HR; Mondria, T; Portman, AT; Ten Kate, JM; van Harten, B; van Kesteren, ME; van Laar, T | 1 |
| Ip, CW; Jost, WH; Kassubek, J; Kohl, Z; Regensburger, M; Schrader, C; Urban, PP | 1 |
| Abdel-Aleem, GA; Abdel-Fattah, DS; El-Sheikh, TF; Elbatch, MM; Mohamed, AS | 1 |
| Nagai, M | 1 |
| Chen, Q; Gold, R; Mosig, A; Pitarokoili, K; Scherbaum, R; Tönges, L; Zella, S | 1 |
| Liao, FF; Lin, G; Wang, Y; Zhong, M; Zhou, FM | 1 |
| Haertlé, T; Jafarkhani, S; Meratan, AA; Muronetz, V; Saboury, AA; Zohoorian-Abootorabi, T | 1 |
| Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Mishima, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T | 1 |
| Artusi, CA; Bozzali, M; Covolo, A; Imbalzano, G; Ledda, C; Lopiano, L; Martone, T; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Aureli, F; Cortelli, P; Leta, V; Metta, V; Ray Chaudhuri, K; Rizos, A; Rodriguez-Blazquez, C; Trivedi, D; van Wamelen, DJ | 1 |
| Amboni, M; Barone, P; Cicero, CE; Cilia, R; De Micco, R; De Rosa, A; Di Fonzo, A; Eleopra, R; Galantucci, S; Iannitti, T; Lazzeri, G; Nicoletti, A; Pacchetti, C; Pellecchia, MT; Picillo, M; Radicati, FG; Russillo, MC; Scaglione, C; Somma, G; Stocchi, F; Tessitore, A; Vacca, L; Vallelunga, A; Volontè, MA; Zangaglia, R | 1 |
| Contreras Chicote, A; Grandas Perez, F; Mas Serrano, M; Velilla Alonso, G | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Xiao, Q; Yang, X | 1 |
| Kuhn, W; Müller, T | 6 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE; Elewa, YHA; Papadakis, M; Zahran, MH | 1 |
| Fanciulli, A; Galli, S; Pontieri, FE; Rinaldi, D | 1 |
| Fasano, A; Gorodetsky, C; Lang, AE; Lozano, AM; Youn, J | 1 |
| Jost, WH; Kulisevsky, J; LeWitt, PA | 1 |
| Danoudis, M; Iansek, R; Paul, E; Sung, CB | 1 |
| Buberwa, W; Gao, D; Kambey, PA; Liu, WY; Nyalali, AMK; Saro, A; Tang, C; Wu, J | 1 |
| Batzu, L; Falup-Pecurariu, C; Leta, V; Qamar, MA; Ray Chaudhuri, K; Tall, P | 1 |
| Cao, Z; Chen, J; Duanmu, X; Guan, X; Guo, T; Huang, P; Liu, X; Qin, J; Tan, S; Wen, J; Wu, C; Wu, H; Wu, J; Xu, X; Zhang, B; Zhang, M; Zhou, C | 1 |
| Bishop, C; Centner, A; Conti Mazza, MM; Werner, DF | 1 |
| Al-Kassmy, J; Huot, P; Sun, C | 1 |
| Bovenzi, R; Cerroni, R; Conti, M; Degoli, GR; Liguori, C; Mercuri, NB; Pierantozzi, M; Pisani, A; Salimei, C; Schirinzi, T; Simonetta, C; Stefani, A | 1 |
| Conn, PJ; Di Menna, L; Dogra, S; Iacovelli, L; Joffe, ME; Nicoletti, F; Orlando, R; Zuena, AR | 1 |
| Antonini, A; Bhidayasiri, R; Borgohain, R; Cardoso, F; Dafsari, HS; Deuschl, G; Espay, AJ; Falup-Pecurariu, C; Fasano, A; Fung, VSC; Hattori, N; Jenner, P; Jost, ST; Kaldenbach, MA; Katzenschlager, R; Kukkle, PL; Martinez-Martin, P; Metta, V; Odin, P; Petry-Schmelzer, JN; Ray Chaudhuri, K; Rodríguez-Violante, M; Schade, S; Stocchi, F; Tan, EK; Timmermann, L; Trenkwalder, C; Weintraub, D | 1 |
| Biermann-Ruben, K; Hartmann, C; Henkel, J; Niccolai, V; Schnitzler, A; van de Vijver, R | 1 |
| Bauer, MP; Chernova, VO; Contarino, MF; Keller, JJ; Kuijper, EJ; Terveer, EM; van der Meulen-de Jong, AE; van Hilten, JJ; van Prehn, J | 1 |
| Mügge, F; Pedrosa, AJ; Pedrosa, DJ; Timmermann, L; Waldthaler, J | 1 |
| Buhmann, C; Hilker-Roggendorf, R; Höglinger, G; Koschel, J; Müller, T; Weise, D; Woitalla, D | 1 |
| Contarino, MF; Dorresteijn, LDA; Geraedts, VJ; Hoffmann, CFE; Kuiper, R; Marinus, J; Middelkoop, HAM; van der Gaag, NA; van Hilten, JJ; van Vugt, JPP; Zutt, R | 1 |
| LeWitt, PA; Martinez-Nunez, AE | 1 |
| Almela, P; Arenas-Betancur, L; Cuenca-Bermejo, L; De Pablos, V; Del Bel, E; Fernández-Villalba, E; Gonzalez-Cuello, A; Herrero, MT; Navarro-Zaragoza, J; Yuste, JE | 1 |
| Saitoh, Y; Takahashi, K | 1 |
| Cao, S; Chen, H; Hu, X; Liang, Z; Liu, Z; Mao, W; Shao, M; Song, Z; Su, W; Tang, B; Wei, W; Wu, Y; Zhang, K | 1 |
| Auffret, M; Bhidayasiri, R; Borovečki, F; Falup-Pecurariu, C; Jenner, P; Jost, WH; Leta, V; Verin, M; Weiss, D | 1 |
| Bonno, D; Bouchard, M; Canissario, R; Déry, C; Dupré, N; Lang, AE; Lizarraga, KJ; Logigian, E; McDermott, MP; Modica, JS; Stanton, M | 1 |
| Anis, S; Fay-Karmon, T; Goldberg, T; Hassin-Baer, S; Redlich, Y; Yogev, D | 1 |
| Wood, H | 2 |
| Hirano, M; Isono, C; Nagai, Y; Samukawa, M | 1 |
| Agostini, S; Citterio, LA; Clerici, M; Mancuso, R; Meloni, M | 1 |
| Brito, MMCM; Cavalcanti, RTO; Del-Bel, E; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V | 1 |
| Kanda, T; Kawai-Uchida, M; Ohno, Y; Okita, E; Shoukei, Y; Soshiroda, K; Uchida, S | 1 |
| Abuzenadah, AM; Alghamdi, BS; Ashraf, GM; Chattopadhyay, S; Gautam, A; Jha, NK; Jonnalagadda, S; Kumar, L; Malik, S; Preetam, S; Rath, R | 1 |
| Arif, C; Koneru, V; Ondo, WG | 1 |
| Gökçe, GGY; Nazan, ŞE; Sehur, ÖS; Tanju, U | 1 |
| Fuller, L; Wexler, RS | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Ballina, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Iansek, R; Jia, J; Kovács, N; Kukreja, P; Ladhani, O; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Huot, P | 1 |
| Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G | 1 |
| Albratty, M; Alhazmi, HA; Anwer, MK; Behl, T; Madaan, P; Makeen, HA; Meraya, AM; Sehgal, A; Verma, R | 1 |
| Alam, MR; Singh, S | 1 |
| Antonini, A; Chaudhuri, KR; Henriksen, T; Trošt, M; van Laar, T | 1 |
| Caiazzo, M; Fens, MHAM; Knol, MJ; Schiffelers, RM; van Vliet, EF | 1 |
| Shih, LC; Wang, R | 1 |
| Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C | 1 |
| Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M | 1 |
| Bell, JG; Glasco, DL; Ho, NHB; Sheelam, A | 1 |
| Auffret, M; Jost, WH; Stocchi, F; Vérin, M; Weiss, D | 1 |
| Chen, TF; Chiu, MJ; Chiu, SI; Chu, YT; Fan, SP; Jang, JR; Lin, CH; Yu, CF | 1 |
| Allegritti, E; Battista, S; Galantini, L; Giansanti, L; Maggi, MA; Marconi, C | 1 |
| Braga-Neto, P; Bruno, LB; Cunha, LCV; de Almeida, SB; de Luna, JRG; Feitosa, CX; Gomes, VC; Gradvohl, LB; Lima, DP; Lindsay Silva Marques, M; Marques da Silva, TA; Monteiro, PA; Montenegro-Júnior, RM; Roriz-Filho, JS; Viana-Júnior, AB | 1 |
| Alberico, SL; Ding, Y; Hu, Y; Jin, L; Kang, UJ; Ma, TC | 1 |
| Finsterer, J | 1 |
| Castilla-Fernández, G; Chaudhuri, KR; Di Foggia, V; Harrison-Jones, G; Marston, XL; Morgante, F | 1 |
| Brooks, A; Fernandez, HH; Ghosh, D; Hogue, O; Liao, J; Shaffer, S; Sonneborn, C; Sperling, SA; Walter, BL; Yu, JRT | 1 |
| Buskens, E; Henriksen, T; Moes, HR; Phokaewvarangkul, O; Sławek, J; van Laar, T | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Nuara, SG | 1 |
| Antonini, A; Isaacson, SH; Kremens, D; Stocchi, F; Torres-Yaghi, Y | 1 |
| Factor, SA; Glover, A; Landes, RD; Larson-Prior, L; Pillai, L; Prior, F; Virmani, T | 1 |
| Bar, MR; Borovečki, F; Katzenschlager, R; Kovacs, N; LeWitt, PA; Perković, R | 1 |
| Bhattacharya, P; Borah, A; Paul, R; Roy, R | 1 |
| Ben-Ami, E; Djaldetti, R; Franken, L; Kreitman, R; Raveh, E; Reiner, J; Rosset, I | 1 |
| Iwaki, H; Mukai, Y; Nishikawa, N; Takahashi, Y | 1 |
| Guo, J; Li, J; Liu, J; Shi, J; Wan, G; Wei, X; Yang, X; Yu, J | 1 |
| Fasano, A; Justich, MB; Rojas, OL | 1 |
| Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN | 1 |
| Hales, CM; Mathew, R; Mitchell, CS; Tandra, G; Wang, M; Yoone, A | 1 |
| Furihata, M; Hagiwara, H; Ishino, H; Kitamura, T; Nakatsu, Y; Nishi, S; Noda, K; Nomoto, Y; Ogiwara, S; Okawa, H; Osada, T; Yano, S | 1 |
| Carrillo-Reid, L; Perez-Becerra, J; Saderi, N; Tellez, LA; Zamora-Ursulo, MA | 1 |
| DiMarco, EK; Haq, IU; Jiang, A; Jones, RE; Kishida, KT; Liebenow, B; Sadibolova, R; Siddiqui, MS; Terhune, DB | 1 |
| Carey, G; Defebvre, L; Dujardin, K; Kuchcinski, G; Leentjens, AFG; Lopes, R; Viard, R | 1 |
| Bhidayasiri, R; Garcia-Ruiz, P; Müller, T; Odin, P; Phokaewvarangkul, O; Riederer, P | 1 |
| Coizet, V; David, O; Duveau, V; Gronlier, E; Habermacher, C; Paccard, A; Roche, Y; Roucard, C; Volle, J | 1 |
| Angelopoulou, E; Bougea, A; Fotakopoulos, G; Fragkiadaki, S; Georgakopoulou, VE; Karpodini, CC; Kontaxopoulou, D; Koros, C; Koutedakis, Y; Papageorgiou, SG; Piperi, C; Stanitsa, E | 1 |
| Antoniuk, S; Grażyńska, A; Siuda, J; Toś, M | 1 |
| Bouillot, C; Chaib, S; Depoortere, R; Levigoureux, E; Newman-Tancredi, A; Vidal, B; Zimmer, L | 1 |
| Je, NK; Ku, M | 1 |
| Cao, X; Gan, C; Gao, M; Ji, M; Shan, A; Sun, H; Wang, L; Yuan, Y; Zhang, H; Zhang, K | 1 |
| Bhidayasiri, R; Henriksen, T; Katzenschlager, R; Lees, A; Lockhart, D; Staines, H | 1 |
| Antonini, A; D'Onofrio, V; Guerra, A | 1 |
| Boltze, J; Gianchandani, S; Le, W; Li, S; Peng, D; Sun, Z; Wang, F | 1 |
| Horiba, M; Imamura, A; Kuroyanagi, G; Matsukawa, N; Murakami, H; Sakai, H; Sato, T; Takahashi, A; Ueki, Y; Usami, T | 1 |
| Chan, P; Chen, J; Chi, CL; Han, C; Li, F; Ma, JH; Zhang, X; Zhao, Y; Zhao, ZZ | 1 |
| Amato, N; Caverzasio, S; Galati, S; Kaelin-Lang, A; Manconi, M; Staedler, C | 1 |
| Arav, Y; Zohar, A | 1 |
| Feng, T; Liu, Z; Ma, H; Su, D; Wang, X; Wang, Z; Yang, Y; Zhou, J | 1 |
| Ares-Pensado, B; Fernández-Pajarín, G; Jiménez-Martín, I; Koukoulis, A; Sesar, A | 1 |
| Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M | 1 |
| Hall, D | 1 |
| Antonini, A; Barone, P; Calabresi, P; Lopiano, L; Morgante, F; Pontieri, FE; Sensi, M; Stocchi, F | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Lu, D; Porreca, F; Samtani, G; Seaton, BT; Sexauer, MR; Sherman, SJ; Siegenthaler, JR; Weintraub, NC | 1 |
| Horowski, R; Riederer, P | 1 |
| Chernova, VO; Contarino, MF; Kuijper, EJ; Terveer, EM; van Hilten, JJ; Vendrik, KE | 1 |
| Gao, F; Gao, L; Miao, J; Yang, Y | 1 |
| Alonso Losada, MG; Alonso, PS; Ávila Rivera, MA; Caballol, N; Cores Bartolomé, C; Cosgaya, M; de Deus Fonticoba, T; Escalante, S; Feal Painceiras, MJ; García Caldentey, J; García Díaz, I; Gómez Mayordomo, V; González Aramburu, I; Íñiguez Alvarado, MC; Jesús, S; Legarda, I; López Ariztegui, N; Martínez Castrillo, JC; Martinez-Martin, P; McAfee, D; Mendoza, Z; Mir, P; Paz, JM; Santos-García, D; Vela, L | 1 |
| Han, YM; Kang, SY; Kim, JH; Kim, JS; Kim, MS; Oh, JS; Seo, SY | 1 |
| Bengoetxea, H; Bidgood, R; Lafuente, JV; Miguelez, C; Morera-Herreras, T; Ortuzar, N; Razquin, J; Ruiz-Ortega, JA; Vaquero-Rodríguez, A; Zubelzu, M | 1 |
| Hida, A; Iwata, A; Iwatsubo, T; Niimi, Y; Sato, K | 1 |
| Abusrair, A; Aquino, CC; Mititelu, A; Pfeffer, G; Rosenegger, L | 1 |
| Kostiuk, K | 1 |
| Dunnett, SB; Lane, EL; Lelos, MJ; Lindgren, HS; Murphy, EM | 1 |
| Dong, N; Li, X; Lin, X; Su, B; Wang, J; Yang, R; Zhou, L; Zhu, B | 1 |
| Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L | 1 |
| Ce, Z; Jiren, Z; Pinyuan, Z; Tian, W; Ting, L; Wenbo, Z; Zhigang, M | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
| Bhidayasiri, R; Bongsebandhu-Phubhakdi, S; Hopetrungraung, T; Phokaewvarangkul, O; Phowthongkum, P; Poorirerngpoom, C; Sathirapatya, T; Thanprasertsuk, S; Vongpaisarnsin, K; Wichit, P | 1 |
| Batzu, L; Bhattacharya, K; Borgohain, R; Chaudhuri, KR; Dhamija, RK; Falup-Pecurariu, C; Goyal, V; Kumar, NSS; Kumar, S; L K, P; Metta, V; Mrudula, R; Rodriguez-Blazquez, C; S, A | 1 |
| Amouzandeh, A; Barbe, MT; Basheer, AA; Bornmann, S; Csoti, I; Ebersbach, G; Falkenburger, B; Flöel, A; Gruber, D; Gülke, E; Gutsmiedl, PK; Haller, B; Haslinger, B; Herting, B; Hormozi, M; Ip, CW; Jergas, H; Jochim, AM; Jost, WH; Klingelhöfer, L; Kohl, Z; Koschel, J; Krause, P; Kühn, AA; Lingor, P; Liszka, R; Maetzler, W; Paschen, S; Pérez-González, P; Pötter-Nerger, M; Prell, T; Pürner, D; Rijntjes, M; Rozanski, V; Scheller, U; Schröter, N; Schwarz, J; Südmeyer, M; Torka, E; van de Loo, S; van Riesen, C; Weiß, D; Wesbuer, S; Wolff, A; Wolz, M | 1 |
| Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Bao, J; Chen, Q; Chen, Y; Dai, J; Feng, S; Guo, P; Hong, Z; Jiang, X; Li, A; Li, T; Li, X; Li, Y; Lin, J; Lin, Y; Liu, J; Liu, K; Liu, T; Lu, Z; Shan, L; Wang, J; Wilde, JJ; Zhang, T | 1 |
| Jenner, P; Leta, V; Pirtošek, Z; Vérin, M | 1 |
| Appel-Cresswell, S; Cirstea, MS; Creus-Cuadros, A; Finlay, BB; Lo, C; Neilson, S; Serapio-Palacios, A; Yu, AC | 1 |
| Aghajan, H; Heidari Beni, MH; Kiani, MM | 1 |
| Andreozzi, V; Cattaneo, C; Oliveros, C; Pellecchia, MT; Picillo, M; Russillo, MC | 1 |
| Caron, MG; Jin, J; Martini, ML; Pogorelov, VM; Wetsel, WC | 1 |
| Bernal-Casas, D; Cascante, M; Franco, R; González-Subías, M; Lillo, A; Marin, S; Navarro, G; Sánchez-Navés, J; Serrano-Marín, J | 1 |
| Hitchings, R; Kelly, L | 1 |
| Espiritu, AI; Jamora, RDG; Pajo, AT | 1 |
| Müller, T; Thiede, HM | 1 |
| Bentivoglio, AR; De Biase, A; Di Sipio, E; Erra, C; Germanotta, M; Imbimbo, I; Mileti, I; Pacilli, A; Padua, L; Palermo, E; Petracca, M; Ricciardi, D; Rossi, S | 1 |
| Goud, KY; Litvan, I; Mishra, RK; Moonla, C; Narayan, R; Wang, J; Yu, C | 1 |
| Boess, F; Constantinovici, N; Ding, Y; Freitas, R; Houghton, R; Ong, R; Verselis, L | 1 |
| Qiu, W; Xu, X | 1 |
| Adamson, MB; Gilmore, G; Gouelle, A; Jog, M; Pieterman, M | 1 |
| Calabresi, P; Standaert, DG | 1 |
| Davis, RL; Lubomski, M; Sue, CM | 1 |
| Chen, H; Feng, T; Jiang, Y; Liu, G; Ma, H; Su, D; Wang, D; Wang, X; Wang, Z; Yang, Y; Zhang, M | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Wang, HK; Wang, Y | 1 |
| Beck, G; Mochizuki, H; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Woo, JM; Zhang, J | 1 |
| Chung, YA; Heo, Y; Im, JJ; Jeong, H; Oh, JK; Park, JS; Song, IU | 1 |
| Appel-Cresswell, S; Barton, JJS; Cherkasova, MV; Corrow, JC; McKeown, MJ; Stoessl, AJ; Stubbs, JL; Taylor, A; Yeung, SC | 1 |
| Aktürk, T; Güntekin, B; Hanoğlu, L; Hanoğlu, T; Yulug, B | 1 |
| Albarrán-Bravo, S; Ávalos-Fuentes, JA; Cortés, H; Erlij, D; Florán, B; Leyva-García, N; Rangel-Barajas, C; Rodriguez-Sánchez, M | 1 |
| Chou, KL; Mossner, JM; Patil, PG | 1 |
| Ferreira, JJ; Gama, H; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Bloem, BR; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, A; Zach, H | 1 |
| Bancila, I; Ciocîrlan, M; Cotruta, B; Dobru, D; Drug, V; Dumitru, E; Gheorghe, C; Goldis, A; Jinga, M; Manuc, M; Mercea, VA; Pitigoi, D; Saftoiu, A; Seicean, A; Tanțău, M | 1 |
| Almeida, L; Barabas, M; Eisinger, RS; Elkouzi, A; Malaty, IA; Okun, MS; Ramirez-Zamora, A; Zeilman, P | 1 |
| Caparros Lefebvre, D | 1 |
| Bloem, BR; de Vries, NM; Joosten, H; Kessels, RPC; Post, B; van der Kolk, NM; Zwinderman, AH | 1 |
| Dibble, LE; Duff, K; Olivier, GN; Paul, SS; Schaefer, SY; Walter, C | 1 |
| Alves, G; Dalen, I; Hiorth, YH; Pedersen, KF; Tysnes, OB | 1 |
| Aboulem, G; Ammour, A; Aouraghe, I; Belahsen, F; Khaissidi, G; Mrabti, M | 1 |
| Hoy, SM | 1 |
| Chatani, M; Handa, K; Hosonuma, M; Inagaki, K; Ishikawa, K; Karakawa, A; Kiuchi, Y; Kiyohara, S; Negishi-Koga, T; Sakai, N; Takami, M; Tsuji, M; Yamakawa, T | 1 |
| Alcaraz, M; Alejo, R; Cacabelos, N; Cacabelos, P; Cacabelos, R; Carrera, I; Carril, JC; Corzo, L; Fernández-Novoa, L; Pego, R; Rodríguez, S; Tellado, I | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Rivero-de-Aguilar, A; Sesar, A | 1 |
| Dutkiewicz, J; Friedman, A; Szlufik, S | 1 |
| Fernández García, J; García Hernández, M; Garrido Durán, C; Khorrami Minaei, S; Legarda Ramírez, I; Sendra Rumbeu, P | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Alam, M; Rönnegård, L; Saqlain, M; Westin, J | 1 |
| Chang, FCF; Fung, VSC; Galea, D; Griffith, J; Ha, AD; Kim, SD; Mahant, N; Morales-Briceño, H; Tsui, D | 1 |
| Artusi, CA; Balestrino, R; Bortolani, S; Fabbri, M; Imbalzano, G; Lopiano, L; Montanaro, E; Tuttobene, S; Zibetti, M | 1 |
| Antonini, A; Chaudhuri, KR; Jenner, P; Leta, V | 1 |
| Gan, C; Ma, K; Si, Q; Wang, L; Wang, M; Yuan, Y; Zhang, K | 1 |
| Antoniades, CA; Buchanan, T; FitzGerald, JJ; Kennard, C; Lu, Z | 1 |
| Cabreira, V; Massano, J | 1 |
| Del Bel, E; Dos-Santos-Pereira, M; Guimarães, FS; Junior, NCF | 1 |
| Choi, YH; Chung, SJ; Lee, JM; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Bezard, E; Eleopra, R; Mercatelli, D; Morari, M; Zaveri, NT | 1 |
| Djordjevic, SP; Giannopoulos, S; Raymond, BBA; Rodgers, KJ; Samardzic, K | 1 |
| Andrusca, A; Berg, D; Deuschl, G; Gavriliuc, O; Paschen, S; Schlenstedt, C | 1 |
| Gaprielian, P; Levy, R; Lowrey, C; Pari, G; Reid, S; Scott, SH | 1 |
| Baille, G; Blaise, AS; Carrière, N; Defebvre, L; Devos, D; Dujardin, K; Grolez, G; Kreisler, A; Kyheng, M; Moreau, C; Mutez, E; Seguy, D | 1 |
| da Silva, CHTP; de Souza, LR; Ferreira, JV; Hage-Melim, LIS; Marino, BLB; Padilha, EC; Sousa, KPA; Taft, CA | 1 |
| Barroso, SDS; Gomes, MZ; Lopes, LES; Santos, KS | 1 |
| Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D | 1 |
| Cao, SW; Gan, CT; Ma, KW; Shen, YT; Si, QQ; Wang, LN; Wang, M; Yuan, YS; Zhang, KZ; Zhi, Y | 1 |
| Abreu, D; Coelho, M; Fabbri, M; Ferreira, JJ | 1 |
| Akbostanci, MC; Bilgiç, B; Bora Tokçaer, A; Çakmur, R; Doğu, O; Elibol, B; Erer Özbek, ÇS; Gültekin, M; Hanağasi, H; İnce Günal, D; Kenangil, G; Mirza, M; Tezcan, S; Ulukan, Ç; Yilmaz Küsbeci, Ö | 1 |
| Asgharnejad, M; Boudiaf, N; Friesen, D; Kalilani, L | 1 |
| Bucciantini, M; Cesaro, S; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY | 1 |
| Contarino, MF; De Angelis, A; Geraedts, VJ; Horne, M; Khodakarami, H; Leake, A; Lyons, KE; Morgante, F; Pahwa, R; Paviour, D; Ricciardi, L | 1 |
| Amadori, K; Steiner, T | 1 |
| Chougule, T; Ingalhalikar, M; Pal, PK; Prasad, S; Safai, A; Saini, J | 1 |
| Cannas, A; Dagostino, S; Follesa, P; Marrosu, F; Pisu, MG; Puligheddu, M; Sanna, A; Serra, M; Solla, P; Tacconi, P | 1 |
| Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Eisinger, RS; Fan, SY; Han, A; Han, CL; Hu, W; Meng, FG; Michitomo, S; Ramirez-Zamora, A; Wang, F; Wang, KL; Wang, Q; Zhang, JG | 1 |
| Bhargava, P; Blum, D; Espay, AJ; Factor, SA; Hauser, RA; Isaacson, S; Leinonen, M; Navia, B; Olanow, CW; Pahwa, R; Sciarappa, K; Shill, HA | 1 |
| Chen, L; Gu, C; Li, D; Li, J; Zhu, M; Zhu, X | 1 |
| Corson, T; de Freitas, PB; Freitas, SMSF; Huang, X; Latash, ML; Lewis, MM; Reschechtko, S | 1 |
| Bereau, M; Bloem, BR; Nonnekes, J | 1 |
| Antonini, A; Chaudhuri, KR; Jenner, P | 3 |
| Reddy, SP; Rieder, CRM; Schumacher-Schuh, AF; Socal, MP | 1 |
| Campbell, MC; Perlmutter, JS; Shannon, W; Snyder, AZ; White, RL; Yang, D | 1 |
| Do, JH; Pepe, D | 1 |
| Baker, MR; Baker, SN; Chatterjee, K; Choudhury, S; Halder, S; Kumar, H; Mondal, B; Roy, A; Singh, R | 1 |
| Fujita, H; Haruyama, Y; Hatano, T; Hattori, N; Hirano, S; Hirata, K; Kadowaki, T; Kaji, Y; Kobashi, G; Kuwabara, S; Miyamoto, M; Okuma, Y; Sakakibara, R; Shimo, Y; Suzuki, K; Uchiyama, T; Yamamoto, T | 1 |
| Arkadir, D; Bergman, H; Eitan, R; Hajyahya, A; Israel, Z; Linetsky, E; Snineh, MA | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Schulz, SJ; Ziegler, K | 1 |
| Cenci, MA; Eidelberg, D; Hauser, RA; Pahwa, R; Riggare, S | 2 |
| Arnaldi, D; Eidelberg, D; Ibarretxe-Bilbao, N; Lucas-Jiménez, O; Morbelli, S; Nobili, F; Ojeda, N; Pagani, M; Pardini, M; Schindlbeck, KA; Tang, CC | 1 |
| Atashzar, SF; Bernardinis, M; Jog, MS; Patel, RV | 1 |
| Agrò, EF; Altavista, MC; Brusa, L; Ceravolo, R; Iani, C; Palermo, G; Ponzo, V; Stanzione, P; Stefani, A; Stocchi, F; Viselli, F; Vitale, C | 1 |
| Choi, DK; Ganesan, P; Karthivashan, G; Lee, HW; Park, SY | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 2 |
| Anouar, Y; Barrière, G; Boulain, M; Chagraoui, A; Deurwaerdère, P; Juvin, L | 1 |
| Mochizuki, H | 2 |
| Isaacson, SH | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Aimrane, A; Draoui, A; El Hiba, O; El Khiat, A; Gamrani, H | 1 |
| Chen, N; Du, TT; Fan, SY; Guo, CJ; Han, CL; Jiang, Y; Liu, YP; Meng, FG; Shimabukuro, M; Sui, YP; Wang, KL; Wang, Q; Yuan, F; Zhang, JG | 1 |
| Chernick, D; Hauser, RA; Hubble, J; Isaacson, SH; Jankovic, J; Johnson, R; Oertel, WH; Pahwa, R; Tanner, CM | 1 |
| Chang, CM; Chen, JC; Huang, YL; Lee, CC | 1 |
| Borah, A; Choudhury, S; Mazumder, MK | 1 |
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Baig, F; Ben-Shlomo, Y; Hu, MT; Kelly, MJ; Lawton, MA | 1 |
| Santos-Lobato, BL; Schumacher-Schuh, AF; Tumas, V | 1 |
| Stocchi, F; Vacca, L | 1 |
| Barth, AL; Brotchie, JM; Cearley, CN; Hill, MP; Johnston, TH; Moskal, JR; Schneider, JS | 1 |
| Aghanavesi, S; Aquilonius, SM; Askmark, H; Bergquist, F; Buvarp, DJ; Constantinescu, R; Ericsson, A; Medvedev, A; Memedi, M; Nyholm, D; Ohlsson, F; Spira, J; Thomas, I; Westin, J | 1 |
| Abdelhafiz, AH; Rose, J; Roycroft, M | 1 |
| Beaudry, F; Bédard, D; Gaudette, F; Gourdon, JC; Hamadjida, A; Huot, P; Michaud, V; Nuara, SG; Panisset, M; Sid-Otmane, L | 1 |
| Berk, AEM; de Bie, RMA; de Haan, RJ; Dijk, JM; Dijkgraaf, MGW; Geurtsen, GJ; Schuurman, PR; Sisodia, V; van Poppelen, D | 1 |
| Harati, A; Müller, T | 2 |
| Castro Caldas, A; Ferreira, JJ; Simões, RM | 1 |
| Campos, J; Domingues, AV; Salgado, AJ; Teixeira, FG; Vilaça-Faria, H | 1 |
| Chalimoniuk, M; Fiszer, U; Jówko, E; Krygowska-Wajs, A; Langfort, J; Michałowska, M; Przybylska, I; Toczylowska, B | 1 |
| Baik, K; Chung, SJ; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 2 |
| Kataoka, H; Kurumatani, N; Obayashi, K; Saeki, K; Sugie, K | 2 |
| Bjørn Nielsen, H; Duscha, A; Gatermann, SG; Haghikia, A; Hegelmaier, T; Holm, JB; Lebbing, M; Przuntek, H; Tomaske, L; Tönges, L | 1 |
| Delaby, L; Durif, F; Fantini, ML; Figorilli, M; Lambert, C; Marques, AR; Meloni, M; Pereira, B; Puligheddu, M; Vidal, T | 1 |
| Armstrong, MJ; Okun, MS | 1 |
| Castello, J; Cortés, M; Friedman, E; Kottmann, A; Malave, L; Rebholz, H; Sibley, DR | 1 |
| Elango, P; Ghanta, MK; L V K S, B | 1 |
| Cao, X; Chen, G; Cheng, C; Nie, S; Tan, Y; Wang, J; Xu, Y; Yang, X; Zeng, W; Zhang, Z; Zheng, C | 1 |
| Chung, SJ; Jeong, Y; Jung, JH; Kim, HR; Lee, PH; Sohn, YH | 1 |
| Haapaniemi, TH; Heikkinen, ER; Katisko, JP; Kauppinen, MT; Lahtinen, MJ; Salokorpi, N | 1 |
| Bezchlibnyk, YB; Boulis, NM; Buetefisch, CM; Cheng, J; DeLong, MR; Factor, SA; Gale, JT; Gross, RE; Isbaine, F; Miocinovic, S; Naik, KB; Sharma, VD; Triche, SD; Wichmann, T; Willie, JT | 1 |
| Calandra-Buonaura, G; Contin, M; Cortelli, P; Lopane, G; Magosso, E; Ursino, M | 1 |
| Fukunaga, K; Haga, H; Izumi, H; Kawahata, I; Miyachi, H; Shinoda, Y; Yamada, R | 1 |
| Anheim, M; Grillon, A; Lipsker, D; Moegle, C; Velter, C | 1 |
| Akhmetzhanov, V; Houlden, H; Kaishibayeva, G; Kaiyrzhanov, R; Karimova, A; Khaibullin, T; Rizig, M; Sadykova, DZ; Seidinova, Z; Shashkin, C; Taskinbayeva, A; Zharkinbekova, N | 1 |
| Barraud, P; Belin, J; Deguil, J; Houeto, JL; Pain, S; Ragot, S | 1 |
| Anderson, S; Bankiewicz, KS; Christine, CW; Curtze, C; Hiller, A; Larson, PS; Leinonen, M; Nutt, JG; Ravina, B; Richardson, RM; Sedkov, A; Thompson, ME; Van Laar, AD | 1 |
| Kashihara, K; Maeda, T; Nakayama, T; Okuma, Y; Saiki, H; Takahashi, Y; Toyama, M; Tsuboi, Y; Yamamoto, M; Yoshida, K | 1 |
| Chen, HJ; He, JC; Jiang, ZY; Wu, K; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Li, K; Li, S; Liao, X; Liu, D; Shuai, B; Wu, N | 1 |
| Paton, DM | 2 |
| Fung, VSC; Griffith, J; Mahant, N; Martin, AJ; Morales-Briceño, H; Tsui, D | 1 |
| Schapira, AHV | 1 |
| Clarke, CE; de Bie, RMA; Espay, AJ; Fox, SH; Lang, AE | 1 |
| Artusi, CA; Fabbri, M; Imbalzano, G; Lopiano, L; Pongmala, C; Romagnolo, A; Zibetti, M | 1 |
| Cham, M; Cilia, R; Fothergill-Misbah, N; Maroo, H; Pezzoli, G; Walker, R | 1 |
| Agosta, F; Canu, E; Donzuso, G; Filippi, M | 1 |
| Aguilar, M; Alonso-Frech, F; Aneiros Díaz, A; Ávila Rivera, MA; Caballol, N; Cabo, I; Catalán, MJ; de Deus Fonticoba, T; Esltelrich Peyret, E; García Caldentey, J; Hernández Vara, J; Jesús, S; López Manzanares, L; Martí Andrés, G; Martí, MJ; Martinez-Martin, P; McAfee, D; Mir, P; Pastor, P; Planellas, LL; Redondo, N; Santos-García, D; Suárez Castro, E; Villanueva, C | 1 |
| Chen, PL; Chu, YT; Lin, CH; Lin, HY | 1 |
| Chen, X; Cheng, C; Le, W; Wang, Y; Wu, H | 1 |
| Eggers, C; Haas, K; Reese, JP; Stangl, S; Tönges, L; Volkmann, J | 1 |
| Bergquist, F; Dizdar, N; Grigoriou, S; Hansson, F; Johansson, A; Nyholm, D; Odin, P; Rinne, J; Sonesson, C; Svenningsson, P; Tedroff, J; Tsitsi, P; Wictorin, K | 1 |
| Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS | 1 |
| Abbruzzese, G; Antonini, A; Bentivoglio, AR; Berardelli, A; Comi, C; Cossu, G; Fabbrini, G; Lopiano, L; Mancini, F; Martino, T; Melchionda, D; Minafra, B; Modugno, N; Pontieri, FE; Riboldazzi, G; Sensi, M; Solla, P; Stefani, A; Stroppa, I; Tambasco, N; Tamma, F; Tessitore, A | 1 |
| Altinkaya, A; Bakhtiari, S; Pack, CC; Sadikot, AF | 1 |
| Baschieri, F; Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Provini, F; Sambati, L; Tonon, C; Vitiello, M | 1 |
| Altmann, C; Becht, B; Fiesel, T; Hoppe, T; Jost, WH; Ringwald, S | 1 |
| Koski, SK; Leino, S; Panula, P; Rannanpää, S; Salminen, O | 1 |
| Parambi, DGT | 1 |
| Abderrakib, A; Blecic, S; Delsaut, B; Delvaux, V; Harmegnies, B; Huet, K; Khalife, M; Lechien, JR; Piccaluga, M; Saussez, S | 1 |
| Duty, S; Fisher, R; Jackson, M; Lincoln, L; Mann, E; Rose, S | 1 |
| Chonpathompikunlert, P; Hutamekalin, P; Nagasaki, Y; Sato, Y; Tanasawet, S; Vong, LB | 1 |
| Cerroni, R; Imbriani, P; Liguori, C; Mercuri, NB; Pierantozzi, M; Pisani, A; Scalise, S; Stefani, A | 1 |
| Brahimi, E; Calabresi, P; Cappelletti, G; Eusebi, P; Filidei, M; Nigro, P; Paoletti, FP; Parnetti, L; Santangelo, V; Simoni, S; Tambasco, N | 1 |
| Borghammer, P; Callesen, MB; Damholdt, MF; Kjær, SW; Larsen, L; Østergaard, K | 1 |
| Cheon, SM; Lee, M; Noh, B; Park, H; Youm, C | 1 |
| Barbosa, ER; Bertholo, AP; Cury, RG; Fiorini, WS; França, C | 1 |
| Borges, V; Ferraz, HB; Hutz, MH; Mata, IF; Rieder, CRM; Santos-Lobato, BL; Schumacher-Schuh, AF; Tumas, V; Zabetian, CP | 1 |
| George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S | 1 |
| Amara, AW; Dhanwani, R; Frazier, A; Goldman, JG; Kuan, R; Lindestam Arlehamn, CS; Litvan, I; Mallal, S; Marder, KS; Peters, B; Pham, J; Phillips, E; Rezende Dutra, J; Roederer, M; Sette, A; Standaert, DG; Sulzer, D | 1 |
| Paik, J | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 1 |
| Kempster, P | 1 |
| Tipton, PW; Wszolek, ZK | 1 |
| Aridon, P; Arnao, V; Buttà, C; Cinturino, A; D'Amelio, M; Maida, C; Mastrilli, S; Tuttolomondo, A | 1 |
| Arai, M; Hayashi, A; Ogino, M; Suzuki, M | 1 |
| Amato, N; Caverzasio, S; Galati, S | 1 |
| Lang, AE; Saranza, G | 2 |
| Antonini, A; Bergmann, L; Gusmaroli, G; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pacchetti, C; Sensi, M; Zibetti, M | 1 |
| Baumann, CR; Oertel, MF; Stieglitz, LH | 1 |
| Antonini, A; Chaudhuri, KR; Leta, V; Teo, J | 1 |
| Chang, Y; Li, Y; Liu, X; Wang, L; Yan, Y; Zhang, L | 1 |
| Aragão Catunda Junior, FE; Basto Souza, R; da Cunha Ferreira, NM; de Sousa Dos Reis, TD; Hardy Lima Pontes, N; Maranguape Silva da Cunha, R; Moreira Vasconcelos, CF; Vasconcelos Aguiar, LM | 1 |
| Paul, DA; Qureshi, ARM; Rana, AQ | 1 |
| Cao, C; Li, D; Litvak, V; Sun, B; Zhan, S; Zhang, C | 1 |
| AlShimemeri, S; Fox, SH; Visanji, NP | 1 |
| King, NKK; Ng, JH; See, AAQ; Xu, Z | 1 |
| Antonini, A; Ashkan, K; Barbe, MT; Dafsari, HS; Evans, J; Fink, GR; Franklin, J; Jost, ST; Loehrer, PA; Martinez-Martin, P; Petry-Schmelzer, JN; Ray-Chaudhuri, K; Reker, P; Rizos, A; Samuel, M; Sauerbier, A; Schnitzler, A; Silverdale, M; Timmermann, L; Visser-Vandewalle, V | 1 |
| Ehlers, C; Honig, H; Odin, P; Timpka, J | 1 |
| Cheng, Y; Li, H; Liang, S; Tong, X; Wang, Y; Yang, H; Yu, Y | 1 |
| Fukuta, H; Hasegawa, K; Hattori, N; Mochizuki, H; Nomoto, M; Okawa, K; Terahara, T; Uchida, E | 1 |
| Bermúdez de León, M; González-Hernández, B; González-Horta, A; Leija-Salazar, M | 1 |
| Bloem, BR; Nonnekes, J | 1 |
| Bezard, E; Crynen, G; De Rosa, A; Eshraghi, M; Galli, N; Li, Q; Nuzzo, T; Ramírez-Jarquín, UN; Rivera, O; Scharager-Tapia, C; Shahani, N; Subramaniam, S; Swarnkar, S; Thiolat, ML; Tsaprailis, G; Usiello, A | 1 |
| Abdelalem Aziz Ahmed, M | 1 |
| Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A | 2 |
| Alhaddad, H; Sari, AT; Sari, Y; Schneider, A | 1 |
| Beretta, VS; da Conceição, NR; Gobbi, LTB; Lirani-Silva, E; Nóbrega-Sousa, P; Orcioli-Silva, D; Vitório, R | 1 |
| Auladell, C; Busquets, O; Camins, A; Cano, A; Ettcheto, M; Folch, J; Manzine, PR; Olloquequi, J; Sánchez-Lopez, E; Verdaguer, E | 1 |
| Baik, JS; Cho, JW; Choi, JH; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Isaacson, SH; Pahwa, R; Pfeiffer, RF | 1 |
| Ebersbach, G; Jost, WH; Kassubek, J; Klebe, S; Tönges, L | 1 |
| Cannas, A; Carta, M; Defazio, G; Farris, R; Figorilli, M; Meloni, M; Puligheddu, M; Sanna, F; Tronci, E | 1 |
| Bonno, D; Lizarraga, KJ; Modica, JS | 1 |
| Bakshi, V; Boyina, HK; Devarakonda, KP; Gangarapu, K; Geethakhrishnan, SL; Guggilla, SR; Panuganti, S | 1 |
| Bortolato, M; Cannas, A; Congiu, P; Defazio, G; Figorilli, M; Laccu, I; Meloni, F; Meloni, M; Puligheddu, M | 1 |
| Mukai, Y; Nishikawa, N; Shiraishi, T; Takahashi, Y | 1 |
| Barone, P; Canoro, V; Cicarelli, G; Erro, R; Picillo, M | 1 |
| García Ruiz-Espiga, P; Linazasoro-Cristóbal, G; López Del Val, LJ; López-Manzanares, L; Luquin-Piudo, MR; Martínez-Castrillo, JC; Mir, P; Pagonabarraga-Mora, J | 1 |
| Bohanec, M; Boshkoska, BM; Fotiadis, D; Gatsios, D; Konitsiotis, S; Miljković, D; Rigas, G; Tsiouris, KM; Valmarska, A | 1 |
| Guo, S; Li, J; Li, Y; Zhang, Y; Zhuang, P | 1 |
| Wang, Y; Yue, Y; Zhang, B; Zhang, J; Zhao, C | 1 |
| Evans, AH; Farrell, M; Sung, S; Vijiaratnam, N | 1 |
| Gao, H; Li, W | 1 |
| Miyaue, N; Nagai, M; Nomoto, M; Yabe, H | 1 |
| D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 2 |
| Fabbri, M; Ferreira, JJ; Kauppila, LA; Rascol, O | 1 |
| Ling, KH; Lu, CB; Tan, JJ; Wang, M | 1 |
| Bai, CH; Chan, L; Hong, CT | 1 |
| Krüger, R; Lorenzl, S; Müller, T; Oelwein, G; Storch, A; Woitalla, D; Wolz, M; Wüllner, U | 1 |
| Chaudhuri, KR; Jones, S; Leta, V; Parry, M; Rizos, A; Sauerbier, A; van Wamelen, DJ | 1 |
| Jagid, J; Luca, CC; Margolesky, J; Moore, H; Shpiner, DS; Singer, C | 1 |
| Aracil-Bolaños, I; Bejr-Kasem, H; Calopa, M; Campolongo, A; Crespo-Cuevas, A; de Fàbregues, O; Horta-Barba, A; Izquierdo-Barrionuevo, C; Kulisevsky, J; Marín-Lahoz, J; Martinez-Horta, S; Pagonabarraga, J; Pascual-Sedano, B; Pérez-Pérez, J; Puente, V | 1 |
| Bergquist, F; Dizdar, N; Hagell, P; Hellqvist, C; Höglund, A; Johansson, A; Johansson, EL; Karlberg, C; Löwed, B; Lundgren, M; Rådberg, J; Sjöström, AC; Willows, T | 1 |
| Boettcher, L; Edinger, G; Erickson, LO; Gardner, J; Kitzmann, R; Nance, MA; Wichmann, R; Wielinski, CL | 1 |
| An, J; Chan, P; Han, C; Jiao, L; Mao, W | 1 |
| Kaski, D; Klarendic, M | 1 |
| Bloem, BR; Dirkx, MF; Helmich, RC; Pasman, JW; Roth, D; Zach, H | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Adnan, M; Nyholm, D; Senek, M | 1 |
| Borovič, M; Dugonik, J; Flisar, D; Novak, D; Verber, D | 1 |
| Fransson, PA; Johansson, R; Magnusson, M; Nilsson, MH; Patel, M; Rehncrona, S; Tjernström, F | 1 |
| Kobylecki, C | 1 |
| Drent, M; Groenendal-Laurensse, JWMJ; Moes, HR; Tissingh, G; van Laar, T | 1 |
| Al-Hashel, JY; Kamel, WA | 1 |
| Al-Fatly, B; Brown, P; Kühn, AA; Meidahl, AC; Tan, H; Tinkhauser, G; Yeh, CH | 1 |
| da Silva, IR; da Silva, RA; Parise, MR; Pereira, M | 1 |
| Bologna, M; De Angelis, A; Edwards, MJ; Faiman, I; Marsili, L; Morgante, F; Pereira, EA; Pradhan, P; Ricciardi, L | 1 |
| Cooney, JW; Gillette, C; Moore, WC; Perry, CJ; Rockich-Winston, N; Sisson, CB | 1 |
| Alamyar, A; Blaabjerg, M; Bogetofte, H; Meyer, M | 1 |
| Asakawa, T; Kobayashi, S; Kurozumi, K; Nozaki, T; Sameshima, T; Sugiyama, K | 1 |
| Ahmed-Farid, OA; Lashin, FM; Re, L; Rizk, HA; Saber, SM; Shehata, AM | 1 |
| Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Adalid-Peralta, L; Álvarez-Luquin, D; Ángeles-Perea, S; Arce-Sillas, A; Boll, MC; Espinosa-Cárdenas, R; Fragoso, G; Garcia-Garcia, E; González-Saavedra, I; Leyva-Hernández, J; Montes-Moratilla, E; Sciutto, E | 1 |
| Bloem, BR; Coelho, M; Dodel, R; Ferreira, JJ; Hommel, AALJ; Hosking, A; Lorenzl, S; Meissner, WG; Odin, P; Schrag, A | 1 |
| Bonomo, R; Mostile, G; Nicoletti, A; Raciti, L; Zappia, M | 1 |
| Ding, J; Hong, W; Huang, J; Ren, Y; Yang, Z | 1 |
| Prakash, N; Simuni, T | 1 |
| Awogbindin, IO; Benadjal, A; Bordeleau, M; Bourque, M; Cantin, L; Di Paolo, T; Gagnon, D; Ibanez, FG; Lecours, C; Parent, M; Picard, K; St-Pierre, MK; Tremblay, ME | 1 |
| Baig, F; Drew, DS; Hu, M; Husain, M; Kelly, M; Manohar, S; Muhammed, K; Okai, D; Saleh, Y; Sarangmat, N | 1 |
| Aradi, SD; Hauser, RA | 1 |
| Claus, I; Dziewas, R; Labeit, B; Muhle, P; Suntrup-Krueger, S; Suttrup, J; Warnecke, T | 1 |
| Bézard, E; Blanchet, PJ; Bogard, S; Duval, C; Goubault, E; Martino, D; Monchi, O; Sarna, J; Vincent, C | 1 |
| Cai, Y; Cao, Q; Fang, L; Liang, B; Tu, T; Ye, X; Yu, C | 1 |
| Crippa, JAS; Marchioni, C; Queiroz, MEC; Santos-Lobato, BL; Tumas, V | 1 |
| Blandini, F; Cerri, S | 1 |
| Hemmerling, D; Wojcik-Pedziwiatr, M | 1 |
| Calabresi, P; Obeso, JA; Olanow, CW | 1 |
| Hong, JY; Kang, SY; Kim, SH; Lee, PH; Sohn, YH; Sunwoo, MK; Yoon, JH | 1 |
| Deuschl, G; Houeto, JL; Krack, P; Martinez-Martin, P; Rau, J; Schade-Brittinger, C; Schnitzler, A; Stoker, V; Timmermann, L; Tonder, L; Vidailhet, M | 1 |
| Giritharan, A; Mancini, M; Morris, R; Nutt, JG; Quinn, J; Stuart, S | 1 |
| Espay, AJ; Poewe, W | 1 |
| Duncan, K; Foerde, K; Sharp, ME; Shohamy, D | 1 |
| Akpalu, A; Bonvegna, S; Cereda, E; Cham, M; Cilia, R; Del Sorbo, F; Laryea, R; Obese, V; Oppon, K; Pezzoli, G; Sarfo, FS; Zecchinelli, AL | 1 |
| Cho, JW; Kim, JS; Kim, M; Park, H; Youn, J | 1 |
| Beaudry, F; Huot, P | 1 |
| Furlong, TM; Gibson, AS; Keefe, KA | 1 |
| Bernad-Elazari, H; Dagan, M; Gazit, E; Giladi, N; Hausdorff, JM; Herman, T; Maidan, I; Manor, B; Mirelman, A | 1 |
| Farzanehfar, P; Horne, M; Woodrow, H | 1 |
| Fernandez, HH; Sy, MAC | 1 |
| Becker, S; Florin, E; Koschmieder, KC; Schnitzler, A | 1 |
| Lamotte, G; Lenka, A; Mittal, SO; Pagan, FL | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Ishida, C; Kato-Motozaki, Y; Komai, K; Tagami, A; Takahashi, K | 1 |
| Kitzler, HH; Klingelhoefer, L; Leonhardt, GK; Linn, J; Podlesek, D; Polanski, WH; Reichmann, H; Schackert, G; Sitoci-Ficici, KH; Sobottka, SB; Zolal, A | 1 |
| Baróti, B; Constantin, V; Forró, T; Kelemen, K; Mihály, I; Nagy, E; Orbán-Kis, K; Rácz, A; Szász, J; Szatmári, S; Török, I | 1 |
| Kish, SJ; Rajput, AH | 1 |
| Arnold, AC; De Jesus, S; Delnomdedieu, M; Duvvuri, S; Eslinger, PJ; Fernandez-Mendoza, J; Gray, DL; Harrington, W; Huang, X; Kong, L; Lewis, MM; Mahoney, SE; Mailman, RB; Miller, AJ; Snyder, B; Sun, D; Van Scoy, LJ; Wang, X | 1 |
| Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A | 1 |
| Lévesque, D; Nekka, F; Robaey, P; Ursino, M; Véronneau-Veilleux, F | 1 |
| Artaud, F; Corvol, JC; Elbaz, A; Lee, PC; Mangone, G; Vidailhet, M | 1 |
| Arjunan, SP; Kempster, P; Kumar, D; Raghav, S; Viswanathan, R | 1 |
| Khojandi, A; Ramdhani, R; Vasudevan, R; Watts, J | 1 |
| Burack, MA; Ghoraani, B; Hssayeni, MD; Jimenez-Shahed, J | 2 |
| Andrusca, A; Deuschl, G; Gavriliuc, O; Helmers, AK; Paschen, S; Schlenstedt, C | 1 |
| Batra, D; Bhattacharya, A; Holla, VV; Kamble, N; Pal, PK; Prasad, S; Sahoo, LK; Yadav, R | 1 |
| Baumann, A; Baumann, CR; Landolt, HP; Linnebank, M; Masneuf, S; Morawska, MM; Moreira, CG; Noain, D; Sommerauer, M | 1 |
| Baumann, CR; Baumann-Vogel, H; Imbach, L; Krauss, P; Oertel, MF; Regli, L; Sarnthein, J; Stieglitz, LH | 1 |
| Altwal, F; Moon, C; Steiner, H; West, AR | 1 |
| Graybiel, AM; Schlossmacher, MG | 1 |
| Corson, T; de Freitas, PB; Falaki, A; Freitas, SMSF; Huang, X; Latash, ML; Lewis, MM | 1 |
| Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G | 1 |
| Gundersen, V; Jusufovic, M; Luth, SM; Nysveen, I; Skogseid, IM | 1 |
| Abbasi, MH; Esmaeili, S; Habibi, SA; Shahidi, GA | 1 |
| Hattori, N; Maeda, T; Nishimura, A; Nomoto, M; Takahashi, R; Takeda, A; Tsuboi, Y; Yoshida, K | 2 |
| de Jong, HR; El Aidy, S; Keshavarzian, A; Nelemans, SA; Permentier, H; van Kessel, SP; van Leeuwen, SS; Winkel, SL | 1 |
| Nekka, F; Robaey, P; Ursino, M; Véronneau-Veilleux, F | 1 |
| Dinelle, K; Felicio, AC; Fu, JF; Matarazzo, M; McKenzie, J; McKeown, MJ; Neilson, N; Sossi, V; Stoessl, AJ; Vafai, N | 1 |
| Nielsen, EI; Nyholm, D; Senek, M | 3 |
| Isaacson, SH; Pahwa, R | 1 |
| Miocinovic, S; Patel, M; Sharma, VD | 1 |
| Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D | 1 |
| Chaudhuri, KR; Jenner, P; Qamar, MA; Urso, D | 1 |
| Cools, R; den Ouden, HEM; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, AJ; Zach, H | 1 |
| Asano, AGC; Asano, NMJ; da Silva, IIFG; De Mascena Diniz Maia, M; de Souza, PRE; Dos Santos, EUD | 1 |
| Choudhary, M; Khatri, DK; Singh, SB; Sood, A | 1 |
| Dragaescu, C; Malinova, V; Pinter, A; Rohde, V; Sixel-Döring, F; Trenkwalder, C; von Eckardstein, KL | 1 |
| Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T | 1 |
| Hellström, PM; Nyholm, D | 1 |
| Beylergil, SB; Fasano, A; Hodaie, M; Kalia, SK; Lozano, AM; McIntyre, CC; Munhoz, RP; Phokaewvarangkul, O; Picillo, M; Poon, YY | 1 |
| Angelopoulou, E; Julian, T; Paudel, YN; Piperi, C; Shaikh, MF | 1 |
| Mittal, SO | 1 |
| Leucuta, DC; Perju-Dumbrava, L; Popa, LC; Popa, SL; Tohanean, N | 1 |
| Atzori, L; Contu, P; Cossu, G; Cusano, R; Fabbri, M; Lopiano, L; Madau, V; Manzin, A; Melis, M; Mereu, A; Morelli, M; Murgia, D; Oppo, V; Palmas, V; Perra, D; Pisanu, S; Santoru, ML; Sarchioto, M; Serra, A; Uva, P; Vascellari, S; Zibetti, M | 1 |
| Alonso-Cánovas, A; Alonso-Frech, FA; Borrue-Fernández, C; Catalán, MJ; En Representación Del Grupo de Trastornos Del Movimiento de la Asociación Madrileña de Neurología, ERDGTDMAMN; Fanjul-Arbós, S; García Ruiz-Espiga, P; García-Cobos, E; García-Ramos, R; Herreros-Rodríguez, J; Kurtis-Urra, M; López-Lozano, JJ; López-Manzanares, L; Martínez-Castrillo, JC; Martínez-Fernández, R; Mata, M; Peña-Llamas, E; Pérez-Sánchez, JR; Posada, IJ; Rodríguez-Sanz, A; Rojo, A; Romero-Muñoz, JP; Ruiz-Huete, C; Sánchez-Alonso, MP; Vivancos-Matellano, F | 1 |
| Barrajón Masa, AJ; Colmenares Bulgheroni, M; Moralejo Lozano, Ó | 1 |
| Akbostancı, MC; Aydemir, ST; Bakirarar, B; Kumcu, MK; Ulukan, Ç | 1 |
| Auinger, P; Charles, PD; Cole-Strauss, A; Elm, JJ; Fischer, DL; Goudreau, JL; Hacker, ML; Kieburtz, K; Lipton, JW; Pickut, BA; Sortwell, CE | 1 |
| Ahn, J; Ferrante, D; Hebron, ML; Matar, S; Moussa, C; Mulki, S; Pagan, FL; Torres-Yaghi, Y; Wilmarth, B | 1 |
| Aygun, D; Kocabicak, E; Temel, Y; Yildiz, O | 1 |
| Bezdicek, O; Dan, R; Goelman, G; Jech, R; Růžička, F | 1 |
| Caughman, CY; Factor, S | 1 |
| Guo, W; Liu, Y; Tang, X; Wang, X; Xu, Y; Yang, J; Yu, L | 1 |
| Huovinen, A; Jaakkola, E; Joutsa, J; Kaasinen, V | 1 |
| Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C | 1 |
| Baik, JS; Lee, JJ | 1 |
| Carroll, DG; Halli-Tierney, AD; Luker, J | 1 |
| Cairns, NJ; Criswell, S; Davis, AA; Hartlein, J; Kotzbauer, PT; Maiti, B; Martin, WRW; Miles, M; Norris, SA; Perlmutter, JS; Perrin, RJ; Racette, BA; Ushe, M; Zhong, Q | 1 |
| Akram, H; Aviles-Olmos, I; Cowie, D; Day, B; Dayal, V; Foltynie, T; Hariz, M; Hyam, J; Jahanshahi, M; Limousin, P; Peters, A; Rajabian, A; Zrinzo, L | 1 |
| Kimpara, T; Takeda, A | 1 |
| Cox, DRA; Li, J; Muralidharan, V; Weinberg, L | 1 |
| Fredholm, BB; Svenningsson, P | 1 |
| Aradi, SD; Hauser, RA; LeWitt, PA; Rascol, O | 1 |
| Bonvegna, S; Cilia, R; Colucci, F; Cossu, G; De Micco, R; Eleopra, R; Elia, AE; Fabbri, M; Ielo, GC; Lopiano, L; Modugno, N; Morgante, F; Novelli, A; Olivola, E; Oppo, V; Pilleri, M; Ricciardi, L; Sensi, M; Sorbera, C; Tessitore, A; Zibetti, M | 1 |
| Albanese, A; Amami, P; De Santis, T; Garavaglia, B; Invernizzi, F | 1 |
| Calvano, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P; Pietrzykowski, T; Rodriguez-Blazquez, C; Smilowska, K; van Wamelen, DJ | 1 |
| Alberts, JL; Fernandez, HH; Koop, MM; Rosenfeldt, AB | 1 |
| Bedard, P; Chen, L; Hallett, M; Horovitz, SG | 1 |
| Alusi, SH; Macerollo, A; Panicker, J; Randall, A | 1 |
| Belfiore, G; Contrafatto, D; Mostile, G; Nicoletti, A; Terranova, R; Zappia, M | 1 |
| Artusi, CA; Fabbri, M; Imbalzano, G; Lopiano, L; Sarro, L | 1 |
| Feng, J; Gao, S; Liu, J; Liu, W; Sun, Y; Wang, Y; Yao, L; Zhang, G; Zhang, Q; Zhou, Y | 1 |
| Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B | 1 |
| Ou, Z; Tong, Q; Wang, L; Xue, L; Zheng, J | 1 |
| Torrey, EF | 1 |
| Baschi, R; Cicero, CE; Davì, M; Luca, A; Monastero, R; Mostile, G; Nicoletti, A; Restivo, V; Zappia, M | 1 |
| Nascimento, D | 1 |
| Aliev, G; Cacabelos, N; Cacabelos, R; Carrera, I; Carril, JC; Martínez, O; Naidoo, V | 1 |
| Azulay, JP; Castelnovo, G; Dubrou, C; Dulac, M; Fluchère, F; Giordana, C; Hache, G; Julien, C | 1 |
| Brüggemann, N; Lohmann, K; Over, L | 1 |
| Cavallieri, F; Fioravanti, V; Valzania, F | 1 |
| Kobylecki, C; Silverdale, MA | 1 |
| He, TZ; Liu, DD; Liu, HJ; Tan, LJ; Wu, Q; Zhang, JL | 1 |
| Dhawan, V; Eidelberg, D; Feigin, A; Fujita, K; Hellman, M; Ma, Y; Peng, S; Tang, CC | 1 |
| Emamikhah, M; Ghadimi, M; Habibi, SAH; Moghaddasi, M; Rohani, M; Saeedi, Y; Shahidi, G | 1 |
| Gillespie, A; Jones, E; Pappert, E; Pike, J; Thach, A; Wright, J | 1 |
| Betrouni, N; Carrière, N; Chupin, M; Defebvre, L; Devos, D; Kuchcinski, G; Lopes, R; Moreau, C; Rolland, AS; Viard, R | 1 |
| Agosti, V; Carotenuto, A; Liparoti, M; Manzo, V; Minino, R; Rucco, R; Sorrentino, G; Sorrentino, P; Tafuri, D; Troisi Lopez, E | 1 |
| Becker, S; Berg, D; Busch, JH; Elshehabi, M; Emmert, K; Hansen, C; Liepelt-Scarfone, I; Maetzler, W; Nussbaum, S; Roeben, B; Schaeffer, E; Synofzik, M; Vaterrodt, T; Zaunbrecher, L | 1 |
| Edden, RAE; Gong, T; Mikkelsen, M; Song, Y; Wang, G; Xiang, Y | 1 |
| Baig, F; Brown, P; He, S; Morgante, F; Mostofi, A; Pereira, EA; Pogosyan, A; Tan, H; Tinkhauser, G; Torrecillos, F; Wiest, C | 1 |
| Bologna, M; Colosimo, C; Marsili, L; Miyasaki, JM | 1 |
| Di Fonzo, A; Fabbrini, G; Falla, M; Hicks, AA; Pramstaller, PP | 1 |
| Guillén Climent, S; Monteagudo, C; Pinazo Canales, MI; Porcar Saura, S | 1 |
| Abrami, A; Agurto, C; Caggiano, V; Heisig, S; Ho, BK | 1 |
| Chen, Q; Li, M; Lin, W; Zhang, X; Zhong, R | 1 |
| Lee, AJ; Poon, LH; Vuong, M; Zuzuarregui, JR | 1 |
| Cao, X; Cong, L; Fu, J; Gao, TL; Han, P; Jiang, JD; Li, XY; Lin, Y; Ma, SR; Pan, LB; Peng, R; Shou, JW; Tong, Q; Wang, Y; Wen, BY; Yu, H; Yu, JB; Zhang, XF; Zhang, ZW; Zhao, ZX | 1 |
| Grassi, A; Stocchi, F; Torti, M; Vacca, L | 1 |
| Carrara, F; Corrù, F; Elia, AE; Fittipaldo, VA; Giossi, R; Lo Re, F; Mazzari, M; Pani, A; Scaglione, F; Schicchi, A; Senatore, M; Tramacere, I | 1 |
| Shekhar, N; Thakur, AK; Yadav, N | 1 |
| Bower, JH; Camerucci, E; Hajeb, M; Martin, P; Mielke, MM; Mullan, AF; Ross, OA; Savica, R; Stang, CD; Turcano, P | 1 |
| Fan, S; Han, C; Li, P; Li, W; Meng, F; Wang, F; Wang, N; Xu, L; Zhang, F; Zhang, J | 1 |
| Dowiasch, S; Sommerkorn, J; Stock, L; Student, J; Timmermann, L; Waldthaler, J | 1 |
| Athanasakis, E; Avgoustaki, A; Boura, I; Chlouverakis, G; Giakoumakis, E; Giannopoulou, IA; Koulentaki, M; Orfanoudaki, E; Spanaki, C | 1 |
| Fabbri, M; Leung, C; Rascol, O | 1 |
| Bergmans, B; Cofré Lizama, LE; Dijkstra, BW; Gilat, M; Mancini, M; Nieuwboer, A; Verschueren, SMP | 1 |
| Artusi, CA; Bozzali, M; Ledda, C; Lopiano, L; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Baik, K; Chung, SJ; Hong, JM; Jung, JH; Kim, YJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 1 |
| Ahn, CH; Bariya, M; Brown, BJ; Davis, N; Javey, A; Ji, W; Nyein, HYY; Tran, B | 1 |
| Chen, ZJ; Cui, L; Gao, BL; Li, XF; Liang, CY; Ren, SM; Xia, YM; Yang, LQ | 1 |
| Carr, RA; Enright, BP; Facheris, MF; Jameel, F; Kym, PR; Liu, W; Lou, X; Mayer, PT; Moussa, EM; Rosebraugh, M; Stolarik, D; Voight, EA; Zhang, GGZ | 1 |
| Adarmes-Gómez, A; Fernández-Rodríguez, P; García-Solís, D; Grothe, MJ; Huertas, I; Jesús, S; Labrador-Espinosa, MA; Macías-García, D; Martín-Rodríguez, JF; Mir, P; Muñoz-Delgado, L | 1 |
| Sgambato, V | 1 |
| Bloem, BR; de Bie, RMA; Esselink, R; Groenewoud, H; Meinders, MJ; Nijhuis, FAP; Post, B | 1 |
| Giritharan, A; Mancini, M; Nutt, JG; Quinn, J; Stuart, S; Vitorio, R | 1 |
| Bocci, T; Bongioanni, P; Orlandi, G; Santin, M; Sartucci, F | 1 |
| Da Silva, JD; Meira-Carvalho, F; Rodrigues, M | 1 |
| Alonso Losada, MG; Álvarez Sauco, M; Ávila Rivera, MA; Bernardo, N; Blázquez Estrada, M; Borrué, C; Caballol, N; Cabo, I; Carrillo Padilla, F; Catalán, MJ; Cores, C; Cosgaya, M; Croitoru, I; Cubo, E; de Deus Fonticoba, T; de Fábregues, O; Escalante, S; García Caldentey, J; García Moreno, JM; Gastón, I; Gómez Mayordomo, V; González Aramburu, I; González Ardura, J; Hernández Vara, J; Infante, J; Jesús, S; José Martí, M; Kulisevsky, J; Kurtis, M; Labandeira, C; Legarda, I; López Ariztegui, N; López Díaz, LM; López Manzanares, L; Martínez Castrillo, JC; Martinez-Martin, P; Menéndez González, M; Mir, P; Miranda, J; Morales-Casado, M; Nogueira, V; Ordás, C; Pastor, P; Prieto, C; Puente, V; Rúiz Martínez, J; Sánchez Alonso, P; Santos García, D; Seijo, M; Solano Vila, B; Suárez Castro, E; Valero, C; Vela, L; Vives, B | 1 |
| Bloem, BR; Klein, C; Okun, MS | 1 |
| Chen, L; Du, J; Jiang, J; Liu, X; Mo, L; Peng, W; Tan, C; Zhou, W; Zhou, X | 1 |
| Ju, H; Kwon, KY; Lee, EJ; Lee, M | 1 |
| Cicero, CE; Donzuso, G; Mostile, G; Nicoletti, A; Rascunà, C; Sciacca, G; Zappia, M | 1 |
| Arai, A; Hanabata, N; Katagai, A; Okudera, R; Tomiyama, M; Ueno, T | 1 |
| Baudendistel, ST; Harrison, IL; Hass, CJ; Roemmich, RT; Schmitt, AC | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Baik, K; Chung, SJ; Hong, N; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 1 |
| Fukae, J; Hatano, T; Hattori, N; Oyama, G; Saiki, S; Shimo, Y; Tsunemi, T | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Arkadir, D; Bergman, H; Bick, AS; Eitan, R; Israel, Z; Lu, BL; Marmor, O; Rappel, P; Sand, D | 1 |
| Bergmann, L; Fasano, A; Gurevich, T; Jech, R; Johnson, A; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Tang, Z; Vela-Desojo, L | 1 |
| Miyaue, N; Nagai, M; Yabe, H | 1 |
| Chae, D; Chung, SJ; Lee, PH; Park, K | 1 |
| Chahine, LM; Coffey, CS; Czech, C; Dukart, J; Dziadek, S; Foroud, T; Galasko, D; Gerken, T; Hutten, SJ; Kremer, T; Marek, K; Mollenhauer, B; Pagano, G; Poston, KL; Seibyl, J; Siebourg-Polster, J; Simuni, T; Staempfli, A; Tanner, CM; Taylor, KI; Toga, AW; Trenkwalder, C; Weintraub, D | 1 |
| Lolekha, P; Sriphanom, T; Vilaichone, RK | 1 |
| Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Scharfenort, M; Timpka, J | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Qiao, JY; Wang, Y; Zang, QM | 1 |
| De Michele, G; De Rosa, A; Dello Iacovo, CDP; Palmieri, GR; Pane, C; Perillo, S; Saccà, F | 1 |
| Feldman, M; Margolesky, J | 1 |
| Benner, J; Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Almendro, N; García-Muñoz, RA; McConnell, J; Morales, V; Pérez-Garnes, M; Sanz, R | 1 |
| Anamnart, C; Kitjarak, R | 1 |
| Aschner, M; Getachew, B; Tizabi, Y | 1 |
| Fujioka, S; Komorita, S; Mishima, T; Nishida, A; Okajima, M; Tsuboi, Y | 1 |
| Ahmed, H; Aziz, MAE; Bahbah, EI; Ebada, MA; Fala, SY; Ghaith, HS; Negida, A | 1 |
| Aldred, J; Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Inguva, S; Jalundhwala, YJ; Kukreja, P; Odin, P; Pahwa, R | 1 |
| De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A | 1 |
| Dulski, J; Grabowski, K; Konkel, A; Libionka, W; Schinwelski, M; Sitek, EJ; Sławek, J; Wąż, P | 1 |
| Katunina, EA | 1 |
| Murer, MG; Paz, RM | 1 |
| Khojandi, A; Nahab, FB; Ramdhani, RA; Vasudevan, R; Watts, J | 1 |
| Alwahchi, WA; Amer El Khedoud, W; Atadzhanov, M; Ayele, BA; Ben Sassi, S; Ben-Adji, D; Carr, J; Charway-Felli, A; Djonga, EE; El-Sadig, SM; Hamid, E; Hooker, J; Kouame-Assouan, AE; Lengané, YTM; Maidal, MA; Massi, DG; Mohamed, MH; Musubire, AK; Neshuku, SN; Nestor, N; Ngwende, GW; Ocampo, C; Okeng'o, K; Okubadejo, NU; Phiri, TE; Razafimahefa, J; Sakadi, F; Shalash, A; Tibar, H | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Florin, E; Schnitzler, A; Sharma, A; Vesper, J; Vidaurre, D | 1 |
| Fernández-Espejo, E; González-Aparicio, R; Rodriguez de Fonseca, F; Santurtún, A; Suárez, J | 1 |
| Alcaraz, M; Alejo, R; Cacabelos, N; Cacabelos, P; Cacabelos, R; Carrera, I; Carril, JC; Corzo, L; Fernández-Novoa, L; Martínez, O; Naidoo, V; Nebril, L; Pego, R; Rodríguez, S; Tellado, I | 1 |
| Nagy, F | 1 |
| Arnoldussen, IA; Boelens Keun, JT; van de Rest, O; Vriend, C | 1 |
| Dehghani Ashkezari, M; Seifati, SM; Zarrin, P | 1 |
| Davis, RL; Holmes, AJ; Lubomski, M; Sue, CM; Xu, X; Yang, JYH | 1 |
| Abbruzzese, G; Barone, P; Lopiano, L; Stocchi, F | 1 |
| Abe, T; Maruyama, H | 1 |
| Barange, K; Barthélémy, C; Brefel-Courbon, C; Dupouy, J; Fabre-Delcros, MH; Fernández-Rodríguez, B; Harroch, E; Loubière, P; Ory-Magne, F; Rascol, O | 1 |
| Botelho, RV; Lopes, RA; Oliveira Júnior, JO; Porto, FHG | 1 |
| Costa, CDM; de Freitas, JL; de Oliveira, MO; Ferraz, JB; Godinho, F; Hamani, C; Queiroz, JWM; Rocha, MSG; Soriano, DC; Tatsch, JFS; Terzian, PR | 1 |
| de Almeida, AG; Finsterer, J; Rodrigues, AM; Scorza, CA; Scorza, FA | 1 |
| Bicho, E; Erlhagen, W; Fernandes, C; Ferreira, F; Gago, MF; Lopes, RL; Sousa, N | 1 |
| Fujioka, S; Fukuchi, T; Furukawa, K; Furune, S; Ikeda, Y; Jin, X; Kato, M; Koike, T; Kubota, E; Murakami, H; Sato, Y; Suzuki, T; Tsuboi, Y; Uehara, T; Yamashita, K; Yamazaki, Y; Yube, Y | 1 |
| Bril, EV; Fedorova, NV; Kulua, TK; Mikhaylova, AD | 1 |
| Gilmore, G; Jog, M; Kulshreshtha, D; Pieterman, M | 1 |
| Baig, F; Boca, M; Cheminais, L; Collin, N; Mooney, L; Rolinski, M; Selikhova, M; Szewczyk-Krolikowski, K; Whone, A | 1 |
| Barbato, LM; Freire-Alvarez, E; Kurča, E; Liu, Y; Lopez Manzanares, L; Pekkonen, E; Sánchez-Soliño, O; Spanaki, C; Vanni, P | 1 |
| Fu, J; Li, Z; Wang, F; Yu, K | 1 |
| Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ | 1 |
| Brown, P; Foltynie, T; He, S; Khawaldeh, S; Kühn, A; Limousin, P; Litvak, V; Oswal, A; Quinn, AJ; Tan, H; Tinkhauser, G; Torrecillos, F; Vidaurre, D; Woolrich, M; Zrinzo, L | 1 |
| Chiken, S; Nambu, A; Takada, M | 1 |
| Ahmed, S; Al-Harrasi, A; Gul, S; Khan, A; Khan, ST | 1 |
| Horne, M; Khodakarami, H; Shokouhi, N | 1 |
| Bowie, EM; Brown, DA; Brown, GL; Camacci, ML; Du, G; Grillo, S; Huang, X; Kim, SD; Kong, L; Lewis, MM; Nguyen, JV; Sundstrom, JM; Ullah, SP | 1 |
| Ashok, A; Balaraman, S; Bellettini, JR; Cardinal-David, B; Chan, VS; Ghosh, S; Hill, DR; Huters, AD; Ji, J; Klix, RC; Kotecki, BJ; Matulenko, MA; Reddy, RE; Shou, M; Simanis, J; Stambuli, J; Towne, TB; Voight, EA | 1 |
| Papić, E; Peterlin, B; Rački, V; Vuletić, V | 1 |
| Ruiz Pardo, J; Sánchez Fuentes, PA; Vidaña Márquez, E | 1 |
| Hickey, AJ; Langer, R; LeWitt, PA; Lipp, MM | 1 |
| Ba, F; Chen, L; Gui, Y; Hu, X; Lai, HY; Lv, W; Shen, T; Xie, F; Yue, Y; Zhang, B; Zhang, W | 1 |
| Bi, F; Chen, Q; Deng, N; Gou, D; Liao, Q; Long, X; Lu, K; Zhou, J | 1 |
| Hattori, N; Hayashi, T; Kobayashi, Y; Saiki, S; Yoritaka, A | 1 |
| Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T | 1 |
| Jost, WH; Koschel, J; Raeder, V; Ray Chaudhuri, K; Thiel, M; Tönges, L | 1 |
| Andica, C; Aoki, S; Hatano, T; Hattori, N; Hori, M; Ito, M; Iwamuro, H; Kamagata, K; Ogawa, T; Oyama, G; Saito, Y; Shimo, Y; Takeshige-Amano, H; Uchida, W; Umemura, A | 1 |
| Cao, B; Chen, YP; Gu, XJ; Hou, YB; Lin, JY; Liu, KC; Ou, RW; Shang, HF; Wei, QQ; Wu, Y; Zhang, LY; Zhao, B | 1 |
| Bejinar, C; Chis, AR; Dijmarescu, C; Dolga, A; Krabbendam, I; Marian, C; Moatar, AI; Rosca, C; Simu, M; Sirbu, IO; Vorovenci, RJ | 1 |
| Zhang, F; Zheng, C | 1 |
| Adams, S; Cushnie-Sparrow, D; Gaballah, A; Parsa, V | 1 |
| Ammendolia, A; de Sire, A; Demeco, A; Marinaro, C; Moggio, L; Petraroli, A; Pino, I | 1 |
| Li, C; Liu, Y; Xu, M; Yin, Y; Zhang, X | 1 |
| Ishii, K; Nakamagoe, K; Tamaoka, A; Tsuji, H | 1 |
| Chen, J; Chen, L; Chen, W; Fu, X; Gu, J; Guo, Q; Hu, Y; Jiang, L; Liu, J; Liu, Y; Qian, H; Wu, L; Xian, W; Xu, S; Yang, C; Ye, J; Zheng, Y | 1 |
| Olanow, CW; Poewe, W; Rascol, O; Stocchi, F | 1 |
| Bai, X; Cheng, W; Feng, J; Gao, T; Gu, L; Gu, Q; Guan, X; Guo, T; Huang, P; Wang, L; Wu, J; Xu, X; Xuan, M; Zhang, B; Zhang, M; Zhou, C | 1 |
| Corti, EJ; Egan, SJ; Gasson, N; Loftus, AM; Nielsen, C; Starkstein, S | 1 |
| Hattori, N; Kamata, N; Kawasaki, T; Morioka, S; Nakamura, J; Narita, M; Nikaido, Y; Ohtsuka, H; Okada, Y; Okamoto, M; Sawada, M; Shomoto, K; Urakami, H; Yamamoto, S | 1 |
| Facheris, MF; Liu, W; Neenan, M; Rosebraugh, M | 1 |
| Barone, P; Buonomo, AR; Erro, R; Pellecchia, MT | 1 |
| Bonifati, V; Dobricic, V; Dulovic Mahlow, M; Höglinger, G; Huppertz, HJ; Kasten, M; Klein, C; König, IR; Kuhnke, N; Lill, CM; Lohmann, K; Madoev, H; Marras, C; Petkovic, S; Respondek, G; Schaake, S; Stamelou, M; Trinh, J; Vollstedt, EJ; Weissbach, A; Wittke, C | 1 |
| Goel, A; Narayan, SK; Sugumaran, R | 1 |
| Hsu, CC; Huang, CL; Lin, YA; Ma, YF; Tsai, YC; Wang, S; Yeh, SR | 1 |
| Del Prete, Z; Martelli, F; Mileti, I; Palermo, E; Paoloni, M; Suppa, A; Zampogna, A | 1 |
| Barkan, S; Guan, I; Hellmers, N; Henchcliffe, C; Hou, Y; Malhotra, A; Sarva, H; Trabilsy, M; Wang, F | 1 |
| Coraci, D; Giovannini, S; Imbimbo, I; Padua, L; Santilli, V | 1 |
| Arai, A; Baba, M; Funamizu, Y; Haga, R; Kon, T; Nishijima, H; Nunomura, JI; Suzuki, C; Tomiyama, M; Ueno, T | 1 |
| Brotini, S; Guidi, L; Schievano, C | 1 |
| Amanzio, M; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M | 1 |
| Brefel-Courbon, C; Celebrini, S; Galitzky, M; Jardiné, V; Ory-Magne, F; Rosito, M; Séverac Cauquil, A | 1 |
| Brundin, P; Halliday, GM; Lang, AE; Poewe, W; Schrag, AE; Seppi, K; Tanner, CM; Volkmann, J | 1 |
| Kim, MS; Yoon, JH | 1 |
| Kumar, H; Pandey, S | 1 |
| Brodsky, M; Factor, SA; Fox, SH; Knowles, N; Lang, AE; Metman, LV; Nutt, JG; Pope, LE; Siffert, J | 1 |
| Fu, YT; Huang, JY; Li, J; Liu, CF; Liu, JY; Ma, LJ; Mao, CJ; Wang, Y; Zhang, HJ | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Abreu, D; Antonini, A; Chendo, I; Coelho, M; Costa, N; Fabbri, M; Ferreira, JJ; Godinho, C; Guedes, LC; Rosa, MM; Sousa, C | 1 |
| Di Paolo, T; Morissette, M | 1 |
| Fasano, A; Naranian, T; Poon, YY; Rohani, M | 1 |
| Clemm von Hohenberg, C; Dreßing, H | 1 |
| Ray Chaudhuri, K; Titova, N | 1 |
| Berardelli, A; Blankenburg, H; Domingues, FS; Fabbrini, G; Falla, M; Pramstaller, PP; Schwienbacher, C | 1 |
| Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ | 1 |
| Kordower, JH | 1 |
| Bajaj, N; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hardy, J; Lawton, MA; Malek, N; Morris, HR; Williams, NM; Wood, N | 1 |
| Bahram, M; Bedarf, JR; Bork, P; Coelho, LP; Goeser, F; Hildebrand, F; Sunagawa, S; Wüllner, U | 1 |
| Ghilardi, MF; Kishore, A; Popa, T; Quartarone, A; Rajan, R | 1 |
| Brokaw, EB; Burack, MA; Heldman, DA; Mari, ZK; Mera, TO; Pulliam, CL | 1 |
| Espay, AJ; Lang, AE | 2 |
| Azulay, JP; Borg, M; Charles, P; Colin, O; Danaila, T; Drapier, S; Dufournet, B; Eusebio, A; Grabli, D; Jacquette, A; Mutez, E; Nguyen, K; Philip, N | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Kataoka, H; Ueno, S | 1 |
| Bohnen, NI; Chou, KL; Gilman, S | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Liu, J; Liu, X; Long, Y; Qin, C; Tong, L; Zheng, F; Zheng, Y | 1 |
| Aiello, M; Eleopra, R; Foroni, F; Rinaldo, S; Rumiati, RI | 1 |
| Calabresi, P; Romoli, M; Tambasco, N | 1 |
| deSouza, RM; Schapira, A | 1 |
| Beyer, F; Brüggemann, N; Heldmann, M; Krauss, JK; Münte, TF; Paracka, L; Rasche, D; Saryyeva, A; Tronnier, VM | 1 |
| Hiller, A; Seier, M | 1 |
| Frazzitta, G; Ghilardi, MF; Hallett, M; Marinelli, L; Quartarone, A | 1 |
| Jankovic, J; Tarakad, A | 1 |
| Bonito-Oliva, A; Fisone, G; Johansson, Y; Ketzef, M; Silberberg, G; Spigolon, G | 1 |
| Chorbadzhieva, E; Dressler, D; Kleimann, A; Loens, S; Schrader, C | 1 |
| Bonnet, CT; Defebvre, L; Delval, A; Szaffarczyk, S | 1 |
| Huang, X; Zhang, Y | 1 |
| Cho, C; Dimov, A; Kopell, BH; Panov, FE; Ramdhani, R; Rasouli, J; Wang, Y; Zhang, Y | 1 |
| Blandini, F; Cerri, S; Siani, F | 1 |
| Bastide, MF; Bézard, E; Bourdenx, M; Doudnikoff, E; Dumont, ÉC; Fernagut, PO; Georges, F; Glangetas, C; Li, Q | 1 |
| Blankenburg, H; Corradi, E; Cortelli, P; Facheris, MF; Falla, M; Foco, L; Giannini, G; Hicks, AA; Panzer, J; Picard, A; Pramstaller, PP; Schwienbacher, C; Serafin, A; Zanigni, S | 1 |
| Albin, RL; Leventhal, DK | 1 |
| Jenner, P; Jeon, BS; Kim, HJ | 1 |
| Colosimo, C; Marconi, R; Marsili, L | 1 |
| Queen, V | 1 |
| Forsyth, D; Torsney, KM | 1 |
| Hashizume, T; Kaneko, S; Kusaka, H; Morise, S; Nakamura, M; Oki, M; Takenouchi, N; Tsuge, A; Wate, R | 1 |
| Ferreira, J; Lees, AJ; Poewe, W; Rascol, O; Reichmann, H; Stocchi, F; Tolosa, E | 1 |
| Akram, H; Ashburner, J; Behrens, T; De Vita, E; Foltynie, T; Hariz, M; Hyam, J; Jahanshahi, M; Limousin, P; Wu, C; Yousry, T; Zrinzo, L | 1 |
| Borges, V; Ferraz, HB; Mata, IF; Santos-Lobato, BL; Tumas, V; Zabetian, CP | 1 |
| Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD | 1 |
| Wagle Shukla, A | 1 |
| Capone, JG; Golfrè Andreasi, N; Preda, F; Rispoli, V; Sensi, M; Sette, E; Simioni, V; Tugnoli, V | 1 |
| Bugdol, M; Czernek, M; Derejczyk, J; Kapko, W; Kawa, J; Marcisz, C; Seiffert, P; Stępień-Wyrobiec, O; Szymszal, J; Torbus, A | 1 |
| Bonomo, R; Cicero, CE; Contrafatto, D; Dibilio, V; Luca, A; Mostile, G; Nicoletti, A; Raciti, L; Sciacca, G; Vasta, R; Zappia, M | 2 |
| Andersen, AD; Binzer, M; Blaabjerg, M; Faergeman, NJ; Gramsbergen, JB; Havelund, JF; Heegaard, NHH; Stenager, E | 1 |
| Antonini, A; Danielsen, EH; de Fabregues, O; Doskas, T; Henselmans, JML; Krüger, R; Lingor, P; Onuk, K; Parra, JC; Sensken, SC; Stefani, A; Yegin, A | 1 |
| Bishop, C; Cantu, MA; Chotibut, T; Kasanga, EA; McInnis, T; Meadows, S; Salvatore, MF | 1 |
| Bove, F; Di Iorio, R; Fasano, A; Gallicchio, L; Luigetti, M; Petruzzellis, A; Recchia, V; Tamma, F | 1 |
| Bichon, A; Boyer, F; Broussolle, E; Castrioto, A; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pélissier, P; Schmitt, E; Thobois, S; Wack, M | 1 |
| Fragola, M; Giannini, G; Lakens, D; Mirabella, G; Modugno, N | 1 |
| Cai, G; Dai, H; Huang, Y; Lin, Z; Luo, S; Ye, Q | 1 |
| Durando, M; Kim, JS; Tiu, H | 1 |
| Dagher, A; Fellows, LK; Simioni, AC | 2 |
| Bentivoglio, AR; Bove, F; Fasano, A; Naranian, T | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Contin, M; Isaias, IU; Laguna, J; Pezzoli, G; Pozzi, NG | 1 |
| Evans, A; Lee, W; Williams, DR | 1 |
| Kang, SH; Kim, HJ; Koh, SB; Kwon, KY; Lee, HM; Pyo, SJ | 1 |
| Ding, W; Krischek, B; Niu, C; Wang, X; Xiong, C; Xu, H; Zheng, F | 1 |
| Coello, C; Foltynie, T; Gunn, RN; Mehta, MA; Niccolini, F; Pagano, G; Politis, M; Rabiner, EA; Searle, GE; Wilson, H | 1 |
| Bai, X; Fei, J; Huang, F; Liu, F; Ni, J; Tang, Y; Wang, J; Wang, W; Wang, Z; Wu, L; Yu, M | 1 |
| Bäumer, T; Brüggemann, N; Hückelheim, K; Kasten, M; Klein, C; König, IR; Lohmann, K; Münchau, A; Pramstaller, PP; Tadic, V; Weissbach, A; Werner, E | 1 |
| Azulay, JP; Blin, O; Guilhaumou, R; Marsot, A | 1 |
| Asselta, R; Barbella, G; Benfante, R; Cereda, E; Cilia, R; Fornasari, D; Goldwurm, S; Marabini, L; Pezzoli, G; Vallauri, D | 1 |
| Erbguth, F; Lange, R | 1 |
| Kang, K; Ko, PW; Lee, HW; Park, D; Park, JS | 1 |
| Eerola-Rautio, J; Kenttämies, A; Kylänpää, L; Lindström, O; Lyytinen, J; Pekkonen, E; Udd, M | 1 |
| Bichon, A; Broussolle, E; Carnicella, S; Castrioto, A; Delpont, B; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Lüscher, C; Pélissier, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, S | 1 |
| Bezard, E; Carta, M; Cheng, LY; Ko, WKD; Li, Q; Morelli, M | 1 |
| Barone, P; Califano, F; Caporaso, G; Iodice, R; Lanzillo, B; Manganelli, F; Nolano, M; Picillo, M; Provitera, V; Saltalamacchia, A; Santoro, L; Stancanelli, A | 1 |
| Chen, SD; Du, JJ | 1 |
| Andréasson, M; Brodin, L; Laffita-Mesa, JM; Svenningsson, P | 1 |
| Haase, R; Li, K; Reichmann, H; Reimann, M; Rüdiger, H; Wolz, M; Ziemssen, T | 1 |
| Fujioka, S; Fukae, J; Hatano, T; Hattori, N; Kashihara, KI; Okuma, Y; Ouma, S; Tsuboi, Y; Yamamoto, S; Yoritaka, A | 1 |
| Ando, R; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Yabe, H | 1 |
| Chen, S; Liu, Y; Wang, D; Wang, L; Wang, X; Yao, X; Yue, T; Zhang, L; Zhao, Z | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Stocchi, F; Torti, M | 1 |
| Espay, AJ; Verhagen Metman, L | 1 |
| Coriolano, MDG; Lins, OG; Mota, IA | 1 |
| Chen, J; Li, J; Liu, X; Lou, Z; Sun, Y | 1 |
| Cai, J; Li, M; Li, N; Luo, F; Wang, J; Wang, N; Wang, Q; Xiao, H; Xie, Z; Zhang, W | 1 |
| De Jesus, S; Foote, KD; Gunduz, A; Hess, CW; Martinez-Ramirez, D; Okun, MS; Rossi, PJ | 1 |
| Abu-Suboh, M; Alvarez-Sabín, J; Armengol, JR; De Fabregues, O; Dot, J; Ferré, A; Gómez, MR; Hernández-Vara, J; Ibarria, M; Puiggros, C; Quintana, M; Raguer, N; Romero, O; Seoane, JL | 1 |
| Okun, MS | 2 |
| Avenali, M; De Icco, R; Fresia, M; Pacchetti, C; Perrotta, A; Sandrini, G; Serrao, M; Tassorelli, C | 1 |
| Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C | 1 |
| Avale, ME; Bernardi, MA; Bordone, MP; Damianich, A; Ferrario, JE; Gershanik, OS; Gomez, G; Hanger, DP; Isaja, L; Sanz-Blasco, S; Taravini, IR | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Almqvist, F; Chorell, E; Kucia, WE; Pawełek, K; Pokrzywa, M; Sarbak, S; Wittung-Stafshede, P | 1 |
| Brooks, DJ; Piccini, P; Politis, M; Wilson, H; Wu, K | 1 |
| Funamizu, Y; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T | 1 |
| Barbiani, D; Benedetti, F; Carlino, E; Dematteis, F; Frisaldi, E; Lanotte, M; Lopiano, L; Zibetti, M | 1 |
| Baj, R; Chaudhuri, KR; Jalundhwala, YJ; Konwea, H; Lowin, J; Marshall, TS; Sail, K | 1 |
| Attia, HN; Maklad, YA | 1 |
| Englesakis, M; Manninen, P; Mehta, J; Rowland, NC; Sheshadri, V; Venkatraghavan, L | 1 |
| Guin, D; Kukreti, R; Kukreti, S; Kushwaha, SS; Mishra, MK; Rawat, C; Talwar, P | 1 |
| Bastiampillai, T; Chuck, W; Dhillon, R; Okungu, A; Tibrewal, P | 1 |
| Damier, P; Delval, A; Derkinderen, P; Destée, A; Meissner, WG; Negre-Pages, L; Perez-Lloret, S; Rascol, O; Tison, F | 1 |
| Alty, JE; Cosgrove, J; Duggan-Carter, P; Jamieson, S; Lones, MA; Naylor, RF; Smith, SL; Turner, AJ | 1 |
| Assogna, F; Pontieri, FE; Rinaldi, D; Sforza, M; Tagliente, S | 1 |
| Abbruzzese, G; Antonini, A; Biundo, R; Calandra-Buonaura, G; Cortelli, P; Jori, MC; Lopiano, L; Marconi, R; Matinella, A; Morgante, F; Nicoletti, A; Tamburini, T; Tinazzi, M; Vorovenci, RJ; Weis, L; Zappia, M | 1 |
| Aragoneses, BL; Ayala, AS; Campa, JMT; Fernandez, FS; Liebana, ES; Portilla, PG; Seijo Zazo, E; Vega, MA | 1 |
| Lim, SY; Poewe, W; Tan, AH | 1 |
| Caine, C; Homma, S; Kim, JK; Monani, UR; Mosharov, EV; Nakanishi, K; Shohat, M | 1 |
| Pagano, G; Politis, M; Yousaf, T | 1 |
| Dizdar, N; Grenholm, P; Groth, K; Kjellander, S; Larsson, J; Nyholm, D; Permert, J; Schmiauke, U; Urbom, A; Widner, H; Willows, T | 1 |
| Chen, K; Shen, X; Ye, M | 1 |
| Chang, YY; Chen, PL; Chen, YF; Lan, MY; Lin, CH | 1 |
| Alarcia-Alejos, R; Almarcegui-Lafita, C; Ara, JR; Capablo-Liesa, JL; Crespo-Burillo, JA; Dolz-Zaera, I; Roche, JC | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| Cicero, CE; Contrafatto, D; Dibilio, V; Luca, A; Mostile, G; Nicoletti, A; Raciti, L; Sciacca, G; Toscano, S; Vasta, R; Zappia, M | 1 |
| Bloem, BR; Klemann, CJHM; Martens, GJM; Poelmans, G; Visser, JE; Xicoy, H | 1 |
| Aghanavesi, S; Dougherty, M; Memedi, M; Nyholm, D; Westin, J | 1 |
| Antonini, A; Barch, D; Bergmann, L; Chaudhuri, KR; Jech, R; Odin, P; Onuk, K; Pickut, B; Pirtošek, Z; Poewe, W; Szasz, J; Valldeoriola, F; Winkler, C; Yegin, A | 1 |
| Aldrin-Kirk, P; Björklund, T; Davidsson, M; Heuer, A; Mattsson, B; Rylander Ottosson, D | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK | 1 |
| Carras, N; Choi, YY; Dhawan, V; Eidelberg, D; Feigin, A; Jourdain, VA; Ma, Y; Markowitz, D; Nardi, D; Nazem, A; Niethammer, M; Peng, S; Schindlbeck, KA; Tang, CC | 1 |
| Brown, P; Herz, DM; Kühn, AA; Pogosyan, A; Tan, H; Tinkhauser, G | 1 |
| Baekelandt, V; Casteels, C; Crabbé, M; Himmelreich, U; Van der Perren, A; Van Laere, K; Weerasekera, A | 1 |
| Fox, SH; Li, MH; Mestre, TA; Taati, B | 3 |
| Domingos, J; Hägglund, M; Riggare, S; Stamford, JA; Sturr, J; Svenningsson, P; Unruh, KT | 1 |
| Carey, JL; Carey, RJ | 1 |
| Arnulf, I; Benchetrit, E; Beudin, P; Cicolin, A; Cormier-Dequaire, F; Corvol, JC; Durif, F; Fantini, ML; Figorilli, M; Lacomblez, L; Lopiano, L; Marques, A; Pereira, B; Puligheddu, M; Zibetti, M | 1 |
| Asser, T; Kadastik-Eerme, L; Taba, N; Taba, P | 1 |
| Chung, SJ; Hong, JY; Kim, JS; Lee, PH; Moon, H; Oh, JS; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Cronin, A; Grealy, M | 1 |
| Fasano, A; Jog, M; Kumar, N; Murgai, A; Naranian, T | 1 |
| Benazzouz, A; Faggiani, E; Janssen, MLF; Naudet, F; Temel, Y | 1 |
| Barber, TR; Ben-Shlomo, Y; Crabbe, M; Drew, D; Hu, MTM; Husain, M; Lawton, M; Muhammed, K; Quinnell, T; Rolinski, M; Zaiwalla, Z | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF | 1 |
| Borgkvist, A; Lieberman, OJ; Sulzer, D | 1 |
| Carnicella, S; Castrioto, A; Chabardes, S; Fraix, V; Krack, P; Moro, E | 1 |
| Andersohn, F; Chatamra, K; Conradt, C; Guo, D; Ismail, C; Miclea, A; Nisslein, T | 1 |
| Batycky, R; Corbin, A; LeWitt, PA; Murck, H; Pahwa, R; Sedkov, A | 1 |
| Iwaki, H; Kondo, H; Nomoto, M; Sakurai, M | 1 |
| de Bie, RMA; Dijk, JM; Odekerken, VJJ; Schuurman, PR; Ten Brinke, TR; van den Munckhof, P; van Dijk, JMC; van Laar, T | 1 |
| Barbosa, PM; Djamshidian, A; Grippe, T; Lees, AJ; O'Sullivan, S; Warner, TT | 1 |
| Olanow, CW; Stocchi, F | 4 |
| Freelance, CB; Willis, GL | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
| Hutz, MH; Rieder, CR | 1 |
| Bronstein, JM; Farrer, MJ; Guella, I; Kusters, CDJ; Paul, KC; Ritz, BR; Sinsheimer, JS | 1 |
| Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E | 1 |
| Compta, Y; Martí, MJ; Muñoz, JE; Ríos, J; Rumià, J; Santacruz, P; Tolosa, E; Valldeoriola, F | 1 |
| Volkmann, J | 1 |
| Calabresi, P; Hernández, LF; Obeso, JA; Picconi, B | 1 |
| Choi, H; Koh, SH | 1 |
| Gulmez Sevim, D; Gultekin, M; Karaca, C; Mirza, GE; Mirza, M; Unlu, M | 1 |
| Bernardi, MA; Ferrario, JE; Gershanik, OS; Gomez, G; Saborido, MD; Taravini, IR | 1 |
| Fairchild, A; Hass, S; Marshall, T; Pugh, A | 1 |
| Biernacka, A; Ciara, E; Czerska, K; Gasperowicz, P; Jacoszek, A; Kosińska, J; Laure-Kamionowska, M; Piekutowska-Abramczuk, D; Pronicka, E; Płoski, R; Rydzanicz, M; Szczałuba, K; Szymańska, K; Walczak, A | 1 |
| Balla, A; Bartha, EN; Blényesi, E; Constantin, V; Fazakas, PA; Grieb, LG; Sárig, M; Szász, JA; Szatmári, S; Szegedi, K | 1 |
| Brefel-Courbon, C; Galitzsky, M; Gerdelat, A; Harroch, E; Ory-Magne, F; Pavy-Le Traon, A; Pellaprat, J; Rascol, O; Rousseau, V | 1 |
| Bartošová, O; Bonnet, C; Perlík, F; Růžička, E; Šíma, M; Slanař, O; Ulmanová, O | 1 |
| Cao, B; Chen, Y; Hou, Y; Liu, H; Ou, R; Shang, H; Song, W; Wei, Q; Yuan, X; Zhang, L | 1 |
| Barton, ME; Burn, DJ; Dukes, GE; Gibson, RA; Hellström, PM; Marrinan, SL; Nyholm, D; Otiker, T; Richards, DB; Sarai, BK; Vasist, LS | 1 |
| Amenechi, C; Blum, K; Modestino, EJ; O'Toole, P; Reinhofer, A | 1 |
| Haddad, F; Karaman, R; Khawaja, Y; Najjar, A; Sawalha, M | 1 |
| Chen, J; Huang, JY; Jin, H; Liu, CF; Mao, CJ; Wang, F; Xu, LL; Yang, Y; Yang, YP; Zhang, HJ; Zhang, JR; Zhong, CK | 1 |
| Bardien, S; Bossert, M; Buckle, C; Carr, J; du Plessis, S; Emsley, R; Seedat, S; van den Heuvel, L; Vink, M | 1 |
| Chiba, T; Sato, Y; Umegaki, K; Yasumiishi, C | 1 |
| Catalán, MJ; Grandas, F; Matías-Arbelo, J; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Gago, MF; Magalhães, R; Marques, P; Moreira, PS; Salgado, AJ; Sousa, N; Teixeira, FG | 1 |
| Kostić, V; Kresojević, N; Svetel, M; Tomić, A | 1 |
| Chondrogiorgi, M; Giannakis, A; Konitsiotis, S; Tatsioni, A; Tsironis, C | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Laguna, J; Pezzoli, G; Raspini, B | 1 |
| Cacciatore, I; Ciulla, M; Di Stefano, A; Eusepi, P; Marinelli, L | 1 |
| Blesa, J; Del Rey, NL; Trigo-Damas, I | 1 |
| Chellam, J; Kannan, RR; Nagarajan, N | 1 |
| Etminan, N; Rahmanifar, E; Yoosefian, M | 1 |
| Chang, MC; Lee, HD | 1 |
| Asha, MJ; Chelvarajah, R; Fisher, B; Garratt, H; Hodson, JA; Kausar, J; Krovvidi, H; Mitchell, RD; Pall, H; Shirley, C; Ughratdar, I; White, A | 1 |
| Morelli, M; Pinna, A; Serra, M; Simola, N | 1 |
| Bair-Marshall, CJ; Girasole, AE; Guenthner, CJ; Kreitzer, AC; Lum, MY; Luo, L; Nathaniel, D; Nelson, AB | 1 |
| Angrisano, S; Artusi, CA; Dematteis, F; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Esqueda-Liquidano, M; García-Gomar, MG; Velasco, AL; Velasco, F | 1 |
| Matarazzo, M; Perez-Soriano, A; Stoessl, AJ | 1 |
| Argyelan, M; DeLucia, I; Eidelberg, D; Fitzpatrick, T; Gluck, M; Herzallah, M; Moustafa, AA; Sako, W; Sarpal, D; Vo, A | 1 |
| Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V | 1 |
| Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z | 1 |
| Brefel-Courbon, C; Chabardès, S; Czernecki, V; Deuschl, G; Durif, F; Elben, S; Hälbig, TD; Houeto, JL; Krack, P; Krüger, R; Kupsch, A; Lhommée, E; Maier, F; Maltête, D; Mehdorn, M; Ory-Magne, F; Pineau, F; Pinsker, M; Rau, J; Regis, JM; Sauvaget, A; Schade-Brittinger, C; Schnitzler, A; Schüpbach, M; Sixel-Döring, F; Thobois, S; Timmermann, L; Tonder, L; Witjas, T; Witt, K; Wojtecki, L | 1 |
| Chou, KL; Fernandez, HH; Miyasaki, J; Oertel, WH; Sethi, K; Simuni, T; Stacy, M; Stocchi, F | 1 |
| Antonini, A; Ashkan, K; Dafsari, HS; Dembek, TA; Evans, J; Mahlstedt, P; Martinez-Martin, P; Ray-Chaudhuri, K; Rizos, A; Sachse, L; Silverdale, M; Steffen, J; Strack, M; Timmermann, L; Visser-Vandewalle, V | 1 |
| Bloem, BR; Dirkx, MF; Hallett, M; Helmich, RC; Zach, H | 1 |
| DeMartinis, N; Duvvuri, S; Gurrell, R; Sun, P | 1 |
| Bakis, G; Nutt, J; Staisch, J | 1 |
| Hagell, P; Horne, M; Iwarsson, S; Nilsson, MH; Odin, P; Rosqvist, K | 1 |
| Alberquilla, S; García-Montes, JR; Moratalla, R; Suarez, LM | 1 |
| Wang, CC; Weng, YC; Wu, YR | 1 |
| Cressatti, M; Gornitsky, M; Kothari, V; Liberman, A; Schipper, HM; Song, W; Velly, AM | 1 |
| D'Abreu, A | 1 |
| Aiba, I; Ando, R; Aoki, M; Hasegawa, K; Iwaki, H; Nagai, M; Nakashima, K; Nishikawa, N; Nomoto, M; Tsuboi, Y; Tsujii, T; Yabe, H | 1 |
| Bordia, T; Perez, XA; Quik, M | 1 |
| Ganjavi, H; MacDonald, PA; Vo, A | 1 |
| Alam, M; Nyholm, D; Senek, M; Thomas, I; Westin, J | 1 |
| Kann, S; Leung, HC; Li, CR; Manza, P; Masson, M; Schwartz, G; Volkow, ND | 1 |
| Hirata, K; Matsubara, T; Okamura, M; Suzuki, K | 1 |
| Cardoso, F | 2 |
| Belvisi, D; Berardelli, A; Conte, A; Costanzo, M; Cutrona, C; Fabbrini, G; Ferrazzano, G | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Charbonnier-Beaupel, F; Corvol, JC; Le Febvre de Nailly, D; Mangone, G; Mariani, LL; You, H | 1 |
| Kundt, FS; Lex, KM; Lorenzl, S | 1 |
| Barajas, JS; Peterson, DS | 1 |
| Alcázar, JP; Caro Aponte, PA; Guzmán, JC; Mayorga, EL; Otálora, CA; Turner, LF | 1 |
| Blasberg, F; Elben, S; Groiss, SJ; Schnitzler, A; Slotty, PJ; Vesper, J; Wojtecki, L | 1 |
| Barreto, GE; Barreto, JA; Bezerra, MA; de Souza, ACA; Dos Santos, AB; Kohlmeier, KA; Rocha, ME | 1 |
| Arbelo, JM; Catalan, MJ; Cubo, E; Martinez-Martin, P; Mir, P; Molina-Arjona, JA | 1 |
| Bahroo, LB; Elkurd, MT; Pahwa, R | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Benesh, J; Boyd, JT; Chatamra, K; Eaton, S; Espay, AJ; Facheris, MF; Fernandez, HH; Fung, VSC; Hall, C; Lew, MF; Robieson, WZ; Rodriguez, RL; Slevin, JT; Standaert, DG; Vanagunas, AD; Zadikoff, C | 1 |
| Antonini, A; Godeiro, C; Moro, E; Reichmann, H | 1 |
| Kim, JS; Lee, JE; Lee, KS; Oh, YS; Ryu, DW; Yoo, IR | 1 |
| Charvin, D | 1 |
| Asano, AGC; Asano, NMJ; Crovella, S; da Silva, RC; de Lima, GDC; de Souza, PRE; Dos Anjos, RSG; Dos Santos, EUD; Sampaio, TF | 1 |
| Andrisani, G; di Biase, L; Di Lazzaro, V; Di Matteo, FM; Di Santo, A; Marano, M; Martino, M; Pandolfi, M; Pizzicannella, M; Rea, R | 1 |
| Gao, X; Guan, E; Guo, E; Huang, S; Li, B; Lin, X; Song, S; Wang, B; Wu, P; Yue, H; Zhang, H | 1 |
| Calandra-Buonaura, G; Chiari, L; Contin, M; Cortelli, P; Corzani, M; Lopane, G; Mellone, S | 1 |
| Katsaiti, I; Nixon, J | 1 |
| Cantù, H; Côté, JN; Hill, A; Jehu, DA; Nantel, J; Paquette, C | 1 |
| Bertram, KL; Hewer, S; Lee, W; Ligtermoet, M; Paul, E; Varley, S; Vijiaratnam, N; Williams, DR | 1 |
| Sue, CM; Vijiaratnam, N | 1 |
| Cenci, MA; Sebastianutto, I | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Robieson, WZ; Yegin, A | 1 |
| Aliev, G; Cacabelos, R; Carrera, I; Fernandez-Novoa, L; Sampedro, C; Tarasov, VV | 1 |
| Bergquist, F; Ericsson, A; Johansson, A; Johansson, D; Medvedev, A; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Thomas, I; Westin, J | 1 |
| Hudson A, L; Miranda C, M | 1 |
| Ando, R; Choudhury, ME; Kannou, M; Kubo, M; Kyaw, WT; Nagai, M; Nishikawa, N; Nomoto, M; Tanaka, J; Yamanishi, Y | 1 |
| Fujioka, S; Fukae, J; Hasegawa, S; Hayashi, Y; Mishima, T; Nose, K; Shiwaku, H; Tsuboi, Y; Umemoto, G; Yamashita, K | 1 |
| Ferreira, JJ; Keller, B; Lees, AJ; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Baek, JS; Ho, HK; Lim, KL; Loo, SCJ; Pang, YY; Tan, EY; Tee, JK | 1 |
| Chen, R; Masani, K; Popovic, MR; Yoshida, T; Zabjek, K | 1 |
| Dafsari, HS; Dembek, TA; Huber, CA; Jung, F; Loehrer, PA; Nettersheim, FS; Pelzer, EA; Timmermann, L; Tittgemeyer, M; Weber, I | 1 |
| Choi, YJ; Kim, JM; Kim, KJ; Kim, N; Lee, DH; Lee, JY; Lee, YJ; Shin, CM | 1 |
| Aguilar, JA; Anlacan, JP; Diestro, JDB; Jamora, RDG; Teleg, RA; Vesagas, TS | 1 |
| Blecic, S; Ghosez, Y; Harmegnies, B; Huet, K; Lechien, JR; Saussez, S | 1 |
| Chen, W; Hou, Y; Hu, J; Lu, D; Lv, P; Tang, M | 1 |
| Hattori, N; Kato, M; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Auinger, P; Cole-Strauss, A; Fischer, DL; Goudreau, JL; Kemp, CJ; Lipton, JW; Paumier, KL; Sortwell, CE | 1 |
| Foki, T; Hitzl, D; Lehrner, J; Novak, K; Pirker, W; Pusswald, G | 1 |
| Bishop, C; Chambers, N; Conti, MM | 1 |
| Baston, C; Ursino, M | 1 |
| Adewusi, JK; Grünewald, RA; Hadjivassiliou, M; Khan, A; O'Connor, KR; Vinagre-Aragón, A; Zis, P | 1 |
| Brahimi, E; Calabresi, P; Filidei, M; Murgia, N; Muzi, G; Nigro, P; Paoletti, FP; Romoli, M; Simoni, S; Tambasco, N | 1 |
| Binde, CD; Gåsemyr, J; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Hortobágyi, T; Kovács, N; Nagy, F; Tollár, J | 2 |
| Ayton, S; Bush, AI; Chung, SJ; Kim, J; Kim, K; Kim, MJ; Kim, MS; Lee, JY; Oh, SB; Ryu, HS | 1 |
| Alunni Fegatelli, D; Berardelli, A; Bologna, M; Giordo, L; Guerra, A; Paparella, G; Rothwell, JC; Vestri, AR | 1 |
| Jamora, RDG; Saranza, GRM; Sumalapao, DEP; Suratos, CTR | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Lacoste, AMB; Lang, AE; Visanji, NP | 1 |
| Artusi, CA; Duker, AP; Espay, AJ; Lopiano, L; Merola, A; Okun, MS; Situ-Kcomt, M; Vizcarra, JA | 1 |
| Möhr, JD; Müller, T | 3 |
| Beudin, P; Debilly, B; Derost, P; Durif, F; Fantini, ML; Figorilli, M; Marques, A; Pereira, B; Vidal, T | 1 |
| Cao, C; Huang, P; Li, D; Li, X; Sun, B; Zeng, K; Zhan, S | 1 |
| Asgharnejad, M; Ceravolo, MG; Chaudhuri, KR; Dunac, A; Gomez Esteban, JC; Joeres, L; Pavese, N; Safavi, A; Schuller, JC; Woitalla, D | 1 |
| Fauser, M; Günther, S; Klingelhoefer, L; Martin, KD; Polanski, WH; Schackert, G; Sobottka, SB; Storch, A | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Iglesias-Canle, J; Masa-Vazquez, L; Sesar, A | 1 |
| Bordia, T; Perez, XA | 1 |
| Alvarez, R; Crespo Cuevas, AM; De Haro, J; Isern, I; Ispierto, L; Planas, A; Sanchez, J; Vilas, D | 1 |
| Allone, C; Bonanno, L; Bramanti, P; Ciurleo, R; Corallo, F; Di Lorenzo, G; Lo Buono, V; Marino, S; Palmeri, R; Versaci, R | 1 |
| Rose, O | 1 |
| Kimura, H; Maruyama, H; Nishikawa, Y; Takahashi, T; Watanabe, K | 1 |
| Budrewicz, S; Koszewicz, M; Koziorowska-Gawron, E; Rączka, D; Szczepańska, A; Słotwiński, K; Zmarzły, A | 1 |
| Breger, LS; Cenci, MA; Fieblinger, T; Lockowandt, M; Lundberg, C; Quintino, L; Sebastianutto, I; Zanetti, L | 1 |
| Frei, K; Tran, TN; Truong, DD; Vo, TNN | 1 |
| Cho, H; Lee, MJ; Lee, MS; Lee, SH; Lyoo, CH | 1 |
| Brusa, L; Caltagirone, C; Koch, G; Picazio, S; Ponzo, V | 1 |
| Burciu, RG; Christou, EA; Chung, JW; Coombes, SA; Hess, CW; Ofori, E; Okun, MS; Vaillancourt, DE | 1 |
| Alam, M; Bergquist, F; Memedi, M; Nyholm, D; Senek, M; Thomas, I; Westin, J | 1 |
| Antonelli, F; Cerquera, C; Ezquerra, M; Fernández-Santiago, R; Malagelada, C; Martí, MJ; Martín-Flores, N; Moreno, V | 1 |
| Antonini, A; Nitu, B | 1 |
| Amboni, M; Barone, P; Cesarelli, M; Fasano, A; Iavarone, A; Iuppariello, L; Lista, I; Palladino, R; Picillo, M; Rucco, R; Sorrentino, G; Varriale, P; Vitale, C | 1 |
| Carta, M; Hirsch, E | 1 |
| Antonini, A; Kleinman, LS; Marshall, TS; Odin, PLA; Onuk, K; Sail, KR; Skalicky, AM; Stoessl, AJ | 1 |
| Brodie, MA; Fung, VSC; Latt, MD; Lord, SR; Menant, JC; Menz, HB; Pelicioni, PHS | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
| Chung, SJ; Jeong, HE; Kim, JS; Kim, SJ; Lee, HS; Lee, PH; Oh, JS; Sohn, YH; Yoo, HS | 1 |
| Anang, JBM | 1 |
| Ballarini, T; Bezdicek, O; Holiga, Š; Jech, R; Möller, HE; Mueller, K; Růžička, E; Růžička, F; Schroeter, ML; Urgošík, D; Vymazal, J | 1 |
| Hagell, P; Iwarsson, S; Nilsson, MH; Odin, P; Rosqvist, K; Storch, A | 1 |
| Cunha, RA; Prediger, RD; S Aguiar, A; Schamne, MG; Speck, AE | 1 |
| Alifirova, VM; Bokhan, NA; Fedorenko, OY; Freidin, MB; Ivanova, SA; Loonen, AJM; Mironova, YA; Osmanova, DZ; Pozhidaev, IV; Tiguntsev, VV; Wilffert, B; Zhukova, IA; Zhukova, NG | 1 |
| Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC | 1 |
| Keam, SJ; Paik, J | 1 |
| Huang, B; Huang, R; Jiang, W; Lin, J; Liu, X; Liu, Y; Wang, J; Wang, L; Yang, W; Zhang, X; Zhang, Y; Zhao, L; Zhong, M | 1 |
| Čierny, D; Grofik, M; Kurča, E; Michalik, J; Nosáľ, V; Sivák, Š; Tatarková, Z; Turčanová Koprušáková, M | 1 |
| Li, L; Sagot, B; Zhou, FM | 1 |
| Antonini, A; Jost, WH | 1 |
| Arnulfo, G; Canessa, A; Isaias, IU; Marotta, G; Olivieri, C; Palmisano, C; Pezzoli, G; Pozzi, NG; Turco, F; Volkmann, J | 1 |
| Lane, EL | 1 |
| Ba, M; Kong, M; Wang, Y; Yang, H; Yu, G; Yu, L | 1 |
| Brooks, D; Poewe, W; Ray Chaudhuri, K | 1 |
| Akyildiz, U; Akyol, A; Dogan, B; Memis, CO; Sair, A; Sevincok, L | 1 |
| Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J | 1 |
| Cova, I; Priori, A | 1 |
| Chagraoui, A; De Deurwaerdère, P; Di Giovanni, G; Galati, S; Puginier, E | 1 |
| Ahn, JH; Cho, JW; Cho, KR; Kim, M; Lee, JI; Park, JH; Park, S; Youn, J | 1 |
| Chung, SJ; Kim, JS; Lee, HS; Lee, PH; Oh, JS; Sohn, YH; Yoo, HS | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Hirozawa, D; Ikenaka, K; Mochizuki, H; Nakano, T; Sasaki, T; Shimamura, M | 1 |
| Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
| Doladé, NG; Figueras, A; García, GC; Lanteri, PF; Leguia, A | 1 |
| Alty, JE; Clissold, BG; Ding, C; Ganga, G; Kempster, PA; McColl, CD; Nagao, K; Reardon, KA; Schiff, M | 1 |
| Dinh, P | 1 |
| Chung, SJ; Kim, JS; Lee, JJ; Lee, PH; Lee, Y; Moon, H; Oh, JS; Sohn, YH | 1 |
| Cervantes-Arriaga, A; Cruz-Fino, D; Cruz-Landero, A; Dávila-Avila, NM; Ospina-García, N; Rodríguez-Violante, M | 1 |
| Cámara, A; Compta, Y; Martí, MJ; Muñoz, E; Roldán, P; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Gul, A; Yousaf, J | 1 |
| Ballarini, T; Bezdicek, O; Jech, R; Mueller, K; Roth, J; Růžička, E; Růžička, F; Schroeter, ML; Villringer, A; Vymazal, J | 1 |
| Castrioto, A; Chabardès, S; David, O; Fraix, V; Kibleur, A; Krack, P; Lescoules, L; Lhommée, E; Martínez-Fernández, R; Moro, E; Pelissier, P | 1 |
| Brock, P; Fisher, JM; Hand, A; Walker, RW | 1 |
| Bezard, E; Calabresi, P; Campanelli, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Marino, G; Mellone, M; Picconi, B; Stanic, J; Thiolat, ML; Zianni, E | 1 |
| Fabbri, M; Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Brotchie, JM; Fox, SH | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Cheng, C; Ji, D; Liu, J; Liu, Q; Liu, Z; Low, SS; Shi, Z; Xu, H; Xu, N; Yu, X; Zhang, T; Zhu, J | 1 |
| Azulay, JP; Benel, L; Boraud, T; Chaigneau, V; Cormier-Dequaire, F; Corvol, JC; Debilly, B; Dellapina, E; Durif, F; Eusebio, A; Galitzky, M; Guimarães-Costa, R; Haddad, R; Houot, M; Lacomblez, L; Mariani, LL; Meissner, WG; Rascol, O; Salis, A; Thalamas, C | 1 |
| Acıbuca, A; Akbostancı, C; Efe, TH; Erken Pamukcu, H; Gerede Uludağ, DM; Sorgun, MH; Tekin Tak, B; Turhan, S | 1 |
| Berry, H; Cornil, A; Cui, Y; de Kerchove d'Exaerde, A; Degos, B; Detraux, B; Perez, S; Prokin, I; Venance, L; Xu, H | 1 |
| Ballarini, T; Holiga, Š; Jech, R; Möller, HE; Mueller, K; Piecha, FA; Růžička, E; Růžička, F; Schroeter, ML; Vymazal, J | 1 |
| Melo, A; Monteiro, L; Nóbrega, AC; Pinho, P; Soares, MFP; Tourinho, L | 1 |
| Ali, M; Chandel, TI; Jahan, I; Khan, RH; Masroor, A; Nayeem, SM; Siddique, IA; Uversky, VN; Zaidi, N; Zaman, M | 1 |
| Arnaldi, D; Babiloni, C; Bonanni, L; Buttinelli, C; Catania, V; D'Antonio, F; De Lena, C; De Pandis, MF; Del Percio, C; Emek-Savaş, DD; Famà, F; Farotti, L; Ferri, R; Fraioli, L; Franciotti, R; Frisoni, GB; Fuhr, P; Giubilei, F; Gschwandtner, U; Güntekin, B; Hanoğlu, L; Lizio, R; Lopez, S; McKeith, I; Nobili, F; Noce, G; Onofrj, M; Orzi, F; Parnetti, L; Pascarelli, MT; Pievani, M; Ransmayr, G; Soricelli, A; Stirpe, P; Stocchi, F; Taylor, JP; Triggiani, AI; Vacca, L; Yener, G | 1 |
| Drapier, D; Drapier, S; Duprez, J; Houvenaghel, JF; Riou, A; Robert, GH; Sauleau, P; Vérin, M | 1 |
| Bickerton, A; Coulthard, EJ; Grogan, JP; Howat, A; Irigoras Izagirre, N; Isotalus, HK; Knight, BE; Knight, LE; Smith, L | 1 |
| Di Battista, ME; Fattapposta, F; Lucarelli, M; Meco, G; Moret, F; Pascale, E; Pierandrei, S; Purcaro, C; Rubino, A; Vanacore, N | 1 |
| Fabbri, M; Ferreira, JJ; Rosa, MM | 2 |
| Amato, N; Galati, S; Kaelin-Lang, A; Manconi, M; Möller, JC; Sarasso, S; Staedler, C; Stanzione, P | 1 |
| Beccaria, L; Fabbri, M; Ferreira, JJ; Lopiano, L; Merola, A; Montanaro, E; Palermo, S; Romagnolo, A; Zibetti, M | 1 |
| Hallett, M; Merello, M; Rivero, AD; Rossi, MD; Wilken, M | 1 |
| Asano, AGC; Asano, NMJ; Bezerra Leite, FC; Crovella, S; da Silva, RC; de Souza, PRE; Dos Santos, EUD; Sampaio, TF; Tenório Dos Santos, AD | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Ray Chaudhuri, K; Robieson, WZ; Sanchez-Soliño, O | 1 |
| Bezard, E; Calabresi, P; Espay, AJ; Fasano, A; Fox, SH; Lang, AE; Marsili, L; Merola, A; Morgante, F; Picconi, B | 1 |
| Fidani, L; Kalinderi, K; Papaliagkas, V | 1 |
| Baik, JS; Cho, J; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Martinez-Castrillo, JC | 1 |
| Chen, S; Cui, S; Du, JJ; Fu, R; Gao, C; Huang, P; Lin, Y; Wang, T; Zhou, H | 1 |
| Ganjavi, H; Hiebert, NM; Jenkins, ME; MacDonald, PA; Mendonça, D; Owen, AM; Seergobin, KN | 1 |
| Christie, M; Coss, P; Ondo, W; Pascual, B | 1 |
| Ahlskog, JE; Bower, JH; Cutsforth-Gregory, JK; Mielke, MM; Parisi, JE; Savica, R; Turcano, P | 1 |
| Dragašević-Mišković, N; Kostić, VS; Petrović, I; Stanković, I | 1 |
| Daud, DB; McDonald, C | 1 |
| Koya Kutty, S; Mohamed Ibrahim, N; Ramli, R; Shah, SA | 1 |
| Atashzar, SF; Bernardinis, M; Jog, M; Patel, RV | 1 |
| Anheim, M; Ansquer, S; Azulay, JP; Bekadar, S; Benatru, I; Brefel-Courbon, C; Brice, A; Castrioto, A; Charbonnier-Beaupel, F; Cormier-Dequaire, F; Corvol, JC; Defebvre, L; Durif, F; Grabli, D; Krack, P; Kreisler, A; Krystkowiak, P; Lacomblez, L; Lagha-Boukbiza, O; Lebbah, S; Lebrun-Vignes, B; Lesage, S; Lhommée, E; Llorca, PM; Maltête, D; Mangone, G; Marques-Raquel, A; Ory-Magne, F; Pelissolo, A; Rascol, O; Roze, E; Tezenas du Montcel, S; Tir, M; Tranchant, C; Vidailhet, M | 1 |
| Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K | 1 |
| Barliya, A; Flash, T; Franzén, E; Horak, FB; Inzelberg, R; Israeli-Korn, SD; Paquette, C | 1 |
| Baig, F; Bajaj, N; Barber, TR; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hu, MTM; Klein, JC; Lawton, M; Malek, N; May, MT; Morris, HR; Swallow, DMA; Williams, N; Wood, NW | 1 |
| Stirpe, P; Stocchi, F; Torti, M; Vacca, L | 1 |
| Belsey, J; Kalabina, S; Mohamed, B; Paterson, B; Pivonka, D; Thomas, C | 1 |
| Kobayashi, S; Matsuda, N; Ugawa, Y | 1 |
| Adamson, MB; Baktash, N; Gilmore, G; Jog, MS; Stratton, TW | 1 |
| Dibble, LE; Lohse, KR; Olivier, GN; Paul, SS; Schaefer, SY; Walter, CS | 1 |
| Andrade, AO; Machado, ARP; Oliveira, FHM | 1 |
| Bay, AA; Corcos, DM; Hackney, ME; Hart, AR; Michael Caudle, W | 1 |
| Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
| Albrecht, F; Ballarini, T; Bezdicek, O; Jech, R; Mueller, K; Roth, J; Růžička, E; Růžička, F; Schroeter, ML; Vymazal, J | 1 |
| Arbelo, JM; Catalán, MIJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Manjunath, MB; Ray, A; Sahu, H; Vikram, NK | 1 |
| Gharabaghi, A; Milosevic, L; Weiss, D | 1 |
| Valldeoriola, F | 1 |
| Barros, MCF; Esteso, MA; Ribeiro, ACF | 1 |
| Bonassi, S; Coletti, C; Radicati, FG; Stocchi, F; Vacca, L | 1 |
| Barbosa Câmara-Souza, M; Fraga do Amaral, C; Heitor Campos, C; Rodrigues Garcia, RCM; Rodrigues Ribeiro, G | 1 |
| Akamatsu, W; Fujimaki, M; Hatano, T; Hattori, N; Ishikawa, KI; Nojiri, S; Oyama, G; Saiki, S; Takeshige-Amano, H; Ueno, SI; Yamaguchi, A | 1 |
| Fung, VSC; Latt, MD; Lewis, S; Zekry, O | 1 |
| Benninger, D; Di Virgilio, G; Du Pasquier, R; Eskioglou, E; Hirt, L; Kuntzer, T; Michel, P; Novy, J; Rossetti, AO; Rouaud, O; Ryvlin, P; Theaudin, M | 1 |
| Hattori, N; Mochizuki, H; Nagai, M; Nakaya, R; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Artusi, CA; Boyne, P; Espay, AJ; Fasano, A; Lopiano, L; Merola, A; Roediger, J; Romagnolo, A; Zibetti, M | 1 |
| Hamel, W; Hariz, M; Köppen, JA; Krack, P; Moll, CKE; Müller, D | 1 |
| Grassini, P; Heller, A; Heller, E; Kieburtz, K; Leinonen, M; Stocchi, F; Torti, M; Vacca, L; Warren Olanow, C | 1 |
| Castejon, M; El Aidy, S; El-Gendy, AO; Frye, AK; Keshavarzian, A; van Dijk, G; van Kessel, SP | 1 |
| Alam, M; Bergquist, F; Johansson, D; Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Fernandez, HH; Hengartner, D | 1 |
| Rascol, O | 10 |
| Batycky, R; Fernandez, HH; Hauser, RA; Isaacson, SH; Lew, M; LeWitt, PA; Lopez-Manzanares, L; Oh, C; Pahwa, R; Pourcher, E; Rudzínska, M; Saint-Hilaire, M; Sedkov, A; Waters, C | 1 |
| Baul, HS; Manikandan, C; Sen, D | 1 |
| Capuano, A; Rafaniello, C; Rossi, F; Scavone, C; Sportiello, L; Stelitano, B | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijkgraaf, MGW; Lang, AE; Munts, AG; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Bressman, S; Saunders-Pullman, R | 1 |
| Atkinson-Clement, C; Azulay, JP; Baunez, C; Cavazzini, É; Eusebio, A; Fluchère, F; Witjas, T; Zénon, A | 1 |
| Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 2 |
| Ba, F; Nathoo, N; Sankar, T; Suchowersky, O | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Che, Y; Feng, X; Li, X; Liu, Q; Zhu, D | 1 |
| Reich, SG; Savitt, JM | 1 |
| Adlard, PA; Billings, JL; Bush, AI; Doble, PA; Finkelstein, DI; Gordon, SL; Hare, DJ; Rawling, T | 1 |
| Antonini, A; Ashkan, K; Barbe, MT; Borgemeester, RWK; Dafsari, HS; Dos Santos Ghilardi, MG; Ebersbach, G; Evans, J; Fink, GR; Fonoff, ET; Henriksen, T; Kramberger, M; Martinez-Martin, P; Odin, P; Petry-Schmelzer, JN; Pirtošek, Z; Ray Chaudhuri, K; Reddy, P; Rizos, A; Sauerbier, A; Silverdale, M; Timmermann, L; Trost, M; Visser-Vandewalle, V | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Sohn, YH; Yoo, HS | 1 |
| Alwardat, M; Di Lazzaro, G; Franco, D; Imbriani, P; Mercuri, NB; Pisani, A; Schirinzi, T; Sinibaldi Salimei, P | 1 |
| Avanzino, L; Cortelli, P | 1 |
| Aghanavesi, S; Bergquist, F; Memedi, M; Nyholm, D; Senek, M | 1 |
| Aschermann, Z; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Pintér, D | 1 |
| Asano, AGC; Asano, NMJ; Damasceno Dos Santos, EU; de Souza, PRE; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Ingvar, M; Jousmäki, V; Lundqvist, D; Piitulainen, H; Svenningsson, P; Tsitsi, P; Vinding, MC; Waldthaler, J | 1 |
| Eriguchi, M; Hara, H; Hattori, N; Iida, K; Ikeda, S; Nagayama, H; Nishioka, K; Osoegawa, M | 1 |
| Corona, AP; Lopes, MDS; Melo, AS; Nóbrega, AC | 1 |
| Dolžan, V; Flisar, D; Georgiev, D; Kojović, M; Kramberger, MG; Pirtošek, Z; Redenšek, S; Trošt, M | 1 |
| Hideshima, M; Hirozawa, D; Ikenaka, K; Ishikura, T; Kitano, T; Konaka, K; Mochizuki, H; Nakano, T; Shimamura, M; Shinzaki, S; Takehara, T | 1 |
| Kang, JK; Lee, MK; Park, HJ | 1 |
| Metzer, WS; Rodrigues, FB | 1 |
| Barclay, CL; Barua, NU; Blinder, S; Boca, M; Boiko, C; Broadfoot, J; Cronin, D; Dharia, S; Fibiger, HC; Gill, SS; Harrison, R; Howell, M; Irving, C; Johnson, D; Johnson, GA; Kinch, S; Lawrence, AD; Lewis, O; Longpre, L; Luz, M; Marshall, C; Mohr, E; Mooney, L; Pritchard, G; Schroers, C; Skinner, P; Sossi, V; Stoessl, AJ; Whone, AL; Woolley, M | 1 |
| Ng, CF; Norlinah, MI; Tan, HJ; Tiau, PW | 1 |
| Kim, JS; Yoo, SW | 1 |
| Constantinescu, AA; den Uil, CA; Friesema, ECH | 1 |
| Ashkan, K; Aziz, TZ; Brown, P; Da Lio, M; De Cecco, M; Fischer, P; Foltynie, T; Fornaser, A; Green, AL; Hyam, J; Limousin, P; Pogosyan, A; Samuel, M; Tan, H; Zrinzo, L | 1 |
| Biro, EE; Bui, CJ; Garces, J; Glynn, R; Gouveia, EE; Hanna, JA; Houghton, D; Kahn, L; Lea, G; Lee, SX; Mathkour, M; McCormack, E; Riffle, J; Scullen, T; Smith, RD; Sulaiman, OA | 1 |
| Abdelkarim, AH; Alkanj, S; Aziz, MAE; Bahbah, EI; Diab, A; Ebada, M; Ebada, MA; Fayed, N; Negida, A; Soliman, AM | 1 |
| Danaila, T; Laurencin, C; Thobois, S | 1 |
| Corvol, JC; Mariani, LL | 1 |
| Arjunan, SP; Kempster, P; Kumar, D; Nagao, KJ; Raghav, S; Viswanthan, R; Wong, K; Zham, P | 1 |
| Cabrera, LY; Sarva, H; Sidiropoulos, C | 1 |
| Martini, ML; Mocco, J; Panov, F | 1 |
| Brandt, G; Canessa, A; Frigo, CA; Isaias, IU; Leporini, A; Maltese, V; Palmisano, C; Pezzoli, G; Pozzi, NG; Volkmann, J | 1 |
| Dong, Q; Fang, L; Li, J; Liao, J; Lu, T; Lu, Z; Peng, F; Qin, F; Qiu, W; Sun, X; Xu, X | 1 |
| Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR | 1 |
| Goodale, MA; MacDonald, PA; Yabe, Y | 1 |
| Cabreira, V; Massano, J; Soares-da-Silva, P | 1 |
| Urs, NM | 1 |
| Mukai, Y; Murata, M; Nishikawa, N; Takahashi, Y | 1 |
| Bergquist, F; Ericsson, A; Johansson, A; Johansson, D; Medvedev, A; Memedi, M; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Thomas, I; Westin, J | 1 |
| Graves, SM; Shen, W; Surmeier, DJ; Zhai, S | 1 |
| Cuzzolaro, M; Melchionda, N | 1 |
| Anderson, KN; Oliver, JR; Xu, Z | 1 |
| Barbagallo, G; Quattrone, A | 1 |
| Cooper, J; Ni, X; Ning, Y; Parks, D; Refoios Camejo, R; Yi, B; Zhao, H | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Del Bello, F; Giannella, M; Giorgioni, G; Piergentili, A; Quaglia, W | 1 |
| Abid, K; Chtioui, H; Grouzmann, E; Sadowski, SM; Tschopp, O; Winzeler, B | 1 |
| Olanow, CW | 11 |
| Ellenbogen, A; Hauser, RA; Isaacson, SH; Kegler-Ebo, DM; Komjathy, SF; Oh, C; Safirstein, BE; Truong, DD; Zhao, P | 1 |
| Artusi, CA; Fabbri, M; Lopiano, L; Pongmala, C; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Jia, J; Jiang, X; Su, W; Wang, K; Wei, J; Yan, Y | 1 |
| Cao, F; Gao, T; Gu, Q; Guan, X; Guo, T; Wang, J; Zeng, Q; Zhang, M; Zhong, J; Zhong, X; Zhou, C | 1 |
| Hou, Y; Jia, G; Liu, D; Wang, Y; Yang, Z; Zhang, J | 1 |
| Hara, K; Hattori, M; Kajita, Y; Katsuno, M; Kawabata, K; Maesawa, S; Nakatsubo, D; Ohdake, R; Sato, M; Sobue, G; Tanaka, Y; Tsuboi, T; Watanabe, H | 1 |
| Agid, Y; Cornu, P; Czernecki, V; Grabli, D; Karachi, C; Lau, B; Meier, N; Navarro, S; Schuepbach, M; Serra, G; Vidailhet, M; Welter, ML | 1 |
| Dong, X; Nao, J; Zheng, D | 1 |
| Kuhn, W; Möhr, JD; Müller, T | 1 |
| Espay, AJ | 3 |
| Pan, Y; Qu, Y; Shen, D; Zhang, L; Zhang, M; Zhang, W | 1 |
| Darevsky, DM; de Hemptinne, C; Gilron, R; Miller, AM; Miocinovic, S; Ostrem, JL; Rajagopalan, SS; Starr, PA; Swann, NC | 1 |
| Bernardo, WM; Rubira, C; Silvinato, A | 1 |
| Azevedo, LF; Castro-Lopes, J; Cavaco, S; Damásio, J; Fernandes, J; Gonçalves, A; Mendes, A; Moreira, I; Vila-Chã, N | 1 |
| Bhatia, KP; Lang, AE; Shetty, AS | 1 |
| Elmer, LW; Hauser, RA; Howard, R; Johnson, R; Kreitzman, DL; Kremens, DE; Nguyen, JT; Patni, R; Walsh, RR | 1 |
| Buhmann, C; Jost, WH; Kassubek, J; Lingor, P; Schrag, A; Schwarz, J; Tönges, L | 1 |
| Ando, R; Iwaki, H; Miyaue, N; Morita, H; Nagai, M; Nishikawa, N; Nomoto, M; Sogo, H; Tada, S; Yabe, H | 1 |
| Farzanehfar, P; Horne, M; Khodakarami, H | 1 |
| Bezard, E; Delamarre, A; Galitzky, M; Li, Q; Meissner, WG; Rascol, O; Tison, F | 1 |
| Di Vico, IA; Novelli, A; Ramat, S; Sorbi, S; Terenzi, F | 1 |
| Januário, C; Morgadinho, A; Reis Carneiro, D; Sousa, M | 1 |
| Bette, S; Di Luca, DG; Margolesky, J; Shpiner, DS | 1 |
| Bajaj, N; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hardy, J; Kanavou, S; Lawton, MA; Malek, N; Morris, HR; Pitz, V; Williams, NM; Wood, N | 1 |
| Friedman, JH | 4 |
| Alam, T; Ali, J; Baboota, S; Gaba, B; Haider, MF; Khan, T; Parvez, S | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Egawa, H; Fukunaga, T; Hatano, T; Hattori, N; Ishibashi, Y; Kaji, S; Kanda, S; Kohira, Y; Oka, S; Oyama, G; Shimo, Y; Yube, Y | 1 |
| Caspell-Garcia, CJ; Coffey, CS; Espay, AJ; Foster, ED; Uribe, L; Weintraub, D | 1 |
| Antonini, A; Bentivoglio, A; Eleopra, R; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Solla, P; Tamma, F; Zangaglia, R | 1 |
| Iwaki, H; Iwasaki, K; Kawakami, K; Nomoto, M; Tagawa, M | 1 |
| Gupta, HV; Lyons, KE; Pahwa, R | 1 |
| Feng, H; Gan, L; Li, C; Li, G; Liu, J; Ma, J; Shang, X; Wang, L; Wu, Z | 1 |
| Chen, XB; Jiang, DQ; Jiang, LL; Li, MX; Zhou, XW | 1 |
| Al Hashel, JY; Damier, P; Kamel, WA | 1 |
| Giladi, N; LeWitt, PA; Navon, N | 1 |
| O'Neill, C | 1 |
| Navon, N | 1 |
| Gupta, HV; Lyons, KE; Pahwa, R; Wachter, N | 1 |
| Fung, VSC; Morales-Briceño, H | 1 |
| Chacko, J; Chakrapani, B; Cyriac, S; George, S | 1 |
| Duma, S; Fung, VS; Griffith, J; Mahant, N; Martin, A; Morales-Briceño, H; Tsui, D | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Kawaguchi, M; Kawashima, M; Miyagi, Y; Okamoto, T; Samura, K; Yoshida, F | 1 |
| Kumar, PM; Lim, EC; Nadkarni, NV; Tan, EK; Wu, J | 1 |
| Biró, I; Mihály, I; Orbán-Kis, K; Péter, C; Szász, JA; Szatmári, S; Viorelia, C | 1 |
| Amberger, P | 1 |
| Benedetti, F; Carlino, E; Frisaldi, E; Guerra, G; Lopiano, L; Piedimonte, A; Romagnolo, A; Vighetti, S | 1 |
| Amjad, F; Bhatti, D; Davis, TL; Kukreja, P; Metman, LV; Oguh, O; Pahwa, R; Zamudio, J | 1 |
| de Jong, L; Frijlink, HW; Hagedoorn, P; Isufi, V; Luinstra, M; Puttenstein, J; Rutgers, AWF; van Laar, T | 1 |
| Antonini, A; Bergmann, L; Kukreja, P; Poewe, W; Robieson, WZ | 1 |
| Baig, F; Barber, TR; Ben-Shlomo, Y; Hu, MT; Kelly, MJ; Klein, JC; Lawton, MA; Lo, C; Ruffmann, C | 1 |
| Jadavji, NM; Murray, LK | 1 |
| Bishop, C; Deak, T; Lanza, K; Perkins, AE | 1 |
| Ahmed, MR; Ahmed, MS; Jayakumar, M; Job, JK; Li, EH; Ohtsu, H; Pittenger, C; Rajadas, J; Tao, J; Zamaleeva, AI | 1 |
| Bourque, MJ; Cannon, T; Cayrol, R; Desjardins, M; Ducrot, C; Fahmy, AM; Gruenheid, S; Laplante, A; Le Campion, A; Matheoud, D; McBride, HM; Penttinen, AM; Ramet, L; Trudeau, LE; Voisin, A; Zhu, L | 1 |
| Cho, JW; Cho, SH; Jang, H; Jo, H; Jung, YH; Kim, HJ; Kim, J; Kim, M; Kim, SJ; Na, DL; Park, JE; Park, S; Seo, SW | 1 |
| Fukuda, K; Hirano, M; Isono, C; Kusunoki, S; Nakamura, Y; Ueno, S | 1 |
| Chung, SJ; Kim, JS; Lee, PH; Lee, YH; Oh, JS; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Cha, J; Chung, SJ; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Boi, L; Carboni, E; Carta, AR; Fenu, S; Greig, NH; Mulas, G; Pisanu, A; Scerba, MT; Spiga, S; Tweedie, D | 1 |
| Januário, C; Moreira, F; Rebelo Gomes, I | 1 |
| Bougea, A; Katoulis, A; Spantideas, N; Stefanis, L | 1 |
| Abosch, A; Francis, D; Ince, NF; Jimenez-Shahed, J; Ozturk, M; Wu, J | 1 |
| Aristieta, A; Lafuente, JV; Miguelez, C; Paredes-Rodriguez, E; Ugedo, L; Vegas-Suarez, S | 1 |
| Zesiewicz, TA | 2 |
| Joutsa, J; Majuri, J | 1 |
| Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L | 1 |
| Bariya, M; Fan, Z; Hettick, M; Hou, L; Javey, A; Ji, W; Liaw, TS; Lin, Y; Nyein, HYY; Tai, LC; Yuan, Z; Zhao, C; Zhao, J | 1 |
| Hsiao, EY; Jameson, KG | 1 |
| Abe, O; Aoki, S; Hattori, N; Hori, M; Ito, K; Kamagata, K; Kuwatsuru, R; Motoi, Y; Nakanishi, A; Sano, T; Sasai, K; Shimoji, K; Suzuki, M; Tomiyama, H | 1 |
| Pandey, S | 1 |
| Asayama, S; Asayama, T; Fujita, K; Ito, H; Kaneko, S; Kusaka, H; Morita, J; Nagashima, M; Nakamura, M; Nakamura, S; Nakano, S; Nishii, M; Oki, M; Saito, A; Tsuge, A; Wate, R | 1 |
| Holiga, Š; Jech, R; Möller, HE; Mueller, K; Růžička, E; Schroeter, ML; Sieger, T; Vymazal, J | 1 |
| Annunziato, L; Conforti, R; De Micco, R; Esposito, F; Giordano, A; Paccone, A; Pignataro, G; Tedeschi, G; Tessitore, A | 1 |
| Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
| de Jong, MH; Van Gool, AR; Zemel, D | 1 |
| Hu, LF; Hu, XW; Li, D; Liu, CF; Qin, SM | 1 |
| Bhambhani, V; Cullinane, A; Introne, WJ; Lungu, C; Toro, C | 1 |
| Bohnen, NI; Burke, DT; Dayalu, P; Kwak, Y; Müller, ML; Seidler, RD | 1 |
| Calia, K; Graham, DJ; Hsueh, YH; Kelman, JA; Levenson, M; Macurdy, TE; Pinheiro, SP; Shih, D; Williams, JR; Worrall, C | 1 |
| Ardouin, C; Benabid, AL; Chabardès, S; Debû, B; Ferraye, MU; Fraix, V; Krack, P; Lhommée, E; Pollak, P; Seigneuret, E | 1 |
| Bastide, M; Bézard, E | 1 |
| Antonini, A; Cornblath, DR; Ebersbach, G; Grandas, FJ; Klostermann, F; Müller, T; Odin, P; Urban, PP; Valldeoriola, F; van Laar, T | 1 |
| Baláž, M; Bočková, M; Chrastina, J; Novák, Z; Rektor, I; Říha, I | 1 |
| Hernández, B; Martínez-Martín, P; Ricart, J | 1 |
| Dhawan, V; Eidelberg, D; Ko, JH; Ma, Y; Mure, H; Spetsieris, P; Tang, CC | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Ossig, C; Reichmann, H | 1 |
| Espay, AJ; Gupta, S; Hauser, RA; Hsu, A; Kell, S; O'Connell, M; Ondo, W; Sethi, K; Stacy, M | 1 |
| Worth, PF | 1 |
| Choonara, YE; du Toit, LC; Kumar, P; Modi, G; Ndesendo, VM; Ngwuluka, NC; Pillay, V | 1 |
| Ahmed, SH; Baekelandt, V; Bezard, E; Cador, M; Engeln, M; Fasano, S; Fernagut, PO | 1 |
| Kieburtz, KD; Luo, S; Ma, J | 1 |
| Magyar, K; Szökő, E; Tábi, T; Vécsei, L | 1 |
| Boroojerdi, B; Giladi, N; Surmann, E | 1 |
| Joshi, V; Mohan, V; Nathan, J; Panjwani, S; Thakurdesai, PA | 1 |
| Lv, Q; Zhang, B | 1 |
| Carignan, B; Daneault, JF; Duval, C; Panisset, M; Sadikot, AF | 1 |
| Giladi, N; Hausdorff, JM; Hendler, T; Herman, T; Jacob, Y; Rosenberg-Katz, K | 1 |
| Ben Djebara, M; Cherif, W; Gargouri, A; Gouider, R; Kacem, I; Khamassi, N | 1 |
| Agarwal, P; Burdick, DJ; Griffith, A | 1 |
| Backer, F; Balachandran, A; Chandran, S; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Pradeep, S | 1 |
| Contini, A; De Deurwaerdère, P; Lagière, M; Navailles, S | 1 |
| Chagas, MH; Crippa, JA; Marchi, KC; Miasso, AI; Tirapelli, CR; Tumas, V | 1 |
| Fransson, PA; Magnusson, M; Nilsson, MH; Patel, M; Rehncrona, S | 1 |
| Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H | 1 |
| Bienkowski, P; Kolaczkowski, M; Kuran, W; Lipczynska-Lojkowska, W; Ryglewicz, D; Samochowiec, J; Scinska, A; Sienkiewicz-Jarosz, H; Swiecicki, L | 1 |
| Morales, I; Rodriguez, M; Sabate, M | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Beuthien-Baumann, B; Grählert, X; Herting, B; Kotzerke, J; Löhle, M; Oehme, L; Perick, M; Reichmann, H; Schwanebeck, U; Storch, A; van den Hoff, J; Wolz, M | 1 |
| Bordia, T; Campos, C; Jordan, K; Letchworth, S; McIntosh, JM; Quik, M; Strachan, JP; Zhang, J | 1 |
| Boulanger, N; Kerkerian-Le Goff, L; Lacombe, E; Lortet, S; Nguyen, C; Rihet, P; Salin, P | 1 |
| Archie, A; Persoons, P; Vandenbulcke, M | 1 |
| Antonini, A; Bertaina, I; Calandrella, D; Cras, C; De Deyn, P; Gasser, UE; Mancini, F; Minafra, B; Odin, P; Opiano, L; Pacchetti, C; Pickut, B; Poewe, W; Spielberger, S; Tomantschger, V; Wolf, E; Zibetti, M | 1 |
| Duarte, MB; Glass, PG; Mueller, M; Negreiros, NN; Oliveira-Filho, J; Valença, GT; Ventura, LM | 1 |
| Arnet, I; Fischer, A; Gasser, UE; Timmermans, JP | 1 |
| Adams, C; Kumar, R | 1 |
| Emre, M; Kieburtz, K; Leinonen, M; Nissinen, H; Poewe, W; Rascol, O; Schapira, AH; Stocchi, F; Warren Olanow, C | 1 |
| Andrea, SB; Arnold, GC; Davis, MD; Dimitrova, DM; Eaton, RW; Hammerschlag, R; Hunt, EA; Johnson, SC; Lou, JS; Nutt, J; Oken, BS | 1 |
| Ziégler, M | 1 |
| Damier, P; Derkinderen, P | 1 |
| Béhé, M; Depboylu, C; Hermanns, G; Höglinger, GU; Matusch, A; Maurer, L; Oertel, WH; Windolph, A | 1 |
| Baumann, CR; Baumann-Vogel, H; Imbach, LL; Sürücü, O; Uhl, M | 1 |
| Alptekin, O; Aygun, D; Guz, H; Kocabicak, E; Kurt, M; Sarihasan, B; Temel, Y | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Schroeteler, FE; Ziegler, K; Zwosta, J | 2 |
| Durso, R; Josephs, E; Modak, A; Rosen, D | 1 |
| Fukuyama, H; Kawashima, S; Matsukawa, N; Mima, T; Ojika, K; Ueki, Y | 1 |
| Li, Q; Liu, W; Sun, YN; Wang, Y; Yang, JF; Zhang, BS; Zhang, W; Zhao, P | 1 |
| Mastaglia, FL; Rodrigues, JP; Teo, WP; Thickbroom, GW | 2 |
| Barone, P; Bovi, T; Censi, D; Fasano, A; Juergenson, I; Montemezzi, S; Squintani, G; Tinazzi, M; Vattemi, G | 1 |
| Erikh, I; Fadel, S; Granovsky, Y; Schlesinger, I; Sprecher, E; Yarnitsky, D | 1 |
| Best, CM; Ifedi, BO; Reichel, LM | 2 |
| Eggers, C; Horstkoetter, N; Kalbe, E; Kuhn, J; Lewis, CJ; Maarouf, M; Maier, F; Moro, E; Timmermann, L; Woopen, C; Zurowski, M | 1 |
| Barbe, MT; Christensen, MS; Florin, E; Herz, DM; Reck, C; Siebner, HR; Timmermann, L; Tittgemeyer, M; Tscheuschler, MK | 1 |
| Blumbergs, P; Kimber, T; Thompson, P | 1 |
| Cantor, C; Chahine, LM; Colcher, A; Dahodwala, N; Daley, J; Duda, JE; Horn, S; Hurtig, H | 1 |
| Bloem, BR; de Greef, MH; Dontje, ML; Kamsma, YP; Krijnen, WP; Munneke, M; Speelman, AD; Stolk, RP; van der Schans, CP; van Nimwegen, M | 1 |
| Arabia, G; Cerasa, A; Gioia, CM; Morelli, M; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Anzak, A; Ashkan, K; Aziz, T; Bogdanovic, M; Brown, P; Foltynie, T; Green, AL; Limousin, P; Pogosyan, A; Tan, H; Zrinzo, L | 1 |
| Cannas, A; Marrosu, F; Marrosu, MG; Solla, P | 2 |
| Daniels, C; Deuschl, G; Falk, D; Granert, O; van Eimeren, T; Volkmann, J; Witt, K | 1 |
| Bolitho, SJ; Gilat, M; Kamsma, YP; Lewis, SJ; Matar, E; Naismith, SL; Shine, JM | 1 |
| Braem, S; Duthoo, W; Houtman, F; Notebaert, W; Santens, P; Schouppe, N | 1 |
| Morais, BA; Ragazzo, PC; Silva, DJ; Souza, JT; Vilela-Filho, O | 1 |
| Angeli, A; Aviles-Olmos, I; Candelario, J; Duran, R; Foley, J; Foltynie, T; Hardy, J; Hariz, M; Jahanshahi, M; Kefalopoulou, Z; Limousin, P; Mencacci, NE; Pradhan, P; Rusbridge, S; Wood, NW; Zrinzo, L | 1 |
| Hurny, A; Michałowska-Wender, G; Wender, M | 1 |
| Apud, JA; Bigelow, LB; Das, S; Egan, MF; Goldberg, TE; Mattay, VS; Weickert, TW; Weinberger, DR | 1 |
| Björklund, T; Cederfjäll, E; Chu, Y; Kirik, D; Kordower, JH; Nikitidou, E; Nilsson, N; Sahin, G | 1 |
| Almeida, QJ; Caetano, MJ; Gobbi, LT; Gobbi, S; Pieruccini-Faria, F; Silveira, CR; Stella, F; Vitório, R | 1 |
| Abbruzzese, G; Bandettini di Poggio, M; Barone, P; Bonuccelli, U; Borelli, P; Ceravolo, R; Contu, P; Cossu, G; Frosini, D; Iodice, R; Lopiano, L; Manca, D; Manganelli, F; Marchese, R; Melis, M; Mereu, A; Merola, A; Nicoletti, V; Paribello, A; Picillo, M; Santoro, L; Zibetti, M | 1 |
| Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E | 1 |
| Harries, A; Hodson, J; Kausar, J; Mitchell, R; Ngoga, D; Pall, H | 1 |
| Angrisano, S; Artusi, CA; Lanotte, M; Lopiano, L; Merola, A; Montanaro, E; Rizzi, L; Rizzone, MG; Zibetti, M | 1 |
| Destee, A; Gao, H; Graf, A; Hattori, N; Hauser, RA; Kenney, C; Lang, AE; Merschhemke, M; Nagel, J; Poewe, W; Rascol, O; Stacy, M; Stocchi, F; Tolosa, E; Trenkwalder, C | 1 |
| Chassin, O; Debilly, B; Derost, P; Durif, F; Lemaire, JJ; Marques, A; Morand, D; Pereira, B; Ulla, M | 1 |
| Ma, YZ; Shen, XM; Zhang, J | 1 |
| Brauer, SG; Hall, LM; Hodges, PW; Horak, F | 1 |
| Beuschlein, F; Brown, S; Eisenhofer, G; Fassnacht, M; Glöckner, S; Januszewicz, A; Lattke, P; Peitzsch, M; Pelzel, D; Prejbisz, A; Reichmann, H; Siegert, G; Stell, A | 1 |
| Brücke, C; Curio, G; Hohlefeld, FU; Huchzermeyer, C; Huebl, J; Kühn, AA; Nikulin, VV; Nolte, G; Schneider, GH; Schönecker, T | 1 |
| Altieri, M; Berardelli, A; Bloise, M; Bologna, M; Fabbrini, G; Fasano, A; Latorre, A; Pietracupa, S; Sarchioto, M | 1 |
| Bencherif, M; Carroll, FI; Letchworth, S; Mallela, A; Quik, M; Sohn, D; Zhang, D | 1 |
| Halje, P; Petersson, P; Richter, U | 1 |
| Aschermann, Z; Komoly, S; Kovács, N | 1 |
| Chen, SY; Hsieh, TC; Hung, HY; Lin, SH; Lin, SZ; Tsai, ST | 1 |
| Brunnschweiler, H; Fuhr, P; Gschwandtner, U; Taub, E | 1 |
| Cai, M; Cao, H; Chen, S; Cheng, Y; Li, J; Liu, C; Qu, Q; Wang, J; Wang, Z; Zhang, B; Zhang, X; Zhang, Z; Zhu, R | 1 |
| Andersson, M; Cenci, MA; Iderberg, H; Lees, AJ; Lindgren, HS; O'Sullivan, SS; Rylander, D; Williams, DR | 1 |
| Dunnett, SB; Heuer, A; Klein, A; Lane, EL; Smith, GA; Vinh, NN | 1 |
| Manson, A; Schrag, A; Stirpe, P | 1 |
| Björklund, A; Decressac, M | 1 |
| Averbeck, BB; Aviles-Olmos, I; Djamshidian, A; Foltynie, T; Lees, AJ; Limousin, P; Noyce, A; O'Sullivan, SS; Zrinzo, L | 1 |
| Benarroch, EE; Calandra, CR; Cersosimo, MG; Gutiérrez, C; Micheli, FE; Pellene, A; Raina, GB | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Arfon, S; Drago, J; Evans, A; Griffiths, RI; Horne, MK; Johnson, W; Kempster, P; Kotschet, K; Raghav, S; Xu, ZM | 1 |
| Earhart, GM; Peterson, DS; Pickett, KA | 1 |
| Salat, D; Tolosa, E | 1 |
| Burack, MA; Giuffrida, JP; Mera, TO | 2 |
| Antczak, JM; Banach, M; Derejko, M; Jakubczyk, T; Jernajczyk, W; Rakowicz, MJ; Sienkiewicz, J; Więcławska, M; Zalewska, U | 1 |
| Hashim, HZ; Nafisah, WY; Norlinah, MI; Raymond, AA; Tamil, AM; Tan, HJ | 1 |
| Appel-Cresswell, S; Barton, JJ; McKeown, MJ; Sharp, ME; Stoessl, AJ; Viswanathan, J | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P | 1 |
| Motherwell, MS; Zuo, L | 1 |
| Fuhrer, H; Gruber, D; Hälbig, TD; Kopp, UA; Kupsch, A; Scherer, P | 1 |
| Grosset, DG; Grosset, KA; Hadley, D; Malek, N; Newman, EJ; Nissen, T; Patterson, J | 1 |
| Aricò, D; Cosentino, FI; Ferri, R; Pizza, F; Plazzi, G | 1 |
| Bohnen, NI; Dayalu, P; Kwak, Y; Müller, ML; Seidler, RD | 2 |
| Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC | 1 |
| Namazi, H | 1 |
| Martey, J; Rajabally, YA | 2 |
| Fedorova, NV; Nikitina, AV | 1 |
| Levin, OS; Liashchenko, EA; Skripkina, NA | 1 |
| Nyholm, D; Rahne, KE; Tagesson, C | 1 |
| Dronamraju, N; Graf, A; Hauser, RA; Kenney, C; Kumar, R; Merschhemke, M; Mostillo, J | 1 |
| Bertram, K; Bras, J; Cheshire, P; Foltynie, T; Halliday, G; Ling, H; McLean, C; O'Sullivan, SS; Storey, E; Williams, DR | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Filipek, B; Pytka, K; Zygmunt, M | 1 |
| Aquino, CC; Borges, V; Celso de Castro, P; Doná, F; Ferraz, HB; Medeiros, L; Silva, SM | 1 |
| Olanow, CW; Schapira, AH | 3 |
| Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Galazky, I; Heinze, HJ; Kluge, C; Kupsch, A; Schoof, J; Stallforth, S | 1 |
| Fahn, S; Gupta, S; Hauser, RA; Hsu, A; Jankovic, J; Kell, S; Lyons, KE; O'Connell, M; Pahwa, R; Pourcher, E | 1 |
| Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Goldenberg, AA; Lindenbach, D; Ostock, CY | 1 |
| Bolla, M; Paparatti, M; Perrotta, A; Pierelli, F; Sandrini, G; Serrao, M; Tassorelli, C | 1 |
| Bohnen, NI; Dayalu, P; Kwak, Y; Miller, NS; Müller, ML; Seidler, RD | 1 |
| Mamalyga, ML | 1 |
| Brown, P; Brücke, C; Huebl, J; Kühn, AA; Litvak, V; Oswal, A; Schneider, GH | 1 |
| Huang, X; Latash, ML; Lewis, MM; Park, J | 1 |
| Argolo, N; Deiró, M; Nóbrega, AC; Pinho, P | 1 |
| Antonini, A; Calandrella, D; Cantello, R; Coletti Moja, M; Comi, C; Dal Fante, M; Lacerenza, M; Mancini, F; Manfredi, L; Oggioni, GD; Pacchetti, C; Riboldazzi, G; Tunesi, S | 1 |
| Warnke, P | 1 |
| Edwards, MJ; Rothwell, JC | 1 |
| Bohnen, NI; Kwak, Y; Schonfeld, D; Seidler, R; Vaillancourt, DE | 1 |
| Catalán, MJ; de Pablo-Fernández, E; Fernández-Diez, S; García-Ramos, R; Lapeña-Montero, T; López-Valdés, E; Villanueva, C | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Medeiros, MS; Monte, TL; Rieck, M; Rieder, CR; Schumacher-Schuh, AF; Tovo-Rodrigues, L | 1 |
| Anderson, ED; Horak, FB; Lasarev, MR; Nutt, JG | 1 |
| Guo, JF; Liu, ZH; Lou, MX; Song, CY; Tang, BS; Xu, Q; Yan, XX; Yu, RH; Zhang, YH | 1 |
| González-Aparicio, R; Moratalla, R | 1 |
| Bonifácio, MJ; Soares-da-Silva, P; Sutcliffe, JS; Torrão, L; Wright, LC | 1 |
| Bargas, J; Barroso-Flores, J; Duhne, M; Galarraga, E; Pérez-Ortega, JE; Plata, V | 1 |
| Annoni, E; Ashkan, K; Chaudhuri, KR; Deuschl, G; Eggington, S; Valldeoriola, F | 1 |
| Brown, P; Cagnan, H; Kuhn, AA | 1 |
| Hirata, K; Komagamine, T; Suzuki, K | 1 |
| Redgrave, P; Stafford, T; Vautrelle, N | 1 |
| Ito, H; Izawa, M | 1 |
| Ludwichowska, A; Szabat, K; Szadejko, K; Sławek, J | 1 |
| Alcalay, RN; Goldman, JS; Greene, PE; Kubisch, C; Thenganatt, MA; Virmani, T | 1 |
| Chillag-Talmor, O; El-Ad, B; Friedman, N; Giladi, N; Gurevich, T; Linn, S; Peretz, C; Silverman, B | 1 |
| Bonnet, AM; Bonnet, C; Charbonnier-Beaupel, F; Cormier-Dequaire, F; Corvol, JC; Costentin, J; Devos, D; Duhamel, A; Lejeune, S; Rouaix, N; Sablonnière, B; Tahiri, K; Vidailhet, M; Zahr, N | 1 |
| Bhatia, K; Björklund, A; Brundin, P; Foltynie, T; Jahanshahi, M; Kefalopoulou, Z; Limousin, P; Lindvall, O; Mencacci, N; Piccini, P; Politis, M; Quinn, N; Rehncrona, S; Widner, H | 1 |
| Atmaca, M | 1 |
| Bonnet, C; Gaymard, B; Jech, R; Novák, D; Růžička, E; Růžička, F; Serranová, T; Sieger, T; Urgošík, D; Wild, J | 1 |
| Okun, MS; Weintraub, D | 1 |
| Azulay, JP; Bruder, N; Eusebio, A; Fluchere, F; Giorgi, R; Leveque, M; Peragut, JC; Regis, J; Witjas, T | 1 |
| Matsui, K; Oguru, M; Oka, N; Okuda, B; Tachibana, H; Toda, K; Yamanishi, T | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G; López-Lozano, JJ; Marey, J; Mir, P; Tolosa, E | 1 |
| Cenci, MA; Francardo, V | 1 |
| Christensen, MS; Florin, E; Herz, DM; Hulme, OJ; Siebner, HR; Timmermann, L | 1 |
| Jahanshahi, M; Karimi, K; Obeso, I; Osman, M; Ryterska, A; Speekenbrink, M; Tu, L | 1 |
| Abbruzzese, G; Albanese, A; Antonini, A; Attar, M; Barone, P; Bonuccelli, U; Colombo, D; Lopiano, L; Morgante, L; Onofrj, M; Posocco, V; Pramstaller, P; Ruggieri, S; Stocchi, F; Tinazzi, M; Zappia, M | 1 |
| Maeda, T | 1 |
| Doi, H; Hirai, S; Kishi, M; Sakakibara, R; Tateno, F; Tsuyuzaki, Y | 1 |
| Melo, A; Monteiro, L | 2 |
| Amarell, M; Barbe, MT; Bloem, BR; Fink, GR; Florin, E; Quatuor, EL; Schönau, E; Snijders, AH; Timmermann, L | 1 |
| Angrisano, S; Artusi, CA; De Angelis, C; Lopiano, L; Merola, A; Reggio, D; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Arnold, C; Gehrig, J; Gispert, S; Kell, CA; Seifried, C | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Nyholm, D; Senek, M | 1 |
| Baumann, CR; Waldvogel, D | 1 |
| Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T | 1 |
| Chen, D; Cundy, KC; Hauser, RA; Huff, FJ; LeWitt, PA; Lissin, D; Zomorodi, K | 1 |
| Kulisevsky, J; Pagonabarraga, J | 2 |
| Buhmann, C; Engel, AK; Gerloff, C; Hamel, W; Hierling, J; Maintz, L; Moll, CK; Vettorazzi, E; Zangemeister, WH | 1 |
| Antonini, A; Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Kieburtz, K; Lenz, RA; Odin, P; Olanow, CW; Othman, AA; Pritchett, Y; Robieson, WZ; Standaert, DG; Vanagunas, A; Widnell, KL | 1 |
| Alegre, M; Artieda, J; Garcia-Garcia, D; Guridi, J; López-Azcárate, J; Obeso, J; Rodriguez-Oroz, M; Toledo, JB; Valencia, M | 1 |
| Anheim, M; Biskup, S; Lagha-Boukbiza, O; Mallaret, M; Namer, IJ; Rudolf, G; Tranchant, C | 1 |
| Alkufri, F; Brown, RG; Burn, DJ; Hindle, JV; Hurt, CS; Landau, S; Samuel, M; Wilson, KC | 1 |
| Bastin, J; Benis, D; Chabardès, S; David, O; Fraix, V; Krack, P; Lachaux, JP; Seigneuret, E | 1 |
| Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M | 1 |
| Narayanan, NS; Rodnitzky, RL | 1 |
| Bassareo, PP; Cannas, A; Corona, A; Marrosu, F; Mulas, CS; Perra, S; Solla, P | 1 |
| Alcalay, RN; Clark, LN; Côté, L; Marder, KS; Nichols, WC; Sharp, ME; Vonsattel, JP | 1 |
| Anzak, A; Brown, P; Kühn, A; Little, S; Pogosyan, A; Tan, H | 1 |
| de Beyl, DZ; Dethy, S; Pickut, BA; Van De Maele, H; van der Linden, C | 1 |
| Bastin, J; Benabid, AL; Chabardes, S; David, O; Debû, B; Ferraye, M; Fraix, V; Goetz, L; Pollak, P | 1 |
| Bhidayasiri, R; Boonrod, N; Jitkritsadakul, O; Rerknimitr, R | 1 |
| Muhlack, S; Müller, T | 6 |
| Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L | 1 |
| Behlau, M | 1 |
| Azevedo, LL; Cardoso, FE; Reis, CA; Souza, IS | 1 |
| Camicioli, R; Emery, D; Gee, M; Sabino, J; Sapkota, S | 1 |
| Devos, H; Münks, L; Nieuwboer, A; Nuttin, B; Vandenberghe, W; Vercruysse, S | 1 |
| Nyholm, D; Stepien, V | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Antonini, A; Pilleri, M | 2 |
| Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R | 1 |
| Fedorova, NV; Kulua, TK | 1 |
| Dutta, S; Othman, AA | 1 |
| Alonso-Canovas, A; Garcia-Ruiz, PJ; Herranz Barcenas, A; Mahillo Fernandez, I; Martinez Castrillo, JC; Mata, M; Olmedilla Gonzalez, N; Sanchez Alonso, P; Vela, L | 1 |
| Dézsi, L; Vécsei, L | 1 |
| Ashkan, K; Brown, RG; Chaudhuri, KR; Forgacs, I; Lin, JP; Martinez-Martin, P; Reddy, P; Samuel, M; Selway, R | 1 |
| Loane, C; Niccolini, F; Politis, M | 1 |
| Chen, H; Chen, HB; Chen, SD; Chen, X; Li, L; Liu, YM; Liu, ZG; Qu, QM; Shao, M; Sun, SG; Wan, X; Wang, G; Wang, J; Wen, HB; Xu, Q; Zhang, BR; Zhang, ZX | 1 |
| Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L | 1 |
| Auxiette, C; Chambres, P; Coulangeon, LM; Dalens, H; Devaux, D; Durif, F; Jalenques, I; Mermillod, M; Mondillon, L; Rieu, I | 1 |
| Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K | 1 |
| Ando, Y; Sakamoto, M; Shindo, Y; Shinoda, M; Tateda, T | 1 |
| Bleuse, S; Defebvre, L; Delval, A; Devos, D; Moreau, C; Ryckewaert, G; Tard, C | 1 |
| Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S | 1 |
| Burn, DJ; Crossman, AR; Kass-Iliyya, L; Kellett, MW; Kobylecki, C; Silverdale, MA | 1 |
| Cao, B; Chen, D; Chen, K; Huang, R; Li, J; Shang, H; Song, W; Yang, R | 1 |
| Bolitho, SJ; Grunstein, RR; Hodges, JR; Lewis, SJ; Naismith, SL; Rajaratnam, SM; Rogers, N; Terpening, Z | 1 |
| Bain, P; Brooks, DJ; Kiferle, L; Loane, C; Molloy, S; Piccini, P; Politis, M; Turkheimer, FE; Wu, K | 1 |
| Katzenschlager, R; Poewe, W | 1 |
| Acar, F; Acar, G; Karadag, F; Ugurlu, TT | 1 |
| Baker, R; Brant, R; Corrêa, JC; de Godoy, W; Greve, JM; Lucareli, PR; Luna, NM; Speciali, DS | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Bezard, E; Ko, WK; Li, Q | 1 |
| An, J; Chan, P; Gu, Z; Wang, C; Zhang, H | 1 |
| Arai, A; Baba, M; Funamizu, Y; Haga, R; Ichinohe, N; Kimura, T; Kon, T; Meguro, R; Migita, K; Miki, Y; Nishijima, H; Suzuki, C; Suzuki, S; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Chowdhury, JH; Chowdhury, TI; Rahman, MM; Uddin, MJ | 1 |
| Evans, AH; Griffiths, RI; Horne, M; Kettlewell, J; Kotschet, K; McGregor, S | 1 |
| Calabresi, P; Picconi, B | 1 |
| Katunina, EA; Titova, NV | 3 |
| Chatterjee, S; Choudhury, S; Das, M; Ghosh, P; Gupta, A; Paul, P; Pradhan, R | 1 |
| Dollé, F; Hantraye, P; Kirik, D; Lavisse, S; Ozgur, M; Rbah-Vidal, L; Sahin, G; Thompson, LH | 1 |
| De Deurwaerdère, P; Di Giovanni, G; Navailles, S | 1 |
| Cakmur, R; Sayın, S; Uğurel, B; Uzunel, F; Yaka, E; Yener, GG | 1 |
| Hou, JG; Lai, EC; Mehanna, R; Moore, S; Sarwar, AI | 1 |
| Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Laitman, Y; Milgrom, R; Rosset, S; Vituri, A; Yahalom, G | 1 |
| Chase, A | 1 |
| Cenci, MA | 2 |
| Akbar, U; Fayad, SM; Hack, N; Hardwick, A; Malaty, IA; McFarland, N; Monari, EH; Okun, MS; Rodriguez, RL; Romrell, J; Wagle Shukla, AA; Ward, HE | 1 |
| Ackermann, H; Graf, H; Groth, K; Kassubek, J; Riecker, A; Wurster, CD | 1 |
| Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH | 1 |
| Klivényi, P; Vécsei, L | 4 |
| Merello, M; Perez-Lloret, S | 1 |
| Dick, J; Hamdy, S; Harris, M; Kellett, M; Michou, E; Rothwell, J; Vania, A | 1 |
| Perlmutter, JS; Semrau, JA; Thoroughman, KA | 1 |
| Akbar, U; Hack, N; Hass, CJ; Roemmich, RT | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Lehnerer, SM; Messner, M | 1 |
| Bendlin, BB; Buyan-Dent, L; Christian, BT; DeJesus, OT; Gallagher, CL; Harding, SJ; Holden, JE; Li, CT; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Stone, CK | 1 |
| Alesch, F; Brücke, C; Huebl, J; Kühn, AA; Kupsch, A; Schneider, GH; Schönecker, T; Spitzer, B | 1 |
| Breit, S; Gharabaghi, A; Krüger, R; Lam, JM; Luft, AR; Wächter, T; Weiss, D | 1 |
| Ham, JH; Hong, JY; Kim, JS; Lee, I; Lee, JE; Lee, PH; Oh, JS; Sohn, YH; Sunwoo, MK | 1 |
| Lewitt, PA; Mouradian, MM | 1 |
| Kimber, TE; Schoeman, M | 1 |
| Chen, L; Li, J; Lin, P; Ran, H; Wang, C; Wang, G; Wang, Y; Zhu, C | 1 |
| Alonso, AC; D'Andréa Greve, JM; de Siqueira, JP; Luna, NM; Prota, C | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Eberly, S; Hyson, C; Jennings, D; Lang, AE; Marek, K; Oakes, D; Seibyl, J; Shoulson, I | 1 |
| Harrington, DL; Lee, D; Poizner, H; Snider, J | 1 |
| Bertram, KL; Lee, W; Louise Rushworth, R; Lubomski, M; Williams, DR | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Chakrabarty, K; Drucker-Colín, R; Garcia-Montes, JR; Herrero, MT; Heumann, R; Moratalla, R; Morelli, M; Simola, N | 1 |
| De Luka, SR; Kostić, VS; Milovanović, B; Pekmezović, T; Svetel, M | 1 |
| Bonuccelli, U; Ceravolo, R; Giuntini, M; Kiferle, L; Linsalata, G; Puccini, G; Volterrani, D | 1 |
| Hattori, N | 3 |
| Fletcher, R; Nicoletti, G; Piro, A; Quattrone, A; Tagarelli, A | 1 |
| Abdullah, R; Basak, I; Larsen, JP; Lee, S; Møller, SG; Patil, KS | 1 |
| Lettow, I; Röther, J | 1 |
| Heusser, K; Lipp, A; Noack, C; Schroeder, C | 1 |
| Caltagirone, C; Carlesimo, GA; Costa, A; Longarzo, M; Mazzù, I; Peppe, A | 1 |
| Chen, H; Huang, X; Kong, L; Lee, EY; Lewis, MM; Lucassen, EB; Sterling, NW | 1 |
| Bishop, C; Goldenberg, AA; Kampton, E; Lindenbach, D; Ostock, CY | 1 |
| Damier, P; Delval, A; Derkinderen, P; Destée, A; Meissner, WG; Negre-Pages, L; Perez-Lloret, S; Rascol, O; Schelosky, L; Tison, F | 1 |
| Antkiewicz-Michaluk, L; Kajta, M; Michaluk, J; Romańska, I; Wąsik, A | 1 |
| Carpintero, P; de Deus, T; de la Fuente-Fernandez, R; Echarri-Piudo, A; Llaneza-Gonzalez, MA; Lopez-Pazos, E; Macias-Arribi, M; Santos-Garcia, D | 1 |
| Fregly, BJ; Hass, CJ; Roemmich, RT | 1 |
| Christensen, MS; Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Rowe, JB; Siebner, HR | 1 |
| Aricò, D; Ferri, R; Figorilli, M; Marrosu, F; Puligheddu, M; Raggi, A | 1 |
| Laxton, AW; Moran, R; Tatter, SB; Witcher, M | 1 |
| Miklya, I | 1 |
| Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Argyris, P; Barla, G; Maltezou, M; Stathis, P; Tzias, V | 1 |
| Eskola, O; Järvelä, JT; Kaasinen, V; Rinne, JO | 1 |
| Lang, AE; Marras, C | 2 |
| Clarke, CE; Gray, A; Gray, R; Ives, N; Jenkinson, C; McIntosh, E; Patel, S; Rick, C; Wheatley, K; Williams, A | 1 |
| Palfreman, J | 1 |
| Di Paolo, T; Fox, S; Gasparini, F; Gomez-Mancilla, B; Kenney, C; Rascol, O | 1 |
| Auladell, C; Beas-Zarate, C; Camins, A; Canudas, AM; de Lemos, ML; Folch, J; Lazarowski, A; Pallàs, M; Pedros, I; Petrov, D | 1 |
| Fujimoto, KI; Funayama, M; Hatano, T; Hattori, N; Kubo, SI; Kunii, Y; Mata, IF; Mizuno, Y; Mori, A; Oji, Y; Oshima, H; Oyama, G; Shimo, Y; Waldherr, SM; Yabe, H; Yoshino, H; Zabetian, CP | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Giugni, JC; Okun, MS | 1 |
| Dziewas, R; Hamacher, C; Oelenberg, S; Warnecke, T | 1 |
| Badri, AV; Blaivas, JG; Purohit, RS; Skenazy, J; Weiss, JP | 1 |
| Bandak, S; Docu-Axelerad, A; Hauser, RA; Kenney, C; Kieburtz, KD; Kozyolkin, O; Lew, M; Meya, U; Neale, A; Olanow, CW; Pourcher, E; Resburg, C | 1 |
| Antonini, A; Poewe, W | 2 |
| Marinus, J; van Hilten, JJ; Zhu, K | 1 |
| Adjei, P; Akassi, J; Akpalu, A; Amboni, M; Bonetti, A; Cereda, E; Cham, M; Cilia, R; Fabbri, M; Pezzoli, G; Sarfo, FS | 1 |
| Dhawan, V; During, MJ; Eidelberg, D; Feigin, A; Kaplitt, MG; Ko, JH; Ma, Y; Mattis, PJ; Tang, CC | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Chan, P; Hallett, M; Hou, Y; Wu, T; Wu, X | 1 |
| Berganzo, K; Gómez-Esteban, JC; Lezcano, E; Somme, JH; Tijero, B; Zarranz, JJ | 1 |
| Nau, JY | 1 |
| Bee, C; Boissy, P; Duval, C; Edwards, R; Jog, M; Rahimi, F | 1 |
| Amanzio, M; Geminiani, G; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M | 1 |
| Averbeck, BB; Aviles-Olmos, I; Djamshidian, A; Foltynie, T; Lees, AJ; Limousin, P; O'Sullivan, SS; Tomassini, A; Warner, TT | 1 |
| Cardoso, MA; de Carvalho, KA; Marson, BM; Pontarolo, R; Pontes, FL; Ribeiro, RP; Vilhena, Rde O | 1 |
| Kiss, LE; Soares-da-Silva, P | 1 |
| Chabardès, S; Debû, B; Espesser, R; Ferraye, M; Fraix, V; Ghio, A; Guirchoum, J; Layani-Zemour, D; Maillet, A; Pinto, S; Pollak, P | 1 |
| Boelmans, K; Buhmann, C; Engel, AK; Gerloff, C; Gulberti, A; Hamel, W; Moll, CK; Schneider, TR; Westphal, M; Zittel, S | 1 |
| Brogan, B; Jansen, RL; Okello, EJ; Whitworth, AJ | 1 |
| Epstein, J; Hayes, MT; Lai, L; Madiedo, CJ | 1 |
| Liang, G; Tao, Y | 1 |
| Anguera-Vila, A; Calle-Pardo, A; Carriedo-Ule, D; Diez-Liebana, MJ; Fernandez-Martinez, MN; Garcia-Vieitez, JJ; Hernandez-Echevarria, L; Sahagún-Prieto, AM; Sierra-Vega, M | 1 |
| Dostrovsky, JO; Hodaie, M; Hutchison, WD; Liu, LD; Lozano, AM; Prescott, IA | 1 |
| Bastide, MF; Bezard, E; Boué-Grabot, E; Bourdenx, M; Dehay, B; Doudnikoff, E; Engeln, M; Fernagut, PO; Gross, CE; Li, Q; Pisani, A; Toulmé, E | 1 |
| Al Dakheel, A; Beaulieu-Boire, I; Fox, SH | 1 |
| Ondo, W | 1 |
| Hong, JM; Lee, JS; Lee, PH; Yong, SW; Yoon, JH | 1 |
| Fox, SH; Johnston, TM | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A | 1 |
| Eleopra, R; Onofrj, M; Uncini, A | 1 |
| Berretta, N; Bonito-Oliva, A; Cappellacci, L; Fisone, G; Ledonne, A; Mango, D; Mercuri, NB; Nisticò, R; Petrelli, R | 1 |
| Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N | 1 |
| Tomiyama, M | 1 |
| Di Paolo, T; Morin, N | 1 |
| Ellmén, J; Kieburtz, K; Kuoppamäki, M; Vahteristo, M | 1 |
| Caboche, J; Feyder, M; Fisone, G; Hansen, K; LaPlant, Q; Nestler, EJ; Santini, E; Södersten, E; Spigolon, G; Vialou, V; Watts, EL | 1 |
| Burack, MA; Giuffrida, JP; Heldman, DA; Mera, TO; Pulliam, CL | 1 |
| Bentivoglio, AR; Bernabei, R; Franceschi, F; Laudisio, A; Meloni, E; Ricciardi, D; Vetrano, DL; Zuccalà, G | 1 |
| Fox, SH; Lang, AE | 2 |
| Ahonen, A; Airaksinen, K; Luoma, J; Mäkelä, JP; Nurminen, J; Pekkonen, E; Taulu, S | 1 |
| Lohr, KM; Miller, GW | 1 |
| Chang, MH; Guo, YJ; Liao, YC; Lin, CH | 1 |
| Averbeck, BB; Aviles-Olmos, I; Djamshidian, A; Foltynie, T; Lawrence, AD; Lees, AJ; Magdalinou, N; O'Sullivan, SS; Tomassini, A; Warner, TT | 1 |
| Baumann, CR; Gassert, R; Imbach, LL; Leuenberger, K; Maier, O; Schreglmann, SR; Sommerauer, M; Uhl, M | 1 |
| Giladi, N; Goldstein, S; Gurevich, T; Hilel, A; Shapira, Y; Zlotnik, Y | 1 |
| Aerts, A; Boon, P; De Letter, M; De Taeye, L; Raedt, R; Santens, P; Van Borsel, J; van Mierlo, P; Van Roost, D; Vanhoutte, S | 1 |
| Antonini, A; Chaudhuri, KR; Dietrichs, E; Douiri, A; Kessel, B; Kozul, TK; Martin, A; Martinez-Martin, P; Odin, P; Rizos, A; Stocchi, F; Todorova, A | 1 |
| Daniels, RN; Moore, BT; Whitfield, AC | 1 |
| Beiske, AG; Kristiansen, IS; Lundqvist, C; Reiertsen, O | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Linsalata, G; Mazzucchi, S; Nicoletti, V; Ripoli, A | 1 |
| Guthikonda, LN; Lyons, KE; Pahwa, R | 1 |
| Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O | 1 |
| Eidelberg, D; Ko, JH; Lerner, RP | 1 |
| Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA | 1 |
| Bäumer, T; Buhmann, C; Gerloff, C; Heinbokel, C; Münchau, A; Niessen, E; Siebner, HR; van der Vegt, JP; Zittel, S | 1 |
| Dillmann, U; Ellenbogen, A; Gupta, S; Hsu, A; Kell, S; Khanna, S; Liang, G; Mahler, A; Rubens, R; Stocchi, F | 1 |
| Sharma, JC; Vassallo, M | 1 |
| Fox, SH; Vijverman, AC | 1 |
| Gershanik, OS | 1 |
| Berg, D; Pilotto, A; Schaeffer, E | 1 |
| Odin, P; Walter, E | 1 |
| Liu, Z; Wang, Q; Xie, C; Zhang, S | 1 |
| Ceci, R; Colamartino, M; Cozzi, R; Duranti, G; Padua, L; Sabatini, S; Santoro, M; Testa, A | 1 |
| Cai, B; Cai, JP; Chen, WJ; Lin, Y; Wang, N | 1 |
| Merello, M; Rossi, M | 1 |
| Fogel, S; Martinu, K; Monchi, O; Nagano-Saito, A | 1 |
| Cohen, AD; Liu, W; Ye, M; Zhang, N; Zhang, Y | 1 |
| Antonini, A; Bryndum, N; Calandrella, D; Chaudhuri, KR; Dafsari, HS; Ebersbach, G; Glad, A; Henriksen, T; Katzenschlager, R; Kramberger, MG; Martin, A; Martinez-Martin, P; Odin, P; Palhagen, S; Pirtosek, Z; Reddy, P; Reichmann, H; Rizos, A; Samuel, M; Storch, A; Svenningsson, P; Timmermann, L; Todorova, A; Tomantschger, V; Trost, M; Volkmann, J; Wenzel, K | 1 |
| Frampton, JE | 1 |
| Liu, Z; Ma, Y; Song, L; Wu, N; Yang, X | 1 |
| Chen, Z; Dragan, EM; Ondo, WG | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Barbosa, ER; Chien, HF; Santos, JG | 1 |
| Bloem, BR; Debû, B; Derost, P; Durif, F; Fraix, V; Krack, P; Lavenne, F; Le Bars, D; Maillet, A; Pollak, P; Redouté, J; Thobois, S | 1 |
| Azmin, S; Hashim, H; Ibrahim, NM; Manaf, MR; Razlan, H; Tan, HJ; Yahya, NW | 1 |
| Alexiou, A; Psiha, M; Vlamos, P | 1 |
| Banou, E | 1 |
| Deng, MZ; Fang, YQ; He, YP; Huang, LP | 1 |
| Bastide, MF; Bézard, E; Boraud, T; de la Crompe, B; Doudnikoff, E; Fernagut, PO; Gross, CE; Mallet, N | 1 |
| Boroojerdi, B; Ghys, L; Giladi, N; Jankovic, J; Surmann, E | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| LeWitt, PA | 12 |
| Borgkvist, A; Mosharov, EV; Sulzer, D | 1 |
| Hasegawa, K; Hattori, N; Kondo, T; Mizuno, Y; Murata, M; Nomoto, M; Takahashi, M; Takeuchi, M; Tomida, T | 1 |
| Berardelli, A; Bloise, MC; Colosimo, C; Defazio, G; Di Biasio, F; Fabbrini, G; Latorre, A | 1 |
| Claassen, DO; Harrison, MB; Kanoff, K; Neimat, JS; van den Wildenberg, WP; van Wouwe, NC; Wylie, SA | 1 |
| Borden, A; Bourre, B; Brun, L; Derrey, S; Fetter, D; Lefaucheur, R; Maltête, D; Wallon, D | 1 |
| Di Luca, M; Gardoni, F | 1 |
| Amalric, M | 1 |
| Bicho, E; Fernandes, V; Ferreira, J; Gago, MF; Rocha, L; Rodrigues, ML; Silva, H; Sousa, N | 1 |
| Caulfield, J; Chung, I; Doty, RL; Dubroff, J; Duda, JE; Hurtig, H; Leon-Sarmiento, FE; Nsoesie, MT; Osman, A; Pawasarat, I; Silas, J; Tekeli, H; Ying, GS | 1 |
| Bautista, A; Haider, JM; Pagano, G; Tagliati, M; Tan, EE | 1 |
| Dolbert, T; Frankemolle, AM; McIntyre, CC; Noecker, AM; Shamir, RR; Walter, BL | 1 |
| Agnati, LF; Borroto-Escuela, DO; Fuxe, K; Guidolin, D | 1 |
| Augustine, EF; Christine, CW; Dewey, RB; Dhall, R; Mari, Z; Pérez, A; Schneider, JS; Simon, DK; Suchowersky, O; Umeh, CC; Wills, AM | 1 |
| Lees, AJ; Olanow, CW; Tolosa, E | 1 |
| Fahn, S; Poewe, W | 1 |
| Aquino, CC; Fox, SH | 1 |
| Beaulieu-Boire, I; Lang, AE | 1 |
| Ács, P; Aschermann, Z; Bosnyák, E; Deli, G; Janszky, J; Komoly, S; Kovács, N | 1 |
| Azulay, JP; Burle, B; Deveaux, M; Eusebio, A; Fluchère, F; Hasbroucq, T; van den Wildenberg, WP; Vidal, F; Witjas, T | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Mazzoni, P; Sharp, ME | 1 |
| Hauser, RA | 6 |
| Campisi, G; De Caro, V; Giannola, LI; Scaturro, AL | 1 |
| Aminoff, MJ; Bodis-Wollner, I; Boyd, JT; Christine, CW; Dhall, R; Fang, JY; Goudreau, JL; Leehey, M; Morgan, JC; Nicholas, AP; Pérez, A; Zweig, RM | 1 |
| Benesh, JA; Chatamra, K; Chouinard, S; Dubow, J; Espay, AJ; Fernandez, HH; Fung, VS; Hall, CM; Hauser, RA; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Standaert, DG; Steiger, M; Suchowersky, O; Yakupov, EZ | 1 |
| Hamer, H; Heilmaier, C; Kostev, K; Mueller, UO; Oertel, WH; Reese, JP; Strzelczyk, A | 1 |
| Burn, DJ; Galna, B; Lord, S; Rochester, L | 1 |
| Aguiar, AS; Bortolanza, M; Del-Bel, E; Padovan-Neto, FE; Prediger, RD; Raisman-Vozari, R; Tumas, V | 1 |
| Bunjes, F; Gharabaghi, A; Govindan, RB; Klotz, R; Krüger, R; Meisner, C; Naros, G; Plewnia, C; Ramos-Murguialday, A; Scholten, M; Weiss, D | 1 |
| Ba, M; Kong, M; Ma, G | 1 |
| Anticoli, S; De Pandis, MF; Fiore, S; Persichino, L | 1 |
| Chang, FC; Drury, M; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Mahant, N; Tsui, DS; Wolfe, N | 1 |
| Antonini, A; Konitsiotis, S; Stathis, P | 1 |
| Calcagno, M; Castelli, F; Contado, C; Cortesi, R; Di Stefano, A; Drechsler, M; Esposito, E; Giuffrida, MC; Longo, F; Morari, M; Ravani, L; Sarpietro, MG; Sozio, P | 1 |
| Čmejla, R; Klempíř, J; Roth, J; Rusz, J; Růžička, E; Růžičková, H; Tykalová, T | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Preda, C; Yegin, A | 1 |
| Cai, M; Chen, S; Cheng, Y; Hu, J; Li, J; Liu, C; Qu, Q; Wang, J; Wang, Z; Zhang, B; Zhang, X; Zhang, Z; Zhu, R | 1 |
| Benesh, J; Chatamra, K; Dubow, J; Eaton, S; Fernandez, HH; Hall, C; Slevin, JT; Zadikoff, C | 1 |
| Kretova, AS; Lyubimov, AV | 1 |
| Hirayama, M; Ohno, K; Tsuda, T; Tsunoda, M | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F | 1 |
| Ferracin, M; Klein, C; Marz, M | 1 |
| Blankenburg, H; Cortelli, P; Domingues, FS; Facheris, MF; Foco, L; Giannini, G; Hicks, AA; Picard, A; Pichler, I; Pramstaller, PP; Schwienbacher, C; Serafin, A; Zanigni, S; Zanon, A | 1 |
| Baracchi, F; Bassetti, CL; Galati, S; Kaelin-Lang, A; Möller, JC; Pace, M; Salvadè, A; Sarasso, S; Städler, C; Stanzione, P | 1 |
| Alves, G; Forsaa, EB; Larsen, JP; Wentzel-Larsen, T | 1 |
| Azevedo, LL; Cardoso, F; Oliveira, PM; Souza, IS | 1 |
| Rudakova, AV; Yakupov, EZ | 1 |
| Chen, H; Fang, J; Feng, T; Gao, L; Li, F | 1 |
| Timofeeva, AA | 1 |
| Barlow, SM; Chu, SY; Lee, J | 1 |
| Allendorfer, JB; Banks, C; Dwivedi, A; Eliassen, JC; Espay, AJ; Fleck, DE; Lang, AE; Linke, MJ; Norris, MM; Smith, MS; Szaflarski, JP | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Aho, V; Christopher, S; Ellmén, J; Haukka, J; Hoti, F; Korhonen, P; Kuoppamäki, M; Prami, T; Pukkala, E; Vahteristo, M | 1 |
| Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Amboni, M; Barone, P; Chaudhuri, KR; Erro, R; Longo, K; Martinez-Martin, P; Moccia, M; Pellecchia, MT; Picillo, M; Santangelo, G; Vitale, C | 1 |
| Björklund, A; Brooks, DJ; Hart, T; Loane, C; Odin, P; Piccini, P; Politis, M; Smith, R; Wu, K | 1 |
| Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Ayton, S; Bertram, KL; Cheshire, P; Finkelstein, DI; Halliday, GM; Li, A; Ling, H; McLean, C; O'Sullivan, SS; Revesz, T; Storey, E; Williams, DR | 1 |
| Hauser, RA; Isaacson, S; McClure, NL; Pahwa, R; Ruby, AE; Sethi, K; Stempien, MJ; Struck, L; Tanner, CM; Truong, D; Went, GT | 1 |
| Hasegawa, T | 1 |
| Kenney, C; Landrian, A; Lenderking, WR; Mannix, S; Petrillo, J; Schrag, AE | 1 |
| Carro, J; Gómez Íñiguez, C; López, DE; López-Alburquerque, T; Martínez-Sánchez, F; Meilán, JJ; Millian-Morell, L; Pujante Valverde, IM | 1 |
| Antonutti, L; Biolo, G; Bursomanno, A; Catalan, M; Cucca, A; Di Girolamo, FG; Gigli, GL; Koscica, N; Mazzucco, S; Pizzolato, G | 1 |
| Ding, Y; Hitchcock, SA; Kang, UJ; Lim, SAO; McGehee, DS; Ray, WJ; Won, L; Xia, R | 1 |
| Alirezaei, M; Dezfoulian, O; Khoshdel, Z; Rashidipour, M; Taghadosi, V | 1 |
| Bezard, E; Carta, M | 2 |
| Af Edholm Arvidsson, K; Björklund, A; Keywood, C; Lowe, DA; Rosenblad, C; Shankar, B; Svenningsson, P; Wictorin, K; Widner, H | 1 |
| Berganzo, K; Gomez-Esteban, JC; Kaufmann, H; Martinez, J; Norcliffe-Kaufmann, L; Palma, JA; Tijero, B | 1 |
| Buhmann, C; Deuschl, G; Margraf, NG; Munser, S; Oehlwein, C; Schulz-Schaeffer, WJ; Wrede, A | 1 |
| Niccolini, F; Politis, M; Rocchi, L | 1 |
| Abbruzzese, G; Antonini, A; Attar, M; Barone, P; Bellia, G; Colombo, D; Franconi, F; Haggiag, S; Simoni, L; Stocchi, F; Zagni, E | 1 |
| Cannas, A; Marrosu, F; Orofino, G; Solla, P | 1 |
| Fahn, S; Kestenbaum, M | 1 |
| Berg, D; Liepelt-Scarfone, I; Maetzler, W; Reilmann, R; Sass, C; Schaeffer, E | 1 |
| Aschermann, Z; Bereczki, D; Dézsi, L; Dibó, G; Klivényi, P; Komoly, S; Kovács, N; Nagy, H; Takáts, A; Tóth, A; Valikovics, A; Varannai, L; Vécsei, L; Zemlényi, G | 1 |
| Agari, T; Date, I; Kameda, M; Yasuhara, T | 1 |
| Abrams, MB; Galter, D; Gellhaar, S; Marcellino, D | 1 |
| Nutt, JG | 16 |
| Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Fasano, A; Lang, AE; Liu, LW; Poon, YY | 1 |
| Berkels, R; Grieger, F; Lauterbach, T; Lorenzl, S; Sieb, JP; Themann, P; Warnecke, T | 1 |
| Deshmukh, R; Sharma, S; Sharma, V; Singh, S; Singh, VP | 1 |
| Doyu, M; Ibi, T; Niwa, J; Taguchi, S | 1 |
| Liu, Z; Sakakibara, R; Uchiyama, T; Yamamoto, T | 1 |
| Castiello, U; Scaravilli, T; Straulino, E | 2 |
| Azulay, JP; Bardyn, T; Bordet, R; Brefel-Courbon, C; Corvol, JC; Debû, B; Defebvre, L; Delval, A; Destée, A; Devedjian, JC; Devos, D; Drapier, S; Duhamel, A; Dujardin, K; Durif, F; Eusebio, A; Faighel, M; Fraix, V; Giordana, C; Guehl, D; Houeto, JL; Labreuche, J; Lagha-Boukbiza, O; Maltête, D; Meguig, S; Moreau, C; Ory-Magne, F; Petyt, G; Rascol, O; Rouaix, N; Sablonnière, B; Saulnier, PJ; Tison, F; Tranchant, C; Vasseur, F; Vidailhet, M | 1 |
| Alatriste-Booth, V; Camacho-Ordoñez, A; Cervantes-Arriaga, A; Rodríguez-Violante, M | 1 |
| Albanese, A; Bagella, CF; Calandrella, D; Del Sorbo, F; Elia, AE; Falsitta, M; Romito, LM | 1 |
| Li, J; Li, Y; Zhang, Y | 1 |
| Braithwaite, SP; Dyavar Shetty, BL; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Voronkov, M; Woo, JM | 1 |
| Fung, VS | 1 |
| Alexoudi, A; Deuschl, G; Knudsen, K; Mehdorn, M; Shalash, A; Volkmann, J; Witt, K | 1 |
| Akram, H; Angeli, A; Foltynie, T; Hariz, M; Limousin, P; Zacharia, A; Zrinzo, L | 1 |
| Bauer, L; Chung, SJ; Ikeda, J; Jeon, BS; Kim, JM; Kim, JW; Singh, P; Thierfelder, S | 2 |
| Chen, C; Cowles, VE; Stover, N; Sweeney, M; Verhagen Metman, L | 1 |
| Cavanaugh, JT; Dibble, LE; Earhart, GM; Ellis, TD; Ford, MP; Foreman, KB | 1 |
| Bankiewicz, K; Beyer, J; Ciesielska, A; Forsayeth, J; Sharma, N | 1 |
| Johnson, L; Mastaglia, F; Rodrigues, J; Stell, R; Teo, WP; Thickbroom, G; Walters, S | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CR; Schneider Medeiros, M; Schumacher-Schuh, AF | 1 |
| Benesh, J; Chatamra, K; Dutta, S; Mohamed, ME; Nagai, M; Othman, AA; Yanagawa, M | 1 |
| Fahn, S | 15 |
| Debilly, B; Derost, P; Durif, F; Fantini, ML; Lemaire, JJ; Marques, A; Morand, D; Pereira, B; Ulla, M | 1 |
| Gambini, O; Islam, L; Piacentini, S; Scarone, S; Soliveri, P | 1 |
| Brown, P; Cagnan, H; Duff, EP | 1 |
| Carlsson, T; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Oertel, WH; Schäfer, MK; Weihe, E | 1 |
| Dzyak, L; Gupta, S; Hsu, A; Kell, S; Khanna, S; Nausieda, P; Rudzinska, M; Silver, DE; Spiegel, J; Tsurkalenko, ES; Waters, CH | 1 |
| Huettner, DP; Kortagere, S; Simms, SL | 1 |
| Lithgow, BJ; Shoushtarian, M | 1 |
| Abbruzzese, G; Amboni, M; Antonini, A; Attar, M; Barone, P; Colombo, D; Morgante, L; Onofrj, M; Ori, A; Ruggieri, S; Simoni, L; Stocchi, F; Tinazzi, M; Zappia, M | 1 |
| Bardinet, E; Belaid, H; Czernecki, V; Demain, A; El Helou, A; Ewenczyk, C; François, C; Grabli, D; Karachi, C; Lau, B; Welter, ML; Yelnik, J | 1 |
| Bezard, E; Carta, M; Chuan, Q; Fidalgo, C; Ko, WK; Li, Q; Stancampiano, R; Tronci, E | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
| Chen, B; Hou, Y; Wu, T; Zhang, J | 1 |
| Dunckley, ED; Meng, L; Xu, X | 1 |
| Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM | 1 |
| Hanna-Pladdy, B; Lyons, KE; Pahwa, R | 1 |
| Fukaya, C; Yamamoto, T | 1 |
| Antonini, A; Cossu, G; Mancini, F; Melis, M; Mereu, A; Murgia, D; Pilleri, M; Ricchi, V; Ricchieri, G | 1 |
| Fernández-Bobadilla, R; Gironell, A; Kulisevsky, J; Martínez-Horta, S; Pagonabarraga, J; Pascual-Sedano, B; Pérez-Pérez, J; Sierra, S | 1 |
| Barrios-Barrios, A; Bustamante-Balén, M; del-Hoyo-Francisco, J; Martínez-Torres, I; Pons-Beltrán, V; Satorres-Paniagua, C | 1 |
| Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR | 1 |
| Pradhan, S; Tandon, R | 1 |
| Johnson, KE | 1 |
| Chen, J; Chen, YH; Lin, HZ; Lin, SY; Pa, JL; Wang, WW; Wang, XD; Xie, CL; Zhang, YY | 1 |
| Fukae, J; Fukuhara, K; Hatano, T; Hattori, N; Higuchi, MA; Kashihara, K; Okuma, Y; Ouma, S; Tsuboi, Y; Tsugawa, J; Yanamoto, S; Yoritaka, A | 1 |
| Hornykiewicz, O | 10 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F | 1 |
| Ding, J; Jiang, S; Tong, Q; Xu, Q; Yuan, Y; Zhang, K; Zhang, L; Zhang, R | 1 |
| Calabresi, P; Corbelli, I; Ghiglieri, V; Mazzocchetti, P; Picconi, B | 1 |
| Eggers, C; Eidelberg, D; Fink, GR; Holtbernd, F; Kracht, L; Ma, Y; Peng, S; Schwartz, F; Tang, CC; Timmermann, L | 1 |
| Chiou, SM | 2 |
| Ahmed, MR; Bychkov, E; Gurevich, EV; Gurevich, VV; Li, L | 1 |
| Baumann, CR; Epprecht, L; Goetze, O; Schreglmann, SR; Waldvogel, D; Woitalla, D | 1 |
| Benninger, F; Djaldetti, R; Keret, O; Khlebtovsky, A; Melamed, E; Roditi, Y; Steiner, I | 1 |
| Benedetti, A; Gros, P; Kaminska, M; Kimoff, RJ; Lafontaine, AL; Mery, VP; Robinson, A | 1 |
| Altavista, MC; Brusa, L; Di Girolamo, S; Di Mauro, R; Moleti, A; Pisani, A; Pisani, V; Sisto, R; Stanzione, P | 1 |
| Cannas, A; Fasano, A; Lang, AE; Marrosu, F; Marrosu, MG; Mulas, CS; Solla, P | 1 |
| Chiou, SM; Huang, HM; Lin, YC | 1 |
| Counsell, CE; Macleod, AD; Scott, NW | 1 |
| Bjerre, LM; Crispo, JA; Emons, M; Fortin, Y; Kohen, DE; Krewski, D; Mattison, D; Perez-Lloret, S; Thibault, DP; Willis, AW | 1 |
| Dam-Larsen, S; Darkahi, B; Glad, A; Gleditsch, D; Gustavsson, L; Halttunen, J; Johansson, KE; Pischel, A; Reiertsen, O; Törnqvist, B; Zebski, H | 1 |
| Bellante, F; Dethy, S; Zegers de Beyl, D | 1 |
| Bäckman, CM; Cadet, JL; Chiang, YH; Diaz, O; Hoffer, BJ; Ladenheim, B; Olson, L; Shan, L; Zhang, Y | 1 |
| Carlson-Kuhta, P; Curtze, C; Horak, FB; Mancini, M; Nutt, JG | 2 |
| Bruno, E; Cicero, CE; Contrafatto, D; Dibilio, V; Giuliano, L; Luca, A; Mostile, G; Nicoletti, A; Pappalardo, I; Raciti, L; Sciacca, G; Sofia, V; Zappia, M | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Berendse, HW; Burgers-Bots, IA; Collette, EH; de Goede, CJ; Ghielen, I; Houniet-de Gier, M; Kwakkel, G; Rutten, S; van den Heuvel, OA; van Vliet, B; van Wegen, EE; Vermunt, K | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Burchiel, KJ; Carlson-Kuhta, P; Horak, FB; King, LA; St George, RJ | 1 |
| Bizzarri, BM; Botta, G; Rotelli, L; Saladino, R; Tortolini, S | 1 |
| Acs, P; Bokor, M; Bosnyák, E; Deli, G; Dibó, G; Herceg, M; Hidasi, E; Horvath, K; Imre, P; Késmárki, I; Klivényi, P; Komoly, S; Kovács, N; Lajtos, J; Nagy, F; Pál, E; Rigó, E; Takács, K; Takáts, A; Tóth, A; Vécsei, L | 1 |
| Cao, ZH; Chen, HX; Ding, ZG; Song, JH; Zhang, GB; Zhou, PY | 1 |
| Cavanagh, JF; Chen, KH; Kingyon, JR; Narayanan, NS; Parker, KL | 1 |
| Bastos Lima, A; Cavaco, S; Damásio, J; Fernandes, J; Gonçalves, A; Mendes, A; Moreira, I; Teixeira-Pinto, A; Vila-Chã, N | 1 |
| Guan, R; Staisch, J; Towle, VL; Warnke, P; Xie, T | 1 |
| Barichella, M; Canesi, M; Cassani, E; Cavanna, F; Cazzola, R; Cereda, E; Cestaro, B; Iorio, L; Natuzzi, F; Pezzoli, G; Pinelli, G; Pusani, C | 1 |
| Ahn, S; Rubchinsky, LL; Witt, T; Worth, RM; Zauber, SE | 1 |
| de Boer, AH; Dijkstra, H; Frijlink, HW; Grasmeijer, F; Hagedoorn, P; Luinstra, M; Rutgers, AW; Vogelzang, JM | 1 |
| Chaote, P; Dewhurst, F; Dotchin, CL; Gray, WK; Massawe, J; Walker, RW | 1 |
| Ahmad, A; Berg, D; deBoni, L; Fröhlich, H; Kaut, O; Khazneh, H; Klein, C; Schmitt, I; Wüllner, U | 1 |
| Logroscino, G | 1 |
| Calandra-Buonaura, G; Chiari, L; Contin, M; Cortelli, P; Lopane, G; Mellone, S | 1 |
| Benesh, JA; Chatamra, K; Fernandez, HH; Standaert, DG | 1 |
| Flisar, D; Kojovic, M; Kramberger, MG; Pirtosek, Z; Zorko, N | 1 |
| Foltynie, T; Georgiev, D; Huang, YT; Jahanshahi, M; Limousin, P; Speekenbrink, M | 1 |
| Endo, T; Nakazawa, M; Ohnishi, H; Okawa, S; Sanpei, Y; Sugawara, M | 1 |
| Chammas, C; Soghomonian, JJ; Zhang, K | 1 |
| Baybas, S; Dirican, A; Dogan, GB; Dogan, VB; Koksal, A | 1 |
| Chiaravalloti, A; Galati, S; Lauretti, B; Olivola, E; Pierantozzi, M; Pisani, V; Prosperetti, C; Rocchi, C; Schillaci, O; Stampanoni Bassi, M; Stefani, A | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Alcacer, C; Angela Cenci, M; Bastide, MF; Bézard, E; Bourdenx, M; Brambilla, R; Carta, M; Crossman, AR; De Deurwaerdère, P; Ding, Y; Engeln, M; Fasano, S; Fernagut, PO; Feyder, M; Fisone, G; Fox, S; Francardo, V; Gardoni, F; Groc, L; Guehl, D; Gurevich, EV; Jon Stoessl, A; Kang, UJ; Ko, WK; Meissner, WG; Mellone, M; Morari, M; Morelli, M; Navailles, S; Picconi, B; Quik, M; Rodriguez, MC; Simola, N; Steece-Collier, K; Tison, F; Tronci, E | 1 |
| Nyholm, D; Nyman, R; van Laar, T | 1 |
| Habersack, A; Haehner, A; Hummel, T; Reichmann, H; Storch, A; Wienecke, M | 1 |
| Wictorin, K; Widner, H | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G | 2 |
| Hietala, M; Kaasinen, V; Kuoppamäki, M | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M; Rajput, A; Rajput, AH | 2 |
| Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sharabi, Y; Sidransky, E; Stefani, A; Sullivan, P | 1 |
| Chang, JW; Chang, WS; Jung, HH; Kim, JH | 1 |
| Dutta, D; Mohanakumar, KP | 1 |
| Arabia, G; Augimeri, A; Cerasa, A; Donzuso, G; Mangone, G; Morelli, M; Passamonti, L; Quattrone, A; Salsone, M | 1 |
| Johansson, A; Linder, J; Memedi, M; Nyholm, D; Pålhagen, S; Westin, J; Widner, H; Willows, T | 1 |
| Ferreira, JJ; Perez-Lloret, S; Rascol, O | 1 |
| Bicho, E; Costa, L; Fernandes, V; Gago, MF; Gago, NF; Rocha, L; Rodrigues, ML; Silva, H; Sousa, N; Yelshyna, D | 1 |
| Benetin, J; Hanakova, M; Harsany, J; Martinkova, J; Minar, M; Singliarova, H; Valkovic, P | 1 |
| Chieng, LO; Madhavan, K; Wang, MY | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Ham, JH; Kim, JS; Lee, DH; Lee, I; Lee, JJ; Lee, PH; Oh, JS; Sohn, YH | 1 |
| Rossi, S; Ulivelli, M | 1 |
| Antonini, A; Chaudhuri, KR; Fox, K; Fox, T; Honig, H; Martinez-Martin, P; Odin, P; Timpka, J | 1 |
| Connor, J; Du, G; Huang, X; Kong, L; Lewis, MM; Liu, T; Mailman, RB; Wang, Y | 1 |
| Lee, KE; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Elfmarková, N; Gajdoš, M; Mekyska, J; Mikl, M; Mračková, M; Rektorová, I | 1 |
| Fernandez, HH | 3 |
| Rajput, A; Rajput, AH; Rajput, ML; Robinson, CA | 1 |
| Amernik, K; Gołąb-Janowska, M; Honczarenko, K; Nowacki, P; Pawlukowska, W; Rotter, I; Safranow, K | 1 |
| Clarke, CE; Muzerengi, S | 2 |
| Chen, HM; Fang, JP; Feng, T; Gao, LY; Hou, YN; Ma, LY; Wang, ZJ; Wu, T; Zhang, JR | 1 |
| Bajwa, JA; Bhidayasiri, R; Chen, RS; Hattori, N; Jamora, RD; Jeon, B; Lee, MK; Mok, VC; Pisarnpong, A; Poewe, W; Syamsudin, T; Tan, LC; Zhang, B | 1 |
| Li, ZJ; Wu, Q; Yi, CJ | 1 |
| Asahina, M; Higuchi, Y; Hirano, S; Kuwabara, S; Uchiyama, T; Yamamoto, T; Yamanaka, Y | 1 |
| Bryant, MS; Collins, RL; Hou, JG; Protas, EJ; Rintala, DH | 1 |
| Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M | 1 |
| Hamasaki, T; Kuratsu, J; Shinojima, N; Yamada, K | 1 |
| Adrien, J; Belaid, H; François, C; Hirsch, EC; Karachi, C | 1 |
| Aquino, CC; Beaulieu-Boire, I; Fox, SH; Lui, JP; Mestre, TA; Phielipp, N; Poon, YY; So, J | 1 |
| Morimoto, Y; Terashima, S; Watabe, A; Yamane, M; Yanagido, Y | 1 |
| Mick, D; Resan, B; Segec, I; Skelac, D; Soldo, SB; Tomic, S | 1 |
| Bezdíček, O; Brožová, H; Dušek, P; Hoskovcová, M; Jech, R; Roth, J; Růžička, E; Sieger, T; Šprdlík, O; Štochl, J; Zárubová, K | 1 |
| Bloem, BR; Borm, GF; Haaxma, CA; Horstink, MW; Lemmens, WA; Zijlmans, JC | 1 |
| Elmer, L; Gil, RA; Gupta, S; Hsu, A; Kell, S; Khanna, S; Modi, NB; Nausieda, PA; Rubens, R; Singer, C; Spiegel, J | 1 |
| Cannas, A; Fasano, A; Marrosu, F; Solla, P | 1 |
| de Boer, AH; Frijlink, HW; Grasmeijer, F; Hagedoorn, P; Luinstra, M; Moes, JR | 1 |
| Dufek, J; Grambalova, Z; Kaiserova, M; Kanovsky, P; Mensíkova, K; Otruba, P; Vastik, M; Zapletalova, J | 1 |
| Chen, H; Guo, Y; Hao, H; Jia, F; Li, L; Wan, S; Zhang, J | 1 |
| Aiba, Y; Doi, H; Kishi, M; Masaka, T; Ogata, T; Sakakibara, R; Sato, M; Shiina, S; Tateno, F; Tateno, H; Tsuyusaki, Y | 1 |
| Toal, M | 1 |
| Abbruzzese, G; Barone, P; Bentivoglio, A; Canesi, M; Cannas, A; Ceravolo, R; Cossu, G; Dallocchio, C; Defazio, G; Fabbrini, G; Fasano, A; Geroin, C; Marconi, R; Mirandola, R; Modugno, N; Morgante, F; Pacchetti, C; Pisani, A; Rossi, S; Tamma, F; Thomas, A; Tinazzi, M; Vitale, C; Volontè, MA; Zappia, M | 1 |
| Galifianakis, NB; Katz, M; Larson, PS; Luciano, MS; Markun, LC; Martin, AJ; Ostrem, JL; Racine, CA; Starr, PA; Ziman, N | 1 |
| Bernardini, A; Cocito, D; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Blomstedt, P; Hägglund, P; Johansson, L; Karlsson, F; Sandström, L | 1 |
| Delooze, C; Ghio, A; Grigoli, C; Mas, M; Mercier, C; Robert, D; Viallet, F | 1 |
| Capece, R; Hauser, RA; Hewitt, D; Ho, TW; Huyck, SB; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F | 1 |
| Fedorova, NV; Gubanova, ЕN; Kulua, TK | 1 |
| Altunbaev, RA; Yakovleva, LA; Zalyalova, ZA | 1 |
| Titova, NV | 1 |
| Chan, P; Feng, T; Hallett, M; Hou, Y; Wu, T; Zhang, J | 1 |
| Alexander, SA; Gopalakrishna, A | 1 |
| Elrington, GM | 1 |
| Braithwaite, R | 1 |
| Ardolino, G; Bianchi, M; Bocci, T; Borroni, B; Cogiamanian, F; Cortese, F; Di Fonzo, A; Ferrucci, R; Padovani, A; Pittera, D; Priori, A; Turrone, R; Vergari, M | 1 |
| Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P | 1 |
| Baas, H; Gerlach, M; Kassubek, J; Müller, T; Reichmann, H; Riederer, P; Schrader, C; Urban, PP; Woitalla, D | 1 |
| Beaudoin-Gobert, M; Sgambato-Faure, V; Tremblay, L | 1 |
| Chaudhuri, KR; Ferdousi, M; Gosal, D; Javed, S; Jeziorska, M; Kass-Iliyya, L; Kobylecki, C; Malik, RA; Marshall, A; Petropoulos, IN; Ponirakis, G; Silverdale, MA; Tavakoli, M | 1 |
| Bloem, BR; de Bie, RM; de Haan, RJ; Deuschl, G; Dijkgraaf, M; Lang, AE; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CV | 1 |
| Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB | 1 |
| Boelmans, K; Buhmann, C; Engel, AK; Gerloff, C; Gulberti, A; Hamel, W; Koeppen, JA; Moll, CK; Schneider, TR; Westphal, M; Zittel, S | 1 |
| Hauser, RA; Seeberger, LC | 2 |
| Albuquerque, L; Coelho, M; Ferreira, JJ; Guedes, L; Martins, IP; Martins, M; Rosa, M | 1 |
| Abou Al-Shaar, H; Al-Ajlan, F; Alkahtani, K; Alkhairallah, T; Bohlega, S; Hasan, N | 1 |
| Cooper, JA; Johnston, K; Kerr, C; Kosmas, CE; Lloyd, AJ; Lloyd, EJ; McIntosh, E; Smith, HT | 1 |
| Antonini, A; Vorovenci, RJ | 1 |
| Mao, ZL; Modi, NB | 1 |
| Antke, C; Hautzel, H; Mueller, HW; Nikolaus, S | 1 |
| Fang, S; Gong, Z; Qian, L; Yan, Y | 1 |
| Tan, LC; Zhang, J | 1 |
| Bonuccelli, U; Ceravolo, R; Del Prete, E; Rossi, C | 1 |
| Horvath, S; Ritz, BR | 1 |
| Antonini, A; Kimber, T | 1 |
| Akram, H; Anzak, A; Ashkan, K; Aziz, T; Brown, P; Foltynie, T; Gill, SS; Green, AL; Javed, S; Khan, S; Limousin, P; Pogosyan, A; Tan, H; Zrinzo, L | 1 |
| Greig, SL; McKeage, K | 1 |
| Benesh, JA; Boyd, JT; Chatamra, K; Chouinard, S; Draganov, PV; Dubow, J; Eaton, S; Espay, AJ; Fasano, A; Fernandez, HH; Fung, VS; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Rodriguez, RL; Schmulewitz, N; Slevin, JT; Stein, DA; Zadikoff, C | 1 |
| Băjenaru, O; Buraga, I; Constantinescu, A; Ene, A; Mureşan, DF; Perju-Dumbrava, L; Popescu, BO; Popescu, CD; Sabău, M; Simu, M; Szász, JA | 1 |
| Stoessl, AJ | 2 |
| Adams, JR; Boileau, I; Furukawa, Y; Guttman, M; Houle, S; Kish, SJ; Payer, DE; Rusjan, P; Tong, J; Wilson, AA | 1 |
| Devos, D; Moreau, C | 1 |
| Bereczki, D; Nagy, H; Takáts, A; Toth, A; Wacha, J | 1 |
| Carrault, G; Jalloul, N; L'Hostis, P; Porée, F; Viardot, G | 1 |
| Karjalainen, PA; Pekkonen, E; Rissanen, SM; Ruonala, V; Tarvainen, MP | 1 |
| Bonato, P; Daneault, JF; Golabchi, FN; Lee, SI; Paganoni, S; Patel, S; Shih, L | 1 |
| Baptista, AM; Barbieri, FA; Beretta, VS; Gobbi, LT; Lirani-Silva, E; Orcioli-Silva, D; Polastri, PF; Simieli, L | 1 |
| Alegre-Abarrategui, J; Bannerman, DM; Bolam, JP; Brimblecombe, K; Cioroch, M; Connor-Robson, N; Cragg, SJ; Deltheil, T; Dodson, PD; Exley, R; Kaufmann, AK; Magill, PJ; Potgieter, D; Sloan, M; Threlfell, S; Wade-Martins, R; Wallings, R | 1 |
| Carta, M; Cenci, MA | 1 |
| Altunkaynak, Y; Baybas, S; Dirican, AC; Köksal, A; Mutluay, B; Vieru, E | 1 |
| Livi, L; Sadeghian, A; Sadeghian, H | 1 |
| Nicoletti, A; Zappia, M | 2 |
| Disse, M; Lee, PK; Reich, H; Schram, SS | 1 |
| Bharath, RD; Jha, M; Jhunjhunwala, K; Lenka, A; Naduthota, RM; Pal, PK; Panda, R; Prajapati, A; Saini, J; Yadav, R | 1 |
| Chang, FC; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Kwan, V; Mahant, N; Tsui, D; van der Poorten, D; Wolfe, N | 1 |
| Baeken, C; Cordenier, A; De Keyser, J; De Raedt, S; Flamez, A; Michiels, V; Parys, E; Smetcoren, S; Van Merhaegen-Wieleman, A | 1 |
| Broussolle, E; Mollion, H; Thobois, S; Ventre-Dominey, J | 1 |
| Lake, WB; Saleh, S; Sillay, KA; Swanson, KI | 1 |
| Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J | 1 |
| Ito, H; Koh, J; Kondo, T; Nagashima, Y; Sakata, M | 1 |
| Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT | 1 |
| Arena, JE; Cerquetti, D; Chaves, H; Dossi, DE; Merello, M; Rollan, C; Rossi, M | 1 |
| Du, N; Guo, Z; Han, M; Huang, Y; Liu, J; Xu, S | 1 |
| Castiñeira Perez, A; Domínguez-Muñoz, JE; Iglesias Canle, J; Parada Gonzalez, P; Uribarri González, L | 1 |
| Jankovic, J; Lotia, M | 1 |
| Kashihara, K; Maeda, T; Mishima, T; Nakashima, K; Nomura, T; Takigawa, H; Tsuboi, Y | 1 |
| Alcaine, S; Annicchiarico, R; Bayes, A; Browne, P; Cabestany, J; Costa, A; Counihan, TJ; Laighin, GÓ; Lewy, H; Mestre, B; Moreno-Aróstegui, JM; Pérez-López, C; Quinlan, LR; Quispe, P; Rodríguez-Martín, D; Rodríguez-Molinero, A; Samà, A; Sweeney, D | 1 |
| Berg, D; Gräber, S; Jäger, G; Przybilski, T; Rommel, O; Schybek, K; Wejwer, D | 1 |
| Čmejla, R; Klempíř, J; Rusz, J; Růžička, E; Tykalová, T | 1 |
| Fazel Nabavi, S; Modak, B; Rastrelli, L; Sobarzo-Sánchez, E; Uriarte, E | 1 |
| Atlas, D | 1 |
| Benussi, A; Brusa, L; Caltagirone, C; Di Lorenzo, F; Koch, G; Picazio, S; Ponzo, V | 1 |
| Cervantes-Arriaga, A; Millán-Cepeda, R; Morales-Briceño, H; Neri-Nani, G; Rodríguez-Violante, M; Velázquez-Osuna, S | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Bang, JI; Jung, IS; Kim, SE; Lee, BC; Moon, BS; Park, HS; Song, YS | 1 |
| Fülöp, F; Majláth, Z; Toldi, J; Vécsei, L | 1 |
| Alty, JE; Clissold, BG; Ding, C; Ganesvaran, G; Kempster, PA; McColl, CD; Reardon, KA; Schiff, M; Srikanth, V | 1 |
| Mueller, BK; Muhlack, S; Müller, T; Trommer, I | 1 |
| Cheng, LG; Du, LJ; Gao, J; He, W; Li, S | 1 |
| Bardinet, E; Burkhard, P; Chabardes, S; Combescure, C; Fleury, V; Gere, J; Krack, P; Krainik, A; Momjian, S; Pollak, P; Romito, L; Tommasi, G; Yelnik, J | 1 |
| Bonizzoni, E; Cattaneo, C; Sardina, M | 1 |
| Jimenez-Shahed, J | 1 |
| Barbon, A; Bono, F; Busi, C; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Kianirad, Y; Simuni, T | 1 |
| Piccini, P; Politis, M; Roussakis, AA; Towey, D | 1 |
| Cerasa, A; Dileone, M; Obeso, I; Quattrone, A | 1 |
| Azulay, JP; Boulamery, A; Eusebio, A; Gayraud, D; Simon, N; Viallet, F | 1 |
| Cicero, CE; Mostile, G; Nicoletti, A; Zappia, M | 1 |
| Bove, F; Espay, AJ; Espay, KJ; Fasano, A; Krikorian, R; Lena, F; Modugno, N; Poon, YY; Ricciardi, L | 1 |
| Berg, D; Braatz, U; Ferreira, JJ; Graessner, H; Heger, T; Hobert, MA; Hucker, S; Maetzler, W; Manoli, Y; Meckler, S; Ramsperger, R; Serrano, JA; van Uem, J | 1 |
| Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Nielsen, SH; Siebner, HR | 1 |
| Majláth, Z; Toldi, J; Török, N; Vécsei, L | 1 |
| Hwang, E; Hwang, O; Jeon, SR; Lee, CJ; Min, J; Suh, JK; Yoon, HH | 1 |
| Arabia, G; Barone, P; Iliceto, G; Lamberti, P; Marconi, R; Morgante, L; Mostile, G; Nicoletti, A; Nicoletti, G; Quattrone, A; Zappia, M | 1 |
| Abreu, D; Antonini, A; Coelho, M; Costa, N; Fabbri, M; Ferreira, JJ; Guedes, LC; Rosa, MM | 1 |
| Azulay, JP; Berg, D; Broussolle, E; Ceballos-Baumann, A; Corvol, JC; Defebvre, L; Derkinderen, P; Di Paolo, T; Durif, F; Eggert, K; Espay, AJ; Feigin, A; Feuerbach, D; Geny, C; Gomez-Mancilla, B; Gostkowski, M; Hockey, HU; Houeto, JL; Jaeger, J; Jakab, A; Johns, D; Linazasoro, G; Maruff, P; Rascol, O; Rozenberg, I; Schwarz, J; Sovago, J; Stocchi, F; Storch, A; Tranchant, C; Trenkwalder, C; Weiss, M; Zhang, L | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CR; Schumacher-Schuh, AF | 1 |
| Arlotti, M; Marceglia, S; Priori, A; Rosa, M; Rossi, L | 1 |
| Carlson-Kuhta, P; Horak, FB; Mancini, M; Nutt, JG; Salarian, A | 1 |
| Atula, S; Autere, J; Eerola-Rautio, J; Kaasinen, V; Kauppinen, M; Martikainen, K; Pekkonen, E; Ruottinen, H; Viljamaa, M | 1 |
| Dhall, R; Kreitzman, DL | 1 |
| Silver, DE; Trosch, RM | 1 |
| Fahn, S; LeWitt, PA | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Di Paolo, T; Litim, N; Morissette, M | 1 |
| Ding, Z; Ge, J; Guo, S; Liu, F; Liu, Z; Tang, Y; Wang, J; Wang, Y; Wu, J; Wu, P; Zuo, C | 1 |
| Bravo-Gomez, JJ; Cabello-De la Rosa, JP; Diaz-Gomez, S; Gallardo-Alcaniz, MJ; Vaamonde-Gamo, J | 1 |
| Amboni, M; Barone, P; Erro, R; Moccia, M; Palladino, R; Pellecchia, MT; Picillo, M; Vitale, C | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Carrillo-Ruiz, JD; Castro, G; Salcido, V; Soto, J; Velasco, AL; Velasco, F | 1 |
| Benita León, V; Campolongo Perillo, A; Fernández Díez, S; Mariscal Pérez, N; Martínez Castrillo, JC; Puente Périz, V; Santos García, D; Seoane Urgorri, A; Udaeta Baldivieso, B | 1 |
| Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K | 1 |
| Bellosta Diago, E; Lopez Del Val, LJ; López Garcia, E; Santos Lasaosa, S; Viloria Alebesque, A | 1 |
| DeFeo-Fraulini, T; Ellenbogen, A; Freed, MI; Grosset, DG; Hampson, NB; Hauser, RA; Kieburtz, KD; Leinonen, M; LeWitt, PA; Saint-Hilaire, MH; Stocchi, F | 1 |
| Jankovic, J; Vijayakumar, D | 1 |
| Barker, RA; Nombela, C; Rowe, JB; Wolpe, N; Zhang, J | 1 |
| Cardoso, F; Lima, LO; Rodrigues-de-Paula, F; Teixeira-Salmela, LF | 1 |
| Day, BL; Di Giulio, I; Kalliolia, E; Limousin, P; Peters, AL; St George, RJ | 1 |
| Geffe, S; Jende, J; Klostermann, F; Marzinzik, F; Mehl, A; Schindlbeck, KA | 1 |
| Abbruzzese, G; Arca, R; Bonuccelli, U; Ceravolo, R; Cossu, G; Lopiano, L; Melis, M; Mereu, A; Merola, A; Murgia, D; Nicoletti, V; Palermo, G; Paribello, A; Ricchi, V; Romagnolo, A; Zibetti, M | 1 |
| Baston, C; Horak, F; Mancini, M; Rocchi, L | 1 |
| Nyholm, D; Odin, P; Wirdefeldt, K | 2 |
| Dziewas, R; Hamacher, C; Oelenberg, S; Osada, N; Schröder, JB; Suntrup, S; Suttrup, I; Warnecke, T | 1 |
| Horak, FB; Peterson, DS | 2 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Chang, J; Li, M; Li, X; Luo, F; Wang, J; Wang, N; Wang, Q; Wen, P; Xiao, H; Xie, Z; Yang, Y; Zhang, W; Zhou, M | 1 |
| Espay, AJ; Fasano, A; Lovera, LC; Rodriguez-Porcel, F; Urrea-Mendoza, E | 1 |
| Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E | 1 |
| Abe, T; Fukae, J; Hatano, T; Hattori, N; Hirasawa, M; Hirayama, M; Kawajiri, S; Kazama, A; Kihara, T; Machida, Y; Maeda, T; Miwa, H; Ohtsuka, C; Okuma, Y; Oyama, G; Saiki, H; Shimo, Y; Shimura, H; Suzuki, C; Tomiyama, M; Watanabe, H; Yoritaka, A | 1 |
| Chung, SJ; Shin, HW; Sohn, YH; Youn, YC | 1 |
| Azulay, JP; Baunez, C; Brown, P; Carron, R; Duclos, Y; Eusebio, A; Régis, J; Witjas, T; Zénon, A | 1 |
| Bozzetti, S; Erro, R; Goffi, F; Mariotto, S; Tinazzi, M | 1 |
| Akpalu, A; Barichella, M; Budu, KO; Cassani, E; Cereda, E; Cilia, R; Contin, M; Isaias, IU; Laguna, J; Pezzoli, G; Scarpa, MT; Sparvoli, F | 1 |
| Eidelberg, D; Fujita, K; Ma, Y; Mattis, PJ; Peng, S; Sako, W; Skidmore, FM; Uluğ, AM; Vo, A | 1 |
| Dronamraju, N; Graf, A; Kenney, C; Poewe, W; Shah, A; Stocchi, F; Trenkwalder, C; von Raison, F | 1 |
| Bezard, E; Corvol, JC; Durif, F; Eggert, K; Goetz, CG; Isaacson, S; Keywood, C; Lew, M; Poli, SM; Rascol, O; Tison, F; Trenkwalder, C; Wakefield, M | 1 |
| Bernardini, A; Espay, AJ; Espay, KJ; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Jog, MS; Kumar, N; Rizek, P | 1 |
| Lyons, KE; Pahwa, R | 2 |
| Di Caudo, C; Gonzalez-Maldonado, R; Gonzalez-Redondo, R | 1 |
| Benazzouz, A; De Deurwaerdère, P; Delaville, C; Lagière, M; Marquis, L; Miguelez, C; Navailles, S; Ugedo, L | 1 |
| Hahn, S; Jeon, B; Kim, JM; Park, BJ; Park, EO; Shin, CW | 1 |
| MacDonald, PA; Morrow, SA; Seergobin, KN; Vo, A | 1 |
| Abreu, L; Bernardo, C; López Gómez, M; Magaz Martínez, M; Martínez Porras, JL; Santiago, J | 1 |
| Baek, JS; Choo, CC; Loo, SC; Qian, C; Shen, Z; Tan, NS | 1 |
| Asgharnejad, M; Barone, P; Bauer, L; Dohin, E; Hauser, RA; Slawek, J; Surmann, E | 1 |
| Defebvre, L; Delval, A; Devanne, H; Tard, C | 1 |
| Mundt-Petersen, U; Odin, P; Timpka, J | 1 |
| Alaylıoğlu, M; Apaydın, H; Atasoy, İL; Bilgiç, B; Candaş, E; Dursun, E; Ertan, S; Genç, G; Gezen-Ak, D; Gündüz, A; Gürvit, H; Hanağası, H; Kızıltan, G; Yılmazer, S | 1 |
| Canepa, C | 1 |
| Banerjee, R; Chatterjee, K; Chatterjee, P; Choudhury, S; Kulsum, MU; Kumar, H; Mondal, B | 1 |
| Campos, CH; Ribeiro, GR; Rodrigues Garcia, RCM | 1 |
| Jon Stoessl, A | 1 |
| Eskow Jaunarajs, KL; Figge, DA; Standaert, DG | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Borah, A; Paul, R | 1 |
| Bergmann, L; Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Kjellander, S; Linder, J; Marshall, TS; Nyholm, D; Pålhagen, SE; Sydow, O; Widner, H | 1 |
| Banerjee, M; Kishore, A; Krishnamoorthy, S; Krishnan, S; Kumar, H; Rajan, R; Sarma, G; Sarma, S | 1 |
| Evans, AH; Looi, JC; Molina Ruiz, RM; Velakoulis, D | 1 |
| Cao, LD; Guo, G; Wu, QY; Xu, S | 1 |
| Amato, MR; De Micco, R; Del Prete, A; Esposito, P; Ferraro, F; Sica, M; Tessitore, A; Zulli, C | 1 |
| Bektaş, O; Günaydın, ZY; Karagöz, A; Özer, FF | 1 |
| Freed, MI; Hampson, NB; Kieburtz, KD; Leinonen, M; LeWitt, PA | 1 |
| Alty, JE; Cosgrove, J; Jamieson, S; Lones, MA; Smith, SL; Trefzer, MA; Turner, AP; Tyrrell, AM | 1 |
| Eissa, AM; El-Gamal, M; Hewedi, DH; Jahanshahi, M; Keri, S; Moustafa, AA; Phillips, JR | 1 |
| Murata, M; Okada, Y; Toda, T | 1 |
| Cao, X; Hou, D; Li, S; Ping, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Durso, R; McNamara, P; Morgan, J; Smart, K | 1 |
| Huang, T; Jiang, Y; Tan, ZG; Zhou, Q | 1 |
| Cubo, E; Giuffrida, JP; Heldman, DA | 1 |
| Fiszer, U; Michałowska, M; Szatanowski, T | 1 |
| Barichella, M; Bolliri, C; Caronni, S; Cassani, E; Cereda, E; Faierman, SA; Ferri, V; Frazzitta, G; Iorio, L; Lignola, C; Lubisco, A; Monajemi, F; Pasqua, M; Petroni, ML; Pezzoli, G; Pinelli, G; Privitera, G; Pusani, C; Valentino, A | 1 |
| Ben El Haj, R; Benomar, A; Bouhouche, A; Bouslam, N; Regragui, W; Skalli, A; Tazi-Ahnini, R; Yahyaoui, M | 1 |
| Antonini, A; Cannas, A; Costanzo, AM; di Luzio Paparatti, U; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Tamma, F | 1 |
| Espay, AJ; Fasano, A; Ricciardi, L | 1 |
| Fountoulakis, KN; Goulis, DG; Kimiskidis, V; Nimatoudis, I; Tegos, T | 1 |
| Cannas, A; Marrosu, F; Meloni, M; Solla, P | 1 |
| Carpenter, MG; Inglis, JT; McKeown, MD; McKeown, MJ; Pasman, EP; Peters, RM | 1 |
| Agro, A; Bilbault, T; Dubow, J; Dzyngel, B; Hauser, RA; Isaacson, S; Olanow, CW; Shill, H | 1 |
| Bloem, BR; de Vries, NM; Helmich, RC; Nonnekes, J; Rascol, O; Timmer, MH | 1 |
| Amboni, M; Barone, P; Erro, R; Moccia, M; Pellecchia, MT; Picillo, M; Santangelo, G; Vitale, C | 1 |
| Arbelo, JM; Catalán, MJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Lee, CA; Qi, L; Smith, SK; Sombers, LA; Thomas, E; White, SH; Wilson, LR | 1 |
| Berman, BD; Kronberg, E; Leehey, M; Shelton, E; Smucny, J; Tregellas, JR; Wylie, KP | 1 |
| Akazawa-Ogawa, Y; Fujimura, H; Hagihara, Y; Hamakubo, T; Hara, Y; Hisahara, S; Itoh, S; Kobayashi, M; Kusunoki, S; Matsumura, A; Mita, Y; Noguchi, N; Saigoh, K; Saito, Y; Shichiri, M; Shimohama, S; Sutou, K; Takamatsu, H; Yoshida, Y | 1 |
| Ebersbach, G; Holtmann, M; Jost, W; Odin, P; Schrader, C; Südmeyer, M; Winkler, C | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Berardelli, A; Bologna, M; Conte, A; Fabbrini, G; Suppa, A | 1 |
| Comoglu, SS; Guven, H; Kocer, B | 1 |
| Scott, LJ | 1 |
| Adachi, H; Takei, T; Toyota, T; Uozumi, T; Yasuda, C; Yuhi, T | 1 |
| Gupta, S | 1 |
| Devigili, G; Eleopra, R; Lettieri, C; Rinaldo, S | 1 |
| Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X | 1 |
| Aziz, T; Bestmann, S; Beudel, M; Brown, P; Cagnan, H; Cheeran, B; Foltynie, T; Hariz, M; Herz, D; Hyam, J; Limousin, P; Little, S; Pogosyan, A; Tripoliti, E; Zrinzo, L | 1 |
| Barros, IS; Brito, BS; de Araújo, DF; de Araújo, IT; de Melo Neto, AP; Gondim, Fde A; Horta, WG; Lima, JW; Oliveira, ÍS | 1 |
| Chang, MH; Chen, YH; Lee, WJ; Lin, CH; Wu, YH | 1 |
| Guttuso, T | 1 |
| Bonkowsky, JL; Chen, YC; Panula, P; Rozov, S; Semenova, S; Sundvik, M | 1 |
| Lambarth, AT | 1 |
| Agorastos, S; Bimpisidis, Z; Cenci, MA; Dewey, SL; Eidelberg, D; Lerner, RP; Scherrer, S | 1 |
| Arjona Aguilera, C; Espinosa Rosso, R; Jiménez Gallo, D; Linares Barrios, M; Rojo Suárez, N | 1 |
| Blumenfeld, Z; Bronte-Stewart, H; Koop, MM; Martin, T; Nikolau, JS; Quinn, EJ; Trager, MH; Velisar, A | 1 |
| Santos-Lobato, BL; Tumas, V | 1 |
| Fossati, C; Stocchi, F; Torti, M | 1 |
| Benitez-Rivero, S; Cheeran, B; Del-Olmo, MF; Hu, M; Jenkinson, N; Koch, G; Lago-Rodriguez, A; Ponzo, V | 1 |
| Oertel, W; Schulz, JB | 1 |
| Amalric, M; Beurrier, C; Camon, J; Guiraudie-Capraz, G; Kerkerian-Le Goff, L; Liberge, M; Maurice, N; Ztaou, S | 1 |
| Abbas, MM; Behari, M; Govindappa, ST; Juyal, RC; Muthane, UB; Sudhaman, S; Thelma, BK | 1 |
| Brzuszkiewicz-Kuzmicka, G; Gorecki, W; Mossakowski, Z; Sobstyl, M; Zabek, M; Zaczynski, A | 1 |
| Balaz, M; Chrastina, J; Feitova, V; Hrabovsky, D; Hummelova, Z; Novak, Z; Rab, M | 1 |
| Cenci, MA; Hopkins, CR; Maslava, N; Sebastianutto, I | 1 |
| Deistung, A; Fazekas, F; Franthal, S; Homayoon, N; Katschnig-Winter, P; Koegl-Wallner, M; Langkammer, C; Pendl, T; Pirpamer, L; Reichenbach, JR; Ropele, S; Schmidt, R; Schweser, F; Schwingenschuh, P; Seiler, S; Stoegerer, EM; Wenzel, K | 1 |
| Huang, B; Huang, R; Liu, B; Wang, L; Wu, K; Yang, W; Zhang, X; Zhang, Y | 1 |
| Ak, F; Cakmakli, GY; Gulunay, A; Karakoc, M; Oztekin, N; Ulusoy, EK; Yon, MI | 1 |
| Ba, M; Guan, L; Kong, M; Yi, M; Zhang, H | 1 |
| Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
| Bariotto, K; Bortolanza, M; Del-Bel, E; Dos-Santos-Pereira, M; Raisman-Vozari, R | 1 |
| Bale, E; Gray, WK; Hand, A; Jones, C; Oates, LL; Todd, A; Walker, RW; Wood, BH; Woolford, M | 1 |
| Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Pellecchia, MT; Picillo, M; Vitale, C | 1 |
| Bilic, B; Markos, P; Miletic, V; Rustemovic, N | 1 |
| Agid, Y | 5 |
| Ahn, MH; Chung, SJ; Hong, JP; Kim, J; Kim, MS; Lee, HB; Lee, T | 1 |
| Brianti, R; Caffarra, P; Galuppo, L; Mammi, P | 1 |
| Fetter, D; Le Goff, F; Lefaucheur, R; Maltête, D; Ozel, G; Rabel, C; Rouillé, A | 1 |
| Chan, P; Gao, LL; Wu, T; Zhang, JR | 1 |
| Hardy, GA; Lee, HJ; Schallert, T; Smith, ES | 1 |
| Herlofson, K; Larsen, JP; Ongre, SO; Tysnes, OB | 1 |
| Fujioka, S; Fukae, J; Tsuboi, Y; Umemoto, G; Yanamoto, S | 1 |
| Stahl, SM | 2 |
| Beigi, M; Gobet, F; Jahanshahi, M; Parton, A; Wilkinson, L | 1 |
| Magalhães, F; Marinho, V; Ribeiro, P; Teixeira, S; Velasques, B | 1 |
| Hallett, M; Li, J; Li, X; Li, Y; Zhang, Y; Zhuang, P | 1 |
| Angius, F; Batetta, B; Carboni, E; Carta, AR; Cossu, G; Espa, E; Fenu, S; Giuffrida, A; Jadžić, D; Lecca, D; Mulas, G; Pillai, E; Simbula, G; Spiga, S; Spolitu, S | 1 |
| Choi, YY; Dhawan, V; Dresel, C; Eidelberg, D; Holtbernd, F; Jourdain, VA; Ma, Y; Tang, CC | 1 |
| Alexander, AL; Bendlin, BB; Dean, DC; Gallagher, CL; Hurley, S; Johnson, SC; Kecskemeti, S; Okonkwo, O; Sojkova, J; Theisen, F | 1 |
| Bokor, M; Györfi, O; Kelemen, O; Kéri, S; Nagy, H | 1 |
| Batycky, R; Freed, MI; Leinonen, M; Lipp, MM; Moore, J | 1 |
| Balzano, F; Biasizzo, M; Brunella, V; Caldera, F; Cavalli, R; Riedo, C; Soster, M; Trotta, F; Uccello Barretta, G | 1 |
| Fox, SH; Freitas, ME; Ruiz-Lopez, M | 1 |
| Cao, LF; Chen, LH; Cheng, RX; Huang, Y; Liu, T; Luo, WF; Peng, XY; Wang, B; Zhou, FM | 1 |
| Deserno, L; Holl, AK; Horstmann, A; Jahanshahi, M; Mathar, D; Neumann, J; Villringer, A; Wilkinson, L | 1 |
| Bonenfant, J; Drapier, S; Haegelen, C; Houvenaghel, JF; Naudet, F; Sauleau, P; Vérin, M | 1 |
| Bulgheroni, M; Castiello, U; D'Amico, E; Scaravilli, T; Straulino, E | 1 |
| Brusa, L; Caltagirone, C; Casula, EP; Koch, G; Pellicciari, MC; Peppe, A; Ponzo, V; Stampanoni Bassi, M; Stanzione, P; Stefani, A; Veniero, D | 1 |
| Agostoni, EC; Bernardi, S; Campolo, J; Cozzi, L; De Maria, R; Gelosa, G; Marraccini, P; Nobili, L; Parolini, M; Piccolo, I; Proserpio, P; Trivella, MG | 1 |
| Maiola, R; Micheli, F; Ramirez Gómez, CC | 1 |
| Miki, Y; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CRM; Schumacher-Schuh, AF | 1 |
| Drew, L | 1 |
| Mages, L | 1 |
| Broderick, PA; Li, YS; Wenning, L | 1 |
| Carlson, M; Deal, JA; Mahajan, A | 1 |
| Ahmed, H; Attia, D; Elfil, M; Essam, A; Farahat, E; Gabr, M; Negida, A | 1 |
| Cataldo, BO; Cury, RG; de Campos Duprat, A; Fonoff, E; Noffs, G; Zarzur, AP | 1 |
| Feng, H; Peng, S; Xiao, J; Xie, Y; Zhang, J | 1 |
| Bojarski, C; Ehlen, F; Klostermann, F; Maier, A; Marzinzik, F; Schindlbeck, KA | 1 |
| Dziewiatowski, K; Robowski, P; Schinwelski, M; Sitek, E; Szabat, K; Szadejko, K; Sławek, J | 1 |
| Brown, L; Fogarty, A; Skelly, R | 1 |
| Garcia-Agua Soler, N; Garcia-Ruiz, AJ; Vivancos-Matellano, F | 1 |
| Bloem, BR; Dirkx, M; Helmich, RC; Pasman, JW; Zach, H | 1 |
| Abreu, L; Magaz Martínez, M; Martínez Porras, JL; Oliva, B | 1 |
| Bestetti, A; Capozza, A; Lacerenza, M; Mancini, F; Manfredi, L | 1 |
| Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH | 1 |
| Chang, YP; Liou, LM; Tsai, CC; Wu, MN | 1 |
| Borgemeester, R; van Laar, T | 1 |
| James, P; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Yahia-Cherif, L | 1 |
| Cohen, OS; Elincx-Benizri, S; Greenbaum, L; Hassin-Baer, S; Israeli-Korn, S; Shabat, C; Stein, E; Strauss, H; Warmann-Alaluf, N; Yahalom, G | 1 |
| Cho, YJ; Kim, KS; Kim, SH; Lee, KE; Lee, MK; Park, HJ; Shin, KS; Zhao, TT | 1 |
| Djamshidian, A; Poewe, W | 1 |
| Altamura, C; Basile, S; Calcagno, M; Garibaldi, S; Pinelli, S; Salerno, MG | 1 |
| Akbostanci, MC; Aytürk, Z; Yilmaz, R | 1 |
| Cacciatore, I; Cortesi, R; Di Stefano, A; Drechsler, M; Esposito, E; Pavoni, G; Sguizzato, M | 1 |
| Ferreira, J; Lees, AJ; McCrory, M; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Alampi, G; Contri, P; Cova, I; Di Battista, ME; Di Pucchio, A; Lacorte, E; Mariani, C; Meco, G; Papi, CP; Pomati, S; Priori, A; Rubino, A; Valente, M; Vanacore, N | 1 |
| Bäckman, L; Håglin, L | 1 |
| Andrade, AO; Bordelon, Y; Cavalheiro, GL; Júnior, JA; Machado, AR; Naves, K; O'Keeffe, A; Oliveira, FH; Paixão, AP; Pereira, AA; Pereira, JM; Pouratian, N; Sharim, J; Vieira, MF; Yang, L; Zaidan, HC; Zhuo, X | 1 |
| Sitte, H; Willeit, M | 1 |
| Alonso-Frech, F; De la Casa-Fages, B; Grandas, F | 1 |
| Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P | 1 |
| Bloem, BR; Dirkx, MF; Helmich, RC; Pasman, JW; Zach, H | 1 |
| Mizuno, Y; Origasa, H; Shimoda, S | 1 |
| Aquilonius, SM; Askmark, H; Bergquist, F; Constantinescu, R; Ericsson, A; Lycke, S; Medvedev, A; Memedi, M; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Westin, J | 1 |
| Cerroni, R; D'Angelo, V; Fedele, E; Galati, S; Hainsworth, AH; Liguori, C; Olivola, E; Pierantozzi, M; Saviozzi, V; Stefani, A | 1 |
| Falaki, A; Huang, X; Latash, ML; Lewis, MM | 1 |
| Blair, HA; Dhillon, S | 1 |
| Alonso-Frech, F; Catalán, MJ; Escribano, PM | 1 |
| Chriscoe, S; Davy, M; Jimenez, T; Upward, J; VanMeter, S; Zesiewicz, TA | 1 |
| Annus, Á; Vécsei, L | 1 |
| Bianchi, ML; Bono, G; Cantello, R; Comi, C; Cosentino, M; Ferrari, M; Magistrelli, L; Marino, F; Riboldazzi, G | 1 |
| Duker, AP; Ellenbogen, A; Farbman, ES; Gupta, S; Hauser, RA; Hsu, A; Kell, S; Khanna, S; Kreitzman, D; Liang, GS; Nausieda, P; Nieves, A; Rubens, R; Tetrud, J | 1 |
| Dietrichs, E; Odin, P | 1 |
| Arnulf, I; Miguel, R | 1 |
| Koehler, PJ; Marinus, J; Overmars, SS; Schilder, JC; van Hilten, JJ | 1 |
| Abreu, D; Albuquerque, L; Carvalho, H; Cattoni, B; Coelho, M; Correia-Guedes, L; Domingos, J; Fabbri, M; Ferreira, AG; Ferreira, JJ; Freitas, V; Godinho, C; Lobo, PP; Pereira, JM; Reimão, S; Rosa, MM | 1 |
| Beer, S; Möller, JC; Mylius, V; Schepelmann, K; Teepker, M; Zouari, HG | 1 |
| Bankiewicz, KS; Ciesielska, A; Dickson, DW; Forsayeth, J; Goldman, S; Samaranch, L; San Sebastian, W | 1 |
| Assis, F; Barbosa, IG; Christo, PP; de Souza, MS; Reis, HJ; Rocha, NP; Scalzo, PL; Teixeira, AL; Vieira, ÉLM | 1 |
| Ács, P; Annus, Á; Aschermann, Z; Dézsi, L; Dibó, G; Harmat, M; Janszky, J; Juhász, A; Karádi, K; Klivényi, P; Komoly, S; Kovács, M; Kovács, N; Makkos, A; Nagy, H; Takáts, A; Tényi, D; Tóth, A; Varannai, L; Vécsei, L; Zádori, D | 1 |
| Battistini, S; Brusa, L; Caltagirone, C; Di Lorenzo, F; Koch, G; Ponzo, V; Ricci, C; Sambucci, M; Schirinzi, T | 1 |
| Debelius, JW; Factor, SA; Hill-Burns, EM; Knight, R; Lewis, MR; Molho, E; Morton, JT; Payami, H; Peddada, SD; Wallen, ZD; Wissemann, WT; Zabetian, CP | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Cicero, CE; Contrafatto, D; Dibilio, V; Luca, A; Mostile, G; Nicoletti, A; Raciti, L; Sciacca, G; Vasta, R; Zappia, M | 1 |
| Ardolino, G; Arlotti, M; Cogiamanian, F; Fonzo, AD; Locatelli, M; Lopiano, L; Marceglia, S; Merola, A; Priori, A; Rampini, PM; Rosa, M; Scelzo, E | 1 |
| Chatamra, K; Dutta, S; Locke, C; Othman, AA; Rosebraugh, M | 1 |
| Herrman, L; Kinkel, M; Muhlack, S; Müller, T | 1 |
| Buhmann, C; Hilker, R; Lingor, P; Reichmann, H; Schrader, C; Schwarz, J; Wolz, M | 1 |
| Bezard, E; Fernagut, PO; Frank, MJ; Grace, AA; Napier, TC; Obeso, J; Rodriguez-Oroz, M; Sgambato-Faure, V; Voon, V | 1 |
| Grabli, D | 1 |
| Gupta, S; Mittur, A; Modi, NB | 1 |
| Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
| Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H | 1 |
| Horak, F; Mancini, M; Peterson, D; Schlenstedt, C | 1 |
| Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I | 1 |
| Artusi, CA; Comi, C; Duker, AP; Espay, AJ; Lanotte, M; Lopiano, L; Maule, S; Merola, A; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Berman, BD; Mohl, B; Shelton, E; Tanabe, J | 1 |
| Herz, DM; Løkkegaard, A; Siebner, HR; Thomsen, BL | 1 |
| Bell, PT; Ehgoetz Martens, KA; Georgiades, MJ; Gilat, M; Hall, JM; Lewis, SJG; Shine, JM; Walton, CC | 1 |
| Aquilonius, SM; Nyholm, D | 1 |
| Bimpisidis, Z; Cenci, MA; Lundblad, C; Maslava, N; Öberg, CM | 1 |
| Park, D | 1 |
| Grünblatt, E; Müller, T; Riederer, P | 1 |
| Albo, J; Hellström, M; Nyholm, D; Senek, M; Svenningsson, P | 1 |
| Benetin, J; Bötzel, K; Brozová, H; Růzicka, E; Valkovic, P | 1 |
| Aprile, I; Cornetta, T; Cozzi, R; Padua, L; Palma, S; Testa, A; Tonali, P | 1 |
| Barbieri, S; Bracchi, F; Cogiamanian, F; Foffani, G; Marceglia, S; Priori, A; Rampini, P; Rossi, L; Tamma, F | 1 |
| Jowi, JO | 1 |
| Beato, R; Bonnet, AM; Cardoso, F; Deweer, B; du Montcel, ST; Dubois, B; Houeto, JL; Levy, R; Pillon, B; Vidal, C | 1 |
| Erdmann, C; Goetze, O; Müller, T; Woitalla, D | 1 |
| Bingefors, K; Isacson, D; Kristiansen, IS; Nyholm, D | 2 |
| Kelly, AM; Kennedy, GA; Willis, GL | 1 |
| Girotti, F; Musicco, M; Ronchetti, G; Scigliano, G | 2 |
| Madigan, EJ | 1 |
| Duong-Hua, M; Lang, A; Marras, C; Rochon, P; Sykora, K; Zadikoff, C | 1 |
| Brusa, L; Caltagirone, C; Carlesimo, GA; Costa, A; Gatto, I; Peppe, A | 2 |
| Barker, RA; Eckstein, D; Fallon, S; Ghosh, BC; Hughes, L; Owen, AM; Rowe, JB; Williams-Gray, CH | 1 |
| Ben-Shlomo, Y; Evans, A; Head, J; Katzenschlager, R; Lees, AJ; Schrag, A | 1 |
| Cacciatore, I; Cantalamessa, F; Cerasa, LS; Cornacchia, C; Di Stefano, A; Giorgioni, G; Iannitelli, A; Nasuti, C; Ricciutelli, M; Sozio, P | 1 |
| Bourdeix, I; Damier, P; Rerat, K; Viallet, F; Ziegler, M | 1 |
| Carta, AR; Frau, L; Morelli, M; Pinna, A; Pontis, S | 1 |
| Berendse, HW; Bosboom, JL; Stam, CJ; Stoffers, D; Wolters, ECh | 1 |
| Welsh, M | 1 |
| Deleu, D | 3 |
| García-Sánchez, C; Gironell, A; Kulisevsky, J; Martínez-Corral, M; Pagonabarraga, J; Pascual-Sedano, B | 1 |
| Busi, C; Fiorentini, C; Missale, C; Spano, P | 1 |
| Galiano, K; Lucas, JA; Obwegeser, AA; Turk, MF; Uitti, RJ; Wharen, RE; Witte, RJ | 1 |
| Chan, P; Hallett, M; Li, K; Long, X; Wang, L; Wu, T; Zang, Y | 1 |
| Jeon, SH; Lee, WY; Rhee, PL; Shin, HY; Yoon, WT | 1 |
| Bordia, T; Campos, C; Huang, L; Quik, M | 1 |
| Adams, F; Boschmann, M; Franke, G; Gottschalk, S; Janke, J; Jordan, J; Kupsch, A; Leisse, MC; Lipp, A; Lobsien, E; Spranger, J | 1 |
| Deuschl, G; Falk, D; Herzog, J; Mehdorn, M; Pinsker, MO; Volkmann, J | 1 |
| Okuma, Y; Yanagisawa, N | 1 |
| Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Soulet, D; Vercammen, L | 1 |
| Salzman, P; Schwid, SR; White, WB | 1 |
| Hsu, A; Khor, SP | 1 |
| Benincasa, D; Buttarelli, FR; Giovannelli, M; Pellicano, C; Pontieri, FE; Ruggieri, S | 1 |
| Doan, JB; Melvin, KG; Suchowersky, O; Whishaw, IQ | 1 |
| Reich, SG; Weiner, WJ | 1 |
| Comella, CL; Fahn, S; Friedman, JH; Marek, K; Oakes, D; Schifitto, G; Shulman, L | 1 |
| Bialecka, M; Drozdzik, M; Klodowska-Duda, G; Kurzawski, M; Opala, G; Tan, EK | 1 |
| Amalric, M; De Leonibus, E; Giordani, F; Lopez, S; Managò, F; Mele, A; Oliverio, A; Petrosino, F | 1 |
| Jenner, P | 3 |
| Eigenraam, L; Hoque, T; McCaig, RG; McKeown, MJ; Palmer, SJ; Troiano, A | 1 |
| Bares, M; Krajcovicová, L; Rektor, I; Rektorová, I | 1 |
| Barbanoj, M; Campolongo, A; García-Sánchez, C; Gich, I; Gironell, A; Kulisevsky, J; Pagonabarraga, J; Pascual-Sedano, B | 1 |
| Garamendi, I; Gómez, JC; Lezcano, E; Rouco, I; Tijero, B; Velasco, F; Zarranz, JJ | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A | 2 |
| Brotchie, JM; Chuang, R; Fox, SH | 1 |
| Aberle, J; Baker, WL; Coleman, CI; Kluger, J; Patel, AA; Silver, D; White, CM | 1 |
| Bradshaw, JL; Charlton, J; Georgiou-Karistianis, N; Klimkeit, EI; Stolwyk, R | 1 |
| Lees, A; Obeso, J; Olanow, CW | 1 |
| Grace, AA | 1 |
| Schapira, AH | 3 |
| Sethi, K | 1 |
| Olanow, CW; Stocchi, F; Tagliati, M | 1 |
| Brown, MS; Furtado, S; Suchowersky, O; Toth, C; Zochodne, D | 1 |
| Bungener, C; Montel, SR | 1 |
| Kelsey, JE; Langelier, NA; Oriel, BS; Reedy, C | 1 |
| Auerbach, S; Cronin-Golomb, A; Durso, R; Harris, E; McNamara, P; Stavitsky, K | 1 |
| Guglielmi, R; Meco, G; Pascale, E; Passarelli, E; Passarelli, F; Purcaro, C; Vestri, AR | 1 |
| Agid, Y; Bonnet, AM; Cornu, P; Dormont, D; El Otmani, H; Jodoin, N; Navarro, S; Pidoux, B; Welter, ML; Yaici, S | 1 |
| Burkhard, PR; Landis, BN | 1 |
| Aste, R; Cannas, A; Congia, S; Floris, G; Marrosu, MG; Solla, P; Tacconi, P | 1 |
| Kieburtz, K | 2 |
| Albanese, A; Del Sorbo, F | 1 |
| Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Nyholm, D | 1 |
| Ballerini, R; Hauser, RA; Mori, A; Roberts, JW; Shulman, LM; Sussman, NM; Trugman, JM | 1 |
| Chigir', IP; Dokadina, LV; Fedorova, NV; Levin, OS; Makhnev, SO; Smolentseva, IG | 1 |
| Jost, WH; Klasser, M; Reichmann, H | 1 |
| Aarsland, D; Ballard, CG; Ehrt, U; Francis, PT; Larsen, JP; Perry, EK; Perry, RH; Piggott, MA; Sharp, SI; Ziabreva, I | 1 |
| Aasly, JO; Beiske, AG; Bekkelund, SI; Dietrichs, E; Larsen, JP; Tysnes, OB; Vilming, ST | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Armand, S; Burkhard, PR; Landis, T; Sztajzel, R | 1 |
| Arntzen, KA; Bekkelund, SI; Lilleng, H | 1 |
| Carrasco, E; Iranzo, A; Kumru, H; Marti, MJ; Santamaria, J; Tolosa, E; Valldeoriola, F | 1 |
| Jog, M; Panisset, M; Réhel, B; Schecter, R; Suchowersky, O | 1 |
| Argyelan, M; Carbon, M; Dhawan, V; Eidelberg, D; Feigin, A; Ghilardi, MF; Mattis, P; Tang, C | 1 |
| Standaert, DG; Yacoubian, TA | 1 |
| Bertoni, JM; Elmer, LW | 1 |
| Bezard, E; Gerfen, CR; Nadjar, A | 1 |
| Cardoso, F; Gomide, L; Kummer, A; Teixeira, AL | 1 |
| Gérard, JM | 1 |
| Bouchard, TP; Camicioli, RM; Somerville, MJ | 1 |
| Currie, LJ; Frysinger, RC; Harrison, MB; Huss, DS; Patrie, JT; Wooten, GF; Wylie, SA | 1 |
| Bhatia, K; Filipović, SR; Rothwell, JC; van de Warrenburg, BP | 1 |
| Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE | 1 |
| Allum, JH; Bloem, BR; Borm, GF; Carpenter, MG; Esselink, RA; Honegger, F; Limousin-Dowsey, P; Visser, JE | 1 |
| Carpinella, I; Crenna, P; Ferrarin, M; Lanotte, M; Lopiano, L; Marzegan, A; Rabuffetti, M; Rizzone, M | 1 |
| Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C | 1 |
| Agid, Y; Bloch, F; Bonneville, F; Chastan, N; Do, MC; Dormont, D; Torny, F; Welter, ML; Westby, GW | 1 |
| Babina, LA; Batysheva, TT; Boiko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaitsev, KA; Zhuravleva, EY | 1 |
| Barker, RA; Bhatia, KP; Cheeran, B; Edwards, MJ; Foltynie, T; Rothwell, JC; Schneider, SA; Weinberger, D; Williams-Gray, CH | 1 |
| Evans, AH; Lawrence, AD; Lees, AJ | 1 |
| Arabia, G; Bagnato, A; Cascini, GL; Cipullo, S; Condino, F; Messina, D; Morelli, M; Morgante, L; Nicoletti, G; Novellino, F; Paglionico, S; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Boecker, H; Ceballos-Baumann, AO; Drzezga, A; Förstl, H; Granert, O; Häussermann, P; Kurz, A; Perneczky, R | 1 |
| Caron, MG; Gainetdinov, RR; Hallett, PJ; Isacson, O; Patterson, M; Reske-Nielsen, C; Sotnikova, TD; Vinuela, A | 1 |
| Emmel, VE; Hilbig, A; Jardim, LB; Rieder, CR; Saraiva-Pereira, ML; Socal, MP | 1 |
| Fornai, F; Paparelli, A; Pasquali, L; Ruffoli, R; Ruggieri, S; Soldani, P | 1 |
| Frisina, PG; Gracies, JM; Hälbig, TD; Koller, WC; Lesser, G; Liang, L; Libow, LS; Neufeld, R; Tarshish, C; Tse, W | 1 |
| Agid, Y; Bardinet, E; Chastan, N; Do, MC; Welter, ML; Westby, GW; Yelnik, J | 1 |
| Han, JH; Jeon, BS; Kim, C; Kim, DG; Lee, JY; Paek, SH | 1 |
| Freeman, T; Godbold, J; Goetz, CG; Gracies, JM; Kordower, JH; Obeso, JA; Olanow, CW; Stoessl, AJ | 1 |
| Jeon, BS; Kim, DG; Kim, HJ; Kim, JY; Lee, JY; Lim, YH; Paek, SH | 1 |
| Chan, P; Feng, T; Li, W; Lu, L; Shi, W; Wang, Y; Zhang, J | 1 |
| Hashiguchi, K; Kawaguchi, M; Miyagi, Y; Morioka, T; Murakami, N; Nagata, S; Sakae, N; Samura, K; Sasaki, T; Yamasaki, R; Yoshida, F | 1 |
| Kondo, T; Miwa, H | 1 |
| Aydemir, T; Bader, H; Cetin, S; Kizkin, S; Meral, H; Ozben, B; Ozben, S; Ozer, F; Ozturk, O; Tiras, R | 1 |
| Csókay, A; Emri, M; Lengyel, Z; Márián, T; Mikecz, P; Trón, L; Valálik, I | 1 |
| Hlustik, P; Kanovsky, P; Langova, K; Nevrly, M; Vranova, H | 2 |
| Sharma, R | 1 |
| Li, XY; Li, YJ; Zhuang, P | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C | 1 |
| Bourdeix, I; Destée, A; Rérat, K | 1 |
| Ayres-Basto, M; Gago, MF; Linhares, P; Rosas, MJ; Sousa, G; Vaz, R | 1 |
| Hadjiconstantinou, M; Neff, NH | 2 |
| Dostrovsky, JO; Hodaie, M; Hutchison, WD; Lozano, AM; Moro, E; Prescott, IA | 1 |
| Abbruzzese, G; Dronamraju, N; Hauser, RA; Kakarieka, A; Mancione, L; Panisset, M | 1 |
| Aziz, T; Brown, P; Brücke, C; Kühn, AA; Kupsch, A; Ray, N; Schneider, GH; Tsui, A | 1 |
| Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM | 1 |
| Kim, DG; Kim, OJ; Koo, YH; Oh, SH | 1 |
| Fitzer-Attas, CJ; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Albanese, A; Bentivoglio, AR; Contarino, MF; Romito, LM; Scerrati, M; Vanacore, N | 1 |
| Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Van der Schyf, CJ | 1 |
| De Nunzio, AM; Godi, M; Guglielmetti, S; Nardone, A; Schieppati, M | 1 |
| Weintraub, D | 1 |
| Olanow, CW; Stern, MB | 1 |
| Azulay, T; Brooks, DJ; Giladi, N; Melamed, E; Oertel, W; Poewe, WH; Rascol, O; Stocchi, F; Tal, J; Tolosa, E | 1 |
| Hattori, N; Ohizumi, H; Tanaka, S; Yoritaka, A | 1 |
| Murata, M | 6 |
| Kubo, M; Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Yokochi, M | 6 |
| Nagatsua, T; Sawadab, M | 1 |
| Fujimura, T; Hattoria, N; Kubo, S; Mochizuki, H; Taka, H; Wanga, M; Yoritaka, A | 1 |
| Stocchi, F | 6 |
| Celik, M; Forta, H; Kenangil, G; Orken, DN; Ur, E | 1 |
| Brusa, L; Finazzi Agrò, E; Iani, C; Koch, G; Lo Gerfo, E; Petta, F; Sciobica, F; Stanzione, P; Torriero, S | 1 |
| Coleman, RA; Green, RL; Lorenz, AN; Sass, MB | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Destée, A; Moreau, C | 1 |
| Benabid, AL; Chabardès, S; Debû, B; Ferraye, MU; Fraix, V; Gerardin, P; LeBas, JF; Pollak, P; Seigneuret, E; Tilikete, C | 1 |
| Litvinenko, IV; Mogil'naia, VI; Odinak, MM; Sakharovskaia, AA; Sologub, OS | 1 |
| Pal, PK; Prashantha, DK | 1 |
| Gluck, MA; Guthrie, M; Myers, CE | 1 |
| Bodenheimer, RE; Davis, TL; Dawant, BM; Li, R; Rao, AS; Voight, C | 1 |
| Li, J; McKeown, MJ; Wang, Z | 1 |
| Baker, W; Coleman, CI; Reinhart, K; Talati, R; White, CM | 1 |
| Calabresi, P; Di Filippo, M; Mercuri, NB | 1 |
| Bono, G; Garavaglia, P; Guidotti, M; Leva, S; Pianezzola, C; Raudino, F; Riboldazzi, G | 1 |
| Hashiguchi, K; Kawaguchi, M; Kishimoto, J; Miyagi, Y; Morioka, T; Murakami, N; Sakae, N; Samura, K; Sasaki, T; Yamasaki, R; Yoshida, F | 1 |
| Broussolle, E; Gan, J; Gervais-Bernard, H; Thobois, S; Vallet, AE; Xie-Brustolin, J | 1 |
| Comella, C; Elmer, L; Hauser, RA; Lyons, KE; Pahwa, R; Simuni, T; Weintraub, D | 2 |
| Frei, K; Truong, DD; Wolters, E | 1 |
| de la Fuente-Fernandez, R; Dinelle, K; Doudet, D; Holden, JE; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ; Topping, GJ | 1 |
| Bloem, BR; Gerschlager, W | 2 |
| Bäumer, T; Buhmann, C; Gerloff, C; Hamel, W; Hidding, U; Moll, CK; Münchau, A; Orth, M; Siebner, HR | 1 |
| Ben-Shlomo, Y; Morris, HR; Wickremaratchi, MM | 1 |
| Burn, DJ; McKeith, IG; Minett, T; Molloy, S; O'Brien, JT | 1 |
| af Bjerkén, S; Cenci, MA; Gerhardt, GA; Lundblad, M; Pomerleau, F; Strömberg, I | 1 |
| Granérus, AK; Lorefält, B; Toss, G | 1 |
| Alvarez, L; Alvarez, M; Carballo, M; Casabona, E; DeLong, MR; Fernández, R; García, I; Guridi, J; Juncos, JL; López, G; Macias, R; Maragoto, C; Obeso, JA; Pavón, N; Pedroso, I; Rodríguez, R; Rodríguez-Oroz, MC; Salazar, S; Teijeiro, J | 1 |
| Bourriez, JL; Defebvre, L; Degardin, A; Derambure, P; Destée, A; Devos, D; Houdayer, E | 1 |
| Marinus, J; van Hilten, JJ; van Rooden, SM; Verbaan, D; Visser, M | 2 |
| Chaves, ML; Fricke, D; Hofmann, KW; Leke, R; Portela, LV; Rieder, CR; Saute, J; Schuh, AF; Souza, DO; Townsend, R | 1 |
| Lundgren, D; Nyholm, D; Nyman, R | 1 |
| Audebert, C; Blin, O; Eusebio, A; Jouve, E; Micallef, J; Rey, M; Rouby, F; Tardieu, S | 1 |
| Brotchie, J; Fitzer-Attas, C | 1 |
| Lang, AE | 4 |
| Poewe, W | 3 |
| Allert, N; Eleopra, R; Houeto, JL; Moro, E; Phan, TM; Stoevelaar, H | 1 |
| Arias-Rodríguez, M; Morís-De la Tassa, G | 1 |
| Baker, WL; Coleman, CI; Patel, AA; Reinhart, K; Talati, R | 1 |
| Ren, XM | 1 |
| Barlas, O; Coban, A; Hanagasi, HA; Karamursel, S | 1 |
| Fernandez, HH; Foote, KD; Garvan, CW; Haq, IU; Hass, CJ; Jacobson, CE; Malaty, IA; Mann, JM; Morishita, T; Okun, MS; Rodriguez, RL; Siddiqui, MS | 1 |
| Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J | 1 |
| Destée, A; Devos, D; Moreau, C | 1 |
| Iida, A; Inoue, N; Kakiuchi, T; Kondo, Y; Muramatsu, S; Nakano, I; Nakayama, T; Okuno, T; Ono, F; Suzuki, Y; Takino, N; Terao, K; Tsukada, H | 1 |
| Devos, D | 1 |
| Elosegi, JA; Gérard, JM | 1 |
| Dikshit, M; Husain, M; Khanna, VK; Maheshwari, PK; Nag, D; Seth, PK; Shukla, R; Srimal, RC | 1 |
| Aalto, S; Bergman, J; Brück, A; Marttila, R; Rauhala, E; Rinne, JO | 1 |
| Bhidayasiri, R; Ling, H | 2 |
| Pirtosek, Z | 2 |
| Berger, SP; Brudney, EG; Foley, K; Johnson, SW; Meshul, CK; Paquette, MA | 1 |
| Altenmüller, DM; Brown, P; Brücke, C; Di Lazzaro, V; Doyle Gaynor, LM; Hoffmann, KT; Kempf, F; Krauss, JK; Kühn, AA; Kupsch, A; Mazzone, P; Salih, F; Schneider, GH; Trottenberg, T; Vesper, J; Wöhrle, J; Yelnik, J | 1 |
| Barchak, AG; Busanello, EN; Camargo, D; Carrion, MJ; da Costa, JC; Dalbem, A; de Mello Rieder, CR; de Sousa Miguel, SR; dos Santos, EF; Miglioranza, A; Rosa, C; Saute, J; Vargas, CR; Wajner, M; Zanatta, A | 1 |
| Caron, MG; Fuentes, R; Nicolelis, MA; Petersson, P; Siesser, WB | 1 |
| Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Ahlskog, JE; Bostwick, JM; Bower, JH; Hecksel, KA; Stevens, SR | 1 |
| Burkhead, LM; Ellis, C; Fernandez, HH; Foote, KD; Okun, MS; Plowman-Prine, EK; Rodriguez, AD; Rosenbek, JC; Sapienza, CM; Shrivastav, R | 1 |
| Silver, DE | 2 |
| Abruzzese, G; Antonini, A; Bonuccelli, U; Canesi, M; Cristina, S; Defazio, G; dell'Aquila, C; Lamberti, P; Livrea, P; Logroscino, G; Marchese, R; Pacchetti, C; Zagaglia, R; Zoccolella, S | 1 |
| Angwin, AJ; Arnott, WL; Chenery, HJ; Copland, DA; Haire, MP; Murdoch, BE; Silburn, PA | 1 |
| Brundin, P; Cenci, MA; Lane, EL | 1 |
| Jankovic, J | 13 |
| Abramov, VG; Nesterova, IuV; Pokhabov, DV | 1 |
| Ding-Fang, C; Guo-Hua, W; Hong-Min, T; Hua-Wei, L; Jun, M; Jun-Peng, G; Shan, S; Wen-Wei, L; Xiang-Yu, W; Ya-Ling, H; Yan-Hong, T; Yi, F; Yue, F; Yun-Ke, Y | 1 |
| Averbeck, B; Azulay, JP; Brown, P; Cantiniaux, S; Eusebio, A; Gaynor, LD; Limousin, P; Pogosyan, A; Wang, S; Witjas, T | 1 |
| Compta, Y; Ezquerra, M; Martí, MJ; Rey, MJ | 1 |
| Bachmann, CG; Brunner, E; Trenkwalder, C; Zapf, A | 1 |
| Abbruzzese, G | 1 |
| Antonini, A; Canesi, M; Pezzoli, G; Zecchinelli, AL | 1 |
| Antonini, A; Odin, P; Wolters, E | 1 |
| Cerasa, LS; Di Stefano, A; Iannitelli, A; Sozio, P | 2 |
| Ballero, M; Kasture, S; Longoni, R; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Spina, L | 1 |
| de la Fuente-Fernández, R; McCormick, S; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Vercammen, L | 1 |
| Branden, L; Greig, NH; Huang, X; Olivares, D; Rogers, JT | 1 |
| Cheon, SM; Kim, JW; Kim, WJ; Park, MJ | 1 |
| Bronzova, J; Hauser, RA; Lang, AE; Rascol, O; Sampaio, C; Theeuwes, A; van de Witte, SV | 2 |
| Deuschl, G; Herzog, J; Möller, B; Pinsker, MO; Volkmann, J; Witt, K | 1 |
| Guarnieri, M; Hubble, JP; Jennings, D; LeWitt, PA; Lyons, KE; Murck, H; Pahwa, R; Rabinowicz, AL; Wang, J | 1 |
| Ebersbach, G; Nebe, A | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Antonini, A; Canesi, M; Chaudhuri, KR; Faye, GC; Forgacs, I; Fox, K; Fox, T; Honig, H; Mancini, F; Martinez-Martin, P; Odin, P | 1 |
| Durairajan, SS; Fong, WL; Gao, J; Kum, WF; Li, M; Lu, JH; Man, SC; Xie, LX | 1 |
| Bordia, T; Campos, C; Huang, LZ; Parameswaran, N; Perez, XA; Quik, M | 1 |
| Oberpichler-Schwenk, H | 2 |
| Clarke, CE; Moore, AP | 3 |
| Chan, P; Chen, Y; Li, K; Wang, L; Wu, T; Zhao, C | 1 |
| Huizenga, HM; Schmand, B; Schuurman, PR; Smeding, HM; Speelman, JD | 1 |
| Diepers, M; Kraft, E; Loichinger, W; Ludolph, AC; Lule, D; Schwarz, J; Storch, A | 1 |
| Hamasaki, T; Kuratsu, J; Yamada, K | 1 |
| Addy, C; Assaid, C; Ellenbogen, A; Gottesdiener, K; Herring, WJ; Hreniuk, D; Jinnah, HA; Kirby, L; Leibowitz, MT; Stewart, RM; Stoch, SA; Stroh, M; Tarsy, D; Tetrud, J; Wagner, J; Xu, Y | 1 |
| Antonini, A; Tolosa, E | 1 |
| Diederich, NJ; Fénelon, G; Goetz, CG; Stebbins, G | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E | 1 |
| Trip, J; Vermeij, JD; Weber, WE; Winogrodzka, A | 1 |
| Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C | 1 |
| Truong, DD | 1 |
| Edelstyn, NM; Ellis, SJ; Jenkinson, PM; Stephens, R | 1 |
| Avanzi, M; Baratti, M; Bonfà, F; Cabri, G; Cabrini, S; Uber, E | 1 |
| Delvaux, V; Garraux, G; Moonen, G | 1 |
| Brown, P; Fogelson, N; Hariz, MI; Kühn, AA; Kupsch, A; Limousin, PD | 1 |
| Montgomery, EB | 5 |
| Ceravolo, MG | 1 |
| Blond, S; Defebvre, L; Delval, A; Destée, A; Devos, D; Dujardin, K; Kreisler, A; Krystkowiak, P; Salleron, J; Simonin, C; Tir, M | 1 |
| Emre, M; Jenner, P; Poewe, W; Schapira, AH | 1 |
| Chan, P; Fang, X; Meng, C; Qin, Z; Sun, F; Tanner, C; Zhang, L | 1 |
| Gruendlinger, L; Hausdorff, JM; O'Herron, S; Scollins, L; Tarsy, D | 1 |
| Stacy, M | 4 |
| Chen, SY; Chou, YC; Hung, HY; Li, CW; Lin, SH; Lin, SZ; Pan, YH; Tsai, ST | 1 |
| Chan, P; Ding, H; Fan, W; Ma, J | 1 |
| Dodaballapur, SK; Jamnadas-Khoda, J; Koshy, S; Mathias, CJ; Muthane, UB; Ragothaman, M | 1 |
| Chen, W; Liu, ZG; Lu, LX; Qi, C; Wu, JY; Zhou, MZ | 1 |
| Kuoppamäki, M; Leinonen, M; Nissinen, H; Schapira, AH | 1 |
| Cordo, PJ; Franzén, E; Gurfinkel, VS; Horak, FB; Nutt, JG; Paquette, C | 1 |
| Araki, H; Inuzuka, T; Kato, T; Moriwaki, H; Murase, M; Nagaki, M; Nishida, H; Tanaka, Y | 1 |
| Jubault, T; Lafontaine, AL; Monchi, O; Monetta, L; Strafella, AP | 1 |
| Abugharbieh, R; McKeown, MJ; Ng, B; Palmer, S | 1 |
| Brusa, L; Caltagirone, C; Carrillo, F; Koch, G; Lo Gerfo, E; Mir, P; Oliveri, M; Stanzione, P; Torriero, S | 1 |
| Alvarez Vega, MA; Blázquez, M; Fernández González, F; Gutiérrez, JC; Lozano Aragoneses, B; Seijo, FJ | 1 |
| Klann, E | 1 |
| Andreadou, E; Boufidou, F; Gournaras, F; Nikolaou, C; Rentzos, M; Tsoutsou, A; Vassilopoulos, D; Zissimopoulos, V; Zournas, C | 1 |
| Aneiros, A; Llaneza, M; Macías, M; Santos-García, D | 1 |
| Amighi, K; Goole, J | 1 |
| Hsu, CH; Wang, HB | 1 |
| Chan, P; Fang, X; Liu, H; Qin, Z; Sun, F; Zhang, L | 1 |
| Allard, M; Burbaud, P; Cuny, E; Farid, K; Guehl, D; Sibon, I | 1 |
| Di Rocco, A; Flancbaum, L; Raguthu, L; Tayler, E; Varanese, S | 1 |
| Tarsy, D | 2 |
| Ikeda, K; Kurokawa, T; Mochizuki, H; Nakao, K; Yoshikawa, S; Yuzawa, N | 1 |
| Berardelli, A; Bloise, M; Colosimo, C; Defazio, G; Fabbrini, G; Suppa, A | 1 |
| Cho, JY; Cho, YJ; Hong, KS; Jeon, BS; Kim, HJ; Lee, DH; Park, SY; Seo, SY | 1 |
| Charles, J; Lantuejoul, S; Leccia, MT; Leroux, D; Robert, C; Salameire, D; Templier, I | 1 |
| Khan, W; Naz, S; Rana, AQ | 1 |
| Letro, GH; Quagliato, EM; Viana, MA | 1 |
| Alkhawajah, M; Alrefai, A; Batayha, W; Darwish, M; El-Salem, K; Habahbih, M; Khader, Y | 1 |
| Chuang, RS; Lang, AE | 1 |
| Ballanger, B; Lang, AE; Miyasaki, JM; Pellecchia, G; Strafella, AP; van Eimeren, T | 1 |
| Cohen, H; Pourcher, E; Rémillard, S | 1 |
| Hayashi, R; Katsumata, Y; Mimura, M; Yamaguchi, S | 1 |
| Casarejos, MJ; de Yébenes, JG; Mena, MA; Solano, RM | 1 |
| Biagioni, F; Fornai, F; Murri, L; Paparelli, A; Pellegrini, A; Ruggieri, S | 1 |
| Campo, R; Cucurella, G; De Fabregues, O; Delgado, T; Garcia, C; Giralt, E; Oliveras, C; Pont-Sunyer, C; Puente, V; Ribera, G; Seoane, A; Vivanco, R | 1 |
| Berezetskaya, NM; Kapustina, MT; Karaban, IN; Lukhanina, EP | 1 |
| Maertens de Noordhout, A | 1 |
| Baldacci, F; Berti, C; Bonuccelli, U; Lucetti, C; Nuti, A; Poletti, M | 1 |
| de Bie, RM; Odekerken, VJ; Post, B; Verschuur, CV | 1 |
| Chiang, TR; Ho, CS; Hu, CJ; Hung, YL; Sheu, JJ; Tseng, IJ; Yeh, CY; Yu, JM; Yuan, RY | 1 |
| Inzelberg, R; Israeli-Korn, SD | 1 |
| Kroenke, K; Murck, H; Stacy, MA | 1 |
| Grosset, D | 1 |
| Cumming, P; Kumakura, Y | 1 |
| Azulay, JP; Cantiniaux, S; Horrelou-Pitek, C; Mancini, J; Robert, D; Vaugoyeau, M; Witjas, T | 1 |
| Cossu, G; Ferrigno, P; Manca, D; Marcia, E; Melis, M; Molari, A; Murgia, D | 1 |
| Jog, MS; Kasravi, N | 1 |
| Barichella, M; Cereda, E; Pezzoli, G | 2 |
| Clarke, CE; Grosset, D; Stewart, D; Worth, P | 1 |
| Bordet, R; Defebvre, L; Devos, D | 1 |
| Bode, M | 1 |
| Caslake, R; Counsell, C; Ives, N; Macleod, A; Stowe, R | 1 |
| Hou, JG; Kurz, MJ | 1 |
| Chihara, N; Lin, Y; Murata, M; Ogawa, M; Tsukamoto, T; Yamamoto, T | 1 |
| Grabli, D; Hartmann, A; Lebreton, M; Palminteri, S; Pessiglione, M; Worbe, Y | 1 |
| Meng, QG; Yu, XD; Zhao, GH | 1 |
| Kato, S; Mizuno, J; Morita, S; Watada, M | 1 |
| Calopa, M; Campdelacreu, J; Jaumà, S; Juncadella, M; Miró, J; Sánchez-Castañeda, C | 1 |
| Enzinger, C; Katschnig, P; Linhart, WE; Ott, E; Schwingenschuh, P; Steinwender, G; Svehlík, M; Zwick, EB | 1 |
| Ohkita, K; Oka, Y; Umemura, A; Yamada, K; Yamawaki, T | 1 |
| Auinger, P; Hauser, RA; Oakes, D | 1 |
| Awa, Y; Hattori, T; Higuchi, Y; Ichikawa, T; Ito, T; Kobayashi, M; Kuwabara, S; Sakakibara, R; Uchiyama, T; Yamaguchi, C; Yamamoto, T; Yamanishi, T; Yanagisawa, M; Yano, M | 1 |
| Clemenceau, S; Czernecki, V; Heran, F; Itti, E; Kinugawa, K; Lepeintre, JF; Mari, I; Roze, E; Vidailhet, M | 1 |
| Barone, P; De Bonis, ML; Galletti, P; Ingrosso, D; Longo, K; Pellecchia, MT; Russo, A; Salvatore, A; Tedeschi, G; Tessitore, A; Zappia, V | 1 |
| Baunez, C; Bezard, E; Fernagut, PO; Juncos, JL; Obeso, JA; Pavon, N; Rodriguez, M; Voon, V; Wickens, J | 1 |
| Azulay, JP; Blin, O; Delaveau, P; Fakra, E; Micallef-Roll, J; Salgado-Pineda, P; Witjas, T | 1 |
| Amanzio, M; Filippi, P; Geminiani, G; Giordano, A; Monteverdi, S; Soliveri, P | 1 |
| Estévez, S; Merello, M; Perez-Lloret, S | 1 |
| Huang, Y; Jiang, X; Tang, A; Wik, G; Zhuo, Y | 1 |
| Annesi, G; Arabia, G; Barone, P; Cozzolino, A; De Mari, M; Epifanio, A; Gallerini, S; Lamberti, P; Marconi, R; Morgante, L; Nicoletti, A; Nicoletti, G; Pugliese, P; Quattrone, A; Torchia, G; Zappia, M | 1 |
| Bramanti, A; Bramanti, P; Lanzafame, P; Marino, S; Sessa, E | 1 |
| Avila, I; Bergstrom, DA; Brazhnik, E; Castañeda, E; Parr-Brownlie, LC; Walters, JR | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Galna, B; Morris, ME; Murphy, AT | 1 |
| Lyte, M | 1 |
| Chan, YH; Chong, WL; Halliwell, B; Huang, SH; Lee, CY; Lim, EC; Looi, WF; Quek, AM; Seet, RC; Tan, JJ; Wang, H | 1 |
| Galter, D; Hoffer, B; Kehr, J; Larsson, NG; Lindqvist, E; Olson, L; Pernold, K; Yoshitake, T | 1 |
| Dharmaindra, A; Dharmarinda, A; Dharminda, A; Gahir, H; Jahanshahi, M; Lagnado, DA; Wilkinson, L | 1 |
| Chung, CY; Hallett, PJ; Isacson, O; Koprich, JB | 1 |
| Schlegel, U; Skodda, S; Visser, W | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Di Rocco, A; Howard, J; Varanese, S | 1 |
| Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV | 1 |
| Askmark, H; Karlsson, E; Lundberg, M; Nyholm, D | 1 |
| Jurjevic, A; Kovacevic, M; Ljubicic, D; Mrsic-Pelcic, J; Perkovic, O; Rudez, J; Vitezic, D; Vitezic, M | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gorgone, G; Ientile, R; Menichetti, C; Pierguidi, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
| Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H | 1 |
| Foote, KD; Morishita, T; Okun, MS | 1 |
| Barrero, FJ; Duran, R; Luna, JD; Morales, B; Ramirez, M; Vives, F | 2 |
| Brodsky, MA; Nutt, JG; Park, BS | 1 |
| Arstrand, K; Dizdar, N; Kullman, A; Nord, M; Zsigmond, P | 1 |
| Benamer, HT; Grosset, DG; Kalra, S | 1 |
| Anaya-Martinez, V; Avila-Costa, MR; Corona, DR; Gutierrez-Valdez, AL; Martinez-Fong, D; Montiel-Flores, E; Ordoñez-Librado, JL | 1 |
| Ekstrand, MI; Galter, D | 1 |
| Chaná, P | 1 |
| Waters, C | 3 |
| Cenci, MA; Ohlin, KE; Rylander, D | 1 |
| Min, K; Park, DH; Yoo, YJ | 1 |
| Antonini, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P | 1 |
| Choonara, Y; Du Toit, LC; Modi, G; Naidoo, D; Ndesendo, V; Ngwuluka, N; Pillay, V | 1 |
| Reichmann, H | 3 |
| Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K | 1 |
| Cenci, MA; Ohlin, KE | 1 |
| Berthet, A; Bezard, E | 1 |
| Antonini, A; Odin, P | 1 |
| Carr, J; Fine, J; Kies, B | 1 |
| Cardinali, DP; Merello, M; Perez-Lloret, S; Rossi, M; Santiago, PL | 1 |
| Björklund, T; Carlsson, T; Carta, M; Cederfjäll, EA; Kirik, D | 1 |
| Allen, JK; Davis, KL; Edin, HM | 1 |
| Plaitakis, A; Spanaki, C; Zafeiris, S | 1 |
| Distler, AM; Mieyal, JJ; Sabens, EA | 1 |
| Au, WL; Lei, N; McKeown, MJ; Oishi, MM | 1 |
| Costentin, J; Edouard, T; Maltête, D; Mihout, B | 1 |
| Suchowersky, O; Toth, C; Zochodne, D | 1 |
| Pezzoli, G; Zini, M | 1 |
| Hamasaki, T; Hirai, T; Kuratsu, J; Yamada, K | 1 |
| Melo, A; Menezes, C | 1 |
| Breit, S; Freudenstein, D; Gasser, T; Krüger, R; Leitner, P; Nägele, T; Schmid-Bielenberg, D; Wächter, T; Weiss, D | 1 |
| Camin, M; Cosentino, A; Fiaschi, A; Picelli, A; Smania, N; Tinazzi, M; Vangelista, A | 1 |
| Cao, HM; Guo, F; Qiao, J; Qu, QM; Wang, RL; Zhe, X | 1 |
| Deuschl, G | 1 |
| Bergmann, L; Jost, WH | 1 |
| Basto, MA; Fonseca, R; Gago, MF; Garrett, C; Linhares, P; Rodrigues, AM; Rosas, MJ; Sousa, C; Sousa, G; Vaz, R | 1 |
| Auff, E; Haubenberger, D; Hochschorner, G; Katzenschlager, R; Kloiber, I; Ott, E; Poewe, W; Ransmayr, G; Schwingenschuh, P; Seppi, K; Wolf, E | 1 |
| Cardinali, DP; Merello, M; Perez Lloret, S; Rossi, M | 1 |
| Huang, Y; Jiang, X; Wik, G; Zhuo, Y | 1 |
| Abelli, P; Aquilani, R; Bazzini, G; Bertotti, G; Frazzitta, G; Maestri, R; Uccellini, D | 1 |
| Berrocal-Izquierdo, N; Castrillo-Sanz, A; Martínez-Pueyo, A; Rodríguez-Vico, JS | 1 |
| Duval, C; Edwards, R; Jog, M; Mann, RK; Zhou, J | 1 |
| Chung, KA; Horak, F; Lobb, BM; McNames, J; Nutt, JG | 1 |
| Danton, AC; Durrieu, G; Lacroix, I; Montastruc, JL; Olivier, P; Senard, JM; Sommet, A | 1 |
| dell'Aquila, C; Lamberti, P; Logroscino, G; Specchio, LM; Zoccolella, S | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Chung, KA; Holford, NH; Nutt, JG | 1 |
| Sethi, KD | 3 |
| Demiray, DY; Erginöz, E; Kenangil, G; Ozekmekçi, S; Sohtaoğlu, M | 1 |
| Gil, S; Koh, H; Lee, J; Park, C | 1 |
| Bagetta, V; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C | 1 |
| Cacciatore, I; Conte, C; Cornacchia, C; Minelli, A; Pinnen, F; Prudenzi, E; Taha, E | 1 |
| Jenner, P; Obeso, JA; Stocchi, F | 1 |
| Lee, GS; Lin, SH | 1 |
| Fukaya, C; Katayama, Y; Kobayashi, K; Nishikawa, Y; Ogasawara, K; Ogawa, A; Oshima, H; Yamamoto, T | 1 |
| Cardoso, F; Dias, FM; Kummer, A; Teixeira, AL | 1 |
| Abe, T; Isobe, C; Terayama, Y | 1 |
| Del Soldato, P; Giustarini, D; Lee, M; McGeer, E; McGeer, PL; Rossi, R; Sparatore, A; Tazzari, V | 1 |
| Boulamery, A; Bruguerolle, B; Simon, N; Vidal, J | 1 |
| Diez, MJ; Díez, R; Fernandez, N; Garcia, JJ; Sahagun, AM; Sierra, M | 1 |
| Bortolato, M; Cannas, A; Marrosu, F; Muroni, A; Puligheddu, M; Solla, P | 1 |
| Factor, S; Sethi, K; Watts, R | 1 |
| Andreoni, S; Begni, B; Brighina, L; Difrancesco, JC; Ferrarese, C; Galbussera, A; Piazza, F; Piolti, R; Prigione, A | 1 |
| Fazeli, G; Gerlach, M; Kuhn, W; Oli, RG; Stopper, H; Walitza, S | 1 |
| Coelho, M; Ferreira, JJ; Marti, MJ; Rosa, M; Sampaio, C; Tolosa, E; Valldeoriola, F | 1 |
| Marconi, S; Stocchi, F | 1 |
| Fujino, J; Tabushi, K; Tanaka, H; Taniguchi, N | 1 |
| Li, HJ; Sun, MS; Wang, WJ; Xie, TH; Yan, M; Zhang, GM | 1 |
| Delea, TE; Hagiwara, M; Mancione, L; Thomas, SK | 1 |
| Diez, MJ; Díez, R; Fernández, N; García, JJ; González, A; Sahagún, AM; Sierra, M | 1 |
| Artemova, IIu; Boĭko, AN; Ganzhula, PA; Ismailov, AM; Ivanov, AK; Khozova, AA; Levin, OS; Lisenker, LN; Nesterova, OS; Otcheskaia, OV; Rotor, LD; Vdovichenko, TV; Zhuravleva, EIu | 1 |
| Dougherty, M; Ghiamati, S; Groth, T; Johansson, A; Memedi, M; Nyholm, D; Westin, J | 1 |
| San Luciano, M; Saunders-Pullman, R | 1 |
| Hälbig, TD; Tse, W | 1 |
| Schneemilch, C | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Koester, J; Lang, AE; Potenza, MN; Siderowf, AD; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR | 1 |
| Byrne, GJ; Dissanayaka, NN; Marsh, R; Matheson, S; Mellick, GD; O'Sullivan, JD; Sellbach, A; Silburn, PA | 1 |
| Cresswell, SA; Evans, AH; Katzenschlager, R; Lawrence, AD; Lees, AJ | 1 |
| Adams, B; Earl, NL; Gray, AM; Hauser, RA; Lyons, KE; Olanow, W; Pahwa, R; Sethi, K; Stern, M; Watts, RL | 1 |
| Bari, M; Bernardi, G; Fezza, F; Galati, S; Maccarrone, M; Moschella, V; Pisani, A; Pisani, V; Stanzione, P | 1 |
| Añón-Seijas, MJ; da Riba-Casaux, M; Llaneza-González, MA; Santos-García, D | 1 |
| Amaro-Junior, E; Andrade, LA; Borges, V; Bressan, RA; Felicio, AC; Ferraz, HB; Godeiro-Junior, C; Hoexter, MQ; Moriyama, TS; Shih, MC; Silva, SM | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Cao, X; Mochizuki, H; Mouradian, MM; Papa, SM; Uthayathas, S; Watts, RL; Yasuda, T | 1 |
| Stiefelhagen, P | 1 |
| Glad, A; Karlsborg, M; Korbo, L; Regeur, L | 1 |
| Nodel', MR | 1 |
| Boonyapisit, K; Nunta-Aree, S; Pisarnpong, A; Sitthinamsuwan, B | 1 |
| Cámara, A; Valldeoriola, F | 1 |
| Kleiner-Fisman, G; Lang, AE; Lozano, A; Moro, E; Poon, YY | 1 |
| Antonini, A; Bareggi, SR; Bondiolotti, G; Natuzzi, F | 1 |
| Fisone, G; Santini, E; Valjent, E | 2 |
| Breithaupt, K; Duan, Y; Ge, S; Suchowersky, O; Terris, JM; Thiessen, A; Toth, C; Wiebe, S; Zochodne, DW | 1 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Amthauer, H; Assion, HJ; Beucke, JC; Endrass, T; Juckel, G; Kupsch, A; Plotkin, M; Uhl, I; Winter, C | 1 |
| Cetas, JS; Fields, JD | 1 |
| Bertotti, G; Frazzitta, G; Maestri, R; Uccellini, D | 1 |
| Avakian, GN; Bezdol'nyĭ, IuN; Katunina, EA; Malykhina, EA; Titova, NV | 1 |
| Bachmann, CG; Linazasoro, G; Sharma, JC | 1 |
| Cordo, PJ; Gurfinkel, VS; Horak, FB; King, LA; Nutt, JG; Wright, WG | 1 |
| Boon, P; De Bodt, M; De Letter, M; Dhooge, I; Santens, P; Van Borsel, J | 1 |
| Ivanov, AK; Levin, OS; Smolentseva, IG | 1 |
| Clarke, CE; Deane, K; Furmston, A; Gray, R; Handley, K; Ives, N; Stowe, R; Wheatley, K | 1 |
| Angoa-Perez, M; Bishop, C; Eskow Jaunarajs, KL; Kuhn, DM | 1 |
| Baldacci, F; Berti, C; Bonuccelli, U; Ceravolo, R; Del Dotto, P; Dolciotti, C; Gambaccini, G; Logi, C; Lucetti, C; Rossi, G | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Calabresi, P; Ghiglieri, V; Picconi, B | 1 |
| Belujon, P; Grace, AA; Lodge, DJ | 1 |
| Bushnell, MC; Mak, E; Nandhagopal, R; Schulzer, M; Stoessl, AJ; Troiano, AR | 1 |
| Bonnici, A; Hornstein, D; Ruiner, CE; St-Laurent, L | 1 |
| Arning, P; Baron, R; Binder, A; Deuschl, G; Gierthmühlen, J; Herzog, J; Wasner, G | 1 |
| Beaugendre, Y; Brugières, P; de Andrade, DC; Fenelon, G; Goujon, C; Gurruchaga, JM; Jarraya, B; Kirov, K; Lepetit, H; Mandat, T; Palfi, S; Tani, N | 1 |
| Bhatia, KP; Cantello, R; Carecchio, M; Collini, A; Comi, C; Monaco, F | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Fuxe, K; Galter, D; Lindqvist, E; Marcellino, D; Müller, CE; Olson, L; Schneider, M | 1 |
| Jouve, L; Kerkerian-Le Goff, L; Melon, C; Salin, P | 1 |
| Aquilonius, SM; Estrada, M; Johansson, A; Lennernäs, H; Nyholm, D | 1 |
| Iliceto, G; Lamberti, P; Lamberti, SV; Logroscino, G; Santamato, A; Zoccolella, S | 1 |
| Adeli, GM; Arenovich, T; Fox, SH; Hung, SW; Lang, AE | 1 |
| Auh, S; Dang, N; Hallett, M; Jin, SH; Kang, SY; Kida, T; Lopez, GJ; Shamim, EA; Ueki, Y; Wasaka, T | 1 |
| Dall'Armi, V; Kulisevsky, J; Lamberti, P; Obeso, JA; Stocchi, F; Zappia, M | 1 |
| Barone, P; Haaksma, M; Hauser, RA; Juhel, N; Mizuno, Y; Poewe, W; Rascol, O; Salin, L; Schapira, AH | 1 |
| Barichella, M; Cereda, E; Pedrolli, C; Pezzoli, G | 1 |
| Azulay, JP; Blin, O; Delaveau, P; Fossati, P; Salgado-Pineda, P; Witjas, T | 1 |
| Attarian, S; Azulay, JP; Eusebio, A; Vacherot, F | 1 |
| de la Fuente-Fernández, R; Dinelle, K; Lidstone, SC; Mak, E; Phillips, AG; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ | 1 |
| Bedard, MA; Blanchet, PJ; Langlois, D; Lemay, M; Parent, M; Tremblay, PL | 1 |
| Becker, ML; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Pandya, M; Zaharna, M | 1 |
| Hattori, N; Mizuno, Y; Motoi, Y; Nakamura, S; Shiotsuki, H | 1 |
| Bugalho, P; da Silva, JA; Neto, B | 1 |
| Frank, MJ; Wiecki, TV | 1 |
| Cenci, MA; Konradi, C | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F | 2 |
| Barbieri, S; Cogiamanian, F; Giannicola, G; Marceglia, S; Mrakic-Sposta, S; Priori, A; Rampini, P; Rossi, L; Tamma, F | 1 |
| Koch, G | 1 |
| Farrell, M; Fok, P; McMeeken, J | 1 |
| Giugni, J; Micheli, F; Seijo, D | 1 |
| Kek, PC; Prakash, KM | 1 |
| Barbosa, ER; Chien, HF; Melo, LM | 1 |
| Grayson, M | 1 |
| Smith, K | 1 |
| Abbott, A | 1 |
| Kaczmarska, J; Konradi, C; Luksik, AS; Naydenov, AV; Vassoler, F | 1 |
| Akat, S; Emre, M; Gurvit, H; Hanagasi, HA; Yazici, J | 1 |
| Cervantes-Arriaga, A; Corona, T; Rodríguez-Violante, M; Villar-Velarde, A | 1 |
| Buck, K; Ferger, B | 1 |
| Carlson-Kuhta, P; Horak, FB; King, LA; Nutt, JG; St George, RJ | 1 |
| Grählert, X; Löhle, M; Reichmann, H; Schneider, C; Schwanebeck, U; Schwarz, J; Storch, A; Strecker, K; Wolz, M | 1 |
| Bokor, M; Szentesi, A | 1 |
| Fan, YB; Lu, HH; Tsai, MC; Tsai, TH; Wang, CL; Wang, HP | 1 |
| Tison, F | 1 |
| Khadem, NR; Nirenberg, MJ | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Bergman, H; Israel, Z; Ritov, Y; Zaidel, A | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Arévalo, GG; Chade, A; Gershanik, O; Gleichgerrcht, E; Manes, F; Roca, M; Torralva, T | 1 |
| Hou, B; Jiang, T; Liu, R | 1 |
| Bishop, C; Button, T; Deak, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY | 1 |
| Deuschl, G; Herzog, J; Volkmann, J; Wailke, S; Witt, K | 1 |
| Antonini, A; Burkhard, PR; Poewe, W; Vingerhoets, F; Zijlmans, JC | 1 |
| Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M | 1 |
| Inoue, T; Koyama, M; Ogata, A; Tani, Y | 1 |
| Lane, EL; Smith, GA | 1 |
| Gárdián, G; Vécsei, L | 1 |
| Bugalho, P; Lampreia, T; Santos, L; Soares, P | 1 |
| Azulay, JP; Balduyck, S; Blin, O; Brefel-Courbon, C; Durif, F; Esquerre, JP; Ory-Magne, F; Payoux, P; Rascol, O; Regragui, W; Thalamas, C; Tison, F | 1 |
| Calabresi, P; Di Filippo, M; Ghiglieri, V; Picconi, B; Tambasco, N | 1 |
| Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D | 1 |
| Lozano, AM; Ponce, FA | 1 |
| Moore, S; Ondo, WG; Shinawi, L | 1 |
| Dewey, RB | 1 |
| Kitamura, Y | 1 |
| Bernardos, VS; Del Pozo, SV; López, IC; Ruiz, PJ | 1 |
| Böselt, S; Dressler, D; Schrader, C; Wedemeyer, J; Weismüller, TJ | 1 |
| Ariga, H; Iguchi-Ariga, SM; Ishikawa, S; Niki, T; Taira, T; Takahashi-Niki, K | 1 |
| Alterman, R; Martin, C; Tagliati, M | 1 |
| Ngamreungphong, S; Nugent, K; Singhatiraj, E | 1 |
| Brefel-Courbon, C; Calvas, F; Gerdelat-Mas, A; Marchand-Pauvert, V; Mazevet, D; Meunier, S; Ory-Magne, F; Simonetta-Moreau, M; Vidailhet, M | 1 |
| Cho, J; Jeon, BS; Lee, EK; Lee, JY; Park, SS | 1 |
| Haahr, A; Hall, EO; Kirkevold, M; Ostergaard, K | 1 |
| de la Fuente-Fernández, R; Grande, M; Llaneza, M; Macías, M; Santos-García, D | 1 |
| Drent, M; Leenders, KL; Meppelink, AM; Nyman, R; Prins, T; van Laar, T | 1 |
| Adler, CH; Caviness, JN; Driver-Dunckley, E; Evidente, VG; Lyons, MK; Premkumar, AP | 1 |
| Chen, KH; Hsu, HY; Huang, TT; Wang, BH | 1 |
| Aono, K; Hanayama, K; Hyodo, M; Kasahara, T; Kodama, M; Koyama, Y; Masakado, Y; Sugaya, M | 1 |
| Kishore, A; Krishnan, S; Panikar, D; Rao, R; Sarma, G; Sarma, S; Sivasanakaran, MP | 1 |
| Martnez-Sánchez, F | 1 |
| Houlden, H; Paisán-Ruiz, C | 1 |
| Gradl, B; Persson, U; Willis, M; Zoellner, Y | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Grönheit, W; Schlegel, U; Skodda, S | 1 |
| Gray, WK; Howells, AR; Walker, RW | 1 |
| Baker, K; Burn, D; Lord, S; Nieuwboer, A; Rochester, L | 1 |
| Alegre, M; Artieda, J; Garcia-Garcia, D; Guridi, J; López-Azcárate, J; Obeso, JA; Rodriguez-Oroz, MC; Toledo, J; Valencia, M | 1 |
| Clarke, CE; Gray, R; Patel, S; Rick, C; Stowe, R; Tomlinson, CL | 1 |
| Bentivoglio, AR; Fasano, A; Pettorruso, M; Ricciardi, L | 1 |
| Colosimo, C; Poewe, W; Zappia, M | 1 |
| Contin, M; Martinelli, P | 1 |
| Hametner, E; Poewe, W; Seppi, K | 1 |
| Berardelli, A; Bloise, M; Di Stasio, F; Fabbrini, G | 1 |
| Echebarria, SG | 1 |
| Atula, S; Heikkinen, E; Jaakkola, MR; Keränen, T; Martikainen, K; Pekka, J; Pekkonen, E; Reijo, M; Sotaniemi, K | 1 |
| Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 1 |
| Nissinen, E | 1 |
| Kaakkola, S | 1 |
| Bougia, P; Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tzallas, AT | 1 |
| Brand, M; Labudda, K; Markowitsch, HJ; Mertens, M; Ollech, I; Woermann, FG | 1 |
| Fiorlli, M; Iaconelli, S; Kusch, I; Lena, F; Mirabella, G; Modugno, N | 1 |
| Hama, T; Hara, T; Hirayama, M; Ito, M; Nakamura, T; Niimi, Y; Ohno, K; Sobue, G; Uchida, K; Watanabe, H | 1 |
| Chapman, J; Cohen, OS; Hassin-Baer, S; Katzav, A; Korczyn, AD; Molchadski, I; Nitzan, Z | 1 |
| Delea, TE; Hagiwara, M; Thomas, SK | 1 |
| Ambermoon, P; Carter, A; Dissanayaka, NN; Hall, WD; O'Sullivan, JD | 1 |
| Amthauer, H; Beucke, JC; Endrass, T; Juckel, G; Kupsch, A; Plotkin, M; Winter, C | 1 |
| Elmongy, A; Gabr, W; Hazem, M; Razek, AA; Zakareyia, S | 1 |
| Cretu, E; Farajian, S; McKeown, MJ; Oishi, MM; Stevenson, JK; Ty, E | 1 |
| Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH | 1 |
| Hamamoto, M; Katayama, Y; Kumagai, T; Nagayama, H; Nishimura, S; Nishiyama, Y; Tsukamoto, K; Ueda, M | 1 |
| Bogdanov, RR; Kotov, SV; Kunitsyna, AN; Turbina, LG | 1 |
| Gan, YC; Mitchell, RD; Mocroft, AP; Nightingale, P; Sutcliffe, AJ | 1 |
| Britt, JP; Ding, Y; Kang, UJ; Lim, SA; McGehee, DS; Won, L | 1 |
| Hakimi, R | 1 |
| Inzelberg, R; Weinberger, M | 1 |
| de Oliveira, GR; Gondim, Fde A; Horta, WG; Peixoto, AA | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Dick, OE; Nozdrachev, AD; Romanov, SP | 1 |
| Fereshtehnejad, SM; Mehrabani, M; Rohani, M; Zamani, B | 1 |
| Barone, P | 2 |
| Bentivoglio, AR; Caliandro, P; Cioni, M; D'Urso, PI; Ferrarin, M; Minciotti, I; Padua, L; Tonali, PA | 1 |
| Beck, J; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Agid, Y; Bellanger, A; Ben Djebara, M; Bonnet, AM; Bonnet, C; Charbonnier-Beaupel, F; Corvol, JC; Costentin, J; Fiévet, MH; Hartmann, A; Hulot, JS; Lacomblez, L; Meliksetyan, G; Roze, E; Vidailhet, M; Vrignaud, C; Zahr, N | 1 |
| Jeon, BS; Kim, HJ; Lee, JY | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Tateno, T; Terada, H | 1 |
| Andersson, D; Cenci, MA; Francardo, V; Nissbrandt, H; Popovic, N; Recchia, A | 1 |
| Fung, VS; Latt, MD; Lord, SR; Menant, JC; Menz, HB | 1 |
| Cantillon, M; Hauser, RA; Huyck, S; Micheli, F; Mok, V; Onofrj, M; Pourcher, E; Wolski, K | 1 |
| Auclair-Ouellet, N; Cantin, L; Chantal, S; Langlois, M; Macoir, J; Prud'homme, M | 1 |
| Holton, JL; Johnson, M; Lees, AJ; O'Sullivan, SS; Perry, EK; Revesz, T; Williams, DR | 1 |
| Gnädinger, M; Kaelin-Lang, A; Mellinghoff, HU | 1 |
| Halliday, GM; Hely, MA; Loy, C; Morris, JG; Reid, WG | 1 |
| Bidet-Ildei, C; Fraix, V; Kandel, S; Orliaguet, JP; Pollak, P | 1 |
| Duffy, A; Eldridge, PR; Fletcher, NA; Fox, SH; Varma, TR; Wong, SH | 1 |
| Ivanov, AK; Levin, OS; Shindriaeva, NN | 1 |
| Fernandez, HH; Odin, P | 1 |
| Cha, DR; Kang, YS; Koh, SB; Kwon, DY; Park, KW; Park, MH; Seo, WK | 1 |
| Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T | 1 |
| Clarke, CE; Deane, K; Furmston, A; Gray, R; Handley, K; Ives, N; Stowe, R; van Hilten, JJ; Wheatley, K | 1 |
| Holford, NH; Nutt, JG | 2 |
| Ahmed, I; Bose, SK; Brooks, DJ; Hammers, A; Hotton, G; Pavese, N; Ramlackhansingh, A; Turkheimer, F | 1 |
| Matsukawa, N; Oka, Y; Okita, K; Umemura, A; Yamada, K | 1 |
| Del-Bel, E; Lazzarini, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Butz, M; Elben, S; Homburger, M; Özkurt, TE; Schnitzler, A; Vesper, J; Wojtecki, L | 1 |
| Bentivoglio, AR; Guidubaldi, A; Petracca, M; Piano, C; Santorelli, FM; Silvestri, G; Tessa, A | 1 |
| Arabia, G; Cerasa, A; Lanza, P; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Fujimoto, K; Hattori, N; Kondo, T; Murata, M | 1 |
| Aquilonius, SM; Askmark, H; Nyholm, D | 1 |
| Lanzillo, B; Nolano, M; Provitera, V; Santoro, L | 1 |
| Brooks, DJ; Lewis, SJ; Pavese, N; Rivero-Bosch, M; Whone, AL | 1 |
| Adams, C; Keep, M; Kumar, R; Martin, K; McVicker, J | 1 |
| Chiang, J; McKeown, MJ; Tropini, G; Ty, E; Wang, ZJ | 1 |
| Arai, M | 3 |
| Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G | 1 |
| Benincasa, D; Fanciulli, A; Pellicano, C; Pontieri, FE | 1 |
| Baek, SM; Cho, ED; Ho, DH; Lee, HJ; Lee, SJ; Suk, JE | 1 |
| Lang, AE; Potenza, MN; Siderowf, AD; Sohr, M; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR | 1 |
| Duker, AP; Espay, AJ; Gartner, M; Revilla, FJ; Sahay, A; Shukla, R; Vaughan, JE | 1 |
| Corcos, DM; Foto, J; Hondzinski, JM; Kadivar, Z | 1 |
| Auinger, P; Hauser, RA | 1 |
| Au, WL; Palmes, P; Rajapakse, JC; Sitoh, YY; Tan, LC; Zhou, J | 1 |
| Dotchin, C; Jusabani, A; Walker, R | 1 |
| Azlin, B; Fazli, A; Rosdinom, R; Ruzyanei, NJ; Srijit, D | 1 |
| Evans, AH; Farrell, MJ; Lim, SY | 1 |
| Bormans, G; Casteels, C; Goffin, K; Grachev, ID; Lunskens, S; Van Laere, K; Vandenberghe, W | 1 |
| Fernandez, HH; Hicks, CW; Itin, I; Pandya, MM | 1 |
| Baker, K; Burn, D; Nieuwboer, A; Rochester, L | 1 |
| Bartolo, M; Buscone, S; Martignoni, E; Pacchetti, C; Perrotta, A; Pierelli, F; Sandrini, G; Serrao, M; Tassorelli, C; Tinazzi, M; Zangaglia, R | 1 |
| Griffith, L; Haes, AJ; Subramaniam, V | 1 |
| McKeown, MJ; Oishi, MM; TalebiFard, P | 1 |
| Giorgi, L; Hunter, B; Schapira, AH; Stocchi, F | 1 |
| Angrisano, S; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Zibetti, M | 1 |
| Bosco, D; Bosco, F; Fava, A; Plastino, M; Rotondo, A | 1 |
| Abi-Saab, W; Berg, D; Cooke, K; Csoti, I; Di Paolo, T; Eggert, K; Gasparini, F; Godau, J; Gomez-Mancilla, B; Hariry, S; Huber, H; Johns, D; Morelli-Canelo, M; Ries, V; Schneider, C; Stamelou, M; Storch, A; Trenkwalder, C; Vandemeulebroecke, M; Wolz, M | 1 |
| Gao, X; Ning, Y | 1 |
| Lee, MS; Lyoo, CH | 1 |
| Flasskamp, A; Schlegel, U; Skodda, S | 1 |
| Chan, A; Chan, J; Cheung, YF; Chung, TH; Kuo, SH; Kwan, P; Lau, C; Mok, V; Tsang, KL; Yeung, J; Yeung, MA | 1 |
| Anderson, E; Nutt, J | 1 |
| Harris, MA; Koehoorn, M; Teschke, K | 1 |
| Cohen, OS; Efrati, L; Hassin-Baer, S; Korczyn, AD; Kozlova, E; Molchadski, I; Nitzan, Z; Tunkel, O | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Cronin-Golomb, A; Stavitsky, K | 1 |
| Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK | 1 |
| Bassi, MS; Bernardi, G; Fedele, E; Galati, S; Marzetti, F; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A; Vitek, J | 1 |
| Bloem, BR; Hovestadt, A; van Laar, T; Vlaar, A | 1 |
| Bachoud-Lévi, AC; Cleret de Langavant, L; Fénelon, G; Soulas, T; Trinkler, I | 1 |
| Abbs, JH; Bendlin, BB; Brooks, BR; Brown, WD; Chung, MK; Dejesus, OT; Dogan, S; Gallagher, CL; Holden, JE; Johnson, SC; Konopacki, RA; Nickles, RJ; Oakes, TR; Pyzalski, RW; Xu, G | 1 |
| Bakay, RA; Beebe, K; Cornfeldt, M; Eisner, W; Fichte, K; Gross, RE; Hauser, RA; Hong, W; Ondo, WG; Reichmann, H; Reissig, E; Sandbrink, R; Siedentop, H; Steiner-Schulze, H; von Kummer, R; Watts, RL | 1 |
| Coelho, M; Ferreira, JJ; Pires, D; Rosa, MM; Sampaio, C; Teodoro, T | 1 |
| Danoudis, M; Iansek, R | 2 |
| Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
| Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S | 1 |
| Barker, RA; Brayne, C; Evans, JR; Foltynie, T; Mason, SL; Robbins, TW; Williams-Gray, CH | 1 |
| Hashim, HZ; Ibrahim, N; Ngiu, CS; Tan, HJ; Wan Musa, WR; Wan Yahya, WN | 1 |
| Arai, H; Doi, N; Hatta, K; Hattori, N; Kamigaichi, R; Kubo, S; Nakamura, H; Nakanishi, A; Usui, C | 1 |
| Ahmed, I; Bose, SK; Brooks, DJ; Pavese, N; Ramlackhansingh, AF; Turkheimer, FE | 1 |
| Hazan, D; Siegert, S; Szyper-Kravitz, M | 1 |
| Chen, C; Cowles, VE; Illarioshkin, SN; Stolyarov, ID; Sweeney, M | 1 |
| Balaboi, I; Benatru, I; Bonaventure, A; Dumurgier, J; Dupupet, JL; Elbaz, A; Fayard, C; Giroud, M; Goldberg, M; Houeto, JL; Houssinot, J; Imbernon, E; Krim, E; Mazurie, JL; Moisan, F; Moreau, T; Ranoux, D; Roze, E; Soumaré, A; Tzourio, C | 1 |
| Carpintero, P; de la Fuente-Fernández, R; Llaneza, M; Macías, M; Sanjurjo, LF; Santos-García, D | 1 |
| Albani, G; Cattaldo, S; De Gennaro, M; El Assawy, N; Gregorini, F; Mauro, A; Pradotto, L | 1 |
| Garcia-Ruiz, PJ | 1 |
| Albanese, A; Dollenz, C; Elia, AE; Soliveri, P | 1 |
| Konitsiotis, S; Maranis, S; Tsouli, S | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gallina, A; Rossi, A; Tambasco, N | 1 |
| Dietrichs, E; Gerdts, R; Gundersen, V; Lilleeng, B; Pedersen, L; Ramm-Pettersen, J; Røste, GK; Skjelland, M; Skogseid, IM; Toft, M | 1 |
| Ludin, HP | 9 |
| Agarwal, P; Alcalay, R; Black, KJ; Chou, KL; Cote, L; Dayalu, P; Frank, S; Friedman, JH; Hartlein, J; Hauser, RA; Lang, AE; Marsh, L; Marshall, F; Moskowitz, C; Ravina, B; Riley, D; Sanchez-Ramos, J; Simon, DK; Simuni, T; Sutton, J; Tuite, P; Weintraub, D; Zesiewicz, T | 1 |
| Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu | 1 |
| Bugalho, P; Cargaleiro, I; da Silva, JA; Neto, B; Serra, M | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Franzén, E; Horak, FB; Jones, GM; Paquette, C | 1 |
| Jakobi, JM; Jones, GR; Powell, C; Roland, KP | 1 |
| Auyeung, M; Cheung, CM; Lee, CN; Li, R; Tang, WK; Tsoi, TH; Yeung, E | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Takahashi, O; Tateno, F; Uchiyama, T; Yamamoto, T; Yamanishi, T; Yokoi, Y | 1 |
| Garlipp, CR; Gobbi, LT; Gobbi, S; Nascimento, CM; Santos, RF; Stella, F | 1 |
| Bernardi, G; Berretta, N; Guatteo, E; Lipski, J; Mercuri, NB; Nistico, R | 1 |
| Bergman, A; Chaudhuri, KR; Findley, LJ; Lowin, J; Morris, S; Roeder, C; Schifflers, M; Wood, E | 1 |
| Defazio, G | 1 |
| Franch, O; Kurtis, MM | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE | 1 |
| Choi, Y; Hong, JY; Kim, HO; Kim, HS; Lee, JE; Lee, PH; Nam, HS; Sohn, YH | 1 |
| Biseul, I; Drapier, D; Drapier, S; Ory, S; Péron, J; Philippot, P; Vérin, M; Vicente, S | 1 |
| Chen, RS; Chuang, WL; Huang, YZ; Lu, CS; Rothwell, JC | 1 |
| Bloem, BR; Munneke, M; Petzinger, GM; Speelman, AD; van de Warrenburg, BP; van Nimwegen, M | 1 |
| Ellenbogen, AL; Gupta, SK; Hauser, RA; Hsu, A; Kell, SH; Metman, LV; Modi, NB; O'Connell, MJ; Yao, HM | 1 |
| Antonini, A; Biundo, R; D'Avella, D; Ferla, S; Landi, A; Padoan, A; Pilleri, M | 1 |
| Bareš, M; Farníková, K; Jech, R; Kaňovský, P; Pavlík, T; Rektor, I; Rektorová, I; Roth, J; Růžička, E; Uhlířová, L; Vydlák, J | 1 |
| Kabuto, H; Yamanushi, TT | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Tateno, F | 1 |
| Holmes, D | 1 |
| Heimrath, J; Kassubek, J; Ludolph, AC; Lulé, D; Pinkhardt, EH; Uttner, I | 1 |
| Arbouw, ME; Egberts, TC; Guchelaar, HJ; Movig, KL; Neef, C | 2 |
| Ballesteros, D; Cerquetti, D; Gerschcovich, ER; Merello, M | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Geiser, E; Kaelin-Lang, A | 1 |
| Jahanshahi, M; Obeso, I; Wilkinson, L | 1 |
| Fook-Chong, S; Lim, LL; Pavanni, R; Tan, EK; Yong, MH | 1 |
| Huynh, T | 1 |
| Liedhegner, EA; Mieyal, JJ; Steller, KM | 1 |
| Calabresi, P; Di Luca, M; Gardoni, F; Pendolino, V; Picconi, B; Sgobio, C | 1 |
| Kincses, ZT; Szabó, N; Toldi, J; Vécsei, L | 1 |
| Ballinari, P; Kaelin-Lang, A; Kipfer, S; Schüpbach, WM; Stephan, MA | 1 |
| Burchiel, KJ; Carlson-Kuhta, P; Hogarth, P; Horak, FB; Robertson, LT; St George, RJ | 1 |
| Bordia, T; Huang, L; Perez, X; Quik, M | 1 |
| Goh, JY; Lim, SY; Lor, TL; Mohamed, H; Ngam, PI; Ooi, E; Schee, JP; Soh, PC; Tan, AK; Tan, ZK | 1 |
| Lew, MF; McCague, K; Somogyi, M; Welsh, M | 1 |
| Balbi, P; Bertotti, G; Boveri, N; Comi, C; Frazzitta, G; Guaglio, G; Maestri, R; Perini, M; Riboldazzi, G; Turla, M; Uccellini, D | 1 |
| Forsberg, MM; Kääriäinen, TM; Käenmäki, M; Männistö, PT; Oinas, N; Tammimäki, A | 1 |
| Dhawan, V; Eidelberg, D; Ma, Y; Mattis, PJ; Tang, CC | 1 |
| Ceballos-Baumann, A; Häck, HJ | 1 |
| Charlton, C; King, JM; Mackey, V; Muthian, G; Smith, M | 1 |
| Cai, XY; Fang, Q; Kong, XM; Ning, P; Xu, YJ; Xue, SR; Zhang, B | 1 |
| McKeown, MJ; Oishi, MM; Stevenson, JK; Talebifard, P; Ty, E | 1 |
| Bowers, D; Fargen, KM; Fernandez, HH; Foote, KD; Hass, CJ; Jacobson, CE; Katayama, Y; Malaty, IA; Morishita, T; Okun, MS; Rahman, M; Rodriguez, RL; Yamamoto, T | 1 |
| Fernandez, HH; Foote, KD; Hwynn, N; Iyer, SS; Jacobson, CE; Malaty, IA; Okun, MS; Oyama, G; Rodriguez, RL; Zeilman, P | 1 |
| Iravani, MM; Jenner, P | 1 |
| Guzman, JN; Sanchez-Padilla, J; Schumacker, PT; Surmeier, DJ | 1 |
| Chen, B; Feng, T; Liu, P; Wang, YJ; Zhang, X | 1 |
| Abdin, AA; Sarhan, NI | 1 |
| Antonini, A; Calandrella, D | 2 |
| Rabey, JM; Stocchi, F | 1 |
| Fox, S; Meissner, WG; Prashanth, LK | 1 |
| Bezard, E; Fisone, G | 1 |
| Brotchie, J; Jenner, P | 1 |
| Lozano, AM; Sankar, T | 1 |
| Collins, C; Holton, JL; Kallis, C; Kuoppamäki, M; Lees, AJ; O'Sullivan, SS; Parkkinen, L; Revesz, T; Williams, DR | 1 |
| Obeso, JA; Olanow, CW | 3 |
| Dubow, J; LeWitt, PA; Singer, C | 1 |
| Brusa, L; Ceravolo, R; Iani, C; Kiferle, L; Koch, G; Monteleone, F; Schillaci, O; Stanzione, P | 1 |
| Dilda, V; Hakim, B; Macdougall, HG; Moore, ST | 1 |
| Depradine, J; Rana, AQ | 1 |
| Joseph, T; Kishore, A; Meunier, S; Popa, T; Velayudhan, B | 1 |
| Crossman, AR; Hill, MP; Kobylecki, C; Ravenscroft, P | 1 |
| Chen, R; Duker, AP; Dunn, E; Espay, AJ; Giuffrida, JP; Heldman, DA; Kim, SJ; Mazzella, F; Payne, M; Revilla, FJ; Sahay, A; Vaughan, JE | 1 |
| Gotoh, J; Isozumi, K; Iwasawa, S; Koto, A; Mihara, B; Morita, Y; Muramatsu, K; Nihei, Y; Ohta, K; Sato, H; Seki, M; Suzuki, N; Takahashi, K; Tomita, Y; Yamaguchi, K | 1 |
| DeLong, MR; Factor, SA; Smith, Y; Wichmann, T | 1 |
| Almer, Z; Gerstenhaber, M; Klein, KS; Marsh, L; Repka, MX | 1 |
| Babiuc, RD; Bajenaru, OA; Ene, A; Negreanu, L; Popescu, BO; Smarandache, GC | 1 |
| Espay, AJ; Giuffrida, JP; Heldman, DA; Mera, TO; Payne, M | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A | 1 |
| Chan, SW; Double, KL; Dunlop, RA; Rodgers, KJ; Rowe, A | 1 |
| Buttarelli, FR; Campanelli, D; Fanciulli, A; Misasi, R; Pontieri, FR | 1 |
| Krajcovicova, L; Marecek, R; Mikl, M; Rektorova, I | 1 |
| Gutiérrez-Alvarez, AM; Hernández-Beltrán, N; Moreno, CB; Munévar, D | 1 |
| Obeso, JA; Olanow, W | 1 |
| Jeon, BS; Kang, D; Kim, C; Kim, DG; Kim, HJ; Kim, MR; Lee, JY; Lim, YH; Paek, SH | 1 |
| Fedorova, NV; Kulua, TK; Popovkina, OA | 1 |
| Eggers, C; Fink, GR; Kahraman, D; Leube, B; Schmidt, M; Timmermann, L; Volk, AE | 1 |
| Ondo, WG | 1 |
| Becker, N; Munhoz, RP; Teive, HA | 1 |
| Benabid, AL | 1 |
| Breckenridge, A; Collier, A; Davidson, DF; Freel, EM; Ghosh, S; Perry, CG | 1 |
| Luquin-Piudo, MR; Sanz, P | 1 |
| de Fabregues, O; Marin, C; Rodriguez-Oroz, MC | 1 |
| Arbelo, JM; del Val, JL; Sesar, A | 1 |
| Herrero, MT; Linazasoro, G; Pagonabarraga, J | 1 |
| Cederfjäll, E; Kirik, D; Sahin, G | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Eng, M; Eura, N; Furiya, Y; Ikada, Y; Ikeda, M; Izumi, T; Kataoka, H; Kiriyama, T; Kitauti, T; Saeki, K; Sugie, K; Tanaka, N; Ueno, S | 1 |
| Kondo, T; Takahashi, K | 1 |
| Albanese, A; Carella, F; Covelli, V; Leonardi, M; Raggi, A; Romito, L; Soliveri, P | 1 |
| Ben-Shlomo, Y; Breen, K; Clarke, CE; Ives, N; Patel, S; Rees, K; Stowe, R | 1 |
| Arabia, G; Cerasa, A; Gioia, MC; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Baker, J; Bryant, MS; Charness, AL; Collins, RL; Fernandez, AL; Hou, JG; Lai, EC; Protas, EJ; Rintala, DH | 1 |
| Jann, MW | 1 |
| Chen, JJ | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Chesselet, MF; Richter, F | 1 |
| Feng, Z; Gorelenkova, O; Yang, J; Zheng, M | 1 |
| Klostermann, F; Kordsachia, C; Krugel, LK; Marzinzik, F; Wahl, M; Wotka, J | 1 |
| Alstrup, AK; Doudet, DJ; Gjedde, A; Høltzermann, M; Jakobsen, S; Landau, AM; Møller, A; Nahimi, A; Simonsen, M; Vang, K; Wegener, G | 1 |
| Carta, M; De Deurwaerdère, P; Guthrie, M; Navailles, S | 1 |
| Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C | 1 |
| Brusselle, G; Camp, Gv; Colao, A; Dieleman, JP; Haag, MD; Haverkamp, W; Herings, R; Luise, Cd; Mazzaglia, G; Mokhles, MM; Ross, D; Schade, R; Sturkenboom, MC; Trifirò, G; van Soest, EM; Verhamme, KM; Zanettini, R | 1 |
| Carrière, N; Defebvre, L; Destée, A; Dujardin, K; Kreisler, A | 1 |
| Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D | 1 |
| Bryant, MS; Hou, JG; Lai, EC; Protas, EJ; Rintala, DH | 1 |
| Liang, L; Pu, X; Wang, J; Wang, X; Wu, Q; Xiang, Y; Zhang, Q; Zhang, X | 1 |
| Schnitzler, A; Südmeyer, M; Wojtecki, L | 1 |
| Akdeniz, M; Yaman, A; Yaman, H | 1 |
| Grice, T; Stagg, P | 1 |
| Kostic, VS; Petrovic, M; Stefanova, E; Stojkovic, T; Ziropadja, Lj | 1 |
| Iravani, MM; Jenner, P; McCreary, AC | 1 |
| Björklund, A; Decressac, M; Lundblad, M; Mattsson, B; Weikop, P | 1 |
| Boskovic, R; Clark, M; Houle, S; Kish, SJ; Meyer, JH; Rabiner, EA; Rusjan, P; Sacher, J; Soliman, A; Wilson, AA | 1 |
| Evidente, V; Lyons, MK; Ziemba, K | 1 |
| Askmark, H; Munro Neville, A; Nyholm, D; Parsons, RW | 1 |
| Fields, V; Goldberg, NR; Meshul, CK; Pflibsen, L; Salvatore, MF | 1 |
| Heetun, ZS; Quigley, EM | 1 |
| De Deurwaerdère, P; Navailles, S | 2 |
| Band, GP; Ridderinkhof, KR; van den Wildenberg, WP; van Wouwe, NC; Wylie, SA | 1 |
| Christine, CW; Marks, WJ; Ostrem, JL | 1 |
| Armentero, MT; Blandini, F | 1 |
| Atassi, F; Fincher, L; Hou, JG; Lai, EC; Moore, S; Nelson, N; Sarwar, A; Ward, C; Wu, LJ; York, M | 1 |
| Starkstein, SE | 1 |
| Bolner, A; De Riva, V; Nordera, GP; Pilleri, M | 1 |
| Dagher, A | 1 |
| Ambermoon, P; Carter, A; Dissanayaka, N; Hall, W; O'Sullivan, J | 1 |
| Añón, MJ; de la Fuente-Fernández, R; Fuster-Sanjurjo, L; Santos-García, D | 1 |
| Cheshire, PA; Williams, DR | 1 |
| Fotiadis, DI; Konitsiotis, S; Tsipouras, MG; Tzallas, AT | 1 |
| Li, M; Li, SD; Liu, Y; Yang, MH | 1 |
| Bloem, BR; Espay, AJ; Fasano, A; Payne, MM; Snijders, AH; van Nuenen, BF | 1 |
| Chen, R | 1 |
| Carrillo, F; Casanova, J; De Fabregues, O; de la Fuente-Fernández, R; Grande, M; Mir, P; Palasí, A; Santos-García, D; Valldeoriola, F | 1 |
| Ferrara, JM; Hunter, C; Mostile, G; Ondo, WG | 1 |
| Ehret, R; Haas, T; Lütge, S; Marg, M; Müller, T | 1 |
| Emre, M; Reichmann, H | 1 |
| Krones, E; Petritsch, W; Zollner, G | 1 |
| Degroot, C; Madjar, C; Martinu, K; Monchi, O; Strafella, AP | 1 |
| Gomis, P; Graftieaux, JP; Malinovsky, JM; Poivert, C; Scherpereel, B | 1 |
| Abbruzzese, G; Amboni, M; Antonini, A; Barone, P; Bernardi, L; Colombo, D; Posocco, V; Stocchi, F; Tamburini, T; Vacca, L | 1 |
| Benko, R; Jain, L; Safranek, S | 1 |
| Coon, EA; Laughlin, RS | 1 |
| Aharon-Peretz, J; Cohen, OS; Dagan, E; Djaldetti, R; Ephraty, L; Fixler Mehr, T; Friedman, E; Gershoni-Baruch, R; Hassin-Baer, S; Inzelberg, L; Inzelberg, R; Kaplan, N; Kozlova, E; Mory, A; Nitsan, Z; Schechtman, E; Schlesinger, I; Tunkel, O | 1 |
| Imamura, K; Nagatsu, T; Okayasu, N | 1 |
| Lyytinen, J; Pekkonen, E; Pursiainen, V | 1 |
| Bentivoglio, AR; Fasano, A; Lena, F; Modugno, N; Ricciardi, L | 1 |
| Brotchie, JM; Fox, SH; Gandy, MN; Gomez-Ramirez, J; Huot, P; Johnston, TH; Lee, J; Lewis, KD; Martin-Iverson, M; McIldowie, M; Millar, Z; Nash, JE; Piggott, MJ; Salomonczyk, D; Thiele, S; Wagg, K; Yong-Kee, CJ | 1 |
| Allemann, O; Bissantz, C; Burgy, G; Diederich, F; Ehler, A; Ellermann, M; Grünstein, D; Jakob-Roetne, R; Lerner, C; Paulini, R; Rudolph, MG; Stihle, M; Tissot, H | 1 |
| Farnikova, K; Kanovsky, P; Obereigneru, R; Prasko, J | 1 |
| Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
| Johansson, A; Klangemo, K; Nyholm, D | 1 |
| Budrewicz, S; Jaskólska, A; Jaskólski, A; Koszewicz, M; Marusiak, J | 1 |
| Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lim, SY | 1 |
| Berardelli, A; Bologna, M; Fabbrini, G; Fasano, A; Modugno, N | 1 |
| Biswas, A; Das, SK; Misra, AK; Naiya, T; Ray, J; Ray, K | 1 |
| Lee, MJ; Lee, MS; Lyoo, CH; Ryu, YH | 1 |
| Chen, R; Hoque, T; Nelson, AJ; Premji, A; Rai, N; Tommerdahl, M | 1 |
| Hasegawa, K; Hattori, N; Sakamoto, T | 1 |
| Caron, MG; Espinoza, S; Gainetdinov, RR; Managò, F; Premont, RT; Salahpour, A; Sotnikova, TD | 1 |
| Brown, P; Day, BL; Lees, AJ; Ling, H; Massey, LA | 1 |
| Bours, V; Caberg, JH; Dive, D; Garraux, G; Jamar, M; Moonen, G; Vanbellinghen, JF | 1 |
| Aron, AR; Obeso, J | 1 |
| Fdez-Villalba, E; Herrero, MT; López-Coronado, J; Molina-Vilaplana, J; Nombela, C; Pedreño-Molina, JL; Ros-Bernal, F | 1 |
| Franzén, E; Gurfinkel, V; Horak, F; Paquette, C | 1 |
| Brotchie, JM; Darr, T; Fox, SH; Hazrati, LN; Huot, P; Johnston, TH; Pires, D; Visanji, NP | 1 |
| Burchiel, KJ; Carlson-Kuhta, P; Frank, N; Hogarth, P; Horak, FB; St George, RJ | 1 |
| Emel'ianov, AK; Iakimovskiĭ, AF; Ivanova, ON; Pchelina, SN | 1 |
| Anders, S; Binkofski, F; Klein, C; Münte, T; Pohl, A; Pramstaller, P; Sack, B | 1 |
| Duval, C; Edwards, R; Fenney, A; Jog, M; Mann, RK; Zhou, J | 1 |
| Djaldetti, R; Gad, A; Khlebtovsky, A; Melamed, E; Rigbi, A; Steiner, I; Ziv, I | 1 |
| Bassi, MS; Galati, S; Imbriani, P; Marzetti, F; Olivola, E; Pastore, FS; Petrucci, S; Pierantozzi, M; Stefani, A; Valente, EM | 1 |
| Hoy, SM; Keating, GM | 1 |
| Augustinsson, LE; Dernroth, N; Dizdar, N; Kullman, A; Zsigmond, P | 1 |
| Cercy, SP; Marasia, JC | 1 |
| Albertini, G; Cimolin, V; De Pandis, MF; Galli, M; Schwartz, MH | 1 |
| Auinger, P; Kang, UJ | 1 |
| Francardo, V; Iderberg, H; Pioli, EY | 1 |
| Melo, A; Monteiro, L; Souza-Machado, A; Valderramas, S | 1 |
| Aebischer, P; Coune, PG; Schneider, BL | 1 |
| Espinoza, S; Gainetdinov, RR; Leo, D; Manago, F; Sotnikova, TD | 1 |
| Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tsouli, S; Tzallas, AT | 1 |
| Aarts, E; Bloem, BR; Chase, HW; Cools, R; Nusselein, B; Smittenaar, P | 1 |
| Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA | 1 |
| Abbadessa, A; Cerasa, LS; Di Stefano, A; Sozio, P | 1 |
| Aldred, JL; Brod, LS; Nutt, JG | 1 |
| Bhatia, KP; Dayan, P; Dolan, RJ; Hill, C; Seymour, B; Shiner, T; Wunderlich, K | 1 |
| Ardouin, C; Aya Kombo, M; Benabid, AL; Bichon, A; Bosson, JL; Broussolle, E; Carnicella, S; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Polo, G; Quesada, JL; Schmitt, E; Seigneuret, E; Thobois, S; Xie, J | 1 |
| Abe, M; Inden, M; Kitamura, Y; Minamino, H; Takata, K; Tooyama, I; Yoshimoto, K | 1 |
| de la Fuente-Fernández, R; Prieto-Formoso, M; Santos-García, D | 1 |
| Aoyagi, K; Arai, E; Arai, M; Higuchi, Y; Imazeki, F; Katsuno, T; Kuwabara, S; Maruoka, D; Matsumura, T; Nagano, O; Nakagawa, T; Saeki, N; Shiina, A; Uchiyama, T; Yamamoto, T; Yamanaka, Y; Yokosuka, O | 1 |
| Utsumi, H | 1 |
| Ionov, ID; Severtsev, NN | 1 |
| Bernardo, M; Fernández-Egea, E; Martí, MJ; Muñiz, A; Pintor, LP; Rami, L; Sánchez, R; Tolosa, E; Valldeoriola, F | 1 |
| Abbruzzese, G; Antonini, A; Barone, P; Bonuccelli, U; Capus, L; Ceravolo, R; Cilia, R; Colosimo, C; Guerra, UP; Lopiano, L; Marconi, R; Morgante, L; Petrone, A; Quatrale, R; Ramat, S; Righini, A; Stefani, A; Tamma, F; Tinazzi, M; Vitale, C; Zappia, M | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Ardolino, G; Barbieri, S; Caputo, E; Cogiamanian, F; Giannicola, G; Locatelli, M; Marceglia, S; Menghetti, C; Pacchetti, C; Priori, A; Rosa, M; Rossi, L; Scelzo, E; Servello, D; Zangaglia, R | 1 |
| Busk, K; Nyholm, D | 1 |
| Martínez-Banaclocha, MA | 1 |
| Christos, PJ; Dorfman, BJ; Henchcliffe, C; Khadem, NR; Nirenberg, MJ; Piboolnurak, P; Zheng, KS | 1 |
| Eidelberg, D; Feigin, A; Niethammer, M | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| Holiga, Š; Jech, R; Möller, HE; Mueller, K; Schroeter, ML; Sieger, T | 1 |
| Brown, P; Kuhn, AA; Little, S; Pogosyan, A | 1 |
| Day, BL; Lees, AJ; Ling, H; Petrovic, I | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Hickey, P; Stacy, M | 1 |
| Chen, R; Chuang, R; Hamani, C; Hodaie, M; Lim, SY; Lozano, AM; Mazzella, F; Moro, E; Neagu, B; Saha, U; Steeves, T; Tsang, EW | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Budzianowska, A; Gołab-Janowska, M; Honczarenko, K | 1 |
| Elroby, SAK; Hilal, RH; Makki, MSI; Sobahi, TR | 1 |
| Balachandran, A; Joseph, T; Kishore, A; Meunier, S; Popa, T; Velayudhan, B | 1 |
| Aman, A; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Canning, CG; Fung, VS; Paul, SS; Sherrington, C | 1 |
| Counsell, CE; Davidson, MB; McGhee, DJ | 1 |
| Doi, H; Kishi, M; Masaka, T; Sakakibara, R; Sato, M; Takahashi, O; Tateno, A; Tateno, F; Tsuyusaki, Y | 1 |
| Cano-de-la-Cuerda, R; Fernández-de-Las-Peñas, C; Fil, A; Macías-Macías, Y; Muñoz-Hellín, E; Ortíz-Gutiérrez, R; Vela, L | 1 |
| Mallya, U; Pahwa, R; Suh, DC | 1 |
| Balbi, P; Bertotti, G; Boveri, N; Comi, C; Felicetti, G; Frazzitta, G; Leva, S; Maestri, R; Morelli, M; Pelosin, E; Riboldazzi, G; Turla, M | 1 |
| Burkhard, PR; Vingerhoets, FJ | 1 |
| Sabetay, S; Schwartz, M | 1 |
| Fuchs, G; Kassubek, J; Randerath, O; Reketat, N; Wüllner, U | 1 |
| Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Linder, J; Nyholm, D; Pålhagen, SE; Sydow, O; Wainwright, M; Widner, H | 1 |
| Gomperts, SN; Growdon, JH; Johnson, KA; Locascio, JJ; Marquie, M; Maye, J; Rentz, DM; Santarlasci, AL | 1 |
| Colebatch, JG; Deuschl, G; Pötter-Nerger, M; Reich, MM; Volkmann, J | 1 |
| Defebvre, L; Degardin, A; Derambure, P; Destée, A; Devanne, H; Devos, D; Plomhause, L | 1 |
| Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G | 1 |
| Anderson, TJ; MacAskill, MR; van Stockum, S | 1 |
| Åström, M; Blomstedt, P; Forsgren, L; Fytagoridis, A; Hariz, MI; Linder, J | 1 |
| Kulkarni, N; Ledeen, RW; Lu, ZH; Wu, G | 1 |
| Munhoz, RP; Teive, HA; Zavala, JA | 1 |
| Harati, A; Müller, T; Peters, S | 1 |
| Debicki, D; Jog, M | 1 |
| Chen, R; Elahi, B; Phielipp, N | 1 |
| Chouinard, S; Gagnon, JF; Latreille, V; Montplaisir, J; Panniset, M; Postuma, RB; Romenets, SR | 1 |
| Belavic, J | 1 |
| Arabia, G; Augimeri, A; Cerasa, A; Gioia, MC; Morelli, M; Novellino, F; Quattrone, A; Salsone, M | 1 |
| Derkinderen, P; Lebouvier, T; Pouclet, H | 1 |
| Coppard, N; Hauser, RA; Leinonen, M; Lewitt, PA; Lu, M; Nicholas, AP; Savola, JM; Weiner, W | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M | 1 |
| Bliwise, DL; Factor, SA; Freeman, A; Greer, SA; Juncos, JJ; Rye, DB; Trotti, LM; Wilson, AG; Wood-Siverio, C | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 1 |
| Singer, C | 1 |
| Khan, TS | 1 |
| Artusi, CA; De Angelis, C; Lopiano, L; Marchisio, A; Merola, A; Montanaro, E; Reggio, D; Ricchi, V; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Afzal, M; Jyoti, S; Khan, S; Naz, F; Shakya, B; Siddique, YH | 1 |
| Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T | 1 |
| Müller, T; Skodda, S | 1 |
| Albertini, G; Cimolin, V; De Pandis, MF; Galli, M; Manetti, E; Vimercati, SL | 1 |
| Brusa, L; Galati, S; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Alberio, T; Cecconi, D; Comi, C; Fasano, M; Lopiano, L; Olgiati, S; Pippione, AC; Zibetti, M | 1 |
| Brown, P; Litvak, V; Oswal, A; Sauleau, P | 1 |
| Nyholm, D | 3 |
| Bharath, MM; Harish, G; Mythri, RB | 1 |
| Hoy, SM; Keating, GM; Lyseng-Williamson, KA | 1 |
| Mochizuki, H; Nakata, Y; Yasuda, T | 1 |
| Caltagirone, C; Cardebat, D; Demonet, JF; Méligne, D; Nemmi, F; Peppe, A; Péran, P; Rascol, O; Sabatini, U | 1 |
| Barichella, M; Cancello, R; Cassani, E; Faillace, G; Moise, G; Pezzoli, G; Privitera, G; Zecchinelli, A; Zulian, A | 1 |
| Agid, Y; Cornu, P; Deuschl, G; Knudsen, K; Pinsker, MO; Rau, J; Schade-Brittinger, C; Schüpbach, M | 1 |
| Barone, P; Busse, M; Debieuvre, C; Fraessdorf, M; Hauser, RA; Mizuno, Y; Poewe, W; Rascol, O; Schapira, AH | 1 |
| Esch, T; Králíčková, M; Kream, RM; Kuzelova, H; Mantione, KJ; Ptacek, R; Stefano, GB | 1 |
| Barnes, G; Brown, P; Eusebio, A; Foltynie, T; Friston, K; Hariz, MI; Jha, A; Limousin, P; Litvak, V; Oostenveld, R; Zrinzo, L | 1 |
| Dunn, E; Espay, AJ; Gallin, E; Li, JY; Litvan, I; Morgante, F; Munhoz, RP; Teive, HA | 1 |
| Hirosawa, T; Kihira, K; Kimura, Y; Onzawa, Y; Shirasuna, M; Taogoshi, T; Uzuhashi, K | 1 |
| Daragon, A; Derrey, S; Lefaucheur, R; Maltête, D; Nicolau, J; Verdet, M | 1 |
| Li, M; Liu, Y; Yang, MH | 1 |
| Aristieta, A; Azkona, G; Miguelez, C; Ruiz-Ortega, JÁ; Sagarduy, A; Sanchez-Pernaute, R; Ugedo, L | 1 |
| Bryant, MS; Hou, JG; Protas, EJ; Rintala, DH | 1 |
| Bagyeva, GKh; Dobrotvorskaia, IS; Fedorova, TN; Illarioshkin, SN; Ivanova-Smolenskaia, IA; Polevaia, EV; Stepanova, MS | 1 |
| Huang, G; Ji, LY; Ji, XT; Li, JM; Liu, WP; Ma, LT; Niu, L; Qu, Y; Zhao, DS | 1 |
| Ankaralı, H; Gunal, DI; Mollahasanoğlu, A; Ozen Barut, B; Turkmen, C | 1 |
| Díaz-Argandoña, E; López-García, JC; Luque-Moreno, C | 1 |
| Cassano, T; Cimmino, CS; Denora, N; Giuffrida, A; Laconca, L; Laquintana, V; Lopalco, A; Trapani, A; Trapani, G | 1 |
| Auxiette, C; Chambres, P; Dalens, H; Derost, P; Durif, F; Jalenques, I; Lemaire, JJ; Marie Coulangeon, L; Marques, A; Mermillod, M; Mondillon, L; Musca, SC; Rieu, I; Ulla, M; Vidal, T | 1 |
| Fedotova, EIu; Illarioshkin, SN; Ivanova-Smolenskaia, IA; Karabanov, AV; Mirkasimov, AF; Poleshchuk, VV; Polevaia, EV; Zagorovskaia, TB | 1 |
| Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; Gutierrez-Valdez, AL; Montiel-Flores, E; Ordoñez-Librado, JL; Reynoso-Erazo, L; Sanchez-Betancourt, J | 1 |
| Liu, ZG; Song, L; Wei, JL; Wu, N; Yang, XX | 1 |
| Gotoh, J; Isozumi, K; Iwasawa, S; Mihara, B; Morita, Y; Muramatsu, K; Nihei, Y; Nogawa, S; Ohta, K; Seki, M; Shirai, T; Suzuki, N; Takahashi, K; Tomita, Y; Uematsu, D; Yamaguchi, K; Yasutomi, D | 1 |
| Curio, G; Hohlefeld, FU; Huchzermeyer, C; Huebl, J; Kühn, AA; Nikulin, VV; Schneider, GH; Schönecker, T | 1 |
| Enzinger, C; Fazekas, F; Gattringer, T; Jehna, M; Katschnig, P; Koegl-Wallner, M; Langkammer, C; Ott, E; Ropele, S; Schmidt, R; Schwingenschuh, P; Seiler, S; Svehlík, M; Wenzel, K | 1 |
| Broussolle, E; Castrioto, A; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, SC | 1 |
| Wurtman, RJ | 1 |
| Barbin, L; Damier, P; Leux, C; Meyniel, C; Nguyen, JM; Pereon, Y; Sauleau, P | 1 |
| Daghem, M; Grosset, DG; Grosset, KA; Macphee, GJ; Newman, EJ; Nissen, T; Odin, P; Pal, G; Stewart, M | 1 |
| Foote, KD; Hassan, A; Iyer, S; McFarland, NR; Okun, MS; Rodriguez, RL; Sriram, A; Ward, HE | 1 |
| Damier, P; Derkinderen, P; Giumelli, B; Meyniel, C | 1 |
| Pekkonen, E; Pursiainen, V | 1 |
| Barbe, MT; Eggers, C; Pauls, KA; Salimi Dafsari, H; Timmermann, L | 1 |
| Puig-Junoy, J; Puig-Peiró, R; Valldeoriola, F | 1 |
| Kéri, S; Nagy, H; Szamosi, A | 1 |
| Burchiel, KJ; Carlson-Kuhta, P; Chiari, L; Hogarth, P; Horak, FB; Rocchi, L | 1 |
| Foley, P | 2 |
| Eskola, O; Jokinen, P; Joutsa, J; Kaasinen, V; Rinne, JO | 1 |
| Berthet, A; Bezard, E; Bloch, B; Boué-Grabot, E; Choquet, D; Chuan, Q; Dehay, B; Doudnikoff, E; Dovero, S; Groc, L; Ladepeche, L; Li, Q; Martin-Négrier, ML; Martinez, A; Normand, E; Porras, G | 1 |
| Bankiewicz, KS; Cummins, A; Eberling, J; Kohutnicka, M; Oiwa, Y; Sanchez-Pernaute, R | 1 |
| Fortuna, G; Pollio, A | 1 |
| Debû, B; Krainik, A; Lagrange, C; Maillet, A; Pinto, S; Pollak, P; Thobois, S; Troprès, I | 1 |
| Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V | 1 |
| Chen, W; Gu, S; Wang, H; Wei, H | 1 |
| Filipović, SR; Kačar, A; Kostić, VS; Kresojević, N; Ljubisavljević, M; Milanović, SD; Rothwell, JC | 1 |
| Butterworth, RF | 1 |
| Choopani, S; Golkar, M; Pourkosary, K; Rezvani, M; Shahidi, GA; Torkaman-Boutorabi, A; Zarrindast, MR | 1 |
| Abdolahi, A; Biglan, KM; Dorsey, ER; Killoran, A; Scoglio, N | 1 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Duty, S | 1 |
| Blomstedt, P; Kulneff, L; Linder, J; Nordh, E; Olofsson, K; Sundstedt, S; van Doorn, J | 1 |
| Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R | 1 |
| Gluck, MA; Herzallah, MM; Moustafa, AA | 1 |
| Bezard, E | 2 |
| Bhatia, KP; Filipović, SR; Rothwell, JC | 1 |
| Dušek, P; Havránková, P; Holiga, Š; Jech, R; Mueller, K; Růžička, E; Růžička, F; Sieger, T; Urgošík, D; Vymazal, J | 1 |
| Choo, YM; Lim, SY; Mahamad, UA; Marras, C; Shahrizaila, N; Yap, AC | 1 |
| Imamura, T; Kashihara, K | 1 |
| Koziara, H; Mandat, T; Nauman, P; Tykocki, T | 1 |
| Blomstedt, P; Karlsson, F; Linder, J; Olofsson, K; van Doorn, J | 1 |
| Burguera, JA; Martínez-Castrillo, JC | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| García-Ruiz, PJ; Luquin, MR | 1 |
| Chacón, JR; Mata, M | 1 |
| Altmann, V; Callegari-Jacques, SM; Fagundes, PT; Francisconi, CL; Hutz, MH; Monte, TL; Rieck, M; Rieder, CR; Schumacher-Schuh, AF | 1 |
| Bravo-Utrera, M; Burguera, JA; Campos-Arillo, VM; Chacón, JR; Durán-Herrera, C; Fernández-García, JM; García-Ramos, R; García-Ruiz, PJ; Gómez-Esteban, JC; Grandas, FJ; Gutierrez, J; Juni, J; Luquin, MR; Martí, MJ; Martínez-Castrillo, JC; Mata, M; Olivares, J; Ribacoba-Montero, R; Rojo, A; Santos-García, D; Sierra, M; Valero-Merino, C; Vela, L | 1 |
| Calleja-Castillo, J; Cervantes-Arriaga, A; Corona, T; Morales-Briceño, H; Rodríguez-Violante, M | 1 |
| Cardoso, FE; Fernandes, AA; Guedes, LU; Parreira, VF; Rodrigues, JM | 1 |
| Bodenheimer, RE; Davis, T; Dawant, BM; Fang, J; Hedera, P; Li, R; Phibbs, F; Rao, AS | 1 |
| Anderson, GM; Fischer, HD; Herrmann, N; Marras, C; Rochon, PA; Wang, X | 1 |
| Haugarvoll, K; Larsen, JP; Müller, B; Skeie, GO; Tveiten, OV; Tysnes, OB | 1 |
| Bömelburg, M; Ebersbach, G; Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Lane, EL; Winkler, C | 1 |
| Enomoto, H; Ugawa, Y | 1 |
| Ahn, YH; Lee, PH; Paik, MJ; Park, HJ; Shin, JY; Sohn, YH | 1 |
| Chen, S; Chen, SD; Chen, W; Wang, G; Xiao, Q | 1 |
| Inoue, Y; Kagimura, T; Nakashima, K; Nomura, T | 1 |
| Barichella, M; Caccialanza, R; Cancello, R; Cassani, E; Cereda, E; Iorio, L; Madio, C; Pezzoli, G; Pusani, C | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
| Bloem, BR; Koopmans, RT; Munneke, M; Poels, PJ; Tissingh, G; Weerkamp, NJ; Zuidema, SU | 1 |
| Altenmüller, E; Bardinet, E; Hälbig, TD; Schüpbach, M; van Vugt, FT; Yelnik, J | 1 |
| Fleury, V; Fraix, V; Krack, P; Krainik, A; Lamalle, L; Maillet, A; Pinto, S; Pollak, P; Sahin, M; Thobois, S; Troprès, I; Villien, M; Warnking, J | 1 |
| Butz, M; Elben, S; Hartmann, CJ; Hirschmann, J; Homburger, M; Özkurt, TE; Schnitzler, A; Vesper, J; Wojtecki, L | 1 |
| Anderson, LC; Fagerlund, K; Gurvich, O | 1 |
| Datieva, VK; Levin, OS; Makotrova, TA | 1 |
| Pagonabarraga, J; Rodríguez-Oroz, MC | 1 |
| Li, J; Liu, A; McKeown, MJ; Wang, ZJ | 1 |
| Allen, GF; Hargreaves, IP; Heales, SJ; Land, JM; Ullah, Y | 1 |
| Chien, WL; Fu, WM; Hung, SY; Kang, KH; Lee, MJ; Lee, TR; Wu, RM | 1 |
| Shweikeh, F; Zahos, PA | 1 |
| Brown, P; Litvak, V; Oswal, A | 1 |
| Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F | 1 |
| Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Hass, SL; Hauser, RA; Lenz, RA; Odin, P; Pritchett, Y; Standaert, DG; Vanagunas, A | 1 |
| Albanese, A; Antonini, A; Chaudhuri, KR; Clarke, CE; de Bie, RM; Deuschl, G; Eggert, K; Houeto, JL; Kulisevsky, J; Nyholm, D; Odin, P; Oertel, W; Poewe, W; Pollak, P; Rabey, JM; Rascol, O; Ruzicka, E; Samuel, M; Speelman, H; Sydow, O; Valldeoriola, F; van der Linden, C; Volkmann, J; Østergaard, K | 1 |
| Apple, DM; Chotibut, T; Jefferis, R; Salvatore, MF | 1 |
| Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N | 1 |
| Kanda, T; Miyauchi, N; Yamada, K | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Fukushima, FB; Valle, AP; Vidal, EI; Villas Boas, PJ | 1 |
| Inzelberg, R | 1 |
| Barker, RA; Brooks, DJ; Burn, DJ; Coleman, S; Duncan, GW; Khoo, TK; O'Brien, JT; Yarnall, AJ | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Sutton, JP | 1 |
| Chen, JF; Eberly, S; Kamp, C; Lang, AE; McDermott, MP; Messing, S; Oakes, D; Schwarzschild, MA; Tanner, CM; Tennis, M; Togasaki, D; Wills, AM | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Berger, SP; Bhide, N; Bishop, C; Goldenberg, AA; Lindenbach, D; Paquette, MA; Surrena, MA | 1 |
| Bhidayasiri, R; Jagota, P; Jitkritsadakul, O; Petchrutchatachart, S; Rerknimitr, R; Sansopha, L | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Berthelot, L; Borden, A; Lefaucheur, R; Maltête, D; Sénant, J | 1 |
| Alty, JE; Clissold, BG; Ganga, G; Kempster, PA; McColl, CD; Reardon, KA; Schiff, M | 1 |
| Munhoz, RP; Teive, HA | 2 |
| Hattori, N; Hirayama, M; Nakahara, T; Ohta, S; Takanashi, M; Yoritaka, A | 1 |
| Krishnan, UM; Mohanraj, K; Sethuraman, S | 1 |
| Carlsson, A | 5 |
| Djaldetti, R; Melamed, E; Ziv, I | 3 |
| Carter, JH; Lea, ES; Nutt, JG; Sexton, GJ | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Langston, JW; LeWitt, P; Oakes, D; Olanow, CW; Penney, JB; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Brotchie, JM; Nash, JE | 1 |
| Antic, R; Rice, JE; Thompson, PD | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Nieoullon, A | 1 |
| Aguiar, PM; Borges, V; Ferraz, FA; Ferraz, HB; Hisatugo, MK; Pinto, RA | 1 |
| Barnes, A; Dhawan, V; Eidelberg, D; Feigin, A; Fukuda, M; Ghez, CP; Ghilardi, MF; Mentis, MJ | 1 |
| Chen, JC; Hwang, JJ; Liao, MH; Lin, KJ; Pan, WH; Ting, G; Wey, SP; Yen, TC | 1 |
| Bonenkamp, JJ; Wobbes, T | 1 |
| Nuijten, MJ; Palmer, CS; Schmier, JK; Snyder, EH; Subedi, P | 1 |
| Fung, VS; Morris, JG; Pell, MF | 1 |
| Huxham, FE; Iansek, R; Rosenfeld, JV | 1 |
| Kapustina, MT; Karaban', IN; Karasevich, NV; Lukhanina, EP | 1 |
| Levenson, D | 1 |
| Olanow, CW; Ruggieri, S; Stocchi, F; Vacca, L | 2 |
| Burn, DJ | 1 |
| Chiari, L; Horak, FB; Rocchi, L | 1 |
| Bonnet, AM | 1 |
| de Boer, A; Jansen, PA; Porsius, AJ; Roos, RA; van de Vijver, DA | 2 |
| Deuschl, G; Fietzek, U; Kopper, F; Krack, P; Mehdorn, HM; Müller, D; Poepping, M; Schrader, B; Wenzelburger, R; Zhang, BR | 1 |
| Factor, SA; Feustel, PJ; Molho, ES; Reddy, S | 1 |
| Dupont, E; Sunde, N; Østergaard, K | 1 |
| Arce, GP; Leiguarda, R; Merello, M; Nouzeilles, MI | 1 |
| Debilly, B; Dordain, G; Durif, F; Lemaire, JJ | 1 |
| Berciano, J; Ferrer, I; Marín, C; Pascual, J; Rey, MJ; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Gertz, HJ; Hermann, W; Müller, U; Reuter, M | 1 |
| Clarke, C; Moore, AP | 4 |
| Schölzel-Dorenbos, CJ | 1 |
| Coelho, C; Goberman, AM | 2 |
| Agid, Y; Mizuno, Y; Olanow, CW | 1 |
| Collins, DR; Wanklyn, P | 1 |
| Liou, HH; Liu, HM; Su, PC; Tseng, HM; Yen, RF | 3 |
| Benabid, AL; Besson, G; Charles, PD; Krack, P; Lee, SL; Pollak, P; Van Blercom, N; Xie, J | 1 |
| Brunner, H; Friess, E; Hogl, B; Trenkwalder, C; Wetter, TC; Yassouridis, A | 1 |
| Barrio, S; Caminero, AB; De La Llave, Y; Garcia-Borreguero, D; Granizo, JJ; Larrosa, O; Pareja, JA | 1 |
| Hauser, RA; Holford, NH | 1 |
| Aurilia, C; Barbanti, P; Fabbrini, G; Meco, G; Pauletti, C; Vanacore, N | 1 |
| Brus, R; Kostrzewa, JP; Kostrzewa, RM | 1 |
| Chase, TN; Oh, JD | 2 |
| Verhagen Metman, L | 1 |
| Ghaemi, M; Heiss, WD; Herholz, K; Hilker, R; Sturm, V; Thiel, A; Voges, J | 1 |
| Mizuno, Y | 7 |
| Ikemoto, K | 1 |
| Katzenschlager, R; Lees, AJ | 1 |
| Kondo, T | 5 |
| Djaldetti, R; Melamed, E | 4 |
| Ohye, C; Shibazaki, T | 1 |
| Cavalcante, JE; Ferraz, FP; Santos, LF; Silva, DJ; Silva, LG; Sousa, JT; Souza, HA; Vilela Filho, O | 1 |
| Froberg, J | 1 |
| Benabid, AL; Esselink, RJ; Moro, E; Pollak, P | 1 |
| Kleiner-Fisman, G; Lang, AE; Lozano, A; Miyasaki, J; Saint-Cyr, JA | 2 |
| Comi, G; Cursi, M; Leocani, L; Magnani, G; Volonté, MA | 1 |
| Manoach, DS; Mechanic, DJ; Press, DZ; Tarsy, D | 1 |
| Czernecki, V; Dubois, B; Houeto, JL; Levy, R; Pillon, B; Pochon, JB | 1 |
| Adler, CH; Beach, TB; Caviness, JN; Gurevich, EV; Joyce, JN; Reiser, M; Ryoo, HL; Stacy, M | 1 |
| Chaudhuri, KR; Landau, S; Winkler, AS | 1 |
| Berthier, ML; Gironell, A; Kulisevsky, J; Molet, J; Parés, P; Pascual-Sedano, B | 1 |
| Dostrovsky, JO; Hutchison, WD; Lang, AE; Levy, R; Lozano, AM | 1 |
| Aquilonius, SM; Askmark, H; Gomes-Trolin, C; Nygren, I | 1 |
| Brown, P; Harnack, D; Kupsch, A; Magill, PJ; Meissner, W; Sharott, A | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Grégoire, L; Grondin, R; Hadj Tahar, A | 1 |
| Widner, H | 1 |
| Gordin, A; Kaakkola, S; Teräväinen, H | 2 |
| Blanchet, PJ; Chase, TN; Metman, LV | 1 |
| Korczyn, AD | 1 |
| Onofrj, M; Stocchi, F; Vacca, L | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Silverdale, MA | 1 |
| Sulkava, R | 1 |
| Eerenberg, JG; Egberts, AC; Rommers, MK; van Deelen, RA | 1 |
| Arstrand, K; Dizdar, N; Kågedal, B | 1 |
| Hall, GM; Nicholson, G; Pereira, AC | 1 |
| Brotchie, JM; Nicholson, SL | 1 |
| Jennings, D; Marek, K; Seibyl, J | 2 |
| Kempster, PA; McColl, CD; Reardon, KA; Shiff, M | 1 |
| Lees, AJ; Manson, AJ; Turner, K | 1 |
| Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
| Arima, K; Baker, M; Delisle, MB; Ghetti, B; Hutton, ML; Kobayashi, T; Komure, O; Kuno, S; Mizuno, Y; Murrell, JR; Rascol, O; Soulages, X; Sunohara, N; Tsuboi, Y; Uitti, RJ; Wszolek, ZK; Yasuda, M | 1 |
| Hamada, I; Hasegawa, N; Okiyama, R; Takahashi, H; Taniguchi, M; Yokochi, F | 2 |
| Clarke, CE; Guttman, M | 1 |
| Bailey, DL; Brooks, DJ; Ito, K; Morrish, PK; Pavese, N; Rakshi, JS; Uema, T | 1 |
| Bonnet, AM; Houeto, JL | 1 |
| Ardouin, C; Benabid, AL; Chabardes, S; Krack, P; Lagrange, E; Moro, E; Pollak, P; Van Blercom, N | 1 |
| Aleksanian, ZA; Manoĭlov, VV; Romanov, SP | 1 |
| Einarson, TR; Iskedjian, M | 1 |
| MacMahon, D; Sharma, J; Stewart, D | 1 |
| Gielen, SC; Horstink, MW; Keijsers, NL | 3 |
| Grandas, F; Kulisevsky, J | 1 |
| Gekht, AB | 2 |
| Baas, H; Fuchs, G; Gemende, I; Hueber, R; Lachenmayer, L; Schneider, E; Schoenberger, B; Werner, M | 1 |
| Cho, IS; Ha, JH; Im, JH; Lee, MC | 1 |
| Quinn, NP | 4 |
| Agid, Y; Bejjani, BP; Houeto, JL; Mallet, L; Mesnage, V; Welter, ML | 1 |
| Diaz-Arrastia, R; Frol, AB; Rogers, JD; Sanchez-Saffon, A | 1 |
| Blatt, JL; Blond, S; Bourriez, JL; Defebvre, L; Destée, A; Duhamel, A; Guieu, JD; Krystkowiak, P; Perina, M | 1 |
| Zegers de Beyl, D | 1 |
| Clarke, CE; Crosby, N; Deane, KH | 1 |
| Büchel, C; Buhmann, C; Glauche, V; Oechsner, M; Stürenburg, HJ; Weiller, C | 1 |
| Brotchie, JM; Crossman, AR; Mora, F; Segovia, G | 1 |
| Eng, JJ; Inkster, LM; MacIntyre, DL; Stoessl, AJ | 1 |
| Arabia, G; Bagalà, A; Bastone, L; Bosco, D; Caracciolo, M; Crescibene, L; Quattrone, A; Scornaienghi, M; Zappia, M | 1 |
| Amabile, G; Del Monte, S; Fattapposta, F; Locuratolo, N; Mostarda, M; My, F; Parisi, L; Pierelli, F; Serrao, M | 1 |
| Albani, G; Astolfi, V; Baudo, S; Bergamasco, B; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Barbieri, S; Baselli, G; Bianchi, A; Caputo, E; Chiesa, V; Egidi, M; Foffani, G; Locatelli, M; Pesenti, A; Priori, A; Rampini, P; Scarlato, G; Tamma, F | 1 |
| Bergamasco, B; Bosticco, E; Lanotte, M; Lopiano, L; Perozzo, P; Rizzone, M; Tavella, A; Torre, E | 1 |
| Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M | 1 |
| da Silva, DJ; Vilela Filho, O | 1 |
| Bonuccelli, U; Caltagirone, C; Carlesimo, GA; Costa, A; Dell'Agnello, G; Murri, L; Peppe, A | 1 |
| Serrano-Dueñas, M | 1 |
| Benabid, AL; Fraix, V; Gentil, M; Pinto, S; Pollak, P | 1 |
| Wooten, GF | 3 |
| Albin, RL; Frey, KA | 1 |
| Cai, DF; Chen, XQ; Gao, Y | 1 |
| Gordin, A; Larsen, JP; Leinonen, M; Reinikainen, K; Sidén, A; Worm-Petersen, J | 1 |
| Clarke, C; Moore, A | 1 |
| Balash, Y; Bartels, AL; Giladi, N; Gurevich, T; Hausdorff, JM; Schaafsma, JD | 3 |
| Kowa, H; Kusumi, M; Nakashima, K; Nakaso, K; Sasaki, K; Takeshima, T; Ueda, K; Yasui, K; Yoshimoto, Y | 1 |
| Defebvre, L; Degreef, JF; Destee, A; Dujardin, K; Krystkowiak, P | 1 |
| Bhattacharya, KF; Kaufmann, H; Nouri, S; Olanow, CW; Yahr, MD | 1 |
| Lai, BC; Marion, S; Schulzer, M; Teschke, K; Tsui, JK | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Morissette, M; Rajput, AH | 1 |
| Freund, HJ; Habel, U; Kornischka, J; Regel, S; Schneider, F; Sturm, V; Volkmann, J | 1 |
| Gerlach, M; Riederer, P | 1 |
| Klockgether, T | 1 |
| Vécsei, L | 1 |
| Akinci, A; Bal, S; Ozçakar, L | 1 |
| Kuhn, W; Müller, T; Woitalla, D | 2 |
| Bassi, A; Boffa, L; Brusa, L; Caramia, MD; Peppe, A; Pierantozzi, M; Ruggieri, S; Stanzione, P; Stefani, A | 1 |
| Bermejo, F; Bourdeix, I; Durif, F; Fénelon, G; Galiano, L; Giménez-Roldán, S; Montastruc, JL; Péré, JJ; Schadrack, J | 1 |
| Behrens, S; Sommerville, K | 1 |
| Castro-Caldas, A; Del Signore, S; Rascol, O; Ziegler, M | 1 |
| Bird, T; Farrer, M; Gancher, S; Gwinn-Hardy, K; Hardy, J; Hussey, J; Lockhart, P; McNeal, MG; Nutt, J; Payami, H; Seltzer, WK; Singleton, AA; Singleton, AB | 1 |
| Cody, FW; O'Boyle, DJ; Zia, S | 1 |
| Guerra, MJ; Labandeira-Garcia, JL; Lopez-Real, A; Rodriguez-Pallares, J | 1 |
| Bilbao, G; Garibi, J; Gómez, JC; Lambarri, I; Lezcano, E; Madoz, P; Molano, A; Zarranz, JJ | 1 |
| Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA | 1 |
| Gill, SS; Heywood, P; Love, S; McCarter, R; O'Sullivan, K; Patel, NK | 1 |
| Faist, M; Lücking, CH; Maurer, C; Mergner, T; Pollak, P; Xie, J | 1 |
| Viallet, F; Witjas, T | 1 |
| Bordet, R; Destée, A | 2 |
| Derkinderen, P; Vidailhet, M | 1 |
| Brefel-Courbon, Ch; Ferreira, JJ; Montastruc, JL; Payoux, P; Rascol, O | 1 |
| Krack, P | 1 |
| Date, I; Fujiwara, K; Kobayashi, K; Miyoshi, Y; Ohmoto, T; Shingo, T; Yoshida, H | 1 |
| Colle, H; Temel, Y; van der Linden, C; Visser-Vandewalle, V | 1 |
| Blanchet, PJ | 2 |
| Martin, WR; Wieler, M | 1 |
| Siderowf, A; Stern, M | 1 |
| Choo, V | 1 |
| López de Juan, M; Martínez, G; Miranda Romero, A; Torrero, MV; Vega Gutiérrez, J | 1 |
| Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H | 1 |
| De Letter, M; Santens, P; Van Borsel, J | 1 |
| Blomgren, M; Goberman, AM | 2 |
| Chmura, TA; Diederich, NJ; Goetz, CG; Leurgans, SE; Moore, CG | 1 |
| Beier, KM; Berger, Ch; Mehrhoff, FW; Meinck, HM | 1 |
| Hagenah, J; Kömpf, D; Moser, A | 1 |
| Calne, DB; De La Fuente-Fernández, R; Furtado, S; Furukawa, Y; Guttman, M; Lee, CS; Ruth, TJ; Stoessl, AJ | 1 |
| MacMahon, DG | 1 |
| Burke, MA; Fernandez, HH; Friedman, JH; Jacques, C; Trieschmann, ME | 1 |
| Ardouin, C; Benabid, AL; Fraix, V; Funkiewiez, A; Krack, P; Moro, E; Pollak, P; Van Blercom, N; Xie, J | 1 |
| Hattori, T; Sakakibara, R; Uchiyama, T; Yamanishi, T | 1 |
| Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY | 1 |
| Kuno, S; Mizuno, Y; Mizuta, E; Takubo, H | 1 |
| Hanyu, N; Hashimoto, T; Tabata, K; Tokuda, T; Yanagisawa, N | 1 |
| Mizuno, Y; Shimoda-Matsubayashi, S; Takubo, H | 1 |
| Benice, T; Kearns, G; Lou, JS; Nutt, J; Sexton, G | 1 |
| van Laar, T | 1 |
| Foley, P; Gerlach, M; Riederer, P | 1 |
| Benz, S; Börnke, C; Müller, T; Przuntek, H; Russ, H | 1 |
| Bagheri, H; Montastruc, JL; Schmitt, L | 1 |
| Calandrella, D; Martignoni, E; Riboldazzi, G; Riva, N | 1 |
| Antonov, K; Aquilonius, SM; Askmark, H | 1 |
| Brodsky, MA; Godbold, J; Olanow, CW; Roth, T | 1 |
| Lasa, A; Linazasoro, G; Van Blercom, N | 1 |
| Carbon, M; Dhawan, V; Edwards, C; Eidelberg, D; Feigin, A; Fukuda, M; Ghez, C; Ghilardi, MF; Margouleff, C | 1 |
| Brockmöller, J; Gasser, T; Grapengiesser, A; Hofer, A; Kaiser, R; Kupsch, A; Roots, I | 1 |
| Kowa, H; Nakashima, K; Nakaso, K; Takeshima, T; Yasui, K | 2 |
| Bembi, B; LaMarca, ME; Orvisky, E; Rosenbaum, H; Schiffmann, R; Sidransky, E; Stubblefield, B; Tayebi, N; Walker, J; Wong, K | 1 |
| Kaji, M; Metoki, N; Sato, Y; Satoh, K; Yoshida, H | 1 |
| Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, L; Perlmutter, JS; Snyder, AZ | 1 |
| Carbon, M; Eidelberg, D; Feigin, A; Fukuda, M; Ghez, C; Ghilardi, MF; Mentis, MJ; Moeller, JR; Silvestri, G | 1 |
| Morrish, PK | 1 |
| Bares, M; Dostál, V; Ehler, E; Fanfrdlová, Z; Fiedler, J; Klajblová, H; Kulist'ák, P; Rektor, I; Rektorová, I; Ressner, P; Svátová, J; Urbánek, K; Velísková, J | 2 |
| Kodama, R; Kondo, T; Miwa, H; Morita, S | 1 |
| Asanuma, M; Miyazaki, I; Ogawa, N | 1 |
| Eldadah, B; Goldstein, DS; Holmes, C; Pechnik, S; Sharabi, Y | 1 |
| Lochner, P; Nardone, R; Tezzon, F | 1 |
| Brooks, DJ; Davis, M; Hauser, RA; Lang, AE; Nahmias, C; Poewe, WH; Rascol, O; Remy, P; Reske, S; Ribeiro, MJ; Stoessl, AJ; Watts, RL; Whone, AL | 1 |
| Bembi, B; Capus, L; Carrozzi, M; Ciana, G; Gioulis, M; Martini, C; Pittis, MG; Sidransky, E; Zambito Marsala, S; Zorzon, M | 1 |
| Broussolle, E; Dominey, PF; Mollion, H; Ventre-Dominey, J | 1 |
| Barker, RA; Cools, R; Robbins, TW; Sahakian, BJ | 1 |
| Fiala, KH; Manyam, BV; Whetteckey, J | 1 |
| Black, KJ; Carl, JL; Hartlein, JM; Hershey, T; Perlmutter, JS; Warren, SL | 1 |
| Apetauerova, D; Norregaard, T; Ryan, P; Tarsy, D | 1 |
| Deuschl, G; Fietzek, U; Hamel, W; Herzog, J; Mehdorn, HM; Morsnowski, A; Müller, D; Pfister, G; Schrader, B; Volkmann, J; Weinert, D | 1 |
| Brooks, DJ; Sagar, H | 1 |
| Aquilonius, SM; Bredenberg, S; Nyholm, D; Nyström, C | 1 |
| Riss, J; Tuite, P | 1 |
| Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA | 1 |
| Agid, Y; Bonifati, V; Bonnet, AM; Brice, A; Broussolle, E; De Michele, G; Destée, A; Durr, A; Fraix, V; Gasparini, F; Gasser, T; Horstink, MW; Lohmann, E; Meco, G; Nicholl, D; Periquet, M; Rascol, O; Raskin, S; Ruberg, M; Teive, H; Verpillat, P; Vidailhet, M; Wood, NW | 1 |
| Decker, PA; Dousa, MK; Muenter, MD; Offord, KP; Tyce, GM; Weinshilboum, RM | 1 |
| Blandini, F; Bono, G; Calandrella, D; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Riboldazzi, G; Samuele, A | 1 |
| Gaini, SM | 1 |
| Alimehmeti, R; Caputo, E; Egidi, M; Locatelli, M; Pesenti, A; Priori, A; Rampini, PM; Rohr, M; Tamma, F | 1 |
| Mazzone, P | 1 |
| Benabou, R; Waters, C | 1 |
| Adeleine, P; Broussolle, E; Hudry, J; Royet, JP; Thobois, S | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Favit, A; Gillespie, M; Morris, MJ; Mouradian, MM; Sherzai, A | 1 |
| Hauser, RA; Hubble, JP; Truong, DD | 1 |
| Karaban', IM; Kolesnikova, IeE; Serebrovs'ka, TV | 1 |
| Bordet, R; Destee, A; Devos, D; Guieu, JD; Kroumova, M; Libersa, C; Vodougnon, H | 1 |
| Azar, NA; de Beyl, DZ; Vokaer, M | 1 |
| Kumar, A; Lee, CS; Mann, S; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ | 1 |
| Barbieri, S; Caputo, E; Cerutti, S; Egidi, M; Foffani, G; Moxon, KA; Priori, A; Rampini, P; Tamma, F | 1 |
| Chaná, P; Fierro, A; Reyes-Parada, M; Sáez-Briones, P | 1 |
| Double, K; Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Pantelie, CM; Schoenfeld, MA; Schwartz, B | 1 |
| Inzelberg, R; Nisipeanu, P; Schechtman, E | 1 |
| Cao, F; Sun, S; Tong, ET | 1 |
| Kohmoto, J; Kondo, T; Miwa, H; Nakanishi, I | 1 |
| Ogawa, N | 6 |
| Okamoto, K; Tanaka, M | 1 |
| Hirato, M; Kita, K; Kondo, T; Okamoto, K; Yuasa, T | 1 |
| BIRKMAYER, W; HORNYKIEWICZ, O | 2 |
| Goto, S; Ushio, Y; Yamada, K | 1 |
| Chacón, J; García-Moreno, JM; Páramo, L | 1 |
| Bernhard, G; Emre, M; Gershanik, O; Sauer, D | 1 |
| Bastian, AJ; Kelly, VE; Mink, JW; Perlmutter, JS | 1 |
| Jähnel, M | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Basile, G; Di Pasquale, G; Epifanio, A; Ferlazzo, B; Gangemi, S; Merendino, RA; Morgante, L; Nicita-Mauro, V | 1 |
| Imke, S | 2 |
| Fernandez, HH; Okun, MS; Romrell, J | 1 |
| Cao, X; Sun, S; Xu, Y | 1 |
| Lökk, J | 1 |
| Benice, T; Kearns, G; Lou, JS; Nutt, J; Oken, B; Sexton, G | 1 |
| Ho, SL; Lee, TM; Li, LS; Tsang, KL; Yip, JT | 1 |
| Deuschl, G; Gölge, M; Hamel, W; Illert, M; Kopper, F; Krack, P; Kuhtz-Buschbeck, J; Weinert, D; Wenzelburger, R; Witt, K; Zhang, BR | 1 |
| Baron, MS; Dalton, WB | 1 |
| de la Llave, Y; Garcia de Yébenes, J; Garcia-Borreguero, D; Larrosa, O; Schwarz, C | 1 |
| Duan, CL; Su, Y; Xu, QY; Yang, H; Zhao, CL; Zhao, HY | 1 |
| Bjugstad, K; Breeze, RE; Freed, CR; Leehey, MA; Thompson, L; Zawada, M | 1 |
| Brooks, DJ; Frey, KA; Marek, KL; Oakes, D; Paty, D; Prentice, R; Shults, CW; Stoessl, AJ | 1 |
| Blandini, F; Calandrella, D; Colombo, C; Cosentino, M; Fancellu, R; Frigo, GM; Mangiagalli, A; Marino, F; Martignoni, E; Nappi, G; Rasini, E; Riboldazzi, G; Samuele, A; Tassorelli, C | 1 |
| Antonini, A; Basile, G; Di Blasi, L; Di Raimondo, G; Di Rosa, AE; Epifanio, A; Imbesi, D; La Spina, P; Martino, G; Morgante, L; Stocchi, F; Tetto, A | 1 |
| Ginestroni, A; Marini, P; Paganini, M; Ramat, S | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R; Scaglione, C | 1 |
| Carboni, T; Curatola, L; Gobbato, R; Paci, C; Sanguigni, S | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Guastamacchia, G; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Battaglia, G; Grassini, P; Onofrj, M; Ruggieri, S; Stocchi, F; Vacca, L; Valente, M | 1 |
| Kelsberg, G; Rich, J; Schreck, J; Ward, R | 1 |
| Lu, CS; Mok, V; Shan, DE; Tsoi, TH; Wong, KS; Yang, CC | 1 |
| Moser, A; Qadri, F; Thümen, A | 1 |
| Ardouin, C; Batir, A; Benabid, AL; Benazzouz, A; Chabardes, S; Fraix, V; Koudsie, A; Krack, P; LeBas, JF; Limousin, PD; Pollak, P; Van Blercom, N | 1 |
| Dengler, R; Joebges, M; Mrowka, M; Odin, P; Schimke, N; Shing, M | 1 |
| Albani, G; Balzola, F; Baudo, S; Bertocco, P; Bicchiega, V; Izzo, G; Mauro, A; Mazzotta, S; Montesano, A; Petroni, ML; Vinci, C; Zorzetto, E | 1 |
| Bergman, J; Eskola, O; Forsback, S; Grönroos, T; Haapalinna, A; Haaparanta, M; Marjamäki, P; Niemi, R; Rinne, J; Solin, O | 1 |
| Hurley, MJ; Jenner, P; Mash, DC | 1 |
| Blond, S; Bourriez, JL; Cassim, F; Defebvre, L; Derambure, P; Destée, A; Devos, D; Guieu, JD; Labyt, E; Reyns, N; Touzet, G | 1 |
| Ishizu, H; Kuroda, S; Terada, S | 1 |
| Boyce, M; Clarke, A; Corn, TH; Johnson, ES; Johnston, A; MacMahon, DG; Mallard, N; Warrington, S | 1 |
| Steiner, I; Wirguin, I | 1 |
| Alvarez-Gonzalez, E; Bertoli-Avella, AM; Bonifati, V; Giroud-Benitez, JL; Heredero-Baute, L; Heutink, P; van Duijn, CM | 1 |
| Carbajal, LO; Domingo, FM; Esteban, RP; Evidente, VG; Parazo, MA | 1 |
| Chan, DK | 1 |
| Standaert, DG | 1 |
| Ongini, E | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Hu, XJ; Yang, XG; Yang, XS | 1 |
| Bourriez, JL; Cassim, F; Defebvre, L; Derambure, P; Destée, A; Devos, D; Guieu, JD; Labyt, E | 1 |
| Albani, F; Baruzzi, A; Contin, M; Dondi, M; Fanti, S; Martinelli, P; Pettinato, C; Riva, R; Scaglione, C | 1 |
| Collier, TJ; Danielson, PD; Kurlan, R; Sladek, JR; Steece-Collier, K; Yurek, DM | 1 |
| Agid, Y; Bonnet, AM; Cornu, P; Duyckaerts, C; Hauw, JJ; Houeto, JL; Jarraya, B | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH | 1 |
| Antonini, A; Berto, P; D'Ausilio, A; Marconi, S; Tamma, F; Valzania, F | 1 |
| Fedorova, NV | 1 |
| Abdelgabar, A; Sharma, J | 1 |
| Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K | 1 |
| Blond, S; Bourriez, JL; Cassim, F; Defebvre, L; Derambure, P; Destée, A; Devos, D; Guieu, JD; Labyt, E; Reyns, N | 1 |
| Chen, JF | 1 |
| Hirose, H; Ishii, K; Kumada, M; Ueki, A; Yamamoto, M | 1 |
| Armellino, K; Di Iorio, A; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A | 1 |
| Koller, WC; Tse, W | 1 |
| LeWitt, PA; Nyholm, D | 1 |
| Alonso, F; Lanciego, JL; Marin, C; Obeso, JA; Rodriguez-Diaz, M; Rodriguez-Oroz, M; Zamarbide, I | 1 |
| Bastia, E; Dunah, AW; Fienberg, AA; Schwarzschild, MA; Sirianni, AC; Standaert, DG | 1 |
| Schulz-Hanke, I | 1 |
| Bellelli, G; Bellwald, C; Frisoni, GB; Guerini, F; Rossi, R; Trabucchi, M | 1 |
| Bremen, D; Kupsch, A; Trottenberg, T | 1 |
| Evans, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Watt, H | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Evatt, ML; Jewart, RD; Jou, HC; Juncos, JL; Potter, LS; Roberts, VJ; Wood, CD; Yeung, PP | 1 |
| Bosch, DA; de Bie, RM; de Haan, RJ; Esselink, RA; Lenders, MW; Nijssen, PC; Schuurman, PR; Smeding, HM; Speelman, JD; Staal, MJ | 1 |
| Argyriou, AA; Chroni, E; Ellul, J; Papapetropoulos, S | 1 |
| Jankovic, J; Le, W; Pan, T | 1 |
| Arlt, S; Beisiegel, U; Buhmann, C; Kontush, A; Möller-Bertram, T; Oechsner, M; Sperber, S; Stuerenburg, HJ | 1 |
| Connemann, BJ; Schönfeldt-Lecuona, C | 2 |
| Nakagawa, M; Nishizawa, Y; Ogura, H; Ohgoh, M | 1 |
| Azevedo, LL; Cardoso, F; Reis, C | 1 |
| Zhu, BT | 1 |
| Barbato, L; Bolner, A; Caraceni, T; Nordera, G; Stocchi, F | 1 |
| Blandini, F | 1 |
| Borg, M; Broussolle, E; Debilly, B; Durif, F; Galitzky, M; Morand, D; Rascol, O; Thobois, S; Viallet, F | 1 |
| Calne, DB; de la Fuente-Fernández, R; Mak, E; Schulzer, M; Stoessl, AJ | 1 |
| Foster, HD; Hoffer, A | 1 |
| Flisar, D; Pirtosek, Z | 1 |
| Kostić, VS | 1 |
| Pagni, CA; Zeme, S; Zenga, F | 1 |
| Burbaud, P; Coman, I; Cuny, E; Gin, H; Guehl, D; Macia, F; Perlemoine, C; Rigalleau, V; Tison, F | 1 |
| Di Rocco, A; Werner, P | 3 |
| Fuchs, D; Leblhuber, F; Schroecksnadel, K | 1 |
| During, MJ; Lawlor, PA | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Harris, RC; Kelsey, JE; Kleckner, NW; Mague, SD; Matthews, RT; Pijanowski, RS | 1 |
| Maurer, C; Mergner, T; Peterka, RJ | 1 |
| Ferrarin, M; Lopiano, L; Pedotti, A; Recalcati, M; Rizzone, M | 1 |
| Cappello, A; Chiari, L; Gross, A; Horak, FB; Rocchi, L | 1 |
| Brooks, DJ; Gerhard, A; Pavese, N; Piccini, P; Rimoldi, O | 1 |
| Agid, Y; Bonnet, AM; Cornu, P; Dormont, D; Houeto, JL; Maltête, D; Mesnage, V; Navarro, S; Pidoux, B; Roche, S; Welter, ML | 1 |
| Klingemann, I; Moser, A; Scholz, J | 1 |
| Blandini, F; Calandrella, D; Cosentino, M; Fancellu, R; Frigo, GM; Mangiagalli, A; Marino, F; Martignoni, E; Nappi, G; Rasini, E; Riboldazzi, G; Samuele, A | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hornykiewicz, O; Rajput, AH | 1 |
| Baltuch, GH; Chou, KL; Forman, MS; Hurtig, HI; Trojanowski, JQ | 1 |
| Bruguerolle, B; Gantcheva, R; Simon, N; Viallet, F | 1 |
| Swope, DM | 1 |
| Bartus, RT; Basile, AS; Cooper, T; Emerich, D; Fu, K; Lafreniere, D; Lo, ES; Novak, L; Salzberg-Brenhouse, H; Snodgrass-Belt, P | 1 |
| Ashkan, K; Bell, BA; Benabid, AL; Wallace, B | 1 |
| Cenci, MA; Lundblad, M; Poewe, W; Stefanova, N; Tison, F; Wenning, GK | 1 |
| Marttila, R | 1 |
| Ando, T; Itoh, M; Nakajima, T; Nimura, T; Shirane, R; Tominaga, T; Yamaguchi, K | 1 |
| Appel, S; Evans, AH; Katzenschlager, R; Lawrence, AD; Lees, AJ; O'Sullivan, JD; Paviour, D | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Lasa, A; Linazaroso, G; van Blercom, N | 1 |
| Bourdeix, I; Destée, A; Durif, F; Péré, JJ; Pollak, P; Rascol, O; Senard, JM; Tison, F | 1 |
| Friedman, A; Harat, M; Opala, G; Sławek, J; Zabek, M | 1 |
| Borowik, H; Drozdowski, W; Kułakowska, A; Pogorzelski, R | 1 |
| Sobolewski, P | 1 |
| Kadziołka, B; Koziara, H; Sobstyl, M; Zabek, M | 1 |
| Lang, AE; Obeso, JA | 1 |
| Adarraga Cansino, MD; Rosa Jiménez, F; Velasco Malagón, MJ; Zambrana García, JL | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
| Marciani, MG; Placidi, F; Romigi, A | 1 |
| Clarke, CE | 3 |
| Hurka, MR; Leopold, NA; Polansky, M | 1 |
| Brotchie, J; Crossman, A; Davies, R; Fletcher, N; Fox, S; Kellett, M; Silverdale, M; Steiger, M | 1 |
| Fellows, SJ; Noth, J | 1 |
| Bain, PG; Carroll, CB | 1 |
| Diaz-Arrastia, R; O'Suilleabhain, P | 1 |
| Kuhn, W; Müller, T; Renger, K | 1 |
| Ozawa, K | 2 |
| Bernardi, G; Calabresi, P; Centonze, D; Picconi, B; Rossi, S | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Kohno, Y; Takeuchi, S | 1 |
| Carter, JH; Nutt, JG; Sexton, GJ | 1 |
| Breeze, RE; Eidelberg, D; Fahn, S; Freed, CR | 1 |
| Gordin, A; Kaakkola, S; Kultalahti, ER; Lyytinen, J; Sovijärvi, A; Teräväinen, H | 1 |
| Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D | 1 |
| Takáts, A | 1 |
| Itakura, T; Kakishita, K; Nakao, N; Shintani-Mizushima, A | 2 |
| Agnati, LF; Antonelli, T; Ferraro, L; Ferré, S; Franco, R; Fuxe, K; Kehr, J; Sandager Nielsen, K; Scheel-Krüger, J; Tanganelli, S | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Derejko, M; Friedman, A; Sławek, J; Zach, M | 1 |
| Clarke, CE; Gray, R; Ives, N; Wheatley, K | 1 |
| Marras, C | 1 |
| Clarke, C; Gray, R; Ives, N; Wheatley, K | 1 |
| Leslie, M | 1 |
| Morgan, JC; Sethi, KD | 2 |
| Brosnan, JT; Brosnan, ME; Jacobs, RL; Stead, LM | 1 |
| Bassi, A; Brusa, L; Fedele, E; Giacomini, P; Lunardi, G; Pierantozzi, M; Stanzione, P | 1 |
| Avanzi, M; Bonfà, F; Uber, E | 1 |
| Bailey, DL; Brooks, DJ; Pavese, N; Remy, P; Whone, AL | 1 |
| Kameyama, M; Kubori, T; Matsui, H; Nishinaka, K; Oda, M; Udaka, F | 1 |
| Finel, M; Kurkela, M; Siiskonen, A; Tammela, P; Taskinen, J; Vuorela, P | 1 |
| Bogousslavsky, J; Burkhard, PR; Combrement, P; Ghika, J; Russmann, H; Villemure, JG; Vingerhoets, FJ | 1 |
| Blandini, F; Calandrella, D; Cosentino, M; Fancellu, R; Frigo, G; Lecchini, S; Mangiagalli, A; Marino, F; Martignoni, E; Nappi, G; Pacchetti, C; Rasini, E; Riboldazzi, G; Samuele, A; Tassorelli, C | 1 |
| Gasser, T; Pöpperl, G; Ruzicka, E; Schwarz, J; Storch, A; Tatsch, K | 1 |
| Azulay, JP; Bernhard, G; Giménez-Roldán, S; Markabi, S; Martin, W; Onofrj, M; Schmidt, W; Thomas, A; Vingerhoets, F | 1 |
| Linazasoro, G | 4 |
| Marinus, J; Schipper, RGB; Stiggelbout, AM; van Hilten, JJ; Visser, M | 1 |
| Germano, IM; Gracies, JM; Koller, WC; Olanow, CW; Tse, W; Weisz, DJ | 1 |
| Williams, A | 1 |
| Chang, FY; Chen, CY; Chen, JD; Lee, SD; Lu, CL; Luo, JC; Shan, DE; Wu, HC | 1 |
| Goto, S; Yamada, K | 1 |
| Graff, H; Hauck, PR; Herdoiza Leiva, MH; Munhoz, RP; Teive, HA; Troiano, AR; Werneck, LC | 1 |
| Alexander-Brown, B; Atassi, F; Barclay, L; Bennett, S; Berry, D; Biglan, K; Borchert, L; Brocht, A; Brown, D; Daigneault, S; DeAngelis, M; Dillon, S; Dobson, J; Evans, S; Factor, S; Fahn, S; Fontaine, D; Ford, B; Fussell, B; Hall, J; Hammerstad, J; Harrigan, M; Hodgeman, K; Holloway, RG; Hubble, J; Jankovic, J; Kamp, C; Kieburtz, K; Kurlan, R; Lang, A; LeWitt, P; Marek, K; McDermott, M; Miyasaki, J; Montgomery, A; Musch, B; O'Connell, C; Pahwa, R; Panisset, M; Pantella, C; Petsinger, G; Pfeiffer, B; Pfeiffer, R; Rainey, P; Rajput, A; Richard, K; Riley, D; Rodnitzky, R; Ross, T; Rost-Ruffner, E; Russell, DS; Seibyl, J; Shinaman, A; Shirley, T; Shoulson, I; Shults, C; Sime, E; Stacy, M; Standaert, D; Suchowersky, O; Sutherland, L; Tennis, M; Waters, C; Watts, A; Weeks, C; Weiner, W; Welsh, M; Wood, S; Wooten, F | 1 |
| Hamani, C; Lozano, A; Toda, H | 1 |
| Follett, KA | 1 |
| Alterman, RL; Gudesblatt, M; Shils, JL; Tagliati, M | 1 |
| Aristova, RA; Belikova, LP; Gusev, EI; Piatnitskiĭ, AN; Selikhova, MV; Vialkova, AB | 1 |
| Leenders, KL; Linazasoro, G | 1 |
| Bonelli, SB; Deibl, M; Lampl, C; Lukas, T; Ransmayr, G; Steffelbauer, M | 1 |
| Cumming, P; Danielsen, EH; Gjedde, A; Kumakura, Y; Reilhac, A | 1 |
| Corvol, JC; Féger, J; Girault, JA; Hanoun, N; Hervé, D; Hirsch, EC; Muriel, MP; Valjent, E | 1 |
| Lo, TC; Thanvi, BR | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M; Scaglione, F | 1 |
| Alcaraz, R; Atarés, B; Bilbao, G; Garibi, J; Gómez-Esteban, JC; Lambarri, I; Lezcano, E; Zarranz, JJ | 1 |
| Castro, A; Dapena, MD; Linazasoro, G; Van Blercom, N | 1 |
| Altibrandi, MG; Bassi, A; Brusa, L; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Clarke, CE; Counsell, C; Gray, R; Ives, NJ; Macleod, A; Marro, J; Stowe, RL; Wheatley, K | 1 |
| Al-Din, A; Lily, O | 1 |
| Calne, DB; de la Fuente-Fernández, R; Furtado, S; Huang, Z; Lu, JQ; Ruth, TJ; Sossi, V; Stoessl, AJ | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Guillet, B; Kerkerian-Le Goff, L; Melon, C; Robelet, S; Salin, P | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Berezetskaia, NM; Burenok, IuA; Karaban', IN; Lukhanina, EP; Mel'nik, NA | 2 |
| Gilbert, GJ | 2 |
| Konietzka, S; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Börnke, Ch; Müller, T; Przuntek, H; Schulte, T | 1 |
| Białecka, M; Droździk, M; Gawrońska-Szklarz, B; Honczarenko, K; Kłodowska-Duda, G; Opala, G; Stankiewicz, J | 1 |
| Lang, AE; Postuma, RB | 1 |
| Agid, Y; Albanese, A; Bonuccelli, U; Bonucelli, U; Damier, P; De Yebenes, J; Gershanik, O; Grandas, F; Guttman, M; Hallett, M; Hornykiewicz, O; Jenner, P; Katzenschlager, R; Langston, WJ; LeWitt, P; Melamed, E; Mena, MA; Michel, PP; Mizuno, Y; Mytilineou, C; Obeso, JA; Olanow, CW; Poewe, W; Quinn, N; Raisman-Vozari, R; Rajput, AH; Rascol, O; Sampaio, C; Stocchi, F | 1 |
| Debilly, B; Durif, F; Lees, AJ; Rascol, O; Zijlmans, JC | 1 |
| Guridi, J; Obeso, JA; Palmero, MR; Rodriguez-Oroz, MC; Zamarbide, I | 1 |
| Lee, SJ; Liao, KK; Liu, RS; Shan, DE; Soong, BW; Sun, CM | 1 |
| Bassi, A; Brusa, L; Fedele, E; Lunardi, G; Pasqualetti, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Bianchi, AM; Foffani, G; Locatelli, M; Moxon, KA; Pellegrini, M; Pesenti, A; Priori, A; Tamma, F; Villani, RM | 1 |
| Nielsen, KK; Stimpel, H; Werdelin, LM; Winge, K | 1 |
| Chapuis, S; Durif, F; Gerbaud, L; Metz, O; Ouchchane, L | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Gross, J; Lehrke, R; Maarouf, M; Schnitzler, A; Sturm, V; Timmermann, L; Treuer, H; Voges, J; Wojtecki, L | 1 |
| Filiano, JJ; Furukawa, Y; Kish, SJ | 1 |
| de Courval, FP; Panisset, M; Proulx, M; Wiseman, MA | 1 |
| Cassel, W; Haja, D; Körner, Y; Krüger, HP; Meindorfner, C; Möller, JC; Oertel, WH; Stiasny-Kolster, K | 1 |
| Costa, DC; Evans, AH; Gacinovic, S; Heales, S; Katzenschlager, R; Lee, P; Lees, AJ; O'sullivan, JD | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| Huxham, F; Iansek, R; Matyas, T; McGinley, J; Morris, M | 1 |
| Bhatia, K; Evans, A; Hoffman, M; Hughes, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Quinn, N; Swinn, L; Watt, H | 1 |
| Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Livrea, P; Zoccolella, S | 1 |
| Bottiglieri, T; Dewey, RB; Diaz-Arrastia, R; O'Suilleabhain, PE; Sharma, S | 1 |
| Happe, S; Helmschmied, K; Neubert, K; Paulus, W; Tings, T; Trenkwalder, C; Wuttke, W | 1 |
| Dostrovsky, JO; Hutchison, WD; Lang, AE; Lozano, AM; Palter, VN; Pereira, LC | 1 |
| Kikuchi, S | 1 |
| Farkas, R; Málly, J; Stone, TW; Tóthfalusi, L | 1 |
| Ferraz, HB; Nova, IC; Perracini, MR | 1 |
| Kang, SY; Lee, MH; Lee, SK; Sohn, YH | 1 |
| de Freitas, RM; dos Santos Souza, MP; Fricke, D; Rieder, CR | 1 |
| Morrish, P | 2 |
| Bandel, D; Capus, L; Mezzarobba, S; Moretti, R; Torre, P | 1 |
| Guarnieri, M; Hubble, J; Kieburtz, K; Langston, JW; Olanow, CW; Stern, M; Watts, R | 1 |
| Bain, PG; Carroll, CB; Fox, P; Hobart, J; Joint, C; Liu, X; Parkin, SG; Teare, L; Wright, D; Wroath, C; Zajicek, JP | 1 |
| Dhanasekaran, M; Hare, TA; Manyam, BV | 1 |
| Borod, JC; Brin, MF; Hälbig, TD; Morrison, CE; Olanow, CW | 1 |
| Giladi, N; Korczyn, AD; Merims, D; Peretz, C; Shabtai, H; Weizman, N | 1 |
| Clarke, CE; Deane, KH; Spieker, S | 2 |
| Cullen, EI; Hahne, WA; Kirby, L; Kumar, D; Okereke, CS; Pratt, RD | 1 |
| Hauser, RA; Lyons, KE | 1 |
| Tetrud, J | 1 |
| Bergamasco, B; Ferrarin, M; Lanotte, M; Lopiano, L; Pedotti, A; Recalcati, M; Rizzone, M | 1 |
| Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D | 1 |
| Kikuchi, S; Murata, M; Ohkuma, Y; Yamamoto, M; Yanagisawa, N | 1 |
| Bäumer, T; Buhmann, C; Demiralay, C; Gorsler, A; Hidding, U; Hinkelmann, K; Münchau, A; Siebner, HR; Weiller, C | 1 |
| Chan, PL; Holford, NH; Nutt, JG | 4 |
| Jung, SK | 1 |
| Cheng, TI; Cheng, TJ; Chiang, SC | 1 |
| Charles, PD; Covington, CD; Davis, TL; Fang, JY; Gill, CE; Konrad, PE; Newman, WJ; Padaliya, BB; So, SA; Tramontana, MG | 1 |
| Evans, A; Katzenschlager, R; Lees, AJ; Manson, A; Patsalos, PN; Ratnaraj, N; Timmermann, L; Van der Giessen, R; Watt, H | 1 |
| Chaná, P; Kuntsmann, C; Reyes-Parada, M; Sáez-Briones, P | 1 |
| Hely, MA; Morris, JG; Reid, WG; Trafficante, R | 1 |
| Magnani, P; Mailland, E; Ottillinger, B | 1 |
| Bouhaddi, M; Cappelle, S; Fortrat, JO; Henriet, MT; Regnard, J; Rumbach, L; Vuillier, F | 1 |
| Bogousslavsky, J; Burkhard, PR; Ghika, J; Robert, B; Russmann, H; Villemure, JG; Vingerhoets, FJ | 1 |
| Bearn, J; Evans, A; Kelleher, M; Lees, A; Turner, K | 1 |
| Alonso-Prieto, E; Michel-Esteban, E; Palmero-Soler, E; Trujillo-Matienzo, C | 1 |
| Fukaya, C; Hashimoto, T; Itakura, T; Katayama, Y; Kobayashi, K; Tanaka, K; Yamamoto, T; Yokoyama, T | 1 |
| Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA | 1 |
| Gluck, MA; Grossman, S; Myers, CE; Sage, J; Shohamy, D | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Hoffmann, A; Klotz, P; Kraus, PH; Lewe, J; Przuntek, H | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Marek, K; Oakes, D; Olanow, CW; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Brotchie, JM; Crossman, AR; Nicholson, SL; Silverdale, MA | 1 |
| Carlsson, M; Ganowiak, W; Granérus, AK; Lorefält, B; Pålhagen, S; Toss, G; Unosson, M | 1 |
| Boas, J; Hakala, A; Macmahon, D; Myllyla, V; Reichmann, H; Reinikainen, K | 1 |
| Weiner, WJ | 5 |
| Roach, ES | 1 |
| Hattori, N; Miyazato, Y; Namihira, T; Shiroma, S | 1 |
| Black, KJ; Carl, JL; Hartlein, JM; Hershey, T; Perlmutter, JS | 1 |
| Brotchie, JM; Lee, J; Venderova, K | 1 |
| Sá, DS; Teive, HA; Troiano, AR; Werneck, LC | 1 |
| Kedia, S; Kumar, R; Lang, AE; Moro, E; Tagliati, M | 1 |
| Braga-Neto, P; da Silva-Júnior, FP; Monte, FS; Nobre E Souza, MÂ; Sales de Bruin, VM | 1 |
| Baba, M; Ichinohe, N; Kimura, T; Matsunaga, M; Mori, F; Tomiyama, M; Wakabayashi, K | 1 |
| Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Rudolph, A; Tanner, CM | 1 |
| Klein, C; Rabey, JM; Stryjer, R; Treves, TA | 1 |
| Antenor, JA; Kotagal, V; McGee-Minnich, L; Moerlein, SM; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J | 1 |
| Björklund, A; Burger, C; Carlsson, T; Cenci, A; Kirik, D; Mandel, RJ; Muzyczka, N; Winkler, C | 1 |
| Mouradian, MM | 2 |
| Aquilonius, SM; Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Jansson, R; Nilsson Remahl, AI; Nyholm, D | 1 |
| Hefter, H; Hueber, R; Jost, WH; Leenders, KL; Müller, T; Odin, P; Schwarz, J | 1 |
| Alvarez, E; Alvarez, L; DeLong, MR; Guridi, J; Juncos, JL; Koller, W; Litvan, I; Lopez, G; Macias, R; Maragoto, C; Obeso, JA; Pavon, N; Rodriguez-Oroz, MC; Tolosa, ES; Vitek, J | 1 |
| Benbir, G; Kaynak, D; Kaynak, H; Kiziltan, G; Uysal, O | 1 |
| Davis, V; Lindsey, N; Marks, WJ; Ostrem, JL; Rau, GM; Simmons, D; Starr, PA; Turner, RS | 1 |
| Iakhno, NN; Zakharov, VV | 1 |
| Gentilucci, M; Negrotti, A; Secchi, C | 1 |
| Borges, N | 1 |
| Nakashima, K; Nakaso, K; Yoshimoto, Y | 1 |
| Turnbull, C | 1 |
| Lo, N; Robinson, T; Thanvi, B | 2 |
| Barker, RA; Lewis, SJ; Owen, AM; Robbins, TW; Slabosz, A | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Pisani, A | 1 |
| Grosset, DG; Grosset, KA | 1 |
| Bowron, A; Guttman, M; Hauser, R; Hughes, K; Larsen, JP; LeWitt, P; Oertel, W; Quinn, N; Sethi, K; Stacy, M; Stocchi, F | 1 |
| Kim, HS; Lee, MS; Lyoo, CH | 1 |
| Ross, IN; Sharma, JC; Vassallo, M | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Levine, J; Lieberman, A; Lyons, K; Myerburg, R | 1 |
| Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Mastronardi, R; Zoccolella, S | 1 |
| Goberman, AM | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Mochi, M; Riva, R | 1 |
| Brus, R; Kostrzewa, JP; Kostrzewa, RA; Kostrzewa, RM; Nowak, P | 1 |
| Kurlan, R | 3 |
| DeRoche, C; Kastenholz, KV; Nausieda, PA; Pfeiffer, RF; Slevin, JT; Tagliati, M | 1 |
| Barker, RA; Michell, AW; Raha, SK; Raha-Chowdhury, R | 1 |
| Brown, P; Dowsey-Limousin, P; Hariz, MI; Hotton, G; Kühn, AA; Kupsch, A; Pogosyan, A; Silberstein, P; Tisch, S | 1 |
| Calne, D; Mak, E; Schulzer, M; Stoessl, AJ | 1 |
| Bergquist, J; Dibó, G; Rajda, C; Vécsei, L | 1 |
| Asanuma, K; Bressman, SB; Carbon-Correll, M; Edwards, C; Eidelberg, D; Huang, C; Ma, Y; Moeller, JR; Raymond, D | 1 |
| Baillet, L; Burbaud, P; Coman, I; Cuny, E; Gin, H; Guehl, D; Macia, F; Perlemoine, C; Rigalleau, V; Tison, F | 1 |
| Calandrella, D; Cosentino, M; Frigo, G; Lecchini, S; Martignoni, E; Michielotto, D; Nappi, G; Pacchetti, C; Riboldazzi, G | 1 |
| De Reuck, J; De Weweire, M; Santens, P; Van Maele, G | 1 |
| Althoff, R; Jacobson, J; Martineau, RJ; Singh, A | 1 |
| Walton-Hadlock, JL | 1 |
| Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
| Brown, P; Doyle, LM; Hariz, M; Kühn, AA; Kupsch, A; Schneider, GH | 1 |
| Kwon, PS; Verghese, J | 1 |
| Brusa, L; Caltagirone, C; Koch, G; Oliveri, M; Stanzione, P | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Camarda, C; Camarda, LK; Camarda, R; Gangitano, M; Grimaldi, S; Monastero, R | 1 |
| Metman, LV; O'Leary, ST | 1 |
| Comella, C; Widnell, KL | 1 |
| Widnell, K | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Di Rocco, A; Huang, N; Marinelli, L; Mazzella, L; Moshier, E; Yahr, MD | 1 |
| Anderson, VC; Burchiel, KJ; Favre, J; Hammerstad, JP; Hogarth, P | 1 |
| Annesi, F; Annesi, G; Arabia, G; Carrideo, S; Cirò-Candiano, IC; Civitelli, D; De Marco, EV; Gambardella, A; Messina, D; Nicoletti, G; Pugliese, P; Quattrone, A; Spadafora, P; Tarantino, P; Zappia, M | 1 |
| Onofrj, M; Thomas, A | 1 |
| Gadoth, N; Huberman, M; Naftali, T; Novis, B | 1 |
| Bundhukul, A; Chankrachang, S; Laptikultham, S; Nidhinandana, S; Pisarnpong, A; Srisuwananukorn, S; Suwantamee, J | 1 |
| Lim, E | 1 |
| Aguiar, PM; Behlau, MS; Ferraz, FA; Ferraz, HB; Mourão, LF | 1 |
| Argyriou, AA; Ellul, J; Papapetropoulos, S | 1 |
| Brown, L; Doan, J; Melvin, KG; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Volpini, R | 1 |
| Artemova, IIu; Batysheva, TT; Boĭko, AN; Chikina, ES; Ganzhula, PA; Ismailov, AM; Khozova, AA; Lisenker, LN; Obydenova, NA; Rotor, LD; Vdovichenko, TV; Vinetskiĭ, IaIa | 1 |
| Bain, PG; Carroll, CB; Liu, X; Wang, SY; Zajicek, J | 1 |
| Comella, CL; Janko, K; Morrissey, M | 1 |
| Aasly, JO; Farrer, M; Fernandez-Mata, I; Hulihan, M; Kachergus, J; Toft, M; White, LR | 1 |
| Hauser, RA; Lyons, KE; Pahwa, R | 1 |
| Corneliusson, O; Elam, M; Holmberg, B | 1 |
| Hariz, M; Limousin, P; Nowak, DA; Rothwell, JC; Tisch, S; Topka, H | 1 |
| Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L | 1 |
| Coccurello, R; Domenici, MR; Martire, A; Pèzzola, A; Popoli, P; Potenza, RL; Reggio, R; Tebano, MT | 1 |
| Konitsiotis, S | 1 |
| Farsang, M; Kovács, T; Szirmai, I; Takáts, A | 1 |
| Apaydin, H; Kiliç, E; Ozekmekçi, S | 1 |
| Aubert, I; Benovic, JL; Bezard, E; Bioulac, BH; Bloch, B; Ferry, S; Fisone, G; Gross, CE; Guigoni, C; Gurevich, EV; Gurevich, VV; Håkansson, K; Leriche, L; Li, Q; Mach, U; Sokoloff, P; Stark, H | 1 |
| Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Matsunaga, M; Tomiyama, M | 1 |
| Araujo Silva, MT; Barbosa, ER; Bermpohl, F; Boggio, PS; Fregni, F; Mansur, CG; Marcolin, MA; Odebrecht Rosa, M; Pascual-Leone, A; Rigonatti, SP; Rosa, M; Rumi, DO | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Agid, Y; Czernecki, V; Dubois, B; Houeto, JL; Mesnage, V; Pillon, B; Welter, ML | 1 |
| Deuschl, G; Govindan, RB; Morsnowski, A; Pohle, S; Raethjen, J; Wenzelburger, R | 1 |
| Aydemir, T; Aydin, B; Hanoglu, L; Meral, H; Oral, T; Ozer, F | 1 |
| Inzelberg, R; Paleacu, D; Schechtman, E | 1 |
| Carlson, NE; Chung, KA; Nutt, JG | 1 |
| Barone, I; Bernardi, G; Bonsi, P; Calabresi, P; Centonze, D; Picconi, B; Pisani, A | 1 |
| Ahn, YH; Cho, KG; Kim, KS; Kim, SU; Lee, MA; Ryu, MY; Snyder, EY; Yoon, SH | 1 |
| Cools, R | 1 |
| Weiss, B | 1 |
| Bernardi, G; Mercuri, NB | 1 |
| Dulloo, AG; Montani, JP | 1 |
| Subramanian, T; Tousi, B | 1 |
| Doggrell, SA | 1 |
| Kishore, A; Lang, AE | 1 |
| Hauser, RA; Maldonado, JL; Sullivan, KL; Tatum, WO; Zesiewicz, TA | 1 |
| Albanese, A; Bellacchio, E; Dallapiccola, B; Elia, AE; Romito, LM; Valente, EM | 1 |
| Fogel, W; Jost, WH; König, J; Krause, M; Lubik, S; Tronnier, V | 1 |
| Chandran, VR; Cheah, SY; Fook-Chong, S; Lum, SY; Tan, EK; Yew, K; Yi, Z | 1 |
| Destee, A | 1 |
| Benecke, R; Wittstock, M | 1 |
| Agid, Y; Brooks, DJ; Eggert, K; Holopainen, A; Ostergaard, K; Widner, H | 1 |
| Agid, Y; Albanese, A; Benabid, AL; Bonnet, AM; Contarino, MF; Fraix, V; Gironell, A; Guridi, J; Hariz, MI; Houeto, JL; Kulisevsky, J; Lang, AE; Lozano, AM; Molet, J; Obeso, JA; Pascual-Sedano, B; Pidoux, B; Pollak, P; Quinn, NP; Rehncrona, S; Rodriguez-Oroz, MC; Romito, L; Saint-Cyr, J; Scerrati, M; Speelman, JD; Van Blercom, N; Volkmann, J; Xie, J; Zamarbide, I | 1 |
| Wedekind, S | 1 |
| Burkhard, PR; Villemure, JG; Vingerhoets, FJ | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Morelli, M; Pinna, A; Simola, N; Wardas, J | 1 |
| Ardolino, G; Barbieri, S; Caputo, E; Cerutti, S; Egidi, M; Foffani, G; Priori, A; Rampini, P; Tamma, F | 1 |
| Altibrandi, MG; Bentivoglio, A; Caruso, G; Cioni, B; Fiorella, C; Insola, A; Lavano, A; Maina, R; Mazzone, P; Pagni, CA; Signorelli, CD; Sturiale, C; Valzania, F; Zeme, S; Zenga, F | 1 |
| Morgan, J; Sethi, KD | 1 |
| Baltuch, GH; Chou, KL; Hurtig, HI; Jaggi, JL; Pelchat, RJ; Weintraub, D | 1 |
| Bares, M; Kanovský, P; Pohanka, M; Pulkrábek, J; Rektor, I | 1 |
| Bronte-Stewart, HM; Hastie, T; Heit, G; Hill, BC; Jefferis, GS; Koop, M; Taylor Tavares, AL | 1 |
| Glover, AL; Iyer, SS; Morgan, JC; Sethi, KD | 1 |
| Chowdhury, M; Scott, M | 1 |
| Ward, C | 1 |
| Angersbach, D; Buchwald, B; Reichmann, H | 1 |
| Apajasalo, M; Findley, LJ; Lees, A; Pitkänen, A; Turunen, H | 1 |
| Cheetham, SC; Jenner, P; Lane, EL | 1 |
| Brotchie, JM | 3 |
| Ahlskog, JE; Bower, JH; Dodd, ML; Geda, YE; Josephs, KA; Klos, KJ | 1 |
| Brown, P; Di Lazzaro, V; Insola, A; Mazzone, P; Oliviero, A; Silberstein, P | 1 |
| Meixensberger, J; Preul, C; Schwarz, J; Strecker, K; Tittgemeyer, M; Winkler, D | 1 |
| Hamada, I; Okiyama, R; Shichi, T; Takahashi, H; Taniguchi, M; Yokochi, F | 1 |
| Kim, MN; Kim, YM; Lee, JJ; Lee, MK | 1 |
| Brown, P; Di Lazzaro, V; Fogelson, N; Insola, A; Kühn, AA; Kupsch, A; Limousin, P; Mazzone, P; Pogosyan, A; Quartarone, A; Speelman, H; Tijssen, M; van Bruggen, G | 1 |
| Amabile, GA; Bartolo, M; Bramanti, P; Fattapposta, F; Locuratolo, N; Parisi, L; Perrotta, A; Pierelli, F; Pujia, F; Serrao, M; Valletta, L | 1 |
| Pfeiffer, RF | 2 |
| Counsell, CE; Ives, N; Macleod, AD; Stowe, R | 1 |
| Burn, DJ; Firbank, MJ; McKeith, IG; O'Brien, JT | 1 |
| Bostantjopoulou, S; Frangia, T; Hatzizisi, O; Katsarou, Z; Kazis, A; Kiosseoglou, G; Kyriazis, G; Papazisis, K | 1 |
| Brooks, DJ; Goerendt, IK; Lawrence, AD; Mehta, MA; Odin, P; Stern, JS | 1 |
| Agostino, R; Bagnato, S; Berardelli, A; Dinapoli, L; Modugno, N | 1 |
| Brefel-Courbon, C; Chollet, F; Montastruc, JL; Ory, F; Payoux, P; Quelven, I; Rascol, O; Thalamas, C | 1 |
| Cassel, W; Körner, Y; Krüger, HP; Meindorfner, C; Möller, JC; Oertel, WH; Rethfeldt, M; Rissling, I; Stiasny-Kolster, K | 1 |
| Adams, JR; Calne, DB; Farrer, M; Gasser, T; Lee, CS; Mak, E; Mckenzie, J; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ; Strongosky, A; Uitti, RJ; van Netten, H; Wszolek, ZK | 1 |
| Stellar, S | 1 |
| Jean-Luc, H | 1 |
| Hayashi, K; Honda, H; Kaneko, K; Kira, J; Koga, H; Kuwabara, Y; Nakagawa, M; Sasaki, M; Taniwaki, T | 1 |
| Cardoso, F; Teixeira-Júnior, AL | 1 |
| Farrer, MJ; Gosal, D; Hulihan, M; Irvine, GB; Johnston, JA; Kachergus, J; Lincoln, SJ; Lynch, T; Mark Gibson, J; Mata, IF; Ross, OA; Taylor, JP; Toft, M; Wiley, J | 1 |
| Ahlskog, JE; Bower, JH; Josephs, KA; Klos, KJ; Matsumoto, JY | 1 |
| Bleda, MJ; Serrano-Dueñas, M | 1 |
| Xiao, L; Yang, J; Yuan, XQ | 1 |
| Baselli, G; Bianchi, AM; Foffani, G; Priori, A | 1 |
| Bakay, RA; Corcos, DM; Metman, LV; Prodoehl, J; Sturman, MM; Vaillancourt, DE | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Nutt, JG; Wooten, GF | 1 |
| Geghman, KD; Gluck, MA; Myers, CE; Sage, J; Shohamy, D | 1 |
| Baba, Y; Putzke, JD; Uitti, RJ; Whaley, NR; Wszolek, ZK | 1 |
| Bernardi, G; Brusa, L; Danieli, R; Filippi, L; Manni, C; Pierantozzi, M; Schillaci, O; Simonetti, G; Stanzione, P | 1 |
| Poryazova, RG; Zachariev, ZI | 1 |
| Braga-Neto, P; da Silva-Júnior, FP; de Bruin, VM; Sueli Monte, F | 1 |
| Lees, A | 1 |
| Ammannati, F; Formiconi, AR; Pupi, A; Ramat, S; Sestini, S; Sorbi, S | 1 |
| Broche, BA; Gibaud, B; Haegelen, C; Jannin, P; Morandi, X; Prigent, F; Verin, M | 1 |
| Curgian, L; Goetz, CG; Leurgans, S; Wuu, J | 1 |
| Antonini, A; Bovi, P; Fiaschi, A; Gambarin, M; Moretto, G; Romito, S; Tinazzi, M | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Chambon, P; Ichinose, H; Ikeguchi, K; Kodera, M; Li, XG; Metzger, D; Muramatsu, C; Muramatsu, S; Nakano, I; Nara, Y; Okada, T; Ozawa, K; Takino, N; Urano, F | 1 |
| Armenise, E; de Mari, M; Defazio, G; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
| Cuadrado-Gamarra, JI; de Pedro-Cuesta, J; Esteban, EM; Giménez-Roldán, S; Lara, G; Luis-González, S | 1 |
| Bremen, D; Erdmann, C; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Arnold, G; Bergamasco, B; Dujardin, M; Frewer, P; Gimenez-Roldan, S; Grosset, DG; Hundemer, HP; Leenders, KL; Lledó, A; Oertel, WH; Sampaio, C; Schwarz, J; Wolters, E; Wood, A | 1 |
| Beiske, AG; Grotli, R; Lundqvist, C; Nystedt, T; Reiertsen, O | 1 |
| Escamilla-Sevilla, F; Minguez-Castellanos, A | 1 |
| Eldadah, BA; Goldstein, DS; Holmes, C; Moak, J; Pechnik, S; Saleem, A; Sharabi, Y | 1 |
| Agil, A; Alba, F; Araúzo, M; Barrero, F; Durán, R; Miranda, MT; Morales, B; Prieto, I; Ramírez, M; Vives, F | 1 |
| Lang, AE; Miyasaki, J; Olanow, CW; Stoessl, AJ; Suchowersky, O | 1 |
| Kumar, S | 1 |
| Maina, R; Pagni, CA; Zeme, S; Zenga, F | 1 |
| Brown, JM; Buzas, B; Candeletti, S; Cox, BM; Di Benedetto, M; Fantin, M; Guerrini, R; Marti, M; Mela, F; Morari, M; Reinscheid, RK; Romualdi, P; Salvadori, S; Simonato, M; Witta, J; Zucchini, S | 1 |
| Kitagawa, M; Tashiro, K | 1 |
| Cercy, SP; Walker, RH; Warwick, R | 1 |
| Asai, H; Hirano, M; Kameyama, M; Kubori, T; Minami, T; Nishinaka, K; Oda, M; Udaka, F; Ueno, S | 1 |
| Haapasalo, H; Honkaniemi, J; Kähärä, V; Liimatainen, S; Paetau, A | 1 |
| Chamberland, M; Drouin, J; Gilbert, F; Lévesque, D; van den Munckhof, P | 1 |
| Jeon, MY; Kang, HY; Lee, EA; Lee, WY; Park, YG | 1 |
| Cappello, A; Chiari, L; Horak, FB; Rocchi, L | 1 |
| Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K | 1 |
| Ackermans, L; Beuls, EA; Blokland, A; Boon, P; Spincemaille, GH; Temel, Y; van Kranen-Mastenbroek, VH; Visser-Vandewalle, V | 1 |
| Burgut, FT; Henchcliffe, C; Schumacher, HC | 1 |
| Bottiglieri, T; Diaz-Arrastia, R; Greenberg, SM; Growdon, JH; Gurol, ME; Hyman, BT; Irizarry, MC; Locascio, JJ; Raju, S; Tennis, M | 1 |
| Jansson, R; Nyholm, D; Remahl, IN; Willows, T | 1 |
| Iyer, SS; Morgan, JC; Sethi, KD | 2 |
| Borek, LL; Friedman, JH | 1 |
| Ransmayr, G | 2 |
| Hirano, M; Kariya, S; Takahashi, N; Ueno, S | 1 |
| Aa Sunde, N; Østergaard, K | 1 |
| Erola, T; Haapaniemi, T; Heikkinen, ER; Juolasmaa, A; Myllylä, VV; Tuominen, J | 1 |
| Agid, Y; Bonnet, AM; Chastan, N; Cornu, P; Czernecki, V; Dormont, D; Hartmann, A; Houeto, JL; Mallet, A; Mallet, L; Maltête, D; Mesnage, V; Navarro, S; Pidoux, B; Schüpbach, WM; Welter, ML | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH | 1 |
| Berciano, J; Combarros, O; Fontalba, A; Infante, J; Leno, C; Mateo, I; Oterino, A; Pascual, J; Polo, JM; Rodríguez, E | 1 |
| Andre, P; Bouhaddi, M; Cappelle, S; Louisy, F; Mikehiev, A; Mourot, L; Regnard, J; Rumbach, L; Vuillier, F; Wolf, JP | 1 |
| Berdeaux, G; Clarke, CE; Deschaseaux-Voinet, C; Khoshnood, B; Péchevis, M; Vieregge, P; Ziegler, M | 1 |
| Dunnett, SB; Monville, C; Torres, EM | 1 |
| Barat, M; Bioulac, B; Burbaud, P; Cuny, E; de Sèze, MP; Dehail, P; Faux, P; Guehl, D; Tison, F | 1 |
| Artem'ev, DV | 1 |
| Dick, AW; Holloway, RG; Noyes, K | 1 |
| Allen, RC; Bakay, RA; Cornfeldt, ML; Raiser, CD; Schweikert, AW; Stover, NP; Subramanian, T; Watts, RL | 1 |
| Hattori, N; Inzelberg, R; Mizuno, Y | 1 |
| Willis, GL | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Chen, JJ; Obering, C | 1 |
| Ando, T; Itoh, M; Nakagawa, A; Nimura, T; Oikawa, T; Shibuya, S; Shirane, R; Tominaga, T; Yamaguchi, K | 1 |
| Fénelon, G; Goetz, CG; Karenberg, A | 1 |
| Nielsen, KK; Skau, AM; Stimpel, H; Werdelin, L; Winge, K | 1 |
| Azouvi, P; Ben Smaïl, D; Régnault, J; Rouy-Thenaisy, K; Samuel, C | 1 |
| Baselli, G; Bianchi, AM; Egidi, M; Foffani, G; Marceglia, S; Priori, A; Tamma, F | 1 |
| Belforte, JE; Benarroch, EE; Cersósimo, MG; Micheli, FE; Pazo, JH; Tumilasci, OR | 1 |
| Antico, J; Merello, M; Obeso, JA; Perez-Lloret, S | 1 |
| Dalvi, A; Gartner, M; Gong, J; Revilla, FJ; Sahay, A; Samaha, FJ; Strong, JA; Welge, JA; Yu, L; Yue, X | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH | 1 |
| Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nisikawa, N; Nomoto, M; Yabe, H | 1 |
| Kameyama, M; Kubori, T; Matsui, H; Nishinaka, K; Oda, M; Tamura, A; Udaka, F | 2 |
| Cannas, A; Floris, G; Solla, P; Tacconi, P | 1 |
| Hurley, MJ; Jenner, P | 1 |
| Balci, K; Celik, Y; Kabayel, L; Turgut, N | 1 |
| Baltuch, G; Chou, KL; Colcher, A; Hurtig, H; Jaggi, JL; Leng, L; Liang, G; Loveland-Jones, C; Maccarone, H; Siderowf, A; Simuni, T; Stern, M; Xie, SX | 1 |
| Cersósimo, MG; Micheli, F; Zúñiga Ramírez, C | 1 |
| Rajput, A; Rajput, AH | 1 |
| Chen, R; Espay, AJ; Gunraj, C; Lang, AE; Morgante, F | 1 |
| Adams, J; de la Fuente-Fernández, R; Schulzer, M; Sossi, V; Stoessl, J | 1 |
| Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA; Weigand, S | 1 |
| Blindauer, K; Eyal, E; Fahn, S; Goetz, C; Goren, S; Kieburtz, K; Levy, R; Nutt, J; Oakes, D; Pagano, M; Salzman, P; Sayag, N; Schwid, S; Scolnik, M; Shoulson, I; Stern, M | 1 |
| Bharmal, A; Lu, C; Suchowersky, O | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Goldstein, DS | 1 |
| Antonello, RM; Cazzato, G; Moretti, R; Pizzolato, G; Torre, P; Ukmar, M | 1 |
| Desole, MS; Esposito, G; Marchetti, B; Miele, E; Migheli, R; Rocchitta, G; Serra, PA | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Visanji, NP | 1 |
| Ardolino, G; Bossi, B; Caputo, E; Egidi, M; Foffani, G; Priori, A | 1 |
| Apetauerova, D; Corapi, K; Norregaard, T; O'Herron, S; Scollins, L; Tarsy, D | 1 |
| Hägglund, J; Heinonen, E; Kaugesaar, T; Mäki-Ikola, O; Pålhagen, S; Palm, R | 1 |
| Antonini, A; Bonetti, A; Cilia, R; De Gaspari, D; Landi, A; Mariani, CB; Morgante, L; Natuzzi, F; Pezzoli, G; Sganzerla, E; Siri, C | 1 |
| Ardouin, C; Benabid, AL; Bioulac, B; Blond, S; Burbaud, P; Cornu, P; Defebvre, L; Destée, A; Fraix, V; Guehl, D; Houeto, JL; Krystkowiak, P; Lagrange, C; Le Pen, C; Ligier, M; Maurel, F; Mesnage, V; Pollak, P; Rougier, A; Welter, ML | 1 |
| Barker, RA; Carpenter, RH; Foltynie, T; Fritz, D; Lewis, SJ; Michell, AW; Robbins, TW; Williams-Gray, CH; Xu, Z | 1 |
| Bonuccelli, U; Ceravolo, R; Del Dotto, P; Gambaccini, G; Logi, C; Lucetti, C; Murri, L; Rossi, G | 1 |
| Andreoni, S; Begni, B; Beretta, S; Brighina, L; Ferrarese, C; Galbussera, A; Garofalo, R; Piolti, R; Prigione, A | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D | 1 |
| Apaydin, H; Benbir, G; Delil, S; Erginöz, E; Ozekmekçi, S | 1 |
| Cochran, JM; Eckert, L; Hudry, J; Keränen, T; Rinne, JO | 1 |
| Karlsborg, M; Regeur, L | 1 |
| Aniel-Quiroga, MA; Barcena, J; Cruz Lachén, M; Gómez, JC; Hurtado, P; Lezcano, E; Pérez Bas, M; Rouco, I; Velasco, F; Zarranz, JJ | 1 |
| Berezetskaya, NM; Burenok, YA; Karaban', IN; Lukhanina, EP; Mel'nik, NA | 1 |
| Esposito, P; Mohr, M; Stilhart, B; Talmant, V; Tranchant, C | 1 |
| Konczak, J; Krawczewski, K; Maschke, M; Pickett, K; Tuite, PJ | 1 |
| Bilbao, I; Ciordia, R; Gómez-Esteban, JC; Lezcano, E; Losada, J; Rouco, I; Velasco, F; Zarranz, JJ | 1 |
| Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Gronseth, G; Perlmutter, J; Reich, S; Suchowersky, O; Weiner, WJ; Zesiewicz, T | 1 |
| Baillet, L; Burbaud, P; Corcuff, JB; Cuny, E; Foubert-Sanier, A; Gin, H; Guehl, D; Krim, E; Perlemoine, C; Rigalleau, V; Tison, F | 1 |
| Amouri, R; Djaldetti, R; Farrer, MJ; Funayama, M; Gouider-Khouja, N; Hasegawa, K; Hatano, Y; Hattori, N; Hattori, T; Hentati, F; Imamichi, Y; Inzelberg, R; Kubo, S; Li, Y; Lu, CS; Melamed, E; Miyajima, H; Mizoguchi, K; Mizuno, Y; Obata, F; Sato, K; Toda, T; Tomiyama, H; Wang, M; Yoshino, H | 1 |
| Aziz, TZ; Jenkinson, N; Nandi, D; Stein, JF | 1 |
| Brown, P; Kühn, AA; Kupsch, A; Schneider, GH | 1 |
| Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
| Balkan, S; Dora, B; Kardelen, F; Mihci, E | 1 |
| Bonci, A; Singh, V | 1 |
| Jain, S; Lo, SE | 1 |
| Linazasoro, G; Magariños, C; Van Blercom, N | 1 |
| Diem, A; Högl, B; Peralta, C; Poewe, W; Seppi, K; Wenning, GK | 1 |
| Chung, SJ; Im, JH; Kim, MJ; Lee, MC; Sung, YH | 1 |
| Atsumi, M; Hattori, N; Li, Y; Sato, K; Tomiyama, H | 1 |
| Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y | 1 |
| Duval, C; Edwards, R; Ghassemi, M; Jog, M; Lemieux, S | 2 |
| Goetze, O; Kim, JI; Müller, T; Nikodem, AB; Przuntek, H; Schmidt, WE; Woitalla, D | 1 |
| Das, SK; Gangopadhya, PK; Ray, J; Roy, T | 1 |
| Adler, CH; Driver-Dunckley, E; Evidente, VG; Fletcher, G; Hernandez, J; Hillman, R; Lyons, MK | 1 |
| Almaguer, M; Jankovic, J; Ondo, WG; Silay, Y | 1 |
| Behari, M; Singh, S | 1 |
| Brodsky, MA; Koudelka, C; Swarztrauber, K | 1 |
| Eberly, SW; Goetz, CG; Oakes, D; Schwid, SR; Shoulson, I | 1 |
| DeSalles, AA; Emerson, J; Gorgulho, A; Krahl, SE; Lam, S; Malkasian, D; Shields, DC | 1 |
| Rowland, M | 1 |
| Anderson, KE; Salter, BC; Weiner, WJ | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; Manrique, M; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M; Zamarbide, I | 1 |
| Abdalla, JA; Castelli-Haley, J; Huse, DM; Lenhart, G; Orsini, LS | 1 |
| Balestrieri, F; Borgheresi, A; Cincotta, M; Giovannelli, F; Ragazzoni, A; Vanni, P; Zaccara, G; Ziemann, U | 1 |
| Bang, JH; Choi, HB; Hong, SH; Joo, IS; Kim, KS; Kim, SU; Kim, TH; Kim, YS; Lee, CS; Lee, MA; Park, IH | 1 |
| Chebrolu, H; Gash, DM; Gerhardt, GA; Kryscio, R; Slevin, JT; Smith, CD; Wagner, R; Walton, A; Young, AB | 1 |
| Loria, D; Rosso, S; Zanetti, R | 1 |
| Angwin, AJ; Chenery, HJ; Copland, DA; Murdoch, BE; Silburn, PA | 2 |
| Durso, R; McNamara, P | 1 |
| Brodsky, MA; Hogarth, P; Nutt, JG | 1 |
| Constantoyannis, C; Honey, CR; Kumar, A; Mandat, T; Mercado, R; Schulzer, M; Stoessl, AJ | 1 |
| Deleu, D; Hanssens, Y | 1 |
| Benabid, AL; Chabardes, S; Chevrier, E; Fraix, V; Krack, P; Pollak, P | 1 |
| Imamura, A; Uitti, RJ; Wszolek, ZK | 1 |
| Götz, W | 1 |
| Böckler, F | 1 |
| Gütschow, M; Meusel, M | 1 |
| Lipp, R; Riebesehl, B | 1 |
| Andren, PE; Svenningsson, P; Zhang, X | 1 |
| Dougherty, MS; Groth, T; Nyholm, D; Palhagen, SE; Westin, J; Yerramsetty, PK | 1 |
| Brusa, L; Cervellino, A; Giacomini, P; Grossi, K; Izzi, F; Marciani, MG; Pierantozzi, M; Placidi, F; Romigi, A; Stanzione, P | 1 |
| Carbon, M; Eidelberg, D | 1 |
| Asmus, F; Bötzel, K; Deutschländer, A; Gasser, T; Klopstock, T; Marelli, E | 1 |
| Kulkantrakorn, K; Pongchaiyakul, C; Pulkes, T; Tiamkao, S | 1 |
| Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A | 1 |
| Bogousslavsky, J; Burkhard, PR; Combremont, P; Ghika, J; Gronchi-Perrin, A; Villemure, JG; Vingerhoets, F; Viollier, S | 1 |
| Hatano, T; Hattori, N; Izawa, N; Kagohashi, M; Mizuno, Y; Mochizuki, H; Mori, H; Nishioka, K; Sato, K; Yamashiro, K | 1 |
| Baltazar, G; Carvalho, CM; Duarte, EP; Saavedra, A; Santos, P | 1 |
| de Souza, M; Duff-Canning, S; Fox, S; Hassan, K; Lang, AE; Miyasaki, J; Voon, V; Zurowski, M | 1 |
| Dean, RT; Hume, PM; Morris, JG; Rodgers, KJ | 1 |
| Goldstein, R; Klein, C; Miniovitz, A; Pollak, L; Prokhorov, T; Rabey, JM; Shpirer, I; Theitler, J | 1 |
| Baldo, C; Barichella, M; De Notaris, R; Marczewska, A; Mauri, A; Pezzoli, G; Savardi, C; Vairo, A | 1 |
| Chen, SD; Cheng, Q; Sun, BM; Sun, XK; Tan, YY; Wang, G; Wang, Y; Wang, Z; Ye, XL; Zheng, R; Zhou, HY | 1 |
| Huxham, F; Iansek, R; McGinley, J | 1 |
| Dzoljić, E; Kostić, V; Krajinović, M; Mirković, D; Nesić, Z; Novaković, I; Prostran, M; Stojanović, R; Todorović, Z | 1 |
| Boon, P; De Bodt, M; De Letter, M; Santens, P; Van Borsel, J | 1 |
| Armenise, E; de Mari, M; Defazio, G; Dell'Aquila, C; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
| Brooks, DJ; Goerendt, IK; Lawrence, AD | 1 |
| Leenders, KL; van Beilen, M | 1 |
| Barcikowska, M; Chodakowska-Zebrowska, M; Czyzewski, K; Lokk, J; Peplonska, B; Religa, D; Stepien, K; Styczynska, M; Winblad, B | 1 |
| Carrillo-Ruiz, JD; García, L; Jiménez, F; Madrigal, A; Márquez, I; Velasco, AL; Velasco, F | 1 |
| Duda, JE; Moberg, PJ; Morales, KH; Stern, MB; Weintraub, D | 1 |
| Klepac, N; Relja, M | 1 |
| Chen, SY; Chien, SL; Hsin, YL; Lee, CW; Liang, CC; Lin, SH; Lin, SZ; Soong, YS | 1 |
| Bergamaschi, A; Bernardi, G; Brusa, L; Fedele, E; Galante, A; Galati, S; Lunardi, G; Magrini, A; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P; Stefani, A | 1 |
| Camicioli, R; Espay, AJ; Lafontaine, AL; Lang, AE; Martin, WR; Postuma, RB; Ranawaya, R; Suchowersky, O; Zadikoff, C | 1 |
| Becker, B; Hagenah, JM; Hedrich, K; Klein, C; Pramstaller, PP; Seidel, G | 1 |
| Dhawan, V; Eidelberg, D; Ma, Y; Spetsieris, PG; Tang, C | 1 |
| Albani, G; Bonanni, L; Bulla, D; Mauro, A; Onofrj, M; Thomas, A | 1 |
| Benabid, AL; Gross, RE; Kopell, BH; Machado, A; Rezai, AR; Sharan, AD | 1 |
| Barbosa, ER; Boggio, PS; Fregni, F; Lima, M; Nitsche, MA; Pascual-Leone, A; Rigonatti, SP; Santos, MC; Silva, MT; Vieira, AL | 1 |
| Nardone, A; Schieppati, M | 1 |
| Blindauer, K; Eberly, S; Elmer, L; Fahn, S; Goetz, C; Kieburtz, K; Oakes, D; Oren, S; Prisco, UL; Salzman, P; Schwid, S; Shoulson, I; Stern, M | 1 |
| Bian, Z; Chung, V; Gao, J; Kum, WF; Leuk Fong, W; Li, M; Liu, L; Zhao, Z | 1 |
| Bogousslavsky, J; Burkhard, PR; Robert, B; Russmann, H; Villemure, JG; Vingerhoets, FJ; Wider, C | 1 |
| Silver, D | 1 |
| Corvol, JC; Girault, JA; Hervé, D | 1 |
| Barker, RA; Clark, L; Cools, R; Lewis, SJ; Robbins, TW | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Defazio, G; Lamberti, P; Livrea, P; Martino, D; Zoccolella, S | 1 |
| Asanuma, K; Dhawan, V; Edwards, C; Eidelberg, D; Feigin, A; Kaplitt, MG; Ma, Y; Mattis, P; Tang, C | 1 |
| Blindauer, K; deMarcaida, JA; Fahn, S; Kieburtz, K; Schwid, SR; Shoulson, I; Stern, M; White, WB | 1 |
| Obeso, JA; Olanow, CW; Stocchi, F | 2 |
| Bernardi, G; Brusa, L; Centonze, D; Iani, C; Koch, G; Stanzione, P; Versace, V | 1 |
| Deuschl, G; Fisman, DN; Herzog, J; Kleiner-Fisman, G; Lang, AE; Lyons, KE; Pahwa, R; Tamma, F | 1 |
| Diamond, A; Jankovic, J | 1 |
| Hauser, R; Stacy, M | 1 |
| Carlson-Kuhta, P; Chiari, L; Gross, A; Horak, FB; Mancini, M; Rocchi, L | 1 |
| Fukaya, C; Kano, T; Katayama, Y; Kobayashi, K; Oshima, H; Yamamoto, T | 1 |
| Bédard, PJ; Rouillard, C; Samadi, P | 1 |
| Chung, EJ; Ki, CS; Kim, IS; Kim, JY; Lee, WY | 1 |
| Haapaniemi, T; Hartikainen, P; Heikkinen, H; Jolma, T; Kaakkola, S; Kinnunen, E; Kuopio, AM; Myllylä, V; Nuutinen, J; Rissanen, A; Satomaa, O | 1 |
| Herkes, GK; McKay, D; Meagher, LJ; Needham, M | 1 |
| Bernardi, S; Meco, G | 1 |
| Amalric, M; Baunez, C; Chezaubernard, C; Maurin, B; Morain, P; Nieoullon, A; Puma, C; Turle-Lorenzo, N | 1 |
| Müller, T; Russ, H | 1 |
| Bourhis, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Suchowersky, O | 2 |
| Muhlack, S; Müller, T; Welnic, J | 1 |
| Hasoon, M; Macnamara, L; Ross, I; Sharma, JC; Vassallo, M | 1 |
| Barker, RA; Lewis, SJ; Owen, AM; Slabosz, A; Smigasiewicz, K; Szymura, B | 1 |
| Larner, AJ | 1 |
| Giladi, N; Gurevich, TY; Korczyn, AD; Shabtai, H; Simon, ES | 1 |
| Douglas, A; Morris, J | 1 |
| Fuchs, G; Hahne, M; Klein, W; Müller, T; Schwarz, M | 1 |
| Schindehütte, J; Trenkwalder, C | 1 |
| Burn, DJ; McKeith, IG; Molloy, SA; O'Brien, JT; Rowan, EN; Wesnes, K | 1 |
| Abdalla, M; Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O | 1 |
| Chung, SJ; Hong, SH; Jeon, SR; Kim, SR; Lee, MC | 1 |
| Chung, SJ; Jeon, SR; Kim, SR; Lee, MC; Sung, YH | 1 |
| Daniels, C; Deuschl, G; Herzog, J; Krack, P; Lorenz, D; Mehdorn, M; Reiff, J; Volkmann, J; Witt, K | 1 |
| Chand, P; Colwell, A; Deleu, D; Jacob, P; Sarre, S | 1 |
| Hastings, TG; Montoya, SE; Perez, RG; Tehranian, R; Van Laar, AD | 1 |
| Goudreau, JL | 1 |
| Dostrovsky, JO; Hodaie, M; Hutchison, WD; Lang, AE; Lozano, AM; Mahant, N; Moro, E; Weinberger, M | 1 |
| Giasson, BI; Ischiropoulos, H; Lynch, DR; Mazzulli, JR; Mishizen, AJ; Nagatsu, T; Nakashima, A; Ota, A; Thomas, SA | 1 |
| Morris, ME | 1 |
| Evans, AH; Katzenschlager, R; Lees, AJ; Silveira-Moriyama, L | 1 |
| Caldas, AC; Del Signore, S; Dubois, B; Lees, A; Rascol, O; Senn, S | 1 |
| Abu-Gharbieh, R; Au, WL; McCaig, RG; McKeown, MJ; Palmer, SJ; Saab, R | 1 |
| Hatano, Y; Hattori, N; Li, Y; Mizuno, Y; Satoh, K; Tomiyama, H; Yoshino, H | 1 |
| Aljanati, R; Buzó, R; Chouza, C; de Medina, O; Dieguez, E; Gomensoro, J; Lisanti, N; Romero, S; Scaramelli, A | 1 |
| Turnbull, GI | 1 |
| Clissold, BG; Kempster, PA; McColl, CD; Reardon, KR; Shiff, M | 1 |
| Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L | 1 |
| Bogomazov, G; Korchounov, A | 1 |
| Cohen, HS; Gracies, JM; MacDougall, HG; Moore, ST; Ondo, WG | 1 |
| Barbosa, ER; Bermpohl, F; Boggio, PS; Fregni, F; Maia, F; Pascual-Leone, A; Rigonatti, SP | 1 |
| Leegwater-Kim, J; Waters, C | 1 |
| Fedorova, NV; Kulua, TK; Levin, OS; Smolentseva, IG | 1 |
| Defebvre, L; Devos, D | 1 |
| Alves, R; Barbosa, E; Scaff, M | 1 |
| Antonini, A; Cilia, R; Landi, A; Pezzoli, G; Sganzerla, E; Vergani, F | 1 |
| de Noordhout, AM; Santens, P | 1 |
| Kanazawa, I; Kondo, T; Kuno, S; Mizuno, Y; Yamamoto, M; Yanagisawa, N | 1 |
| Bowers, D; Fernandez, H; Foote, K; Kirsch-Darrow, L; Mikos, A; Miller, K; Okun, M; Springer, U | 1 |
| Lees, AJ; Oertel, WH; Ratziu, V; Tolosa, E | 1 |
| Colebrooke, RE; Emson, PC; Humby, T; Lynch, PJ; McGowan, DP; Xia, J | 1 |
| Brooks, DJ; Evans, AH; Hotton, G; Lees, AJ; Pavese, N; Piccini, P; Tai, YF | 1 |
| Di Rocco, A; Nasser, S; Werner, P | 1 |
| Barone, P; Clarke, Z; Ellis, A; Lamb, J | 1 |
| Barbanoj, M; García-Sánchez, C; Gironell, A; Kulisevsky, J; Pagonabarraga, J; Pascual-Sedano, B | 1 |
| Chaná C, P; Juri C, C | 1 |
| Borek, LL; Friedman, JH; Kohn, R | 1 |
| Pifl, C; Sperk, G | 1 |
| Caron, MG; Gainetdinov, RR | 1 |
| Brooks, DJ | 2 |
| Mash, DC; Papapetropoulos, S | 1 |
| Audiffren, M; Ballanger, B; Desmurget, M; Gil, R | 1 |
| Barbieri, S; Caputo, E; Cogiamanian, F; Egidi, M; Foffani, G; Marceglia, S; Mrakic-Sposta, S; Priori, A | 1 |
| Hideyama, T; Kwak, S; Momose, T; Shimizu, J; Tsuji, S | 1 |
| Hornykiewicz, O; Kish, SJ; Tong, J | 1 |
| Hauser, RA; McDermott, MP; Messing, S | 1 |
| Al-Refai, AH; Amador, SC; Briand, KA; Cain, AE; Hood, AJ; Schiess, MC; Sereno, AB | 1 |
| Harn, HJ; Lin, JJ; Lin, SZ; Liu, JT; Yueh, KC | 1 |
| Androulidakis, AG; Blomstedt, P; Brown, P; Chen, CC; Dowsey-Limousin, P; Doyle, L; Hariz, MI; Kempf, F; Kühn, AA; Kupsch, A; Schneider, GH | 1 |
| Cao, X; Chen, Z; Guan, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Cardoso, FE; Kummer, A; Maia, DP; Salgado, JV; Teixeira, AL | 1 |
| Waldvogel, D | 1 |
| Deuschl, G; Raethjen, J | 1 |
| Al Hassan, K; Lang, AE; Miyasaki, JM; Voon, V | 1 |
| Brachet, P; Damier, P; Henry, V; Lescaudron, L; Paillé, V | 1 |
| Pal, PK; Sathyaprabha, TN; Thennarasu, K; Tuhina, P | 1 |
| Brusa, L; Galati, S; Lozano, AM; Mazzone, P; Peppe, A; Pierantozzi, M; Scarnati, E; Stanzione, P; Stefani, A; Tropepi, D | 1 |
| Rosso, S; Zanetti, R | 1 |
| Davis, JT; Lyons, KE; Pahwa, R | 1 |
| Levin, OS | 1 |
| Huot, P; Parent, A | 1 |
| Aydemir, T; Cetin, S; Hanoglu, L; Koldas, M; Meral, H; Ozer, F; Ozturk, O; Seval, H; Yilsen, M | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Broussolle, E; Thobois, S | 1 |
| Brefel-Courbon, C; Mas-Gerdelat, A; Ory-Magne, F; Rascol, O; Slaoui, T | 1 |
| Kozhevnikova, ZhV; Krivonos, OV; Puzin, MN | 1 |
| Acar, M; Albayrak, R; Caliskan, G; Degirmenci, B; Haktanir, A; Yaman, M | 1 |
| Amri, M; Gubellini, P; Kachidian, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P; Sgambato-Faure, V | 1 |
| Bäzner, H; Blahak, C; Capelle, HH; Grips, E; Hennerici, MG; Krauss, JK; Weigel, R; Wöhrle, JC | 1 |
| Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C | 1 |
| Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Carlson, NE; Carter, JH; Nutt, JG | 1 |
| Grandas, F; Hernández, B | 1 |
| Churchyard, A; Dahl, HH; Hutchison, WM; Kirby, DM; Thyagarajan, D; Wilcox, RA | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M | 1 |
| Castaño, B; Giménez-Roldán, S; Mateo, D | 1 |
| Friedman, A; Koziorowski, D | 1 |
| Guan, Y; Li, D; Shen, J; Sun, B; Zan, S; Zhao, Y; Zuo, C | 1 |
| Baron, R; Binder, A; Binder, S; Deuschl, G; Guballa, C; Herzog, J; Ludwig, J; Remien, P; Schattschneider, J; Volkmann, J; Wasner, G | 1 |
| Constantinescu, R; Kieburtz, K; Romer, M | 1 |
| Hauser, RA; Samanta, J | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Pursiainen, V; Sotaniemi, KA | 1 |
| Chou, KL; Stacy, MA | 1 |
| Fiddian-Green, RG | 1 |
| Brayne, C; Cheesbrough, A; Ishihara, LS; Schrag, A | 1 |
| Erginöz, E; Ertan, S; Ertan, T; Kiziltan, G; Ozekmekçi, S | 1 |
| Bertoni, J; Kricorian, G; Leehey, M; Lew, MF; Pahwa, R | 1 |
| Berendse, HW; Bosboom, JL; Deijen, JB; Stam, CJ; Stoffers, D; Wolters, EC | 1 |
| Haeger, DA; Hock, K; Müller, T; Russ, H; Woitalla, D | 1 |
| Bertucci Filho, D; Teive, HA; Werneck, LC | 1 |
| Tetrud, JW | 1 |
| Angersbach, D; Buchwald, B; Jost, WH | 1 |
| Brotchie, JM; Fabbrini, G; Goetz, CG; Grandas, F; Nomoto, M | 1 |
| Fernandez, HH; Halkias, IA; Haq, I; Huang, Z | 1 |
| Kim, JS; Lee, KS; Song, IU | 1 |
| Alonso-Navarro, H; Jiménez-Jiménez, FJ | 1 |
| Hagell, P; Nygren, C | 1 |
| Ellrichmann, G; Müller, T; Russ, H | 1 |
| Dostrovsky, JO; Hutchison, WD; Lang, AE; Lozano, AM; Miyasaki, JM; Moro, E; Piboolnurak, P; Poon, YY; Saint-Cyr, JA | 1 |
| Annanmaki, T; Murros, K; Muuronen, A | 1 |
| Finkelstein, MM; Jerrett, M | 1 |
| Memon, SA; Parvez, SH; Qureshi, AA; Qureshi, GA | 1 |
| Bares, M; Kanovský, P; Rektor, I | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D | 1 |
| Barget, M; Debilly, B; Derost, PP; Durif, F; Lemaire, JJ; Llorca, PM; Morand, D; Ouchchane, L; Ulla, M | 1 |
| Brusa, L; Finazzi-Agrò, E; Iani, C; Miano, R; Moschella, V; Petta, F; Pisani, A; Stanzione, P | 1 |
| Borsini, F; Morelli, M; Pinna, A; Pontis, S | 1 |
| Costa, D; Evans, A; Fontes, F; Gacinovic, S; Katzenschlager, R; Lees, AJ; Zijlmans, J | 1 |
| Lindh, J | 1 |
| Bai, P; Belger, A; Huang, X; Lewis, MM; Mailman, RB; McKeown, MJ; Slagle, CG; Smith, AB; Truong, Y | 1 |
| Durner, J; Fuchs, G; Greulich, W; Henningsen, H; Herting, B; Jost, WH; Koch, R; Kuhn, W; Kupsch, A; Müller, T; Niklowitz, P; Oertel, WH; Reichmann, H; Spiegel, J; Storch, A; Vieregge, P | 1 |
| Brefel-Courbon, C; Gerdelat-Mas, A; Ory-Magne, F; Rascol, O; Simonetta-Moreau, M; Slaoui, T; Thalamas, C | 1 |
| Giroux, ML | 1 |
| Boon, P; De Bodt, M; De Letter, M; Santens, P; Van Borsel, J; Van Maele, G | 1 |
| Frederiksen, K; Friis, S; Olsen, JH; Tangerud, K; Wermuth, L | 1 |
| Constantinescu, R; Kamp, C; Kieburtz, K; McDermott, MP; Romer, M | 1 |
| Bliwise, DL; Rye, DB; Trotti, LM | 1 |
| Arnaud, P; Bannier, S; Boirie, Y; Brandolini-Bunlon, M; Derost, P; Durif, F; Giraudet, C; Montaurier, C; Morio, B | 1 |
| Loria, DI; Rosso, S; Zanetti, R | 1 |
| Bishop, C; Dupre, KB; Eskow, KL; Negron, G | 1 |
| Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X | 1 |
| Aarsland, D; Boeve, B; Gjerstad, MD; Larsen, JP; Wentzel-Larsen, T | 1 |
| Avanzi, M; Baratti, M; Bonfà, F; Brighetti, G; Cabrini, S; Uber, E | 1 |
| Alicock, LM | 1 |
| Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D | 1 |
| Angelopoulos, E; Boufidou, F; Evangelopoulos, ME; Kararizou, E; Nikolaou, C; Triantafyllou, NI; Tsounis, S; Vassilopoulos, D | 1 |
| Damier, P; Meyniel, C | 1 |
| Benice, TS; Eaton, R; Lou, JS; Nutt, J | 1 |
| Barcena, J; Gómez-Esteban, JC; Jauregui, A; Lachen, MC; Lezcano, E; Rouco, I; Tijero, B; Ugarte, A; Velasco, F; Zarranz, JJ | 1 |
| Evans, AH; Gallagher, DA; Lees, AJ; O'Sullivan, SS; Schrag, A | 1 |
| Arrúe, A; Grandoso, L; Hernández, RM; Linazasoro, G; Manuel, I; Orive, G; Pedraz, JL; Ponce, S; Rodríguez, A; Rodríguez-Puertas, R; Ruiz-Ortega, JA; Ugedo, L; Ulibarri, I; Zumárraga, M | 1 |
| Shulman, LM | 2 |
| Kagamihara, Y | 1 |
| Aimi, Y; Arai, R; Kudo, M; Nagatsu, I; Taki, K; Yamada, H | 1 |
| Rezak, M | 1 |
| Holton, J; Kempster, PA; Lees, AJ; Revesz, T; Selikhova, M; Williams, DR | 1 |
| Muhlack, S; Müller, T; Welnic, J; Woitalla, D | 1 |
| Bargalló, N; Giménez, M; Junqué, C; Martí, MJ; Ramírez-Ruiz, B; Tolosa, E; Valldeoriola, F | 1 |
| Davidson, DF; Grosset, D; Grosset, K | 1 |
| Karamanakos, PN; Marselos, M; Pappas, P | 1 |
| Anderson, T; Frampton, C; Huckabee, ML; Leow, L; Lim, A | 1 |
| Abe, T; Hasegawa, K; Kanazawa, I; Kondo, T; Kuno, S; Mizuno, Y; Nakashima, M; Yamamoto, M | 1 |
| Hauser, RA; Sullivan, KL; Zesiewicz, TA | 1 |
| Biglan, KM; Holloway, RG; McDermott, MP; Richard, IH | 1 |
| Cao, X; Factor, S; Greenamyre, JT; Griffith, DA; Hadcock, JR; Iredale, PA; Liang, L; Menniti, FS; Papa, SM | 1 |
| Jankovic, J; Stacy, M | 1 |
| Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV | 1 |
| Kaneda, D; Oyanagi, K; Shintaku, M | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Winkler, C | 1 |
| Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB | 1 |
| Antonini, A; Canesi, M; Dal Fante, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Pezzoli, G; Zibetti, M | 1 |
| Marini, P; Paganini, M; Ramat, S; Righi, S; Viggiano, MP | 1 |
| Keating, GM; Oldfield, V; Perry, CM | 1 |
| Duval, C; Edwards, R; Ghassemi, M; Gour, J; Jog, M; Lemieux, S | 1 |
| Arabia, G; Cerasa, A; Fera, F; Gallo, O; Gioia, MC; Nicoletti, G; Pugliese, P; Quattrone, A; Romeo, N; Zappia, M | 1 |
| Androulidakis, AG; Aziz, T; Brown, P; Brücke, C; Chen, CC; Kempf, F; Kühn, AA; Kupsch, A; Nuttin, B; Schneider, GH; Vandenberghe, W; Wang, S | 1 |
| Cordo, PJ; Gurfinkel, VS; Horak, FB; Nutt, J; Wright, WG | 1 |
| Chen, JJ; Fernandez, HH | 2 |
| Benecke, R; Wolters, A | 1 |
| Blond, S; Cassim, F; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Krystkowiak, P; Reyns, N; Tir, M; Touzet, G | 1 |
| Ho, B; Morgan, JC; Prakash, R; Sethi, KD | 1 |
| Calon, F; Di Paolo, T; Morelli, M; Schwarzschild, MA; Wardas, J; Xiao, D | 1 |
| Brighina, F; D'Amelio, M; Daniele, O; Fierro, B; Lupo, I; Palermo, A; Ragonese, P; Savettieri, G | 1 |
| Gracies, JM; MacDougall, HG; Moore, ST; Ondo, WG | 1 |
| Levy, G | 1 |
| Chen, XH; Kui, Y; Li, Y | 1 |
| Hauser, RA; Schapira, AH; Simonson, W | 1 |
| Burkhard, PR; Grötzsch, H; Sztajzel, R | 1 |
| Boon, P; De Bodt, M; De Letter, M; Estercam, I; Santens, P; Van Borsel, J; Van Maele, G | 1 |
| Miller, EM; Nieburg, HA | 1 |
| De Deyn, PP; Hauser, RA; Jon Stoessl, A; Korczyn, AD; Lang, AE; Poewe, W; Rascol, O; Watts, RL | 1 |
| Funakoshi, T; Iwata, S; Wakamatsu, M; Yoshimoto, M | 1 |
| di Poggio, AB; Fornai, F; Paparelli, A; Pellegrini, A; Ruggieri, S | 1 |
| Dunnett, S; Lane, E | 1 |
| Armstrong, VW; Bachmann, CG; Guth, N; Happe, S; Helmschmied, K; Paulus, W | 1 |
| Angle, C; Baser, SM; Birk, C; Cohen, DB; Oh, MY; Whiting, A; Whiting, DM | 1 |
| Aydemir, T; Cetin, S; Erol, C; Hanoglu, L; Meral, H; Ozben, S; Ozer, F; Ozkayran, T; Ozturk, O; Yilsen, M | 1 |
| Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Di Iorio, W; Gorgone, G; Ientile, R; Menichetti, C; Parisi, G; Parnetti, L; Pisani, F; Rossi, A | 1 |
| Erikh, I; Schlesinger, I; Yarnitsky, D | 1 |
| Gerlach, M; Müller, T; Reichmann, H; Riederer, P | 1 |
| MacDougall, HG; Moore, ST; Ondo, WG | 1 |
| Hagell, P; Lindskov, S; Westergren, A | 1 |
| Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G | 1 |
| Ives, NJ; Ramaker, CC; Stowe, R; van Hilten, JJ | 2 |
| Pahwa, R | 1 |
| Tse, W | 1 |
| Libow, LS | 1 |
| Borges, V; Ferraz, HB; Silva, SM; Souza, RG | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Chang, LJ; Furukawa, Y; Guttman, M; Hornykiewicz, O; Kish, SJ; Rajput, A; Tong, J | 1 |
| Bedard, MA; Blanchet, PJ; Chouinard, S; Filion, J; Lemay, M; Levesque, M; Paquet, F; Scherzer, P; Tremblay, PL | 1 |
| Guo Qiang, L; Jian Fang, M; Jian Qing, D; Jing, Z; Li, B; Li, C; Qin, X; Sheng Di, C; Ting, Z; Ying, W | 1 |
| Ahn Jo, S; Han, C; Jo, I; Lee, JM; Park, KW; Park, MH; Seo, WK | 1 |
| Bhatia, KP; Cordivari, C; Hanna, MG; Holton, JL; Phadke, R; Quinn, NP; Ryan, AM; van de Warrenburg, BP | 1 |
| Frank, MJ; Moustafa, AA; Samanta, J; Sherman, SJ | 1 |
| Higuchi, Y; Horikawa, Y; Iijima, K; Ijichi, K; Okajima, H; Tanaka, O; Tanaka, Y; Ushio, M | 1 |
| Cai, DF | 1 |
| Gao, JP; Li, WW; Zhao, H | 1 |
| Lian, XF; Luo, XD | 1 |
| García-Horsman, JA; Huotari, M; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Hermanowicz, N | 1 |
| Chung, SJ; Kim, SR; Lee, MC; Sung, YH | 1 |
| Dressler, D; Lindemann, C; Miranda, M; Slachevsky, A; Walter, U | 1 |
| Andrich, J; Meiler, B; Müller, T | 1 |
| Giladi, N; Merims, D | 1 |
| Quattrone, A; Zappia, M | 2 |
| Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B | 1 |
| Brown, P; Eusebio, A | 1 |
| Lee, PW; McKeown, MJ; Palmer, SJ; Wang, Z | 1 |
| Carpinella, I; Crenna, P; Ferrarin, M; Lopiano, L; Marzegan, A; Rabuffetti, M; Rizzone, M | 1 |
| Duggal, HS; Singh, I | 1 |
| Boulenger, V; Broussolle, E; Jeannerod, M; Mechtouff, L; Nazir, TA; Thobois, S | 1 |
| Chen, JJ; Swope, DM | 1 |
| Haeger, DA; Hock, K; Mueller, T; Russ, H; Woitalla, D | 1 |
| Braun, M; Groiss, S; Gross, J; Krause, H; Maarouf, M; Ostrowski, S; Ploner, M; Pollok, B; Schnitzler, A; Sturm, V; Südmeyer, M; Timmermann, L; Voges, J; Wojtecki, L | 1 |
| Stewart, JT | 1 |
| De Pandis, MF; Stocchi, F | 1 |
| Angelopoulos, E; Boufidou, F; Evangelopoulos, ME; Kararizou, E; Nikolaou, C; Rentzos, M; Triantafyllou, NI; Vassilopoulos, D | 1 |
| Chaves, ML; Kumru, H; Marti, MJ; Schestatsky, P; Tolosa, E; Valldeoriola, F; Valls-Solé, J | 1 |
| Duval, C; Fenney, A; Jog, MS | 1 |
| Baláz, M; Pulkrábek, J; Rektor, I | 1 |
| Holford, N; Nutt, JG | 1 |
| Krogh, K; Laurberg, S; Ostergaard, K; Sabroe, S | 1 |
| Chiari, L; Horak, FB; Mancini, M; Rocchi, L | 1 |
| Bejjani, BP; Jabre, MG | 1 |
| Bradshaw, JL; Ho, AK; Iansek, R | 1 |
| Jeon, BS; Kim, DG; Kim, HJ; Kim, JY; Lee, JY; Paek, SH | 1 |
| Fukaya, C; Kano, T; Katayama, Y; Kobayashi, K; Oshima, H; Suzuki, Y; Yamamoto, T | 1 |
| Grünewald, A; Janetzky, B; Klein, C; Klockgether, T; Knapp, M; Möller, JC; Paus, S; Wüllner, U; Zimprich, A | 1 |
| Accornero, N; Agostino, R; Berardelli, A; Bologna, M; Dinapoli, L; Fabbrini, G; Gregori, B | 1 |
| Barker, RA; Hampshire, A; Owen, AM; Williams-Gray, CH | 1 |
| Goto, S; Hamasaki, T; Kuratsu, JI; Yamada, K | 1 |
| Dafotakis, M; Fink, GR; Nowak, DA | 1 |
| Baker, R; Huxham, F; Iansek, R; Morris, ME | 1 |
| Boesch, S; Ceballos-Baumann, A; Dressler, D; Eggert, K; Gasser, T; Honig, H; Müller, T; Odin, P; Poewe, W; Reichmann, H; Sieb, JP; Storch, A; Trenkwalder, C | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G | 1 |
| Baranowska, I; Płonka, J | 1 |
| Almeida, QJ; Hyson, HC | 1 |
| Lennernäs, H; Nyholm, D | 1 |
| Kaasinen, V; Kiers, HA; Koning, M; Leenders, KL; Maguire, RP; Portman, AT; Pruim, J; van Beilen, M | 1 |
| Amick, MM; Chou, KL; Friedman, JH | 1 |
| Vieregge, P | 1 |
| Baldwin, CM; Keating, GM | 1 |
| Cerasa, LS; Di Stefano, A; Sozio, P | 1 |
| Brooks, DJ; Kuoppamäki, M; Leinonen, M; Nissinen, H | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Doudnikoff, E; Fälth, M; Guigoni, C; Kultima, K; Li, Q; Scholz, B; Sköld, K; Svensson, M | 1 |
| Brock, DG; Cooper, MK; McDaniel, CM | 1 |
| Allum, JH; Bloem, BR; Borm, GF; Carpenter, MG; Esselink, RA; Speelman, JD; Visser, JE | 1 |
| Bernson, M; Darmopil, S; de Ceballos, ML; Moratalla, R; Muñetón-Gómez, VC | 1 |
| Sydow, O | 1 |
| Androulidakis, AG; Brown, P; Di Lazzaro, V; Dileone, M; Gaynor, LM; Litvak, V; Mazzone, P; Penny, W; Tisch, S | 1 |
| Fertl, E | 1 |
| Bareggi, SR; Bet, L; Bondiolotti, G; Meola, G; Pacei, F; Schapira, AH | 1 |
| Horak, FB; King, LA | 1 |
| Dengler, R; Joppich, G; Möbes, J; Schröder, C; Stiebritz, F | 1 |
| Adena, MA; Halliday, GM; Hely, MA; Morris, JG; Reid, WG | 1 |
| Ishii, F; Oka, Y; Toyoda, T; Umemura, A; Yamada, K; Yamamoto, K | 1 |
| Antonini, A; Canesi, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Nappi, G; Natuzzi, F; Pacchetti, C; Pezzoli, G; Zangaglia, R; Zibetti, M | 1 |
| Bonuccelli, U; Ceravolo, R | 1 |
| Andrade, AD; Britto, RR; Diório, AC; Goulart, F; Guedes, LU; Parreira, VF | 1 |
| Annesi, F; Annesi, G; Cirò Candiano, IC; Civitelli, D; D'Amelio, M; Quattrone, A; Ragonese, P; Salemi, G; Savettieri, G; Tarantino, P; Terruso, V | 1 |
| Rodgers, KJ; Shiozawa, N | 1 |
| Caltagirone, C; Chiavalon, C; Fermi, E; Gasbarra, A; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Brown, L; Dickson, D; Farrer, M; Skipper, L; Solida, A; Vingerhoets, FJ; Wider, C; Wszolek, ZK | 1 |
| de Haan, RJ; Post, B; Speelman, JD | 1 |
| Brown, P; Lalo, E; Mertens, P; Pogosyan, A; Polo, G; Sharott, A; Thobois, S | 1 |
| Brooks, D; Rascol, O; Ross, IN; Sharma, JC | 1 |
| Destée, A; Fénelon, G; Kreisler, A; Mastain, B; Tison, F | 1 |
| Anderson, KE; Fishman, PS; Gruber-Baldini, AL; Reich, SG; Shulman, LM; Vaughan, CG; Weiner, WJ | 1 |
| Kamogawa, K; Kawabata, K; Okamoto, K; Okuda, B; Tachibana, H | 1 |
| Almeida, KJ; Campos-Sousa, RN; da Silva, BB; Dos Santos, AR; Lopes-Costa, PV | 1 |
| Beuter, A; Blanchet, PJ; Hernández, R; Modolo, J; Rigal, R | 1 |
| García-Sánchez, C; Gironell, A; Kulisevsky, J; Llebaria, G; Pagonabarraga, J; Pascual-Sedano, B | 1 |
| Guridi, J; Lozano, AA; Manrique, M; Obeso, JA; Rodriguez-Oroz, MC | 1 |
| Lee, SS; Lum, SY; S, FC; Tan, EK | 1 |
| Austermann, K; Deuschl, G; Papengut, F; Raethjen, J; Witt, K; Zeuner, KE | 1 |
| Crucian, GP; Drago, V; Foster, PS; Heilman, KM; Skidmore, F; Skoblar, BM | 1 |
| Kamath, V; Mathew, T; Roy, AK; Sarma, GRK | 1 |
| Li, J; McKeown, MJ; Palmer, SJ; Wang, ZJ | 1 |
| Hovestadt, A; Lees, AJ; van Laar, T; Volkmann, J; Wolters, E | 1 |
| Apaydin, H; Ince, B; Oncel, C; Ozekmekçi, S; Uludüz, D | 1 |
| Giladi, N; Hausdorff, JM; Plotnik, M | 1 |
| Benabid, AL; Chabardès, S; Debû, B; Ferraye, MU; Fraix, V; Krack, P; Pollak, P; Xie-Brustolin, J | 1 |
| Asanuma, K; Carbon, M; Dhawan, V; Eidelberg, D; Feigin, A; Hirano, S; Ma, Y; Tang, C | 1 |
| Andren, PE; Chergui, K; Svenningsson, P; Zhang, X | 1 |
| Clarke, C; Ferreira, J; Gray, R; Hawker, RJ; Ives, NJ; Shah, L; Stowe, RL; van Hilten, J; Wheatley, K | 1 |
| Babina, LA; Batysheva, TT; Boĭko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaĭtsev, KA; Zhuravleva, EIu | 1 |
| Bioulac, B; Burbaud, P; Demany, L; Guehl, D; Lorenzi, C; Ramos, C; Semal, C | 1 |
| Azulay, JP; Bourdeix, I; Durif, F; Rerat, K; Rogez, R; Tranchant, C | 1 |
| Evangelou, A; Konitsiotis, S; Marselos, M; Tsironis, C | 1 |
| Chan, DK; Cordato, DJ; O'Rourke, F | 1 |
| Gross, RE | 1 |
| Encarnacion, EV; Hauser, RA | 1 |
| Alvarez, C; Andreatini, R; da Silva, TM; Ferraz, AC; Kiss, A; Munhoz, RP; Naliwaiko, K | 1 |
| Drago, J; Finkelstein, DI; Henderson, J; Horne, MH; Horne, MK; Lawrence, AJ; Lee, J; O'Connor, L; Stanic, D; Tomas, D; Zhu, WM | 1 |
| Barbeau, A | 11 |
| Burton, K; Calne, DB | 2 |
| Horstink, MW | 1 |
| Speelman, JD; Tans, RJ; van Manen, J | 1 |
| Lakke, JP; Staal-Schreinemachers, A; van Weerden, TW | 1 |
| De Mattei, M; Gentile, S; Pinessi, L; Sabbatini, F | 1 |
| Hefti, F; Liebman, J; Melamed, E; Schlosberg, AJ; Wurtman, RJ | 1 |
| Calne, DB; Plotkin, CN; Rosin, AJ; Teychenne, PF | 1 |
| Lees, AJ; Stern, GM | 4 |
| Massey, EW; Riley, TL | 1 |
| Hallett, M | 2 |
| Bathien, N; Koutlidis, RM; Rondot, P | 1 |
| Koskinen, V; Lönnberg, P; Rinne, UK | 1 |
| Hunter, KR | 1 |
| Enna, SJ; Lake, CR; Teychenné, PF; Ziegler, MG | 1 |
| Marsden, CD; Parkes, JD; Quinn, N | 2 |
| Lauschke, HP; Thieme, F | 1 |
| Bodis-Wollner, I; Mylin, L; Thornton, J; Yahr, MD | 1 |
| Larsen, TA; Teräväinen, H | 1 |
| Weiner, M | 1 |
| Goldstein, M; Lieberman, A; Pearson, J | 1 |
| Clough, CG | 2 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 2 |
| Hellemans, J; Hens, L | 1 |
| Marsden, CD | 8 |
| Calne, DB | 6 |
| Shoulson, I | 1 |
| Jeste, DV; Karson, CN; LeWitt, PA; Wyatt, RJ | 1 |
| Hassler, RG | 1 |
| Iizuka, R; Nagatsu, T; Narabayashi, H; Yokochi, M | 1 |
| Bergmann, KJ; Limongi, JC; Lowe, YH; Mendoza, MR; Yahr, MD | 1 |
| Curtis, L; Lees, AJ; Marmot, MG; Stern, GM | 1 |
| Kurako, IuL; Volianskiĭ, VE | 1 |
| Colucci d'Amato, C; Cristillo, A; Puccini, A; Vizioli, R | 1 |
| Ishimitsu, H; Nakasone, S; Namba, S | 2 |
| Yaar, I | 2 |
| Calne, DB; Ebert, MH; Eisler, T; Kopin, IJ; Krebs, H; Lake, CR; Murphy, DL; Nelson, R; Teräväinen, H; Weise, V; Whetzel, N | 1 |
| Edwards, DJ; Rizk, M; Spiker, DG | 1 |
| Jellinger, K | 2 |
| Bistolaki, E; Hadjikonstantinou, M; Markianos, M | 1 |
| Fischer, PA; Schneider, E | 1 |
| Jörg, J | 3 |
| Burns, RS; Chiueh, CC; Ebert, MH; Jacobowitz, DM; Kopin, IJ; Markey, SP | 1 |
| Biesemeyer, H; Ludin, HP; Ringwald, E | 1 |
| Rinne, UK; Tenovuo, O; Viljanen, MK | 1 |
| Fahn, S; Jiang, D; Reches, A | 1 |
| Iadgarov, IS | 1 |
| Aimard, G; Devic, M; Henry, E | 1 |
| Beckman, J; Burton, K; Calne, DB; Martin, WR | 1 |
| Still, CN | 1 |
| Petit, H | 2 |
| Yung, CY | 1 |
| Frackowiak, RS; Gibbs, JM; Jones, T; Lammertsma, AA; Leenders, KL | 1 |
| Hefti, F; Melamed, E; Wurtman, RJ | 1 |
| Hadjikonstantinou, M; Markianos, M | 1 |
| Krieger, DT; Wiesen, M; Yahr, MD | 1 |
| Herrera-Marschitz, M; Ungerstedt, U; Zetterström, T | 1 |
| Lakke, JP; van der Burg, W; Wiegman, J | 1 |
| Rinne, UK | 19 |
| Laakso, K; Laihinen, A; Lönnberg, P; Rinne, JK; Rinne, JO; Rinne, UK | 1 |
| Koskinen, V; Laakso, K; Lönnberg, P; Rinne, JK; Rinne, JO; Rinne, UK; Tenovuo, O | 1 |
| Cohen, G | 1 |
| Agid, Y; Baron, JC; Bustany, P; Collard, P; Comar, D; Rougemont, D | 1 |
| Bosch, DA; Lakke, JP; Pasmans, J | 1 |
| Narabayashi, H | 13 |
| Hershey, L; Reilly, DK; Rivera-Calimlim, L; Shoulson, I | 1 |
| Glatt, S; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Calne, DB; Dambrosia, JM; Foster, N; Larsen, TA; LeWitt, PA; Newman, RP; Raphaelson, MI; Ward, CD | 1 |
| Mejer Nielsen, B | 1 |
| Mayeux, R; Stern, Y | 1 |
| Patten, BM | 1 |
| Wajsbort, J; Youdim, MB | 1 |
| Gildenberg, PL | 1 |
| Bianchine, JR; Dippel, RL; Hutton, JT; Meyer, PG; Strahlendorf, HK | 1 |
| Fischer, PA; Majer, M; Przuntek, H; Welzel, D | 1 |
| Nakajima, Y; Narabayashi, H; Yokochi, F | 1 |
| Coffey, CE; Massey, EW; Olanow, CW; Ross, DR | 1 |
| Iadgarov, IS; Kandel', EI | 1 |
| Blair, RD; Lang, AE | 1 |
| Selby, G | 5 |
| Finberg, JP; Wajsbort, J; Youdim, MB | 1 |
| Fischer, PA | 3 |
| Koller, WC | 9 |
| Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB | 1 |
| Aiello, G; Caraceni, T; Carella, F; Girotti, F; Pederzoli, M; Scigliano, G | 1 |
| Gallai, M; Tariska, I | 1 |
| Bihari, K; Fekete, M; Katona, G; Tárczy, M | 1 |
| Birkmayer, W; Riederer, P | 2 |
| Hayashi, A; Kondo, T; Nagatsu, T; Narabayashi, H; Suzuki, T | 1 |
| Bihari, K; Csanda, E; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Rabey, MJ; Streifler, M | 1 |
| Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Goodgold, A; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Tang, LC | 1 |
| Birkmayer, W | 4 |
| Csanda, E; Tárczy, M | 2 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Hajba, A; Presthus, J | 1 |
| Portin, R; Rinne, UK | 2 |
| Bergmann, KJ; Mendoza, MR; Moros, D; Yahr, MD | 1 |
| Pearce, JM | 3 |
| Kuroda, H; Nukina, I; Ogawa, N; Ota, Z; Yamamoto, M | 1 |
| Alonso, RJ; Covington, TR; Mancall, EL | 1 |
| Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Beers, MF; Hurtig, H; Melvin, G; Scarpa, A; Stern, M | 1 |
| Johnson, RT; Price, DL | 1 |
| Gerber, JC; Grossman, MH; Hare, TA; Katz, L; Manyam, NV | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Spano, PF; Trabucchi, M | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Parati, EA; Zanardi, P | 1 |
| Robinson, MB | 1 |
| Joshita, Y; Kaneko, J; Mizuno, Y; Nagatsuka, Y; Tanaka, Y; Yoshida, M | 1 |
| Arnal García, C; Bermejo Pareja, F; Calandre Hoenigsfeld, L; Molina Arjona, JA | 1 |
| Priebe, S | 1 |
| De Bruyne, H; Jeanty, P; Lowenthal, A; Van den Kerchove, M | 1 |
| Indo, T | 3 |
| de Jong, GJ; Meerwaldt, JD | 2 |
| Burns, R | 1 |
| Morris, JG | 5 |
| Flowers, KA; Pearce, I; Pearce, JM | 1 |
| Baratti, M; Calzetti, S | 1 |
| Bitton, V; Globus, M; Hefti, F; Melamed, E | 1 |
| Spencer, SE; Wooten, GF | 2 |
| Dukhovnaia, MA; Evtushenko, SK; Neĭmark, EZ | 1 |
| Friedrich, FJ; Posner, MI; Rafal, RD; Walker, JA | 1 |
| Itoga, E; Kito, S; Yamamoto, M | 1 |
| Bouchard, S; Grimes, JD; King, DB; Kofman, OS; Molina-Negro, P; Wilson, AF | 1 |
| Asahara, K; Hirose, S; Imaizumi, M; Ishimitsu, T | 1 |
| Katsuki, T; Mizuno, Y; Shimizu, N | 1 |
| Davies, CL; Dolan, AL; Finnerty, GT; Parkes, JD; Shindler, JS; Towlson, K | 1 |
| Havlík, I; Janků, I; Stika, L; Terziivanov, D | 1 |
| Kostić, V; Nikolić, M | 1 |
| Calne, DB; Kopin, IJ; Trombley, IK; Ward, CD | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 2 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Mutani, R; Sechi, GP; Tanda, F | 1 |
| Calne, DB; Larsen, TA; LeWitt, P; Newman, R | 1 |
| Baroni, A; Benvenuti, F; Fantini, L; Pantaleo, T; Urbani, F | 1 |
| Agid, Y; Barroche, G; de Smet, Y; Lhermitte, F; Mear, JY; Weber, M | 1 |
| Laverty, WH; Rajput, AH; Stern, W | 1 |
| Fahn, S; Jackson-Lewis, V; Reches, A; Wagner, HR; Yablonskaya-Alter, E | 1 |
| Holt, P | 1 |
| Oleĭnik, LI | 1 |
| Glover, V; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Birkmayer, W; Danielczyk, W; Riederer, P | 1 |
| Cote, L; Fahn, S; Lobo Antunes, J | 1 |
| Mizuno, M; Shimizu, N | 1 |
| Maier Hoehn, MM | 1 |
| Rondot, P; Ziegler, M | 1 |
| Parkes, JD | 1 |
| Ballard, P; Langston, JW | 1 |
| Jones, T; Leenders, KL; Wolfson, L | 1 |
| Read, D; Young, A | 1 |
| Brown, MJ; Causon, RC; Leenders, KL; Wolfson, L | 1 |
| Baldassarre, G; Fazio, B | 1 |
| Aitken, JA; Turnbull, CJ | 1 |
| Hens, L; Laduron, PM; Laterre, CE; Maloteaux, JM | 1 |
| Mouren, A; Mouren, P; Nguyen Quang, N; Oppenheim, G; Poinso, Y | 1 |
| Chase, TN; Chen, KM; Doi, H; Uebayashi, Y; Yanagihara, RT | 1 |
| Aguado, EG; Bazán, E; de Yébenes, JG; Gervas, JJ; Muradás, V | 1 |
| Fischer, PA; Hubener, K; Schneider, E | 2 |
| Friedlender, E; Globus, M; Melamed, E; Rosenthal, J | 1 |
| Schiffter, R; Vogel, HP | 1 |
| Anderson, JL; Carter, JH; Hammerstad, JP; Nutt, JG; Woodward, WR | 1 |
| Hefti, F; Melamed, E | 1 |
| Fahn, S; Reches, A | 2 |
| Portin, R; Raininko, R; Rinne, UK | 1 |
| Beard, CM; Kurland, LT; Offord, K; Rajput, AH | 1 |
| Côté, L; Mayeux, R; Stern, Y; Williams, JB | 1 |
| Coignet, A; de Recondo, J; Rondot, P; Ziegler, M | 1 |
| Baum, R; Glantz, R; Klawans, HL; Nausieda, PA; Weber, S | 1 |
| Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Forssberg, H; Johnels, B; Steg, G | 1 |
| de Jong, PJ; Lakke, JP; Teelken, AW | 1 |
| Brincat, S; Lang, AE; Marsden, CD; Parkes, JD; Quinn, NP; Thompson, C | 1 |
| Caraceni, T; Carella, F; Giovannini, P; Grassi, MP; Parati, E; Scigliano, G | 1 |
| Diamond, SG; Markham, CH | 6 |
| Gerdes, U; Lehmann, K; Ulm, G | 1 |
| Lipcsey, A; Peres, A | 1 |
| Brennan, L; Gajraj, N; Howcroft, B; Parkes, JD; Ruiz, J; Thompson, C | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Quinn, N; Testa, B; van de Waterbeemd, H | 1 |
| Callieco, R; Cosi, V; Romani, A; Zerbi, F | 1 |
| Rajput, AH | 2 |
| Muenter, MD | 3 |
| Bressman, SB; Fahn, S | 1 |
| Kofman, OS | 1 |
| Montastruc, JL; Rascol, A; Rascol, O | 4 |
| Goldstein, M; Gopinathan, G; Hassouri, H; Lieberman, AN; Neophytides, A | 1 |
| Calne, DB; Newman, RP | 1 |
| Bermejo Pareja, F; Martínez-Martín, P | 1 |
| Hardie, RJ; Lees, AJ; Stern, GM | 3 |
| Klawans, HL | 4 |
| Reilly, DK; Rivera-Calimlim, L | 1 |
| Agid, Y; Bokobza, B; Javoy-Agid, F; Ruberg, M; Scatton, B | 1 |
| Fischer, PA; Grotz, A; Jacobi, P; Schneider, E | 1 |
| Brincat, S; Lang, AE; Marsden, CD; Parkes, JD; Quinn, N | 1 |
| Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Morocutti, C; Piccinin, GL; Piccirilli, M | 1 |
| Reiderer, P; Reynolds, GP | 1 |
| Bear, G; Casson, I; Durso, R; Foo, SH; Goldstein, M; Khayali, M; Kupersmith, M; Lieberman, A; Neophytides, A | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Marttila, R; Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Lawton, NF; MacDermot, J | 1 |
| Jenner, P; Marsden, CD; Parkes, JD; Schachter, M; Testa, B | 1 |
| Allain, H; Bentue-Ferrer, D; Pape, D; Reymann, JM; Sabouraud, O; van den Driessche, J | 1 |
| Mann, DM; Yates, PO | 1 |
| Nasar, A | 1 |
| Tippett, GO | 1 |
| Matthews, D; Mawdsley, C; Pentland, B | 2 |
| Bateman, DN; Cooper, RG; Gibson, GJ; Peel, ET; Wandless, I | 1 |
| Liu, DK | 3 |
| Coffey, CE; Ferren, EL; Olanow, CW; Ross, DR; Walker, JI | 1 |
| Alaghband-Zadeh, J; Das, PK; Gawel, MJ; Lavin, PJ; Rose, FC | 1 |
| Dean, BC; McLellan, DL | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Vartanian, KZ | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Elsworth, JD; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Calne, DB; Eisler, T; Kaiser, DL; MacLeod, RM; Thorner, MO | 1 |
| Fahn, S; Prasad, AL | 1 |
| Birkmayer, W; Riederer, P; Youdim, MB | 1 |
| Uono, M | 1 |
| Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Neophytides, A; Walker, R | 1 |
| Amaral, R; Cunha, L; Dinis, M; Gonçalves, AF; Oliveira, C | 1 |
| Shapiro, MB; Yaar, I | 1 |
| Agostini, L; Piccinin, GL; Piccirilli, M; Rizzo, PA | 1 |
| Agnoli, A; Baldassarre, M; Bocola, V; Del Roscio, S; Denaro, A; Ruggieri, S | 1 |
| Goetz, CG; Klawans, HL; Nausieda, PA; Tanner, CM; Weiner, WJ | 1 |
| Bragdon, AC; Coffey, CE; Ferren, EL; Hurwitz, BJ; Olanow, CW; Ross, DR | 1 |
| Cote, LJ; Fahn, S; Ilson, J; Mayeux, R; Snider, SR | 1 |
| Goldstein, M; Goodgold, A; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R | 2 |
| Balík, J; Filip, V; Filipova, M; Janků, I; Stika, L; Terziivanov, D | 1 |
| Delwaide, PJ; Schoenen, J | 1 |
| Glantz, RH; Glatt, SL; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Gresh, C | 1 |
| Kadykov, AS | 3 |
| Guttridge, D | 1 |
| Fischer, T | 1 |
| Iveson-Iveson, J | 1 |
| Garrett, E | 1 |
| Kruger, LB | 1 |
| Dambreville, F | 1 |
| Broe, GA; Evans, MA; Triggs, EJ | 1 |
| Mintz, M; Myslobodsky, MS; Radwan, H; Tomer, R | 1 |
| Lehmann, J | 1 |
| Colucci d'Amato, C; De Angelis, G; Giordano, L; Iaccarino, C; Marmo, E; Mastrosimone, F | 1 |
| Brown, MJ; Dollery, CT; Reid, JL; Rossor, MN; Watkins, J | 1 |
| Baker, H; Gauthier, S; Magnussen, I; Osterland, CK; Sternberg, EM; Van Woert, MH; Young, SN | 1 |
| Gillingham, FJ; Kelly, PJ | 1 |
| Vasil'ev, VN | 1 |
| Fodor, M; Solymosi, L; Szántó, J | 1 |
| Ando, K | 4 |
| Aabro, E; Andersen, J; Gulmann, N; Hjelmsted, A; Pedersen, HE | 1 |
| Boshes, B | 1 |
| Kase, M; Kuroiwa, Y; Narabayashi, H; Nishitani, Y; Ohmoto, T; Shiozawa, R; Toyokura, Y; Uono, K | 1 |
| Calne, DB; Teräväinen, H | 2 |
| Calne, DB; Le Witt, PA | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, A; Neophytides, A; Walker, R; Zasorin, N | 1 |
| Glantz, R; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 2 |
| Adam, WR; Campbell, DJ; Funder, JW; Mendelsohn, FA | 1 |
| Critchley, EM | 2 |
| Goetz, CG; Nausieda, PA; Tanner, CM | 1 |
| Goldstein, M; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R | 2 |
| Kameyama, M; Nakamura, S | 1 |
| Lipman, AG; Yosselson-Superstine, S | 1 |
| Bassi, S; Frattola, L; Trabucchi, M | 1 |
| Klawans, HL; Tanner, CM | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Goetz, CG; Klawans, HL; Stein, RW; Tanner, CM | 1 |
| Bauer, RB; Reveno, WS; Rosenbaum, H; Stevens, C | 1 |
| Avila, C; Bazán, E; García de Yébenes, J; García, E; Gervás, J; Maseda, C; Mena, M; Muradas, V; Ramos, JA | 1 |
| Haas, JA; Lakke, JP | 1 |
| Manyam, BV | 2 |
| Nausieda, PA; Weiner, WJ | 2 |
| Ando, K; Mano, Y; Muramoto, O; Riku, S | 1 |
| Hildick-Smith, M | 2 |
| Duvoisin, RC | 7 |
| Gauthier, G; Martins da Silva, A | 1 |
| Harada, H; Nishikawa, S; Takahashi, K | 1 |
| Edwards, M | 1 |
| Kaplan, LR; Klawans, HL; Nausieda, PA; Weber, S; Weiner, WJ | 1 |
| Calne, DB; Karson, CN; LeWitt, PA; Wyatt, RJ | 1 |
| Agid, Y; de Smet, Y; Dubois, B; Lhermitte, F; Ruberg, M; Serdaru, M | 1 |
| Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S | 1 |
| Brihaye-Van Geertruyden, MF; De Jong, PT; Demols, EE; Van Rens, GH | 1 |
| Brennan, MJ; Sandyk, R | 1 |
| Alexander, MP; Direnfeld, LK; Feldman, RG; Kelly-Hayes, M | 1 |
| Caraceni, T | 1 |
| Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
| Berger, JR; Kelley, RE | 1 |
| Calne, DB; Eisler, T; Eng, N; Plotkin, C | 1 |
| Goldman, JW; Haldeman, S; Hyde, J; Pribram, HF | 1 |
| Goetz, CG; Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
| Hefti, F; Liebman, J; Melamed, E; Pettibone, DJ; Wurtman, RJ | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, A; Neophytides, A; Pact, V | 1 |
| Agid, Y; Illas, A; Lhermitte, F; Quinn, N | 1 |
| Bergsrud, D; Elton, RL; Racy, A; Teychenne, PF; Vern, B | 1 |
| De Yébenes, JG | 1 |
| Broe, GA; Cheung, M; Creasey, H; Evans, MA; Paull, PD; Triggs, EJ | 1 |
| Alexander, MP; Delis, D; Direnfeld, L; Kaplan, E | 1 |
| Gilden, ER; Hansch, EC; Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Kent, S | 2 |
| George, RJ; Guiloff, RJ; Marsden, CD | 1 |
| Hadjikonstantinou, M; Markianos, M; Sfagos, C | 1 |
| Lieberman, AN; Plasse, HM | 1 |
| Ulm, G | 1 |
| Riederer, P | 1 |
| Gil Núñez, A; Giménez-Roldán, S; Mateo, D | 1 |
| Gerstenbrand, F; Gründig, E | 1 |
| Grimes, JD; Hassan, MN | 1 |
| Bierer, DW; Quebbemann, AJ | 1 |
| Das, P; Gawel, MJ; Rose, FC; Vincent, S | 1 |
| Agid, Y; Lhermitte, F; Quinn, N | 1 |
| Stewart, RM | 1 |
| Fischer, PA; Jacobi, P; Kolb, R; Schneider, E | 1 |
| Hoehn, MM | 7 |
| Findley, LJ; Hanks, G; Park, DM; Sandler, M | 1 |
| Ciannella, L; Dell'Aria, V; Melone, MA | 2 |
| Barnes, TR; White, NJ | 1 |
| Arakawa, Y; Imai, K; Matsue, M; Mizuno, Y; Narabayashi, H; Seki, J; Tamura, Z; Yamada, K; Yoshiue, S | 1 |
| Agnoli, A; Baldassarre, M; Falaschi, P; Rocco, A; Ruggieri, S; Urso, RD | 1 |
| Piccinin, GL; Piccirilli, M | 1 |
| Agostini, L; Piccinin, GL; Piccirilli, M | 1 |
| Bøttcher, J; Grøn, U | 1 |
| Clough, CG; Mendoza, M; Yahr, MD | 1 |
| La Medica, A; Piccinin, GL; Piccirilli, M | 1 |
| Balldin, J; Granérus, AK; Lindstedt, G; Modigh, K; Wålinder, J | 1 |
| Kaeser, HE | 1 |
| Coffey, CE; Ross, DR; Walker, JI | 1 |
| Caraceni, T; Giovannini, P; Girotti, F; Parati, E; Pederzoli, M; Scigliano, G | 1 |
| Caraceni, T; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A; Parati, E | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Beasley, BL; Chase, TN; Davenport, RW; Nutt, JG | 1 |
| Balldin, J; Edén, S; Granérus, AK; Modigh, K; Svanborg, A; Wålinder, J; Wallin, L | 1 |
| Bental, E; Goshen, H; Lavie, P; Sharf, B | 1 |
| Broe, GA; Evans, MA; Saines, N; Triggs, EJ | 1 |
| Bellizzi, J; Hale, MS | 1 |
| Avrami, E; Rabey, JM; Streifler, M | 1 |
| Godwin-Austen, RB; Hanks, G; Higgins, J; Twomey, JA | 1 |
| Cardenas, A; Giménez-Roldán, S; Martin Moro, M; Mateo, D | 1 |
| Habara, T; Morioka, T; Nakajima, E; Nitanai, T; Sasahara, K | 2 |
| Kuramoto, S; Yoshida, M | 1 |
| Casson, I; Durso, R; Foo, SH; Goldstein, M; Gopinathan, G; Khayali, M; Kupersmith, M; Lieberman, AN; Neophytides, A; Tartaro, T | 1 |
| Barrett, RE; Côté, LJ; Fahn, S; Snider, SR | 1 |
| Godwin-Austen, RB | 2 |
| Lander, CM; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Duvoisin, RC; Mendoza, MM; Yahr, MD | 1 |
| Dziatolowski, M; Gopinathan, G; Korein, J; Kupersmith, M; Lieberman, A; Neophytides, A | 1 |
| Hurtig, HI | 2 |
| Reilly, DK; Rivera-Calimlim, L; Van Dyke, D | 1 |
| Bédard, P; Debono, AG; Dorow, R; Horowski, R; Jenner, P; Keenan, J; Marsden, CD; Parkes, JD; Price, P; Rosenthaler, J; Schachter, M; Smith, B | 1 |
| Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Hikiji, A; Ideshita, H; Morita, H; Sasaki, T; Yoshinaga, J | 1 |
| McKenna, P; Pratt, RT; Stern, GM; Ward, C | 1 |
| Caviglia, A; Cellitti, M; Di Bianco, V; Di Castro, A; Pavoncello, S | 1 |
| Pfaff, G | 1 |
| Guillard, A | 6 |
| Lees, AJ; Shaw, KM; Stern, GM | 4 |
| Gil, R; Lefevre, JP | 1 |
| Marsden, CD; Parkes, JD; Schachter, M; Sheehy, MP | 1 |
| Dostrovsky, JO; Duff, J; Galvez-Jimenez, N; Hutchinson, WD; Lang, AE; Lozano, AM; Miyasaki, J | 1 |
| Boomsma, F; Man in 't Veld, A; Schalekamp, M; van den Meiracker, A | 1 |
| Casas Parera, I; Diaz, S; Fernández Pardal, MM; Gatto, E; Micheli, F | 1 |
| Heinz, A; Pietzcker, A; Przuntek, H; Winterer, G | 1 |
| Daniel, SE; Eve, DJ; Foster, OJ; Kingsbury, A; Lees, AJ; Marsden, CD; Nisbet, AP | 1 |
| Ghika, J | 2 |
| Dessibourg, CA; Gachoud, JP | 1 |
| Christensen, NJ; Eldrup, E; Jacobsen, J; Mogensen, P; Pakkenberg, H | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Andrade, LA; Azevedo-Silva, SM; Borges, V; Ferraz, HB; Rocha, MS | 1 |
| Eadie, MJ | 3 |
| Du, C; Mochizuki, Y; Oishi, M; Takasu, T | 1 |
| Ellgring, H; Oertel, WH | 1 |
| Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H | 1 |
| Alessandria, A; Bonifati, V; Giustini, P; Meco, G | 1 |
| Ossowska, K | 1 |
| Braat, EA; Lighart, GJ; Middelkoop, HA; Roos, RA; van der Velde, EA; van Dijk, JG; van Hilten, JJ | 1 |
| Danhof, M; Jansen, EN; Neef, C; Roos, RA; van Laar, T | 1 |
| Duvoisin, RC; Mark, MH; Miller, DC; Sage, JI; Walters, AS | 1 |
| Ishikawa, A; Miyatake, T | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Brandt, T; Hawken, M; Krafczyk, S; Oertel, WH; Paulus, W; Trenkwalder, C | 1 |
| Blomsterwall, E; Johnels, B; Matousek, M; Steg, G; Wikkelsö, C | 1 |
| Fitzpatrick, AJ | 1 |
| Halliwell, B; Jenner, P; Spencer, JP | 1 |
| Kempster, PA; Shif, M | 1 |
| Channon, S; Lees, AJ; Ramponi, C; Sieradzan, K; Stern, GM; Youdim, MB | 1 |
| Heerschap, A; Hinshaw, DB; Holshouser, BA; Kolem, H; Komu, M; Masur, H; Möller, HE; Sonninen, P; Vermathen, P; Zijlmans, J | 1 |
| Cho, MS; Jung, SR; Kim, SS; Kim, SY; Kim, TH; Kim, YC; Lee, YG | 1 |
| Kuno, S; Mizuta, E; Nakatake, M; Yamasaki, S | 1 |
| DeMaggio, AJ; Juneau, PL; LeWitt, PA; Loeffler, DA; Matson, WR; Milbury, PE | 1 |
| Corboy, DL; Sage, JI; Wagner, ML | 1 |
| Clinnick, S; Fonda, D; Schwarz, J | 1 |
| Xu, DL | 1 |
| Laitinen, LV | 1 |
| Jimenez, F; Velasco, AL; Velasco, F; Velasco, M | 1 |
| Aceves, J; Flores, G; Ondarza, R; Velasco, F; Velasco, M | 1 |
| Calliauw, J; Konings, CH; Kuiper, MA; Mulder, C; Wolters, EC | 1 |
| Russ, MO; Seger, L | 1 |
| Adachi, K; Hirooka, Y; Mitsuma, T; Oiso, Y; Otake, K | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Iacono, RP; Lonser, RR; Oh, A; Yamada, S | 1 |
| Carter, JH; Nutt, JG; Woodward, WR | 4 |
| Fujita, K; Ichinose, H; Nagatsu, T; Ohye, T; Yokochi, M | 1 |
| D'Costa, DF; Moore-Smith, B; Phillips, PA; Sheehan, LJ | 1 |
| Agid, Y; Bonnet, AM; Gouider-Khouja, N; Pichon, J; Vidailhet, M | 1 |
| Cooper, JM; Daniel, SE; Marsden, CD; Schapira, AH | 1 |
| Carter, JH; Maricle, RA; Nutt, JG | 1 |
| Albani, G; Alfonsi, E; Godi, L; Martignoni, E; Nappi, G; Pacchetti, C | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Blin, O; Fabre, N; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Janjua, R; Roos, RA; van Kempen, GM | 1 |
| Kawabata, K; Okuda, B; Sugita, M; Tachibana, H; Takeda, M | 1 |
| Markopoulou, K; Pfeiffer, RF; Wszolek, ZK | 1 |
| Aguglia, U; Branca, D; Colao, R; Montesanti, R; Nicoletti, G; Palmieri, A; Parlato, G; Quattrone, A; Rizzo, M; Zappia, M | 1 |
| During, MJ; Geller, AI; Naegele, JR; O'Malley, KL | 1 |
| Inoue, A; Misu, Y; Nakata, Y; Okumura, F; Ozaki, N; Sato, K; Ueda, H; Yue, JL | 1 |
| Dias, JA; Falcäo, JM; Felgueiras, MM; Gonçalves, JM; Pimenta, ZP; Sanchez, JP | 1 |
| Sweeney, PJ | 1 |
| Broussolle, E; Chazot, G; Decety, J; Dominey, P; Jeannerod, M | 1 |
| Carter, JH; Maricle, RA; Nutt, JG; Valentine, RJ | 1 |
| Aquaron, R; Barthet, C; Désiré, S; Fayet, G; Viallet, F | 1 |
| Myers, R; Sawle, GV | 1 |
| Arnold, G; Bandmann, O; Bondy, B; Gasser, T; Oertel, WH; Poewe, W; Schwarz, J; Trenkwalder, C; Wagner, M | 1 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Angeleri, V; Bonuccelli, U; Cossutta, E; De Mari, M; Foschi, N; Lamberti, P; Martignoni, E; Muratorio, A; Pacchetti, C; Pezzoli, G | 1 |
| Bergmans, PL; Kuiper, MA; Tissingh, G; Wolters, EC | 1 |
| Baetge, EE; Doherty, E; Frydel, B; Gentile, FT; Hammang, JP; Lindner, MD; McDermott, PE; Schallert, T; Ullman, MD; Winn, SR | 1 |
| Brooks, DJ; Weeks, RA | 1 |
| Greene, P | 1 |
| Haigh, RA; Thomas, M | 1 |
| Aiba, I; Indo, T; Takahashi, A | 1 |
| Cutson, TM; Laub, KC; Schenkman, M | 1 |
| Fukuuchi, Y; Kobari, M; Nogawa, S; Obara, K; Shinohara, T | 1 |
| Hamamoto, M; Ishikura, N; Miyazaki, T; Ohtsubo, K | 1 |
| Abe, T; Hamato, F; Saheki, M; Sasaki, K; Takahashi, S; Tohgi, H | 1 |
| Giladi, N; Honigman, S | 1 |
| Bakheit, AM | 1 |
| Goshima, Y; Misu, Y; Ueda, H | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Dodel, RC; Oertel, WH | 1 |
| Iacono, RP; Lonser, RR; Yamada, S | 1 |
| Baas, H; Bergemann, N; Demisch, L; Harder, S; Rietbrock, S | 1 |
| Carter, J; Fahn, S; Gauthier, S; Goetz, CG; Golbe, LI; Jankovic, J; Koller, W; Lang, AE; McDermott, MP; Olanow, CW | 1 |
| Dai, J; Kennedy, J; Meltzer, HY; Parsa, M; Riley, D | 1 |
| Walkinshaw, G; Waters, CM | 1 |
| Bernardi, G; De Angelis, D; Peppe, A; Pierantozzi, M; Pierelli, F; Stanzione, P | 1 |
| Hastie, IR; Mukherjee, D | 1 |
| Almazán, J; de Pedro-Cuesta, J; Gudmundsson, G; Johansson, H; Petersen, IJ; Stawiarz, L; Tulinius, H | 1 |
| Abraira, V; de Pedro-Cuesta, J; Stawiarz, L; Wermuth, L | 1 |
| Laihinen, AO; Lehikoinen, PK; Någren, KA; Oikonen, VJ; Rinne, JO; Rinne, UK; Ruotsalainen, UH; Ruottinen, HM | 1 |
| Heinonen, EH; Kilkku, OI; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA | 1 |
| Huszonek, JJ | 1 |
| Bliwise, DL; Hughes, M; Irbe, D; Rye, DB; Watts, N; Watts, RL | 1 |
| Colao, R; Montesanti, R; Quattrone, A; Zappia, M | 1 |
| Camicioli, R; Joseph, CL; McWhorter, K; Siple, J | 1 |
| Kawai, H; Mitsui, T; Miyata, M; Saito, S; Sakoda, S | 1 |
| Mark, MH; Sage, JI | 7 |
| Brannan, T; Yahr, MD | 1 |
| Ebner, TJ; Johnson, MT; Kipnis, AN; Mendez, A; Silverstein, P; Zwiebel, F | 1 |
| Kuno, S | 5 |
| Goto, I; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N | 3 |
| Marsh, CB; Mazzaferri, EL | 1 |
| Caparros-Lefebvre, D; Duhamel, A; Pécheux, N; Petit, H; Petit, V | 1 |
| Kömpf, D; Stüven, F; Verleger, R; Vieregge, P; Wascher, E | 1 |
| Maruyama, W; Naoi, M; Narabayashi, H | 2 |
| Bhatia, M; Jain, S; Maheshwari, MC | 1 |
| Korczyn, AD; Kuritzky, A; Nisipeanu, P | 1 |
| Inzelberg, R; Ridding, MC; Rothwell, JC | 1 |
| Bressi, S; Caraceni, T; Cortelli, P; Fazio, F; Gentrini, S; Grassi, F; Perani, D; Savoiardo, M; Testa, D | 1 |
| Haas, RH; Hill, LR; Nakano, K; Nasirian, F; Pay, M; Shults, CW; Ward, DM | 1 |
| Brown, LK | 1 |
| Brown, D; Factor, SA; Molho, ES; Podskalny, GD | 1 |
| Bennett, KM; Castiello, U | 1 |
| Ansari, AA; Breeze, RE; Freed, CR; Hutchinson, M; Kriek, EH; Mayne, A; Mazziotta, JC; O'Brien, CF; Schneck, SA; Zhang, YB | 1 |
| Bravo, G; Brera, B; Dargallo, J; Insausti, J; López-Lozano, JJ; Millán, I; Salmeán, J; Uría, J | 2 |
| de Yebenes, JG; Mena, MA; Neira, WD; Sanchez, V | 1 |
| Achiron, A; Djaldetti, R; Koren, M; Melamed, E; Ziv, I | 1 |
| Beizer, JL | 1 |
| Quinn, N | 2 |
| Hineno, T; Horiguchi, J; Kakimoto, Y; Mizobuchi, M; Nishimatsu, O | 1 |
| Dobato, JL; Giménez-Roldán, S; Mateo, D | 3 |
| Factor, SA; Schneider, AS | 1 |
| Ben-Shlomo, Y; Marmot, MG | 1 |
| Korczyn, AD; Neufeld, MY; Orlov, E; Rabey, JM; Treves, TA | 1 |
| Block, RE; Bowen, BC; Lampman, DA; Murdoch, JB; Pattany, PM; Quencer, RM; Sanchez-Ramos, J | 1 |
| Bédard, PJ; Blanchet, P; Britton, DR; Kebabian, JW | 1 |
| Aufdembrinke, B; Bruggi, P; Godi, L; Martignoni, E; Miltenburger, C; Nappi, G; Pacchetti, C; Voet, B | 1 |
| Lera, G; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Boldry, RC; Chase, TN; Engber, TM | 1 |
| Ishikawa, A | 3 |
| Chouinard, G; Miller, R | 1 |
| Caligiuri, MP | 1 |
| Arnold, G; Oertel, WH; Schwarz, J; Trenkwalder, C | 1 |
| Ben Shlomo, Y; Daniel, SE; Magalhães, M; Quinn, NP; Wenning, GK | 1 |
| Mahler, ME; Scharre, DW | 1 |
| Agid, Y; Bonnet, AM; Gouider-Khouja, N; Marconi, R; Vidailhet, M | 1 |
| Chacón, J; Garcia de Yebenes, J; Giminez Roldán, S; Pastor, M | 1 |
| Khalil, R; Milandre, L | 1 |
| Bodagh, IY; Robertson, DR | 1 |
| Klockgether, T; Löschmann, PA; Wüllner, U | 1 |
| Kuzuhara, S; Naito, Y; Narita, Y; Sasaki, R; Taniguchi, A | 1 |
| Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T | 1 |
| Playford, ED | 1 |
| Aruoma, OI; Dexter, DT; Evans, PJ; Halliwell, B; Jenner, A; Jenner, P; Kaur, H; Lees, AJ; Marsden, DC; Spencer, JP | 1 |
| Aronowitz, JS; Gordon, MF; Kane, JM; Lieberman, JA; Pollack, S; Safferman, AZ | 1 |
| Yoshida, M | 2 |
| Kempster, PA; Lees, AJ | 1 |
| Bennett, JP; Dietrich, S; Landow, ER; Schuh, LA | 1 |
| Angeleri, VA; Bonuccelli, U; Cossutta, E; De Mari, M; Foschi, N; Lamberti, P; Martignoni, E; Muratorio, A; Pacchetti, C; Pezzoli, G | 1 |
| Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Chase, TN; Hoff, J; Metman, LV; Mouradian, MM | 1 |
| Fries, JF; Lieberman, A; Montgomery, EB; Singh, G | 1 |
| Bravi, D; Chase, TN; Hoff, JI; Metman, LV; Mouradian, MM; Roberts, JR; Sethy, VH | 1 |
| Achiron, A; Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R | 1 |
| Gimeno Alava, A | 1 |
| Baas, H; Bergemann, N; Fischer, PA | 1 |
| Larmande, P; Maillot, F; Palisson, E; Saikali, I | 1 |
| Duché, B; Loiseau, P; Tison, F | 1 |
| Albani, C; Bächli, E | 1 |
| Copeland, LG; Dutton, J; Playfer, JR; Roberts, NB | 2 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW; Sohn, YH | 1 |
| Defer, G; Geny, C; Hantraye, P; Jeny, R; Monfort, JC; N'Guyen, JP; Peschanski, M; Remy, P; Ricolfi, F; Samson, Y | 1 |
| Albani, F; Baruzzi, A; Contin, M; Cortelli, P; Martinelli, P; Riva, R | 3 |
| Brooks, DJ; Burn, DJ; Lammertsma, AA; Luthra, S; Morrish, PK; Osman, S; Sawle, GV; Snow, BJ | 1 |
| Antonini, A; Beer, HF; Leenders, KL; Madeja, UD; Oertel, WH; Schwarz, J | 1 |
| Fahn, S; Lew, MF; Moskowitz, CB; Shindo, M; Waters, CH; Wilhelmsen, KC | 1 |
| Friedman, A | 2 |
| Paulson, GW | 1 |
| Bennett, JP; Landow, ER; Schuh, LA | 1 |
| Glosser, DS; Hurtig, H; Kim, E; McAllister, TW; Stern, M; Zwil, AS | 1 |
| Koller, WC; Pahwa, R | 2 |
| Kondo, T; Mizuno, Y; Mori, H | 1 |
| Martí, MJ; Tolosa, ES; Valldeoriola, F | 1 |
| Poewe, WH | 1 |
| Broe, GA; Hely, MA; Margrie, S; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 1 |
| Alexander, GM; Grothusen, JR; Hooker, MD; Nukes, TA; Schwartzman, RJ | 1 |
| Kondo, T; Mizuno, Y; Takubo, H; Yokochi, F | 2 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 3 |
| Jeanneau, A; Olie, JP | 1 |
| Standaert, DG; Stern, MB | 1 |
| Lange, KW; Riederer, P; Youdim, MB | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM | 1 |
| Gervason-Tournier, CL; Hommel, M; Limousin, P; Perret, JE; Pollak, P | 1 |
| DaPrada, M; Pletscher, A | 1 |
| Poewe, W; Schelosky, L | 1 |
| Strange, PG | 1 |
| Blum, S; Jacqmotte, N; Jacquy, J; Mettens, P; Vanderheyden, JE | 1 |
| Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF | 1 |
| Ferrarese, C; Piolti, R; Pozzi, C | 1 |
| Chase, TN; Davis, TL; Giuffra, M; Mouradian, MM; Ownby, J | 1 |
| Alvarez, L; Gonzalez, C; Molina, H; Muñoz, J; Ortega, I; Quiñones, R; Suárez, C | 1 |
| Björklund, A; Brooks, D; Brundin, P; Frackowiak, R; Lindvall, O; Marsden, CD; Odin, P; Rothwell, JC; Sawle, G; Widner, H | 1 |
| Heinonen, E; Myllylä, V | 2 |
| Illi, A; Keränen, T; Myllylä, VV; Sotaniemi, KA; Suominen, K | 1 |
| Yanagisawa, N | 5 |
| Finali, G; Piccinin, GL; Piccirilli, M | 1 |
| Caligiuri, MP; Peterson, S | 1 |
| Calne, DB; Duvoisin, RC; Koller, WC | 1 |
| Kiauta, T; Mesec, A; Sega, S | 1 |
| Costa, DC; Lees, AJ; Markus, HS | 1 |
| Bovingdon, M; Gordin, A; Lees, AJ; Merello, M; Webster, R | 1 |
| Fiszer, U; Fredrikson, S; Kostulas, V; Link, H; Mix, E; Olsson, T | 1 |
| Calne, DB; Uitti, RJ; Vingerhoets, FJ | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Lefebvre-Caparros, D; Marconi, R; Vidailhet, M | 1 |
| Fahn, S; Grimes, JD; Hurtig, H; Jankovic, J; Klawans, H; Kurlan, R; Muenter, M; Olanow, CW; Shoulson, I; Stern, M | 1 |
| Dichgans, J; Klockgether, T | 1 |
| Mendis, L | 1 |
| Barbato, L; Marsden, CD; O'Connel, MT; Patsalos, PN; Quinn, NP; Ruggieri, S; Stocchi, F | 1 |
| Bonifati, V; Cipriani, R; Fabrizio, E; Meco, G; Vanacore, N | 1 |
| Fouillet, N; Henry, P; Tison, F | 1 |
| Fernandez Pardal, M; Gatto, M; Melero, M; Micheli, F; Scorticati, C; Zurru, C | 1 |
| Deffond, D; Dordain, G; Durif, F; Tournilhac, M | 1 |
| Karimova, MKh; Kubatiev, AA; Mamysheva, OD; Petelin, LS | 1 |
| Asari, S; Date, I; Furuta, T; Imaoka, T; Miyoshi, Y; Ohmoto, T; Yoshimoto, Y | 1 |
| Frankel, JP; Hughes, AJ; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Aotsuka, A; Bravi, D; Chase, TN; Linfante, I; Metman, LV; Mouradian, MM; Sohn, YH | 1 |
| Kempster, PA; Wahlqvist, ML | 1 |
| Kon, K; Kurokawa, T; Sakuragawa, N | 1 |
| Accornero, N; Berardelli, A; Inghilleri, M; Manfredi, M; Priori, A | 1 |
| Beckner, RM; Berggren, K; Carter, JH; Gancher, ST; Gordin, A; Hammerstad, JP; Nutt, JG; Stone, CK; Woodward, WR | 1 |
| Rausing, A; Rosén, U | 1 |
| Hirai, S; Kondo, T; Mizuno, Y; Mori, H; Suda, K; Tanabe, K; Yokochi, F | 1 |
| Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR | 1 |
| George, A; Gray, P; Grimes, JD; Mendis, T; Mohr, E; Rusk, IN | 1 |
| Blin, O; Fabre, N; Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Hashimoto, K; Sai, I; Sakuta, M; Terao, Y; Yazawa, I | 1 |
| Lera, G; Luquin, MR; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Celsis, P; Chollet, F; Fabre, N; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Gancher, ST; Nutt, JG | 2 |
| Helscher, RJ; Pinter, MM; Sattler, AP | 1 |
| Lauterbach, EC | 1 |
| Bulgaru, D; Büttner, T; Klotz, P; Kuhn, W; Przuntek, H; Steinberg, R; Voss, L | 1 |
| Kuno, S; Mizuta, E | 1 |
| Aquilonius, SM; Bredberg, E; Johansson, K; Johnels, B; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Abe, H; Harada, T; Ishizaki, F; Katayama, S; Nakamura, S | 1 |
| Golbe, LI; Goodman, JC; Jankovic, J; Rajput, AH | 1 |
| Cooper, JA; Sagar, HJ; Sullivan, EV | 1 |
| Comella, CL; Ristanovic, RK; Tanner, CM | 1 |
| Calne, DB; Nygaard, TG; Snow, BJ; Takahashi, H | 2 |
| Clavería, LE; Coria, F; Duarte, J; Moreno, C; Pérez, A | 1 |
| Breimer, DD; Roos, RA; Tijssen, MA; van der Velde, EA | 1 |
| Essink, AW; Jansen, EN; Neef, C; Oosterloo, S; Roos, RA; van Laar, T | 1 |
| Coakley, D; Feely, J; O'Mahony, D; O'Neill, D; Rowan, M; Walsh, JB | 1 |
| Andrew, R; Best, SA; Midgley, JM; Petty, RK; Watson, DG; Wenlong, H | 1 |
| Klockgether, T; Löschmann, PA; Schugens, MM | 1 |
| Lieberman, A | 6 |
| Blumenthal, HJ | 1 |
| Hossain, MA; Weiner, N | 1 |
| Chase, TN; Engber, TM; Mouradian, MM | 1 |
| Abi-Dargham, A; Baldwin, RM; Innis, RB; Laruelle, M; Scanley, BE; Seibyl, JP; Wallace, E; Wang, S; Zea-Ponce, Y; Zoghbi, S | 1 |
| Bergen, M; Fowler, SB | 1 |
| Cooper, JA; Sagar, HJ | 1 |
| Komai, N | 1 |
| Walsh, TJ | 1 |
| Agid, Y; Duyckaerts, C; Hauw, JJ; Hirsch, EC; Javoy-Agid, F; Strada, O | 1 |
| Friedman, EH | 1 |
| Ahtila, S; Gordin, A; Kaakkola, S; Rita, H; Teräväinen, H | 1 |
| Knoll, J | 5 |
| Stern, G | 2 |
| Hamada, T; Matsuura, T; Moriwaka, F; Tashiro, K; Yoshida, K | 1 |
| Heinonen, EH; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA | 1 |
| Allain, H; Neukirch, HC; Pollak, P | 1 |
| Chandra, V; Korczyn, AD; Treves, TA | 1 |
| Fullerton, T | 1 |
| Elias, JW; Hutton, JT; Morris, JL | 1 |
| Aranda, B; Cramer, P | 1 |
| Fernandez, W; Lees, AJ; Turjanski, N | 1 |
| Helscher, RJ; Pinter, MM | 2 |
| Chen, RC; Chiu, HC; Wang, M; Wu, RM | 1 |
| Hirose, K; Isozaki, E; Miyamoto, K; Noda, K; Oda, M; Tanabe, H | 1 |
| Cheng, FC; Chia, LG; Kuo, JS | 1 |
| Rumbach, L; Tranchant, C; Viel, JF; Warter, JM | 1 |
| Churchyard, A; Donnan, GA; Howells, DW; Hughes, A; Kalnins, RM; Mendelsohn, FA; Paxinos, G; Wong, JY; Woodhouse, D | 1 |
| Factor, SA; Weiner, WJ | 2 |
| Sawle, GV | 1 |
| Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B | 1 |
| Atchison, PR; Frackowiak, RS; Marsden, CD; Thompson, PD | 1 |
| Achiron, A; Goldberg, H; Goren, M; Melamed, E; Sroka, H; Ziv, I; Zoldan, Y | 1 |
| Cedarbaum, JM; Evans, A; Gjedde, A; Guttman, M; Kuwabara, H; Léger, G; Reches, A | 1 |
| Arevalo, GJ; Gershanik, OS | 1 |
| Jimenez-Jimenez, J; Legarda, I; Obeso, JA; Vaamonde, J; Zubieta, JL | 1 |
| Lang, AE; Riley, DE | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Bhatia, K; Brooks, DJ; Burn, DJ; Marsden, CD; Sawle, GV; Turjanski, N | 1 |
| Auff, E; Doppelbauer, A; Fertl, E; Waldhauser, F | 2 |
| Beksinska, M; James, M; Leigh, PN; Marsden, CD; Owen, AM; Quinn, NP; Robbins, TW; Sahakian, BJ; Summers, BA | 1 |
| Boulton, AA; Juorio, AV; Li, XM; Paterson, IA | 1 |
| Chase, TN; Davis, TL; Giuffra, ME; Mouradian, MM; Sethy, VH | 1 |
| Chanter, DO | 1 |
| Henningson, C; Karlsson, S; Svensson, P | 1 |
| Bergmans, PL; Konings, CH; Kuiper, MA; Wolters, EC | 1 |
| Broe, GA; Creasey, HM | 1 |
| Ahlskog, JE; Atkinson, EJ; Cha, RH; Maraganore, DM; Muenter, MD; O'Brien, PC; Uitti, RJ | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
| Kornhuber, J; Weller, M | 1 |
| Marder, K; Mayeux, R; Stern, Y; Tang, MX | 1 |
| Goetz, CG; Irwin, I; Kurth, MC; Langston, JW; Stebbins, GT; Tanner, CM; Tetrud, JW | 1 |
| Beckner, RM; Cedarbaum, JM; Gauger, LL; Hauser, RA; Nutt, JG; Olanow, CW; Woodward, WR | 1 |
| Cumming, P; Gjedde, A; Guttman, M; Hoshi, H; Kuwabara, H; Léger, G | 1 |
| Brianti, R; Ludovico, L; Mazzucchi, A; Nappi, G; Pacchetti, C; Parma, M; Sinforiani, E; Turla, M | 1 |
| Holmberg, B; Ingvarsson, PE; Johnels, B; Matousek, M; Steg, G | 1 |
| Yahr, MD | 6 |
| Albani, C; Buck, A | 1 |
| Chollet, F; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, OJ; Sabatini, U | 1 |
| Lange, KW; Marsden, CD; Paul, GM; Robbins, TW | 1 |
| Hirato, M; Horikoshi, S; Kawashima, Y; Ohye, C; Satake, K; Shibazaki, T | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Caldas, AC; Levy, A; Lima, AB; Lopes, G; Neves, G; Sampaio, C | 1 |
| Caraceni, T; Carella, F; Giovannini, P; Girotti, F; Testa, D | 1 |
| Furukawa, Y; Kondo, T; Mizuno, Y; Narabayashi, H; Nishi, K | 2 |
| Nomura, Y; Segawa, M | 1 |
| Nygaard, TG | 1 |
| Bhatt, MH; Calne, DB; Nakamura, K; Nomoto, M; Okada, A; Osame, M; Snow, BJ | 1 |
| Daniel, SE; Hughes, AJ; Lees, AJ | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Horstink, MW; Jansen, EN; Roos, RA; Wolters, EC | 2 |
| Baronti, F; Bramante, L; Monge, A; Ruggieri, S; Stefano, E; Stocchi, F; Viselli, F | 1 |
| Bösch, S; Kleedorfer, B; Poewe, W; Schelosky, L; Wagner, M | 1 |
| Graff, E; Harsat, A; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Künig, G; Neubauer, M; Ransmayr, G; Wagner, M | 1 |
| Fornadi, F; Pantelatos, A | 1 |
| Chase, TN; Dambrosia, JM; Peppe, A | 1 |
| Cote, L; Fahn, S; Greene, P | 1 |
| Hubble, JP; Koller, WC; Waters, C | 1 |
| Koren, G | 1 |
| Cornelius, L; Factor, SA; Ingenito, A; Sanchez-Ramos, JR; Sheldon, C; Singer, C; Weiner, WJ | 1 |
| García-Ruiz, P; García-Urra, D; Jiménez-Jiménez, FJ; Vázquez, A | 1 |
| Koivikko, L; Portin, R; Revonsuo, A; Rinne, JO; Rinne, UK | 1 |
| Durso, R; Feldman, RG; Isaac, K; Perry, L; Saint-Hilaire, M | 1 |
| Blankson, S; Daniel, SE; Hughes, AJ; Lees, AJ | 1 |
| Abe, T; Takahashi, S; Tohgi, H | 1 |
| Baas, H; Fischer, PA; Stecker, K | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| De Deyn, PP; Gonce, M; Jacquy, J; Van den Kerchove, M | 1 |
| Blond, S; Caparros-Lefebvre, D; Guieu, JD; Pécheux, N; Petit, H; Vermersch, P | 1 |
| Battistin, L; Borsato, N; Briani, C; Chierichetti, F; Dam, M; Ferlin, G; Pizzolato, G; Rossato, A; Saitta, B; Zanco, P | 1 |
| Hadar, U; Rose, FC | 1 |
| Goldenberg, JN; Sanchez-Ramos, JR; Singer, C; Weiner, WJ | 1 |
| Busenbark, K; Hubble, JP; Huber, SJ; Koller, WC; Michalek, D; Pahwa, R | 1 |
| Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W | 1 |
| Bonuccelli, U; Corsini, GU; Del Dotto, P; Muratorio, A; Piccini, P; Rossi, G | 1 |
| Bishop, S; Fernandez, W; Hughes, AJ; Kleedorfer, B; Lees, AJ; Stern, GM; Turjanski, N | 1 |
| Factor, SA | 2 |
| Kabel, JF; Kerkhof, GA; Kramer, CG; Middelkoop, HA; Roos, RA; van Hilten, JJ | 1 |
| Caraceni, T; Fetoni, V; Geminiani, GC; Genitrini, S; Giovannini, P; Girotti, F; Parati, EA; Soliveri, P; Testa, D | 1 |
| Benson, R; Charlton, C; Crowell, B; Doonquah, K; Hill, B | 1 |
| Hesselink, JM | 1 |
| Bradshaw, JA; Bradshaw, JL; Iansek, R; Jones, DL; Phillips, JG | 1 |
| Duchek, M; Ekberg, R; Fehling, C; Johansson, F; Johnels, B; Lindvall, B; Nordin, G; Olsson, JE; Sidén, A; Steg, G | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Hixon, TJ; Solomon, NP | 1 |
| Cashaw, JL | 1 |
| Cote, LJ; Richards, M; Stern, Y | 1 |
| Bartley, EA; Carvey, PM; Goetz, CG; MacLeod, CM; Stebbins, GT; Thelen, JA | 1 |
| Irwin, I; Kurth, MC; Langston, JW; Lyness, WH; Tetrud, JW | 1 |
| Delwaide, PJ; Maertens de Noordhout, A; Pepin, JL | 1 |
| Bowes, SG; Charlett, A; Dickins, J; Dobbs, RJ; Dobbs, SM; Frith, C; Henley, M | 1 |
| Benson, R; Charlton, CG; Crowell, BG; Shockley, D | 1 |
| Aotsuka, A; Asahina, M; Hirayama, K; Inoue, O; Shinotoh, H; Suhara, T; Tateno, Y; Yamazaki, T | 1 |
| Anderson, JJ; Baronti, F; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Poewe, W; Wagner, M | 1 |
| Miranda, M; Saéz, D | 1 |
| Finali, G; Piccirilli, M; Rizzuto, S | 1 |
| Falk, M; Künig, G; Neubauer, M; Ransmayr, G; Wagner, M | 1 |
| Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD | 1 |
| Gorchein, A | 1 |
| Baig, S; Bednar, I; Forsberg, G; Qureshi, GA; Siden, A; Södersten, P | 1 |
| Montastruc, JL; Rascol, O; Sénard, JM; Verwaerde, P | 1 |
| Harrison, J; Henderson, L; Kennard, C | 1 |
| Bateman, DE | 1 |
| DiStefano, L; Kean, A; Schneider, JS | 1 |
| Silverstein, PM | 1 |
| Baas, H; Harder, S; Rietbrock, S | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| O'Connell, MT; Patsalos, PN; Quinn, NP; Wenning, GK | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Marconi, R; Serre, I | 1 |
| Benabid, AL; Benazzouz, A; Broussolle, E; Hoffmann, D; Limousin, P; Perret, JE; Pollak, P | 1 |
| Lees, AJ | 5 |
| Rinne, UK; Ruottinen, HM | 4 |
| Hammerstad, JP; Robertson, LT | 1 |
| Li, G | 1 |
| Caffarra, P; Chiodera, P; Coiro, V; Maestri, D; Scaglioni, A; Volpi, R | 1 |
| Büttner, T; Kuhn, W; Patzold, T; Przuntek, H | 1 |
| Asahina, M; Hirayama, K; Inoue, O; Shinotoh, H; Suhara, T; Tateno, Y | 1 |
| Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C | 1 |
| Artem'ev, DV; Damulin, IV; Iakhno, NN | 1 |
| Nakashima, K; Sakuma, K; Shimoda, M; Takahashi, K; Wang, Y | 1 |
| Agid, Y; Faucheux, BA; Hauw, JJ; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Levy, R; Obeso, JA; Villares, J | 1 |
| Byth, K; Einstein, R; Henderson, JM; Jackson, DM; Morris, JG | 1 |
| Heinonen, E; Kilkku, O; Mäki-Ikola, O | 1 |
| Anderson, KE; Girdwood, AC; Wilson, JA | 1 |
| Godbold, JH; Koller, W; Olanow, CW | 1 |
| Jenner, P; Silva, MT; Watts, PM | 1 |
| Bland, R; MacMahon, DG | 1 |
| Boulton, AA; Lai, CT; Yu, PH | 1 |
| Gerlach, M; Riederer, P; Vogt, H | 1 |
| Jellinger, KA | 1 |
| Burleigh, A; Frank, J; Horak, F; Nutt, J | 1 |
| Hattori, N; Mizuno, Y; Stadtman, ER; Tanaka, M; Uchida, K; Yoritaka, A | 1 |
| Di Rocco, A; Kollmeier, B; Molinari, SP; Yahr, MD | 1 |
| Caraceni, T; Fetoni, V; Giovannini, P; Girotti, F; Musicco, M; Scigliano, G; Soliveri, P | 1 |
| Dickson, DW; Duvoisin, RC; Mark, MH; Sage, JI | 1 |
| Benhadjali, J; Bughin, M; Delalande, I; Destée, A; Forzy, G; Hache, JC | 1 |
| Furukawa, Y; Mizuno, Y; Narabayashi, H | 1 |
| Albanese, A; Colosimo, C; Lees, AJ; Tonali, P | 1 |
| Battistin, L; Cagnin, A; Chierichetti, F; Dam, M; Fabbri, M; Ferlin, G; Pizzolato, G; Rossato, A | 2 |
| Azulay, JP; Blin, O; Mestre, DR; Serratrice, G; van den Brand, CL | 1 |
| Bayülkem, B; Bayülkem, K; Erişir, K; Tuncel, A | 1 |
| Brefel, C; Fuell, D; Lees, AJ; Montastruc, JL; Pirtosek, Z; Rascol, O; Senard, JM | 1 |
| Friedberg, G; Melamed, E; Weizman, A; Zoldan, J | 1 |
| Friedberg, G; Melamed, E; Weizmann, A; Ziv, I; Zoldan, J | 1 |
| DeCarvalho, GC; Kestle, JR; Li, CS; Tasker, RR | 1 |
| Barbanti, P; Bramante, L; DePandis, F; Fabbrini, G; Manfredi, M; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Breakefield, XO; Calne, D; Gasser, T; Gusella, J; Ozelius, L; Pfeiffer, RF; Supala, A; Trofatter, J; Uitti, RJ; Wszolek, Z | 1 |
| Ahlskog, JE; Low, PA; Nickander, KK; O'Brien, JF; Tyce, GM; Uitti, RJ | 1 |
| Berardelli, A; Inghilleri, M; Manfredi, M; Rona, S | 1 |
| Durso, R; Folkerth, RD | 1 |
| Aquilonius, SM; Hartvig, P; Jacobsson, G; Långström, B; Pedersen, M; Tedroff, J | 1 |
| Brownlee, HJ; Stacy, M | 1 |
| Dubuis, R; Limousin, P; Perret, JE; Pfefen, JP; Pollak, P; Tournier-Gervason, CL | 1 |
| Newton, W | 1 |
| Bergus, G | 1 |
| Gordon, N | 1 |
| Chaudhuri, KR; D'Olhaberriague, L; Jellinger, K; Litvan, I; Mangone, CA; McKee, A; Parsa, A; Pearce, RK; Verny, M | 1 |
| Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K | 2 |
| Agid, Y; Bonnet, AM; Carpentier, AF; Vidailhet, M | 1 |
| Barnes, GR; Collins, S; Grealy, MA; Waterston, JA | 1 |
| Frank, M; Kellner, H; Liegl, U; Zoller, WG | 1 |
| Corona, T; Otero, E; Rivera, C; Stopp, L | 1 |
| Antonijoan, R; Arcelus, R; Avila, A; Barbanoj, M; Kulisevsky, J; Torres, J | 1 |
| Coltz, JD; Ebner, TJ; Gupta, A; Johnson, MT; Kipnis, AN; Silverstein, P; Zwiebel, F | 1 |
| Damecour, CL; Turcotte, JR | 1 |
| Fahn, S; Salgado, M; Tan, A | 1 |
| Agid, Y; Faucheux, B; Herrero, MT; Hirsch, EC; Levy, R; Obeso, JA; Vila, M | 1 |
| Kishore, A; Snow, BJ | 1 |
| López de Munain, A; Martí Massó, JF; Poza, JJ | 1 |
| Delwaide, PJ | 1 |
| Jost, WH; Schimrigk, K | 1 |
| Cabello López, J; Galvañ Berenguer, B; Gómez García, J; Leiva Santana, C | 1 |
| Berciano, J; Fernández, JM; Guitera, V; Pascual, J | 1 |
| Roberts, J | 1 |
| Falip, R; López-Arlandis, J; Manzanares, R; Martín, R; Matías-Guiu, J; Provencio, R; Ruiz, C | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Limousin, P; Perret, JE; Pollak, P | 1 |
| Jongen, JC; Roos, RA; van der Velde, EA | 1 |
| Blanchet, PJ; Chase, TN; de Jong, D; Metman, LV; Mouradian, MM | 1 |
| Carreras, MC; Fernandez Pardal, MM; Gatto, EM; Llesuy, S; Pargament, GA; Poderoso, JJ; Reides, C; Repetto, M; Riobo, NA | 1 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Brin, MF; Dwork, AJ; Fahn, S; Goetz, CG; Rajput, AH; Weiner, WJ | 1 |
| Facca, A; Sanchez-Ramos, J | 1 |
| Ahlskog, JE; Maraganore, DM; Uitti, RJ | 1 |
| Graybiel, AM | 1 |
| Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY | 2 |
| Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF | 1 |
| Fuell, D; Lees, AJ; Montastruc, JL; Pirtosek, Z; Rascol, O; Senard, JM | 1 |
| Sandyk, R | 10 |
| Du, CM; Hara, M; Mochizuki, Y; Oishi, M; Takasu, T | 1 |
| Andrade, LA; Borges, V; Ferraz, HB; Rocha, MS | 1 |
| Akiguchi, I; Fukuyama, H; Imai, T; Kawamura, J; Kimura, J | 1 |
| Barbato, L; Bramante, L; Nordera, G; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Colosimo, C; Merello, M; Pontieri, FE | 1 |
| Kovacs, AB; Mally, J; Stone, TW | 1 |
| Hirato, M; Horikoshi, S; Ishihara, J; Ohye, C; Shibazaki, T | 1 |
| Melamed, E | 6 |
| Bassi, A; Cicardi, MC; Loberti, M; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Piccoli, F; Riuggeri, RM | 1 |
| Brooks, DJ; Burn, DJ; Torjanski, N | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C | 1 |
| Iacono, RP; Kuniyoshi, S; Lonser, RR; Maeda, G; Mandybur, G; Warner, D; Yamada, S | 1 |
| Charlton, CG; Crowell, B | 1 |
| Klockgether, T; Spieker, S; Stetter, F | 1 |
| Avila, A; Berthier, ML; Kulisevsky, J | 1 |
| Botti, C; Faglioni, P; Ferrari, V; Scarpa, M | 1 |
| Dierks, T; Grosse, H; Kuhn, W; Müller, T; Rommelspacher, H | 1 |
| Meara, JR; Sutcliffe, RL | 1 |
| Adena, MA; Broe, GA; Hely, MA; Morris, JG; O'Sullivan, DJ; Reid, WG; Williamson, PM | 1 |
| Dubois, B; Montastruc, JL | 1 |
| Azulay, JP; Blin, O; Mestre, D; Pouget, J; Sangla, I; Serratrice, G; Van Den Brand, C | 1 |
| Burg, G; Kleinhans, M; Schmid-Grendelmeier, P | 1 |
| Dowling, GA | 1 |
| Buhrfiend, C; Carvey, PM; Goetz, CG; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Revell, SP; Shulman, LM; von Graevenitz, KS | 1 |
| Bloem, BR; Klaassen, AA; van Hilten, JJ | 1 |
| Fazzini, E; Fowler, JS; Volkow, ND | 1 |
| Korczyn, AD; Nisipeanu, P | 1 |
| Kolaj, M; Petravic, D; Relja, MA | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R; Triggs, EJ | 1 |
| Dubinsky, R; Hubble, JP; Koller, WC; Lyons, K; McGuire, D; Pahwa, R | 1 |
| Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH | 1 |
| Hasegawa, T; Mizutani, Y; Nabeshima, T; Ogawa, M; Okada, Y | 1 |
| Bonamartini, A; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Albani, F; Baruzzi, A; Contin, M; Riva, R | 1 |
| Frank, J; Horak, FB; Nutt, J | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Hunt, WB; Kirollos, C; Kosik, R; Mozol, K; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Blurton-Jones, M; Cherry, SR; DeSalles, AA; Huang, SC; Melega, WP; Morton, GG; Phelps, ME; Raleigh, MJ; Stout, DB | 1 |
| Grasso, M; Mazzini, L; Schieppati, M | 1 |
| Koller, WC; Lyons, K; Marjama, J; McGuire, D; Pahwa, R; Silverstein, P; Ward, R; Zwiebel, F | 1 |
| Ho, HH; Kwan, SY; Shan, DE; Su, MS | 1 |
| Bartholomé, K; Brand, MP; Clayton, PT; Clelland, JD; Flatmark, T; Heales, SJ; Knappskog, PM; Lüdecke, B; Surtees, RA | 1 |
| Fünfgeld, EW | 1 |
| Baas, H; Bürklin, F; Demisch, L; Fischer, PA; Harder, S; Stecker, K | 1 |
| Danielczyk, W | 2 |
| Gsell, W; Lange, KW; Naumann, M; Paul, GM | 1 |
| Caparros-Lefebvre, D; Duffau, H; Mazoyer, B; Parker, F; Tzourio, N | 1 |
| Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J | 1 |
| Blümner, E; Danielczyk, W; Gerlach, M; Kaiser, HJ; Kraus, PH; Letzel, H; Przuntek, H; Riederer, P; Uberla, K; Welzel, D | 1 |
| Brooks, S; Kaur, S; Starr, BS; Starr, MS | 1 |
| Gerlach, M; Klotz, P; Kuhn, W; Müller, T; Przuntek, H | 1 |
| Bermejo, F; Del Ser, T; Pondal, M | 1 |
| Muilenburg, ND | 1 |
| Agid, Y; Deweer, B; Dubois, B; Ertle, S; Pillon, B; Sarazin, M | 1 |
| Hely, MA; Morris, JG | 1 |
| Dihenia, B; Krendel, DA; Qureshi, AI; Schneider, JA; Wilmot, G | 1 |
| Allard, P; Bédard, PJ; Blanchet, PJ; Grégoire, L; Tardif, F | 1 |
| Miwa, H; Mizuno, Y | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV; Mouradian, MM | 1 |
| Gancher, ST; Nutt, JG; Woodward, WR | 4 |
| Attanasio, R; Costa, A; Cozzi, R; Dallabonzana, D; Horowski, R; Liuzzi, A; Martignoni, E; Nappi, G; Rainer, E | 1 |
| Rundshagen, I | 1 |
| Anderson, T; El-Debas, T; Findley, LJ; Marsden, CD; Steiger, MJ | 1 |
| Brotchie, JM; Henry, B | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 2 |
| Albani, F; Baruzzi, A; Charles, BG; Contin, M; Cortelli, P; Martinelli, P; Riva, R; Triggs, EJ | 1 |
| Durrieu, G; Llau, ME; Montastruc, JL; Rascol, O; Senard, JM; Tran, MA | 1 |
| Angus, C; Lang, AE; Sandor, P; Singal, S | 1 |
| Bueri, JA; Garretto, NS; Rey, RD; Sanz, OP; Sica, RE; Simonetti, DD | 1 |
| Goshima, Y; Misu, Y; Okamura, H; Ueda, H | 1 |
| Ebinger, G; Michotte, Y; Sarre, S | 1 |
| Akiguchi, I; Fukuyama, H; Hanakawa, T; Kato, M; Kimura, J; Shibasaki, H | 1 |
| del Toro Cervera, J; García Castaño, J; Muiño Miguez, A; Segado Soriano, A | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Tesselaar, HJ; Wolters, EC | 1 |
| Prange, AJ | 1 |
| Lang, AE; Provias, JP; Tuite, PJ | 1 |
| Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F | 1 |
| Temlett, JA | 1 |
| Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Rinne, UK; Sotaniemi, K | 1 |
| Bodis-Wollner, I; Tagliati, M; Yahr, MD | 1 |
| Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Marsden, CD; Steiger, MJ; Thompson, PD | 1 |
| O'Connell, MT; Patsalos, PN; Quinn, NP; Tison, F | 1 |
| Huston, JP; Schwarting, RK | 1 |
| Riederer, P; Youdim, MB | 1 |
| Agid, Y; Faucheux, B; Herrero, MT; Hirsch, EC; Levy, R; Obeso, JA; Ruberg, M; Vila, M | 1 |
| Kraus, PH | 1 |
| Lengyel, J; Magyar, K; Szende, B; Tekes, K | 1 |
| Bennett, DJ; Jhamandas, JH; Patrick, SK; Prochazka, A; Roberts, T; Sears-Duru, R; Stephens, MJ | 1 |
| Barzilai, A; Melamed, E; Offen, D; Shirvan, A; Zilkha-Falb, R; Ziv, I | 1 |
| Antonini, A; Leenders, KL; Oertel, WH; Pogarell, O; Schwarz, J | 1 |
| Aguglia, U; Branca, D; Colao, R; Montesanti, R; Nicoletti, G; Quattrone, A; Zappia, M | 1 |
| Shan, DE; Yeh, SI | 1 |
| MacMahon, D | 1 |
| Lloyd, GK; Menzaghi, F; Rao, TS; Risbrough, VB; Whelan, KT | 1 |
| Lee, ST; Lu, CS | 1 |
| Fahn, S; Godbold, J; Langston, JW; Olanow, CW | 1 |
| Heinonen, E; Mäki-Ikola, O | 1 |
| Adler, CH; Chernik, DA; Dorflinger, EE; Hilaire, MS; Kurth, MC; LeWitt, P; Singer, C; Waters, C; Yoo, K | 1 |
| Araya, F; Castillo, JL; Miranda, CM; Sáez, D | 1 |
| Antonijoan, R; Avila, A; Barbanoj, M; Berthier, ML; Gironell, A; Kulisevsky, J | 1 |
| Dostert, P; Maruyama, W; Naoi, M; Narabayashi, H | 1 |
| Danielczik, S; Gerstner, A; Häcker, R; Kuhn, W; Mattern, C; Müller, T; Przuntek, H; Winkel, R | 1 |
| Kanazawa, I; Mizusawa, H; Murata, M; Yamanouchi, H | 1 |
| Kanazawa, I; Murata, M | 2 |
| Nakamura, Y | 1 |
| Takubo, H | 1 |
| Hatori, K; Kondo, T; Mizuno, Y | 1 |
| Block, G; Irr, J; Liss, C; Nibbelink, D; Reines, S | 1 |
| Ajax, T; Dobson, J; Rodnitzky, R | 1 |
| Burguera, JA; Chacón, J; Forcadell, F; Giménez-Roldán, S; Liaño, H; Tolosa, E | 1 |
| Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK | 1 |
| Fahn, S; Klatka, LA; Liu, Y; Louis, ED | 1 |
| Cannon, RO; Eisenhofer, G; Goldstein, DS; Holmes, C; Kopin, IJ | 1 |
| Hariz, M; Johansson, F; Malm, J; Nordh, E | 1 |
| Dike, GL | 1 |
| Campbell, G; Chaudhuri, KR; D'Olhaberriague, L; Jellinger, K; Litvan, I; Mangone, CA; McKee, A; Pearce, RK; Verny, M | 1 |
| Brefel, C; Celsis, P; Chollet, F; Fabre, N; Loubinoux, I; Montastruc, JL; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Cicardi, MC; Loberti, M; Peppe, A; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Stallibrass, C | 1 |
| Myllylä, VV; Sotaniemi, K; Suominen, K; Tolonen, U; Turkka, J | 1 |
| Hartvig, P; Långström, B; Tedroff, J; Torstenson, R; Westerberg, G | 1 |
| Nilsson, H | 1 |
| Lanska, DJ | 1 |
| Andersen, EB; Boesen, F | 1 |
| Boas, J; Larsen, JP | 1 |
| Cui, L; LeWitt, P; Oakes, D | 1 |
| Burleigh-Jacobs, A; Horak, FB; Nutt, JG; Obeso, JA | 1 |
| Dujovny, M; Fernandez, PM | 1 |
| Arenas, J; Benito-León, J; Campos, Y; Gasalla, T; Jiménez-Jiménez, FJ; Martín, MA; Molina, JA; Ortí-Pareja, M; Rubio, JC | 1 |
| Amyot, D; Demong, C; Duff, J; Gray, P; Murphy, D; Watson, J; Wilson, W | 1 |
| Marsden, CD; Nordera, G; Stocchi, F | 1 |
| Gachoud, JP; Gasser, U; Ghika, J | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Hodges, JR; Iddon, JL; Owen, AM; Robbins, TW; Summers, BA | 1 |
| Armstrong, RA; Blair, JA; Hodgkins, PS; Winsper, SJ | 1 |
| Bennett, JP; Currie, LJ; Harrison, MB; Trugman, JM; Wooten, GF | 2 |
| Bowers, MB | 1 |
| De Grandis, D; Lucchi, D; Quatrale, R; Santangelo, M; Strafella, AP; Tassinari, CA; Tropeani, A; Valzania, F | 1 |
| Freese, A; Stern, MB | 1 |
| Goetz, CG | 4 |
| Chase, TN; Mouradian, MM | 2 |
| Harmon, S; Haycock, J; Moffat, M; O'Malley, KL | 1 |
| Männistö, PT; Tuomainen, P | 1 |
| Katayama, K; Mochio, S; Oka, H; Sato, H | 1 |
| Kurth, MC | 1 |
| Hakulinen, P; Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Sotaniemi, KA | 1 |
| Pulst, SM; Sutton, JP | 1 |
| Calne, DB; Lee, CS; Schulzer, M; Shinotoh, H; Tsui, J; Uitti, RJ; Vingerhoets, FJ | 1 |
| Garcia, S; Gershanik, O; Gomez Arevalo, G; Jorge, R; Scipioni, O | 1 |
| Carter, JH; Lea, ES; Nutt, JG; Woodward, WR | 1 |
| Cooper, JM; Daniel, SE; Gash, MT; Gu, M; Marsden, CD; Quinn, NP; Schapira, AH; Wenning, GK | 1 |
| Bolton, CF; Kishore, A; Rajput, A; Rajput, AH; Snow, B | 1 |
| Fuchs, G | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Hildebrand, J; Laute, MA; Van Blercom, N | 1 |
| Chan, GL; Doudet, DJ; Holden, JE; Morrison, KS; Ruth, TJ; Wyatt, RJ | 1 |
| Nakajima, T | 1 |
| Kondo, T; Mizuno, Y | 1 |
| Burke, WJ; McArthur-Campbell, D; Pfeiffer, RF; Widman, LP | 1 |
| Schulzer, M | 1 |
| Playfer, JR | 1 |
| Chase, TN; Del Dotto, P; Oh, JD | 1 |
| Caraceni, T; Fetoni, V; Genitrini, S; Girotti, F; Monza, D; Soliveri, P; Testa, D | 1 |
| Esteban Muñoz, J; Marín, C; Martí, MJ; Tolosa, E | 1 |
| Hattori, Y; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Narabayashi, H; Tohgi, H; Tsukamoto, Y; Yamamoto, M; Yanagisawa, N; Yokochi, M | 1 |
| Scheidtmann, K; Schwarz, J; Trenkwalder, C | 1 |
| Fénelon, G | 2 |
| Pollak, P | 1 |
| Brefel-Courbon, C; Fabre, N; Rascol, O | 1 |
| Chiang, JH; Fuh, JL; Lee, RC; Lin, CH; Liu, HC; Wang, PN; Wang, SJ | 1 |
| Aquilonius, SM; Cheng, H; Ekblom, J; Gomes-Trolin, C; Löfberg, C; Oreland, L; Steinberg, A | 1 |
| Arai, H; Hattori, T; Shinotoh, H | 1 |
| Kimber, JR; Mathias, CJ; Watson, L | 1 |
| Fournet, N; Moreaud, O; Naegele, B; Pellat, J; Roulin, JL | 1 |
| Cabrera-Valdivia, F; Fernández-Lliria, A; Gasalla, T; Jiménez-Jiménez, FJ; Ortí-Pareja, M; Tallón-Barranco, A | 1 |
| Stern, MB | 1 |
| Watts, RL | 1 |
| Benabid, AL; Krack, P; Limousin, P; Pollak, P | 2 |
| Allain, H; Bentué-Ferrer, D | 1 |
| Hariz, MI | 1 |
| Alterman, RL; Beric, A; Eidelberg, D; Fazzini, E; Kelly, P; Perrine, K; Sterio, D | 1 |
| Dostrovsky, JO; Gross, RE; Hutchison, WD; Lang, AE; Lozano, AM; Tasker, RR | 1 |
| Martí Massó, JF | 1 |
| Chacón, J; Cordero, M; García de Yébenes, J; Giménez Roldán, S; Mateo, D; Mena, MA; Morales, B; Pastor, M; Pino, MA; Sánchez, V | 1 |
| Caraceni, T; Girotti, F; Musicco, M; Radice, D; Scigliano, G; Soliveri, P | 1 |
| Chutorian, A | 1 |
| Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P | 1 |
| Colosimo, C; Hoffman, M; Hughes, A; Leiguarda, R; Merello, M; Starkstein, S | 1 |
| Carvey, PM; Goetz, CG; Ling, ZD; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Alessandri, A; Bonifati, V; Giustini, P; Meco, G | 1 |
| Grossberg, GT; Nymeyer, L | 1 |
| Albani, C; Glattfelder, AH; Suri, RE | 2 |
| Tashiro, K | 1 |
| Hastings, TG; Zigmond, MJ | 1 |
| Aguglia, U; Colao, R; Gambardella, A; Montesanti, R; Oliveri, RL; Quattrone, A; Rizzo, M; Zappia, M | 1 |
| Grossman, RG; Jankovic, J; Krauss, JK; Lai, EC; Rettig, GM | 1 |
| Duma, CM; Jacques, DS; Kopyov, OV; Lieberman, A; Rogers, RL | 1 |
| Jenner, P; Schapira, AH; Silva, MT | 1 |
| Pfützner, W; Przybilla, B | 1 |
| Bünger, N; Jeune, B; Joensen, P; Wermuth, L | 1 |
| Chaudhuri, KR; Dawson, J; Ellis, CM; Leigh, PN; Lemmens, G; Simmons, A; Williams, SC | 1 |
| Hasegawa, K; Kowa, H | 1 |
| Hayashi, T; Ishikawa, A; Takahashi, H; Tanaka, H; Tsuji, S | 1 |
| Mizuno, Y; Yanagisawa, N | 1 |
| Grandas, F; López-Ariztegui, N | 1 |
| Castro-García, A | 1 |
| Kulisevsky, J; López-Villegas, D | 1 |
| Jiménez-Jiménez, FJ; Molina, JA | 2 |
| Antkiewicz-Michaluk, L; Krygowska-Wajs, A; Romańska, I; Szczudlik, A; Vetulani, J | 1 |
| Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Agid, Y; Destée, A; Durif, F; Montastruc, JL; Pollak, P | 1 |
| Logemann, JA | 1 |
| Bailey, P; Deptula, D; Dorflinger, E; Kurth, M; LeWitt, P; Pedder, S; Shulman, LM; Waters, CH | 2 |
| Blanchet, P; Chase, TN; Klaassen, AA; Metman, LV; Mouradian, MM; van den Munckhof, P | 1 |
| Brooks, DJ; Lees, AJ; Turjanski, N | 1 |
| Browne, TR; Durso, R; Evans, BA; Evans, JE; Handler, JS; Jennings, D; Josephs, E; Szabo, GK | 1 |
| Carter, JH; Nutt, JG; Van Houten, L; Woodward, WR | 1 |
| Byth, K; Einstein, R; Henderson, JM; Jackson, D; Morris, JG; Yiannikas, C | 1 |
| Manyam, BV; Woofter, MJ | 1 |
| DeMaggio, AJ; Havaich, MK; Juneau, PL; LeWitt, PA; Loeffler, DA | 1 |
| Block, GA; Cyhan, G; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, WR | 1 |
| Giménez-Roldán, S; Mateo, D | 1 |
| Bharucha, A; Chitrit, I; LeWitt, PA; Patil, S; Pichurko, B; Schork, MA; Takis, C | 1 |
| Bioulac, B; Boraud, T; Gross, C; Guehl, D; Julien, J; Rougier, A | 1 |
| Bedard, PJ; Cioni, M; Lemieux, R; Malouin, F; Richards, CL | 1 |
| Männistö, PT | 1 |
| Barbato, L; Marsden, CD; Monge, A; Nordera, G; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 5 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M | 1 |
| Adler, CH; Atkinson, EJ; Boylan, KB; Caviness, JN; Finton, MJ; Goerss, SJ; Graff-Radford, NR; Kall, BA; Lucas, JA; Turk, MF; Uitti, RJ; Wharen, RE | 1 |
| Alterman, RL; Antonini, A; Beric, A; Dhawan, V; Eidelberg, D; Fazzini, E; Kazumata, K; Kelly, P; Moeller, JR; Sterio, D | 1 |
| Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G | 2 |
| Bencsics, C; Kang, UJ; Wachtel, SR | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Tolosa, E; Valldeoriola, F | 1 |
| Albanese, A | 1 |
| Cambier, J | 1 |
| Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J | 1 |
| de Yébenes, JG; García-Ruiz, PJ; Sánchez-Pernaute, R | 1 |
| Birdi, S; Fenton, Me; Macaulay, R; Rajput, AH | 1 |
| Koller, WC; Lyons, K; McGuire, D; Pahwa, R; Robischon, M; Silverstein, P; Zwiebel, F | 1 |
| Bosch, DA; de Bie, RM; Schuurman, PR; Speelman, JD | 1 |
| Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N | 1 |
| Blandini, F; Desideri, S; Martignoni, E; Nappi, G; Pacchetti, C; Rivellini, D | 1 |
| Brooks, DJ; Piccini, P; Weeks, RA | 1 |
| Sakajiri, K; Takamori, M | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| De Mari, M; Federico, F; Giannini, P; Iliceto, G; Lamberti, P; Lucivero, V; Mezzapesa, DM; Simone, IL; Tarantino, A | 1 |
| Burgunder, JM; Dorflinger, E; Dupont, E; Findley, LJ; Olsson, JE | 1 |
| McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF | 1 |
| Busenbark, K; Hubble, J; Koller, WC; Lyons, K; McGuire, D; Michalek, D; Miyawaki, E; Pahwa, R; Smith, D; Tröster, AI | 1 |
| Oakes, D | 1 |
| Austin, S; Crameri, J; Hughes, AJ; Hunter, PC; Woodward, MC | 1 |
| Kumar, R; Lang, AE | 1 |
| Matsuishi, T; Shoji, H; Yamada, S; Zhou, G | 1 |
| Giaschi, D; Lang, A; Regan, D | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Pikielny, RT | 1 |
| Aarsland, D; Langeveld, JH; Larsen, JP; Waage, O | 1 |
| Berger, M; Frauenknecht, S; Hesslinger, B; Normann, C; Walden, J | 1 |
| Ringendahl, H; Sierla, T | 1 |
| Itakura, T; Nakai, K; Nakao, N | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Stanzione, P; Stefani, A; Vangelista, T | 1 |
| Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F | 1 |
| Iansek, R; Matyas, T; Morris, M; Summers, J | 1 |
| Gerritsen, JJ; Lammers, GJ; Meinders, AE; Roos, RA; van Laar, T | 1 |
| Aguilar, M; Gorospe, A; Guridi, J; Linazasoro, G; Obeso, JA; Ramos, E; Rodríguez, MC; Tolosa, E; Vela, L | 1 |
| Chase, TN | 4 |
| Fariello, RG | 1 |
| Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK | 1 |
| Blasucci, LM; Carvey, PM; Goetz, CG; Ling, ZD; Nora, MV; Pappert, EJ; Stebbins, GT | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Koudsie, A; Krack, P; Le Bas, JF; Limousin, P; Pollak, P | 1 |
| Grossman, RG; Jankovic, J; Krauss, JK; Lai, EC; Schwartz, K | 1 |
| Albani, G; Berardesca, E; Godi, L; Mancini, F; Martignoni, E; Nappi, G; Pacchetti, C; Vignoli, GP | 1 |
| Crevoisier, C; Dingemanse, J; Gasser, UE; Kleinbloesem, CH; Lankhaar, G | 1 |
| Friedman, JH; Goren, JL | 1 |
| Agid, Y; Chase, T; Marsden, D | 1 |
| Leiva, C | 1 |
| Aquilonius, SM; Hansson, LE; Johansson, K; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Bonnet, AM; Deweer, B; Dubois, B; Hahn-Barma, V; Pillon, B; Vidailhet, M | 1 |
| Dodel, RC; Eggert, KM; Eichhorn, TE; Oertel, WH; Pogarell, O; Singer, MS | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Hildebrand, J; Van Blercom, N; Wikler, D | 1 |
| Mark, MH; Murphy, J; Sage, JI; Syed, N; Zimmerman, T | 1 |
| Chase, TN; Lenz, FA; van den Munckhof, P | 1 |
| Branston, NM; Brooks, DJ; Caputo, E; Lees, AJ; Marsden, CD; Quinn, NP; Rothwell, JC; Samuel, M; Scaravilli, T; Schrag, A; Thomas, DG | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P; Xie, J | 1 |
| Brefel, C; Celsis, P; Chollet, F; Fabre, N; Montastruc, JL; Rai, S; Rascol, O; Sabatini, U; Senard, JM; Viallard, G | 1 |
| Breteler, MM | 1 |
| Abrams, KR | 1 |
| Melzi d'Eril, G; Moratti, R; Perucca, E | 1 |
| Hazlett, T; Li, RH; White, M; Williams, S | 1 |
| Arenas, J; Benito-León, J; Cisneros, E; de Bustos, F; Gasalla, T; Jiménez-Jiménez, FJ; Molina, JA; Navarro, JA; Ortí-Pareja, M; Tallón-Barranco, A | 1 |
| Chouinard, S; Fahn, S | 1 |
| De Weerdt, W; Dom, R; Lesaffre, E; Nieuwboer, A | 1 |
| Alberts, JL; Stelmach, GE; Tresilian, JR | 1 |
| Ben-Shlomo, Y; Churchyard, A; Head, J; Hurwitz, B; Lees, AJ; Ockelford, J; Overstall, P | 1 |
| Kobayashi, T; Muneta, S; Saeki, H | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G | 1 |
| Adler, CH; Kurth, MC | 1 |
| Jorga, KM | 1 |
| Dorflinger, E; Martin, W; Pedder, S; Rajput, AH; Saint-Hilaire, MH | 1 |
| Rampen, F | 1 |
| Chase, TN; Del Dotto, P; Fang, J; Mouradian, MM; van den Munckhof, P; Verhagen Metman, L | 1 |
| Blanco, M; García, S; Gershanik, OS; Gómez-Arévalo, G; Högl, BE; Rubio, M; Scipioni, O | 1 |
| Friedman, JH; Growdon, JH; Kieburtz, K; McDermott, MP; Panisset, M | 1 |
| Colzi, A; Lees, AJ; Turner, K | 1 |
| Adipietro, A; Fattapposta, F; Pierelli, F; Pozzessere, G; Scoppetta, C; Soldati, G | 1 |
| Friedman, JH; Koller, WC; Lannon, MC; LeWitt, PA; O'Brien, CF; Pahwa, R; Seeberger, LC; Smith, D; Trosch, RM | 1 |
| Adler, CH; Caselli, RJ; Caviness, JN; Muenter, MD; Newman, S | 1 |
| Barbato, L; Berardelli, A; Nordera, G; Ruggieri, S; Stocchi, F | 1 |
| Koller, WC; Wasielewski, PG | 1 |
| Grandas, F; Linazasoro, G; Martínez-Martín, P | 1 |
| Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P | 1 |
| Cheng, FC; Chia, LG; Dryhurst, G; Kuo, JS | 1 |
| Brannan, T; Martínez-Tica, J; Prikhojan, A; Yahr, MD | 1 |
| Starr, MS | 1 |
| Calne, DB; Caselli, RJ; Forno, LS; Hornykiewicz, O; Howard, FM; Kish, SJ; Maraganore, DM; Muenter, MD; Okazaki, H; Snow, BJ | 1 |
| Chang, YS; Jeon, BS; Jeong, JM; Kim, JM; Kim, KM; Lee, MC; Lee, SB; Park, SS; Song, HC; Yoon, KY | 1 |
| Koller, WC; Tolosa, E | 1 |
| Martí, MJ; Molinuevo, JL; Tolosa, E; Valldeoriola, F | 1 |
| Capildeo, R | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Martínez-Martín, P; O'Brien, CF | 1 |
| Brin, MF; Jenner, PG | 1 |
| Carter, J; Maricle, RA; Nutt, JG; Valentine, RJ | 1 |
| Carter, JH; Nutt, JG; Thulin, PC; Woodward, WR | 1 |
| Cahill, LM; Charles, BG; Murdoch, BE; Theodoros, DG; Triggs, EJ; Yao, AA | 1 |
| Brown, RG; Jahanshahi, M | 1 |
| Hayashi, R; Koyama, J; Makishita, H; Tako, K; Yanagisawa, N | 1 |
| Contreras-Vidal, JL; Poluha, P; Stelmach, GE; Teulings, HL | 1 |
| Andoh, T; Furuya, R; Hirai, A; Kudoh, I; Okumura, F | 1 |
| Huh, K; Kim, GW; Kim, JS; Sohn, YH | 1 |
| Heinonen, EH; Myllylä, V | 1 |
| Arias, M; Lema, C; Requena, I | 1 |
| Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P | 1 |
| Blasko, J; Burkhart, WA; Goiney, RC; Grimm, P; Posewitz, A; Shumway-Cook, A; Vermeulen, SS; Young, RF | 1 |
| Fernandez, HH; Friedman, JH | 2 |
| Eagle, KS; Jacques, DS; Kopyov, OV | 1 |
| Gordin, A; Karlsson, MO; Naukkarinen, TH; Rinne, UK; Ruottinen, HM; Trocóniz, IF | 1 |
| Beric, A; Devinsky, O; Dogali, M; Eidelberg, D; Fazzini, E; Kolodny, E; Perrine, K; Sterio, D | 1 |
| Coyle, J; Hobson, P; Meara, J | 1 |
| Gerstner, A; Goetz, ME; Kuhn, W; Müller, T; Winkel, R | 1 |
| Adler, CH; Deptula, D; Dorflinger, E; Hauser, RA; Lew, MF; Marek, KL; O'Brien, C; Pedder, S; Singer, C; Yoo, K | 1 |
| Hägglund, J; Heinonen, EH; Kaugesaar, T; Kontants, H; Mäki-Ikola, O; Pålhagen, S; Palm, R; Turunen, J | 1 |
| Horstink, MW; Praamstra, P | 1 |
| Amano, K; Takakura, K | 1 |
| Harper, J; Vieira, B | 1 |
| Cabaret, M; Caparros-Lefebvre, D; Godefroy, O; Petit, H; Rémy, P; Samson, Y; Steinling, M | 1 |
| Aguilar, MV; de Bustos, F; González-Muñoz, MJ; Jiménez-Jiménez, FJ; Martínez-Para, MC; Martínez-Salio, A; Mateos-Vega, CJ; Meseguer, I; Molina, JA; Ortí-Pareja, M; Zurdo, M | 1 |
| Ebinger, G; Izurieta-Sánchez, P; Michotte, Y; Sarre, S | 1 |
| Wills, AJ | 1 |
| Baas, H; Harder, S | 1 |
| Friedman, MB; Snyder, RD | 1 |
| Bassi, A; Bernardi, G; Formisano, R; Peppe, A; Piccolino, M; Pierantozzi, M; Santilli, AM; Semprini, R; Stanzione, P | 1 |
| Bourriez, JL; Defebvre, L; Derambure, P; Destee, A; Duhamel, A; Guieu, JD | 1 |
| Goetz, CG; Stebbins, GT; Tanner, CM; Vogel, C | 1 |
| Heinonen, EH; Kilkku, O; Lammintausta, R; Larsen, JP; Mäki-Ikola, O; Myllylä, VV; Olanow, CW; Pålhagen, S; Przuntek, H; Rinne, UK; Sotaniemi, KA | 1 |
| Brooks, D; Jenner, P; Olanow, CW | 1 |
| Bandmann, O; Marsden, CD; Wood, NW | 1 |
| Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, LA; Perlmutter, JS; Stambuk, MK | 1 |
| Bennett, JP; Laws, ER; Skalabrin, EJ | 1 |
| Hempel, AG; Maaty, MA; Sage, JI; Wagner, ML | 1 |
| Ardouin, C; Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P | 1 |
| Lang, AE; Lozano, AM | 1 |
| Onofrj, M; Paci, C; Thomas, A | 2 |
| Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Playfer, J; Sawle, GV; Schapira, AH; Stewart, D; Williams, AC | 1 |
| Fahn, S; Hurtig, H; Lieberman, A; Olanow, CW; Sethi, K; Swanson, P; Waters, CH; Yahr, M | 1 |
| MacKay-Lyons, M | 1 |
| Horstink, MW; Jonkman, EJ; Notermans, SL; Pasman, JW; Poortvliet, DJ; Stegeman, DF; van't Hof, MA; Zijlmans, JC | 1 |
| Assal, G; Fankhauser, H; Favre, J; Ghika, J; Ghika-Schmid, F; Villemure, JG | 1 |
| Larsen, JP; Rinne, UK; Siden, A; Worm-Petersen, J | 1 |
| Standaert, D | 1 |
| Ben-Shlomo, Y; Brown, R; Marsden, CD; Quinn, N; Schrag, A | 1 |
| Dillon, LC; Hoffman, M; Hughes, AJ; O'Sullivan, JD; Said, CM | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Papadopoulos, S; Pidoux, B; Vidailhet, M | 1 |
| Counsell, C | 1 |
| Brookshire, RH; Poluha, PC; Teulings, HL | 1 |
| Mahmood, I | 1 |
| Avraham, M; Djaldetti, R; Dressler, R; Melamed, E; Michaelov, Y; Ziv, I; Zoldan, J | 1 |
| Turk, MF; Uitti, RJ; Wharen, RE | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| García de Yébenes, J; García Ruiz, P | 1 |
| Castro García, A; Sesar Ignacio, A | 1 |
| Albanese, A; Ben-Shlomo, Y; Fowler, C; Gilman, S; Kaufmann, H; Klockgether, T; Lang, A; Lantos, P; Litvan, I; Low, P; Mathias, C; Oliver, E; Quinn, N; Robertson, D; Schatz, I; Wenning, G | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L | 1 |
| Colombo, JA; Napp, MI | 1 |
| Asamoto, S; Doi, H; Hirabayashi, K; Matsumoto, K; Nakama, H; Sugiura, K; Sugiyama, H; Tanaka, S; Yokochi, M | 1 |
| Adler, C; Crook, R; DeVrieze, FW; Farrer, M; Gwinn-Hardy, K; Hardy, J; Lincoln, S; MacElwee, K; Maraganore, D; McCarthy, P; Miller, C; Muenter, M; Newman, S; Perez-Tur, J; Waters, C | 1 |
| Aaltonen, H; Heinonen, E; Kilkku, O; Mäki-Ikola, O | 1 |
| Guay, DR | 1 |
| Damier, P; Dubois, B; Le Bras, C; Pillon, B | 1 |
| Ekesbo, A; Låengström, B; Rydin, E; Sydow, O; Tedroff, J; Torstenson, R | 1 |
| Cabrera-Valdivia, F; Gasalla, T; Jiménez-Jiménez, FJ; Ortí-Pareja, M; Tallón-Barranco, A; Zurdo, M | 1 |
| Gelb, DJ; Gilman, S; Oliver, E | 1 |
| Jankovic, J; Winikates, J | 1 |
| Bardin, PG; Battistin, L; Ferro-Milone, F; Ravenna, C; Reboldi, G; Toso, V | 1 |
| Meco, G; Raschetti, R; Spila-Alegiani, S; Vanacore, N | 1 |
| Colosimo, C; Pontieri, FE | 1 |
| Evidente, VG; Hardy, KG | 1 |
| Hughes, AJ; Lees, AJ; O'Sullivan, JD | 1 |
| Appel, SH; Jankovic, J; Le, WD; Rowe, DB; Xie, W | 1 |
| Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD | 1 |
| Bonifati, V; Meco, G | 1 |
| Conrad, B; Dichgans, J; Kraus, PH; Krauseneck, P; Pergande, G; Przuntek, H; Rinne, U; Schimrigk, K; Schnitker, J; Vogel, HP | 1 |
| Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M | 1 |
| Avraham, M; Dabby, R; Djaldetti, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Aguglia, U; Bastone, L; Bosco, D; Crescibene, L; Gambardella, A; Montesanti, R; Oliveri, RL; Plastino, M; Quattrone, A; Rizzo, M; Zappia, M | 1 |
| Buchholz, J; Iacono, RP; Kuniyoshi, S; Liu, H; Schoonenberg, T | 1 |
| Roos, RA; van Hilten, JJ | 1 |
| Foster, OJ; Kingsbury, AE; Marsden, CD | 1 |
| Agid, Y; Debilly, B; Durif, F; Vidailhet, M | 1 |
| Bédard, PJ; Hadj Tahar, A | 1 |
| Hauser, RA; Zesiewicz, TA | 1 |
| Hubble, JP | 2 |
| Bourriez, JL; Defebvre, L; Derambure, P; Destée, A; Guieu, JD | 1 |
| Broussolle, E | 2 |
| Defer, GL | 1 |
| Furlanut, M; Wu, G | 1 |
| Bryson, HM; Chrisp, P; Milne, RJ | 1 |
| Oertel, WH; Pinter, MM; Pogarell, O | 1 |
| Brown, P; Lees, AJ; Wang, HC | 1 |
| Fetoni, V; Girotti, F; Monza, D; Soliveri, P; Testa, D | 1 |
| Antonio Molina, J; Figueiras-Méndez, R; Jiménez-Jiménez, FJ; López-Pino, MA; Magariños, C; Marín-Zarza, F; Martínez, V; Ortí-Pareja, M | 1 |
| Diószeghy, P; Hidasi, E; Mechler, F | 1 |
| Colosimo, C; De Michele, M | 1 |
| Agid, Y; Debré, P; Dugas, B; Dugas, N; Faucheux, B; Hartmann, A; Hirsch, EC; Hunot, S; Tardieu, M | 1 |
| Ballinger, JR; Erami, SS; Ichise, M; Kim, YJ; Lang, AE; Tanaka, F; Vines, D | 1 |
| Bermejo Pareja, F; Fernández Ponsatí, JT; García-Escrig, M | 1 |
| Bennett, JP; Piercey, MF | 1 |
| Albanese, A; Ben-Shlomo, Y; Fowler, CJ; Gilman, S; Kaufmann, H; Klockgether, T; Lang, AE; Lantos, PL; Litvan, I; Low, PA; Mathias, CJ; Oliver, E; Quinn, N; Robertson, D; Schatz, I; Wenning, GK | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Pidoux, B; Samson, Y; Thivard, L | 1 |
| Boronat, A; Herreros, R; Serrat, I | 1 |
| Alcaraz-Zubeldia, M; Boll, MC; Otero, E; Rios, C; Sotelo, J | 1 |
| Anderson, JM; Crucian, GP; Heilman, KM; Hughes, JD; Rothi, LJ | 1 |
| Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL | 1 |
| Jansen, EN | 2 |
| Djaldetti, R; Melamed, E; Merims, D; Ziv, I | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Mosberg-Galili, R; Sroka, H | 1 |
| Castronuovo, J; Feigin, A; Innis, RB; Marek, KL; Seibyl, JP; Sheff, K; Zoghbi, S | 1 |
| Hagell, P; Widner, H | 1 |
| Fernandez, HH; Friedman, JH; Jacques, C; Rosenfeld, M | 1 |
| Klockgether, T; Löschmann, PA; Spieker, S | 1 |
| Caparros-Lefebvre, D; Lannuzel, A; Strobel, M; Tiberghien, F | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Djaldetti, R; Salman, H | 2 |
| Brophy, BP; Kimber, TE; Semmler, J; Thompson, PD; Tsai, CS | 1 |
| Benabid, AL; Benazzouz, A; Deuschl, G; Krack, P; Limousin, P; Pollak, P | 1 |
| Evidente, VG; Gwinn-Hardy, K; Hardy, J; Muenter, MD; Waters, C | 1 |
| Bornkessel, B | 1 |
| Breit, S; Dichgans, J; Klockgether, T; Spieker, S | 1 |
| Djaldetti, R; Galili-Mosberg, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Galiano, ML; Grandas, F | 1 |
| Iansek, R; Morris, ME; Urquhart, DM | 1 |
| Hagenah, J; Klein, C; Sieberer, M; Vieregge, P | 1 |
| Björklund, A; Dunnett, SB | 1 |
| Kobayashi, S; Oguro, H; Okada, K; Suyama, N; Yamaguchi, S | 1 |
| Fowler, B; Kuhn, W; Müller, T; Werne, B | 1 |
| Holme, E; Melberg, A; Moslemi, AR; Oldfors, A | 1 |
| Arnold, LA; Blanchet, PJ; Chase, TN; Fang, J; Hyland, K; Mouradian, MM | 1 |
| Simuni, T; Stern, MB | 1 |
| Tedroff, JM | 1 |
| Ingvarsson, PE; Johnels, B; Olsson, T; Steg, G | 2 |
| Brefel-Courbon, C; Descombes, S; Montastruc, JL; Rascol, O | 1 |
| Damier, P | 1 |
| Agid, Y; Bédard, MA; Dubois, B; Duchesne, N; Masson, H; Pillon, B | 1 |
| Behari, M; Denny, AP | 1 |
| Moerlein, SM; Perlmutter, JS | 1 |
| Brunt, ER; Korczyn, AD; Larsen, JP; Nagy, Z; Poewe, WH; Ruggieri, S | 1 |
| Kempster, PA; Reardon, KA; Shiff, M | 1 |
| Brown, DF | 1 |
| Hanson, DG; Jiang, J; Lin, E; Wang, J | 1 |
| Aguglia, U; Bosco, D; Branca, D; Gambardella, A; Nicoletti, G; Oliveri, RL; Plastino, M; Quattrone, A; Zappia, M | 1 |
| Benabid, AL; Blond, S; Caparros-Lefebvre, D; Feltin, MP; Pollak, P | 1 |
| Anezaki, T; Awamori, K; Takahashi, H; Toyoshima, Y; Tsuji, S; Wakabayashi, K; Yoshimoto, M | 1 |
| King, DB | 1 |
| Barclay, CL; Rivest, J; Suchowersky, O | 1 |
| Grimes, DA; Lang, AE | 1 |
| Conley, SC; Kirchner, JT | 1 |
| Bland, J; Chaudhuri, KR; Clough, C; Ellis, CM; Hu, MT | 1 |
| Blandini, F; Desideri, S; Godi, L; Mancini, F; Martignoni, E; Nappi, G; Pacchetti, C | 1 |
| Barcenilla, B; Berbel, A; de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Molina, JA; Villanueva, C; Zurdo, M | 1 |
| Bonnefoi, F; Broussolle, E; Comar, D; Croisile, B; Dentresangle, C; Froment, JC; Galy, G; Garcia-Larrea, L; Hibert, O; Landais, P; Pollak, P | 1 |
| Ellis, CM; Ray Chaudhuri, K; Reuter, I | 1 |
| Arnold, G; Kupsch, A | 1 |
| Phillips, P | 1 |
| Agid, Y; Bonnet, AM; Durif, F; Marconi, R; Vidailhet, M | 1 |
| Defer, GL; Widner, H | 1 |
| Nutt, J | 1 |
| Amenta, F; Barbanti, P; Bronzetti, E; Calderaro, C; Caronti, B; Cerbo, R; Fabbrini, G; Felici, L; Lenzi, GL; Meco, G; Ricci, A; Stocchi, F | 1 |
| Capilldeo, R; Hutton, JT; Koller, WC; Tolosa, E | 1 |
| Giduz, T; Pact, V | 1 |
| Ben-Arie, L; Grossman, R; Jankovic, J; Krauss, JK; Lai, E | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Dizdar, N; Granérus, AK; Hannestad, U; Kågedal, B; Kullman, A; Ljungdahl, A; Olsson, JE | 1 |
| Brandabur, MM | 1 |
| Neef, C; van Laar, T | 1 |
| Blandini, F; di Jeso, F; Martignoni, E; Nappi, G; Ricotti, R | 1 |
| Gokden, MS; Perlmutter, JS; Racette, BA; Tychsen, LS | 1 |
| Cumming, P; Gjedde, A; Hermansen, F | 1 |
| Benabid, AL; Gentil, M; Pollak, P; Tournier, CL | 1 |
| Burnett, CA; Clifford, TJ; Lamey, PJ; Warsi, MJ | 1 |
| Aguglia, U; Andreoli, V; Annesi, G; Branca, D; Cittadella, R; Civitelli, D; Gambardella, A; Montesanti, R; Nicoletti, G; Oliveri, RL; Pasqua, AA; Quattrone, A; Spadafora, P; Zappia, M | 1 |
| Battistini, N; Ghiglieri, O; Pasqualetti, P; Passero, S; Rossi, S; Rossini, PM; Ulivelli, M | 1 |
| Sourkes, TL | 2 |
| Andringa, G; Cools, AR; Stoof, JC | 1 |
| Alexander, GM; Azizi, SA; Prockop, DJ; Schwarz, EJ | 1 |
| Baraldo, M; Furlanut, M; Wu, G | 1 |
| Gershanik, O; Murer, MG; Raisman-Vozari, R | 1 |
| Scheife, RT | 2 |
| Gottwald, MD | 1 |
| Luer, MS | 1 |
| Chuda, M; Hayabara, T; Ihara, Y; Kuroda, S | 1 |
| Gwinn-Hardy, K; Hardy, J | 1 |
| Beute, GN; Bosch, DA; de Bie, RM; de Haan, RJ; Haaxma, R; Nijssen, PC; Rutgers, AW; Schmand, B; Schuurman, PR; Speelman, JD; Staal, MJ | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Bosch, A; Figueras, A; Pedrós, C; Sabaté, M | 1 |
| Agid, Y; Ahlskog, E; Albanese, A; Calne, D; Chase, T; De Yebenes, J; Factor, S; Fahn, S; Gershanik, O; Goetz, C; Koller, W; Kurth, M; Lang, A; Lees, A; Lewitt, P; Marsden, D; Melamed, E; Michel, PP; Mizuno, Y; Obeso, J; Oertel, W; Olanow, W; Poewe, W; Pollak, P; Tolosa, E | 1 |
| Ahlskog, JE; Burnett, OL; Maraganore, DM; Matsumoto, JY; O'Connor, MK; Stark, KF; Turk, MF; Uitti, RJ | 1 |
| Factor, SA; Molho, ES | 1 |
| Brousolle, E; Dentresangle, C; Froment, JC; Guerin, J; Lavenne, F; Le Bars, D; Pierre, C; Pollak, P; Veyre, L | 1 |
| Anderson, VC; Burchiel, KJ; Favre, J; Hammerstad, JP | 1 |
| Calne, DB; Dobko, T; Mak, E; Markopoulou, K; Samii, A; Sossi, V; Stoessl, AJ; Wszolek, ZK | 1 |
| Archer, T; Fredriksson, A; Palomo, T | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 2 |
| Byrne, P; Detta, A; Hitchcock, E; Kudoh, C; Meyer, C | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Choi, C; Kim, J; Lee, JH; Sohn, YH | 1 |
| Hashimoto, S; Inoue, T; Iwata, M; Sawada, T; Yamamoto, K | 1 |
| Cannizzaro, C; Dass, B; Jenner, P; Owen, A; Rose, S; Tel, BC; Zeng, BY | 1 |
| Chase, TN; Konitsiotis, S; Metman, LV | 1 |
| Finken, MJ; Ramaker, C; van de Beek, WJ; van Hilten, BJ | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 2 |
| Chaná, P; Miranda, M | 1 |
| Apaydin, H; Ertan, S; Ozekmekçi, S | 1 |
| Canavero, S; Paolotti, R | 1 |
| Carter, JH; Nutt, JG | 1 |
| Azulay, JP; Blin, O; Darmon, A; Pouget, J | 1 |
| Amblard, B; Azulay, JP; Mesure, S; Pouget, J | 1 |
| Berchou, RC | 1 |
| Asselman, P; Brown, P; Buckwell, D; Lees, AJ; Manson, AJ; O'Sullivan, JD | 1 |
| Andrews, TC; Brooks, DJ; Chaudhuri, KR; Clough, C; Hu, MT; Reuter, I | 1 |
| Benchetrit, G; Linard, JP; Pollak, P; Vercueil, L; Wuyam, B | 1 |
| Bernardi, G; Federici, M; Mercuri, NB | 1 |
| Galiano, ML; Grandas, F; Tabernero, C | 1 |
| Gorospe, A; Guridi, J; Linazasoro, G; Obeso, JA; Ramos, E; Rodríguez, MC | 1 |
| Guridi, J; Linazasoro, G; Obeso, JA; Ramos, E; Rodriguez-Oroz, MC | 1 |
| Agid, Y; Bejjani, BP; Damier, P; Demeret, S; Gaymard, B; Pierrot-Deseilligny, C; Ploner, CJ; Rivaud-Péchoux, S; Vermersch, AI | 1 |
| Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Polkey, CE; Robbins, TW; Rogers, RD; Sahakian, BJ; Summers, BA; Swainson, R | 1 |
| Alegret, M; Junqué, C; Nobbe, FA; Rumià, J; Tolosa, E; Valldeoriola, F; Vendrell, P | 1 |
| Kuhn, DM | 1 |
| Aitchison, KJ; Arranz, MJ; Forsyth, J; Graham, JM; Grünewald, RA; Li, T; Makoff, AJ; Shaikh, S | 1 |
| Damier, P; Féger, J; Hirsch, EC; Tremblay, L | 1 |
| Farde, L; Halldin, C; Hietala, J; Kaasinen, V; Någren, K; Oikonen, V; Rinne, JO; Vilkman, H | 1 |
| Iakovidou, E; Lees, AJ; Manson, AJ | 1 |
| Chin, S; Dhawan, V; Eidelberg, D; Fahn, S; Frucht, S | 1 |
| Montastruc, JL | 1 |
| Kumar, R; Lang, AE; Lozano, AM; Saint-Cyr, JA; Trépanier, LL | 1 |
| Ferrer, E; Molinuevo, JL; Nobbe, FA; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Philippon, J; Pidoux, B; Yelnik, J | 1 |
| Sealfon, SC | 1 |
| DeLong, MR; Obeso, JA; Olanow, CW; Rodriguez, M; Rodriguez-Oroz, MC | 1 |
| Gerfen, CR | 1 |
| Filion, M | 1 |
| Canales, JJ; Graybiel, AM | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Giacomini, P | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
| Hirsch, EC | 1 |
| Brooks, DJ; Piccini, P; Samuel, M; Turjanski, N | 1 |
| Benabid, AL; Benazzouz, A; Koudsie, A; Krack, P; Limousin, P; Piallat, B; Pollak, P | 1 |
| Iacono, RP; Nahab, FB; Nahab, FH | 1 |
| Brooks, DJ; Gordin, A; Karlsson, M; Korpela, K; Pavese, N; Piccini, P | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Demeret, S; Gervais, D; Papadopoulos, S | 1 |
| Agid, Y; Arnulf, I; Bejjani, PB; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Houeto, JL; Pidoux, B; Staedler, C | 1 |
| Di Perri, R; Di Rosa, AE; Epifanio, A; Grigoletto, F; Meneghini, F; Morgante, L; Patti, F; Ragonese, P; Reggio, A; Salemi, G; Savettieri, G | 1 |
| Shill, H; Stacy, M | 1 |
| Cáceres, M; Costello, G; Herrera, EJ; Suárez, JC; Suárez, M; Viano, JC | 1 |
| Clarke C, E; Speller J, M | 2 |
| Finken, MJ; Ramaker, C; Van de Beek, WJ; van Hilten, JJ | 1 |
| Clarke, CE; Speller, JM | 2 |
| Chai, SY; Horne, MK; Mendelsohn, FA; Reardon, KA | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Damier, P; Demeret, S; Houeto, JL | 1 |
| Calne, DB; de la Fuente-Fernández, R; Kishore, A; Mak, EK; Pal, PK; Ruth, TJ; Schulzer, M; Snow, BJ; Stoessl, AJ; Vingerhoets, FJ | 1 |
| Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P | 1 |
| Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA | 2 |
| Kuhn, W; Müller, T; Peters, S; Przuntek, H; Schulz, D; Woitalla, D | 1 |
| Capildeo, R; Hutton, JT; Morris, JL; Tolosa, ES | 1 |
| Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O | 1 |
| Bosco, D; Branca, D; Caracciolo, M; Gambardella, A; Napoli, ID; Nicoletti, G; Oliveri, RL; Quattrone, A; Zappia, M | 1 |
| Blasucci, LM; Goetz, CG; Stebbins, GT | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Chernik, D; Dorflinger, E; Waters, C; Welsh, MD | 1 |
| Bressman, SB; Ford, B; Greene, PE; Hyland, K | 1 |
| Kawasoe, T; Miyata, S; Ochiai, H; Yamakawa, Y | 1 |
| Chen, RC; Tai, CH; Wu, RM | 1 |
| Le, MT; Lévesque, MF; Rogers, R; Swope, D; Taylor, S | 1 |
| Hamilton, JL; Lehman, RM; Micheli-Tzanakou, E; Zheng, J | 1 |
| Brooks, DJ; Forsyth, D; Playfer, JR; Williams, AC | 1 |
| Delogu, MR; Desole, MS; Enrico, P; Esposito, G; Grella, G; Miele, E; Miele, M; Migheli, R; Mura, MA; Serra, PA | 1 |
| Björklund, A; Brooks, DJ; Brundin, P; Crabb, L; Gustavii, B; Hagell, P; Kupsch, A; Lindvall, O; Marsden, CD; Odin, P; Oertel, WH; Piccini, P; Pogarell, O; Quinn, NP; Rehncrona, S; Schrag, A; Widner, H | 1 |
| Dawson, TM; Marsh, L | 1 |
| Kondo, M; Makino, M; Nakajima, K; Ueda, Y | 1 |
| Bisulli, A; Nassetti, SA; Santangelo, M; Strafella, AP; Tassinari, CA; Tropeani, A; Valzania, F | 1 |
| Schiess, MC; Van Horn, G | 1 |
| Ferrer, E; Molinuevo, JL; Roldan, H; Rumia, J; Tolosa, E; Valldeoriola, F; Valls-Sole, J | 1 |
| Brooks, D; Macmahon, D; Smith, R | 1 |
| Myllylä, V | 1 |
| Batchelor, PE; Donnan, GA; Howells, DW; Hughes, AJ; Kalnins, R; Porritt, MJ | 1 |
| Allain, H; Bentué-Ferrer, D; Destée, A; Le Cavorzin, P; Patay, M; Petit, H; Schück, S | 1 |
| Giladi, N; Melamed, E | 1 |
| Sit, SY | 1 |
| Becker, G; Berg, D; Reiners, K | 1 |
| Clarke, CE; Deane, KH | 5 |
| Clarke C, E; Clarke J, A; Speller J, M | 1 |
| Ramaker, C; van Hilten, JJ | 1 |
| Brefel-Courbon, C | 1 |
| Rosenblatt, BK; Schneider, DC; Siple, JF; Wanlass, WA | 1 |
| Foster, OJ; Kingsbury, AE; Tong, ZY | 1 |
| Mark, LP; Mueller, WR; Prieto, TE; Reynolds, NC; Terry, LC | 1 |
| Barbanoj, M; Berthier, ML; Estévez-González, A; García-Sánchez, C; Gironell, A; Kulisevsky, J; Pascual-Sedano, B | 1 |
| Anderson, WM; Gauger, L; Hauser, RA; Zesiewicz, TA | 1 |
| Busek, P; Jech, R; Roth, J; Růzicka, E | 1 |
| Mohan, PK; Mohanakumar, KP; Nagashayana, N; Nampoothiri, MR; Sankarankutty, P | 1 |
| Agid, Y; Ardouin, C; Benabid, AL; Bonnet, AM; Damier, P; Houeto, JL; Klinger, H; Krack, P; Pillon, B; Pollak, P | 1 |
| Burns, JB; Connolly, CI; Jog, MS | 1 |
| Asanuma, M; Ogawa, N; Tanaka, K | 1 |
| Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ | 1 |
| Kuritzky, A; Melamed, E; Merims, D; Ziv, I; Zoldan, J | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D | 1 |
| Fotteler, B; Jorga, KM; Modi, M; Rabbia, M | 1 |
| Ferreira, JJ; Rascol, O | 1 |
| Bruce, S; Cannon, RO; Goldstein, DS; Holmes, C; Li, ST; Metman, LV | 1 |
| Lessell, S | 1 |
| Melamed, E; Offen, D; Shirvan, A; Ziv, I | 1 |
| Cassel, W; Krüger, HP; Möller, JC; Oertel, WH; Peter, JH; Stiasny, K | 1 |
| Earnhart, M; Hiner, BC | 1 |
| Frucht, S | 1 |
| Yamamoto, T | 1 |
| Maruyama, W; Naoi, M; Strolin-Benedetti, M | 1 |
| Karlsen, K; Larsen, JP; Tandberg, E | 1 |
| Lea, ES; Nutt, JG; Schuff, RA; Sexton, GJ; Van Houten, L | 1 |
| Baas, H; Engelhardt, M; Harder, S; Reuter, I | 1 |
| Bermejo, F; Fraile, A; Jiménez-Jiménez, FJ; Molina, JA; Ortí-Pareja, M; Sáinz-Artiga, MJ; Villanueva, C | 1 |
| Bösch, S; Luginger, E; Poewe, W; Wenning, GK | 1 |
| Kimber, TE; Thompson, PD | 1 |
| Galili-Mosberg, R; Melamed, E; Merims, D | 1 |
| Bhatia, KP; Münchau, A | 1 |
| Barbarino-Monnier, P; Denis, E; Lurel, S; Routiot, T | 1 |
| Aguiar, PM; Andrade, LA; Ferraz, FP; Ferraz, HB; Hisatugo, MK; Saba, RA | 1 |
| Prabhakar, S; Srivastava, T; Syal, P | 1 |
| Fung, VS; Hely, MA; Morris, JG | 1 |
| Andren, PE; Gunne, L; Svenningsson, P | 1 |
| Calmes, J; Hendersen, N; Jankovic, J; Olson, S; Ondo, W; Overby, A; Warrior, D | 1 |
| Sacks, O | 1 |
| Clarke, CE; Davies, P | 1 |
| Tanner, CM | 1 |
| DeLong, M | 1 |
| Hristova, AH; Koller, WC | 1 |
| Bogaerts, K; De Weerdt, W; Dom, R; Nieuwboer, A; Nuyens, G | 1 |
| Quinn, N; Schrag, A | 1 |
| Cersósimo, MG; Micheli, FE; Scorticati, MC | 1 |
| Nutt, JG; Obeso, JA; Olanow, CW | 1 |
| Artieda, J; Gonzalo, N; Lanciego, JL; Obeso, JA; Olanow, CW; Rodríguez, M; Rodríguez-Oroz, MC | 1 |
| Bernardi, G; Calabresi, P; Centonze, D | 1 |
| Nutt, JG; Obeso, JA; Stocchi, F | 1 |
| Olanow, W; Rascol, O; Schapira, AH | 1 |
| Frank, JS; Horak, FB; Nutt, J | 1 |
| Kanazawa, I; Momose, Y; Murata, M | 1 |
| Hasegawa, K | 1 |
| Saiki, H; Takeuchi, J; Yamagami, T | 1 |
| Katayama, Y | 1 |
| Itakura, T; Nakao, N; Uematsu, Y | 1 |
| Yokochi, F | 2 |
| Date, I; Ohmoto, T; Tomita, S | 1 |
| Namba, H; Sugiyama, K; Yokoyama, T | 1 |
| Fujimoto, K; Nakano, I | 1 |
| Bergman, J; Eskola, O; Hinkka, SM; Nurmi, E; Rinne, JO; Solin, O; Sonninen, P | 1 |
| Black, KJ; Carl, JL; Hershey, T; Perlmutter, JS | 1 |
| Hagell, P | 1 |
| Crevits, L; De Ridder, K; Hanse, M; Versijpt, J | 1 |
| Balakrishnan, S; Joseph, S; Kishore, A; Panikar, D; Sarma, S | 1 |
| Benz, S; Müller, T; Przuntek, H | 2 |
| Gielen, CC; Hoff, JI; Horstink, MW; Keijsers, NL; van Hilten, JJ | 1 |
| Dromey, C; Kumar, R; Lang, AE; Lozano, AM | 1 |
| Benabid, AL; Fraix, V; Koudsie, A; Krack, P; Pollak, P; Van Blercom, N; Xie, J | 2 |
| Jenner, P; McNaught, KS | 1 |
| Lachenmayer, L; Reichmann, H | 1 |
| Bares, M; Hejduková, B; Hortová, H; Jech, R; Kanovský, P; Mecír, P; Rektor, I; Rektorová, I; Roth, J; Růzicka, E; Streitová, H | 1 |
| Hebenstreit, E; Pinter, MM; Rutgers, AW | 1 |
| Chana, P; Lera, G; Obeso, JA; Olanow, CW; Rodriguez, M; Rodriguez-Oroz, MC | 1 |
| Dingemanse, J | 1 |
| Haapaniemi, TH; Kallio, MA; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Brown, P; Di Lazzaro, V; Insola, A; Mazzone, P; Oliviero, A; Tonali, P | 1 |
| Brattström, L | 1 |
| Bennett, G; Walsh, K | 1 |
| Lee, MS; Lyoo, CH; Rinne, JO; Syvänen, AC; Ulmanen, I | 1 |
| Bergman, J; Eronen, E; Eskola, O; Niinivirta, M; Oikonen, V; Rinne, UK; Ruottinen, HM; Solin, O; Sonninen, P | 1 |
| Arnulf, I; Herer, B; Housset, B | 1 |
| Blin, O; Carter, JH; Currie, LJ; Fabre, N; Giardina, WW; Goetz, CG; Nutt, JG; Rascol, O; Soubrouillard, C; Thalamas, C; Trugman, JM; Wright, S | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Golubev, VL; Sadekov, RA; Vendrova, MI | 1 |
| Baas, H | 1 |
| Cooper, SD; Frank, C; Ismail, HA | 1 |
| Hoff, JI; van den Plas, AA; van Hilten, JJ; Wagemans, EA | 1 |
| Alvarez, E; Alvarez, L; DeLong, MR; Guridi, J; Hetherington, H; Juncos, J; Lopez, G; Macias, R; Maragoto, C; Obeso, JA; Ochoa, L; Pavon, N; Rodriguez-Oroz, MC; Teijeiro, J; Torres, A | 1 |
| Arenas, J; Barcenilla, B; Berbel, A; Camacho, A; De Bustos, F; Gómez, P; Gómez-Escalonilla, C; Jiménez-Jiménez, FJ; Molina, JA; Vargas, C; Zurdo, M | 1 |
| Boecker, H; Ceballos-Baumann, AO; Conrad, B; Erhard, P; Haslinger, B; Kämpfe, N; Rummeny, E; Schwaiger, M | 1 |
| Allert, N; Freund, HJ; Sturm, V; Voges, J; Volkmann, J; Weiss, PH | 1 |
| Bergamasco, B; Lanotte, M; Lopiano, L; Perozzo, P; Rizzone, M; Tavella, A; Torre, E; Valentini, MC | 1 |
| Helmuth, L | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Glosser, G; Grossman, M; Hurtig, HI; Kalmanson, J; Morris, J; Stern, MB | 1 |
| Bourdeix, I; Delumeau, JC; Devaux, I; Durif, F; Pere, JJ | 1 |
| Chao, LY; Lee, SJ; Shan, DE; Yeh, SI | 1 |
| Corcos, DM; Marsden, CD; McAuley, JH; Quinn, NP; Rothwell, JC | 1 |
| de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Frey, KA | 1 |
| Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S | 1 |
| Brüne, M; Gerlach, G; Schröder, SG | 1 |
| Masson, C | 2 |
| Hummel, T; Kuhn, W; Müller, T; Woitalla, D | 1 |
| Brown, P; Cassidy, M | 1 |
| Fukaya, C; Kasai, M; Katayama, Y; Oshima, H; Yamamoto, T | 1 |
| Clarke, CE; Deane, KD | 1 |
| Defebvre, L; Kemoun, G | 2 |
| Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M | 1 |
| Ashby, P; Dostrovsky, JO; Levy, R; Tasker, RR; Wu, YR | 1 |
| Bergenheim, AT; Hariz, MI | 1 |
| Deleu, D; Hanssens, Y; Northway, MG | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Barreto, SR; Barreto, WJ; deOliveira, LF; Mangrich, AS; Paschoal, FM; Santos, MA; Schimid, R | 1 |
| White, FJ | 1 |
| Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H | 1 |
| Agid, Y; Arnulf, I; Bareille, MP; Bonnet, AM; Descombes, S; Dingemanse, J; Gasser, UE; Rascol, O; Thalamas, C | 1 |
| Gálvez-Jiménez, N; Hanson, MR | 1 |
| Ebbitt, B; Tuite, P | 1 |
| Chew, EL; Ong, KC; Ong, YY | 1 |
| Blandini, F; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Samuele, A | 1 |
| Tan, AK | 1 |
| Garcia-Rill, E; Rasco, L; Skinner, RD; Teo, C | 1 |
| Hagell, P; Lindvall, O | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Ahlskog, JE; Muenter, MD | 3 |
| Barrett, R; Bennett, JP; Calabrese, VP; Calne, DB; Chase, TN; Hutton, JT; Juncos, JL; Koller, WC; LeWitt, PA; Metman, LV; Morris, JL; Pahwa, R; Samii, A; Tsui, JK; Waters, CH | 1 |
| Brefel-Courbon, C; Desboeuf, K; Lapeyre-Mestre, M; Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Bernardini, S; Bonuccelli, U; Chase, TN; Del Dotto, P; Gambaccini, G; Metman, LV; Pavese, N | 1 |
| Fahn, S; Ford, B; Louis, ED; Winfield, L | 1 |
| Benetello, P; Furlanut , M; Furlanut, M | 1 |
| Guttman, M; Houle, S; Hussey, D; Kish, S; Stewart, D; Wilson, A | 1 |
| Waters, CH | 2 |
| Danysz, W | 1 |
| Baas, H; Harder, S; Kohnen, R; Loetsch, J; Selzer, R; Zehrden, F | 1 |
| Möller, JC; Oertel, WH; Wächter, T | 1 |
| Ichikawa, K; Kojima, M | 1 |
| Castro-Caldas, A; Ferreira, JJ; Montastruc, JL; Rascol, O; Thalamas, C | 1 |
| Le Pen, C; Lilliu, H; Maurel, F | 1 |
| Chen, B; Liu, ZL; Wang, J | 1 |
| Fowler, B; Hauptmann, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
| Deuschl, G; Hamel, W; Herzog, J; Klebe, S; Krack, P; Lorenz, D; Mehdorn, HM; Poepping, M; Raethjen, J; Schrader, B; Stolze, H; Wenzelburger, R | 1 |
| Baas, H; Dietz, M; Graff, J; Harder, S; Künig, G; Leenders, KL; Vontobel, P | 1 |
| Abe, T; Takahashi, S; Tohgi, H; Utsugisawa, K | 1 |
| Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A | 1 |
| Bergamasco, B; Lanotte, M; Lopiano, L; Melcarne, A; Perozzo, P; Rizzone, M; Tavella, A; Torre, A | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Berger, W; Faist, M; Kurz, D; Lücking, CH; Maurer, C; Pollak, P; Xie, J | 1 |
| Díaz, V; Miranda, M; Venegas, P; Villagra, R | 1 |
| Ball, J | 1 |
| Milanov, I | 1 |
| Bressanelli, M; Broggi, G; Carella, F; Geminiani, G; Genitrini, S; Girotti, F; Piacentini, S; Servello, D; Soliveri, P | 1 |
| Agid, Y; Arnulf, I; Bejjani, B; Bonnet, AM; Brefel-Courbon, C; Descombes, S; Fabre, N; Montastruc, JL; Peyro-Saint Paul, H; Rascol, O; Thalamas, C; Vidailhet, M | 1 |
| Factor, SA; Lava, NS | 1 |
| Bezard, E; Brotchie, JM; Gross, CE | 1 |
| Carpinelli, A; Comi, G; Fazio, F; Gobbo, C; Messa, C; Moresco, RM; Rizzo, G; Volonté, MA | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Bergamasco, B; Lanotte, M; Lopiano, L; Perozzo, P; Rizzone, M; Tavella, A; Torre, E | 2 |
| Ammannati, F; Marini, P; Mennonna, P; Scotto di Luzio, AE; Sorbi, S | 1 |
| Fedele, E; Frasca, S; Galante, A; Giacomini, P; Lunardi, G; Marciani, MG; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P | 1 |
| Barbato, L; De Pandis, MF; Ruggieri, S; Stocchi, F; Vacca, L; Valente, M | 1 |
| Haapaniemi, H; Kultalahti, ER; Leinonen, M; Myllylä, VV | 1 |
| Alexander, GM; Azizi, SA; Class, R; Prockop, DJ; Reger, RL; Schwarz, EJ | 1 |
| Bosch, DA; de Bie, RM; de Haan, RJ; Schmand, B; Schuurman, PR; Speelman, JD | 1 |
| Miyoshi, K | 1 |
| Peschanski, M | 1 |
| Benabou, R; Cubo, E; Goetz, CG; Gracies, JM; Leurgans, S; Olanow, CW; Raman, R | 1 |
| Bamias, C; Hardy, P; Pocock, S; Warner, J; White, IR | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Côte, LJ; Fahn, S; Levy, G; Louis, ED; Marder, K; Mejia, H | 1 |
| Hashimoto, T; Hayashi, R; Ikeda, S; Tada, T | 1 |
| Horiuchi, M; Komo, T; Sugihara, H; Takahashi, Y; Uehara, K | 1 |
| Bullard, J; Dewey, RB; O'Suilleabhain, P | 1 |
| Etminan, M; Rochon, PA; Samii, A; Takkouche, B | 1 |
| Benz, S; Börnke, C; Müller, T | 1 |
| Borri-Voltattorni, C; Burkhard, P; Dominici, P; Jansonius, JN; Malashkevich, VN | 1 |
| Julow, J; Sági, S; Solymosi, D; Valálik, I | 1 |
| Couzin, J | 1 |
| Bieganski, RM; Conway, KA; Lansbury, PT; Rochet, JC | 1 |
| Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ | 1 |
| Fedele, E; Galante, A; Giacomini, P; Lunardi, G; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P | 1 |
| Kleinow, J; Ramig, LO; Smith, A | 1 |
| Allen, FH; Booze, MW; Colcher, A; Gibson, RA; Goetz, CG; Haines, JL; Hiner, BC; Hubble, JP; Jankovic, J; Koller, WC; Laing, NG; Lyons, K; Mastaglia, F; Masterman, D; Middleton, LT; Nance, MA; Ondo, WG; Pahwa, R; Pericak-Vance, MA; Rampersaud, E; Ribble, RC; Roses, AD; Scott, BL; Scott, WK; Slotterbeck, B; Small, GW; Stajich, JM; Stern, MB; Vance, JM; Watts, RL; West, SG | 1 |
| Altibrandi, MG; Brusa, L; Giacomini, P; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P | 1 |
| Becker, G; Berg, D; Naumann, M; Reiners, K | 1 |
| Anderson, VC; Burchiel, KJ; Carter, JH; Hammerstad, JP; Nutt, JG; Pahwa, R; Rufener, SL | 1 |
| Goetz, CG; Leurgans, S; Pappert, EJ; Raman, R; Stemer, AB | 1 |
| Dhawan, V; Eidelberg, D; Feigin, A; Fukuda, M; Jackson-Lewis, V; Mentis, MJ; Moeller, JR; Przedborski, S | 1 |
| Brotchie, JM; Crossman, AR; Dick, JP; Fox, SH; Hill, M; Sieradzan, KA | 1 |
| Ohye, C | 1 |
| Doder, M; Hely, M; Koller, W; Lees, A | 1 |
| Frucht, SJ; Gordon, PH | 1 |
| Berding, G; Brooks, DJ; Dengler, R; Fricke, H; Knapp, WH; Kolbe, H; Matthies, C; Nikkhah, G; Odin, P; Peschel, T; Samii, M; Shing, M; van Den Hoff, J | 1 |
| Badarna, S; Front, A; Giladi, N; Hardoff, R; Honigman, S; Soil, A; Sula, M; Tamir, A | 1 |
| Apartis, E; Arné, P; Jedynak, CP; Tison, F; Vidailhet, M | 1 |
| Schrag, A; Trimble, M | 1 |
| Hillman, R; Parvez, F; Pendleton, RG; Sayed, M | 1 |
| Horiuchi, E; Kanazawa, I; Murata, M | 1 |
| Blatt, JL; Blond, S; Bourriez, JL; Defebvre, L; Destée, A; Duhamel, A; Guieu, JD; Kemoun, G; Krystkowiak, P; Perina, M | 1 |
| Bischoff, A | 1 |
| Hattori, T; Sakakibara, R; Uchiyama, T; Yoshiyama, M | 1 |
| Kobinger, W | 1 |
| Müngersdorf, M; Reichmann, H; Sommer, M; Sommer, U | 1 |
| Inoue, K; Mochio, S; Oka, H | 1 |
| Gallena, S; Ludlow, CL; Smith, PJ; Zeffiro, T | 1 |
| Fukaya, C; Kasai, M; Katayama, Y; Mizutani, T; Ogawa, K; Oshima, H; Yamamoto, T | 1 |
| Bessho, T; Itakura, T; Kakishita, K; Naito, Y; Nakai, K; Nakao, N; Uematsu, Y; Yoshimasu, T | 1 |
| Albanese, A; Bentivoglio, AR; Bonifati, V; Brancati, F; Breteler, MM; Brice, A; Caputo, V; Cortelli, P; Dallapiccola, B; Davis, MB; De Michele, G; Dürr, A; Ferraris, A; Filla, A; Gasser, T; Graham, EA; Harhangi, BS; Meco, G; Oostra, BA; Rawal, N; Valente, EM; Wassilowsky, D; Wood, NW | 1 |
| Kostić, VS; Marinković, J; Przedborski, S; Stefanova, E; Svetel, M | 1 |
| Ahlskog, JE; Apaydin, H; Boeve, BF; Dickson, DW; Parisi, JE | 1 |
| Bandini, F; Bodis-Wollner, I; Pierantozzi, M | 1 |
| Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ | 1 |
| Albani, F; Avoni, P; Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Ebadi, M; El Refaey, H; Sharma, S; Shavali, S | 1 |
| Ding, Y; Li, Y; Shao, M; Zhao, G | 1 |
| Alvarez, M; Chacón, JR; Durán, E; Durán, JA | 1 |
| Bastian, AJ; Hyngstrom, AS; Kelly, VE; Rundle, MM | 1 |
| Cruz, NF; Dienel, GA; Harik, SI; Uc, EY | 1 |
| Blatt, JL; Blond, S; Bourriez, JL; Defebvre, LJ; Destée, A; Duhamel, A; Guieu, JD; Krystkowiak, P; Périna, M | 1 |
| Ferrer, E; Molinuevo, JL; Pilleri, M; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Bareš, M; Hortová, H; Kanovský, P; Kubová, D; Rektor, I; Streitová, H; Znojil, V | 1 |
| Indakoetxea, B; Lasa, A; Linazasoro, G; Ruiz, J; Van Blercom, N | 1 |
| Sanchez-Ramos, J | 1 |
| Ghika, J; Pollo, C; Pralong, E; Temperli, P; Villemure, JG; Vingerhoets, FJ | 1 |
| Bartalini, S; Battistini, N; Giannini, F; Lombardi, C; Lugaresi, E; Passero, S; Rocchi, R; Rossi, S; Ulivelli, M | 1 |
| Hanaoka, K; Horai, T; Nishiyama, T; Yamamoto, H | 1 |
| Hwang, WJ; Shen, LH; Ting, G; Wey, SP; Yao, WJ | 1 |
| Cutler, NR; Dockens, RC; Frackiewicz, EJ; Jhee, SS; Salazar, DE; Shiovitz, TM; Topham, C; Webster, J; Whigan, D | 1 |
| Bédard, PJ; Birdi, S; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH | 1 |
| Amabile, G; Del Monte, S; Fattapposta, F; Morocutti, A; Mostarda, M; My, F; Parisi, L; Pierelli, F; Serrao, M | 1 |
| Aktan, S; Bekiroglu, N; Gunal, DI; Nurichalichi, K; Tuncer, N | 1 |
| Berar-Yanay, N; Carasso, RL; Davidovich, A; Inzelberg, R; Magadle, R; Nisipeanu, P; Weiner, P | 1 |
| Bansal, B; Garg, RJ; Raghav, S; Rajani, M | 1 |
| Avikainen, S; Brown, P; Hari, R; Kaakkola, S; Salenius, S | 1 |
| Barker, RA; Cools, R; Owen, AM; Robbins, TW; Stefanova, E | 1 |
| Seeman, P | 1 |
| Akiyama, A; Nakazato, T | 1 |
| Fattapposta, F; Martini, A; Parisi, L; Pierelli, F; Rossi, P; Serrao, M; Valente, G | 1 |
| Annesi, G; Quattrone, A; Zappia, M | 1 |
| Hironishi, M; Kondo, T; Miwa, H | 1 |
| Arai, A; Baba, M; Kannari, K; Kurahashi, K; Maeda, T; Matsunaga, M; Suda, T; Tomiyama, M | 1 |
| Mazzoni, P | 1 |
| Danisi, F | 1 |
| McAuley, L | 1 |
| Aquilonius, SM; Nilsson, D; Nyholm, D | 1 |
| Elble, RJ | 1 |
| Deuschl, G; Herzog, J; Klebe, S; Krack, P; Lorenz, D; Pohle, S; Wenzelburger, R; Wilms, H; Zhang, BR | 1 |
| Bjorklund, A; Burger, C; Georgievska, B; Kirik, D; Mandel, RJ; Muzyczka, N; Winkler, C | 1 |
| Ang, LC; Birdi, S; Fenton, ME; George, D; Hornykiewicz, O; Macaulay, R; Rajput, AH; Rozdilsky, B; Senthilselvan, A | 1 |
| De Mari, M; Lamberti, P; Zenzola, A | 1 |
| Ahuja, M; Srivastava, M; Srivastava, T; Trivedi, A | 1 |
| Klopman, G; Sedykh, A | 1 |
| Linazasoro, G; Suárez, JA | 1 |
| Brenninkmeijer, JH; Freijzer, PL | 1 |
| Deuschl, G; Gordin, A; Kultalahti, ER; Leinonen, M; Poewe, WH | 1 |
| García Ruiz, PJ; Meseguer, E | 1 |
| Benabid, AL; Fraix, V; Krack, P; Mendes, A; Pollak, P | 1 |
| Rassoulpour, A; Schwarcz, R; Wu, HQ | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F | 1 |
| Lum, SY; Tan, EK; Wong, MC | 1 |
| Bailbé, M; Dumas, P; Gil, R; Karolewicz, S; Neau, JP | 1 |
| Freund, HJ; Müller, U; Schubert, T; Sturm, V; Voges, J; Volkmann, J; Von Cramon, DY | 1 |
| Keens, J; Schrag, A; Warner, J | 1 |
| Calandrella, D; Cosentino, M; Frigo, G; Lecchini, S; Leoni, O; Martignoni, E; Michielotto, D; Nappi, G; Oria, C; Riboldazzi, G; Zangaglia, R | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Burgunder, JM; Krauss, JK; Loher, TJ; Pohle, T; Sommerhalder, R; Weber, S | 1 |
| Adler, CH; Blasucci, L; Carvey, P; Caviness, JN; Chase, WM; Ferry, JJ; Goetz, CG; Kompoliti, K; Leibowitz, MT; Leurgans, S; Pincus, JH; Raman, R; Tan, E; Yones, LC | 1 |
| Benabid, AL; Krack, P; Pollak, P; Xie, J | 1 |
| Bittkau, S; Bliesath, H; Büttner, U; Fuchs, G; Glass, J; Haller, H; Klockgether, T; Kraus, P; Lachenmayer, L; Müller, D; Müller, T; Przuntek, H; Rathay, B; Sgonina, J; Steinijans, V; Teshmar, E; Ulm, G; Volc, D | 1 |
| Ashby, P; Dostrovsky, JO; Hutchison, WD; Lang, AE; Levy, R; Lozano, AM | 1 |
| Abe, Y; Arahata, Y; Brooks, DJ; Hatano, K; Ito, K; Kachi, T; Kato, T; Kawasumi, Y; Nagano-Saito, A; Nakamura, A; Yamada, T | 1 |
| Balestre, E; Bioulac, B; Chrysostome, V; Ghorayeb, I; Tison, F; Yekhlef, F | 1 |
| Hunter, C; Jankovic, J | 1 |
| Benz, S; Müller, T | 1 |
| Dewey, RB; O'Suilleabhain, PE | 1 |
| Chen, R; Cunic, D; Khan, FI; Lang, AE; Lozano, AM; Roshan, L | 1 |
| Bringmann, G; Feineis, D; God, R; Luborzewski, A; Moser, A; Riederer, F; Scholz, J | 1 |
| Defebvre, L; Krystkowiak, P | 1 |
| Steur, EN | 1 |
| Fowler, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
| Hilten, JJ; Ramaker, C | 1 |
| Bosch, A; Brown, P; Di Lazzaro, V; Insola, A; Mazzone, P; Oliviero, A; Quartarone, A; Speelman, H; Tijssen, M; Van Bruggen, G; Williams, D | 1 |
| Henchcliffe, C; Waters, C | 1 |
| Burke, MA; Fernandez, HH; Friedman, JH; Trieschmann, ME | 1 |
| Blond, S; Bourriez, JL; Cassim, DF; Defebvre, L; Derambure, P; Destée, A; Devos, D; Guieu, JD | 1 |
| Davidson, L; Hornykiewicz, O; Lloyd, KG | 1 |
| Walker, E | 1 |
| Greer, M | 3 |
| Shahani, BT; Young, RR | 1 |
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Morley, JB | 1 |
| Winkelman, AC | 1 |
| Bastard, J; Chanelet, J; Emile, J; Six, P; Truelle, JL | 2 |
| Wieck, HH | 1 |
| Battista, AF; Fuxe, K; Goldstein, M; Lew, JY; Lieberman, A; Nakamura, S | 1 |
| Kaumeier, S | 1 |
| Granerus, AK; Jagenburg, R; Svanborg, A | 2 |
| Granerus, AK | 1 |
| Lloyd, KG | 3 |
| Hungerbühler, JP; Regli, F | 1 |
| Estey, E; Goldstein, M; Goodgold, A; Gopinathan, G; Kupersmith, M; Lieberman, AN | 2 |
| Costentin, J | 1 |
| Przuntek, H | 1 |
| Caraceni, T; Celano, I; Cocchi, D; Frigerio, C; Girotti, F; Müller, EE; Parati, EA | 1 |
| Bartholini, G | 1 |
| Bell, RD; Boyar, RM; Carruth, A; Rosenberg, RN | 1 |
| Calne, DB; Fellows, LE; Findley, LJ; Sandler, M | 1 |
| Sacks, W; Simpson, GM | 1 |
| Drachman, DA; Stahl, S | 1 |
| Rajput, AH; Rozdilsky, B | 1 |
| Marsden, CD; Parkes, JD; Tarsy, D | 3 |
| Pearce, I; Pearce, J | 1 |
| Cohen, HP; Maritn, WE; Tolosa, ES | 1 |
| Bamji, AN; Calne, DB; Greenacre, JK; Leigh, PN; Petrie, A; Reid, JL; Teychenne, PF | 1 |
| Leibowitz, M; Lieberman, A | 1 |
| Debono, AG; Donaldson, I; Marsden, CD; Parkes, JD | 1 |
| Daniel, PM; Moorhouse, RS; Pratt, OE | 1 |
| Marsden, CD; Parkes, JD | 2 |
| Debono, AG; Marsden, CD; Parkes, JD | 3 |
| Birket-Smith, E; Dupont, E; Hansen, E; Hyyppä, M; Marttila, R; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rinne, UK | 1 |
| Bedard, P; Marsden, CD; Parkes, JD | 3 |
| Calne, DB; Gielen, AC; Gillespie, MM; Kartzinel, R; Perlow, M; Sadowsky, DA; TEYCHENNE, P | 1 |
| Lipper, S | 1 |
| Ambrozi, L; Birkmayer, W; Riederer, P; Youdim, MB | 2 |
| Wajsbort, J | 1 |
| Delaney, P; Fermaglich, J | 2 |
| Elsworth, JD; Kohout, LJ; Lees, AJ; Sandler, M; Shaw, KM; Stern, GM; Youdim, MB | 1 |
| Coxon, A; Greenacre, JK; Petrie, A; Reid, JL | 1 |
| Calne, DB; Neophytides, A; Nutt, JG; Plotkin, C; Teychenne, PF; Williams, AC | 1 |
| Caird, FI; Williamson, J | 1 |
| Glaubman, H; Rabey, JM; Streifler, M; Vardi, J | 1 |
| Berendes, K; Dörstelmann, D | 1 |
| Lörincz, P; Ludin, HP; Ringwald, E | 1 |
| Marsden, CD; Parkes, JD; Price, P | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, AN; Mehl, S; Neophytides, A; Serby, M | 1 |
| Becker, H; Beyer, M; Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Ferel, D | 1 |
| Klawans, HL; Lupton, MD; Moskovitz, C; Sharf, B | 2 |
| Allain, H; Bentue-Ferrer, D; Madigand, M; Pape, D; Reymann, JM; Van den Driessche, J | 1 |
| Itoga, E; Kamiya, K; Kishida, T; Kito, S; Yamamoto, M | 1 |
| Jiang, Y; Liu, D | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Cotzias, GC; Mena, I; Mendez, JS; Papavasiliou, PS | 1 |
| Postma, JU; Van Tilburg, W | 1 |
| Moskowitz, MA; Wurtman, RJ | 1 |
| Chase, T; Shoulson, I | 1 |
| Gerstenbrand, F; Gründig, E; Weiss, J | 1 |
| Klawans, H | 1 |
| Sears, ES | 1 |
| Goetz, C; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Casey, DE | 1 |
| Barkhatova, VP; Insarova, NG; Ivanova-Smolenskaia, IA; Markova, ED | 1 |
| Ericsson, SG; Gill, H; Widmalm, S; Widmalm, SE | 1 |
| Calne, DB; Eisler, T | 1 |
| Aminoff, MJ; Keenan, J; Kremer, M; Millar, JG; Wilcox, CS | 1 |
| Anderson, JR; Benson, GS; Corriere, JN; Raezer, DM; Saunders, CD | 1 |
| Calne, DB; Kartzinel, R; Shoulson, I | 2 |
| Kristensen, V | 1 |
| Belmaker, RH; Berman, M; Biederman, J; Ebstein, RP; Stern, R; van Praag, HM | 1 |
| Cler, JM; Mathé, JF; Venisse, JL | 1 |
| Marais, C | 1 |
| Borison, RL; Diamond, BI | 1 |
| Koskinen, V; Laaksonen, H; Rinne, UK; Tenovuo, O | 1 |
| Hill, JW | 1 |
| Birkmayer, W; Riederer, P; Youdim, BH | 1 |
| Barbeau, A; Butterworth, RF; Campanella, G; Yamada, K | 1 |
| McFarland, HR | 1 |
| Gilbert, JC | 1 |
| Korf, J; Lakke, JP; van Praagen, HM | 1 |
| Bender, JL | 1 |
| Taylor, J | 1 |
| Lees, A; Stern, G | 2 |
| de Saxce, H | 1 |
| Arbit, J; Blonsky, ER; Boshes, B; Dolkart, M | 1 |
| Bonduelle, M; Degos, CF | 1 |
| Beilin, B; Herishanu, Y; Rosenberg, P | 1 |
| Gilland, O | 1 |
| Cohen, MM; Scheife, RT | 1 |
| Savery, F | 2 |
| Holzbauer, M; Youdim, MB | 1 |
| Godwin-Austen, RB; Smith, NJ | 1 |
| Gron, U | 1 |
| Hansen, E; Kristensen, O | 1 |
| Estey, E; Goldstein, M; Gopinathan, G; Kupersmith, M; Lieberman, A | 1 |
| Rix, A | 1 |
| Calne, DB; Fahn, S | 1 |
| Agnoli, A; Casacchia, M; Ruggieri, S | 1 |
| Battistin, L; Meneghetti, G; Rigotti, S; Saia, A | 1 |
| Pearce, I; Pearce, JM | 1 |
| Timberlake, WH; Vance, MA | 1 |
| Forno, LS; Langston, JW | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 3 |
| Marttila, RJ; Rinne, UK | 2 |
| Marsden, CD; Parkes, JD; Price, PA | 1 |
| Birket-Smith, E; Bøttcher, J; Dupont, E; Holm, P; Jensen, JP; Kristensen, O; Køhler, O; Mikkelsen, B | 1 |
| Lakke, JP; Lindeboom, SF | 1 |
| Cotzias, GC; Miller, ST; Papavasiliou, PS; Rosal, VL | 1 |
| Bateman, DN; Coxon, A; Legg, NJ; Reid, JL | 1 |
| Dorner, A; Wajsbort, E; Wajsbort, J | 1 |
| Hokkanen, E; Myllylä, VV; Saarinen, A; Tokola, O | 1 |
| Antal, J; Antóny, M; Csanaky, A; Csanda, E | 1 |
| Lance, JW; Mackenzie, RA | 2 |
| Carlyle, D; Williams, BO | 1 |
| Thomas, L | 1 |
| Agid, Y; Barroche, G; Bonnet, AM; Javoy-Agid, F; Kato, G; Lhermitte, F; Pollak, P; Signoret, JL | 1 |
| Parkes, D | 2 |
| Calne, DB; Eng, N; Nutt, J; Plotkin, C; Williams, A; Ziegler, M | 1 |
| Gilligan, B; O'Halloran, M; Stark, R; Wodak, J | 1 |
| Dumas, M; Dumond, JJ; Garoux, R; Leger, JM; Lombertie, E | 1 |
| Enström, MS; Liedén, G; Linström, FD | 1 |
| Gerlach, J | 3 |
| Martin, S | 1 |
| Chassan, JB; Joseph, C; Koch, ML | 1 |
| Marx, JL | 1 |
| Calne, DB; Devereux, D; Eng, N; Rosin, AJ | 1 |
| Hökendorf, H | 1 |
| Clanet, M; David, J; Guiraud, B; Montastruc, JL; Rascol, A | 1 |
| Jörg, J; Kleine, D | 1 |
| Hirayama, K; Kondo, T; Kuruma, I; Narabayashi, H; Yokochi, M | 2 |
| Green, J; Haycook, W; Kilgore, M; Stephens, R | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Passerini, D; Trabucchi, M | 1 |
| Check, WA | 1 |
| Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P | 1 |
| Barone, DA; Martin, HL | 1 |
| Mace, M; Rawlins, MD | 1 |
| Lander, CM; Lees, AJ; Stern, GM | 1 |
| Bernstein, RM | 1 |
| Bender, DA; Earl, CJ; Lees, AJ | 1 |
| Becker, H; Fischer, PA; Hacker, H; Jacobi, P; Schneider, E | 1 |
| McDowell, FH; Miller, ST; Papavasiliou, PS; Rosal, V | 1 |
| Glaubman, H; Rabey, J; Streifler, M; Vardi, J | 1 |
| Martinelli, P; Montagna, P | 1 |
| Allelov, M; Flechter, S; Hertzberg, M; Oberman, Z; Rabey, JM; Streifler, M; Vardi, J | 1 |
| Brown, MJ; Dollery, CT; Reid, JL; Rossor, M; Watkins, J | 1 |
| Balík, J; Filip, V; Filipová, M; Krejcová, H; Rodný, J | 1 |
| Iwamoto, K; Iwayama, K; Kawano, T; Mori, K; Yamashiro, K; Yoshida, T | 1 |
| Bannister, R; Mackay, AV; Quik, M; Spokes, EG | 1 |
| Sjönell, G | 1 |
| Goetz, CG; Klawans, HL | 1 |
| Völler, GW | 1 |
| Durocher, AM; Graux, P | 1 |
| Conte, P; Julien, J; Moulinier, J; Reiffers, J | 1 |
| Dziatolowski, M; Goldstein, M; Goodgold, A; Korein, J; Kupersmith, M; Lieberman, A; Serby, M | 1 |
| Cotzias, GC; Lazarus, CB; Papavasiliou, PS; Tolosa, ES | 1 |
| Barthal, JS; Garrett, G; Schultz, DR | 1 |
| Johnson, JC; Maeder, MC; Mazzaferri, EL; Spagna, VA | 1 |
| Sharpless, NS; Tabaddor, K; Wolfson, LI | 1 |
| Jotkowitz, S | 3 |
| McDowell, FH; Miller, ST; Papavasiliou, PS; Rosal, V; Wang, YY | 1 |
| Barrett, RE; Cote, LJ; Fahn, S; Isgreen, WP; Snider, SR | 1 |
| Hershman, JM; Wingert, TD | 1 |
| Barrett, RE; Cote, LJ; Fahn, S; Isgreen, WP; Lesser, RP; Snider, SR | 1 |
| Mölsä, P; Rinne, UK | 1 |
| Fahn, S; Hutt, CS; Snider, SR | 1 |
| Murphy, MJ | 1 |
| Morel-Maroger, A | 1 |
| Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM | 1 |
| Caraceni, TA; Celano, I; Girotti, F; Parati, E | 1 |
| Ho, YM; Shau-Fong, K | 1 |
| Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M | 3 |
| Petelin, LS; Romenskaia, LKh; Vartanian, KZ | 1 |
| Gimenez-Roldan, S; Mateo, D; Villanueva, J | 1 |
| Cotzias, GC; Papavasiliou, PS; Rosal, VL; Rubin, JI; Wang, YY | 1 |
| Antoncić, N; Ledić, P; Sepcić, J | 1 |
| Cotzias, GC; McDowell, FH; Papavasilliou, PS; Rosal, VL; Sheehan, PJ | 1 |
| Paal, G | 1 |
| Tyler, HR | 1 |
| Ligezińska, B; Pakszys, W | 1 |
| Coscia, CJ; Mitchell, J | 1 |
| Azevedo, M; Coelho, H; e Silva, JM; Manso, C; Proença, C | 1 |
| Worm-Petersen, J | 1 |
| Klawans, HL; Moses, H; Moskovitz, C | 1 |
| Bern, SM; Calne, DB; McInturff, D; Pfeiffer, RF; Teychenne, PF | 1 |
| Klawans, HL; Kramer, J; Nausieda, PA; Wiener, WJ | 1 |
| Haddad, S; Kohout, LJ; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Sober, AJ; Wick, MM | 1 |
| Koskinen, V; Laaksonen, H; Lönnberg, P; Rinne, UK; Sonninen, V | 1 |
| Bozzetti, F; Costa, A; Galante, E | 1 |
| Choi, CR | 1 |
| Farley, IJ; Hornykiewicz, O; Lee, T; Rajput, A; Seeman, P | 1 |
| Jeuring, HJ; Lakke, JP; Muskiet, FA; Teelken, AW; Wolthers, BG | 1 |
| Kamenetskiĭ, VK | 1 |
| Economou, SG; Stefanis, CN | 1 |
| de Vries, JA; Fremouw-Ottevangers, DC; Muskiet, FA; Nagel, GT; Wolthers, BG | 1 |
| Enulescu, O; Stoica, E | 1 |
| Presthus, J | 2 |
| Brown, E; Brown, GM; Kofman, O; Quarrington, B | 1 |
| Marttila, R; Rinne, UK | 1 |
| Chastang, C; Guillard, A | 1 |
| Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R | 1 |
| Bentin, S; Cooper, G; Lavy, S; Melamed, E | 1 |
| Bodis-Wollner, I; Yahr, MD | 1 |
| Direnfeld, L; Marotta, J; Seeman, P; Spero, L | 1 |
| Lees, AJ; Sandler, M; Stern, GM | 1 |
| Rinne, UK; Siirtola, T; Sonninen, V | 2 |
| Gilligan, B; Stark, R; Wodak, J | 1 |
| Antarkar, DS; Mankodi, NA; Purohit, AV; Rajagopalan, TG; Tathed, PS; Vaidya, AB; Wadia, NH | 1 |
| Bladin, PF; Donnan, GA; Vajda, FJ | 1 |
| Fisher, MA; Milner-Brown, HS; Weiner, WJ | 1 |
| Clemens, R | 1 |
| Chase, TN; Shoulson, I | 2 |
| Ferriss, GS; Martinez, RD; Paddison, RM | 1 |
| Gey, KF; Pletscher, A | 1 |
| Deze, J; Völler, GW | 1 |
| Barry, VC; Klawans, HL | 1 |
| Arfel, G; Derome, P; Guiot, G; Jedynak, P; Walter, S | 1 |
| Marsden, CD; Mindham, RH; Parkes, JD | 1 |
| Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM | 1 |
| Bissessur, S; De Man, JJ; Lakke, JP; Moll, L; Seegers, J; Wesseling, H; Witt, FG | 1 |
| Barbeau, A; Gonce, M | 1 |
| Kunz, F; Lörincz, P; Ludin, HP; Ringwald, E | 1 |
| Bianchine, JR; Shaw, GM | 1 |
| Couto, B; Freitas, MR; Mattos, JP; Oliveira, C | 1 |
| Derome, P; Guiot, G; Robert, G | 1 |
| Bacon, M; Garvin, JS; Waldrop, W; Wolfe, VI | 1 |
| Eisenlohr, JJ; Gehlen, W | 2 |
| Fahn, S; Isgreen, WP | 1 |
| Bharucha, EP | 1 |
| Chase, TN; Glaubiger, GA; Shoulson, I | 1 |
| Cullinan, T; Riklan, M; Whelihan, W | 1 |
| Bhandari, Y; Stellar, S | 1 |
| Hanzal, F | 2 |
| Barbeau, A; Cloutier, T; Inoué, N | 1 |
| Ayalon, D; Herzberg, M; Oberman, Z; Rabey, I; Streifler, M; Vardi, J | 1 |
| Chouza, C; Gomensoro, JB; Romero, S | 4 |
| Uono, K | 1 |
| Kishikawa, H; Namba, S; Omoto, T | 1 |
| Lee, MC; Lippert, DM; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Markianos, ES; Rüther, E | 1 |
| Bianchine, JR | 2 |
| McKinney, AS | 1 |
| Darley, FL; Muenter, MD; Sharpless, NS; Tyce, GM | 1 |
| Lizogub, VG; Man'kovskii, NB; Vanishtok, AB | 1 |
| Kristensen, V; Olsen, M; Theilgaard, A | 1 |
| Anderson, F; Joynt, R; Rivera-Calimlim, L; Tandon, D | 1 |
| Krishnamoorthy, MS; Sachdev, KK; Singh, N | 1 |
| Halgin, R; Misiak, H; Riklan, M | 1 |
| Bathien, N; Rondot, P | 1 |
| Comoy, E; Lhermitte, F; Rosa, A | 1 |
| Hayek, J | 1 |
| Houeland, T; Sjaastad, O; Slettnes, O | 1 |
| Celesia, GG; Quaglieri, CE | 1 |
| Herishanu, Y; Rosenberg, P | 1 |
| Slome, R | 1 |
| Algeri, S; Campanella, G; Cerletti, C; Dolfini, E; Jori, A; Rinaldi, F | 1 |
| Galea-Debono, A; Jenner, P; Marsden, CD; Parkes, JD; Tarsy, D; Walters, J | 1 |
| Lukasiewicz, K | 1 |
| Braden, W | 1 |
| Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ | 1 |
| Dupont, E; Jakobsen, P; Magnussen, I | 1 |
| Bala, SP; Cohen, B; Mendoza, M; Shimizu, N; Yahr, MD | 1 |
| Askenazi, JJ; Rabey, JM; Streifler, M; Vardi, J | 1 |
| Agid, Y; Lhermitte, F; Signoret, JL; Studler, JM | 1 |
| Fischer, GJ; Glass, J; Schubert, U | 1 |
| Rampton, DS | 1 |
| De la Garza, R; Lombardo, L | 1 |
| Ogawa, M; Tohgi, H | 1 |
| Burke, W; Coscia, CJ; Jamroz, G; Lasala, JM; McFarlane, J; Mitchell, J; O'Toole, MM; Wilson, ML | 1 |
| Rabey, JM; Streifler, M; Vardy, J | 1 |
| Birkmayer, W; Riederer, P; Seemann, D; Wuketich, S | 1 |
| Calne, DB; Teychenne, PF | 1 |
| Cler, JM; Feve, JR; Mathé, JF; Mussini, JM; Nomballais, MF | 1 |
| Grbesa, B; Velicković, A | 1 |
| Clark, EC; Feinstein, B | 1 |
| Marttila, R; Rinne, UK; Sonninen, V | 2 |
| Mortimer, JA; Webster, DD | 1 |
| Calne, DB; Pfeiffer, RF; Teychenne, PF | 1 |
| Singer, E | 2 |
| Allen, N; Knopp, W | 1 |
| Klawans, HL; Lupton, M; Simon, L | 1 |
| Feigenson, JS; Goodell, H; Loranger, AW; McDowell, FH; Sweet, RD | 1 |
| Barbeau, A; Roy, M | 1 |
| Cote, LJ; Fahn, S; Isgreen, WP; Snider, SR | 1 |
| Feigenson, JS; McDowell, FH; Sweet, RD | 1 |
| Calne, DB; Kartznel, R | 1 |
| Lin, JT; Ziegler, DK | 1 |
| Celesia, GG; Koeller, AA; Wanamaker, SJ; Wanamaker, WM | 1 |
| Iivanainen, M; Kaste, M | 1 |
| Siegfried, J; Zumstein, H | 1 |
| Goodwin, BL; Johnson, RD; Ruthven, CR; Sandler, M | 1 |
| Bass-Verrey, F; Ludin, HP | 1 |
| Riederer, P; Wuketich, S | 1 |
| Anggård, E; Samuelsson, K | 1 |
| Carrera, N; Marti-Masso, JF; Martínez-Lage, JM | 1 |
| Bowers, MB; Extein, I; Roth, RH; Van Woert, M | 1 |
| Gulmann, NC | 1 |
| Arbit, J; Bieber, M; Blonsky, ER; Boshes, B; Dolkart, M; Huprikar, SV; Zeller, EA | 1 |
| Mizuno, Y; Obayashi, T; Ueki, A; Yoshida, M | 1 |
| Andre, JM; Kissel, P | 1 |
| McLellan, DL | 1 |
| Estey, E; Goldstein, M; Kupersmith, M; Lieberman, A | 1 |
| Agnoli, A; Casacchia, M; Meco, G; Zamponi, A | 1 |
| Hausner, R | 1 |
| Pakszys, W | 1 |
| Crowley, TJ; Hoehn, MM; Rutledge, CO | 1 |
| Bowen, FP | 1 |
| Cotzias, GC; Ginos, JZ; Papavasiliou, PS | 1 |
| Delwaide, PJ; Olivier, R; Schoenen, J | 1 |
| Kadykov, AS; Kistenev, BA; Pivovarova, VM | 1 |
| Evtushenko, SK | 1 |
| Londoõ, R | 1 |
| Ljungberg, T; Ungerstedt, U | 1 |
| Raz, S | 1 |
| Ito, K | 1 |
| Mano, T | 1 |
| Omoto, T | 1 |
| Torshin, MB | 1 |
| Cotzias, GC; Langan, RJ | 1 |
| Duvoisin, R | 1 |
| Bergen, D; Goetz, C; Klawans, HL | 1 |
| Forno, LS; Langston, JW; Schober, R | 1 |
| Brignone, A; Genco, S; Puca, FM; Serlenga, L; Specchio, LM | 1 |
| Chalmers, RJ; Johnson, RH; McLellan, DL | 1 |
| Martocci, RJ | 1 |
| Aiba, H; Kuramoto, S; Watanabe, M | 1 |
| Gabreëls, FJ; Joosten, EM; Keyser, A; Korten, JJ | 1 |
| Bathien, N; Dumas, JL; Rondot, P | 1 |
| Bassendine, MF; Calne, DB; Claveria, LE; Petrie, A; Teychenne, PF | 1 |
| Bronaugh, RL; Hoehn, MM; MacMurtry, RJ; Rutledge, CO | 1 |
| Gillingham, FJ | 1 |
| Baker, J; Iversen, LL; Iversen, SD; Pilling, JB; Robbins, T | 1 |
| Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D | 1 |
| Callaghan, N; Fitzpatrick, E; O'Mahony, JB | 1 |
| Jaatoul, N; Kertesz, A; McInnis, W; Paty, DW | 1 |
| Goodgold, A; Jonas, S; Leibowitz, M; Lieberman, A | 1 |
| Bastard, J; Chanelet, J; Emile, J; Truelle, JL | 1 |
| Baker, AB; Lee, MC; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Critchley, E | 1 |
| Ciunru, M; Gavril, A; Koropitzer, I; Merling, M; Nemteanu, E; Oprisan, C; Pendefunda, G; Pollingher, B; Stefanache, F | 1 |
| Boczán, G; Borus, F; Rózsa, L | 1 |
| Chase, TN; Pelton, EW | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Cotzias, GC; Mena, I | 1 |
| Mosso, JA; Rand, RW | 1 |
| Vladyka, V | 1 |
| Zieve, FJ | 1 |
| Pelliniemi, TT; Riekkinen, P; Rinne, UK; Sonninen, V | 1 |
| Dougan, D; Mearrick, P; Wade, D | 1 |
| Bermanzohn, PC; Lipper, S | 1 |
| berger, H; jarosch, E; Ludescher, E | 1 |
| Constantinidis, J; Dick, P; Tissot, R; Yanniotis, G | 1 |
| Misztal, S; Rudkowska, A | 1 |
| Keichian, AH; Oliver, RE; Rivera, VM | 1 |
| Nurzia, A | 1 |
| Hüttemann, U; Oppel, F | 1 |
| Katzman, R; Wade, LA | 1 |
| Bengesser, G | 1 |
| Duvoisin, RC; Jenner, P; Marsden, CD; Parkes, JD; Pycock, C; Tarsy, D | 1 |
| Birkmayer, W; Danielczyk, W; Neumayer, E; Riederer, P | 1 |
| Dietrichson, P; Holmsen, R; Presthus, J | 1 |
| Greenberg, J; Horowitz, G | 1 |
| Krane, RJ; Murdock, MI; Olsson, CA; Sax, DS | 1 |
| Muenter, MD; Sharpless, NS; Tyce, GM | 2 |
| Watson, E; Wilk, S | 1 |
| Birket-Smith, E | 1 |
| McDowell, FH; Stern, PH; Sweet, RD; Wasterlain, CG | 1 |
| Kishikawa, H; Ohmoto, T | 1 |
| Calne, DB; Findley, LJ; Lewis, PJ; Teychenne, PF | 1 |
| McDowell, FH; Sweet, RD | 3 |
| Mars, H | 1 |
| Bergen, D; Klawans, HL; Topel, JL | 1 |
| Cohen, HP; Jacobson, RL; Martin, WE; Tolosa, ES | 1 |
| Crossett, P; Dana, N; Klawans, HL | 1 |
| Bowen, FP; Burns, MM; Kamienny, RS; Yahr, M | 1 |
| Hoehn, MM; Rutledge, CO | 1 |
| Crosset, P; Dana, N; Klawans, HL; Margolin, DI | 1 |
| Jarcho, LW; Petajan, JH | 1 |
| Birkmayer, W; Linauer, W; Riederer, P; Youdim, MB | 1 |
| Posner, DM | 1 |
| Ansari, KA; Johnson, A | 1 |
| Barrucand, D; Benradi, F; Bensouda, J; Sebti, F | 1 |
| Ramseyer, JC | 1 |
| Castaigne, P | 1 |
| Barbeau, A; Botez, MI | 1 |
| Goodell, H; Loranger, A; McDowell, F; Sweet, RD | 1 |
| Husby, J; Korsgaard, AG | 1 |
| Bhaskar, EA; Bhaskar, PA; Jagannathan, K | 1 |
| Bronaugh, RL; Hattox, SE; Hoehn, MM; Murphy, RC; Rutledge, CO | 1 |
| Gasparini, M; Spinnler, H | 1 |
| Andersson, I; Granerus, AK; Jagenburg, R; Svanborg, A | 1 |
| Godwin-Austen, R | 1 |
| Mawdsley, C | 1 |
| Gilligan, B; Hancock, R | 1 |
| Bernales, JV; Mere, AF; Portillo, R | 1 |
| Fahn, S; Isgreen, WP; Prasad, AL | 1 |
| Hicks, EP; O'Halloran, MW | 1 |
| Bogolepov, NK; Gorbunov, FE | 1 |
| Arbit, J; Blonsky, ER; Boshes, B; Dolkart, M; Kovach, JW | 1 |
| Cerone, G; Nurzia, A; Pirro, R; Vacca, U | 1 |
| Capone, D; Ombrato, M | 1 |
| Morocutti, A; Rizzo, PA | 1 |
| Iliukhina, VA | 1 |
| Fau, R; Israël, L; Ohlmann, T; Perret, J | 1 |
| Campanelli, C; Campriani, S; Cozzolino, G | 1 |
| Cotzias, GC; Papavasiliou, PS | 1 |
| Bukhovtsev, PP; Mis'kiv, IaI; Proniv, DI; Sirotina, OS | 1 |
| Yuill, GM | 1 |
| Algeri, S; Bonollo, L; Buniva, G; Cerletti, C; Curcio, M; Minazzi, M; Minoli, G; Morselli, PL | 1 |
| Holmsen, R | 1 |
| Cotzias, GC; Tang, LC | 1 |
| Bowers, D; Greer, M; Heilman, KM; Watson, RT | 1 |
| Celesia, GG; Wanamaker, WM | 1 |
| Stimmel, GL | 1 |
| Grad, B; Rosenberg, G; Wener, J; Wener, S | 1 |
| Nevsímal, O; Roth, B; Vymazal, J | 1 |
| Dettman, G | 1 |
| Sambrook, MA | 1 |
| Parkenberg, H | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK | 1 |
| Davis, JM; Dekirmenjian, H; Manian, AA; Rajan, KS | 1 |
| Calne, DB; Fermaglich, J | 1 |
| Bieniowa, A; Kolasa, M; Reichowa, J | 2 |
| Agnetti, V; Aiello, I; Farris, A; Maioli, M; Rosati, G | 1 |
| Agnoli, A; Algeri, S; Casacchia, M; Miranda, F; Morselli, PL; Ruggieri, S | 1 |
| Reid, WG | 1 |
| Deffond, D; Durif, F; Eschalier, A; Tournilhac, M | 1 |
| Ogawa, N; Yamawaki, Y | 2 |
| Hirano, F; Kimura, K; Makino, I; Narita, S | 1 |
| Asanuma, M; Hirata, H; Kondo, Y; Ogawa, N | 1 |
| Bygdeman, M; Freedman, R; Gerhardt, G; Hoffer, BJ; Leenders, KL; Olson, L; Seiger, A; Strömberg, I; Young, D; Zerbe, GO | 1 |
| Johnels, B; Karlsson, S; Persson, M | 1 |
| Astarloa, R; de la Vega, L; de Yébenes, JG; Mena, MA; Sánchez, V | 1 |
| Anninos, PA; Derpapas, K; Sandyk, R; Tsagas, N | 1 |
| Bruyland, M; De Keyser, J; Ebinger, G; Herroelen, L; Vervaeck, M | 1 |
| Quinn, NP; Steiger, MJ | 1 |
| Baba, T; Hishida, R; Kurahashi, K; Matsunaga, M; Narita, S | 1 |
| Granérus, AK; Karlsson, S; Osterberg, T; Persson, M | 1 |
| Grandas, F; Laguna, J; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Vaamonde, J | 1 |
| Brown, D; Factor, SA | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Broussolle, E; Marion, MH; Pollak, P | 1 |
| Siemers, E | 1 |
| Nag, D | 1 |
| Brown, RG; Jahanshahi, M; Marsden, CD | 1 |
| Hasegawa, S; Konagaya, Y; Maruyama, W; Mokuno, K; Nakahara, D; Naoi, M; Takahashi, A; Watanabe, H | 1 |
| Horowski, R; Runge, I | 2 |
| Morocutti, C; Peppe, A; Pierelli, F; Rizzo, PA; Stanzione, P; Stefano, E; Tagliati, M | 1 |
| Baran, H; Jellinger, K | 1 |
| Heinz, A; Klewin, I; Klotz, P; Kuhn, W; Przuntek, H; Suchy, I | 1 |
| Grandas, F; Lera, G; Luquin, MR; Obeso, JA; Rodríguez, M; Vaamonde, J | 1 |
| Haider, SA; Thaller, VT | 1 |
| Barzen, G; Cordes, M; Felix, R; Henkes, H; Hierholzer, J; Horowski, R; Keske, U; Poewe, W; Schelosky, L | 1 |
| Horak, FB; Nashner, LM; Nutt, JG | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ | 2 |
| Chia, LG; Liu, LH | 1 |
| Gancher, ST; Irwin, RP; Nutt, JG; Woodward, WR | 1 |
| Kraus, PH; Letzel, H; Przuntek, H; Schwarzmann, D; Welzel, D | 1 |
| Goto, I; Iwata, M; Kanazawa, I; Kowa, H; Mannen, T; Mizuno, Y; Nakanishi, T; Nishitani, H; Ogawa, N; Takahashi, A | 6 |
| Dethlefsen, J; Vieregge, P | 1 |
| Wagner, GC; Walsh, SL | 1 |
| Grafton, S; Hoehn, M; Iacono, RP; Mazziotta, JC; Tang, ZS | 1 |
| Ashford, JW; Hargrave, R | 1 |
| Manji, HK; Potter, WZ; Rudorfer, MV | 1 |
| Carter, JH; Gancher, ST; Nutt, JG; Woodward, WR | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Trenkwalder, C | 1 |
| Castillo, J; Castro, A; Lema, M; Martínez, F; Noya, M | 1 |
| Calne, DB; Fahn, S; Heiman, GA; Nygaard, TG; Snow, BJ; Takahashi, H | 1 |
| Hibi, K; Hirooka, Y; Ishikawa, A; Mitsuma, T; Naruse, T; Sobue, G; Yuasa, K | 1 |
| Blümner, E; Danielczyk, W; Kaiser, HJ; Kraus, PH; Letzel, H; Przuntek, H; Riederer, P; Schwarzmann, D; Welzel, D; Wolf, H | 1 |
| Ahuja, GK; Behari, M; Prasad, K; Singh, K | 1 |
| Andersson, U; Aquilonius, SM; Freccero-Rosman, K; Lindvall, O; Nylander, B; Odin, P | 1 |
| Bokor, M; Faragó, A; Garam, T; Schnabel, R | 1 |
| Colosimo, C; Daniel, SE; Hughes, AJ; Kleedorfer, B; Lees, AJ | 1 |
| Lees, AJ; Merello, M | 1 |
| Agid, Y; Bonnet, AM; Marconi, R; Vidailhet, M | 1 |
| Dietrichs, E | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; O'Neill, CJ | 1 |
| Baronti, F; Brughitta, G; Chase, TN; Conant, KE; Davis, TL; Giuffra, M; Mouradian, MM | 1 |
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Akai, M; Idemura, Y; Ishizaki, T; Matsubara, R; Miyaho, S; Nakaguki, K; Nakai, T; Sasaki, F; Uchiki, H | 1 |
| Brun, JM; Giroud, M; Putelat, R; Vaillant, G; Vergès, B; Verges-Patois, B | 1 |
| Levivier, M; Przedborski, S | 1 |
| Laihinen, A; Rinne, UK; Suchy, I | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Henley, M; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Hughes, J; Lubel, DD; Mehta, R; O'Neill, CJ; Weller, C | 1 |
| Cooper, JA; Doherty, SM; Jordan, N; Sagar, HJ; Sullivan, EV; Tidswell, P | 1 |
| Murofushi, T; Osanai, R; Yamane, M | 1 |
| Kovács, A | 1 |
| Haas, JA; Jansen, EN; Lakke, JP; Staal-Schreinemachers, A; van der Sande, JJ | 1 |
| Collin, C; Eckernäs, SA; Grahnén, A; Ling-Andersson, A; Nilsson, M; Tiger, G | 1 |
| Sontag, KH | 1 |
| Fukuuchi, Y; Kobari, M; Nogawa, S; Shinohara, T; Takahashi, K | 1 |
| Durrieu, G; LLau, ME; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Bolzani, R; Cipolli, C; Massetani, R; Muratorio, A; Murri, L | 1 |
| Thompson, L | 1 |
| Fenton, ML; Harnett, DS; Rosenthal, SH | 1 |
| Lannon, MC; Ott, BR | 1 |
| Adba, MA; Aranda, B; Cramer, P | 1 |
| Graff, E; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Bennett, JP; Orosz, D | 1 |
| Hildebrand, J; Moussa, Z; Przedborski, S; Raftopoulos, C | 1 |
| Caligiuri, MP; Heindel, WC; Lohr, JB | 1 |
| Akane, A; Fukushima, S; Kobayashi, S; Matsubara, K; Shiono, H | 1 |
| Anderson, TJ; Donaldson, IM; Ewer, TC; Gilchrist, NL | 1 |
| Rodnitzky, RL | 1 |
| Hutton, JT; Morris, JL | 2 |
| Baronti, F; Boldry, RC; Chase, TN; Davis, TL; Mouradian, MM | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K; Trenkwalder, C | 1 |
| Barr, SI; Paré, S; Ross, SE | 1 |
| Brooks, D; Fahn, S; Freeman, T; Goetz, CG; Langston, JW; Watts, R; Widner, H | 1 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Baker, JR; Davey, NJ; Ellaway, PH; Friedland, CL | 1 |
| Artieda, J; Jahanshahi, M; Obeso, JA; Pastor, MA | 2 |
| Jansen, EN; Kölling, P | 1 |
| Ardouin, C; Crouzet, G; Durif, F; Hommel, M; Le Bas, JF; Perret, J; Pollak, P | 1 |
| Antonozzi, I; Bonifati, V; Lestingi, L; Meco, G; Stocchi, F | 1 |
| Clough, CG; Good, PA; Henderson, B; Hitchcock, ER; Hughes, RC; Kenny, BG | 1 |
| Calne, DB; Cooper, S; Cordes, M; Morrison, S; Schofield, P; Snow, BJ; Sossi, V; Takahashi, H | 1 |
| Málly, J | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Amyot, D; Gauthier, S | 1 |
| Aquilonius, SM; Bjurling, P; Bredberg, E; Hartvig, P; Långström, B; Tedroff, J | 1 |
| Brundin, P; Frackowiak, R; Gustavii, B; Leenders, KL; Lindvall, O; Odin, P; Rehncrona, S; Rothwell, JC; Sawle, G; Widner, H | 1 |
| Bannister, R; Brooks, DJ; Frackowiak, RS; Ibanez, V; Lees, AJ; Marsden, CD; Mathias, CJ; Playford, ED; Quinn, N; Sawle, GV | 1 |
| Gancher, ST; Grandas, F; Lera, G; Nutt, JG; Obeso, JA; Rodriguez, M | 1 |
| Esteguy, M; Leiguarda, R; Merello, M; Perazzo, F | 1 |
| Page, RD | 1 |
| Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM | 1 |
| Juncos, JL | 1 |
| Madeja, UD | 1 |
| Bathien, N; Feve, AP; Rondot, P | 2 |
| Bonuccelli, U; Corsini, GU; Muratorio, A; Piccini, P | 1 |
| Caradoc-Davies, TH; Dixon, GS; Weatherall, M | 1 |
| Lees, AJ; Turjanski, N | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| Blond, S; Caparros-Lefebvre, D; Pasquier, F; Pécheux, N; Petit, H | 1 |
| James, M; Lange, KW; Marsden, CD; Owen, AM; Paul, GM; Robbins, TW | 1 |
| Meiner, Z; Reches, A | 1 |
| Anderson, JJ; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R; Gillespie, M | 1 |
| Agnoli, A; Carta, A; Jenner, P; Marsden, CD; Quinn, N; Ruggieri, S; Ryatt, J; Stocchi, F | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Dickson, DW; Duvoisin, RC; Mark, MH; Sage, JI; Schwarz, KO | 1 |
| Kaufmann, B; Wegmann, W | 1 |
| Cutlip, WD; Makela, EH | 1 |
| Boyce, S; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Abercrombie, ED; Hastings, TG; Zigmond, MJ | 1 |
| Cooper, JA; Jordan, N; Sagar, HJ | 1 |
| Brooks, DJ; Findley, LJ; Ibanez, V; Marsden, CD; Playford, ED; Sawle, GV; Thompson, PD | 1 |
| Ahlskog, JE; Carmichael, SW; Kelly, PJ; Nelson, A; Okazaki, H; Richelson, E; Stoddard, SL; Tyce, GM; van Heerden, JA | 1 |
| Allain, H; Bentue-Ferrer, D; Decombe, R; Lemaitre, MH; Martinet, JP; Milon, D | 1 |
| Beaman, BL; Kohbata, S | 1 |
| Angelberger, P; Brücke, T; Deecke, L; Küfferle, B; Müller, C; Podreka, I; Topitz, A; Wenger, S | 1 |
| Hofman, R; Pfeiffer, RF | 1 |
| Lee, RG | 1 |
| Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD | 1 |
| Arnold, G; Fritsch, K; Gasser, T; Oertel, W | 1 |
| Arts, N; Horstink, M; Tacke, T; van de Vlasakker, C | 1 |
| Agnoli, A; Baronti, F; Horowski, R; Lucarelli, C; Ruggieri, S; Stocchi, F; Viselli, F | 1 |
| Bottomley, JM; Kleedorfer, B; Lees, AJ; Sree-Haran, N; Stern, GM | 1 |
| Baronti, F; Berrettini, WH; Brughitta, G; Chase, TN; Conant, KE; Davis, TL; Giuffra, M; Iadarola, MJ; Mouradian, MM | 1 |
| Heinonen, EH; Lammintausta, R | 1 |
| Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D | 1 |
| Lindvall, B; Olsson, JE | 2 |
| Kuhn, W; Przuntek, H | 2 |
| Evseev, VA; Karaban', IN; Kryzhanovskiĭ, GN; Magaeva, SV; Man'kovskiĭ, NB; Trekova, NA; Vetrilé, LA | 1 |
| Pleet, AB | 1 |
| Fahn, S; Flaster, E; Giladi, N; Guillory, S; Kostic, V; McMahon, D; Przedborski, S | 1 |
| Neufeld, MY | 1 |
| Karstaedt, PJ; Pincus, JH | 1 |
| Allain, H; Bentue-Ferrer, D; Brunet-Bourgin, F; Chaumet-Riffaud, P; Decombe, R; Gandon, JM; Goulley, F; Le Coz, F; Loria, Y; Reymann, JM | 1 |
| Abbott, RJ; D'Costa, DF; Millac, PA; Pye, IF | 1 |
| Fassl, H; Jörg, J; Kleinhenz, J; Kömpf, D; Vieregge, P | 1 |
| Deleu, D; Ebinger, G; Michotte, Y | 1 |
| Bowes, SG; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ | 1 |
| Abrams, R; Rasmussen, K | 1 |
| de Pedro-Cuesta, J; Stawiarz, L | 1 |
| Riggs, JE | 1 |
| Jamieson, PW | 1 |
| Graff, E; Harsat, A; Rabey, JM; Schwartz, M; Vered, Y | 1 |
| Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW | 1 |
| Aguilera, M; Catrejon, H; Cuevas, C; Franco-Bourland, R; Guizar-Zahagun, G; Madrazo, I; Madrazo, M; Magallon, E; Ostrosky-Solis, F | 1 |
| Członkowska, A; Fiszer, U; Korlak, J; Piotrowska, K | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, S; Tohgi, H | 1 |
| Blin, O; Ferrandez, AM | 1 |
| Aquilonius, SM | 1 |
| Fazzini, E; Lieberman, A | 1 |
| Allain, H; Cougnard, J; Neukirch, HC | 1 |
| Rinne, JO | 1 |
| Hashida, H; Masaki, T; Nagao, T; Sakuta, M; Takagi, K | 1 |
| Caride, AE; Ferreiro, JL; Pugliese, MI | 1 |
| Ahlskog, JE; Fealey, RD; Low, PA; Sandroni, P | 1 |
| Gervason, CL; Pollak, P | 1 |
| Agid, Y; Holemans, S; Javoy, F; Laterre, EC; Maloteaux, JM | 1 |
| Nakashima, K; Takahashi, K | 1 |
| Chariá, P; Díaz, F; Liberman, C | 1 |
| Jiménez, F; Jurado, J; Olvera, J; Rodríguez Cuevas, H; Velasco, F; Velasco, M | 1 |
| Epstein, LG; Gelbard, HA; Greenamyre, JT; Kieburtz, KD | 1 |
| Chaná, P; Díaz, F | 1 |
| Blum, C; Burke, R; Cote, L; Dwork, AJ; Fazzini, E; Goodman, RR; Jacobs, TP; Naini, AB; Pezzoli, G; Pullman, S | 1 |
| Chen, RC | 1 |
| Cedarbaum, JM; Gauger, LL; Olanow, CW | 1 |
| Chen, E | 1 |
| Fritz, VU; Ming, A; Temlett, JA | 1 |
| Baronti, F; Chase, TN; Conant, K; Davis, TL; Giuffra, M; Heuser, IJ; Mouradian, MM | 1 |
| Blin, O; Ferrandez, AM; Pailhous, J; Serratrice, G | 2 |
| Berry, EM; Caballero, B; Growdon, JH; Wurtman, JJ; Wurtman, RJ | 1 |
| Andersson, Y; Antoni, G; Bjurling, P; Hartvig, P; Långström, B; Tedroff, J | 1 |
| Morimatsu, M | 1 |
| Mark, MH; McHale, DM; Sage, JI; Sonsalla, PK; Vitagliano, D | 1 |
| Benke, T; Berger, W; Poewe, W; Schelosky, L | 1 |
| Bhatt, MH; Calne, DB; Martin, WR; Pate, BD; Ruth, TJ; Snow, BJ | 1 |
| Matsumoto, W; Nomoto, M; Osame, M; Umehara, F; Usuki, F | 1 |
| Findley, L; Prasher, D | 1 |
| Clough, CG; Henderson, BT; Hitchcock, ER; Hughes, RC; Kenny, BG | 1 |
| Elizan, TS; Moros, DA; Yahr, MD | 1 |
| Carey, RJ | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Bruggi, P; Martignoni, E; Nappi, G; Pacchetti, C; Pedevilla, M; Sibilla, L | 1 |
| Grimes, JD | 1 |
| Jacobs, MB; Varon, J | 1 |
| Cedarbaum, JM; Green-Parsons, A; Toy, LH | 1 |
| Asari, S; Goldstein, M; Nakashima, H; Nishimoto, A | 1 |
| Azevedo, MS; Coelho, MH; Manso, CF; Silva, IJ | 1 |
| Cedarbaum, JM; Guttman, M; Leger, G | 1 |
| Ahlskog, JE; Fox, MW; Kelly, PJ | 1 |
| Graham, SJ; Higgins, BM; Morris, JG; Panegyres, PK; Williams, BK | 1 |
| Cedarbaum, JM; Olanow, CW | 1 |
| Horstink, MW; van de Vlasakker, CJ | 1 |
| Eriksson, T; Oberg, B; Pedersen, SW | 1 |
| Hauser, RA; Olanow, CW | 1 |
| Larsen, JP | 1 |
| Da Prada, M | 1 |
| Hughes, AJ; Lees, AJ; Stern, GM | 3 |
| Spokes, E | 1 |
| Aksnes, V; Brodtkorb, E; Helle, JR; Hestnes, A; Holmsen, R; Hunstad, NA; Johnson, S; Larsen, JP; Nessler, EG; Vilming, S | 1 |
| Gilhus, NE | 1 |
| Friedman, A; Sienkiewicz, J | 1 |
| Bulling, MT; Burns, RJ; Wing, LM | 1 |
| Agid, Y; Blin, J; Bonnet, AM; Brandabur, M; Dubois, B; Vidailhet, M | 1 |
| Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H | 1 |
| Berger, W; Bitschnau, W; Karamat, E; Kemmler, GW; Poewe, W; Ransmayr, G; Schmidhuber-Eiler, B | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
| Coleman, RJ; Marsden, CD; Quinn, NP; Traub, M | 1 |
| Crossman, AR | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
| Agid, Y; Belal, S; Bonnet, AM; Dubois, B; Marle, C; Vidailhet, MJ | 1 |
| Maj, J; Rogóz, Z; Skuza, G; Sowińska, H; Superata, J | 1 |
| Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM | 1 |
| Goldstein, M; Gopinathan, G; Lieberman, AN; Pasternack, P | 1 |
| Agid, Y; Blin, J; Dubois, B; Graybiel, AM; Hirsch, E; Javoy-Agid, F; Ruberg, M | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
| Darchen, F; Henry, JP; Horellou, P; Mallet, J; Marlier, L; Privat, A; Scherman, D | 1 |
| Aguilera, M; Alvarez, F; Cuevas, C; Franco-Bourland, R; Madrazo, I; Magallon, E; Morelos, A; Ostrosky-Solis, F; Zamorano, C | 1 |
| Flaster, E; Kostic, V; Przedborski, S; Sternic, N | 1 |
| Flaten, TP | 1 |
| Cerrato, PL | 1 |
| Glaeske, CS; Hofman, R; Pfeiffer, RF; Wilken, KE | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 4 |
| Arentsen, J; Dupont, E; Matthiesen, T; Rittig, S; Sørensen, K | 1 |
| Caraceni, T; Geminiani, G; Genitrini, S; Giovannini, P; Girotti, F; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ; Toone, B | 1 |
| Caraceni, T; Musicco, M; Scigliano, G | 1 |
| Lefeber, EJ; Rainer, C; Scheinost, NA | 1 |
| Crawford, TJ; Day, S; Everitt, BS; Goodrich, S; Henderson, L; Jones, F; Kennard, C; Park, DM | 1 |
| Backlund, EO; Ebendal, T; Freedman, R; Hamberger, B; Hansson, P; Hoffer, B; Lindblom, U; Meyerson, B; Olson, L; Strömberg, I | 1 |
| Coughlin, SS; Karstaedt, PJ; Pincus, JH | 1 |
| Bedini, L; Bellatreccia, A; Bonifati, V; Franzese, A; Meco, G; Vanacore, N | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Sage, JI; Zimmerman, T | 1 |
| Kleedorfer, B; Poewe, W; Schelosky, L | 1 |
| Cedarbaum, JM; Gandy, SE; McDowell, FH | 1 |
| Baronti, F; Brughitta, G; Davis, TL; Mouradian, MM | 1 |
| Appollonio, I; Cocco, E; Ferrarese, C; Frattola, L; Panerai, AE; Piolti, R; Rovati, L | 1 |
| Kleedorfer, B; Lees, AJ; Milroy, C; Ryan, R; Stern, GM; Turjanski, N | 1 |
| Chong, PN | 1 |
| Durrieu, G; Montastruc, JL; Rascol, A; Senard, JM; Tran, MA | 1 |
| Graham, JS; Henderson, JM; Morris, JG; Yiannikas, C | 1 |
| Altus, P; Hencey, MA; Weissman, MS | 1 |
| Battistin, L; Bracco, F; Malesani, R; Saladini, M | 1 |
| Cunningham, MA; Darby, DG; Donnan, GA | 1 |
| George, CF; Higginson, I; Macklin, BS; Renwick, AG; Robertson, DR; Waller, DG | 1 |
| MacMahon, DG; Marshall, T; Overstall, PW | 1 |
| Bowes, SG; Charlett, A; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 2 |
| Abbott, RJ; Millac, PA; Ray-Chaudhuri, K | 1 |
| Driver, PS | 1 |
| de Pedro-Cuesta, J; Garcia-Inesta, A; Micheli, F; Petersen, IJ; Vassilopoulos, D | 1 |
| Goldswain, PR; Harrison, WB; Reutens, DC | 1 |
| Kayser, S; Richter, M | 1 |
| Bishop, S; Hughes, AJ; Lees, AJ; Stern, GM | 1 |
| Agnoli, A; Carta, A; Marsden, CD; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Block, G; Bush, D; Last, B; Liss, C; Manyam, B; Nakano, K; Nausieda, P; Olanow, CW; Tetrud, JA | 1 |
| Aquilonius, SM; Bredberg, E; Paalzow, L; Tedroff, J | 1 |
| George, CF; Robertson, DR | 1 |
| Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M | 1 |
| Baas, H; Fischer, PA | 3 |
| Duvoisin, RC; Heikkila, RE; McHale, DM; Sage, JI; Sonsalla, PK | 2 |
| Bodian, CA; Elizan, TS; Mendoza, MR; Moros, DA; Pang, S; Yahr, MD | 3 |
| Fornadi, F; Ulm, G | 2 |
| Korczyn, AD; Rabey, JM; Streifler, M; Treves, T | 2 |
| Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 1 |
| Susel, Z; Yarnitsky, D | 1 |
| Edwards, RL; Oliver, WA; Todman, DH | 1 |
| Jellinger, K; Pearce, RK; Seeman, P; Tourtellotte, WW | 1 |
| Fassl, H; Jörg, J; Kleinhenz, J; Vieregge, P | 1 |
| Bergen, M; Hening, WA; McHale, D; Sage, JI; Walters, AS | 1 |
| Hodges, LC; Rapp, CG | 1 |
| Sanchez-Ramos, J; Singer, C; Weiner, WJ | 1 |
| Berlan, M; Chatelut, E; Durrieu, G; Montastruc, JL; Montastruc, P; Rascol, A; Rispail, Y | 1 |
| Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H | 1 |
| Cedarbaum, JM | 2 |
| Blackburn, NA; Boddie, HG; Ellis, CJ; Kendal, BR; MacMahon, DG; Sachdev, D | 1 |
| Montastruc, JL; Rascol, O; Salachas, F | 1 |
| Coleman, RJ | 1 |
| Hauglie-Hanssen, E; Wester, K | 1 |
| Appley, AJ; Apuzzo, ML; Boyd, SD; Couldwell, WT; Neal, JH; Waters, CH; Weiner, LP; Wheelock, VH | 1 |
| Abercrombie, ED; Stricker, EM; Zigmond, MJ | 1 |
| Allain, H; Giraud, JR; Jacquemard, F; Palaric, JC | 1 |
| Bonavita, V; Marshall, RW; Sasso, E; Tedeschi, G | 1 |
| Bowes, SG; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Cowan, A | 1 |
| Calne, DB; Chu, NS; Lu, CS; Martin, WR; Peppard, RF; Teal, P | 1 |
| Dupont, E; Fabre, N; Hirt, D; Hoyer, M; Lataste, X; Lücking, C; Poewe, W; Rascol, O; Rinne, U; Teräväinen, H | 1 |
| Hamaguchi, K; Iwasaki, A; Iwasaki, S; Narabayashi, Y; Takakusagi, M | 2 |
| Belliardo, F; Betto, P; Corradini, C; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Stocchi, F | 1 |
| Hubble, JP; Koller, WC | 1 |
| Abascal, J; Bravo, G; Lopez-Lozano, JJ | 2 |
| Agid, Y; Dubois, B; Lhermitte, F; Pilon, B | 1 |
| Baas, H; Briebach, T; Fischer, PA | 1 |
| Delwaide, PJ; Olivier, E | 1 |
| Gibb, WR; Ward, CD | 1 |
| Korczyn, A; Salganik, I | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM | 4 |
| Aquilonius, SM; Gudjónsson, O; Hartvig, P | 1 |
| Olsson, JE | 1 |
| Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 2 |
| Pletscher, A | 2 |
| Youdim, MB | 2 |
| Jansen, EN; Meerwaldtt, JD | 1 |
| Birkmayer, JG; Birkmayer, W; Paletta, B; Vrecko, K | 1 |
| Di Paolo, T; Harnois, C | 1 |
| Genitrini, S; Giovannini, P; Girotti, F; Piccolo, I; Scigliano, G; Suchy, I; Testa, D | 1 |
| Becker, AL; Bilchik, TR; Blumenfeld, A; Fourie, PB; Fritz, VU; Ming, A; Reef, HE; Saling, M; Temlett, JA | 1 |
| Klockgether, T; Turski, L | 1 |
| Lera, G; Muruzabal, J; Obeso, JA; Vaamonde, J | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Harts, A; McDowell, FH; Silvestri, M; Toy, L | 1 |
| Abe, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Covicković-Sternić, N; Kostić, VS | 1 |
| Lang, AE; Lataste, X; Riley, DE; Vachon, L | 1 |
| Ang, L; Rajput, A; Rajput, AH; Rozdilsky, B | 1 |
| Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM | 2 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Pirtosek, Z; Stern, GM; Webster, R | 1 |
| Meltzer, HY; Parsa, MA; Ramirez, LF; Rohr, T | 1 |
| Boyce, S; Clarke, CA; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Bruggi, P; Martignoni, E; Nappi, G; Pacchetti, C; Sibilla, L; Turla, M | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Bakay, RA; Goetz, CG; Grossman, RG; Klawans, HL; Koller, WC; Penn, RD; Stebbins, GT | 1 |
| Cahill, DW; Olanow, CW | 1 |
| Baratta, P; Falini, A; Ferrante, C; Motti, E; Mulazzi, D; Pezzoli, G; Pizzuti, A; Silani, V; Vegeto, A; Zecchinelli, A | 1 |
| Clough, CG; Detta, A; Henderson, BT; Hitchcock, ER; Hughes, RC; Kenny, BG | 1 |
| Campbell, NR; Goodridge, AE; Hasinoff, BB; Kara, M; Rankine, D | 1 |
| Bolduc, PL; Preziosi, TJ; Robinson, RG; Starkstein, SE | 1 |
| Imai, H; Narabayashi, H | 1 |
| de Yebenes, JG; Fahn, S; Nygaard, TG; Trugman, JM | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; LeWitt, PA; Nelson, MV | 1 |
| Caraceni, T; Giovannini, P; Girotti, F; Musicco, M; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Heuser, IJ; Juncos, JL; Stein, MB; Uhde, TW | 1 |
| Baronti, F; Chase, TN; Heuser, IJ; Mouradian, MM | 1 |
| Bowes, SG; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Hughes, JR; Leeman, AL; Nicholson, PW; O'Neill, CJ | 1 |
| Avoni, P; Baruzzi, A; Contin, M; Cortelli, P; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; Blexrud, MD; Carmichael, SW; Kelly, PJ; Stoddard, SL; Tyce, GM; van Heerden, JA; Windebank, AJ | 1 |
| Hara, Y; Imai, T; Sakakura, T; Takebe, Y; Takeuchi, J; Yasuda, T | 1 |
| Boyson, SJ | 1 |
| Benabid, AL; Champay, AS; Gaio, JM; Hommel, M; Perret, J; Pollak, P | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| McHale, DM; Sage, JI; Sonsalla, PK; Vitagliano, D | 1 |
| Kortis, HI; Sage, JI; Sommer, W | 1 |
| Allen, G; Burns, RS; Calne, DB; Peppard, RF; Petruk, KC; Tsui, JK | 1 |
| Baumann, G; Chin, L; Gopinathan, G; Lieberman, A; Miller, E; Neophytides, A | 1 |
| Juncos, JL; Pullman, SL; Sanes, JN; Watts, RL | 1 |
| Jansen, EN; van Laar, T | 1 |
| Cedarbaum, JM; Kutt, H; Silvestri, M | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Askenasy, JJ; Braun, Z; Keren, O; Mendelson, L | 1 |
| Dousa, MK; Muenter, MD; Tyce, GM | 1 |
| Camerlingo, M; Casto, L; Cesana, BM; Ferraro, B; Gazzaniga, GC; Mamoli, A | 1 |
| Alagia, G; Bellomo, G; Ciuffetti, G; Mercuri, M; Santambrogio, L | 1 |
| Boucher, B; Gancher, ST; Gliessman, P; Nutt, JG; Woodward, WR | 1 |
| Dufresne, JJ | 1 |
| Brown, LK; Miller, A; Moros, DA; Zupnick, HM | 1 |
| Graber, B; Hofman, R; Kang, J; Pfeiffer, RF; Wilson, J | 1 |
| Roos, RA; van der Velde, EA; Vredevoogd, CB | 1 |
| Kahane, A; Rahamim, E; Sharon, R | 1 |
| Sollazzo, D | 1 |
| Braun-Falco, O; Landthaler, M; Przybilla, B; Schwab, U | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Vescovi, A | 1 |
| Cote, L; Dyrenfurth, I; Frantz, A; Mayeux, R; Stern, Y; Williams, JB | 1 |
| Albani, G; Amabile, G; Fattapposta, F; Morocutti, C; Pozzessere, G; Rizzo, PA; Sanarelli, L | 1 |
| Benecke, R; Buruma, O; Cantello, R; Day, BL; Dick, JP; Gioux, M; Marsden, CD; Rothwell, JC; Thompson, PD | 1 |
| Andersen, K; Balldin, J; Gottfries, CG; Granérus, AK; Modigh, K; Svennerholm, L; Wallin, A | 1 |
| Heikkila, RE; McHale, DM; Sage, JI; Sonsalla, P; Vitagliano, D | 1 |
| Araki, H; Kondo, T; Muramoto, S; Narabayashi, H; Nishi, K; Takubo, H | 1 |
| Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V | 1 |
| Kraus, P; Kuhn, W; Przuntek, H | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM; Webster, R | 1 |
| Lewin, R | 2 |
| Langston, JW; Tetrud, JW | 2 |
| Adam, MJ; Allen, G; Burns, RS; Calne, DB; Guttman, M; Martin, WR; Parker, RA; Peppard, RF; Ruth, TJ; Tulipan, NB | 1 |
| Eatough, VM; Frankel, JP; Kempster, PA; Lees, AJ; Nathanson, M; Stern, GM; Stibe, CM | 1 |
| Heinonen, EH; Rinne, UK | 1 |
| Heinonen, EH; Rinne, UK; Tuominen, J | 1 |
| Parker, S; Teychenne, PF | 1 |
| Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A | 1 |
| Eatough, V; Frankel, J; Lees, AJ; Stern, GM | 1 |
| Boesen, F; Dupont, E; Heinonen, E; Mikkelsen, B; Mogensen, P; Rasmussen, C; Sivertsen, B | 1 |
| Elizan, TS; Moros, D; Yahr, MD | 1 |
| Gershanik, OS; Rubinstein, M; Stefano, F | 1 |
| Fiszer, U | 1 |
| Chase, TN; Cox, C; Fabbrini, G; Fedio, P; Mohr, E; Schlegel, J; Williams, J | 1 |
| Deleu, D; Ebinger, G; Jacques, M; Michotte, Y | 2 |
| Calne, DB; Wolters, EC | 1 |
| Agnoli, A; Carta, A; Ruggieri, S; Stocchi, F | 1 |
| Fletcher, NA; Harding, AE; Holt, IJ; Mallet, J; Marsden, CD; Nygaard, TG | 1 |
| Bottomley, JM; Frankel, JP; Haran, NS; Kapoon, R; Lees, AJ; Pirtosek, Z; Stern, GM | 1 |
| Agnoli, A; Carta, A; Catarci, M; Ruggieri, S; Stocchi, F | 1 |
| Agid, Y; Bonnet, AM; Jenner, PG; Lataste, X; Markstein, R; Marsden, CD; Pourcher, E; Quinn, NP; Temlett, JA | 1 |
| Fisher, LJ; Friedmann, T; Iuvone, PM; Jinnah, HA; Langlais, PJ; O'Malley, KL; Rosenberg, MB; Shimohama, S; Wolff, JA; Xu, L | 1 |
| Gauger, LL; Olanow, CW; Werner, EG | 1 |
| Goetz, CG; Klawans, HL; Rajput, AH; Tanner, CM; Thiessen, B; Uitti, RJ | 1 |
| Caraceni, T; Geminiani, G; Tamma, F | 1 |
| Kohsaka, S; Uchida, K | 1 |
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Heikkila, RE; Sage, JI; Sonsalla, PK; Trooskin, S | 1 |
| Gilley, DW; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Aymard, N; Rondot, P; Teinturier, A; Ziegler, M | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Aarli, JA; Gilhus, NE | 1 |
| Gerdes, U; Haagen, K; Ulm, G | 1 |
| Dickins, QS; Dobson, J; Rodnitzky, RL | 1 |
| Askenasy, JJ; Catz, A; Mendelson, L | 1 |
| Crossley, J; Ferguson, I; Peachey, RD; Reynolds, NJ | 1 |
| Dordain, G; Dostert, P; Strolin Benedetti, M; Vernay, D | 1 |
| Hara, H; Kawase, J; Wakayama, Y | 1 |
| Jenner, P; Marsden, CD; Rose, S; Thomas, K | 1 |
| Davoudi, H; Durso, R; Feldman, RG; Szabo, G | 1 |
| Bar, M; Graff, E; Isakov, A; Oberman, Z; Rabey, JM; Scharf, M | 1 |
| Downes, JJ; Evenden, JL; Morris, RG; Robbins, TW; Roberts, AC; Sahakian, BJ | 1 |
| Birkmayer, GJ; Birkmayer, W | 1 |
| Broe, GA; Genge, S; Hely, MA; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 2 |
| Carter, JH; Hatcher, LF; Nutt, JG; Trotman, TL; Woodward, WR | 1 |
| Cedarbaum, JM; Hoey, M; McDowell, FH | 1 |
| Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA | 1 |
| Grandas, F; Lera, G; Luquin, MR; Martínez-Lage, JM; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Jankovic, J; Schwartz, K; Vander Linden, C | 1 |
| Bush, DF; Liss, CL; Morton, A | 1 |
| Artieda, J; Grandas, F; Lera, G; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Rodriguez, ME; Vaamonde, J | 1 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 2 |
| Bush, DF; Hutton, JT; Liss, CL; Morris, JL; Reines, S; Smith, ME | 1 |
| Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM | 2 |
| Feldman, RG; Kelly, MR; Mosbach, PA; Saint Hilaire, MH; Thomas, CA | 1 |
| Banerjee, AK; Falkai, PG; Savidge, M | 1 |
| Kande'l, EI | 1 |
| Hardie, RJ | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Agid, Y; Bonnet, AM; Cusimano, G; Dubois, B; Lhermitte, F; Pillon, B | 1 |
| Chacon, J; Chaparro, P; Iriarte, LM; Madrazo, J; Vadillo, J | 1 |
| Gibb, WR; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Factor, SA; Ingenito, AM; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Smith, RG; Wilson, JA | 1 |
| Allen, GS; Burns, RS; Parker, RA; Tulipan, NB | 1 |
| Grandas, F; Obeso, JA | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| Glatt, S; Hassanein, R; Koller, WC; Vetere-Overfield, B | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Esteguy, M; Guimaraes, J; Lhermitte, F; Pillon, B; Vigouret, JM | 1 |
| Dubois, B | 1 |
| d'Anglejan Chatillon, J | 1 |
| Bondi, JV; Coleman, RJ; Hichens, M; Lange, KW; Loper, AE; Marsden, CD; Quinn, NP; Stahl, SM | 1 |
| Cosio, MG; Darauay, CM; Vincken, WG | 1 |
| Emskötter, T; Heidenreich, C; Lachenmayer, L | 1 |
| Carter, JH; Nutt, JG; Trotman, TL; Woodward, WR | 1 |
| Benabid, AL; Champay, AS; Hommel, M; Perret, JE; Pollak, P | 1 |
| Arikawa, K; Inanaga, K; Kuniyoshi, M; Miura, C | 1 |
| Gerstenbrand, F; Kleedorfer, B; Poewe, W | 1 |
| Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Allain, H; Bentue-Ferrer, D; Defawe, G; Jacquemard, F; Milon, D; Moran, P | 1 |
| Friedman, JH; Lannon, MC | 1 |
| Fisher, H; Sandyk, R | 1 |
| Ackermann, H; Oertel, WH; Ziegler, W | 1 |
| Agnoli, A; Agostini, C; Barbato, L; Bragoni, M; Carta, A; Ruggieri, S; Stocchi, F | 1 |
| Gil, R; Lefèvre, JP; Neau, JP; Rivasseau-Jonveaux, T; Toullat, G | 1 |
| Golden, WE; Lavender, RC; Metzer, WS | 1 |
| Boomsma, F; Hovestadt, A; Man in't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Villares, JC | 1 |
| Calne, D; Hertzman, C; Snow, B; Wiens, M | 1 |
| Degl'Innocenti, F; Marini, P; Maurello, MT | 1 |
| Diamond, SG; Hoehn, MM; Markham, CH; McDowell, FH; Muenter, MD | 2 |
| Boucher, B; Gancher, ST; Nutt, JG; Woodward, WR | 1 |
| Factor, SA; Hefti, F; Weiner, WJ | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Kefalos, J; Pourcher, E | 1 |
| Astedt, B; Björklund, A; Brundin, P; Bygdeman, M; Frackowiak, R; Freedman, R; Gustavii, B; Hoffer, BJ; Johnels, B; Leenders, KL; Lindholm, T; Lindvall, O; Marsden, D; Olson, L; Rehncrona, S; Rothwell, JC; Seiger, A; Steg, G; Strömberg, I; Widner, H | 1 |
| Bushmann, M; Dobmeyer, SM; Leeker, L; Perlmutter, JS | 1 |
| Berthier, ML; Bolduc, PL; Mayberg, HS; Preziosi, TJ; Robinson, RG; Starkstein, SE | 1 |
| Clanet, M; Doyon, B; Montastruc, JL; Rascol, A; Rascol, O; Simonetta, M; Soulier-Esteve, MJ | 1 |
| Bennett, JP; Landow, E; Turk, M | 1 |
| Barter, R; Koller, WC; Vetere-Overfield, B | 1 |
| Kuroda, S; Nakashima, M; Otsuki, S; Ujike, H | 1 |
| Douyon, R; Klutchko, B; Rotrosen, J; Serby, M | 1 |
| Kagamihara, Y; Nagaoka, M; Nakajima, Y; Tanaka, R | 1 |
| Ando, S; Inose, T; Miyakawa, K; Miyakawa, M; Mizushima, S; Oyanagi, S | 1 |
| Case, TC; Hruby, VJ; Rockway, T; Snider, SR | 1 |
| Chase, TN; Fabbrini, G; Juncos, J; Serrati, C | 1 |
| Dichgans, J; Scholz, E | 1 |
| Pan, JB | 1 |
| Arévalo, R; Castro, R; Palarea, MD; Pérez, J; Rodríguez, M | 1 |
| Pincus, JH | 1 |
| Critchley, P; Grandas Perez, FJ; Jenner, PG; Marsden, CD; Nomoto, M; Parkes, JD; Quinn, NP; Stahl, S | 1 |
| Harvey, NS | 3 |
| Leathwood, PD | 1 |
| Rajput, AH; Uitti, RJ | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Coleman, R; Critchley, P; Grandas Perez, F; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Brown, RG; Gotham, AM; Marsden, CD | 2 |
| Critchley, P; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Schnaberth, G | 2 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA | 1 |
| Chen, SD; Pan, GB; Xu, DL; Yu, WC | 1 |
| Grandas, F; Martínez-Lage, JM; Obeso, JA; Rosario Luguin, M; Vaamonde, J | 1 |
| Johansson, F; von Knorring, L | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Testa, B; van de Waterbeemd, H | 1 |
| Burton, K | 1 |
| Karaban', IN; Man'kovskiĭ, NB | 1 |
| Casabona, J; Jankovic, J | 1 |
| Kempster, PA; Lees, AJ; Stern, GM; Stibe, CM | 1 |
| Huber, M | 1 |
| Baumann, G; Chin, L; Lieberman, A | 1 |
| Boyce, S; Jenner, P; Marsden, CD | 1 |
| Goldstein, M; Leibowitz, M; Lieberman, AN | 1 |
| Nagatsu, T | 1 |
| Cummings, JL; Friedenberg, DL | 1 |
| Albani, C; Hacisalihzade, SS; Mansour, M | 1 |
| Caltagirone, C; Carlesimo, A; Nocentini, U; Vicari, S | 1 |
| Crichton, P; Frankel, JP; Kempster, PA; Lees, AJ; Shorvon, P | 1 |
| Huber, SJ; Paulson, GW; Shulman, HG; Shuttleworth, EC | 2 |
| Guttman, M; Seeman, P | 2 |
| Guttman, M; Jellinger, K; Reynolds, GP; Riederer, P; Seeman, P; Tourtellotte, WW | 1 |
| Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA | 1 |
| Canal, N; Cecchetto, R; Franceschi, M; Panerai, AE; Smirne, S; Truci, G | 1 |
| Barone, P; Braun, A; Chase, TN; Fabbrini, G; Mouradian, MM; Serrati, C | 1 |
| Bazan, E; de Yebenes, JG; Mena, MA; Muradas, V; Reiriz, J | 1 |
| Fernandez Pardal, M; Gatto, M; Micheli, F; Perez y Gonzalez, N | 1 |
| García, S; Gershanik, OS; Scipioni, O | 1 |
| Heikkila, RE; Manzino, L; Sonsalla, PK | 1 |
| Agid, Y; Bonnet, AM; De Smet, Y; Grove, J; Saint-Hilaire, MH; Schechter, PJ; Tell, G | 1 |
| Agnoli, A; Antonini, A; Baronti, F; Bellantuono, P; Bravi, D; Brughita, G; Ruggieri, S; Stocchi, F | 1 |
| Cossutta, E; Ferrante, C; Pezzoli, G; Scarlato, G; Tesei, S; Zecchinelli, A | 2 |
| Agid, Y; Bonnet, AM; Javoy-Agid, F; Ruberg, M | 1 |
| Sandyk, R; Snider, SR | 1 |
| Berlan, M; Boneu, B; Caranobe, C; Lafontan, M; Montastruc, JL; Rascol, A; Villeneuve, A | 1 |
| Sommer, H | 1 |
| Basciani, M; Gambi, D; Ghilardi, MF; Onofrj, M | 1 |
| Globus, M; Melamed, E; Mildworf, B | 1 |
| Escalona-Zapata, J; Giménez-Roldán, S; Mateo, D | 1 |
| Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD | 1 |
| Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO | 2 |
| Herskovits, E; Leston, J; Yorio, A | 1 |
| Bumbasirević, Lj; Kostić, V; Nikolić, M; Sternić, N | 1 |
| Laihinen, A; Rinne, UK | 1 |
| Agnoli, A; Carta, A; Denaro, A; Meco, G; Ruggieri, S; Stocchi, F | 1 |
| Cedarbaum, JM; Dhar, AK; Kutt, H; McDowell, FH; Watkins, S | 1 |
| Bitton, V; Melamed, E; Zelig, O | 2 |
| Ketsche, R; Vogel, HP | 1 |
| Caradoc-Davies, TH | 1 |
| Jenner, P; Marsden, CD | 1 |
| Clark, JC; Firnau, G; Garnett, ES; Jones, T; Leenders, KL; Marsden, CD; Nahmias, C; Palmer, AJ; Quinn, N | 1 |
| Mondal, BK; Mondal, KN | 1 |
| Delwaide, PJ; Maertens de Noordhout, A | 1 |
| Cacudi, N; de Mari, M; Ferrari, E; Iliceto, G; Lamberti, P | 1 |
| Caraceni, T; Giovannini, P; Piccolo, I; Scigliano, G | 1 |
| Birkmayer, GD; Birkmayer, W | 1 |
| Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Martignoni, E; Nappi, G; Pacchetti, C; Piccolo, I | 1 |
| Finberg, JP; Youdim, MB | 1 |
| Bodis-Wollner, I; Onofrj, M | 1 |
| Bergmann, KJ; Mendoza, MR; Yahr, MD | 1 |
| Kuskowski, MA; Mortimer, JA; Webster, DD | 1 |
| Bruno, G; Chase, TN; Fabbrini, G; Juncos, J; Serrati, C | 1 |
| Bermejo, F; Calandre, L; De Yebenes, JG; Martinez, P; Molina, JA | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Kondo, T; Nagatsu, T; Narabayashi, H; Yokochi, F | 1 |
| Jansen, EN; Meerwaldt, JD | 2 |
| Adam, MJ; Ammann, W; Bergstrom, M; Harrop, R; Laihinen, A; Martin, WR; Rogers, JG; Ruth, TJ; Sayre, CI; Stoessl, AJ | 1 |
| Albani, C; Asper, R; Baumgartner, G | 1 |
| Gibberd, FB | 2 |
| Aminoff, MJ | 1 |
| Berstad, J; Lien, K; Presthus, J | 1 |
| Dubuis, R | 1 |
| Duvoisin, RC; Golbe, LI | 1 |
| Foo, SH; Gopinathan, G; Lieberman, AN; Neophytides, A | 1 |
| Kurlan, R; Lichter, D; Miller, C; Nutt, JG; Rothfield, KP; Shoulson, I; Woodward, WR | 1 |
| Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN | 1 |
| Bottacchi, E; Camerlingo, M; Franceschi, M; Mamoli, A; Perego, L; Truci, G | 1 |
| Dai, J | 1 |
| Demonet, JF; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Simonetta, M | 1 |
| Calne, DB; Rinne, UK | 1 |
| Martin, WR | 1 |
| Gillman, MA; Sandyk, R | 1 |
| Holland, OB; Kennedy, B; Lake, CR; Murphy, D; Ziegler, MG | 1 |
| Delwaide, PJ; Gonce, M | 1 |
| Agnoli, A; Antonini, A; Baronti, F; Bellantuono, P; Bravi, D; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Etemadzadeh, E; Kaakkola, S; Lindén, IB; Männistö, P; Nissinen, E; Pohto, P | 1 |
| Lieberman, AN | 3 |
| Leicester, J; Morris, J; Pamphlett, R | 1 |
| De Jong, GJ; Hovestadt, A; Meerwaldt, JD | 1 |
| Hietanen, M; Teräväinen, H | 1 |
| Grandas, F; Luquin, MR; Martínez Lage, JM; Obeso, JA; Vaamonde, J | 2 |
| Agnoli, A; Bragoni, M; Bravi, D; Carta, A; Giorgi, L; Ruggieri, S; Stocchi, F | 1 |
| Aleuov, ShA; Karimova, MKh; Petelin, LS | 1 |
| Gershanik, OS; Luquin, MR; Obeso, JA; Scipioni, O | 1 |
| Ishizaki, F; Nishikawa, S | 1 |
| Cantini, R; Ferrito, G; Lutzemberger, L; Marcacci, G | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mohr, E; Mouradian, MM; Schlegel, J | 1 |
| Bartko, JJ; Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Schlegel, J | 1 |
| Betto, P; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Ruggeri, S; Stocchi, F | 1 |
| Karimova, MKh; Vartanian, KZ | 1 |
| Gibb, WR | 1 |
| Agnoli, A; Antonini, A; Bragoni, M; Carta, A; Ruggieri, SA; Stocchi, F | 1 |
| Fukuda, H; Fukuyama, H; Hara, K; Kameyama, M; Nakamura, S | 1 |
| Frackowiak, RS; Leenders, KL; Marsden, CD; Quinn, N | 1 |
| Albrecht, JW; Hutton, JT; Kopetzky, MT; Román, GC | 1 |
| Bouchard, S; Gawel, MJ; King, DB; Libman, I; McLean, DR; Paulseth, R; Raphy, B; Riopelle, RJ | 1 |
| Wallis, WE | 2 |
| Carroll, VS; Carvey, PM; Gilley, D; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 1 |
| Hassan, MN; Thakar, JH | 1 |
| Bliesath, H; Jellinger, K | 1 |
| de Pedro Cuesta, J | 1 |
| Bouchard, S; Gawel, MJ; Libman, I; Riopelle, RJ | 1 |
| Aymard, N; Holzer, J; Rondot, P; Ziegler, M | 2 |
| Marion, MH; Marsden, CD; Quinn, NP | 1 |
| Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 1 |
| D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP | 1 |
| Lees, AJ; Poewe, WH; Stern, GM | 4 |
| Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J | 1 |
| Grundmann, M; Schimrigk, K | 1 |
| Ane, M; Belin, J; Montastruc, JL; Rascol, A; Rascol, O | 1 |
| Denham, MJ; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Royston, JP | 1 |
| Backlund, EO | 1 |
| Berger, J; Factor, SA; Sanchez-Ramos, J; Weiner, WJ | 1 |
| Nadeau, S | 1 |
| Ferraro, TN; Hare, TA; Manyam, BV | 1 |
| Chase, TN; Juncos, JL; Pullman, SL; Sanes, JN; Watts, RL | 1 |
| Como, P; Kurlan, R | 1 |
| Calne, DB; Hurwitz, TA; Waterman, K | 1 |
| Bill, PL; Cosnett, JE | 1 |
| Duvoisin, RC; Heikkila, RE; Sage, JI; Schuh, L | 1 |
| Allain, H; Bentué-Ferrer, D; Reymann, JM; Sabouraud, O; Van den Driessche, J | 1 |
| Angel, RW; Garcia, F; Koch, K; Weinrich, M | 1 |
| Gancher, ST; Nutt, JG; Woodward, W | 1 |
| Mortimer, JA | 1 |
| Møller, A; Pedersen, H; Perrild, H; Siersbaek-Nielsen, K | 1 |
| Cedarbaum, JM; Hoey, M; Kutt, H; McDowell, FH | 1 |
| Wermuth, L | 1 |
| Lang, AE; Riley, D | 1 |
| Larsen, JP; Nessler, EG; Strandjord, R | 1 |
| Elias, JW; Hutton, JT; Imke, SC; Morris, JL; Román, GC | 1 |
| Caraceni, T; Giovannini, P; Piccolo, I; Scigliano, G; Soliveri, P; Suchy, I | 1 |
| Duncsak, P; Duvoisin, RC; Heikkila, RE; Manzino, L; Reddell, M; Sage, JI; Schuh, L; Sonsalla, PK; Trooskin, S | 1 |
| Greenberg, HS; Hirschorn, KA | 1 |
| Bergamasco, B; Chiadò, I; De Gennaro, T; Delsedime, M; Gilli, M; Rainero, I; Riccio, A | 1 |
| Carruthers, M; Quinn, N | 1 |
| Carter, JH; Kurlan, R; Lichter, D; Miller, C; Nutt, JG; Rothfield, K; Shoulson, I; Woodward, WR | 1 |
| Gibb, WR; Lees, AJ | 1 |
| Agid, Y; Blin, J; Bonnet, AM | 1 |
| Duvoisin, RC; Heikkila, R; Sage, JI; Sonsalla, PK; Trooskin, S | 1 |
| Bukhanov, VP | 1 |
| Comella, CL; Goetz, CG; Klawans, HL; Penn, RD; Shannon, KM; Tanner, CM; Witt, TR | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R; Tonello, C; Zoni, E | 1 |
| Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A | 1 |
| Siegfried, J | 1 |
| Ben-David, J; Fradis, M; Podoshin, L; Pratt, H | 1 |
| Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
| Nashef, L; Rose, FC | 1 |
| Indo, T; Takahashi, A | 4 |
| Gollomp, SM; Hurtig, HI; Stern, MB; Vernon, GM | 1 |
| Gerstenbrand, F; Ransmayr, G | 1 |
| Battistin, L; Bracco, F; Saladini, M | 1 |
| Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Gopinathan, G; Lieberman, AN; Neophytides, A; Pasternack, P | 1 |
| Nishizaki, K; Ogawa, N; Ota, Z; Sato, H; Takayama, H | 1 |
| Carvey, PM; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Bhatia, R; Weinrich, M | 1 |
| Friedman, J | 2 |
| Barbeau, A; Cloutier, T; Paris, S; Plasse, L; Roy, M | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Palmeri, S; Serrati, C | 1 |
| Robertson, GS; Robertson, HA | 1 |
| Friedman, JH; Max, J; Swift, R | 1 |
| Janota, I; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Fahn, S; Mayeux, R; Shale, H | 1 |
| Duvoisin, RC; Katchen, M | 1 |
| Birnbaum, A; Blair, RD; Kierans, C; Lang, AE | 1 |
| Critchley, P; Marsden, CD; Quinn, N | 1 |
| Agostino, R; Berardelli, A; Cruccu, G; Manfredi, M; Stocchi, F | 1 |
| Agniel, A; Celsis, P; Demonet, JF; Doyon, B; Marc-Vergnes, JP; Montastruc, JL; Puel, M; Rascol, A | 1 |
| Bracco, F; Ferla, S; Giometto, B; Meneghetti, G; Schergna, E | 1 |
| Marsden, CD; Obeso, JA; Rothwell, JC | 1 |
| Fischer, R; Iizuka, J | 1 |
| Dupont, E; Jakobsen, J; Mikkelsen, B | 1 |
| Kalow, W | 1 |
| Allen, JG; Hardie, RJ; Lees, AJ; Malcolm, SL; Stern, GM | 1 |
| Caraceni, TA; Giovannini, P; Girotti, F; Parati, E | 1 |
| Lees, AJ; Poewe, WH | 1 |
| Gaio, JM; Hommel, M; Mallaret, M; Perret, J; Pollak, P | 1 |
| Jenner, P; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 2 |
| Bouchard, S; Gawel, M; Libman, I; Riopelle, R | 1 |
| Jankovic, J; Orman, J | 1 |
| Alberts, MJ; Olanow, CW | 1 |
| Feldman, RG; Kaye, JA | 1 |
| Benecke, R; Day, BL; Dick, JP; Marsden, CD; Rothwell, JC | 1 |
| Lima, B; Neves, G; Nora, M | 1 |
| de Pedro, J | 1 |
| Goetz, CG; Shannon, KM; Tanner, CM | 1 |
| Herbster, G; Koller, WC | 2 |
| Hirayama, K; Yamada, T | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Kask, AM; Mouradian, MM; Serrati, C | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Serrati, C | 3 |
| Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 2 |
| Chase, TN; Fabbrini, G; Juncos, J; Mouradian, MM; Serrati, C | 1 |
| Kenny, A; Murrin, LC; Pfeiffer, RF | 1 |
| Kidron, D; Melamed, E | 1 |
| Iacono, RP; Sandyk, R; Snider, SR | 1 |
| Gancher, ST; Merrick, D; Nutt, JG; Woodward, WR | 1 |
| de Figueiredo, RJ; Hacisalihzade, SS; Senning, MF; Strotz, R | 1 |
| Corbin, DO; Williams, AC | 1 |
| Fletcher, WA; Lang, AE; Sharpe, JA; Zackon, DH | 1 |
| Bruno, G; Campbell, G; Jaffe, MJ; Karson, CN; Lavine, RA; Weinberger, DR | 1 |
| Gibson, JM; Kennard, C; Pimlott, R | 1 |
| Agid, Y; Bonnet, AM; Lhermitte, F; Loria, Y; Saint-Hilaire, MH | 1 |
| de Jong, GJ; Meerwaldt, JD; Schmitz, PI | 1 |
| Barry, KM; Pincus, JH | 1 |
| Breck, L; Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Hara, K; Iijima, S; Kameyama, M; Nakamura, S | 1 |
| Bloxham, CA; Dick, DJ; Moore, M | 1 |
| Khuraibet, AJ; Simpson, JA | 1 |
| Bulens, C; Meerwaldt, JD; Van der Wildt, GJ; Van Deursen, JB | 1 |
| Riopelle, RJ | 1 |
| Bouchard, S | 1 |
| Catarzi, L; Degl'Innocenti, F; Ginanneschi, A; Magnolfi, S; Marini, P | 1 |
| Nutt, JG; Woodward, WR | 1 |
| Kadykov, AS; Pivovarova, VM; Shvedkov, VV; Stoliarova, LG | 1 |
| Bergsrud, D; Elton, RL; Racy, A; Teychenne, PF | 1 |
| Bozek, CB; Calne, DB; Calne, S; Purves, S; Suchowersky, O | 1 |
| Demling, J | 1 |
| Patterson, JF | 1 |
| Burns, RS; LeWitt, PA; Newman, RP | 1 |
| Klawans, HL; Paleologos, N | 1 |
| Lakke, JP; Staal-Schreinemachers, AL; Wesseling, H | 1 |
| Caraceni, T; Carella, F; Girotti, F; Grassi, MP; Marano, R; Soliveri, P | 1 |
| Bhaskar, EA; Bhaskar, PA; Devaprabhu, A; Ganesan, RA; Vanchilingam, S | 1 |
| Draper, IT | 1 |
| Wilson, JA | 1 |
| Albizzati, MG; Bassi, S; Calloni, E; Frattola, L; Sbacchi, M | 1 |
| Clarke, A; Kurlan, R; Miller, C; Rivera-Calimlim, L; Rubin, AJ; Shoulson, I | 1 |
| Duvoisin, RC; Nygaard, TG | 1 |
| Langdon, N; Malcolm, PN; Parkes, JD | 1 |
| Calne, DB; Glover, R; Lau, E; Schulzer, M; Waterman, K | 1 |
| Gerstenbrand, F; Poewe, W | 1 |
| Berardelli, A; Day, BL; Dick, JP; Marsden, CD; Rothwell, JC | 1 |
| Gibb, WR; Griffith, DN | 1 |
| Chastang, C; Fenelon, G; Guillard, A | 1 |
| Devathasan, G; Hagihara, B; McCabe, M | 1 |
| Schneevoigt, K; von Kummer, R | 1 |
| Carlini, EA; Frochtengarten, ML; Maluf, E; Villares, JC | 1 |
| Critchley, P; Parkes, D | 1 |
| Cabranes, JA; Cantizano, L; Hernandez, ER; Krisnik, I; Rico, H; Varela de Seijas, E; Vazquez, A | 1 |
| Maesner, JE | 1 |
| Doe, J | 1 |
| Johnson, K; Lang, AE | 1 |
| Johnels, B | 1 |
| Gershanik, OS; Leist, A | 1 |
| Kase, M; Nomura, Y; Segawa, M | 1 |
| Gardner, WN; Langdon, N; Parkes, JD | 1 |
| Gibson, JM; Kennard, C | 1 |
| Aljanati, R; Caamaño, JL; Chouza, C; De Medina, O; Lorenzo, J; Romero, S; Scaramelli, A | 1 |
| Armstrong, GW; Grimes, JD; Halle, D; Hassan, MN; Trent, G | 1 |
| Lees, AJ; Poewe, W; Steiger, D; Stern, GM | 1 |
| Bieliauskas, L; Glantz, RH; Paleologos, N | 1 |
| Cheng, SC; Diercks, MJ; Glaeske, C; Hsieh, HH; Jefferson, A; Pfeiffer, RF | 1 |
| Cedarbaum, JM; McDowell, FH | 1 |
| Albani, C; Asper, R; Baumgartner, G; Hacisalihzade, SS | 1 |
| Globus, M; Melamed, E; Rosenthal, J; Uzzan, A | 1 |
| van der Drift, JH | 1 |
| Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 2 |
| Birbamer, G; Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Barry, K; Pincus, JH | 1 |
| Homma, Y; Ikuta, F; Takahashi, H; Takeda, S | 1 |
| de Pedro, J; Rosenqvist, U | 2 |
| Kobayashi, I; Maruyama, S; Ohta, K; Osawa, M | 1 |
| Benoit, P; Peutillot, A | 1 |
| Hacisalihzade, SS | 1 |
| Boas, J; Henriksen, L | 1 |
| Ballard, PA; Langston, JW; Tetrud, JW | 1 |
| Perlmutter, JS; Raichle, ME | 1 |
| Hardie, R | 1 |
| Fonda, D | 1 |
| Caranasos, GJ; Cluff, LE; Stewart, RB | 1 |
| Duvoisin, RC; Sage, JI | 1 |
| Bakker, K; Bruno, G; Chase, TN; Ruggieri, S; Tamminga, CA | 1 |
| Goldstein, M; Lieberman, AN | 1 |
| Backlund, EO; Freed, W; Herrera-Marschitz, M; Hoffer, B; Olson, L; Seiger, A; Strömberg, I | 1 |
| Feldman, RG; Lannon, MC | 1 |
| Kapfhammer, HP; Kuss, HJ; Rüther, E | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Reches, A | 1 |
| Adam, AM | 1 |
| Daniele, D; Gillio, S; Scarzella, L; Trebini, F | 1 |
| Wirz, D | 1 |
| Ogawa, N; Takayama, H; Yamamoto, M | 1 |
| Goetz, CG; Lutge, W; Tanner, CM | 1 |
| Jankovic, J; Nour, F | 1 |
| Luquin, MR; Martínez Lage, JM; Obeso, JA | 2 |
| Gopinathan, G; Lieberman, AN; Neophytides, A | 1 |
| Peterson, SL | 1 |
| Hachinski, V | 1 |
| Bailey, BA; Boulton, AA; Durden, DA; Yu, PH | 1 |
| Agid, Y; Dubois, B | 1 |
| Elton, RL; Hoehn, MM | 1 |
| De Keyser, J; Vincken, W | 1 |
| Di Battista, G; Di Meo, L; Figà-Talamanca, L; Gualandi, C; Lo Russo, F; Neri, G | 1 |
| Berglund, B; Kaijser, L; Sachs, C | 1 |
| Causon, R; Gibbs, JM; Jones, T; Leenders, KL; Legg, NJ; Wise, RJ; Wolfson, L | 1 |
| Delgado, MR; Grimes, JD | 1 |
| Cook, DG; Klawans, HL | 1 |
| Kapfhammer, HP; Rüther, E | 1 |
| Askenasy, JJ; Yahr, MD | 1 |
| Calne, DB; Jaffe, M; Larsen, TA; LeWitt, PA; Newman, RP | 1 |
| Ando, K; Mano, Y; Satoyoshi, E; Sunohara, N | 1 |
| Baas, H; Fischer, PA; Japp, G; Schneider, E | 2 |
| Bulpitt, CJ; Clifton, P; Davies, JB; Reid, JL; Shaw, K; Stern, G | 1 |
| Arlazoroff, A; Barber, Y; Bleicher, Z; Flechtir, S; Goldexberg, E | 1 |
| Rampen, FH | 1 |
| Kochar, AS | 1 |
| Grau-Veciana, JM; Peiró Grasa, A | 1 |
| Murray, TS; Wilson, JA | 1 |
| Cote, L; Mayeux, R; Mulvey, K; Stern, Y | 1 |
| Schott, GD | 1 |
| Hershey, LA | 1 |
| Agid, Y; Bonnet, AM; Esteguy, M; Kefalos, J; Lhermitte, F | 1 |
| Feinberg, SS; Feldman, RG; Friedman, JH | 1 |
| Admani, AK; Cordingley, GJ; Harris, RI; Verma, S | 1 |
| Alfonsi, E; Horowski, R; Martignoni, E; Nappi, G; Sandrini, G | 1 |
| Benvenuti, F; Bindi, A; Costantini, S; De Scisciolo, G; Pantaleo, T; Rossi, L; Zappoli, R | 1 |
| Harsch, HH; Miller, M; Young, LD | 1 |
| Anderson, JL; Nutt, JG; Woodward, WR | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Bermejo Pareja, F; de Yébenes, JG; Martinez-Martin, P; Muradas, V | 1 |
| Fitzmaurice, H; Fowler, CJ; Kirby, RS; Marsden, CD; Milroy, EJ; Quinn, NP; Rickards, D; Turner-Warwick, RT | 1 |
| Hirose, S; Ishimitsu, T | 1 |
| Jyoichi, T; Kobayashi, M; Miyahara, T; Ogura, Y; Sato, S; Shimojyo, S; Yasuda, K | 1 |
| Bamji, AN; Calne, DB; Greenacre, JK; Leigh, PN; Teychenne, PF | 1 |
| Ambani, L; Burrow, GN; Donabedian, R; Spaulding, SW; Van Woert, M | 1 |
| Bédard, P; Boucher, R; Langelier, P; Larochelle, L; Parent, A; Poirier, LJ; Roberge, AG | 1 |
| Poirier, LJ | 1 |
| Glasgow, GL; Henley, JW; Willoughby, EW | 1 |
| Garelis, E; Lal, S; Sourkes, TL; Young, SN | 1 |
| Ferrari, E | 1 |
| Van Loon, GR | 1 |
| Hinterbuchner, C; Hinterbuchner, LP | 1 |
| Swanson, PD | 1 |
| Rondot, P | 1 |
| Grad, B; Rosenberg, G; Wener, J; Wener, SW | 1 |
| Antal, J | 1 |
| Devereaux, MW; Mancall, EL | 1 |
| Rosin, AJ | 1 |
| Jenner, WN; Rose, FA | 1 |
| Boal, D; Le Brun, Y; Lieberman, A; Zolfaghari, M | 1 |
| Calne, DB; Claveria, LE; Eastman, R; Greenacre, JK; Petrie, A; Teychenne, PF | 1 |
| Radbill, R; Rosenberg, G; Schwartz, A | 1 |
| Braham, J; Sarova-Pinhas, I | 1 |
| Holmsen, R; Presthus, J | 1 |
| Sandler, M | 1 |
| Cotzias, GC; Mena, I; Mendez, J; Papavasiliou, PS | 1 |
| Ericsson, AD; McCann, DS | 1 |
| Allen, JG; Caine, DB; Claveria, LE | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Markham, CH | 1 |
| Korf, J; Lakke, JP; Nienhuis, RJ; Schut, D; van Praag, HM | 1 |
| Carreray, N; Del Amo, F; Delgado, G; Marti-Massó, JF; Martínez-Lage, JM | 1 |
| Cotzias, GC | 1 |
| Fischer, PA; Gundelsheimer, W; Jacobi, P; Schneider, E | 1 |
| Il'inskiĭ, IA; Safronov, VA; Vasin, NIa | 1 |
| Granerus, AK; Jagenburg, R; Rödjer, S; Svanborg, A | 1 |
| Nittner, K | 1 |
| Mayer, RF | 1 |
| McDowell, FH; Sweet, RD; Wasterlain, C | 1 |
| Chakravorty, NK | 1 |
| Campanella, G; Pennetta, R | 1 |
| Masi, G; Megna, GF; Puca, FM; Specchio, LM | 1 |
| Bartholini, G; Bigler, R; Brossi, A; Burns, JJ; Kaiser, A; Pletscher, A; Pool, W; Sheppard, H | 1 |
| Klawans, HL; Topel, JL | 1 |
| Johnson, SE; Norman, N; Sjaastad, O | 1 |
| Tonge, D | 1 |
| Gordon, VC; Oster, C | 1 |
| Birkett, DJ; Mearrick, PT; Morris, J; Wade, DN | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
| Fermaglich, J | 1 |
| Steinhäusl, H | 1 |
| Baker, AB; Loewenson, RB; Martin, WE; Resch, JA | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Borromei, A; Manzini, A | 1 |
| Strouthidis, TM | 1 |
| Hollmann, TD; Kravitz, EA | 1 |
| Boulton, AA; Wu, PH | 1 |
| Cane, DB | 1 |
| Tóth, S | 1 |
| Fischer, PA; Jacobi, P; Maxion, H; Schneider, E | 1 |
| Callagham, N; Mcllroy, M; O'Connor, M | 1 |
| Calaghan, N; McIlroy, M; O'Connor, M | 1 |
| Feldman, RD; Pearlman, CA; Sax, DS | 1 |
| Bianco, A; Borzone, A; Butti, A; Cagossi, M; Fianchini, A; Ghirlanda, G; Lojacono, L; Nanni, G; Suraci, V | 1 |
| Bergmann, S; Frears, CC; Godwin-Austen, RB | 1 |
| Chen, KM | 1 |
| Ezrielev, GZ | 1 |
1569 review(s) available for levodopa and Parkinson Disease
| Article | Year |
|---|---|
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Purines; Randomized Controlled Trials as Topic; Receptor, Adenosine A2A; Treatment Outcome | 2021 |
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2021 |
"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive; Systematic Reviews as Topic | 2021 |
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease | 2021 |
The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Rhabdomyolysis Associated with Severe Levodopa-Induced Dyskinesia in Parkinson's Disease: A Report of Two Cases and Literature Review.
Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rhabdomyolysis | 2021 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Topics: Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Practice Guidelines as Topic | 2021 |
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Topics: Antiparkinson Agents; Dietary Supplements; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodopa; Memantine; Microscopy, Electron; Multiple Sclerosis; Neuronal Plasticity; Neurons; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Synapses; Synaptic Transmission; Tetrabenazine | 2021 |
Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
Topics: Antiparkinson Agents; Combined Modality Therapy; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Pramipexole; Treatment Outcome | 2021 |
[Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Spain; Treatment Outcome | 2021 |
GOCOVRI
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Hypotension, Orthostatic; Levodopa; Monoamine Oxidase; Parkinson Disease | 2022 |
Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Pharmaceutical Preparations; Psychotic Disorders; United States | 2021 |
Freezing of gait: overview on etiology, treatment, and future directions.
Topics: Causality; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2022 |
Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias.
Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease | 2022 |
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
[Relevance of COMT inhibitors in the treatment of motor fluctuations].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinson Disease; Tolcapone | 2022 |
Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
Topics: Brain-Derived Neurotrophic Factor; Dopamine; Dyskinesias; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Signal Transduction | 2022 |
Stem Cell-based and Advanced Therapeutic Modalities for Parkinson's Disease: A Risk-effectiveness Patient-centered Analysis.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Patient-Centered Care; Quality of Life | 2022 |
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Recent Advances in Drug Therapy for Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2023 |
Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2022 |
Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Randomized Controlled Trials as Topic | 2022 |
Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
Topics: Antiparkinson Agents; Blood-Brain Barrier; Dopamine; Humans; Levodopa; Parkinson Disease; Prodrugs | 2022 |
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide | 2023 |
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2022 |
COMT Inhibitors in the Management of Parkinson's Disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Topics: Humans; Indans; Levodopa; Parkinson Disease; Pramipexole | 2022 |
Striatal synaptic adaptations in Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; Interneurons; Levodopa; Mice; Parkinson Disease | 2022 |
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Striatal glutamatergic hyperactivity in Parkinson's disease.
Topics: Animals; Basal Ganglia; Corpus Striatum; Levodopa; Neostriatum; Parkinson Disease | 2022 |
Restoration and targeting of aberrant neurotransmitters in Parkinson's disease therapeutics.
Topics: Basal Ganglia; Dopamine; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2022 |
Acupuncture for Parkinson's disease: From theory to practice.
Topics: Acupuncture Therapy; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Prospective Studies | 2022 |
From the tyrosine hydroxylase hypothesis of Parkinson's disease to modern strategies: a short historical overview.
Topics: Animals; Catecholamines; Dopaminergic Neurons; Levodopa; Parkinson Disease; Tyrosine 3-Monooxygenase | 2022 |
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease | 2022 |
[Parkinson's Disease with Intolerable Painful Dystonia: Classification and Therapeutic Choices of Pain in Parkinson' Disease].
Topics: Antiparkinson Agents; Dystonia; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Topics: Catechol O-Methyltransferase; Dyskinesias; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide | 2023 |
Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.
Topics: Dementia; Drug Development; Humans; Levodopa; Lewy Body Disease; Parkinson Disease | 2022 |
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
Topics: Carbidopa; COVID-19; COVID-19 Vaccines; Deep Brain Stimulation; Drug Combinations; Humans; Immunization, Secondary; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome; Vaccination | 2022 |
Closing the loop for patients with Parkinson disease: where are we?
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2022 |
Determination of levodopa by chromatography-based methods in biological samples: a review.
Topics: Carbidopa; Catecholamines; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2022 |
Neuroprotective approaches to halt Parkinson's disease progression.
Topics: Antiparkinson Agents; Disease Progression; Dopamine; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2022 |
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Topics: Adult; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Parkinsonian Disorders; Syndrome; Tremor | 2022 |
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.
Topics: alpha-Synuclein; Biological Products; Biomarkers; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2022 |
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
Topics: Antiparkinson Agents; Drugs, Investigational; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
The Prephase Nursing in Levodopa Carbidopa Intestinal Gel Therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
Topics: Activities of Daily Living; Bayes Theorem; Deep Brain Stimulation; Globus Pallidus; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials.
Topics: Antiparkinson Agents; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 2022 |
The Role of Microelectrode Recording in Deep Brain Stimulation Surgery for Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Deep Brain Stimulation; Humans; Levodopa; Microelectrodes; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2022 |
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep | 2022 |
How I treat Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Topics: 3-Hydroxyanthranilic Acid; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Levodopa; Parkinson Disease; Quinolinic Acid; Tryptophan | 2022 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2023 |
Autopallidotomy: From Colloquial Term to Scientific Theory.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesias; Globus Pallidus; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2022 |
Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease.
Topics: Aged; Biological Products; Carbidopa; Cholinergic Antagonists; Dopamine; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Short and Long-Term Cognitive Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease and Identification of Relevant Factors.
Topics: Cognition; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2022 |
Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies.
Topics: Botulinum Toxins; Cholinergic Antagonists; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2022 |
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease | 2022 |
Relationship Between Gut Bacteria and Levodopa Metabolism.
Topics: Antiparkinson Agents; Bacteria; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Middle Aged; Parkinson Disease; Quality of Life | 2022 |
Deep Brain Stimulation-Withdrawal Syndrome in Parkinson's Disease: Risk Factors and Pathophysiological Hypotheses of a Life-Threatening Emergency.
Topics: COVID-19; Deep Brain Stimulation; Humans; Levodopa; Pandemics; Parkinson Disease; Treatment Outcome | 2023 |
Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pramipexole | 2023 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Aged; Apomorphine; Carbidopa; Humans; Levodopa; Middle Aged; Network Meta-Analysis; Parkinson Disease; Quality of Life | 2022 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life | 2022 |
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease | 2022 |
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
Topics: Dopaminergic Neurons; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Dopamine; Receptors, G-Protein-Coupled | 2023 |
Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
Topics: Antiparkinson Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Pharmacogenetics; Prospective Studies | 2023 |
The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease.
Topics: Antiparkinson Agents; Calcium Channels; Corpus Striatum; Humans; Levodopa; Parkinson Disease | 2023 |
Serotonin 5-HT
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin | 2023 |
Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson's Disease.
Topics: Antiparkinson Agents; Cognition; Humans; Levodopa; Parkinson Disease; Postural Balance | 2023 |
Acute/subacutae demyelinating polyneuropathy in Parkinson's Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Prospective Studies | 2023 |
An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson's disease.
Topics: Dopamine Agonists; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life; Sleep Wake Disorders | 2023 |
Efficacy of Deep Brain Stimulation for Camptocormia in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Databases, Factual; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Subthalamic Nucleus | 2023 |
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2023 |
Cognition and freezing of gait in Parkinson's disease: A systematic review and meta-analysis.
Topics: Cognition; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2023 |
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
Topics: Antiparkinson Agents; Gastrointestinal Tract; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2023 |
Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.
Topics: Brain; Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Receptors, Purinergic P1 | 2023 |
Restorative cell and gene therapies for Parkinson's disease.
Topics: Central Nervous System; Corpus Striatum; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference.
Topics: Amino Acids; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease | 2023 |
Ambiental Factors in Parkinson's Disease Progression: A Systematic Review.
Topics: Aged; Air Pollutants; Disease Progression; Female; Humans; Levodopa; Parkinson Disease; Particulate Matter | 2023 |
Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
Topics: Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Role of P11 through serotonergic and glutamatergic pathways in LID.
Topics: Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa, homocysteine and Parkinson's disease: What's the problem?
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamin B Complex | 2023 |
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2023 |
The role of istradefylline in the Parkinson's disease armamentarium.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Purines | 2023 |
Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
Topics: Dopaminergic Neurons; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Substantia Nigra | 2023 |
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Powders; Quality of Life | 2023 |
The Use of Liquid Sinemet in Routine Clinical Practice of Advanced Parkinson's Disease: A Comparison of Available Options.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Postural Balance; Time and Motion Studies | 2023 |
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Parkinson Disease; Sleep; Sleep Wake Disorders | 2023 |
5-HT
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2023 |
GPCR interactions involving metabotropic glutamate receptors and their relevance to the pathophysiology and treatment of CNS disorders.
Topics: Alzheimer Disease; Basal Ganglia; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2023 |
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2023 |
Non-lesional treatments for tremor in Parkinson's disease: A systematic review and meta-analysis.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Role of dopamine agonists in Parkinson's disease therapy.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2023 |
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2023 |
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Epilepsy; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12; Vitamin B 6; Vitamins | 2023 |
Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease.
Topics: Dopamine; Humans; Levodopa; Lipids; Neurodegenerative Diseases; Parkinson Disease | 2023 |
Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach.
Topics: Analgesics, Opioid; Dyskinesias; Humans; Levodopa; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Quality of Life; Receptors, Cannabinoid | 2023 |
Infusion Therapies in the Treatment of Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease.
Topics: Brain; Dopamine; Humans; Levodopa; Nanoparticles; Parkinson Disease | 2023 |
Parkinson's disease - current treatment.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole | 2023 |
Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Patient Preference; Prognosis; Uncertainty | 2023 |
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Combating Dopaminergic Neurodegeneration in Parkinson's Disease through Nanovesicle Technology.
Topics: alpha-Synuclein; Brain; Dopamine; Dopaminergic Neurons; Humans; Levodopa; Parkinson Disease | 2023 |
The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease.
Topics: Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2023 |
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamins | 2023 |
Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson's Disease: An Updated Review.
Topics: Acupuncture Therapy; Antidepressive Agents, Tricyclic; Depression; Humans; Levodopa; Parkinson Disease | 2023 |
Current and novel infusion therapies for patients with Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2023 |
Cell-therapy for Parkinson's disease: a systematic review and meta-analysis.
Topics: Allogeneic Cells; Humans; Levodopa; Parkinson Disease; Transplantation, Autologous; Transplantation, Homologous | 2023 |
Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Arthroplasty, Replacement, Hip; Carbidopa; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease | 2023 |
L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.
Topics: Antiparkinson Agents; Berlin; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment.
Topics: Animals; Disabled Persons; Humans; Levodopa; Motor Disorders; Nerve Growth Factors; Parkinson Disease | 2023 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate | 2023 |
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease; Quality of Life; Standard of Care | 2023 |
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Xerostomia | 2019 |
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Levodopa; Parkinson Disease | 2019 |
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
Percutaneous Endoscopic Gastrostomy with Jejunal Extension Tube for the Delivery of Levodopa Carbidopa Intestinal Gel: Clinical Practice Guidelines of the Romanian Society of Digestive Endoscopy.
Topics: Antiparkinson Agents; Carbidopa; Consensus; Drug Administration Routes; Drug Combinations; Drug Compounding; Endoscopy, Gastrointestinal; Equipment Design; Gastrostomy; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Food toxins and the Caribbean Parkinson plus types.
Topics: Annonaceae; Caribbean Region; Dementia; Drug Resistance; Food; Guadeloupe; Humans; Levodopa; Martinique; Parkinson Disease; Parkinsonian Disorders; Teas, Herbal; West Indies | 2019 |
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Drug Delivery Systems; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2019 |
The effect of levodopa on saccades - Oxford Quantification in Parkinsonism study.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Eye Movement Measurements; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Saccades | 2019 |
[Parkinson's Disease: Clinical Review and Update].
Topics: Antiparkinson Agents; Biomarkers; Deep Brain Stimulation; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Symptom Assessment | 2019 |
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Cannabidiol; Cannabinoids; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2020 |
Managing Parkinson's disease: moving ON with NOP.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dopaminergic Neurons; Humans; Levodopa; Nociceptin; Nociceptin Receptor; Opioid Peptides; Parkinson Disease; Receptors, Opioid; Substantia Nigra | 2020 |
Opicapone for the treatment of Parkinson's disease: an update.
Topics: Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2019 |
Parkinson's Disease: A Review from Pathophysiology to Treatment.
Topics: Biomarkers; Cholinergic Antagonists; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Life Expectancy; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease | 2020 |
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patents as Topic | 2019 |
Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies.
Topics: Dopamine; Dopamine Agents; Dopaminergic Neurons; Humans; Levodopa; Lipids; Parkinson Disease | 2020 |
L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.
Topics: Animals; Corpus Striatum; Dopamine; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Serotonergic Neurons | 2019 |
Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson Disease.
Topics: Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Parkinson Disease | 2020 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Parkinson's disease: From bench to bedside.
Topics: Dopaminergic Neurons; Humans; Levodopa; Parkinson Disease | 2020 |
A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Diagnosis and Treatment of Parkinson Disease: A Review.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis | 2020 |
Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease.
Topics: Dopaminergic Neurons; Humans; Levodopa; Neuroprotection; Neuroprotective Agents; Parkinson Disease | 2020 |
The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2020 |
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Purines; Receptor, Adenosine A2A | 2020 |
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Time Factors; Treatment Outcome | 2020 |
MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease | 2020 |
Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review.
Topics: Adult; Asian People; Cohort Studies; Female; Genetic Association Studies; Group VI Phospholipases A2; High-Throughput Nucleotide Sequencing; Humans; Levodopa; Male; Middle Aged; Mutation; Neuroaxonal Dystrophies; Parkinson Disease; Parkinsonian Disorders; Phenotype | 2020 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats | 2020 |
[Care of patients with Parkinson's disease in Germany].
Topics: Deep Brain Stimulation; Germany; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
Medical management after subthalamic stimulation in Parkinson's disease: a phenotype perspective.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Phenotype; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2020 |
Levodopa Inhalation Powder: A Review in Parkinson's Disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Powders | 2020 |
Clinical implication of high-density EEG sleep recordings in Parkinson's disease.
Topics: Antiparkinson Agents; Electroencephalography; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Sleep | 2020 |
Levodopa challenge test: indications, protocol, and guide.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Peripheral neuropathy in Parkinson's disease.
Topics: Humans; Levodopa; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin B 12 | 2020 |
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2019 |
Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain-Derived Neurotrophic Factor; Dopamine; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2020 |
The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Development; Drug Evaluation, Preclinical; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2020 |
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Gastritis; Gastroparesis; Helicobacter Infections; Humans; Levodopa; Parkinson Disease; Peptic Ulcer | 2020 |
In Silico and In Vivo Studies on Quercetin as Potential Anti-Parkinson Agent.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Catechol O-Methyltransferase; Humans; Levodopa; Molecular Docking Simulation; Parkinson Disease; Quercetin | 2020 |
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease; Patient Selection; Treatment Outcome | 2020 |
Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease.
Topics: Antiparkinson Agents; Disease Management; Disease Progression; Humans; Levodopa; Palliative Care; Parkinson Disease | 2020 |
Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside.
Topics: Animals; Cell Differentiation; Cell- and Tissue-Based Therapy; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Levodopa; Mesencephalon; Models, Neurological; Nerve Regeneration; Neurogenesis; Parkinson Disease; Translational Research, Biomedical | 2020 |
The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis.
Topics: Caffeine; Coffee; Cohort Studies; Disease Progression; Humans; Levodopa; Parkinson Disease; Proportional Hazards Models | 2020 |
[The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2020 |
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dopamine Agonists; Humans; Injection Site Reaction; Injections, Subcutaneous; Levodopa; Parkinson Disease; Subcutaneous Tissue | 2020 |
Safinamide in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2020 |
Infusion Therapies for Parkinson's Disease.
Topics: Antiparkinson Agents; Gels; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Quality of Life | 2020 |
Medical Management and Prevention of Motor Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Management; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2020 |
Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.
Topics: Antiparkinson Agents; Catechols; Drug Combinations; Humans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Tablets | 2020 |
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2020 |
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Topics: Antiparkinson Agents; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2020 |
A Pragmatic Approach to the Perioperative Management of Parkinson's Disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Postoperative Period | 2021 |
Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients.
Topics: Humans; Levodopa; Parkinson Disease; Therapeutic Misconception | 2020 |
Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease.
Topics: Antiparkinson Agents; Cost of Illness; Disease Progression; Humans; Levodopa; Parkinson Disease; Physician-Patient Relations; Quality of Life | 2020 |
Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Thalamus; Treatment Outcome | 2020 |
Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Progression; Drug Delivery Systems; Half-Life; Humans; Levodopa; Parkinson Disease | 2020 |
Anxiety: An ignored aspect of Parkinson's disease lacking attention.
Topics: Animals; Anti-Anxiety Agents; Antiparkinson Agents; Anxiety; Disease Progression; Humans; Levodopa; Parkinson Disease | 2020 |
Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
Topics: Dopamine Agents; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2021 |
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Biological; Molecular Targeted Therapy; Oxidative Stress; Parkinson Disease; Proto-Oncogene Proteins c-fyn | 2021 |
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2021 |
Why target brain adenosine receptors? A historical perspective.
Topics: Animals; Basal Ganglia; Brain; Humans; Levodopa; Parkinson Disease; Receptors, Purinergic P1 | 2020 |
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Safety and efficacy of tolcapone in Parkinson's disease: systematic review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemical and Drug Induced Liver Injury; Humans; Levodopa; Liver Function Tests; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Tolcapone | 2021 |
Clinical features associated with drooling in Parkinson's disease.
Topics: Aged; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; REM Sleep Behavior Disorder; Sialorrhea | 2021 |
The clinical meaning of levodopa equivalent daily dose in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Clinical Trials as Topic; Drug Dosage Calculations; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Retrospective Studies | 2021 |
Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.
Topics: alpha-Synuclein; Antiparkinson Agents; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mutation; Parkinson Disease; Protein Deglycase DJ-1; Protein Kinases; Ubiquitin-Protein Ligases; Vesicular Transport Proteins | 2021 |
[Systematic review and screening of basic Chinese herbs for traditional Chinese medicine compounds combined with levodopa medicine in treatment of Parkinson's disease].
Topics: China; Drugs, Chinese Herbal; Glycyrrhiza; Humans; Levodopa; Medicine; Medicine, Chinese Traditional; Parkinson Disease | 2020 |
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Helicobacter pylori infection is associated with a poor response to levodopa in patients with Parkinson's disease: a systematic review and meta-analysis.
Topics: Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2022 |
Amantadine Associated Myoclonus: Case Report and Review of the Literature.
Topics: Aged, 80 and over; Amantadine; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease | 2021 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopaminergic Neurons; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2021 |
Comparison chart: Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopamine Agonists; Humans; Kidney Diseases; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2020 |
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2021 |
Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview.
Topics: Anti-Bacterial Agents; Humans; Levodopa; Parkinson Disease; Pars Compacta; Substantia Nigra | 2021 |
Antisaccades in Parkinson's Disease: A Meta-Analysis.
Topics: Cognition Disorders; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2021 |
COVID-19 and Parkinson's Disease: What Do We Know So Far?
Topics: Antiparkinson Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Humans; Levodopa; Parkinson Disease; Vitamin D | 2021 |
Association of Parkinson's Disease With Microbes and Microbiological Therapy.
Topics: Catechol O-Methyltransferase; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Humans; Levodopa; Parkinson Disease | 2021 |
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Parkinson's disease.
Topics: Antiparkinson Agents; Disease Management; Humans; Levodopa; Parkinson Disease; Prodromal Symptoms; Time Factors; Tremor | 2021 |
Phytobezoar Associated with Levodopa-carbidopa Intestinal Gel Infusion in Patients with Parkinson's Disease: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Bezoars; Carbidopa; Humans; Levodopa; Parkinson Disease | 2021 |
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Othello syndrome in Parkinson's disease: a systematic review and report of a case series.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Delusions; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life | 2021 |
Opicapone for the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Clinical Trials, Phase IV as Topic; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2023 |
Novel Pharmacotherapies in Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Brain; Butyrates; Dopamine Agents; Dopaminergic Neurons; Drug Therapy, Combination; Humans; Levodopa; Nicotine; Parkinson Disease | 2021 |
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease | 2021 |
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease; Quality of Life; Retrospective Studies | 2021 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease | 2021 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
[The questions of the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2021 |
Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.
Topics: Antiparkinson Agents; Diet; Humans; Levodopa; Parkinson Disease; Vitamin B 12 | 2021 |
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Treatment Outcome | 2021 |
[Progressive supranuclear palsy].
Topics: Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Neuroimaging; Parkinson Disease; Supranuclear Palsy, Progressive | 2021 |
Prevalence of malnutrition/malnutrition risk and nutrition-related risk factors among patients with Parkinson's disease: systematic review and meta-analysis.
Topics: Humans; Levodopa; Malnutrition; Nutrition Assessment; Nutritional Status; Parkinson Disease; Prevalence; Risk Factors | 2022 |
Search for safer and potent natural inhibitors of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Biological Products; Brain; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Plant Extracts | 2021 |
A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Genotype; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pharmacogenetics; Pharmacogenomic Variants; Translational Research, Biomedical | 2021 |
Implications of dopaminergic medication withdrawal in Parkinson's disease.
Topics: Amantadine; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 2022 |
New insights into pathogenesis of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of rehabilitation on reducing dyskinesias in a Parkinson's disease patient abusing therapy with levodopa-carbidopa intestinal gel: a paradigmatic case report and literature review.
Topics: Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Topics: Catechol O-Methyltransferase; Dyskinesias; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease | 2021 |
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Topics: Antiparkinson Agents; Apathy; Apomorphine; Humans; Levodopa; Parkinson Disease | 2021 |
Effectiveness of Long-Term Physiotherapy in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2021 |
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Topics: Genotype; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Phenotype | 2021 |
Zonisamide in Parkinson's disease: a current update.
Topics: Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Zonisamide | 2021 |
Parkinson disease.
Topics: alpha-Synuclein; Antiparkinson Agents; Biomarkers; Dopamine Agonists; Genetic Therapy; Humans; Levodopa; Mitochondria; Oxidative Stress; Parkinson Disease; Quality of Life | 2017 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
Non-human primate models of PD to test novel therapies.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Intrajejunal levodopa infusion therapy for Parkinson's disease: practical and pragmatic tips for successful maintenance of therapy.
Topics: Antiparkinson Agents; Caregivers; Humans; Levodopa; Parkinson Disease; Quality of Life | 2017 |
Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: Connecting the dots in a multicomponent network.
Topics: Cerebellum; Connectome; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Cortex; Neuronal Plasticity; Parkinson Disease | 2017 |
Levodopa in Parkinson's Disease: Current Status and Future Developments.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2018 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Parkinson's disease and pregnancy: An updated review.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Female; Humans; Levodopa; Parkinson Disease; Pregnancy; Treatment Outcome | 2017 |
The many facets of motor learning and their relevance for Parkinson's disease.
Topics: Exercise; Humans; Learning; Levodopa; Motor Cortex; Motor Skills; Parkinson Disease | 2017 |
Diagnosis and Management of Parkinson's Disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Tremor | 2017 |
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Design; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease | 2017 |
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
The missing, the short, and the long: Levodopa responses and dopamine actions.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Time | 2017 |
Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
Topics: Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2017 |
Treatment Strategies in Early Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Respiratory dysfunction in Parkinson's disease.
Topics: Airway Obstruction; Humans; Levodopa; Parkinson Disease; Pulmonary Ventilation; Respiratory Tract Diseases | 2017 |
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2017 |
Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review.
Topics: Activities of Daily Living; Aged; Deep Brain Stimulation; Dose-Response Relationship, Drug; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Publication Bias; Subthalamic Nucleus | 2017 |
Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis.
Topics: Animals; Humans; Levodopa; Parkinson Disease | 2017 |
[Parkinson's disease in the elderly].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Community Integration; Comorbidity; Diagnosis, Differential; Disability Evaluation; Drug Therapy, Combination; Germany; Humans; Incidence; Levodopa; Mobility Limitation; Parkinson Disease; Quality of Life; Social Environment | 2017 |
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.
Topics: Clinical Trials as Topic; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2017 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Constipation in Parkinson's Disease.
Topics: Antiparkinson Agents; Constipation; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Levodopa; Parkinson Disease | 2017 |
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2017 |
Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2017 |
A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson's disease.
Topics: Administration, Oral; Dosage Forms; Gastrointestinal Tract; Humans; Intestinal Absorption; Levodopa; Models, Biological; Parkinson Disease; Patient-Specific Modeling | 2017 |
Levodopa treatment and dendritic spine pathology.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dendritic Spines; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Putamen | 2018 |
Comparison of General and Local Anesthesia for Deep Brain Stimulator Insertion: A Systematic Review.
Topics: Anesthesia, Local; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2017 |
A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.
Topics: Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Protein Interaction Maps | 2017 |
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Positron-Emission Tomography | 2017 |
Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review.
Topics: Asian People; Deep Brain Stimulation; Dyskinesias; Female; Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Levodopa; Middle Aged; Mutation; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome; Vesicular Transport Proteins | 2017 |
Synaptic plasticity may underlie l-DOPA induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2018 |
Reversing dopaminergic sensitization.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2017 |
Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Databases, Bibliographic; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Netherlands; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome | 2018 |
Levodopa: A new look at an old friend.
Topics: Age Factors; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2018 |
Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; beta Catenin; Dopamine; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3; Humans; Levodopa; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease | 2018 |
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
Topics: Animals; Dopamine; Drug Carriers; Humans; Levodopa; Parkinson Disease; Prodrugs | 2017 |
[A Systematic Review to Identify Unacceptable Intake Levels of Vitamin B6 among Patients Taking Levodopa].
Topics: Databases, Bibliographic; Dietary Supplements; Drug Interactions; Female; Humans; Levodopa; Male; No-Observed-Adverse-Effect Level; Nonprescription Drugs; Parkinson Disease; Vitamin B 6 | 2017 |
Safinamide: a new hope for Parkinson's disease?
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2018 |
Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Topics: Adult; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Food-Drug Interactions; Half-Life; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2018 |
Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
Topics: Antiparkinson Agents; Causality; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Regression Analysis | 2018 |
Advances in prodrug design for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine; Drug Design; Humans; Levodopa; Parkinson Disease; Prodrugs; Tissue Distribution | 2018 |
Novel models for Parkinson's disease and their impact on future drug discovery.
Topics: Aged; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Design; Drug Discovery; Humans; Levodopa; Models, Biological; Parkinson Disease | 2018 |
Role of adenosine A
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2018 |
Dyskinesias and levodopa therapy: why wait?
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2018 |
Atypical presentation of dopa-responsive dystonia in Taiwan.
Topics: Adult; Age of Onset; Botulinum Toxins, Type A; Dopamine Agents; Drug Resistance; Dystonic Disorders; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Neuromuscular Agents; Parkinson Disease; Pedigree; Taiwan; Treatment Outcome | 2018 |
Parkinson's disease: A Quick Update.
Topics: Disease Management; Dopamine Agonists; Exercise; Humans; Levodopa; Parkinson Disease | 2018 |
The striatal cholinergic system in L-dopa-induced dyskinesias.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Parkinson Disease | 2018 |
Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Humans; Levodopa; Models, Biological; Motor Activity; Parkinson Disease | 2018 |
Using tube feeding and levodopa-carbidopa intestinal gel application in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Quality of Life | 2018 |
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Medical and surgical management of advanced Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2018 |
mGlu
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Models, Neurological; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate | 2018 |
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Tolcapone; Treatment Outcome | 2018 |
Levodopa-carbidopa intestinal gel: 'dismantling the road blocks of a journey'.
Topics: Administration, Intranasal; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Humans; Jejunostomy; Jejunum; Levodopa; Parkinson Disease; Patient Compliance | 2018 |
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2018 |
Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease.
Topics: Animals; Curcumin; Dopaminergic Neurons; Ginsenosides; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Resveratrol; Vicia faba | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cholinergic Neurons; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2018 |
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2018 |
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
Topics: Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Humans; Levodopa; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus | 2019 |
Long-term management of Parkinson's disease using levodopa combinations.
Topics: Antioxidants; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Oxidative Stress; Parkinson Disease | 2018 |
Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias.
Topics: Aged; Cholinergic Agents; Cholinergic Neurons; Corpus Striatum; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease | 2019 |
Pharmacotherapy in Parkinson’s disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Guideline Adherence; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2016 |
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Risk Factors | 2018 |
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2018 |
Amantadine Extended-Release (GOCOVRI
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Duodenum; Humans; Infusions, Intravenous; Infusions, Parenteral; Jejunum; Levodopa; Movement Disorders; Parkinson Disease | 2018 |
L-DOPA for Parkinson's disease-a bittersweet pill.
Topics: Animals; Antiparkinson Agents; Cell Transplantation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features.
Topics: Antiparkinson Agents; Behavioral Symptoms; Cognition Disorders; Humans; Levodopa; Parkinson Disease; Risk Factors | 2018 |
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Topics: alpha-Synuclein; Biomarkers; Brain; Cognition Disorders; Constipation; Depression; Early Diagnosis; Genetic Predisposition to Disease; Humans; Inflammation; Levodopa; Metabolomics; Microbiota; Movement Disorders; Neuroimaging; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder; Symptom Assessment; Vision Disorders | 2018 |
Reciprocal interaction between monoaminergic systems and the pedunculopontine nucleus: Implication in the mechanism of L-DOPA.
Topics: Adrenergic Neurons; Animals; Antiparkinson Agents; Dopaminergic Neurons; Humans; Levodopa; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Serotonergic Neurons | 2019 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2018 |
Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Dysarthria; Dysphonia; Female; Humans; Levodopa; Male; Parkinson Disease; Speech Production Measurement; Voice; Voice Quality | 2018 |
Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Pharmacogenetics and levodopa induced motor complications.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pharmacogenetics | 2019 |
Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
Medical and surgical care for patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Constipation; Delirium; Dizziness; Dopamine Agonists; Hospitalization; Humans; Levodopa; Mobility Limitation; Monoamine Oxidase Inhibitors; Pain; Parkinson Disease | 2018 |
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
Topics: Administration, Inhalation; Aerosols; Antiparkinson Agents; Biological Availability; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2018 |
The Pioneering and Unknown Stereotactic Approach of Roeder and Orthner from Göttingen. Part II: Long-Term Outcome and Postmortem Analysis of Bilateral Pallidotomy in the Pre-Levodopa Era.
Topics: Adult; Aged; Chorea; Diagnosis; Dyskinesias; Female; Globus Pallidus; Humans; Imaging, Three-Dimensional; Levodopa; Male; Middle Aged; Movement Disorders; Pallidotomy; Parkinson Disease; Psychosurgery; Stereotaxic Techniques; Thalamus; Treatment Outcome; Tremor | 2018 |
The next chapter in symptomatic Parkinson disease treatments.
Topics: Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2019 |
Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.
Topics: Cannabinoids; Dopaminergic Neurons; Endocannabinoids; Humans; Levodopa; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Receptors, Cannabinoid | 2019 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
Parkinson's Disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Diagnosis, Differential; Humans; Hypokinesia; Levodopa; Parkinson Disease; Tremor | 2019 |
[Selection of the optimal device-aided therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Hungary; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
Topics: Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Neurosurgical Approaches to Levodopa-Induced Dyskinesia.
Topics: Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Transcranial Magnetic Stimulation | 2019 |
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine Agonists; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2019 |
Dopaminergic modulation of striatal function and Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Neurotransmitter | 2019 |
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.
Topics: Antiparkinson Agents; Disease Progression; Dopamine; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index | 2019 |
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2019 |
Deep brain stimulation in parkinson disease.
Topics: Antiparkinson Agents; Brazil; Clinical Decision-Making; Deep Brain Stimulation; Humans; Levodopa; Motor Activity; Parkinson Disease; Risk Factors; Treatment Outcome | 2019 |
Dystonia and Parkinson's disease: What is the relationship?
Topics: alpha-Synuclein; Deep Brain Stimulation; Dystonia; GTP Cyclohydrolase; Humans; Levodopa; Parkinson Disease | 2019 |
Dyskinesia in multiple system atrophy and progressive supranuclear palsy.
Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Supranuclear Palsy, Progressive | 2019 |
CVT-301 for the treatment of Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Old Drugs, New Delivery Systems in Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Delivery Systems; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2019 |
Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
Topics: Activities of Daily Living; Combined Modality Therapy; Drug Therapy, Combination; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Selegiline; Treatment Outcome | 2020 |
The Accordion Pill
Topics: Administration, Oral; Carbidopa; Delayed-Action Preparations; Gastrointestinal Tract; Half-Life; Humans; Levodopa; Parkinson Disease; Solubility | 2019 |
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Observational Studies as Topic; Parkinson Disease; Precision Medicine; Prospective Studies; United States | 2019 |
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms.
Topics: Animals; Diet; Folic Acid; Genetic Predisposition to Disease; Homocysteine; Humans; Levodopa; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Nutritional Status; One-Carbon Group Transferases; Parkinson Disease; Polymorphism, Genetic; Vitamin B Complex | 2019 |
Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Skin Diseases | 2019 |
[What is the Best Initial Treatment for Parkinson's Disease? New Clinical Practice Guideline and My Personal Opinion].
Topics: Disease Progression; Dopamine; Exercise; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Substantia Nigra | 2019 |
Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease; Serotonergic Neurons | 2019 |
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2019 |
Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Therapies, Investigational | 2019 |
Parkinson's disease: recent advances.
Topics: Antiparkinson Agents; Brain; Depression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2012 |
Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Databases, Factual; Homocysteine; Humans; Levodopa; Parkinson Disease | 2013 |
Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.
Topics: Animals; Antiparkinson Agents; Case-Control Studies; Drug Delivery Systems; Duodenum; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2013 |
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.
Topics: Animals; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2013 |
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
Topics: Animals; Disease Management; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills; Parkinson Disease; Recovery of Function; Signal-To-Noise Ratio | 2013 |
Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Microdialysis; Neostriatum; Parkinson Disease; Rats; Serotonergic Neurons; Serotonin | 2013 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
[Advanced Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease | 2006 |
[Specificities of the treatment of Parkinson's disease in the elderly].
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2013 |
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.
Topics: Aging; Animals; Antioxidants; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Inactivation, Metabolic; Levodopa; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2013 |
Mechanisms underlying cortical resonant states: implications for levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2013 |
Non-dopaminergic treatments for motor control in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Mesencephalon; Molecular Targeted Therapy; Monoamine Oxidase Inhibitors; Neurons; Off-Label Use; Parkinson Disease; Serotonin Antagonists; Tremor | 2013 |
[Practical aspects of the treatment of Parkinson's disease].
Topics: Algorithms; Antiparkinson Agents; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 2013 |
Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.
Topics: Antiparkinson Agents; Disease Management; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Quality of Life; Risk Factors | 2012 |
Levodopa in the treatment of Parkinson's disease: current status and new developments.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2013 |
The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Topics: Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mitochondria; Mutation; Neurons; Parkinson Disease; Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Ubiquitin-Protein Ligases | 2013 |
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2013 |
[Pharmacotherapy of Parkinson's disease: progress or regress?].
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2013 |
Therapeutic prospects for Parkinson disease.
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease | 2013 |
Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Multimerization; Receptors, N-Methyl-D-Aspartate | 2013 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Dopamine overdose hypothesis: evidence and clinical implications.
Topics: Brain; Cognition Disorders; Dopamine; Dopamine Agents; Humans; Learning Disabilities; Levodopa; Parkinson Disease | 2013 |
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 4. Parkinson's disease: progress in the medical treatment].
Topics: Antiparkinson Agents; Drugs, Investigational; Humans; Japan; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome; United States | 2013 |
[Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Topics: Catechol O-Methyltransferase Inhibitors; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Vitamin B Complex | 2013 |
Drug-induced impulse control disorders: a review.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2014 |
Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
Topics: Antiparkinson Agents; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2014 |
[Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Drug Tolerance; Drugs, Chinese Herbal; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease; Phytotherapy | 2013 |
Continuous drug delivery in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dopamine Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2014 |
[The treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Physical Therapy Modalities | 2013 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
Novel levodopa formulations in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Chemistry, Pharmaceutical; Drug Administration Routes; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2014 |
[Pharmacotherapy of Parkinson's disease].
Topics: Activities of Daily Living; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Infusions, Parenteral; Levodopa; Neurologic Examination; Parkinson Disease | 2013 |
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Humans; Levodopa; Parkinson Disease | 2014 |
Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography | 2014 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
[The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2013 |
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Humans; Jejunum; Levodopa; Parkinson Disease | 2014 |
Predicting dopaminergic effects of L-DOPA in the treatment for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Predictive Value of Tests; Treatment Outcome | 2014 |
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
Topics: Animals; Dyskinesias; Dystonia; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2014 |
[Clinical studies with levodopa/carbidopa intestinal gel].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Cognition; Confounding Factors, Epidemiologic; Dopamine Agents; Drug Delivery Systems; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; Quality of Life; Research Design; Sample Size; Sleep | 2014 |
Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2014 |
Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.
Topics: Animals; Cannabinoids; Cell Transplantation; Chromatin; Deep Brain Stimulation; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Histones; Humans; Levodopa; Motor Activity; Parkinson Disease; Phosphorylation; Psychomotor Performance; Receptors, Dopamine D1; Signal Transduction; Transcranial Magnetic Stimulation | 2014 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation | 2014 |
[Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Duodenum; Gastrointestinal Diseases; Gastrostomy; Granuloma; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Multicenter Studies as Topic; Observational Studies as Topic; Pain; Parkinson Disease; Peritonitis; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Stomas | 2014 |
Neuronal oscillations in Parkinson's disease.
Topics: Basal Ganglia; Cerebral Cortex; Deep Brain Stimulation; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease; Thalamus | 2014 |
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2014 |
Mavoglurant as a treatment for Parkinson's disease.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life; Receptor, Metabotropic Glutamate 5 | 2014 |
Treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
A review of lower urinary tract symptoms in patients with Parkinson's disease.
Topics: Cholinergic Antagonists; Dopamine Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Lower Urinary Tract Symptoms; Male; Parkinson Disease; Tibial Nerve; Transurethral Resection of Prostate; Urinary Bladder; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urinary Catheterization; Urinary Diversion | 2014 |
Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Topics: Adenosine A2 Receptor Antagonists; Drug Synergism; Humans; Levodopa; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Receptor, Adenosine A2A | 2015 |
Emerging drugs for levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Design; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine; Signal Transduction | 2014 |
IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Time Factors | 2014 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primates | 2015 |
Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management.
Topics: Administration, Oral; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2015 |
Adenosine receptors and dyskinesia in pathophysiology.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1 | 2014 |
Pooled analysis of phase III with entacapone in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline | 2014 |
Classics in chemical neuroscience: levodopa.
Topics: Animals; Antiparkinson Agents; History, 19th Century; History, 20th Century; Humans; Levodopa; Neurosciences; Parkinson Disease | 2014 |
Effects of levodopa on regional cerebral metabolism and blood flow.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Cognition Disorders; Humans; Levodopa; Neuroimaging; Parkinson Disease; Regional Blood Flow | 2015 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2014 |
Prognostic significance of weight changes in Parkinson's disease: the Park-weight phenotype.
Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Energy Intake; Female; Humans; Levodopa; Male; Nutritional Status; Parkinson Disease; Quality of Life; Sex Factors; Smell; Thinness; Treatment Outcome; Weight Loss | 2014 |
New treatments for the motor symptoms of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agents; Drug Delivery Systems; Drug Design; Humans; Levodopa; Parkinson Disease | 2014 |
Improving L-dopa therapy: the development of enzyme inhibitors.
Topics: Animals; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2015 |
Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2014 |
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2015 |
Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Parkinson Disease; Patient Acuity; Pramipexole; Treatment Outcome | 2014 |
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Parkinson Disease | 2015 |
Presynaptic effects of levodopa and their possible role in dyskinesia.
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Presynaptic Terminals | 2015 |
Targeting glutamatergic synapses in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Ionotropic Glutamate; Synaptic Transmission | 2015 |
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate | 2015 |
[Levodopa: the story continues].
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Novel formulations and modes of delivery of levodopa.
Topics: Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2015 |
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
Topics: Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; GABA Antagonists; Humans; Levodopa; Parkinson Disease; Serotonin Antagonists; Serotonin Receptor Agonists | 2015 |
Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dopamine Antagonists; Drug Partial Agonism; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Dopamine | 2015 |
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Topics: Antiparkinson Agents; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Levodopa; Male; Neurology; Nobel Prize; Parkinson Disease; Pharmacology | 2015 |
Clinical spectrum of levodopa-induced complications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Levodopa: effect on cell death and the natural history of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Death; Clinical Trials as Topic; Humans; In Vitro Techniques; Levodopa; Oxidative Stress; Parkinson Disease | 2015 |
Nitric oxide, a new player in L-DOPA-induced dyskinesia?
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitric Oxide; Parkinson Disease | 2015 |
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time | 2015 |
[Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Europe; Humans; Levodopa; Parkinson Disease | 2014 |
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2014 |
Management of Parkinson׳s disease: Current and future pharmacotherapy.
Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; Parkinson Disease | 2015 |
Molecular imaging of levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Receptors, Dopamine | 2015 |
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease | 2015 |
Regenerative medicine for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Combined Modality Therapy; Dopaminergic Neurons; Drug Discovery; Fetal Stem Cells; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factors; Humans; Levodopa; Parkinson Disease; Pluripotent Stem Cells; Regenerative Medicine; Substantia Nigra | 2015 |
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Topics: Animals; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Carbidopa/levodopa extended-release capsules (Rytary).
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2015 |
Deep brain stimulation for Parkinson's disease: recent trends and future direction.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2015 |
Approach to the patient with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Parkinson Disease; Primary Health Care; Risk Factors | 2015 |
Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
Topics: Animals; Antiparkinson Agents; Chemotherapy, Adjuvant; Databases, Bibliographic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Organ Sparing Treatments; Parkinson Disease; Randomized Controlled Trials as Topic | 2015 |
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Topics: Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hippocampus; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2015 |
Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.
Topics: Antiparkinson Agents; Carbidopa; Gastrostomy; Gels; Humans; Levodopa; Parkinson Disease; Patient Selection; Postoperative Complications; Quality of Life; Scandinavian and Nordic Countries | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity.
Topics: Dopamine; Dopaminergic Neurons; Dyskinesias; Humans; Levodopa; Oxidative Stress; Parkinson Disease; Peptides; Peptidomimetics; Prodrugs | 2015 |
[Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2015 |
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Central Nervous System; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Drug Administration Routes; Drug Combinations; Drug Costs; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2015 |
Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Drug Synergism; Humans; Levodopa; Parkinson Disease; Polyphenols; Tea | 2015 |
New treatments for levodopa-induced motor complications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Deep brain stimulation as a treatment for Parkinson's disease related camptocormia.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Lidocaine; Male; Middle Aged; Muscular Atrophy, Spinal; Neurosurgical Procedures; Parkinson Disease; Posture; Spinal Curvatures; Spine; Treatment Outcome | 2015 |
2015 Update on Parkinson disease.
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Symptom Assessment; Tomography, Emission-Computed, Single-Photon | 2015 |
Initial drug treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2015 |
Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.
Topics: Antiparkinson Agents; Asian People; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2015 |
New levodopa therapeutic strategies.
Topics: Animals; Antiparkinson Agents; Drug Combinations; Drug Delivery Systems; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2016 |
[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Controlled Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Pramipexole; Quality of Life; Tremor | 2015 |
Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.
Topics: Clinical Laboratory Techniques; Confusion; Dementia; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Psychotic Disorders; Vitamins | 2016 |
Carbidopa levodopa enteral suspension.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Suspensions | 2015 |
Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies.
Topics: Animals; Antiparkinson Agents; Brain; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Evidence-Based Medicine; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Protein Binding | 2016 |
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
Topics: Age Factors; Aged; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2016 |
Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Movement disorders: advances in 2015.
Topics: Animals; Antiparkinson Agents; Carbidopa; DNA-Binding Proteins; Drug Combinations; Humans; Levodopa; Mitochondrial Proteins; Movement Disorders; Parkinson Disease; Transcription Factors | 2016 |
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Dyskinesias; Gastrostomy; Gels; Humans; Intestines; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2015 |
A Review of the Association Between Parkinson Disease and Malignant Melanoma.
Topics: Antiparkinson Agents; Environment; Genetic Predisposition to Disease; Humans; Levodopa; Melanoma; Parkinson Disease; Risk Factors; Skin Neoplasms; Skin Pigmentation | 2016 |
New and emerging medical therapies in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
Aporphines and Parkinson's Disease: Medical Tools for the Future.
Topics: Alkaloids; Animals; Humans; Levodopa; Molecular Structure; Neuroprotective Agents; Parkinson Disease | 2016 |
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Kynurenine; Levodopa; Molecular Structure; Parkinson Disease | 2016 |
Subthalamic stimulation may inhibit the beneficial effects of levodopa on akinesia and gait.
Topics: Adult; Aged; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agents; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2016 |
A review of current and novel levodopa formulations for the treatment of Parkinson's disease.
Topics: Administration, Inhalation; Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Compounding; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease | 2016 |
Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2016 |
Promising therapeutic agents for the treatment of Parkinson's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Genetic Therapy; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa therapy for Parkinson disease: A look backward and forward.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Dopamine; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2016 |
Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Topics: Animals; Antiparkinson Agents; Biomedical Research; Drug Delivery Systems; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2017 |
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Predictive Value of Tests; Severity of Illness Index | 2016 |
Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Topics: Administration, Cutaneous; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Dopamine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2016 |
A guide to management of neuropsychiatric manifestations of Parkinson's disease.
Topics: Humans; Levodopa; Mental Disorders; Parkinson Disease; Practice Guidelines as Topic; Psychotropic Drugs | 2016 |
Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Dopamine; Humans; Levodopa; Parkinson Disease; Serotonin | 2016 |
Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials.
Topics: Deep Brain Stimulation; Depression; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2016 |
Unmasking levodopa resistance in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Resistance; Humans; Levodopa; Parkinson Disease | 2016 |
[Practical Use of the Levodopa Pump].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Duodenum; Equipment Design; Gastrostomy; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Neurologic Examination; Parkinson Disease | 2016 |
The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Motor Cortex; Pain; Parkinson Disease | 2017 |
Opicapone: A Review in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
A case of Parkinson's disease following dystonia.
Topics: Aged; Dopamine Plasma Membrane Transport Proteins; Dystonia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Radiography, Thoracic; Radionuclide Imaging | 2016 |
Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Intestines; Levodopa; Parkinson Disease | 2016 |
Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2016 |
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Agonists; Humans; Immunotherapy; Levodopa; Monoamine Oxidase Inhibitors; Neurosciences; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2016 |
Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Pharmacology, Clinical | 2016 |
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Topics: Animals; Antiparkinson Agents; Astrocytes; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Neurons; Parkinson Disease | 2016 |
Novel Levodopa Formulations for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chemistry, Pharmaceutical; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2016 |
Interventions in Parkinson's disease: Role of executive function.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Executive Function; Exercise Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Caffeine; the Forgotten Potential for Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Caffeine; Drug Synergism; Humans; Levodopa; Parkinson Disease | 2017 |
Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Cognition Disorders; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Vitamin B 12 | 2017 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Topics: Animals; Antiparkinson Agents; Apomorphine; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2016 |
Safinamide: A Review in Parkinson's Disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2017 |
Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
Topics: Antiparkinson Agents; Drug Design; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2017 |
Algorithms for the treatment of motor problems in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Consensus; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2017 |
The terminology of akinesia, bradykinesia and hypokinesia: Past, present and future.
Topics: Antiparkinson Agents; Forecasting; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Hypokinesia; Levodopa; Parkinson Disease; Terminology as Topic | 2017 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
Topics: Antiparkinson Agents; Articulation Disorders; Corpus Striatum; Deglutition Disorders; Disease Progression; Dopamine Agonists; Dopaminergic Neurons; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Movement; Muscle Hypertonia; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Sensation Disorders; Substantia Nigra; Tremor | 2017 |
Pharmacokinetics of Rytary
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Humans; Levodopa; Parkinson Disease | 2017 |
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2017 |
Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.
Topics: Animals; Carbidopa; Central Nervous System; Drug Approval; Drug Combinations; Drug Delivery Systems; Drug Design; European Union; Gels; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Tablets | 2017 |
L-DOPA.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2017 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Gene Expression Regulation; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2008 |
Treatment challenges in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Communication; Continuity of Patient Care; Decision Trees; Disease Progression; Dopamine Agents; Drug Monitoring; Humans; Interprofessional Relations; Levodopa; Monoamine Oxidase Inhibitors; Nurse Practitioners; Nurse's Role; Nursing Assessment; Parkinson Disease; Primary Health Care; Surveys and Questionnaires | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Molecular; Oxidopamine; Parkinson Disease; Protein Subunits; Rats; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2008 |
The clinical spectrum of freezing of gait in Parkinson's disease.
Topics: Disease Progression; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2008 |
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Carbidopa; Drug Interactions; Humans; Levodopa; Parkinson Disease; Tissue Distribution | 2007 |
Molecular mechanisms of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease | 2008 |
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
Topics: Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin | 2008 |
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Topics: Animals; Basal Ganglia; Clinical Trials as Topic; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Isoforms; Receptors, Serotonin; Serotonin | 2008 |
Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
Topics: Databases, Bibliographic; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2009 |
Driving ability in Parkinson's disease: current status of research.
Topics: Accidents, Traffic; Antiparkinson Agents; Automobile Driver Examination; Automobile Driving; Automobiles; Behavior; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Practice Guidelines as Topic; Psychomotor Performance; Severity of Illness Index | 2009 |
Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Enzyme Inhibitors; Humans; Levodopa; Neurons; Parkinson Disease; Substantia Nigra | 2008 |
The history of dopamine and levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Dopamine; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2008 |
Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Neurons; Nucleus Accumbens; Parkinson Disease; Receptors, Dopamine; Synapses; Synaptic Transmission | 2008 |
Pharmacokinetics and pharmacodynamics of levodopa.
Topics: Antiparkinson Agents; Humans; Kinetics; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Time Factors | 2008 |
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Topics: Antiparkinson Agents; Denervation; Dopamine; Drug Administration Schedule; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 2008 |
Levodopa-related motor complications--phenomenology.
Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Drug Administration Schedule; Dyskinesias; Fatigue; Humans; Levodopa; Mood Disorders; Motor Activity; Parkinson Disease; Treatment Failure | 2008 |
Levodopa unresponsive symptoms in Parkinson disease.
Topics: Antiparkinson Agents; Anxiety; Depression; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Sweating; Xerostomia | 2008 |
Treatment of levodopa-induced motor complications.
Topics: Adsorption; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Movement Disorders; Parkinson Disease; Safety | 2008 |
Therapeutic strategies to prevent motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
Levodopa-induced dyskinesias and their management.
Topics: Antiparkinson Agents; Chorea; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2008 |
[Motor symptoms in Parkinson disease].
Topics: Age Factors; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Dystonia; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Selegiline; Treatment Outcome; Tremor | 2008 |
Targets for neuroprotection in Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Carbazoles; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Nerve Growth Factors; Neuroprotective Agents; Oxepins; Parkinson Disease | 2009 |
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
Topics: Animals; Clinical Trials as Topic; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Decarboxylation; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2008 |
Levodopa for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Brain Stem; Dopamine; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Practice Guidelines as Topic | 2008 |
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Central Nervous System; Dopamine; Drug Therapy, Combination; Dyskinesias; Haplorhini; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Adenosine A2; Xanthines | 2009 |
How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Risk Factors; Treatment Outcome | 2008 |
Levodopa in the early treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 2009 |
Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Individuality; Levodopa; Parkinson Disease | 2009 |
Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Drug Evaluation; Humans; Levodopa; Limbic System; Parkinson Disease | 2009 |
L-dopa therapy for Parkinson's disease: past, present, and future.
Topics: Antiparkinson Agents; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2009 |
Levodopa therapeutics for Parkinson's disease: new developments.
Topics: Antiparkinson Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2009 |
Toxic effects of dopamine metabolism in Parkinson's disease.
Topics: Aldehydes; alpha-Synuclein; Animals; Dopamine; Humans; Levodopa; Mitochondria; Oxidative Stress; Parkinson Disease | 2009 |
The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Animals; Dopamine Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 2009 |
Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Databases, Bibliographic; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Monoamine Oxidase; Parkinson Disease; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Statistics, Nonparametric | 2009 |
Treatment of early Parkinson's disease. Part 1.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Patient Compliance | 2009 |
Treatment of early Parkinson's disease. Part 2.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Clinical Trials as Topic; Cognition Disorders; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Olfaction Disorders; Pain; Parkinson Disease; Psychotic Disorders; Sleep Wake Disorders; Time Factors | 2009 |
The effect of onset age on the clinical features of Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenotype; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
[Therapy of Parkinson's disease--up to date].
Topics: Anticonvulsants; Antiparkinson Agents; Carbazoles; Dopamine Agents; Dopamine Agonists; Drug Design; Genetic Therapy; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra; Zonisamide | 2008 |
Mechanisms compensating for dopamine loss in early Parkinson disease.
Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease | 2009 |
Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease | 2009 |
When and how should treatment be started in Parkinson disease?
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2009 |
Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Topics: Animals; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2009 |
Treatments for Parkinson disease--past achievements and current clinical needs.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cholinesterase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Excitatory Amino Acid Antagonists; History, 20th Century; Humans; Levodopa; Parkinson Disease; Serotonin Agents | 2009 |
[Treatment of motor symptoms in Parkinson's disease].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2009 |
Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Levodopa-related wearing-off in Parkinson's disease: identification and management.
Topics: Antiparkinson Agents; Cost of Illness; Disabled Persons; Disease Progression; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Health Surveys; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Surveys and Questionnaires; Time Factors | 2009 |
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Thailand | 2009 |
'Bad guys' among the antiparkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Cholinergic Antagonists; Cognition; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Survival Rate; Tolcapone; Treatment Outcome | 2009 |
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.
Topics: Accidental Falls; Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Disease Progression; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Patient Care Planning; Practice Guidelines as Topic; Quality of Life; Safety Management | 2007 |
[Pharmacologic treatment of Parkinson disease].
Topics: Age of Onset; Antiparkinson Agents; Dopamine Agonists; Glutathione; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Superoxide Dismutase; Zonisamide | 2009 |
Optimising levodopa therapy.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2008 |
Use of apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dopamine Agonists; Humans; Levodopa; Lisuride; Parkinson Disease | 2008 |
New drug delivery strategies for improved Parkinson's disease therapy.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2009 |
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Topics: alpha-Synuclein; Animals; Ferric Compounds; Humans; Levodopa; Lewy Bodies; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Protein Binding; Protein Processing, Post-Translational; RNA | 2009 |
Levodopa: past, present, and future.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechol O-Methyltransferase Inhibitors; History, 20th Century; History, 21st Century; Humans; Levodopa; Models, Neurological; Parkinson Disease | 2009 |
Multiple roles for nicotine in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Humans; Levodopa; Motor Skills; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Smoking; Substantia Nigra | 2009 |
Parkinson's disease.
Topics: Deep Brain Stimulation; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2007 |
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
Topics: Anticonvulsants; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Patient Selection; Risk Assessment; Risk Factors | 2009 |
Hallucinations in Parkinson disease.
Topics: Animals; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Hallucinations; Humans; Illusions; Levodopa; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Sleep Wake Disorders | 2009 |
Parkinson's disease, levodopa-use and the risk of melanoma.
Topics: Animals; Humans; Levodopa; Melanoma; Parkinson Disease; Risk Factors; Skin Neoplasms | 2009 |
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 2009 |
Rehabilitation goals and strategies in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Exercise Therapy; Humans; Levodopa; Parkinson Disease | 2009 |
Levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
Therapeutic extradural cortical stimulation for Parkinson's Disease: report of six cases and review of the literature.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Contraindications; Deep Brain Stimulation; Dura Mater; Electric Stimulation Therapy; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Male; Motor Cortex; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2009 |
Thwarting dyskinesia by targeting mTORC1.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Disease Models, Animal; Humans; Levodopa; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinson Disease; Phosphotransferases (Alcohol Group Acceptor); Proteins; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2009 |
Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
Topics: Basal Ganglia; Dopamine; Dosage Forms; Drug Administration Routes; Drug Delivery Systems; Humans; Levodopa; Models, Neurological; Parkinson Disease | 2009 |
Half a century of L-DOPA.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Neurons; Parkinson Disease | 2009 |
Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain.
Topics: Animals; Behavior, Addictive; Brain; Humans; Levodopa; Methamphetamine; Parkinson Disease | 2009 |
[Management of Parkinson's disease in 2009].
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primary Dysautonomias; Prognosis; Risk Factors | 2009 |
The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.
Topics: Antiparkinson Agents; Causality; Comorbidity; Humans; Levodopa; Mass Screening; Melanoma; Parkinson Disease; Risk Factors; Skin Neoplasms | 2009 |
Therapy adherence issues in Parkinson's disease.
Topics: Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance; Time Factors | 2010 |
PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.
Topics: Animals; Brain; Computer Simulation; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Humans; Levodopa; Parkinson Disease; Pharmacokinetics; Positron-Emission Tomography | 2009 |
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2009 |
[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
Topics: Accidental Falls; Antiparkinson Agents; Cholinergic Agents; Dopamine Agents; Droxidopa; Gait Disorders, Neurologic; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Serotonin Receptor Agonists; Synaptic Transmission | 2010 |
[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2009 |
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Topics: Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 2009 |
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
Topics: Antiparkinson Agents; Automatism; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gambling; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Sexual Behavior | 2009 |
INPH and Parkinson disease: differentiation by levodopa response.
Topics: Algorithms; Antiparkinson Agents; Clinical Trials as Topic; Guidelines as Topic; Humans; Hydrocephalus, Normal Pressure; Levodopa; Parkinson Disease; Tomography, X-Ray Computed | 2010 |
Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review.
Topics: Age Factors; Antiparkinson Agents; Brain; Cerebrovascular Disorders; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Gait; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tremor | 2010 |
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2010 |
The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Electron Transport; Humans; Levodopa; Mice; Mice, Transgenic; Mitochondrial Diseases; Mitochondrial Proteins; Neurons; Parkinson Disease; Transcription Factors | 2009 |
[Advances in the medical treatment of Parkinson's disease].
Topics: Antiparasitic Agents; Disorders of Excessive Somnolence; Dopamine Agonists; Hallucinations; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2009 |
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain-Derived Neurotrophic Factor; Dyskinesia, Drug-Induced; Humans; Levodopa; Microvessels; Neuronal Plasticity; Parkinson Disease; Serotonin | 2009 |
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.
Topics: Administration, Oral; Clinical Protocols; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Treatment Outcome | 2010 |
Levodopa delivery systems: advancements in delivery of the gold standard.
Topics: Antiparkinson Agents; Dosage Forms; Drug Administration Routes; Drug Compounding; Drug Delivery Systems; Humans; Levodopa; Models, Biological; Models, Neurological; Parkinson Disease; Treatment Outcome | 2010 |
[Diagnosis and therapy of idiopathic Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
Rodent models of treatment-induced motor complications in Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Motor Skills Disorders; Parkinson Disease; Rats | 2009 |
Dopamine receptors and L-dopa-induced dyskinesia.
Topics: Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2009 |
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
Topics: Animals; Apomorphine; Drug Delivery Systems; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2009 |
Controlled-protein dietary regimens for Parkinson's disease.
Topics: Amino Acids, Aromatic; Binding, Competitive; Chronotherapy; Diet, Mediterranean; Diet, Protein-Restricted; Food-Drug Interactions; Humans; Levodopa; Parkinson Disease | 2010 |
Levodopa in Parkinson's disease: from the past to the future.
Topics: Antiparkinson Agents; Humans; Levodopa; MEDLINE; Parkinson Disease; Treatment Outcome | 2010 |
Does levodopa improve swallowing dysfunction in Parkinson's disease patients?
Topics: Antiparkinson Agents; Deglutition Disorders; Humans; Levodopa; Parkinson Disease | 2009 |
[Parkinson's disease - the future of invasive therapy].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Genetic Therapy; Humans; Levodopa; Parkinson Disease; Stem Cell Transplantation | 2010 |
[Clinical data of the prolonged-release formulation of ropinirole].
Topics: Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Quality of Life | 2010 |
[Dopaminergic stimulation in the non-motor symptoms of Parkinson's disease].
Topics: Autonomic Nervous System Diseases; Digestive System Diseases; Disorders of Excessive Somnolence; Dopamine Agonists; Humans; Levodopa; Mental Disorders; Parkinson Disease; REM Sleep Parasomnias; Sexual Dysfunction, Physiological; Sleep Apnea Syndromes; Urologic Diseases | 2010 |
Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?
Topics: Animals; Antiparkinson Agents; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2010 |
The impact of levodopa on quality of life in patients with Parkinson disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Quality of Life | 2010 |
Early pharmacologic treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Ubiquinone; Vitamin E | 2010 |
Synaptic dysfunction in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carrier Proteins; Dyskinesias; Humans; Levodopa; Nerve Tissue Proteins; Neuronal Plasticity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Synapses; Synaptic Transmission | 2010 |
When do levodopa motor fluctuations first appear in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Models, Neurological; Motor Activity; Parkinson Disease; Time Factors; Treatment Outcome | 2010 |
Effects of dietary factors on levodopa pharmacokinetics.
Topics: Animals; Antiparkinson Agents; Dietary Fiber; Dietary Proteins; Food-Drug Interactions; Half-Life; Humans; Intestinal Absorption; Levodopa; Parkinson Disease | 2010 |
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors | 2010 |
Substance abuse and movement disorders.
Topics: Alcoholism; Animals; Apomorphine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substance Withdrawal Syndrome; Substance-Related Disorders | 2009 |
[Intraduodenal infusion of levodopa].
Topics: Carbidopa; Deep Brain Stimulation; Dopamine Agents; Drug Administration Routes; Duodenum; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2010 |
Entacapone.
Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease | 2010 |
[Levodopa: from a discovery to new elaborations].
Topics: Antiparkinson Agents; Dopamine Agents; Drug Discovery; Humans; Levodopa; Parkinson Disease | 2010 |
Classifying risk factors for dyskinesia in Parkinson's disease.
Topics: Age Factors; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Sex Factors | 2010 |
[Non-motor fluctuations in Parkinson's disease].
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Humans; Levodopa; Mental Disorders; Motor Activity; Parkinson Disease; Somatosensory Disorders | 2010 |
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemotherapy, Adjuvant; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic | 2010 |
Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.
Topics: Animals; Antiparkinson Agents; Anxiety; Depression; Disease Models, Animal; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2011 |
Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia?
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurons; Parkinson Disease | 2010 |
Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review.
Topics: Animals; Dietary Proteins; Dopamine Agents; Humans; Levodopa; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Proteins; PubMed; Randomized Controlled Trials as Topic | 2010 |
rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
Topics: Animals; Antiparkinson Agents; Cerebellum; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Prefrontal Cortex; Transcranial Magnetic Stimulation | 2010 |
L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Management of motor complications in Parkinson disease: current and emerging therapies.
Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2010 |
["Red flags": when to be alerted and how to explore?].
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Biomarkers; Diagnosis, Differential; Humans; Levodopa; Lewy Body Disease; Magnetic Resonance Imaging; Multiple System Atrophy; Parkinson Disease; Supranuclear Palsy, Progressive | 2010 |
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Understanding graft-induced dyskinesia.
Topics: Cell Transplantation; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2010 |
Medical treatment of Parkinson's disease: today and the future.
Topics: Dopamine Agonists; Humans; Kynurenine; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2010 |
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2010 |
Deep brain stimulation state of the art and novel stimulation targets.
Topics: Animals; Antiparkinson Agents; Contraindications; Deep Brain Stimulation; Disease Progression; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 2010 |
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
Topics: Animals; Azepines; Benzothiazoles; Brain; Dopamine; Dopamine Agonists; Embryonic Stem Cells; Humans; Levodopa; Mice; Microglia; Nerve Net; Nerve Regeneration; Neuroprotective Agents; Parkinson Disease; Planarians; Pramipexole; Rats | 2010 |
[Treatment and pathogenesis of Parkinson's disease].
Topics: Humans; Levodopa; Parkinson Disease | 2010 |
[Speech and voice disorders in Parkinson's disease].
Topics: Antiparkinson Agents; Dysarthria; Humans; Levodopa; Parkinson Disease; Phonation; Speech Acoustics; Speech Disorders; Voice Disorders; Voice Quality | 2010 |
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2010 |
A brief history of levodopa.
Topics: Animals; Antiparkinson Agents; Brain Chemistry; Dopamine; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2010 |
Pharmacokinetics of levodopa.
Topics: Antiparkinson Agents; Humans; Intestinal Absorption; Levodopa; Parkinson Disease | 2010 |
The role of the long-duration response to levodopa in Parkinson's disease.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Time; Time Factors | 2010 |
The clinical spectrum of levodopa-induced motor complications.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Soluble and controlled-release preparations of levodopa: do we really need them?
Topics: Antiparkinson Agents; Delayed-Action Preparations; Humans; Levodopa; Parkinson Disease; Solubility | 2010 |
Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinson Disease | 2010 |
Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Humans; Levodopa; Parkinson Disease; S-Adenosylmethionine | 2010 |
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2010 |
Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field.
Topics: Adult; Aged; Behavior, Addictive; Binge-Eating Disorder; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Epidemiologic Factors; Epidemiologic Methods; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Substance-Related Disorders | 2011 |
[Therapy options in the case of advanced therapy resistant Morbus Parkinson].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Cross-Sectional Studies; Deep Brain Stimulation; Drug Resistance; Humans; Infusion Pumps, Implantable; Levodopa; Neurologic Examination; Parkinson Disease; Population Dynamics | 2010 |
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2011 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dopamine Agonists; Humans; Levodopa; Nortriptyline; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2011 |
Parkinson's disease and the bones.
Topics: Accidental Falls; Antiparkinson Agents; Bone and Bones; Bone Density; Fractures, Bone; Humans; Levodopa; Osteoporosis; Parkinson Disease; Risk Assessment; Vitamin D | 2011 |
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; MEDLINE; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Antiparkinson Agents; Clinical Trials as Topic; Disability Evaluation; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2011 |
Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
Topics: Animals; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Models, Neurological; Motor Activity; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Signal Transduction; Synaptic Transmission | 2011 |
Myths and realities of continuous dopaminergic stimulation.
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Basal Ganglia; Brain; Deep Brain Stimulation; Delayed-Action Preparations; Dopamine; Dopamine Agonists; Drug Administration Schedule; Humans; Infusions, Intravenous; Levodopa; Metabolic Clearance Rate; Mythology; Neural Pathways; Neurons; Parkinson Disease; Substantia Nigra | 2011 |
Motor complications, levodopa metabolism and progression of Parkinson's disease.
Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission | 2011 |
Cancer and Parkinson's disease: the odd couple.
Topics: Humans; Levodopa; Life Style; Melanoma; Neoplasms; Parkinson Disease; Smoking; Social Class | 2011 |
The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Reaction Time; Time Factors; Treatment Outcome | 2011 |
The treatment of early Parkinson's disease: levodopa rehabilitated.
Topics: Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2011 |
Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2011 |
Factors related to functional independence in females with Parkinson's disease: a systematic review.
Topics: Activities of Daily Living; Dyskinesias; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Postural Balance; Psychomotor Performance; Quality of Life; Sex Factors | 2011 |
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Dopamine; Dopaminergic Neurons; Humans; Levodopa; Mitochondria; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2011 |
How might physical activity benefit patients with Parkinson disease?
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cognition; Constipation; Depressive Disorder; Dopamine; Humans; Levodopa; Motor Activity; Muscle Fatigue; Osteoporosis; Parkinson Disease; Psychomotor Performance; Quality of Life; Sedentary Behavior; Sleep Wake Disorders | 2011 |
Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Topics: Antiparkinson Agents; Humans; Kynurenine; Levodopa; Parkinson Disease; Tryptophan | 2011 |
Targeting nicotinic receptors for Parkinson's disease therapy.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Molecular Targeted Therapy; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic | 2011 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Rats; Serotonergic Neurons; Serotonin | 2011 |
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Neurotransmitter Agents; Parkinson Disease; Signal Transduction | 2011 |
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.
Topics: Animals; Calcium; Calcium Channels, L-Type; Dopamine Agents; Dopaminergic Neurons; Humans; Levodopa; Mitochondria; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2011 |
Pharmacokinetic evaluation of pramipexole.
Topics: Benzothiazoles; Dopamine Agonists; Drug Delivery Systems; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Heart Valve Diseases; Humans; Levodopa; Parkinson Disease; Pharmacogenetics; Pramipexole; Receptors, Dopamine; Restless Legs Syndrome | 2011 |
l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
Topics: Animals; Antiparkinson Agents; Dyskinesias; History, 20th Century; Humans; Levodopa; Parkinson Disease; Risk Factors | 2011 |
Molecular mechanisms of l-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate-Early; Humans; Levodopa; Neurons; Parkinson Disease; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Signal Transduction; Sirolimus | 2011 |
New approaches to therapy.
Topics: Animals; Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, Biogenic Amine | 2011 |
Surgical approach to l-dopa-induced dyskinesias.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgery; Parkinson Disease | 2011 |
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.
Topics: Antiparkinson Agents; Brain Tissue Transplantation; Cognition Disorders; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2012 |
Central neuropathic pain in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Neuralgia; Pain Measurement; Parkinson Disease | 2012 |
Motor complications in Parkinson's disease.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Levodopa; Parkinson Disease | 2011 |
Future treatments for Parkinson's disease: surfing the PD pipeline.
Topics: Antiparkinson Agents; Gene Transfer Techniques; Genetic Therapy; Humans; Levodopa; Neuropharmacology; Parkinson Disease | 2011 |
[Stimulation therapies for Parkinson's disease: over the past two decades].
Topics: Animals; Cytoprotection; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2010 |
Continuous dopaminergic stimulation: clinical aspects and experimental bases.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA-A | 2011 |
Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?".
Topics: Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Dyskinesia, Drug-Induced; Goals; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2011 |
Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2011 |
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Brain Chemistry; Dependovirus; Dihydroxyphenylalanine; Drug Delivery Systems; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Parkinson Disease; Tyrosine 3-Monooxygenase | 2012 |
Helicobacter pylori eradication for Parkinson's disease.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
Topics: Animals; Drug Design; Humans; Levodopa; Molecular Structure; Parkinson Disease; Prodrugs; Structure-Activity Relationship | 2011 |
Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality-Adjusted Life Years; Secondary Prevention | 2011 |
Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care.
Topics: Antiparkinson Agents; Costs and Cost Analysis; Disease Progression; Dose-Response Relationship, Drug; Exercise; Humans; Levodopa; Managed Care Programs; Parkinson Disease; Patient-Centered Care; Physical Therapy Modalities; Quality of Life; Sickness Impact Profile | 2011 |
Modelling of Parkinson's disease in mice.
Topics: Animals; Disease Models, Animal; Levodopa; Mice; Neuroprotective Agents; Parkinson Disease | 2011 |
L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Humans; Levodopa; Parkinson Disease; Serotonergic Neurons; Serotonin | 2011 |
[Current treatment strategies for Parkinson's disease].
Topics: Aged; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Critical Care; Deep Brain Stimulation; Dementia; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Europe; Female; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychotic Disorders; Sleep Wake Disorders; Tremor | 2011 |
How best to address these common movement disorders.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Anticonvulsants; Antiparkinson Agents; Essential Tremor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Practice Guidelines as Topic; Primidone; Propranolol; Tetrabenazine; Tourette Syndrome; Treatment Outcome | 2011 |
Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.
Topics: Animals; Dopamine Agonists; Dopaminergic Neurons; Drug Delivery Systems; Humans; Levodopa; Molecular Mimicry; Parkinson Disease | 2012 |
Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2012 |
Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2012 |
Gastroparesis and Parkinson's disease: a systematic review.
Topics: Antiparkinson Agents; Databases, Bibliographic; Gastroparesis; Humans; Levodopa; Parkinson Disease; Quality of Life | 2012 |
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease | 2012 |
Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Serotonin; Subthalamic Nucleus | 2012 |
New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.
Topics: Animals; Antiparkinson Agents; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Glutamate; Receptors, Purinergic P1 | 2012 |
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin | 2012 |
Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.
Topics: Aged; Aged, 80 and over; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Polyneuropathies; Vitamin B 12 Deficiency | 2012 |
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2012 |
IPX066: a novel carbidopa-levodopa extended-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Clinical inquiry. Which drugs work best for early Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Family Practice; Humans; Indoles; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease | 2012 |
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
Animal models of L-DOPA-induced dyskinesia: an update on the current options.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Reproducibility of Results | 2012 |
The effect of levodopa on pulmonary function in Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Forced Expiratory Volume; Humans; Levodopa; Lung Diseases; Models, Statistical; Parkinson Disease; Peak Expiratory Flow Rate; Vital Capacity | 2012 |
Parkinson's disease: gene therapies.
Topics: alpha-Synuclein; Dependovirus; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Glutamate Decarboxylase; Humans; Lentivirus; Levodopa; Parkinson Disease; Ubiquitin-Protein Ligases | 2012 |
Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
Topics: Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine; Humans; Levodopa; Parkinson Disease; Receptors, G-Protein-Coupled | 2012 |
Designing prodrugs for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Blood-Brain Barrier; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Design; Humans; Levodopa; Mice; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Prodrugs; Rats | 2012 |
Functional neuroimaging in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Diseases, Metabolic; Cognition Disorders; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Functional Neuroimaging; Humans; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Positron-Emission Tomography; Psychomotor Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2012 |
What can we expect from the serotonergic side of L-DOPA?
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonergic Neurons; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Synaptic Transmission | 2012 |
Adenosine A2A antagonists in Parkinson's disease: what's next?
Topics: Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2012 |
[Resistance to treatment in movement disorders].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Drug Resistance; Essential Tremor; Humans; Levodopa; Movement Disorders; Neurosurgery; Parkinson Disease; Treatment Failure | 2012 |
An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2012 |
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Severity of Illness Index | 2012 |
Managing the patient with newly diagnosed Parkinson disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Exercise Therapy; Humans; Levodopa; Parkinson Disease | 2012 |
Off spells and dyskinesias: pharmacologic management of motor complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine | 2012 |
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
Topics: Animals; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2012 |
Therapeutic potential of natural products in Parkinson's disease.
Topics: Animals; Biological Products; Botulinum Toxins; Humans; Levodopa; Neuroprotective Agents; Nicotine; Parkinson Disease; Patents as Topic; Phytic Acid; Phytotherapy; Piper nigrum; Plant Extracts; Zingiber officinale | 2012 |
Recent progress in gene therapy for Parkinson's disease.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Dopamine Agonists; Dopaminergic Neurons; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glutamate Decarboxylase; GTP Cyclohydrolase; Humans; Infectious Anemia Virus, Equine; Levodopa; Neurturin; Parkinson Disease; Tyrosine 3-Monooxygenase | 2012 |
Parkinson's disease, L-DOPA, and endogenous morphine: a revisit.
Topics: Animals; Codeine; Humans; Levodopa; Morphine; Parkinson Disease; Tetrahydropapaveroline | 2012 |
[Parkinson's disease: current standards in diagnostics and therapy].
Topics: Antidepressive Agents; Antiparkinson Agents; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Drug Implants; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 2012 |
Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Parkinsonism in cirrhosis: pathogenesis and current therapeutic options.
Topics: Antiparkinson Agents; Brain Chemistry; Chelating Agents; Dopamine; Dopamine Agents; Humans; Hyperammonemia; Levodopa; Liver Cirrhosis; Liver Transplantation; Manganese Poisoning; Parkinson Disease | 2013 |
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, AMPA; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2012 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Levodopa; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2012 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease | 2012 |
[Candidate patient for subcutaneous apomorphine injection].
Topics: Abnormalities, Drug-Induced; Antiparkinson Agents; Apomorphine; Contraindications; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Injections, Subcutaneous; Lactation; Levodopa; Parkinson Disease; Patient Selection; Pregnancy; Pregnancy Complications; Psychoses, Substance-Induced | 2012 |
[Levodopa in the treatment of Parkinson's disease: myths and realties].
Topics: Antiparkinson Agents; Humans; Levodopa; Mental Disorders; Motor Activity; Parkinson Disease; Quality of Life; Sleep Wake Disorders | 2012 |
L-DOPA- and graft-induced dyskinesia following transplantation.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2012 |
Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence.
Topics: Antiparkinson Agents; Deglutition; Deglutition Disorders; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease | 2013 |
[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Topics: Antiparkinson Agents; Attention; Clinical Trials as Topic; Cognition Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Fatigue; Headache; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Multicenter Studies as Topic; Nausea; Neuroprotective Agents; Parkinson Disease; Severity of Illness Index | 2013 |
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Administration Routes; Evidence-Based Practice; Humans; Levodopa; Parkinson Disease | 2013 |
[Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy].
Topics: Animals; Antiparkinson Agents; Apomorphine; Circadian Rhythm; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Receptors, Dopamine; Salvage Therapy; Self Administration | 2013 |
The awakening of artistic creativity and Parkinson's disease.
Topics: Antiparkinson Agents; Art; Creativity; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2013 |
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2013 |
Dysphagia in Parkinson's disease is responsive to levodopa.
Topics: Antiparkinson Agents; Deglutition; Deglutition Disorders; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease | 2013 |
Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Neurology; Parkinson Disease; Research | 2002 |
Dopamine and the regulation of cognition and attention.
Topics: Adult; Aged; Aging; Animals; Antiparkinson Agents; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Basal Ganglia; Child; Cognition; Cognition Disorders; Dopamine; Dopamine Agonists; Humans; Levodopa; Limbic System; Middle Aged; Models, Neurological; Models, Psychological; Parkinson Disease; Phylogeny; Receptors, Dopamine; Schizophrenic Psychology | 2002 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
[Alpha-2 adrenergic receptors and Parkinson's disease].
Topics: Adrenergic alpha-2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Neuroprotective Agents; Norepinephrine; Parkinson Disease; Piribedil; Receptors, Adrenergic, alpha-2 | 2002 |
Levodopa: management of Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Psychomotor Disorders; Psychomotor Performance; Randomized Controlled Trials as Topic | 2002 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.
Topics: Dopamine Agonists; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Lisuride; Parkinson Disease; Psychomotor Disorders; Randomized Controlled Trials as Topic | 2002 |
DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Psychomotor Disorders; Randomized Controlled Trials as Topic | 2002 |
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Psychomotor Disorders; Randomized Controlled Trials as Topic; Thiazoles | 2002 |
Treatment of depression in idiopathic Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2002 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Risk Factors; Speech Acoustics; Speech Disorders; Speech Production Measurement; Speech Therapy; Treatment Outcome | 2002 |
Acoustic analysis of parkinsonian speech II: L-Dopa related fluctuations and methodological issues.
Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Severity of Illness Index; Speech Acoustics; Speech Production Measurement; Speech Therapy; Treatment Outcome | 2002 |
Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species | 2002 |
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Motor Activity; Parkinson Disease; Receptors, Cell Surface | 2002 |
Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2002 |
[Progress in diagnosis and therapy for Parkinson's disease].
Topics: Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Genes, Dominant; Genes, Recessive; Humans; Levodopa; Ligases; Mutation; Nerve Tissue Proteins; Parkinson Disease; Synucleins; tau Proteins; Ubiquitin-Protein Ligases | 2002 |
[Human striatal D-neurons and their significance].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Droxidopa; Humans; Levodopa; Mental Disorders; Neurons; Norepinephrine; Parkinson Disease; Pluripotent Stem Cells | 2002 |
Treatment of Parkinson's disease: levodopa as the first choice.
Topics: Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2002 |
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2002 |
New drugs in the future treatment of Parkinson's disease.
Topics: Animals; Antioxidants; Antipsychotic Agents; Dopamine Agonists; Drug Therapy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Psychotic Disorders | 2002 |
Parkinson's disease: current scientific understanding, and John's story.
Topics: Antiparkinson Agents; Disease Progression; Drug Monitoring; Drug Therapy, Combination; History, 19th Century; History, 20th Century; Humans; Levodopa; Male; Parkinson Disease | 2002 |
Dopaminergic substitution in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2002 |
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine | 2003 |
Strategies to modify levodopa treatment.
Topics: Antiparkinson Agents; Drug Interactions; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2003 |
Position of COMT inhibition in the treatment of Parkinson's disease.
Topics: Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Risk Assessment | 2003 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2003 |
Dopaminergic drugs in development for Parkinson's disease.
Topics: Brain; Dopamine Agonists; Drug Design; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2003 |
Are there clinically significant differences between dopamine agonists.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Disorders of Excessive Somnolence; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2003 |
Potential nondopaminergic drugs for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Therapy, Combination; Humans; Levodopa; Models, Neurological; Neural Pathways; Neurotransmitter Agents; Parkinson Disease; Receptors, Neurotransmitter; Substantia Nigra | 2003 |
Differential diagnosis between early Parkinson's disease and dementia with Lewy bodies.
Topics: Brain; Cognition Disorders; Diagnosis, Differential; Disease Progression; Hallucinations; Humans; Levodopa; Lewy Body Disease; Mood Disorders; Parkinson Disease | 2003 |
Parkinson's disease and anaesthesia.
Topics: Anesthesia; Anesthetics, Inhalation; Anesthetics, Intravenous; Humans; Levodopa; Monoamine Oxidase Inhibitors; Narcotics; Parkinson Disease | 2002 |
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Delivery Systems; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Agents | 2002 |
Do dopamine agonists or levodopa modify Parkinson's disease progression?
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Dihydroxyphenylalanine; Disease Progression; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; Indoles; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
[Use of dopamine analogs in Parkinson's disease treatment].
Topics: Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Piribedil; Treatment Outcome | 2002 |
Neuroprotection in idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Cell Death; Dopamine Agonists; Humans; Indoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Which factors influence therapeutic decisions in Parkinson's disease?
Topics: Age Factors; Dopamine Agonists; Drug Interactions; Dyskinesias; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Health Care Costs; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Quality of Life; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2002 |
Measuring motor complications in clinical trials for early Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Risk | 2003 |
Should levodopa be used anymore?
Topics: Antiparkinson Agents; Brain; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2002 |
Amantadine in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2003 |
Initial agonist treatment of Parkinson disease: a critique.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2003 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 2002 |
Recent advances in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 2002 |
[Neuroplasticity and Parkinson disease].
Topics: Antiparkinson Agents; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2002 |
[Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
[Dyskinesia caused by L-DOPA].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
[Management of levodopa-induced dyskinesia].
Topics: Algorithms; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
[Parkinson disease: deep cerebral stimulation].
Topics: Adult; Aged; Aged, 80 and over; Electric Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Subthalamic Nucleus | 2002 |
The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.
Topics: Animals; Drug Administration Schedule; Dyskinesias; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Receptors, Opioid | 2003 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Holistic Health; Humans; Levodopa; Musculoskeletal Manipulations; Neuroprotective Agents; Occupational Therapy; Parkinson Disease; Speech Therapy | 2003 |
Update on Parkinson disease.
Topics: Antiparkinson Agents; Cell Transplantation; Dopamine Agonists; Environment; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease | 2003 |
Malignant syndrome in Parkinson's disease: concept and review of the literature.
Topics: Antiparkinson Agents; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.
Topics: Age Factors; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Time Factors; Treatment Outcome | 2003 |
The relevance of preclinical studies for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Evaluation, Preclinical; Humans; Levodopa; Neuroprotective Agents; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 2003 |
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamine Agents; Female; Fluoxetine; Gambling; Humans; Levodopa; Middle Aged; Parkinson Disease | 2003 |
Motor complications of Parkinson's disease.
Topics: Drug Resistance; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease; Treatment Failure | 2003 |
Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.
Topics: Animals; Dopamine; Dopamine Agents; Free Radicals; Humans; Levodopa; Monophenol Monooxygenase; Neurotoxicity Syndromes; Parkinson Disease | 2003 |
Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Melanoma; Middle Aged; Parkinson Disease; Retrospective Studies; Skin Neoplasms | 2003 |
Tremor.
Topics: Acetates; Amines; Anticonvulsants; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Electromyography; Essential Tremor; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Muscle, Skeletal; Parkinson Disease; Posture; Primidone; Randomized Controlled Trials as Topic; Severity of Illness Index; Somatosensory Cortex; Topiramate; Tremor | 2003 |
Recent developments in the pharmacological treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedule; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine; Treatment Outcome | 2003 |
Trends in movement disorders' therapy.
Topics: Animals; Antiparkinson Agents; Electric Stimulation Therapy; Humans; Levodopa; Neurosciences; Neurosurgery; Parkinson Disease; Stereotaxic Techniques | 2003 |
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Prevention and treatment of motor fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Parkinson's disease: is the initial treatment established?
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2003 |
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Selegiline | 2003 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Movement Disorders; Nitriles; Parkinson Disease; Tablets | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
[Etiology and physiopathology of patients with parkinson's disease].
Topics: Aging; Dopamine; Dopamine Agonists; Free Radicals; Humans; Levodopa; Ligases; Mutation; Nerve Tissue Proteins; Parkinson Disease; Synucleins; Ubiquitin-Protein Ligases | 2003 |
[Therapy for patients with progressive Parkinson's disease].
Topics: Antiparkinson Agents; Disease Progression; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Style; Parkinson Disease | 2003 |
Clinical strategies to prevent and delay motor complications.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Present and future directions in the management of motor complications in patients with advanced PD.
Topics: Antiparkinson Agents; Chronic Disease; Disease Management; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinson Disease | 2003 |
Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
Topics: Antiparkinson Agents; Biomarkers; Clinical Trials as Topic; Diagnostic Imaging; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Radionuclide Imaging; Treatment Outcome | 2003 |
Rationale for current therapies in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2003 |
[Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels].
Topics: Animals; Antiparkinson Agents; Biomarkers; Blood-Brain Barrier; Folic Acid Deficiency; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12 Deficiency | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
Topics: Animals; Basal Ganglia; Biomarkers; Cocaine; Diagnostic Imaging; Dihydroxyphenylalanine; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease; Radiopharmaceuticals; Technology Assessment, Biomedical; Tetrabenazine; Tomography, Emission-Computed, Single-Photon; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Clinical inquiries. What is the best initial treatment of Parkinson's disease?
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2003 |
[Parkinson's disease].
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cognition Disorders; Depressive Disorder; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2003 |
Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesias; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease | 2003 |
Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
Topics: Animals; Basal Ganglia; Dopamine Agonists; Dyskinesia, Drug-Induced; Efferent Pathways; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Sleep disorders in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Sleep; Sleep Wake Disorders | 2003 |
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Caffeine; Dopamine; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A; Treatment Failure | 2003 |
Unmet medical needs in Parkinson's disease.
Topics: Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2004 |
New developments in levodopa therapy.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug | 2004 |
The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Progression; Dopamine; Humans; Levodopa; Nerve Net; Neurons; Parkinson Disease | 2004 |
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
Topics: Animals; Antiparkinson Agents; Area Under Curve; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2004 |
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Coenzymes; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone | 2004 |
CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
Topics: Animals; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Central Nervous System; Diet; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Models, Neurological; Oxidation-Reduction; Parkinson Disease | 2004 |
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
Topics: Animals; Antiparkinson Agents; Brain; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1 | 2003 |
[Treatment of Parkinson's disease: use of piribedil].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Piribedil | 2004 |
Neuroprotection and dopamine agonists.
Topics: Animals; Cell Death; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2004 |
Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Depression; Dyskinesia, Drug-Induced; Forecasting; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Psychoses, Substance-Induced | 2004 |
Gene therapy for Parkinson's disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Parkinson Disease; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2004 |
[Parkinson's disease, familial Parkinson's disease].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Reference Standards | 2004 |
Rapid treatment of "wearing off" in Parkinson's disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease; Salvage Therapy; Time Factors | 2004 |
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on?
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agents; Electric Stimulation Therapy; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Patient Selection; Postoperative Care; Subthalamic Nucleus | 2004 |
[Which drug to use for the initiation of treatment for early Parkinson's disease].
Topics: Aged; Clinical Trials as Topic; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Finland; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
[Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
Topics: Adult; Antiparkinson Agents; Behavior, Addictive; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Reward; Visual Cortex | 2004 |
[Treatment of Parkinson disease in patients with surgical problems].
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Health Status; Humans; Levodopa; Parkinson Disease; Postoperative Period | 2003 |
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
Topics: Antiparkinson Agents; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Neurosurgery; Parkinson Disease; Substantia Nigra | 2004 |
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Topics: Antiparkinson Agents; Brain; Cost-Benefit Analysis; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Selegiline; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2004 |
[AAV vector-mediated gene transfer and its application to the nervous system].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Parkinson Disease | 2003 |
[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2003 |
Methylation demand: a key determinant of homocysteine metabolism.
Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation; Methyltransferases; Models, Biological; Models, Chemical; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Rats | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure | 2004 |
Deep brain stimulation in the treatment of dyskinesia and dystonia.
Topics: Dyskinesia, Drug-Induced; Dyskinesias; Dystonic Disorders; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Molecular Chaperones; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2004 |
Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Dyskinesias; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Organ Specificity; Parkinson Disease; Subthalamic Nucleus; Thalamus; Treatment Outcome | 2004 |
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Forecasting; Humans; Levodopa; Parkinson Disease | 2004 |
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Topics: Antiparkinson Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Psychomotor Disorders; Randomized Controlled Trials as Topic | 2004 |
Clinical advantages of COMT inhibition with entacapone - a review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Quality of Life | 2004 |
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra | 2004 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2004 |
[Treatment for patients with early Parkinson's disease].
Topics: Aged; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2004 |
[The therapy of wearing-off].
Topics: Age Factors; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2004 |
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Pergolide; Tolcapone | 2004 |
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Future therapies for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Forecasting; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2004 |
Treatment challenges in early stage Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Disease Progression; Early Diagnosis; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 2004 |
ALS lessons learned from other neurological diseases. Parkinson's disease.
Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Behavioral Symptoms; Coenzymes; Controlled Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone | 2004 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 2003 |
["How I do it" no. 8, dopa-resistant Parkinson's disease].
Topics: Adult; Antiparkinson Agents; Brain; Drug Resistance; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Tomography, X-Ray Computed | 2004 |
[Are there innovations in the treatment of Parkinson's disease?].
Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors | 2004 |
Initial treatment of Parkinson disease: levodopa or dopamine agonists.
Topics: Disease Management; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2004 |
Initial Parkinson disease therapy: levodopa, dopamine agonists, or both?
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2004 |
Levodopa-induced dyskinesia in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2005 |
[Progress in the basic and clinical aspects of Parkinson's disease].
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 2004 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus | 2004 |
Ropinirole: current status of the studies.
Topics: Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Indoles; Levodopa; Neuroprotective Agents; Parkinson Disease | 2004 |
Is levodopa toxic?
Topics: Animals; Dose-Response Relationship, Drug; Homocysteine; Humans; Levodopa; Nerve Degeneration; Neurotoxins; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2004 |
Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Topics: Adenosine Triphosphate; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Chemical and Drug Induced Liver Injury; Half-Life; Humans; Levodopa; Liver; Mitochondria; Nitrophenols; Oxidative Stress; Parkinson Disease; Phosphorylation; Safety; Tolcapone | 2005 |
Vascular parkinsonism--an important cause of parkinsonism in older people.
Topics: Aged; Antiparkinson Agents; Brain; Cerebral Infarction; Diagnostic Imaging; Humans; Intracranial Arteriosclerosis; Levodopa; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; Treatment Outcome | 2005 |
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Learning; Levodopa; Motor Skills; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Rats; Synapses | 2005 |
Peculiarities of L: -DOPA treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Biological Transport; Brain Chemistry; Dopamine; Dyskinesias; Humans; Hydroxyl Radical; Levodopa; Parkinson Disease; Rats; Receptors, Dopamine | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of surgery in the treatment of motor complications.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Thalamus | 2005 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Pathophysiology of motor fluctuations in Parkinson's disease.
Topics: Adaptation, Physiological; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Hypokinesia; Levodopa; Muscle Rigidity; Neural Pathways; Parkinson Disease; Receptors, Neurotransmitter; Thalamus; Tremor | 2005 |
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index | 2005 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
A walk through the management of Parkinson s disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Deep Brain Stimulation; Disease Progression; Dopamine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine | 2005 |
Ropinirole therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Parkinson Disease | 2004 |
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
Novel pharmacological strategies for motor complications in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction | 2005 |
[Clinical features of corticobasal degeneration].
Topics: Aged; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Diagnosis, Differential; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Degeneration; Neurodegenerative Diseases; Parkinson Disease | 2005 |
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2005 |
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome | 2005 |
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Denervation; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neostriatum; Neuronal Plasticity; Parkinson Disease; Parkinson Disease, Secondary; Rats; Synapses | 2005 |
Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cognition; Dopamine; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2006 |
Economic implications of manganese neurotoxicity.
Topics: Adult; Age Factors; Aged; Animals; Female; Humans; Intelligence; Levodopa; Male; Manganese Poisoning; Middle Aged; Neural Pathways; Neurotoxicity Syndromes; Parkinson Disease; Risk Factors | 2006 |
The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2005 |
Recent important trials of pharmacotherapy in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease | 2005 |
[Therapeutic strategies for Parkinson's disease].
Topics: Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Patient Selection | 2005 |
[Current treatment of Parkinson's disease: problems and controversies].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Muscarinic Antagonists; Parkinson Disease | 2005 |
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Primates; Purines; Receptor, Adenosine A2A | 2005 |
Pregnancy in Parkinson's disease: unique case report and review of the literature.
Topics: Adult; Antiparkinson Agents; Female; Humans; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2005 |
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2005 |
New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Pharmacogenetics | 2005 |
[Unilateral subthalamic stimulation for early-stage Parkinson's disease].
Topics: Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2005 |
A promising new technology for Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2005 |
Monoamine oxidase B inhibitors for early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline | 2005 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2005 |
[Idiopathic Parkinson's disease: practical hints for the treatment].
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Benserazide; Cholinesterase Inhibitors; Clozapine; Dementia; Depression; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep Wake Disorders; Time Factors | 2005 |
Parkinson's disease.
Topics: Deep Brain Stimulation; Deglutition Disorders; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus | 2005 |
Clinical practice. Diagnosis and initial management of Parkinson's disease.
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
REM sleep behavior disorder in patients with Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Clonazepam; Humans; Levodopa; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder | 2005 |
Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Muscarinic Antagonists; Parkinson Disease; Quality of Life | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Levodopa therapy from the neuroprotection viewpoint. From a clinical outlook.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease | 2005 |
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Topics: Antiparkinson Agents; Brain; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Optimising levodopa therapy for the management of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2005 |
Progress in clinical neurosciences: a forum on the early management of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Movement Disorders; Parkinson Disease | 2005 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
[Atypical Parkinsonian syndromes, a challenging group of diseases].
Topics: Brain; Diagnosis, Differential; Female; Finland; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Prognosis; Risk Factors; Severity of Illness Index; Treatment Failure | 2005 |
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2005 |
[Medication treatment for Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2005 |
Advances in the delivery of treatments for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; Drug Delivery Systems; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Forecasting; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2005 |
The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Melatonin; Parkinson Disease | 2005 |
A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Economics, Pharmaceutical; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease | 2005 |
What has been learnt from study of dopamine receptors in Parkinson's disease?
Topics: Animals; Genes, Immediate-Early; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Signal Transduction | 2006 |
Parkinson's disease management strategies.
Topics: Age Factors; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Disease Management; Electric Stimulation Therapy; Expert Testimony; Humans; Levodopa; Parkinson Disease | 2006 |
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Topics: Administration, Oral; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Half-Life; Humans; Levodopa; Parkinson Disease | 2006 |
Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease.
Topics: Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 2006 |
Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Ganglia, Sympathetic; Humans; Levodopa; Neurons; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Transplantation, Autologous; Vesicular Monoamine Transport Proteins | 2006 |
Psychosis in Parkinson's disease: case studies.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychotic Disorders; Severity of Illness Index | 2006 |
Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.
Topics: Animals; Humans; Levodopa; Melanoma; Mice; Parkinson Disease; Skin Neoplasms | 2006 |
Neuropharmacological treatment of mental dysfunction in Parkinson's disease.
Topics: Basal Ganglia; Cholinergic Agents; Cognition Disorders; Dopamine Agonists; Frontal Lobe; Humans; Levodopa; Mood Disorders; Norepinephrine; Parkinson Disease | 2006 |
[Receptor-mediated Parkinson drugs].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Muscarinic; Receptors, N-Methyl-D-Aspartate | 2006 |
[Enzyme inhibitors in Parkinson treatment].
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopa Decarboxylase; Dopamine; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2006 |
[Dosage forms in Parkinson treatment].
Topics: Antiparkinson Agents; Delayed-Action Preparations; Dosage Forms; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2006 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2006 |
Visual hallucinations in Parkinson's disease: clues to separate origins.
Topics: Antiparkinson Agents; Evoked Potentials, Visual; Hallucinations; Humans; Levodopa; Longitudinal Studies; Models, Biological; Parkinson Disease; REM Sleep Behavior Disorder | 2006 |
Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review.
Topics: Antiparkinson Agents; Complementary Therapies; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Levodopa; Parkinson Disease; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Impact of functional age on the use of dopamine agonists in patients with Parkinson disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Life Expectancy; Parkinson Disease | 2006 |
[Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].
Topics: Antiparkinson Agents; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; GTP-Binding Proteins; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2006 |
Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses.
Topics: Adolescent; Adult; Animals; Case-Control Studies; Catechol O-Methyltransferase; Cystathionine beta-Synthase; Dopamine Agents; Dystonia; Homocysteine; Humans; Huntington Disease; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 2006 |
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease; Receptors, Dopamine | 2006 |
An update on the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Transplants | 2006 |
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.
Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2006 |
Treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Cognition Disorders; Humans; Levodopa; Mental Disorders; Parkinson Disease; Sleep Wake Disorders | 2006 |
Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
Topics: Animals; Disease Progression; Dyskinesias; Humans; Levodopa; Motor Neuron Disease; Parkinson Disease; Risk Factors | 2006 |
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
Emerging drugs for Parkinson's disease.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Technology, Pharmaceutical | 2006 |
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug | 2007 |
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease | 2006 |
Levodopa--toxic or neuroprotective?
Topics: Animals; Antiparkinson Agents; Brain; Clinical Trials as Topic; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2006 |
Medical management of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Treatment Outcome | 2006 |
Locomotor training in people with Parkinson disease.
Topics: Antiparkinson Agents; Disease Management; Disease Progression; Humans; Levodopa; Locomotion; Parkinson Disease; Physical Therapy Modalities | 2006 |
The discovery of dopamine deficiency in the parkinsonian brain.
Topics: Antiparkinson Agents; Brain Chemistry; Dopamine; History, 20th Century; Humans; Levodopa; Neostriatum; Parkinson Disease | 2006 |
Progress in familial Parkinson's disease.
Topics: Age of Onset; alpha-Synuclein; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Ubiquitin-Protein Ligases | 2006 |
A new look at levodopa based on the ELLDOPA study.
Topics: Animals; Antiparkinson Agents; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2006 |
Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2006 |
Motor fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurosurgical Procedures; Parkinson Disease; Tremor | 2006 |
Tolcapone in the management of Parkinson's disease.
Topics: Animals; Benzophenones; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2006 |
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Topics: Carbidopa; Dyskinesias; Gels; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Parkinson Disease | 2006 |
[Levodopa for Parkinson's disease: What have we learned?].
Topics: Antiparkinson Agents; Chile; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Synapses | 2007 |
[Clinical criteria of Parkinson's disease].
Topics: Age Factors; Aged; Antiparkinson Agents; Cognition Disorders; Dementia; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Risk Factors; Time Factors; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2007 |
[Medical treatment of Parkinson's disease].
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cholinergic Antagonists; Controlled Clinical Trials as Topic; Dementia; Depression; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Hallucinations; Humans; Levodopa; Middle Aged; Multicenter Studies as Topic; Pain; Parkinson Disease; Quality of Life; Therapeutic Equivalency; Time Factors | 2007 |
[Tremor].
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antiparkinson Agents; Botulinum Toxins; Cholinergic Agents; Diagnosis, Differential; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Patient Compliance; Primidone; Propranolol; Radionuclide Imaging; Time Factors; Tremor | 2007 |
[The current approaches to diagnostics and therapy of fluctuations in Parkinson's disease].
Topics: Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2006 |
Dopaminergic neurons intrinsic to the striatum.
Topics: Animals; Corpus Striatum; Dopamine; Haplorhini; Humans; Huntington Disease; Levodopa; Mice; Neurons; Parkinson Disease; Phenotype; Rats; Tyrosine 3-Monooxygenase | 2007 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
[Initial management of Parkinson disease].
Topics: Age Factors; Aged; Antiparkinson Agents; Decision Making; Exercise Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease | 2007 |
Homocysteine and Parkinson's disease: a dangerous liaison?
Topics: Brain; Brain Diseases, Metabolic; Causality; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Nerve Degeneration; Parkinson Disease | 2007 |
Duodenal levodopa infusion for the treatment of Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Clinical Trials as Topic; Half-Life; Humans; Infusions, Parenteral; Intestinal Absorption; Levodopa; Parkinson Disease; Quality of Life | 2007 |
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Neuronal Plasticity; Neurons; Parkinson Disease | 2007 |
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Quality of Life; Risk Factors | 2007 |
Levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; PubMed; Quality of Life; Review Literature as Topic | 2007 |
[Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease | 2007 |
When should levodopa therapy be initiated in patients with Parkinson's disease?
Topics: Antiparkinson Agents; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 2007 |
[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
Topics: Antiparkinson Agents; Basal Ganglia; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Risk Factors | 2007 |
Levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2006 |
Parkinson disease: managing a complex, progressive disease at all stages.
Topics: Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Gait; Humans; Levodopa; Parkinson Disease | 2007 |
Parkinson's disease and cancer.
Topics: Antiparkinson Agents; Cohort Studies; Humans; Levodopa; Melanoma; Neoplasms; Parkinson Disease | 2007 |
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2007 |
Managing patients with Parkinson's disease.
Topics: Antiparkinson Agents; Depressive Disorder; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Patient Care Planning; Selective Serotonin Reuptake Inhibitors | 2007 |
[Lewy body dementia and Parkinson disease dementia].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists | 2007 |
Gender differences in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Drug Interactions; Estrogen Replacement Therapy; Estrogens; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Selection; Sex Factors | 2007 |
Current pharmacotherapeutic treatment options in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2007 |
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2007 |
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2007 |
Rasagiline: a review of its use in the management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2007 |
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline | 2007 |
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor].
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Electroencephalography; Humans; Levodopa; Middle Aged; Parkinson Disease; Practice Guidelines as Topic; Primidone; Tremor | 2007 |
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate | 2007 |
The relationship of Parkinson disease with aging.
Topics: Aging; Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Gait; Humans; Levodopa; Parkinson Disease; Posture | 2007 |
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index | 2007 |
[Mesolimbic and mesocortical pathways in Parkinson disease].
Topics: Animals; Behavior; Humans; Levodopa; Neural Pathways; Parkinson Disease | 2007 |
Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Locus Coeruleus; Neurons; Norepinephrine; Parkinson Disease; Receptors, Adrenergic; Receptors, Dopamine | 2007 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics | 2008 |
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
Topics: Animals; Dopamine; Dopamine Agents; Humans; Levodopa; Models, Biological; Parkinson Disease | 2007 |
Bromocriptine versus levodopa in early Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2007 |
Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2007 |
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Topics: Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2006 |
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 2006 |
Beating a dead horse: dopamine and Parkinson disease.
Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Constipation; Deep Brain Stimulation; Dopamine; Humans; Levodopa; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder | 2007 |
Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
Topics: Antiparkinson Agents; Behavioral Symptoms; Dopamine; Gambling; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders | 2008 |
Paradoxes of functional neurosurgery: clues from basal ganglia recordings.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Essential Tremor; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease | 2008 |
[Gene therapy using AAV].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Fabry Disease; Genetic Therapy; Genetic Vectors; Hemophilia A; Humans; Levodopa; Neoplasms; Parkinson Disease | 2007 |
Pharmacotherapy for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Utility of tolcapone in fluctuating Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Periodicity; Severity of Illness Index; Tolcapone | 2006 |
Management of motor complications in advanced Parkinson's disease.
Topics: Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Fetal Stem Cells; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Receptors, Dopamine; Substantia Nigra; Thalamus | 2007 |
The evolution of pharmacological treatment for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Drug Administration Routes; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2008 |
Irregular gastrointestinal drug absorption in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Biological Availability; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Parkinson Disease | 2008 |
[Idiopathic Parkinson's disease].
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Hyperkinesis; Levodopa; Mental Disorders; Parkinson Disease; Physical Therapy Modalities | 2008 |
Antiparkinson prodrugs.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Prodrugs; Receptors, Dopamine | 2008 |
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechols; Clinical Trials, Phase III as Topic; Dopa Decarboxylase; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Time; Treatment Outcome | 2008 |
Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.
Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Duodenum; Humans; Infusion Pumps; Levodopa; Parkinson Disease | 2008 |
Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
Topics: Animals; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Signal Transduction | 2008 |
The safety of dopamine agonists in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2008 |
Misincorporation of amino acid analogues into proteins by biosynthesis.
Topics: Amino Acids; Amino Acids, Diamino; Aminoacylation; Animals; Bacteria; Canavanine; Ethionine; Humans; Levodopa; Lupus Erythematosus, Systemic; Oxidation-Reduction; Parkinson Disease; Plants; Protein Biosynthesis; Tryptophan | 2008 |
L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2008 |
[The development of therapeutic agents for Parkinson's disease and problems in their clinical application].
Topics: Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
Dopamine agonist therapy in early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2008 |
Management for motor and non-motor complications in late Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Comorbidity; Dementia; Dyskinesias; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Sleep Wake Disorders | 2008 |
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Quality of Life; Receptors, Glutamate; Severity of Illness Index | 2008 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
Current views on Parkinson's disease.
Topics: Animals; Basal Ganglia; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 1983 |
Catecholamine systems of retina: a model for studying synaptic mechanisms.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Darkness; Dopamine; Electrophysiology; Enzyme Activation; Epinephrine; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Humans; Levodopa; Light; Melatonin; Narcotics; Neurons; Norepinephrine; Parkinson Disease; Receptors, Adrenergic; Retina; Schizophrenia; Serotonin | 1984 |
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Lisuride; Oxprenolol; Parkinson Disease; Piracetam; Piribedil; Propranolol | 1984 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Selegiline; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 1984 |
Pharmacology of Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Biopterins; Dopamine; Histamine H1 Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Norepinephrine; Parasympatholytics; Parkinson Disease | 1984 |
Involuntary movement disorders.
Topics: Brain; Chorea; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Meige Syndrome; Movement Disorders; Parasympatholytics; Parkinson Disease | 1984 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
Positron emission tomography of the brain: new possibilities for the investigation of human cerebral pathophysiology.
Topics: Aging; Amino Acids; Arterial Occlusive Diseases; Brain; Brain Ischemia; Brain Neoplasms; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Dementia; Epilepsy; Fluorine; Forecasting; Homeostasis; Humans; Huntington Disease; Isotopes; Levodopa; Mental Disorders; Models, Biological; Neurology; Oxygen Radioisotopes; Parkinson Disease; Radioisotopes; Receptors, Drug; Reference Values; Respiration; Tomography, Emission-Computed | 1984 |
Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
Topics: Corpus Striatum; Dopa Decarboxylase; Dopamine; Humans; Interneurons; Levodopa; Neurons, Efferent; Norepinephrine; Parkinson Disease; Serotonin; Synaptic Transmission | 1980 |
Intellectual dysfunction and dementia in Parkinson disease.
Topics: Aged; Atrophy; Basal Ganglia; Cerebral Cortex; Dementia; Humans; Intelligence; Levodopa; Middle Aged; Parkinson Disease; Psychological Tests | 1983 |
[Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
Topics: Adult; Aged; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine beta-Hydroxylase; Droxidopa; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Terminology as Topic | 1983 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Pyridines; Receptors, Dopamine; Time Factors | 1984 |
Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease.
Topics: Brain; Humans; Isoenzymes; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1984 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline | 1984 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Growth hormone secretion in neurological disorders.
Topics: Benserazide; Disease Models, Animal; Dopamine; Growth Hormone; Humans; Huntington Disease; Levodopa; Nervous System Diseases; Parkinson Disease | 1981 |
Drug holiday in the management of Parkinson disease.
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Parkinson Disease | 1982 |
[L-dopa in the therapy of Parkinson's disease today].
Topics: Humans; Levodopa; Parkinson Disease | 1982 |
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Receptors, Dopamine | 1980 |
Sinemet and the treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Chemical Phenomena; Chemistry; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis | 1981 |
Is aldosterone secretion under dopaminergic control?
Topics: Aldosterone; Bromocriptine; Chlorpromazine; Dopamine; Dopamine Antagonists; Edema; Humans; Levodopa; Methyldopa; Metoclopramide; Parkinson Disease; Sulpiride | 1981 |
Speech disorders of Parkinsonism: a review.
Topics: Humans; Levodopa; Parkinson Disease; Respiration; Speech; Speech Disorders; Stereotaxic Techniques; Thalamus | 1981 |
[Biochemical aspects of involuntary movements (author's transl)].
Topics: Adenosine Triphosphate; Brain; Calcium; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Movement Disorders; Norepinephrine; Parkinson Disease; Serotonin | 1981 |
The management of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Nausea; Parasympatholytics; Parkinson Disease | 1982 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease Models, Animal; Excitatory Amino Acids; Levodopa; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats | 1994 |
[Stage-adjusted treatment of idiopathic Parkinson syndrome].
Topics: Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Cholinergic Antagonists; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline | 1995 |
[Treatment of Parkinson disease].
Topics: Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Treatment Failure | 1995 |
Management of parkinsonism and treatment of associated complications.
Topics: Antiparkinson Agents; Brain; Dopamine Agents; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Dopamine | 1995 |
Apomorphine for motor fluctuations and freezing in Parkinson's disease.
Topics: Administration, Intranasal; Administration, Rectal; Administration, Sublingual; Apomorphine; Clinical Trials as Topic; Half-Life; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.
Topics: Aged; Case-Control Studies; Cause of Death; Death Certificates; England; Frail Elderly; Humans; Levodopa; Parkinson Disease; Survival Rate; Treatment Outcome; Wales | 1995 |
Parkinson's disease: managing symptoms and preserving function.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combinations; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
[Parkinson disease and alkaptonuria: fortuitous association or striatonigral ochronosis?].
Topics: Alkaptonuria; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Levodopa; Middle Aged; Ochronosis; Parkinson Disease | 1995 |
The role of positron emission tomography in the assessment of human neurotransplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Basal Ganglia; Brain Tissue Transplantation; Caudate Nucleus; Fetal Tissue Transplantation; Fluorine Radioisotopes; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Tomography, Emission-Computed; Transplantation, Heterotopic; Treatment Outcome | 1993 |
Dopamine agonists in Parkinson's disease.
Topics: Aged; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1995 |
Positron emission tomography and central neurotransmitter systems in movement disorders.
Topics: Basal Ganglia; Dopamine; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine; Receptors, GABA-A; Receptors, Opioid; Tomography, Emission-Computed; Tourette Syndrome | 1994 |
Pharmacological and nonpharmacological interventions in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1995 |
[Changing drug therapy of Parkinson disease].
Topics: Antiparkinson Agents; Corpus Striatum; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Synaptic Transmission | 1993 |
Neurotransmitter-like actions of L-DOPA.
Topics: Animals; Brain; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 1995 |
Parkinson's disease.
Topics: Cognition Disorders; Disabled Persons; Gait; Humans; Levodopa; Medical Audit; Movement Disorders; Neurocognitive Disorders; Neurosurgery; Parkinson Disease; Postural Balance; Practice Guidelines as Topic; Speech Disorders | 1994 |
Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.
Topics: Animals; Brain; Bromocriptine; Corpus Striatum; Dopamine Agonists; Free Radicals; Humans; Levodopa; Mice; Parkinson Disease; Parkinson Disease, Secondary; Premedication; Reactive Oxygen Species; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 1994 |
Diagnosis and treatment of Parkinson's disease in the elderly.
Topics: Aged; Humans; Levodopa; Parkinson Disease | 1994 |
Respiratory dysfunction in Parkinson's disease.
Topics: Ergotamines; Humans; Levodopa; Parkinson Disease; Respiratory Insufficiency; Respiratory Mechanics | 1994 |
Parkinson's disease: drug-induced psychiatric states.
Topics: Aged; Anxiety; Bipolar Disorder; Clozapine; Depression; Electroconvulsive Therapy; Humans; Levodopa; Lisuride; Male; Ondansetron; Parkinson Disease; Psychoses, Substance-Induced; Sexual Dysfunctions, Psychological | 1995 |
Treatment options in Parkinson's disease.
Topics: Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline | 1995 |
Drug treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
[Progress in diagnosis and treatment of juvenile parkinsonism].
Topics: Adolescent; Adult; Age of Onset; Child; Drug Tolerance; Female; Humans; Isoproterenol; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
Topics: Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Cholinergic; Receptors, Dopamine; Schizophrenia | 1993 |
[Parkinson's disease].
Topics: Dopamine Agents; Drug Tolerance; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Prognosis | 1994 |
A risk-benefit assessment of drugs used in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Risk Assessment | 1994 |
New medical and surgical treatments for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electric Stimulation; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Substantia Nigra; Thalamic Nuclei | 1994 |
Positron emission tomography: applications to the investigation of movement disorders.
Topics: Cerebrovascular Circulation; Humans; Levodopa; Movement; Movement Disorders; Parkinson Disease; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1994 |
The use of clozapine in neurologic disorders.
Topics: Clinical Trials as Topic; Clozapine; Drug Administration Schedule; Humans; Levodopa; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Tremor | 1994 |
[Parkinson's disease--current topics].
Topics: Adult; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1994 |
[Treatment of Parkinson disease with L-DOPA and dopamine agonists].
Topics: Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1994 |
[Current treatment of Parkinson disease].
Topics: Humans; Levodopa; Parkinson Disease | 1994 |
[Vascular hemi-parkinson disease].
Topics: Aged; Aspirin; Benserazide; Brain Ischemia; Drug Therapy, Combination; Female; Functional Laterality; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Neostriatum; Parkinson Disease | 1993 |
Basic mechanisms of motor fluctuations.
Topics: Animals; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1994 |
Treating motor fluctuations with controlled-release levodopa preparations.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1994 |
Various aspects of motor fluctuations and their management in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1994 |
New and emerging strategies for improving levodopa treatment.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1994 |
Clinical aspects of motor fluctuations in Parkinson's disease.
Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 1994 |
[Clinical aspects on juvenile parkinsonism].
Topics: Adolescent; Adult; Child; Dystonia; Female; Genes, Dominant; Genes, Recessive; Humans; Levodopa; Male; Parkinson Disease | 1994 |
[Depression in Parkinson disease. Clinical and etiopathogenic aspects].
Topics: Depressive Disorder; Humans; Levodopa; Parkinson Disease | 1994 |
Update on the management of Parkinson's disease.
Topics: Depression; Diagnosis, Differential; Dopamine Agents; Hallucinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1993 |
Three types of akinesia in the progressive course of Parkinson's disease.
Topics: Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agents; Droxidopa; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Thalamic Nuclei | 1993 |
Recent advances in pharmacological therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Droxidopa; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; NAD; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
Pharmacotherapy of Parkinson's disease: research from 1960 to 1991.
Topics: Antiparkinson Agents; Carboxy-Lyases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Substantia Nigra | 1993 |
Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease | 1993 |
Strategies in the treatment of early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Topics: Basal Ganglia; Basal Ganglia Diseases; Brain; Clozapine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Humans; Levodopa; Male; Neostriatum; Neural Pathways; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1993 |
Treatment of Parkinson's disease. From theory to practice.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline | 1994 |
Dietary factors in the management of Parkinson's disease.
Topics: Brain; Diet; Energy Metabolism; Levodopa; Parkinson Disease | 1994 |
[Recent progress of therapy in patients with Parkinson's disease].
Topics: Brain; Bromocriptine; Delayed-Action Preparations; Droxidopa; Drug Resistance; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine | 1993 |
Motor response complications and the function of striatal efferent systems.
Topics: Animals; Corpus Striatum; Humans; Levodopa; Muscles; Neurons, Efferent; Parkinson Disease; Rats | 1993 |
Clinical and pathophysiologic aspects of late levodopa failure.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors; Treatment Failure | 1993 |
Levodopa therapeutics: new treatment strategies.
Topics: Digestive System; Humans; Intubation, Gastrointestinal; Levodopa; Parkinson Disease | 1993 |
[Surgical treatment of Parkinson's disease].
Topics: Adrenal Medulla; Brain Tissue Transplantation; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Substantia Nigra; Thalamus | 1993 |
Site-specific pharmacology for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Cerebral Cortex; Flumazenil; Hippocampus; Humans; Levodopa; Neurons; Parkinson Disease | 1993 |
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
Topics: Aging; Alzheimer Disease; Animals; Avoidance Learning; Catalase; Corpus Striatum; Drug Therapy, Combination; Learning; Levodopa; Male; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase | 1993 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
Parkinson's and Alzheimer's diseases: epidemiological comparison. 1. Descriptive aspects.
Topics: Age Factors; Aged; Alzheimer Disease; Female; Humans; Incidence; Levodopa; Male; Morbidity; Parkinson Disease; Prevalence | 1993 |
Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
Topics: Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 1993 |
The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?
Topics: Blood-Brain Barrier; Brain; Diagnosis, Differential; Dopamine; Female; Humans; Levodopa; Lewy Bodies; Male; Parkinson Disease; Prospective Studies; Tomography, Emission-Computed | 1993 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Syndrome; Tomography, X-Ray Computed | 1993 |
Parkinson's disease. The L-dopa era.
Topics: Brain; Dopamine; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
L-dopa and frontal cognitive function in Parkinson's disease.
Topics: Aged; Dementia; Frontal Lobe; Humans; Levodopa; Mental Processes; Neuropsychological Tests; Parkinson Disease; Prefrontal Cortex; Substance Withdrawal Syndrome | 1993 |
Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
Topics: Activities of Daily Living; Adolescent; Adult; Brain; Diagnosis, Differential; Female; Humans; Levodopa; Male; Movement Disorders; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Dystonia and Parkinson's disease.
Topics: Diagnosis, Differential; Dose-Response Relationship, Drug; Dystonia; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease | 1993 |
Hereditary progressive dystonia with marked diurnal fluctuation. Pathophysiological importance of the age of onset.
Topics: Adolescent; Adult; Age Factors; Basal Ganglia; Brain Stem; Child; Circadian Rhythm; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary; Sex Factors; Sleep Stages | 1993 |
Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
Topics: Adolescent; Adult; Child; Diagnosis, Differential; Dystonia; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Phenotype | 1993 |
MAO-B inhibitors in Parkinson's disease.
Topics: Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Levodopa, melanoma, and Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Contraindications; Female; Follow-Up Studies; Humans; Levodopa; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Parkinson Disease; Skin Neoplasms | 1993 |
Speech breathing in Parkinson's disease.
Topics: Adult; Aged; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Respiration; Speech; Speech Disorders; Speech Perception; Speech Production Measurement | 1993 |
Treatment of Parkinson's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Moderate Parkinson's disease. Strategies for maximizing treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Concentration-effect relationship of levodopa in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1995 |
Controversies in the therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Serotonin | 1996 |
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Topics: Circadian Rhythm; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Time Factors | 1996 |
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Nervous System; Parkinson Disease | 1995 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Dopa-responsive dystonia: a widening spectrum.
Topics: Child; Dystonia; Humans; Levodopa; Parkinson Disease | 1996 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
[Present strategy and future perspective of therapy in Parkinson's disease].
Topics: Adrenal Cortex; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Thalamus | 1996 |
Drug management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl | 1996 |
[Drug treatment of frequent disorders in patients with Parkinson's disease].
Topics: Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Calcium Channel Blockers; Depressive Disorder; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Tranquilizing Agents | 1996 |
Basal ganglia: new therapeutic approaches to Parkinson's disease.
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Humans; Levodopa; Nerve Growth Factors; Neurosurgery; Parkinson Disease; Tyrosine 3-Monooxygenase | 1996 |
Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1995 |
Ropinirole in the symptomatic treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Dopamine Agonists; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Levodopa; Parkinson Disease | 1995 |
[Levodopa and malignant melanoma--case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma].
Topics: Aged; Antiparkinson Agents; Cell Transformation, Neoplastic; Humans; Levodopa; Long-Term Care; Male; Melanoma; Parkinson Disease; Skin; Skin Neoplasms | 1996 |
Motor fluctuations in levodopa treatment: clinical pharmacology.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1996 |
Management of motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Drug Tolerance; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1996 |
Pharmacokinetic optimisation in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Disease Progression; Dopamine Agonists; Humans; Levodopa; Muscarinic Antagonists; Parkinson Disease | 1996 |
Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 1995 |
Twenty-five years of amantadine therapy in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
Controversies in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 1996 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Neurobiology of L-DOPAergic systems.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Brain Stem; Cardiovascular Physiological Phenomena; Central Nervous System; Corpus Striatum; Disease Models, Animal; Humans; Hypothalamus; Levodopa; Models, Neurological; Motor Activity; Neurons; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Pressoreceptors; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Neurotransmitter | 1996 |
Novel uses of thyroid hormones in patients with affective disorders.
Topics: Antidepressive Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Levodopa; Lithium; Male; Mood Disorders; Parkinson Disease; Thyroid Diseases; Thyroid Gland; Thyroid Hormones | 1996 |
(-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Treatment of Parkinson's disease. Advances in the pharmacological therapy.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 1996 |
Is levodopa toxic?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1996 |
Role of selegiline in combination therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine Agonists; Functional Laterality; Humans; Levodopa; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1996 |
Early diagnosis in Parkinson's disease--limitation of biochemical markers and instrumental methods.
Topics: Apomorphine; Biomarkers; Cell Death; Corpus Striatum; Diagnostic Imaging; Electrophysiology; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Substantia Nigra; Time Factors | 1996 |
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Topics: Age Factors; Animals; Apoptosis; Dopamine; Humans; Hypertension; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Norepinephrine; Parkinson Disease; PC12 Cells; Rats; Selegiline | 1996 |
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Selegiline and mortality in Parkinson's disease.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cisapride; Drug Therapy, Combination; Gastric Emptying; Humans; Injections, Intramuscular; Intestinal Absorption; Levodopa; Parasympathomimetics; Parkinson Disease; Piperidines | 1996 |
[Clinical characteristics and trends in research of Parkinson's disease and parkinsonism in Japan].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Child; Child, Preschool; Disease Progression; Dopamine Agonists; Female; Humans; Infant; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 1997 |
[Clinical classifications of Parkinson's disease].
Topics: Age of Onset; Antiparkinson Agents; Disease Progression; Drug Tolerance; Humans; Levodopa; Parkinson Disease | 1997 |
[New therapeutic strategy for Parkinson's disease based on pharmacological profiles].
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1997 |
[Guidelines of drug therapies for Parkinson's disease].
Topics: Anxiety; Cholinergic Antagonists; Dopamine Agonists; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Quality of Life; Urination Disorders | 1997 |
[Treatment of Parkinson's disease with multiple drugs].
Topics: Amantadine; Bromocriptine; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1997 |
[Problems of long-term levodopa therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Drug Tolerance; Humans; Levodopa; Parkinson Disease | 1997 |
[Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness].
Topics: Adult; Age of Onset; Antiparkinson Agents; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Prognosis | 1997 |
[Brain tumor and parkinsonism].
Topics: Antiparkinson Agents; Brain Neoplasms; Disease Progression; Humans; Levodopa; Parkinson Disease | 1997 |
Pallidotomy, editorial review.
Topics: Basal Ganglia; Dopamine; Globus Pallidus; Humans; Levodopa; Models, Neurological; Parkinson Disease; Patient Selection; Treatment Failure | 1997 |
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
Topics: Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Globus Pallidus; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Sleep Wake Disorders; Stereotaxic Techniques; Thalamus | 1997 |
Parkinson's disease: diagnosis, pathology, and treatment.
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline; Syndrome | 1997 |
Problems with current pharmacologic treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease; Posture | 1997 |
New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
Topics: Antiparkinson Agents; Chemistry, Pharmaceutical; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1997 |
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Topics: Dyskinesia, Drug-Induced; Genetic Therapy; Humans; Levodopa; Parkinson Disease | 1997 |
Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
Topics: Administration, Oral; Aging; Antiparkinson Agents; Central Nervous System; Gastric Emptying; Humans; Injections, Intravenous; Intestinal Absorption; Levodopa; Parkinson Disease; Solutions | 1997 |
Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.
Topics: 5-Hydroxytryptophan; Amino Acids; Animals; Depressive Disorder; Droxidopa; Histidine; Humans; Levodopa; Parkinson Disease | 1996 |
Parkinson's disease.
Topics: Aged; Aging; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1997 |
Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1997 |
The role of dopamine agonists in early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1997 |
[Parkinson disease: interrogations and solutions].
Topics: Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1997 |
Controversies in pallidal surgery.
Topics: Brain Mapping; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques | 1997 |
[Parkinsonian syndromes in children].
Topics: Adolescent; Adult; Child; Chromosome Aberrations; Chromosome Disorders; Humans; Levodopa; Parkinson Disease | 1997 |
[Motor dysfunction in the aged--approach to involuntary movements].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blepharospasm; Botulinum Toxins; Humans; Levodopa; Middle Aged; Parkinson Disease; Tremor | 1997 |
Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.
Topics: Animals; Antioxidants; Dopamine; Humans; Incidence; Levodopa; Middle Aged; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Reactive Oxygen Species | 1997 |
Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature.
Topics: Aged; Antiparkinson Agents; Back; Biopsy; Humans; Levodopa; Male; Melanoma; Middle Aged; Nose Neoplasms; Parkinson Disease; Skin; Skin Neoplasms | 1997 |
Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 1997 |
Familial juvenile parkinsonism.
Topics: Adolescent; Adult; Age of Onset; Antiparkinson Agents; Child; Female; Genes, Dominant; Genes, Recessive; Humans; Levodopa; Lewy Bodies; Male; Parkinson Disease | 1997 |
[Physiopathology of the dyskinesias induced by L-dopa].
Topics: Age of Onset; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1997 |
[Psychiatric complications of L-dopa: physiopathology and treatment].
Topics: Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroconvulsive Therapy; Humans; Incidence; Levodopa; Mental Disorders; Parkinson Disease | 1997 |
[Initial treatment of Parkinson's disease].
Topics: Amantadine; Antioxidants; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1997 |
[Pharmacological therapy of complicated Parkinson's disease].
Topics: Antiparkinson Agents; Ascorbic Acid; Combined Modality Therapy; Diet Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 1997 |
[Neuroprotective and neurorestorative therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Apoptosis; Brain Tissue Transplantation; Chelation Therapy; Corpus Striatum; Dopamine; Erythrocytes; Free Radicals; Gangliosides; Genetic Therapy; Glutathione Peroxidase; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Selegiline; Selenium; Vitamin E | 1997 |
Early idiopathic parkinsonism: initiation and optimization of treatment.
Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1994 |
Mid-stage parkinsonism with mild motor fluctuations.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1994 |
Problems with long-term levodopa therapy for Parkinson's disease.
Topics: Cognition Disorders; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Parkinson Disease; Speech Disorders; Time Factors | 1994 |
Emerging treatments in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Neuroprotective Agents; Neurosurgical Procedures; Parkinson Disease | 1997 |
[Parkinson disease. Medical treatment].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1997 |
[Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Motor Skills; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 1997 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
[Freezing phenomenon in Parkinson disease].
Topics: Antiparkinson Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypokinesia; Levodopa; Locus Coeruleus; Neurotransmitter Agents; Parkinson Disease; Physical Therapy Modalities; Substantia Nigra | 1997 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; Drug Tolerance; Female; Humans; Levodopa; Male; Movement Disorders; Neurons; Parkinson Disease; Rats; Receptors, Dopamine; Receptors, GABA; Signal Transduction; Synaptic Transmission | 1998 |
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1998 |
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic | 1998 |
Levodopa: is toxicity a myth?
Topics: Animals; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 1998 |
COMT inhibition: a new treatment strategy for Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Influence of COMT inhibition on levodopa pharmacology and therapy.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1998 |
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Topics: Antiparkinson Agents; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Volunteers | 1998 |
Functional anatomical and behavioral consequences of dopamine receptor stimulation.
Topics: Animals; Basal Ganglia; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1997 |
Sleep disorders in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Middle Aged; Motor Activity; Muscle, Skeletal; Parkinson Disease; Respiration; Sleep Wake Disorders | 1998 |
Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms.
Topics: Animals; Biotransformation; Brain; Drug Synergism; Excitatory Amino Acid Antagonists; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1995 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
Adjuncts to levodopa therapy: dopamine agonists.
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
Extending levodopa action: COMT inhibition.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Pentanones; Tolcapone | 1998 |
Levodopa neurotoxicity: experimental studies versus clinical relevance.
Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Survival; Dopamine; Humans; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Reactive Oxygen Species; Substantia Nigra | 1998 |
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1998 |
Use of posteroventral pallidotomy for treatment of Parkinson's disease: is pallidotomy still an experimental procedure? A review and commentary.
Topics: Basal Ganglia; Forecasting; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 1998 |
Management of response fluctuations: practical guidelines.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Prodrugs | 1998 |
Effective strategies in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills Disorders; Parkinson Disease; Time Factors | 1998 |
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline; Survival Rate | 1998 |
Neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E | 1998 |
Dopamine agonists and neuroprotection in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Levodopa; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease | 1998 |
Atypical presentations of dopa-responsive dystonia.
Topics: Cerebral Palsy; Diagnosis, Differential; Dopamine Agents; Dystonia Musculorum Deformans; Humans; Levodopa; Parkinson Disease | 1998 |
Parkinson's disease. Second of two parts.
Topics: Antiparkinson Agents; Humans; Levodopa; Models, Biological; Parkinson Disease | 1998 |
Stereotactic surgery and Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1998 |
COMT inhibition in the treatment of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
Topics: Adrenergic Antagonists; Animals; Antiparkinson Agents; Cannabinoids; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Narcotic Antagonists; Neurons; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1998 |
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Selegiline | 1998 |
[Long-term complications of treatment with levodopa].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 1998 |
Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Cerebellar Diseases; Clinical Laboratory Techniques; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Pyramidal Tracts; Urinary Tract Physiological Phenomena | 1998 |
Levodopa effective parkinsonism associated with aqueductal stenosis: a case report and review of the literature.
Topics: Adolescent; Cerebral Aqueduct; Constriction, Pathologic; Female; Humans; Hydrocephalus; Levodopa; Parkinson Disease; Ventriculoperitoneal Shunt | 1998 |
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline; Survival Analysis; Treatment Outcome | 1998 |
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Humans; Levodopa; Multicenter Studies as Topic; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Diagnostic criteria for Parkinson disease.
Topics: Antiparkinson Agents; Diagnostic Imaging; Humans; Levodopa; Parkinson Disease; Posture; Probability; Tremor | 1999 |
New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1999 |
[Drug therapy in Parkinson's disease].
Topics: Amantadine; Antiparkinson Agents; Clozapine; Dopamine Agonists; Dopamine Antagonists; Female; History, 19th Century; History, 20th Century; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1999 |
[Understanding and treating levodopa-induced dyskinesias].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1998 |
Management of early Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Outcome | 1999 |
Managing late complications of Parkinson's disease.
Topics: Cognition Disorders; Disease Progression; Dopamine Agents; Gait; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 1999 |
Novel drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Dopamine Agonists; Free Radical Scavengers; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1999 |
[Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Free Radicals; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors | 1999 |
[Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Mental Disorders; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors; Treatment Outcome | 1999 |
[Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Time Factors | 1999 |
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
Topics: Cost of Illness; Humans; Levodopa; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 1992 |
Motor fluctuations in Parkinson's disease: pathophysiology and treatment.
Topics: Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease | 1999 |
Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Motor Activity; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 1999 |
Consensus statement on the diagnosis of multiple system atrophy.
Topics: Autonomic Nervous System Diseases; Cerebellar Ataxia; Diagnosis, Differential; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Urination Disorders | 1999 |
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Levodopa; Neurology; Outcome Assessment, Health Care; Parkinson Disease; Practice Patterns, Physicians' | 1999 |
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
Prospects for new restorative and neuroprotective treatments in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Death; Gene Transfer Techniques; Humans; Levodopa; Mutation; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 1999 |
[Modern therapeutic possibilities in Parkinson disease].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Nitrophenols; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tolcapone | 1999 |
Does levodopa accelerate Parkinson's disease?
Topics: Animals; Clinical Trials as Topic; Dopamine; Humans; Levodopa; Nervous System Diseases; Oxidative Stress; Parkinson Disease | 1999 |
Functional consequences of dopaminergic degeneration in Parkinson's disease.
Topics: Adaptation, Physiological; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Receptors, Dopamine D2 | 1999 |
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1999 |
Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine beta-Hydroxylase; Droxidopa; Globus Pallidus; Humans; Levodopa; Norepinephrine; Parkinson Disease; Thalamus | 1999 |
New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group.
Topics: Animals; Antiparkinson Agents; Brain; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation; Humans; Levodopa; Neurology; Parkinson Disease | 1999 |
PET measurements of dopaminergic pathways in the brain.
Topics: Adrenergic Fibers; Brain Diseases; Cerebrovascular Circulation; Dopamine; Dopamine Agents; Dystonia; Humans; Levodopa; Neural Pathways; Parkinson Disease; Radiopharmaceuticals; Receptors, Dopamine; Schizophrenia; Tomography, Emission-Computed | 1999 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 1999 |
Lewy body dementia.
Topics: Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Parkinson Disease; Prevalence | 1999 |
Parkinson's disease--levodopa complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Parkinson Disease | 1999 |
Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 1999 |
COMT inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1999 |
Treatment of early Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Time Factors | 1999 |
Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life.
Topics: Age Factors; Aged; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease | 1999 |
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Narcotics; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin | 1999 |
Rating scales for dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Current therapy in Parkinson's disease.
Topics: Adrenal Medulla; Antiparkinson Agents; Combined Modality Therapy; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Thalamus; Transplantation, Autologous | 1999 |
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Parkinson Disease; Time Factors | 1999 |
"Rational hope" in the early treatment of Parkinson's disease.
Topics: Apomorphine; Aporphines; Harmine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1999 |
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?
Topics: Animals; Antiparkinson Agents; Brain; Humans; Levodopa; Parkinson Disease | 1999 |
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease | 1999 |
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Topics: Animals; Antiparkinson Agents; Brain; Cell Death; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1999 |
Cholinergic-drug induced sicca syndrome in Parkinson's disease: a case report and a review of the literature.
Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Diagnosis, Differential; Female; Humans; Levodopa; Parkinson Disease; Sjogren's Syndrome | 1999 |
Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Humans; Levodopa; Motor Skills; Neural Pathways; Neurons; Parkinson Disease; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Presynaptic; Substantia Nigra; Treatment Outcome | 2000 |
The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2000 |
[Posture and gait modulation using sensory or attentional cues in Parkinson's disease. A possible approach to the mechanism of episodic freezing].
Topics: Adaptation, Physiological; Aged; Antiparkinson Agents; Attention; Cognitive Behavioral Therapy; Cues; Gait; Humans; Levodopa; Parkinson Disease; Posture; Psychomotor Disorders | 1999 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
Maximizing the benefit of pharmacotherapy in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Synergism; Humans; Levodopa; Parkinson Disease | 2000 |
Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function.
Topics: Amphetamines; Animals; Antiparkinson Agents; Brain; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin; Tryptophan Hydroxylase | 1999 |
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors | 2000 |
The spectrum of levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Dopamine receptors and locomotor responses: molecular aspects.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Ion Channel Gating; Levodopa; Locomotion; Parkinson Disease; Receptors, Dopamine | 2000 |
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
Topics: Basal Ganglia; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Dopamine-mediated gene regulation in models of Parkinson's disease.
Topics: Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Gene Expression; Humans; Levodopa; Neurons; Parkinson Disease | 2000 |
Physiologic basis of dyskinesia.
Topics: Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Patterns of gene expression and behavior induced by chronic dopamine treatments.
Topics: Brain Chemistry; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease | 2000 |
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2000 |
Molecular basis of levodopa-induced dyskinesias.
Topics: Animals; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease | 2000 |
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
Topics: Cell Communication; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease | 2000 |
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
Topics: Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Substantia Nigra | 2000 |
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Topics: Animals; Corpus Striatum; Dopamine Agents; Humans; Levodopa; Motor Neurons; Parkinson Disease; Parkinson Disease, Secondary | 2000 |
Clinical physiology of dopa dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease | 2000 |
Neuroimaging of dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed | 2000 |
Clinical pharmacology of levodopa-induced dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Preventing levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Medical treatment of levodopa-induced dyskinesias.
Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Dyskinesias and the subthalamic nucleus.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2000 |
Surgery for levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Respiratory function in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Respiration; Respiration Disorders; Respiratory Mechanics | 1998 |
Pergolide for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide | 2000 |
Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide | 2000 |
Bromocriptine for levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 2000 |
Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease | 2000 |
Lisuride for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease | 2000 |
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Patient Selection; Tolcapone | 2000 |
The role of entacapone in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Placebos | 2000 |
Parkinson's: integrating the primary and secondary care guidelines.
Topics: Algorithms; Antiparkinson Agents; Dopamine Agonists; Family Practice; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Referral and Consultation | 2000 |
[Drug therapy of Parkinson's disease].
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 1997 |
The role of functional neurosurgery in Parkinson's disease.
Topics: Globus Pallidus; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease | 2000 |
Dopamine agonists in the treatment of Parkinson s disease past, present and future.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Structure-Activity Relationship | 2000 |
Ropinirole for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
Bromocriptine versus levodopa in early Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
[Dopa-therapy in the treatment of early stage Parkinson's disease].
Topics: Age of Onset; Aged; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2000 |
[ What drug strategies are advisable for patients with advanced-stage Parkinson's].
Topics: Age Factors; Aged; Antiparkinson Agents; Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2000 |
Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.
Topics: Animals; Cognition; Cognition Disorders; Dopamine; Humans; Levodopa; Memory; Parkinson Disease; Prefrontal Cortex | 2000 |
Levodopa therapy and the risk of malignant melanoma.
Topics: Antiparkinson Agents; Humans; Levodopa; Melanoma; Parkinson Disease | 2000 |
Factors affecting levodopa effects in Parkinson's disease.
Topics: Absorption; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blood-Brain Barrier; Dopamine; Enzyme Inhibitors; Levodopa; Parkinson Disease | 2000 |
Too many treatments for Parkinson's disease: how should they be used?
Topics: Antiparkinson Agents; Carbidopa; Decision Making; Drug Combinations; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2000 |
Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2000 |
Levodopa--an exotoxin or a therapeutic drug?
Topics: Animals; Humans; Levodopa; Neurotoxins; Parkinson Disease | 2000 |
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?].
Topics: Accidents, Traffic; Automobile Driving; Benzothiazoles; Contraindications; Dopamine Agents; Dopamine Agonists; Germany; Humans; Indoles; Legislation, Drug; Levodopa; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Pharmacological treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
[Parkinson's disease and pregnancy: case report and literature review].
Topics: Adult; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2000 |
Treatment of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Anxiety; Catechol O-Methyltransferase Inhibitors; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 2000 |
Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.
Topics: Apomorphine; Diagnostic Tests, Routine; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2000 |
Early Parkinson's disease: what is the best approach to treatment.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Free Radicals; Humans; Levodopa; Parkinson Disease | 2000 |
Levodopa motor complications in Parkinson's disease.
Topics: Age of Onset; Antiparkinson Agents; Brain; Cost of Illness; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 2000 |
Pathophysiology of the basal ganglia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neurons; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine | 2000 |
Electrophysiology of dopamine in normal and denervated striatal neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease | 2000 |
PET studies and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Fluorine Radioisotopes; Humans; Levodopa; Neural Pathways; Opioid Peptides; Parkinson Disease; Pulse Therapy, Drug; Putamen; Receptors, Opioid; Tomography, Emission-Computed | 2000 |
Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index | 2000 |
Continuous dopamine-receptor stimulation in early Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index | 2000 |
Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
[A prospect of treatment for Parkinson's disease in the 21st century].
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy; Forecasting; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Nitrophenols; Parkinson Disease; Quality of Life; Tolcapone | 2000 |
[Drug therapy of patients with early-stage parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Severity of Illness Index | 2000 |
[Treatment of advanced Parkinson's disease].
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Severity of Illness Index | 2000 |
[The new Parkinson's disease drugs].
Topics: Antiparkinson Agents; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
[Details and indications of pallidotomy and thalamotomy for Parkinson's disease].
Topics: Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Stereotaxic Techniques; Thalamus; Tremor | 2000 |
[Deep brain stimulation(DBS) therapy for parkkinson,s disease].
Topics: Clinical Trials as Topic; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Subthalamic Nucleus; Tremor; Ventral Thalamic Nuclei | 2000 |
[Cell transplantation therapy for Parkinson's disease].
Topics: Cell Transplantation; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Ganglia, Sympathetic; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Transplantation, Autologous | 2000 |
[Pharmacological treatment of parkinsonian tremor].
Topics: Adrenergic beta-Antagonists; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Histamine H1 Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Tremor | 2000 |
[Wearing-off phenomenon--neurological approach].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Administration Routes; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
[Neurosurgical therapy for parkinson's disease].
Topics: Adrenal Medulla; Antiparkinson Agents; Cell Transplantation; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Peripheral Nerves; Stereotaxic Techniques; Subthalamic Nucleus | 2000 |
[Medical treatment of L-dopa induced dyskinesia].
Topics: Antiparkinson Agents; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
[Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson's disease patients].
Topics: Antiparkinson Agents; Brain Tissue Transplantation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Thalamus | 2000 |
[Rating scale and functional prognosis of Parkinson's disease].
Topics: Disability Evaluation; Disease Progression; Humans; Levodopa; Movement; Parkinson Disease; Prognosis; Severity of Illness Index; Stereotaxic Techniques | 2000 |
Restorative neurology in movement disorders.
Topics: Adrenal Medulla; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Corpus Striatum; Fetal Tissue Transplantation; Graft Survival; Humans; Levodopa; Movement Disorders; Neurons; Parkinson Disease; Transplantation, Autologous | 2000 |
The evolution and origin of motor complications in Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 2000 |
Levodopa in the treatment of Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 2000 |
Issues important for rational COMT inhibition.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
Topics: Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 2000 |
Parkinson's disease and anxiety.
Topics: Aged; Anti-Anxiety Agents; Antiparkinson Agents; Anxiety Disorders; Humans; Levodopa; Parkinson Disease; Prevalence; Psychomotor Disorders | 2001 |
Complications and limitations of drug therapy for Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 2000 |
Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
Topics: Corpus Striatum; Drug Therapy; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Neural Pathways; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2000 |
[Parkinson's disease: diagnostic and therapeutic criteria. Short text].
Topics: Antiparkinson Agents; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Neurosurgical Procedures; Parkinson Disease; Patient Education as Topic; Physical Therapy Modalities; Severity of Illness Index; Stereotaxic Techniques | 2000 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Globus Pallidus; Humans; Indoles; Levodopa; Lewy Body Disease; Lisuride; Male; Mental Status Schedule; Neurosurgery; Parkinson Disease; Parkinsonian Disorders; Piribedil; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Stereotaxic Techniques; Supranuclear Palsy, Progressive; Surveys and Questionnaires; Thalamus | 2001 |
Ropinirole for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Cabergoline for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
[Gait disorders in Parkinson disease. Clinical description, analysis of posture, initiation of stabilized gait].
Topics: Antiparkinson Agents; Basal Ganglia; Gait; Humans; Levodopa; Parkinson Disease; Postural Balance; Posture; Walking | 2001 |
[Gait disorders in Parkinson disease. Gait freezing and falls: therapeutic management].
Topics: Accidental Falls; Antiparkinson Agents; Gait; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities; Thalamus | 2001 |
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Dopamine Agents; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Dopamine agonists.
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Drug Costs; Humans; Levodopa; Parkinson Disease | 2001 |
Current and emerging treatments in Parkinson's disease.
Topics: Age Factors; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2001 |
Cell therapy and transplantation in Parkinson's disease.
Topics: Animals; Hematopoietic Stem Cell Transplantation; Humans; Levodopa; Neurons; Parkinson Disease; Phenotype; Swine; Time Factors; Tomography, Emission-Computed | 2001 |
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Australia; Canada; Drug Tolerance; Dyskinesia, Drug-Induced; Europe; Humans; Hypokinesia; Levodopa; Middle Aged; Parkinson Disease; Prevalence; Risk; Time Factors; United States | 2001 |
Monitoring of L-dopa concentrations in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2001 |
Neurotoxicity as a mechanism for neurodegenerative disorders: basic and clinical aspects.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Humans; Levodopa; Nerve Growth Factor; Neuroprotective Agents; Nicotine; Parkinson Disease | 2001 |
[Pharmacological effects of cabergoline against parkinsonism].
Topics: Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2001 |
New therapies for Parkinson's disease.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Fetal Tissue Transplantation; Genetic Therapy; Humans; Levodopa; Middle Aged; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 2001 |
[Therapy of idiopathic Parkinson syndrome 1817 to 2001. A success story?].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2001 |
[Parkinson disease].
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2001 |
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
Motor fluctuations and dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Movement; Parkinson Disease | 2001 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline | 2001 |
Parkinson's disease: medical and surgical treatment.
Topics: Antiparkinson Agents; Brain Tissue Transplantation; Catechol O-Methyltransferase Inhibitors; Cerebral Cortex; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Neurons; Parkinson Disease; Subthalamic Nucleus; Thalamus | 2001 |
The protective role of levodopa in the human substantia nigra.
Topics: Adult; Animals; Antiparkinson Agents; Child; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2001 |
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Benzothiazoles; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; MEDLINE; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2001 |
Use of selective thalamotomy for various kinds of movement disorder, based on basic studies.
Topics: Antiparkinson Agents; Cerebral Hemorrhage; Chorea; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Muscle Rigidity; Paresthesia; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Surgery, Computer-Assisted; Thalamic Nuclei; Tomography, X-Ray Computed; Treatment Outcome; Tremor | 2000 |
[Disturbance of micturition in Parkinson's disease].
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex, Abnormal; Trihexyphenidyl; Urinary Bladder, Neurogenic; Urination; Urination Disorders; Urodynamics | 2001 |
Parkinson's disease therapy: treatment of early and late disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors | 2001 |
Recent advances in the genetics and pathogenesis of Parkinson disease.
Topics: alpha-Synuclein; Humans; Levodopa; Ligases; Nerve Tissue Proteins; Parkinson Disease; Peptide Fragments; Protein Conformation; Protein Folding; Synucleins; Thiolester Hydrolases; Ubiquitin Thiolesterase; Ubiquitin-Protein Ligases | 2002 |
Neuroprotective actions of selegiline.
Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Selegiline; Treatment Outcome | 2002 |
Atypical antipsychotics: mechanism of action.
Topics: Antipsychotic Agents; Drug Administration Schedule; Humans; Levodopa; Neural Pathways; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Dopamine D2; Receptors, Serotonin; Schizophrenia | 2002 |
Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2002 |
Levodopa strengths and weaknesses.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2002 |
Long-term studies of dopamine agonists.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Long-Term Care; Parkinson Disease | 2002 |
Tremor and dopamine agonists.
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2002 |
Postoperative management of subthalamic nucleus stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Competence; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Parkinson Disease; Patient Care; Subthalamic Nucleus; Treatment Outcome | 2002 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
Parkinson's disease: medical treatment of moderate to advanced disease.
Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Cognition Disorders; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2002 |
Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2002 |
Entacapone in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2002 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Mental Disorders; Neural Pathways; Neurons; Neurotransmitter Agents; Norepinephrine; Parasympathetic Nervous System; Parkinson Disease; Serotonin | 1978 |
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phosphodiesterase Inhibitors; Piribedil; Tremor | 1978 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Aetiology and natural history of Parkinson's disease.
Topics: Aged; Atrophy; Brain; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Prognosis; Substantia Nigra | 1978 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Striatum; Dogs; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Hypothermia; Levodopa; Memory; Mice; Opioid-Related Disorders; Parkinson Disease; Psychotic Disorders; Rats; Receptors, Dopamine; Sleep; Stereotyped Behavior; Substantia Nigra; Synapses; Synaptic Transmission | 1979 |
[Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Histamine H1 Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; MSH Release-Inhibiting Hormone; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Posture; Psychoses, Substance-Induced; Tremor | 1979 |
Developments in understanding the physiology and pharmacology of parkinsonism.
Topics: Animals; Basal Ganglia; Extrapyramidal Tracts; Humans; Levodopa; Nervous System; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1979 |
Catecholamines and neurologic diseases (second of two parts).
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Diseases; Catecholamines; Cerebrovascular Disorders; Dopamine; Dysautonomia, Familial; Dystonia Musculorum Deformans; Hepatic Encephalopathy; Homovanillic Acid; Humans; Huntington Disease; Levodopa; Movement Disorders; Multiple Sclerosis; Nervous System Diseases; Parkinson Disease; Phenylketonurias; Seizures; Spinal Cord Injuries; Torticollis; Tourette Syndrome | 1975 |
The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
Topics: Acetylcholine; Animals; Biogenic Amines; Brain; Brain Chemistry; Butyrophenones; Corpus Striatum; Dopamine; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Serotonin; Tourette Syndrome; Tranquilizing Agents | 1975 |
Levodopa.
Topics: Benserazide; Drug Interactions; Hepatic Encephalopathy; Humans; Huntington Disease; Levodopa; Melanoma; Parkinson Disease; Pituitary Function Tests | 1975 |
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1975 |
Recent developments in Parkinson's disease and Huntington's chorea.
Topics: Basal Ganglia; Biogenic Amines; Humans; Huntington Disease; Levodopa; Parkinson Disease | 1976 |
Deanol in the management of involuntary movement disorders: a review.
Topics: Acetylcholine; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Models, Neurological; Movement Disorders; Parkinson Disease; Physostigmine; Research Design; Time Factors | 1977 |
The pathogensis and medical treatment of extrapyramidal disease.
Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Administration Schedule; Dystonia; Female; gamma-Aminobutyric Acid; Glutamates; Haloperidol; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tic Disorders | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1978 |
Pharmacotherapy of Parkinson's disease.
Topics: Dopamine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Synapses | 1977 |
Are there MAO inhibitors specific for dopamine metabolism?
Topics: Animals; Binding Sites; Brain; Clorgyline; Dopamine; Drug Synergism; Humans; In Vitro Techniques; Levodopa; Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines | 1977 |
Considerations in the management of parkinsonism.
Topics: Amantadine; Carboxy-Lyases; Levodopa; Parasympatholytics; Parkinson Disease | 1978 |
The treatment of Parkinson's disease.
Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1977 |
Bromocriptine in Parkinsonism.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1978 |
On the dual nature of monoamine oxidase.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Catecholamines; Clorgyline; Dose-Response Relationship, Drug; Humans; Levodopa; Mitochondria; Mitochondria, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nictitating Membrane; Norepinephrine; Parkinson Disease; Phenethylamines; Propylamines; Protein Binding; Serotonin; Structure-Activity Relationship; Tyramine | 1978 |
Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1979 |
Drug therapy: Bromocriptine.
Topics: Acromegaly; Adenoma; Amantadine; Bromocriptine; Female; Galactorrhea; Growth Hormone; Humans; Infertility; Lactation; Levodopa; Male; Parkinson Disease; Pituitary Neoplasms; Pregnancy; Prolactin | 1979 |
A review of some aspects of the pharmacology of levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Arrhythmias, Cardiac; Cardiovascular System; Chemical Phenomena; Chemistry; Corpus Striatum; Delayed-Action Preparations; Dopamine; Humans; Hypotension, Orthostatic; Intestinal Absorption; Levodopa; Nausea; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Tissue Distribution; Vomiting | 1978 |
[Psychiatric manifestations induced by dopamine precursors or antagonists].
Topics: Anxiety; Bromocriptine; Confusion; Dopamine Antagonists; Dreams; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sulpiride | 1979 |
Treatment of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1976 |
Monoamine precursors and analogues.
Topics: 5-Hydroxytryptophan; Animals; Biogenic Amines; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Drug Interactions; Drug Synergism; Humans; Levodopa; Mice; Parkinson Disease; Rats; Receptors, Drug; Stimulation, Chemical; Tremor; Tryptophan; Tyrosine | 1975 |
Monoamine oxidase inhibitors and the extrapyramidal system.
Topics: Amines; Amino Acids; Animals; Drug Therapy, Combination; Extrapyramidal Tracts; Humans; In Vitro Techniques; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats | 1976 |
Progress in understanding and treating Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Enzyme Inhibitors; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Peptides; Phenethylamines; Piribedil | 1976 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopamine; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Humans; Levodopa; Luteinizing Hormone; Male; Movement Disorders; Parkinson Disease; Schizophrenia; Steroids; Thinness | 1976 |
Advances in the management of parkinson's disease.
Topics: Amantadine; Anesthesia; Humans; Levodopa; Orphenadrine; Parasympatholytics; Parkinson Disease; Social Adjustment; Trihexyphenidyl | 1976 |
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Topics: Benserazide; Binding Sites; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Hydrazines; Kinetics; Levodopa; Liver Function Tests; Parkinson Disease | 1976 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine Antagonists; Humans; Levodopa; Mental Disorders; Movement Disorders; Neurosecretory Systems; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Pyridoxine; Stereotaxic Techniques | 1976 |
Clinical pharmacokinetics of levodopa in parkinson's disease.
Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gastric Mucosa; Gastrointestinal Diseases; Homovanillic Acid; Humans; Intestinal Absorption; Kinetics; Levodopa; Mental Disorders; Parkinson Disease; Pyridoxine; Stimulation, Chemical; Time Factors | 1976 |
Recent advances in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Depression, Chemical; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Pyridoxine; Stereotaxic Techniques | 1975 |
L-Dopa and the treatment of extrapyramidal disease.
Topics: Adjuvants, Pharmaceutic; Animals; Basal Ganglia Diseases; Biodegradation, Environmental; Catecholamines; Dopamine; Humans; Levodopa; Mice; Parkinson Disease; Rats | 1975 |
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
Topics: Aged; Antithrombins; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease | 1992 |
[A case of parkinsonism due to pontine and extrapontine myelinolysis].
Topics: Addison Disease; Adult; Brain Diseases; Demyelinating Diseases; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Pons; Tomography, X-Ray Computed | 1992 |
[Japanese clinical statistical data of patients with parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Intravenous; Levodopa; Parkinson Disease; Substantia Nigra | 1992 |
Initiating treatment of Parkinson's disease.
Topics: Amantadine; Antioxidants; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide | 1992 |
Motor response to repeated dopaminergic stimulation in Parkinson's disease.
Topics: Animals; Apomorphine; Dopamine Agents; Haplorhini; Humans; Levodopa; Movement; Parkinson Disease | 1992 |
An integrated approach to patient management in Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Recent progress in the treatment of Parkinson's disease.
Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1992 |
Drug therapy of Parkinson's disease. An overview.
Topics: Antiparkinson Agents; Brain; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1992 |
Early therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline | 1992 |
Clinical classification of dopaminergic effects in parkinsonism.
Topics: Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1992 |
Parkinson's disease.
Topics: Dopamine; Environmental Pollutants; Humans; Levodopa; MPTP Poisoning; Parkinson Disease | 1992 |
[Drug therapy of Parkinson disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
Parkinsonism: myths, dogma and the hope of prophylaxis. Therapeutics in the Elderly Research Group.
Topics: Aged; Carboxy-Lyases; Combined Modality Therapy; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Patient Care Team | 1992 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
["Widening horizons" in the clinical application of selegiline].
Topics: Alzheimer Disease; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
In vitro and in vivo experiments--what is more informative?
Topics: Animals; Axons; Dendrites; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Levodopa; Neurons; Parkinson Disease; Research Design; Synapses | 1992 |
[Dysautonomia and multi-systemic atrophy of the nervous system (Shy-Drager's syndrome)].
Topics: Aged; Anus Diseases; Autonomic Nervous System Diseases; Eye Diseases; Female; Fludrocortisone; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Shy-Drager Syndrome; Time Factors; Urinary Bladder Diseases; Vasoconstrictor Agents | 1992 |
[From Parkinson's disease to Lewy body disease].
Topics: Alzheimer Disease; Dementia; Depressive Disorder; Humans; Levodopa; Lewy Bodies; Parkinson Disease | 1992 |
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Time Factors | 1992 |
Sustained release antiparkinson agents: controlled release levodopa.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Humans; Levodopa; Parkinson Disease | 1992 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus | 1992 |
The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras.
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1992 |
Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.
Topics: Corpus Striatum; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1992 |
Treatment strategies for extension of levodopa effect.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Selegiline | 1992 |
[The dopamine agonist, lisuride, in the therapy of Parkinson disease].
Topics: Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1992 |
[Neuropsychological evaluation before and after thalamic stimulation in 9 patients with Parkinson disease].
Topics: Aged; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychophysiologic Disorders; Stereotaxic Techniques; Thalamic Nuclei; Thalamus; Tremor | 1992 |
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats | 1992 |
A review of the pharmacology of selegiline.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Levodopa; Monoamine Oxidase; Neurotransmitter Agents; Parkinson Disease; Selegiline; Survival Rate | 1991 |
Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors | 1990 |
Newly-diagnosed Parkinson's disease: a therapeutic update.
Topics: Antiparkinson Agents; Brain; Carbidopa; Humans; Levodopa; Parkinson Disease | 1992 |
Treatment of Parkinson's disease with electroconvulsive therapy.
Topics: Aged; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
What has PET told us about Parkinson's disease?
Topics: Animals; Brain; Corpus Striatum; Dopamine; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Tomography, Emission-Computed | 1991 |
Nigral degeneration in Parkinson's disease in relation to clinical features.
Topics: Corpus Striatum; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Neurologic Examination; Parkinson Disease; Selegiline; Substantia Nigra | 1991 |
[Use of apomorphine in the treatment of Parkinson's disease].
Topics: Apomorphine; Domperidone; Drug Combinations; Humans; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Parkinson Disease | 1991 |
Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.
Topics: Adult; AIDS Dementia Complex; Brain; Clinical Trials, Phase I as Topic; Dopamine; Humans; Levodopa; Male; Neurons; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Zidovudine | 1991 |
[Diagnosis and treatment of Parkinson's disease in the elderly].
Topics: Aged; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 1991 |
Deprenyl: the exciting possibility of protective effect.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
Parkinson's disease.
Topics: Aged; Brain Tissue Transplantation; Fetal Tissue Transplantation; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Topics: Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1990 |
Early dopamine agonist treatment in Parkinson's disease.
Topics: Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1990 |
The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
Topics: Brain; Brain Mapping; Corpus Striatum; Humans; Levodopa; Long-Term Care; Neural Pathways; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Receptors, Neurotransmitter; Substantia Nigra | 1990 |
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
Topics: Aged; Carbidopa; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Drug treatment of Parkinson's disease: current concepts.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1991 |
[Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].
Topics: Aged; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease | 1991 |
[Recent progress in treatment of Parkinson's disease].
Topics: Droxidopa; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Substantia Nigra; Thalamus | 1990 |
Drug therapy for Parkinson's disease in the elderly.
Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1990 |
The modern management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline | 1990 |
[Slowing the progression of Parkinson syndrome by early administration of deprenyl].
Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline | 1990 |
[Protective therapy in Parkinson's disease].
Topics: Animals; Humans; Levodopa; Pargyline; Parkinson Disease; Selegiline | 1990 |
Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission | 1990 |
Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1990 |
[Neuroleptic malignant-like syndrome following levodopa withdrawal].
Topics: Aged; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1990 |
Rational management of the 'on-off' syndrome in Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1990 |
Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Parkinson Disease; Substantia Nigra | 1990 |
[Parkinson disease and pregnancy. Apropos of a case].
Topics: Adult; Female; Humans; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications | 1990 |
Oxidation reactions in Parkinson's disease.
Topics: Free Radicals; Humans; Levodopa; Models, Neurological; Oxygen; Parkinson Disease | 1990 |
Levodopa therapy in Parkinson's disease.
Topics: Carboxy-Lyases; Corpus Striatum; Delayed-Action Preparations; Dopamine; Humans; Injections, Intravenous; Levodopa; Movement; Parkinson Disease | 1990 |
Motor response complications with chronic levodopa therapy.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
Inhibitors of dopamine inactivating systems as antiparkinson drugs.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Antagonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine | 1990 |
Selegiline in the treatment of Parkinson's disease.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Parkinson's disease.
Topics: Adrenal Glands; Antioxidants; Caudate Nucleus; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Prognosis | 1989 |
[Parkinson's disease: some physiopathologic aspects and clinical practice].
Topics: Cognition Disorders; Dopamine; Dopamine Agents; Humans; Levodopa; Motor Activity; Neurons; Parkinson Disease; Substantia Nigra | 1989 |
[Current approaches in the treatment of Parkinson disease].
Topics: Delayed-Action Preparations; Dopamine Agents; Drug Therapy, Combination; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Syndrome; Time Factors | 1989 |
Medical treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1989 |
Overcoming pharmacokinetic problems in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1989 |
The promise and limitations of controlled-release oral levodopa administration.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
The on-off phenomenon.
Topics: Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1989 |
Hypothalamic-locus coeruleus mechanisms in the pathophysiology of "on-off" in L-dopa treated Parkinson's disease: a hypothesis.
Topics: Animals; Endorphins; Humans; Hypothalamus; Levodopa; Locus Coeruleus; Parkinson Disease | 1989 |
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Topics: Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Psychoses, Substance-Induced | 1989 |
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease.
Topics: Affect; Humans; Levodopa; Locus Coeruleus; Parkinson Disease; Pineal Gland | 1989 |
Visual hallucinations in the elderly associated with the use of levodopa.
Topics: Aged; Aged, 80 and over; Female; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Vision, Ocular | 1989 |
[Melanoma as a possible complication of the treatment of parkinsonism with L-dopa preparations (review of the literature)].
Topics: Humans; Levodopa; Melanoma; Parkinson Disease; Skin Neoplasms | 1989 |
Problems and unanswered questions concerning levodopa treatment in Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1989 |
[Current perspectives in the treatment of Parkinson disease].
Topics: Biopterins; Brain Chemistry; Dopamine; Dopamine Antagonists; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Synaptic Transmission; Tyrosine 3-Monooxygenase | 1985 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug Interactions; Ergolines; Humans; Levodopa; Libido; Memory; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Sexual Behavior; Substance-Related Disorders; Visual Perception | 1986 |
[Possibilities for neurotransmitter correction in parkinsonism (a review)].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 1987 |
[Parkinson disease. The clinical picture and therapy].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1988 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
[Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Dopamine Agents; Droxidopa; Humans; Levodopa; Nerve Tissue; Parkinson Disease; Pyridines; Serine | 1988 |
The case for and concerns about continuous dopamine stimulation in Parkinson's disease.
Topics: Administration, Oral; Animals; Delayed-Action Preparations; Dopamine; Drug Tolerance; Humans; Infusion Pumps; Levodopa; Methyldopa; Parkinson Disease; Stimulation, Chemical | 1988 |
Psychiatric side effects during the treatment of Parkinson's disease.
Topics: Dreams; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Mental Disorders; Paranoid Disorders; Parkinson Disease; Serotonin; Severity of Illness Index; Sleep Wake Disorders | 1988 |
Pathogenetic studies of motor fluctuations in Parkinson's disease.
Topics: Biomechanical Phenomena; Humans; Levodopa; Movement; Parkinson Disease; Time Factors | 1988 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
Central mechanisms and levodopa response fluctuations in Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1988 |
Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease.
Topics: Brain; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1988 |
[Treatment Parkinson disease using levodopa].
Topics: Humans; Levodopa; Parkinson Disease | 1987 |
New perspectives in the treatment of Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline; Sincalide | 1986 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
Pharmacological approaches to Parkinson's disease in the different phases of evolution.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline | 1986 |
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Topics: Animals; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tyramine | 1986 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism | 1987 |
Controversies in the management of Parkinson's disease.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1986 |
Positron emission tomography in movement disorders.
Topics: Brain; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dystonia; Glucose; Humans; Huntington Disease; Levodopa; Movement Disorders; Oxygen Consumption; Parkinson Disease; Synapses; Tomography, Emission-Computed | 1985 |
Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 1988 |
Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease.
Topics: Adrenal Glands; Animals; Brain; Humans; Levodopa; Parkinson Disease | 1988 |
Dopamine receptors in Parkinson's disease.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1988 |
Studies on the prevalence of paralysis agitans by tracer methodology.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Epidemiologic Methods; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden | 1987 |
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
Topics: Blood-Brain Barrier; Dose-Response Relationship, Drug; Levodopa; Movement Disorders; Parkinson Disease | 1987 |
Practical therapy of Parkinson's disease.
Topics: Diagnosis, Differential; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1987 |
Somatosensory evoked potentials in myoclonus.
Topics: Brain Diseases, Metabolic; Cerebral Cortex; Clonazepam; Electroencephalography; Electromyography; Evoked Potentials, Somatosensory; Humans; Levodopa; Myoclonus; Parkinson Disease; Pyramidal Tracts | 1986 |
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; Homovanillic Acid; Humans; Levodopa; Male; Mental Disorders; Nomifensine; Nortriptyline; Parkinson Disease; Personality; Psychotic Disorders; Serotonin; Tryptophan | 1986 |
Ethnic differences in reactions to drugs and xenobiotics. Conjugation reactions.
Topics: Acetaminophen; Amobarbital; Asian People; Canada; Catechol O-Methyltransferase; Ethnicity; Female; Ghana; Half-Life; Humans; Inactivation, Metabolic; Levodopa; London; Male; Metabolic Clearance Rate; New York; Parkinson Disease; Philippines; Scotland; White People | 1986 |
L-dopa treatment and Parkinson's disease.
Topics: Aged; History, 20th Century; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1986 |
Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 1986 |
Modern treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1987 |
The pharmacology of foot dystonia in parkinsonism.
Topics: Dystonia; Foot Diseases; Humans; Levodopa; Parkinson Disease | 1987 |
The role of L-dopa holiday in the long-term management of Parkinson's disease.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Parkinson's disease in the elderly: psychiatric manifestations.
Topics: Aged; Amantadine; Depression; Humans; Levodopa; Mood Disorders; Parasympatholytics; Parkinson Disease; Personality Disorders | 1985 |
'Drug holidays' in the treatment of Parkinson's disease. A brief review.
Topics: Aged; Drug Administration Schedule; Follow-Up Studies; Holidays; Humans; Levodopa; Parkinson Disease; Time Factors | 1985 |
Clinically desirable drug interactions.
Topics: Aminoglycosides; Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbidopa; Diuretics; Drug Combinations; Drug Interactions; Drug Synergism; Humans; Hydroxamic Acids; Hypokalemia; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Penicillins; Probenecid; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1985 |
Long-term use of dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Corpus Striatum; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pergolide; Receptors, Dopamine; Time Factors | 1985 |
The controversial role of bromocriptine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Time Factors | 1985 |
Bromocriptine in Parkinson disease.
Topics: Aged; Animals; Bromocriptine; Drug Administration Schedule; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1985 |
Transplantation of monoamine-producing cell systems in oculo and intracranially: experiments in search of a treatment for Parkinson's Disease.
Topics: Adrenal Medulla; Amines; Animals; Brain; Chromaffin System; Denervation; Disease Models, Animal; Dopamine; Electrophysiology; Epinephrine; Eye; Female; Graft Survival; Hippocampus; Humans; Levodopa; Locus Coeruleus; Male; Middle Aged; Nerve Fibers; Nerve Growth Factors; Nerve Tissue; Neurons; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Substantia Nigra | 1985 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodopa; Locus Coeruleus; Myocardium; Norepinephrine; Pargyline; Parkinson Disease; Serine; Stereoisomerism; Tyrosine | 1985 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
The clinical physiology of side effects in long-term L-DOPA therapy.
Topics: Acetylcholine; Basal Ganglia; Brain Chemistry; Brain Stem; Creatinine; Diagnosis, Differential; Dopamine; gamma-Aminobutyric Acid; Humans; Hypothalamus; Levodopa; Movement Disorders; Norepinephrine; Parkinson Disease; Potassium; Receptors, Drug; Serotonin; Sodium; Time Factors | 1974 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Olivary Nucleus; Parkinson Disease; Putamen; Rats; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Tremor | 1974 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Catecholamines; Chemical Phenomena; Chemistry; Dogs; Dopamine; Electroencephalography; Guinea Pigs; Haplorhini; Hemodynamics; Humans; Kinetics; Levodopa; Mice; Movement Disorders; Parasympatholytics; Parkinson Disease; Rabbits; Rats; Serotonin; Virus Diseases | 1974 |
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.
Topics: Animals; Biological Transport, Active; Brain; Cats; Cerebral Ventricles; Cerebrospinal Fluid; Choroid Plexus; Dihydroxyphenylalanine; Dogs; Dopamine; Fenclonine; Glycols; Haplorhini; Homovanillic Acid; Humans; Hydrocephalus; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Parkinson Disease; Phenylacetates; Probenecid; Serotonin; Spinal Cord; Spinal Cord Injuries; Tryptophan | 1974 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extrapyramidal Tracts; Fenclonine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Imipramine; Levodopa; Muscular Diseases; Paralysis; Parkinson Disease; Parkinson Disease, Secondary; Probenecid; Reserpine; Serotonin; Spinal Cord Diseases; Tetrabenazine; Time Factors | 1974 |
The role of brain catecholamines in the regulation of ACTH secretion.
Topics: 17-Hydroxycorticosteroids; Acetylcholine; Adrenal Cortex Hormones; Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Brain; Catecholamines; Chlorpromazine; Corpus Striatum; Depression, Chemical; Dogs; Dopamine; Histocytochemistry; Hypophysectomy; Hypothalamus; Levodopa; Limbic System; Methyltyrosines; Mice; Microscopy, Fluorescence; Norepinephrine; Parkinson Disease; Pituitary Gland, Anterior; Rats; Reserpine; Serotonin; Stress, Physiological; Synaptic Transmission | 1974 |
Parkinson's disease and levodopa. A five-year follow-up and review.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Animals; Athetosis; Basal Ganglia; Chorea; Corpus Striatum; Dementia; Depression; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Postencephalitic; Sexual Behavior; Substantia Nigra; Vomiting | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
[Therapy of Parkinsonism. II].
Topics: Amantadine; Amitriptyline; Humans; Imipramine; Levodopa; Parkinson Disease; Physical Therapy Modalities | 1974 |
The mechanisms of action of L-dopa in Parkinson's disease.
Topics: Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Disease; Serotonin | 1974 |
1313 trial(s) available for levodopa and Parkinson Disease
| Article | Year |
|---|---|
[Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cognition; Cognitive Dysfunction; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease | 2021 |
Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Eating; Fasting; Female; Gels; Humans; Intestines; Levodopa; Lunch; Male; Motor Activity; Parkinson Disease | 2021 |
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Proof of Concept Study; Treatment Outcome | 2021 |
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Zonisamide | 2021 |
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chemotherapy, Adjuvant; Dopamine Agonists; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Antiparkinsonian Drug Reduction After Directional Versus Omnidirectional Bilateral Subthalamic Deep Brain Stimulation.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2023 |
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2022 |
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Humans; Levodopa; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Purines; Randomized Controlled Trials as Topic | 2022 |
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Parkinson Disease | 2022 |
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease | 2022 |
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Humans; Levodopa; Parkinson Disease | 2022 |
Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Germany; Humans; Levodopa; Parkinson Disease; Quality of Life; Switzerland | 2022 |
Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 2023 |
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Healthy Volunteers; Humans; Levodopa; Parkinson Disease | 2023 |
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Topics: Antiparkinson Agents; China; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Topics: Antiparkinson Agents; Carbidopa; Cellulitis; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression; Dopamine Agents; Double-Blind Method; Humans; Iron; Iron Chelating Agents; Levodopa; Neutropenia; Parkinson Disease; Substantia Nigra | 2022 |
Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson's disease: Results from a single-center trial.
Topics: Benserazide; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Risk Factors | 2023 |
Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2023 |
Safety and feasibility of faecal microbiota transplantation for patients with Parkinson's disease: a protocol for a self-controlled interventional donor-FMT pilot study.
Topics: Feasibility Studies; Fecal Microbiota Transplantation; Feces; Humans; Levodopa; Parkinson Disease; Pilot Projects; Prospective Studies; Treatment Outcome | 2023 |
The effects of safinamide according to gender in Chinese parkinsonian patients.
Topics: Antiparkinson Agents; Double-Blind Method; East Asian People; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life | 2023 |
Safety Profile of Opicapone in the Management of Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2019 |
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
Topics: Accidental Falls; Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Double-Blind Method; Exercise Therapy; Female; Humans; Levodopa; Male; Middle Aged; Muscle Stretching Exercises; Netherlands; Parkinson Disease; Patient Compliance; Patient Dropouts; Self Care; Tachycardia; Telemedicine; Treatment Outcome | 2019 |
Dopamine replacement improves motor learning of an upper extremity task in people with Parkinson disease.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurological Rehabilitation; Outcome Assessment, Health Care; Parkinson Disease; Practice, Psychological; Severity of Illness Index; Transfer, Psychology; Upper Extremity | 2020 |
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.
Topics: ATP-Binding Cassette Transporters; Biological Products; Cytochrome P-450 Enzyme System; Dopamine; Electroencephalography; Female; Genetic Pleiotropy; Genetic Variation; Genotyping Techniques; Glutathione Transferase; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Vicia faba | 2019 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels.
Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Theta Rhythm; Transcranial Magnetic Stimulation | 2020 |
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Homes for the Aged; Humans; Levodopa; Male; Medicare; Monte Carlo Method; Nursing Homes; Parkinson Disease; Physical Functional Performance; Severity of Illness Index; United States | 2020 |
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Topics: Administration, Sublingual; Adult; Aged; Antiparkinson Agents; Apomorphine; Canada; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; United States | 2020 |
Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Pharmaceutical Preparations | 2020 |
Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment.
Topics: Botulinum Toxins; Dystonic Disorders; Humans; Levodopa; Movement; Parkinson Disease | 2019 |
The Minimal Clinically Relevant Change of the FOG Score.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Minimal Clinically Important Difference; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index; Single-Blind Method; Video Recording | 2020 |
Differential Temporal Perception Abilities in Parkinson's Disease Patients Based on Timing Magnitude.
Topics: Aged; Basal Ganglia; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Perception; Visual Perception | 2019 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
Topics: Aged; Antiparkinson Agents; Costs and Cost Analysis; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Research Design | 2020 |
Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease.
Topics: Bacteria; Case-Control Studies; Cathartics; Diet; Female; Gastrointestinal Microbiome; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phylogeny; Principal Component Analysis | 2020 |
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
Topics: Antiparkinson Agents; Cerebral Cortex; Dementia; Double-Blind Method; Humans; Levodopa; Parkinson Disease | 2020 |
Adherence to treatment guideline recommendations for Parkinson's disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016.
Topics: Adult; Aged; Databases, Factual; Dopamine Antagonists; Female; Guideline Adherence; Humans; Insurance Claim Review; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Practice Guidelines as Topic; Retrospective Studies | 2020 |
A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Fatigue; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sleep; Subthalamic Nucleus; Treatment Outcome | 2020 |
Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Indoles; Levodopa; Parkinson Disease; Tablets | 2020 |
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Rats | 2020 |
Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
Topics: Antiparkinson Agents; Carbidopa; Cognition; Cross-Over Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease.
Topics: Accelerometry; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Netherlands; Parkinson Disease; Treatment Outcome; Tremor | 2020 |
Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-
Topics: Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Pramipexole; Quality of Life; Tumor Necrosis Factor-alpha | 2020 |
Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy.
Topics: Cholinergic Agents; Dopamine; Gait; Humans; Levodopa; Parkinson Disease; Prefrontal Cortex | 2020 |
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Topics: Aged; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D5; Severity of Illness Index | 2020 |
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Humans; Japan; Levodopa; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome; United Kingdom | 2021 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Topics: Carbidopa; Catechol O-Methyltransferase; Catechols; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Gels; Genotype; Humans; Levodopa; Male; Models, Biological; Nitriles; Parkinson Disease; Polymorphism, Genetic | 2020 |
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2021 |
Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2021 |
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.
Topics: Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Early Diagnosis; Female; Genetic Variation; Humans; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2020 |
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Pyrimidines; Quality of Life | 2021 |
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Topics: Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Time Factors | 2021 |
High intensity aerobic exercise improves information processing and motor performance in individuals with Parkinson's disease.
Topics: Antiparkinson Agents; Exercise; Exercise Therapy; Humans; Levodopa; Parkinson Disease | 2021 |
Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Japan; Levodopa; Oxadiazoles; Parkinson Disease | 2021 |
Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial.
Topics: Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance | 2021 |
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Research Design; Vitamin B 12 | 2021 |
Parkinson's disease: Research puts spotlight on thiamine deficiency and cardiovascular health.
Topics: Folic Acid; Homocysteine; Humans; Levodopa; Parkinson Disease; Thiamine Deficiency; Vitamin B 12 | 2021 |
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study.
Topics: Aged; Animals; Antiparkinson Agents; Double-Blind Method; Humans; Hydrogen; Levodopa; Parkinson Disease; Pilot Projects; Treatment Outcome | 2021 |
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
Topics: Adult; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Parkinson Disease; Single-Blind Method | 2021 |
Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
Topics: Affect; Aged; Antiparkinson Agents; Drug Therapy, Combination; Duloxetine Hydrochloride; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2017 |
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects; Quinidine | 2017 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; North America; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Motor Activity; Mucuna; Parkinson Disease; Phytotherapy; Powders; Seeds; Treatment Outcome | 2017 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Levodopa; Lung; Male; Middle Aged; Parkinson Disease; Vital Capacity | 2018 |
Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
Topics: Age Factors; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes | 2018 |
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piperidines; Statistics, Nonparametric; Treatment Outcome | 2018 |
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Outcome Assessment, Health Care; Parkinson Disease; Phytotherapy; Pilot Projects; Plant Preparations; Seeds | 2018 |
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
Topics: Adult; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Female; France; Germany; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Subthalamic Nucleus | 2018 |
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.
Topics: Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Organic Chemicals; Parkinson Disease; Receptors, Dopamine D1; Time Factors | 2018 |
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Double-Blind Method; Drug Combinations; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Polyneuropathies; Weight Loss | 2018 |
Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.
Topics: Aged; Antiparkinson Agents; Computers, Handheld; Drug Monitoring; Female; Health Communication; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Patient Satisfaction; Physicians; Pilot Projects; Reproducibility of Results; Self-Management; Smartphone; Sphygmomanometers; Telemedicine | 2018 |
DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
Topics: Aged; Antiemetics; Antiparkinson Agents; Domperidone; Double-Blind Method; Female; Gastric Emptying; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Plant Preparations; Stomach; Treatment Outcome | 2018 |
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2018 |
A High-Intensity Multicomponent Agility Intervention Improves Parkinson Patients' Clinical and Motor Symptoms.
Topics: Activities of Daily Living; Aged; Disability Evaluation; Exercise Therapy; Feedback, Sensory; Female; Humans; Levodopa; Male; Middle Aged; Mobility Limitation; Motor Skills; Movement; Parkinson Disease; Photic Stimulation; Postural Balance; Research Design; Standing Position; Time and Motion Studies; Treatment Outcome | 2018 |
A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
Topics: Aged; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2018 |
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study.
Topics: Aged; Cross-Over Studies; Deep Brain Stimulation; Dopamine Agents; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Pilot Projects; Single-Blind Method; Substantia Nigra; Subthalamic Nucleus | 2019 |
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naphthoquinones; Parkinson Disease; Treatment Outcome | 2019 |
Two-Year Agility Maintenance Training Slows the Progression of Parkinsonian Symptoms.
Topics: Aged; Antiparkinson Agents; Disease Progression; Exercise Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease; Postural Balance; Quality of Life; Treatment Outcome | 2019 |
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Combinations; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Dorsal striatum does not mediate feedback-based, stimulus-response learning: An event-related fMRI study in patients with Parkinson's disease tested on and off dopaminergic therapy.
Topics: Aged; Antiparkinson Agents; Association Learning; Brain Mapping; Corpus Striatum; Decision Making; Evoked Potentials; Female; Formative Feedback; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease | 2019 |
Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
Topics: Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording | 2018 |
Predicting Motor Sequence Learning in People With Parkinson Disease.
Topics: Aged; Combined Modality Therapy; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurological Rehabilitation; Parkinson Disease; Postural Balance; Practice, Psychological; Serial Learning | 2019 |
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Treatment Outcome | 2019 |
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Powders; Treatment Outcome | 2019 |
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time-to-Treatment | 2019 |
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2019 |
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
Topics: Administration, Inhalation; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Levodopa imparts a normalizing effect on default-mode network connectivity in non-demented Parkinson's disease.
Topics: Aged; Brain; Case-Control Studies; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neural Pathways; Parkinson Disease; Rest | 2019 |
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prevalence | 2019 |
Virtual Reality Rehabilitation Versus Conventional Physical Therapy for Improving Balance and Gait in Parkinson's Disease Patients: A Randomized Controlled Trial.
Topics: Aged; Exercise Therapy; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Postural Balance; Reproducibility of Results; Stroke Rehabilitation; Time and Motion Studies; Virtual Reality; Virtual Reality Exposure Therapy; Walking | 2019 |
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Cross-Over Studies; Drug Combinations; Drug Compounding; Drug Delivery Systems; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Proof of Concept Study; Treatment Outcome | 2019 |
The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Singapore; Treatment Outcome | 2019 |
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Topics: Adult; Aged; Benserazide; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Combinations; Drugs, Generic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2019 |
Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.
Topics: Aged; Antiparkinson Agents; Brain; Double-Blind Method; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Rest | 2013 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cardiovascular Diseases; Catechols; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Risk; Treatment Outcome | 2013 |
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Topics: Aged; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Treatment Outcome | 2013 |
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Survival Analysis; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Efficacy and safety of standardized extract of Trigonella foenum-graecum L seeds as an adjuvant to L-Dopa in the management of patients with Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Aged; Dihydroxyphenylalanine; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plant Extracts; Seeds; Trigonella | 2014 |
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Corpus Striatum; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Single-Blind Method; Treatment Outcome | 2013 |
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Parkinson Disease; Predictive Value of Tests; Time Factors | 2013 |
Effect of expectancy and personality on cortical excitability in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cerebral Cortex; Double-Blind Method; Evoked Potentials, Motor; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Motor Activity; Parkinson Disease; Personality; Personality Inventory; Surveys and Questionnaires | 2013 |
A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.
Topics: Brain; Carbidopa; Dopa Decarboxylase; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.
Topics: Aged; Antiparkinson Agents; Caudate Nucleus; Cognition Disorders; Deep Brain Stimulation; Double-Blind Method; Electrodes; Female; Functional Laterality; Globus Pallidus; Humans; Lead; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Parkinson Disease; Statistics, Nonparametric; Subthalamic Nucleus | 2013 |
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; International Cooperation; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors | 2013 |
Central pain modulation after subthalamic nucleus stimulation: A crossover randomized trial.
Topics: Antiparkinson Agents; Cross-Over Studies; Deep Brain Stimulation; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Pain Threshold; Parkinson Disease; Subthalamic Nucleus | 2013 |
Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Topics: Benserazide; Data Interpretation, Statistical; Drug Combinations; Drugs, Chinese Herbal; Humans; Levodopa; Medicine, Chinese Traditional; Parkinson Disease; Phytotherapy; Piribedil; Quality of Life | 2013 |
The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
Topics: Aged; Antiparkinson Agents; Asian People; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets, Enteric-Coated; Treatment Outcome | 2013 |
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Early Termination of Clinical Trials; Excitatory Amino Acid Antagonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Kainic Acid; Sample Size; Severity of Illness Index; Tremor | 2016 |
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Modulation of corticomotor excitability after maximal or sustainable-rate repetitive finger movement is impaired in Parkinson's disease and is reversed by levodopa.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dopamine; Evoked Potentials, Motor; Exercise; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Muscle, Skeletal; Parkinson Disease | 2014 |
The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Resistance; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; ROC Curve | 2014 |
Controlled general anaesthesia for subthalamic nucleus stimulation in Parkinson's disease.
Topics: Aged; Anesthesia, General; Deep Brain Stimulation; Deep Sedation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Subthalamic Nucleus; Treatment Outcome | 2014 |
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2014 |
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Treatment Outcome | 2014 |
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Topics: Aged; Carbidopa; Double-Blind Method; Female; Gels; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Treatment Outcome | 2014 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compassionate Use Trials; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Supranuclear Palsy, Progressive; Treatment Outcome | 2014 |
[Nocturnal symptoms of Parkinson's disease and approaches to their correction].
Topics: Carbidopa; Catechols; Drug Combinations; Dyskinesias; Humans; Levodopa; Muscle Cramp; Nocturia; Parkinson Disease; Restless Legs Syndrome | 2013 |
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets | 2014 |
Auditory cueing of gait initiation in Parkinson's disease patients with freezing of gait.
Topics: Analysis of Variance; Cues; Dopamine Agents; Female; Gait; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 2014 |
Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fructose; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Topiramate | 2014 |
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Raclopride; Radionuclide Imaging; Radiopharmaceuticals; Serotonergic Neurons; Serotonin 5-HT1 Receptor Agonists; Synapses; Treatment Outcome | 2014 |
Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome; Video Recording | 2014 |
Randomized cross-over trial to investigate the efficacy of a two-week physiotherapy programme with repetitive exercises of cueing to reduce the severity of freezing of gait in patients with Parkinson's disease.
Topics: Aged; Cross-Over Studies; Cues; Exercise Therapy; Female; Gait Disorders, Neurologic; Germany; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Outpatients; Parkinson Disease; Severity of Illness Index | 2014 |
Cardiovascular effects of levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Neuromuscular complexity during gait is not responsive to medication in persons with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Electromyography; Female; Gait; Humans; Leg; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Walking | 2014 |
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2014 |
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Internationality; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Network modulation following sham surgery in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Cerebellum; Computer Simulation; Double-Blind Method; Female; Functional Neuroimaging; Genetic Therapy; Glutamate Decarboxylase; Humans; Levodopa; Limbic System; Male; Metabolic Networks and Pathways; Middle Aged; Models, Neurological; Monte Carlo Method; Parkinson Disease; Placebo Effect; Placebos; Positron-Emission Tomography | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Data Interpretation, Statistical; Deep Brain Stimulation; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Preoperative Period; Prospective Studies; Psychomotor Performance; Respiration; Semantics; Speech; Speech Intelligibility; Subthalamic Nucleus | 2014 |
A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters.
Topics: Aged; Animals; Cholesterol, LDL; Dietary Fiber; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plantago; Seeds; Triglycerides | 2014 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome; Walking | 2014 |
The heterogeneity of non-motor symptoms of Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Asian People; Digestive System Abnormalities; Female; Humans; Levodopa; Male; Mental Status Schedule; Metabolic Diseases; Middle Aged; Mood Disorders; Parkinson Disease; Retrospective Studies; Sensation Disorders; Severity of Illness Index; Sleep Wake Disorders; Young Adult | 2015 |
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Clarithromycin; Comorbidity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesias; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2014 |
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Female; Humans; Indoles; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2014 |
No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
Topics: Aged; Canada; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sex Factors; Treatment Outcome; United States | 2014 |
[The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Gels; Health Status; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2014 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Topics: Aged; Antiparkinson Agents; Carbidopa; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Asian People; Delayed-Action Preparations; Drug Liberation; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Young Adult | 2015 |
Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Topics: Age Factors; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Delivery Systems; Female; Gels; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
[The use of stalevo in the treatment of patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
Topics: Aged; Antiparkinson Agents; Cost of Illness; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Placebo Effect; Prospective Studies; Treatment Outcome | 2015 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2015 |
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2015 |
Amino acid supplementation in l-dopa treated Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Amino Acids; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diet, Protein-Restricted; Dietary Supplements; Double-Blind Method; Female; Glutathione; Humans; Insulin; Insulin Resistance; Levodopa; Male; Middle Aged; Nutrition Assessment; Oxidative Stress; Parkinson Disease; Pilot Projects; Prospective Studies; Treatment Outcome; Triglycerides | 2015 |
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines | 2015 |
Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Caregivers; Cross-Sectional Studies; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physicians; Pilot Projects; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2015 |
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Topics: Aged; Catechol O-Methyltransferase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Middle Aged; Parkinson Disease; Polymorphism, Genetic | 2015 |
Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Tetrahydronaphthalenes; Thiophenes | 2015 |
Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Precision Medicine; Tablets | 2015 |
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2015 |
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
PPNa-DBS for gait and balance disorders in Parkinson's disease: a double-blind, randomised study.
Topics: Aged; Antiparasitic Agents; Deep Brain Stimulation; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Postural Balance; Sensation Disorders; Surveys and Questionnaires | 2015 |
Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.
Topics: Adult; Aged; Appetite; Benserazide; Breath Tests; Caprylates; Dopamine Agents; Drug Combinations; Gastric Emptying; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2015 |
Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Prospective Studies; Range of Motion, Articular; Treatment Outcome | 2015 |
Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
Topics: Aged; Arousal; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Apnea, Obstructive; Wakefulness | 2016 |
BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: study protocol for a randomized controlled trial.
Topics: Anxiety; Awareness; Clinical Protocols; Humans; Levodopa; Outcome Assessment, Health Care; Parkinson Disease; Physical Therapy Modalities; Sample Size; Single-Blind Method | 2015 |
Compensatory stepping in Parkinson's disease is still a problem after deep brain stimulation randomized to STN or GPi.
Topics: Aged; Biomechanical Phenomena; Case-Control Studies; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Subthalamic Nucleus; Walking | 2015 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Periodicity; Piribedil; Postural Balance; Pramipexole; Walking | 2015 |
Memantine and reduced time with dyskinesia in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease | 2016 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial.
Topics: Aged; China; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Transcranial Magnetic Stimulation; Treatment Outcome | 2015 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?
Topics: Aged; Clinical Trials, Phase II as Topic; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Outcome Assessment | 2015 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Treatment Outcome | 2015 |
Speech intelligibility in Parkinson's disease patients with zona incerta deep brain stimulation.
Topics: Aged; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Intelligibility; Treatment Outcome; Zona Incerta | 2015 |
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2015 |
Neural correlates underlying micrographia in Parkinson's disease.
Topics: Aged; Attention; Basal Ganglia; Benserazide; Brain Mapping; Case-Control Studies; Cerebellum; Drug Combinations; Female; Gyrus Cinguli; Handwriting; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease | 2016 |
Small fiber neuropathy in Parkinson's disease: A clinical, pathological and corneal confocal microscopy study.
Topics: Aged; Antiparkinson Agents; Cornea; Epidermis; Female; Foot; Heart Rate; Humans; Levodopa; Male; Microscopy, Confocal; Middle Aged; Nerve Fibers, Unmyelinated; Neural Conduction; Ophthalmic Nerve; Parasympathetic Nervous System; Parkinson Disease; Peripheral Nerves; Sensory Thresholds; Severity of Illness Index | 2015 |
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Netherlands; Parkinson Disease; Quality of Life; Time-to-Treatment | 2015 |
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Capsules; Carbidopa; Cohort Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Oxadiazoles; Parkinson Disease | 2016 |
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Australia; Carbidopa; Dopamine Agents; Duodenum; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies; Psychomotor Performance; Quality of Life | 2016 |
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial.
Topics: Aged; Antiparkinson Agents; Female; Humans; Hypnotics and Sedatives; Indenes; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Surveys and Questionnaires; Treatment Outcome | 2016 |
Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Drug Combinations; Female; GPI-Linked Proteins; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Pilot Projects | 2016 |
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Antiparkinson Agents; Azabicyclo Compounds; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines | 2016 |
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
Topics: Administration, Inhalation; Aged; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Hydrogen; Levodopa; Male; Middle Aged; Parkinson Disease; Water | 2016 |
Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Single-Blind Method; Statistics, Nonparametric; Transcranial Magnetic Stimulation; Treatment Outcome | 2016 |
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5 | 2016 |
Levodopa impairs probabilistic reversal learning in healthy young adults.
Topics: Adult; Analysis of Variance; Brain; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Parkinson Disease; Reversal Learning; Reward; Young Adult | 2016 |
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Apathy; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Single session intermittent theta-burst stimulation on the left premotor cortex does not alleviate freezing of gait in Parkinson's disease.
Topics: Aged; Biomechanical Phenomena; Cross-Over Studies; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prefrontal Cortex; Transcranial Magnetic Stimulation; Treatment Outcome | 2016 |
Parkinson's disease impairs masticatory function.
Topics: Aged; Antiparkinson Agents; Bite Force; Cross-Sectional Studies; Denture, Partial, Removable; Female; Humans; Levodopa; Male; Mastication; Parkinson Disease; Range of Motion, Articular | 2017 |
Effects of levodopa therapy on global left ventricular systolic function in patients with Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Spirometry; Treatment Outcome | 2017 |
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Proof of Concept Study | 2016 |
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2016 |
Altered Resting-State Functional Connectivity of the Striatum in Parkinson's Disease after Levodopa Administration.
Topics: Aged; Cognition; Corpus Striatum; Female; Healthy Volunteers; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Putamen | 2016 |
A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease.
Topics: Antiparkinson Agents; Attention; Female; Humans; Inhibition, Psychological; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Perception; Psychoses, Substance-Induced | 2017 |
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Dogs; Drug Compounding; Drug Evaluation, Preclinical; Healthy Volunteers; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Powders; Translational Research, Biomedical | 2016 |
Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Brazil; Carbidopa; Drug Administration Schedule; Drug Combinations; Electromyography; Female; Humans; Laryngeal Muscles; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Predictive Value of Tests; Prospective Studies; Time Factors; Treatment Outcome; Voice Quality | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Nitriles; Parkinson Disease; Treatment Outcome | 2017 |
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Oxadiazoles; Parkinson Disease; Severity of Illness Index | 2017 |
Dopaminergic modulation of multi-muscle synergies in postural tasks performed by patients with Parkinson's disease.
Topics: Adult; Aged; Dopamine Agents; Female; Humans; Levodopa; Male; Muscle Contraction; Muscle, Skeletal; Parkinson Disease; Postural Balance; Posture | 2017 |
A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Levodopa; Maintenance Chemotherapy; Male; Parkinson Disease | 2017 |
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Gels; Humans; Levodopa; Parkinson Disease | 2017 |
Push-and-release test predicts Parkinson fallers and nonfallers better than the pull test: comparison in OFF and ON medication states.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Ataxia; Diagnostic Techniques, Neurological; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Predictive Value of Tests; Risk; Sensitivity and Specificity; Severity of Illness Index | 2008 |
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Breath Tests; Caprylates; Carbidopa; Carbon Isotopes; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Solubility | 2008 |
Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Depressive Disorder; Disease Progression; Duodenum; Female; Gait Disorders, Neurologic; Humans; Hyperkinesis; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Patient Satisfaction; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome | 2008 |
Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Cholesterol; Dopamine Agents; Female; Humans; Levodopa; Lipids; Male; Middle Aged; Odds Ratio; Parkinson Disease; Retrospective Studies; Risk; Sympathetic Nervous System; Triglycerides; Vascular Diseases | 2009 |
Levodopa improves time-based prospective memory in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Attention; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Intention; Levodopa; Male; Mental Recall; Middle Aged; Parkinson Disease; Time Perception | 2008 |
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life; Selegiline | 2008 |
Motor changes during sertraline treatment in depressed patients with Parkinson's disease*.
Topics: Aged; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Cohort Studies; Depression; Depressive Disorder; Dopamine; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Quality of Life; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Severity of Illness Index | 2008 |
Regional homogeneity changes in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Case-Control Studies; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Parkinson Disease; Rest; Statistics as Topic | 2009 |
Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2008 |
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Food; Humans; Hypertension; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Postprandial Period; Supine Position; Telephone; Tyramine | 2008 |
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Pilot Projects | 2009 |
Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disability Evaluation; Double-Blind Method; Drug Combinations; Feeding Behavior; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2008 |
Fatigue in levodopa-naive subjects with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Brain; Carbidopa; Double-Blind Method; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2008 |
The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymerase Chain Reaction; Polymorphism, Genetic | 2008 |
Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Brain Mapping; Case-Control Studies; Female; Functional Laterality; Hand Strength; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Models, Biological; Movement; Nonlinear Dynamics; Oxygen; Parkinson Disease; Psychomotor Performance | 2009 |
Levodopa and executive performance in Parkinson's disease: a randomized study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Problem Solving; Severity of Illness Index; Time Factors | 2008 |
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Topics: Administration, Oral; Aged; Apomorphine; Cross-Over Studies; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2008 |
[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders; Severity of Illness Index | 2008 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Canada; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Surveys and Questionnaires; Treatment Outcome | 2008 |
Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Medical Records; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Transcranial Magnetic Stimulation; Treatment Outcome | 2009 |
Spike-timing-related plasticity is preserved in Parkinson's disease and is enhanced by dopamine: evidence from transcranial magnetic stimulation.
Topics: Acyclovir; Aged; Analysis of Variance; Dopamine; Dopamine Agents; Electric Stimulation; Evoked Potentials, Motor; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Reaction Time; Transcranial Magnetic Stimulation | 2008 |
Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Arm; Biomechanical Phenomena; Case-Control Studies; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Muscle, Skeletal; Parkinson Disease; Postural Balance; Psychomotor Performance; Severity of Illness Index; Subthalamic Nucleus; Young Adult | 2008 |
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.
Topics: Adult; Affect; Aged; Antiparkinson Agents; Central Nervous System Stimulants; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Euphoria; Female; Humans; Levodopa; Long-Term Care; Male; Methylphenidate; Middle Aged; Motivation; Neurologic Examination; Pain Measurement; Parkinson Disease; Psychomotor Performance; Reward | 2009 |
The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; New York City; Nursing Homes; Parkinson Disease; Severity of Illness Index; Substance Withdrawal Syndrome | 2008 |
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
Topics: Antiparkinson Agents; Cell Transplantation; Double-Blind Method; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Substantia Nigra; Videotape Recording | 2009 |
Two-year follow-up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Combined Modality Therapy; Deep Brain Stimulation; Drug Resistance; Female; Follow-Up Studies; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Care; Posture; Preoperative Care; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires; Time Factors; Tremor | 2009 |
Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; Dopamine Agonists; Drug Therapy, Combination; Echocardiography; Female; Heart Valve Diseases; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Single-Blind Method; Young Adult | 2009 |
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2009 |
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechols; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2009 |
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2009 |
Pathological synchronisation in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity.
Topics: Adult; Aged; Aged, 80 and over; Deep Brain Stimulation; Electroencephalography; Evoked Potentials; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Spectrum Analysis; Statistics as Topic; Subthalamic Nucleus | 2009 |
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation.
Topics: Deep Brain Stimulation; Disability Evaluation; Dopamine Agents; Electrodes, Implanted; Female; Humans; Levodopa; Longitudinal Studies; Male; Motor Activity; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2009 |
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechols; Double-Blind Method; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Nitriles; Parkinson Disease; Principal Component Analysis; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires | 2009 |
[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Time Factors; Treatment Outcome | 2009 |
Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Chi-Square Distribution; Deep Brain Stimulation; Electrodes, Implanted; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Motor Cortex; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Transcranial Magnetic Stimulation | 2009 |
Levodopa use and sleep in patients with dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Lewy Body Disease; Male; Mental Status Schedule; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders; Surveys and Questionnaires; Time Factors | 2009 |
Patterns of motor and non-motor features in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Depression; Factor Analysis, Statistical; Female; Humans; Levodopa; Linear Models; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Movement; Parkinson Disease; Reproducibility of Results; Treatment Outcome | 2009 |
Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Connective Tissue; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2009 |
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cross-Over Studies; Double-Blind Method; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Pramipexole; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2009 |
Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Topics: Acupuncture Therapy; Aged; Benserazide; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2008 |
Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Resistance; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Pallidotomy; Parkinson Disease; Pilot Projects; Prospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2009 |
Brain penetration effects of microelectrodes and DBS leads in STN or GPi.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Microelectrodes; Middle Aged; Movement; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome; Tremor | 2009 |
Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cysteine; Female; Glycine; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2009 |
Deep brain stimulation for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Disease Progression; Female; Humans; Levodopa; Male; Neurosurgical Procedures; Parkinson Disease | 2009 |
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Dementia; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2009 |
Atomoxetine for freezing of gait in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Antiparkinson Agents; Atomoxetine Hydrochloride; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propylamines; Severity of Illness Index | 2009 |
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.
Topics: Aged; Benzoxazoles; Chemotherapy, Adjuvant; Dopamine Agonists; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Piperazines; Treatment Outcome | 2009 |
Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2009 |
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2009 |
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Topics: Aged; Antiparkinson Agents; Disability Evaluation; Duodenum; Endoscopes, Gastrointestinal; Female; Humans; International Cooperation; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2009 |
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors; Tyrosine | 2009 |
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cohort Studies; Disability Evaluation; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Quality of Life; Time; Treatment Outcome | 2009 |
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Pyrimidines; Receptors, N-Methyl-D-Aspartate | 2009 |
Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort.
Topics: Aged; Antiparkinson Agents; Asian People; Cohort Studies; Disability Evaluation; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Regression Analysis; Severity of Illness Index; Statistics, Nonparametric | 2009 |
Deep brain stimulation effects on gait variability in Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2009 |
Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.
Topics: Aged; Antiparkinson Agents; China; Cohort Studies; Depressive Disorder; Disease Progression; Double-Blind Method; Female; Ganoderma; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phytotherapy; Quality of Life; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2009 |
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
Topics: Benzothiazoles; Dopamine Agonists; Frontal Lobe; Gambling; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pramipexole; Psychomotor Performance; Reward; Risk-Taking | 2009 |
Affect in Parkinson's disease: validation of the two-factor approach.
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Depression; Dopamine; Female; Humans; Hyperkinesis; Hypokinesia; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Reproducibility of Results; Serotonin; Time Factors | 2010 |
Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disability Evaluation; Duodenum; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index | 2010 |
Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.
Topics: Activities of Daily Living; Behavioral Symptoms; Carbidopa; Disability Evaluation; Dopamine Agents; Female; Humans; Levodopa; Male; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Botulinum toxin in the treatment of lingual movement disorders.
Topics: Aged; Anti-Dyskinesia Agents; Antiparkinson Agents; Botulinum Toxins; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Time Factors; Tongue Diseases | 2009 |
Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
Topics: Aged; Antiparkinson Agents; Cost-Benefit Analysis; Cross-Over Studies; Decision Trees; Drug Costs; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality-Adjusted Life Years; Sweden | 2009 |
Role of an electronic armband in motor function monitoring in patients with Parkinson's disease.
Topics: Arm; Basal Metabolism; Diet, Protein-Restricted; Dyskinesia, Drug-Induced; Electronics; Energy Metabolism; Humans; Levodopa; Monitoring, Ambulatory; Motor Activity; Movement; Parkinson Disease | 2010 |
[A multi-centered randomized double-blinded controlled clinical study on efficacy of gulling pa'an capsule in treating Parkinson's disease].
Topics: Aged; Double-Blind Method; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy | 2009 |
Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Rheology; Severity of Illness Index; Statistics, Nonparametric; Urinary Bladder Diseases; Urodynamics | 2009 |
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Amygdala; Dopamine; Emotions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Recognition, Psychology | 2009 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Homocysteine; Humans; Levodopa; Memantine; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2010 |
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Brain; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome | 2010 |
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2010 |
Complementary acupuncture in Parkinson's disease: a spect study.
Topics: Acupuncture Therapy; Aged; Antiparkinson Agents; Basal Ganglia; Cerebrovascular Circulation; Combined Modality Therapy; Data Interpretation, Statistical; Dopamine Plasma Membrane Transport Proteins; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2010 |
Rehabilitation in Parkinson's disease: assessing the outcome using objective metabolic measurements.
Topics: Aged; Antiparkinson Agents; Biomarkers; Energy Metabolism; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Walking | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Residence Characteristics; Severity of Illness Index; Surveys and Questionnaires; Tolcapone; United States; Young Adult | 2010 |
[Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson's disease].
Topics: Adult; Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Pramipexole; Quality of Life; Tremor | 2010 |
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Long-term efficacy of rasagiline in early Parkinson's disease.
Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
Parkinson's disease rehabilitation: a pilot study with 1 year follow up.
Topics: Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Pilot Projects; Severity of Illness Index; Treatment Outcome | 2010 |
Levodopa response in dementia with lewy bodies: a 1-year follow-up study.
Topics: Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Lewy Body Disease; Male; Parkinson Disease | 2010 |
Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Sensation Disorders; Sensory Thresholds; Statistics, Nonparametric; Subthalamic Nucleus; Surveys and Questionnaires | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
Patient perception of dyskinesia in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Health Knowledge, Attitudes, Practice; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Perception | 2010 |
Characteristics of the sequence effect in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Disability Evaluation; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Transcranial Magnetic Stimulation | 2010 |
Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Intention to Treat Analysis; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2010 |
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Pramipexole; Quality of Life; Severity of Illness Index; Treatment Outcome | 2010 |
Dopaminergic modulation of the default mode network in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Parkinson Disease; Psychomotor Performance | 2010 |
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome | 2010 |
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders | 2011 |
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Treatment Outcome | 2010 |
Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience.
Topics: Adult; Antiparkinson Agents; Attention; Cognition Disorders; Deep Brain Stimulation; Dyskinesias; Executive Function; Female; Humans; India; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Single-Blind Method; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2010 |
Active theater as a complementary therapy for Parkinson's disease rehabilitation: a pilot study.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Complementary Therapies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Single-Blind Method; Treatment Outcome | 2010 |
[Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Topics: Aged; Antiparkinson Agents; Biological Availability; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Genotype; Humans; Levodopa; Male; Methionine; Middle Aged; Nitriles; Parkinson Disease; Pharmacogenetics; Polymorphism, Genetic; Valine | 2011 |
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Pyrimidines; Triazoles | 2011 |
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 2011 |
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam; Treatment Outcome | 2011 |
Impulse control disorders in Parkinson disease: a multicenter case--control study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Cross-Sectional Studies; Disability Evaluation; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 2011 |
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
Topics: Aged; Antiparkinson Agents; Botulinum Toxins, Type A; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Male; Neuromuscular Agents; Parkinson Disease; Treatment Outcome | 2011 |
Effect of step training and rhythmic auditory stimulation on functional performance in Parkinson patients.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antiparkinson Agents; Exercise Therapy; Female; Functional Laterality; Gait; Gait Disorders, Neurologic; Humans; Learning; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Postural Balance; Treatment Outcome | 2011 |
Determination of minimal clinically important change in early and advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Placebo Effect; ROC Curve; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson's disease: selective responses to internal and external cues.
Topics: Aged; Antiparkinson Agents; Cues; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Walking | 2011 |
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2011 |
Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
Topics: Antiparkinson Agents; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life | 2011 |
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Treatment Outcome | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Piracetam; Severity of Illness Index; Time Factors; Video Recording | 2011 |
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.
Topics: Adult; Aged; Corpus Striatum; Double-Blind Method; Drug Carriers; Epithelial Cells; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Retinal Pigment Epithelium; Treatment Outcome | 2011 |
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Single-Blind Method | 2011 |
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Dibenzothiazepines; Disease Progression; Electroconvulsive Therapy; Electroencephalography; Female; Humans; Inpatients; Levodopa; Male; Middle Aged; Parkinson Disease; Psychotic Disorders; Quetiapine Fumarate; Regional Blood Flow; Risk Factors; Time Factors; Tokyo; Tomography, Emission-Computed, Single-Photon | 2011 |
Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets; Time Factors | 2012 |
Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Emotions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Time | 2012 |
Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypodermoclysis; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2012 |
[Levodopa medications in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2011 |
Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Constipation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Serum homocysteine and physical exercise in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Exercise; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Mental Status Schedule; Middle Aged; Parkinson Disease | 2011 |
Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Muscle Contraction; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation | 2011 |
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 2011 |
Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disability Evaluation; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neural Inhibition; Parkinson Disease | 2011 |
Site of deep brain stimulation and jaw velocity in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Combined Modality Therapy; Deep Brain Stimulation; Deglutition Disorders; Double-Blind Method; Female; Globus Pallidus; Humans; Jaw; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Disorders; Subthalamic Nucleus; Treatment Outcome | 2011 |
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies; Quality of Life; Single-Blind Method | 2011 |
Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up.
Topics: Acoustic Stimulation; Activities of Daily Living; Aged; Antiparkinson Agents; Critical Care; Cues; Disease Progression; Exercise Test; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Photic Stimulation; Physical Therapy Modalities; Pilot Projects; Statistics, Nonparametric; Treatment Outcome | 2012 |
Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sleep; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2011 |
Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome | 2011 |
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dysarthria; Facial Expression; Female; Humans; Hypokinesia; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Muscle Rigidity; Nitriles; Parkinson Disease; Severity of Illness Index; Tremor | 2011 |
Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Electroencephalography; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Levodopa; Linear Models; Long-Term Potentiation; Male; Middle Aged; Motor Cortex; Motor Skills; Neuronal Plasticity; Parkinson Disease; Rest; Theta Rhythm; Transcranial Magnetic Stimulation | 2012 |
Feasibility of home-based automated Parkinson's disease motor assessment.
Topics: Algorithms; Antiparkinson Agents; Computers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Patient Compliance; Software | 2012 |
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Female; Flow Cytometry; Gene Expression Regulation; Humans; Indoles; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Pramipexole | 2011 |
[Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Disorders, Intrinsic | 2011 |
Modulation of habit formation by levodopa in Parkinson's disease.
Topics: Aged; Analysis of Variance; Case-Control Studies; Conditioning, Psychological; Cues; Dopamine; Dopamine Agents; Feedback, Physiological; Female; Habits; Humans; Learning; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time | 2011 |
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Factor Analysis, Statistical; Female; Humans; Levodopa; Lewy Body Disease; Male; Memantine; Neuropsychological Tests; Parkinson Disease; Quality of Life; Treatment Outcome | 2011 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechols; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pilot Projects; Self Report; Single-Blind Method; Sweden; Tolcapone; Tyrosine | 2012 |
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Topics: Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Combinations; Harmine; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Positron-Emission Tomography; Prefrontal Cortex; Protein Binding; Serotonin; Substrate Specificity; Time Factors; Tryptophan | 2012 |
[Effects of bushenhuoxue granules on sleep quality in Parkinson's patients].
Topics: Aged; Aged, 80 and over; Benserazide; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2011 |
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
Topics: Adult; Aged; Antiparkinson Agents; Benzoxazoles; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Piperazines; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Basal Ganglia; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Oxygen; Parkinson Disease; Reaction Time; Serial Learning; Single-Blind Method; Time Factors | 2012 |
Effects of subthalamic nucleus deep brain stimulation and L-DOPA on blinking in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Blinking; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2012 |
Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Asian People; Delayed-Action Preparations; Dopamine Agonists; Female; Follow-Up Studies; Food-Drug Interactions; Humans; Indoles; Levodopa; Male; Parkinson Disease; Tablets | 2012 |
The effects of subthalamic and pallidal deep brain stimulation on postural responses in patients with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Combined Modality Therapy; Deep Brain Stimulation; Dominance, Cerebral; Double-Blind Method; Electromyography; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Subthalamic Nucleus | 2012 |
Use of the Gait Deviation index for the evaluation of patients with Parkinson's disease.
Topics: Aged; Feasibility Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2012 |
Activity enhances dopaminergic long-duration response in Parkinson disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Task Performance and Analysis | 2012 |
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Association Learning; Carbidopa; Choice Behavior; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Generalization, Psychological; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nucleus Accumbens; Oxygen; Parkinson Disease; Photic Stimulation; Prefrontal Cortex; Psychomotor Performance; Reinforcement, Psychology | 2012 |
Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance | 2012 |
Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time; Treatment Outcome | 2012 |
Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease.
Topics: Adult; Aged; Dopamine; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2012 |
Thermal and mechanical pain thresholds in patients with fluctuating Parkinson's disease.
Topics: Aged; Cold Temperature; Female; Hot Temperature; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinson Disease; Pressure | 2012 |
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2012 |
Unilateral caudal zona incerta deep brain stimulation for Parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Drug Resistance; Female; Follow-Up Studies; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Subthalamus; Treatment Outcome; Tremor | 2012 |
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Severity of Illness Index; Treatment Outcome | 2012 |
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study.
Topics: Adult; Behavior; Deep Brain Stimulation; Dyskinesias; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Risk; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2013 |
Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
[Effects of "attenuation and synergia" for Bushenhuoxue Granules on Parkinson's patients].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Constipation; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Treatment Outcome; Urination Disorders | 2012 |
[Analysis of sustained attention in patients with Parkinson's disease being treated with dopamine precursors].
Topics: Aged; Antiparkinson Agents; Attention; Dopamine; Drug Monitoring; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Psychological Tests; Severity of Illness Index | 2012 |
The combined effect of subthalamic nuclei deep brain stimulation and L-dopa increases emotion recognition in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Emotions; Facial Expression; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual; Perceptual Disorders; Subthalamic Nucleus | 2012 |
Psychostimulant effect of levodopa: reversing sensitisation is possible.
Topics: Anxiety; Basal Ganglia; Deep Brain Stimulation; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Subthalamic Nucleus | 2013 |
Effects of deep brain stimulation in the subthalamic nucleus or globus pallidus internus on step initiation in Parkinson disease: laboratory investigation.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Combined Modality Therapy; Deep Brain Stimulation; Female; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Subthalamic Nucleus; Treatment Outcome; Walking | 2012 |
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease; Pilot Projects; Sample Size | 2013 |
The subthalamic microlesion story in Parkinson's disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRI.
Topics: Deep Brain Stimulation; Edema; Electric Stimulation Therapy; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Parkinson Disease; Subthalamic Nucleus; Thalamus | 2012 |
Levodopa does not change cerebral vasoreactivity in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies | 2013 |
[The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin | 2013 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2013 |
Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Administration Routes; Drug Combinations; Duodenum; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Prospective Studies; Severity of Illness Index; Sleep Disorders, Intrinsic; Treatment Outcome | 2013 |
Caffeine consumption and risk of dyskinesia in CALM-PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Caffeine; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Retrospective Studies; Risk | 2013 |
Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Monitoring, Physiologic; Motion; Parkinson Disease; Wireless Technology | 2012 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Topics: Aged; Arginine Vasopressin; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Inappropriate ADH Syndrome; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2012 |
Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Hydrogen; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Severity of Illness Index; Statistics, Nonparametric; Water | 2013 |
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Double-Blind Method; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Psychiatric Status Rating Scales; Selegiline; Time Factors; Treatment Outcome | 2002 |
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Topics: Aged; Antioxidants; Antiparkinson Agents; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Tocopherols; Treatment Outcome | 2002 |
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Topics: Aged; Antiparkinson Agents; Catechols; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Levodopa; Markov Chains; Nitriles; Parkinson Disease; Patient Satisfaction; Quality-Adjusted Life Years; Treatment Outcome; United States | 2002 |
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Postoperative Period; Prospective Studies; Subthalamic Nucleus | 2002 |
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Dyskinesias; Home Infusion Therapy; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2002 |
Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Combined Modality Therapy; Double-Blind Method; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 2002 |
Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.
Topics: Aged; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Dominance, Cerebral; Double-Blind Method; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus | 2002 |
Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
Topics: Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Predictive Value of Tests | 2002 |
Subthalamotomy for advanced Parkinson disease.
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Functional Laterality; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Radiosurgery; Subthalamic Nucleus; Treatment Outcome; Tremor | 2002 |
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Topics: Activities of Daily Living; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Withholding Treatment | 2002 |
Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
Topics: Adult; Antiparkinson Agents; Dose-Response Relationship, Drug; Down-Regulation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Subthalamic Nucleus; Treatment Outcome | 2002 |
Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Reaction Time; Subthalamic Nucleus; Wrist | 2002 |
Increased red blood cell polyamines in ALS and Parkinson's disease.
Topics: Amyotrophic Lateral Sclerosis; Biogenic Polyamines; Erythrocytes; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putrescine; Spermidine; Spermine; Time Factors | 2002 |
A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.
Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Disease Progression; Fluorine Radioisotopes; Follow-Up Studies; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 2002 |
[Pergolide: a useful agonist for the treatment of Parkinson disease].
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 2002 |
Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD.
Topics: Antiparkinson Agents; Electric Stimulation Therapy; Emotions; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Social Behavior; Subthalamic Nucleus | 2002 |
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Topics: Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Treatment Outcome | 2003 |
Effects of subthalamic nucleus stimulation and levodopa treatment on gait abnormalities in Parkinson disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2003 |
Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 2002 |
Combination of two different dopamine agonists in the management of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2002 |
Bilateral subthalamic stimulation effects on oral force control in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement; Neurosurgical Procedures; Parkinson Disease; Psychomotor Performance; Reaction Time; Speech Articulation Tests; Subthalamic Nucleus | 2003 |
Executive function differences in multiple system atrophy and Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Color Perception; Disease Progression; Female; Humans; Levodopa; Male; Memory; Middle Aged; Multiple System Atrophy; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Verbal Behavior | 2003 |
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Supine Position | 2003 |
Pramipexole in comparison to l-dopa: a neuropsychological study.
Topics: Aged; Analysis of Variance; Benzothiazoles; Cognition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Topics: Aged; Catechols; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2003 |
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piribedil; Treatment Outcome | 2003 |
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Pyridoxal Phosphate; Risk Factors; Vitamin B 12; Vitamin B Complex | 2003 |
Effect of chronic bilateral subthalamic nucleus (STN) stimulation on postural control in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Electric Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Sensation Disorders; Subthalamic Nucleus; Tilt-Table Test | 2003 |
Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Smooth; Parkinson Disease; Severity of Illness Index; Time Factors; Urethra; Urinary Bladder; Urinary Incontinence; Urination Disorders; Urodynamics | 2003 |
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor | 2003 |
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Double-Blind Method; Drug Administration Routes; Drug Tolerance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2003 |
Effects of levodopa on motor sequence learning in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Cognition; Dopamine Agents; Female; Humans; Learning; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tomography, Emission-Computed | 2003 |
Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Receptors, Dopamine; Regional Blood Flow; Severity of Illness Index; Tomography, Emission-Computed; Treatment Outcome | 2003 |
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pergolide; Placebos; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome | 2003 |
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Topics: Adult; Aged; Brain; Caudate Nucleus; Corpus Striatum; Disease Progression; Dopamine; Dopamine Agonists; Double-Blind Method; Female; Fluorine Radioisotopes; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Putamen; Receptors, Dopamine D2; Severity of Illness Index; Substantia Nigra; Tomography, Emission-Computed | 2003 |
Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Association Learning; Cognition; Discrimination Learning; Dopamine Agents; Drug Administration Schedule; Humans; Levodopa; Matched-Pair Analysis; Memory; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Space Perception | 2003 |
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Attention; Choice Behavior; Cognition; Decision Making; Drug Administration Schedule; Female; Humans; Impulsive Behavior; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Parkinson Disease; Psychomotor Performance | 2003 |
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Nitriles; Parkinson Disease | 2003 |
An automatic dose dispenser for microtablets--a new concept for individual dosage of drugs in tablet form.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets; Technology, Pharmaceutical | 2003 |
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome | 2003 |
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome | 2003 |
Effects of levodopa on upper limb mobility and gait in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Fingers; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Treatment Outcome | 2003 |
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Combinations; Fatigue; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Muscle Contraction; Parkinson Disease; Psychomotor Performance; Regression Analysis; Surveys and Questionnaires; Time Factors | 2003 |
Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements.
Topics: Antiparkinson Agents; Arm; Dyskinesias; Electric Stimulation Therapy; Fingers; Hand Strength; Humans; Levodopa; Movement; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2003 |
Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate | 2003 |
L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
Topics: Aged; Antiparkinson Agents; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Reaction Time; Selegiline | 2003 |
Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation?
Topics: Brain; Brain Tissue Transplantation; Disease Progression; Dopamine; Double-Blind Method; Embryo, Mammalian; Fetal Tissue Transplantation; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Stem Cell Transplantation; Tomography, Emission-Computed; Transplants; Treatment Outcome | 2003 |
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Hong Kong; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Software Design; Taiwan; Thiazoles; Treatment Outcome | 2003 |
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Topics: Administration, Oral; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Satisfaction; Reference Values; Selegiline; Treatment Outcome; Tyramine | 2003 |
Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
Topics: Adult; Aged; Asian People; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piribedil; Prospective Studies; Statistics, Nonparametric | 2003 |
[Clinical observation on the efficacy enhancing and toxicity attenuating effect of nuzhen yangyin granule to the anti-parkinsonism therapy mainly with Medopa].
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy | 2003 |
Effect of L-Dopa on the pattern of movement-related (de)synchronisation in advanced Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Beta Rhythm; Biomechanical Phenomena; Cortical Synchronization; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 2003 |
[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Piribedil; Placebos; Time Factors; Treatment Outcome | 2003 |
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Topics: Aged; Amantadine; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2004 |
Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate | 2004 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Delusions; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate | 2004 |
Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Netherlands; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Subthalamic Nucleus; Treatment Outcome | 2004 |
The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbazoles; Diarrhea; Double-Blind Method; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Protein Kinase Inhibitors; Treatment Outcome | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Topics: Aged; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method | 2004 |
Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
Topics: Aged; Antiparkinson Agents; Clozapine; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Serotonin Receptor Agonists; Treatment Outcome | 2004 |
Further experience with extradural motor cortex stimulation for treatment of advanced Parkinson's disease. Report of 3 new cases.
Topics: Aged; Deglutition Disorders; Dura Mater; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Electrodes, Implanted; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Cortex; Muscle Rigidity; Parkinson Disease; Treatment Outcome; Tremor | 2003 |
Comparison between subthalamic nucleus and globus pallidus internus stimulation for postural performance in Parkinson's disease.
Topics: Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Postural Balance; Posture; Subthalamic Nucleus | 2004 |
Cardiovascular effects of methamphetamine in Parkinson's disease patients.
Topics: Adrenergic Fibers; Analysis of Variance; Blood Pressure; Brain; Catecholamines; Dopamine Agents; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Injections, Intravenous; Levodopa; Male; Methamphetamine; Middle Aged; Myocardium; Parkinson Disease; Presynaptic Terminals; Psychomotor Agitation; Tomography, Emission-Computed | 2004 |
The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, sigma; Severity of Illness Index; Tomography, Emission-Computed | 2004 |
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.
Topics: Aged; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Feasibility Studies; Female; Follow-Up Studies; GABA Antagonists; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Psychoses, Substance-Induced | 2004 |
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease; Videotape Recording | 2004 |
The dopamine transporter: importance in Parkinson's disease.
Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Routes; Drug Synergism; Dyskinesias; Emotions; Female; Heart Rate; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Middle Aged; Motor Activity; Nerve Tissue Proteins; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Time Factors; Walking | 2004 |
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hemodynamics; Humans; Levodopa; Male; Middle Aged; Nitriles; Norepinephrine; Oxygen Consumption; Parkinson Disease; Pulmonary Gas Exchange; Respiratory Mechanics | 2002 |
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Biological Availability; Dihydroxyphenylalanine; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Tyrosine | 2004 |
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transplantation; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Female; Ganglia, Sympathetic; Graft Survival; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine; Transplantation, Heterologous; Tyrosine 3-Monooxygenase; Up-Regulation; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |
Ropinirole versus levodopa in Parkinson's disease.
Topics: Adult; Aged; Double-Blind Method; Humans; Indoles; Internationality; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Tomography, Emission-Computed | 2004 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2004 |
A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
Topics: Algorithms; Antiparkinson Agents; Canada; Dihydroxyphenylalanine; Dopamine Agents; France; Germany; Humans; Image Interpretation, Computer-Assisted; Indoles; Levodopa; Parkinson Disease; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome; United Kingdom | 2004 |
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Apoptosis; Caspase 3; Caspases; Cell Survival; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System; Proto-Oncogene Proteins c-bcl-2; Receptors, GABA-A; Superoxide Dismutase | 2004 |
Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
Topics: Adolescent; Aged; Caudate Nucleus; Dihydroergocryptine; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neostriatum; Nerve Tissue Proteins; Parkinson Disease; Putamen; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes | 2004 |
Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2004 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Topics: Aged; Benzothiazoles; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Thiazoles | 2004 |
Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Blood-Brain Barrier; Body Fluid Compartments; Brain; Cerebellum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Drug Synergism; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Presynaptic Terminals; Putamen; Reference Values; Tomography, Emission-Computed | 2004 |
Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Area Under Curve; Drug Therapy, Combination; Emulsions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 2004 |
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Double-Blind Method; Electromagnetic Phenomena; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric | 2004 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Topics: Antiparkinson Agents; Apomorphine; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease | 2004 |
Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2004 |
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2004 |
Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sex Characteristics; Surveys and Questionnaires; Urinary Bladder Diseases; Urination Disorders; Urodynamics; Urologic Diseases | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder.
Topics: Aged; Ankle Joint; Antiparkinson Agents; Biomechanical Phenomena; Cues; Female; Gait Disorders, Neurologic; Hip; Humans; Knee; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2005 |
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Prospective Studies; Self-Assessment; Statistics, Nonparametric | 2005 |
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Catechols; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Levodopa; Linear Models; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Disability Evaluation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Female; Human Growth Hormone; Humans; Hydrocortisone; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2004 |
Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Disease Progression; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome | 2004 |
Levodopa effect upon functional balance of Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postural Balance; Posture; Tremor | 2004 |
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome | 2004 |
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.
Topics: Aged; Antiparkinson Agents; Cannabis; Cross-Over Studies; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plant Extracts | 2004 |
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
Topics: Aged; Antiparkinson Agents; Cognition; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance | 2004 |
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 2004 |
Effects of bilateral subthalamic stimulation on gait kinematics and kinetics in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Deep Brain Stimulation; Electrodes, Implanted; Female; Functional Laterality; Gait; Gait Disorders, Neurologic; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Range of Motion, Articular; Recovery of Function; Subthalamic Nucleus; Treatment Outcome | 2005 |
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 2005 |
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease; Phytotherapy; Placebos; Plant Preparations; Seeds; Severity of Illness Index; Treatment Outcome | 2004 |
Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered.
Topics: Absorption; Administration, Oral; Antiparkinson Agents; Circadian Rhythm; Female; Humans; Levodopa; Male; Parkinson Disease | 2004 |
Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dihydroergocryptine; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Posture; Psychomotor Performance; Speech Disorders; Tremor | 2004 |
Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
Topics: Aged; Autonomic Nervous System Diseases; Baroreflex; Blood Pressure; Catecholamines; Female; Heart Function Tests; Heart Rate; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Supine Position; Time | 2004 |
The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cognition; Conditioning, Operant; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Serial Learning | 2005 |
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2004 |
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Quality of Life | 2005 |
Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
Topics: Aged; Analysis of Variance; Cognition Disorders; Depression; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Statistics, Nonparametric | 2005 |
Parkinsonism associated with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neurocysticercosis; Parkinson Disease | 2005 |
The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Pulse; Rest; Selegiline; Supine Position | 2005 |
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Suspensions; Videotape Recording | 2005 |
Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Polysomnography; Prospective Studies; Sleep Stages; Sleep Wake Disorders | 2005 |
Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque.
Topics: Action Potentials; Adolescent; Adult; Aged; Animals; Antiparkinson Agents; Dystonia; Electromyography; Female; Globus Pallidus; Humans; Levodopa; Macaca; Male; Middle Aged; Neurons; Parkinson Disease; Severity of Illness Index; Time Factors | 2005 |
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Topics: Aged; Aged, 80 and over; Anorexia; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting; Weight Loss | 2005 |
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
Topics: Aged; Analysis of Variance; Attention; Cognition; Dopamine; Dopamine Agents; Humans; Levodopa; Matched-Pair Analysis; Memory, Short-Term; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Set, Psychology | 2005 |
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12 | 2005 |
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase; Drug Interactions; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pharmacogenetics; Polymorphism, Genetic; Reaction Time | 2005 |
A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Satisfaction; Surveys and Questionnaires; Tablets | 2005 |
Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Cohort Studies; Dyskinesia, Drug-Induced; Female; Human Development; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Smoking; Time Factors | 2005 |
Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease.
Topics: Adult; Aged; Beta Rhythm; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time; Signal Processing, Computer-Assisted; Statistics as Topic; Subthalamic Nucleus | 2005 |
Memory for time intervals is impaired in left hemi-Parkinson patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Memory Disorders; Middle Aged; Parkinson Disease; Task Performance and Analysis; Time Factors | 2005 |
Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Hypokinesia; Intraoperative Complications; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Pilot Projects; Postoperative Complications; Subthalamic Nucleus; Treatment Outcome; Tremor | 2005 |
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cohort Studies; DNA Mutational Analysis; DNA Repeat Expansion; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Levodopa; Male; Multivariate Analysis; Parkinson Disease; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Dopamine D2; Sex Characteristics | 2005 |
Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piribedil | 2004 |
Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Deep Brain Stimulation; Follow-Up Studies; Functional Laterality; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Psychomotor Performance; Statistics, Nonparametric; Treatment Outcome | 2005 |
Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
Topics: Age Factors; Aged; Antiparkinson Agents; Brain; Circadian Rhythm; Constipation; Dizziness; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Pergolide; Placebos; Sex Factors; Sleep; Sleep Wake Disorders; Treatment Outcome | 2005 |
Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Chi-Square Distribution; Combined Modality Therapy; Disability Evaluation; Electric Stimulation Therapy; Female; Follow-Up Studies; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2005 |
The beneficial effects of subthalamic nucleus stimulation on manipulative finger force control in Parkinson's disease.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Deep Brain Stimulation; Female; Fingers; Hand Strength; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Subthalamic Nucleus; Weight Lifting | 2005 |
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Functional Laterality; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Periodicity; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Transcranial Magnetic Stimulation | 2005 |
Short-term paroxetine treatment does not alter the motor response to levodopa in PD.
Topics: Accidental Falls; Aged; Brain; Cross-Over Studies; Dizziness; Dopamine; Dopamine Agents; Double-Blind Method; Drug Interactions; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Paroxetine; Presynaptic Terminals; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Failure; Vestibular Diseases | 2005 |
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2005 |
Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Gait; Humans; Leg; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Posture; Recovery of Function; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2006 |
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechol O-Methyltransferase; Cross-Over Studies; Dopa Decarboxylase; Dose-Response Relationship, Drug; Female; Genetic Variation; Genotype; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Polymorphism, Genetic; Prospective Studies; Psychomotor Performance; Pyridoxine; Treatment Outcome; Vitamin B Complex | 2005 |
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2005 |
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2005 |
Extradural motor cortex stimulation (EMCS) for Parkinson's disease. History and first results by the study group of the Italian neurosurgical society.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Comorbidity; Deep Brain Stimulation; Dura Mater; Electrodes, Implanted; Female; Humans; Italy; Levodopa; Male; Middle Aged; Motor Cortex; Movement Disorders; Parkinson Disease; Pilot Projects; Prognosis; Recovery of Function; Risk Assessment; Treatment Outcome | 2005 |
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Cocaine; Corpus Striatum; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
Topics: Aged; Antiparkinson Agents; Erectile Dysfunction; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Prolactin; Prospective Studies; Sexual Dysfunction, Physiological | 2005 |
[Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Germany; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Product Surveillance, Postmarketing; Treatment Outcome | 2005 |
Pathological gambling caused by drugs used to treat Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Review Literature as Topic | 2005 |
Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Electric Stimulation; Electromyography; Electrophysiology; Face; Female; Head Movements; Humans; Levodopa; Linear Models; Male; Middle Aged; Muscle, Skeletal; Pain; Parkinson Disease; Reaction Time; Reflex | 2005 |
Neither simple nor sequential arm movements are bradykinetic in parkinsonian patients with peak-dose dyskinesias.
Topics: Aged; Antiparkinson Agents; Arm; Biomechanical Phenomena; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 2005 |
Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Cerebral Cortex; Cerebrovascular Circulation; Humans; Levodopa; Middle Aged; Pain; Pain Clinics; Pain Measurement; Pain Threshold; Parkinson Disease; Positron-Emission Tomography | 2005 |
PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Female; Fluorodeoxyglucose F18; Glucose; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Tissue Distribution | 2005 |
Movement-related frequency modulation of beta oscillatory activity in the human subthalamic nucleus.
Topics: Adult; Aged; Beta Rhythm; Dopamine Agents; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2005 |
The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Artifacts; Brain; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Female; Humans; Image Enhancement; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Placebos; Treatment Outcome | 2005 |
Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT.
Topics: Antiparasitic Agents; Brain; Brain Mapping; Cerebrovascular Circulation; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Nerve Net; Parkinson Disease; Recovery of Function; Thalamus; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Topics: Adult; Age of Onset; Aged; Brain; Dopamine Agonists; Double-Blind Method; Dyskinesias; Early Diagnosis; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Prospective Studies; Radionuclide Imaging; Surveys and Questionnaires | 2006 |
Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.
Topics: Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Levodopa; Linear Models; Lipid Peroxidation; Neurotransmitter Agents; Oxidative Stress; Parkinson Disease; Plasma; Spectrometry, Fluorescence | 2006 |
Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzamides; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Levodopa; Morpholines; Parkinson Disease; Positron-Emission Tomography; Receptors, Serotonin, 5-HT4; Serotonin Receptor Agonists; Stomach | 2005 |
Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance.
Topics: Activities of Daily Living; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Reaction Time; Retrospective Studies; Subthalamic Nucleus; Task Performance and Analysis | 2006 |
Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Postoperative Complications; Prospective Studies; Recovery of Function; Risk Assessment; Substantia Nigra; Subthalamic Nucleus; Treatment Outcome | 2006 |
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Dopamine Agents; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Models, Biological; Motor Activity; Parkinson Disease; Time Factors | 2005 |
Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Double-Blind Method; Female; Health Expenditures; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Prospective Studies; Reproducibility of Results; Sex Factors; Thiazoles; Time Factors; Treatment Outcome | 2005 |
Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease.
Topics: Antiparkinson Agents; Cells, Cultured; Cerebral Hemorrhage; Corpus Striatum; Depressive Disorder; Gelatin; Graft Survival; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Pigment Epithelium of Eye; Pilot Projects; Postoperative Complications; Putamen; Recovery of Function; Stereotaxic Techniques; Treatment Outcome | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Dopamine-dependent non-linear correlation between subthalamic rhythms in Parkinson's disease.
Topics: Adult; Basal Ganglia; Beta Rhythm; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Nonlinear Dynamics; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2006 |
Quantitative study of salivary secretion in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Domperidone; Dopamine Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rest; Salivation; Secretory Rate | 2006 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease.
Topics: Adult; Aged; Cognition; Deep Brain Stimulation; Emotions; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Quality of Life; Treatment Outcome | 2006 |
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Topics: Aged; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Prodrugs; Reaction Time; Treatment Outcome | 2006 |
Selegiline slows the progression of the symptoms of Parkinson disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors | 2006 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Tyrosine | 2006 |
Laboratory and clinical investigations of the region of the rostral brainstem in motor control.
Topics: Animals; Antiparkinson Agents; Bicuculline; Deep Brain Stimulation; Dose-Response Relationship, Radiation; Female; GABA Antagonists; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Retrospective Studies | 2006 |
Levodopa availability improves with progression of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors | 2006 |
Quality of life in Parkinson's disease--Indian scenario.
Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; India; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome | 2006 |
Verbal and visual memory in patients with early Parkinson's disease: effect of levodopa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Child; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Activity; Parkinson Disease; Patient Selection; Speech; Visual Perception | 2006 |
The influence of dopamine on semantic activation in Parkinson's disease: evidence from a multipriming task.
Topics: Aged; Case-Control Studies; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Paired-Associate Learning; Parkinson Disease; Reaction Time; Semantics; Time Factors | 2006 |
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation.
Topics: Adult; Aged; Antiparkinson Agents; Awareness; Combined Modality Therapy; Deep Brain Stimulation; Dominance, Cerebral; Dopamine Agonists; Double-Blind Method; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Placebo Effect; Set, Psychology; Subthalamic Nucleus | 2006 |
Dopamine agonist therapy for Parkinson disease and pathological gambling.
Topics: Carbidopa; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Male; MEDLINE; Middle Aged; Parkinson Disease; Retrospective Studies | 2006 |
Functional imaging of sequence learning in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Cerebral Cortex; Deep Brain Stimulation; Dopamine Plasma Membrane Transport Proteins; Female; Functional Laterality; Humans; Learning; Levodopa; Longitudinal Studies; Male; Middle Aged; Nerve Net; Neuropsychological Tests; Oxygen Radioisotopes; Parkinson Disease; Positron-Emission Tomography | 2006 |
Levodopa induced motor complications in Thai Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Thailand | 2006 |
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Prospective Studies; S-Adenosylhomocysteine; Tolcapone | 2006 |
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome | 2006 |
Prospective prevalence of pathologic gambling and medication association in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Ontario; Parkinson Disease; Prevalence; Prospective Studies; Risk Assessment; Risk Factors | 2006 |
Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Cross-Over Studies; Diet, Protein-Restricted; Drug Therapy, Combination; Female; Food-Drug Interactions; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Satisfaction; Pilot Projects; Postprandial Period; Single-Blind Method | 2006 |
Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Threonine; Time Factors | 2006 |
Comparative evaluation of the effects of unilateral lesion versus electrical stimulation of the globus pallidus internus in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Deep Brain Stimulation; Functional Laterality; Globus Pallidus; Humans; Levodopa; Monitoring, Intraoperative; Parkinson Disease; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
The efficacy of quantitative gait analysis by the GAITRite system in evaluation of parkinsonian bradykinesia.
Topics: Adult; Antiparkinson Agents; Diagnosis, Computer-Assisted; Disability Evaluation; Gait; Humans; Hypokinesia; Levodopa; Middle Aged; Parkinson Disease | 2006 |
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Topics: Aged; Antiparkinson Agents; Canada; Catechols; Double-Blind Method; Drug Combinations; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Placebo Effect; Treatment Outcome; United States; Vitamin B 12; Vitamins | 2006 |
Distinguishing early-onset PD from dopa-responsive dystonia with transcranial sonography.
Topics: Adult; Age of Onset; Antiparkinson Agents; Diagnosis, Differential; Dystonia; Female; Humans; In Vitro Techniques; Levodopa; Middle Aged; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Doppler, Transcranial | 2006 |
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Topics: Aged; Behavioral Symptoms; Case-Control Studies; Cognition; Dopamine Agents; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease | 2006 |
Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2006 |
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nucleus Accumbens; Oxygen; Parkinson Disease; Prefrontal Cortex; Reversal Learning | 2007 |
Network modulation in the treatment of Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Cerebellum; Deep Brain Stimulation; Female; Fluorodeoxyglucose F18; Globus Pallidus; Glucose; Humans; Levodopa; Linear Models; Male; Middle Aged; Motor Cortex; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Putamen; Subthalamic Nucleus; Treatment Outcome | 2006 |
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Food-Drug Interactions; Heart Rate; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Tyramine | 2006 |
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome | 2006 |
Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2006 |
Clinical features and gene analysis in Korean patients with early-onset Parkinson disease.
Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Female; Humans; Korea; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Protein Kinases; Ubiquitin-Protein Ligases | 2006 |
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2006 |
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Down-Regulation; Enzyme Inhibitors; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Raphe Nuclei; Serotonin; Tyrosine | 2007 |
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Weight Loss | 2006 |
The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Attention; Dopamine; Female; Humans; Learning; Levodopa; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2006 |
Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Attention; Cognition; Cognition Disorders; Female; Humans; Levodopa; Lewy Body Disease; Male; Motor Skills; Parkinson Disease; Treatment Outcome | 2006 |
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
Topics: Antiparkinson Agents; Confidence Intervals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Longitudinal Studies; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Survival Analysis | 2006 |
Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piribedil; Severity of Illness Index; Single-Blind Method; Time Factors | 2006 |
Cortical muscle coupling in Parkinson's disease (PD) bradykinesia.
Topics: Antiparkinson Agents; Data Collection; Electroencephalography; Electromyography; Humans; Hypokinesia; Levodopa; Motor Cortex; Muscle, Skeletal; Parkinson Disease; Psychomotor Performance | 2006 |
Longitudinal study of the motor response to levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease | 2006 |
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pilot Projects; Treatment Outcome | 2006 |
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Topics: Absenteeism; Antiparkinson Agents; Catechols; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Employment; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Self Concept | 2006 |
Immediate placebo effect in Parkinson's disease--is the subjective relief accompanied by objective improvement?
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Placebo Effect; Placebos; Reaction Time; Transcranial Magnetic Stimulation | 2006 |
[Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2006 |
Extradural motor cortex stimulation in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electric Stimulation; Female; Humans; Levodopa; Male; Motor Cortex; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2007 |
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2007 |
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiparkinson Agents; Aspartate Aminotransferases; Benzophenones; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2007 |
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
Topics: Adult; Benzimidazoles; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2007 |
Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
Topics: Administration, Oral; Affect; Aged; Antiparkinson Agents; Anxiety; Case-Control Studies; Cross-Over Studies; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Time Factors | 2007 |
The speed of lexical activation is altered in Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Case-Control Studies; Comprehension; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Paired-Associate Learning; Parkinson Disease; Reaction Time; Semantics; Time Factors | 2007 |
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Prospective Studies; Retrospective Studies | 2006 |
Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Contraindications; Deep Brain Stimulation; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Predictive Value of Tests; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2007 |
Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cognition; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Statistics, Nonparametric; Vitamin B 12 | 2006 |
[Levodopa modifies pain thresholds in Parkinson's disease patients].
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Pain Threshold; Parkinson Disease | 2007 |
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
Topics: Antiparkinson Agents; Cohort Studies; Computer Simulation; Disease Progression; Follow-Up Studies; Humans; Levodopa; Models, Biological; Parkinson Disease; Predictive Value of Tests; Reproducibility of Results; Research Design; Time Factors; Treatment Outcome | 2007 |
Tremor reduction by subthalamic nucleus stimulation and medication in advanced Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Subthalamic Nucleus; Tremor | 2007 |
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Time Perception; Tremor; Walking | 2007 |
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Early Diagnosis; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Time; Time Factors; Treatment Outcome | 2007 |
[Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Topics: Aged; Ambulatory Care; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatient Clinics, Hospital; Parkinson Disease; Prospective Studies; Subcutaneous Tissue; Telephone | 2007 |
Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Administration Routes; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular Physiological Phenomena; Deep Brain Stimulation; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome; Vasoconstriction | 2007 |
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Polypharmacy; Selegiline; Tablets; Time Factors; Treatment Outcome | 2007 |
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Statistics, Nonparametric; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2007 |
Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Electric Stimulation; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors; Transcranial Magnetic Stimulation | 2007 |
Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
Topics: Acute Disease; Carbidopa; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypogastric Plexus; Levodopa; Male; Middle Aged; Parasympathetic Fibers, Postganglionic; Parkinson Disease; Synaptic Transmission; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urination Disorders | 2007 |
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Topics: Adult; Aged; Antioxidants; Cell Respiration; Coenzymes; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Energy Metabolism; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Placebos; Substantia Nigra; Treatment Outcome; Ubiquinone; Vitamins | 2007 |
Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Threshold; Parkinson Disease | 2007 |
Treatment with levodopa and risk for malignant melanoma.
Topics: Antiparkinson Agents; Case-Control Studies; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Melanoma; Odds Ratio; Parkinson Disease; Retrospective Studies; Risk | 2007 |
Impact of pramipexole on the onset of levodopa-related dyskinesias.
Topics: Aged; Akathisia, Drug-Induced; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Probability | 2007 |
Comment on Shpirer et al. ("Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnographic study").
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Polysomnography; Reaction Time; Statistics, Nonparametric | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2007 |
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Folic Acid; Humans; Immunoassay; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2007 |
Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Catecholamines; Creatinine; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Metanephrine; Middle Aged; Norepinephrine; Normetanephrine; Parkinson Disease; Pheochromocytoma | 2007 |
Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Case-Control Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Mobility Limitation; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2007 |
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
Topics: Adult; Age Distribution; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cohort Studies; Comorbidity; Disorders of Excessive Somnolence; Double-Blind Method; Edema; Female; Hallucinations; Heart Diseases; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Risk Factors; Sex Distribution | 2007 |
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients.
Topics: Adult; Aged; Antiparkinson Agents; Cohort Studies; Combined Modality Therapy; Deep Brain Stimulation; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Radiography; Severity of Illness Index; Subthalamic Nucleus | 2007 |
Motor intracortical inhibition in PD: L-DOPA modulation of high-frequency rTMS effects.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Neural Inhibition; Parkinson Disease; Transcranial Magnetic Stimulation | 2008 |
Locomotor response to levodopa in fluctuating Parkinson's disease.
Topics: Administration, Oral; Age of Onset; Aged; Antiparkinson Agents; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Reaction Time; Severity of Illness Index | 2008 |
[Clinical observation on abdominal acupuncture plus Madopa for treatment of Parkinson's disease].
Topics: Abdomen; Acupuncture Therapy; Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
L-tryptophan in the treatment of levodopa induced psychiatric disorders.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Serotonin; Single-Blind Method; Treatment Outcome; Tryptophan | 1974 |
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2007 |
A controlled trial of an educational programme for people with Parkinson's disease.
Topics: Aged; Ambulatory Care Facilities; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Education as Topic; Sweden | 2007 |
[Clinical trial on treatment of Parkinson's disease of Gan-Shen yin deficiency type by recipe for nourishing Gan-Shen].
Topics: Aged; Diagnosis, Differential; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Medicine, Chinese Traditional; Middle Aged; Parkinson Disease; Phytotherapy; Treatment Outcome; Yin Deficiency | 2007 |
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Medicine, Chinese Traditional; Middle Aged; Parkinson Disease; Phytotherapy; Prospective Studies; Syndrome; Treatment Outcome | 2007 |
Effect of L-dopa and subthalamic nucleus stimulation on arm and leg swing during gait in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Arm; Deep Brain Stimulation; Gait; Humans; Leg; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2007 |
Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Task Performance and Analysis; Treatment Outcome | 2008 |
Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Topics: Affect; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Vitamin B 12 | 2008 |
Neurophysiologic study of central pain in patients with Parkinson disease.
Topics: Activities of Daily Living; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinson Disease; Reaction Time | 2007 |
Effects of Parkinson's disease and levodopa on functional limits of stability.
Topics: Aged; Biomechanical Phenomena; Case-Control Studies; Gravitation; Humans; Kinesthesis; Levodopa; Middle Aged; Motor Skills; Movement; Parkinson Disease; Postural Balance; Posture; Pressure | 2008 |
Should levodopa dose be reduced when switched to stalevo?
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2008 |
Oscillatory activity in the pedunculopontine area of patients with Parkinson's disease.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Electroencephalography; Female; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Psychomotor Performance | 2008 |
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Nitriles; Parkinson Disease; Severity of Illness Index | 2008 |
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Topics: Adult; Aged; Antiemetics; Antiparkinson Agents; Benserazide; Domperidone; Drug Administration Schedule; Exercise Test; Exercise Therapy; Exercise Tolerance; Hand Strength; Humans; Hydrocortisone; Levodopa; Middle Aged; Muscle Strength; Parkinson Disease; Physical Endurance; Physical Fitness; Stress, Physiological; Treatment Outcome | 2008 |
Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
Topics: Aged; Analysis of Variance; Carbidopa; Dopamine Agents; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 2009 |
[The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Topics: Activities of Daily Living; Aged; Ambulatory Care Facilities; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
Auditory temporal processing in Parkinson's disease.
Topics: Acoustic Stimulation; Adult; Aged; Antiparkinson Agents; Audiometry; Auditory Perception; Auditory Threshold; Discrimination, Psychological; Electric Stimulation Therapy; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Task Performance and Analysis; Temporal Lobe; Time Perception; Treatment Outcome | 2008 |
Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Brazil; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Dietary Supplements; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Levodopa; Male; Middle Aged; Mineral Oil; Parkinson Disease; Personality Inventory; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Treatment Outcome | 2008 |
Levodopa reduces risk factors for vascular disease in parkinsonian patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Blood Glucose; Blood Pressure; Cholesterol; Female; Humans; Levodopa; Lipid Metabolism; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Vascular Diseases | 2008 |
Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonist.
Topics: Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Drug Synergism; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease; Receptors, Cell Surface; Receptors, GABA-A | 1984 |
Deprenyl in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1981 |
Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
Topics: Adult; Aged; Antiparkinson Agents; Bulbar Palsy, Progressive; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Placebos | 1983 |
On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
Topics: Aged; Ascorbic Acid; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1983 |
A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
Topics: Clinical Trials as Topic; Disability Evaluation; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide; Sleep; Time Factors | 1983 |
Comparison of pergolide and bromocriptine therapy in parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1983 |
Tiapride in levodopa-induced involuntary movements.
Topics: Aged; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Tiapamil Hydrochloride | 1983 |
A new selective suicide inhibitor of peripheral DOPA decarboxylase.
Topics: Aged; Antiparkinson Agents; Brain Diseases; Carboxy-Lyases; Clinical Trials as Topic; Electroencephalography; Female; Humans; Hyperbilirubinemia; Hypertension; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Topics: Aged; Benserazide; Bromocriptine; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Random Allocation; Time Factors | 1984 |
Dyskinesias associated with lithium therapy in parkinsonism.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Random Allocation | 1984 |
[Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Topics: Aged; Carboxy-Lyases; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Pergolide in late-stage Parkinson disease.
Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Sleep Wake Disorders | 1982 |
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
Topics: Aged; Biotransformation; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1980 |
Levodopa dosage and ventilatory function in Parkinson's disease.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration; Respiratory Function Tests | 1981 |
Prolactin secretion in Parkinson disease.
Topics: Adult; Aged; Blood-Brain Barrier; Bromocriptine; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Hypothalamus, Anterior; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Placebos; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone | 1981 |
Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients.
Topics: Aged; Clinical Trials as Topic; Dopamine; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Myoclonus; Parkinson Disease; Scleroderma, Systemic; Serotonin | 1980 |
[Evaluation of combined L-dopa-cyproheptadine therapy of patients with Parkinson's disease].
Topics: Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1980 |
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA.
Topics: Aged; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nortriptyline; Parkinson Disease | 1980 |
[The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
Topics: Adult; Amantadine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Assessment of hypokinesia in Parkinsonism.
Topics: Adult; Aged; Bromocriptine; Clinical Trials as Topic; Ergolines; Humans; Levodopa; Lisuride; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Placebos; Posture; Time Factors | 1981 |
Recent advances in the treatment of Parkinson's disease: the role of bromocriptine.
Topics: Bromocriptine; Carbidopa; Clinical Trials as Topic; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1981 |
Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1981 |
The effect of bromocriptine (BCT) on the on-off phenomenon.
Topics: Bromocriptine; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease | 1981 |
Weekly drug holiday in Parkinson disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Lisuride combined with levodopa in advanced Parkinson disease.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1981 |
Absorption of levodopa after rectal administration.
Topics: Absorption; Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rectum | 1981 |
Bromocriptine and domperidone in the treatment of Parkinson disease.
Topics: Benzimidazoles; Bromocriptine; Domperidone; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Piperidines; Vomiting | 1981 |
Bromocriptine: low-dose therapy in Parkinson disease.
Topics: Aged; Bromocriptine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tremor | 1982 |
Parkinson's disease: Cogentin with Sinemet, a better response.
Topics: Aged; Antiparkinson Agents; Benztropine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Tropanes | 1982 |
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Topics: Amantadine; Amino Acids; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Piperidines | 1980 |
Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Effect of GPi pallidotomy on motor function in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Stereotaxic Techniques; Tremor; Videotape Recording | 1995 |
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Topics: Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1991 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
Topics: Aged; Antiparkinson Agents; Apomorphine; Biological Availability; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Exercise Test; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Suppositories; Treatment Outcome | 1995 |
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Parkinson Disease; Psychomotor Performance | 1995 |
Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Aspartic Acid; Carbidopa; Choline; Corpus Striatum; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Spectroscopy; Male; Middle Aged; Parkinson Disease; Pilot Projects; Protons | 1995 |
Ventroposterolateral pallidotomy.
Topics: Adult; Aged; Drug Resistance; Globus Pallidus; Humans; Hypokinesia; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Thalamus | 1994 |
Long-term effects of medical and surgical treatments on Parkinson's disease.
Topics: Adrenal Medulla; Adult; Aged; Analysis of Variance; Caudate Nucleus; Cholinergic Antagonists; Combined Modality Therapy; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Thalamus | 1994 |
Hypothalamic dysfunction in Parkinson's disease patients.
Topics: Administration, Oral; Adult; Aged; Female; Growth Hormone; Humans; Hypothalamus; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Radioimmunoassay; Thyrotropin; Thyrotropin-Releasing Hormone | 1994 |
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
Topics: Aged; Drug Therapy, Combination; Female; Fluoxetine; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Pilot Projects; Prospective Studies; Treatment Outcome | 1995 |
Motor imagery of a lateralized sequential task is asymmetrically slowed in hemi-Parkinson's patients.
Topics: Adult; Basal Ganglia; Female; Fingers; Functional Laterality; Humans; Imagination; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Rotation | 1995 |
Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.
Topics: Affect; Aged; Anxiety; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes.
Topics: Adult; Aged; Butaclamol; Diagnosis, Differential; Double-Blind Method; Female; Humans; Kinetics; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Prospective Studies; Spiperone; Tremor | 1993 |
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1995 |
Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation.
Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1995 |
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
Topics: Adult; Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors; Selegiline; Sex Factors; Vitamin E | 1995 |
Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine.
Topics: Aged; Clozapine; Female; Humans; Levodopa; Male; Parkinson Disease; Psychoses, Substance-Induced | 1995 |
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials.
Topics: Aged; Electroretinography; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual | 1995 |
Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
Topics: Aged; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Random Allocation; Selegiline; Treatment Outcome | 1995 |
Usefulness of movement time in the assessment of Parkinson's disease.
Topics: Adult; Aged; Biperiden; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1994 |
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome | 1995 |
Auditory selective attention is impaired in Parkinson's disease--event-related evidence from EEG potentials.
Topics: Acoustic Stimulation; Adult; Aged; Attention; Electroencephalography; Electrooculography; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time | 1994 |
Changes in excitability of motor cortical circuitry in patients with Parkinson's disease.
Topics: Aged; Cerebral Cortex; Electromyography; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Neural Pathways; Parkinson Disease; Sensory Thresholds | 1995 |
Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Carbidopa; Citrate (si)-Synthase; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Multienzyme Complexes; NAD(P)H Dehydrogenase (Quinone); Oxidoreductases; Parkinson Disease; Plateletpheresis; Selegiline; Succinate Dehydrogenase | 1995 |
Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease.
Topics: Animals; Antibody Formation; Antibody-Dependent Cell Cytotoxicity; Brain Tissue Transplantation; Cell Line; Cyclosporine; Cytotoxicity, Immunologic; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Immunity, Cellular; Levodopa; Lymph Nodes; Mesencephalon; Parkinson Disease; Prednisone; Primates; Spleen; T-Lymphocytes, Cytotoxic; Time Factors; Transplantation, Homologous | 1995 |
Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the Clinica Puerta de Hierro experience. CPH Neural Transplantation Group.
Topics: Aged; Analysis of Variance; Brain Tissue Transplantation; Caudate Nucleus; Fetal Tissue Transplantation; Fetus; Follow-Up Studies; Gestational Age; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1995 |
Effect of cisapride on response fluctuations in Parkinson's disease.
Topics: Aged; Cisapride; Drug Therapy, Combination; Gastric Emptying; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Reaction Time | 1995 |
Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Clozapine; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1995 |
Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infant; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide; Single-Blind Method; Treatment Outcome | 1994 |
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease | 1994 |
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Solutions; Tablets; Therapeutic Equivalency | 1994 |
Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board.
Topics: Activities of Daily Living; Aged; Cost-Benefit Analysis; Health Promotion; Health Services; Humans; Levodopa; Parkinson Disease; Patient Compliance; Patient Education as Topic; Prognosis; Program Evaluation; Quality of Life; Severity of Illness Index; Treatment Outcome | 1994 |
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Piperidines | 1994 |
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
[Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Drug Synergism; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Nitriles; Occipital Lobe; Parkinson Disease; Tomography, Emission-Computed | 1994 |
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure | 1994 |
Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.
Topics: Aged; Albuterol; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Topics: Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies | 1994 |
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Topics: Adult; Brain; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Oxindoles; Parkinson Disease; Pyridines; Receptors, Dopamine | 1993 |
Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
Topics: Aged; Benzophenones; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 1993 |
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Dynorphin agonist therapy of Parkinson's disease.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dynorphins; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Pyrrolidines | 1993 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Hemodynamics; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Pulse; Respiration | 1993 |
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Topics: Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1994 |
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1994 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1994 |
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study.
Topics: Aged; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Buspirone in levodopa-induced dyskinesias.
Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids | 1994 |
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Topics: Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1994 |
A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1993 |
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Topics: Adult; Aged; Biological Availability; Catechol O-Methyltransferase Inhibitors; Catechols; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1994 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
Selegiline in de novo parkinsonian patients: the Finnish study.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Finland; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 1993 |
Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study.
Topics: Aged; Clozapine; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 1993 |
Progress note on Japanese multicenter bromocriptine monotherapy.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Japan; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease | 1993 |
Milacemide therapy for Parkinson's disease.
Topics: Acetamides; Aged; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Single-Blind Method; Synaptic Transmission | 1993 |
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Treatment Outcome | 1993 |
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Double-Blind Method; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets | 1993 |
Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine and lisuride infusion. A comparative chronic study.
Topics: Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Lisuride; Long-Term Care; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease | 1993 |
Broad bean (Vicia faba) consumption and Parkinson's disease.
Topics: Carbidopa; Fabaceae; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1993 |
Effects of selegiline dosing on motor fluctuations in Parkinson's disease.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Selegiline | 1993 |
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Bromocriptine; Chorea; Double-Blind Method; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1993 |
Apomorphine test for dopaminergic responsiveness: a dose assessment study.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
[L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
Topics: Bromocriptine; Drug Therapy, Combination; Dystonia; Female; Humans; Hyperkinesis; Levodopa; Male; Motor Activity; Parkinson Disease; Time Factors | 1993 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise.
Topics: Aged; Exercise; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion | 1993 |
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
Topics: Activity Cycles; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Solutions; Tablets | 1993 |
[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Neuropsychological characteristics of parkinsonian patients with lateralized motor impairment.
Topics: Aged; Antiparkinson Agents; Functional Laterality; Humans; Intelligence Tests; Levodopa; Male; Movement; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Speech | 1995 |
Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.
Topics: Adult; Aged; Aging; Antiparkinson Agents; Bromocriptine; Disease Progression; Female; Gait; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Psychomotor Performance; Tremor | 1995 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Maternal-Fetal Exchange; Parkinson Disease; Pregnancy; Tyrosine | 1995 |
Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians.
Topics: Blood Pressure; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Female; Fourier Analysis; Heart; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Supine Position | 1995 |
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1995 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure | 1995 |
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
Topics: Aged; Antiparkinson Agents; Biological Availability; Catechols; Cross-Over Studies; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Motor Activity; Nitriles; Parkinson Disease | 1996 |
Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.
Topics: Antiparkinson Agents; Electromagnetic Fields; Electromyography; Female; Humans; Jaw; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease.
Topics: Adrenocorticotropic Hormone; Humans; Levodopa; Luteinizing Hormone; Male; Middle Aged; Naloxone; Parkinson Disease | 1994 |
L-Dopa improves colour vision in Parkinson's disease.
Topics: Adult; Color Perception; Discrimination, Psychological; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Visual Acuity | 1994 |
[The use of the Sinemet-CR preparation in treating Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Higher Nervous Activity; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Shortened silent period produced by magnetic cortical stimulation in patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Cerebral Cortex; Dopamine; Electromyography; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Physical Stimulation; Reticular Formation | 1995 |
'Atypical' tremor.
Topics: Benserazide; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Combinations; Electromyography; Female; Humans; Infant; Levodopa; Male; Parkinson Disease; Propranolol; Tremor | 1995 |
Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Esters; Ethanol; Humans; Injections, Intramuscular; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease; Prodrugs; Time Factors | 1996 |
Parkinson's disease: progression and mortality in the L-DOPA era.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cause of Death; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Survival Analysis | 1996 |
Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy.
Topics: Aged; Antiparkinson Agents; Blood Vessels; Cerebrovascular Circulation; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Prognosis; Regional Blood Flow; Survival Analysis | 1996 |
The clinicopathologic spectrum of Lewy body disease.
Topics: Adolescent; Aged; Antiparkinson Agents; Brain; Dementia; Family; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Nervous System Diseases; Parkinson Disease | 1996 |
Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's disease and multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Atrophy; Contrast Sensitivity; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Motion Perception; Movement; Nervous System Diseases; Parkinson Disease; Space Perception; Time Perception; Vision, Monocular | 1996 |
Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia.
Topics: Adolescent; Adult; Age of Onset; Aged; Antiparkinson Agents; Biopterins; Child; Child, Preschool; Diagnosis, Differential; Dystonia; Female; Genetic Linkage; Humans; Levodopa; Male; Middle Aged; Neopterin; Parkinson Disease; Tremor | 1996 |
The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism.
Topics: Aged; Antiparkinson Agents; Atrophy; Autonomic Nervous System; Brain; Dopamine Agents; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Nervous System Diseases; Parkinson Disease; Prospective Studies; Retrospective Studies | 1996 |
Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Topics: Adult; Age of Onset; Aged; Aging; Antiparkinson Agents; Disease Progression; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1996 |
Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Contrast Sensitivity; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Space Perception; Time Perception | 1996 |
A study on the effect and tolerance of lisuride on Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Disease Progression; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Psychiatric Status Rating Scales | 1996 |
A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine D2 | 1996 |
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Delusions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Ondansetron; Parkinson Disease; Serotonin Antagonists | 1996 |
Does thalamotomy alter the course of Parkinson's disease?
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Thalamus; Treatment Outcome; Tremor | 1996 |
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Topics: Antiparkinson Agents; Benzamides; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease | 1996 |
Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Chromosome Mapping; Female; Genes, Dominant; Genetic Linkage; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Repetitive Sequences, Nucleic Acid | 1996 |
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Tolcapone | 1995 |
Single vs multiple daily dosing of aminoglycosides.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Treatment Outcome | 1996 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Adult; Antiparkinson Agents; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Propranolol; Prospective Studies; Treatment Outcome | 1996 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1996 |
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Treatment Outcome | 1996 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1996 |
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 1996 |
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Electrooculography; Event-Related Potentials, P300; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, X-Ray Computed | 1996 |
Bromocriptine therapy in early-stage Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Disease Progression; Drug Therapy, Combination; Evaluation Studies as Topic; Follow-Up Studies; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Time Factors; Treatment Outcome | 1996 |
Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester.
Topics: Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Circadian Rhythm; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects | 1996 |
Age at onset: the major determinant of outcome in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Postural Balance; Treatment Outcome; Tremor | 1995 |
Quantifying rigidity with a new computerized elbow device.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Elbow Joint; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Reproducibility of Results | 1996 |
Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Dihydroxyphenylalanine; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Patient Dropouts; Placebos; Treatment Outcome | 1996 |
Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone.
Topics: Antiparkinson Agents; Dopamine; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle Tonus; Muscle, Skeletal; Parkinson Disease; Posture; Psychomotor Performance | 1996 |
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Physical Exertion; Reproducibility of Results; Sensitivity and Specificity; Torque; Trihexyphenidyl | 1996 |
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Motor Skills; Neurologic Examination; Parkinson Disease; Therapeutic Equivalency | 1996 |
Computerised brain electrical activity findings of parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Dopamine Agonists; Electroencephalography; Humans; Hyperkinesis; Levodopa; Middle Aged; Nootropic Agents; Parkinson Disease; Signal Processing, Computer-Assisted; Treatment Outcome | 1995 |
Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
Topics: Antiparkinson Agents; Apomorphine; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Cognition Disorders; Dopamine; Dopamine Agents; Female; Frontal Lobe; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease | 1995 |
Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after L-dopa with positron emission tomography.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Hand; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Movement; Parkinson Disease; Rest; Tomography, Emission-Computed; Tremor | 1996 |
Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Denmark; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease | 1996 |
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Topics: Aged; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1996 |
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Neurons; Parkinson Disease; Prospective Studies; Time Factors | 1996 |
Sustained-release of levodopa: single dose study of a new formulation.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Anticholinergic therapy and dementia in patients with Parkinson's disease.
Topics: Adult; Aged; Cholinergic Antagonists; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricles; Combined Modality Therapy; Dopamine; Droxidopa; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Reference Values; Stereotaxic Techniques; Thalamus | 1996 |
Memory for spatial location is affected in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition; Humans; Learning; Levodopa; Memory; Mental Recall; Middle Aged; Neuropsychological Tests; Parkinson Disease; Space Perception; Verbal Learning | 1996 |
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Psychomotor Performance | 1996 |
Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Female; Humans; Hyperprolactinemia; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pituitary Function Tests; Pituitary Gland, Anterior; Pituitary Hormones, Anterior | 1996 |
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
Topics: Adult; Aged; Blood Pressure; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Placebos; Severity of Illness Index; Time Factors | 1996 |
A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine; Epinephrine; Female; Heart Rate; Human Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Peripheral Nervous System; Prolactin; Sensitivity and Specificity | 1996 |
Remoxipride in the treatment of levodopa-induced psychosis.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Psychoses, Substance-Induced; Remoxipride | 1996 |
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; International Cooperation; Levodopa; Middle Aged; Parkinson Disease | 1996 |
Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Area Under Curve; Drug Monitoring; Half-Life; Humans; Levodopa; Microdialysis; Parkinson Disease; Tyrosine | 1996 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method | 1996 |
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Topics: Aged; Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitrophenols; Parkinson Disease; Placebos; Tolcapone; Treatment Outcome | 1997 |
Stereospecific occurrence of a parkinsonism-inducing catechol isoquinoline, N-methyl(R)salsolinol, in the human intraventricular fluid.
Topics: Aged; Antiparkinson Agents; Body Fluids; Cerebral Ventricles; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Molecular Structure; Neurotoxins; Parkinson Disease; Stereoisomerism | 1996 |
Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Dihydropteridine Reductase; Enzyme Activation; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; NAD; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Prospective Studies; Severity of Illness Index; Tyrosine 3-Monooxygenase | 1996 |
[Levodopa loading test as an early marker of Parkinson's disease].
Topics: Acetaminophen; Aged; Biomarkers; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease | 1997 |
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Placebos; Prospective Studies | 1997 |
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Topics: Aged; Antiparkinson Agents; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
Topics: Analysis of Variance; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Reflex; Selegiline; Tilt-Table Test | 1997 |
Sympathetic vasoconstrictor reflexes in Parkinson's disease with autonomic dysfunction.
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System Diseases; Blood Pressure; Enzyme Inhibitors; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Reflex; Sympathetic Nervous System; Vasoconstriction | 1997 |
The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Denmark; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease; Selegiline | 1997 |
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
Topics: Activities of Daily Living; Adult; Aged; Antioxidants; Antiparkinson Agents; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome; Vitamin E | 1997 |
Cerebrospinal fluid carnitine levels in patients with Parkinson's disease.
Topics: Acylation; Aged; Antiparkinson Agents; Carnitine; Female; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Standards; Selegiline | 1997 |
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Patient Dropouts; Psychomotor Agitation | 1997 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Spatial and non-spatial working memory at different stages of Parkinson's disease.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Parkinson Disease; Space Perception; Verbal Behavior; Visual Perception | 1997 |
Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
Topics: Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Prospective Studies; Regression Analysis; Selegiline; Time Factors | 1997 |
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Anticonvulsants; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Lamotrigine; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Treatment Outcome; Triazines | 1997 |
Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. Clinica Puerta de Hierro Neural Transplantation Group.
Topics: Aged; Caudate Nucleus; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Mental Disorders; Mesencephalon; Middle Aged; Motor Activity; Parkinson Disease; Postoperative Complications; Postoperative Period; Time Factors; Treatment Outcome | 1997 |
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Topics: Antiparkinson Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Prospective Studies; Research Design; Selegiline; United Kingdom | 1997 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1997 |
The effects of pallidotomy on Parkinson's disease: study design and assessment techniques.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Complications; Single-Blind Method; Stereotaxic Techniques; Video Recording | 1997 |
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
Topics: Age of Onset; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plasma | 1997 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline | 1997 |
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.
Topics: Aged; Antipsychotic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Psychoses, Substance-Induced; Risperidone; Severity of Illness Index; Time Factors | 1997 |
Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue.
Topics: Aged; Corpus Striatum; Dose-Response Relationship, Drug; Female; Fetal Tissue Transplantation; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 1997 |
Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
Topics: Adult; Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dementia; Female; Homovanillic Acid; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Tyrosine | 1997 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1997 |
Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
Topics: Antiparkinson Agents; Benzophenones; Bromocriptine; Drug Therapy, Combination; Drug Tolerance; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzophenones; Diarrhea; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Sickness Impact Profile; Tolcapone; Treatment Outcome | 1997 |
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebos; Severity of Illness Index | 1997 |
Short- and long-duration responses to levodopa during the first year of levodopa therapy.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 1997 |
Postural tremor of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propranolol; Tremor | 1994 |
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Topics: Absorption; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies | 1994 |
Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effects.
Topics: Adult; Aged; Antiparkinson Agents; Exercise Test; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Physical Exertion | 1994 |
Characteristics of the electromyographic patterns of lower limb muscles during gait in patients with Parkinson's disease when OFF and ON L-Dopa treatment.
Topics: Adult; Aged; Antiparkinson Agents; Electromyography; Female; Gait; Humans; Leg; Levodopa; Male; Middle Aged; Movement; Muscle, Skeletal; Parkinson Disease | 1997 |
Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Individuality; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Time Factors | 1997 |
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone | 1997 |
Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Carbidopa; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Matched-Pair Analysis; Motor Skills; Parkinson Disease; Quality of Life; Sickness Impact Profile | 1997 |
Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Japan; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group.
Topics: Administration, Oral; Antiparkinson Agents; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Medicine, Ayurvedic; Middle Aged; Parkinson Disease; Plant Extracts; Severity of Illness Index | 1995 |
[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Topics: Adult; Aged; Apomorphine; Atrophy; Benzamides; Binding Sites; Cerebral Cortex; Dopamine; Dopamine Agonists; Dopamine Antagonists; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Predictive Value of Tests; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1997 |
Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone | 1997 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index | 1997 |
Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Thalamic Nuclei; Thalamus; Treatment Outcome | 1997 |
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1998 |
Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles; Levodopa; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Severity of Illness Index; Treatment Outcome | 1998 |
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1998 |
Opposite motor effects of pallidal stimulation in Parkinson's disease.
Topics: Apomorphine; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1998 |
Is seborrhea a sign of autonomic impairment in Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Dermatitis, Seborrheic; Female; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Sex Characteristics; Skin | 1997 |
Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Female; Food; Humans; Levodopa; Male; Parkinson Disease; Tablets; Tyrosine | 1998 |
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Disease Progression; Duodenum; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies; Time Factors; Treatment Outcome; Videotape Recording | 1998 |
Experience with tranylcypromine in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders; Time Factors; Tranylcypromine; Tyramine | 1998 |
[Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
Topics: Antiparkinson Agents; Bromocriptine; Cause of Death; Disabled Persons; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Proportional Hazards Models; Selegiline; Survival Rate; Treatment Failure | 1998 |
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzophenones; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Treatment Outcome | 1998 |
Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Topics: Aged; Antiparkinson Agents; Benzophenones; Canada; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Psychomotor Performance; Tolcapone; United States | 1998 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 1998 |
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Clozapine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 1998 |
Sleep disorders in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Middle Aged; Motor Activity; Muscle, Skeletal; Parkinson Disease; Respiration; Sleep Wake Disorders | 1998 |
Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 1998 |
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Antitussive Agents; Dextromethorphan; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1998 |
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1998 |
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
Topics: Aged; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Eating; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1998 |
Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Platelets; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenotype | 1998 |
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disabled Persons; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Probability; Selegiline; Time Factors | 1998 |
Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Topics: Aged; Aged, 80 and over; Bromocriptine; Carbidopa; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Stereotaxic Techniques; Treatment Outcome | 1997 |
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Brain Injuries; Dopamine; Electroencephalography; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pattern Recognition, Visual; Photic Stimulation; Retina; Space Perception; Vision, Monocular | 1998 |
Influence of chronic administration of L-DOPA on event-related desynchronization of mu rhythm preceding voluntary movement in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Cortical Synchronization; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1998 |
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Topics: Administration, Intranasal; Aerosols; Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Premedication; Treatment Outcome | 1998 |
Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 1998 |
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.
Topics: Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Levodopa; Male; Parkinson Disease; Prospective Studies | 1998 |
A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Kinetics; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies | 1998 |
EEG findings in patients with vascular parkinsonism.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Electroencephalography; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary | 1998 |
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease | 1998 |
Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1998 |
Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
Topics: Aged; Antiparkinson Agents; Benzophenones; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1999 |
At which steps of spatial working memory processing do striatofrontal circuits intervene in humans?
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Memory, Short-Term; Mental Processes; Middle Aged; Neostriatum; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance; Space Perception | 1999 |
Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study.
Topics: Aged; Antiparkinson Agents; Dihydroergotoxine; Disabled Persons; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1999 |
Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors | 1999 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Tyrosine | 1999 |
Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation.
Topics: Aged; Drug Interactions; Female; Humans; Levodopa; Male; Models, Statistical; Parkinson Disease; Tyrosine | 1999 |
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 1999 |
Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Prefrontal Cortex | 1999 |
Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy.
Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Middle Aged; Mood Disorders; Multiple System Atrophy; Parkinson Disease | 1999 |
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone | 1999 |
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Topics: Aged; Antiparkinson Agents; Biological Transport; Carbidopa; Cocaine; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Monoamine Oxidase; Occipital Lobe; Parkinson Disease; Selegiline; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate; Severity of Illness Index | 1999 |
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index | 1999 |
Tremorlytic activity of budipine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Electromyography; Female; Humans; Levodopa; Male; Parkinson Disease; Piperidines; Tremor | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Estradiol; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Postmenopause | 1999 |
Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.
Topics: Acute Disease; Cholinergic Antagonists; Cognition Disorders; Corpus Striatum; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Middle Aged; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Scopolamine; Severity of Illness Index; Substantia Nigra; Syndrome; Time Factors; Trihexyphenidyl | 1999 |
Motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Risk Factors | 1999 |
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1999 |
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
Topics: Antiparkinson Agents; Biomarkers; Blood Platelets; Dopamine; Female; Gentisates; Humans; Hydroxybenzoates; Hydroxyl Radical; In Vitro Techniques; Levodopa; Linear Models; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Sodium Salicylate; Superoxide Dismutase; Tyrosine | 1999 |
Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Sleep Wake Disorders | 1999 |
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
Topics: Activities of Daily Living; Aged; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electrochemistry; Female; Humans; Hydroxybenzoates; Hydroxyl Radical; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1999 |
Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial.
Topics: Aged; Antiparkinson Agents; Dominance, Cerebral; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Single-Blind Method; Stereotaxic Techniques; Treatment Outcome | 1999 |
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Topics: Aged; Brain; Brain Mapping; Carbidopa; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Motor Skills; Nerve Tissue Proteins; Parkinson Disease; Pergolide; Putamen; Tomography, Emission-Computed, Single-Photon | 1999 |
Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study.
Topics: Adult; Aged; Double-Blind Method; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Subthalamic Nucleus; Treatment Outcome | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors; Treatment Outcome | 2000 |
An ambulatory dyskinesia monitor.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index | 2000 |
Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.
Topics: Adult; Antiparkinson Agents; Discrimination, Psychological; Epilepsy; Female; Frontal Lobe; Humans; Learning Disabilities; Levodopa; Male; Models, Statistical; Neostriatum; Parkinson Disease; Pattern Recognition, Visual; Reversal Learning; Space Perception; Temporal Lobe; Visual Perception | 2000 |
Effects of unilateral posteroventral pallidotomy on 'on-off' cognitive fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Tomography, X-Ray Computed | 2000 |
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
Topics: Alleles; Antiparkinson Agents; Dopamine Agonists; Female; Gene Frequency; Genetic Linkage; Genetic Predisposition to Disease; Genotype; Hallucinations; Haplotypes; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2000 |
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
Topics: Brain; Carbon Radioisotopes; Dopamine Agents; Dopamine Antagonists; Female; Gyrus Cinguli; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Pyrrolidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Salicylamides; Thalamus; Tomography, Emission-Computed | 2000 |
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Failure | 2000 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2000 |
Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.
Topics: Adult; Antiparkinson Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2000 |
Subthalamic stimulation in Parkinson disease: a multidisciplinary approach.
Topics: Activities of Daily Living; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sickness Impact Profile; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2000 |
Posteroventral pallidotomy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Disorders; Treatment Outcome | 2000 |
The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Double-Blind Method; Humans; Levodopa; Middle Aged; Parkinson Disease; Perindopril; Pilot Projects | 2000 |
Tolcapone increases maximum concentration of levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Topics: Aged; Antiparkinson Agents; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Risk Factors | 2000 |
Response to L-dopa in PD: the long and the short of it.
Topics: Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 2000 |
The long-duration response to L-dopa in the treatment of early PD.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2000 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Sick Role; Sickness Impact Profile; Tolcapone; Treatment Outcome | 2000 |
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain Tissue Transplantation; Caudate Nucleus; Dopamine; Female; Fetal Tissue Transplantation; Follow-Up Studies; Graft Survival; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pregnatrienes; Putamen; Tomography, Emission-Computed | 2000 |
Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study.
Topics: Aged; Analysis of Variance; Drug Administration Schedule; Drug Therapy, Combination; Electric Stimulation; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Parkinson Disease; Pergolide; Reaction Time; Sensory Thresholds; Severity of Illness Index; Transcranial Magnetic Stimulation | 2000 |
Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2000 |
Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 2000 |
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pergolide | 2000 |
Pramipexole-induced somnolence and episodes of daytime sleep.
Topics: Aged; Antiparkinson Agents; Automobile Driving; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Polysomnography; Pramipexole; Retrospective Studies; Thiazoles | 2000 |
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Cognition; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Verbal Learning | 2000 |
[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1999 |
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
Topics: Adult; Antiparkinson Agents; Benzophenones; Cross-Over Studies; Desipramine; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Hemodynamics; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa.
Topics: Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Cross-Over Studies; Dyskinesias; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2000 |
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2000 |
P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs.
Topics: Adult; Aged; Antiparkinson Agents; Cognition; Dementia; Event-Related Potentials, P300; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Predictive Value of Tests; Prognosis; Reaction Time | 2000 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Topics: Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Dyskinesias; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2000 |
Centrally initiated postural adjustments in parkinsonian patients on and off levodopa.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Postural Balance; Posture; Reaction Time; Toes; Torque | 2000 |
Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
Topics: Adult; Aged; Antiparkinson Agents; Biological Transport; Carrier Proteins; Cocaine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Reproducibility of Results; Tomography, Emission-Computed | 2000 |
Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Psychiatric Status Rating Scales; Saccades | 2000 |
Evidence of functional somatotopy in GPi from results of pallidotomy.
Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Neurologic Examination; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Severity of Illness Index; Treatment Outcome | 2000 |
[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol].
Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Treatment Outcome | 2000 |
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Medical Records; Middle Aged; Movement Disorders; Parkinson Disease; Safety; Severity of Illness Index; Treatment Outcome | 2000 |
An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2000 |
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
Topics: Aged; Blood Pressure; Bromocriptine; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 2000 |
Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease.
Topics: Biological Clocks; Dopamine; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Membrane Potentials; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2001 |
Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Catechol O-Methyltransferase; Female; Genotype; Humans; Korea; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Polymorphism, Single Nucleotide | 2001 |
Effects of levodopa on pulmonary function in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Airway Obstruction; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Function Tests; Respiratory Mechanics; Spirometry | 2001 |
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Pyridines; Receptors, Dopamine D1; Tetrahydronaphthalenes | 2001 |
[Efficiency of new forms of madopar in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2000 |
Dorsal subthalamotomy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesias; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Pilot Projects; Postoperative Period; Subthalamic Nucleus | 2001 |
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome | 2001 |
Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
Topics: Aged; Antiparkinson Agents; Benzophenones; Biological Availability; Double-Blind Method; Female; Gait; Half-Life; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Suppressed sympathetic skin response in Parkinson disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System | 2000 |
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease.
Topics: Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 2001 |
The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Diagnostic Techniques, Neurological; Humans; Indoles; Levodopa; Locomotion; Middle Aged; Parkinson Disease; Posture | 2001 |
Disinhibition of the sleep state-dependent p1 potential in Parkinson's disease-improvement after pallidotomy.
Topics: Analysis of Variance; Evoked Potentials, Auditory; Female; Globus Pallidus; Habituation, Psychophysiologic; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Sleep | 1998 |
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2; Tetrahydronaphthalenes; Therapeutic Equivalency; Thiophenes; Treatment Outcome | 2001 |
Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Female; Follow-Up Studies; France; Humans; Levodopa; Male; Middle Aged; Mortality; Parkinson Disease; Prospective Studies; Treatment Outcome | 2001 |
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Remission Induction | 2001 |
Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain Chemistry; Carbon Radioisotopes; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Receptors, Dopamine; Thiazoles; Tomography, Emission-Computed | 2001 |
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Topics: Aged; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Effect of bilateral subthalamic nucleus stimulation on gait in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Electric Stimulation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2001 |
A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Biperiden; Cross-Over Studies; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Tremor | 2001 |
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects | 2001 |
Deep brain stimulation of the subthalamic nucleus: selection of patients and clinical results.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Patient Selection; Subthalamic Nucleus; Treatment Outcome | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome | 2001 |
Which target for DBS in Parkinson's disease? Subthalamic nucleus versus globus pallidus internus.
Topics: Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Subthalamic Nucleus; Treatment Outcome | 2001 |
Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
Topics: Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Time Factors; Treatment Outcome | 2001 |
Twelve-month safety of entacapone in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Disability Evaluation; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Safety; Time Factors | 2001 |
Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients.
Topics: Activities of Daily Living; Antiparkinson Agents; Cognition; Combined Modality Therapy; Disabled Persons; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Predictive Value of Tests; Quality of Life; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2001 |
Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.
Topics: Acetamides; Activities of Daily Living; Anticonvulsants; Dyskinesias; Humans; Informed Consent; Levodopa; Medical Records; Mental Status Schedule; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Placebos; Reproducibility of Results; Treatment Outcome | 2001 |
Delay of simple reaction time after levodopa intake.
Topics: Adult; Aged; Antiparkinson Agents; Behavior; Benserazide; Cognition; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychiatric Status Rating Scales; Reaction Time; Reference Values | 2001 |
CT-guided unilateral thalamotomy with macroelectrode mapping for the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Electrodes; Electrophysiology; Female; Humans; Levodopa; Male; Mental Health; Middle Aged; Morbidity; Parkinson Disease; Quality of Life; Radiography, Interventional; Severity of Illness Index; Stereotaxic Techniques; Thalamus; Tomography, X-Ray Computed; Treatment Outcome; Tremor | 2001 |
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome | 2001 |
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Drug Therapy, Combination; Helicobacter Infections; Humans; Intestinal Absorption; Levodopa; Omeprazole; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2001 |
Morphine in tardive and idiopathic dystonia (short communication).
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Middle Aged; Morphine; Neostriatum; Pain; Parkinson Disease; Pilot Projects; Receptors, Dopamine; Treatment Outcome | 2001 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug | 2001 |
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Pergolide; Quality of Life; Tolcapone; Treatment Outcome | 2001 |
Zonisamide has beneficial effects on Parkinson's disease patients.
Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide | 2001 |
Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system.
Topics: Aged; Antiparkinson Agents; Dyskinesias; Electric Stimulation Therapy; Female; Gait; Globus Pallidus; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2001 |
High-dose therapy with ropinirole in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Prospective Studies | 2001 |
Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Time Factors; Treatment Outcome; Tremor | 2001 |
Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease.
Topics: Antiparkinson Agents; Catecholamines; Caudate Nucleus; Female; Follow-Up Studies; Ganglia, Sympathetic; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Psychomotor Performance; Putamen; Stereotaxic Techniques; Transplantation, Autologous; Treatment Outcome | 2001 |
The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Muscle Rigidity; Parkinson Disease; Sex Characteristics; Tremor | 2002 |
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Asian People; Black or African American; Cognition; Drug Therapy, Combination; Electrophysiology; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Treatment Outcome; Visual Perception | 2002 |
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans; Levodopa; Male; Middle Aged; Olanzapine; Parkinson Disease; Pirenzepine; Prospective Studies; Psychoses, Substance-Induced | 2002 |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2002 |
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Heterocyclic Compounds, 2-Ring; Humans; Levodopa; Male; Middle Aged; Oximes; Parkinson Disease; Treatment Outcome | 2002 |
L-dopa effects on preprogramming and control activity in a skilled motor act in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Psychomotor Performance | 2002 |
L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Female; Hand; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Spinal Nerves | 2002 |
[Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
Topics: Adult; Aged; Dyskinesias; Female; Humans; Isoindoles; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Pyrimidines; Serotonin Receptor Agonists; Treatment Outcome | 2002 |
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Topics: Aged; Antiparkinson Agents; Austria; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Germany; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2002 |
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease | 2002 |
Ropinirole for the treatment of tremor in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor | 2002 |
Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2002 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Parkinson Disease; Postmenopause; Pramipexole; Sex Factors; Thiazoles | 2002 |
Effect of bilateral subthalamic nucleus stimulation on parkinsonian gait.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Electric Stimulation Therapy; Female; Gait; Gait Disorders, Neurologic; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2001 |
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Treatment Outcome | 2002 |
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Placebos; Riluzole; Severity of Illness Index; Time Factors | 2002 |
Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease; Subthalamic Nucleus | 2002 |
Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans.
Topics: Adult; Aged; Basal Ganglia; Biological Clocks; Cerebral Cortex; Dopamine; Electrodes, Implanted; Electroencephalography; Female; Frontal Lobe; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Periodicity; Subthalamic Nucleus; Wakefulness | 2002 |
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.
Topics: Aged; Antipsychotic Agents; Dibenzothiazepines; Humans; Levodopa; Lewy Body Disease; Parkinson Disease; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Quetiapine Fumarate; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2002 |
Influence of internal globus pallidus stimulation on motor cortex activation pattern in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cortical Synchronization; Electric Stimulation; Electrodes, Implanted; Electroencephalography; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Muscle, Skeletal; Parkinson Disease | 2002 |
Letter: Oxprenolol and levodopa in parkinsonian patients.
Topics: Catecholamines; Clinical Trials as Topic; Drug Interactions; Humans; Levodopa; Oxprenolol; Parkinson Disease | 1975 |
Letter: Metoclopramide in parkinsonism.
Topics: Clinical Trials as Topic; Humans; Levodopa; Metoclopramide; Nausea; Parkinson Disease; Promethazine; Vomiting | 1975 |
Idiopathic parkinsonism treated with bromocriptine.
Topics: Aged; Clinical Trials as Topic; Ergot Alkaloids; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1975 |
Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Clinical Trials as Topic; Drug Synergism; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement; MSH Release-Inhibiting Hormone; Parkinson Disease | 1975 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
Topics: Adult; Aged; Arrhythmias, Cardiac; Carbidopa; Cardiac Complexes, Premature; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Tachycardia | 1975 |
Letter: Bromocriptine in parkinsonism.
Topics: Bromocriptine; Drug Evaluation; Ergolines; Humans; Levodopa; Parkinson Disease | 1975 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Vomiting | 1975 |
Letter: Chorea and torsion in parkinsonism.
Topics: Chorea; Humans; Levodopa; Parkinson Disease; Torsion Abnormality | 1976 |
Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1976 |
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Injections, Intravenous; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Time Factors | 1977 |
Deprenyl in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1977 |
Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Topics: Aged; Benserazide; Carbidopa; Consumer Behavior; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Bromocriptine in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piperidines; Thioxanthenes; Trihexyphenidyl | 1978 |
Pergolide and lisuride for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1979 |
Caffeine and the antiparkinsonian response to levodopa or piribedil.
Topics: Adult; Aged; Caffeine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil | 1975 |
An ergot derivative in the treatment of Parkinson's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Bromocriptine; Clinical Trials as Topic; Ergolines; Humans; Levodopa; Parkinson Disease | 1976 |
[Levodopa and decarboxylase inhibitors in Parkinson's disease].
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1977 |
Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Humans; Individuality; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1977 |
Bromocriptine in the treatment of advanced Parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1977 |
Nomifensine in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Placebos; Trihexyphenidyl | 1977 |
Treatment of Parkinson's disease with lergotrile mesylate.
Topics: Acetonitriles; Antiparkinson Agents; Bromocriptine; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Parkinson Disease | 1977 |
Evaluation of an experimental anticholinergic drug, elantrine, in treating the tremor of parkinsonism.
Topics: Clinical Trials as Topic; Dibenzazepines; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Placebos | 1977 |
[Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism].
Topics: Aged; Clinical Trials as Topic; Drug Evaluation; Electrophysiology; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil | 1977 |
Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Placebos; Psychiatric Status Rating Scales | 1978 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depression; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1978 |
Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Substance Withdrawal Syndrome | 1978 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1978 |
Level of blood pressure in patients with Parkinson's disease. A case-control study.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1977 |
Sodium valproate in the treatment of levodopa-induced dyskinesia.
Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valerates; Valproic Acid | 1978 |
Baclofen in Parkinson's disease.
Topics: Aged; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 1978 |
Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Isoquinolines; Levodopa; Parkinson Disease; Placebos; Receptors, Dopamine | 1978 |
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Topics: Aged; Clinical Trials as Topic; Deanol; Double-Blind Method; Drug Evaluation; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physostigmine; Placebos | 1978 |
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Topics: Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Syndrome | 1978 |
A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Electrocardiography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
Topics: Adult; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Experiences with L-deprenyl in Parkinsonism.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1978 |
A double-blind trial of bromocriptine in Parkinson's disease.
Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1978 |
Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
Topics: Activities of Daily Living; Aged; Benserazide; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 1979 |
An evaluation of bromocriptine in the treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 1978 |
Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets, Enteric-Coated | 1979 |
Levodopa in Parkinson disease: a long-term appraisal of mortality.
Topics: Clinical Trials as Topic; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 1978 |
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Plasma catecholamines and the acute effects of oral L-dopa in Parkinsonian patients [proceedings].
Topics: Catecholamines; Humans; Levodopa; Parkinson Disease | 1979 |
Levodopa with benserazide or carbidopa in Parkinson disease.
Topics: Benserazide; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Clonidine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos | 1976 |
Electroencephalographic findings in patients with mild Parkinson's disease treated with L-dopa and placebo.
Topics: Aged; Clinical Trials as Topic; Electroencephalography; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Prognosis | 1976 |
[The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Ergolines; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Tremor | 1976 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interview, Psychological; Levodopa; Male; Mental Status Schedule; Methyldopa; Middle Aged; Parkinson Disease; Placebos; Recurrence; Trihexyphenidyl | 1976 |
[Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Topics: Benserazide; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1976 |
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines | 1976 |
[Clinical experience with bromocriptine, a central dopaminergic stimulator].
Topics: Aged; Amantadine; Bromocriptine; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Trihexyphenidyl | 1976 |
The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Placebos | 1976 |
Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Skills; Parkinson Disease | 1975 |
Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1976 |
Levodopa treatment of presenile dementia.
Topics: Adult; Cognition Disorders; Dementia; Drug Evaluation; Female; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Wechsler Scales | 1977 |
Mental symptoms in Parkinson's disease during chronic treatment with levodopa.
Topics: Adult; Aged; Delirium; Dementia; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Tryptophan | 1976 |
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
Topics: Aged; Antiparkinson Agents; Chorea; Clinical Trials as Topic; Confusion; Dioxoles; Dopamine; Drug Evaluation; Electromyography; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Motor Skills; Muscle Rigidity; Nausea; Parkinson Disease; Parkinson Disease, Postencephalitic; Piperazines; Pyrimidines; Tremor | 1975 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Serine | 1975 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Secondary; Pimozide; Placebos; Promethazine | 1975 |
Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Piperazines; Piribedil; Reflex, Monosynaptic; Tremor | 1975 |
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Topics: Aged; Brain; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos; Serotonin | 1975 |
Dopaminergic agonists in Parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1975 |
Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Aged; Clinical Trials as Topic; Dopamine; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Tritium | 1975 |
Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
Topics: Activities of Daily Living; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evaluation; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Motor Skills; Parkinson Disease; Time Factors | 1975 |
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Postencephalitic; Posture; Structure-Activity Relationship; Tremor | 1975 |
Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos | 1975 |
Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1975 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
[Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopa Decarboxylase; Drug Combinations; Drug Evaluation; Electrodiagnosis; Electromyography; Humans; Levodopa; Medical Records; Muscle Tonus; Oscillometry; Parkinson Disease; Piribedil; Tremor | 1975 |
The effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Nausea; Parkinson Disease; Vomiting | 1975 |
L-dopa and carbidopa (sinemet) in the management of parkinsonism.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1975 |
The treatment with L-dopa and amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
The effect of Dopaflex and Viregyt-K on gait and postural disturbances of operated and non-operated Parkinsonian patients.
Topics: Amantadine; Clinical Trials as Topic; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.
Topics: Administration, Oral; Aged; Decarboxylation; Dosage Forms; Eating; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.
Topics: Age Factors; Aged; Bromocriptine; Carbidopa; Dementia; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease | 1992 |
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Satisfaction; Sleep Stages | 1992 |
A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.
Topics: Dopamine Agents; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Research Design; Selegiline; Severity of Illness Index | 1992 |
Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
Topics: Amino Acids; Blood Pressure; Brain; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypotension; Infusions, Intravenous; Levodopa; Locomotion; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenylalanine | 1992 |
Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
Topics: Benserazide; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease; Prospective Studies; Psychomotor Performance | 1992 |
Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: analysis on the maintenance and the change of the original mode of treatment.
Topics: Activities of Daily Living; Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gait; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report.
Topics: Activities of Daily Living; Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies | 1992 |
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.
Topics: Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychomotor Performance | 1992 |
Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 1992 |
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
Topics: Adult; Aged; Bromocriptine; Cognition Disorders; Female; Follow-Up Studies; Frontal Lobe; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Motor Activity; Movement; Parasympatholytics; Parkinson Disease; Psychomotor Performance; Visual Perception | 1992 |
Parlodel SRO in Parkinson's disease: a double-blind randomized comparison of Parlodel standard and Parlodel SRO.
Topics: Administration, Oral; Aged; Bromocriptine; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Methyldopa; Neurologic Examination; Parkinson Disease | 1992 |
Trial of Sinemet CR4 in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1992 |
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Topics: Affect; Aged; Catalase; Free Radicals; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Superoxide Dismutase | 1992 |
TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Motor Skills; Neurologic Examination; Parkinson Disease; Prolactin; Receptors, Dopamine; Thyrotropin; Thyrotropin-Releasing Hormone | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction.
Topics: Brain Diseases; Cognition Disorders; Discrimination, Psychological; Female; Frontal Lobe; Humans; Learning; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome | 1992 |
Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1992 |
CQA 206-291 in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Dopamine Agents; Double-Blind Method; Drug Interactions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease | 1991 |
Antagonist effect of terguride in Parkinson's disease.
Topics: Adult; Aged; Dopamine Agents; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1991 |
Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.
Topics: Adult; Aged; Aged, 80 and over; Behavior; Bromocriptine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Sleep Initiation and Maintenance Disorders; Sleep Stages; Temazepam | 1991 |
Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1991 |
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1991 |
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
Topics: Dihydroergotoxine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Synapses; Time Factors | 1991 |
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors | 1991 |
A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease | 1991 |
Sublingual apomorphine solution in Parkinson's disease.
Topics: Administration, Oral; Administration, Sublingual; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Single-Blind Method | 1991 |
[Treatment of Parkinson disease with levodopa depot preparations].
Topics: Aged; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
[Apomorphine in Parkinson disease].
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
Topics: Aged; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1990 |
An open trial of high-dosage antioxidants in early Parkinson's disease.
Topics: Adult; Aged; Ascorbic Acid; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Vitamin E | 1991 |
Sinemet CR in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1991 |
The hemodynamic effects of triglycyl-lysine-vasopressin (Glypressin) in patients with parkinsonism and orthostatic hypotension.
Topics: Aged; Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Lypressin; Male; Middle Aged; Parkinson Disease; Single-Blind Method; Terlipressin; Vascular Resistance | 1991 |
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease | 1991 |
Treatment of Parkinson's disease with proglumide, a CCK antagonist.
Topics: Aged; Cholecystokinin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proglumide | 1991 |
A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.
Topics: Acetaminophen; Adult; Dietary Proteins; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Male; Parkinson Disease | 1991 |
Simplification of the initiation of bromocriptine in elderly patients with advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Bromocriptine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Carbidopa; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Random Allocation | 1991 |
Depression treatment in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Carbidopa; Depression; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Nortriptyline; Parkinson Disease | 1991 |
Circadian secretion pattern of melatonin in Parkinson's disease.
Topics: Adult; Aged; Biomarkers; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Parkinson Disease | 1991 |
An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1991 |
Deprenyl and the progression of Parkinson's disease.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1990 |
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Topics: Aged; Carbidopa; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline | 1990 |
The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Long-Term Care; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Humans; Japan; Levodopa; Middle Aged; Multicenter Studies as Topic; Parkinson Disease | 1990 |
Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Topics: Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine; Drug Combinations; Female; Follow-Up Studies; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
[Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Prospective Studies; Psychomotor Disorders; Randomized Controlled Trials as Topic | 1990 |
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Motor Skills; Multicenter Studies as Topic; Neurologic Examination; Parkinson Disease | 1990 |
Tremor in Parkinson disease: acute response to oral levodopa.
Topics: Administration, Oral; Diagnosis, Computer-Assisted; Humans; Levodopa; Parkinson Disease; Posture; Rest; Time Factors; Tremor | 1990 |
Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.
Topics: Aged; Aged, 80 and over; Blood Pressure; Carbidopa; Double-Blind Method; Female; Gait; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Randomized Controlled Trials as Topic | 1990 |
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
A long-term study of Parkinson's patients subjected to autoimplants of perfused adrenal medulla into the caudate nucleus. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perfusion; Tissue Transplantation; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Vitamin E therapy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Retrospective Studies; Vitamin E | 1990 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Madopar HBS in nocturnal symptoms of Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Sleep Stages | 1990 |
Adjunctive therapy with bromocriptine in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1990 |
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Statistics as Topic; Time Factors | 1990 |
Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
Topics: Adult; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Diurnal differences in response to oral levodopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Circadian Rhythm; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants.
Topics: Adrenal Medulla; Adult; Carbidopa; Corpus Striatum; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Random Allocation | 1990 |
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Electroconvulsive Therapy; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease | 1987 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
Big first scored with nerve diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra | 1989 |
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline | 1989 |
Pergolide and selegiline for Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Pergolide; Phenethylamines; Selegiline | 1989 |
Effect of deprenyl on the progression of disability in early Parkinson's disease.
Topics: Activities of Daily Living; Clinical Trials as Topic; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline; Vitamin E | 1989 |
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline | 1989 |
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline | 1989 |
A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline | 1989 |
Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline | 1989 |
Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468.
Topics: Dopamine Agents; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects | 1989 |
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Topics: Adult; Aged; Aminoquinolines; Antiparkinson Agents; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
Topics: Aged; Amino Acids; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Topics: Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Random Allocation | 1989 |
A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
Topics: Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Random Allocation | 1989 |
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Multicenter Studies as Topic; Parkinson Disease; Random Allocation; Time Factors | 1989 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
Topics: Activities of Daily Living; Aged; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Clinical Trials as Topic; Drug Therapy, Combination; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1989 |
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1 | 1987 |
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Ergolines; Humans; Hydrazines; Infusion Pumps; Levodopa; Lisuride; Parkinson Disease; Severity of Illness Index | 1988 |
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors | 1988 |
A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Movement; Parkinson Disease | 1988 |
Treatment of Parkinson's disease with pergolide: a double-blind study.
Topics: Activities of Daily Living; Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1988 |
Pergolide: long-term use in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Placebos; Retrospective Studies | 1988 |
Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Long term bromocriptine treatment in de novo parkinsonian patients.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1988 |
Multicenter trial of L-Deprenyl in Parkinson disease.
Topics: Adult; Affect; Aged; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Tremor | 1986 |
Long-lasting drug holiday in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Receptors, Dopamine | 1987 |
Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Random Allocation; Selegiline | 1987 |
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Self Concept | 1987 |
Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.
Topics: Aged; Clinical Trials as Topic; Depression; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Thioxanthenes | 1987 |
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline | 1987 |
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Deprenyl versus placebo in Parkinson disease: a double-blind study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline | 1988 |
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
Topics: Aged; Animals; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Selegiline | 1988 |
Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Parkinson Disease; Random Allocation | 1988 |
A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
Topics: Bromocriptine; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Prospective Studies | 1988 |
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1987 |
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 1987 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Biological Availability; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Infant, Newborn; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Secondary; Tremor | 1987 |
[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1987 |
Does papaverine interact with levodopa in Parkinson's disease?
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Papaverine; Parkinson Disease; Random Allocation | 1987 |
Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.
Topics: Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease; Random Allocation; Sleep | 1987 |
A double-blind evaluation of ciladopa in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Piperazines; Random Allocation | 1987 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies | 1988 |
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Chronic Disease; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Does an inhibitory action of levodopa contribute to motor fluctuations?
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Placebos | 1988 |
Therapeutic effect of lisuride in advanced Parkinson's disease.
Topics: Aged; Clinical Trials as Topic; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
[Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Random Allocation | 1986 |
Mesulergine in early Parkinson's disease: a double blind controlled trial.
Topics: Aged; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1986 |
The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
Topics: Absorption; Administration, Oral; Adult; Carboxy-Lyases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Intravenous; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1986 |
Patients sought for New Zealand multi-centre Parkinson's disease trial.
Topics: Bromocriptine; Clinical Trials as Topic; Humans; Levodopa; New Zealand; Parkinson Disease | 1987 |
Blood pressure effects of apomorphine and domperidone in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Blood Pressure; Clinical Trials as Topic; Domperidone; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Shy-Drager Syndrome | 1987 |
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Treatment of early morning akinesia with low-dose bromocriptine.
Topics: Aged; Aged, 80 and over; Bromocriptine; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1987 |
Parallel double-blind study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Pergolide; Random Allocation | 1987 |
Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1987 |
The Sydney multicentre study of Parkinson's disease. The first 18 months.
Topics: Australia; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
Adjuvant therapy of parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clonazepam; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Primidone; Propranolol; Random Allocation; Tremor; Trihexyphenidyl | 1987 |
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
Bromocriptine and the clinical spectrum of Parkinson's disease.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1987 |
Double-blind trial of pergolide for Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1985 |
Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Ergolines; Gait; Humans; Levodopa; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Pergolide; Random Allocation | 1985 |
Caerulein treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline | 1985 |
L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Topics: Aged; Clinical Trials as Topic; Droxidopa; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Serine | 1985 |
Low dosages of bromocriptine added to levodopa in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1985 |
Motor function in the normal aging population: treatment with levodopa.
Topics: Aged; Aging; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Parkinson Disease | 1985 |
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Topics: Activities of Daily Living; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
Topics: Adult; Aged; Blood Pressure; Bromocriptine; Drug Administration Schedule; Ergolines; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1985 |
L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Clinical Trials as Topic; Depression, Chemical; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Placebos; Posture; Vomiting | 1974 |
Bromocriptine in Parkinsonism.
Topics: Aged; Blood Pressure; Bromine; Dopamine; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pulse; Receptors, Drug | 1974 |
[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Evaluation Studies as Topic; Gastrointestinal Diseases; Gymnastics; Humans; Hydrazines; Levodopa; Parkinson Disease; Speech Therapy | 1973 |
A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease.
Topics: Affective Symptoms; Aged; Anxiety; Clinical Trials as Topic; Confusion; Drug Evaluation; Drug Therapy, Combination; Female; Hallucinations; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Placebos; Sleep Wake Disorders; Time Factors; Trihexyphenidyl; Vomiting | 1974 |
[Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Methods; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pyramidal Tracts; Time Factors; Tremor | 1974 |
Refinement in the measurement of treatment response with combined L-dopa and amantadine in Parkinsonism.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Humans; Intelligence; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Personality Inventory; Placebos; Psychological Tests; Vocabulary; Wechsler Scales | 1974 |
Piribedil in Parkinsonism.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Confusion; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease | 1974 |
Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
Topics: Aged; Amides; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior; Clinical Trials as Topic; Depression; Dopa Decarboxylase; Female; Follow-Up Studies; Humans; Injections, Intravenous; Levodopa; Male; Melanocyte-Stimulating Hormones; Middle Aged; Oligopeptides; Parkinson Disease; Pituitary Hormone-Releasing Hormones; Placebos; Psychomotor Disorders; Sleep Wake Disorders | 1974 |
Sinemet.
Topics: Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1974 |
An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease.
Topics: Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1974 |
Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 1974 |
Incidence of side effects from levodopa during the introduction of treatment.
Topics: Aged; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Parkinson Disease | 1971 |
5699 other study(ies) available for levodopa and Parkinson Disease
| Article | Year |
|---|---|
Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease.
Topics: Analysis of Variance; Animals; Antioxidants; Antiparkinson Agents; Area Under Curve; Chromatography, High Pressure Liquid; Corpus Striatum; Half-Life; Humans; Injections, Intraventricular; Levodopa; Parkinson Disease; Rats; Spectrophotometry, Ultraviolet; Sulfur | 2009 |
Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Brain; Catalepsy; Glutathione; Glutathione Peroxidase; Haloperidol; Male; Malondialdehyde; Mice; Oxidative Stress; Parkinson Disease; Pyrimidines; Superoxide Dismutase; Thiourea; Urea | 2009 |
Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.
Topics: Administration, Oral; Animals; Dopamine; Drug Design; Free Radical Scavengers; Humans; Hydrolysis; Imidazoles; Kinetics; Levodopa; Neuroprotective Agents; Parkinson Disease; Prodrugs; Rats | 2010 |
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Topics: Amides; Animals; Drug Design; Levodopa; Male; Oxidopamine; Parkinson Disease; Prodrugs; Rats; Rats, Wistar | 2010 |
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Female; Indenes; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A | 2010 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Parkinson Disease; Pyridones; Recombinant Proteins; Structure-Activity Relationship | 2012 |
In vitro and in vivo neuroprotective effect of novel mPGES-1 inhibitor in animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Prostaglandins E; Rats | 2022 |
2-(Fluoromethoxy)-4'-(
Topics: Animals; Biphenyl Compounds; Cocaine; Dopamine; Dopamine Agents; Dopamine Agonists; Humans; Indazoles; Levodopa; Ligands; Mice; Nitrofurans; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1 | 2022 |
Effects of Levodopa Therapy on Cerebral Arteries and Perfusion in Parkinson's Disease Patients.
Topics: Aged; Cerebral Arteries; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perfusion; Prospective Studies; Spin Labels | 2022 |
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2021 |
Short- and long-term motor outcome of STN-DBS in Parkinson's Disease: focus on sex differences.
Topics: Deep Brain Stimulation; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Sex Characteristics; Treatment Outcome | 2022 |
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Ketamine; Levodopa; Male; Microglia; Parkinson Disease; Phagocytosis; Rats; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2021 |
Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease.
Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Prognosis; Putamen | 2022 |
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.
Topics: Antiparkinson Agents; Catechols; Colitis, Lymphocytic; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2021 |
Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesias; Female; Hedgehog Proteins; Levodopa; Male; Mice; Parkinson Disease | 2021 |
Editorial for "Effects of Levodopa Therapy on Cerebral Arteries and Perfusion in Parkinson's Disease Patients".
Topics: Cerebral Arteries; Head; Humans; Levodopa; Parkinson Disease; Perfusion | 2022 |
Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2021 |
Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Alleles; Biomarkers; Disease Susceptibility; Dyskinesia, Drug-Induced; Exome Sequencing; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Symptom Assessment | 2021 |
Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Treatment Outcome; Trypsin | 2022 |
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson's Disease: Long-Term Results.
Topics: Aged; Essential Tremor; Humans; Levodopa; Middle Aged; Parkinson Disease; Thalamus; Treatment Outcome; Tremor | 2022 |
Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
Topics: Dysarthria; Female; Humans; Levodopa; Parkinson Disease; Speech; Speech Disorders | 2021 |
Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Registries; Risk Factors; Thailand; Time and Motion Studies; Treatment Outcome; Withholding Treatment | 2021 |
Effect of deep brain stimulation on brain network and white matter integrity in Parkinson's disease.
Topics: Aged; Brain; Deep Brain Stimulation; Diffusion Tensor Imaging; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; White Matter | 2022 |
\\Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
Topics: Antiparkinson Agents; Colitis, Microscopic; Humans; Levodopa; Parkinson Disease; Sweden | 2021 |
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Brain Waves; Drug Monitoring; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Reproducibility of Results; Treatment Outcome | 2021 |
How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?
Topics: Aged; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Symptom Assessment; Time Factors; Tremor | 2021 |
Levodopa Challenge Test Predicts STN-DBS Outcomes in Various Parkinson's Disease Motor Subtypes: A More Accurate Judgment.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Judgment; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
Topics: Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2021 |
Falls risk is predictive of dysphagia in Parkinson's disease.
Topics: Accidental Falls; Deglutition Disorders; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2022 |
Synthesis, characterization and in-vitro prolonged release of L-DOPA using a novel amphiphilic hydrogel based on sodium alginate-polypyrrole.
Topics: Administration, Oral; Alginates; Antioxidants; Antiparkinson Agents; Drug Liberation; Fibroblasts; Humans; Hydrogels; Levodopa; Parkinson Disease; Polymers; Pyrroles | 2021 |
The effects of levodopa in the spatiotemporal gait parameters are mediated by self-selected gait speed in Parkinson's disease.
Topics: Bayes Theorem; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Walking Speed | 2021 |
Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2021 |
Guess Who: dopamine agonist and creativity?
Topics: Antiparkinson Agents; Creativity; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2021 |
White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; White Matter | 2022 |
Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2022 |
Temporal dynamics of cortical activity and postural control in response to the first levodopa dose of the day in people with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebral Cortex; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2022 |
The role of frailty in Parkinson's disease: a cross-sectional study.
Topics: Cross-Sectional Studies; Frailty; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2022 |
Influence of inter-electrode distance on subthalamic nucleus local field potential recordings in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Membrane Potentials; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2022 |
L-DOPA, a treatment for Parkinson's disease, and its enantiomer D-DOPA inhibit severe fever with thrombocytopenia syndrome virus infection in vitro.
Topics: Bunyaviridae Infections; Hemorrhagic Fevers, Viral; Humans; Levodopa; Parkinson Disease; Phlebovirus; Severe Fever with Thrombocytopenia Syndrome; Thrombocytopenia | 2022 |
Correlation between Serum Zinc Levels and Levodopa in Parkinson's Disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Chelating Agents; Deficiency Diseases; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Zinc | 2021 |
Melanochrome-based colorimetric assay for quantitative detection of levodopa in co-presence of carbidopa and its application to relevant anti-Parkinson drugs.
Topics: Antiparkinson Agents; Carbidopa; Colorimetry; Drug Combinations; Humans; Levodopa; Parkinson Disease; Tablets | 2022 |
Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's disease.
Topics: Age Factors; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photoperiod; Sex Factors; Sleep Wake Disorders | 2021 |
Effect of onset age on the levodopa threshold dosage for dyskinesia in Parkinson's disease.
Topics: Age of Onset; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; ROC Curve | 2022 |
Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.
Topics: Antiparkinson Agents; Chromatography, Liquid; Dyskinesia, Drug-Induced; Humans; Levodopa; Metabolome; Neuroinflammatory Diseases; Parkinson Disease; Tandem Mass Spectrometry | 2022 |
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Carbidopa; Cerebral Cortex; Chlorocebus aethiops; Dopamine; Electrodes, Implanted; Eye-Tracking Technology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Net; Organic Chemicals; Parkinson Disease; Parkinsonian Disorders; Pupil; Stereotaxic Techniques | 2021 |
Disruption of the Cortical-Vagal Communication Network in Parkinson's Disease.
Topics: Autonomic Nervous System; Heart Rate; Humans; Levodopa; Parkinson Disease; Vagus Nerve | 2021 |
Comparative Analysis of Acute Levodopa Challenge Test and the Outcomes of Deep Brain Stimulation in Parkinson's Disease.
Topics: Deep Brain Stimulation; Humans; Hypokinesia; Levodopa; Muscle Rigidity; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2022 |
Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson's disease.
Topics: Dopamine; Drug Delivery Systems; Gold; Humans; Levodopa; Metal Nanoparticles; Parkinson Disease | 2022 |
Factors correlated with therapeutic effects of globus pallidus deep brain stimulation on freezing of gait in advanced Parkinson's disease: A pilot study.
Topics: Deep Brain Stimulation; Gait; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Pilot Projects; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2022 |
Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Japan; Levodopa; Parkinson Disease; Prospective Studies; Purines; Quality of Life; Treatment Outcome | 2022 |
Nephrotic Syndrome and Atypical Posterior Reversible Encephalopathy Syndrome in a Patient with Parkinson's Disease.
Topics: Antiparkinson Agents; Brain; Drug Combinations; Gels; Humans; Levodopa; Male; Middle Aged; Nephrotic Syndrome; Parkinson Disease; Posterior Leukoencephalopathy Syndrome | 2022 |
[Clinical picture of patients with Parkinson's disease attending a regional core hospital in Ehime].
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Hospitals; Humans; Levodopa; Male; Parkinson Disease | 2022 |
Assessment of the Effect of Subthalamic Deep Brain Stimulation on Sleep Quality of Parkinson's Disease Patients.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Sleep Quality; Subthalamic Nucleus; Treatment Outcome | 2022 |
Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Case-Control Studies; Clinical Protocols; Comorbidity; Disease Progression; Geriatrics; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Acuity; Thailand | 2021 |
Surface Plasmon Resonance Identifies High-Affinity Binding of l-DOPA to Siderocalin/Lipocalin-2 through Iron-Siderophore Action: Implications for Parkinson's Disease Treatment.
Topics: Antiparkinson Agents; Humans; Iron; Levodopa; Lipocalin-2; Parkinson Disease; Siderophores; Surface Plasmon Resonance | 2022 |
Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Nitric Oxide; Parkinson Disease | 2022 |
Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.
Topics: Animals; Colforsin; Disease Models, Animal; Dopaminergic Neurons; Humans; Levodopa; Mesencephalon; Neurodegenerative Diseases; Parkinson Disease; Protein Kinases; Rats; Substantia Nigra | 2022 |
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson's disease.
Topics: Antiparkinson Agents; Cholinergic Agents; Dopamine; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Tremor | 2022 |
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2022 |
Abnormal connectivity model of raphe nuclei with sensory-associated cortex in Parkinson's disease with chronic pain.
Topics: Brain Mapping; Chronic Pain; Humans; Levodopa; Magnetic Resonance Imaging; Neural Pathways; Parietal Lobe; Parkinson Disease; Raphe Nuclei | 2022 |
The Entropy of Adaptively Segmented Beta Oscillations Predict Motor Improvement in Patients With Parkinson's Disease.
Topics: Beta Rhythm; Deep Brain Stimulation; Entropy; Humans; Levodopa; Parkinson Disease | 2022 |
PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study.
Topics: Aged; Gastrostomy; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
Commentary: Forel Fields' Brain Stimulation Improves Levodopa-Unresponsive Gait and Balance Disorders in Parkinson's Disease: A Case Series Study.
Topics: Brain; Deep Brain Stimulation; Gait; Humans; Levodopa; Parkinson Disease | 2022 |
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Powders | 2022 |
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
Topics: Humans; Levodopa; Parkinson Disease; Patient Acceptance of Health Care; Quality of Life; Surveys and Questionnaires | 2022 |
Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
Topics: Animals; Bacteria; Carbidopa; Cross-Sectional Studies; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Levodopa; Parkinson Disease; Rats; Tyrosine Decarboxylase | 2022 |
Mapping dopaminergic projections in the human brain with resting-state fMRI.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Brain; Cohort Studies; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease | 2022 |
Propofol Withdrawal Dyskinesia in a Parkinson's Disease Patient with Levodopa-Induced Dyskinesia.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Propofol | 2023 |
Doxorubicin induced aggregation of α-synuclein: Insights into the mechanism of drug induced Parkinsonism.
Topics: alpha-Synuclein; Doxorubicin; Humans; Levodopa; Molecular Docking Simulation; Parkinson Disease | 2022 |
COVID-19 infection presented as severe dyskinesia in a patient with Parkinson's disease: a case with daily video recording.
Topics: Antiparkinson Agents; COVID-19; Dyskinesias; Humans; Levodopa; Parkinson Disease; Video Recording | 2022 |
The quality of life in patients with Parkinson's disease: Focus on gender difference.
Topics: Cross-Sectional Studies; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Sex Factors; Surveys and Questionnaires | 2022 |
Subthalamic Nucleus Deep Brain Stimulation in a Patient with Severe Axial Symptoms and Suboptimal Levodopa Responsive Parkinson's Disease.
Topics: Deep Brain Stimulation; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2022 |
Electrode Fixation with Bone Cement or Stimloc® in Deep Brain Stimulation Surgery: A Comparative Study.
Topics: Bone Cements; Brain Neoplasms; Deep Brain Stimulation; Electrodes; Humans; Levodopa; Parkinson Disease; Pneumocephalus; Treatment Outcome; Wakefulness | 2022 |
Unpredictable motor fluctuations caused by cholecystitis in Parkinson's disease.
Topics: Antiparkinson Agents; Cholecystitis; Humans; Levodopa; Parkinson Disease | 2023 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2022 |
Improvement of non-motor and motor behavioral alterations associated with Parkinson-like disease in Drosophila melanogaster: Comparative effects of treatments with hesperidin and L-dopa.
Topics: Animals; Disease Models, Animal; Dopamine; Drosophila melanogaster; Hesperidin; Levodopa; Parkinson Disease | 2022 |
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders | 2022 |
Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson's Disease.
Topics: Biosensing Techniques; Electrodes; Humans; Levodopa; Parkinson Disease; Wearable Electronic Devices | 2022 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5 | 2022 |
[Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Tertiary Care Centers | 2022 |
What are the main considerations when prescribing pharmacotherapy for Parkinson's disease?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2022 |
Brain Morphometry Associated With Response to Levodopa and Deep Brain Stimulation in Parkinson Disease.
Topics: Brain; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2023 |
Energy Delivered by Subthalamic Deep Brain Stimulation for Parkinson Disease Correlates With Depressive Personality Trait Shift.
Topics: Aged; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Personality; Quality of Life; Treatment Outcome | 2023 |
Rare missense variants in the PPP2R5D gene associated with Parkinson's disease in the Han Chinese population.
Topics: Age of Onset; Asian People; China; Humans; Levodopa; Mutation; Mutation, Missense; Parkinson Disease; Protein Phosphatase 2 | 2022 |
Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease.
Topics: Dopamine; Gait; Humans; Hypokinesia; Levodopa; Parkinson Disease | 2022 |
Crocin Protects Malathion-Induced Striatal Biochemical Deficits by Inhibiting Apoptosis and Increasing α-Synuclein in Rats' Striatum.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Apoptosis; bcl-2-Associated X Protein; Carotenoids; Levodopa; Malathion; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Wistar; RNA, Messenger | 2022 |
Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson's disease.
Topics: Animals; Antioxidants; Dopaminergic Neurons; HEK293 Cells; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Rats; Rotenone | 2022 |
Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
Topics: Gait; Glucose; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Quality of Life | 2022 |
Effect of Levodopa Medication on Human Brain Connectome in Parkinson's Disease-A Combined Graph Theory and EEG Study.
Topics: Antiparkinson Agents; Brain; Connectome; Electroencephalography; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease | 2022 |
[Parkinson's Disease - What is New?]
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure.
Topics: Animals; Biological Availability; Brain; Dopamine; Levodopa; Parkinson Disease; Rats | 2022 |
Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson's Disease: A Cross-Sectional Study.
Topics: Cross-Sectional Studies; Female; Hallucinations; Homocysteine; Humans; Levodopa; Male; Parkinson Disease | 2022 |
Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease.
Topics: Aged; Dopamine; Dopamine Agents; Electroencephalography; Humans; Levodopa; Parkinson Disease; Postural Balance; Time and Motion Studies | 2022 |
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; United States; United States Food and Drug Administration | 2022 |
Expression of BDNF-Associated lncRNAs in Parkinson's disease.
Topics: Brain-Derived Neurotrophic Factor; Female; Humans; Levodopa; Male; Parkinson Disease; RNA, Long Noncoding | 2022 |
Dopamine depletion can be predicted by the aperiodic component of subthalamic local field potentials.
Topics: Animals; Basal Ganglia; Biomarkers; Deep Brain Stimulation; Dopamine; Levodopa; Parkinson Disease; Rats | 2022 |
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Costs and Cost Analysis; Double-Blind Method; Humans; Levodopa; Oxadiazoles; Parkinson Disease; United Kingdom | 2022 |
The Impact of Wearable Electronics in Assessing the Effectiveness of Levodopa Treatment in Parkinson's Disease.
Topics: Humans; Hypokinesia; Levodopa; Parkinson Disease; Tremor; Wearable Electronic Devices | 2022 |
Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease | 2022 |
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
Topics: Activities of Daily Living; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Germany; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Novel insights into the effects of levodopa on the up- and downstrokes of writing sequences.
Topics: Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Writing | 2022 |
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2022 |
Risk factors for motor complications in female patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Multivariate Analysis; Parkinson Disease; Risk Factors | 2022 |
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
The correlation between genetic factors and freezing of gait in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Protein Serine-Threonine Kinases; Receptors, Dopamine D2 | 2022 |
Clustering of Parkinson subtypes reveals strong influence of DRD2 polymorphism and gender.
Topics: Cluster Analysis; Female; Humans; Levodopa; Male; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2 | 2022 |
Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Case report: cold medicines cause neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease | 2022 |
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
Topics: Carbidopa; Dopamine; Dyskinesias; Humans; Levodopa; Motor Cortex; Parkinson Disease | 2022 |
Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells.
Topics: Animals; Antioxidants; Humans; Levodopa; Mice; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Xanthophylls | 2022 |
Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Disabled Persons; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease; Phosphoric Diester Hydrolases; Primates | 2022 |
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.
Topics: Adenosine Deaminase; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Gastrointestinal Microbiome; Humans; Intercellular Signaling Peptides and Proteins; Levodopa; Nitriles; Parkinson Disease; Pilot Projects; RNA, Ribosomal, 16S | 2022 |
Fiber selectivity of peripheral neuropathy in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Human Embryonic Stem Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2022 |
A rare complication of jejunal extension of a percutaneous endoscopic gastrostomy tube for levodopa-carbidopa intestinal gel administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2022 |
Pressure ulcer induced by discontinuation of levodopa: Case report of an older patient with Parkinson's disease.
Topics: Aged, 80 and over; Female; Humans; Levodopa; Parkinson Disease; Pressure Ulcer | 2022 |
Buried Bumper Syndrome is not caused by levodopa infusion. Reply to Dr Kotzampassi's Letter to the Editor. Concerning the publication: Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease. By: Spanaki C, Bour
Topics: Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2022 |
The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
Topics: Age of Onset; Cross-Sectional Studies; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Registries | 2022 |
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Quality of Life; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2022 |
Identifying rates and risk factors for medication errors during hospitalization in the Australian Parkinson's disease population: A 3-year, multi-center study.
Topics: Australia; Hospitalization; Hospitals, Urban; Humans; Levodopa; Medication Errors; Parkinson Disease; Retrospective Studies; Risk Factors | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2022 |
Refractory status epilepticus due to vitamin B
Topics: Carbidopa; Humans; Levodopa; Parkinson Disease; Status Epilepticus; Vitamin B 6; Vitamins | 2022 |
Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Surveys and Questionnaires | 2022 |
Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Levodopa; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Retina; Tyrosine 3-Monooxygenase | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2022 |
Sensitivity to gait improvement after levodopa intake in Parkinson's disease: A comparison study among synthetic kinematic indices.
Topics: Antiparkinson Agents; Biomechanical Phenomena; Dyskinesias; Gait; Humans; Levodopa; Parkinson Disease | 2022 |
Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently.
Topics: Deep Brain Stimulation; Gait; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2023 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2022 |
Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson's Disease.
Topics: Animals; Curcumin; Drug Carriers; Levodopa; Nanoparticles; Parkinson Disease; Polyesters; Polyethylene Glycols; Polymers; Rats | 2022 |
Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts.
Topics: Aged; Anemia; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Myelodysplastic Syndromes; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamin B 6 Deficiency | 2022 |
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tetrabenazine | 2022 |
Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Topics: Antiparkinson Agents; Anxiety; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease | 2023 |
A Kinematic Data-Driven Approach to Differentiate Involuntary Choreic Movements in Individuals With Neurological Conditions.
Topics: Biomechanical Phenomena; Chorea; Humans; Huntington Disease; Levodopa; Parkinson Disease | 2022 |
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2022 |
Levodopa ONOFF-state freezing of gait: Defining the gait and non-motor phenotype.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Phenotype; Quality of Life | 2022 |
Treatment initiation for parkinson's disease in Australia 2013-2018: a nation-wide study.
Topics: Adult; Aged; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2022 |
Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.
Topics: Animals; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Parkinson Disease | 2022 |
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome.
Topics: Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Dystonia; Dystonic Disorders; Humans; Hypoventilation; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2022 |
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Humans; Levodopa; Magnesium Oxide; Parkinson Disease | 2022 |
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2022 |
Subthalamic nucleus deep brain stimulation programming settings do not correlate with Parkinson's disease severity.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2022 |
Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Levodopa; Magnetic Resonance Imaging; Multimodal Imaging; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2022 |
Up-regulated expression of miRNA-29b in patients with Parkinson's disease on levodopa gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; MicroRNAs; Parkinson Disease | 2023 |
Measures of motor segmentation from rapid isometric force pulses are reliable and differentiate Parkinson's disease from age-related slowing.
Topics: Aged; Aged, 80 and over; Humans; Isometric Contraction; Levodopa; Movement; Parkinson Disease; Reproducibility of Results | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones | 2022 |
Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamins | 2022 |
Reply: Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamins | 2022 |
Interaction Between Levodopa and Banana in a Patient With Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Musa; Parkinson Disease | 2022 |
A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism.
Topics: Humans; Levodopa; Lewy Body Disease; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders | 2022 |
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
Topics: Bayes Theorem; Humans; Inosine; Levodopa; Parkinson Disease; Severity of Illness Index; Tremor; Uric Acid | 2022 |
Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test?
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease | 2022 |
[Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report].
Topics: Aged; Antiparkinson Agents; Drug Overdose; Dyskinesias; Female; Fever; Humans; Levodopa; Parkinson Disease; Purines | 2022 |
Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Weight Loss | 2022 |
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Thalamus | 2022 |
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies | 2022 |
Identifying the therapeutic zone in globus pallidus deep brain stimulation for Parkinson's disease.
Topics: Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2023 |
Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants.
Topics: Dopamine; Glucosylceramidase; Humans; Levodopa; Mutation; Parkinson Disease; Retrospective Studies | 2022 |
An approach to acute clinical deterioration in patients with late-stage Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Deterioration; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome; Wakefulness | 2023 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2022 |
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Topics: Genetic Therapy; Humans; Levodopa; Parkinson Disease | 2022 |
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Topics: Genetic Therapy; Humans; Levodopa; Parkinson Disease | 2022 |
Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Topics: Genetic Therapy; Humans; Levodopa; Parkinson Disease | 2022 |
Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Topics: Genetic Therapy; Humans; Levodopa; Parkinson Disease | 2022 |
Clinical correlates of movement disorders in adult Niemann-Pick type C patients measured via a Personal KinetiGraph.
Topics: Adult; Dyskinesias; Humans; Hypokinesia; Levodopa; Niemann-Pick Disease, Type C; Parkinson Disease | 2022 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |
Does dopamine deficiency affect sex-dependent prognosis in Parkinson's disease?
Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Prognosis | 2022 |
Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease.
Topics: alpha-Synuclein; Biomarkers; Constipation; Humans; Lactates; Levodopa; Parkinson Disease; Serum Albumin | 2022 |
Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
Topics: Gastrointestinal Motility; Gastrointestinal Tract; Glucose; Humans; Levodopa; Parkinson Disease | 2022 |
Identifying the white matter structural network of motor reserve in early Parkinson's disease.
Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; White Matter | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |
Non-reference genome transposable elements (TEs) have a significant impact on the progression of the Parkinson's disease.
Topics: Cross-Sectional Studies; Disease Progression; DNA Transposable Elements; Genome-Wide Association Study; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Polymorphism, Single Nucleotide; Retroelements | 2022 |
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Retrospective Studies | 2022 |
Discovery of levodopa-induced dyskinesia-associated genes using genomic studies in patients and Drosophila behavioral analyses.
Topics: Animals; Drosophila; Dyskinesia, Drug-Induced; Genome-Wide Association Study; Genomics; Levodopa; Parkinson Disease | 2022 |
Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Survey-Based Study.
Topics: Humans; Levodopa; Parkinson Disease; REM Sleep Behavior Disorder; Sleep; Surveys and Questionnaires | 2023 |
Levodopa responsiveness in Parkinson's disease: harnessing real-life experience with machine-learning analysis.
Topics: Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Machine Learning; Parkinson Disease | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; Gastrointestinal Microbiome; Levodopa; Metabolome; Methionine; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Neuroprotective Agents; Parkinson Disease; RNA, Ribosomal, 16S; Sarcosine | 2022 |
Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.
Topics: Essential Tremor; Humans; Levodopa; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Parkinson Disease; Pilot Projects; Thalamus; Treatment Outcome; Tremor | 2022 |
Pre-operative cognitive burden as predictor of motor outcome following bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease.
Topics: Cognition; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2022 |
Adenosine A
Topics: Adenosine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2023 |
Initiating dopamine agonists rather than levodopa in early Parkinson's disease does not delay the need for deep brain stimulation.
Topics: Deep Brain Stimulation; Dopamine Agonists; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2022 |
The effect of age and disease duration on the efficacy of subthalamic nuclei deep brain stimulation in Parkinson's disease patients.
Topics: Deep Brain Stimulation; Humans; Hypokinesia; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2022 |
Targeting Accuracy and Clinical Outcomes of Awake versus Asleep Interventional Magnetic Resonance Imaging-Guided Deep Brain Stimulation for Parkinson's Disease: The University of California, San Francisco Experience.
Topics: Deep Brain Stimulation; Humans; Levodopa; Magnetic Resonance Imaging, Interventional; Parkinson Disease; San Francisco; Treatment Outcome; Wakefulness | 2022 |
Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease.
Topics: Age of Onset; Biological Specimen Banks; Data Analysis; Humans; Late Onset Disorders; Levodopa; Parkinson Disease | 2022 |
Levodopa-dependent differences in the non-oscillatory activity of the subthalamic nucleus.
Topics: Basal Ganglia; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Parkinson Disease; Subthalamic Nucleus | 2022 |
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 2023 |
Development of l-Dopa-containing diketopiperazines as blood-brain barrier shuttle.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Caco-2 Cells; Carcinoma, Renal Cell; Diketopiperazines; Humans; Kidney Neoplasms; Levodopa; Oxidative Stress; Parkinson Disease; Rats | 2022 |
Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson's disease patients.
Topics: Administration, Oral; Adult; Computer Simulation; Delayed-Action Preparations; Drug Liberation; Humans; In Vitro Techniques; Levodopa; Models, Biological; Parkinson Disease; Solubility | 2022 |
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies.
Topics: alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Atropine Derivatives; Carbidopa; Cholinergic Antagonists; Datura metel; Dopa Decarboxylase; Haloperidol; Levodopa; Methanol; Mice; Molecular Docking Simulation; Parkinson Disease; Phytochemicals; Plant Extracts; Scopolamine | 2023 |
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipruritics; Corpus Striatum; Desipramine; Dopamine; Levodopa; Norepinephrine; Oxidopamine; Parkinson Disease; Platelet Aggregation Inhibitors; Rats; Serotonin | 2022 |
Challenges in managing late-stage Parkinson's disease: Practical approaches and pitfalls.
Topics: Humans; Levodopa; Neurodegenerative Diseases; Pain; Parkinson Disease; Psychotic Disorders | 2022 |
Probing cellular health at the muscle level-Multi-frequency bioimpedance in Parkinson's disease.
Topics: Arm; Female; Forearm; Humans; Levodopa; Male; Muscle, Skeletal; Parkinson Disease | 2022 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson's disease.
Topics: Deep Brain Stimulation; Dopamine Plasma Membrane Transport Proteins; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Tomography, X-Ray Computed; Treatment Outcome | 2022 |
Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.
Topics: COVID-19; Disabled Persons; Ethnicity; Humans; Levodopa; Motor Disorders; Palliative Care; Pandemics; Parkinson Disease; Quality of Life | 2022 |
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; NF-kappa B; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Rotenone; Signal Transduction; Toll-Like Receptor 4 | 2022 |
Neurologists' preferences for device-aided therapy for advanced Parkinson's disease in Japan.
Topics: Antiparkinson Agents; Bayes Theorem; Carbidopa; Humans; Japan; Levodopa; Neurologists; Parkinson Disease | 2023 |
Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease.
Topics: Antiparkinson Agents; Chromatography, Liquid; Cross-Sectional Studies; Humans; Levodopa; Parkinson Disease; Tyrosine Decarboxylase | 2022 |
Levodopa alters resting-state functional connectivity more selectively in Parkinson's disease with freezing of gait.
Topics: Brain; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease | 2023 |
Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia.
Topics: Cellular Senescence; Dementia; DNA, Mitochondrial; Humans; Levodopa; Lewy Body Disease; Organelle Biogenesis; Parkinson Disease; Telomere | 2022 |
[The factors impact on the urgent daytime sleepiness degree in the Parkinson's disease].
Topics: Aged; Disorders of Excessive Somnolence; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Sleep Wake Disorders; Sleepiness | 2022 |
Thermofluor-Based Optimization Strategy for the Stabilization of Recombinant Human Soluble Catechol-
Topics: Carboxy-Lyases; Catechol O-Methyltransferase; Catechols; Cysteine; Dopamine; Estrogens; Glycerol; Humans; Ionic Liquids; Levodopa; Metanephrine; Parkinson Disease; Trehalose | 2022 |
Tocotrienol-Rich Fraction and Levodopa Regulate Proteins Involved in Parkinson's Disease-Associated Pathways in Differentiated Neuroblastoma Cells: Insights from Quantitative Proteomic Analysis.
Topics: Chromatography, Liquid; Humans; Levodopa; Neuroblastoma; Parkinson Disease; Proteomics; Tandem Mass Spectrometry; Tocotrienols; Vitamin E | 2022 |
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies | 2022 |
Reversible Pisa syndrome caused by chronic subdural hematoma in a patient with Parkinson's disease: a case report.
Topics: Dopamine Agonists; Female; Hematoma, Subdural, Chronic; Humans; Levodopa; Parkinson Disease; Syndrome | 2022 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Direct Current Stimulation; Transcranial Magnetic Stimulation | 2023 |
Exploring the effects of dopamine on sensorimotor inhibition and mobility in older adults.
Topics: Aged; Dopamine; Gait; Humans; Levodopa; Male; Parkinson Disease; Walking | 2023 |
Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson's disease: Final report of a post-marketing surveillance study in Japan.
Topics: Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Hallucinations; Humans; Japan; Levodopa; Male; Parkinson Disease; Product Surveillance, Postmarketing; Prospective Studies | 2022 |
Revisiting levodopa for advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2022 |
Amino acid transporter Asc-1 (SLC7A10) expression is altered in basal ganglia in experimental Parkinsonism and L-dopa-induced dyskinesia model mice.
Topics: Amino Acid Transport System ASC; Amino Acid Transport System y+; Animals; Basal Ganglia; Dopamine; Dyskinesias; Levodopa; Mice; Parkinson Disease; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Serine | 2023 |
Quality of Life and Motor Outcomes in Patients With Parkinson's Disease 12 Months After Deep Brain Stimulation in China.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2023 |
Highly-sensitive single-step sensing of levodopa by swellable microneedle-mounted nanogap sensors.
Topics: Animals; Biosensing Techniques; Extracellular Fluid; Levodopa; Needles; Parkinson Disease; Swine | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Levodopa responsiveness and white matter alterations in Parkinson's disease: A DTI-based study and brain network analysis: A cross-sectional study.
Topics: Brain; Cross-Sectional Studies; Diffusion Tensor Imaging; Humans; Leukoaraiosis; Levodopa; Parkinson Disease; White Matter | 2022 |
The Importance of Early Identification for Parkinson's Disease Patients with Postural Instability and Gait Disturbance.
Topics: Gait; Humans; Levodopa; Logistic Models; Parkinson Disease; Tremor | 2022 |
[Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage].
Topics: Adult; Aged; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piribedil; Quality of Life; Sialorrhea; Upper Gastrointestinal Tract | 2022 |
Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Topics: Cross-Sectional Studies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Methylphenidate; Parkinson Disease; Positron-Emission Tomography; Tomography, X-Ray Computed | 2022 |
Quantitative Transcranial Sonography Evaluation of Substantia Nigra Hyperechogenicity Is Useful for Predicting Levodopa-Induced Dyskinesia in Parkinson Disease.
Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Ultrasonography; Ultrasonography, Doppler, Transcranial | 2023 |
Sleep benefit in patients with Parkinson's disease is associated with the dopamine transporter expression in putamen.
Topics: Cocaine; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Putamen; Sleep; Tremor | 2023 |
Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up.
Topics: Aged; Deep Brain Stimulation; Dyskinesias; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Tremor | 2023 |
Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Reduced Short-Latency Afferent Inhibition in Parkinson's Disease Patients with L-dopa-Unresponsive Freezing of Gait.
Topics: Dopamine; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Walking | 2022 |
Effects of Contralateral Deep Brain Stimulation and Levodopa on Subthalamic Nucleus Oscillatory Activity and Phase-Amplitude Coupling.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2023 |
Artificial Neural Network-Assisted Wearable Flexible Sweat Patch for Drug Management in Parkinson's Patients Based on Vacancy-Engineered Processing of g-C
Topics: Biosensing Techniques; Glucose; Humans; Levodopa; Parkinson Disease; Sweat; Wearable Electronic Devices | 2022 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Psychotic Disorders; Quality of Life; Rats; Rats, Sprague-Dawley | 2023 |
Time until modification of antiparkinsonian therapy in a group of patients from Colombia.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Colombia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2023 |
A Digital Architecture for the Real-Time Tracking of Wearing off Phenomenon in Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2022 |
Extra-Basal Ganglia Brain Structures Are Related to Motor Reserve in Parkinson's Disease.
Topics: Basal Ganglia; Brain; Diffusion Tensor Imaging; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
Persistent intolerable abdominal pain in patients with Parkinson's disease.
Topics: Abdominal Pain; Aged; Aged, 80 and over; Antiparkinson Agents; Disabled Persons; Humans; Levodopa; Male; Motor Disorders; Parkinson Disease; Quality of Life | 2023 |
Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease.
Topics: Aged; Deep Brain Stimulation; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2023 |
Correlation of response to subthalamic deep brain stimulation in Parkinson's disease patients with striatal dopamine transporter density on 99mtc-TRODAT-1 SPECT.
Topics: Deep Brain Stimulation; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2023 |
Pulmonary function and medication effect in mild-stage subjects with Parkinson's disease.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Humans; Levodopa; Lung; Parkinson Disease | 2022 |
Deep Brain Stimulation of the Subthalamic Nucleus and the Postoperative Levodopa Response?
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2023 |
Unilateral Focused Ultrasound Subthalamotomy for Parkinson Disease: Long-term Efficacy and Safety.
Topics: Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2023 |
The cannabinoid CB
Topics: Angiotensins; Animals; Cannabinoids; Corpus Striatum; Levodopa; Oxidopamine; Parkinson Disease; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Angiotensin; Receptors, Cannabinoid | 2023 |
Prognostic factors of unilateral prelemniscal radiations radiofrequency lesions: A surgical technique for the treatment of Parkinson's disease motor symptoms.
Topics: Child; Child, Preschool; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Treatment Outcome; Tremor | 2023 |
Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease.
Topics: Deep Brain Stimulation; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2023 |
Analysis of LIN28A variants in patients with Parkinson's disease.
Topics: Genetic Predisposition to Disease; Humans; Levodopa; Loss of Heterozygosity; Middle Aged; Parkinson Disease | 2023 |
Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study.
Topics: Behavior, Addictive; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Male; Parkinson Disease; Quality of Life | 2023 |
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
Topics: Antiparkinson Agents; Cross-Cultural Comparison; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.
Topics: Animals; Carbidopa; Catalepsy; Dopamine; Levodopa; Parkinson Disease; Rats | 2022 |
Parkinson disease primer, part 1: diagnosis.
Topics: Canada; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Patients | 2023 |
Moving chin left and right: levodopa induced dyskinesia in spinocerebellar ataxia type 3?
Topics: Antiparkinson Agents; Chin; Dyskinesias; Humans; Levodopa; Machado-Joseph Disease; Parkinson Disease | 2023 |
Stimulation of the Presupplementary Motor Area Cluster of the Subthalamic Nucleus Predicts More Consistent Clinical Outcomes.
Topics: Deep Brain Stimulation; Diffusion Tensor Imaging; Humans; Levodopa; Motor Cortex; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2023 |
Oxidative stress parameters and their relation to motor subtype of Parkinson's disease and levodopa treatment status.
Topics: Antioxidants; Female; Glutathione; Humans; Levodopa; Oxidative Stress; Parkinson Disease; Uric Acid | 2023 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Urea | 2023 |
Evoked resonant neural activity in subthalamic local field potentials reflects basal ganglia network dynamics.
Topics: Basal Ganglia; Deep Brain Stimulation; Evoked Potentials; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2023 |
Are the EEG microstates correlated with motor and non-motor parameters in patients with Parkinson's disease?
Topics: Cross-Sectional Studies; Electroencephalography; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
A novel treatment option for intrajejunal levodopa administration.
Topics: Antiparkinson Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: an In Silico Repurposing Approach.
Topics: Antipsychotic Agents; Drug Repositioning; Humans; Levodopa; Ligands; Molecular Docking Simulation; Parkinson Disease; Quality of Life; Ubiquitin-Protein Ligases | 2023 |
A case report of Parkinson's disease with acute and unmanageable myoclonic dyskinesia.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
The effect of levodopa treatment on vascular endothelial function in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2023 |
Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
Topics: Dyskinesias; Humans; Levodopa; Magnetic Resonance Imaging; Multimodal Imaging; Parkinson Disease; Substantia Nigra | 2023 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome.
Topics: Carbidopa; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2023 |
Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide | 2023 |
Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Norepinephrine Plasma Membrane Transport Proteins; Parkinson Disease | 2023 |
Parkinson disease primer, part 2: management of motor and nonmotor symptoms.
Topics: Humans; Levodopa; Mental Disorders; Parkinson Disease; Quality of Life | 2023 |
Long-term levodopa ameliorates sequence effect in simple, but not complex walking in early Parkinson's disease patients.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Walking | 2023 |
Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
Topics: Antiparkinson Agents; Cognition; Dihydropyridines; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Humans; Hypertension; Levodopa; Parkinson Disease | 2023 |
Enhanced Physicochemical Stability of the L-DOPA Extract of
Topics: Levodopa; Mucuna; Parkinson Disease; Phyllanthus emblica; Plant Extracts; Seeds; Solvents; Water | 2023 |
Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Learning; Levodopa; Parkinson Disease; Time Factors | 2023 |
The Early Treatment Phase in Parkinson's Disease: Not a Honeymoon for All, Not a Honeymoon at All?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2023 |
An Explainable Spatial-Temporal Graphical Convolutional Network to Score Freezing of Gait in Parkinsonian Patients.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Movement; Parkinson Disease | 2023 |
Artificial Intelligence-Based Voice Assessment of Patients with Parkinson's Disease Off and On Treatment: Machine vs. Deep-Learning Comparison.
Topics: Artificial Intelligence; Bayes Theorem; Deep Learning; Humans; Levodopa; Parkinson Disease | 2023 |
Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Topics: Antiparkinson Agents; Apomorphine; Feasibility Studies; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Drug-Induced; Levodopa; Male; Neurosteroids; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Glucagon-Like Peptide-1 Receptor; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid | 2023 |
Predicting impulse control disorder in Parkinson's Disease: Is there a formula?
Topics: Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Food, Formulated; Humans; Levodopa; Parkinson Disease | 2023 |
The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Deglutition Disorders; Dementia; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Timely referral for device-aided therapy in Parkinson's disease. Development of a screening tool.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Dyskinesias; Humans; Levodopa; Parkinson Disease; Referral and Consultation | 2023 |
Biochemical study of the effect of mesenchymal stem cells-derived exosome versus L-Dopa in experimentally induced Parkinson's disease in rats.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Exosomes; Humans; Levodopa; Male; Mesenchymal Stem Cells; MicroRNAs; Neurodegenerative Diseases; Parkinson Disease; Rats; RNA, Circular; Ubiquitin-Protein Ligases | 2023 |
[Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?]
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2023 |
Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort.
Topics: Germany; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease | 2023 |
Dopamine-independent development and maintenance of mouse striatal medium spiny neuron dendritic spines.
Topics: Animals; Corpus Striatum; Dendritic Spines; Dopamine; Levodopa; Medium Spiny Neurons; Mice; Neurons; Parkinson Disease | 2023 |
Modulation of cytotoxic amyloid fibrillation and mitochondrial damage of α-synuclein by catechols mediated conformational changes.
Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Catechols; Humans; Levodopa; Neuroblastoma; Parkinson Disease | 2023 |
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease; Quality of Life; Risk Factors; Zonisamide | 2023 |
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson's disease patient with Parkin gene mutation: a case report.
Topics: Adult; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Male; Mutation; Parkinson Disease; Pramipexole; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2023 |
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Retrospective Studies | 2023 |
Gender differences in microRNA expression in levodopa-naive PD patients.
Topics: Biomarkers; Female; Humans; Levodopa; Male; MicroRNAs; Parkinson Disease; Sex Factors | 2023 |
New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease | 2023 |
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease | 2023 |
[Motor and autonomic disorders influence on pain syndrome of patients with Parkinson's disease of the I-III H&Y stages].
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piribedil; Quality of Life | 2023 |
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?
Topics: Atrophy; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Poland Syndrome | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Normalization effect of dopamine replacement therapy on brain functional connectome in Parkinson's disease.
Topics: Brain; Connectome; Dopamine; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Retrospective Studies | 2023 |
Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine; Gain of Function Mutation; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2023 |
Shaping the course of early-onset Parkinson's disease: insights from a longitudinal cohort.
Topics: Age of Onset; Brain; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Reduced syntactic recursion in spontaneous speech of Parkinson's disease patients.
Topics: Humans; Language; Levodopa; Parkinson Disease; Semantics; Speech | 2023 |
Fecal microbiota transplantation for Parkinson's disease using levodopa - carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Fecal Microbiota Transplantation; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Predicting Motor Outcome and Quality of Life After Subthalamic Deep Brain Stimulation for Parkinson's Disease: The Role of Standard Screening Measures and Wearable-Data.
Topics: Cohort Studies; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome; Wearable Electronic Devices | 2023 |
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Primates; Quality of Life | 2023 |
[Current Pharmacological Treatment for Parkinson's Disease].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2023 |
Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
Topics: Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; East Asian People; Humans; Levodopa; Parkinson Disease; Prospective Studies; Treatment Outcome | 2023 |
Long-term safety of medical cannabis in Parkinson's disease: A retrospective case-control study.
Topics: Aged; Case-Control Studies; Humans; Levodopa; Medical Marijuana; Middle Aged; Parkinson Disease; Retrospective Studies | 2023 |
Continuous levodopa production by an artificial enzyme.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2023 |
The effects of safinamide on dysphagia in Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies | 2023 |
Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson's Disease.
Topics: alpha-Synuclein; Biomarkers; Humans; Levodopa; MicroRNAs; Parkinson Disease | 2023 |
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.
Topics: Antiparkinson Agents; Double-Blind Method; Doxycycline; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
The adenosine A
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Drug Inverse Agonism; Levodopa; Motor Activity; Parkinson Disease; Receptor, Adenosine A2A | 2023 |
Task Specific Tremor in Parkinson's Disease Responds to Apomorphine.
Topics: Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Effects of the combined treatment of bilateral subthalamic nucleus stimulation and levodopa on balance and mobility in Parkinson's disease.
Topics: Adult; Aged; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2023 |
Intravenous Magnesium Sulfate Reduces Tremor Severity: A Case Series.
Topics: Activities of Daily Living; Humans; Levodopa; Magnesium Sulfate; Parkinson Disease; Tremor | 2023 |
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2023 |
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; Levodopa; Oxidopamine; Parkinson Disease | 2023 |
Understanding the Molecular Aspects of Vitamins in Parkinson's Disease: Present-day Concepts and Perspectives.
Topics: Antioxidants; Humans; Levodopa; Parkinson Disease; Vitamin A; Vitamin K; Vitamins | 2023 |
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats | 2023 |
Smartphone-based detection of levodopa in human sweat using 3D printed sensors.
Topics: Humans; Levodopa; Parkinson Disease; Printing, Three-Dimensional; Smartphone; Sweat | 2023 |
Substantia nigra nigrosome-1 imaging correlates with the severity of motor symptoms in Parkinson's disease.
Topics: Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Substantia Nigra | 2023 |
Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation.
Topics: Ascorbic Acid; Drug Carriers; Humans; Levodopa; Liposomes; Parkinson Disease | 2023 |
Screening Tools for Sarcopenia in Mild to Moderate Parkinson's Disease: Assessing the Accuracy of SARC-F and Calf Circumference.
Topics: Adult; Cross-Sectional Studies; Female; Hand Strength; Humans; Levodopa; Male; Parkinson Disease; Sarcopenia; Surveys and Questionnaires | 2023 |
Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; GABAergic Neurons; Halorhodopsins; Levodopa; Mice; Parkinson Disease; Pars Reticulata; Substantia Nigra | 2023 |
Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Response to 'Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out'.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Patient Acceptance of Health Care; Retrospective Studies | 2023 |
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration.
Topics: Antiparkinson Agents; Hospitalization; Humans; Inpatients; Levodopa; Parkinson Disease | 2023 |
Effect of the mGlu
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders; Rats | 2023 |
Gait Declines Differentially in, and Improves Prediction of, People with Parkinson's Disease Converting to a Freezing of Gait Phenotype.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2023 |
Are Parkinson's disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged?
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson's disease.
Topics: Aged; Disease Progression; Female; Humans; Levodopa; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Severity of Illness Index | 2023 |
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
Topics: Animals; Drugs, Chinese Herbal; Levodopa; Nardostachys; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2023 |
Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiparkinson Agents; Artificial Intelligence; Dopamine; Histamine Antagonists; Humans; Levodopa; Parkinson Disease | 2023 |
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Reversal of pathological motor behavior in a model of Parkinson's disease by striatal dopamine uncaging.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Mice; Neostriatum; Parkinson Disease | 2023 |
Time perception reflects individual differences in motor and non-motor symptoms of Parkinson's disease.
Topics: Dopamine; Humans; Individuality; Levodopa; Parkinson Disease; Time Perception | 2023 |
Anxiety in Parkinson's Disease Is Associated with Changes in Brain Structural Connectivity.
Topics: Anxiety; Brain; Gray Matter; Humans; Levodopa; Parkinson Disease | 2023 |
Evoked responses to single pulse electrical stimulation reveal impaired striatal excitability in a rat model of Parkinson's disease.
Topics: Animals; Dopamine; Electric Stimulation; Levodopa; Oxidopamine; Parkinson Disease; Quality of Life; Rats | 2023 |
Impulse Control Disorders in the Polish Population of Patients with Parkinson's Disease.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease; Poland; Prospective Studies | 2023 |
Multimodal imaging study of the 5-HT
Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin | 2023 |
Exploring the prescribing trends and factors affecting initial anti-parkinsonian drug selection in Korea: A nationwide population-based cohort study.
Topics: Aged; Alzheimer Disease; Cohort Studies; Humans; Levodopa; Parkinson Disease; Peptic Ulcer; Republic of Korea | 2023 |
Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Transcranial Magnetic Stimulation | 2023 |
A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
Topics: Antiparkinson Agents; COVID-19; COVID-19 Vaccines; Humans; Levodopa; Parkinson Disease; Vaccination | 2023 |
Slow wave activity across sleep-night could predict levodopa-induced dyskinesia.
Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Sleep; Sleep, Slow-Wave | 2023 |
Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.
Topics: Delayed-Action Preparations; Humans; Levodopa; Maintenance; Parkinson Disease; Patient Compliance | 2023 |
Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson's disease: Results of acute levodopa challenge test.
Topics: Antiparkinson Agents; Blood Pressure; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Risk Factors | 2023 |
[Subthalamic deep brain stimulation in a case of idiopathic Parkinson's disease and schizophrenia].
Topics: Antipsychotic Agents; Deep Brain Stimulation; Humans; Levodopa; Male; Parkinson Disease; Schizophrenia | 2023 |
SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Topics: Benzylamines; Humans; Levodopa; Parkinson Disease; Synapses | 2023 |
Device-aided therapies for Parkinson's disease: "All for one, one for all, that is our device".
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2023 |
The role of opicapone in the management of Parkinson's disease: an Italian consensus through a combined Nominal Group Technique and Delphi approach.
Topics: Catechol O-Methyltransferase; Consensus; Humans; Levodopa; Parkinson Disease | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2023 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study.
Topics: Aged; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2023 |
Scaling problem in Parkinson's disease patients with pain.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
[Survey on the Current Advertising and Sales of Mucuna pruriens in Consumer-to-consumer Internet Trading in Japan].
Topics: Advertising; Humans; Japan; Levodopa; Mucuna; Parkinson Disease; Phytotherapy; Plant Extracts | 2023 |
Novel RAB39B variant associated intellectual disability and levodopa-responsive young-onset parkinsonism.
Topics: Adult; Child; Humans; Intellectual Disability; Levodopa; Male; Mutation; Parkinson Disease; Parkinsonian Disorders | 2023 |
Stereotactic Staged Asymmetric Bilateral Radiofrequency Lesioning for Parkinson's Disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Thalamus; Treatment Outcome | 2023 |
COF-Coated Microelectrode for Space-Confined Electrochemical Sensing of Dopamine in Parkinson's Disease Model Mouse Brain.
Topics: Animals; Brain; Dopamine; Levodopa; Metal-Organic Frameworks; Mice; Microelectrodes; Parkinson Disease | 2023 |
Antinociceptive effects of carbidopa levodopa on normal rats and Parkinson's disease mice.
Topics: Analgesics; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Mice; Pain; Parkinson Disease; Rats | 2023 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Levodopa-induced dyskinesia in early-onset Parkinson's disease (EOPD) associates with glucocerebrosidase mutation: A next-generation sequencing study in EOPD patients in Thailand.
Topics: Age of Onset; Dyskinesias; Glucosylceramidase; High-Throughput Nucleotide Sequencing; Homozygote; Humans; Levodopa; Mutation; Parkinson Disease; Sequence Deletion; Thailand | 2023 |
Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; Inflammation; Levodopa; Mice; Microglia; Minocycline; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Genetic Therapy; Humans; Levodopa; Mice; Neurons; Parkinson Disease; Primates; Receptors, Dopamine D1 | 2023 |
A novel pathway of levodopa metabolism by commensal Bifidobacteria.
Topics: Bifidobacterium; Bifidobacterium bifidum; Humans; Levodopa; Parkinson Disease | 2023 |
Aberrations in temporal dynamics of cognitive processing induced by Parkinson's disease and Levodopa.
Topics: Antiparkinson Agents; Brain; Cognition; Humans; Levodopa; Parkinson Disease | 2023 |
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinson Disease | 2023 |
A metabolomics study in aqueous humor discloses altered arginine metabolism in Parkinson's disease.
Topics: Aqueous Humor; Arginine; Biomarkers; Humans; Levodopa; Parkinson Disease; Putrescine | 2023 |
Drug Metabolism as a Community Effort.
Topics: Bacteria; Gastrointestinal Microbiome; Humans; Levodopa; Parkinson Disease | 2019 |
Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Immediate effects of rhythmic auditory stimulation on gait kinematics in Parkinson's disease ON/OFF medication.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antiparkinson Agents; Biomechanical Phenomena; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Treatment Outcome | 2019 |
Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management.
Topics: Antiparkinson Agents; Biosensing Techniques; Electrochemical Techniques; Electrodes; Equipment Design; Humans; Levodopa; Parkinson Disease | 2019 |
Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies; United States | 2019 |
Comment on "Small Fiber Neuropathy in Parkinson's disease explored by the sudoscan".
Topics: Humans; Levodopa; Parkinson Disease; Small Fiber Neuropathy | 2019 |
Forward and backward walking in Parkinson disease: A factor analysis.
Topics: Aged; Case-Control Studies; Factor Analysis, Statistical; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Walking | 2019 |
The gut microbiota: A novel therapeutic target in Parkinson's disease?
Topics: Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Levodopa; Parkinson Disease; Tyrosine Decarboxylase | 2019 |
Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
Topics: Antiparkinson Agents; China; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Risk Factors | 2020 |
Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neostriatum; Parkinson Disease; Protein Isoforms; Proto-Oncogene Proteins c-fos; Up-Regulation | 2019 |
Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2019 |
Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner.
Topics: Aged; Decision Making; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk-Taking | 2019 |
The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in parkinsonian visual hallucinations: Electrophysiological correlates.
Topics: Aged, 80 and over; Antiparkinson Agents; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Transcranial Magnetic Stimulation | 2019 |
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Topics: Animals; Cyclic AMP; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction | 2019 |
Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.
Topics: Aged; Deep Brain Stimulation; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus | 2019 |
Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson's tremor.
Topics: Aged; Basal Ganglia; Brain; Cerebellum; Dopamine; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease; Thalamus; Tremor | 2019 |
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2019 |
Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Pressure; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2019 |
A new semi-supervised approach for characterizing the Arabic on-line handwriting of Parkinson's disease patients.
Topics: Aged; Algorithms; Case-Control Studies; Cluster Analysis; Handwriting; Humans; Language; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Pattern Recognition, Automated; Principal Component Analysis; Programming Languages; Software; Support Vector Machine | 2020 |
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.
Topics: Animals; Antiparkinson Agents; Bone Diseases, Metabolic; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Osteoporosis; Parkinson Disease | 2019 |
[Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
Topics: Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Dopamine; Drug Combinations; Duodenum; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Metabolic Networks and Pathways; Methionine; Middle Aged; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2019 |
"New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction".
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Female; Galvanic Skin Response; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sweating | 2019 |
Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenoscopy; Female; Gastrostomy; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Precision Medicine; Stochastic Processes | 2020 |
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cause of Death; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Brain; Case-Control Studies; Cerebral Cortex; Connectome; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Thalamus; White Matter | 2019 |
Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies | 2019 |
L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered.
Topics: Humans; Levodopa; Mitochondria; Parkinson Disease | 2019 |
Spin turns in advanced Parkinson's disease: A new clinical gait sign?
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Integrated robotics platform with haptic control differentiates subjects with Parkinson's disease from controls and quantifies the motor effects of levodopa.
Topics: Aged; Antiparkinson Agents; Exoskeleton Device; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Robotics | 2019 |
Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Female; France; Gastrostomy; Gels; Humans; Infusion Pumps; Intestinal Absorption; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes | 2020 |
The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia.
Topics: Adult; Age of Onset; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease | 2019 |
Levodopa response in later stages of Parkinson's disease: A case-control study.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dementia; Disease Progression; Female; Humans; Levodopa; Male; Parkinson Disease | 2020 |
Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
Topics: Activities of Daily Living; Aged; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results | 2020 |
The characteristics and treatment patterns of patients with Parkinson's disease in the United States and United Kingdom: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Databases, Factual; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; United Kingdom; United States | 2019 |
Insight into the molecular mechanism underlying the inhibition of α-synuclein aggregation by hydroxytyrosol.
Topics: Acetates; alpha-Synuclein; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Cyclopentane Monoterpenes; Humans; Levodopa; Molecular Structure; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Binding; Protein Conformation; Proteolysis; Pyrans | 2020 |
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Wearable Electronic Devices; Wrist; Wrist Joint | 2019 |
[Parkinson's syndromes in geriatric patients : Epidemiological, clinical and therapeutic characteristics].
Topics: Aged; Germany; Humans; Levodopa; Parkinson Disease; Speech Therapy; Syndrome | 2019 |
Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
Topics: Aged; Anisotropy; Antiparkinson Agents; Atlases as Topic; Diffusion Tensor Imaging; Female; Humans; Levodopa; Male; Melanins; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Substantia Nigra; White Matter | 2020 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2020 |
Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cystatin C; Female; Homocysteine; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Risk Factors; Triglycerides | 2020 |
Synergic control of action in levodopa-naïve Parkinson's disease patients: I. Multi-finger interaction and coordination.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Psychomotor Performance | 2020 |
Freezing of Gait and Its Levodopa Paradox.
Topics: Antiparkinson Agents; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2020 |
Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2019 |
Analyzing Apomorphine-Mediated Effects in a Cell Model for Parkinson's Disease with Partial Least Squares Structure Equation Modeling.
Topics: Apomorphine; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Least-Squares Analysis; Levodopa; Male; Microarray Analysis; Nausea; Parkinson Disease; Transcriptome | 2020 |
Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study.
Topics: Aged; Body Mass Index; Case-Control Studies; Constipation; Deglutition Disorders; Dopamine Agents; Dyskinesias; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2020 |
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
Topics: Aged; Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2020 |
Dyskinesia matters.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Metabolic Network Abnormalities in Drug-Naïve Parkinson's Disease.
Topics: Humans; Italy; Levodopa; Metabolic Networks and Pathways; Parkinson Disease; Pharmaceutical Preparations | 2020 |
Extended release levodopa at bedtime as a treatment for nocturiain Parkinson's disease: An open label study.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Urinary Bladder, Overactive; Urination Disorders | 2020 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
[Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease].
Topics: alpha-Synuclein; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Biomarkers; Computational Biology; Disease Models, Animal; Dyskinesias; Gene Expression Profiling; Gene Regulatory Networks; Immunohistochemistry; Levodopa; Models, Biological; Parkinson Disease; Rats; RNA, Long Noncoding; Transcriptome | 2020 |
Improving Automatic Tremor and Movement Motor Disorder Severity Assessment for Parkinson's Disease with Deep Joint Training.
Topics: Cohort Studies; Diagnosis, Computer-Assisted; Hand; Humans; Levodopa; Motor Disorders; Parkinson Disease; Severity of Illness Index; Tremor | 2019 |
Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
Topics: Acetylcholinesterase; Animals; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cholinesterase Inhibitors; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phytochemicals | 2020 |
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
Reply to: "Predictors of motor complications in early Parkinson's disease".
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Prospective Studies | 2020 |
Predictors of Motor Complications in Early Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Prospective Studies | 2020 |
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Disease Models, Animal; Levodopa; Parkinson Disease; Primates | 2020 |
A multiple motion sensors index for motor state quantification in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Support Vector Machine; Sweden; Walking; Wearable Electronic Devices; Wrist | 2020 |
Patient-controlled variable dosing of levodopa for Parkinson's disease.
Topics: Aged, 80 and over; Anxiety; Drug Administration Schedule; Female; Humans; Levodopa; Parkinson Disease; Self Administration | 2020 |
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; GABA Modulators; Levodopa; Male; MPTP Poisoning; Parkinson Disease; Psychoses, Substance-Induced; Pyridines; Receptors, Metabotropic Glutamate; Sulfonamides | 2020 |
Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.
Topics: Adult; Aged; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time | 2020 |
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Humans; Levodopa; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Motor Activity; Neostriatum; Oxidopamine; Parkinson Disease; Phenotype; Rats, Sprague-Dawley; Reproducibility of Results; Substantia Nigra | 2020 |
Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide | 2020 |
Istradefylline (Nourianz) for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Comorbidity; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Leukoaraiosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Risk | 2020 |
Objective sleep measures between patients with Parkinson's disease and community-based older adults.
Topics: Aged; Cross-Sectional Studies; Humans; Levodopa; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders | 2020 |
Does REM sleep behavior disorder change in the progression of Parkinson's disease?
Topics: Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Sleep, REM | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease; Receptors, Dopamine D5 | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, Drug-Induced; Electrophysiology; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2020 |
Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease.
Topics: Brain; Dopamine; Humans; Levodopa; Magnetic Resonance Imaging; Neural Pathways; Parkinson Disease | 2020 |
A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2020 |
Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI- and MER-guided lead placement.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Subthalamic Nucleus; Thalamus; Treatment Outcome | 2020 |
Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Motor Activity; Parkinson Disease; Time Factors; Treatment Outcome | 2020 |
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood-Brain Barrier; Cell Death; Cognitive Dysfunction; Disease Models, Animal; Dopaminergic Neurons; Fatty Acid Binding Protein 3; Levodopa; Ligands; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological | 2020 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gonorrhea; Humans; Levodopa; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Tetrahydronaphthalenes; Thiophenes | 2020 |
Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Female; Humans; Kazakhstan; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Sex Factors; Young Adult | 2020 |
Regulation of Protein Synthesis and Apoptosis in Lymphocytes of Parkinson Patients: The Effect of Dopaminergic Treatment.
Topics: Antiparkinson Agents; Apoptosis; Dopamine Agents; eIF-2 Kinase; Female; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; TOR Serine-Threonine Kinases | 2019 |
Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesias; Genetic Therapy; Humans; Levodopa; Parkinson Disease | 2020 |
Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study.
Topics: Cross-Sectional Studies; Fatigue; Humans; Japan; Levodopa; Parkinson Disease; Severity of Illness Index | 2020 |
"On-State" Freezing of Gait: Insights and Treatment With Levodopa Intestinal Gel Infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
A pragmatic, personalised approach to treatment initiation in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Precision Medicine | 2020 |
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gels; Humans; Levodopa; Parkinson Disease; Pilot Projects; Posture | 2020 |
Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?
Topics: Africa South of the Sahara; Developing Countries; Dopamine Agents; Ghana; Humans; Levodopa; Mucuna; Parkinson Disease; Plant Preparations; Seeds | 2020 |
Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects | 2020 |
The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Quality of Life | 2020 |
The Role of the Subthalamic Nucleus in Inhibitory Control of Oculomotor Behavior in Parkinson's Disease.
Topics: Aged; Deep Brain Stimulation; Eye Movements; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Saccades; Subthalamic Nucleus | 2020 |
The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population.
Topics: Aged; Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Prospective Studies | 2020 |
Influence of levodopa on orthostatic hypotension in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Synaptic Transmission; Up-Regulation | 2020 |
Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Diagnostic Techniques, Neurological; Facial Muscles; Female; Humans; Levodopa; Male; Middle Aged; Mouth; Muscle Strength; Parkinson Disease; Prospective Studies; Voice Quality | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate | 2020 |
Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.
Topics: Animals; Cattle; Cell Line; Disease Models, Animal; Dopamine; Dyskinesias; Indoles; Levodopa; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Nanoparticles; Parkinson Disease; Polymers | 2020 |
Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Patient Dropouts; Sex Factors | 2020 |
Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation.
Topics: Aged; Aged, 80 and over; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dyskinesias; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Surveys and Questionnaires | 2020 |
Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls.
Topics: Aged; Cognitive Dysfunction; Decision Making; Dopamine Agents; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2020 |
Gait Characteristics under Imposed Challenge Speed Conditions in Patients with Parkinson's Disease During Overground Walking.
Topics: Aged; Case-Control Studies; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Walking; Walking Speed; Wearable Electronic Devices | 2020 |
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials | 2020 |
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Cytokines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurons; Parkinson Disease; T-Lymphocytes | 2020 |
Initial motor reserve and long-term prognosis in Parkinson's disease.
Topics: Aged; Corpus Striatum; Disease Progression; Dopamine; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Prognosis; Time Factors | 2020 |
Predicting levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
What can Parkinson's disease teach us about COVID-19?
Topics: Antiparkinson Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Levodopa; Pandemics; Parkinson Disease; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Impaired circadian heart rate variability in Parkinson's disease: a time-domain analysis in ambulatory setting.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Circadian Rhythm; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease; Pilot Projects; Primary Dysautonomias | 2020 |
Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2020 |
[Movement Disorders: What Are You Doing? What Can We Do?]
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Essential Tremor; Humans; Levodopa; Parkinson Disease | 2020 |
Outcome of Parkinson's Disease Patients Affected by COVID-19.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Carbidopa; Coronavirus Infections; COVID-19; Female; Humans; Levodopa; Male; Pandemics; Parkinson Disease; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Analysis of factors associated with brittle response in patients with Parkinson's disease.
Topics: Adult; Body Mass Index; Body Weight; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Time Factors | 2020 |
Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Disease Models, Animal; Eugenol; Glutathione; Levodopa; Lipid Peroxidation; Male; Motor Activity; Neuroprotective Agents; Nitrites; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2020 |
L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Parkinson Disease | 2020 |
Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.
Topics: Antiparkinson Agents; Cost Savings; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2020 |
Levodopa infusion in Parkinson's disease: Individual quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Cost of Illness; Drug Combinations; Female; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prospective Studies; Psychomotor Performance; Quality of Life; Treatment Outcome | 2020 |
Clinical experience of comprehensive treatment on the balance function of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Disability Evaluation; Disabled Persons; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Care Team; Physical Therapy Modalities; Postural Balance; Psychotherapy; Quality of Life; Subthalamic Nucleus | 2020 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger | 2020 |
Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini.
Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Dyskinesia Matters: But Not as Much as It Used to.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
Biphasic Levodopa-Induced Freezing of Gait in Parkinson's Disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease | 2020 |
RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; DNA-Binding Proteins; Dyskinesia, Drug-Induced; Guanine Nucleotide Exchange Factors; Humans; Levodopa; Mammals; Parkinson Disease; TOR Serine-Threonine Kinases | 2020 |
Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid | 2020 |
Levodopa Facilitates Prefrontal Cortex Activation During Dual Task Walking in Parkinson Disease.
Topics: Aged; Dopamine Agents; Executive Function; Female; Functional Neuroimaging; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance; Spectroscopy, Near-Infrared | 2020 |
Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease.
Topics: Anger; Antiparkinson Agents; Case-Control Studies; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Obsessive Behavior; Parkinson Disease; Risk Factors; Sensitivity and Specificity; Treatment Failure | 2019 |
[New Therapeutic Options for the Individualised Titration of Levodopa].
Topics: Antiparkinson Agents; Carbidopa; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Pearls and Oy-sters: Vitamin B
Topics: Aged, 80 and over; Antiparkinson Agents; Carbidopa; Electroencephalography; Epilepsy; Fatal Outcome; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Status Epilepticus; Vitamin B 6 Deficiency | 2020 |
Association between dopaminergic medications and REM sleep behavior disorder in Parkinson's disease: a preliminary cohort study.
Topics: Cohort Studies; Humans; Levodopa; Parkinson Disease; REM Sleep Behavior Disorder; Retrospective Studies | 2020 |
High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Hyponatremia; Levodopa; Parkinson Disease | 2020 |
Decision Support for Medication Change of Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Europe; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Optimal target localisation and eight-year outcome for subthalamic stimulation in patients with Parkinson's disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2021 |
Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.
Topics: Alleles; Asian People; Case-Control Studies; Catechol O-Methyltransferase; Female; Haplotypes; Humans; Levodopa; Linkage Disequilibrium; Male; Parkinson Disease; Polymorphism, Single Nucleotide | 2020 |
Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Pain; Parkinson Disease | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Dopaminergic Neurons; Drugs, Chinese Herbal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Fallopia multiflora; Forelimb; Levodopa; Medial Forebrain Bundle; Mesencephalon; Open Field Test; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rehmannia | 2020 |
Gastrointestinal surgical procedures affect levodopa pharmacokinetics in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Digestive System Surgical Procedures; Gastrectomy; Gastric Bypass; Humans; Levodopa; Male; Parkinson Disease | 2020 |
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
Topics: Aged; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cost Savings; Delivery of Health Care; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Retrospective Studies | 2020 |
From Mucuna Pruriens to deep brain stimulation: A two-decade case history.
Topics: Deep Brain Stimulation; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease | 2020 |
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies | 2020 |
Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Hospital Departments; Hospitalization; Hospitals, Urban; Humans; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease; Process Assessment, Health Care; Quality Improvement; Time Factors | 2020 |
Early morning off in patients with Parkinson's disease: a Chinese nationwide study and a 7-question screening scale.
Topics: Aged; China; Dystonia; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Surveys and Questionnaires | 2020 |
Deep brain stimulation and eye movements.
Topics: Deep Brain Stimulation; Eye Movements; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2021 |
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease | 2020 |
EQUIDopa: A responsive web application for the levodopa equivalent dose calculator.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2020 |
Effects of Deep Brain Stimulation on Postural Control in Parkinson's Disease.
Topics: Aged; Deep Brain Stimulation; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Tremor | 2020 |
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2020 |
Update on the diagnosis and management of Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome; Tremor | 2020 |
Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2020 |
Waveform changes with the evolution of beta bursts in the human subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Beta Rhythm; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2020 |
Prospecting for new catechol-
Topics: Aged; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Humans; Levodopa; Molecular Docking Simulation; Molecular Dynamics Simulation; Parkinson Disease | 2021 |
Hypomimia in Parkinson's disease: an axial sign responsive to levodopa.
Topics: Antiparkinson Agents; Facial Expression; Humans; Hypokinesia; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Quality of Life | 2020 |
Levodopa inhalation powder in a patient with persistent asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dopamine Agents; Dry Powder Inhalers; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Powders | 2020 |
Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; History, 20th Century; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pars Compacta | 2020 |
Development of a novel gripping test for the evaluation of the finger fine motor ability in MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Deep Brain Stimulation; Disease Models, Animal; Fingers; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; MPTP Poisoning; Neuropsychological Tests; Parkinson Disease; Reproducibility of Results; Subthalamic Nucleus | 2020 |
Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil.
Topics: Animals; Behavior, Animal; Carbidopa; Coconut Oil; Corpus Striatum; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Rats, Sprague-Dawley | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Immunomodulatory effect and clinical outcome in Parkinson's disease patients on levodopa-pramipexole combo therapy: A two-year prospective study.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Factors; Levodopa; Longitudinal Studies; Parkinson Disease; Pramipexole; Prospective Studies; Time Factors; Treatment Outcome | 2020 |
Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home.
Topics: Cross-Sectional Studies; Humans; Levodopa; Nursing Homes; Parkinson Disease; Parkinsonian Disorders | 2021 |
Base-peak assessment of levodopa response and detection of fluctuating patients in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease | 2020 |
Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca fascicularis; Microglia; Parkinson Disease | 2020 |
Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder.
Topics: Aged; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reward | 2020 |
Predictors of Pharyngeal Dysphagia in Patients with Parkinson's Disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Deglutition Disorders; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Risk; Severity of Illness Index; Tremor | 2020 |
Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease.
Topics: Activities of Daily Living; Aged; Cross-Sectional Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Social Participation | 2020 |
Differential coulometry based on dual screen-printed strips for high accuracy levodopa determination towards Parkinson's disease management.
Topics: Antiparkinson Agents; Disease Management; Electrochemical Techniques; Electrodes; Humans; Levodopa; Parkinson Disease | 2020 |
Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Chromatography, High Pressure Liquid; Dyskinesia, Drug-Induced; Endocannabinoids; Humans; Levodopa; Parkinson Disease | 2020 |
Prediction and Estimation of Parkinson's Disease Severity Based on Voice Signal.
Topics: Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Speech; Voice | 2022 |
Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Handwriting; Humans; Levodopa; Movement; Parkinson Disease | 2020 |
Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors | 2020 |
Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study.
Topics: Activities of Daily Living; Cohort Studies; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2020 |
Long duration response in Parkinson's disease: levodopa revisited.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Time Factors | 2020 |
Dopamine is associated with prioritization of reward-associated memories in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine; Female; Humans; Learning; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Reinforcement, Psychology; Reward | 2020 |
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Motor Disorders; Parkinson Disease | 2020 |
GraphNet-based imaging biomarker model to explain levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Biomarkers; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
Accelerated habitual learning resulting from L-dopa exposure in rats is prevented by N-acetylcysteine.
Topics: Acetylcysteine; Animals; Antioxidants; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Dopamine; Dopamine Agents; Glutamic Acid; Habits; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Long-Evans | 2020 |
Dopaminergic therapy and prefrontal activation during walking in individuals with Parkinson's disease: does the levodopa overdose hypothesis extend to gait?
Topics: Dopamine; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Walking | 2021 |
Assessment of Wearing Off in Parkinson's disease using objective measurement.
Topics: Antiparkinson Agents; Humans; Hypokinesia; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Recovery of Impaired Endogenous Pain Modulation by Dopaminergic Medication in Parkinson's Disease.
Topics: Dopamine Agents; Humans; Levodopa; Pain; Pain Threshold; Parkinson Disease | 2020 |
Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy.
Topics: Aged; Antiparkinson Agents; Circadian Rhythm; Cross-Sectional Studies; Humans; Levodopa; Melatonin; Parkinson Disease | 2020 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features.
Topics: Diagnosis, Differential; Humans; Levodopa; Magnetic Resonance Imaging; Multiple System Atrophy; Parkinson Disease; Putamen; Supranuclear Palsy, Progressive | 2021 |
Parcellation of the Subthalamic Nucleus in Parkinson's Disease: A Retrospective Analysis of Atlas- and Diffusion-Based Methods.
Topics: Aged; Atlases as Topic; Cluster Analysis; Deep Brain Stimulation; Diffusion Tensor Imaging; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2020 |
The importance of evaluation of gastrointestinal symptoms in advanced Parkinson’s disease
Topics: Antiparkinson Agents; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2020 |
Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases | 2020 |
Nonlinear pharmacodynamics of levodopa through Parkinson's disease progression.
Topics: Antiparkinson Agents; Basal Ganglia; Disease Progression; Humans; Levodopa; Parkinson Disease | 2020 |
Longitudinal association between dopamine agonists and weight in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Compulsive Behavior; Dopamine Agonists; Feeding and Eating Disorders; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Weight Gain; Weight Loss | 2020 |
Estimation of Parkinson's disease severity from voice features of vowels and consonant.
Topics: Humans; Levodopa; Parkinson Disease; Phonation; Voice | 2020 |
Optimizing Individualized Treatment Planning for Parkinson's Disease Using Deep Reinforcement Learning.
Topics: Clinical Decision-Making; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Dyskinesia Severity Estimation in Patients with Parkinson's Disease Using Wearable Sensors and A Deep LSTM Network.
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Wearable Electronic Devices | 2020 |
Clinical patterns of gait freezing in Parkinson's disease and their response to interventions: An observer-blinded study.
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Single-Blind Method; Subthalamic Nucleus; Treatment Outcome; Video Recording | 2020 |
Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Hypokinesia; Infant, Newborn; Levodopa; Parkinson Disease; Treatment Outcome; Tremor; Trihexyphenidyl | 2020 |
Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Dopamine Plasma Membrane Transport Proteins; Eating; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Parkinson Disease; Psychomotor Performance; Tolcapone; Vesicular Monoamine Transport Proteins | 2020 |
Intraoperative Neurophysiologic Assessment in Deep Brain Stimulation Surgery and its Impact on Lead Placement.
Topics: Aged; Deep Brain Stimulation; Female; Humans; Intraoperative Neurophysiological Monitoring; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2021 |
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2020 |
Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
Topics: Dopamine; History, 20th Century; Humans; Levodopa; Male; Neurosciences; Parkinson Disease; Physicians | 2020 |
Synergic control of action in levodopa-naïve Parkinson's disease patients: II. Multi-muscle synergies stabilizing vertical posture.
Topics: Humans; Levodopa; Muscle, Skeletal; Parkinson Disease; Postural Balance; Posture | 2020 |
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease | 2021 |
A man in his fifties with increasing motor fluctuations, sleep impairment and altered mental status.
Topics: Antiparkinson Agents; Dyskinesias; Electroconvulsive Therapy; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Sleep | 2020 |
Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Depression; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Pramipexole; Psychotic Disorders; Quality of Life | 2020 |
Gut bacterial deamination of residual levodopa medication for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Clostridium; Deamination; Gastrointestinal Microbiome; Gastrointestinal Motility; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Transaminases | 2020 |
An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.
Topics: Basal Ganglia; Computer Simulation; Disease Progression; Dopamine; Humans; Levodopa; Models, Neurological; Motor Activity; Parkinson Disease; Synaptic Transmission | 2021 |
Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
Topics: Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Putamen | 2021 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
Topics: Aged; Antiparkinson Agents; Benserazide; Computer Simulation; Conditioning, Operant; Dopamine Agonists; Drug Combinations; Female; Humans; Learning; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Phenotype; Punishment; Reward; Tremor | 2020 |
Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Topics: Catechol O-Methyltransferase; Cohort Studies; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2020 |
The role of intraoperative microelectrode recording and stimulation in subthalamic lead placement for Parkinson's disease.
Topics: Clinical Decision-Making; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Motor Activity; Parkinson Disease; Practice Guidelines as Topic; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2020 |
Levodopa responsive-generalized dystonic spells and moaning in DNAJC6 related Juvenile Parkinson's disease.
Topics: Adolescent; Dopamine Agents; Dystonia; HSP40 Heat-Shock Proteins; Humans; Levodopa; Male; Parkinson Disease | 2020 |
Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Drug Combinations; Female; Humans; Injections; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Romania | 2020 |
Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Metabolome; Parkinson Disease; RNA, Ribosomal, 16S | 2021 |
[Clinical experience in the treatment of motor fluctuations in Parkinson's disease. Delphi consensus of a group of experts in movement disorders].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Consensus; Dopamine Agonists; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2020 |
Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2021 |
Patient preference of device-based treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Patient Preference; Treatment Outcome | 2022 |
Effects of Deep Brain Stimulation of the Subthalamic Nucleus on the Postoperative Levodopa Response: One Year Follow Up.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Care; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2021 |
Altered sensorimotor fMRI directed connectivity in Parkinson's disease patients.
Topics: Brain Mapping; Humans; Levodopa; Magnetic Resonance Imaging; Neural Pathways; Parkinson Disease; Rest | 2021 |
Association of sleep disturbance and freezing of gait in Parkinson disease: prevention/delay implications.
Topics: Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Sleep | 2021 |
No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease; Prevalence | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2021 |
Peripheral Neuropathy in
Topics: Adult; Aged; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk Factors; Uric Acid; Vitamin B 12 | 2020 |
Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2020 |
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
Topics: Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2021 |
Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series.
Topics: Deep Brain Stimulation; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Pedunculopontine Tegmental Nucleus | 2021 |
[Parkinson's Disease in the Oldest-Old].
Topics: Age of Onset; Aged; Aged, 80 and over; Hallucinations; Humans; Levodopa; Parkinson Disease; Prevalence | 2020 |
Small intestine enterostomy for the intraoperative delivery of levodopa in a patient with severe Parkinson's disease.
Topics: Adenocarcinoma; Aged, 80 and over; Ampulla of Vater; Antiparkinson Agents; Common Bile Duct Neoplasms; Enterostomy; Gastric Bypass; Humans; Intraoperative Care; Levodopa; Male; Pancreaticoduodenectomy; Parkinson Disease; Severity of Illness Index | 2020 |
The challenge of developing adenosine A
Topics: Adenosine; Animals; Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Impulse control behavior in GBA-mutated parkinsonian patients.
Topics: Dopamine Agonists; Glucosylceramidase; Heterozygote; Humans; Levodopa; Mutation; Parkinson Disease | 2021 |
Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
Topics: Dopamine; Humans; Levodopa; Magnetic Resonance Imaging; Neural Pathways; Parkinson Disease | 2021 |
To assess whether a "virtual admission" can be useful for Parkinson's disease patients with severe motor fluctuations.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2021 |
Acute motor effects induced by opioid antagonists in Parkinson's disease: could naloxone be a rescue therapy?
Topics: Analgesics, Opioid; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease | 2021 |
Inhibition of striatal dopamine D
Topics: Animals; Benzazepines; Dopamine; Dopamine Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley; Receptors, Dopamine D5 | 2021 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2021 |
Acute motor axonal polyneuropathy in one parkinsonian patient receiving moderate dosage of oral levodopa.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2021 |
Parkinson's: the weirdest disease.
Topics: Animals; Gambling; Humans; Levodopa; Milk; Nicotine; Parkinson Disease; Risk Factors | 2021 |
Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort.
Topics: Aged; Attention; Cognitive Dysfunction; Cohort Studies; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Proportional Hazards Models; Severity of Illness Index | 2021 |
Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease.
Topics: Aged; Biomarkers; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Pharmacogenetics; Serotonin | 2021 |
Opicapone and acute levodopa challenge test: the big issue.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2021 |
Author response to comment on "The association between pain and impulse control behaviours in Parkinson's disease".
Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Pain; Parkinson Disease | 2021 |
Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia.
Topics: Antiparkinson Agents; Blood-Brain Barrier; Dyskinesias; Humans; Levodopa; Parkinson Disease; Permeability | 2021 |
Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinson's disease.
Topics: Accidental Falls; Adult; Aged; Antiparkinson Agents; Cholinergic Antagonists; Female; Gait; Gait Disorders, Neurologic; Humans; Incidence; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Time Factors | 2021 |
Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Topics: Aged; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Regression Analysis; Surveys and Questionnaires; Symptom Flare Up; United States | 2021 |
Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Brain; Dyskinesia, Drug-Induced; Female; Gray Matter; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease | 2021 |
A synthetic kinematic index of trunk displacement conveying the overall motor condition in Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Case-Control Studies; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Severity of Illness Index; Spatio-Temporal Analysis; Torso | 2021 |
Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement; Parkinson Disease; Sleep; Sleep Wake Disorders | 2021 |
Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
Topics: Brain Stem; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease | 2021 |
Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Gamma Rhythm; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2021 |
Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2021 |
Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 2021 |
Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Female; Humans; Hyperpigmentation; Levodopa; Melanins; Melanocytes; Melanoma; Parkinson Disease; Predictive Value of Tests; Skin; Skin Neoplasms; Skin Pigmentation; Treatment Outcome | 2021 |
Parkinson's disease medication state and severity assessment based on coordination during walking.
Topics: Aged; Dopamine Agents; Female; Gait; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Psychomotor Performance; Severity of Illness Index; Walking; Wearable Electronic Devices | 2021 |
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
Topics: Animals; Berberine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Enterococcus faecalis; Enterococcus faecium; Gastrointestinal Microbiome; Humans; Levodopa; Mice; Parkinson Disease; Tyrosine 3-Monooxygenase | 2021 |
An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Biological Availability; Humans; Levodopa; Parkinson Disease | 2021 |
Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010-2015).
Topics: Adult; Age of Onset; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders | 2021 |
Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Deep Brain Stimulation; Electrodes; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2021 |
Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Enteral Nutrition; Equipment Failure; Female; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Prospective Studies; Retrospective Studies | 2021 |
Opicapone for Parkinson's disease: clinical evidence and future perspectives.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2021 |
Impaired Weight-Shift Amplitude in People with Parkinson's Disease with Freezing of Gait.
Topics: Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2021 |
Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson's Disease.
Topics: Antiparkinson Agents; Body Weight; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Muscle, Skeletal; Parkinson Disease; Sarcopenia | 2021 |
A wearable patch for continuous analysis of thermoregulatory sweat at rest.
Topics: Biosensing Techniques; Body Temperature Regulation; Human Body; Humans; Hydrogen-Ion Concentration; Hypoglycemia; Levodopa; Microfluidics; Parkinson Disease; Rest; Stress, Physiological; Sweat; Sweating; Walking; Wearable Electronic Devices | 2021 |
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum.
Topics: Aged; Cohort Studies; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Prognosis; Retrospective Studies; Sensorimotor Cortex; Tomography, Emission-Computed, Single-Photon | 2021 |
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
Topics: Animals; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Haplorhini; Humans; Levodopa; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Serotonin | 2021 |
High-resolution ultrasound changes of the vagus nerve in idiopathic Parkinson's disease (IPD): a possible additional index of disease.
Topics: Aged; Aged, 80 and over; Atrophy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Ultrasonography; Vagus Nerve | 2021 |
Opicapone in Parkinson's Disease: Real-World Data from a Portuguese Center.
Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Portugal | 2021 |
Falls Predict Acute Hospitalization in Parkinson's Disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Risk Factors; Spain | 2023 |
Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Wearable Electronic Devices | 2021 |
Levodopa responsiveness in Parkinson's disease patients and white matter alterations in diffusion tensor imaging: a cross-sectional tract-based spatial statistics study.
Topics: Aged; Antiparkinson Agents; Brain; Cross-Sectional Studies; Diffusion Tensor Imaging; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; White Matter | 2021 |
Early suspicion of progressive supranuclear palsy using dopamine transporter imaging: an illustrative case presenting with levodopa-responsive parkinsonism.
Topics: Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2021 |
Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
Topics: Antiparkinson Agents; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Time Factors | 2021 |
Levodopa facilitates improvements in gait kinetics at the hip, not the ankle, in individuals with Parkinson's disease.
Topics: Ankle; Biomechanical Phenomena; Gait; Humans; Kinetics; Levodopa; Parkinson Disease; Walking | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Hypoglycemic Agents; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Machine learning-based personalized subthalamic biomarkers predict ON-OFF levodopa states in Parkinson patients.
Topics: Biomarkers; Deep Brain Stimulation; Humans; Levodopa; Machine Learning; Parkinson Disease | 2021 |
Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
Gastrointestinal surgery improved the absorption of levodopa in Parkinson's disease.
Topics: Aged; Anastomosis, Roux-en-Y; Antiparkinson Agents; Gastrectomy; Humans; Levodopa; Male; Parkinson Disease; Stomach Neoplasms | 2021 |
Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real-world Unified Parkinson's Disease Rating Scale.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Models, Biological; Parkinson Disease; Retrospective Studies; Severity of Illness Index | 2021 |
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Homovanillic Acid; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2021 |
Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial).
Topics: Aged; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Quality of Life | 2021 |
Close relationships in Parkinson´s disease patients with device-aided therapy.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Pilot Projects; Prospective Studies; Retrospective Studies | 2021 |
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson's Disease Population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Social Values | 2020 |
L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
Topics: Antiparkinson Agents; Drug Liberation; Humans; Levodopa; Nanoparticles; Parkinson Disease; Particle Size; Porosity; Silicon Dioxide; Surface Properties | 2021 |
[Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].
Topics: Activities of Daily Living; Carbidopa; Dyskinesias; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease | 2021 |
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
The Impact of Subthalamic Deep Brain Stimulation on Restless Legs Syndrome in Parkinson's Disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Restless Legs Syndrome; Subthalamic Nucleus; Treatment Outcome | 2022 |
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19].
Topics: Amantadine; Antiparkinson Agents; COVID-19; Humans; Levodopa; Parkinson Disease; SARS-CoV-2 | 2021 |
Improving Medication Regimen Recommendation for Parkinson's Disease Using Sensor Technology.
Topics: Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Technology | 2021 |
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
Topics: Africa; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Surveys and Questionnaires | 2021 |
Differential dopaminergic modulation of spontaneous cortico-subthalamic activity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Waves; Dopamine Agents; Dopaminergic Neurons; Evoked Potentials, Motor; Female; Humans; Levodopa; Machine Learning; Magnetoencephalography; Male; Markov Chains; Middle Aged; Motor Cortex; Parkinson Disease; Signal Processing, Computer-Assisted; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2021 |
ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson's disease.
Topics: Aged; Biomarkers; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proton-Translocating ATPases; Severity of Illness Index | 2021 |
Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics.
Topics: Arylamine N-Acetyltransferase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Membrane Glycoproteins; Neuroprotection; Parkinson Disease; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins | 2021 |
Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Exosomes; Humans; Levodopa; Liposomes; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2021 |
The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
[Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
Topics: Dopamine Agonists; Drug Substitution; Hallucinations; Humans; Levodopa; Parkinson Disease; Zonisamide | 2021 |
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease.
Topics: Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2021 |
Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
Topics: Antiparkinson Agents; Body Mass Index; Carbidopa; Case-Control Studies; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Standard of Care; Subthalamic Nucleus | 2021 |
Effect of medication withdrawal on pain in Parkinson's disease patients - an observational study based on a sample of patients without antiparkinsonian medications.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Pain; Parkinson Disease | 2021 |
Fields of Forel Brain Stimulation Improves Levodopa-Unresponsive Gait and Balance Disorders in Parkinson's Disease.
Topics: Brain; Deep Brain Stimulation; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Postural Balance; Quality of Life | 2021 |
Discrimination of idiopathic Parkinson's disease and vascular parkinsonism based on gait time series and the levodopa effect.
Topics: Antiparkinson Agents; Gait; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2021 |
The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Time Factors; Treatment Outcome | 2022 |
Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous.
Topics: Aged; Antiparkinson Agents; Carbidopa; Digestive System Surgical Procedures; Drug Combinations; Female; Gastrostomy; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Surgery, Computer-Assisted | 2021 |
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Resveratrol; Substantia Nigra | 2021 |
Balance between competing spectral states in subthalamic nucleus is linked to motor impairment in Parkinson's disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Motor Disorders; Parkinson Disease; Subthalamic Nucleus | 2022 |
Altered Dynamic Information Flow through the Cortico-Basal Ganglia Pathways Mediates Parkinson's Disease Symptoms.
Topics: Basal Ganglia; Globus Pallidus; Humans; Levodopa; Neural Pathways; Parkinson Disease | 2021 |
A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor.
Topics: Algorithms; Antiparkinson Agents; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease | 2021 |
Choroidal Thickness Correlates with Clinical and Imaging Metrics of Parkinson's Disease: A Pilot Study.
Topics: Benchmarking; Choroid; Humans; Iron; Levodopa; Parkinson Disease; Pilot Projects; Tomography, Optical Coherence | 2021 |
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.
Topics: Carbidopa; Humans; Hydrogenation; Levodopa; Parkinson Disease; Pharmaceutical Preparations | 2022 |
Surgical treatment of buried bumper syndrome in patients with Parkinson´s disease and duodenal levodopa/carbidopa infusion therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2021 |
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Technology | 2021 |
Normal-sized basal ganglia perivascular space related to motor phenotype in Parkinson freezers.
Topics: Aged; Basal Ganglia; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Phenotype | 2021 |
Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease.
Topics: Biomarkers; Case-Control Studies; Early Diagnosis; Female; Humans; Levodopa; Male; MicroRNAs; Middle Aged; Parkinson Disease; Sensitivity and Specificity | 2021 |
Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Regression Analysis; Retrospective Studies; Sleep; Tetrahydronaphthalenes; Thiophenes | 2021 |
White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Biomarkers; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Fibers; Odds Ratio; Parkinson Disease; Temporal Lobe; White Matter | 2021 |
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson's disease.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Genetic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests | 2021 |
Plasma hsa-mir-19b is a potential LevoDopa therapy marker.
Topics: Aged; Antiparkinson Agents; Biomarkers; Female; Humans; Levodopa; Male; MicroRNAs; Middle Aged; Parkinson Disease | 2021 |
Improved Estimation of Parkinsonian Vowel Quality through Acoustic Feature Assimilation.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Speech Acoustics; Speech Therapy; Tape Recording; Voice Disorders; Voice Quality | 2021 |
Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2021 |
Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
Topics: Aged; Antiparkinson Agents; China; Cognition; Deep Brain Stimulation; Emotions; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Sleep Quality; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome | 2021 |
Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.
Topics: Animals; Humans; Levodopa; Locus Coeruleus; Magnetic Resonance Imaging; Parkinson Disease; Quality of Life; Retrospective Studies | 2021 |
Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Prognosis; Treatment Outcome | 2021 |
Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease.
Topics: COVID-19; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; RNA, Messenger; RNA, Viral; SARS-CoV-2; Vaccines | 2021 |
Lactiplantibacillus plantarum PS128 Alleviates Exaggerated Cortical Beta Oscillations and Motor Deficits in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Deep Brain Stimulation; Dopamine; Levodopa; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleus | 2023 |
Early balance impairment in Parkinson's Disease: Evidence from Robot-assisted axial rotations.
Topics: Aged; Antiparkinson Agents; Early Diagnosis; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Robotics; Rotation; Wearable Electronic Devices | 2021 |
Comparison of the Parkinson's KinetiGraph to off/on levodopa response testing: Single center experience.
Topics: Aged; Antiparkinson Agents; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Symptom Assessment; Treatment Outcome | 2021 |
Consideration about "Polyneuropathy in levodopa-treated Parkinson's patients".
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2017 |
Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Amides; Antipsychotic Agents; Ethanolamines; Female; Humans; Levodopa; Male; Palmitic Acids; Parkinson Disease; Prospective Studies; Statistics, Nonparametric | 2017 |
A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease.
Topics: Aged; Awareness; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Regression Analysis; Theory of Mind | 2017 |
Parkinson's patients can rely on perspective cues to perceive 3D space.
Topics: Aged; Aged, 80 and over; Cues; Depth Perception; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Photic Stimulation; Vision, Binocular; Vision, Monocular; Visual Cortex; Visual Perception | 2017 |
Dopa-responsive dystonia presenting with predominant hemifacial dystonia.
Topics: Dystonic Disorders; Female; Functional Laterality; GTP Cyclohydrolase; Humans; Levodopa; Magnetic Resonance Imaging; Mutation; Parkinson Disease; Positron-Emission Tomography; Tropanes; Young Adult | 2017 |
Assessment of striatal & postural deformities in patients with Parkinson's disease.
Topics: Adult; Aged; Corpus Striatum; Dyskinesias; Female; Hand; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy, Spinal; Parkinson Disease; Posture; Scoliosis; Spinal Curvatures; Tertiary Care Centers | 2016 |
Pain Correlates with Sleep Disturbances in Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Depression; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Musculoskeletal Pain; Pain; Pain Measurement; Parkinson Disease; Polysomnography; Quality of Life; Sleep; Sleep Wake Disorders; Sleep, REM | 2018 |
Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Blood Pressure; Cross-Sectional Studies; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Pain; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Visual Analog Scale | 2017 |
SCL20A2 mutation mimicking fluctuating Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Mutation; Parkinson Disease; Sodium-Phosphate Cotransporter Proteins, Type III | 2017 |
[Stealing as an Impulse Control Disorder Associated with Pramipexole - A Case Report from Forensic Psychiatric Practice].
Topics: Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Expert Testimony; Female; Humans; Levodopa; Mental Competency; Middle Aged; Parkinson Disease; Pramipexole; Risk Factors; Theft | 2017 |
A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
Topics: Antiparkinson Agents; Computer Communication Networks; Dyskinesia, Drug-Induced; Health Resources; Humans; Levodopa; Parkinson Disease | 2017 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P | 2017 |
What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.
Topics: Aged; Brain; Cognitive Dysfunction; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; United Kingdom | 2017 |
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.
Topics: Aged; Bacteria; Gastrointestinal Microbiome; Humans; Levodopa; Male; Metagenome; Middle Aged; Parkinson Disease; Sequence Analysis, DNA; Viruses | 2017 |
Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.
Topics: Aged; Algorithms; Biomechanical Phenomena; Cohort Studies; Drug Monitoring; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; ROC Curve; Wearable Electronic Devices | 2018 |
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2017 |
Parkinson's disease associated with 22q11.2 deletion: Clinical characteristics and response to treatment.
Topics: 22q11 Deletion Syndrome; Adult; Cohort Studies; Deep Brain Stimulation; Female; France; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenotype; Treatment Outcome | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Can postural abnormality really respond to levodopa in Parkinson's disease?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Sensation Disorders; Severity of Illness Index | 2017 |
Association between autonomic dysfunction and fatigue in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Cross-Sectional Studies; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Severity of Illness Index; Surveys and Questionnaires; Tetrabenazine | 2017 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
Preliminary Analysis of Parkinson-like Motor Coordination Abnormityin Brain-specific hS100B Transgenic Mice.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; G-Protein-Coupled Receptor Kinase 2; Homovanillic Acid; Levodopa; Mice; Mice, Knockout; Mice, Transgenic; Parkinson Disease; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; Tyrosine 3-Monooxygenase | 2017 |
Weight gain after STN-DBS: The role of reward sensitivity and impulsivity.
Topics: Adult; Aged; Deep Brain Stimulation; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Reward; Subthalamic Nucleus; Weight Gain | 2017 |
Human subthalamic nucleus - Automatic auditory change detection as a basis for action selection.
Topics: Acoustic Stimulation; Adult; Aged; Antiparkinson Agents; Brain Mapping; Choice Behavior; Deep Brain Stimulation; Electroencephalography; Evoked Potentials, Auditory; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Signal Detection, Psychological; Subthalamic Nucleus | 2017 |
Dopamine Depletion Impairs Bilateral Sensory Processing in the Striatum in a Pathway-Dependent Manner.
Topics: Animals; Dopamine; Dopamine Agents; Functional Laterality; Levodopa; Mice; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Receptors, Dopamine D1; Receptors, Dopamine D2; Somatosensory Cortex; Touch; Vibrissae | 2017 |
Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin B Complex | 2017 |
Levodopa has primarily negative influences on postural control in patients with Parkinson's disease.
Topics: Adult; Aged; Behavior; Female; Head; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Psychomotor Performance | 2017 |
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy.
Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2017 |
Utilization of Quantitative Susceptibility Mapping for Direct Targeting of the Subthalamic Nucleus During Deep Brain Stimulation Surgery.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Neurologic Examination; Parkinson Disease; Postoperative Care; Psychomotor Disorders; Subthalamic Nucleus; Treatment Outcome | 2018 |
Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Septal Nuclei | 2017 |
Plasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease.
Topics: Antiparkinson Agents; Biomarkers; Female; Humans; Leukocytes; Levodopa; Male; MicroRNAs; Parkinson Disease | 2017 |
Caring for patients with Parkinson's disease in general hospital settings.
Topics: Antiparkinson Agents; Caregivers; Communication; Disease Management; England; Fluid Therapy; Geriatric Nursing; Hospitalization; Hospitals, General; Humans; Levodopa; Nurse-Patient Relations; Nurse's Role; Nutritional Support; Parkinson Disease; Patient Discharge; Receptors, Cell Surface; Time Factors | 2017 |
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene Expression; Isoxazoles; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Zonisamide | 2017 |
l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
Topics: Adult; Aged; Connectome; Corpus Striatum; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prefrontal Cortex; Sensorimotor Cortex; Subthalamic Nucleus | 2017 |
Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nitric Oxide Synthase Type I; Parkinson Disease; Polymorphism, Single Nucleotide | 2018 |
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2017 |
Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies; Vitamin B Complex; Vitamin D Deficiency | 2017 |
Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Benserazide; Case-Control Studies; Cross-Sectional Studies; Dopamine; Dopamine Agents; Drug Combinations; Female; Frail Elderly; Frailty; Geriatric Assessment; Geriatrics; Humans; Inpatients; Levodopa; Male; Parkinson Disease; Phenotype; Poland; Predictive Value of Tests; Prevalence; Severity of Illness Index | 2017 |
Quantitative estimation of motor fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Exercise Therapy; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Retrospective Studies; ROC Curve; Severity of Illness Index; Treatment Outcome; Walking | 2017 |
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Denmark; Dyskinesia, Drug-Induced; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Parkinson Disease; Signal Transduction; Single-Blind Method | 2017 |
An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2017 |
Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Neural Conduction; Parkinson Disease; Peripheral Nervous System; Polyneuropathies; Prospective Studies | 2017 |
Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
Topics: Adult; Aged; Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Dopamine; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Personality; Statistics, Nonparametric; Subthalamic Nucleus; Surveys and Questionnaires | 2017 |
Inhibitory control is not lateralized in Parkinson's patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Female; Functional Laterality; Humans; Inhibition, Psychological; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time | 2017 |
Continuous quantitative monitoring of physical activity in Parkinson's disease patients by using wearable devices: a case-control study.
Topics: Accelerometry; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Educational Status; Exercise; Feasibility Studies; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Telemedicine; Wearable Electronic Devices; Wireless Technology | 2017 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Crohn Disease; Donepezil; Drug Combinations; Fluid Therapy; Humans; Indans; Kidney Calculi; Levodopa; Male; Parkinson Disease; Piperidines; Severity of Illness Index; Sulfasalazine; Ultrasonography | 2017 |
Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
Topics: Aged; Brain Mapping; Dopamine; Executive Function; Female; Humans; Levodopa; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Nerve Net; Neural Pathways; Parietal Lobe; Parkinson Disease | 2017 |
Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gels; Humans; Levodopa; Male; Parkinson Disease | 2017 |
Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perception; Sleep; Surveys and Questionnaires; Wakefulness | 2017 |
Recuperation of slow walking in de novo Parkinson's disease is more closely associated with increased cadence, rather than with expanded stride length.
Topics: Aged; Female; Gait; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Walking; Walking Speed | 2017 |
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain Mapping; Carbon Radioisotopes; Cognition; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phosphodiesterase 4 Inhibitors; Positron-Emission Tomography; Radiopharmaceuticals; Rolipram; Spatial Memory | 2017 |
Downregulation of blood serum microRNA 29 family in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Down-Regulation; Female; Gene Expression Profiling; Humans; Levodopa; Male; MicroRNAs; Middle Aged; Parkinson Disease; Severity of Illness Index; Sex Factors | 2017 |
Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers.
Topics: Case-Control Studies; Female; Heterozygote; Humans; Levodopa; Male; Middle Aged; Movement; Mutation; Parkinson Disease; Pharmacogenomic Testing; Protein Kinases; Statistics, Nonparametric; Ubiquitin-Protein Ligases | 2017 |
Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Pharmacogenomic Variants; Receptors, Opioid, kappa; Time Factors | 2018 |
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Middle Aged; Neural Conduction; Neuralgia; Pain Measurement; Parkinson Disease; Prevalence; Severity of Illness Index; Vitamin B 12 | 2017 |
Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Weight Loss | 2017 |
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
Topics: Aged; Behavior, Addictive; Central Nervous System Stimulants; Depressive Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Substance-Related Disorders | 2017 |
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Piperazines; Time Factors | 2017 |
Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients.
Topics: Antiparkinson Agents; Autonomic Pathways; Female; Fingers; Functional Laterality; Humans; Leg; Levodopa; Male; Microscopy, Confocal; Middle Aged; Parkinson Disease; Sensation Disorders; Sensory Receptor Cells; Skin | 2017 |
Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.
Topics: Aged; Catechol O-Methyltransferase; Cognition Disorders; Cross-Sectional Studies; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Single Nucleotide; Polyneuropathies; Statistics, Nonparametric; Vitamins | 2017 |
Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Cardiovascular Physiological Phenomena; Deep Brain Stimulation; Electrocardiography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration; Subthalamic Nucleus | 2017 |
The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cross-Sectional Studies; Disease Progression; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Risk Factors; Sex Factors | 2017 |
Cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Barium; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Radiography; Stomach Diseases | 2017 |
Serum Growth Differentiation Factor 15 in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Growth Differentiation Factor 15; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Risk Factors; ROC Curve; Sex Characteristics | 2017 |
Teaching Video Neuro
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Videotape Recording | 2017 |
Bereitschaftspotential preceding eyelid blinks in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Blinking; Case-Control Studies; Contingent Negative Variation; Electrodes, Implanted; Electroencephalography; Eyelids; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Time Factors | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephalography Phase Synchronization; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Pars Reticulata; Rats; Rats, Sprague-Dawley | 2017 |
Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires | 2017 |
Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Monitoring; Female; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life; Spain; Time; Treatment Outcome | 2017 |
Management of Parkinson Disease in 2017: Personalized Approaches for Patient-Specific Needs.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Infusion Pumps; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Precision Medicine | 2017 |
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Pain; Pain Measurement; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2017 |
The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Topics: Animals; Benzodioxoles; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Movement; Neostriatum; Parkinson Disease; Phosphorylation; Protein Subunits; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2018 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; alpha-Synuclein; Amyloid; Animals; Animals, Genetically Modified; Behavior, Animal; Brain; Disease Models, Animal; Drosophila melanogaster; Female; Humans; Levodopa; Locomotion; Motor Activity; Parkinson Disease; Pyridones; Recombinant Proteins; Spectroscopy, Fourier Transform Infrared | 2017 |
Chronic exposure to dopamine agonists affects the integrity of striatal D
Topics: Aged; Antiparkinson Agents; Caudate Nucleus; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Receptors, Dopamine D2 | 2017 |
The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
Topics: Aged; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Placebo Effect | 2017 |
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Female; Gels; Health Expenditures; Health Resources; Humans; Ireland; Levodopa; Male; Markov Chains; Parkinson Disease; Quality-Adjusted Life Years | 2017 |
Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals.
Topics: Animals; Disease Models, Animal; Levodopa; Male; Mice; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Protein Carbonylation; Ubiquinone | 2018 |
Beyond L-DOPA: hope for Parkinson's treatment and diagnosis.
Topics: alpha-Synuclein; Brain; Glucagon-Like Peptide-1 Receptor; Humans; Levodopa; Mitochondria; Parkinson Disease; T-Lymphocytes, Cytotoxic | 2017 |
Conversion Parkinson's disease with levodopa abuse and psychosis.
Topics: Adult; Antiparkinson Agents; Conversion Disorder; Female; Humans; Levodopa; Parkinson Disease; Psychotic Disorders; Substance-Related Disorders | 2017 |
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2017 |
A New Evolutionary Algorithm-Based Home Monitoring Device for Parkinson's Dyskinesia.
Topics: Algorithms; Antiparkinson Agents; Dyskinesias; Home Care Services; Humans; Levodopa; Parkinson Disease; Quality of Life | 2017 |
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Executive Function; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Treatment Outcome | 2018 |
Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
Topics: Aged; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Deep Brain Stimulation in Patients with Parkinson's Disease: Effect on Psychiatric Symptoms and Quality of Life.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome | 2018 |
Levodopa and Parkinson Disease-Myths Revisited.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2017 |
Levodopa and Parkinson Disease-Myths Revisited-Reply.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2017 |
A pathogenic S250F missense mutation results in a mouse model of mild aromatic l-amino acid decarboxylase (AADC) deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Genetic Therapy; Humans; Levodopa; Male; Mice; Mutation, Missense; Neostriatum; Parkinson Disease; Polymorphism, Single Nucleotide; Serotonin; Substantia Nigra | 2017 |
Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Telemedicine; Time Factors; Treatment Outcome; Video Recording | 2017 |
Anesthetic management for retrieval of a large aspirated denture in a patient with Parkinson's disease.
Topics: Aged, 80 and over; Anesthesia; Bronchoscopes; Bronchoscopy; Dentures; Etomidate; Foreign Bodies; Humans; Hypnotics and Sedatives; Levodopa; Male; Parkinson Disease; Piperidines; Remifentanil; Respiratory Aspiration; Trachea | 2017 |
[Relationship between homocysteinaemia and sympathetic skin response in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Female; Humans; Hyperhomocysteinemia; Levodopa; Male; Parkinson Disease; Skin Physiological Phenomena; Sympathetic Nervous System | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Severity of Illness Index | 2017 |
Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; RNA, Messenger; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2018 |
Verification of a Method for Measuring Parkinson's Disease Related Temporal Irregularity in Spiral Drawings.
Topics: Humans; Levodopa; Movement; Parkinson Disease; Reproducibility of Results; Smartphone; Temporal Lobe | 2017 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease; Registries | 2017 |
Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum.
Topics: Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Interneurons; Levodopa; Locomotion; Male; Parkinson Disease; Rats, Long-Evans; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2018 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Metformin; Mice, Inbred C57BL; Parkinson Disease; Signal Transduction | 2018 |
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hypercapnia; Levodopa; Male; Middle Aged; Neuroimaging; Parkinson Disease; Putamen; Sensorimotor Cortex | 2017 |
Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication.
Topics: Aged; Basal Ganglia; Beta Rhythm; Deep Brain Stimulation; Dopamine Agents; Electroencephalography; Electroencephalography Phase Synchronization; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prosthesis Implantation; Subthalamic Nucleus | 2017 |
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Putamen; Rats, Wistar; Receptor, Metabotropic Glutamate 5 | 2018 |
Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Machine Learning; Parkinson Disease | 2017 |
Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia.
Topics: Dyskinesias; Female; Humans; Levodopa; Middle Aged; Nicotine; Parkinson Disease; Placebos | 2017 |
The bioengineering of stem cells to create dopamine replacement neurons is not the solution for Parkinson's.
Topics: Cell Engineering; Dopaminergic Neurons; Humans; Levodopa; Parkinson Disease; Stem Cell Transplantation | 2017 |
Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder.
Topics: Aged; Antidepressive Agents; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Sleep; Video Recording | 2018 |
Factors associated with motor complications in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Long Term Adverse Effects; Male; Middle Aged; Parkinson Disease; Time-to-Treatment; Treatment Outcome | 2017 |
Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron Emission Tomography Computed Tomography; Prognosis; Synapses; Time Factors; Tropanes | 2018 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2018 |
Serotonergic neurons mediate the anxiolytic effect of l-DOPA: Neuronal correlates in the amygdala.
Topics: Animals; Antiparkinson Agents; Anxiety; Basolateral Nuclear Complex; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonergic Neurons | 2018 |
Apathy in rapid eye movement sleep behaviour disorder is common and under-recognized.
Topics: Aged; Aged, 80 and over; Apathy; Cognition; Cohort Studies; Depression; Dopamine Agonists; Emotions; Female; Humans; Levodopa; Male; Mass Screening; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder | 2018 |
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidative Stress; Parkinson Disease; Poly(ADP-ribose) Polymerases; Rats; Reactive Oxygen Species; Substantia Nigra; Thioctic Acid | 2018 |
Increased Prevalence of Polyneuropathy in Parkinson's Disease Patients: An Observational Study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polyneuropathies; Prevalence; Vitamin B 12 Deficiency | 2018 |
Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa.
Topics: Antiparkinson Agents; Compulsive Behavior; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sexual Behavior | 2018 |
The effect of intravitreal cholinergic drugs on motor control.
Topics: Animals; Brain; Cholinergic Agents; Circadian Rhythm; Dopamine; Levodopa; Male; Motor Activity; Parkinson Disease; Rats, Sprague-Dawley | 2018 |
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2017 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |
The future of pharmacogenetics in Parkinson's disease treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Motor Activity; Parkinson Disease; Pharmacogenetics; Receptors, Dopamine | 2018 |
Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
Topics: Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Community Health Planning; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Association Studies; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Retrospective Studies | 2018 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens | 2018 |
l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2017 |
Subthalamotomy for Parkinson's disease: back to the future?
Topics: Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2018 |
Evaluation of Retinal Changes in Progressive Supranuclear Palsy and Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Nerve Fibers; Non-Randomized Controlled Trials as Topic; Optic Disk; Parkinson Disease; Prospective Studies; Retinal Diseases; Retinal Ganglion Cells; Supranuclear Palsy, Progressive; Tomography, Optical Coherence | 2018 |
Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fyn; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2018 |
Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Choice Behavior; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Duodenum; Equipment Design; Female; Humans; Infusion Pumps; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Surveys and Questionnaires; United States | 2017 |
A de novo loss-of-function DYNC1H1 mutation in a patient with parkinsonian features and a favourable response to levodopa.
Topics: Cytoplasmic Dyneins; Humans; Levodopa; Male; Mutation; Parkinson Disease | 2018 |
[The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Topics: Aged; Ambulatory Care Facilities; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Hungary; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies | 2017 |
Abnormal pain perception in patients with Multiple System Atrophy.
Topics: Aged; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Pain; Pain Measurement; Pain Perception; Pain Threshold; Parkinson Disease; Physical Stimulation; Psychiatric Status Rating Scales; Psychological Tests | 2018 |
Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pupil | 2018 |
Vascular risk factors and depression in Parkinson's disease.
Topics: Aged; Alcohol Drinking; Antiparkinson Agents; Anxiety; Asian People; Cohort Studies; Cross-Sectional Studies; Depressive Disorder; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Obesity; Overweight; Parkinson Disease; Psychiatric Status Rating Scales; Risk Factors; Sex Factors; Vascular Diseases | 2018 |
Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Disease Progression; Educational Status; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2018 |
Serum sodium and chloride are inversely associated with dyskinesia in Parkinson's disease patients.
Topics: Age of Onset; Aged; Antiparkinson Agents; Chlorides; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Sodium; Time Factors | 2017 |
Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motivation; Oxygen; Parkinson Disease; Prefrontal Cortex; Reaction Time; Reward; Ventral Striatum | 2018 |
Continuous intestinal infusion of levodopa-carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Spain | 2021 |
Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
Topics: Amino Acid Substitution; Computer Simulation; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Molecular Docking Simulation; Mutation, Missense; Parkinson Disease; Protein Kinase Inhibitors | 2018 |
Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.
Topics: Adsorption; Benserazide; Electrons; Hydrogen Bonding; Levodopa; Models, Molecular; Molecular Conformation; Nanotubes, Carbon; Parkinson Disease; Quantum Theory | 2018 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Motor Cortex; Muscle Rigidity; Muscular Atrophy, Spinal; Parkinson Disease; Positron-Emission Tomography; Tremor | 2017 |
Subthalamic deep brain stimulation under general anesthesia and neurophysiological guidance while on dopaminergic medication: comparative cohort study.
Topics: Aged; Anesthesia, General; Cohort Studies; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Prospective Studies; Subthalamic Nucleus | 2018 |
A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Neural Pathways; Neurons; Optogenetics; Parkinson Disease | 2018 |
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2018 |
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2018 |
Dopamine modulates striatal response to reward and punishment in patients with Parkinson's disease: a pharmacological challenge fMRI study.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pramipexole; Punishment; Reward | 2018 |
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Abnormalities; Deep Brain Stimulation; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Quality of Life; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome | 2018 |
The nature of postural tremor in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cluster Analysis; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Posture; Prevalence; Rest; Tremor | 2018 |
A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Hernia, Hiatal; Humans; Levodopa; Male; Parkinson Disease | 2018 |
Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Topics: Accelerometry; Aged; Aged, 80 and over; Antidepressive Agents; Antiparkinson Agents; Depression; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychotropic Drugs; Severity of Illness Index; Sweden | 2018 |
Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Topics: Action Potentials; Animals; Dendrites; Dopamine Agents; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Substantia Nigra; Synapses; Synaptic Potentials; Transcription Factors | 2018 |
Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Female; Heme Oxygenase-1; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; ROC Curve; Saliva; Sex Factors | 2018 |
The Clinical Findings Useful for Driving Safety Advice for Parkinson's Disease Patients.
Topics: Accidents, Traffic; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Automobile Driving; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Surveys and Questionnaires | 2018 |
Levodopa has mood-enhancing effects in healthy elderly adults.
Topics: Affect; Aged; Antiparkinson Agents; Anxiety; Apathy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2018 |
Individual dose-response models for levodopa infusion dose optimization.
Topics: Algorithms; Antiparkinson Agents; Computer Simulation; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease; Tissue Distribution | 2018 |
Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease.
Topics: Aged; Corpus Striatum; Dopamine; Dopamine Agents; Executive Function; Female; Humans; Inhibition, Psychological; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Signal Transduction | 2018 |
Restlessness restricted to the perianal region in a patient with Parkinson's disease.
Topics: Aged, 80 and over; Anal Canal; Aromatic Amino Acid Decarboxylase Inhibitors; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Restless Legs Syndrome | 2018 |
Vitamin B12 and Parkinson's Disease: What is the Relationship?
Topics: Case-Control Studies; Humans; Levodopa; Parkinson Disease; Vitamin B 12 | 2018 |
Re-emergent tremor in Parkinson's disease: the effect of dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Recurrence; Treatment Outcome; Tremor | 2018 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
First-trial protective step performance before and after short-term perturbation practice in people with Parkinson's disease.
Topics: Accidental Falls; Age Factors; Aged; Analysis of Variance; Antiparkinson Agents; Biomechanical Phenomena; Humans; Levodopa; Parkinson Disease; Postural Balance; Treatment Outcome; Walking | 2018 |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |
Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Cognition; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome; Wakefulness | 2018 |
Hair in Parkinson's disease patients exhibits differences in Calcium, Iron and Zinc concentrations measured by flame atomic absorption spectrometry - FAAS.
Topics: Aged; Aged, 80 and over; Calcium; Case-Control Studies; Female; Hair; Humans; Iron; Levodopa; Male; Middle Aged; Parkinson Disease; Spectrophotometry, Atomic; Zinc | 2018 |
Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Comorbidity; Cost of Illness; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Psychotropic Drugs; Quality of Life; Severity of Illness Index; Sleep; Treatment Outcome | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Cardiac Sympathetic Denervation Can Predict the Wearing-off Phenomenon in Patients with Parkinson Disease.
Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System | 2018 |
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Brazil; Catechol O-Methyltransferase; Dopamine; Dose-Response Relationship, Drug; Dyskinesias; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Retrospective Studies; Sex Characteristics; Surveys and Questionnaires | 2018 |
Jejunal pulling syndrome: A peculiar LCIG complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Intestinal Volvulus; Jejunum; Levodopa; Male; Parkinson Disease | 2018 |
3-Dimensional hollow graphene balls for voltammetric sensing of levodopa in the presence of uric acid.
Topics: Electrochemical Techniques; Electrodes; Graphite; Humans; Levodopa; Metal Nanoparticles; Nickel; Parkinson Disease; Tin Compounds; Uric Acid | 2018 |
Medication and trial duration influence postural and pointing parameters during a standing repetitive pointing task in individuals with Parkinson's disease.
Topics: Accidental Falls; Aged; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Posture; Surveys and Questionnaires | 2018 |
Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention?
Topics: Administration, Intranasal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunostomy; Jejunum; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease | 2018 |
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2018 |
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.
Topics: Accelerometry; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Parkinson Disease; Precision Medicine; Quality of Life; Single-Blind Method; Tablets; Treatment Outcome | 2018 |
[Severe leg edema associated with the use of dopaminergic drugs in Parkinson's disease. Report of one case].
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Edema; Humans; Leg; Levodopa; Male; Parkinson Disease; Pramipexole | 2017 |
Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arousal; Benzhydryl Compounds; Biogenic Monoamines; Disease Models, Animal; Disorders of Excessive Somnolence; Drug Therapy, Combination; Levodopa; Male; Mice, Inbred C57BL; Modafinil; Parkinson Disease; Photoperiod | 2018 |
Acute cholecystitis induced by surgery for levodopa-carbidopa intestinal gel therapy: Possible relationship to pre-existing gallstones.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholecystitis, Acute; Drug Combinations; Gallstones; Humans; Infusions, Parenteral; Jejunostomy; Levodopa; Male; Parkinson Disease | 2018 |
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2018 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain Chemistry; Capsules; Carbidopa; Catechols; Dopamine; Drug Compounding; Female; Hydrophobic and Hydrophilic Interactions; Levodopa; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nitriles; Parkinson Disease | 2018 |
Dynamic cortical participation during bilateral, cyclical ankle movements: Effects of Parkinson's disease.
Topics: Aged; Ankle; Biomechanical Phenomena; Case-Control Studies; Cognition; Electroencephalography; Electromyography; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Range of Motion, Articular | 2018 |
Dopamine substitution alters effective connectivity of cortical prefrontal, premotor, and motor regions during complex bimanual finger movements in Parkinson's disease.
Topics: Adult; Brain Waves; Dopamine Agents; Electroencephalography Phase Synchronization; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Motor Activity; Motor Cortex; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance | 2019 |
Deep Brain Stimulation for Parkinson Disease in the Philippines: Outcomes of the Philippine Movement Disorder Surgery Center.
Topics: Adult; Deep Brain Stimulation; Female; Follow-Up Studies; Hospitals, Private; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Philippines; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2018 |
Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
Topics: Antiparkinson Agents; Dysphonia; Facial Muscles; Humans; Levodopa; Muscle Strength; Parkinson Disease; Phonation; Preliminary Data; Prospective Studies; Recovery of Function; Speech Acoustics; Time Factors; Treatment Outcome; Voice Quality | 2019 |
Vagally Mediated Paroxysmal Atrial Fibrillation Derived from the Central Nervous System.
Topics: Antiparkinson Agents; Atrial Fibrillation; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tilt-Table Test | 2018 |
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Image Interpretation, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Reported Outcome Measures; Sensitivity and Specificity; Severity of Illness Index; Video Recording | 2018 |
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Retrospective Studies; Severity of Illness Index; Time Factors | 2018 |
Individual cognitive change after DBS-surgery in Parkinson's disease patients using Reliable Change Index Methodology.
Topics: Cognition; Cognitive Dysfunction; Deep Brain Stimulation; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2018 |
Aberrant learning in Parkinson's disease: A neurocomputational study on bradykinesia.
Topics: Basal Ganglia; Dopamine; Dopamine Agents; Humans; Hypokinesia; Levodopa; Models, Theoretical; Neuronal Plasticity; Parkinson Disease; Psychomotor Performance | 2018 |
Sensory neuropathic symptoms in idiopathic Parkinson's disease: prevalence and impact on quality of life.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Quality of Life; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires | 2018 |
Levodopa-responsive breathing discomfort in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration; Respiratory Function Tests | 2018 |
Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Case-Control Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Parkinson Disease; Tablets; Young Adult | 2018 |
Association of metals with the risk and clinical characteristics of Parkinson's disease.
Topics: Aged; Copper; Dyskinesia, Drug-Induced; Female; Humans; Iron; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Sex Characteristics | 2018 |
Neurophysiological correlates of bradykinesia in Parkinson's disease.
Topics: Aged; Biomechanical Phenomena; Evoked Potentials, Motor; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Neuronal Plasticity; Neurophysiology; Parkinson Disease; Transcranial Magnetic Stimulation | 2018 |
Quality of life and Parkinson's disease: Philippine translation and validation of the Parkinson's disease questionnaire.
Topics: Activities of Daily Living; Adult; Aged; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Philippines; Quality of Life; Surveys and Questionnaires; Translations | 2018 |
Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.
Topics: Aged; Case-Control Studies; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Restless Legs Syndrome | 2018 |
Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Brain; Brain Waves; Cortical Synchronization; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Parkinson Disease; Signal Processing, Computer-Assisted | 2019 |
Application of the Six Sigma concept for quality assessment of different strategies in DBS surgery.
Topics: Aged; Deep Brain Stimulation; Humans; Intracranial Hemorrhages; Levodopa; Middle Aged; Parkinson Disease; Quality Assurance, Health Care; Subthalamic Nucleus; Total Quality Management; Treatment Outcome | 2018 |
[Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease].
Topics: Aged; Algorithms; Ambulatory Care; Antiparkinson Agents; Carbidopa; Clinical Protocols; Disease Management; Drug Combinations; Duodenum; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 2018 |
Distinctive Olfactory Pattern in Parkinson's Disease and Non-Neurodegenerative Causes of Hyposmia.
Topics: Aged; Aged, 80 and over; Agnosia; Brain Injuries, Traumatic; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Olfaction Disorders; Parkinson Disease; Smell | 2018 |
Assessment of Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2018 |
The effect of medication on vastus lateralis muscle activation patterns in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Isometric Contraction; Levodopa; Male; Middle Aged; Parkinson Disease; Quadriceps Muscle | 2018 |
Clinical and nutritional correlations in Parkinson's disease: Preliminary report.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Female; Humans; Levodopa; Male; Malnutrition; Middle Aged; Nutritional Status; Parkinson Disease; Severity of Illness Index | 2019 |
Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Mice; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Striatonigral Degeneration | 2018 |
Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apraxias; Arm; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Female; Fingers; Functional Laterality; Humans; Hypokinesia; Imaging, Three-Dimensional; Levodopa; Male; Middle Aged; Motor Skills; Muscle Rigidity; Parkinson Disease; Positron-Emission Tomography; Severity of Illness Index; Substantia Nigra | 2018 |
Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Impulsive Behavior; Levodopa; Male; Motor Activity; Parkinson Disease; Reaction Time | 2018 |
Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Physical Therapy Modalities; Subthalamic Nucleus | 2018 |
A Treatment-Response Index From Wearable Sensors for Quantifying Parkinson's Disease Motor States.
Topics: Accelerometry; Aged; Antiparkinson Agents; Drug Monitoring; Female; Humans; Levodopa; Machine Learning; Male; Middle Aged; Parkinson Disease; Signal Processing, Computer-Assisted; Wearable Electronic Devices | 2018 |
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
Topics: Alleles; Dyskinesia, Drug-Induced; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide; Retrospective Studies; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Cognitive Dysfunction; Disease Progression; Executive Function; Female; Follow-Up Studies; Gait; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies | 2018 |
Dyskinesia in Parkinson's disease: a clinical complication and an open scientific question.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Consensus; Drug Combinations; Europe; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Specialization; Young Adult | 2018 |
Head and trunk stability during gait before and after levodopa intake in Parkinson's disease subtypes.
Topics: Aged; Female; Gait; Head; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postural Balance; Torso; Tremor | 2018 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies | 2018 |
Levodopa-Carbidopa-Related Rash in Parkinson's Disease: A Case Series.
Topics: Adult; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Exanthema; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2018 |
Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2018 |
Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Dopamine Agents; Fatigue; Female; Humans; Levodopa; Male; Mood Disorders; Parkinson Disease; Treatment Outcome | 2018 |
Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; Tyrosine 3-Monooxygenase | 2019 |
Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Regression Analysis | 2018 |
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease; Phytochemicals; Phytotherapy; Reactive Oxygen Species; Terpenes; Zonisamide | 2018 |
Effects of levodopa therapy on voxel-based degree centrality in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease | 2019 |
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Polyneuropathies; Statistics, Nonparametric | 2018 |
Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
Topics: Animals; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Homeodomain Proteins; Hyperkinesis; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Receptors, Dopamine D1; Substantia Nigra; Transcription Factors | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2018 |
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Peptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; src-Family Kinases | 2019 |
The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Depressive Disorder; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Temperament | 2019 |
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Binding; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sulfonamides | 2018 |
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies | 2018 |
Bilateral subthalamic deep brain stimulation is an effective and safe treatment option for the older patients with Parkinson's disease.
Topics: Adult; Aged; Aging; Brain; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2018 |
The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease.
Topics: Biomarkers; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Positron-Emission Tomography; Prognosis; Tropanes | 2018 |
[Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy].
Topics: Aged; Antiparkinson Agents; Carbidopa; Dosage Forms; Drug Combinations; Drug Compounding; Duodenal Ulcer; Gastric Bypass; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2018 |
The effect of continuous levodopa treatment during the afternoon hours.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2019 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |
Drug-induced gambling disorder: A not so rare but underreported condition.
Topics: Aged; Aged, 80 and over; Dopamine Agonists; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2018 |
Inferring the long duration response to levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors | 2019 |
The presence of depression in de novo Parkinson's disease reflects poor motor compensation.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Cohort Studies; Depression; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tropanes | 2018 |
Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Cross-Sectional Studies; Disability Evaluation; Dopamine Agonists; Educational Status; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Quality of Life; Reference Values; Statistics, Nonparametric; Surveys and Questionnaires | 2018 |
Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Cognition; Cognitive Dysfunction; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2019 |
Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson's disease patients.
Topics: Case-Control Studies; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Parkinson Disease; Time Factors | 2018 |
Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Deep Brain Stimulation; Electroencephalography; Emotions; Evoked Potentials; Facial Expression; Facial Recognition; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stroop Test; Subthalamic Nucleus; Treatment Outcome | 2018 |
Highlighting the goals for Parkinson's care: commentary on NICE Guidelines for Parkinson's in Adults (NG71).
Topics: Antiparkinson Agents; Clozapine; Hallucinations; Humans; Levodopa; Parkinson Disease; Patient Care Team; Patient Education as Topic; Practice Guidelines as Topic | 2019 |
NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses | 2019 |
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
Topics: Animals; Drug Development; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Translational Research, Biomedical | 2019 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Smartphone-based differential pulse amperometry system for real-time monitoring of levodopa with carbon nanotubes and gold nanoparticles modified screen-printing electrodes.
Topics: Antiparkinson Agents; Biosensing Techniques; Drug Monitoring; Electrochemical Techniques; Electrodes; Equipment Design; Gold; Humans; Levodopa; Limit of Detection; Metal Nanoparticles; Models, Molecular; Nanotubes, Carbon; Parkinson Disease; Smartphone | 2019 |
Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography.
Topics: Aged; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Turkey; Ventricular Dysfunction, Left | 2018 |
Dopamine-endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum.
Topics: Action Potentials; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Endocannabinoids; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neostriatum; Parkinson Disease; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2018 |
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Cerebellum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Rest | 2019 |
A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin.
Topics: Amyloid; Benserazide; Cell Line, Tumor; Cell Survival; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Protein Aggregates; Serum Albumin, Human | 2019 |
Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms.
Topics: Aged; Antiparkinson Agents; Cerebral Cortex; Cognitive Dysfunction; Electroencephalography; Female; Humans; Levodopa; Male; Parkinson Disease; Rest | 2019 |
Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
Topics: Antiparkinson Agents; Apomorphine; Cognition; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Mental Disorders; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Effects of Parkinson's disease and dopamine on digit span measures of working memory.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Levodopa; Male; Memory, Short-Term; Mental Recall; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2018 |
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Alleles; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Italy; Levodopa; Male; Minisatellite Repeats; Parkinson Disease; Polymorphism, Genetic; Prevalence | 2019 |
Levodopa-induced dyskinesia in Parkinson disease: Sleep matters.
Topics: Actigraphy; Adult; Aged; Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Psychiatric Status Rating Scales; Sleep Wake Disorders; Statistics, Nonparametric | 2018 |
Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Weight Loss | 2019 |
Latency of re-emergent tremor in Parkinson's disease is influenced by levodopa.
Topics: Accelerometry; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Recurrence; Time Factors; Tremor | 2019 |
The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Brazil; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Female; Genotype; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Receptors, Dopamine D2; Severity of Illness Index; Sex Factors; Treatment Outcome | 2019 |
Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cost of Illness; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Zinc | 2018 |
Impulse control disorders in Parkinson's disease: a hard-turning point.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2019 |
Clinical characteristics and quality of life in Chinese patients with multiple system atrophy.
Topics: Antiparkinson Agents; Anxiety Disorders; Asian People; China; Cognitive Dysfunction; Depressive Disorder; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Quality of Life | 2018 |
Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Preference; Retrospective Studies | 2019 |
Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2018 |
Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Complications; Diabetes Mellitus; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Parkinsonian Disorders | 2018 |
Visual Displacement Perception in Parkinson's Disease Analyzed Using a Computer-Generated Graphical Tool.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Computers; Humans; Levodopa; Middle Aged; Parkinson Disease; Vision Disorders; Vision Tests; Vision, Ocular; Visual Perception | 2018 |
Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
Topics: Adult; Aged; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Opioid, mu; Risk Factors | 2018 |
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2018 |
Intersegmental coordination patterns are differently affected in Parkinson's disease and cerebellar ataxia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Biomechanical Phenomena; Cerebellar Ataxia; Cerebellum; Female; Gait; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Models, Neurological; Muscle, Skeletal; Parkinson Disease | 2019 |
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.
Topics: Aged; Disease Progression; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index | 2018 |
Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Health Expenditures; Health Services; Health Status; Humans; Infusion Pumps, Implantable; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality-Adjusted Life Years; Scotland; Severity of Illness Index; Wales | 2019 |
[Devotion to painting in a Parkinson's disease patient].
Topics: Aged; Disease Progression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Levodopa; Male; Paintings; Parkinson Disease; Substance-Related Disorders | 2018 |
Medication status and dual-tasking on turning strategies in Parkinson disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Biomechanical Phenomena; Fear; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Task Performance and Analysis; Video Recording | 2019 |
On the Use of
Topics: Algorithms; Antiparkinson Agents; Data Visualization; Deep Brain Stimulation; Electromyography; Humans; Levodopa; Machine Learning; Motor Skills; Nonlinear Dynamics; Parkinson Disease; Principal Component Analysis; Stochastic Processes; Support Vector Machine | 2018 |
The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Severity of Illness Index | 2019 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Regional gray matter changes and age predict individual treatment response in Parkinson's disease.
Topics: Age Factors; Aged; Aging; Antiparkinson Agents; Brain; Female; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Treatment Outcome | 2019 |
Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2019 |
Neuroleptic malignant-like syndrome causing thrombocytopaenia: a rare association.
Topics: Diagnosis, Differential; Glasgow Coma Scale; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Patient Compliance; Thrombocytopenia | 2018 |
Deep brain stimulation of the substantia nigra for freezing of gait in Parkinson's disease: is it about stimulation frequency?
Topics: Deep Brain Stimulation; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Pars Reticulata; Pilot Projects; Substantia Nigra; Subthalamic Nucleus | 2019 |
Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study.
Topics: Deep Brain Stimulation; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease; Pars Reticulata; Pilot Projects; Substantia Nigra; Subthalamic Nucleus | 2019 |
Cyclodextrins in Parkinson's Disease.
Topics: Cyclodextrins; Diffusion; Humans; Levodopa; Models, Theoretical; Parkinson Disease; Temperature; Thermodynamics; Viscosity | 2018 |
Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Appointments and Schedules; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pilot Projects; Surveys and Questionnaires; Treatment Failure | 2019 |
Masticatory function and oral sensorimotor ability in Parkinson's disease: Levodopa on versus off periods.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Bite Force; Female; Humans; Jaw, Edentulous; Levodopa; Male; Mastication; Mouth, Edentulous; Parkinson Disease; Psychomotor Performance; Range of Motion, Articular | 2019 |
Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carnitine; Fatty Acids; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Metabolome; Middle Aged; Mitochondria; Oxidation-Reduction; Parkinson Disease; Pilot Projects; Severity of Illness Index; Zonisamide | 2018 |
Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
[Neurology].
Topics: Antiparkinson Agents; Disease Progression; Drug Combinations; Humans; Levodopa; Neurology; Parkinson Disease | 2019 |
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis.
Topics: Adult; Aged; Deep Brain Stimulation; Dopamine; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy, Spinal; Parkinson Disease; Posture; Spinal Curvatures; Subthalamic Nucleus | 2019 |
Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Bacteria; Female; Gastrointestinal Microbiome; Humans; Intestine, Small; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Tyrosine Decarboxylase | 2019 |
Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.
Topics: Actigraphy; Administration, Oral; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Wearable Electronic Devices | 2019 |
CVT-301 for Parkinson's disease: dose and effect size issues.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Levodopa; Parkinson Disease | 2019 |
Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Gambling; Humans; Italy; Levodopa; Male; Parkinson Disease; Pramipexole | 2020 |
When to Start Levodopa Therapy for Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2019 |
Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition; Decision Making; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Quality of Life; Reward; Subthalamic Nucleus | 2019 |
Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Crystallization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Emulsions; Female; Levodopa; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Parkinson Disease; Structure-Activity Relationship; Temperature | 2019 |
l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopaminergic Neurons; Humans; Iron; Iron Overload; Levodopa; Mice; Mice, Transgenic; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2019 |
EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2019 |
Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Risk Factors; Time Factors | 2019 |
The influence of postural deformities on neck function and pain in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Disabled Persons; Female; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy, Spinal; Neck Pain; Pain; Parkinson Disease; Pilot Projects; Postural Balance; Spinal Curvatures | 2019 |
Choosing Wisely: five recommendations related to tests, treatments, and procedures at risk of inappropriateness in the cure of Parkinson's disease (LIMPE-DISMOV Academy).
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Italy; Levodopa; Myocardial Perfusion Imaging; Parkinson Disease; Practice Guidelines as Topic; Societies; Tomography, Emission-Computed, Single-Photon | 2019 |
Motion Sensor-Based Assessment of Parkinson's Disease Motor Symptoms During Leg Agility Tests: Results From Levodopa Challenge.
Topics: Aged; Exercise Test; Female; Gait; Humans; Levodopa; Lower Extremity; Male; Models, Statistical; Monitoring, Physiologic; Parkinson Disease; Support Vector Machine; Wearable Electronic Devices | 2020 |
Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
Topics: Aged; Alleles; Antiparkinson Agents; Female; Genetic Predisposition to Disease; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide | 2019 |
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies | 2019 |
Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Beta Rhythm; Feedback, Sensory; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Parkinson Disease; Proprioception | 2019 |
Parkinsonism Relating to Intoxication with Glyphosate.
Topics: Adult; Glycine; Glyphosate; Herbicides; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Rigidity; Parkinson Disease; Treatment Outcome | 2019 |
Effect of levodopa on cochlear mechanics and efferent auditory system of Parkinson's disease individuals.
Topics: Acoustic Stimulation; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Auditory Pathways; Female; Humans; Levodopa; Male; Middle Aged; Otoacoustic Emissions, Spontaneous; Parkinson Disease | 2019 |
Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Genetic Predisposition to Disease; Genotype; Humans; Inflammation; Levodopa; Male; Oxidative Stress; Parkinson Disease; Polymorphism, Single Nucleotide | 2019 |
[Analysis of PEG-J associated complications in 14 adult patients treated with levodopa-carbidopa intestinal gel].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrostomy; Gels; Humans; Intestinal Perforation; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Peritonitis; Retrospective Studies; Skin Diseases; Surgical Stomas | 2019 |
1-
Topics: Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Death; Cell Proliferation; Dopaminergic Neurons; Gene Expression Regulation; Humans; Hydroquinones; JNK Mitogen-Activated Protein Kinases; Levodopa; MAP Kinase Signaling System; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; PC12 Cells; Rats | 2019 |
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.
Topics: Carbidopa; Catechols; Humans; Levodopa; Nitriles; Parkinson Disease | 2019 |
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Randomized Controlled Trials as Topic | 2019 |
Levodopa-induced myocardial infarction in a patient with Parkinson's disease and severe coronary artery disease.
Topics: Aged; Antiparkinson Agents; Coronary Angiography; Coronary Artery Disease; Electrocardiography; Humans; Levodopa; Male; Non-ST Elevated Myocardial Infarction; Parkinson Disease; Severity of Illness Index | 2019 |
Contralateral levodopa-induced hemichorea in a patient with severe asymmetric Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Chorea; Drug Tapering; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon | 2020 |
Vasodilation through levodopa for Parkinson's disease may require high left ventricular assist device flow.
Topics: Acute Kidney Injury; Heart Failure; Heart Ventricles; Heart-Assist Devices; Humans; Ischemia; Kidney; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Vasodilation | 2019 |
Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine.
Topics: Action Potentials; Aged; Antiparkinson Agents; Basal Ganglia; Beta Rhythm; Cerebral Cortex; Deep Brain Stimulation; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Nerve Net; Parkinson Disease; Psychomotor Performance | 2019 |
Long-term outcomes of deep brain stimulation in severe Parkinson's disease utilizing UPDRS III and modified Hoehn and Yahr as a severity scale.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Psychomotor Performance; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2019 |
[Parkinson's disease treatment: from honey moon to motor fluctuations].
Topics: Humans; Levodopa; Parkinson Disease; Quality of Life | 2018 |
[Therapeutic and pharmacologic perspectives in Parkinson's disease].
Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2018 |
Effect of levodopa on handwriting tasks of different complexity in Parkinson's disease: a kinematic study.
Topics: Aged; Agraphia; Biomechanical Phenomena; Dopamine Agents; Female; Handwriting; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 2019 |
Perspectives on the Earlier Use of Deep Brain Stimulation for Parkinson Disease from a Qualitative Study of U.S. Clinicians.
Topics: Antiparkinson Agents; Attitude of Health Personnel; Deep Brain Stimulation; Disease Progression; Early Medical Intervention; Female; Humans; Levodopa; Male; Neurologists; Neurosurgeons; Parkinson Disease; Patient Selection; Pilot Projects; Qualitative Research; Quality of Life; Severity of Illness Index; Time Factors | 2019 |
Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benserazide; Case-Control Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Quality of Life; Sensitivity and Specificity; Sitting Position; Walking | 2019 |
Clinical utility of SUDOSCAN in predicting autonomic neuropathy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Electrophysiology; Female; Galvanic Skin Response; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Investigating the perceived timing of sensory events triggering actions in patients with Parkinson's disease and the effects of dopaminergic therapy.
Topics: Adult; Aged; Antiparkinson Agents; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Perception; Young Adult | 2019 |
Methods to Investigate the Role of β-Arrestin Signaling in Parkinson's Disease.
Topics: Animals; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesias; Humans; Levodopa; Locomotion; Mice, Knockout; Molecular Biology; Parkinson Disease; Signal Transduction; Stereotaxic Techniques | 2019 |
[Complications and troubleshooting at the initial introduction of Levodopa-carbidopa continuous infusion gel therapy: A single-center study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gastrostomy; Gels; Glycosides; Humans; Infusion Pumps; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Pregnanes; Retrospective Studies; Skin Diseases, Infectious | 2019 |
Evaluation of a sensor algorithm for motor state rating in Parkinson's disease.
Topics: Accelerometry; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Support Vector Machine; Wearable Electronic Devices | 2019 |
Parkinson's disease, dopamine, and eating and weight disorders: an illness in the disease?
Topics: Binge-Eating Disorder; Craving; Dopamine; Dopamine Agents; Dopamine Agonists; Food Addiction; Humans; Levodopa; Obesity; Parkinson Disease | 2019 |
Parasomnia overlap disorder with adolescent-onset presumed REM sleep behavior disorder converting to Parkinson's disease after 48 years.
Topics: Adolescent; Aged; Humans; Levodopa; Male; Parasomnias; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Somnambulism | 2019 |
Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2019 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Paraganglioma; Parkinson Disease; Pheochromocytoma | 2019 |
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Gels; Humans; Intestinal Mucosa; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Wakefulness | 2019 |
Impact of subthalamic nucleus stimulation did not differ on young-onset and older-onset Parkinson's disease: A three-year follow up.
Topics: Adult; Age of Onset; Aged; Combined Modality Therapy; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2019 |
Clinical correlates of repetitive speech disorders in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Dyskinesias; Female; Humans; Levodopa; Male; Memory; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Sex Factors; Speech Disorders; Speech Production Measurement; Stroop Test; Verbal Behavior | 2019 |
Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prognosis; Subthalamic Nucleus | 2019 |
Measurement of serum cystatin C: A valuable tool for evaluating dyskinesia in Parkinson's disease.
Topics: Aged; Case-Control Studies; Cystatin C; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2019 |
The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies: The LEAP Trial.
Topics: Antiparkinson Agents; Dopamine Agents; Early Medical Intervention; Humans; Levodopa; Parkinson Disease; Prognosis; Time-to-Treatment | 2019 |
Probable RBD Associates with the Development of RLS in Parkinson's Disease: A Cross-Sectional Study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; REM Sleep Behavior Disorder; Restless Legs Syndrome; Surveys and Questionnaires | 2019 |
Effect of levodopa on electroencephalographic biomarkers of the parkinsonian state.
Topics: Aged; Antiparkinson Agents; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Anxiety; Depression; Disabled Persons; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neuralgia; Parkinson Disease; Surveys and Questionnaires | 2019 |
Using Spontaneous Eye-blink Rates to Predict the Motor Status of Patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Blinking; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Predictive Value of Tests; ROC Curve | 2019 |
The Use of Data from the Parkinson's KinetiGraph to Identify Potential Candidates for Device Assisted Therapies.
Topics: Aged; Algorithms; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Sensitivity and Specificity; Tremor | 2019 |
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Biomarkers; Creatine Kinase; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2019 |
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Drug Therapy, Combination; Fever; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2019 |
Dopamine dysregulation syndrome induced by proxy.
Topics: Aged; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders; Syndrome | 2019 |
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2019 |
Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease.
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease | 2019 |
Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
Topics: Administration, Intranasal; Animals; Antioxidants; Behavior, Animal; Emulsions; Female; Flavanones; Levodopa; Male; Nanoparticles; Oxidative Stress; Oxidopamine; Parkinson Disease; Particle Size; Rats; Rats, Wistar; Solubility; Viscosity; Vitamin E | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline | 2019 |
Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.
Topics: Affect; Aged; Antidepressive Agents; Antiparkinson Agents; Cognition; Depression; Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome | 2019 |
Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusion Pumps; Italy; Jejunum; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Retrospective Studies; Treatment Outcome | 2019 |
Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Symptom Assessment; Treatment Outcome; Zonisamide | 2019 |
Inhaled levodopa (Inbrija) for Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Dry Powder Inhalers; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
How do Parkinson's disease patients manage Ramadan fasting? An observational study.
Topics: Adult; Aged; Circadian Rhythm; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fasting; Female; Follow-Up Studies; Humans; Islam; Kuwait; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Religion and Medicine; Self Care; Surveys and Questionnaires | 2019 |
Gut microbes metabolize Parkinson's disease drug.
Topics: Bacteria; Gastrointestinal Microbiome; Humans; Levodopa; Parkinson Disease | 2019 |
Long Term Response to Levodopa in Parkinson's Disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors | 2019 |
You shall not pass! Gut bacteria can convert levodopa to dopamine.
Topics: Bacteria; Dopamine; Gastrointestinal Microbiome; Humans; Levodopa; Parkinson Disease; Tyrosine Decarboxylase | 2019 |
A tale of two patients: Levodopa and creative awakening in parkinson's disease - A qualitative report.
Topics: Aged; Creativity; Dopamine Agents; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Qualitative Research | 2019 |
Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Muscular Atrophy, Spinal; Parkinson Disease; Spinal Curvatures; Treatment Outcome | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Disability Evaluation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus | 2019 |
[Dopamine agonists in Parkinson's disease therapy - 15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study].
Topics: Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2019 |
[Parkinson disease : how to improve the voice and the quality of life].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Voice Disorders | 2019 |
Verbal communication about drug dosage balances drug reduction in Parkinson's disease: Behavioral and electrophysiological evidences.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Electroencephalography; Evoked Potentials; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Neurologists; Parkinson Disease; Persuasive Communication; Physician-Patient Relations; Placebo Effect; Psychomotor Performance; Severity of Illness Index | 2019 |
Learning from Parkinson's patients: Usability of the Cyclops dry powder inhaler.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Packaging; Dry Powder Inhalers; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Registries; Retrospective Studies | 2019 |
Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Cohort Studies; Depression; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index | 2019 |
Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.
Topics: Aging; Animals; Dyskinesia, Drug-Induced; Gene Expression; Inflammation; Interleukin-1beta; Interleukin-6; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred F344; Risk Factors | 2019 |
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinase 3; Histamine H2 Antagonists; Levodopa; MAP Kinase Signaling System; Mice, Inbred C57BL; Parkinson Disease; Proto-Oncogene Proteins c-fos; Ranitidine; Receptors, Histamine H2 | 2019 |
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1
Topics: Animals; Antigen Presentation; Autoantigens; Axons; CD8-Positive T-Lymphocytes; Citrobacter rodentium; Disease Models, Animal; Dopaminergic Neurons; Enterobacteriaceae Infections; Female; Intestines; Levodopa; Male; Mice; Mitochondria; Neostriatum; Parkinson Disease; Protein Kinases; Ubiquitin-Protein Ligases | 2019 |
Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T).
Topics: Alzheimer Disease; Amino Acid Substitution; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Neuroimaging; Parkinson Disease; Positron-Emission Tomography; Presenilin-1 | 2019 |
Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2019 |
White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Prognosis; Retrospective Studies; White Matter | 2019 |
Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Estrogens; Female; Humans; Levodopa; Menarche; Menopause; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Postmenopause; Reproductive History; Severity of Illness Index; Substantia Nigra | 2019 |
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunologic Factors; Interleukin-10; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha | 2019 |
Freezing of gait and postural instability: the unpredictable response to levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Gait Disorders, Neurologic; Humans; Levodopa; Male; Oxadiazoles; Parkinson Disease; Postural Balance; Sensation Disorders | 2019 |
Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease.
Topics: Adult; Aged; Beta Rhythm; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2020 |
Molecular imaging of impulse control disorders in Parkinson's disease.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Molecular Imaging; Parkinson Disease | 2019 |
Wearable Sweat Band for Noninvasive Levodopa Monitoring.
Topics: Drug Monitoring; Female; Humans; Levodopa; Parkinson Disease; Sweat; Wearable Electronic Devices | 2019 |
A novel pathway for microbial metabolism of levodopa.
Topics: Bacteria; Gastrointestinal Microbiome; Humans; Levodopa; Parkinson Disease | 2019 |
Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis.
Topics: Aged; Anisotropy; Brain; Brain Mapping; Case-Control Studies; Cognition; Cognition Disorders; Corpus Callosum; Dementia; Diffusion Tensor Imaging; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Nerve Fibers, Myelinated; Parkinson Disease | 2013 |
Levodopa challenge test and (123) I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors | 2013 |
Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Disability Evaluation; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index | 2013 |
Neurostimulation earlier for selected adults with Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Treatment Outcome | 2013 |
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Carbidopa; Catechols; Clozapine; Diagnosis, Differential; Fluphenazine; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism.
Topics: Antiparkinson Agents; Chediak-Higashi Syndrome; Electromyography; Humans; Hyperpigmentation; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Mutation, Missense; Neurologic Examination; Parkinson Disease; Skin; Young Adult | 2013 |
Commentary for "Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism".
Topics: Antiparkinson Agents; Chediak-Higashi Syndrome; Humans; Levodopa; Male; Parkinson Disease | 2013 |
Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.
Topics: Aged; Alleles; Antiparkinson Agents; Data Interpretation, Statistical; Dopamine; Female; Genotype; Heterozygote; Humans; Learning; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Genetic; Psychomotor Performance; Receptors, Dopamine D2 | 2013 |
Levodopa-resistant freezing of gait and executive dysfunction in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Executive Function; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus | 2013 |
[PSD-95 expression controls L-Dopa dyskinesia].
Topics: Animals; Disks Large Homolog 4 Protein; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Models, Genetic; Parkinson Disease; Protein Transport; Receptors, Dopamine D1 | 2013 |
The role of brain shift, patient age, and Parkinson's disease duration in the difference between anatomical and electrophysiological targets for subthalamic stimulation.
Topics: Age Factors; Brain; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2013 |
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Socioeconomic Factors; Spain | 2014 |
Parkinson's disease: increased motor network activity in the absence of movement.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Cerebrovascular Circulation; Cohort Studies; Deep Brain Stimulation; Deuterium Oxide; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neural Pathways; Parkinson Disease; Positron-Emission Tomography; Subthalamic Nucleus | 2013 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Extended-release carbidopa-levodopa in Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Motor Skills Disorders; Parkinson Disease | 2013 |
Design of an interpolyelectrolyte gastroretentive matrix for the site-specific zero-order delivery of levodopa in Parkinson's disease.
Topics: Adhesiveness; Animals; Antiparkinson Agents; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Galactans; Gastric Mucosa; Hardness; Humans; Hydrogen-Ion Concentration; Kinetics; Levodopa; Mannans; Methacrylates; Models, Chemical; Models, Molecular; Molecular Conformation; Parkinson Disease; Plant Gums; Polymers; Solubility; Solvents; Spectroscopy, Fourier Transform Infrared; Swine; Technology, Pharmaceutical | 2013 |
Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
Topics: Adenoviridae; alpha-Synuclein; Animals; Antiparkinson Agents; Conditioning, Operant; Disease Models, Animal; Dopaminergic Neurons; Food Preferences; Humans; Levodopa; Male; Mutation; Parkinson Disease; Rats; Rats, Wistar; Reward; Saccharin; Substantia Nigra; Sweetening Agents; Taste; Transduction, Genetic; Tyrosine 3-Monooxygenase; Ubiquitin | 2013 |
Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions.
Topics: Bayes Theorem; Computer Simulation; Humans; Levodopa; Longitudinal Studies; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2013 |
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Topics: Administration, Oral; Amphetamine; Biological Availability; Drug Evaluation; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tablets | 2013 |
Gray matter atrophy distinguishes between Parkinson disease motor subtypes.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Cognition; Data Interpretation, Statistical; Female; Gait Disorders, Neurologic; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Nerve Net; Neural Pathways; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Risk Factors | 2013 |
[Parkinson's disease following hypothyroidism: clinical and therapeutic implications].
Topics: Aged; Antiparkinson Agents; Female; Humans; Hypothyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2013 |
Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Mydriasis; Parkinson Disease | 2013 |
Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients.
Topics: Adult; Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electromyography; Evoked Potentials, Motor; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Transcranial Magnetic Stimulation | 2014 |
[Adherence to medication among patients with Parkinson's disease treated at a specialized outpatient unit].
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Medication Adherence; Middle Aged; Outpatients; Parkinson Disease | 2013 |
Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Data Interpretation, Statistical; Deep Brain Stimulation; Eye Movements; Female; Humans; Levodopa; Male; Middle Aged; Oculomotor Muscles; Parkinson Disease; Psychomotor Performance; Pursuit, Smooth; Saccades; Subthalamic Nucleus | 2013 |
Sweet liking in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Food Preferences; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Smell; Sucrose; Sweetening Agents; Taste; Taste Threshold | 2013 |
Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease.
Topics: Action Potentials; Animals; Cell Death; Corpus Striatum; Dopamine; Dopamine Agents; Glutamic Acid; Intralaminar Thalamic Nuclei; Levodopa; Male; Microglia; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synapses; Synaptic Transmission; Vesicular Glutamate Transport Protein 2 | 2013 |
NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; Blotting, Western; Corpus Striatum; Down-Regulation; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Statistics, Nonparametric | 2013 |
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Azabicyclo Compounds; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nerve Tissue Proteins; Neurons; Nicotinic Agonists; Parkinson Disease; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Synaptosomes | 2013 |
Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.
Topics: Animals; Behavior, Animal; Cluster Analysis; Corpus Striatum; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electric Stimulation; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Metabolic Networks and Pathways; Parkinson Disease; Rats; Subthalamic Nucleus | 2013 |
[The use of clozapine and levodopa for the treatment of persistent visual hallucinations and parkinsonism in Lewy body dementia].
Topics: Aged; Antipsychotic Agents; Brain; Clozapine; Comorbidity; Hallucinations; Humans; Levodopa; Lewy Body Disease; Male; Parkinson Disease; Treatment Outcome | 2013 |
Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care.
Topics: Aged; Antiparkinson Agents; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2013 |
Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Smoking | 2013 |
Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
Topics: Benserazide; Capsules; Color; Dopamine Agents; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Quality Control; Tablets; Therapeutic Equivalency | 2013 |
The effect of estrogen in a man with Parkinson's disease and a review of its therapeutic potential.
Topics: Antiparkinson Agents; Drug Implants; Estrogens; Feminization; Gender Identity; Humans; Levodopa; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Parkinson Disease; Spironolactone | 2013 |
Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Levodopa; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Parkinson Disease; Pramipexole; Presynaptic Terminals; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2013 |
Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive pain in Parkinson's disease.
Topics: Aged; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2013 |
Conversion of local anesthesia-guided deep brain stimulation of the subthalamic nucleus to general anesthesia.
Topics: Adult; Anesthesia, General; Anesthesia, Local; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Fear; Female; Humans; Intraoperative Complications; Levodopa; Microelectrodes; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2013 |
Levodopa changes the severity of freezing in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biomechanical Phenomena; Cognition; Disease Progression; Dose-Response Relationship, Drug; Female; Gait; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease | 2013 |
Differences in dopaminergic modulation to motor cortical plasticity between Parkinson's disease and multiple system atrophy.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Cortex; Multiple System Atrophy; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation; Wrist | 2013 |
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Topics: Aged; Catechols; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Nitriles; Parkinson Disease | 2013 |
Comparing kinematic changes between a finger-tapping task and unconstrained finger flexion-extension task in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Biomechanical Phenomena; Female; Fingers; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 2013 |
Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Atrophy; Dystonia; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Paraspinal Muscles; Parkinson Disease; Posture; Radiography; Spine; Thorax | 2013 |
Asymmetric pain processing in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Functional Laterality; Humans; Hyperalgesia; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Perception; Pain Threshold; Parkinson Disease; Psychophysics | 2013 |
Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Causality; Drug Combinations; Fracture Fixation, Internal; Humans; Levodopa; Male; Middle Aged; Ossification, Heterotopic; Parkinson Disease; Radiography; Radius Fractures | 2013 |
Patients' expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: a mixed-method approach.
Topics: Adult; Aged; Antiparkinson Agents; Apathy; Culture; Deep Brain Stimulation; Depressive Disorder; Disability Evaluation; Female; Humans; Illness Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Patient Selection; Prospective Studies; Quality of Life; Subthalamic Nucleus; Symptom Assessment; Treatment Outcome | 2013 |
Dopamine replacement modulates oscillatory coupling between premotor and motor cortical areas in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bayes Theorem; Brain Waves; Case-Control Studies; Deep Brain Stimulation; Electroencephalography; Electromyography; Female; Fourier Analysis; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Methyldopa; Middle Aged; Motor Cortex; Muscle, Skeletal; Neural Pathways; Oxygen; Parkinson Disease; Time Factors | 2014 |
Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease.
Topics: Adult; Biopsy; Humans; Levodopa; Middle Aged; Parkinson Disease; Polyneuropathies; Treatment Outcome | 2013 |
Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agents; Female; Humans; Hypnotics and Sedatives; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Polysomnography; Sleep; Sleep Stages; Sleep Wake Disorders; Sleep, REM | 2013 |
Quantifying daily physical activity and determinants in sedentary patients with Parkinson's disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Anxiety; Body Mass Index; Depression; Educational Status; Energy Metabolism; Female; Guidelines as Topic; Humans; Levodopa; Linear Models; Male; Middle Aged; Motor Activity; Netherlands; Parkinson Disease; Physical Fitness; Sedentary Behavior; Self Efficacy; Sex Factors; Socioeconomic Factors | 2013 |
Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neurodegenerative Diseases; Normal Distribution; Parkinson Disease; Substantia Nigra | 2013 |
Complementary roles of different oscillatory activities in the subthalamic nucleus in coding motor effort in Parkinsonism.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Deep Brain Stimulation; Electroencephalography; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Subthalamic Nucleus | 2013 |
Dopamine dysregulation syndrome in Parkinson's disease patients on duodenal levodopa infusion.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Antiparkinson Agents; Dopamine; Duodenum; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease | 2013 |
Variability of Stepping during a Virtual Reality Paradigm in Parkinson's Disease Patients with and without Freezing of Gait.
Topics: Aged; Antiparkinson Agents; Computer Simulation; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease | 2013 |
Dopaminergic medication counteracts conflict adaptation in patients with Parkinson's disease.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Conflict, Psychological; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Stroop Test | 2013 |
Possible mechanisms involved in subthalamotomy-induced dyskinesia in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Subthalamic Nucleus; Subthalamus | 2013 |
Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation.
Topics: Adult; Age of Onset; Antiparkinson Agents; Child; Deep Brain Stimulation; Dopamine Agents; Exons; Female; Gene Amplification; Genotype; Glucosylceramidase; Heterozygote; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Phenotype; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Ubiquitin-Protein Ligases; Young Adult | 2013 |
Impact of L-DOPA treatment of patients with Parkinson's disease on mononuclear subsets and phagocytosis in the peripheral blood.
Topics: Aged; Aged, 80 and over; Female; Humans; Leukocytes, Mononuclear; Levodopa; Male; Middle Aged; Parkinson Disease; Phagocytosis; Treatment Outcome | 2013 |
Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.
Topics: Adult; Aged; Association Learning; Dopamine Agents; Female; Humans; Learning Disabilities; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Schizophrenia; Young Adult | 2013 |
Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.
Topics: Animals; Dependovirus; Disease Models, Animal; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Transduction, Genetic; Transgenes | 2013 |
Evaluating the acute contributions of dopaminergic replacement to gait with obstacles in Parkinson's disease.
Topics: Aged; Anticipation, Psychological; Antiparkinson Agents; Biomechanical Phenomena; Cues; Data Interpretation, Statistical; Dopamine Agents; Female; Foot; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Proprioception; Reproducibility of Results | 2013 |
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
Topics: Aged; Antiparkinson Agents; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk; Vitamin B 12 | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2013 |
Deep brain stimulation improves survival in severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cause of Death; Deep Brain Stimulation; Depression; Female; Humans; Kaplan-Meier Estimate; Levodopa; Logistic Models; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Regression Analysis; Subthalamic Nucleus; Survival; Survival Analysis; Treatment Outcome | 2014 |
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2014 |
The effect of Parkinson's disease and levodopa on adaptation of anticipatory postural adjustments.
Topics: Adaptation, Physiological; Aged; Antiparkinson Agents; Biomechanical Phenomena; Data Interpretation, Statistical; Female; Humans; Leg; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Photic Stimulation; Postural Balance; Posture; Proprioception | 2013 |
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Dopamine; Epinephrine; Female; Humans; Levodopa; Male; Metanephrine; Middle Aged; Norepinephrine; Normetanephrine; Paraganglioma; Parkinson Disease; Pheochromocytoma; Tandem Mass Spectrometry | 2014 |
Functional and effective connectivity in subthalamic local field potential recordings of patients with Parkinson's disease.
Topics: Aged; Algorithms; Antiparkinson Agents; Beta Rhythm; Data Interpretation, Statistical; Deep Brain Stimulation; Dopamine Agents; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Psychomotor Performance; Subthalamic Nucleus | 2013 |
Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms.
Topics: Aged; Aged, 80 and over; Awareness; Diagnostic Self Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording | 2013 |
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Saimiri | 2013 |
[Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
Topics: Activities of Daily Living; Adult; Age of Onset; Antiparkinson Agents; Cognition; Cohort Studies; Cross-Sectional Studies; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease; Prognosis; Subthalamic Nucleus; Treatment Outcome | 2013 |
Parkinson disease: Long-term levodopa exposure may increase risk of neuropathy in patients with PD.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases | 2013 |
Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Autoradiography; Basal Ganglia; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Postmortem Changes; Proto-Oncogene Proteins c-fos; Putamen; Up-Regulation | 2011 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Stereotyped Behavior | 2012 |
mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Chi-Square Distribution; Deep Brain Stimulation; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease | 2013 |
Dry mouth: an overlooked autonomic symptom of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System Diseases; Female; Humans; Levodopa; Male; Middle Aged; Mouth Diseases; Parkinson Disease; Prevalence; Sialorrhea; Surveys and Questionnaires | 2011 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Automated assessment of bradykinesia and dyskinesia in Parkinson's disease.
Topics: Adult; Algorithms; Antiparkinson Agents; Case-Control Studies; Dyskinesias; Electronic Data Processing; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Spectrum Analysis; Time Factors | 2012 |
Effects of levodopa on vividness of motor imagery in Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Case-Control Studies; Female; Humans; Image Processing, Computer-Assisted; Imagination; Kinesthesis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Parkinson Disease; Photic Stimulation; Surveys and Questionnaires | 2012 |
Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Tremor; Wrist | 2013 |
Negative influence of L-dopa on subjectively assessed sleep but not on nocturnal polysomnography in Parkinson's disease.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep; Sleep Wake Disorders; Surveys and Questionnaires | 2013 |
Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Malaysia; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Factors; Severity of Illness Index | 2014 |
Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Decision Making; Disruptive, Impulse Control, and Conduct Disorders; Female; Games, Experimental; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Probability; Psychometrics; Risk-Taking | 2013 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Benzamides; Brain; Case-Control Studies; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin; Sulfonamides; Thiazoles | 2013 |
Levodopa inhibits habit-learning in Parkinson’s disease.
Topics: Adult; Aged; Antiparkinson Agents; Association Learning; Choice Behavior; Cues; Ecosystem; Female; Humans; Learning Disabilities; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Putamen; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tropanes | 2014 |
The timing between REM sleep behavior disorder and Parkinson's disease.
Topics: Aged; Cognition Disorders; Disease Progression; Dopamine Agents; Dose-Response Relationship, Drug; Electromyography; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Time Factors | 2014 |
Striatal denervation pattern predicts levodopa effects on sequence learning in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Data Interpretation, Statistical; Denervation; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Neostriatum; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Serial Learning; Tetrabenazine | 2013 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological | 2013 |
Letter regarding "Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa".
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
In reply.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease.
Topics: Adult; Aged; Aging; Antiparkinson Agents; Cross-Sectional Studies; Female; Folic Acid; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Parkinson Disease; Vitamin B 12 | 2013 |
[Impulsive-compulsive syndrome in Parkinson's disease].
Topics: Aged; Aged, 80 and over; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Risk Factors; Russia; Surveys and Questionnaires; Syndrome | 2013 |
Motor fluctuations and Helicobacter pylori in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Breath Tests; Female; Folic Acid; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Levodopa; Male; Parkinson Disease; Treatment Outcome; Vitamin B 12 | 2013 |
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide; Prevalence; Time Factors | 2014 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Reduction in Parkinson's disease therapy improved punding but not feeling of presence.
Topics: Antiparkinson Agents; Benserazide; Compulsive Behavior; Emotions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2013 |
Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Guillain-Barre Syndrome; Humans; Levodopa; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2014 |
Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; MAP Kinase Signaling System; Parkinson Disease; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2013 |
Enhanced temporal pain processing in multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Multiple System Atrophy; Pain; Pain Measurement; Pain Threshold; Parkinson Disease; Psychophysics; Reflex | 2013 |
The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbon Isotopes; Cluster Analysis; Corpus Striatum; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Positron-Emission Tomography; Psychomotor Performance; Tetrabenazine; Time Factors; Time Perception | 2013 |
[Сhanges in heart rate variability in presymptomatic and symptomatic stages of Parkinson's disease under pharmacological influences: an experimental study].
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System; Circadian Rhythm; Disease Models, Animal; Electrocardiography; Heart; Heart Rate; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease | 2013 |
Cognitive factors modulate activity within the human subthalamic nucleus during voluntary movement in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Beta Rhythm; Brain Mapping; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Movement; Neurons; Parkinson Disease; Subthalamic Nucleus | 2013 |
Dopaminergic modulation of motor coordinaton in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Psychomotor Performance | 2014 |
Levodopa treatment in Parkinson's disease: how does it affect dysphagia management?
Topics: Antiparkinson Agents; Deglutition; Deglutition Disorders; Humans; Levodopa; Parkinson Disease | 2014 |
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Electromyography; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Vitamin B 12 | 2014 |
Deep brain stimulation for movement disorders: what counts in the end is the end result.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Essential Tremor; Female; Humans; Levodopa; Male; Parkinson Disease; Subthalamic Nucleus | 2014 |
Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2013 |
Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
Topics: Carrier Proteins; Female; Homer Scaffolding Proteins; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Performance of a motor task learned on levodopa deteriorates when subsequently practiced off.
Topics: Aged; Antiparkinson Agents; Female; Humans; Learning; Levodopa; Male; Middle Aged; Motor Skills; Movement; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance | 2014 |
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2013 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oleic Acids; Oxidopamine; Parkinson Disease; TRPV Cation Channels | 2014 |
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Topics: Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dopamine Agents; Drug Interactions; Female; Levodopa; Macaca fascicularis; Male; Oxadiazoles; Parkinson Disease | 2014 |
Direct evaluation of L-DOPA actions on neuronal activity of Parkinsonian tissue in vitro.
Topics: Animals; Calcium; Corpus Striatum; Disease Models, Animal; Humans; Levodopa; Mice; Molecular Imaging; Neurons; Parkinson Disease; Rats | 2013 |
Co-modulation of finely tuned high-gamma band activity across hemispheres in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Brain Waves; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agents; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2014 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2013 |
Darkening of white hair following levodopa therapy in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Hair Color; Humans; Levodopa; Male; Parkinson Disease | 2013 |
Interpretive conundrums when practice doesn't always make perfect.
Topics: Antiparkinson Agents; Female; Humans; Learning; Levodopa; Male; Parkinson Disease; Psychomotor Performance | 2014 |
Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia.
Topics: Adolescent; Adult; Age of Onset; Antiparkinson Agents; Dystonic Disorders; Female; Group VI Phospholipases A2; Humans; Levodopa; Male; Ocular Motility Disorders; Parkinson Disease; Siblings; Young Adult | 2014 |
Parkinson's disease patients first treated at age 75 years or older: a comparative study.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Survival Rate | 2014 |
Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.
Topics: Corpus Striatum; Dopaminergic Neurons; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Time Factors; Treatment Outcome | 2014 |
Basal ganglia neuronal activity during scanning eye movements in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Brain Mapping; Deep Brain Stimulation; Electrodes, Implanted; Eye Movements; Female; Globus Pallidus; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Neurons; Parkinson Disease; Pattern Recognition, Visual; Reading; Substantia Nigra; Subthalamic Nucleus | 2013 |
Clinical correlates of anhedonia in patients with Parkinson's disease.
Topics: Aged; Anhedonia; Antiparkinson Agents; Anxiety; Depression; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life | 2013 |
Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Neural Pathways; Parkinson Disease; Prefrontal Cortex | 2014 |
The effects of dopaminergic medication on dynamic decision making in Parkinson's disease.
Topics: Aged; Cues; Decision Making; Dopamine Agents; Female; Goals; Humans; Learning; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Task Performance and Analysis | 2014 |
Early DEtection of wEaring off in Parkinson disease: the DEEP study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2014 |
[Treatment & management guidelines 2011 for Parkinson disease].
Topics: Antiparkinson Agents; Cognition Disorders; Depression; Dopamine Agonists; Drug Administration Schedule; Humans; Japan; Levodopa; Movement Disorders; Neurology; Parkinson Disease; Practice Guidelines as Topic; Societies, Medical | 2013 |
[Clinical experiences of the Japanese treatment guideline on Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Drug Tolerance; Evidence-Based Medicine; Female; Humans; Japan; Levodopa; Middle Aged; Neurology; Parkinson Disease; Practice Guidelines as Topic; Precision Medicine; Societies, Medical | 2013 |
Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence. Authors' reply.
Topics: Antiparkinson Agents; Deglutition; Deglutition Disorders; Humans; Levodopa; Parkinson Disease | 2014 |
Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait.
Topics: Aged; Antiparkinson Agents; Data Interpretation, Statistical; Dyskinesias; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Surveys and Questionnaires; Upper Extremity | 2014 |
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Pathomechanisms and compensatory efforts related to Parkinsonian speech.
Topics: Aged; Antiparkinson Agents; Biofeedback, Psychology; Brain; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Parkinson Disease; Psychoacoustics; Reading; Speech Disorders; Voice Disorders | 2014 |
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture | 2013 |
Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease.
Topics: Aged; Automobile Driving; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2014 |
Jejunal levodopa infusion in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
High beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease.
Topics: Antiparkinson Agents; Beta Rhythm; Cerebral Cortex; Deep Brain Stimulation; Electroencephalography; Female; Gait Apraxia; Humans; Implantable Neurostimulators; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Subthalamic Nucleus | 2014 |
SPG15: a cause of juvenile atypical levodopa responsive parkinsonism.
Topics: Adolescent; Antiparkinson Agents; Brain; Carrier Proteins; Consanguinity; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Paraplegia; Parkinson Disease | 2014 |
Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease.
Topics: Affect; Aged; Antiparkinson Agents; Cohort Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenotype | 2014 |
Subthalamic nucleus activity dissociates proactive and reactive inhibition in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Attention; Beta Rhythm; Deep Brain Stimulation; Electrodes, Implanted; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Motor Cortex; Neural Pathways; Parkinson Disease; Psychomotor Performance; Reaction Time; Reactive Inhibition; Subthalamic Nucleus | 2014 |
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2014 |
Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Fatigue; Female; Humans; Italy; Levodopa; Logistic Models; Male; Middle Aged; Movement Disorders; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Quality of Life | 2014 |
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.
Topics: Adult; Gene Dosage; Humans; Levodopa; Lewy Bodies; Male; Mutation; Parkinson Disease; Substantia Nigra; Ubiquitin-Protein Ligases | 2014 |
Bilateral functional connectivity of the basal ganglia in patients with Parkinson's disease and its modulation by dopaminergic treatment.
Topics: Action Potentials; Basal Ganglia; Beta Rhythm; Electroencephalography Phase Synchronization; Humans; Levodopa; Middle Aged; Nerve Net; Parkinson Disease; Subthalamic Nucleus | 2013 |
Intestinal levodopa infusion: the Belgian experience.
Topics: Aged; Antiparkinson Agents; Belgium; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2014 |
Pedunculopontine nucleus area oscillations during stance, stepping and freezing in Parkinson's disease.
Topics: Adult; Behavior; Cerebral Cortex; Electroencephalography; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Posture | 2013 |
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Chromatography, Reverse-Phase; Cysteine; Dipeptides; Drug Delivery Systems; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2014 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Prosodic expression and levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Speech | 2013 |
Prosody and levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Speech; Speech Acoustics; Speech Production Measurement; Time Factors; Voice Quality | 2013 |
Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Atrophy; Brain; Dilatation; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2014 |
Levodopa fractionation in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease | 2014 |
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2014 |
Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Attitude to Health; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Outcome Assessment; Severity of Illness Index; Treatment Outcome | 2014 |
Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Asian People; China; Cross-Sectional Studies; Cultural Characteristics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Treatment Outcome | 2014 |
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.
Topics: Affect; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Emotions; Facial Expression; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2014 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine Agents; Hallucinations; Humans; Illusions; Levodopa; Logistic Models; Multivariate Analysis; Parkinson Disease; Psychotic Disorders; Risk Factors; Selegiline; Surveys and Questionnaires | 2014 |
[Case of neuroleptic malignant syndrome following open heart surgery for thoracic aortic aneurysm with parkinson's disease].
Topics: Aged, 80 and over; Anesthesia; Aortic Aneurysm, Thoracic; Cardiac Surgical Procedures; Dantrolene; Extracorporeal Circulation; Female; Humans; Infusions, Intravenous; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Perioperative Care; Postoperative Complications | 2013 |
Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Hypokinesia; Levodopa; Macaca mulatta; Male; Morphine; Motor Activity; Parkinson Disease; Postural Balance; Tremor | 2014 |
Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China.
Topics: Adult; Aged; Antiparkinson Agents; China; Data Collection; Deep Brain Stimulation; Dopamine Agonists; Female; Health Knowledge, Attitudes, Practice; Hospitals; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neurology; Parkinson Disease; Patients; Physicians; Practice Patterns, Physicians' | 2014 |
Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease.
Topics: Actigraphy; Antiparkinson Agents; Case-Control Studies; Chronobiology Disorders; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Parkinson Disease; Polysomnography; Saliva | 2014 |
Parkinson disease: Intestinal levodopa infusion in PD--the first randomized trial.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Manic episode following deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a case report.
Topics: Antiparkinson Agents; Anxiety; Bipolar Disorder; Citalopram; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Medial Forebrain Bundle; Middle Aged; Parkinson Disease; Postoperative Complications; Selective Serotonin Reuptake Inhibitors; Subthalamic Nucleus | 2014 |
Validation of GDI, GPS and GVS for use in Parkinson's disease through evaluation of effects of subthalamic deep brain stimulation and levodopa.
Topics: Analysis of Variance; Antiparkinson Agents; Deep Brain Stimulation; Female; Gait Disorders, Neurologic; Humans; Joints; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pelvis; Walking | 2014 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Tryptophan | 2014 |
Non-motor symptoms in treated and untreated Chinese patients with early Parkinson's disease.
Topics: Age Factors; Antiparkinson Agents; China; Cohort Studies; Constipation; Depression; Dopamine Agonists; Humans; Levodopa; Logistic Models; Parkinson Disease; Sex Factors; Sleep Wake Disorders; Time Factors | 2014 |
Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
Topics: Animals; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Neurites; Neurons; Parkinson Disease; Rats, Wistar; Synapses | 2014 |
Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.
Topics: Aged; Anxiety; Apathy; Compulsive Behavior; Conditioning, Psychological; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesias; Humans; Hypokinesia; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Weights and Measures | 2014 |
Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2014 |
Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Retrospective Studies; Severity of Illness Index | 2014 |
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Benzamides; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Extracellular Space; Female; Levodopa; Microdialysis; Neostriatum; Nomifensine; Parkinson Disease; Positron-Emission Tomography; Proto-Oncogene Proteins c-fos; Pyrrolidines; Rats, Sprague-Dawley; Receptors, Dopamine; Serotonin | 2014 |
New research holds promise for Parkinson's treatment. New drugs and stem cell research offer encouraging glimpses of future therapies.
Topics: Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pluripotent Stem Cells | 2013 |
Comparing clinical features of young onset, middle onset and late onset Parkinson's disease.
Topics: Adult; Age Distribution; Age of Onset; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2014 |
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Minisatellite Repeats; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D2 | 2014 |
Parkinson disease: A role for serotonergic neurons in levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Serotonergic Neurons | 2014 |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Female; Hematologic Tests; Humans; Levodopa; Male; Medication Adherence; Middle Aged; Nursing Homes; Parkinson Disease; Psychotic Disorders; Retrospective Studies | 2014 |
Neural correlates of rate-dependent finger-tapping in Parkinson's disease.
Topics: Aged; Basal Ganglia; Brain; Brain Mapping; Female; Fingers; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease | 2015 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos | 2014 |
Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pyramidal Tracts; Surveys and Questionnaires; Transcranial Magnetic Stimulation; United Kingdom | 2014 |
Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state.
Topics: Adaptation, Physiological; Aged; Antiparkinson Agents; Arm; Dopamine Agents; Humans; Levodopa; Motor Activity; Parkinson Disease; Photic Stimulation; Psychophysics; Rotation; Visual Perception | 2014 |
Effects of dopaminergic therapy on locomotor adaptation and adaptive learning in persons with Parkinson's disease.
Topics: Adaptation, Physiological; Aged; Antiparkinson Agents; Biomechanical Phenomena; Female; Gait; Humans; Learning; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Walking | 2014 |
Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2014 |
A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tyrosine | 2014 |
Oscillatory subthalamic nucleus activity is modulated by dopamine during emotional processing in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine; Electroencephalography; Emotions; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Subthalamic Nucleus | 2014 |
The subthalamic nucleus modulates the early phase of probabilistic classification learning.
Topics: Aged; Antiparkinson Agents; Association Learning; Brain; Case-Control Studies; Deep Brain Stimulation; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Parkinson Disease; Probability Learning; Severity of Illness Index; Subthalamic Nucleus | 2014 |
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Topics: Aged; Antiparkinson Agents; Chi-Square Distribution; Cohort Studies; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Tropanes | 2014 |
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals | 2014 |
Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Assessment of postural balance among individuals with Parkinson disease with and without effects from dopaminergic medications.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Reference Values; Severity of Illness Index; Treatment Outcome | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Randomized Controlled Trials as Topic | 2014 |
Scaling and coordination deficits during dynamic object manipulation in Parkinson's disease.
Topics: Aged; Case-Control Studies; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Motor Skills; Parkinson Disease; Thalamus | 2014 |
Sex differences in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Australia; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Sex Characteristics | 2014 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Anxiety; Autonomic Nervous System; Case-Control Studies; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; Serbia; Severity of Illness Index; Time Factors | 2014 |
Caudate dopaminergic denervation and visual hallucinations: evidence from a ¹²³I-FP-CIT SPECT study.
Topics: Aged; Caudate Nucleus; Denervation; Dopamine; Dopaminergic Neurons; Female; Hallucinations; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes | 2014 |
Color vision impairment in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Color Vision; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
PARK13 regulates PINK1 and subcellular relocation patterns under oxidative stress in neurons.
Topics: Cell Line, Tumor; Cytoskeleton; Dopamine Agents; Gene Expression Regulation; Humans; Hydrogen Peroxide; Levodopa; Mutation; Neuroblastoma; Neurons; Oxidants; Oxidative Stress; Parkinson Disease; Protein Kinases; RNA, Messenger; Subcellular Fractions; Time Factors; Transfection | 2014 |
[Medical treatment of Parkinson's disease in elderly and multimorbid patients].
Topics: Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Piperidines | 2014 |
Dopamine treatment and cognitive functioning in individuals with Parkinson's disease: the "cognitive flexibility" hypothesis seems to work.
Topics: Aged; Antiparkinson Agents; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reaction Time; Treatment Outcome | 2014 |
History of smoking and olfaction in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Monoamine Oxidase Inhibitors; Olfaction Disorders; Parkinson Disease; Smell; Smoking | 2014 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins | 2014 |
Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Female; France; Gait; Humans; Levodopa; Male; Muscarinic Antagonists; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Time Factors | 2014 |
1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous neurotoxic compound, disturbs the behavioral and biochemical effects of L-DOPA: in vivo and ex vivo studies in the rat.
Topics: Animals; Corpus Striatum; Dopamine; Hippocampus; Hyperkinesis; In Vitro Techniques; Levodopa; Male; Neurotoxins; Parkinson Disease; Rats; Rats, Wistar; Serotonin; Substantia Nigra; Tetrahydroisoquinolines | 2014 |
The acute brain response to levodopa heralds dyskinesias in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Decision Making; Dyskinesia, Drug-Induced; Female; Head Movements; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease; Psychomotor Performance; Reaction Time; Time Factors | 2014 |
Time structure of leg movement activity during sleep in untreated Parkinson disease and effects of dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Antagonists; Female; Humans; Levodopa; Male; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Prospective Studies; Time Factors | 2014 |
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine | 2014 |
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
Gastric bezoar complication of Duodopa(®) therapy in Parkinson's disease, treated with Coca-Cola(®).
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Carbonated Beverages; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Stomach | 2014 |
Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect.
Topics: Aged; Corpus Striatum; Dopamine; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Survival Analysis | 2014 |
Initiating dopaminergic treatment in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease | 2014 |
Who dropped the ball on L-DOPA? A patient's lament.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2014 |
Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
Topics: Adult; Aged; Asian People; Cohort Studies; Exons; Female; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Pedigree; Protein Serine-Threonine Kinases; Sequence Analysis, DNA | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Off and on state assessment of swallowing function in Parkinson's disease.
Topics: Antiparkinson Agents; Deglutition; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Cohort Studies; Cross-Sectional Studies; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors | 2014 |
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Age of Onset; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Data Interpretation, Statistical; Disease Progression; Dyskinesia, Drug-Induced; Female; Ghana; Humans; Italy; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Young Adult | 2014 |
Frequency-dependent neural activity in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Mapping; Cohort Studies; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Rest; Severity of Illness Index | 2014 |
Impulse control and repetitive behaviors in Parkinson's disease - are there differences in the relation to dopamine agonist treatment?
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2014 |
[Parkinson, what's new? L-Dopa, The Lancet answers].
Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Publishing | 2014 |
Using ecological whole body kinematics to evaluate effects of medication adjustment in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Severity of Illness Index; Walking; Wireless Technology | 2014 |
Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease.
Topics: Aged; Awareness; Dopamine Agents; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Self Concept | 2014 |
In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease.
Topics: Aged; Analysis of Variance; Chi-Square Distribution; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Reaction Time; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2014 |
A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, Liquid; Drug Monitoring; Drug Stability; Female; Humans; Hydrophobic and Hydrophilic Interactions; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Topics: Acetophenones; Animals; Catalysis; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Levodopa; Male; Models, Molecular; Nitriles; Oxadiazoles; Parkinson Disease; Prodrugs; Rats | 2014 |
Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Auditory Cortex; Combined Modality Therapy; Deep Brain Stimulation; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sensory Gating; Subthalamic Nucleus | 2015 |
Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model.
Topics: Animals; Bacopa; Centella; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; India; Levodopa; Medicine, Ayurvedic; Motor Activity; Mucuna; Parkinson Disease; Plant Extracts; Plants, Medicinal; Protein Serine-Threonine Kinases; Withania | 2014 |
Successful treatment of dopamine dysregulation syndrome with valproic acid.
Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Valproic Acid | 2014 |
Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
Topics: Action Potentials; Aged; Antiparkinson Agents; Basal Ganglia; Biophysical Phenomena; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Nerve Net; Neurons; Parkinson Disease; Severity of Illness Index; Statistics as Topic | 2014 |
Parkinson disease: Can a new trial end controversy over when to use levodopa?
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2016 |
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Topics: Aged; Antiparkinson Agents; Brachial Artery; Catechols; Dilatation; Endothelium; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Nitriles; Parkinson Disease; Statistics, Nonparametric | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A | 2014 |
Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Topics: Action Potentials; Age Factors; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Inhibitory Postsynaptic Potentials; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease; Pars Reticulata; Receptor, Adenosine A1; Receptors, Dopamine D1; Xanthines | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2015 |
Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; GABAergic Neurons; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Metabotropic Glutamate; Receptors, Purinergic P1 | 2014 |
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Ribosomal Protein S6 Kinases, 90-kDa | 2016 |
Motion sensor dyskinesia assessment during activities of daily living.
Topics: Activities of Daily Living; Adult; Aged; Algorithms; Antiparkinson Agents; Dyskinesias; Female; Hand; Humans; Levodopa; Male; Middle Aged; Motion Perception; Movement; Parkinson Disease; Severity of Illness Index | 2014 |
Dopaminergic agents and nutritional status in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Levodopa; Male; Malnutrition; Middle Aged; Nutritional Status; Parkinson Disease | 2014 |
'Don't delay, start today': delaying levodopa does not delay motor complications.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Cortico-muscular coherence in advanced Parkinson's disease with deep brain stimulation.
Topics: Aged; Cerebral Cortex; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Muscle Rigidity; Muscle, Skeletal; Parkinson Disease; Subthalamic Nucleus; Tremor | 2015 |
VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Levodopa; Mice; Neurons; Parkinson Disease; Vesicular Monoamine Transport Proteins | 2014 |
Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Taiwan | 2014 |
Perceptual decision-making in patients with Parkinson's disease.
Topics: Aged; Case-Control Studies; Color Perception Tests; Decision Making; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time | 2014 |
Dopamine-responsive pattern in tremor patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor | 2014 |
Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case.
Topics: Adult; Antiparkinson Agents; Carbidopa; Female; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Pregnancy; Treatment Outcome | 2014 |
Electrophysiological registration of phonological perception in the subthalamic nucleus of patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Perception; Subthalamic Nucleus | 2014 |
Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Disabled Persons; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2014 |
Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Duodenum; Female; Humans; Intubation; Levodopa; Male; Middle Aged; Norway; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2014 |
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2015 |
Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors | 2015 |
Effects of dopaminergic treatment on functional cortico-cortical connectivity in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Nerve Net; Neural Pathways; Parkinson Disease; Transcranial Magnetic Stimulation | 2015 |
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Cost-Benefit Analysis; Deep Brain Stimulation; Drug Administration Schedule; Gels; Germany; Humans; Injections, Subcutaneous; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years | 2015 |
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Neurons; Oxidopamine; Parkinson Disease; Protein Binding; Protein Interaction Domains and Motifs; Rats; Receptors, Dopamine D2 | 2014 |
Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Topics: Antioxidants; Carbidopa; Cells, Cultured; DNA Damage; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2015 |
Teaching NeuroImages: Pisa syndrome in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Dystonia; Humans; Indoles; Levodopa; Male; Parkinson Disease; Posture; Scoliosis | 2014 |
Asymmetrical effect of levodopa on the neural activity of motor regions in PD.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Cerebellum; Female; Hand; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease | 2014 |
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Female; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinson Disease; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1 | 2014 |
Does idiopathic restless legs syndrome delay onset and reduce severity of Parkinson's disease: a pilot study.
Topics: Age Factors; Aged; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pilot Projects; Restless Legs Syndrome; Severity of Illness Index | 2015 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
Specificity and sensibility of 9-Itens Wearing-off Questionnaire in Brazilian Parkinson disease patient sample.
Topics: Adult; Aged; Aged, 80 and over; Brazil; Cross-Sectional Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Statistics, Nonparametric; Surveys and Questionnaires; Translations | 2014 |
Neural substrates of levodopa-responsive gait disorders and freezing in advanced Parkinson's disease: a kinesthetic imagery approach.
Topics: Aged; Antiparkinson Agents; Brain; Female; Gait Disorders, Neurologic; Humans; Imagination; Kinesthesis; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography | 2015 |
Towards an expert system for accurate diagnosis and progress monitoring of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Biomarkers; Carbidopa; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Expert Systems; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2015 |
Kinesia paradoxa: a challenging Parkinson's phenomenon for simulation.
Topics: Adrenal Medulla; Antiparkinson Agents; Basal Ganglia; Cerebellum; Humans; Levodopa; Models, Neurological; Parkinson Disease; Physiological Phenomena; Running; Stress, Psychological; Walking | 2015 |
β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Dopaminergic Neurons; Down-Regulation; Drug Interactions; Female; Levodopa; Male; Mesencephalon; Microtubule-Associated Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Transcription Factor TFIIH; Transcription Factors; Up-Regulation | 2015 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophysiology; Female; Genes, Immediate-Early; Habenula; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2016 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation | 2015 |
Dyskinesias and motor symptoms onset in Parkinson disease.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Movement; Parkinson Disease; Retrospective Studies | 2014 |
Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
Topics: Antiparkinson Agents; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time | 2015 |
Non-motor fluctuations in Parkinson's disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients.
Topics: Age Factors; Aged; Antiparkinson Agents; Case Management; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Primary Dysautonomias | 2014 |
The effect of levodopa on postural stability evaluated by wearable inertial measurement units for idiopathic and vascular Parkinson's disease.
Topics: Aged; Aged, 80 and over; Biomechanical Phenomena; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Treatment Outcome | 2015 |
Taste function in early stage treated and untreated Parkinson's disease.
Topics: Antiparkinson Agents; Case-Control Studies; Cohort Studies; Female; Humans; Levodopa; Male; Mental Status Schedule; Mouth; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Taste Disorders; Taste Perception | 2015 |
Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Constipation; Cross-Sectional Studies; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
A method for predicting the outcomes of combined pharmacologic and deep brain stimulation therapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Combined Modality Therapy; Deep Brain Stimulation; Female; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2014 |
Levodopa: 50 years of a revolutionary drug for Parkinson disease.
Topics: Antiparkinson Agents; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2015 |
Behavioral effects of levodopa.
Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease | 2015 |
Dopa therapy and action impulsivity: subthreshold error activation and suppression in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Dopamine; Dopamine Agonists; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time | 2015 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
What is the best initial treatment in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease | 2014 |
Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease | 2015 |
Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
Topics: Antiparkinson Agents; Drug Delivery Systems; Drug Stability; Levodopa; Mouth; Mouth Mucosa; Parkinson Disease; Prodrugs | 2016 |
Parkinson's disease severity and use of dopaminergic medications.
Topics: Dopamine Agents; Dopamine Agonists; Double-Blind Method; Female; Humans; Hypotension, Orthostatic; Levodopa; Longitudinal Studies; Male; Multicenter Studies as Topic; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric | 2015 |
Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Time Factors | 2015 |
Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype.
Topics: Aged; Cognition Disorders; Cohort Studies; Disability Evaluation; Disease Progression; Dopamine Agents; Female; Gait Disorders, Neurologic; Humans; Incidence; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phenotype; Walking | 2015 |
Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Cortical Synchronization; Deep Brain Stimulation; Evoked Potentials, Motor; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Cortex; Nerve Net; Neural Pathways; Parkinson Disease; Psychomotor Performance; Subthalamus; Time Factors; Treatment Outcome | 2015 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2015 |
A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Agonists; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2014 |
24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 2015 |
Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Calorimetry, Differential Scanning; Cryoelectron Microscopy; Disease Models, Animal; Drug Carriers; Lecithins; Levodopa; Lipids; Mice, Inbred C57BL; Parkinson Disease; Prodrugs; Spectroscopy, Fourier Transform Infrared; Triglycerides | 2015 |
Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study.
Topics: Adult; Aged; Dopamine Agents; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech; Speech Acoustics; Speech Disorders | 2015 |
Noninvasive monitoring of plasma L-dopa concentrations using sweat samples in Parkinson's disease.
Topics: Blood Chemical Analysis; Humans; Levodopa; Parkinson Disease; Sweat | 2015 |
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2015 |
MicroRNAs as biomarker of Parkinson disease? Small but mighty.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; MicroRNAs; Parkinson Disease | 2015 |
Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD.
Topics: Aged; Antiparkinson Agents; Biomarkers, Pharmacological; Computer Simulation; Female; Humans; Levodopa; Male; MicroRNAs; Parkinson Disease; Real-Time Polymerase Chain Reaction | 2015 |
Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dyskinesia, Drug-Induced; Homeostasis; Levodopa; Male; Neuronal Plasticity; Parkinson Disease; Rats, Sprague-Dawley; Sleep; Sleep Deprivation | 2015 |
A 12-year population-based study of freezing of gait in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Community Health Planning; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index | 2015 |
Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Acoustics; Speech Disorders; Speech Therapy; Treatment Outcome | 2015 |
Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; China; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; ROC Curve; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Face-referenced measurement of perioral stiffness and speech kinematics in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Case-Control Studies; Electromyography; Face; Facial Muscles; Female; Humans; Labial Frenum; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Regression Analysis; Speech | 2015 |
Entacapone and prostate cancer risk in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Therapy, Combination; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Prostatic Neoplasms; Registries; Risk; Time Factors | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase | 2015 |
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index; Urologic Diseases | 2015 |
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
Topics: Aged; Dopamine; Dyskinesias; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Serotonergic Neurons; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Synapses | 2015 |
Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Biomarkers; Case-Control Studies; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra | 2015 |
[Neurological common diseases in the super-elder society. Topics: IV. Parkinson's disease; 2. Current and new drugs for initial treatment of Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2014 |
Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychometrics; Qualitative Research; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Speech rate in Parkinson's disease: A controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Speech | 2016 |
Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Cholinergic Neurons; Corpus Striatum; Dicyclomine; Disease Models, Animal; Dyskinesia, Drug-Induced; Famotidine; Histamine H2 Antagonists; Interneurons; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Receptors, Histamine H2 | 2015 |
Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.
Topics: Animals; Antioxidants; Benserazide; Betaine; Brain; Dopamine; Dopamine Agents; Drug Combinations; Glutathione; Glutathione Peroxidase; Humans; Hyperhomocysteinemia; Levodopa; Lipid Peroxidation; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2015 |
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Piperazines | 2015 |
Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?
Topics: Age Factors; Aged; Antiparkinson Agents; Blood Pressure; Europe; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; United States | 2015 |
Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration.
Topics: Aged; Aged, 80 and over; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Muscular Atrophy, Spinal; Parkinson Disease; Retrospective Studies; Spinal Curvatures; Subthalamic Nucleus; Treatment Outcome; Visual Analog Scale | 2015 |
The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study.
Topics: Aged; Akathisia, Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors | 2015 |
Fluctuating Cotard syndrome in a patient with advanced Parkinson disease.
Topics: Aged; Antiparkinson Agents; Delusions; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease | 2015 |
Quantitative motor assessment of dyskinesias in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; ROC Curve; Severity of Illness Index | 2015 |
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Gels; Humans; Hungary; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Random Allocation | 2015 |
Continuous levodopa infusion is better—for now.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P | 2015 |
Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
Topics: Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Outpatients; Parkinson Disease | 2015 |
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline | 2015 |
Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscle Weakness; Parkinson Disease; Quality of Life; Sensation; Severity of Illness Index; Sex Factors; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urination Disorders; Urodynamics | 2015 |
Social intentions in Parkinson's disease patients: A kinematic study.
Topics: Antiparkinson Agents; Basal Ganglia; Biomechanical Phenomena; Case-Control Studies; Female; Hand Strength; Humans; Intention; Interpersonal Relations; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Social Behavior | 2015 |
Prevalence and correlates of sleep disorders in Parkinson's disease: a polysomnographic study.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Cross-Sectional Studies; Female; Humans; Levodopa; Logistic Models; Male; Mexico; Middle Aged; Parkinson Disease; Polysomnography; Prevalence; REM Sleep Behavior Disorder; Risk Factors; Sex Factors; Sleep Apnea Syndromes; Sleep, REM | 2015 |
Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease.
Topics: Aged; Antiparkinson Agents; Duodenum; Female; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Long-term follow-up of bilateral subthalamic nucleus stimulation in Chinese Parkinson's disease patients.
Topics: Activities of Daily Living; Adult; Aged; China; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Time; Treatment Outcome | 2015 |
Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
Topics: Analgesics, Opioid; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Male; Nalbuphine; Neostriatum; Parkinson Disease; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2015 |
New and emerging treatments for Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2015 |
Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesias; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Time Factors; Treatment Outcome; Tremor | 2015 |
Toward Understanding Ambulatory Activity Decline in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Disability Evaluation; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Mobility Limitation; Parkinson Disease; Postural Balance; Prospective Studies; Quality of Life; Self Efficacy; Surveys and Questionnaires; Upper Extremity | 2015 |
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Carbidopa; Chromatography, High Pressure Liquid; Corpus Striatum; Dependovirus; Dopamine; Electrochemical Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunohistochemistry; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2015 |
Interactive effects of GPI stimulation and levodopa on postural control in Parkinson's disease.
Topics: Aged; Deep Brain Stimulation; Dopamine Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2015 |
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Association Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Receptor, Adenosine A2A | 2015 |
Reply: Oleh Hornykiewicz's contribution to the l-dopa story.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2015 |
Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dopaminergic Neurons; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Restless Legs Syndrome; Subthalamic Nucleus | 2015 |
Capgras delusion for animals and inanimate objects in Parkinson's Disease: a case report.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Capgras Syndrome; Carbidopa; Clozapine; Cognitive Dysfunction; Delusions; Dibenzothiazepines; Dogs; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Pets; Plants; Quetiapine Fumarate | 2015 |
The relative phases of basal ganglia activities dynamically shape effective connectivity in Parkinson's disease.
Topics: Adult; Beta Rhythm; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-fos; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2015 |
In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Butylamines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3 | 2016 |
Parkinson's disease: disturbed vestibular function and levodopa.
Topics: Aged; Case-Control Studies; Electrodiagnosis; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Postural Balance; Vestibule, Labyrinth | 2015 |
Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Freezing Reaction, Cataleptic; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Quality of Life; Risk Factors; Self Report; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |
[Local brain activity in different motor subtypes of Parkinson's disease with fMRI].
Topics: Cerebellum; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Tremor | 2015 |
[Effects of a single dose levodopa on heart rate variability in Parkinson's disease].
Topics: Electrocardiography; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation | 2015 |
Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Topics: Aged; Attention; Cognition Disorders; Dopamine Agonists; Executive Function; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Motor Activity; Multivariate Analysis; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Space Perception; Verbal Learning | 2015 |
Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Italy; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apathy; Benzothiazoles; Cross-Sectional Studies; Dopamine Agonists; Educational Status; Female; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Prospective Studies; Psychotropic Drugs; Spain | 2015 |
Knotting of Duodopa® duodenal infusion system.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheterization; Catheters; Drug Combinations; Duodenum; Equipment Failure; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Levodopa; Male; Microarray Analysis; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
Progressive supra-nuclear palsy: frequency of cardinal extrapyramidal features at first presentation.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Early Diagnosis; Female; Humans; India; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture; Practice Guidelines as Topic; Prevalence; Supranuclear Palsy, Progressive | 2015 |
Utility of the Japanese version of the 9-item Wearing-off Questionnaire.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires; Translations; Treatment Outcome | 2015 |
50 years of levodopa.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome | 2015 |
Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Taurine | 2016 |
Dopaminergic correlates of metabolic network activity in Parkinson's disease.
Topics: Adult; Brain; Brain Mapping; Dopamine; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Sex-Related Prognostic Predictors for Parkinson Disease Undergoing Subthalamic Stimulation.
Topics: Antiparkinson Agents; Cognition; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Prognosis; Retrospective Studies; Sex Characteristics; Subthalamic Nucleus; Treatment Outcome | 2015 |
GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesias; G-Protein-Coupled Receptor Kinase 3; Gene Expression; Gene Knockdown Techniques; Levodopa; Parkinson Disease; Protein Interaction Domains and Motifs; Rats; RGS Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction | 2015 |
An investigation of hearing impairment in de-novo Parkinson's disease patients: A preliminary study.
Topics: Aged; Antiparkinson Agents; Audiometry, Pure-Tone; Auditory Pathways; Auditory Threshold; Cochlea; Female; Hearing Loss; Hearing Tests; Humans; Levodopa; Male; Middle Aged; Otoacoustic Emissions, Spontaneous; Parkinson Disease | 2015 |
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Anhedonia; Apathy; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2015 |
One-year Outcome of Bilateral Subthalamic Stimulation in Parkinson Disease: An Eastern Experience.
Topics: Adult; Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Retrospective Studies; Speech Disorders; Subthalamic Nucleus; Taiwan; Treatment Outcome | 2015 |
Motor complications in an incident Parkinson's disease cohort.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Scotland | 2016 |
Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Drug Utilization; Female; Humans; Inpatients; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Patterns, Physicians'; United States | 2015 |
Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy.
Topics: Adult; Aged; Antiparkinson Agents; Anxiety; Carbidopa; Depression; Drug Combinations; Female; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Time Factors | 2016 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Mice; Parkinson Disease; Receptors, Neurotransmitter; Severity of Illness Index; Time Factors | 2015 |
Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Exercise Test; Female; Gait; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Postural Balance; Severity of Illness Index | 2015 |
Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Carbidopa; Drug Combinations; Electroencephalography; Female; Frontal Lobe; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Occipital Lobe; Parkinson Disease; Severity of Illness Index | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?].
Topics: Antiparkinson Agents; Cognition; Factor Analysis, Statistical; Humans; Hungary; Language; Levodopa; Movement Disorders; Observer Variation; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Translations; Tremor | 2014 |
Medial frontal ∼4-Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical dopamine depletion.
Topics: Animals; Antiparkinson Agents; Conditioning, Operant; Delta Rhythm; Dopamine; Electroencephalography; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Neurons; Neuropsychological Tests; Oxidopamine; Parkinson Disease; Rats, Long-Evans; Theta Rhythm; Time Perception | 2015 |
Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Smell; Surveys and Questionnaires; Treatment Outcome | 2015 |
Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
Topics: Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Distress Syndrome; Subthalamic Nucleus; Treatment Outcome | 2015 |
Endothelial progenitor cells: Cardiovascular protection in Parkinson's disease?
Topics: Aged; Cardiovascular Diseases; Endothelial Progenitor Cells; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Interaction of synchronized dynamics in cortex and basal ganglia in Parkinson's disease.
Topics: Action Potentials; Aged; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Cortical Synchronization; Deep Brain Stimulation; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Signal Processing, Computer-Assisted; Subthalamic Nucleus | 2015 |
Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Airway Resistance; Antiparkinson Agents; Dry Powder Inhalers; Equipment Design; Female; Humans; Inhalation; Levodopa; Male; Middle Aged; Parkinson Disease; Pressure | 2015 |
Parkinson's disease related dyskinesia in a Tanzanian population.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tanzania | 2015 |
L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
Topics: Age Factors; Aged; alpha-Synuclein; Cells, Cultured; CpG Islands; DNA Methylation; Dopamine Agents; Female; Gene Expression Regulation; Genotype; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Regression Analysis; ROC Curve; Sex Factors | 2015 |
A community study outlines how to prevent Parkinson's disease motor complications in the clinic.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Residence Characteristics | 2016 |
Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Posture; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index; Signal Detection, Psychological | 2015 |
Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Decision Making; Dopamine Agonists; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Motion Perception; Parkinson Disease; Reaction Time; Task Performance and Analysis | 2015 |
Parkinsonism Improved With Levodopa After Endoscopic Third Ventriculostomy in Shunted Hydrocephalus Due to Aqueductal Stenosis.
Topics: Antiparkinson Agents; Humans; Hydrocephalus; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Third Ventricle; Ventriculoperitoneal Shunt | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Glutamate Decarboxylase; Levodopa; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine D1; Receptors, G-Protein-Coupled | 2015 |
Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Depression; Depressive Disorder; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Sleep Wake Disorders; Surveys and Questionnaires | 2015 |
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Female; Hand Strength; Heart; Humans; Levodopa; Male; Middle Aged; Myocardial Perfusion Imaging; Neurologic Examination; Parkinson Disease; Radiopharmaceuticals; Severity of Illness Index; Time Factors | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Equipment Failure; Female; Follow-Up Studies; Gastric Bypass; Gastroscopy; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Safety; Postoperative Complications; Prospective Studies; Treatment Outcome; Vascular Access Devices | 2016 |
Early Parkinson's disease patients on rasagiline present with better odor discrimination.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Discrimination, Psychological; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Odorants; Olfaction Disorders; Olfactory Perception; Parkinson Disease; Physical Stimulation; Prospective Studies; Psychophysics; Sensory Thresholds; Severity of Illness Index; Treatment Outcome | 2015 |
Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease | 2015 |
[Parkinson's disease associated with a mutation in the PARK2 gene].
Topics: Age of Onset; Disease Progression; Finland; Genotype; Humans; Levodopa; Mutation; Parkinson Disease; Phenotype; Ubiquitin-Protein Ligases | 2015 |
Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Ovariectomy; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1B | 2015 |
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.
Topics: Autopsy; Catecholamines; Fluorodeoxyglucose F18; Humans; Levodopa; Neurodegenerative Diseases; Neurons; Parkinson Disease; Putamen; Synaptic Vesicles | 2015 |
Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Period; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2015 |
The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Inhibition; Parkinson Disease | 2015 |
Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease.
Topics: Aged; Disease Progression; Female; Humans; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Telemedicine; Telemetry; User-Computer Interface | 2015 |
Compensatory postural adjustments in Parkinson's disease assessed via a virtual reality environment.
Topics: Aged; Aged, 80 and over; Biomechanical Phenomena; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; User-Computer Interface | 2016 |
Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cross-Sectional Studies; Depression; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Pain; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Is normosmic Parkinson disease a unique clinical phenotype?
Topics: Adult; Aged; Aged, 80 and over; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Neurogenesis; Parkinson Disease; Phenotype; Tomography, Emission-Computed, Single-Photon | 2015 |
The olfactory side of Parkinson disease: Relevance for clinical practice.
Topics: Corpus Striatum; Female; Humans; Levodopa; Male; Neurogenesis; Parkinson Disease | 2015 |
Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dyskinesias; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Quality of Life | 2016 |
Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
Topics: Aged; Biomarkers; Female; Humans; Image Processing, Computer-Assisted; Iron; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Parkinson Disease | 2016 |
L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.
Topics: Adrenergic Agents; Animals; Caspase 3; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Levodopa; MAP Kinase Signaling System; Mesencephalon; Oxidopamine; Parkinson Disease; PC12 Cells; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Time Factors | 2016 |
Impact of Parkinson's disease and levodopa on resting state functional connectivity related to speech prosody control.
Topics: Aged; Brain; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Neural Pathways; Parkinson Disease; Rest; Speech; Speech Disorders | 2016 |
Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autopsy; Diagnostic Errors; Essential Tremor; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Young Adult | 2015 |
Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Articulation Disorders; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Jaw; Levodopa; Lip; Male; Middle Aged; Parkinson Disease; Phonation; Phonetics; Range of Motion, Articular; Reflex, Abnormal; Respiration; Severity of Illness Index | 2015 |
Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson's disease: a resting-state fMRI study.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Mapping; Female; Gait Disorders, Neurologic; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Organ Size; Parkinson Disease; Rest; Tremor | 2015 |
Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Area Under Curve; Catecholamines; Deep Brain Stimulation; Female; Homovanillic Acid; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Postoperative Period; Quality of Life; ROC Curve; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2015 |
Gait variability in Parkinson's disease: levodopa and walking direction.
Topics: Aged; Antiparkinson Agents; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2016 |
Parkinson's disease: initial treatment of motor disorders.
Topics: Age Factors; Antiparkinson Agents; Drug Administration Schedule; Humans; Indoles; Levodopa; Motor Activity; Parkinson Disease; Physical Therapy Modalities; Time-to-Treatment; Treatment Outcome | 2015 |
Subthalamic nucleus stimulation improves Parkinson's disease-associated camptocormia in parallel to its preoperative levodopa responsiveness.
Topics: Aged; Combined Modality Therapy; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy, Spinal; Neurologic Examination; Parkinson Disease; Posture; Preoperative Period; Prognosis; Spinal Curvatures; Statistics as Topic; Subthalamic Nucleus | 2016 |
Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Central Nervous System Depressants; Disease Models, Animal; Levodopa; Macaca fascicularis; Male; Melatonin; Parkinson Disease; Sleep Wake Disorders | 2015 |
[Perioperative Management of a Patient with Severe Parkinson's Disease with Intravenous Levodopa Administration].
Topics: Aged; Antiparkinson Agents; Aortic Aneurysm, Thoracic; Humans; Infusions, Intravenous; Levodopa; Male; Parkinson Disease; Perioperative Period | 2015 |
Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
Topics: Antiparkinson Agents; Carbidopa; Crohn Disease; Drug Combinations; Duodenum; Humans; Intestine, Small; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Predicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State?
Topics: Accidental Falls; Aged; Aged, 80 and over; Fear; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Prospective Studies; Risk Factors; Severity of Illness Index; Walking | 2015 |
Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2015 |
Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Behavior, Addictive; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Syndrome | 2015 |
A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.
Topics: Administration, Inhalation; Aerosols; Antiparkinson Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Dry Powder Inhalers; Excipients; Humans; Leucine; Levodopa; Parkinson Disease; Reproducibility of Results; Tissue Distribution | 2015 |
Peripheral neuropathy in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Comorbidity; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases | 2015 |
Variable frequency stimulation of subthalamic nucleus for freezing of gait in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Pramipexole; Subthalamic Nucleus | 2015 |
Levodopa Does Not Worsen Gastric Emptying in Parkinson's Disease.
Topics: Aged; Dopamine Agents; Drug Monitoring; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome | 2015 |
The BMJ, take heed: almost all studies have some degree of bias.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2015 |
Pisa syndrome in Parkinson disease: An observational multicenter Italian study.
Topics: Aged; Cohort Studies; Cross-Sectional Studies; Dopamine Agonists; Dystonia; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2015 |
Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Equipment Failure; Female; Humans; Levodopa; Magnetic Resonance Imaging, Interventional; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Prospective Studies; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2016 |
Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies | 2016 |
[F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].
Topics: Case-Control Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Phonation; Speech Acoustics; Speech Disorders; Treatment Outcome | 2014 |
[The use of piribedil in early and late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piribedil | 2015 |
[Pain fluctuations in Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease | 2015 |
Understanding Parkinson Disease: A Complex and Multifaceted Illness.
Topics: Basal Ganglia; Dopaminergic Neurons; Humans; Levodopa; Nurse's Role; Parkinson Disease; Substantia Nigra; Tremor | 2015 |
Review on initial drug treatment in Parkinson's disease did not mention entacapone.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2015 |
Reboxetine has no antidepressant effect at all.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2015 |
Authors' reply to Braithwaite and Elrington.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2015 |
Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Transcranial Direct Current Stimulation; Treatment Outcome | 2016 |
Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2016 |
[An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Parkinson Disease; Serotonergic Neurons | 2015 |
Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus | 2016 |
Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Auditory Perception; Beta Rhythm; Cerebral Cortex; Deep Brain Stimulation; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2015 |
Advanced Parkinson disease patients have impairment in prosody processing.
Topics: Aged; Auditory Perception; Emotions; Facial Expression; Facial Recognition; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recognition, Psychology; Social Perception; Verbal Behavior | 2016 |
Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Duodenum; Female; Gels; Humans; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Quality of Life | 2015 |
Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
Topics: Adult; Aged; Antiparkinson Agents; Choice Behavior; Female; France; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Spain; Surveys and Questionnaires; United Kingdom | 2016 |
The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Humans; Japan; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Purines | 2015 |
[Association of VEGFR2 gene polymorphisms with the effect of L-dopa and dyskinesia complications].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Polymorphism, Genetic; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aging; DNA Methylation; Epigenesis, Genetic; Female; Granulocytes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2015 |
Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2016 |
Subcortical evoked activity and motor enhancement in Parkinson's disease.
Topics: Acoustic Stimulation; Adult; Aged; Antiparkinson Agents; Cues; Deep Brain Stimulation; Electromyography; Evoked Potentials; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Photic Stimulation; Psychoacoustics; Reaction Time; Subthalamic Nucleus | 2016 |
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Parkinson Disease; Prospective Studies | 2016 |
Reply to letter: Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2016 |
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Retrospective Studies; Romania | 2016 |
Building on 50 years of levodopa therapy.
Topics: Antiparkinson Agents; Congresses as Topic; Humans; Levodopa; Parkinson Disease; Time Factors | 2016 |
Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.
Topics: Aged; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebellum; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Activity; Motor Cortex; Neural Pathways; Parkinson Disease; Putamen; Severity of Illness Index | 2016 |
Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D3 | 2016 |
D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
Topics: Aged; Carbon Radioisotopes; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3; Up-Regulation; Ventral Striatum | 2016 |
Opicapone for motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2016 |
Detection of Levodopa Induced Dyskinesia in Parkinson's Disease patients based on activity classification.
Topics: Accelerometry; Activities of Daily Living; Aged; Algorithms; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Autonomic nervous system response to L-dopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Autonomic Nervous System; Deep Brain Stimulation; Electrocardiography; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parasympathetic Nervous System; Parkinson Disease; Time Factors | 2015 |
A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Wearable Electronic Devices | 2015 |
Effects of disease severity and medication state on postural control asymmetry during challenging postural tasks in individuals with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Severity of Illness Index; Weight-Bearing | 2016 |
LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Topics: Action Potentials; Aging; Amino Acid Substitution; Animals; Antiparkinson Agents; Cell Death; Chromosomes, Artificial, Bacterial; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Mutation; Parkinson Disease; Promoter Regions, Genetic; Protein Domains; Rats; Rats, Transgenic; Substantia Nigra | 2016 |
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists | 2016 |
The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Uric Acid | 2016 |
Discrimination and Characterization of Parkinsonian Rest Tremors by Analyzing Long-Term Correlations and Multifractal Signatures.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Signal Processing, Computer-Assisted; Support Vector Machine; Tremor | 2016 |
Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Coffee; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Freezing of gait in Parkinson's disease is associated with altered functional brain connectivity.
Topics: Adult; Aged; Antiparasitic Agents; Brain; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Oxygen; Parkinson Disease; Severity of Illness Index | 2016 |
Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2016 |
Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
Topics: Adult; Aged; Association Learning; Deep Brain Stimulation; Disability Evaluation; Dopamine; Dopamine Agents; Female; Humans; Learning Disabilities; Levodopa; Male; Maze Learning; Middle Aged; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Reaction Time; Retention, Psychology; Subthalamic Nucleus; Time Factors | 2016 |
Awake Neurophysiologically Guided versus Asleep MRI-Guided STN DBS for Parkinson Disease: A Comparison of Outcomes Using Levodopa Equivalents.
Topics: Adult; Aged; Deep Brain Stimulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2015 |
Parkinson's disease: fewer treatment withdrawals with levodopa.
Topics: Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2015 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopamine; Levodopa; Macaca; Male; Parkinson Disease; Parkinson Disease, Secondary; Permeability; Pyridines | 2016 |
Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Diet; Double-Blind Method; Female; Glycine max; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease | 2016 |
Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome; White Matter | 2016 |
Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Hydrazines; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Oxadiazoles; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
Percutaneous endoscopic gastrostomy assisted by laparoscopy: is it a valid choice?
Topics: Aged; Antiparkinson Agents; Gastroscopy; Gastrostomy; Humans; Intubation, Gastrointestinal; Laparoscopy; Levodopa; Male; Parkinson Disease | 2016 |
Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer.
Topics: Accelerometry; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Monitoring, Physiologic; Parkinson Disease; Support Vector Machine | 2016 |
[Lumbar back pain in patients with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Analgesics; Antiparkinson Agents; Combined Modality Therapy; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Low Back Pain; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Retrospective Studies; Treatment Outcome | 2016 |
Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
Topics: Adult; Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Speech Disorders | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation; Sympatholytics; Time Factors | 2016 |
Altered inhibitory interaction among inferior frontal and motor cortex in l-dopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2016 |
Frequency and clinical correlates of postural and striatal deformities in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Corpus Striatum; Female; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 2016 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Topics: Animals; Benserazide; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Neostriatum; Nortropanes; Parkinson Disease; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Tomography, X-Ray Computed; Tyrosine 3-Monooxygenase | 2016 |
Study of levodopa response in Parkinson's disease: Observations on rates of motor progression.
Topics: Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2016 |
Ultrasound Strain Elastography in Assessment of Muscle Stiffness in Acute Levodopa Challenge Test: A Feasibility Study.
Topics: Aged; Antiparkinson Agents; Elastic Modulus; Elasticity Imaging Techniques; Feasibility Studies; Humans; Image Interpretation, Computer-Assisted; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Stress, Mechanical | 2016 |
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Parkinson Disease; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar | 2016 |
Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Topics: Aged; Biomarkers; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon | 2016 |
Dopamine depletion affects communicative intentionality in Parkinson's disease patients: Evidence from action kinematics.
Topics: Biomechanical Phenomena; Dopamine; Female; Hand Strength; Humans; Intention; Interpersonal Relations; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 2016 |
Transcranial Non-Invasive Brain Stimulation in Parkinson's Disease Patients with Dyskinesias. Where is the Optimal Target?
Topics: Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Prospective Studies | 2016 |
A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Combinations; Drug Therapy, Combination; Edema; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Treatment Outcome | 2016 |
24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Muscle Rigidity; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders | 2016 |
Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Video Recording | 2016 |
Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Connectome; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Prognosis; Putamen; Sensorimotor Cortex | 2016 |
Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Optogenetics; Parkinson Disease; Rats; Subthalamic Nucleus | 2016 |
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Humans; Interviews as Topic; Italy; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Phenotype; Risk; Severity of Illness Index; Time Factors | 2016 |
Do patients with late-stage Parkinson's disease still respond to levodopa?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Validation of the UPDRS section IV for detection of motor fluctuations in Parkinson's disease.
Topics: Aged; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2016 |
Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Polymorphism, Single Nucleotide; Sex Factors | 2016 |
What can you tell me about levodopa, the drug used to treat Parkinson's disease?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2013 |
An external portable device for adaptive deep brain stimulation (aDBS) clinical research in advanced Parkinson's Disease.
Topics: Deep Brain Stimulation; Electrophysiological Phenomena; Equipment Design; Humans; Levodopa; Parkinson Disease; Time Factors | 2016 |
Balance and Gait Represent Independent Domains of Mobility in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Cross-Sectional Studies; Factor Analysis, Statistical; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Mobility Limitation; Parkinson Disease; Postural Balance; Signal Processing, Computer-Assisted | 2016 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction | 2016 |
[Update on Current Care Guideline: Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic | 2016 |
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Topics: Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Levodopa; Parkinson Disease; Physicians | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.
Topics: Aged; Brain; Cerebral Cortex; Cognitive Dysfunction; Dementia; Female; Fluorodeoxyglucose F18; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography | 2016 |
[Supra-on state freezing of gait: two case reports].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Gait; Humans; Levodopa; Male; Parkinson Disease | 2016 |
Gender and non motor fluctuations in Parkinson's disease: A prospective study.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sex Characteristics | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
Unilateral Stimulation of Prelemniscal Radiations for the Treatment of Acral Symptoms of Parkinson's Disease: Long-Term Results.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2016 |
Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Clinical Trials as Topic; Databases, Bibliographic; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Neural Stem Cells; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2016 |
Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Brief Psychiatric Rating Scale; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Prevalence; REM Sleep Behavior Disorder | 2017 |
Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Decision Making; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Severity of Illness Index; Time Perception | 2016 |
Work and power reduced in L-dopa naïve patients in the early-stages of Parkinson's disease.
Topics: Activities of Daily Living; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Parkinson Disease; Reference Values; Statistics, Nonparametric; Time Factors; Torso | 2016 |
Maintaining balance against force perturbations: impaired mechanisms unresponsive to levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Feedback, Physiological; Female; Gait; Humans; Joints; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Sensation Disorders | 2016 |
The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Executive Function; Humans; Inhibition, Psychological; Learning; Levodopa; Middle Aged; Parkinson Disease | 2016 |
Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cohort Studies; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Neuralgia; Parkinson Disease; Risk Factors; Treatment Outcome | 2016 |
Effects of Levodopa on Postural Strategies in Parkinson's disease.
Topics: Adult; Aged; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture | 2016 |
Objective Gait and Balance Impairments Relate to Balance Confidence and Perceived Mobility in People With Parkinson Disease.
Topics: Aged; Aged, 80 and over; Disability Evaluation; Dopamine Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Postural Balance; Severity of Illness Index; Surveys and Questionnaires | 2016 |
Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Humans; Levodopa; Middle Aged; Parkinson Disease | 2016 |
The Effect of Levodopa on Improvements in Protective Stepping in People With Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Female; Follow-Up Studies; Gait Disorders, Neurologic; Generalization, Psychological; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Retention, Psychology | 2016 |
The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Sprague-Dawley; Spectrum Analysis; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Walking | 2016 |
Flamenco dancer posture: Unique "off" complication in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Dystonia; Humans; Levodopa; Male; Parkinson Disease | 2016 |
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Rats, Sprague-Dawley | 2016 |
The human subthalamic nucleus encodes the subjective value of reward and the cost of effort during decision-making.
Topics: Action Potentials; Conflict, Psychological; Decision Making; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion; Reward; Subthalamic Nucleus | 2016 |
l-dopa-induced off: Functional overlay in Parkinson disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Psychophysiologic Disorders; Video Recording | 2016 |
Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Compounding; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease; Phytotherapy; Plant Extracts; Seeds | 2016 |
Parkinson's disease-related network topographies characterized with resting state functional MRI.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Mapping; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Levodopa; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Oxygen; Parkinson Disease; Positron-Emission Tomography; Reproducibility of Results; Rest | 2017 |
Advanced therapies in Parkinson's disease: Long-term retrospective study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Thalamus; Treatment Outcome | 2016 |
Outpatient titration of carbidopa/levodopa enteral suspension (Duopa).
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatients; Parkinson Disease; Suspensions; Treatment Outcome | 2017 |
[Benefits of the combination of mucuna, green tea and levodopa/benserazide in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Mucuna; Parkinson Disease; Tea | 2016 |
L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
Topics: Action Potentials; Animals; Antiparkinson Agents; Cholestanols; Citalopram; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Hippocampus; Hydroxyindoleacetic Acid; Levodopa; Male; Organ Specificity; Parkinson Disease; Prefrontal Cortex; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin; Single-Cell Analysis; Synaptic Transmission | 2016 |
Endoscopic alternative to buried bumper syndrome secondary to Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Device Removal; Drug Combinations; Emergencies; Equipment Design; Foreign-Body Migration; Gastroscopes; Gastroscopy; Gastrostomy; Humans; Infusion Pumps, Implantable; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed | 2017 |
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
Topics: Animals; Caproates; Capsules; Carbidopa; Catechols; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Lactones; Levodopa; Microscopy, Confocal; Nitriles; Parkinson Disease; Polyesters | 2016 |
GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Calcifediol; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Levodopa; Luminescent Measurements; Male; Middle Aged; Parkinson Disease; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Risk; RNA, Messenger; Turkey; Vitamin D-Binding Protein; Young Adult | 2017 |
Park sleep: a non-motor dominant Parkinson's disease phenotype.
Topics: Aged; Clonazepam; Humans; Levodopa; Male; Parkinson Disease; REM Sleep Behavior Disorder | 2016 |
Mirror movements in Parkinson's disease: An under-appreciated clinical sign.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Female; Functional Laterality; Humans; India; Levodopa; Lower Extremity; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Prevalence; Severity of Illness Index; Tertiary Care Centers; Upper Extremity | 2016 |
Raul de la Fuente-Fernandez, February 22, 1959-May 11, 2016.
Topics: History, 20th Century; History, 21st Century; Levodopa; Neurology; Parkinson Disease; Placebo Effect | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Gels; Health Care Costs; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Visual Analog Scale | 2016 |
Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
Topics: Adult; Aged; Asian People; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Dopamine D3 | 2016 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2016 |
Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2016 |
Using epigenetic networks for the analysis of movement associated with levodopa therapy for Parkinson's disease.
Topics: Accelerometry; Antiparkinson Agents; Data Mining; Dyskinesia, Drug-Induced; Epigenomics; Gene Regulatory Networks; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease | 2016 |
Effects of Levodopa on Vowel Articulation in Patients with Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Articulation Disorders; Case-Control Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech; Speech Articulation Tests | 2015 |
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.
Topics: Animals; Biocompatible Materials; Blotting, Western; Chitosan; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Immunohistochemistry; Levodopa; Liposomes; Male; MAP Kinase Signaling System; Nanoparticles; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Reproducibility of Results; Treatment Outcome | 2016 |
A potential case of remission of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Male; Meditation; Parkinson Disease; Psychophysiology; Remission Induction | 2016 |
Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Referral and Consultation; Retrospective Studies; Severity of Illness Index | 2016 |
[Motor levodopa-induced complications in Parkinson's disease].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2016 |
Dietary habits and neurological features of Parkinson's disease patients: Implications for practice.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Constipation; Cross-Sectional Studies; Diet, Healthy; Energy Intake; Feeding Behavior; Female; Food-Drug Interactions; Hospitals, Special; Humans; Italy; Levodopa; Male; Malnutrition; Middle Aged; Outpatient Clinics, Hospital; Parkinson Disease; Patient Compliance; Prevalence; Risk; Severity of Illness Index | 2017 |
A Novel Homozygous p.L539F Mutation Identified in PINK1 Gene in a Moroccan Patient with Parkinsonism.
Topics: Amino Acid Motifs; Chromosomes; Cognition Disorders; Computational Biology; Disease Progression; Exons; Homozygote; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Morocco; Mutation; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Pedigree; Phenotype; Protein Domains; Protein Kinases; Sequence Analysis, DNA | 2016 |
Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life | 2016 |
Response to: Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 2016 |
Treatment of a female patient with persistent genital arousal and Parkinson's disease with paliperidone.
Topics: Dopamine Agents; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Middle Aged; Orgasm; Paliperidone Palmitate; Parkinson Disease; Sexual Dysfunction, Physiological | 2017 |
Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 2016 |
Plantar cutaneous function in Parkinson's disease patients ON and OFF L-dopa.
Topics: Aged; Carbidopa; Discrimination, Psychological; Drug Combinations; Electromyography; Female; Foot; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Physical Stimulation; Reflex, Abnormal; Touch; Touch Perception; Vibration | 2016 |
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study.
Topics: Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Quality of Life; Severity of Illness Index; Sex Factors; Symptom Assessment | 2016 |
Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Spain | 2016 |
Unmasking the Effects of L-DOPA on Rapid Dopamine Signaling with an Improved Approach for Nafion Coating Carbon-Fiber Microelectrodes.
Topics: Animals; Brain; Carbon; Carbon Fiber; Dopamine; Electrochemical Techniques; Electrodes, Implanted; Evoked Potentials; Levodopa; Male; Microelectrodes; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2016 |
Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Connectome; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Parkinson Disease | 2016 |
Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients.
Topics: Aged; Animals; Cysteine; Disease Models, Animal; Erythrocytes; Female; Humans; Levodopa; Macaca fascicularis; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Proteasome Endopeptidase Complex; Protein Deglycase DJ-1; Protein Multimerization | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus; Tremor | 2016 |
Advances in levodopa therapy for Parkinson disease.
Topics: Administration, Oral; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2016 |
Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Potentials; Fourier Analysis; Levodopa; Locomotion; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar; Time Factors | 2016 |
Effects of freezing of gait on postural motor learning in people with Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Gait Disorders, Neurologic; Humans; Learning; Levodopa; Male; Memory; Motor Activity; Parkinson Disease; Posture | 2016 |
Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting.
Topics: Beta Rhythm; Deep Brain Stimulation; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Speech Intelligibility; Subthalamic Nucleus | 2016 |
Small (autonomic) and large fiber neuropathy in Parkinson disease and parkinsonism.
Topics: Age Factors; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Autonomic Pathways; Diabetes Complications; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Neuromuscular Junction; Parkinson Disease; Parkinsonian Disorders; Peripheral Nervous System Diseases; Skin | 2016 |
Premotor Symptoms as Predictors of Outcome in Parkinsons Disease: A Case-Control Study.
Topics: Case-Control Studies; Comorbidity; Databases, Factual; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pneumonia, Aspiration; Prognosis; Psychotic Disorders; Risk Factors; Taiwan | 2016 |
Low-dose lithium adjunct therapy associated with reduced off-time in Parkinson's disease: A case series.
Topics: Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Lithium Chloride; Male; Middle Aged; Parkinson Disease | 2016 |
A Novel Developmental Role for Dopaminergic Signaling to Specify Hypothalamic Neurotransmitter Identity.
Topics: Animals; Dopaminergic Neurons; Histamine; Hypothalamus; Levodopa; Neurotransmitter Agents; Orexins; Parkinson Disease; Serotonergic Neurons; Sleep Wake Disorders; Synaptic Transmission; Tyrosine 3-Monooxygenase; Zebrafish; Zebrafish Proteins | 2016 |
Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Review Literature as Topic | 2016 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Hemodynamics; Isoflurane; Ketamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sympatholytics | 2016 |
Resolution of inverse psoriasis after treatment with levodopa for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Parkinson Disease; Psoriasis; Remission Induction; Skin; Treatment Outcome | 2017 |
Subthalamic beta oscillations are attenuated after withdrawal of chronic high frequency neurostimulation in Parkinson's disease.
Topics: Adult; Aged; Beta Rhythm; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Implantable Neurostimulators; Levodopa; Male; Middle Aged; Parkinson Disease; Spectrum Analysis; Subthalamic Nucleus; Time Factors | 2016 |
Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s.
Topics: Antiparkinson Agents; History, 20th Century; Levodopa; Neurology; Parkinson Disease | 2016 |
Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biophysics; Case-Control Studies; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Parkinson Disease; Theta Rhythm; Transcranial Magnetic Stimulation | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Functional Laterality; Genotype; Hypokinesia; Levodopa; Luminescent Proteins; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Optogenetics; Oxidopamine; Parkinson Disease; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Transduction, Genetic | 2016 |
Early Onset Parkinson's disease due to DJ1 mutations: An Indian study.
Topics: Age of Onset; Aged; Antiparasitic Agents; Asian People; Computational Biology; DNA Mutational Analysis; Exons; Female; Humans; India; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Pedigree; Protein Deglycase DJ-1; Retrospective Studies | 2016 |
Unilateral Subthalamic Nucleus Stimulation in the Treatment of Asymmetric Parkinson"s Disease with Early Motor Complications.
Topics: Aftercare; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2017 |
Factors responsible for early postoperative mental alterations after bilateral implantation of subthalamic electrodes.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Risk Factors; Subthalamic Nucleus; Third Ventricle | 2017 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Outcome Assessment, Health Care; Oxidopamine; Parkinson Disease; Reproducibility of Results; Time Factors | 2016 |
Quantitative Susceptibility Mapping in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Female; Globus Pallidus; Humans; Image Interpretation, Computer-Assisted; Iron; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Red Nucleus; Severity of Illness Index; Substantia Nigra; Thalamus | 2016 |
Pathophysiology underlying drooling in Parkinson's disease: oropharyngeal bradykinesia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Freezing Reaction, Cataleptic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Sialorrhea; Speech Disorders; Statistics, Nonparametric; Surveys and Questionnaires | 2016 |
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Parkinson Disease; Problem Behavior; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Transcranial Magnetic Stimulation; Tyrosine 3-Monooxygenase | 2016 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: A balance of symptoms and side-effects?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; England; Female; Home Care Services; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Quality of Life; Retrospective Studies; Sensation Disorders | 2016 |
Caffeine consumption and the 4-year progression of de novo Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Caffeine; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Quality of Life; Surveys and Questionnaires; Time Factors | 2016 |
Jejunal catheter placement for levodopa-carbidopa infusion in a patient with Billroth I gastrectomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrectomy; Gastroenterostomy; Humans; Infusion Pumps; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2016 |
Commentary: Dealing with the Aftermath.
Topics: Deep Brain Stimulation; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus | 2016 |
Increased suicide risk and clinical correlates of suicide among patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Suicide | 2016 |
Subarachnoid hemorrhage and extrapyramidal symptoms: a case report.
Topics: Basal Ganglia Diseases; Humans; Hydrocephalus; Levodopa; Male; Middle Aged; Parkinson Disease; Subarachnoid Hemorrhage; Tomography, X-Ray Computed | 2016 |
Subjective Perceived Motor Improvement after Acute Levodopa Challenge in Parkinson's Disease.
Topics: Aged; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Reported Outcome Measures | 2016 |
Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Case-Control Studies; Female; Globus Pallidus; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Oxygen; Parkinson Disease; Subthalamic Nucleus | 2017 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley | 2016 |
Fatigue in early Parkinson's disease: the Norwegian ParkWest study.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Norway; Parkinson Disease; Prospective Studies | 2017 |
A case of sudden deterioration in Parkinson disease.
Topics: Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Female; Humans; Levodopa; Parkinson Disease; Tablets | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin; Urea | 2016 |
Levodopa medication improves incidental sequence learning in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Awareness; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Probability Learning; Reaction Time; Recognition, Psychology; Severity of Illness Index | 2016 |
Proposal for using time estimation training for the treatment of Parkinson's disease.
Topics: Attention; Basal Ganglia; Brain; Cerebral Cortex; Cognition; Dopamine; Humans; Levodopa; Memory; Models, Neurological; Nerve Net; Neural Pathways; Parkinson Disease; Time Perception | 2016 |
Subthalamic oscillatory activity in parkinsonian patients with off-period dystonia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2016 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dyskinesia, Drug-Induced; Encephalitis; Functional Laterality; Gene Expression Regulation; Levodopa; Lipopolysaccharides; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics; Tumor Necrosis Factor-alpha | 2016 |
Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vasomotor System | 2016 |
Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study.
Topics: Aged; Antiparkinson Agents; Brain; Cross-Sectional Studies; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Myelin Sheath; Neuroimaging; Parkinson Disease | 2016 |
Molecularly imprinted cyclodextrin nanosponges for the controlled delivery of L-DOPA: perspectives for the treatment of Parkinson's disease.
Topics: beta-Cyclodextrins; Imidazoles; Levodopa; Molecular Imprinting; Parkinson Disease; Polymers | 2016 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxidopamine; Pain; Parkinson Disease; Rats, Sprague-Dawley; Spinal Cord | 2016 |
The role of dopamine in positive and negative prediction error utilization during incidental learning - Insights from Positron Emission Tomography, Parkinson's disease and Huntington's disease.
Topics: Aged; Dopamine; Female; Humans; Huntington Disease; Learning; Levodopa; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Raclopride; Reinforcement, Psychology; Ventral Striatum | 2017 |
Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Contraindications; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Neurosurgery; Parkinson Disease; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Time Factors; Treatment Outcome; Visual Analog Scale | 2017 |
It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
Topics: Antiparkinson Agents; Biomechanical Phenomena; Cognition; Cooperative Behavior; Dopamine; Dopamine Agents; Female; Hand; Humans; Interpersonal Relations; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease | 2016 |
Subthalamic stimulation and levodopa modulate cortical reactivity in Parkinson's patients.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Cerebral Cortex; Deep Brain Stimulation; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Spectrum Analysis; Subthalamic Nucleus; Transcranial Magnetic Stimulation | 2017 |
Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Dopamine Agonists; Drug Therapy, Combination; Female; Glutathione; Humans; Levodopa; Logistic Models; Male; Middle Aged; Neopterin; Parkinson Disease; Prodromal Symptoms; Smell; Valsalva Maneuver | 2016 |
Lingual protrusion dystonia: Manifestation during "on" periods in Parkinson's disease.
Topics: Aged, 80 and over; Antiparkinson Agents; Botulinum Toxins, Type A; Diagnosis, Differential; Dystonia; Humans; Levodopa; Male; Neuromuscular Agents; Parkinson Disease; Tongue Diseases | 2016 |
Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dopamine Agents; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Prefrontal Cortex; Pyramidal Tracts; Rats, Wistar | 2017 |
Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
Topics: Aged; Female; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2018 |
Two hundred steps.
Topics: alpha-Synuclein; Creatine; Deep Brain Stimulation; Disease Progression; Dopamine; Fetal Tissue Transplantation; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Levodopa; Lewy Bodies; Neostriatum; Neurons; Parkinson Disease; Parkinson Disease, Postencephalitic; Prion Diseases; Substantia Nigra; Thalamus | 2016 |
Management of levodopa for residents with Parkinson's disease.
Topics: Aged; Humans; Levodopa; Nursing Homes; Parkinson Disease; Patient-Centered Care | 2016 |
Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.
Topics: Animals; Antiparkinson Agents; Biosensing Techniques; Bromocriptine; Catecholamines; Dopamine Agonists; Dopaminergic Neurons; Equipment Design; Levodopa; Mice; Molecular Imaging; Nanotechnology; Neuroimaging; Parkinson Disease; Precision Medicine; Substantia Nigra | 2017 |
Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Polyneuropathy in levodopa-treated Parkinson's patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polyneuropathies; Risk Factors; Severity of Illness Index | 2016 |
Delayed administration of dopaminergic drugs is not associated with prolonged length of stay of hospitalized patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Length of Stay; Levodopa; Male; Parkinson Disease | 2017 |
[Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Deep Brain Stimulation; Economics, Pharmaceutical; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years | 2016 |
The patient's perspective: The effect of levodopa on Parkinson symptoms.
Topics: Accelerometry; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Physician-Patient Relations; Treatment Outcome; Tremor | 2017 |
Jejunitis secondary to Duodopa® probe, a different complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Humans; Infusion Pumps, Implantable; Jejunal Diseases; Levodopa; Parkinson Disease | 2016 |
Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Gastric Emptying; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging | 2017 |
Levodopa reverse stridor and prevent subsequent endotracheal intubation in Parkinson disease patients with bilateral vocal cord palsy: A case report.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Intubation, Intratracheal; Levodopa; Male; Parkinson Disease; Respiratory Sounds; Risk Assessment; Severity of Illness Index; Treatment Outcome; Vocal Cord Paralysis | 2016 |
Motor cortex plasticity can indicate vulnerability to motor fluctuation and high L-DOPA need in drug-naïve Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2017 |
The impact of early versus late levodopa administration.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Time Factors | 2017 |
Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gynostemma; Humans; Levodopa; Male; Memory; Mice; Mice, Inbred C57BL; Parkinson Disease; Plant Extracts; Protective Agents; Substantia Nigra | 2017 |
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?
Topics: Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2017 |
Re-emergent tremor in Parkinson's disease: Clinical and accelerometric properties.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Positioning; Rest; Tremor | 2017 |
L-dopa co-drugs in nanostructured lipid carriers: A comparative study.
Topics: Caffeic Acids; Drug Carriers; Drug Liberation; Half-Life; Humans; Kinetics; Levodopa; Lipids; Microscopy, Electron, Transmission; Nanostructures; Parkinson Disease; Thioctic Acid | 2017 |
Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Italy; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Severity of Illness Index; Translating | 2017 |
Covariation between plasma phosphate and daytime cortisol in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Circadian Rhythm; Cognition; Female; Humans; Hydrocortisone; Levodopa; Logistic Models; Male; Malnutrition; Middle Aged; Nutrition Assessment; Parkinson Disease; Phosphates; Serum Albumin; Transferrin | 2016 |
Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Introduction to the Special Issue on dopamine celebrating the 90th birthday of Oleh Hornykiewicz.
Topics: Dopamine; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Research | 2017 |
Effect of subthalamic nucleus deep brain stimulation on balance in Parkinson's disease: A static posturographic analysis.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postural Balance; Sensitivity and Specificity; Subthalamic Nucleus | 2017 |
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor.
Topics: Accelerometry; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognitive Behavioral Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rest; Severity of Illness Index; Tremor | 2017 |
Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor | 2018 |
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Tablets | 2017 |
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Topics: Aged; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease | 2017 |
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Alleles; Animals; Disease Progression; Dyskinesias; Female; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptors, Dopamine | 2017 |
Phasic activity during non REM sleep.
Topics: Antiparkinson Agents; Citalopram; Humans; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Selective Serotonin Reuptake Inhibitors; Sleep, REM | 2017 |
Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.
Topics: Activities of Daily Living; Deep Brain Stimulation; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2017 |
Clinical correlates of sural neurography impairment within normal limits in patients with Parkinsons disease.
Topics: Adult; Aged; Axons; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polyneuropathies | 2017 |
Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Topics: Aged; Aged, 80 and over; Animals; Aromatic-L-Amino-Acid Decarboxylases; Caudate Nucleus; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Enzyme Activation; Female; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Macaca mulatta; Male; Parkinson Disease; Putamen; Rats | 2017 |
Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; CD4-Positive T-Lymphocytes; Cytokines; Female; Humans; Immunophenotyping; Leukocytes, Mononuclear; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2018 |
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Long-Term Potentiation; Male; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Transcranial Magnetic Stimulation | 2017 |
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Topics: Age Factors; Antiparkinson Agents; Bifidobacterium; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Confounding Factors, Epidemiologic; Diet; Drug Combinations; Dysbiosis; Female; Fruit; Gastrointestinal Microbiome; Humans; Lactobacillaceae; Levodopa; Male; Parkinson Disease; Pasteurellaceae; Risk Factors; RNA, Ribosomal, 16S; Sex Factors; United States; Vegetables; Verrucomicrobia | 2017 |
Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Retrospective Studies; Vomiting | 2017 |
Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
Topics: Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Humans; Levodopa; Outcome Assessment, Health Care; Parkinson Disease | 2017 |
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine | 2017 |
Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Decision Support Systems, Clinical; Drug Combinations; Drug Therapy, Combination; Humans; Infusion Pumps; Levodopa; Parkinson Disease | 2017 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 2017 |
Anticipatory Postural Adjustment During Self-Initiated, Cued, and Compensatory Stepping in Healthy Older Adults and Patients With Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Cross-Sectional Studies; Cues; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Postural Balance; Walking | 2017 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesias; Functional Laterality; Levodopa; Male; Optogenetics; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2017 |
Prevalence and burden of dysautonomia in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Prevalence; Primary Dysautonomias; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires | 2017 |
Levodopa response differs in Parkinson's motor subtypes: A task-based effective connectivity study.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Oxygen; Parkinson Disease; Postural Balance; Psychomotor Performance; Sensation Disorders; Tremor | 2017 |
Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
Topics: Attention; Brain Mapping; Cerebellum; Cerebral Cortex; Corpus Striatum; Dopamine; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Motor Activity; Parkinson Disease; Virtual Reality | 2017 |
An implantable microelectrode array for dopamine and electrophysiological recordings in response to L-dopa therapy for Parkinson's disease.
Topics: Animals; Dopamine; Electrophysiological Phenomena; Humans; Levodopa; Microelectrodes; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2016 |
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Gases; Isoflurane; Ketamine; Levodopa; Parkinson Disease; Rats | 2017 |
Correspondence: The pathophysiology of pramipexole-associated dystonia in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dystonia; Humans; Levodopa; Parkinson Disease; Pramipexole | 2017 |
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome | 2017 |
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 2017 |
Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Cells; Comet Assay; DNA Damage; Female; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2009 |
Subthalamic local field potential oscillations during ongoing deep brain stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2008 |
Parkinson's disease.
Topics: Africa; Humans; Levodopa; Parkinson Disease; United States | 2008 |
Working memory in Parkinson's disease patients: clinical features and response to levodopa.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Memory; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parkinson Disease; Space Perception | 2008 |
Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Circadian Rhythm; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Eye Enucleation; Functional Laterality; Hypothalamic Area, Lateral; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereotyped Behavior; Substantia Nigra | 2008 |
A 77-year-old man with Parkinson's disease and hyperthermia.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Combined Modality Therapy; Emergency Service, Hospital; Emergency Treatment; Follow-Up Studies; Humans; Levodopa; Male; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome | 2008 |
Pergolide associated cardiac valvulopathy based on Ontario administrative data.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Databases, Factual; Dopamine Agonists; Female; Health Services Administration; Heart Failure; Heart Valve Diseases; Humans; Levodopa; Male; Ontario; Parkinson Disease; Pergolide | 2008 |
Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Cognition; Dopamine Agents; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Neuropsychological Tests; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance; Reaction Time; Reward | 2008 |
New L-dopa codrugs as potential antiparkinson agents.
Topics: Administration, Oral; Animals; Antioxidants; Antiparkinson Agents; Caffeic Acids; Carnosine; Corpus Striatum; Dopamine; Glutathione Peroxidase; Levodopa; Parkinson Disease; Rats; Superoxide Dismutase | 2008 |
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Dopa Decarboxylase; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; France; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Practice Patterns, Physicians'; Retrospective Studies | 2008 |
Dopaminergic modulation of cortico-cortical functional connectivity in Parkinson's disease: an MEG study.
Topics: Aged; Cerebral Cortex; Dopamine; Dopamine Agents; Evoked Potentials; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Movement; Nerve Net; Neural Pathways; Parkinson Disease; Synaptic Transmission | 2008 |
Levodopa, motor complications and disease progression.
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
Correlation of outcome to neurosurgical lesions: confirmation of a new method using data after microelectrode-guided pallidotomy.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain Mapping; Cognition; Female; Functional Laterality; Globus Pallidus; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Motor Activity; Outcome Assessment, Health Care; Pallidotomy; Parkinson Disease | 2008 |
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Infusion Pumps; Levodopa; Male; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2008 |
Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease.
Topics: Adipocytes; Adipose Tissue; Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Female; Glycerol; Humans; Isoproterenol; Levodopa; Male; Microdialysis; Middle Aged; Muscle, Skeletal; Parkinson Disease; Regional Blood Flow; Subcutaneous Fat | 2008 |
Accuracy and distortion of deep brain stimulation electrodes on postoperative MRI and CT.
Topics: Anesthesia, General; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Postoperative Period; Prosthesis Implantation; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed | 2008 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Histocompatibility Antigens Class II; Levodopa; Male; Microscopy, Electron, Transmission; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Synapses; Tissue Transplantation; Tyrosine 3-Monooxygenase | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Dyskinesias; Embryo, Mammalian; Encephalitis; Female; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin Transplantation | 2008 |
Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease | 2008 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Memory Disorders; Mice; Movement; Oxidopamine; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Space Perception; Vision Disorders | 2009 |
Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2008 |
[Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Survival Rate | 2008 |
Levodopa therapy for Parkinson's disease: challenges and future prospects.
Topics: Activities of Daily Living; Antiparkinson Agents; Humans; Hypotension; Levodopa; Nausea; Parkinson Disease; Quality of Life; Vomiting | 2008 |
The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Blood-Brain Barrier; Clinical Trials as Topic; Disease Models, Animal; Humans; Levodopa; Parkinson Disease | 2008 |
Neuropathy as a potential complication of levodopa use in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Retrospective Studies; Vitamin B 12 | 2008 |
Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Cognition; Deep Brain Stimulation; Depression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Education as Topic; Psychomotor Performance; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2009 |
The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Globus Pallidus; Injections; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans | 2009 |
Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks.
Topics: Aged; Antiparkinson Agents; Brain; Cognition Disorders; Disorders of Excessive Somnolence; Dreams; Female; Functional Laterality; Hallucinations; Humans; Levodopa; Male; Nerve Net; Neuropsychological Tests; Parkinson Disease; Sleep, REM | 2008 |
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects.
Topics: Aged; Antiparkinson Agents; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Statistics, Nonparametric | 2009 |
[Can subthalamic nucleus stimulation reveal parkinsonian rest tremor?].
Topics: Adrenal Rest Tumor; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Tremor | 2009 |
Rhinorrhea and olfaction in Parkinson disease.
Topics: Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Comorbidity; Female; Humans; Levodopa; Male; Middle Aged; Nasal Mucosa; Olfaction Disorders; Parasympathetic Fibers, Postganglionic; Parkinson Disease; Prevalence; Rhinitis; Sex Distribution; Sympathetic Fibers, Postganglionic | 2008 |
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dystonic Disorders; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2008 |
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 2008 |
Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Aged, 80 and over; Antidepressive Agents; Antiparkinson Agents; Autopsy; Cerebral Cortex; Dementia; Depression; Female; Humans; Levodopa; Lewy Body Disease; Male; Middle Aged; Parkinson Disease; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Temporal Lobe | 2008 |
Dyskinesia-induced postural instability in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Body Weight; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Postural Balance; Posture | 2009 |
[Subacute worsening of rigidity in a patient with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Rigidity; Muscle Spasticity; Parkinson Disease | 2008 |
Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Arousal; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Polysomnography; Pramipexole; Prospective Studies; REM Sleep Behavior Disorder; Video Recording | 2008 |
Dopaminergic suppression of brain deactivation responses during sequence learning.
Topics: Aged; Brain; Dopamine; Female; Humans; Learning; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time | 2008 |
Use of clozapine in Brazilian patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Retrospective Studies | 2008 |
[Initial management and adaptation of Parkinson's disease treatment].
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2008 |
Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Cognition; Creatinine; Female; Folic Acid; Genotype; Homocysteine; Humans; Inactivation, Metabolic; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Vitamin B Complex | 2009 |
UPDRS activity of daily living score as a marker of Parkinson's disease progression.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 2009 |
Influence of basal ganglia on upper limb locomotor synergies. Evidence from deep brain stimulation and L-DOPA treatment in Parkinson's disease.
Topics: Aged; Arm; Basal Ganglia; Combined Modality Therapy; Deep Brain Stimulation; Exercise Test; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Thigh | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2008 |
Gait and balance disorders in Parkinson's disease: impaired active braking of the fall of centre of gravity.
Topics: Antiparkinson Agents; Basal Ganglia; Biomechanical Phenomena; Brain; Case-Control Studies; Dopamine; Female; Gait Apraxia; Gravitation; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Organ Size; Parkinson Disease; Postural Balance; Sensation Disorders; Walking | 2009 |
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Gene Expression; Genotype; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic; Receptor, trkB; Risk Factors; Synapses; Time Factors | 2009 |
Cardiac MIBG scintigraphy in Primary Progressive Freezing Gait.
Topics: 3-Iodobenzylguanidine; Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Female; Gait; Gait Apraxia; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Reference Values; Treatment Outcome | 2009 |
Activities of daily living, cerebral glucose metabolism, and cognitive reserve in Lewy body and Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Brain Chemistry; Cognition; Data Interpretation, Statistical; Dementia; Education; Female; Functional Laterality; Glucose; Humans; Image Processing, Computer-Assisted; Levodopa; Lewy Body Disease; Male; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography | 2008 |
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Graft Survival; Levodopa; Mesencephalon; Microdialysis; Neurons; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2008 |
Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions.
Topics: Adult; Age of Onset; Antiparkinson Agents; Ataxin-3; Ataxins; DNA Repeat Expansion; Family; Female; Genes, Dominant; Genetic Variation; Humans; Levodopa; Machado-Joseph Disease; Male; Middle Aged; Nerve Tissue Proteins; Nuclear Proteins; Parkinson Disease; Pedigree; Phenotype; Repressor Proteins; Spinocerebellar Degenerations | 2009 |
Methamphetamine fails to alter the noradrenergic integrity of the heart.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Denervation; Dopamine Agonists; Heart; Humans; Hypotension, Orthostatic; Levodopa; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Neurotoxins; Norepinephrine; Parkinson Disease | 2008 |
Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Disability Evaluation; Electromyography; Female; Gait; Humans; Leg; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Postural Balance; Substantia Nigra; Treatment Outcome | 2009 |
Electrode position determined by fused images of preoperative and postoperative magnetic resonance imaging and surgical outcome after subthalamic nucleus deep brain stimulation.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Speech Disorders; Subthalamic Nucleus; Treatment Outcome | 2008 |
Acute stepwise challenge test with levodopa in treated patients with parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Cohort Studies; Deep Brain Stimulation; Demography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Predictive Value of Tests; Prospective Studies; ROC Curve; Treatment Outcome | 2009 |
Intractable facial pain in advanced Parkinson's disease alleviated by subthalamic nucleus stimulation.
Topics: Carboxy-Lyases; Deep Brain Stimulation; Facial Pain; Female; Humans; Levodopa; Middle Aged; Pain, Intractable; Parkinson Disease; Postoperative Period; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2008 |
Alteration of eating behaviors in patients with Parkinson's disease: possibly overlooked?
Topics: Adult; Aged; Antiparkinson Agents; Compulsive Behavior; Dopamine Agonists; Feeding Behavior; Female; Food Preferences; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2008 |
Pallidal deep brain stimulation and L-dopa effect on PET motor activation in advanced Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Brain; Brain Mapping; Butanols; Deep Brain Stimulation; Disease Progression; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Oxygen Radioisotopes; Parkinson Disease; Positron-Emission Tomography; Reaction Time; Task Performance and Analysis | 2009 |
Reversing a difficult airway.
Topics: Aged, 80 and over; Antiparkinson Agents; Humans; Intubation, Intratracheal; Jaw Diseases; Levodopa; Male; Parkinson Disease | 2008 |
[Patterns of neuronal activity in the basal ganglia nucleus in parkinsonian patients with levodopa-induced dyskinesia].
Topics: Adult; Aged; Basal Ganglia; Electrophysiology; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus | 2008 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Models, Animal; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2009 |
Transient disabling dyskinesias: a predictor of good outcome in subthalamic nucleus deep brain stimulation in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Radiography; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2009 |
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Evoked Potentials; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Neuronal Plasticity; Parkinson Disease; Stimulation, Chemical; Substantia Nigra | 2009 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Risk Factors; Rotation; Species Specificity; Sympatholytics; Time Factors; Treatment Outcome | 2009 |
Development of Holmes' tremor in a patient with Parkinson's disease following acute cerebellar infarction.
Topics: Acute Disease; Aged, 80 and over; Antiparkinson Agents; Cerebellum; Cerebral Infarction; Disease Progression; Female; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Tremor | 2009 |
Walking along circular trajectories in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Exercise Therapy; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Psychomotor Performance; Regression Analysis; Severity of Illness Index; Walking | 2009 |
Dopamine and impulse control disorders in Parkinson's disease.
Topics: Brain; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Levodopa; Male; Parkinson Disease; Risk Factors | 2008 |
Parkinson's disease: unresolved issues.
Topics: Animals; Antiparkinson Agents; Dopamine; Humans; Levodopa; Parkinson Disease | 2008 |
Drug selection and timing of initiation of treatment in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Indans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Time Factors | 2008 |
Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences?
Topics: Age Factors; Aged; Antiparkinson Agents; Brain; Brain Mapping; Constipation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Odds Ratio; Parkinson Disease; REM Sleep Behavior Disorder; Sex Factors; Tomography, Emission-Computed, Single-Photon | 2009 |
The relation of testosterone levels with fatigue and apathy in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Fatigue; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Testosterone | 2009 |
Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prostatic Neoplasms; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Transcranial Magnetic Stimulation; Urinary Bladder, Overactive; Urodynamics | 2009 |
A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Topics: alpha-Synuclein; Amyloid; Antiparkinson Agents; Computer Simulation; Dopamine; Gene Expression; Humans; Levodopa; Lewy Bodies; Lysosomes; Models, Neurological; Monoamine Oxidase Inhibitors; Neurotoxins; Parkinson Disease; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Systems Theory; Ubiquitin | 2009 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
A new perspective on brain derived neurotrophin factor polymorphism in L-dopa induced dyskinesia.
Topics: Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Genetic Markers; Genotype; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic | 2009 |
Pedunculopontine nucleus stimulation induces monocular oscillopsia.
Topics: Aged; Antiparkinson Agents; Electric Stimulation; Electrodes, Implanted; Eye Movements; Gait Disorders, Neurologic; Humans; Levodopa; Mesencephalon; Oculomotor Nerve Diseases; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Vision, Monocular | 2009 |
Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue; Trihexyphenidyl | 2009 |
A neurocomputational model of tonic and phasic dopamine in action selection: a comparison with cognitive deficits in Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Cognition Disorders; Computer Simulation; Dopamine; Humans; Levodopa; Models, Neurological; Neural Networks, Computer; Neural Pathways; Neurons; Parkinson Disease; Reward | 2009 |
Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos.
Topics: Analysis of Variance; Antiparkinson Agents; Biomedical Engineering; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Tremor; Video Recording | 2008 |
Learning brain connectivity with the false-discovery-rate-controlled PC-algorithm.
Topics: Algorithms; Bayes Theorem; Brain; False Positive Reactions; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Models, Neurological; Models, Statistical; Nerve Net; Parkinson Disease; Reproducibility of Results | 2008 |
Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dopamine; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Signal Transduction; Substantia Nigra | 2009 |
Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2009 |
Possible Parkinson's disease revealed by a pure head resting tremor.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Diagnosis, Differential; Electromyography; Female; Head Movements; Humans; Levodopa; Muscle, Skeletal; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tremor | 2009 |
Case studies in the advancement of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2008 |
Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.
Topics: Animals; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Rats; Rats, Sprague-Dawley; Synapses | 2009 |
Hiccups associated with levodopa in Parkinson's disease.
Topics: Aged, 80 and over; Antiparkinson Agents; Hiccup; Humans; Levodopa; Male; Parkinson Disease | 2009 |
Chronic intermittent L-DOPA treatment induces changes in dopamine release.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Potassium; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2009 |
[Recent progress in Parkinson's disease].
Topics: alpha-Synuclein; Humans; Levodopa; Lewy Bodies; Parkinson Disease | 2008 |
Weight loss, body fat mass, and leptin in Parkinson's disease.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Leptin; Levodopa; Male; Middle Aged; Parkinson Disease; Radioimmunoassay; Sex Factors; Statistics, Nonparametric; Weight Loss | 2009 |
Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cognition; Drug Resistance; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2009 |
Deficient "sensory" beta synchronization in Parkinson's disease.
Topics: Afferent Pathways; Aged; Antiparkinson Agents; Beta Rhythm; Cortical Synchronization; Disability Evaluation; Electric Stimulation; Electroencephalography; Female; Humans; Levodopa; Male; Motor Cortex; Movement; Neural Pathways; Neurologic Examination; Parkinson Disease; Peripheral Nerves; Predictive Value of Tests; Sensation | 2009 |
Interleukin-6 serum levels in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Female; Humans; Interleukin-6; Levodopa; Male; Middle Aged; Parkinson Disease | 2009 |
A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease.
Topics: Age Factors; Aged; Cognition Disorders; Deep Brain Stimulation; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Referral and Consultation | 2009 |
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity.
Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole | 2009 |
Levodopa for Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2009 |
Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Cocaine; Disease Models, Animal; Dopamine; Dopamine Agents; Embryonic Stem Cells; Levodopa; Macaca fascicularis; Methamphetamine; Movement Disorders; Neurons; Parkinson Disease; Positron-Emission Tomography; Putamen; Raclopride; Tyrosine 3-Monooxygenase | 2009 |
Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dementia; Duodenum; Female; Gait Disorders, Neurologic; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Personal Autonomy; Quality of Life; Retrospective Studies; Treatment Outcome | 2009 |
Levodopa for Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Neostriatum; Parkinson Disease | 2009 |
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Blood Platelets; Disease Progression; Female; Humans; India; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Young Adult | 2009 |
A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.
Topics: Aged; Brain Mapping; Disease Progression; Female; Fluorodeoxyglucose F18; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Nonlinear Dynamics; Parkinson Disease; Positron-Emission Tomography; Postmortem Changes; Putamen; Time Factors | 2009 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Piperazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Sigma-1 Receptor | 2009 |
Gamma activity and reactivity in human thalamic local field potentials.
Topics: Acoustic Stimulation; Adolescent; Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Periodicity; Reaction Time; Sleep; Spectrum Analysis; Thalamus | 2009 |
Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
Topics: Analysis of Variance; Case-Control Studies; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Nerve Degeneration; Parkinson Disease; Reference Values; Statistics, Nonparametric; Vitamin B 12 | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Electrophysiological Phenomena; Humans; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Cortex; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Spinal Cord | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2009 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Compulsive Behavior; Dopamine Agonists; Female; Gambling; Humans; Indoles; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies | 2009 |
Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sound Spectrography; Speech; Speech Acoustics; Speech Intelligibility; Voice Quality | 2009 |
Semantic activation in Parkinson's disease patients on and off levodopa.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cognition; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reaction Time; Semantics; Task Performance and Analysis; Time Factors | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesias; Embryo, Mammalian; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Transplants; Tyrosine 3-Monooxygenase | 2009 |
[Rehabilitation of gait disorders in patients with Parkinson's disease and vascular parkinsonism].
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Exercise Therapy; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Resonance in subthalamo-cortical circuits in Parkinson's disease.
Topics: Antiparkinson Agents; Biological Clocks; Deep Brain Stimulation; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Neural Pathways; Parkinson Disease; Signal Processing, Computer-Assisted; Subthalamic Nucleus | 2009 |
Parkinsonism, dysautonomia, REM behaviour disorder and visual hallucinations mimicking synucleinopathy in a patient with progressive supranuclear palsy.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Brain; Fatal Outcome; Female; Hallucinations; Humans; Levodopa; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Supranuclear Palsy, Progressive; Synucleins; tau Proteins | 2009 |
Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Topics: Age of Onset; Aged; Antiparkinson Agents; Body Mass Index; Body Weight; Dopamine Agents; Dyskinesias; Eating; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Time Factors; Weight Loss | 2009 |
Clinical experience of tolcapone in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2008 |
Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.
Topics: Antiparkinson Agents; Dopamine Agonists; Duodenum; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Parkinson Disease; Suspensions | 2008 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; CD11b Antigen; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Jaw; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Movement; Mucuna; Neuroprotective Agents; Oxidopamine; Parasympathomimetics; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley; Seeds; Sympatholytics; Tacrine; Time Factors; Vibrissae | 2009 |
Visualizing vesicular dopamine dynamics in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Carbon Radioisotopes; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Nonlinear Dynamics; Parkinson Disease; Positron-Emission Tomography; Tetrabenazine | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics | 2009 |
Non-motor off symptoms in Parkinson's disease.
Topics: Aged; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Pain intensity on and off levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires | 2009 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; China; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Time Factors | 2009 |
[Parkinson treatment--where to begin?].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2009 |
Changes of functional connectivity of the motor network in the resting state in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Cerebral Cortex; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Models, Neurological; Neural Pathways; Oxygen; Parkinson Disease; Rest | 2009 |
Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease.
Topics: Affect; Antiparkinson Agents; Behavior; Cerebral Ventriculography; Cognition; Deep Brain Stimulation; Executive Function; Humans; Individuality; Levodopa; Magnetic Resonance Imaging; Neuropsychological Tests; Parkinson Disease; Quality of Life; Radiosurgery; Subthalamic Nucleus; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study.
Topics: Adult; Aged; Corpus Striatum; Female; Hand Strength; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2009 |
Subthalamic nucleus stimulation applied in the earlier vs. advanced stage of Parkinson's disease - retrospective evaluation of postoperative independence in pursuing daily activities.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regression Analysis; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus | 2009 |
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Gene Transfer Techniques; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Mutation, Missense; Neurons; Nomifensine; Parkinson Disease; Protein Serine-Threonine Kinases | 2009 |
Why are some Parkinson disease patients unaware of their dyskinesias?
Topics: Aged; Antiparkinson Agents; Awareness; Dyskinesia, Drug-Induced; Feedback, Psychological; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Self Concept | 2009 |
Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Caregivers; Compulsive Personality Disorder; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agents; Female; Gambling; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Personality Tests; Psychometrics; Reward; ROC Curve; Surveys and Questionnaires | 2009 |
Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Therapy, Combination; Follow-Up Studies; Gambling; Humans; Levodopa; Male; Parkinson Disease; Pramipexole | 2009 |
[Treatment of early Parkinson's disease].
Topics: Adrenergic beta-Antagonists; Antiparkinson Agents; Benzodiazepines; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Early Diagnosis; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Prognosis; Quality of Life; Treatment Outcome | 2009 |
Frequency-specific effects of stimulation of the subthalamic area in treated Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Subthalamic Nucleus | 2009 |
Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.
Topics: Bromocriptine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Indoles; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Randomized Controlled Trials as Topic; Time; Treatment Outcome | 2009 |
Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corpus Striatum; Digestive System Physiological Phenomena; Dopamine Agonists; Enzyme Inhibitors; Humans; Hypotension, Orthostatic; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Motor Activity; Movement Disorders; Neurons; Parkinson Disease; Sleep Wake Disorders; Substantia Nigra | 2009 |
Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cognition; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Prognosis; Sex Factors; Subthalamic Nucleus; Time Factors; Treatment Outcome; Tremor | 2009 |
Impulse control disorders in Parkinson's disease in a Chinese population.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antiparkinson Agents; China; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires | 2009 |
Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?
Topics: Adult; Aged; Antiparkinson Agents; Blood Pressure; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Outpatients; Parkinson Disease; Postural Balance; Prospective Studies; Surveys and Questionnaires; Tilt-Table Test; Time Factors | 2009 |
[Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies | 2009 |
Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Analysis of Variance; Case-Control Studies; Disability Evaluation; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Neck; Parkinson Disease; Postural Balance; Psychomotor Performance; Severity of Illness Index; Walking | 2009 |
Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Carbon Isotopes; Dopamine Agents; Dyskinesias; Female; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2009 |
[Long term experience with Stalevo in Szeged, Hungary].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.
Topics: Aged; Cognition; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease | 2009 |
Focusing effects of L-dopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Cerebellum; Cerebrovascular Circulation; Disability Evaluation; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Neuropsychological Tests; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance; Treatment Outcome | 2010 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Catechols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2009 |
Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease.
Topics: Aged; Analysis of Variance; Cerebellum; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic Stimulation | 2009 |
Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Uric Acid | 2009 |
Suicide following duodenal levodopa infusion for Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Duodenum; Humans; Levodopa; Male; Parkinson Disease; Suicide | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Severe gastroparesis in a patient with advanced Parkinson's disease.
Topics: Aged, 80 and over; Benserazide; Dopamine Agents; Drug Combinations; Enzyme Inhibitors; Follow-Up Studies; Gastroparesis; Humans; Levodopa; Male; Parkinson Disease; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Brain dopaminergic modulation associated with executive function in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Cognition Disorders; Dopamine; Executive Function; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease | 2009 |
Fava beans and Parkinson's disease: useful 'natural supplement' or useless risk?
Topics: Favism; Humans; Jews; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Vicia faba | 2009 |
Does subthalamotomy have a place in the treatment of Parkinson's disease?
Topics: Antiparkinson Agents; Drug Resistance; Dyskinesias; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Subthalamic Nucleus | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Levodopa; Male; Microdialysis; Morphinans; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation; Spiro Compounds; Time Factors | 2009 |
Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Hand Strength; Humans; Italy; Levodopa; Male; Middle Aged; Motor Skills; Movement; Movement Disorders; Parkinson Disease; Retrospective Studies | 2009 |
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Comorbidity; Disability Evaluation; Dopamine Agonists; Female; Gastrointestinal Diseases; Humans; Indoles; Levodopa; Male; Memory Disorders; Middle Aged; Mood Disorders; Movement Disorders; Neurologic Examination; Nocturia; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Prevalence; Restless Legs Syndrome; Treatment Outcome | 2009 |
Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease.
Topics: DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Levodopa; Male; Melanoma; Middle Aged; Parkinson Disease; Skin Neoplasms; Ultraviolet Rays | 2009 |
Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
Topics: Antiparkinson Agents; Catechols; Drug Resistance; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Respiratory Mechanics; Respiratory Tract Diseases | 2009 |
Pain in Parkinson's disease.
Topics: Antiparkinson Agents; Depression; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Prospective Studies | 2009 |
Prevalence of Parkinson's disease in Northern Jordan.
Topics: Adult; Age Factors; Age of Onset; Antiparkinson Agents; Dopamine Agonists; Drug Utilization; Female; Humans; Jordan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Rural Population; Sex Factors; Urban Population | 2009 |
Rasagiline-induced spontaneous ejaculation.
Topics: Aged; Antiparkinson Agents; Ejaculation; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Sexual Behavior; Sexual Dysfunction, Physiological; Spinal Dysraphism | 2009 |
Room tilt illusion in Parkinson's disease: loss of spatial reference frames?
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Humans; Illusions; Levodopa; Male; Orientation; Parietal Lobe; Parkinson Disease; Perceptual Disorders; Psychomotor Performance; Space Perception; Tomography, Emission-Computed, Single-Photon; Visual Cortex; Visual Pathways; Visual Perception | 2009 |
Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Auditory Cortex; Event-Related Potentials, P300; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Neural Inhibition; Parkinson Disease | 2009 |
Decision-making impairment in a patient with new concomitant diagnoses of Parkinson's disease and HIV.
Topics: Antiparkinson Agents; Brain; Cognition Disorders; Decision Making; Diagnosis, Differential; HIV Infections; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Radionuclide Imaging; Treatment Outcome | 2009 |
[Early treatment of Parkinson's disease with levodopa].
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2009 |
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Topics: Age Distribution; Aged; Aged, 80 and over; Amino Acid Substitution; Antiparkinson Agents; Base Sequence; Biomarkers; DNA Mutational Analysis; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Dehydrogenase (NAD+); Parkinson Disease; Polymorphism, Genetic; Sex Distribution | 2009 |
Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?
Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech; Speech Disorders; Walking | 2010 |
Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Topics: Aged; Antiparkinson Agents; Catechols; Encephalitis; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Peripheral Nervous System Diseases | 2009 |
Levodopa influences the regularity of the ankle joint kinematics in individuals with Parkinson's disease.
Topics: Aged; Ankle Joint; Antiparkinson Agents; Biomechanical Phenomena; Hip Joint; Humans; Knee Joint; Levodopa; Motor Activity; Parkinson Disease; Walking | 2010 |
[Severe kyphosis and esophagus hiatal hernia affected in the levodopa absorption of a patient with Parkinson's disease].
Topics: Aged, 80 and over; Antiparkinson Agents; Female; Hernia, Hiatal; Humans; Intestinal Absorption; Kyphosis; Levodopa; Parkinson Disease; Posture; Severity of Illness Index | 2009 |
Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes.
Topics: Adolescent; Adult; Avoidance Learning; Conditioning, Psychological; Cues; Dopamine Agonists; Dopamine Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reward; Risperidone; Subliminal Stimulation; Tourette Syndrome | 2009 |
[Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
Topics: Aged; Anesthesia, General; Antiparkinson Agents; Female; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Perioperative Care; Prolapse; Urinary Bladder Diseases | 2009 |
Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Duodenum; Female; Humans; Levodopa; Male; Parkinson Disease | 2010 |
Gait analysis in patients with Parkinson's disease off dopaminergic therapy.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Range of Motion, Articular | 2009 |
Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postural Balance; Posture; Recurrence; Retrospective Studies; Subthalamic Nucleus | 2010 |
Levodopa response in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2009 |
Subacute dopa-responsive Parkinsonism after successful surgical treatment of aqueductal stenosis.
Topics: Antipsychotic Agents; Cerebral Aqueduct; Constriction, Pathologic; Humans; Hydrocephalus; Injections, Subcutaneous; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Erythrocytes; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; S-Adenosylhomocysteine; S-Adenosylmethionine | 2010 |
ADAGIO misses a beat?
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2009 |
Impaired awareness of movement disorders in Parkinson's disease.
Topics: Adult; Aged; Agnosia; Analysis of Variance; Antiparkinson Agents; Awareness; Female; Humans; Hypokinesia; Levodopa; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Self Concept; Statistics, Nonparametric | 2010 |
Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?
Topics: Diagnosis, Differential; Dopamine Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Multiple System Atrophy; Parkinson Disease; Sensitivity and Specificity | 2009 |
Complementary acupuncture treatment increases cerebral metabolism in patients with Parkinson's disease.
Topics: Acupuncture Therapy; Aged; Antiparkinson Agents; Benserazide; Brain Chemistry; Combined Modality Therapy; Drug Combinations; Energy Metabolism; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dopamine Agonists; Dyskinesias; Environment; Female; Genetic Predisposition to Disease; Geography; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Sequence Analysis, DNA; Severity of Illness Index; Spouses; Surveys and Questionnaires | 2010 |
The effect of L-Dopa administration on pursuit ocular movements in suspected Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Eye Movement Measurements; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pursuit, Smooth; Severity of Illness Index; Treatment Outcome | 2010 |
Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat.
Topics: Action Potentials; Animals; Antiparkinson Agents; Basal Ganglia; Beta Rhythm; Dopamine; Electromyography; Evoked Potentials; Exercise Test; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans; Rest; Tyrosine 3-Monooxygenase; Walking | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Obstacle crossing in people with Parkinson's disease: foot clearance and spatiotemporal deficits.
Topics: Acclimatization; Adaptation, Physiological; Aged; Antiparkinson Agents; Body Height; Body Weight; Female; Foot; Gait; Humans; Levodopa; Locomotion; Male; Parkinson Disease; Postural Balance; Posture; Psychomotor Performance; Reference Values; Walking | 2010 |
Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Biological Availability; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2010 |
Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.
Topics: Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Disease Progression; DNA; F2-Isoprostanes; Female; Humans; Hydroxyeicosatetraenoic Acids; Levodopa; Lipids; Male; Middle Aged; Oxidative Stress; Oxygen; Parkinson Disease | 2010 |
MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
Topics: Animals; Base Pairing; Disease Progression; DNA Primers; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; High Mobility Group Proteins; Levodopa; Male; Mesencephalon; Mice; Mice, Knockout; Models, Genetic; Motor Activity; Parkinson Disease; Polymerase Chain Reaction; Posture | 2010 |
Medication impairs probabilistic classification learning in Parkinson's disease.
Topics: Aged; Association Learning; Case-Control Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Photic Stimulation; Probability Learning; Psychomotor Performance | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expression; Gene Expression Profiling; Humans; In Vitro Techniques; Leupeptins; Levodopa; Models, Neurological; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; rab3 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Vesicles; Ventral Tegmental Area | 2009 |
Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.
Topics: Adult; Aged; Dopamine Agents; Dysarthria; Female; Follow-Up Studies; Humans; Language Tests; Levodopa; Male; Middle Aged; Parkinson Disease; Phonetics; Reading; Severity of Illness Index; Sex Factors; Speech; Speech Production Measurement; Time Factors | 2010 |
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Memantine; N-Methylaspartate; Parkinson Disease | 2010 |
Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Sex Factors; Sweden; Time Factors | 2010 |
Sildenafil induced choreoathetosis in men with Parkinson's disease.
Topics: Antiparkinson Agents; Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2010 |
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients.
Topics: Aged; Cross-Sectional Studies; Dopamine Agents; Female; Genetic Predisposition to Disease; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Secondary Prevention; Treatment Outcome; Vitamin B 12 | 2010 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2010 |
Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
Topics: Aged; alpha-Synuclein; Antiparkinson Agents; Drug Therapy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Catechols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Mepivacaine; Microdialysis; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2010 |
L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.
Topics: Acetates; Administration, Inhalation; Animals; Antiparkinson Agents; Chlorides; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Manganese Compounds; Mice; Motor Activity; Organometallic Compounds; Parkinson Disease | 2010 |
Did levodopa vs. dopamine agonist trials teach us when and how to start symptomatic therapy?
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 2009 |
Electroenzymatic synthesis of l-DOPA.
Topics: Bioreactors; Electrochemical Techniques; Electrodes; Enzymes, Immobilized; Kinetics; Levodopa; Linear Models; Monophenol Monooxygenase; Parkinson Disease; Tyrosine | 2010 |
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium Channel Blockers; Cell Transplantation; Dendritic Spines; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Male; Neurons; Nimodipine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Vibrissae | 2010 |
Guideline for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Cholinergic Antagonists; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2009 |
Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy.
Topics: Actigraphy; Activities of Daily Living; Aged; Case-Control Studies; Circadian Rhythm; Dopamine Agents; Female; Humans; Levodopa; Male; Pain Measurement; Parkinson Disease; Polysomnography; Predictive Value of Tests; Psychiatric Status Rating Scales; Sleep Wake Disorders; Statistics, Nonparametric; Wakefulness | 2010 |
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.
Topics: Animals; Chickens; Corpus Striatum; Dependovirus; Disease Models, Animal; Dyskinesias; Female; Gene Transfer Techniques; Genetic Vectors; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley | 2010 |
Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
Topics: Aged; Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Female; Health Care Costs; Health Services; Humans; Insurance Claim Review; Insurance, Health, Reimbursement; Levodopa; Male; Managed Care Programs; North Carolina; Parkinson Disease; Patient Compliance; Prevalence | 2010 |
Levodopa-aggravated lateral flexion of the neck and trunk as a delayed phenomenon of unilateral pallidotomy.
Topics: Antiparkinson Agents; Humans; Levodopa; Male; Middle Aged; Neck; Pallidotomy; Parkinson Disease | 2010 |
Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.
Topics: Antioxidants; Cell Death; Cell Survival; Cells, Cultured; Disulfides; Dopamine; Homeostasis; Humans; Levodopa; Neurons; Parkinson Disease; Protein Carbonylation; Proto-Oncogene Proteins c-bcl-2; Thioredoxins | 2010 |
L-dopa induces under-damped visually guided motor responses in Parkinson's disease.
Topics: Aged; Brain; Dopamine Agents; Feedback, Sensory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Reinforcement, Psychology | 2010 |
Increased erythrocyte catechol-O-methyltransferase activity in elderly: relationship to clinical peculiarities in Parkinson's disease?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 2010 |
Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2010 |
A positive correlation between fractional white matter volume and the response of Parkinson disease patients to subthalamic stimulation.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dominance, Cerebral; Electrodes, Implanted; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Neurologic Examination; Neuronavigation; Parkinson Disease; Patient Selection; Prognosis; Software; Statistics as Topic; Subthalamic Nucleus; Treatment Outcome | 2010 |
Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease.
Topics: DNA Mutational Analysis; Electric Stimulation Therapy; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation, Missense; Parkinson Disease; Predictive Value of Tests; Protein Serine-Threonine Kinases; Subthalamic Nucleus; Time; Treatment Outcome | 2010 |
Three-dimensional motion analysis of the effects of auditory cueing on gait pattern in patients with Parkinson's disease: a preliminary investigation.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Biomechanical Phenomena; Cues; Female; Gait; Humans; Kinetics; Levodopa; Male; Middle Aged; Motion; Movement; Neuropsychological Tests; Parkinson Disease; Range of Motion, Articular | 2010 |
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin; Transplants | 2010 |
[The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; China; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Severity of Illness Index; Surveys and Questionnaires; Trihexyphenidyl | 2009 |
Suicide attempts after subthalamic nucleus stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Suicide | 2010 |
Actigraphic evaluation of motor fluctuations in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Movement; Parkinson Disease; Posture; Wrist | 2010 |
Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Chorea; Dyskinesia, Drug-Induced; Extremities; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index | 2010 |
Objective measurement of dyskinesia in Parkinson's disease using a force plate.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Pressure; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index | 2010 |
Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.
Topics: Antiparkinson Agents; Databases, Factual; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2010 |
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
Topics: Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2010 |
Long term follow-up of Parkinson's disease patients with impulse control disorders.
Topics: Adult; Age Factors; Aged; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase | 2010 |
Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Apoptosis; Cells, Cultured; Cytoprotection; Female; Glutathione; Heme Oxygenase-1; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidative Stress; Parkinson Disease; Pregnancy | 2010 |
Changes of rhythm of vocal fundamental frequency in sensorineural hearing loss and in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Fourier Analysis; Hearing Loss, Sensorineural; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Signal Processing, Computer-Assisted | 2009 |
Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease--case report.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2010 |
Low frequency of bipolar disorder, dopamine dysregulation syndrome, and punding in Brazilian patients with Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Bipolar Disorder; Brazil; Confidence Intervals; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotyped Behavior; Syndrome | 2010 |
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; Statistics, Nonparametric | 2010 |
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease.
Topics: Animals; Cell Line; Cell Line, Tumor; Humans; Hydrogen Sulfide; Interleukin-6; Levodopa; Mitochondria; Models, Biological; Neuroglia; Neuroprotective Agents; Nitric Oxide; Parkinson Disease; Rats; Tumor Necrosis Factor-alpha | 2010 |
Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
Topics: Animals; Circadian Rhythm; Corpus Striatum; Dopamine; Humans; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Sympatholytics; Telemetry | 2010 |
Treatment of benign essential blepharospasm with finasteride: a case report.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Blepharospasm; Botulinum Toxins, Type A; Finasteride; Humans; Levodopa; Male; Parkinson Disease; Prostatic Hyperplasia | 2010 |
Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Topics: Aged; alpha-Synuclein; Antiparkinson Agents; Autophagy; Female; Gene Frequency; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Promoter Regions, Genetic; Reactive Oxygen Species; Sex Distribution; Tyrosine | 2010 |
No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cells, Cultured; Chromatography, Liquid; Chromosomes; Deoxyguanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fluorescence Recovery After Photobleaching; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Rats; Tandem Mass Spectrometry | 2010 |
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort.
Topics: Aged; Aged, 80 and over; Cohort Studies; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Parkinson Disease; Portugal; Prevalence; Severity of Illness Index; Spain | 2010 |
Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2010 |
[Recombinant adenovirus-mediated expression of tyrosine hydroxylase in 293 cells and activity assay of the expressed protein in vitro by capillary electrophoresis].
Topics: Adenoviridae; Cell Line; Electrophoresis, Capillary; Escherichia coli; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Parkinson Disease; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tyrosine 3-Monooxygenase | 2010 |
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Dosage Forms; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies; Tablets | 2010 |
Effects of slowed gastrointestinal motility on levodopa pharmacokinetics.
Topics: Animals; Gastrointestinal Motility; Intestinal Absorption; Levodopa; Parkinson Disease; Rabbits | 2010 |
A new computer method for assessing drawing impairment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Art; Diagnosis, Computer-Assisted; Female; Humans; Image Processing, Computer-Assisted; Internet; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Skills; Motor Skills Disorders; Observer Variation; Parkinson Disease; Principal Component Analysis; Severity of Illness Index; Telemedicine | 2010 |
Skin picking in Parkinson's disease: a behavioral side-effect of dopaminergic treatment?
Topics: Dopamine Agents; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Self-Injurious Behavior | 2010 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Binge-Eating Disorder; Comorbidity; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prevalence; Risk Factors; Sexual Dysfunctions, Psychological | 2010 |
Anxiety disorders in Parkinson's disease: prevalence and risk factors.
Topics: Aged; Antiparkinson Agents; Anxiety Disorders; Cognition Disorders; Comorbidity; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Functional Laterality; Gait; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Posture; Prevalence; Risk Factors; Severity of Illness Index | 2010 |
Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.
Topics: Affect; Compulsive Behavior; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome | 2010 |
Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients.
Topics: Aged; Arachidonic Acids; Biomarkers; Dopamine Agonists; Endocannabinoids; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polyunsaturated Alkamides | 2010 |
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2010 |
[Duodenal levodopa infusion tube obstruction solved under real-time fluoroscopic X-ray imaging].
Topics: Aged; Duodenal Obstruction; Fluoroscopy; Humans; Levodopa; Male; Parkinson Disease; X-Rays | 2010 |
Higher dopamine transporter density in Parkinson's disease patients with depression.
Topics: Aged; Brain; Case-Control Studies; Depression; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Organotechnetium Compounds; Parkinson Disease; Protein Binding; Radiopharmaceuticals; Statistics, Nonparametric; Tomography, Emission-Computed, Single-Photon; Tropanes | 2010 |
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functional Laterality; Gene Expression Regulation; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Levodopa; Male; Motor Activity; Mutation; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sympatholytics; Time Factors | 2010 |
[Dysphagia, constipation, impacted feces: Parkinson disease is also a gastrointestinal disease].
Topics: Antiparkinson Agents; Constipation; Deglutition Disorders; Fecal Impaction; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2010 |
Duodopa pump treatment in patients with advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2010 |
[Optimal time for beginning treatment with levodopa].
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2010 |
SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson's disease.
Topics: Adult; Asian People; Deep Brain Stimulation; Dopamine Agonists; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Quality of Life; Retrospective Studies; Severity of Illness Index; Subthalamic Nucleus; Thailand; Time Factors; Treatment Outcome | 2010 |
Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Child; Child, Preschool; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Male; Pallidotomy; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric | 2010 |
Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Duodenum; Female; Home Infusion Therapy; Homocysteine; Humans; Infusions, Parenteral; Levodopa; Male; Methyldopa; Parkinson Disease | 2010 |
mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Levodopa; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinson Disease; Proteins; Receptors, Dopamine D1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Databases, Factual; Fasting; Female; Humans; Levodopa; Male; Methylmalonic Acid; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Prospective Studies; Severity of Illness Index | 2010 |
Serotonergic neurotransmission in early Parkinson's disease: a pilot study to assess implications for depression in this disorder.
Topics: Aged; Depressive Disorder; Dopamine Plasma Membrane Transport Proteins; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Membrane Transport Proteins; Middle Aged; Parkinson Disease; Pilot Projects; Receptors, Serotonin; Serotonin; Synaptic Transmission; Tomography, Emission-Computed, Single-Photon | 2010 |
Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Subarachnoid Hemorrhage; Substantia Nigra | 2010 |
Axial kinesthesia is impaired in Parkinson's disease: effects of levodopa.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Functional Laterality; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Somatosensory Disorders | 2010 |
Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech; Speech Disorders | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluorescent Dyes; Levodopa; Long-Term Potentiation; Neuronal Plasticity; Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Response to heat pain stimulation in idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Hot Temperature; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinson Disease | 2010 |
An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Enteral Nutrition; Food-Drug Interactions; Humans; Intensive Care Units; Length of Stay; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 2010 |
Paroxysmal positive symptoms caused by hardware malfunctioning in deep brain stimulation.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Equipment Failure; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2010 |
Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.
Topics: Aged; Antiparkinson Agents; Dancing; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease | 2010 |
Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Disease Models, Animal; Dopamine; Dopamine Agents; Levodopa; Mice; Mice, Inbred Strains; Motor Activity; Parkinson Disease; Time Factors; Treatment Outcome; Xanthines | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transport Complex IV; Feedback, Sensory; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tachykinins; Thalamus | 2010 |
Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
Excitability of the lower-limb area of the motor cortex in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2010 |
Effects of expectation on placebo-induced dopamine release in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Attitude to Health; Basal Ganglia; British Columbia; Clinical Trials as Topic; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebo Effect; Placebos; Positron-Emission Tomography; Raclopride; Research Design; Reward | 2010 |
Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Data Interpretation, Statistical; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Parkinson Disease; Photic Stimulation; Reaction Time; Serial Learning; Treatment Outcome | 2010 |
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users.
Topics: Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Cohort Studies; Female; Humans; Levodopa; Male; Organic Cation Transporter 1; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Survival Analysis | 2011 |
Levodopa addiction and factitious disorder in a patient with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Factitious Disorders; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders | 2010 |
Dopamine deficiency may lead to capgras syndrome in Parkinson's disease with dementia.
Topics: Antiparkinson Agents; Capgras Syndrome; Dementia; Dopamine; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Treatment Outcome | 2010 |
Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Disease Progression; Female; Hallucinations; Humans; Levodopa; Male; Movement; Parkinson Disease; Polysomnography; Prognosis; REM Sleep Behavior Disorder; Surveys and Questionnaires; Tremor | 2011 |
Neurocomputational models of motor and cognitive deficits in Parkinson's disease.
Topics: Animals; Basal Ganglia; Cognition; Computer Simulation; Dopamine; Humans; Learning; Levodopa; Memory; Models, Neurological; Neural Inhibition; Neural Pathways; Parkinson Disease | 2010 |
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Rats; Signal Transduction | 2010 |
Benefit from jejunal levodopa in a patient with apomorphine pump.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
The effects of levodopa and ongoing deep brain stimulation on subthalamic beta oscillations in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Beta Rhythm; Combined Modality Therapy; Data Interpretation, Statistical; Deep Brain Stimulation; Female; Humans; Levodopa; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed | 2010 |
Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
Topics: Aged; Aminopeptidases; Antiparkinson Agents; Carbidopa; Case-Control Studies; Female; Humans; Lactates; Levodopa; Lipid Peroxides; Lipids; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2011 |
Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Area Under Curve; Circadian Rhythm; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamins | 2010 |
Prioritizing gait in dual-task conditions in people with Parkinson's.
Topics: Age of Onset; Aged; Attention; Body Height; Brain Damage, Chronic; Choice Behavior; Disabled Persons; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Physical Therapy Specialty; Walking | 2010 |
Are hiccups non-motor symptoms?
Topics: Dopamine Agonists; Electromyography; Female; Hiccup; Humans; Inclusion Bodies; Levodopa; Male; Parkinson Disease; Synucleins | 2010 |
Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
Topics: Antiparkinson Agents; Antithyroid Agents; Benserazide; Carbimazole; Drug Combinations; Female; Graves Disease; Heart Rate; Humans; Hyperthyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Thyroxine | 2010 |
Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations.
Topics: Aged; Antiparkinson Agents; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2010 |
Treatment frontiers.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Cell- and Tissue-Based Therapy; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Research | 2010 |
Levodopa: the story so far.
Topics: Antiparkinson Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2010 |
Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; DNA, Mitochondrial; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Mitochondria; Neurons; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Putamen; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial | 2010 |
Pain is common in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Depression; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales | 2011 |
Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Female; Humans; Levodopa; Male; Mexico; Middle Aged; Parkinson Disease; Surveys and Questionnaires | 2010 |
Preparation for compensatory forward stepping in Parkinson's disease.
Topics: Accidental Falls; Aged; Case-Control Studies; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2010 |
[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Observation; Parkinson Disease; Quality of Life; Treatment Outcome | 2010 |
Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Dopamine; Drug Carriers; Glycine; Humans; Intestinal Absorption; Levodopa; Microdialysis; Microvilli; Parkinson Disease; Peptide Transporter 1; Rats; Rats, Wistar; Rotarod Performance Test; Symporters; Transport Vesicles | 2010 |
Carbidopa/levodopa pharmacy errors in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Medication Errors; Parkinson Disease; Pharmacies; Prospective Studies | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Levodopa and subthalamic deep brain stimulation responses are not congruent.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics as Topic; Subthalamic Nucleus; Treatment Outcome | 2010 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
Impairments in social cognition in early medicated and unmedicated Parkinson disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition; Disease Progression; Executive Function; Humans; Levodopa; Matched-Pair Analysis; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reference Values; Social Perception; Statistics, Nonparametric; Theory of Mind; Time Factors | 2010 |
Deep-brain stimulation for Parkinson's disease.
Topics: Depression; Dopamine Agents; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2010 |
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Topics: Amygdala; Animals; Anxiety; Behavioral Research; Biogenic Monoamines; Chromatography, High Pressure Liquid; Corpus Striatum; Depression; Dopamine; Dopamine Agents; Hippocampus; Humans; Levodopa; Male; Models, Animal; Motor Activity; Oxidopamine; Parkinson Disease; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 2010 |
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Catechols; Drug Therapy, Combination; Humans; Levodopa; Male; Nitriles; Parkinson Disease | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Partial Agonism; Dyskinesia, Drug-Induced; Hyperkinesis; Levodopa; Male; Microdialysis; Motor Activity; Oxazepines; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2010 |
Delayed-onset parkinsonian tremor following a mesencephalic lesion.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease; Tegmentum Mesencephali; Tremor | 2011 |
Motor activation in multiple system atrophy and Parkinson disease: a PET study.
Topics: Aged; Brain Mapping; Case-Control Studies; Deuterium Oxide; Dopamine Agents; Functional Laterality; Hand; Humans; Levodopa; Motor Cortex; Movement; Multiple System Atrophy; Parkinson Disease; Positron-Emission Tomography; Statistics, Nonparametric | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2010 |
Pathological gambling in PD: did the devil make me do it?
Topics: Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Levodopa; Parkinson Disease | 2010 |
Motor complications in Parkinson's disease: ten year follow-up study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric | 2010 |
Asparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy.
Topics: Aged; Antiparkinson Agents; Asparagus Plant; Bezoars; Dentures; Equipment Failure; Feeding Behavior; Gastrostomy; Humans; Infusion Pumps, Implantable; Intubation; Jejunum; Levodopa; Male; Parkinson Disease | 2011 |
Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene.
Topics: Animals; Cell Line; Dopamine; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Mice; Mice, Knockout; Oncogene Proteins; Parkinson Disease; Peroxiredoxins; Protein Deglycase DJ-1; Response Elements; RNA, Small Interfering; Transcriptional Activation; Tyrosine 3-Monooxygenase | 2010 |
Lack of motor symptoms progression in Parkinson's disease patients with long-term bilateral subthalamic deep brain stimulation.
Topics: Aged; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome; Tremor | 2010 |
Acute dopamine depletion syndrome.
Topics: Aged; Alzheimer Disease; Confusion; Creatine Kinase; Dopamine; Dopamine Agents; Female; Fever; Humans; Hypothyroidism; Levodopa; Muscle Rigidity; Parkinson Disease | 2010 |
Both L-DOPA and HFS-STN restore the enhanced group II spinal reflex excitation to a normal level in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Reflex | 2011 |
Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Probability; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2011 |
Living with advanced Parkinson's disease: a constant struggle with unpredictability.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Aged; Attitude to Health; Chronic Disease; Deep Brain Stimulation; Disease Progression; Drug Administration Schedule; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nursing Methodology Research; Parkinson Disease; Qualitative Research | 2011 |
Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Thiamine | 2011 |
Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Severity of Illness Index; Treatment Outcome | 2011 |
Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Globus Pallidus; Humans; Levodopa; Longitudinal Studies; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Time; Treatment Outcome | 2011 |
Quality of life in Parkinson's disease patients: validation of the Short-Form Eight-item Parkinson's Disease Questionnaire (PDQ-8) in Taiwan.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychometrics; Quality of Life; Surveys and Questionnaires; Taiwan | 2011 |
Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Dystonia; Evoked Potentials, Motor; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Transcranial Magnetic Stimulation | 2011 |
Common pathogenic pathways in melanoma and Parkinson disease.
Topics: Brain Neoplasms; Group VI Phospholipases A2; Humans; Levodopa; Melanoma; Neural Pathways; Parkinson Disease; Tyrosine | 2010 |
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Costs; Duodenum; Government Agencies; Humans; Levodopa; Models, Economic; Parkinson Disease; Reimbursement Mechanisms; Sweden; Treatment Outcome | 2010 |
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2010 |
Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Dysarthria; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Acoustics | 2011 |
The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Prognosis | 2011 |
Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction?
Topics: Aged; Attention; Depression; Dopamine Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Regression Analysis; Severity of Illness Index; Time Factors | 2011 |
Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Brain Waves; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electrophysiology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2011 |
Management of punding in Parkinson's disease: an open-label prospective study.
Topics: Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quetiapine Fumarate; Stereotypic Movement Disorder | 2011 |
Levodopa: back to the future.
Topics: Antiparkinson Agents; Forecasting; Humans; Levodopa; Parkinson Disease | 2010 |
Late-stage Parkinson's disease in the Lisbon-Barcelona cohorts: past phenomenology and today's clinical needs.
Topics: Clinical Trials as Topic; Cohort Studies; Humans; Levodopa; Parkinson Disease; Portugal; Spain | 2011 |
[Update on current care guidelines. Parkinson's disease].
Topics: Age Factors; Aged; Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic | 2010 |
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Automated Levodopa-induced dyskinesia assessment.
Topics: Acceleration; Algorithms; Antiparkinson Agents; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Equipment Design; Humans; Levodopa; Models, Statistical; Monitoring, Ambulatory; Parkinson Disease; Programming Languages; Reproducibility of Results; Signal Processing, Computer-Assisted | 2010 |
Decision making under risk condition in patients with Parkinson's disease: a behavioural and fMRI study.
Topics: Aged; Antiparkinson Agents; Behavior; Decision Making; Dopamine Agonists; Feedback, Psychological; Female; Gambling; Games, Experimental; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Memory; Movement Disorders; Neuropsychological Tests; Oxygen; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Risk-Taking | 2010 |
Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Deoxyguanosine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Oxidative Stress; Parkinson Disease; Reference Values | 2011 |
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apolipoproteins E; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Retrospective Studies | 2011 |
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Levodopa; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies | 2011 |
Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease--a [123 I]-ADAM SPECT study.
Topics: Aged; Antiparkinson Agents; Early Diagnosis; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2011 |
Idiopathic Parkinson disease effect of levodopa on apparent diffusion coefficient value of the brain.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Diffusion Magnetic Resonance Imaging; Echo-Planar Imaging; Female; Humans; Levodopa; Male; Parkinson Disease; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2011 |
Response to sensory uncertainty in Parkinson's disease: a marker of cerebellar dysfunction?
Topics: Aged; Antiparkinson Agents; Cerebellar Diseases; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Sensation; Uncertainty | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Statistics, Nonparametric; Time Factors | 2011 |
General anaesthesia for deep brain stimulator electrode insertion in Parkinson's disease.
Topics: Anesthesia, General; Anesthesia, Local; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; England; Female; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Length of Stay; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Time and Motion Studies | 2011 |
Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Aminoacetonitrile; Animals; Aphakia; Choline O-Acetyltransferase; Cholinergic Fibers; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Homeodomain Proteins; Levodopa; Mice; Mice, Transgenic; Neurons; Parkinson Disease; Phosphorylation; Transcription Factors | 2011 |
"Double crush" in Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; Sensory Thresholds | 2010 |
A case series of peripheral neuropathy in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Retrospective Studies; Vitamin B Complex | 2010 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Analysis of differences between physiological and pathological tremor of human fingers.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Electromyography; Fingers; Humans; Isometric Contraction; Levodopa; Middle Aged; Parkinson Disease; Tremor | 2010 |
Evaluation of cerebral vasomotor reactivity in Parkinson's disease: is there any association with orthostatic hypotension?
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; Female; Humans; Hypotension, Orthostatic; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Muscle, Smooth, Vascular; Parkinson Disease; Tomography, X-Ray Computed; Ultrasonography, Doppler, Transcranial; Vasodilation | 2011 |
Levodopa effect on electromyographic activation patterns of tibialis anterior muscle during walking in Parkinson's disease.
Topics: Aged; Drug Administration Schedule; Electromyography; Female; Gait; Humans; Levodopa; Lower Extremity; Male; Motor Activity; Muscle, Skeletal; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Treatment Outcome; Walking | 2011 |
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotypic Movement Disorder; Time Factors | 2011 |
Is pathological gambling in Parkinson's disease reduced by amantadine?
Topics: Aged; Amantadine; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Does levodopa affect metaiodobenzylguanidine myocardial accumulation in Parkinson's disease?
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Myocardium; Parkinson Disease; Radionuclide Imaging | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Motor Activity; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra | 2011 |
Postural sway approaches center of mass stability limits in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Postural Balance; Posture; Reproducibility of Results; Sensation Disorders; Statistics as Topic | 2011 |
Transient executive dysfunction following STNDBS in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Executive Function; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2011 |
The effect of drug treatment on neurogenesis in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cell Differentiation; Cerebral Ventricles; Female; Gene Expression Regulation; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neural Stem Cells; Neurogenesis; Parkinson Disease; Postmortem Changes; Regression Analysis; Retrospective Studies; RNA-Binding Proteins | 2011 |
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Cognition; Cohort Studies; Dementia; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; New South Wales; Parkinson Disease; Survival Analysis | 2011 |
Handwriting in patients with Parkinson disease: effect of L-dopa and stimulation of the sub-thalamic nucleus on motor anticipation.
Topics: Adult; Anticipation, Psychological; Antiparkinson Agents; Attention; Computer Graphics; Deep Brain Stimulation; Female; Handwriting; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Reference Values; Subthalamic Nucleus | 2011 |
Two cases of unexpected long-term improvement of Parkinson's disease after subthalamic nucleus deep brain stimulation removal.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Device Removal; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2011 |
[Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2011 |
Rapidly deteriorating parkinsonism and dysautonomia in patient with central pontine and extrapontine myelinolysis.
Topics: Antiparkinson Agents; Blood Pressure; Fatal Outcome; Gait Disorders, Neurologic; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease; Primary Dysautonomias; Psychomotor Agitation | 2011 |
Interpreting the results of Parkinson's disease clinical trials: time for a change.
Topics: Antiparkinson Agents; Humans; Levodopa; Models, Biological; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
Topics: Aged; Analysis of Variance; Brain; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Receptors, N-Methyl-D-Aspartate | 2011 |
Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Delusions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2011 |
High frequency oscillations in the subthalamic nucleus: a neurophysiological marker of the motor state in Parkinson's disease.
Topics: Aged; Basal Ganglia; Biological Clocks; Deep Brain Stimulation; Electrodes, Implanted; Electrophysiology; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2011 |
Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism.
Topics: Adult; Antiparkinson Agents; Female; Genome-Wide Association Study; Humans; Levodopa; Magnetic Resonance Imaging; Mutation; Parkinson Disease; Proteins; Spastic Paraplegia, Hereditary | 2011 |
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Statistics, Nonparametric | 2011 |
[Patients' perspective on Parkinson disease therapies: results of a large-scale survey in Japan].
Topics: Aged; Antiparkinson Agents; Attitude; Dyskinesias; Female; Humans; Interviews as Topic; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Surveys and Questionnaires | 2011 |
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
Topics: Antiparkinson Agents; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease | 2011 |
Neuropathy in idiopathic Parkinson disease: an iatrogenic problem?
Topics: Humans; Iatrogenic Disease; Levodopa; Parkinson Disease; Polyneuropathies | 2011 |
Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study.
Topics: Amino Acid Transport Systems, Neutral; Antiparkinson Agents; Biogenic Monoamines; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Levodopa; Longitudinal Studies; Male; Middle Aged; Norepinephrine; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Serotonin | 2011 |
Acute induction of levodopa-resistant freezing of gait upon subthalamic nucleus electrode implantation.
Topics: Aged; Deep Brain Stimulation; Dopamine Agonists; Electrodes, Implanted; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Subthalamic Nucleus | 2011 |
Altered directional connectivity in Parkinson's disease during performance of a visually guided task.
Topics: Aged; Antiparkinson Agents; Brain; Electroencephalography; Female; Humans; Levodopa; Male; Neural Pathways; Parkinson Disease; Psychomotor Performance; Reaction Time | 2011 |
Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Topics: Aged; Arginine Vasopressin; Benzothiazoles; Carbidopa; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2011 |
Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bupropion; Compulsive Behavior; Dopamine Uptake Inhibitors; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Treatment Outcome | 2011 |
Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.
Topics: alpha-Synuclein; Blotting, Western; Cell Line, Tumor; Dopamine; Humans; Levodopa; Neurons; Parkinson Disease; Substantia Nigra | 2011 |
Levodopa and the feedback process on set-shifting in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Set, Psychology | 2012 |
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Tanzania | 2011 |
Factors associated with cognitive impairment in patients with Parkinson disease: an urban study.
Topics: Activities of Daily Living; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Caregivers; Cognition Disorders; Cross-Sectional Studies; Educational Status; Ethnicity; Female; Follow-Up Studies; Humans; Levodopa; Malaysia; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Urban Population | 2011 |
Parkinson's disease and pain--nondopaminergic mechanisms are likely to be important too.
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Pain; Pain Measurement; Parkinson Disease | 2011 |
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Dopaminergic Neurons; Female; Humans; Levodopa; Limbic System; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Receptor, Cannabinoid, CB1; Substantia Nigra; Up-Regulation | 2012 |
Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
Topics: Adult; Anticonvulsants; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 2011 |
Facilitated temporal summation of pain at spinal level in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinson Disease; Physical Stimulation; Psychophysics; Reflex; Severity of Illness Index; Spinal Cord | 2011 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Carbidopa; Dipeptides; Female; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Tyrosine | 2011 |
Varying nanoparticle pseudostationary phase plug length during capillary electrophoresis.
Topics: Catechols; Dopamine; Electrophoresis, Capillary; Epinephrine; Fatty Acids; Humans; Levodopa; Nanoparticles; Parkinson Disease; Sulfhydryl Compounds | 2011 |
Assessing manual pursuit tracking in Parkinson's disease via linear dynamical systems.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Female; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Parkinson Disease; Psychomotor Performance | 2011 |
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome | 2011 |
Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.
Topics: Aged; Anesthetics, Intravenous; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Midazolam; Parkinson Disease; Rhabdomyolysis | 2011 |
Instability of syllable repetition in Parkinson's disease--influence of levodopa and deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Deep Brain Stimulation; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Speech Disorders | 2011 |
A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Asian People; Female; Hong Kong; Humans; Language; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Predictive Value of Tests; Reproducibility of Results; Surveys and Questionnaires | 2011 |
Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Patient Selection; Prevalence | 2011 |
Gender effect on time to levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Risk Factors; Sex Factors | 2011 |
Sleep quality in Parkinson disease: an examination of clinical variables.
Topics: Actigraphy; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sleep; Sleep Wake Disorders; Surveys and Questionnaires | 2011 |
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus.
Topics: Aged; Antiparkinson Agents; Cyclic GMP; Deep Brain Stimulation; gamma-Aminobutyric Acid; Humans; Levodopa; Middle Aged; Parkinson Disease; Statistics, Nonparametric; Subthalamic Nucleus; Thalamus | 2011 |
Feeling of presence in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Perceptual Disorders; Psychotic Disorders; Surveys and Questionnaires | 2011 |
A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
Topics: Aged; Aging; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Longitudinal Studies; Male; Middle Aged; Muscle Strength; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Psychomotor Performance; Radiopharmaceuticals; Reaction Time; Retrospective Studies; Sex Characteristics; Tongue | 2011 |
Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2011 |
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid | 2011 |
The natural history of treated Parkinson's disease in an incident, community based cohort.
Topics: Age Factors; Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Quality of Life; tau Proteins | 2011 |
Parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adult; Antidotes; Antiparkinson Agents; Benserazide; Cholinesterase Inhibitors; Humans; Insecticides; Levodopa; Male; Organophosphate Poisoning; Parkinson Disease; Pralidoxime Compounds; Trihexyphenidyl | 2011 |
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Aged; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A | 2011 |
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss | 2011 |
Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France.
Topics: Aged; Antiparkinson Agents; Consensus Development Conferences as Topic; Dopamine Agonists; Female; France; Guideline Adherence; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2011 |
Electrogastrographyc activity in Parkinson's disease patients with and without motor fluctuations.
Topics: Aged; Antiparkinson Agents; Electrophysiology; Female; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Random Allocation | 2011 |
Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Historical review.
Topics: Antiparkinson Agents; Disease Progression; Gait Disorders, Neurologic; History, 19th Century; Humans; Levodopa; Parkinson Disease | 2011 |
Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Drug Combinations; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Respiration Disorders | 2011 |
Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Survival Analysis | 2011 |
[2011: not just PRAXIS, also dopa turns 100 years old...].
Topics: Antiparkinson Agents; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Periodicals as Topic; Publishing; Switzerland | 2011 |
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Delusions; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales | 2011 |
Psychiatric symptoms screening in the early stages of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Cognition; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Levodopa; Male; Mental Disorders; Neuropsychological Tests; Obsessive-Compulsive Disorder; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance; Psychotic Disorders; Surveys and Questionnaires | 2012 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
Walking in circles: navigation deficits from Parkinson's disease but not from cerebellar ataxia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Biomechanical Phenomena; Cerebellar Ataxia; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Walking | 2011 |
Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.
Topics: Aged; Antiparkinson Agents; Asian People; Bromocriptine; China; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Therapy, Combination; Ergot Alkaloids; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2011 |
Jejunal levodopa infusion in long-term DBS patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Drug Administration Routes; Enteritis; Humans; Levodopa; Male; Parkinson Disease; Subthalamic Nucleus | 2011 |
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Gels; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years; United Kingdom | 2011 |
The natural history of treated PD in an incident, community-based cohort: does the future begin?
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease | 2011 |
Tardive syndrome and Parkinson's disease responsive to concomitant tetrabenazine and levodopa therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Depression; Female; Flupenthixol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Tetrabenazine | 2011 |
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Comparison of endothelial progenitor cells in Parkinson's disease patients treated with levodopa and levodopa/COMT inhibitor.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Endothelial Cells; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stem Cells | 2011 |
Subjective emotional experience at different stages of Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Emotions; Facial Expression; Female; Humans; Levodopa; Male; Middle Aged; Motion Pictures; Parkinson Disease; Photic Stimulation | 2011 |
Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α-synuclein gene.
Topics: Adult; alpha-Synuclein; Antiparkinson Agents; Deep Brain Stimulation; Depressive Disorder; Dystonia; Executive Function; Female; Follow-Up Studies; Functional Laterality; Gene Duplication; Humans; Levodopa; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2012 |
Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?
Topics: Adult; Aged; Aged, 80 and over; Disability Evaluation; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires | 2012 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Eugenol; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Guaiacol; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Superoxide Dismutase | 2011 |
Constipation triggered the malignant syndrome in Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Constipation; Humans; Levodopa; Male; Panax; Parkinson Disease; Plant Extracts; Receptors, Serotonin, 5-HT3; Tomography, X-Ray Computed; Zanthoxylum; Zingiberaceae | 2012 |
Jay Nutt: a boatman's calling.
Topics: Awards and Prizes; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; United States | 2011 |
Deep brain stimulation and behavioural changes: is comedication the most important factor?
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Risk-Taking; Subthalamic Nucleus | 2012 |
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain Ischemia; Case-Control Studies; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Hospitalization; Humans; Ischemia; Levodopa; Male; Myocardial Ischemia; Netherlands; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Raynaud Disease; Severity of Illness Index | 2012 |
Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; ROC Curve; Severity of Illness Index | 2011 |
Malnutritional neuropathy under intestinal levodopa infusion.
Topics: Aged; Carbidopa; Humans; Infusions, Parenteral; Levodopa; Male; Malnutrition; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Polyneuropathies | 2012 |
The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Auditory Perception; Benserazide; Cohort Studies; Dopamine Agents; Female; Humans; Inhibition, Psychological; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Severity of Illness Index | 2011 |
Case control polysomnographic studies of sleep disorders in Parkinson's disease.
Topics: Aged; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Respiration; Restless Legs Syndrome; Sex Characteristics; Sleep Wake Disorders; Surveys and Questionnaires | 2011 |
The Parkinson's disease market.
Topics: Antiparkinson Agents; Drug Discovery; Humans; Levodopa; Parkinson Disease | 2011 |
Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.
Topics: Anthracenes; Antiparkinson Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Levodopa; MAP Kinase Kinase Kinase 5; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Pyridines | 2011 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Membrane Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions; Time Factors | 2012 |
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Assessment; Risk Factors; Tremor | 2011 |
Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP.
Topics: Age of Onset; Asian People; Compulsive Behavior; Dopamine Agonists; Female; Humans; Impulsive Behavior; Levodopa; Malaysia; Male; Parkinson Disease; Prevalence; Surveys and Questionnaires | 2011 |
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Topics: Administration, Oral; Animals; Corpus Striatum; Disease Models, Animal; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation | 2012 |
Network correlates of the cognitive response to levodopa in Parkinson disease.
Topics: Aged; Cognition; Cognition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Treatment Outcome; Verbal Learning | 2011 |
Reduced serum caeruloplasmin levels in non-wilsonian movement disorders.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Ceruloplasmin; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Regression Analysis; Retrospective Studies | 2011 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Female; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2011 |
An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2012 |
DBS candidates that fall short on a levodopa challenge test: alternative and important indications.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Respiration Disorders | 2011 |
Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis.
Topics: Adult; Aged; Aged, 80 and over; Cluster Analysis; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Parkinson Disease; Phenotype; Quality of Life; Treatment Outcome | 2011 |
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Topics: Animals; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Levodopa; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rotenone; Thioctic Acid; Uncoupling Agents | 2011 |
Editor's note: does levodopa accelerate the pathologic process in Parkinson disease brain?
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Substantia Nigra | 2011 |
Does levodopa accelerate the pathologic process in Parkinson disease brain?
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cell Count; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Lewy Bodies; Longitudinal Studies; Male; Middle Aged; Neurons; Parkinson Disease; Severity of Illness Index; Substantia Nigra | 2011 |
Levodopa toxicity and Parkinson disease: still a need for equipoise.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Substantia Nigra | 2011 |
Is levodopa toxic? Insights from a brain bank.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Substantia Nigra | 2011 |
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients.
Topics: Aged; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nerve Net; Parkinson Disease; Positron-Emission Tomography; Theta Rhythm; Transcranial Magnetic Stimulation | 2012 |
Validation of 24-hour ambulatory gait assessment in Parkinson's disease with simultaneous video observation.
Topics: Acceleration; Aged; Female; Gait; Humans; Levodopa; Male; Monitoring, Ambulatory; Parkinson Disease | 2011 |
Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease.
Topics: Abdominal Pain; Aged; Antiparkinson Agents; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Fructose; Levodopa; Male; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Topiramate | 2011 |
Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Drug Monitoring; Humans; Hypokinesia; Levodopa; Middle Aged; Movement; Neurologic Examination; Neurology; Observer Variation; Parkinson Disease; Videotape Recording | 2011 |
Camptocormia in Japanese patients with Parkinson's disease: a multicenter study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Asian People; Comorbidity; Cross-Sectional Studies; Female; Humans; Japan; Levodopa; Male; Muscular Atrophy, Spinal; Parkinson Disease; Prevalence; Severity of Illness Index; Spinal Curvatures | 2011 |
Ocular motor and sensory function in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Combined Modality Therapy; Convergence, Ocular; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinson Disease; Prospective Studies; Quality of Life; Sensation; Surveys and Questionnaires; Visual Acuity | 2012 |
Duodopa infusion treatment: a point of view from the gastroenterologist.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastroenterology; Gels; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Proceedings of the International Symposium on "Levodopa: Back to the Future", April 3-4, 2009, Catania, Italy.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2010 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
Topics: Animals; Dynorphins; Dyskinesias; Enkephalins; Female; Immunohistochemistry; Levodopa; Male; Mass Spectrometry; Mice; Mice, Knockout; Parkinson Disease; Protein Precursors; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro.
Topics: Antiparkinson Agents; Apoptosis; Blood Protein Electrophoresis; Brain Chemistry; Caspases; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA Fragmentation; Humans; Hydrolysis; Indicators and Reagents; L-Lactate Dehydrogenase; Levodopa; Microscopy, Electron; Microscopy, Fluorescence; Mitochondrial Membranes; Nerve Tissue Proteins; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Quinolines | 2012 |
The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease; Photic Stimulation | 2012 |
Continuing efforts to obtain continuous delivery of levodopa.
Topics: Animals; Chemistry, Pharmaceutical; Dopamine Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2011 |
Electrode position and the clinical outcome after bilateral subthalamic nucleus stimulation.
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2011 |
Are Dopa-responsive dystonia and Parkinson's disease related disorders? A case report.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2012 |
Lees' syndrome: a case series.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2011 |
A phaeochromocytoma occurring in a patient with Parkinson's disease on L-dopa therapy: a diagnostic challenge.
Topics: Adrenal Gland Neoplasms; Antiparkinson Agents; Creatinine; Humans; Levodopa; Male; Metanephrine; Middle Aged; Normetanephrine; Parkinson Disease; Pheochromocytoma; Tomography, X-Ray Computed | 2012 |
Dopamine receptors, motor responses, and dopaminergic agonists.
Topics: Adenylyl Cyclases; Antiparkinson Agents; Arachidonic Acid; Calcium Channels; Dopamine; Dopamine Agonists; GTP-Binding Proteins; Humans; Levodopa; Motor Activity; Parkinson Disease; Protein Isoforms; Receptors, Dopamine | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Risk of falling in Parkinson's disease at the Hoehn-Yahr stage III.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Logistic Models; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Surveys and Questionnaires; Video Recording | 2011 |
[Translation and linguistic validation of the Japanese version of the wearing-off questionnaires(WOQ-19 and WOQ-9)].
Topics: Antiparkinson Agents; Drug Administration Schedule; Drug Resistance; Humans; Japan; Language; Levodopa; Parkinson Disease; Surveys and Questionnaires; Translating | 2011 |
Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Disability Evaluation; Disabled Persons; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Quality of Life; Self Report; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires | 2012 |
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
Topics: Adult; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Oxygen; Parkinson Disease; Prefrontal Cortex; Regression Analysis; Severity of Illness Index | 2012 |
Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Walking | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
A liquid phase based C. elegans behavioral analysis system identifies motor activity loss in a nematode Parkinson's disease model.
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Electronic Data Processing; Glutamic Acid; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Motor Activity; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Serine; Software | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Carbon Isotopes; Cocaine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Microdialysis; Motor Activity; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonergic Neurons; Serotonin Receptor Agonists | 2012 |
The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cohort Studies; Dopamine Agonists; Female; Heart Failure; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2012 |
[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Cohort Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Socioeconomic Factors; Withholding Treatment | 2012 |
Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Walking | 2011 |
Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Drug Delivery Systems; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Random Allocation; Scorpion Venoms | 2012 |
Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
Topics: Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbidopa; Drug Combinations; Fracture Fixation, Internal; Fractures, Bone; Humans; Humerus; Intraoperative Awareness; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Perioperative Care | 2011 |
Apathy and depression in Parkinson's disease: the Belgrade PD study report.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Apathy; Community Health Planning; Depression; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prevalence; Regression Analysis; Serbia | 2012 |
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Symptoms; Cell Count; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; ELAV Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Humans; Levodopa; Mesencephalon; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regulatory Elements, Transcriptional; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2012 |
Multichannel microelectrode recording influences final electrode placement in pallidal deep brain stimulation for Parkinson's disease: report of twenty consecutive cases.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Electrophysiology; Female; Globus Pallidus; Humans; Intraoperative Complications; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Monitoring, Intraoperative; Parkinson Disease; Postoperative Care; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Stereotaxic Techniques; Treatment Outcome | 2011 |
Parkinson disease: the controversy of levodopa toxicity in Parkinson disease.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Neurons; Parkinson Disease | 2011 |
Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Environment; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Psychomotor Performance; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease.
Topics: Aged; Analysis of Variance; Computer Simulation; Corpus Striatum; Decision Making; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Models, Psychological; Parkinson Disease; Photic Stimulation; Probability Learning; Psychiatric Status Rating Scales; Psychomotor Performance; Reward; Surveys and Questionnaires | 2012 |
Development of Parkinson's disease in patients with Narcolepsy.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain Stimulation; Dextroamphetamine; Female; Humans; Hypokinesia; Indans; International Classification of Diseases; Levodopa; Male; Middle Aged; Narcolepsy; Neuroprotective Agents; Parkinson Disease; Sleep; Young Adult | 2012 |
Assessment of appropriate medication administration for hospitalized patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparasitic Agents; Female; Hospitalization; Hospitals, Veterans; Humans; Levodopa; Male; Medical Records Systems, Computerized; Medication Adherence; Medication Errors; Middle Aged; Parkinson Disease; Patient Admission; Pharmaceutical Services; Retrospective Studies; Statistics, Nonparametric; Veterans | 2012 |
Apathy in Parkinson's disease: diagnostic and etiological dilemmas.
Topics: Antiparkinson Agents; Apathy; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2012 |
Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aged, 80 and over; Antiparkinson Agents; Biomarkers; Case-Control Studies; Chromatography, High Pressure Liquid; Deoxyglucose; Deoxyguanosine; DNA Damage; DNA Repair; Electrochemical Techniques; Female; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2011 |
Addiction as aberrant learning-evidence from Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Reinforcement, Psychology; Substance-Related Disorders; Syndrome | 2012 |
Stimulating debate in the field of addiction.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders | 2012 |
Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Duodenostomy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Spouses; Stress, Psychological; Surveys and Questionnaires | 2012 |
On automated assessment of Levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Automation; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2011 |
"On" state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Behavior; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenotype | 2012 |
Paradoxical worsening of gait with levodopa in Parkinson disease.
Topics: Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Apomorphine injections: predictors of initial common adverse events and long term tolerability.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Time Factors | 2012 |
Trichophagia affects response to duodenal levodopa/carbidopa gel administration.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Drug Administration Routes; Drug Therapy, Combination; Duodenum; Feeding Behavior; Hair; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Knotting of percutaneous endoscopic jejunostomy feeding tubes in two patients with Parkinson's disease and continuous Duodopa® treatment.
Topics: Endoscopy, Gastrointestinal; Enteral Nutrition; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Prosthesis Failure; Treatment Outcome | 2012 |
Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Cerebral Cortex; Corpus Striatum; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Oxygen; Parkinson Disease; Psychomotor Performance; Reaction Time; Severity of Illness Index | 2012 |
[Transcient improvement of extrapyramidal syndrome after general anaesthesia].
Topics: Aged; Anesthesia, General; Antiparkinson Agents; Basal Ganglia Diseases; Female; Humans; Levodopa; Meningioma; Neural Pathways; Parkinson Disease; Perioperative Care | 2012 |
Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease.
Topics: Aged; Cohort Studies; Disability Evaluation; Female; Humans; Italy; Levodopa; Linguistics; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Psychometrics; Surveys and Questionnaires | 2012 |
Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Burning Mouth Syndrome; Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pramipexole | 2012 |
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Ethnicity; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Jews; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Logistic Models; Male; Middle Aged; Mutation; Neoplasms; Parkinson Disease; Protein Serine-Threonine Kinases; Sex Factors; Survival Analysis | 2012 |
Cerebral blood flow and freezing of gait in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Circulation; Disability Evaluation; Drug Therapy, Combination; Female; Gait Disorders, Neurologic; Humans; Iofetamine; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Selegiline; Tomography, Emission-Computed, Single-Photon | 2012 |
Effect of duodenal levodopa infusion on blood pressure and sweating.
Topics: Aged; Blood Pressure; Drug Administration Routes; Duodenum; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Sweating; Treatment Outcome | 2012 |
Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Topics: Adult; Aged; Antiparkinson Agents; Caregivers; Cohort Studies; Disability Evaluation; Female; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Oral formulations of L-dopa and continuous dopaminergic stimulation.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Delivery Systems; Female; Humans; Levodopa; Male; Parkinson Disease | 2012 |
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
Topics: Animals; Antiparkinson Agents; Benzodioxoles; Cell Line, Tumor; Drug Synergism; Levodopa; Male; Methylamines; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2012 |
Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.
Topics: Binding Sites; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Crystallography, X-Ray; Deoxyribose; Dopamine; Drug Design; Levodopa; Models, Molecular; Parkinson Disease; Ribose; S-Adenosylmethionine | 2012 |
Comparison of personality characteristics in Parkinson disease patients with and without impulse control disorders and in healthy volunteers.
Topics: Aged; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; MMPI; Parkinson Disease; Time Factors | 2012 |
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12 | 2012 |
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2012 |
Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Body Mass Index; Electromyography; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Muscle Contraction; Muscle Rigidity; Muscle, Skeletal; Parkinson Disease; Piribedil; Stress, Mechanical | 2012 |
Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Mood Disorders; Parkinson Disease; Regression Analysis; Severity of Illness Index; Time Factors | 2012 |
Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.
Topics: Adult; Asian People; DNA Mutational Analysis; Dopamine Agents; Dystonia; Family Health; Female; Genetic Predisposition to Disease; GTP Cyclohydrolase; Humans; India; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease | 2012 |
Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Sensation Disorders; Touch Perception; Tropanes | 2012 |
Dopamine alters tactile perception in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Dopamine Agents; Female; Humans; Judgment; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Perceptual Disorders; Physical Stimulation; Psychophysics; Retrospective Studies; Touch Perception | 2012 |
The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.
Topics: Animals; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; G-Protein-Coupled Receptor Kinases; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Parkinson Disease; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease.
Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Case-Control Studies; Cognition; Disease Progression; Dopamine Agents; Female; Fingers; Handwriting; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Supranuclear Palsy, Progressive | 2012 |
Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism.
Topics: Adult; Age of Onset; alpha-Synuclein; Antiparkinson Agents; Chromosomes, Human, Pair 4; Dihydroxyphenylalanine; Dopamine Agonists; Female; Gene Duplication; Humans; Intellectual Disability; Karyotyping; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Trisomy | 2012 |
Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia?
Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Prefrontal Cortex | 2012 |
Dopamine modulation affects the performance of parkinsonian patients in a precision motor task measured by an antropomorphic device.
Topics: Aged; Anthropometry; Antiparkinson Agents; Cholinergic Antagonists; Disability Evaluation; Dopamine; Dopamine Agents; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pinch Strength; Psychomotor Performance; Reaction Time; Reference Values; Signal Processing, Computer-Assisted; Weight Perception | 2012 |
Light and heavy touch reduces postural sway and modifies axial tone in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Dopamine Agents; Hand Strength; Hip; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Postural Balance; Posture; Pressure; Sensation Disorders; Severity of Illness Index; Torque; Touch | 2012 |
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autoradiography; Brain; Female; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Receptor, Serotonin, 5-HT1A; Visual Pathways | 2012 |
[Clinical features of LRRK2-associated Parkinson's disease].
Topics: Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Mutation; Parkinson Disease; Pedigree; Protein Serine-Threonine Kinases; Protein Structure, Tertiary | 2011 |
Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele.
Topics: Adult; Alleles; Analysis of Variance; Brain; Case-Control Studies; Executive Function; Face; Facial Expression; Family Health; Female; Fluorodeoxyglucose F18; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Oxygen; Parkinson Disease; Pattern Recognition, Visual; Photic Stimulation; Positron-Emission Tomography; Recognition, Psychology; Self Report; Severity of Illness Index; Ubiquitin-Protein Ligases | 2012 |
Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Electromyography; Entropy; Evoked Potentials, Motor; Female; Forearm; Functional Laterality; Human Body; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 2012 |
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.
Topics: Aged; Antiparkinson Agents; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regression Analysis; Social Change; Social Perception; Surveys and Questionnaires | 2012 |
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dystonia; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2013 |
Stereotactic microdialysis of the basal ganglia in Parkinson's disease.
Topics: Aged; Basal Ganglia; Chromatography, High Pressure Liquid; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Microdialysis; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Stereotaxic Techniques | 2012 |
Combined delusional misidentification syndrome in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Capgras Syndrome; Cognition Disorders; Delusions; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naïve older patients with Parkinson's disease: A before-after study.
Topics: Arginine Vasopressin; Carbidopa; Controlled Before-After Studies; Humans; Levodopa; Parkinson Disease | 2012 |
An automated methodology for levodopa-induced dyskinesia: assessment based on gyroscope and accelerometer signals.
Topics: Aged; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2012 |
Decomposing effects of dopaminergic medication in Parkinson's disease on probabilistic action selection--learning or performance?
Topics: Dopamine; Dopamine Agents; Female; Humans; Learning; Levodopa; Male; Middle Aged; Parkinson Disease; Probability; Psychomotor Performance; Reaction Time | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2013 |
Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus | 2012 |
Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Fluoxetine; Histones; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinson Disease; Phosphorylation; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease.
Topics: Acetates; Aged; Antiparkinson Agents; Breath Tests; Carbon Isotopes; Deep Brain Stimulation; Female; Gastric Emptying; Ghrelin; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics as Topic; Statistics, Nonparametric; Subthalamic Nucleus | 2012 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Histamine; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Time Factors | 2012 |
Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Resistance; Electroconvulsive Therapy; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Walking | 2012 |
The relationship between cerebral vascular disease and parkinsonism: The VADO study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Cohort Studies; Corpus Striatum; Cross-Sectional Studies; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
The effects of levodopa and deep brain stimulation on subthalamic local field low-frequency oscillations in Parkinson's disease.
Topics: Adult; Aged; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2013 |
Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2012 |
N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?
Topics: Acetylcysteine; Animals; Drug Therapy, Combination; Glutathione; Humans; Levodopa; Models, Theoretical; Oxidative Stress; Parkinson Disease | 2012 |
Clinical characteristics of exacerbations in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement; Outcome Assessment, Health Care; Outpatients; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index | 2012 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Accounting for movement increases sensitivity in detecting brain activity in Parkinson's disease.
Topics: Analysis of Variance; Biomechanical Phenomena; Brain; Brain Mapping; Dopamine Agents; Fingers; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 2012 |
β band stability over time correlates with Parkinsonian rigidity and bradykinesia.
Topics: Aged; Basal Ganglia; Beta Rhythm; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Time Factors | 2012 |
Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease.
Topics: Administration, Intranasal; Female; Humans; Levodopa; Middle Aged; Motor Skills Disorders; Nicotine; Parkinson Disease; Smoking | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Precision Medicine; Selegiline; Subthalamic Nucleus; Treatment Outcome | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
[Autonomic disorders in Parkinson's disease].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Causality; Comorbidity; Constipation; Deglutition Disorders; Erectile Dysfunction; Female; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Incidence; Levodopa; Male; Middle Aged; Nocturia; Parkinson Disease; Severity of Illness Index; Sex Distribution; Sialorrhea; Statistics, Nonparametric; Urinary Incontinence; Urologic Diseases; Vomiting | 2011 |
Toward the understanding of the metabolism of levodopa I. DFT investigation of the equilibrium geometries, acid-base properties and levodopa-water complexes.
Topics: Decarboxylation; Dopamine; Humans; Hydrogen Bonding; Levodopa; Models, Chemical; Models, Molecular; Parkinson Disease; Water | 2012 |
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4 | 2012 |
Motor and cognitive impairments in Parkinson disease: relationships with specific balance and mobility tasks.
Topics: Adult; Antiparkinson Agents; Cognition Disorders; Female; Humans; Leg; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement; Muscle Strength; Muscle, Skeletal; Parkinson Disease; Postural Balance; Predictive Value of Tests; Psychomotor Performance; Residence Characteristics; Task Performance and Analysis | 2013 |
Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Dopamine Agonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Patient Satisfaction; Prospective Studies; Treatment Outcome | 2012 |
Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Breath Tests; Female; Gastric Emptying; Gastroparesis; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cysteine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Databases, Factual; Dyskinesia, Drug-Induced; Female; Health Care Costs; Humans; Insurance, Health; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; United States | 2012 |
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments.
Topics: Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Exercise Test; Exercise Therapy; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Physical Therapy Modalities; Pilot Projects; Treatment Outcome | 2012 |
Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2012 |
Brain amyloid and cognition in Lewy body diseases.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Antiparkinson Agents; Apolipoprotein E3; Cognition; Cognitive Dysfunction; Female; Genotype; Humans; Levodopa; Lewy Body Disease; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2012 |
Differential effect of dopa and subthalamic stimulation on vestibular activity in Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Cerebral Cortex; Deep Brain Stimulation; Electromyography; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Subthalamic Nucleus; Vestibular Diseases; Vestibule, Labyrinth | 2012 |
Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Motor Skills; Parkinson Disease; Theta Rhythm; Transcranial Magnetic Stimulation | 2012 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Predisposition to Disease; Glycine; Humans; Israel; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Longitudinal Studies; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Retrospective Studies; Serine; Statistics, Nonparametric; Young Adult | 2012 |
Impairment of voluntary saccades and facilitation of reflexive saccades do not co-occur in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Parkinson Disease; Photic Stimulation; Reaction Time; Reflex; Saccades; Statistics as Topic | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aging; Animals; Antiparkinson Agents; Blotting, Western; Cell Count; Dopamine; Dopaminergic Neurons; Female; G(M1) Ganglioside; Gangliosides; Humans; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Acetylgalactosaminyltransferases; Parkinson Disease; Polypeptide N-acetylgalactosaminyltransferase; Synucleins; Tyrosine 3-Monooxygenase | 2012 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline | 2012 |
Levodopa increases speed of alternating movements in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 2013 |
Dyskinesia in Parkinson disease - an unmet therapeutic challenge.
Topics: Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2012 |
Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Cohort Studies; Color Perception; Female; Hallucinations; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Polysomnography; Psychomotor Performance; REM Sleep Behavior Disorder; Smell; Socioeconomic Factors | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Parkinson Disease; Prefrontal Cortex | 2013 |
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease | 2013 |
Subthalamic activity during diphasic dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm | 2012 |
Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Attention; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polysomnography; Wakefulness | 2012 |
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplantation; Central Nervous System Stimulants; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Female; Functional Laterality; Levodopa; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Serotonergic Neurons; Statistics as Topic; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2012 |
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Disability Evaluation; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Statistics, Nonparametric | 2013 |
Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease.
Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Brain; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drosophila; Drosophila Proteins; Gait Disorders, Neurologic; Humans; Levodopa; Membrane Proteins; Neurons; Parkinson Disease; Transcription Factors | 2012 |
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease Progression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Risk Factors; Self Report; Sex Distribution; Surveys and Questionnaires | 2012 |
Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Seizures; Treatment Outcome; Vitamin B 6; Vitamin B 6 Deficiency | 2013 |
Spiral analysis in subjects with Parkinson's disease before and after levodopa treatment: a new protocol with stereophotogrammetric systems.
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Photogrammetry; Severity of Illness Index | 2014 |
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agents; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedunculopontine Tegmental Nucleus | 2010 |
Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease.
Topics: Adult; Aged; Blotting, Western; Corpus Striatum; Dopamine; Dopamine Agonists; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression; Humans; Levodopa; Male; Middle Aged; Mitochondrial Proton-Translocating ATPases; Parkinson Disease; Proteasome Endopeptidase Complex; Proteome; Proteomics; T-Lymphocytes | 2012 |
Beta reactivity, prospective facilitation of executive processing, and its dependence on dopaminergic therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Basal Ganglia; Cues; Deep Brain Stimulation; Executive Function; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Subthalamic Nucleus | 2012 |
Rasagiline: a guide to its use in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
Topics: Antiparkinson Agents; Brain; Humans; Imagination; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Activity; Parkinson Disease; Psychomotor Performance; Speech | 2013 |
The sleeve gastrectomy intervention to treat morbid obesity in a Parkinson's disease patient.
Topics: Bariatric Surgery; Body Mass Index; Female; Gastrectomy; Humans; Levodopa; Middle Aged; Obesity, Morbid; Parkinson Disease; Treatment Outcome; Weight Loss | 2013 |
Movement-related changes in local and long-range synchronization in Parkinson's disease revealed by simultaneous magnetoencephalography and intracranial recordings.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Cortical Synchronization; Deep Brain Stimulation; Electroencephalography; Female; Fingers; Functional Laterality; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Movement; Neurons; Parkinson Disease; Psychomotor Performance; Spectrum Analysis; Statistics as Topic; Subthalamic Nucleus; Time Factors | 2012 |
Long-duration Parkinson's disease: role of lateralization of motor features.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Case-Control Studies; Dementia; Disease Progression; Female; Functional Laterality; Humans; Levodopa; Longevity; Male; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Tremor | 2013 |
Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Wistar; Tyrosine | 2012 |
Recurrent bilateral metatarsal "stress-and-insufficiency" fractures in a levodopa-treated young woman with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Fractures, Stress; Humans; Levodopa; Metatarsal Bones; Middle Aged; Osteoporotic Fractures; Parkinson Disease; Radiography; Recurrence | 2013 |
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regression Analysis; Subthalamic Nucleus | 2012 |
Reliability of the non-instrumented walk test in persons with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agents; Exercise Test; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Walking | 2013 |
[Mexidant increases the effectiveness of levadopa treatment of Parkinson's disease].
Topics: Aged; Amantadine; Antioxidants; Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Levodopa; Lipid Peroxidation; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Pyridines | 2012 |
Effect of bilateral deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Subthalamic Nucleus | 2012 |
Clinical and cognitive profiles of patients with both Parkinson's disease and essential tremor.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Attention; Cognition; Cognition Disorders; Essential Tremor; Executive Function; Female; Humans; Levodopa; Male; Memory; Middle Aged; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Primidone; Space Perception | 2013 |
Novel codrugs with GABAergic activity for dopamine delivery in the brain.
Topics: 1-Octanol; Acetamides; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Cattle; Cell Membrane; Cells, Cultured; Dogs; Dopamine; Dopamine Agents; Endothelial Cells; Levodopa; Madin Darby Canine Kidney Cells; Male; Oxidopamine; Parkinson Disease; Prodrugs; Rats; Rats, Wistar; Receptors, GABA-A; Rhodamine 123; Water | 2012 |
[A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Manganese mixture inhalation is a reliable Parkinson disease model in rats.
Topics: Administration, Inhalation; Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Feeding Behavior; Levodopa; Locomotion; Male; Manganese Compounds; Manganese Poisoning; Mice; Motor Activity; Neurologic Examination; Parkinson Disease; Phosphopyruvate Hydratase; Psychomotor Performance; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase; Video Recording | 2012 |
[Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease].
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesias; G-Protein-Coupled Receptor Kinases; Levodopa; Male; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley | 2012 |
Clinical features and varieties of non-motor fluctuations in Parkinson's disease: a Japanese multicenter study.
Topics: Aged; Aged, 80 and over; Asian People; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Surveys and Questionnaires | 2013 |
Long-range temporal correlations in the subthalamic nucleus of patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Beta Rhythm; Cortical Synchronization; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2012 |
No association between neuropathy and restless legs in Parkinson's disease.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Restless Legs Syndrome; Vitamin B 12 | 2013 |
Levodopa changes brain motor network function during ankle movements in Parkinson's disease.
Topics: Aged; Ankle; Antiparkinson Agents; Brain Mapping; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease; Putamen; Thalamus | 2013 |
Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits.
Topics: alpha-Synuclein; Alzheimer Disease; Antiparkinson Agents; Biomarkers; Cognition; Cognition Disorders; Diagnosis, Differential; Diagnostic Imaging; Frontotemporal Dementia; Genetic Markers; Genetic Testing; Glucosylceramidase; Humans; Huntington Disease; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Lewy Body Disease; Mutation; Parkinson Disease; Precision Medicine; Protein Serine-Threonine Kinases | 2013 |
Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Confidence Intervals; Disorders of Excessive Somnolence; Disruptive, Impulse Control, and Conduct Disorders; Dizziness; Dopamine Agonists; Drug Therapy, Combination; Female; Hallucinations; Humans; Indoles; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Time Factors | 2012 |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 2013 |
Continuous buccolingual masticatory dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Mastication; Movement Disorders; Parkinson Disease; Pergolide | 2012 |
[Duodenal levodopa infusion for advanced Parkinson's disease in Finland 2006-2010].
Topics: Antiparkinson Agents; Deep Brain Stimulation; Duodenum; Female; Finland; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2012 |
Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Topics: Antiparkinson Agents; Carbidopa; Costs and Cost Analysis; Deep Brain Stimulation; Health Resources; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Spain; Surveys and Questionnaires | 2013 |
Delay discounting of reward and caudate nucleus volume in individuals with α-synuclein gene duplication before and after the development of Parkinson's disease.
Topics: Adult; alpha-Synuclein; Antiparkinson Agents; Caudate Nucleus; Cerebral Cortex; Decision Making; Dopamine; Female; Follow-Up Studies; Gene Duplication; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Reaction Time; Reward; Surveys and Questionnaires | 2013 |
Mind the gap: Response to Garcia-Ruiz PJ (2011) Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Journal of the Neurological Sciences 307: 15-17.
Topics: Antiparkinson Agents; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2012 |
Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Seasons | 2012 |
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.
Topics: Animals; Corpus Striatum; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Macaca; Male; Membrane Proteins; Parkinson Disease; Protein Transport; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synapses | 2012 |
Preclinical models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2004 |
Drug-induced burning mouth syndrome: a new clinico-pathological entity?
Topics: Antiparkinson Agents; Burning Mouth Syndrome; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 2012 |
Levodopa effects on hand and speech movements in patients with Parkinson's disease: a FMRI study.
Topics: Aged; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease; Speech | 2012 |
History of exposure to dopaminergic medication does not affect motor cortex plasticity and excitability in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Data Interpretation, Statistical; Dopamine Agents; Electric Stimulation; Electromyography; Female; Hand; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle Contraction; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation; Tremor | 2013 |
The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; DNA Mutational Analysis; Female; Gene Frequency; Genotype; Humans; Iran; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide | 2012 |
Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.
Topics: Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Reproducibility of Results; Severity of Illness Index; Telemedicine; Tremor | 2013 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
Deep brain stimulation - effects on swallowing function in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Deglutition; Diagnostic Self Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Observer Variation; Parkinson Disease; Pneumonia, Aspiration; Severity of Illness Index; Subthalamic Nucleus | 2013 |
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2013 |
Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.
Topics: Animals; Basal Ganglia; Cognition; Dopamine Agonists; Dopaminergic Neurons; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Learning; Levodopa; Memory; Models, Neurological; Parkinson Disease; Prefrontal Cortex; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2013 |
Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesias; Levodopa; Male; Parkinson Disease | 2013 |
1-Hz repetitive transcranial magnetic stimulation and diphasic dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson's disease?
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polyneuropathies; Prevalence | 2013 |
Frequency and clinical correlates of retrocollis in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Muscle Rigidity; Neck; Neuropsychological Tests; Parkinson Disease; Posture; Torticollis | 2013 |
Microlesion effect as a predictor of the effectiveness of subthalamic deep brain stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2013 |
Pitch variability in patients with Parkinson's disease: effects of deep brain stimulation of caudal zona incerta and subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Linguistics; Male; Middle Aged; Parkinson Disease; Reading; Speech; Speech Production Measurement; Subthalamic Nucleus; Subthalamus; Voice | 2013 |
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Receptors, Dopamine D2 | 2012 |
Overweight is more prevalent in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mexico; Middle Aged; Obesity; Overweight; Parkinson Disease; Prevalence; Severity of Illness Index; Thinness | 2012 |
Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction.
Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Dopamine; Female; Humans; Inspiratory Capacity; Levodopa; Male; Middle Aged; Muscle Strength; Parkinson Disease; Pressure; Respiratory Mechanics; Respiratory Muscles; Sex Factors; Total Lung Capacity | 2012 |
Validating an objective video-based dyskinesia severity score in Parkinson's disease patients.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Observer Variation; Parkinson Disease; Severity of Illness Index; Video Recording | 2013 |
Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.
Topics: Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Drug Dosage Calculations; Drug Prescriptions; Female; Humans; Levodopa; Long-Term Care; Male; Medication Adherence; Neuropsychiatry; Parkinson Disease; Retrospective Studies | 2013 |
Treatment in early Parkinson's disease: the Norwegian ParkWest study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cohort Studies; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
[Medical therapy for Parkinson's disease--the current state of the art].
Topics: Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
[Abnormal plasticity and drug effect in Parkinson's disease].
Topics: Antiparkinson Agents; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2012 |
Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model.
Topics: Animals; Blotting, Western; Dopamine Agonists; Flow Cytometry; Homocysteine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Parkinson Disease; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Current clinical practice for Parkinson's disease among Chinese physicians, general neurologists and movement disorders specialists: a national survey.
Topics: Antiparkinson Agents; China; Cross-Sectional Studies; Health Care Surveys; Humans; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians'; Surveys and Questionnaires | 2012 |
Clinical significance of REM sleep behavior disorder in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Cross-Sectional Studies; Dementia; Disability Evaluation; Dose-Response Relationship, Drug; Female; Heart; Humans; Hypotension, Orthostatic; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Polysomnography; Prognosis; Proportional Hazards Models; REM Sleep Behavior Disorder; Sleep Stages; Tilt-Table Test | 2013 |
Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinson's disease outpatients hospitalised on a scheduled basis.
Topics: Aged; Confidence Intervals; Constipation; Deglutition Disorders; Female; Gastrointestinal Diseases; Hospitalization; Humans; Levodopa; Male; Malnutrition; Middle Aged; Nutritional Status; Odds Ratio; Outpatients; Parkinson Disease; Prevalence; Primary Dysautonomias; Risk Factors; Severity of Illness Index; Sialorrhea; Weight Loss | 2013 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |
Motor profile and drug treatment of nursing home residents with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dyskinesias; Female; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease | 2012 |
Effects of dopaminergic and subthalamic stimulation on musical performance.
Topics: Adult; Auditory Perceptual Disorders; Deep Brain Stimulation; Dopamine Agents; Humans; Indoles; Levodopa; Male; Movement; Music; Parkinson Disease; Psychomotor Performance; Subthalamic Nucleus; Time Perception | 2013 |
Differential modulation of STN-cortical and cortico-muscular coherence by movement and levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Electromyography; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Movement; Muscle, Skeletal; Parkinson Disease; Subthalamic Nucleus | 2013 |
Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
Topics: Aged; Antiparkinson Agents; Carbidopa; Comorbidity; Drug Combinations; Electronic Health Records; Female; Half-Life; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Surgical Procedures, Operative | 2013 |
A computationally efficient, exploratory approach to brain connectivity incorporating false discovery rate control, a priori knowledge, and group inference.
Topics: Algorithms; Bayes Theorem; Brain; Brain Mapping; Computer Graphics; Computer Simulation; False Positive Reactions; Humans; Levodopa; Magnetic Resonance Imaging; Models, Biological; Models, Statistical; Models, Theoretical; Multivariate Analysis; Parkinson Disease; Probability | 2012 |
Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Brain; Cell Line, Tumor; Dopamine; Glutathione; Humans; Levodopa; Neurons; Parkinson Disease | 2013 |
Increase of oxidative stress by a novel PINK1 mutation, P209A.
Topics: Age of Onset; Cell Line; Female; Genetic Predisposition to Disease; Heme Oxygenase-1; Heterozygote; Humans; Levodopa; Male; Mutation; Oxidative Stress; Parkinson Disease; Phosphorylation; Protein Kinases; Superoxide Dismutase | 2013 |
Frameless deep brain stimulation surgery: a community hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Data Interpretation, Statistical; Deep Brain Stimulation; Essential Tremor; Female; Follow-Up Studies; Hospitals, Community; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Treatment Outcome | 2013 |
Movement related dynamics of subthalmo-cortical alpha connectivity in Parkinson's disease.
Topics: Alpha Rhythm; Antiparkinson Agents; Cerebral Cortex; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2013 |
Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Topics: Animals; Biological Transport; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Levodopa; Male; Neostriatum; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Synapses; Synaptosomes; Tyrosine 3-Monooxygenase | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2013 |
Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Topics: Aged, 80 and over; Antiparkinson Agents; Dementia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease | 2013 |
The spectrum of nonmotor symptoms in early Parkinson disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Cognition; Cohort Studies; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Parkinson Disease; Surveys and Questionnaires | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1 | 2013 |
Recurrent pancreatitis as a rare complication of duodenal levodopa infusion treatment.
Topics: Antiparkinson Agents; Duodenum; Humans; Levodopa; Male; Middle Aged; Pancreatitis; Parkinson Disease; Radiography; Tomography Scanners, X-Ray Computed | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Acute genital pain during non-motor fluctuations improved by apomorphine.
Topics: Aged; Antiparkinson Agents; Genital Diseases, Male; Humans; Levodopa; Male; Pain; Parkinson Disease | 2013 |
Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dementia; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2013 |
Darkening of white hair in Parkinson's disease during use of levodopa rich Mucuna pruriens extract powder.
Topics: Aged, 80 and over; Dopamine Agents; Female; Hair Color; Humans; Hyperpigmentation; Levodopa; Mucuna; Parkinson Disease; Plant Extracts | 2013 |
Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Biocompatible Materials; Biological Availability; Blood-Brain Barrier; Butylene Glycols; Delayed-Action Preparations; Drug Delivery Systems; Humans; Levodopa; Materials Testing; Microscopy, Electron, Scanning; Microspheres; Parkinson Disease; Polymers; Porosity; Solvents; Surface Properties; Surface-Active Agents | 2013 |
Evolution of the response to levodopa during the first 4 years of therapy.
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 2002 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Microinjections; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Piperidines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2002 |
Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders | 2002 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
[Daily living activities evaluation in Parkinson's disease patients underwent to stereotactic surgery].
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques | 2002 |
Effects of levodopa infusion on motor activation responses in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Dopamine Agents; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Oxygen Radioisotopes; Parkinson Disease; Psychomotor Performance; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Cocaine; Dopamine Agents; Humans; Levodopa; Male; Methylphenidate; Mice; Mice, Inbred ICR; Organotechnetium Compounds; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Tropanes | 2002 |
[Melanoma while using levodopa due to Parkinson's disease--causal association unlikely].
Topics: Aged; Antiparkinson Agents; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Leg; Levodopa; Lymph Node Excision; Lymphatic Metastasis; Melanins; Melanoma, Amelanotic; Parkinson Disease; Skin Neoplasms | 2002 |
Surgical treatment for Parkinson's disease.
Topics: Antiparkinson Agents; Australia; Humans; Levodopa; Parkinson Disease; Patient Selection; Postoperative Complications | 2002 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
New medication recommended for Parkinson's disease.
Topics: Clozapine; Dibenzothiazepines; Dopamine Agonists; Dyskinesias; Hallucinations; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; United States | 2001 |
The effects of deep brain stimulation and levodopa on postural sway in subjects with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 2002 |
"Stiff in the closet"--who provides care for Parkinsonian patients?
Topics: Antiparkinson Agents; Canada; Dopamine Agents; Health Care Costs; Humans; Levodopa; Parkinson Disease; Quality of Health Care; Quality of Life | 2002 |
Mirror, mirror on the wall, which enantiomer is fairest of them all?
Topics: Drug Interactions; Humans; Levodopa; Parkinson Disease; Psychotropic Drugs; Stereoisomerism | 2002 |
Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; France; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Treatment Outcome | 2002 |
Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus.
Topics: Dose-Response Relationship, Drug; Dyskinesias; Electric Stimulation Therapy; Hand Strength; Humans; Levodopa; Parkinson Disease; Reference Values; Severity of Illness Index; Subthalamic Nucleus; Time Factors | 2002 |
The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate; Retrospective Studies | 2002 |
Long-term follow-up of globus pallidus chronic stimulation in advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life | 2002 |
Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study.
Topics: Brain; Combined Modality Therapy; Diagnosis, Differential; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Receptors, Presynaptic; Subthalamic Nucleus | 2002 |
[Levodopa dependency in Parkinson's disease: case report and review].
Topics: Adult; Antiparkinson Agents; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Humans; Levodopa; Limbic System; Male; Mental Status Schedule; Mesencephalon; Neurologic Examination; Parkinson Disease; Patient Care Team; Psychoses, Substance-Induced; Receptors, Dopamine; Substance-Related Disorders | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Synergism; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Levodopa: why the controversy?
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2002 |
Hiccoughs--an unusual dyskinetic side-effect of L-Dopa.
Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Hiccup; Humans; Levodopa; Male; Parkinson Disease | 2002 |
Predictors of effective bilateral subthalamic nucleus stimulation for PD.
Topics: Adult; Age Factors; Aged; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Preoperative Care; Regression Analysis; Statistics, Nonparametric; Subthalamic Nucleus | 2002 |
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
Topics: Aged; Brain; Cabergoline; Delta Rhythm; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep, REM; Wakefulness | 2002 |
Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
Topics: Aged; Dopamine Agonists; Electromyography; Female; Humans; Levodopa; Male; Movement Disorders; Muscle Tonus; Parkinson Disease; Severity of Illness Index; Sleep, REM | 2002 |
Excessive daytime sleepiness in de novo and treated Parkinson's disease.
Topics: Disorders of Excessive Somnolence; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Topics: Animals; Antiparkinson Agents; Brain; Catecholamines; Dopamine; History, 20th Century; History, 21st Century; Humans; Levodopa; Molecular Structure; Parkinson Disease | 2002 |
Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET.
Topics: Aged; Antiparkinson Agents; Brain Chemistry; Electric Stimulation Therapy; Fluorodeoxyglucose F18; Functional Laterality; Gait; Glucose; Humans; Levodopa; Male; Parkinson Disease; Radiopharmaceuticals; Subthalamic Nucleus; Tomography, Emission-Computed | 2002 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2001 |
Stereotactic subthalamic nucleus lesioning for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Confusion; Dysarthria; Dyskinesias; Electric Stimulation; Electrocoagulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prospective Studies; Recurrence; Safety; Severity of Illness Index; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Subthalamic DBS replaces levodopa in Parkinson's disease.
Topics: Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2002 |
Acute effects of L-dopa on event-related desynchronization in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Cerebral Cortex; Electroencephalography; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time; Treatment Outcome | 2002 |
Cognitive slowing in Parkinson's disease resolves after practice.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Humans; Levodopa; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Random Allocation; Reaction Time; Severity of Illness Index | 2002 |
Motivation, reward, and Parkinson's disease: influence of dopatherapy.
Topics: Adult; Antiparkinson Agents; Cognition Disorders; Corpus Striatum; Depressive Disorder, Major; Extinction, Psychological; Female; Frontal Lobe; Humans; Levodopa; Male; Motivation; Nerve Net; Neuropsychological Tests; Parkinson Disease; Reinforcement, Psychology; Reward | 2002 |
Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Corpus Striatum; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2; Receptors, Dopamine D3; Retrospective Studies; RNA, Messenger; Tyrosine 3-Monooxygenase | 2002 |
Serum prolactin levels in Parkinson's disease and multiple system atrophy.
Topics: Aged; Diagnosis, Differential; Dopamine Agents; Female; Head-Down Tilt; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Prolactin | 2002 |
Mania following deep brain stimulation for Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Bipolar Disorder; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
Oscillatory local field potentials recorded from the subthalamic nucleus of the alert rat.
Topics: Animals; Antiparkinson Agents; Biological Clocks; Dopamine Agonists; Dyskinesias; Female; Humans; Levodopa; Male; Membrane Potentials; Middle Aged; Motor Activity; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Reference Values; Rest; Subthalamic Nucleus; Wakefulness | 2002 |
[Hypersexuality during use of levodopa].
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Drug Overdose; Humans; Levodopa; Male; Parkinson Disease; Sexual Dysfunction, Physiological | 2002 |
Analysis of L-dopa in human serum.
Topics: Antiparkinson Agents; Chromatography, Affinity; Edetic Acid; Formates; Humans; Hydrogen-Ion Concentration; Levodopa; Methyldopa; Parkinson Disease; Reference Standards | 2002 |
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2002 |
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2002 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Clinical and genetic studies of families with the tau N279K mutation (FTDP-17).
Topics: Adult; Antiparkinson Agents; Chromosomes, Human, Pair 17; Dementia; DNA; Founder Effect; France; Frontal Lobe; Humans; Japan; Levodopa; Male; Microsatellite Repeats; Molecular Biology; Mutation; Nerve Degeneration; Parkinson Disease; Penetrance; tau Proteins; Temporal Lobe; United States | 2002 |
[Variance in effects of subthalamic nucleus stimulation].
Topics: Aged; Dyskinesias; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2002 |
[Tremor characteristics in the norm and in the diagnosis and treatment of parkinsonism].
Topics: Adult; Basal Ganglia; Diagnosis, Differential; Female; Fingers; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tremor | 2002 |
Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Canada; Caregivers; Cost Savings; Dopamine Agonists; Drug Costs; Health Care Costs; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Treatment Outcome | 2003 |
Dopamine agonists for Parkinson's disease.
Topics: Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2003 |
Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neurologic Examination; Observer Variation; Parkinson Disease; Sensitivity and Specificity | 2003 |
Treatment of Parkinson's disease in Spain.
Topics: Adult; Aged; Antiparkinson Agents; Cross-Sectional Studies; Drug Utilization; Female; Health Surveys; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Care Team; Spain | 2003 |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Topics: Confusion; Depression; Dopamine Agonists; Dysarthria; Electric Stimulation Therapy; Follow-Up Studies; Humans; Levodopa; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome; Subthalamic Nucleus; Time; Treatment Outcome | 2003 |
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary.
Topics: Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Humans; Indoles; Levodopa; Parkinson Disease | 2003 |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Topics: Confusion; Depression; Dopamine Agonists; Electric Stimulation Therapy; Follow-Up Studies; Levodopa; Mood Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease; Quality of Life; Social Behavior Disorders; Substance Withdrawal Syndrome; Subthalamic Nucleus; Time; Treatment Outcome | 2003 |
Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Coronary Artery Disease; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamin B 12 | 2003 |
Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients.
Topics: Adult; Aged; Antiparkinson Agents; Case-Control Studies; Female; Fingers; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Motor Skills; Parkinson Disease | 2003 |
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Cannabinoid Receptor Modulators; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hyperkinesis; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reserpine; Time Factors | 2003 |
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Hip; Humans; Knee; Levodopa; Lower Extremity; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Posture; Random Allocation; Severity of Illness Index | 2003 |
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
Topics: Administration, Oral; Aged; Body Weight; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 2002 |
Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Parkinson Disease; Psychomotor Performance | 2002 |
Movement-related modulation of neural activity in human basal ganglia and its L-DOPA dependency: recordings from deep brain stimulation electrodes in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Basal Ganglia; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Electromyography; Fingers; Globus Pallidus; Humans; Levodopa; Movement; Parkinson Disease; Subthalamic Nucleus | 2002 |
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2002 |
Unilateral subthalamic nucleus lesioning: a safe and effective treatment for Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2002 |
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
Topics: Apomorphine; Cognition; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Task Performance and Analysis; Visual Perception | 2003 |
Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients.
Topics: Adult; Aged; Analysis of Variance; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Agonists vs levodopa in PD: the thrilla of whitha.
Topics: Dopamine; Dopamine Agonists; Endpoint Determination; Humans; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
[Effect of bushen yanggan recipe on nigrostriatal function in parkinsonian model rats after long-term levodopa treatment].
Topics: Animals; Corpus Striatum; Drugs, Chinese Herbal; Levodopa; Male; Parkinson Disease; Phytotherapy; Random Allocation; Rats; Rats, Sprague-Dawley | 2002 |
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Treatment Outcome | 2003 |
Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait.
Topics: Aged; Female; Gait; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Regression Analysis; Statistics, Nonparametric; Walking | 2003 |
Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype.
Topics: Aged; Analysis of Variance; Carotid Arteries; Female; Homocysteine; Humans; Hypertrophy; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Statistics, Nonparametric; Tunica Intima; Ultrasonography | 2003 |
The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology.
Topics: Adult; Aged; Antiparkinson Agents; British Columbia; Bromocriptine; Data Interpretation, Statistical; Databases, Factual; Drug Prescriptions; Drug Utilization; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 2003 |
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autoradiography; Brain; Case-Control Studies; Dopamine; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Postmortem Changes; Receptors, GABA; Receptors, GABA-A; Receptors, GABA-B | 2003 |
Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease.
Topics: Basal Ganglia; Brain; Cognition; Dopamine; Electric Stimulation Therapy; Emotions; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Skills; Parkinson Disease; Psychiatric Status Rating Scales; Subthalamic Nucleus; Synaptic Transmission; Treatment Outcome; Verbal Behavior | 2003 |
Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Acceleration; Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Joints; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Neural Networks, Computer; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Software | 2003 |
[Current preclinical findings on substances against Parkinson's disease].
Topics: Animals; Antiparkinson Agents; Caenorhabditis elegans; Corpus Striatum; Dopamine Agonists; Drug Evaluation, Preclinical; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders | 2003 |
[Medicinal treatment of idiopathic Parkinson's disease].
Topics: Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Dopamine; Dopamine Agonists; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Treatment Outcome | 2003 |
Upper extremity contractures heralding Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Arm; Contracture; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2003 |
Benefit of folic acid supplementation in parkinsonian patients treated with levodopa.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Folic Acid; Hematinics; Humans; Levodopa; Parkinson Disease; Risk Assessment | 2003 |
Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA.
Topics: Antiparkinson Agents; Congresses as Topic; Humans; Intestinal Absorption; Levodopa; Movement Disorders; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2003 |
SCA2 may present as levodopa-responsive parkinsonism.
Topics: Adult; Aged; Alleles; Anticipation, Genetic; Antiparkinson Agents; Ataxins; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Pedigree; Phenotype; Proteins; Treatment Outcome; Trinucleotide Repeats | 2003 |
Discrimination of bilateral differences in the loci of tactile stimulation is impaired in subjects with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Somatosensory Disorders; Touch | 2003 |
Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Female; Fluorescent Antibody Technique; Immunohistochemistry; Levodopa; Microscopy, Confocal; Models, Animal; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase | 2003 |
[Neuropsychological changes and bilateral subthalamic deep brain stimulation in Parkinson's disease].
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cohort Studies; Depression; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Quality of Life; Statistics as Topic; Subthalamic Nucleus | 2003 |
[Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2003 |
Unilateral subthalamotomy in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Catheter Ablation; Female; Follow-Up Studies; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Postoperative Period; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome | 2003 |
Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: a preclinical primate study.
Topics: Animals; Brain Tissue Transplantation; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Macaca; Magnetic Resonance Imaging; Parkinson Disease; PC12 Cells; Rats; Stereotaxic Techniques | 2003 |
Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy--parkinsonism. Report of four cases.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzamides; Combined Modality Therapy; Contrast Media; Electric Stimulation Therapy; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pyrrolidines; Subthalamic Nucleus; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
Research on patients was done in uncivilised way.
Topics: Confidentiality; Ethics, Research; Human Rights; Humans; Levodopa; Parkinson Disease; Patient Selection; Scientific Misconduct; Singapore | 2003 |
Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison's disease.
Topics: Addison Disease; Aged; Diagnosis, Differential; Female; Fludrocortisone; Foot Dermatoses; Hand Dermatoses; Humans; Hydrocortisone; Hyperpigmentation; Levodopa; Mouth Mucosa; Parkinson Disease; Syndrome; Vulva | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2003 |
The effects of levodopa on tongue strength and endurance in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Area Under Curve; Female; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Physical Endurance; Statistics, Nonparametric; Tongue | 2003 |
Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Reading; Speech Production Measurement; Stuttering | 2003 |
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Comorbidity; Databases, Factual; Disease Progression; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease; Prevalence; Risk Assessment; Risk Factors; Severity of Illness Index | 2003 |
[Sexual delinquency and Parkinson's disease].
Topics: Antiparkinson Agents; Awareness; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exhibitionism; Expert Testimony; Humans; Impulsive Behavior; Indoles; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Pedophilia; Sex Offenses | 2003 |
[Hallucinations in Parkinson's disease].
Topics: Antiparkinson Agents; Brain; Diagnosis, Differential; Dopamine Agonists; Hallucinations; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Risk Factors | 2003 |
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
Topics: Adolescent; Adult; Carbon Radioisotopes; Corpus Striatum; Cytoplasmic Vesicles; Dopamine; Dopamine Agents; Dystonic Disorders; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Middle Aged; Neuropeptides; Parkinson Disease; Raclopride; Tetrabenazine; Tomography, Emission-Computed; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2003 |
Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Severity of Illness Index | 2003 |
Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Electric Stimulation Therapy; Female; Frontal Lobe; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychological Tests; Psychomotor Disorders; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires; Time | 2003 |
Treatment of advanced Parkinson's disease by subthalamotomy: one-year results.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Electrocoagulation; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Posture; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires; Time | 2003 |
Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dehydration; Female; Fever; Health Status; Humans; Incidence; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Risk Factors; Substance Withdrawal Syndrome | 2003 |
Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Creatine Kinase; Female; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson's disease.
Topics: Aged; Analysis of Variance; Area Under Curve; Cerebral Cortex; Evoked Potentials, Motor; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption--a nation-wide perspective in Sweden.
Topics: Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Pharmacoepidemiology; Practice Patterns, Physicians'; Sweden | 2003 |
Sleepiness in Parkinson's disease: a controlled study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Contraindications; Disorders of Excessive Somnolence; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Stages; Surveys and Questionnaires | 2003 |
Unilateral subthalamic deep brain stimulation in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2003 |
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Polymorphism, Genetic; Psychoses, Substance-Induced; Receptors, Dopamine; Retrospective Studies | 2003 |
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2003 |
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
Topics: Adult; Blotting, Southern; Brain; Deoxyribonucleases, Type II Site-Specific; Female; Gaucher Disease; Genetic Predisposition to Disease; Glucosylceramidase; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Psychosine; Sphingosine | 2003 |
Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Reference Values; Risk Factors; Time Factors | 2003 |
Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents.
Topics: Aged; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antiparkinson Agents; Blood Coagulation Disorders; Case-Control Studies; Dopamine Agents; Drug Therapy, Combination; E-Selectin; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysin; Fibrinolysis; Humans; International Normalized Ratio; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Peptide Fragments; Prothrombin; Thrombomodulin | 2003 |
Learning networks in health and Parkinson's disease: reproducibility and treatment effects.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Mapping; Humans; Image Processing, Computer-Assisted; Learning; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Task Performance and Analysis; Tomography, Emission-Computed | 2003 |
REAL and CALM: what have we learned?
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Corpus Striatum; Disease Progression; Dopamine; Feasibility Studies; Humans; Indoles; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Putamen; Reference Values; Sensitivity and Specificity; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
[Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cabergoline; Dibenzothiazepines; Ergolines; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate | 2003 |
Association between supine hypertension and orthostatic hypotension in autonomic failure.
Topics: Aged; Autonomic Nervous System Diseases; Baroreflex; Blood Pressure; Female; Fludrocortisone; Heart; Humans; Hypertension; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Retrospective Studies; Supine Position; Sympathetic Nervous System; Vagus Nerve; Valsalva Maneuver | 2003 |
Hemiparkinson-hemiatrophy syndrome: a transcranial magnetic stimulation study.
Topics: Antiparkinson Agents; Diagnosis, Differential; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy; Parkinson Disease; Predictive Value of Tests; Syndrome; Transcranial Magnetic Stimulation | 2003 |
Gaucher's disease with Parkinson's disease: clinical and pathological aspects.
Topics: Adult; Age of Onset; Aged; Anemia; Antiparkinson Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance; Female; Gaucher Disease; Glucosylceramidase; Hepatomegaly; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Recombinant Proteins; Siblings; Splenomegaly; Thrombocytopenia; Tremor | 2003 |
Monoamine oxidase inhibitors--is it time to up the TEMPO?
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 2003 |
Rapid intravenous loading of levodopa for human research: clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Tourette Syndrome | 2003 |
Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy.
Topics: Antiparkinson Agents; Atrophy; Carbidopa; Combined Modality Therapy; Contraindications; Deglutition Disorders; Diagnosis, Differential; Dysarthria; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pons; Putamen; Subthalamic Nucleus | 2003 |
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts.
Topics: Aged; Algorithms; Antiparkinson Agents; Artifacts; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2003 |
Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index | 2003 |
How much phenotypic variation can be attributed to parkin genotype?
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Exons; Female; Genetic Variation; Genotype; Heterozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Mutation, Missense; Parkinson Disease; Phenotype; Ubiquitin-Protein Ligases | 2003 |
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Topics: Adenosine Diphosphate; Aged; Arylsulfotransferase; Biotransformation; Blood Platelets; Carbidopa; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Drug Combinations; Erythrocytes; Female; Humans; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Sulfates | 2003 |
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Benzophenones; Blood Platelets; Catechols; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Retrospective Studies; Sex Characteristics; Tolcapone; Tyrosine; Up-Regulation | 2003 |
Multiple sequential image-fusion and direct MRI localisation of the subthalamic nucleus for deep brain stimulation.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Postoperative Period; Red Nucleus; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed | 2003 |
Deep brain stimulation in Parkinson's disease: bilateral implantation of globus pallidus and subthalamic nucleus.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Electric Stimulation Therapy; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2003 |
Evidence for deficiencies in perceptual and semantic olfactory processes in Parkinson's disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Odorants; Olfaction Disorders; Parkinson Disease; Perception; Semantics; Sensory Thresholds; Smell; Task Performance and Analysis | 2003 |
[Respiratory regulation during adaptation to intermittent hypoxia in patients with Parkinson disease].
Topics: Adaptation, Physiological; Carbidopa; Dopamine Agents; Humans; Levodopa; Middle Aged; Oxygen; Parkinson Disease; Respiratory Mechanics | 2003 |
Heart rate variability and Parkinson's disease severity.
Topics: Autonomic Nervous System Diseases; Cardiovascular System; Chronobiology Disorders; Disease Progression; Female; Heart Rate; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires; Sympathetic Nervous System; Up-Regulation; Vagus Nerve | 2003 |
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine; Fingers; Humans; Image Processing, Computer-Assisted; Levodopa; Middle Aged; Movement; Parkinson Disease; Reaction Time; Synaptic Vesicles; Tetrabenazine; Tomography, Emission-Computed | 2003 |
300-Hz subthalamic oscillations in Parkinson's disease.
Topics: Adult; Aged; Basal Ganglia; Dopamine Agents; Electric Stimulation Therapy; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Parkinson Disease; Signal Processing, Computer-Assisted; Subthalamic Nucleus; Tomography, X-Ray Computed | 2003 |
Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia.
Topics: Antiparkinson Agents; Gait Ataxia; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Postural Balance; Speech Disorders; Tremor | 2003 |
Clinical criteria for the switch of treatment strategies in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Care Planning; Prognosis; Retrospective Studies; Severity of Illness Index | 2003 |
Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats.
Topics: Animals; Apoptosis; Dihydroxyphenylalanine; Drug Interactions; Drugs, Chinese Herbal; Ginkgo biloba; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Random Allocation; Rats; Rats, Wistar; Substantia Nigra | 2003 |
[Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Zonisamide | 2003 |
[Therapy for patients with early-stage Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl | 2003 |
[Diagnosis and therapy for patients with Parkinson's disease (discussion)].
Topics: Autonomic Nervous System Diseases; Disease Progression; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Life Style; Low Back Pain; Mental Disorders; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2003 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson Disease; Parkinsonian Disorders; Pharmacology; Reserpine; Toxicology | 1964 |
GPi pallidotomy for Parkinson's disease with drug-induced psychosis.
Topics: Adult; Aged; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Period; Preoperative Care; Psychoses, Substance-Induced; Regression Analysis; Retrospective Studies; Statistics, Nonparametric | 2003 |
Oral L-dopa solution therapy of menstrual-related fluctuations in Parkinson's disease.
Topics: Administration, Oral; Female; Humans; Levodopa; Menstrual Cycle; Middle Aged; Parkinson Disease; Pharmaceutical Solutions | 2003 |
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Catechols; Confidence Intervals; Drug Therapy, Combination; Female; Humans; Internationality; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2003 |
Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Biomechanical Phenomena; Combined Modality Therapy; Female; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Severity of Illness Index; Stereotaxic Techniques; Treatment Outcome | 2003 |
[Pseudopheochromocytoma in Parkinson disease and depression].
Topics: Adrenal Gland Neoplasms; Antidepressive Agents; Antiparkinson Agents; Catecholamines; Depressive Disorder; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Female; Flushing; Homovanillic Acid; Humans; Hypertension; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Chemokine CCL5; Female; Humans; Interleukin-15; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
Parkinson's disease. More than meets the eye.
Topics: Antioxidants; Antiparkinson Agents; Complementary Therapies; Diagnosis, Differential; Drug Administration Schedule; Humans; Internet; Intestinal Absorption; Levodopa; Neuroprotective Agents; Nursing Assessment; Parkinson Disease; Patient Education as Topic; United States | 2003 |
Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Sprague-Dawley | 2003 |
Emotion recognition in patients with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Attention; Case-Control Studies; Cognition Disorders; Discrimination, Psychological; Emotions; Facial Expression; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Recognition, Psychology; Visual Perception | 2003 |
[Expression and assessment of double genes of tyrosine hydroxylase gene and aromatic L-amino acid decarboxylase gene in vitro].
Topics: Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dopamine; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Parkinson Disease; RNA, Messenger; Substantia Nigra; Transfection; Tyrosine 3-Monooxygenase | 2003 |
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease.
Topics: Adult; Aged; Apoptosis; Cardiotonic Agents; Case-Control Studies; Caspase 3; Caspases; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Superoxide Dismutase | 2003 |
Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Humans; Levodopa; Longitudinal Studies; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 2003 |
Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Cross-Sectional Studies; Dopamine Agents; Drug Evaluation; Female; Humans; Language Tests; Levodopa; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parkinson Disease; Verbal Learning | 2003 |
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benserazide; Case-Control Studies; Dyskinesias; Female; Half-Life; Humans; Levodopa; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Sex Characteristics | 2003 |
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.
Topics: Antiparkinson Agents; Catechols; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Motor Activity; Neurologic Examination; Nitriles; Parkinson Disease; Prospective Studies; Time Factors | 2003 |
Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Arousal; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Polysomnography; Restless Legs Syndrome; Sleep; Sleep Apnea Syndromes | 2003 |
Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.
Topics: Catechols; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease; Time Factors | 2003 |
Modulation of striatal serotonin and opioid receptor mRNA expression following systemic N-methyl-norsalsolinol administration.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Gene Expression; Levodopa; Male; Neostriatum; Parkinson Disease; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Opioid, delta; Receptors, Opioid, mu; RNA, Messenger; Serotonin; Tetrahydroisoquinolines; Up-Regulation | 2003 |
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2003 |
Three-dimensional computerized analysis of diadochokinetic movements of Parkinsonian patients.
Topics: Adult; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Treatment Outcome; Ultrasonics | 2003 |
Body composition in advanced-stage Parkinson's disease.
Topics: Absorptiometry, Photon; Aged; Antiparkinson Agents; Body Composition; Body Mass Index; Bone Density; Female; Humans; Hydroxycholecalciferols; Levodopa; Male; Muscle, Skeletal; Parkinson Disease; Skinfold Thickness | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central Nervous System Stimulants; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agonists; Functional Laterality; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Propionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autopsy; Biomarkers; Case-Control Studies; Cerebellum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2003 |
Subthalamic stimulation influences postmovement cortical somatosensory processing in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Beta Rhythm; Brain Mapping; Electric Stimulation; Electroencephalography; Electromyography; Electronic Data Processing; Female; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Somatosensory Cortex; Subthalamic Nucleus | 2003 |
Levodopa addiction in non-parkinsonian patients.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders | 2003 |
Agonists versus levodopa in PD: the thrilla of whitha.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2003 |
Suggestive linkage to chromosome 19 in a large Cuban family with late-onset Parkinson's disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Brain; Chromosomes, Human, Pair 19; Female; Follow-Up Studies; Genetic Linkage; Haplotypes; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pedigree; Polymerase Chain Reaction; Severity of Illness Index; Tomography, X-Ray Computed | 2003 |
The art of treating Parkinson disease in the older patient.
Topics: Aged; Antiparkinson Agents; Australia; Dopamine Agonists; Dyskinesia, Drug-Induced; Family Practice; Female; Geriatrics; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Treatment Outcome | 2003 |
Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Central Nervous System; Depression; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Sleep Wake Disorders | 2003 |
Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT.
Topics: Antiparkinson Agents; Brain; Computer Simulation; Dopamine; Female; Fluorine Radioisotopes; Half-Life; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2003 |
Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Forelimb; Hyperkinesis; Levodopa; Male; Mesencephalon; Neurons; Parkinson Disease; Postoperative Complications; Rats; Rats, Inbred F344 | 2003 |
Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fatal Outcome; Female; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Tremor | 2003 |
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Binding Sites; Binding, Competitive; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Radioligand Assay; Receptors, N-Methyl-D-Aspartate | 2003 |
[Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
Topics: Antiparkinson Agents; Apomorphine; Costs and Cost Analysis; Dopamine Agonists; Drug Costs; Electric Stimulation Therapy; Health Resources; Health Surveys; Hospital Costs; Humans; Infusion Pumps; Insurance, Health, Reimbursement; Italy; Levodopa; National Health Programs; Outpatient Clinics, Hospital; Parkinson Disease | 2003 |
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes | 2003 |
Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biological Clocks; Combined Modality Therapy; Cortical Synchronization; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus | 2004 |
Involuntary expiratory phonation as a dose-related consequence of L-dopa therapy in a patient with Parkinson's disease.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Electromyography; Female; Humans; Laryngoscopy; Levodopa; Middle Aged; Parkinson Disease; Phonation; Vocal Cords | 2003 |
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Gene Expression; Levodopa; Male; Mice; Mice, Inbred C57BL; Models, Animal; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Phosphoproteins; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fyn; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions | 2004 |
[Parkinson disease therapy: how great is the progress? Possibilities, limitations and future prospects?].
Topics: Antiparkinson Agents; Dopamine Agonists; Electric Stimulation Therapy; Humans; Levodopa; Motor Activity; Parkinson Disease; Prognosis; Prostheses and Implants; Time Factors; Treatment Outcome | 2003 |
Subcortical vascular lesions predict functional recovery after rehabilitation in patients with L-dopa refractory parkinsonism.
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Comorbidity; Female; Humans; Italy; Levodopa; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Recovery of Function; Tomography, X-Ray Computed | 2004 |
The value of post-marketing medication surveys in Parkinson's disease.
Topics: Catechols; Humans; Levodopa; Nitriles; Parkinson Disease; Product Surveillance, Postmarketing | 2004 |
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Product Surveillance, Postmarketing; Quality of Life; Treatment Outcome | 2004 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Artifacts; Benzothiazoles; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Severity of Illness Index; Single-Blind Method; Thiazoles | 2004 |
Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.
Topics: Aged; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Statistics, Nonparametric | 2004 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Benzothiazoles; Biological Transport; Cell Line, Tumor; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Indoles; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuroblastoma; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
Topics: Adult; alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Biomarkers; Brain; Dopamine; Female; Humans; Levodopa; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Values; Sulfhydryl Compounds; Ubiquinone; Up-Regulation | 2004 |
Aripiprazole and Parkinson's disease psychosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Quinolones | 2004 |
Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Functional Laterality; Levodopa; Male; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2004 |
[Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa].
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Language; Levodopa; Middle Aged; Parkinson Disease; Phonation; Sound Spectrography; Speech Acoustics; Speech Disorders; Speech Production Measurement; Voice Quality | 2003 |
Ziprasidone in Parkinson's disease psychosis.
Topics: Aged; Antipsychotic Agents; Dopamine Agonists; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2004 |
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
Topics: Antiparkinson Agents; Biological Clocks; Circadian Rhythm; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Models, Statistical; Parkinson Disease; Presynaptic Terminals; Synaptic Vesicles | 2004 |
The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Hallucinations; Humans; Levodopa; Multiple Sclerosis; Oxidative Stress; Parkinson Disease; Parkinson Disease, Postencephalitic; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Vitamin B Complex | 2004 |
Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.
Topics: Aged; Antiparkinson Agents; Body Composition; Body Mass Index; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Energy Metabolism; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome; Weight Gain | 2004 |
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylation; Parkinson Disease; S-Adenosylmethionine; Vitamin B Complex | 2004 |
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neopterin; Parkinson Disease; Vitamin B Complex | 2004 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats.
Topics: Adrenergic Agents; Animals; Brain; Dizocilpine Maleate; Dopamine Agents; Drug Interactions; Gait; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2004 |
Abnormal resonance behavior of the postural control loop in Parkinson's disease.
Topics: Basal Ganglia; Biological Clocks; Combined Modality Therapy; Electric Stimulation Therapy; Feedback; Humans; Levodopa; Models, Neurological; Muscle, Skeletal; Neural Pathways; Parkinson Disease; Posture; Recovery of Function; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2004 |
Effects of subthalamic nucleus stimulation and L-dopa in trunk kinematics of patients with Parkinson's disease.
Topics: Aged; Biomechanical Phenomena; Child, Preschool; Electric Stimulation Therapy; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Walking | 2004 |
Subthalamic stimulation in Parkinson disease: with or without anesthesia?
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disability Evaluation; Dose-Response Relationship, Radiation; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Statistics, Nonparametric; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2004 |
Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Female; Humans; Inactivation, Metabolic; Isoquinolines; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Reference Values; Salsoline Alkaloids | 2004 |
Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs.
Topics: Analysis of Variance; Antiparkinson Agents; Apoptosis; Biomarkers; Caspase 3; Caspases; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Reference Values; Superoxide Dismutase | 2003 |
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Topics: Aged; Autoradiography; Brain Chemistry; Case-Control Studies; Dopamine; Dyskinesias; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2004 |
Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report.
Topics: Antiparkinson Agents; Basal Ganglia; Brain Stem; Cerebellum; Diagnosis, Differential; Electric Stimulation Therapy; Fatal Outcome; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Substantia Nigra; Subthalamic Nucleus | 2004 |
The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.
Topics: Adult; Aged; Area Under Curve; Dietary Proteins; Female; Food-Drug Interactions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Statistics, Nonparametric | 2004 |
A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.
Topics: Administration, Inhalation; Animals; Chemistry, Pharmaceutical; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2004 |
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Forelimb; Image Processing, Computer-Assisted; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Striatonigral Degeneration | 2004 |
Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.
Topics: Aged; Cognition Disorders; Dopamine; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neuropsychological Tests; Obsessive-Compulsive Disorder; Occupations; Parkinson Disease; Stereotyped Behavior; Videotape Recording | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Benzylamines; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Locus Coeruleus; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Statistics, Nonparametric; Tyrosine | 2004 |
[Consensus regarding indications for surgical treatment of Parkinson disease].
Topics: Antiparkinson Agents; Brain; Combined Modality Therapy; Consensus; Humans; Levodopa; Magnetic Resonance Imaging; Neurosurgical Procedures; Parkinson Disease | 2003 |
[Wearing off phenomenon presenting with features of paroxysmal abdominal pain].
Topics: Abdominal Pain; Aged; Antiparkinson Agents; Female; Gastrointestinal Motility; Humans; Levodopa; Parkinson Disease; Wasting Syndrome; Weight Loss | 2003 |
[Evaluation of quality of life in Parkinson disease treatment].
Topics: Antiparkinson Agents; Brain; Combined Modality Therapy; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Thalamus | 2003 |
[Malignant dopaminergic syndrome].
Topics: Aged; Dopamine Agents; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
L-dopa-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
Topics: Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nocturnal Myoclonus Syndrome; Parkinson Disease; Predictive Value of Tests; Sleep Apnea, Obstructive | 2004 |
Drug adherence in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chronic Disease; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; Humans; Levodopa; Male; Medication Systems; Parkinson Disease; Patient Compliance; Surveys and Questionnaires | 2004 |
Grip force abnormalities in de novo Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2004 |
Do on-off variations cause discrepancies in the historical items of the UPDRS?
Topics: Activities of Daily Living; Antiparkinson Agents; Cannabis; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Phytotherapy | 2004 |
Stalevo for Parkinson's disease.
Topics: Carbidopa; Catechols; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Nausea; Nitriles; Parkinson Disease | 2004 |
Levodopa elevates homocysteine: is this a problem?
Topics: Antiparkinson Agents; Brain; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; S-Adenosylmethionine | 2004 |
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Chromatography, High Pressure Liquid; Electrophysiology; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Conduction; Parkinson Disease; Sural Nerve | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Models, Animal; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Synaptic Transmission | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
Preoperative response to levodopa is the best predictor of transplant outcome.
Topics: Adult; Aged; Clinical Trials as Topic; Dopamine Agents; Double-Blind Method; Humans; Levodopa; Middle Aged; Parkinson Disease; Predictive Value of Tests; Preoperative Care; Transplantation; Treatment Outcome | 2004 |
[Treatment in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Mice; Nerve Net; Neuronal Plasticity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Triazoles | 2004 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
Quality of life in Polish patients with long-lasting Parkinson's disease.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Depressive Disorder, Major; Dopamine Agents; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Poland; Quality of Life; Regression Analysis; Socioeconomic Factors; Surveys and Questionnaires; Time Factors | 2004 |
Cabergoline versus levodopa monotherapy.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 2004 |
Re: Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Surveys and Questionnaires | 2004 |
Role of entacapone in later Parkinson's disease not yet established.
Topics: Antiparkinson Agents; Catechols; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
Stem cell savior.
Topics: Animals; Cell Survival; Levodopa; Mice; Neurons; Parkinson Disease; Stem Cell Transplantation; Stem Cells | 2004 |
Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dose-Response Relationship, Drug; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Self Medication | 2004 |
[Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cataract Extraction; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Remission Induction; Risperidone; Visual Perception | 2004 |
Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2004 |
L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 2004 |
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechols; Disability Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2004 |
Assessing comorbidity in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition Disorders; Comorbidity; Disability Evaluation; Gastrointestinal Diseases; Humans; Levodopa; Male; Male Urogenital Diseases; Neuropsychological Tests; Parkinson Disease; Primary Health Care; Surveys and Questionnaires | 2004 |
The patient with Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2004 |
Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.
Topics: Aged; Antiparkinson Agents; Electromyography; Female; Humans; Levodopa; Male; Myoelectric Complex, Migrating; Parkinson Disease; Stomach | 2004 |
Bilateral subthalamic nucleus stimulation results in reversal of alopecia in Parkinson's disease.
Topics: Aged; Alopecia; Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Hair; Humans; Levodopa; Male; Parkinson Disease; Subthalamic Nucleus | 2004 |
Parkinson's disease and thyroid dysfunction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Hypothyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Sex Distribution; Thyrotropin | 2004 |
Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report.
Topics: Antiparkinson Agents; Device Removal; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Equipment Design; Female; Humans; Leg; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Parkinson Disease; Remission Induction; Subthalamic Nucleus | 2004 |
[A differentiated approach to Parkinson's disease treatment in early stage of the disease].
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; International Classification of Diseases; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 2004 |
PET studies and physiopathology of motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Movement; Parkinson Disease; Tetrabenazine; Tomography, Emission-Computed | 2004 |
L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.
Topics: Aged; Aged, 80 and over; Dementia; Dopamine Agonists; Female; Humans; Levodopa; Lewy Body Disease; Male; Parkinson Disease; Predictive Value of Tests; Prospective Studies | 2004 |
Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Female; GTP-Binding Protein alpha Subunits; Humans; Levodopa; Male; Middle Aged; Oxidopamine; Parkinson Disease; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Sympatholytics | 2004 |
Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report.
Topics: Antiparkinson Agents; Benzamides; Dopamine Antagonists; Electric Stimulation Therapy; Follow-Up Studies; Humans; Immunohistochemistry; Levodopa; Male; Middle Aged; Multiple System Atrophy; Nerve Tissue Proteins; Neurons; Parkinson Disease; Pyrrolidines; Retrospective Studies; Staining and Labeling; Subthalamic Nucleus; Synucleins; Tomography, Emission-Computed, Single-Photon | 2004 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Consciousness Disorders; Dantrolene; Deep Brain Stimulation; Diagnosis, Differential; Diagnostic Errors; Dystonic Disorders; Encephalitis; Female; Fluid Therapy; Foot; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Muscle Relaxants, Central; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tachycardia | 2004 |
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus | 2004 |
Case study: cerebrovascular parkinsonism with levodopa addiction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Female; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Caudate Nucleus; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Synapses | 2004 |
Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Drug Administration Schedule; Excitatory Amino Acid Transporter 2; Extracellular Fluid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
[Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease].
Topics: Aged; Amino Acids; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2004 |
Biceps pain as the presenting symptom of Parkinson disease: effective treatment with L-dopa.
Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Levodopa; Muscle, Skeletal; Parkinson Disease; Shoulder Pain | 2004 |
MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Cytosine; Female; Folic Acid; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Tetrahydrofolates; Thymine | 2004 |
Simple movement sequences better correlate to levodopa plasma levels than complex ones.
Topics: Adult; Aged; Analysis of Variance; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric | 2004 |
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Polymorphism, Genetic; Retrospective Studies | 2004 |
Hypothyroidism and Parkinson's disease.
Topics: Antiparkinson Agents; Drug Resistance; Humans; Hypothyroidism; Levodopa; Parkinson Disease; Prevalence | 2004 |
Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications.
Topics: Aged; Alleles; Antiparkinson Agents; Ataxins; Caudate Nucleus; DNA Mutational Analysis; Dominance, Cerebral; Genetic Carrier Screening; Genetic Testing; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neurologic Examination; Parkinson Disease; Polymerase Chain Reaction; Positron-Emission Tomography; Proteins; Putamen; Spinocerebellar Ataxias; Treatment Outcome; Trinucleotide Repeats; Ubiquitin-Protein Ligases | 2004 |
Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Alpha Rhythm; Antiparkinson Agents; Apomorphine; Beta Rhythm; Biological Clocks; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Neurons; Orphenadrine; Parkinson Disease; Periodicity; Subthalamic Nucleus | 2004 |
Impact of the motor complications of Parkinson's disease on the quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Health Status Indicators; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2005 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Ten-Hertz stimulation of subthalamic nucleus deteriorates motor symptoms in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dominance, Cerebral; Drug Therapy, Combination; Electric Conductivity; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nerve Net; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Surgery, Computer-Assisted; Treatment Failure; Tremor | 2004 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Male; Parkinson Disease; Pedigree; Phenotype; Point Mutation | 2004 |
Salivary production in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Salivation; Secretory Rate; Sex Factors; Xerostomia | 2005 |
Predictors of sudden onset of sleep in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Comorbidity; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pramipexole; Risk Factors; Surveys and Questionnaires; Thiazoles | 2004 |
L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings.
Topics: Adult; Antiparkinson Agents; Benzamides; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Phenylketonurias; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tropanes | 2004 |
Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Folic Acid; Humans; Hyperhomocysteinemia; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Vitamin B 12 | 2004 |
Neuronal activity in the globus pallidus of multiple system atrophy patients.
Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Multiple System Atrophy; Neurosurgical Procedures; Parkinson Disease | 2004 |
Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum.
Topics: Adolescent; Antiparkinson Agents; Benztropine; Cognition Disorders; Corpus Callosum; Electroencephalography; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Weakness; Neuropsychological Tests; Parkinson Disease; Selegiline; Spastic Paraplegia, Hereditary; Tremor | 2004 |
Superficial siderosis of the central nervous system associated with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Central Nervous System Diseases; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Siderosis | 2004 |
The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease.
Topics: Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2005 |
[Freezing of gait is a symptom of Parkinson disease].
Topics: Antiparkinson Agents; Attention; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Physical Therapy Modalities; Psychomotor Performance; Space Perception; Time Factors | 2004 |
Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Topics: Animals; Dose-Response Relationship, Drug; Levodopa; Male; Mitochondria; Mucuna; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phytotherapy; Plant Components, Aerial; Random Allocation; Rats; Rats, Sprague-Dawley | 2004 |
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Dementia; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; United Kingdom | 2004 |
Session 3 "Analyzer Workshop" evolution of therapeutic strategies in Parkinson's disease.
Topics: Antiparkinson Agents; Diagnosis, Differential; Guideline Adherence; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2004 |
Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Motor Cortex; Motor Skills; Parkinson Disease | 2004 |
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Statistics, Nonparametric; Time Factors | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
Association of aspirin with eosinophilia in peripheral blood.
Topics: Aged; Antiparkinson Agents; Aspirin; Eosinophilia; Humans; Levodopa; Male; Parkinson Disease; Platelet Aggregation Inhibitors; Stroke | 2004 |
Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Drug Costs; Electrodes, Implanted; Enzyme Inhibitors; Humans; Levodopa; Models, Economic; Neurosurgical Procedures; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2004 |
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Dementia; Disease Progression; Dose-Response Relationship, Drug; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Mortality; Movement Disorders; Multicenter Studies as Topic; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Time Factors | 2005 |
Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Assessment; Treatment Outcome | 2004 |
Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study.
Topics: Adult; Aged; Comorbidity; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Statistics, Nonparametric; Substance-Related Disorders | 2004 |
[Influence of levodopa on cognition of idiopathic Parkinson's disease].
Topics: Antiparkinson Agents; Cognition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2004 |
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2005 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Analysis of the course of Parkinson's disease under dopaminergic therapy: performance of "fast tapping" is not a suitable parameter.
Topics: Bromocriptine; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Fructose; Levodopa; MPTP Poisoning; Parkinson Disease; Topiramate | 2005 |
Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Female; Follow-Up Studies; Humans; Levodopa; Male; Motor Activity; Movement Disorders; Nausea; Parkinson Disease; Smell; Weight Loss | 2005 |
Autosomal recessive juvenile Parkinson's disease with partial trisomy of chromosome 6q syndrome: a case report.
Topics: Adult; Antiparkinson Agents; Chromosome Disorders; Chromosomes, Human, Pair 6; Humans; Levodopa; Male; Parkinson Disease; Trisomy | 2004 |
Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.
Topics: Affect; Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease | 2005 |
Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Restless Legs Syndrome; Subthalamic Nucleus | 2004 |
Swallowing abnormalities and dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Deglutition Disorders; Dyskinesia, Drug-Induced; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Oropharynx; Parkinson Disease; Severity of Illness Index; Videotape Recording | 2005 |
Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Dyskinesias; Globus Pallidus; Hypertrophy; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2004 |
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Topics: Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Likelihood Functions; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Selegiline; Survival Analysis; Time; Tocopherols | 2005 |
[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Topics: Adult; Antiparkinson Agents; Brain; Carbidopa; Drug Combinations; Female; Fluorodeoxyglucose F18; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Manganese Poisoning; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine | 2005 |
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Topics: Animals; Corpus Striatum; Dependovirus; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2005 |
Should levodopa be infused into the duodenum?
Topics: Administration, Oral; Antiparkinson Agents; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Gels; Humans; Intubation; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Single-Blind Method; Surveys and Questionnaires; Suspensions | 2005 |
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cognition; Combined Modality Therapy; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Postoperative Complications; Radiosurgery; Subthalamic Nucleus; Treatment Outcome | 2005 |
[Cognitive dysfunction in patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dementia; Dopamine Agonists; Female; Frontal Lobe; Functional Laterality; Hippocampus; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index | 2005 |
Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Fees, Pharmaceutical; Humans; Levodopa; Parkinson Disease | 2005 |
Effects of disease progression and L-dopa therapy on the control of reaching-grasping in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Biomechanical Phenomena; Case-Control Studies; Disease Progression; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Task Performance and Analysis | 2005 |
L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells.
Topics: alpha-Methyltyrosine; Animals; Cathepsin B; Cell Survival; Dopamine; Leupeptins; Levodopa; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Tyrosine 3-Monooxygenase; Ubiquitin | 2005 |
Vascular parkinsonism--an important update.
Topics: Antiparkinson Agents; Diagnosis, Differential; Diagnostic Imaging; Humans; Intracranial Arteriosclerosis; Levodopa; Neurologic Examination; Neuropsychological Tests; Olfaction Disorders; Parkinson Disease; Parkinson Disease, Secondary; Sensitivity and Specificity | 2005 |
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Topics: Activities of Daily Living; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Communication; Decision Making; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Patient Participation; Patient Satisfaction; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2005 |
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Cognition; Cognition Disorders; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2005 |
"Off" gait freezing and temporal discrimination threshold in patients with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perceptual Disorders; Posture; Reflex, Abnormal; Sensory Thresholds; Somatosensory Disorders; Time Perception; Toes; Touch | 2005 |
Current controversies: levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2005 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
Improving quality of life in early Parkinson's.
Topics: Aged; Antiparkinson Agents; Catechols; Drug Synergism; Humans; Levodopa; Nitriles; Parkinson Disease; Quality of Life | 2005 |
Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Ubiquinone | 2005 |
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Speech Acoustics; Time Factors | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein.
Topics: Age Factors; Aged; alpha-Synuclein; DNA Primers; Fatal Outcome; Humans; Levodopa; Male; Nerve Tissue Proteins; Parkinson Disease; Periodicity; Point Mutation; Polymerase Chain Reaction; Synucleins | 2005 |
Cortico-cortical coupling in Parkinson's disease and its modulation by therapy.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Cortical Synchronization; Deep Brain Stimulation; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2005 |
Treatment for the progression of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Research Design | 2005 |
Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Electrophoresis, Capillary; Female; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Neuroimmunomodulation; Parkinson Disease; Up-Regulation | 2005 |
The metabolic pathology of dopa-responsive dystonia.
Topics: Adult; Brain; Brain Mapping; Dystonia; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography | 2005 |
Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease.
Topics: Antiparkinson Agents; Blood Glucose; Blood Proteins; Electric Stimulation; Energy Intake; Energy Metabolism; Fasting; Female; Glucose; Humans; Levodopa; Lipids; Male; Middle Aged; Oxidation-Reduction; Parkinson Disease; Subthalamic Nucleus; Weight Gain | 2005 |
Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy.
Topics: Adult; Aged; Antiparkinson Agents; Comorbidity; Cross-Sectional Studies; Drug Prescriptions; Electric Stimulation Therapy; Female; Health Services; Hospitalization; Humans; Italy; Levodopa; Male; Middle Aged; Neurology; Office Visits; Parkinson Disease; Patient Care Team; Utilization Review | 2005 |
Pramipexole, ropinirole, and mania in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Bipolar Disorder; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2005 |
Levodopa and the progression of Parkinson's disease.
Topics: Antiparkinson Agents; Half-Life; Humans; Levodopa; Limbic System; Motor Activity; Parkinson Disease | 2005 |
Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12 | 2005 |
Walking while talking: a dopamine-responsive task in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Monitoring; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease | 2005 |
Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biomechanical Phenomena; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 2005 |
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Predictive Value of Tests; Risk Factors | 2005 |
Acute akinesia in Parkinson disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Akinetic Mutism; Apomorphine; Body Temperature; Cohort Studies; Comorbidity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Resistance; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Mortality; Neuroleptic Malignant Syndrome; Parkinson Disease; Prospective Studies; Recovery of Function; Treatment Failure | 2005 |
Electrogastrography in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Electrophysiology; Female; Gastrointestinal Motility; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
Acoustic voice assessment in Parkinson's disease patients submitted to posteroventral pallidotomy.
Topics: Aged; Antiparkinson Agents; Dysarthria; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech Acoustics; Treatment Outcome; Voice Disorders; Voice Quality | 2005 |
Factors associated with drug-induced visual hallucinations in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Female; Greece; Hallucinations; Humans; Interviews as Topic; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Prevalence; Psychoses, Substance-Induced; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Visual Acuity | 2005 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Synergism; Levodopa; Male; Molecular Structure; Parkinson Disease; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Tritium | 2005 |
[Use of tremonorm in treatment of Parkinson's disease: outpatient experience of Moscow Municipal Health Care Service].
Topics: Carbidopa; Data Interpretation, Statistical; Drug Combinations; Dyspepsia; Humans; Levodopa; Mental Status Schedule; Moscow; Outpatients; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2004 |
Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Arm; Disability Evaluation; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Spectrum Analysis | 2005 |
Clinical features of LRRK2-associated Parkinson's disease in central Norway.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Heterozygote; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Muscle Rigidity; Mutation; Norway; Parkinson Disease; Pedigree; Protein Serine-Threonine Kinases; Tremor | 2005 |
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; France; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2005 |
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Levodopa; Male; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Phenylacetates; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Sympatholytics; Tritium | 2005 |
Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Clonazepam; Dyskinesias; Female; GABA Modulators; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Severity of Illness Index | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dynorphins; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Parkinson Disease; Rats; Rats, Wistar; Serotonin Receptor Agonists | 2005 |
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Antagonists; Dynorphins; Enkephalins; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Levodopa; Male; Neurons; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Steroid; RNA, Messenger; Transcription Factors; Tyrosine 3-Monooxygenase | 2005 |
Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
Topics: Antiparkinson Agents; Deep Brain Stimulation; Extinction, Psychological; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Motivation; Neurosurgical Procedures; Parkinson Disease; Reward; Severity of Illness Index; Subthalamic Nucleus | 2005 |
Parkinsonian action tremor: interference with object manipulation and lacking levodopa response.
Topics: Adult; Aged; Dopamine Agents; Female; Hand; Hand Strength; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Skills; Movement; Parkinson Disease; Tremor; Weight-Bearing | 2005 |
Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome.
Topics: Antiparkinson Agents; Dopamine Agents; Drug Administration Schedule; Electroconvulsive Therapy; Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Psychoses, Substance-Induced | 2005 |
Association between family history of dementia and hallucinations in Parkinson disease.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Cross-Sectional Studies; Dementia; DNA Mutational Analysis; Female; Genetic Testing; Hallucinations; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prevalence; Risk Factors; Surveys and Questionnaires; Ubiquitin-Protein Ligases | 2005 |
Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats.
Topics: Animals; Behavior, Animal; Cell Differentiation; Female; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2005 |
Obesity in Parkinson's disease patients on electrotherapy: collateral damage, adiposity rebound or secular trends?
Topics: Antiparkinson Agents; Body Mass Index; Brain; Combined Modality Therapy; Dopamine; Electric Stimulation Therapy; Humans; Levodopa; Malnutrition; Obesity; Parkinson Disease; Receptors, Dopamine D2; Subthalamic Nucleus | 2005 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam | 2005 |
Normalization of voice in spasmodic dysphonia during transient global amnesia.
Topics: Aged; Amnesia, Transient Global; Antiparkinson Agents; Female; Humans; Levodopa; Parkinson Disease; Pergolide; Speech Therapy; Voice Disorders; Voice Training | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piracetam | 2005 |
The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease.
Topics: Age of Onset; Brain; Diagnosis, Differential; Dopamine Agents; Energy Metabolism; Genetic Predisposition to Disease; Humans; Italy; Levodopa; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Mutation; Parkinson Disease; Parkinsonian Disorders; Phenotype; Protein Kinases; Shy-Drager Syndrome; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
[Diagnosis and therapy of Parkinson's disease].
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agents; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 2005 |
[Two phases of the contingent negative variation in humans: connection with motor and mental functions].
Topics: Aged; Antiparkinson Agents; Contingent Negative Variation; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Thinking | 2005 |
[L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
Topics: Antiparkinson Agents; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Treatment Outcome | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Physiological recordings from electrodes implanted in the basal ganglia for deep brain stimulation in Parkinson's disease. the relevance of fast subthalamic rhythms.
Topics: Basal Ganglia; Biological Clocks; Brain Mapping; Deep Brain Stimulation; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2005 |
Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators.
Topics: Antiparkinson Agents; Antipsychotic Agents; Deep Brain Stimulation; Depressive Disorder, Major; Dibenzothiazepines; Electroconvulsive Therapy; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Quetiapine Fumarate; Subthalamic Nucleus | 2005 |
Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation.
Topics: Biomechanical Phenomena; Brain; Deep Brain Stimulation; Disability Evaluation; Dopamine Agonists; Electrodes, Implanted; Electromyography; Fingers; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Periodicity; Postoperative Care; Preoperative Care; Severity of Illness Index; Surveys and Questionnaires; User-Computer Interface | 2005 |
Throat clicking as the initial symptom of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Male; Myoclonus; Palate, Soft; Parkinson Disease; Tongue; Tremor; Voice | 2005 |
Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
Topics: Aged; Antiparkinson Agents; Confusion; Dantrolene; Deep Brain Stimulation; Dehydration; Dopamine Agents; Drug Monitoring; Electrolytes; Fever; Humans; Leukocyte Count; Levodopa; Magnetic Resonance Imaging; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Nurse's Role; Nursing Assessment; Parkinson Disease; Physical Examination; Substance Withdrawal Syndrome; Time Factors; Urinalysis | 2005 |
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Child; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; United Kingdom | 2005 |
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Topics: Adrenergic Agents; Animals; Behavior, Animal; Chlorobenzenes; Cyclobutanes; Disease Models, Animal; Dopamine Agents; Drug Interactions; Levodopa; Male; Models, Biological; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotarod Performance Test; Rotation; Stereotyped Behavior; Time Factors | 2006 |
Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease.
Topics: Action Potentials; Antiparkinson Agents; Arm; Biological Clocks; Dyskinesia, Drug-Induced; Electromyography; Female; Globus Pallidus; Humans; Levodopa; Middle Aged; Muscle, Skeletal; Neurons; Parkinson Disease | 2005 |
The first evaluation of brain shift during functional neurosurgery by deformation field analysis.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Gait; Humans; Imaging, Three-Dimensional; Intraoperative Care; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Movement Disorders; Neurosurgical Procedures; Parkinson Disease; Psychoses, Substance-Induced; Radiosurgery; Subthalamic Nucleus | 2005 |
Inhibition of dopamine biosynthesis by tetrahydropapaveroline.
Topics: Adrenal Medulla; Animals; Antioxidants; Cattle; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Levodopa; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; PC12 Cells; Rats; Tetrahydropapaveroline; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Reciprocal interactions between oscillatory activities of different frequencies in the subthalamic region of patients with Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Biological Clocks; Dopamine Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus | 2005 |
Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Cholinesterase Inhibitors; Dementia; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Lewy Body Disease; Longitudinal Studies; Male; Motor Activity; Parkinson Disease; Psychological Tests; Tomography, Emission-Computed, Single-Photon | 2005 |
[Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Intubation, Gastrointestinal; Levodopa; Parkinson Disease | 2005 |
Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; E-Selectin; Endothelium, Vascular; Fasting; Female; Homocysteine; Humans; Hyperhomocysteinemia; Intercellular Adhesion Molecule-1; Levodopa; Male; Middle Aged; Nitric Oxide; Parkinson Disease; Superoxide Dismutase | 2005 |
Distributed neural actions of anti-parkinsonian therapies as revealed by PET.
Topics: Aged; Antiparkinson Agents; Brain; Cohort Studies; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Positron-Emission Tomography | 2006 |
Daytime sleep latency in medication-matched Parkinsonian patients with and without sudden onset of sleep.
Topics: Aged; Case-Control Studies; Chi-Square Distribution; Disorders of Excessive Somnolence; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Sleep Stages | 2005 |
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Topics: Adult; Age Factors; Aged; Brain; Carbon Radioisotopes; Carboxy-Lyases; Case-Control Studies; Dopamine Plasma Membrane Transport Proteins; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Methylphenidate; Middle Aged; Mutation; Parkinson Disease; Phenotype; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Receptors, Dopamine D2; Regression Analysis; Tetrabenazine | 2005 |
Reminiscences on stereotactic neurosurgery.
Topics: History, 21st Century; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2005 |
Factitious disorder mimicking addiction to levodopa in a patient with advanced Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Diagnosis, Dual (Psychiatry); Factitious Disorders; Female; Humans; Levodopa; Panic Disorder; Parkinson Disease; Self Medication | 2005 |
Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.
Topics: Adult; Amino Acid Substitution; Antiparkinson Agents; Cognition; Disease Progression; Functional Laterality; Haplotypes; Humans; Ireland; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Neuropsychological Tests; Parkinson Disease; Protein Serine-Threonine Kinases | 2005 |
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Catechols; Databases, Factual; Dopamine Agonists; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Multiple System Atrophy; Nitriles; Parkinson Disease; Pramipexole; Sexual Dysfunctions, Psychological; Thiazoles | 2005 |
Delirium in Parkinson's disease patients. a five-year follow-up study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Delirium; Dementia; Female; Follow-Up Studies; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Regression Analysis; Risk Factors; Survival Analysis | 2005 |
[Clinical analysis of 15 cases of Dopa-responsive dystonia].
Topics: Adolescent; Adult; Child; Child, Preschool; Diagnosis, Differential; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2004 |
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease.
Topics: Ankle Joint; Antiparkinson Agents; Biomechanical Phenomena; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Electromyography; Humans; Hypokinesia; Isometric Contraction; Levodopa; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Reference Values; Signal Processing, Computer-Assisted; Statistics as Topic; Torque; Treatment Outcome; Tremor | 2006 |
Ambulatory motor assessment in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Algorithms; Antiparkinson Agents; Female; Humans; Hypokinesia; Levodopa; Male; Mathematical Computing; Middle Aged; Monitoring, Ambulatory; Neurologic Examination; Parkinson Disease; Reproducibility of Results; Signal Processing, Computer-Assisted; Tremor; Videotape Recording | 2006 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
L-dopa impairs learning, but spares generalization, in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Discrimination, Psychological; Female; Generalization, Psychological; Humans; Learning; Learning Disabilities; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2006 |
Gender and the Parkinson's disease phenotype.
Topics: Activities of Daily Living; Age of Onset; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cohort Studies; Databases, Factual; Depression; Female; Functional Laterality; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Phenotype; Retrospective Studies; Sex Factors; Time Factors; Tremor | 2005 |
Does subthalamic nucleus stimulation affect the frontal limbic areas? A single-photon emission computed tomography study using a manual anatomical segmentation method.
Topics: Antiparkinson Agents; Cerebrovascular Circulation; Cognition; Deep Brain Stimulation; Female; Frontal Lobe; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Levodopa; Limbic System; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Prefrontal Cortex; Prospective Studies; Subthalamic Nucleus; Tomography, Emission-Computed, Single-Photon | 2005 |
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
Topics: Age Factors; Aged; Antiparkinson Agents; Cerebral Cortex; Drug Therapy, Combination; Female; Hallucinations; Humans; Interview, Psychological; Levodopa; Longitudinal Studies; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Risk Factors | 2006 |
Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cerebral Cortex; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Dystonia Musculorum Deformans; Female; Humans; Levodopa; Parkinson Disease; Syndrome; Tomography, Emission-Computed, Single-Photon | 2006 |
Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Estrogen Receptor alpha; Estrogen Receptor Modulators; Genetic Therapy; Genetic Vectors; Humans; Integrases; Levodopa; Male; Mice; Neurons; Parkinson Disease; Rats; Rats, Wistar; Recombination, Genetic; Stereotyped Behavior; Tamoxifen; Tyrosine 3-Monooxygenase; Viral Proteins | 2006 |
Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Topics: Aged; Case-Control Studies; Cognition Disorders; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
Epidemiological assessment of levodopa use in Cuba: 1993-1998.
Topics: Cuba; Drug Utilization; Humans; Levodopa; Parkinson Disease; Time Factors | 2006 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2006 |
[Continuous treatment with levodopa of Parkinson disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Humans; Infusion Pumps; Levodopa; Middle Aged; Parkinson Disease | 2005 |
Pallidal vs subthalamic deep brain stimulation for Parkinson disease: winner and loser or a sharing of honors?
Topics: Antiparkinson Agents; Deep Brain Stimulation; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2005 |
Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Blood Circulation; Female; Heart; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Reflex; Sympathetic Nervous System; Vagus Nerve; Valsalva Maneuver | 2005 |
Punding in Parkinson's disease related to high-dose levodopa therapy.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Motor Activity; Parkinson Disease; Stereotyped Behavior | 2005 |
Extradural motor cortex stimulation in advanced Parkinson's disease: the Turin experience: technical case report.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Dose-Response Relationship, Radiation; Dura Mater; Electrodes, Implanted; Female; Humans; Italy; Levodopa; Male; Motor Cortex; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2005 |
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Degeneration; Nociceptin; Opioid Peptides; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synaptic Transmission | 2005 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; Humans; Japan; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Time Factors | 2005 |
Augmentation of artistic productivity in Parkinson's disease.
Topics: Antiparkinson Agents; Art; Carbidopa; Creativity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Frontal Lobe; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Poetry as Topic | 2006 |
Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Aphakia; Autoradiography; Biomarkers; Homeodomain Proteins; In Situ Hybridization; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Neostriatum; Neuropeptides; Parkinson Disease; Phenotype; Receptors, Dopamine; Receptors, Dopamine D2; Transcription Factors | 2006 |
Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Cells, Cultured; Data Interpretation, Statistical; Dopamine; Female; Fibroblasts; Forelimb; Genetic Therapy; Levodopa; Medial Forebrain Bundle; Microscopy, Immunoelectron; Parkinson Disease; Rats; Rats, Inbred F344; Subcellular Fractions; Vesicular Monoamine Transport Proteins | 2006 |
Identification of distinct characteristics of postural sway in Parkinson's disease: a feature selection procedure based on principal component analysis.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Posture; Pressure; Principal Component Analysis; Proprioception; Psychomotor Performance | 2006 |
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Homocysteine; Humans; Hyperhomocysteinemia; Immobilization; Incidence; Japan; Levodopa; Osteoporosis; Parkinson Disease; Proportional Hazards Models; Risk Factors | 2005 |
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Peptides; Brain; Causality; Cerebral Amyloid Angiopathy; Cognition Disorders; Creatinine; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Predictive Value of Tests; Vitamin B 12 | 2005 |
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Topics: Akinetic Mutism; Antiparkinson Agents; Chronobiology Disorders; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Duodenum; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Sleep Wake Disorders; Time; Time Factors; Treatment Outcome | 2005 |
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Levodopa addiction in idiopathic Parkinson disease.
Topics: Aged; Bipolar Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quadriplegia; Spinal Cord Diseases; Substance-Related Disorders | 2005 |
[The role of dopaminagonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 2005 |
Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
Topics: Animals; Antiparkinson Agents; Dopamine; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Parkinson Disease; Pregnancy; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2005 |
Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus.
Topics: Activities of Daily Living; Adult; Aged; Analysis of Variance; Antiparkinson Agents; Body Weight; Deep Brain Stimulation; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2006 |
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2005 |
LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Female; Gene Frequency; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Spain | 2006 |
Side-effects of L-dopa on venous tone in Parkinson's disease: a leg-weighing assessment.
Topics: Adult; Aged; Antiparkinson Agents; Blood Pressure; Cardiac Output; Dopamine Agents; Epinephrine; Female; Heart Rate; Humans; Leg; Levodopa; Male; Middle Aged; Norepinephrine; Organ Size; Parkinson Disease; Plethysmography; Posture; Reproducibility of Results; Tilt-Table Test | 2006 |
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dopa Decarboxylase; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Levodopa; Longitudinal Studies; Male; Middle Aged; Models, Biological; Parkinson Disease | 2005 |
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Depression; Dyskinesias; Europe; Female; Health Care Costs; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Female; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reproducibility of Results; Sympatholytics | 2005 |
Evolution of postural stability after subthalamic nucleus stimulation in Parkinson's disease: a combined clinical and posturometric study.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Muscle, Skeletal; Neural Pathways; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Postural Balance; Subthalamic Nucleus; Treatment Outcome | 2006 |
[Modern aproaches to the treatment of early stages of Parkinson disease].
Topics: Adult; Aged; Amantadine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Piribedil; Severity of Illness Index | 2005 |
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
Topics: Adult; Age of Onset; Brain; Dopamine; Ethnicity; Female; Genetic Carrier Screening; Genetic Predisposition to Disease; Heterozygote; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Tremor; Ubiquitin-Protein Ligases | 2005 |
Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Topics: Aged; Caudate Nucleus; Corpus Striatum; Deep Brain Stimulation; Dopamine; Dopamine Agents; Dopamine Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Raclopride; Severity of Illness Index; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2005 |
Hallucinations in Parkinson disease in the prelevodopa era.
Topics: Affective Symptoms; Brain; Dementia; Dopamine; Dopamine Agents; Hallucinations; History, 19th Century; History, 20th Century; Humans; Levodopa; Neurology; Parkinson Disease; Psychotic Disorders | 2006 |
Prevalence of bladder dysfunction in Parkinsons disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Denmark; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prostatic Diseases; Regression Analysis; Surveys and Questionnaires; Urinary Bladder Diseases; Urodynamics | 2006 |
Bromocriptine in traumatic brain injury.
Topics: Brain Injuries; Bromocriptine; Cognition; Dopamine Agonists; Head Injuries, Closed; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2006 |
Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dominance, Cerebral; Dyskinesias; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Postoperative Complications; Subthalamic Nucleus; Treatment Outcome | 2006 |
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine; Receptors, Opioid, mu; Risk; Smoking | 2006 |
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity | 2006 |
[Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Area Under Curve; Domperidone; Dopamine Antagonists; Drug Interactions; Humans; Individuality; Levodopa; Parkinson Disease | 2005 |
Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Hallucinations; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Regression Analysis; Risk Factors; Statistics as Topic; Vision Tests; Visual Acuity | 2006 |
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Paraphilic Disorders; Parkinson Disease; Pedophilia; Pergolide | 2006 |
Proximal myotonic dystrophy associated with parkinsonism.
Topics: Adult; Antiparkinson Agents; Atrophy; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Muscle Weakness; Myotonic Disorders; Parkinson Disease; Tomography, X-Ray Computed | 2006 |
Hereditary spastic paraplegia associated with dopa-responsive parkinsonism.
Topics: Antiparkinson Agents; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Spastic Paraplegia, Hereditary | 2006 |
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2006 |
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 2006 |
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Minnesota; Parkinson Disease; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index | 2006 |
Impulse control disorders and dopaminergic drugs.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease | 2006 |
Gambling and Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Gambling; Humans; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Thiazoles | 2006 |
Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database.
Topics: Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Databases, Factual; Gambling; Humans; Levodopa; Parkinson Disease; Reproducibility of Results; United States; United States Food and Drug Administration | 2006 |
Orthostatic hypotension as an early finding in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Diagnosis, Differential; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Parkinson Disease; Time Factors | 2006 |
[Role of the cerebellum in the control of distal motor activities in patients with akinetic-rigid Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Case-Control Studies; Cerebellum; Cerebral Cortex; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2005 |
Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
Topics: Animals; Ascorbic Acid; Corpus Striatum; Dopamine; Levodopa; Light; Male; Melatonin; Microdialysis; Movement; Oxidation-Reduction; Parkinson Disease; Quinones; Rats; Rats, Wistar | 2006 |
Parkinson's disease following panic disorder.
Topics: Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Levodopa; Middle Aged; Panic Disorder; Parkinson Disease; Statistics as Topic | 2006 |
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Chorea; Disease Models, Animal; Female; Histamine Agonists; Levodopa; Parkinson Disease; Receptors, Histamine H3 | 2006 |
Subthalamic oscillatory activities at beta or higher frequency do not change after high-frequency DBS in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Basal Ganglia; Biological Clocks; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus | 2006 |
Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
Topics: Aged; Deep Brain Stimulation; Disease Progression; Follow-Up Studies; Gait; Humans; Hypokinesia; Levodopa; Middle Aged; Motor Skills; Muscle Rigidity; Parkinson Disease; Severity of Illness Index; Thalamus; Tremor; Verbal Behavior | 2005 |
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2006 |
Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cost-Benefit Analysis; Deep Brain Stimulation; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome | 2006 |
Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Decision Making; Female; Humans; Individuality; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Reproducibility of Results; Saccades | 2006 |
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Bromocriptine; Disability Evaluation; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pergolide; Prognosis; Survival Analysis | 2006 |
Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Glutathione Reductase; Humans; Leukocytes, Mononuclear; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Signal Transduction | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors | 2006 |
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hospitals, University; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Patient Admission; Retrospective Studies; Risk Factors; Turkey | 2006 |
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Drug Utilization; Finland; Humans; Indans; Levodopa; Markov Chains; Models, Statistical; Parkinson Disease; Treatment Outcome | 2006 |
[New types of dopaminergic treatment. The Danish Society of Movement Disorders].
Topics: Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Duodenum; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Parkinson Disease; Tablets | 2006 |
[Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
Topics: Aged; Antiparkinson Agents; Apomorphine; Autonomic Nervous System; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Norepinephrine; Parkinson Disease | 2006 |
Two phases of the contingent negative variation in humans: association with motor and mental functions.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Contingent Negative Variation; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Mental Processes; Middle Aged; Muscle, Skeletal; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance; Time Factors | 2006 |
[Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report].
Topics: Adenoma; alpha-Synuclein; Antiparkinson Agents; Biomarkers; Brain; Brain Chemistry; Combined Modality Therapy; Deep Brain Stimulation; Diagnostic Errors; Disease Progression; Fatal Outcome; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Prostatectomy; Prostatic Neoplasms; Substantia Nigra; Subthalamic Nucleus; Ubiquitin | 2006 |
Perception of heaviness in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Female; Gravitation; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Proprioception; Reference Values; Sensory Thresholds; Weight Perception; Weight-Bearing | 2006 |
Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Sickness Impact Profile; Sleep Wake Disorders; Statistics as Topic | 2006 |
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Accidental Falls; Complementary Therapies; Humans; Levodopa; Neurology; Parkinson Disease; Quality Assurance, Health Care; United States | 2006 |
Subthalamic nucleus stimulation in patients with Parkinson's disease does not increase serum ghrelin levels.
Topics: Deep Brain Stimulation; Ghrelin; Humans; Levodopa; Parkinson Disease; Peptide Hormones; Subthalamic Nucleus | 2006 |
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
Topics: Antiparkinson Agents; Exons; Family; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Mutation; Parkinson Disease; Pedigree; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases | 2006 |
Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease.
Topics: Action Potentials; Antiparkinson Agents; Cortical Synchronization; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2006 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Orthostatic heart rate variability analysis in idiopathic Parkinson's disease.
Topics: Age Factors; Antiparkinson Agents; Autonomic Nervous System; Case-Control Studies; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tilt-Table Test; Time Factors | 2006 |
Dopamine dysregulation syndrome in Parkinson's disease patients: from reward to penalty.
Topics: Antiparkinson Agents; Behavior; Dopamine; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography | 2006 |
Three in one: case report supporting different origins of essential and parkinsonian tremors.
Topics: Aged; Antiparkinson Agents; Antithyroid Agents; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Essential Tremor; Female; Humans; Hyperthyroidism; Levodopa; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Tremor; Ventral Thalamic Nuclei | 2006 |
Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy.
Topics: Aged; Disorders of Excessive Somnolence; Dopamine Agents; Humans; Levodopa; Middle Aged; Multiple System Atrophy; Parkinson Disease | 2006 |
Levodopa-responsive parkinsonism associated with hydrocephalus.
Topics: Antiparkinson Agents; Brain; Female; Humans; Hydrocephalus; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease | 2006 |
[A 62-year-old woman with early-onset Parkinson's disease associated with the PINKi gene deletion].
Topics: Age Factors; Antiparkinson Agents; Dementia; Dystonia; Female; Gene Deletion; Humans; Levodopa; Middle Aged; Mutation; Parkinson Disease; Protein Kinases | 2006 |
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine | 2006 |
Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2006 |
Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Thalamus | 2006 |
Subthalamic deep brain stimulation in patients with a previous pallidotomy.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Functional Laterality; Humans; Levodopa; Middle Aged; Motor Cortex; Pallidotomy; Parkinson Disease; Thalamus | 2006 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Databases, Factual; Dementia; Dopamine Agonists; Drug Prescriptions; Drug Utilization; Geriatrics; Humans; Levodopa; Male; Medicine; Middle Aged; Neurology; Northwestern United States; Parkinson Disease; Practice Patterns, Physicians'; Primary Health Care; Psychiatry; Psychology; Retrospective Studies; Selegiline; Specialization; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Safety of rasagiline in elderly patients with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Confusion; Disorders of Excessive Somnolence; Dopamine Agonists; Double-Blind Method; Female; Hallucinations; Humans; Hypotension, Orthostatic; Incidence; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic | 2006 |
Eyelid apraxia associated with subthalamic nucleus deep brain stimulation.
Topics: Antiparkinson Agents; Apraxias; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Eyelids; Female; Humans; Levodopa; Microelectrodes; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Trigeminal Caudal Nucleus | 2006 |
Editorial to the second issue dedicated to Lewis Sheiner.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Levodopa; Models, Biological; Models, Statistical; Parkinson Disease; Pharmacokinetics; Pharmacology; Software | 2006 |
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Apomorphine; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2006 |
Patterns of initial pharmacotherapy for Parkinson's disease in the United States.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; United States | 2006 |
Surface electromyography shows increased mirroring in Parkinson's disease patients without overt mirror movements.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dopamine Agonists; Electromyography; Female; Functional Laterality; Humans; Isometric Contraction; Levodopa; Male; Middle Aged; Nerve Net; Parkinson Disease; Pyramidal Tracts; Reference Values | 2006 |
Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease.
Topics: Animals; Blotting, Western; Brain Tissue Transplantation; Cell Line; Cell Transplantation; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Female; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Multipotent Stem Cells; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2006 |
Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Topics: Aged; Antiparkinson Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Putamen; Severity of Illness Index; Treatment Outcome | 2006 |
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Topics: Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Duodenum; Humans; Infusion Pumps; Levodopa; Parkinson Disease; Treatment Outcome | 2006 |
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus | 2006 |
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Topics: Animals; Antiparkinson Agents; Cocaine; Dihydroxyphenylalanine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Duodenum; Humans; Indoles; Infusion Pumps; Levodopa; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2006 |
Is there a role for physiotherapy during deep brain stimulation surgery in patients with Parkinson's disease?
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Therapy Modalities; Retrospective Studies; Treatment Outcome | 2006 |
[History of treatment of Parkinson disease].
Topics: Antiparkinson Agents; Cholinergic Antagonists; Dopamine Antagonists; History, 19th Century; History, 20th Century; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2006 |
Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Schedule; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinson Disease; Protein Binding; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subthalamic Nucleus; Tritium | 2006 |
Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dopamine Agents; Drug Administration Routes; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Treatment Outcome | 2006 |
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Wakefulness | 2006 |
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Hypokinesia; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Neurologic Examination; Optic Atrophy; Parkinson Disease | 2006 |
Does subthalamic nucleus deep brain stimulation really improve quality of life in Parkinson's disease?
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Retrospective Studies; Subthalamic Nucleus | 2006 |
Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Japan; Levodopa; Male; Middle Aged; Mobility Limitation; Neurologic Examination; Parkinson Disease; Prognosis; Retrospective Studies; Severity of Illness Index; Sex Factors | 2006 |
Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
Topics: Animals; Animals, Newborn; Antibodies; Astrocytes; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cytoprotection; Dopamine; Dopamine Agents; Glial Cell Line-Derived Neurotrophic Factor; Hydrogen Peroxide; Levodopa; Nerve Degeneration; Neurons; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; RNA, Messenger; Substantia Nigra; Sympatholytics | 2006 |
Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
Topics: Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; Hydrolysis; Levodopa; Lymphocytes; Male; Methyldopa; Parkinson Disease; Proteins | 2006 |
Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzodiazepines; Clonazepam; Cohort Studies; Comorbidity; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Reference Values; Restless Legs Syndrome; Sleep Stages; Wakefulness | 2006 |
Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiparkinson Agents; China; Combined Modality Therapy; Cost of Illness; Costs and Cost Analysis; Delivery of Health Care; Developing Countries; Female; Health Care Costs; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Admission; Patient Care Team; Population Dynamics; Retrospective Studies | 2006 |
The sequence effect and gait festination in Parkinson disease: contributors to freezing of gait?
Topics: Aged; Antiparkinson Agents; Attention; Basal Ganglia; Cues; Drug Therapy, Combination; Female; Gait Apraxia; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Mobility Limitation; Neurologic Examination; Parkinson Disease; Risk Factors; Sensory Deprivation; Visual Perception; Walking | 2006 |
Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Articulation Disorders; Brain; Disease Progression; Dopamine; Female; Humans; Levodopa; Male; Neural Pathways; Parkinson Disease; Speech; Treatment Outcome | 2006 |
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.
Topics: Cross-Sectional Studies; Dyskinesias; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2006 |
Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy.
Topics: Aged; Anger; Antiparkinson Agents; Dopamine Agents; Emotions; Exploratory Behavior; Facial Expression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Personality Tests; Social Perception; Substance Withdrawal Syndrome | 2007 |
Putamen FDOPA uptake and its relationship tot cognitive functioning in PD.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Levodopa; Memory; Models, Biological; Neuropsychological Tests; Parkinson Disease; Problem Solving; Putamen; Tomography, Emission-Computed | 2006 |
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Reference Values; Vitamin B 12 | 2006 |
Parkinson's goal: ease symptoms, slow progression.
Topics: Antiparkinson Agents; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease | 2006 |
Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Comorbidity; Depressive Disorder; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychotic Disorders | 2006 |
A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Case-Control Studies; Cognition; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole | 2006 |
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Topics: Aged; Anti-Bacterial Agents; Comorbidity; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebo Effect; Treatment Outcome | 2006 |
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.
Topics: Aged; Algorithms; Antiparkinson Agents; Biomarkers; Brain; Cerebrovascular Circulation; Deep Brain Stimulation; Female; Glucose; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Metabolic Networks and Pathways; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Sensitivity and Specificity; Software | 2007 |
Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management.
Topics: Antiparkinson Agents; Brain; Brain Mapping; Deep Brain Stimulation; Diagnosis, Differential; Electrodes, Implanted; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Neurosurgical Procedures; Parkinson Disease; Patient Selection; Postoperative Care; Preoperative Care; Stereotaxic Techniques | 2006 |
Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Deep Brain Stimulation; Dominance, Cerebral; Double-Blind Method; Electrodes; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Motor Skills; Neurologic Examination; Parkinson Disease; Prefrontal Cortex; Statistics as Topic | 2006 |
Balance in Parkinson's disease under static and dynamic conditions.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Head Movements; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postural Balance | 2006 |
After the diagnosis: living with Parkinson's. There's no cure for Parkinson's disease, but new treatments can ease the symptoms and prolong independence.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Disease Progression; Drug Tolerance; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Tolerance; Female; Humans; Levodopa; Male; Parkinson Disease; Surveys and Questionnaires | 2007 |
Step initiation in Parkinson's disease: influence of initial stance conditions.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Female; Gait; Gait Disorders, Neurologic; Humans; Leg; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Postural Balance | 2006 |
Opioids and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Opioid | 2006 |
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries | 2006 |
Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipsychotic Agents; Clomipramine; Clozapine; Delusions; Depressive Disorder; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders | 2007 |
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Levodopa; Male; Mazindol; Motor Activity; Parkinson Disease; Piribedil; Rats; Rats, Wistar; Reaction Time | 2006 |
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Agents; Drug Resistance; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neural Pathways; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D3; Receptors, Steroid; Transcription Factors | 2006 |
Treatment of Parkinson's disease--where do we go from here?
Topics: Antiparkinson Agents; Dopamine Agonists; Gambling; Humans; Levodopa; Parkinson Disease | 2006 |
Medical hazards of the internet: gambling in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Therapy, Combination; Gambling; Humans; Internet; Levodopa; Male; Parkinson Disease; Pergolide | 2006 |
Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Drug Therapy, Combination; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Neurologic Examination; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor | 2006 |
It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Fever; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 2006 |
The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Human Body; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Rotation; Severity of Illness Index | 2007 |
Diagnostic aspects of early Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Cognition Disorders; Depression; Humans; Levodopa; Parkinson Disease; Perceptual Disorders | 2006 |
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Laughter; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Psychoses, Substance-Induced; Quetiapine Fumarate; Thiazoles | 2007 |
Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech Acoustics; Vocal Cords; Voice Disorders; Voice Quality | 2008 |
Efficacy and safety of simultaneous bilateral pallidotomy in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiosurgery; Treatment Outcome | 2006 |
Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus | 2006 |
Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease.
Topics: Affect; Antiparkinson Agents; Cognition; Deep Brain Stimulation; Depressive Disorder; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Movement; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance; Subthalamic Nucleus | 2006 |
Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.
Topics: alpha-Synuclein; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Dopamine; Feedback, Physiological; Homeostasis; Levodopa; Mice; Mutation; Neurons; Parkinson Disease; Phosphorylation; Rats; Substantia Nigra; Transfection; Tyrosine 3-Monooxygenase | 2006 |
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Beta Rhythm; Data Interpretation, Statistical; Dopamine; Dopamine Agents; Electrodes, Implanted; Electrophysiology; Evoked Potentials; Female; Fourier Analysis; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Movement; Neurons; Parkinson Disease; Subthalamic Nucleus; Tremor | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase | 2006 |
Punding and dyskinesias.
Topics: Aged; Aged, 80 and over; Demography; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Stereotyped Behavior | 2006 |
Changes in gait and symptoms after bilateral pallidotomy: a client with Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Disease Progression; Female; Gait; Globus Pallidus; Humans; Levodopa; Middle Aged; Pallidotomy; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Long-term monitoring of gait in Parkinson's disease.
Topics: Adult; Algorithms; Antiparkinson Agents; Calibration; Computers, Handheld; Drug Monitoring; Dyskinesia, Drug-Induced; Electronics, Medical; Feasibility Studies; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease | 2007 |
Effect of deep brain stimulation and L-Dopa on electrocortical rhythms related to movement in Parkinson's disease.
Topics: Antiparkinson Agents; Beta Rhythm; Cortical Synchronization; Deep Brain Stimulation; Electroencephalography; Electromyography; Humans; Levodopa; Motor Cortex; Movement; Parkinson Disease | 2006 |
Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
Topics: Antiparkinson Agents; Brain Injuries; Child, Preschool; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Substantia Nigra | 2006 |
Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey.
Topics: Aged; Antiparkinson Agents; Anxiety; Belgium; Humans; Levodopa; Mood Disorders; Movement Disorders; Parkinson Disease; Surveys and Questionnaires | 2006 |
Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Arousal; Blinking; Depression; Dopamine Agents; Emotions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time; Reflex, Startle; Severity of Illness Index | 2006 |
Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Mutant Strains; Motor Activity; Motor Skills; Nerve Degeneration; Parkinson Disease; Phosphorylation; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2006 |
Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
Topics: Administration, Oral; Carbon Radioisotopes; Corpus Striatum; Disability Evaluation; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Administration Schedule; Female; Humans; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Raclopride; Synaptic Transmission; Treatment Outcome | 2006 |
Inhaled cocaine used to relieve "off" periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases.
Topics: Administration, Inhalation; Cocaine; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Self Medication | 2006 |
Phenomenology of dreams in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dreams; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Semantics; Severity of Illness Index; Sleep Wake Disorders; Sleep, REM | 2007 |
Current topics in brain dopamine research: a tribute to Professor Oleh Hornykiewicz.
Topics: Antiparkinson Agents; Austria; Brain; Dopamine; History, 20th Century; Humans; Levodopa; Parkinson Disease; Research | 2006 |
Dopamine: from pharmacology to molecular biology and back.
Topics: Amphetamines; Animals; Antiparkinson Agents; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Humans; Levodopa; Locomotion; Mice; Mice, Knockout; Parkinson Disease; Parkinsonian Disorders; Receptors, G-Protein-Coupled; Signal Transduction | 2006 |
Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.
Topics: Antiparkinson Agents; Arousal; Brain; Brain Mapping; Diagnostic Imaging; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Movement; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon | 2006 |
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Brain; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Tissue Donors | 2007 |
Perceptual factors contribute to akinesia in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Perception; Psychomotor Performance; Reaction Time | 2007 |
Gender-related differences in the human subthalamic area: a local field potential study.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Biological Clocks; Corpus Striatum; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Neurons; Parkinson Disease; Sex Characteristics; Subthalamic Nucleus | 2006 |
A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Motor Neuron Disease; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Spiperone; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2006 |
Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
Topics: Aged; Antiparkinson Agents; Autopsy; Brain Chemistry; Case-Control Studies; Dopamine; Female; Humans; Levodopa; Locus Coeruleus; Male; Norepinephrine; Nucleus Accumbens; Parkinson Disease; Substantia Nigra | 2006 |
Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Parkinson Disease; Psychomotor Performance; Reaction Time; Saccades | 2007 |
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Homozygote; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Predictive Value of Tests; Psychoses, Substance-Induced; Risk Factors | 2007 |
Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Cohort Studies; Databases, Factual; Depression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2007 |
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Accidental Falls; Complementary Therapies; Humans; Levodopa; Neurology; Parkinson Disease; Quality Assurance, Health Care; United States | 2007 |
Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Signal Processing, Computer-Assisted; Subthalamic Nucleus | 2007 |
Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias.
Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Neurons; Oligonucleotides, Antisense; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2006 |
Dopamine dysregulation syndrome in Parkinson's disease: case report.
Topics: Aged; Antiparkinson Agents; Dopamine; Humans; Levodopa; Male; Mood Disorders; Parkinson Disease; Substance-Related Disorders; Syndrome | 2006 |
Punding prevalence in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Prevalence; Psychomotor Disorders | 2007 |
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Extremities; Levodopa; Male; Mesencephalon; Nerve Degeneration; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
Topics: Adult; Antiparkinson Agents; Female; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Respiratory Function Tests; Severity of Illness Index | 2007 |
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Posture; Severity of Illness Index; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Levodopa and the risk of melanoma.
Topics: Antiparkinson Agents; Case-Control Studies; Humans; Levodopa; Melanoma; Parkinson Disease; Registries; Risk Factors; Smoking | 2007 |
[Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease].
Topics: Antiparkinson Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.
Topics: Animals; Biomarkers; Deep Brain Stimulation; Denervation; Disease Models, Animal; Drug Synergism; Dyskinesias; Electron Transport Complex IV; Levodopa; Male; Motor Cortex; Neuropeptides; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Subthalamic Nucleus | 2007 |
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Levodopa; Magnetic Resonance Spectroscopy; Parkinson Disease; Reference Values | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions.
Topics: Adult; Antiparkinson Agents; Chromosome Deletion; DNA, Mitochondrial; Humans; Levodopa; Male; Parkinson Disease; Pharmacogenetics | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission | 2007 |
FDG-PET study of the bilateral subthalamic nucleus stimulation effects on the regional cerebral metabolism in advanced Parkinson disease.
Topics: Antiparkinson Agents; Brain; Brain Mapping; Deep Brain Stimulation; Dose-Response Relationship, Drug; Fluorodeoxyglucose F18; Follow-Up Studies; Functional Laterality; Humans; Informed Consent; Levodopa; Parkinson Disease; Positron-Emission Tomography; Preoperative Care; Radiography; Radiopharmaceuticals; Subthalamic Nucleus | 2006 |
Malignant melanoma in early Parkinson's disease: the DATATOP trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Comorbidity; Cross-Sectional Studies; Female; Humans; Incidence; Levodopa; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic; Reference Values; Retrospective Studies; Skin Neoplasms | 2007 |
Blood pressure and heart rate in parkinsonian patients with and without wearing-off.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2007 |
Skin rash associated with Sinemet does not equal levodopa allergy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Skin; Withholding Treatment | 2007 |
Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Topics: Antiparkinson Agents; Brain; Cytokines; Dyskinesia, Drug-Induced; Endotoxins; Energy Metabolism; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Levodopa; Parkinson Disease | 2007 |
Estimated life expectancy of Parkinson's patients compared with the UK population.
Topics: Adult; Age Distribution; Age of Onset; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Sex Distribution; United Kingdom | 2007 |
Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
Topics: Age of Onset; Aged; Aging; Antiparkinson Agents; Delusions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Statistics, Nonparametric | 2007 |
Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Topics: Aged; Antiparkinson Agents; Biological Clocks; Brain; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Magnetic Resonance Imaging; Magnetoencephalography; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Signal Processing, Computer-Assisted; Time Factors | 2007 |
Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesias; Female; Germany; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Treatment Outcome | 2007 |
Early-onset Parkinson's disease and depression.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; Risk Factors | 2007 |
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Disability Evaluation; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 2007 |
Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Evidence-Based Medicine; Female; Humans; Levodopa; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 2007 |
Dopa-responsive camptocormia in a patient with multiple system atrophy.
Topics: 3-Iodobenzylguanidine; Antiparkinson Agents; Female; Heart; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Multiple System Atrophy; Parkinson Disease; Posture; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
Topics: Anxiety Disorders; Benzothiazoles; Carbidopa; Central Nervous System; Diazepam; Dopamine Agonists; Dose-Response Relationship, Drug; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Panic Disorder; Parkinson Disease; Pramipexole; Self Administration | 2007 |
The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Disability Evaluation; Evidence-Based Medicine; Female; Geriatric Assessment; Humans; Levodopa; Male; Middle Aged; Mobility Limitation; Parkinson Disease; Psychometrics; Quality of Life; Reproducibility of Results; Sick Role; Surveys and Questionnaires; Sweden | 2007 |
Low plasma uric acid level in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Energy Intake; Female; Ferritins; Humans; Levodopa; Male; Mass Screening; Middle Aged; Parkinson Disease; Plasma; Risk Factors; Selegiline; Spouses; Uric Acid | 2007 |
A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities.
Topics: Adult; Aged; Air Pollutants; Antiparkinson Agents; Canada; Case-Control Studies; Cities; Cohort Studies; Humans; Levodopa; Manganese; Middle Aged; Parkinson Disease; Vehicle Emissions | 2007 |
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Copper; Female; Humans; Iron; Levodopa; Male; Metals, Heavy; Middle Aged; Parkinson Disease; Selenium; Spectrophotometry, Atomic; Zinc | 2006 |
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents | 2007 |
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Bipolar Disorder; Catechols; Cognition; Combined Modality Therapy; Communication; Deep Brain Stimulation; Dysarthria; Electrodes, Implanted; Emotions; Female; Humans; Levodopa; Male; Middle Aged; Movement; Neuropsychological Tests; Nitriles; Parkinson Disease; Pergolide; Prejudice; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome; Weight Gain | 2007 |
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Topics: Antiparkinson Agents; Carbon; Catechol O-Methyltransferase Inhibitors; Catechols; Folic Acid; Humans; Hyperhomocysteinemia; Levodopa; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; S-Adenosylmethionine; Time Factors; Vitamin B 12; Vitamin B 6 | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functional Laterality; Immunohistochemistry; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazoles; Tyrosine 3-Monooxygenase; Vibrissae | 2007 |
[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Statistics, Nonparametric; Tomography, Emission-Computed, Single-Photon; Tropanes | 2007 |
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.
Topics: Adolescent; Antiparkinson Agents; Bromocriptine; Catechols; Drug Therapy, Combination; Epilepsy; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Prenatal Exposure Delayed Effects | 2007 |
Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries.
Topics: Antiparkinson Agents; Basal Ganglia; Brain; Case-Control Studies; Cerebellum; Cerebral Cortex; Humans; Intention; Levodopa; Magnetic Resonance Imaging; Matched-Pair Analysis; Neural Pathways; Parkinson Disease; Psychomotor Performance; Thalamus; Tomography, Emission-Computed, Single-Photon; Twins, Monozygotic | 2007 |
The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dysarthria; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Phonation; Pulmonary Ventilation; Respiratory Insufficiency; Sex Factors; Speech Intelligibility; Spirometry; Vital Capacity | 2007 |
Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation.
Topics: Antiparkinson Agents; Basal Metabolism; Body Composition; Calorimetry, Indirect; Deep Brain Stimulation; Eating; Electrodes, Implanted; Energy Intake; Energy Metabolism; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome; Weight Gain | 2007 |
Neurotoxicity of levodopa: treatment-associated homocysteine increase.
Topics: Animals; Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agents; Drug Interactions; Dyskinesias; gamma-Aminobutyric Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Serotonin Receptor Agonists; Stereotyped Behavior; Triglycerides | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors | 2007 |
Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Neurologic Examination; Neuropsychological Tests; Norway; Parkinson Disease; Parkinsonian Disorders; Prospective Studies; REM Sleep Behavior Disorder; Sex Factors | 2008 |
The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?
Topics: Aged; Automobile Driving; Dopamine Agents; Humans; Levodopa; Male; Parkinson Disease; Psychomotor Performance | 2008 |
Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Factor Analysis, Statistical; Female; Hand; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Weight Lifting | 2007 |
Restless legs syndrome in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Disorders of Excessive Somnolence; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Quality of Life; Restless Legs Syndrome; Sick Role | 2007 |
Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
Topics: Adult; Aged; Chi-Square Distribution; Dopamine; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Prospective Studies; Reaction Time; Retrospective Studies; Risk Factors | 2007 |
Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line; Cell Survival; Corpus Striatum; Dopamine; Drug Compounding; Drug Delivery Systems; Fibroblasts; Glial Cell Line-Derived Neurotrophic Factor; Homovanillic Acid; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2007 |
[Atypical corticobasal degeneration with clinical pictures of Parkinson's disease--an L-dopa-effective case].
Topics: Aged; Basal Ganglia; Cerebral Cortex; Diagnosis, Differential; Dopamine Agents; Female; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2007 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Male; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2007 |
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study.
Topics: Accidental Falls; Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Disease Progression; Female; Hallucinations; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2007 |
Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Cerebrovascular Circulation; Drug Synergism; Exercise Therapy; Exercise Tolerance; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Hypothalamus; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion; Pituitary Gland, Anterior | 2007 |
Cerebral atrophy in Parkinson's disease patients with visual hallucinations.
Topics: Antiparkinson Agents; Antipsychotic Agents; Atrophy; Cerebral Cortex; Female; Hallucinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parietal Lobe; Parkinson Disease; Severity of Illness Index; Temporal Lobe; Visual Cortex; Visual Pathways | 2007 |
Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Chlorpheniramine; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Serotonin Receptor Agonists | 2008 |
A pilot study of respiration and swallowing integration in Parkinson's disease: "on" and "off" levodopa.
Topics: Aged; Antiparkinson Agents; Deglutition; Deglutition Disorders; Female; Humans; Levodopa; Lung; Male; Middle Aged; Parkinson Disease; Pilot Projects; Psychological Tests; Psychometrics; Respiration; Respiratory Function Tests; Respiratory Tract Diseases | 2008 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Molecular Structure; Parkinson Disease; Receptor, Cannabinoid, CB1; Triazines | 2007 |
Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 1; Opioid Peptides; Oxidopamine; Parkinson Disease; Pergolide; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Signal Transduction; Up-Regulation | 2007 |
Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case.
Topics: Aged; Amyotrophic Lateral Sclerosis; Autopsy; Dementia; Diagnosis, Differential; Dopamine Agents; Fatal Outcome; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra | 2007 |
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2007 |
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Tyrosine 3-Monooxygenase | 2007 |
Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Classification; Contrast Sensitivity; Dopamine; Female; Form Perception; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Recognition, Psychology; Reference Values; Statistics, Nonparametric | 2007 |
Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Entropy; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Spectrum Analysis | 2007 |
Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Brain Mapping; Cognition Disorders; Dopamine; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease; Prefrontal Cortex; Random Allocation; Reaction Time | 2007 |
Modulation by dopamine of human basal ganglia involvement in feedback control of movement.
Topics: Basal Ganglia; Dopamine; Feedback, Psychological; Humans; Levodopa; Motor Activity; Parkinson Disease; Subthalamic Nucleus | 2007 |
Axial hypertonicity in Parkinson's disease: direct measurements of trunk and hip torque.
Topics: Abdomen; Acceleration; Aged; Antiparkinson Agents; Female; Hip; Humans; Levodopa; Male; Middle Aged; Muscle Hypertonia; Muscle Rigidity; Parkinson Disease; Posture; Rotation; Severity of Illness Index; Thorax; Torque | 2007 |
A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
Topics: Diagnosis, Differential; Dystonia; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
Levodopa-induced ocular dyskinesia in Parkinson's disease.
Topics: Aged; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Parkinson Disease; Prospective Studies | 2007 |
Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Linguistics; Male; Middle Aged; Parkinson Disease; Pergolide; Sound Spectrography; Speech Acoustics; Speech Intelligibility; Speech Production Measurement; Verbal Behavior | 2007 |
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Exploratory Behavior; Humans; Levodopa; Male; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Peptide Fragments; Pergolide; Receptors, Dopamine D2 | 2008 |
Homocysteine in restless legs syndrome.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Reference Values; Restless Legs Syndrome; Vitamin B 12; Vitamin B 6 | 2008 |
Fast-track programming and rehabilitation model: a novel approach to postoperative deep brain stimulation patient care.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Clinical Protocols; Cohort Studies; Deep Brain Stimulation; Drug Utilization; Female; Humans; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Care Management; Postoperative Care | 2007 |
Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Comorbidity; Dementia; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; REM Sleep Behavior Disorder; Statistics as Topic | 2007 |
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Vitamin B 12 | 2007 |
Paradoxical kinesia at war.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Anxiety; Cues; Depression; Dyskinesias; Fear; Female; Humans; Israel; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Stress, Psychological; Warfare | 2007 |
Ambulatory monitoring of freezing of gait in Parkinson's disease.
Topics: Adult; Aged; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Spectrum Analysis | 2008 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Optimizing clinical outcomes in residents with Parkinson's disease. Introduction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 2006 |
Quality of life scale in Parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Reproducibility of Results; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires | 2007 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase | 2008 |
Sensorimotor adaptation in Parkinson's disease: evidence for a dopamine dependent remapping disturbance.
Topics: Adaptation, Physiological; Aged; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Psychomotor Performance | 2008 |
Nighttime sleep problems and daytime sleepiness in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Demography; Depressive Disorder; Disorders of Excessive Somnolence; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Risk Factors; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires | 2008 |
The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Antiparkinson Agents; Case-Control Studies; China; DNA; Female; Founder Effect; Genotype; Haplotypes; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Phenotype; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Carotid intima-media thickness in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cardiovascular Diseases; Carotid Arteries; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Assessment; Ultrasonography | 2007 |
The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Botulinum Toxins, Type A; Electromyography; Electrophysiology; Female; Fibrosis; Head; Humans; Levodopa; Male; Middle Aged; Movement; Multiple System Atrophy; Muscle, Skeletal; Neck; Neuromuscular Agents; Parkinson Disease | 2007 |
Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Conflict, Psychological; Decision Making; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Impulsive Behavior; Learning; Levodopa; Male; Middle Aged; Models, Neurological; Neural Networks, Computer; Parkinson Disease; Reaction Time; Reinforcement, Psychology; Subthalamic Nucleus | 2007 |
Bilateral subthalamotomy for advanced Parkinson disease.
Topics: Aged; Catheter Ablation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Microelectrodes; Middle Aged; Muscle Rigidity; Neural Pathways; Parkinson Disease; Radiosurgery; Subthalamic Nucleus; Time; Treatment Outcome; Tremor | 2007 |
[Anesthetic management of a patient with deep brain stimulators].
Topics: Aged; Anesthesia, General; Antiparkinson Agents; Deep Brain Stimulation; Emergencies; Humans; Ileus; Levodopa; Male; Parkinson Disease; Perioperative Care; Severity of Illness Index | 2007 |
[Thinking on research of integrated Chinese and Western medicine in treating Parkinson's Disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Integrative Medicine; Levodopa; Parkinson Disease; Phytotherapy | 2007 |
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Hydroxyindoleacetic Acid; Infusion Pumps, Implantable; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D2; Serotonin; Substantia Nigra; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Fatal gastroparesis in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Fatal Outcome; Gastroparesis; Humans; Levodopa; Male; Parkinson Disease; Pneumonia, Aspiration; Vomiting | 2008 |
Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease.
Topics: Aged; Demography; Dopamine Agonists; Extremities; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Prospective Studies; Rest; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Tremor | 2008 |
Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease.
Topics: Adult; Diagnosis, Differential; Dopamine Agonists; Drug Resistance; Echoencephalography; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Ultrasonography, Doppler, Transcranial; Welding | 2008 |
Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Duodenum; Female; Humans; Infusions, Parenteral; Jejunostomy; Levodopa; Male; Parkinson Disease; Time Factors | 2008 |
Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?
Topics: Corpus Striatum; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesia, Drug-Induced; Electric Stimulation; In Vitro Techniques; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2008 |
Spectral clustering of fMRI data within regions of interest: clarification of L-dopa effects in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Brain; Brain Mapping; Cluster Analysis; Humans; Image Interpretation, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Prognosis; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Treatment Outcome | 2007 |
Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
Topics: Acute Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2008 |
Word processing in Parkinson's disease is impaired for action verbs but not for concrete nouns.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cues; Female; Humans; Language Disorders; Levodopa; Male; Middle Aged; Motor Cortex; Motor Skills; Parkinson Disease; Reaction Time; Reference Values; Semantics; Terminology as Topic | 2008 |
The management approaches to dyskinesia vary from country to country.
Topics: Antiparkinson Agents; Critical Pathways; Cross-Cultural Comparison; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Humans; Incidence; Japan; Levodopa; Outcome Assessment, Health Care; Parkinson Disease; Referral and Consultation; Retrospective Studies; United States | 2007 |
Frégoli syndrome associated with levodopa treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychotic Disorders; Schizophrenia, Paranoid | 2008 |
Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Topics: Aged; Antiparkinson Agents; Arm; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Thorax; Time Factors | 2008 |
Participation of the subthalamic nucleus in executive functions: An intracerebral recording study.
Topics: Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Evoked Potentials; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus | 2008 |
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Models, Biological; Parkinson Disease; Time Factors | 2008 |
Clinical aspects of bowel symptoms in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Anal Canal; Antiparkinson Agents; Autonomic Pathways; Central Nervous System; Comorbidity; Constipation; Disability Evaluation; Disease Progression; Enteric Nervous System; Fecal Incontinence; Female; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Surveys and Questionnaires | 2008 |
The variability of levodopa response in Parkinson's disease: is sensitization reversible?
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pergolide; Treatment Outcome | 2008 |
For better or worse: The effect of levodopa on speech in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech; Speech Disorders; Verbal Behavior; Voice Disorders | 2008 |
Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia.
Topics: Adult; Antiparkinson Agents; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus | 2008 |
Direct inhibition of levodopa-induced beginning-of-dose motor deterioration by subthalamic nucleus stimulation in a patient with Parkinson disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2008 |
The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
Topics: Aged; Dopamine Agonists; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Treatment Outcome | 2008 |
Voluntary, spontaneous, and reflex blinking in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Blinking; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Volition | 2008 |
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.
Topics: Aged; Antiparkinson Agents; Attention; Brain Mapping; Catechol O-Methyltransferase; Cognition Disorders; Female; Frontal Lobe; Genotype; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Polymorphism, Genetic; Prefrontal Cortex | 2008 |
Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture; Psychoses, Substance-Induced; Retrospective Studies; Subthalamic Nucleus; Tremor | 2008 |
Dopaminergic drug-induced tics in PARK2-positive Parkinson's disease.
Topics: Adult; Dopamine Agonists; Humans; Levodopa; Male; Parkinson Disease; Tics; Ubiquitin-Protein Ligases | 2008 |
Footstep adjustments used to turn during walking in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Reference Values; Walking | 2008 |
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Contraindications; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections; Injections, Subcutaneous; Levodopa; Neurologic Examination; Parkinson Disease | 2008 |
Determination of levodopa and biogenic amines in urine samples using high-performance liquid chromatography.
Topics: Biogenic Amines; Chromatography, High Pressure Liquid; Humans; Levodopa; Parkinson Disease; Reproducibility of Results | 2008 |
Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study.
Topics: Aged; Cognition; Corpus Striatum; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Problem Solving; Verbal Learning | 2008 |
Rhinorrhea and olfaction in Parkinson disease.
Topics: Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Comorbidity; Female; Humans; Levodopa; Male; Middle Aged; Nasal Mucosa; Olfaction Disorders; Parasympathetic Fibers, Postganglionic; Parkinson Disease; Prevalence; Rhinitis; Sex Distribution; Sympathetic Fibers, Postganglionic | 2008 |
Spotlight on rotigotine in Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2008 |
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Macaca; Mass Spectrometry; Parkinson Disease; Protein Processing, Post-Translational; Proteomics; Rats | 2008 |
Interaction between levodopa and enteral nutrition.
Topics: Aged; Enteral Nutrition; Food-Drug Interactions; Humans; Levodopa; Male; Parkinson Disease | 2008 |
Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Subthalamic Nucleus; Treatment Outcome | 2008 |
Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Count; Cell Proliferation; Corpus Striatum; Denervation; Dopamine; Dopamine Plasma Membrane Transport Proteins; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
Comment to the paper of Medeiros CAM, et al. (2007) J Neurol 254:459-464.
Topics: Antiparkinson Agents; Central Nervous System Depressants; Circadian Rhythm; Drug Administration Schedule; Drug Interactions; Humans; Levodopa; Melatonin; Parkinson Disease; Placebo Effect; Randomized Controlled Trials as Topic; Sleep; Sleep Wake Disorders; Time Factors | 2008 |
Lateral stepping for postural correction in Parkinson's disease.
Topics: Accidental Falls; Adult; Aged; Ambulatory Care; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Gait; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Reaction Time; Reference Values; Severity of Illness Index; Statistics, Nonparametric | 2008 |
Emotional speech in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Cabergoline; Emotions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Phonation; Speech | 2008 |
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Australia; Dementia; Dyskinesias; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2008 |
Apraxia of eyelid opening after subthalamic deep brain stimulation may be caused by reduction of levodopa.
Topics: Antiparkinson Agents; Apraxias; Deep Brain Stimulation; Eyelids; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2008 |
Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; History, 20th Century; Humans; Levodopa; Neural Pathways; Parkinson Disease; Substantia Nigra | 2008 |
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Topics: Disease Progression; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease; Prospective Studies; Quality of Life | 2008 |
Electromyographic activity of sternocleidomastoid muscle in patients with Parkinson's disease.
Topics: Aged; Electromyography; Female; Humans; Inhalation; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Respiratory Muscles | 2009 |
Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease.
Topics: Age of Onset; Aged; Amino Acid Sequence; Antiparkinson Agents; Cognition Disorders; Exons; Gene Deletion; Genotype; Humans; Levodopa; Male; Molecular Sequence Data; Mutation; Parkinson Disease; Pedigree; Phenotype; Protein Kinases | 2008 |
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease?
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Deep Brain Stimulation; Electrodes, Implanted; Electromyography; Female; Humans; Intralaminar Thalamic Nuclei; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Tremor | 2008 |
Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Chromosome Disorders; Dihydroxyphenylalanine; DNA Mutational Analysis; Female; Genes, Dominant; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Pedigree; Phenotype; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Clinical heterogeneity in newly diagnosed Parkinson's disease.
Topics: Adult; Age Distribution; Age of Onset; Aged; Aged, 80 and over; Anxiety Disorders; Cluster Analysis; Cohort Studies; Comorbidity; Depressive Disorder; Disability Evaluation; Disease Progression; Female; Humans; Immunity, Innate; Levodopa; Male; Middle Aged; Movement Disorders; Netherlands; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life | 2008 |
Patterns of bidirectional communication between cortex and basal ganglia during movement in patients with Parkinson disease.
Topics: Aged; Analysis of Variance; Brain Mapping; Cerebral Cortex; Deep Brain Stimulation; Dopamine Agonists; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Subthalamic Nucleus | 2008 |
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
Topics: Age Factors; Aged; Antiparkinson Agents; Body Size; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease | 2008 |
[Multi-infarct disorder presenting as corticobasal degeneration (DCB): vascular pseudo-corticobasal degeneration?].
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dementia, Multi-Infarct; Diagnosis, Differential; Disease Progression; Drug Resistance; Electroencephalography; Epilepsies, Myoclonic; Female; Functional Laterality; Gait Apraxia; Humans; Hypertension; Levodopa; Magnetic Resonance Imaging; Middle Aged; Nerve Degeneration; Neurologic Examination; Parkinson Disease; Phenotype | 2007 |
The evolution of disability in Parkinson disease.
Topics: Activities of Daily Living; Aged; Diagnosis, Differential; Disabled Persons; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Self Care; Severity of Illness Index; Tremor | 2008 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Primitive reflexes distinguish vascular parkinsonism from Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Neurons; Neuropsychological Tests; Parkinson Disease; Parkinsonian Disorders; Reflex | 2008 |
Multiparity after an initial diagnosis of Parkinson's disease: a report on a rare case.
Topics: Adult; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Live Birth; Natural Childbirth; Parity; Parkinson Disease; Pregnancy; Pregnancy Complications | 2008 |
Postural sway and effect of levodopa in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2008 |
Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.
Topics: Aged; Brain; Cognition Disorders; Female; Frontal Lobe; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Evidence of increased odds of essential tremor in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Essential Tremor; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2008 |
Provocation of Parkinsonian tremor.
Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tremor | 2008 |
A case of parkinsonism worsened by losartan: a probable new adverse effect.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dopamine Agonists; Drug Interactions; Humans; Hypertension; Levodopa; Losartan; Male; Parkinson Disease; Severity of Illness Index | 2008 |
[Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure].
Topics: Corpus Striatum; Drug Administration Schedule; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2008 |
Dynamic Bayesian network modeling of fMRI: a comparison of group-analysis methods.
Topics: Aged; Antiparkinson Agents; Bayes Theorem; Brain; Female; Humans; Image Interpretation, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Models, Neurological; Parkinson Disease | 2008 |
Managing Parkinson's disease with continuous dopaminergic stimulation.
Topics: Dopamine Agonists; Drug Administration Routes; Humans; Injections, Intravenous; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
Hypertrophy of intima media of the carotid artery due to L-dopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carotid Arteries; Female; Humans; Hypertrophy; Levodopa; Male; Parkinson Disease; Tunica Intima; Ultrasonography | 2008 |
Bilateral coordination of walking and freezing of gait in Parkinson's disease.
Topics: Antiparkinson Agents; Female; Functional Laterality; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Walking | 2008 |
Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease.
Topics: Adult; Aged; Deep Brain Stimulation; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2008 |
Dopaminergic modulation of prospective memory in Parkinson's disease.
Topics: Adult; Aged; Cognition; Corpus Striatum; Dopamine Agonists; Female; Frontal Lobe; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2008 |
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.
Topics: Aged; Blood Flow Velocity; Cerebrovascular Circulation; Deep Brain Stimulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Subthalamic Nucleus | 2008 |
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cocaine; Disease Models, Animal; Dopamine; Feedback; Functional Laterality; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Peptide Fragments; Quinolines; Radioisotopes; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-3; Serine; Substance P; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
[Precoce survey: a new self-assessment patient card for early detection and management of Parkinson disease fluctuations].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Reproducibility of Results; Surveys and Questionnaires | 2008 |
The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary?
Topics: Animals; Basal Ganglia; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Rats; Rats, Wistar | 2008 |
The paradoxical role of dopamine after subthalamic nucleus deep brain stimulation--downstream is upstream in a circuit diagram. Comment on "Does dopamine still have a leading role in advanced Parkinson's disease after subthalamic stimulation?" (Stereotact
Topics: Deep Brain Stimulation; Dopamine; Humans; Levodopa; Nerve Net; Parkinson Disease; Signal Transduction; Subthalamic Nucleus | 2008 |
Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Topics: Animals; Callithrix; Corpus Striatum; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Models, Animal; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Rats; Rats, Wistar; Substantia Nigra | 2008 |
Diagnostic problems in Parkinson's disease.
Topics: Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Psychomotor Performance | 1984 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Neurons; Parkinson Disease; Pergolide; Piribedil; Receptors, Dopamine | 1984 |
Problems of levodopa treatment.
Topics: Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1984 |
Indications for surgical treatment of Parkinson's disease after levodopa therapy.
Topics: Combined Modality Therapy; Dominance, Cerebral; Follow-Up Studies; Humans; Levodopa; Nerve Fibers; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Thalamic Nuclei | 1984 |
Axial apraxia, a distinct phenomenon.
Topics: Adult; Aged; Apraxias; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1984 |
[Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
Topics: Benserazide; Dopamine; Endorphins; Humans; Hypothalamo-Hypophyseal System; Levodopa; Nerve Tissue Proteins; Parkinson Disease; Prolactin; Receptors, Dopamine; Synaptic Transmission; Thyrotropin; Thyrotropin-Releasing Hormone | 1984 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Homovanillic Acid; Levodopa; Parkinson Disease; Raphe Nuclei; Rats; Serotonin; Tyrosine 3-Monooxygenase | 1980 |
Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
Topics: Aged; Blood Pressure; Bromocriptine; Drug Tolerance; Ergolines; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Bromocriptine in treatment of levodopa-induced end-of-dose dystonia.
Topics: Bromocriptine; Dystonia; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
Managing the patient with Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Health Education; Histamine H1 Antagonists; Humans; Levodopa; Parkinson Disease; Self-Help Devices; Tremor | 1980 |
Bromocriptine for levodopa-induced end-of-dose dystonia.
Topics: Aged; Bromocriptine; Dystonia; Female; Humans; Levodopa; Parkinson Disease | 1981 |
[Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
Topics: Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1981 |
Dopamine receptors in the Parkinsonian brain.
Topics: Aged; Antipsychotic Agents; Brain; Caudate Nucleus; Female; Humans; Kinetics; Levodopa; Male; Parkinson Disease; Postmortem Changes; Putamen; Receptors, Dopamine; Spiperone | 1981 |
The role of anticholinergic drugs in extra-pyramidal syndromes.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1981 |
Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Radioligand Assay | 1982 |
Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
Topics: Administration, Oral; Carbidopa; Dopamine; Drug Combinations; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Adrenergic; Time Factors | 1982 |
[Parkinson disease].
Topics: Atropine; Automobile Driving; Biogenic Amines; Diagnosis, Differential; Disability Evaluation; Extrapyramidal Tracts; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Physical Therapy Modalities; Substantia Nigra | 1981 |
Dopaminergic deficiency and delayed visual evoked potentials in humans.
Topics: Adult; Antipsychotic Agents; Carbidopa; Dopamine; Drug Therapy, Combination; Evoked Potentials, Visual; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenothiazines; Schizophrenia | 1982 |
[Drug therapy of parkinsonism].
Topics: Amantadine; Bromocriptine; Dopamine Antagonists; Humans; Levodopa; Neurotransmitter Agents; Parasympatholytics; Parkinson Disease | 1982 |
Relatively high levels of dopamine in nucleus accumbens of levodopa treated patients with Parkinson's disease.
Topics: Aged; Dopamine; Globus Pallidus; Humans; Immunoenzyme Techniques; Levodopa; Male; Nucleus Accumbens; Parkinson Disease; Putamen; Septal Nuclei; Substantia Nigra; Tyrosine 3-Monooxygenase | 1982 |
On/off syndrome in Parkinson's disease and intravenous levodopa.
Topics: Brain; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 1982 |
Deprenyl in Parkinson's disease.
Topics: Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1982 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Time Factors | 1982 |
On-off syndrome in Parkinson's disease and intravenous levodopa.
Topics: Brain; Infusions, Parenteral; Levodopa; Parkinson Disease; Receptors, Dopamine; Syndrome | 1982 |
[Problems and future perspectives in the treatment of Parkinson's disease].
Topics: Acetylcholine; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1982 |
Basal ganglia disease.
Topics: Basal Ganglia Diseases; Dopamine; Humans; Huntington Disease; Levodopa; Models, Biological; Movement Disorders; Neurotransmitter Agents; Parasympatholytics; Parkinson Disease | 1982 |
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary | 1983 |
A comparison of two iatrogenic dyskinesias.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Extremities; Facial Muscles; Female; Humans; Iatrogenic Disease; Jaw; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue | 1983 |
Chairman's introduction: role of the pallidum and its transmitters in the therapy of parkinsonian rigidity and akinesia.
Topics: Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Stereotaxic Techniques | 1984 |
Juvenile parkinsonism--some clinical, pharmacological, and neuropathological aspects.
Topics: Adult; Brain; Female; Humans; Levodopa; Locus Coeruleus; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 1984 |
Parkinson's disease, 1984.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
Effect of L-dopa on course of Parkinson's disease.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
[Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
Topics: Adult; Aged; Animals; Brain Chemistry; Carboxy-Lyases; Dopamine; Drug Therapy, Combination; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine; Rats | 1980 |
The effect of levodopa treatment on the visual evoked potentials in Parkinsonian patients.
Topics: Evoked Potentials; Humans; Levodopa; Parkinson Disease; Photic Stimulation | 1980 |
Effects of L-DOPA on the excretion of alcoholic metabolites of catecholamines and trace amines in rat and human urine.
Topics: 3-Methoxy-4-hydroxyphenylethanol; Amines; Animals; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Parkinson Disease; Phenylethyl Alcohol; Rats | 1981 |
Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment.
Topics: Aged; Cyclic AMP; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Parkinson Disease; Serotonin | 1982 |
Long-term experience with bromocriptine in advanced parkinsonism. Results after one year's treatment.
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1982 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocriptine; Depression; Fludrocortisone; Humans; Hypotension, Orthostatic; Levodopa; Midodrine; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Thalamus; Tremor | 1983 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Animal; Dopamine; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Posture; Pyridines; Substantia Nigra | 1983 |
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1983 |
Substance P immunoreactivity in the post-mortem parkinsonian brain.
Topics: Aged; Antipsychotic Agents; Brain Chemistry; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Radioimmunoassay; Substance P; Substantia Nigra | 1984 |
Normal erythrocyte uptake of L-DOPA in Parkinson's, Huntington's, and related diseases.
Topics: Biological Transport; Erythrocytes; Humans; Huntington Disease; Levodopa; Neuromuscular Diseases; Parkinson Disease | 1983 |
[Circadian rhythm of catecholamine excretion, effect of L-DOPA and Nacom in various diseases of the nervous system].
Topics: Adult; Aged; Carbidopa; Catecholamines; Drug Combinations; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Muscular Dystrophies; Nervous System Diseases; Neurotic Disorders; Parkinson Disease | 1983 |
[Parkinson's disease. Retrospective study of 302 clinical case records].
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1984 |
Dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1984 |
[Early or late dopa therapy in Parkinson's disease].
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1984 |
Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
Topics: Aged; Carbidopa; Cyclic AMP; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates | 1981 |
Plasma beta-lipotropin levels in Parkinson's disease.
Topics: Adrenocorticotropic Hormone; Aged; beta-Lipotropin; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Reference Values | 1982 |
Dopamine neurotransmission and brain function.
Topics: Brain; Dopamine; Humans; Levodopa; Parkinson Disease; Synapses; Synaptic Transmission | 1982 |
Abnormalities in postural reflexes and voluntarily induced automatic movements in Parkinson patients.
Topics: Basal Ganglia; Humans; Levodopa; Movement Disorders; Parkinson Disease; Posture; Reflex, Abnormal | 1982 |
Dopamine agonists in the treatment of Parkinson's disease.
Topics: Blood Pressure; Bromocriptine; Disability Evaluation; Domperidone; Dopamine; Ergolines; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Pleural Effusion; Receptors, Neurotransmitter; Time Factors | 1983 |
Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Topics: Apomorphine; Brain; Bromocriptine; Humans; Levodopa; Parkinson Disease; Prolactin; Receptors, Dopamine; Receptors, Opioid; Thyrotropin-Releasing Hormone | 1983 |
Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
Topics: Animals; Corpus Striatum; Dopamine; Feedback; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission | 1983 |
Brain enkephalin receptors in Parkinson's disease.
Topics: Aged; Brain; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Female; Humans; Kinetics; Levodopa; Male; Naloxone; Nucleus Accumbens; Parkinson Disease; Receptors, Dopamine; Receptors, Opioid; Substantia Nigra | 1983 |
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Topics: Animals; Brain; Catalase; Catecholamines; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Levodopa; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Selegiline; Superoxide Dismutase; Superoxides | 1983 |
Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease.
Topics: Antiparkinson Agents; Autoradiography; Blood Glucose; Brain; Deoxyglucose; Drug Therapy, Combination; Fluorodeoxyglucose F18; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1984 |
[Experiences with stereotaxis in Parkinson patients treated with levodopa].
Topics: Aged; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Ventromedial Hypothalamic Nucleus | 1983 |
Recent status of stereotaxic surgery.
Topics: Brain Diseases; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1983 |
A personal tribute to Dr. George C. Cotzias, clinician and scientist.
Topics: History, 20th Century; Humans; Levodopa; Melanins; Parkinson Disease; United States | 1983 |
The present role of stereotactic surgery in the management of Parkinson's disease.
Topics: Combined Modality Therapy; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1984 |
Levodopa-induced dyskinesia and thalamotomy.
Topics: Adolescent; Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microsurgery; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei | 1984 |
[Combined (surgical and drug) therapy of parkinsonism].
Topics: Benserazide; Catecholamines; Combined Modality Therapy; Diencephalon; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1984 |
The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson's disease.
Topics: Adult; Aged; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Prognosis; Stereotaxic Techniques | 1984 |
[Drug treatment of Parkinson syndrome].
Topics: Dopamine Antagonists; Humans; Levodopa; Long-Term Care; Parkinson Disease | 1983 |
Intermittent levodopa therapy in parkinsonism.
Topics: Aged; Biomechanical Phenomena; Corpus Striatum; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1983 |
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
Topics: Adult; Age Factors; Aged; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1983 |
Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
Topics: Aged; Benserazide; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
Topics: Animals; Brain Chemistry; Dextroamphetamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline; Stereotyped Behavior | 1984 |
DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
Topics: Aged; Antiparkinson Agents; Blood-Brain Barrier; Carboxy-Lyases; Dopamine; Droxidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Serine | 1984 |
Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
Topics: Benzamides; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Tiapamil Hydrochloride | 1984 |
Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
Topics: Aged; Disability Evaluation; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1984 |
A personal and scientific biography of Dr. George C. Cotzias.
Topics: Brain Chemistry; Dihydroxyphenylalanine; Dopamine; History, 20th Century; Humans; Levodopa; Manganese Poisoning; Parkinson Disease; Trace Elements | 1984 |
Deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Outcome and Process Assessment, Health Care; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment.
Topics: Aged; Arousal; Behavior; Cognition; Drug Therapy, Combination; Emotions; Female; Humans; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).
Topics: Drug Therapy, Combination; Humans; Levodopa; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors | 1983 |
Drug treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1984 |
Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Topics: Aged; Benserazide; Droxidopa; Gait; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Parkinson Disease; Serine | 1984 |
Therapy of neurologic disorders in the elderly.
Topics: Aged; Amantadine; Anticoagulants; Brain Ischemia; Bromocriptine; Carbidopa; Dexamethasone; Drug Interactions; Heparin; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Trihexyphenidyl | 1984 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Hydroxydopamines; Kinetics; Levodopa; Male; Membranes; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1984 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
Topics: Adult; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Epinephrine; Humans; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Tyrosine | 1984 |
Chronic neurological diseases: their societal burdens and potential solutions.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Ataxia; Axons; Brain Diseases; Cerebral Cortex; Chronic Disease; Dopamine; Humans; Huntington Disease; Immunoglobulin G; Levodopa; Motor Neurons; Multiple Sclerosis; Parkinson Disease | 1980 |
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.
Topics: Brain Chemistry; Cerebellar Diseases; Creatine Kinase; Dementia; Diet; Encephalitis; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Hypoxia; Levodopa; Multiple Sclerosis; Muscular Dystrophies; Nervous System Diseases; Parkinson Disease; Tissue Preservation | 1980 |
Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Topics: Aged; Carbidopa; Dystonia; Ergolines; Female; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1980 |
[Levodopa].
Topics: Humans; Levodopa; Parkinson Disease | 1980 |
[Effects of the "drug holiday" on problems of long-term levodopa therapy against Parkinson's disease].
Topics: Aged; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1984 |
[Early morning dystonia: a complication of levodopa therapy in Parkinson disease. Presentation of 4 cases].
Topics: Dystonia; Female; Foot; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1984 |
Levodopa dependence: a case report.
Topics: Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Substance-Related Disorders | 1984 |
Pergolide therapy in Parkinson's disease.
Topics: Aged; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
[Parkinson's disease and neurotransmitters].
Topics: Aged; Depressive Disorder; Dopamine; Humans; Levodopa; Parkinson Disease | 1984 |
[Long-term therapy of the Parkinson syndrome].
Topics: Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parasympatholytics; Parkinson Disease; Time Factors | 1984 |
Study on the striatal dopamine availability in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors | 1984 |
Response variations in the treatment of Parkinson's disease.
Topics: Carboxy-Lyases; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies | 1984 |
The natural history of Parkinson's disease.
Topics: Activities of Daily Living; Dementia; Dysarthria; Gait; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Parkinson Disease; Thalamus; Time Factors; Tremor | 1984 |
Difficulties in long term management of Parkinson's disease.
Topics: Dementia; Depression; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Parkinson Disease; Time Factors | 1984 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease | 1984 |
Recognition memory in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Female; Humans; Levodopa; Male; Memory; Memory, Short-Term; Middle Aged; Paired-Associate Learning; Parasympatholytics; Parkinson Disease; Psychological Tests; Verbal Behavior; Visual Perception | 1984 |
Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease.
Topics: Autonomic Nervous System; Blood Pressure; Carboxy-Lyases; Female; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 1984 |
Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Antagonists; Hydrazines; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra | 1984 |
Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration.
Topics: Animals; Behavior, Animal; Brain; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Substantia Nigra | 1984 |
[Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
Topics: Administration, Oral; Adult; Aged; Combined Modality Therapy; Electrophoresis; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1984 |
Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.
Topics: Adult; Aged; Attention; Basal Ganglia; Carbidopa; Cognition Disorders; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Activity; Movement; Parkinson Disease; Reaction Time | 1984 |
Neuroendocrinological studies of Parkinson disease.
Topics: Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Neurosecretory Systems; Parkinson Disease; Prolactin; Thyrotropin | 1984 |
Bromocriptine in the management of end of dose deterioration in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease | 1984 |
The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Dopamine; Humans; Levodopa; Methyltyrosines; Parkinson Disease; Tyrosine | 1984 |
[Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
Topics: Adult; Aged; Biological Availability; Corpus Striatum; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
[Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease | 1984 |
Domperidone and levodopa in Parkinson's disease.
Topics: Aged; Blood Pressure; Domperidone; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
[Comparison of the biological availability of levodopa in the preparations Dopaflex and Nakom in patients with parkinson disease].
Topics: Biological Availability; Humans; Kinetics; Levodopa; Parkinson Disease | 1984 |
[Complications of long-term levodopa therapy in Parkinson's disease].
Topics: Humans; Levodopa; Parkinson Disease | 1984 |
L-dopa decarboxylation in chronically treated patients.
Topics: Adult; Carbidopa; Chemistry, Organic; Decarboxylation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Organic Chemistry Phenomena; Parkinson Disease; Time Factors | 1984 |
Long-term treatment with pergolide: decreased efficacy with time.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1984 |
Combined use of benserazide and carbidopa in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease | 1984 |
Fatal hyperpyrexia after withdrawal of levodopa.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1984 |
Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Brain Chemistry; Catecholamines; Disease Models, Animal; Humans; Levodopa; Manganese; Manganese Poisoning; Melanins; Melanocyte-Stimulating Hormones; Parkinson Disease; Substantia Nigra | 1984 |
Severity of Parkinson's disease and the dosage of bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1984 |
Human ballistic arm abduction movements: effects of L-dopa treatment in Parkinson's disease.
Topics: Adult; Aged; Arm; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Substantia Nigra | 1984 |
Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy.
Topics: Humans; Levodopa; Parkinson Disease | 1984 |
Control of on/off phenomenon by continuous intravenous infusion of levodopa.
Topics: Administration, Oral; Adult; Humans; Infusions, Parenteral; Levodopa; Middle Aged; Parkinson Disease | 1984 |
Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.
Topics: Animals; Corpus Striatum; Denervation; Ergolines; Levodopa; Male; Parkinson Disease; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1984 |
Parkinson's disease.
Topics: Activities of Daily Living; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease | 1983 |
[Vascular parkinsonism and current methods for its drug treatment].
Topics: Adamantane; Aged; Humans; Intracranial Arteriosclerosis; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease | 1984 |
Platelet phenolsulphotransferase activity in Parkinson's disease.
Topics: Age Factors; Arylsulfotransferase; Blood Platelets; Carbidopa; Drug Combinations; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Sulfurtransferases; Time Factors | 1983 |
Pharmacological basis of akinesia in Parkinson's disease.
Topics: Brain; Dopamine; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Tremor | 1983 |
Symptoms and side effects in the course of Parkinson's disease.
Topics: Autonomic Nervous System Diseases; Dementia; Diagnosis, Differential; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Dopamine | 1983 |
Normal pressure hydrocephalus and Parkinson's disease.
Topics: Aged; Cerebrospinal Fluid Shunts; Combined Modality Therapy; Dementia; Female; Gait; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed | 1983 |
Oculomotor characteristics of parkinsonism in comparison with those of cerebellar ataxia.
Topics: Adult; Aged; Caloric Tests; Cerebellar Ataxia; Eye Movements; Female; Humans; Levodopa; Male; Meniere Disease; Middle Aged; Nystagmus, Pathologic; Ophthalmoplegia; Parkinson Disease; Postural Balance; Posture; Pursuit, Smooth; Saccades | 1983 |
Parkinsonism treated with levodopa: progression and mortality.
Topics: Aged; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1983 |
Dystonia--L-dopa responsive or juvenile parkinsonism?
Topics: Adolescent; Benserazide; Carbidopa; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Follow-Up Studies; Growth Hormone; Humans; Infant; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Problems associated with long-term levodopa treatment of Parkinson's disease.
Topics: Dementia; Differential Threshold; Disability Evaluation; Humans; Intelligence; Levodopa; Parkinson Disease; Risk | 1983 |
Variability in Parkinson's disease; clinical aspects, causes and treatment.
Topics: Aging; Fatigue; Humans; Levodopa; Movement Disorders; Neurasthenia; Parkinson Disease; Sleep | 1983 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
Cerebral blood flow and oxygen metabolism measurement with positron emission tomography in Parkinson's disease.
Topics: Brain; Cerebrovascular Circulation; Humans; Levodopa; Oxygen Consumption; Parkinson Disease; Regional Blood Flow; Tomography, Emission-Computed | 1984 |
Stridor and parkinsonism.
Topics: Aged; Female; Humans; Levodopa; Parkinson Disease; Respiratory Sounds | 1983 |
High-performance liquid chromatography with amperometric detection of plasma L-3,4-dihydroxyphenylalanine in Parkinsonian patients.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Humans; Hydrogen-Ion Concentration; Levodopa; Parkinson Disease | 1983 |
[Exploration of the tubero-hypophyseal dopaminergic system in patients with chronic parkinsonism during chronic treatment with L-DOPA].
Topics: Aged; Benserazide; Blood-Brain Barrier; Humans; Hypothalamo-Hypophyseal System; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Diagnosis and management of parkinsonism in the elderly.
Topics: Age Factors; Aged; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1983 |
Failure of a peripheral dopaminergic marker in Parkinson's disease.
Topics: Adult; Aged; Humans; Levodopa; Lymphocytes; Middle Aged; Parkinson Disease; Receptors, Dopamine; Spiperone; Tritium | 1983 |
[Parkinson's disease and mental deterioration. Apropos of 30 cases].
Topics: Adult; Aged; Female; Humans; Intelligence Tests; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Psychometrics; Rorschach Test | 1983 |
[Effect of L-dopa on clinical duration and quality of life of patients with Parkinsonism-dementia in Guam].
Topics: Age Factors; Aged; Asian People; Dementia; Female; Guam; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Sex Factors | 1983 |
Effects of 3-OM-dopa on monoamine metabolism in rat brain.
Topics: alpha-Methyltyrosine; Animals; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1983 |
Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1983 |
Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains | 1983 |
Relationship of motor symptoms to intellectual deficits in PD.
Topics: Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1983 |
Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
Topics: Benserazide; Bromocriptine; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sexual Dysfunction, Physiological | 1983 |
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
Topics: Administration, Oral; Aged; Amino Acids; Biological Transport; Blood-Brain Barrier; Brain; Dietary Proteins; Female; Humans; Infusions, Parenteral; Intestinal Absorption; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1984 |
Progress in Parkinson's disease.
Topics: Animals; Humans; Levodopa; Parkinson Disease | 1984 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.
Topics: Acetylcholine; Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Physostigmine; Time Factors | 1984 |
Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Topics: Corpus Striatum; Dopa Decarboxylase; Dopamine; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Time Factors | 1984 |
Catechol-O-methyltransferase and Parkinson's disease.
Topics: Animals; Brain; Catechol O-Methyltransferase; Corpus Striatum; Levodopa; Male; Methyldopa; Parkinson Disease; Propiophenones; Rats; Rats, Inbred Strains | 1984 |
Neuropsychological disturbances and cerebral atrophy determined by computerized tomography in parkinsonian patients with long-term levodopa treatment.
Topics: Brain; Cognition Disorders; Dementia; Humans; Levodopa; Parkinson Disease; Tomography, X-Ray Computed | 1984 |
Epidemiological survey of dementia in parkinsonism and control population.
Topics: Age Factors; Dementia; Humans; Levodopa; Parkinson Disease; Sex Factors | 1984 |
Depression and Parkinson's disease.
Topics: Depressive Disorder; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Personality Assessment | 1984 |
Mental disorders in Parkinson's disease after treatment with L-DOPA.
Topics: Aged; Anxiety Disorders; Confusion; Delirium; Dementia; Depressive Disorder; Female; Hallucinations; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1984 |
Psychiatric complications of levodopa therapy of Parkinson's disease.
Topics: Circadian Rhythm; Hallucinations; Humans; Hydrocortisone; Levodopa; Mental Disorders; Mood Disorders; Parkinson Disease; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Thinking | 1984 |
Structure of psychomotor functions in parkinsonian patients during long-term treatment.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychological Tests; Psychomotor Performance | 1984 |
Is parkinsonian gait caused by a regression to an immature walking pattern?
Topics: Adult; Aged; Biological Evolution; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1984 |
CSF GABA levels in Parkinson's disease.
Topics: Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease; Probenecid | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Domperidone; Ergolines; Humans; Levodopa; Mental Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Pergolide | 1984 |
Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Bromocriptine and lisuride in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1984 |
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Topics: Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1984 |
Clinical administration of parlodel in low doses.
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Rolipram in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Pyrrolidinones; Rolipram | 1984 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Levodopa; Limbic System; Male; Mice; Parkinson Disease; Reserpine | 1984 |
Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Evoked Potentials, Visual; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1984 |
Epidemiology of Parkinson's disease.
Topics: Adult; Aged; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Minnesota; Parkinson Disease | 1984 |
Should levodopa therapy be started early or late?
Topics: Disability Evaluation; Humans; Levodopa; Parkinson Disease; Time Factors | 1984 |
Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment.
Topics: Adult; Aged; Biomechanical Phenomena; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Time Factors | 1984 |
Are levodopa "drug holidays" justified?
Topics: Humans; Levodopa; Movement; Outcome and Process Assessment, Health Care; Parkinson Disease; Time Factors | 1984 |
Should dopamine agonists be given early or late in the treatment of Parkinson's disease?
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1984 |
Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine.
Topics: Aged; Bromocriptine; Drug Evaluation; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1984 |
Diagnosis and management of Parkinson's disease.
Topics: Bromocriptine; Diagnosis, Differential; Humans; Levodopa; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Tremor | 1984 |
[Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 1984 |
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1984 |
What to do when Sinemet fails: Part one.
Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1984 |
Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Asian People; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Erythrocytes; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; White People | 1984 |
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
Topics: Aged; Brain; Butyrophenones; Caudate Nucleus; Dopamine; Homovanillic Acid; Humans; Levodopa; Nucleus Accumbens; Paralysis; Parkinson Disease; Phenylacetates; Putamen; Receptors, Dopamine; Spiperone; Substantia Nigra | 1984 |
"On-off" phenomenon in Parkinson's disease.
Topics: Animals; Carbidopa; Humans; Levodopa; Methyldopa; Parkinson Disease | 1984 |
[Exogenous psychoses in Parkinson syndrome. Frequency and causal conditions].
Topics: Adult; Aged; Antiparkinson Agents; Brain; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Dopamine; Risk | 1984 |
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.
Topics: Aged; Brain Chemistry; Dopamine; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; Phenethylamines; Selegiline; Serotonin | 1980 |
[Usefulness of new drugs].
Topics: Cost-Benefit Analysis; Humans; Hypertension; Influenza Vaccines; Levodopa; Measles Vaccine; Parkinson Disease; Poliomyelitis; Poliovirus Vaccine, Oral; Psychotropic Drugs; Tuberculosis; Vaccination | 1980 |
Long-term efficacy of bromocriptine in Parkinson disease.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1980 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Long-term responses of Parkinson's disease to levodopa therapy.
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 1980 |
Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin-Releasing Hormone | 1980 |
The use of bromocriptine for testing central dopaminergic reactivity.
Topics: Blood Pressure; Brain; Bromocriptine; Drug Resistance; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine; Renin | 1980 |
Levodopa: long-term impact on Parkinson's disease.
Topics: Atrophy; Cerebral Cortex; Dementia; Hallucinations; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1981 |
Levodopa: long-term impact on Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1981 |
Levodopa: long-term impact on Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1981 |
Levodopa: long-term impact on Parkinson's disease.
Topics: Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Humans; Levodopa; Parkinson Disease; Shy-Drager Syndrome | 1981 |
Levodopa: long-term impact on Parkinson's disease.
Topics: Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1981 |
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Topics: Aged; Benserazide; Drug Combinations; Electromyography; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Thyrotropin; Thyrotropin-Releasing Hormone | 1980 |
"On-off" syndrome treated with lithium carbonate: a case report.
Topics: Adult; Athetosis; Chorea; Humans; Levodopa; Lithium; Lithium Carbonate; Male; Parkinson Disease; Receptors, Dopamine | 1981 |
Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide.
Topics: Benserazide; Drug Administration Schedule; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1982 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
[Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
Topics: Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Combinations; Epinephrine; Humans; Levodopa; Norepinephrine; Parkinson Disease | 1981 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
Topics: Amphetamine; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Levodopa; Methamphetamine; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1982 |
A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients.
Topics: Autoanalysis; Dihydroxyphenylalanine; Erythrocytes; Humans; Levodopa; Methyltyrosines; Parkinson Disease; Spectrometry, Fluorescence; Tyrosine | 1982 |
(-)Deprenyl in the treatment of Parkinson's disease.
Topics: 5-Hydroxytryptophan; Brain; Dopamine; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin | 1982 |
[Treatment of Parkinson disease].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease | 1982 |
Bromocriptine and lisuride in Parkinson disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1983 |
Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients.
Topics: Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Probenecid | 1983 |
A quantitative study of the electroencephalographic response to levodopa treatment in parkinsonian patients.
Topics: Aged; Carbidopa; Cerebral Cortex; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1983 |
[Effect of lisuride in the "on-off" phenomena due to L-dopa].
Topics: Aged; Antiparkinson Agents; Drug Evaluation; Drug Resistance; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1983 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine | 1983 |
Abnormal involuntary movements: a study of dopaminergic receptor interaction.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Receptors, Dopamine | 1983 |
Levodopa-free periods ("drug holidays") in the management of parkinsonism.
Topics: Aged; Ambulatory Care; Female; Health Planning Guidelines; Hospitalization; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1983 |
The effect of lithium on the "on-off" phenomenon in parkinsonism.
Topics: Adult; Double-Blind Method; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Movement Disorders; Parkinson Disease; Random Allocation | 1983 |
Pergolide treatment in parkinsonism.
Topics: Adult; Aged; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Respiration Disorders | 1983 |
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1983 |
Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Disability Evaluation; Drug Evaluation; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1983 |
Changes in electroretinogram and serum potassium during L-DOPA treatment in parkinsonism.
Topics: Aged; Electroretinography; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Potassium; Receptors, Dopamine; Retina | 1983 |
[Bromocriptine (Parlodel) in the treatment of Parkinson's disease. Summary of 7 years' experience].
Topics: Bromocriptine; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1983 |
Pergolide mesylate and idiopathic Parkinson disease.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 1982 |
Further studies with pergolide in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Confusion; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1982 |
Weekly drug holiday in PD.
Topics: Humans; Levodopa; Parkinson Disease | 1982 |
Helpful tips you can give your patients with Parkinson's disease.
Topics: Humans; Levodopa; Locomotion; Male; Middle Aged; Movement; Parkinson Disease; Patient Education as Topic | 1980 |
[Parkinsonism].
Topics: Aged; Amantadine; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
Levodopa-carbidopa.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Parkinson Disease; Pregnancy | 1980 |
[L. Dopa].
Topics: Adult; Drug Interactions; Humans; Levodopa; Parkinson Disease | 1980 |
Students' forum. Let's look at a problem: Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Parkinsonism: forgotten considerations in medical treatment and nursing care.
Topics: Adult; Blood-Brain Barrier; Humans; Levodopa; Middle Aged; Parkinson Disease | 1982 |
Normal pressure hydrocephalus in the parkinsonian patient.
Topics: Aged; Cerebrospinal Fluid Shunts; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Male; Parkinson Disease; Serum Albumin, Radio-Iodinated; Tomography, X-Ray Computed | 1982 |
[Therapy: anti-Parkinson medication].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1982 |
Senile Parkinsonism and dopa pharmacokinetics.
Topics: Aged; Gastric Emptying; Humans; Kinetics; Levodopa; Middle Aged; Parkinson Disease | 1981 |
Clinical analysis of akinesia.
Topics: Dopamine; Humans; Levodopa; Motor Skills; Movement Disorders; Muscle Rigidity; Parkinson Disease; Thalamus | 1980 |
Recent advances in the treatment of Parkinson's disease.
Topics: Brain; Bromocriptine; Drug Therapy, Combination; Endorphins; Enkephalins; Humans; Levodopa; Mental Disorders; Parkinson Disease; Receptors, Dopamine | 1980 |
Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
Topics: Aged; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1981 |
A comparison of levodopa treatment and task demands on visual evoked potentials in hemi-parkinsonism.
Topics: Adult; Aged; Attention; Carbidopa; Dominance, Cerebral; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Tryptophan deficiency stupor--a new psychiatric syndrome.
Topics: Aged; Animals; Carcinoid Tumor; Female; Humans; Levodopa; Malabsorption Syndromes; Male; Mental Disorders; Middle Aged; Muscles; Parkinson Disease; Serotonin; Syndrome; Tryptophan | 1982 |
Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
Topics: Amantadine; Amitriptyline; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Hyperkinesis; Levodopa; Lithium; Middle Aged; Parkinson Disease; Trazodone | 1980 |
The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study.
Topics: Activities of Daily Living; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1980 |
[Clinical application of insulin and L-dopa tests for evaluating the sympathico-adrenal system].
Topics: Adrenal Glands; Adult; Aged; Humans; Hypertension; Insulin; Levodopa; Middle Aged; Parkinson Disease; Schizophrenia; Stomach Ulcer; Sympathetic Nervous System | 1980 |
Chlordiazepoxide interaction with levodopa.
Topics: Aged; Chlordiazepoxide; Drug Interactions; Female; Humans; Levodopa; Parkinson Disease | 1982 |
Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Naloxone; Parkinson Disease; Receptors, Dopamine | 1982 |
Pergolide mesylate: new therapy for Parkinson disease.
Topics: Antiparkinson Agents; Arrhythmias, Cardiac; Ergolines; Humans; Levodopa; Parkinson Disease; Pergolide | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
A pure parkinsonian syndrome following acute carbon monoxide intoxication.
Topics: Acute Disease; Carbon Monoxide Poisoning; Female; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Tomography, X-Ray Computed | 1982 |
L-dopa treatment of Parkinson's disease: a ten-year follow up study.
Topics: Aged; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic | 1982 |
The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation; Time Factors | 1982 |
[Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Dose-Response Relationship, Drug; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin | 1982 |
[Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
Topics: Adult; Aged; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Topics: Aged; Carbidopa; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease.
Topics: Aged; Blepharospasm; Carbidopa; Dystonia; Facial Muscles; Female; Humans; Levodopa; Male; Mandibular Diseases; Middle Aged; Parkinson Disease; Syndrome; Time Factors | 1982 |
[Two cases of Parkinson's disease with diphasic dyskinesia, seen during levodopa treatment (author's transl)].
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Parkinsonism in the elderly.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease | 1982 |
[Treatment of Parkinson's syndrome].
Topics: Amantadine; Extrapyramidal Tracts; Humans; Levodopa; Parkinson Disease; Sulfates | 1982 |
Management of patients who fail to respond to levodopa therapy.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1982 |
Management of motor side effects of chronic levodopa therapy.
Topics: Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1982 |
Initial treatment of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Prognosis | 1982 |
Behavioral alterations and the therapy of parkinsonism.
Topics: Bipolar Disorder; Bromocriptine; Dementia; Depressive Disorder; Humans; Levodopa; Mental Processes; Parkinson Disease; Psychoses, Substance-Induced | 1982 |
The role of various forms of treatment in the management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1982 |
Bromocriptine combined with levodopa in Parkinson's disease.
Topics: Aged; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease | 1982 |
[Clinical study on headache in patients with Parkinson's disease].
Topics: Adult; Aged; Female; Headache; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Adverse interaction of levodopa with tricyclic antidepressants.
Topics: Aged; Amitriptyline; Carbidopa; Drug Combinations; Drug Interactions; Female; Humans; Imipramine; Levodopa; Parkinson Disease | 1982 |
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Homovanillic Acid; Levodopa; Male; Methyltyrosines; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1982 |
Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.
Topics: Aged; Bromocriptine; Carbidopa; Dreams; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Sleep Stages | 1982 |
Parkinson's disease: long-term results of levodopa therapy.
Topics: Adult; Aged; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance-Related Disorders | 1982 |
Blink rates in parkinsonism.
Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Confusion, dementia and anticholinergics in Parkinson's disease.
Topics: Cognition Disorders; Confusion; Dementia; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1982 |
New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Topics: Adult; Aged; Benserazide; Carbidopa; Choline; Cytidine Diphosphate Choline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
Uveal malignant melanoma and levodopa therapy in Parkinson's disease.
Topics: Aged; Ciliary Body; Female; Humans; Levodopa; Melanoma; Middle Aged; Parkinson Disease; Uveal Neoplasms | 1982 |
[A study on long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1982 |
[Pathophysiological mechanisms of adverse effects from levodopa therapy].
Topics: Brain; Dopamine; Humans; Kinetics; Levodopa; Parkinson Disease | 1982 |
Impairment of somatosensory feedback control of the tongue in Parkinson's disease: effect of L-Dopa therapy.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Disorders; Tongue | 1982 |
Is L-DOPA drug holiday useful?
Topics: Activities of Daily Living; Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1980 |
Parkinsonism and long-term levodopa.
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1980 |
Drug holiday and management of Parkinson disease.
Topics: Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1980 |
Thyroid function in Parkinson disease.
Topics: Aged; Carbidopa; Humans; Hypothyroidism; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Thyroid Diseases; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 1981 |
Evidence to support early levodopa therapy in Parkinson disease.
Topics: Athetosis; Chorea; Drug Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs.
Topics: Aged; Atrophy; Basal Ganglia Diseases; Benztropine; Cerebellum; Eye Movements; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Speech; Tomography, X-Ray Computed; Tropanes | 1981 |
Complications of chronic levodopa therapy: long-term efficacy of drug holiday.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome | 1981 |
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Diseases; Corpus Striatum; Dopamine; Glutamate Decarboxylase; Kainic Acid; Levodopa; Male; Neurons; Parkinson Disease; Rats; Serotonin | 1981 |
Treatment of advanced Parkinson disease with pergolide.
Topics: Aged; Arrhythmias, Cardiac; Brain; Dopamine; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Pergolide; Random Allocation | 1981 |
Alternate day levodopa therapy in parkinsonism.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Drug-induced asterixis in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Muscle Contraction; Muscular Diseases; Parkinson Disease; Posture | 1982 |
Drug holidays in management of Parkinson disease.
Topics: Humans; Levodopa; Parkinson Disease | 1982 |
Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
Topics: Administration, Oral; Age Factors; Aged; Biological Availability; Dopa Decarboxylase; Female; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Parkinson Disease | 1981 |
Cognitive fluctuations associated with on-off phenomenon in Parkinson disease.
Topics: Adult; Cognition; Humans; Levodopa; Male; Parkinson Disease; Psychological Tests; Receptors, Dopamine | 1982 |
Assessing L-dopa therapy for Parkinson's.
Topics: Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1981 |
Reversible supranuclear ophthalmoplegia associated with Parkinsonism.
Topics: Aged; Diagnosis, Differential; Female; Humans; Levodopa; Male; Ophthalmoplegia; Parkinson Disease | 1980 |
Normal plasma dopamine-beta-hydroxylase in non-treated and treated Parkinson patients.
Topics: Aged; Dopamine beta-Hydroxylase; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Bilateral vocal cord paralysis in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tracheotomy; Vocal Cord Paralysis | 1981 |
[Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
L-dopa competes with tyrosine and tryptophan for human brain uptake.
Topics: Aged; Benserazide; Blood-Brain Barrier; Brain; Female; Humans; Levodopa; Male; Parkinson Disease; Tryptophan; Tyrosine | 1980 |
[Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
Topics: Aged; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1980 |
Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Interference of levodopa and its metabolites with colorimetry of uric acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Colorimetry; Dopamine; Homovanillic Acid; Humans; Levodopa; Parkinson Disease; Uric Acid | 1981 |
Visual and auditory evoked responses in patients with Parkinson's disease.
Topics: Aged; Auditory Perception; Dominance, Cerebral; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Visual Perception | 1981 |
[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benzimidazoles; Bromocriptine; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1981 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
[Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
Topics: Adult; Aged; Female; Germany, West; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1981 |
Bromocriptine and its use in Parkinsonism.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease | 1981 |
Nomifensine: effect in Parkinsonian patients not receiving levodopa.
Topics: Aged; Double-Blind Method; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease | 1981 |
[L-dopa-resistant parkinsonism with cerebral atrophy: striato-nigral degeneration? 2 cases].
Topics: Atrophy; Brain; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1981 |
Senile parkinsonism, a study of current treatment.
Topics: Aged; Carboxy-Lyases; Data Collection; Dementia; Dopamine Antagonists; England; Humans; Levodopa; Parkinson Disease; Phenothiazines | 1981 |
Carbidopa-levodopa ratio in Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1981 |
High-performance liquid chromatographic determination of L-3,4-dihydroxy-phenylalanine (L-DOPA) and its metabolites in the urine of patients with Parkinson's disease, control patients and normal subjects after oral administration of L-DOPA.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine; Reference Values | 1981 |
Treatment of Parkinson's disease: problems with a progressing disease.
Topics: Bromocriptine; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis; Receptors, Dopamine | 1981 |
[L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Atrophy; Brain Diseases; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1981 |
L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
Topics: Aromatic-L-Amino-Acid Decarboxylases; Dopa Decarboxylase; Drug Resistance; Humans; Levodopa; Parkinson Disease | 1981 |
[Mental disorders in patients with Parkinson's disease treated with L-dopa].
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1981 |
[Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Trazodone | 1981 |
Chronic levodopa and renal function.
Topics: Blood Urea Nitrogen; Female; Glomerular Filtration Rate; Humans; Kidney; Levodopa; Male; Middle Aged; Parkinson Disease; Potassium; Sodium | 1981 |
[Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism].
Topics: Adult; Aged; Bromocriptine; Female; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Diseases | 1981 |
A case of sporadic juvenile Parkinson's disease.
Topics: Adult; Aging; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 1981 |
[The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease | 1981 |
Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.
Topics: Aged; Apomorphine; Electroconvulsive Therapy; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Prolactin | 1981 |
[Therapy of Parkinson (author's transl)].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1981 |
The "on-off" syndrome presenting as a conversion disorder.
Topics: Adult; Conversion Disorder; Diagnosis, Differential; Humans; Levodopa; Male; Parkinson Disease | 1981 |
"Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic | 1981 |
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine | 1981 |
Dystonic foot response of Parkinsonism.
Topics: Aged; Carbidopa; Dystonia; Foot Diseases; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1980 |
Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Treatment with tryptophan of levodopa-associated psychiatric disturbances.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Tryptophan | 1980 |
Electroconvulsive therapy in Parkinson's syndrome with "on-off" phenomenon.
Topics: Aged; Depression; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
REM ocular activity in Parkinsonian patients chronically treated with levodopa.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep, REM | 1980 |
Systemic activity of orally administered L-dopa in the elderly Parkinson patient.
Topics: Administration, Oral; Adult; Age Factors; Aged; Biological Availability; Female; Humans; Intestinal Absorption; Kinetics; Levodopa; Male; Metabolic Clearance Rate; Parkinson Disease | 1980 |
Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perphenazine; Psychotic Disorders | 1980 |
L-dopa and the secretion of sebum in Parkinsonian patients.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sebum | 1980 |
Oxpentifylline in Parkinson's disease.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pentoxifylline; Theobromine | 1980 |
Sinemet - 25/100.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1980 |
[Changeable aspects in the epidemiology of Parkinson disease (analysis of 262 cases during a period of 9 years].
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Spain; Time Factors | 1980 |
Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.
Topics: Administration, Oral; Aged; Animals; Biological Availability; Dogs; Female; Humans; Injections, Intravenous; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Species Specificity | 1980 |
Enteric coated levodopa for the medical management of parkinsonism.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets, Enteric-Coated | 1980 |
Bromocriptine in Parkinson's disease: report on 106 patients treated for up to 5 years.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
Further experiences with low doses of bromocriptine in Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease | 1980 |
Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
The role of bromocriptine in the treatment of Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
A comparative study of bromocriptine and levodopa in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Evaluation of Parkinson's disease.
Topics: Humans; Levodopa; Mental Disorders; Middle Aged; Parkinson Disease | 1980 |
Anticholinergics for Parkinson disease.
Topics: Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1980 |
Catechol-O-methyltransferase activity: a determinant of levodopa response.
Topics: Aged; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Erythrocytes; Female; Humans; Kidney; Levodopa; Liver; Male; Methyldopa; Middle Aged; Parkinson Disease; Time Factors | 1980 |
The role of D-1 and D-2 receptors.
Topics: Adenylyl Cyclases; Bromocriptine; Growth Hormone; Humans; Levodopa; Lisuride; Metoclopramide; Parkinson Disease; Pimozide; Prolactin; Receptors, Dopamine | 1980 |
[A study on mental symptoms developing during the treatment of Parkinson's disease (author's transl)].
Topics: Aged; Amantadine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Hypertension; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
[Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
Topics: Adult; Benserazide; Electrocardiography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1980 |
Electroconvulsive therapy in Parkinsonian patients with the "on-off" syndrome.
Topics: Depression; Dyskinesia, Drug-Induced; Dystonia; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
[Neurological aspects and modern trends in therapy of Parkinson's disease].
Topics: Atropine; Biperiden; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1980 |
[Amantadine in the therapy of Parkinson syndromes].
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Stimulation, Chemical | 1980 |
[Treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1980 |
Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Dogs; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
The impact of treatment with levodopa on Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1980 |
[A psychometric study of a group of Parkinsonian patients].
Topics: Female; Humans; Intelligence Tests; Levodopa; Male; Parkinson Disease; Psychometrics; Wechsler Scales | 1980 |
Lisuride in the treatment of Parkinsonism.
Topics: Administration, Oral; Aged; Bromocriptine; Drug Therapy, Combination; Ergolines; Humans; Injections, Intravenous; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1980 |
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Topics: Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Cross-Sectional Studies; Dialysis; Drug Synergism; Enzyme Inhibitors; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease | 1995 |
[Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms].
Topics: Aged; Brain; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychoses, Substance-Induced; Schizophrenia; Schizophrenic Psychology; Synaptic Transmission | 1995 |
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Autoradiography; Basal Ganglia; Dopamine Agents; Enkephalins; Female; Gene Expression; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Protein Precursors; RNA, Messenger; Sensitivity and Specificity; Tachykinins | 1995 |
[Initiation of treatment in Parkinson disease].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1995 |
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Humans; Levodopa; Lumbosacral Region; Male; Middle Aged; Norepinephrine; Parkinson Disease; Severity of Illness Index | 1995 |
[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline | 1995 |
Contingent negative variation and movement-related cortical potentials in parkinsonism.
Topics: Aged; Contingent Negative Variation; Evoked Potentials, Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Reaction Time | 1995 |
Parkinson's disease--medical education and psychosocial aspects.
Topics: Activities of Daily Living; Adaptation, Psychological; Curriculum; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Education as Topic; Spouses | 1995 |
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.
Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disease; Psychometrics; Serotonin | 1993 |
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antipsychotic Agents; Hallucinations; Humans; Isoxazoles; Levodopa; Parkinson Disease; Piperidines; Risperidone | 1994 |
Parkinson's disease: moving forward.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1995 |
Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Activity; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1995 |
Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases.
Topics: Aged; Atrophy; Brain; Cerebral Arteries; Dementia, Multi-Infarct; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Supranuclear Palsy, Progressive | 1995 |
A family with hereditary juvenile dystonia-parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Chromosome Aberrations; Chromosome Disorders; Dystonia; Female; Follow-Up Studies; Genes, Dominant; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pedigree; Torticollis | 1995 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Postural stability differentiates "lower body" from idiopathic parkinsonism.
Topics: Aged; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Severity of Illness Index | 1995 |
Motor performance in normal pressure hydrocephalus assessed with an optoelectronic measurement technique.
Topics: Aged; Antiparkinson Agents; Brain; Cohort Studies; Diagnosis, Computer-Assisted; Female; Humans; Hydrocephalus; Levodopa; Locomotion; Male; Parkinson Disease; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 1995 |
Upper airway obstruction in Parkinson's disease.
Topics: Airway Obstruction; Carbidopa; Dopamine Antagonists; Fasting; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Apnea Syndromes | 1995 |
Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease.
Topics: Dopamine; Glutathione; Humans; Levodopa; Oxidation-Reduction; Parkinson Disease; Superoxides | 1995 |
Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1994 |
Profound hypotension immediately following insertion of methyl methacrylate during bipolar endoprosthesis in a patient with long-term levodopa-treated paralysis agitans.
Topics: Aged; Hip Prosthesis; Humans; Hypotension; Levodopa; Male; Methylmethacrylate; Methylmethacrylates; Parkinson Disease | 1995 |
Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period.
Topics: Body Temperature; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Menstrual Cycle; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 1993 |
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Parkinson Disease; Rabbits; Reserpine | 1995 |
Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
Topics: Administration, Oral; Aged; Benserazide; Bromocriptine; Deglutition; Deglutition Disorders; Drug Administration Schedule; Eating; Humans; Levodopa; Male; Parkinson Disease | 1995 |
Medical treatment of Parkinson's disease.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
Topics: Adult; Aged; Biperiden; Carbidopa; Evaluation Studies as Topic; Humans; Levodopa; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Treatment Outcome | 1994 |
CSF acetylcholinesterase in Parkinson disease: decreased enzyme activity and immunoreactivity in demented patients.
Topics: Acetylcholinesterase; Age Factors; Aged; Biomarkers; Dementia; Enzyme-Linked Immunosorbent Assay; Female; Humans; Levodopa; Male; Parkinson Disease; Sex Factors | 1995 |
The effect of task complexity on reaction times in memory scanning and visual discrimination in Parkinson's disease.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychometrics; Reaction Time; Task Performance and Analysis; Visual Perception | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
New pathophysiology of Parkinson's disease revealed by posteroventral pallidotomy.
Topics: Combined Modality Therapy; Gait; Globus Pallidus; Humans; Levodopa; Movement Disorders; Parkinson Disease; Serotonin; Thalamus; Treatment Outcome; Tremor | 1995 |
Long-duration response to levodopa.
Topics: Female; Humans; Levodopa; Male; Parkinson Disease; Time Factors | 1995 |
GTP cyclohydrolase I activity in mononuclear blood cells in juvenile parkinsonism.
Topics: Basal Ganglia; Dystonia; GTP Cyclohydrolase; Humans; Levodopa; Lymphocytes; Monocytes; Parkinson Disease | 1995 |
The levodopa test in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time; Walking | 1995 |
"Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study.
Topics: Aged; Corpus Striatum; Diagnosis, Differential; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Substantia Nigra | 1995 |
L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
Topics: Aged; Aged, 80 and over; Brain; Female; Humans; Levodopa; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Nerve Degeneration; Neural Pathways; Parkinson Disease; Putamen; Substantia Nigra | 1995 |
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
Topics: Affect; Aged; Anxiety; Arousal; Carbidopa; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1995 |
"Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
Topics: Aged; Botulinum Toxins; Dystonia; Electromyography; Female; Foot; Humans; Injections, Intramuscular; Levodopa; Male; Middle Aged; Muscle Contraction; Neurologic Examination; Pain; Parkinson Disease; Walking | 1995 |
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome | 1995 |
Visual evoked potentials (VEPs) in Parkinson's disease: correlation of pattern VEPs abnormality with dementia.
Topics: Aged; Dementia; Dominance, Cerebral; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Mental Status Schedule; Occipital Lobe; Parkinson Disease; Pattern Recognition, Visual; Reaction Time | 1995 |
A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation.
Topics: Adult; Aged; Female; Greece; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree; Phenotype; United States | 1995 |
The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1995 |
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.
Topics: Animals; Base Sequence; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Male; Molecular Sequence Data; Motor Activity; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Simplexvirus; Tyrosine 3-Monooxygenase | 1994 |
Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; GTP Phosphohydrolases; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1995 |
The prevalence of Parkinson's disease in Portugal. A population approach.
Topics: Adult; Age Factors; Aged; Cross-Sectional Studies; Disease Notification; Family Practice; Female; Follow-Up Studies; Hospitalization; Humans; Levodopa; Male; Middle Aged; Neurology; Parkinson Disease; Population Surveillance; Portugal; Prevalence; Referral and Consultation; Sex Factors | 1994 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |
Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms.
Topics: Animals; Base Sequence; Behavior, Animal; Capsules; Cell Line; Cloning, Molecular; Corpus Striatum; Dopamine; Drug Implants; Glial Cell Line-Derived Neurotrophic Factor; Kidney; Levodopa; Male; Molecular Sequence Data; Nerve Growth Factors; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; PC12 Cells; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 1995 |
Clozapine therapeutic plunge in patient with Parkinson's disease.
Topics: Carbidopa; Clozapine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1995 |
Dysphagia, a reversible cause not to be forgotten.
Topics: Aged; Aged, 80 and over; Deglutition Disorders; Humans; Levodopa; Male; Parkinson Disease | 1995 |
[The effects of dopamine on regional cerebral blood flow in patients with Parkinson's disease before and after L-dopa--measurement by Xe-enhanced CT].
Topics: Aged; Cerebrovascular Circulation; Corpus Striatum; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiographic Image Enhancement; Tomography, X-Ray Computed; Xenon | 1994 |
Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed; Treatment Outcome; Xenon | 1995 |
[A pharmacological study of levodopa solution therapy for a patient with Parkinson's disease with motor fluctuations].
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Solutions | 1995 |
Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment.
Topics: Aged; Glutathione; Glutathione Disulfide; Humans; Levodopa; Middle Aged; Parkinson Disease; Vitamin E | 1995 |
Hormones and Parkinson's disease.
Topics: Female; Hormones; Humans; Levodopa; Menstrual Cycle; Middle Aged; Parkinson Disease | 1995 |
Early diagnosis of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Facial Expression; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
International guide to drugs for Parkinson's disease.
Topics: Adamantane; Cholinergic Antagonists; Dopamine Antagonists; Histamine Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1995 |
Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.
Topics: Antiparkinson Agents; Brain Mapping; Carbidopa; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postoperative Complications | 1994 |
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.
Topics: Animals; Apoptosis; Catecholamines; DNA Damage; Dose-Response Relationship, Drug; Levodopa; Parkinson Disease; PC12 Cells; Rats; Reactive Oxygen Species; Time Factors | 1995 |
Parkinson's disease.
Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Europarkinson Preparatory Activity Research Group.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cluster Analysis; Cohort Studies; Cross-Cultural Comparison; Drug Prescriptions; Drug Utilization; Female; Humans; Iceland; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Whooping Cough | 1995 |
Levodopa use in Denmark: high levels in Greenland and the Faroe Islands. Europarkinson Preparatory Activity Research Group.
Topics: Adult; Aged; Aged, 80 and over; Cross-Cultural Comparison; Denmark; Drug Utilization; Female; Greenland; Humans; Infant; Infant Mortality; Infant, Newborn; Levodopa; Male; Middle Aged; Parkinson Disease; Population Dynamics; Socioeconomic Factors | 1995 |
PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
Topics: Adult; Aged; Brain; Carbon Radioisotopes; Caudate Nucleus; Cerebellum; Cocaine; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Serotonin; Thalamus; Tomography, Emission-Computed | 1995 |
Anticholinergic effects in a depressed parkinsonian patient.
Topics: Aged; Benztropine; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 1995 |
Disruptive nocturnal behavior in Parkinson's disease and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Behavior; Circadian Rhythm; Confusion; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Psychomotor Agitation; Sleep, REM | 1995 |
Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Frail Elderly; Hallucinations; Humans; Levodopa; Male; Mental Status Schedule; Parkinson Disease; Severity of Illness Index | 1995 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguinity; Drug Resistance; Female; Genes, Recessive; Globus Pallidus; Homovanillic Acid; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Pedigree; Trihexyphenidyl | 1994 |
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating | 1995 |
Acute effects of levodopa on wrist movement in Parkinson's disease. Kinematics, volitional EMG modulation and reflex amplitude modulation.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Reflex; Wrist | 1994 |
Dilemma in the treatment of Parkinson's disease with L-dopa.
Topics: Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Receptors, Dopamine; Survival Rate | 1994 |
Seven-year follow-up study of bromocriptine therapy for Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Neurons; Parkinson Disease; Substantia Nigra | 1994 |
Leg pain and numbness in an elderly man.
Topics: Aged; Aged, 80 and over; Bed Rest; Carbidopa; Humans; Leg; Levodopa; Male; Pain; Paresthesia; Parkinson Disease; Posture; Radiography; Spinal Stenosis | 1995 |
Which factors predict cognitive decline in Parkinson's disease?
Topics: Activities of Daily Living; Age of Onset; Aged; Cognition Disorders; Depressive Disorder; Educational Status; Humans; Levodopa; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Prognosis; Severity of Illness Index; Task Performance and Analysis; Tremor | 1995 |
[The effect of droxidopa on the monoamine metabolsim in the human brain].
Topics: Adult; Biogenic Monoamines; Brain; Droxidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Role of selegiline as initial monotherapy in early Parkinson's disease.
Topics: Activities of Daily Living; Drug Tolerance; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Safety; Selegiline; Time Factors; Tremor | 1994 |
Familial levodopa-responsive parkinsonian-pyramidal syndrome.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Carbidopa; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Pedigree | 1994 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl | 1994 |
Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study.
Topics: Atrophy; Brain Diseases; Corpus Striatum; Deoxyglucose; Female; Fluorodeoxyglucose F18; Glucose; Humans; Levodopa; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Substantia Nigra; Tomography, Emission-Computed | 1995 |
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception | 1994 |
The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.
Topics: Aged; Cisapride; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Psychomotor Performance | 1995 |
Day-night variation of urine volume in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Trihexyphenidyl; Urine | 1994 |
[Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations].
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1995 |
Peripheral catecholamine output in Parkinson's disease: effects of drug treatment.
Topics: Adrenal Medulla; Aged; Carbidopa; Catecholamines; Corpus Striatum; Epinephrine; Female; Humans; Levodopa; Male; Metanephrine; Middle Aged; Norepinephrine; Parkinson Disease; Vanilmandelic Acid | 1995 |
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cause of Death; Comorbidity; England; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Survival Rate; Wales | 1995 |
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Creatine; Dementia; Energy Metabolism; Female; Humans; Lactates; Levodopa; Magnetic Resonance Spectroscopy; Male; Middle Aged; Occipital Lobe; Oxidation-Reduction; Parkinson Disease; Phosphocreatine; Protons | 1995 |
Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.
Topics: Adult; Aged; Dopamine; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Placebos | 1993 |
Cabergoline in Parkinson's disease: long-term follow-up.
Topics: Adult; Aged; Cabergoline; Dopamine Agents; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain Diseases; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Male; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1994 |
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
Topics: Adult; Aged; Brain Diseases; Cerebellar Diseases; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Olivopontocerebellar Atrophies; Parkinson Disease; Substantia Nigra; Tremor | 1994 |
Parkinson's disease: making the diagnosis, selecting drug therapies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Foot; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects.
Topics: Adult; Aged; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1994 |
Levodopa and survival.
Topics: Humans; Levodopa; Parkinson Disease | 1994 |
[Tumoral Parkinson hemi-syndrome sensitive to L-dopa].
Topics: Benserazide; Brain Neoplasms; Drug Therapy, Combination; Glioblastoma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease | 1994 |
[A family of parkinsonism in which the clinical feature of constituents varied with the age of onset].
Topics: Age of Onset; Circadian Rhythm; Dystonia; Female; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedigree | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors | 1994 |
Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.
Topics: Brain Chemistry; Catalysis; Copper; DNA; DNA Damage; Dopamine; Humans; Hydrogen Peroxide; Iron; Levodopa; Oxidation-Reduction; Parkinson Disease; Tyrosine | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Brain; Functional Laterality; Humans; Levodopa; Motor Skills; Parkinson Disease | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
Topics: Aged; Clozapine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Middle Aged; Parkinson Disease; Postoperative Complications; Vagotomy; Vagus Nerve | 1994 |
Punding on levodopa.
Topics: Aged; Brain; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Stereotyped Behavior | 1994 |
[Disappearance of akinesia in Parkinson disease during a manic attack].
Topics: Aged; Bipolar Disorder; Dopamine; Female; Humans; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease | 1993 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
Routine outpatient L-dopa monitoring in elderly patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance | 1994 |
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Topics: Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Half-Life; Humans; Levodopa; Middle Aged; Movement; Neuronal Plasticity; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 1994 |
Levodopa: rational and irrational pharmacology.
Topics: Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1994 |
Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.
Topics: Adult; Aged; Brain Tissue Transplantation; Corpus Striatum; Female; Fetal Tissue Transplantation; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Motor Activity; Parkinson Disease; Tomography, Emission-Computed | 1994 |
Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kinetics; Levodopa; Longitudinal Studies; Male; Middle Aged; Models, Neurological; Monitoring, Physiologic; Motor Activity; Osmolar Concentration; Parkinson Disease; Placebos | 1994 |
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Topics: Adult; Aged; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Lisuride; Macaca mulatta; Male; Middle Aged; Parkinson Disease; Raclopride; Receptors, Dopamine D2; Salicylamides; Tomography, Emission-Computed | 1994 |
Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
Topics: Airway Obstruction; Antiparkinson Agents; Botulinum Toxins; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Electromyography; Genes, Recessive; Humans; Injections, Intramuscular; Laryngeal Diseases; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration Disorders; Respiratory Insufficiency; Respiratory Sounds; Sex Chromosome Aberrations; X Chromosome | 1994 |
Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1994 |
Therapy of patients with Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
Topics: Aged; Clozapine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Treatment of organic bipolar mood disorders in Parkinson's disease.
Topics: Bipolar Disorder; Clozapine; Drug Therapy, Combination; Female; Humans; Levodopa; Lithium Carbonate; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Recurrence | 1994 |
Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.
Topics: Aged; Biogenic Monoamines; Carbidopa; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Drugs for Parkinson's disease.
Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1993 |
[Long-latency auditory evoked responses in Parkinson disease and in parkinsonism induced by neuroleptics].
Topics: Aged; Antipsychotic Agents; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time | 1993 |
Terguride for dyskinesias.
Topics: Dopamine Agents; Humans; Levodopa; Lisuride; Parkinson Disease | 1993 |
Computer assisted CT-guided stereotactic transplantation of foetal ventral mesencephalon to the caudate nucleus and putamen in Parkinson's disease.
Topics: Caudate Nucleus; Drug Administration Schedule; Female; Fetal Tissue Transplantation; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Putamen; Stereotaxic Techniques; Therapy, Computer-Assisted; Tomography, X-Ray Computed | 1993 |
Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease.
Topics: Brain Tissue Transplantation; Dihydroxyphenylalanine; Dopamine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Putamen | 1994 |
Early treatment of Parkinson's disease. Open studies are unreliable.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease | 1994 |
[Diagnosis and treatment of Parkinson's disease in the elderly].
Topics: Aged; Brain; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sulpiride; Tiapamil Hydrochloride | 1993 |
Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism.
Topics: Aged; Attention; Female; Frontal Lobe; Humans; Language; Learning; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline; Space Perception; Verbal Learning | 1994 |
A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Basal Ganglia; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Tremor | 1993 |
Individualizing therapy in patients with disabling Parkinson's disease symptoms.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1994 |
The influence of the type, duration, severity and levodopa treatment of Parkinson's disease on cardiovascular autonomic responses.
Topics: Adult; Aged; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Severity of Illness Index; Tremor | 1993 |
HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.
Topics: Aged; Brain; Female; Humans; Levodopa; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1994 |
gamma delta+ T cells are increased in patients with Parkinson's disease.
Topics: Aged; Blood Cells; Cerebrospinal Fluid; Female; Headache; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Nervous System Diseases; Parkinson Disease; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes | 1994 |
Deprenyl and the issue of neuroprotection.
Topics: Antioxidants; Cell Survival; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Neurons; Parkinson Disease; Selegiline; Substantia Nigra; Vitamin E | 1994 |
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Topics: Activities of Daily Living; Adult; Aged; Chorea; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine D1; Video Recording | 1994 |
Levodopa, rice eating and on-off phenomenon.
Topics: Dietary Carbohydrates; Dietary Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Oryza; Parkinson Disease | 1993 |
Apomorphine increases blood glucose concentrations in Parkinson's disease.
Topics: Aged; Apomorphine; Blood Glucose; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
L-dopa malabsorption in a parkinsonian patient with Strongyloides stercoralis duodenitis.
Topics: Aged; Animals; Duodenitis; Humans; Intestinal Diseases, Parasitic; Levodopa; Male; Mebendazole; Metronidazole; Parkinson Disease; Strongyloides stercoralis; Strongyloidiasis | 1994 |
Apomorphine and diphasic dyskinesia.
Topics: Aged; Apomorphine; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
[The characteristics of catecholamine excretion in parkinsonism patients in effective treatment and therapeutic resistance].
Topics: Catecholamines; Chronic Disease; Drug Resistance; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1993 |
Cografts of adrenal medulla with peripheral nerve for Parkinson's disease.
Topics: Adrenal Medulla; Adrenalectomy; Adult; Benserazide; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Humans; Levodopa; Parkinson Disease; Peripheral Nerves; Time Factors; Transplantation, Autologous | 1994 |
Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1994 |
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Topics: Apomorphine; Cell Survival; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Reaction Time | 1994 |
Oral pulse levodopa therapy in mild Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance; Treatment Outcome | 1993 |
[Juvenile Parkinson's disease initially presenting as bulbar incoordination: a case report].
Topics: Adolescent; Bulbar Palsy, Progressive; Electromyography; Female; Humans; Levodopa; Parkinson Disease | 1994 |
Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
Topics: Adult; Aged; Biperiden; Brain; Electric Stimulation; Evoked Potentials; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Motor Cortex; Muscles; Parkinson Disease; Parkinson Disease, Secondary; Peripheral Nerves | 1994 |
Black cartilage after therapy with levodopa and methyldopa.
Topics: Aged; Aged, 80 and over; Cartilage, Articular; Dose-Response Relationship, Drug; Female; Humans; Intervertebral Disc; Levodopa; Male; Methyldopa; Microscopy, Electron; Parkinson Disease; Pigmentation; Ribs; Time Factors | 1994 |
[A 75-year-old man with parkinsonism and delirium].
Topics: Aged; Delirium; Fever; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substantia Nigra | 1994 |
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Limbic System; Long-Term Care; Male; Mesencephalon; Middle Aged; Parkinson Disease; Pilot Projects; Psychoses, Substance-Induced; Receptors, Dopamine D2; Remoxipride | 1994 |
N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
Topics: Aged; Dextromethorphan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1994 |
[Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid].
Topics: Aged; Female; Gastric Acid; Gastric Acidity Determination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Dose-Response Relationship, Drug; Female; Functional Laterality; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1994 |
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
Topics: Adult; Aged; Analysis of Variance; Brain Mapping; Cerebral Cortex; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors; Tomography, Emission-Computed, Single-Photon | 1994 |
Parkinson's disease dyskinesias.
Topics: Clozapine; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1994 |
Parkinson's disease dyskinesias.
Topics: Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1994 |
[Apomorphine test in Parkinson disease--dose and corresponding parameters].
Topics: Adult; Aged; Anthropometry; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Visual Perception | 1993 |
Disturbance of colour perception in Parkinson's disease.
Topics: Adult; Aged; Color Perception; Color Perception Tests; Computers; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1993 |
Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease.
Topics: Absorption; Adult; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Parkinson Disease; Penicillamine | 1993 |
Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.
Topics: Administration, Oral; Aged; Carbidopa; Colloids; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1993 |
Relationship between osteopenia and clinical characteristics of Parkinson's disease.
Topics: Absorptiometry, Photon; Aged; Bone Diseases, Metabolic; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease | 1993 |
What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis.
Topics: Atrophy; Autonomic Nervous System Diseases; Brain; Carbon Monoxide Poisoning; Deglutition Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Ophthalmoplegia; Parkinson Disease | 1993 |
Short-term memory and temporal ordering in early Parkinson's disease: effects of disease chronicity and medication.
Topics: Adult; Aged; Brain; Bromocriptine; Dementia; Female; Frontal Lobe; Humans; Language Tests; Levodopa; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parasympatholytics; Parkinson Disease; Psychiatric Status Rating Scales; Reaction Time; Task Performance and Analysis | 1993 |
Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
Topics: Aged; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Sleep; Sleep, REM | 1993 |
Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism.
Topics: Adolescent; Adult; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Dystonia; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Tomography, Emission-Computed | 1993 |
[Efficacy of the proteic redistribution diet (PRD) in the antiparkinsonian effect of L-dopa].
Topics: Aged; Combined Modality Therapy; Dietary Proteins; Energy Intake; Female; Food, Formulated; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Drug Administration Schedule; Drug Combinations; Eating; Female; Humans; Intestinal Absorption; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison.
Topics: Aged; Alzheimer Disease; Dementia; Evoked Potentials; Evoked Potentials, Visual; Humans; Levodopa; Mental Status Schedule; Parkinson Disease; Reaction Time; Regression Analysis | 1993 |
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
Topics: Biogenic Monoamines; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxydopamines; Levodopa; Norepinephrine; Oxidopamine; Parkinson Disease; Tyramine | 1993 |
Combination therapy for PD.
Topics: Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Randomized Controlled Trials as Topic | 1993 |
Combination therapy for PD.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 1993 |
Controlled-release levodopa.
Topics: Delayed-Action Preparations; Humans; Levodopa; Parkinson Disease | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Receptors, Dopamine D1; Receptors, Dopamine D2; Sensitivity and Specificity; Substantia Nigra; Time Factors | 1993 |
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Reference Values; Tomography, Emission-Computed, Single-Photon | 1993 |
Continuous duodenal infusions of levodopa.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Duodenum; Female; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Education as Topic | 1993 |
Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Learning; Levodopa; Male; Memory, Short-Term; Mental Recall; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Space Perception; Wechsler Scales | 1993 |
Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease.
Topics: Adrenal Medulla; Autopsy; Corpus Striatum; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Nerve Growth Factor; Transplantation, Autologous; Transplantation, Heterotopic | 1993 |
Reaction times and L-dopa.
Topics: Administration, Oral; Humans; Levodopa; Parkinson Disease; Pulsatile Flow; Reaction Time | 1994 |
Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.
Topics: Aged; Electroencephalography; Electromyography; Epilepsies, Myoclonic; Epilepsy, Generalized; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Seizures; Valproic Acid | 1993 |
[Parkinson disease: therapy].
Topics: Affective Symptoms; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1993 |
[Parkinson's disease: modern evolution].
Topics: Humans; Intelligence; Levodopa; Movement Disorders; Parkinson Disease | 1993 |
Levodopa pharmacodynamics.
Topics: Carbidopa; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; United States; United States Food and Drug Administration | 1994 |
Levodopa improves spatial contrast sensitivity in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Contrast Sensitivity; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Effects of apomorphine and L-dopa on the parkinsonian bladder.
Topics: Aged; Aged, 80 and over; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex, Abnormal; Urinary Bladder | 1993 |
The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine; Substance Withdrawal Syndrome | 1993 |
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychotic Disorders | 1993 |
Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Regression Analysis; Risk Factors | 1993 |
[Rhythmical involuntary movement at rest associated with olivo-ponto-cerebellar atrophy (OPCA)].
Topics: Adolescent; Aged; Brain; Clonazepam; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Olivopontocerebellar Atrophies; Parkinson Disease; Rest; Trihexyphenidyl | 1993 |
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Topics: Aged; Benserazide; Biogenic Monoamines; China; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
Event-related potentials in Parkinson's disease: a 12-month follow-up study.
Topics: Adult; Aged; Bromocriptine; Cognition; Drug Therapy, Combination; Evoked Potentials, Auditory; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 1993 |
Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors.
Topics: Aged; Atrophy; Autoradiography; Corpus Striatum; Drug Resistance; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Receptors, Dopamine D1; Receptors, Dopamine D2; Synapses | 1993 |
Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
Topics: Ascorbic Acid; Brain; Brain Neoplasms; Catecholamines; Cell Line; Drug Interactions; Female; Humans; Levodopa; Male; Neuroblastoma; Parkinson Disease; Quinones; Selegiline | 1993 |
Primary progressive freezing gait.
Topics: Aged; Diagnosis, Differential; Droxidopa; Female; Gait; Humans; Levodopa; Locomotion; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Posture; Tomography, X-Ray Computed | 1993 |
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Topics: Animals; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Fluorine Radioisotopes; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Nitriles; Parkinson Disease; Tomography, Emission-Computed | 1993 |
Levodopa-responsive parkinsonism associated with basal ganglia calcification and primary hypoparathyroidism.
Topics: Adult; Basal Ganglia; Basal Ganglia Diseases; Brain; Calcinosis; Calcium; Humans; Hypoparathyroidism; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinson Disease; Tomography, X-Ray Computed; Vitamin D | 1993 |
The spectrum of levodopa-related fluctuations in Parkinson's disease.
Topics: Aged; Depression; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Restless Legs Syndrome; Urinary Incontinence | 1993 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
Topics: Adult; Age Factors; Caudate Nucleus; Dihydroxyphenylalanine; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Tomography, Emission-Computed | 1993 |
Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
Topics: Aged; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Radioimmunoassay; Tremor | 1993 |
Visuospatial memory deficits at different stages of Parkinson's disease.
Topics: Aged; Attention; Discrimination Learning; Female; Humans; Levodopa; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Orientation; Parkinson Disease; Pattern Recognition, Visual | 1993 |
New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Topics: Brain; Central Nervous System Diseases; Dopamine; Female; Gene Expression; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1993 |
Parkinson's disease study.
Topics: Benserazide; Bias; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1993 |
Speech motor control in Parkinson's disease: a comparison between a clinical assessment protocol and a quantitative analysis of mandibular movements.
Topics: Aged; Dysarthria; Female; Humans; Levodopa; Male; Mandible; Middle Aged; Parkinson Disease; Phonation; Verbal Behavior | 1993 |
Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Topics: Aged; Aged, 80 and over; Atrophy; Basal Ganglia Diseases; Blood Platelets; Brain; Dopamine; Enzyme Induction; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Olivopontocerebellar Atrophies; Parkinson Disease; Shy-Drager Syndrome | 1993 |
Parkinson's disease.
Topics: Aged; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Topics: Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Minnesota; Parkinson Disease; Parkinson Disease, Secondary; Survival Analysis; Survival Rate; Time Factors | 1993 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
Antecedent clinical features associated with dementia in Parkinson's disease.
Topics: Aged; Dementia; Depression; Humans; Levodopa; Middle Aged; Odds Ratio; Parkinson Disease; Prevalence; Psychoses, Substance-Induced; Risk Factors | 1993 |
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Topics: Amino Acids; Biological Transport; Blood-Brain Barrier; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylalanine | 1993 |
6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
Topics: Adult; Caudate Nucleus; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Levodopa; Middle Aged; Models, Biological; Parkinson Disease; Putamen; Tomography, Emission-Computed | 1993 |
Reaction time responses in parkinsonian and hemiparkinsonian patients.
Topics: Attention; Dominance, Cerebral; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time | 1993 |
Single-dose L-dopa response in early Parkinson's disease: measurements with optoelectronic recording technique.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Locomotion; Male; Microcomputers; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Posture; Psychomotor Performance; Reference Values; Regression Analysis; User-Computer Interface; Video Recording | 1993 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Tremor | 1993 |
Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Topics: Aged; Apomorphine; Brain; Dopamine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Regional Blood Flow; Somatosensory Cortex; Tomography, Emission-Computed, Single-Photon | 1993 |
Different cerebral metabolism between parkinsonian rigidity and hyperkinesia (DID, chorea, dystonia). A PET study.
Topics: Basal Ganglia; Blood Glucose; Brain Mapping; Cerebral Cortex; Chorea; Dominance, Cerebral; Dystonia; Energy Metabolism; Humans; Hyperkinesis; Levodopa; Muscle Rigidity; Neural Pathways; Oxygen Consumption; Parkinson Disease; Thalamic Nuclei; Tomography, Emission-Computed | 1993 |
IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Dopamine; Homovanillic Acid; Humans; Levodopa; Neurons; Parkinson Disease | 1993 |
Parkinson's disease before age 30.
Topics: Adult; Aged; Brain; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tomography, X-Ray Computed | 1993 |
CSF biopterin levels and clinical features of patients with juvenile parkinsonism.
Topics: Adult; Biopterins; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neopterin; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; Thalamic Nuclei | 1993 |
Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Topics: Adult; Aged; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Tomography, Emission-Computed | 1993 |
PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Dystonia; Female; Humans; Japan; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Tomography, Emission-Computed | 1993 |
The clinical features of Parkinson's disease in 100 histologically proven cases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Corpus Striatum; Dementia; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Neurofibrillary Tangles; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Tissue Donors | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Protective effect of selegiline in the early and late phases of Parkinson's disease.
Topics: Age Factors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
Topics: Age Factors; Aged; Brain; Dementia; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Motor Activity; Motor Skills; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
Topics: Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clozapine; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1993 |
Awakenings: using a popular movie to teach clinical pharmacology.
Topics: Humans; Levodopa; Motion Pictures; Parkinson Disease; Pharmacology, Clinical; Surveys and Questionnaires | 1993 |
"Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Panic Disorder; Parkinson Disease; Psychiatric Status Rating Scales; Recurrence; Regression Analysis; Time Factors | 1993 |
Slowing of information processing in Parkinson's disease.
Topics: Aged; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Problem Solving; Reaction Time; Selegiline; Thinking | 1993 |
Age influences magnitude but not duration of response to levodopa.
Topics: Adult; Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1993 |
A clinicopathologic study of 100 cases of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Movement Disorders; Nervous System Diseases; Parkinson Disease; Survival Analysis | 1993 |
Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease | 1993 |
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Topics: Aged; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Droxidopa; Female; Gait; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 1993 |
Speed and power of higher cerebral functions in parkinsonian patients.
Topics: Arousal; Cognition; Female; Humans; Intelligence Tests; Levodopa; Male; Mental Processes; Middle Aged; Parkinson Disease; Perception; Psychomotor Performance | 1993 |
Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease.
Topics: Aged; Dementia; Depression; Depressive Disorder; Disability Evaluation; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Reference Values; Tremor | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Sustained-release levodopa in parkinsonian patients with nocturnal disabilities.
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Humans; Levodopa; Longitudinal Studies; Middle Aged; Movement Disorders; Parkinson Disease; Sleep Wake Disorders | 1993 |
Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.
Topics: Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electromyography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prostheses and Implants; Thalamic Nuclei; Tremor | 1993 |
Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
Topics: Adult; Aged; Basal Ganglia; Benzamides; Female; Humans; Levodopa; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1993 |
Is parkinsonian arm tremor a resting tremor?
Topics: Aged; Aged, 80 and over; Female; Fourier Analysis; Humans; Levodopa; Male; Microcomputers; Middle Aged; Muscle Contraction; Muscle Relaxation; Parkinson Disease; Posture; Signal Processing, Computer-Assisted; Tremor | 1993 |
Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 1993 |
Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aromatic Amino Acid Decarboxylase Inhibitors; Chromatography, High Pressure Liquid; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Topics: Adult; Aged; Apomorphine; Female; Follow-Up Studies; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
Topics: Acetazolamide; Adult; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Menstruation Disturbances; Neurologic Examination; Parkinson Disease | 1993 |
Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring.
Topics: Adult; Aged; Circadian Rhythm; Data Display; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microcomputers; Middle Aged; Monitoring, Physiologic; Motor Activity; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted; Sleep Stages | 1993 |
Response to L-DOPA in multiple system atrophy.
Topics: Adult; Aged; Carbidopa; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Movement Disorders; Muscle Rigidity; Olivopontocerebellar Atrophies; Parkinson Disease; Tremor | 1993 |
The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance.
Topics: Adenosine Triphosphate; Animals; Brain; Chromatography, High Pressure Liquid; Drug Interactions; Levodopa; Male; Methionine; Methionine Adenosyltransferase; Mice; Parkinson Disease; S-Adenosylmethionine | 1993 |
Serotonin and Parkinson's disease.
Topics: Basal Ganglia Diseases; Depressive Disorder; Dopamine; Drug Therapy, Combination; Fluoxetine; Humans; Levodopa; Parkinson Disease; Serotonin; Tryptophan | 1993 |
Coding of movement direction and amplitude in Parkinson's disease: are they differentially impaired (or unimportant)?
Topics: Aged; Attention; Humans; Levodopa; Male; Middle Aged; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time | 1993 |
Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Topics: Adsorption; Aluminum Oxide; Antiparkinson Agents; Carbidopa; Cation Exchange Resins; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Drug Combinations; Electrochemistry; Humans; Levodopa; Parkinson Disease; Resins, Synthetic; Silanes; Tetrahydropapaveroline | 1993 |
Executive function in Parkinson's disease: set-shifting or set-maintenance?
Topics: Aged; Attention; Basal Ganglia Diseases; Humans; Levodopa; Mental Processes; Neuropsychological Tests; Parkinson Disease; Regression Analysis | 1993 |
The audiospinal reaction in parkinsonian patients reflects functional changes in reticular nuclei.
Topics: Acoustic Stimulation; Aged; Electromyography; Female; H-Reflex; Habituation, Psychophysiologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Reticular Formation | 1993 |
Hypothesis: the bradyphrenia of parkinsonism is a nosological entity.
Topics: Adult; Aged; Aging; Alcohol Drinking; Antiparkinson Agents; Cognition; Cognition Disorders; Depressive Disorder; Ethanol; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Probability; Psychological Tests; Reaction Time | 1993 |
S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms.
Topics: Animals; Behavior, Animal; Catecholamines; Immobilization; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tremor | 1993 |
Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.
Topics: Adult; Aged; Brain; Brain Diseases; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Putamen; Radiography; Receptors, Dopamine D1; Tomography, Emission-Computed | 1993 |
No evidence for altered muscle mitochondrial function in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain Diseases; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria, Muscle; Multienzyme Complexes; NADH Dehydrogenase; Oxygen Consumption; Parkinson Disease; Respiratory Function Tests; Substantia Nigra | 1993 |
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Treatment of Parkinson's disease in a patient with acute intermittent porphyria.
Topics: Aged; Antiparkinson Agents; Benserazide; Chlorpromazine; Dopamine Antagonists; Drug Interactions; Female; Humans; Levodopa; Parkinson Disease; Porphyria, Acute Intermittent; Trihexyphenidyl | 1995 |
Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease.
Topics: Aged; Arginine; Female; Humans; Levodopa; Male; Middle Aged; Nitric Oxide; Nitrites; Parkinson Disease; Treatment Outcome | 1995 |
Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of levodopa treatment.
Topics: Analysis of Variance; Humans; Levodopa; Parkinson Disease; Reaction Time; Refractory Period, Electrophysiological | 1995 |
A simple model to explain the motor fluctuations seen in Parkinson's disease.
Topics: Humans; Levodopa; Models, Neurological; Movement; Parkinson Disease | 1995 |
GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; G(M1) Ganglioside; Levodopa; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Substantia Nigra | 1995 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antitubercular Agents; Dopa Decarboxylase; Homovanillic Acid; Humans; Isoniazid; Levodopa; Male; Middle Aged; Parkinson Disease; Rifampin; Tuberculosis, Pulmonary | 1995 |
Bilateral subthalamic nucleus stimulation for severe Parkinson's disease.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Electric Stimulation; Electrodes, Implanted; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Thalamic Nuclei | 1995 |
Selegiline in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Failure; United Kingdom | 1995 |
Clinical analysis of Parkinson's disease treated by integration of traditional Chinese and western medicine.
Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography.
Topics: Aged; Binding, Competitive; Brain; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Muscarinic; Tomography, Emission-Computed; Trihexyphenidyl | 1994 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Autoradiography; Basal Ganglia; Brain; Cell Death; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Nerve Degeneration; Neurons; Parkinson Disease; Radioligand Assay; Receptors, Transferrin; Reference Values | 1995 |
Pharmacodynamics of levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease | 1995 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Meta-Analysis as Topic; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
Topics: Antiparkinson Agents; Double-Blind Method; Levodopa; Parkinson Disease; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
Topics: Antiparkinson Agents; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
Topics: Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Research Design; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Levodopa reduces muscle tone and lower extremity tremor in Parkinson's disease.
Topics: Aged; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Tremor | 1995 |
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldehydes; Autopsy; Cross-Linking Reagents; Female; Humans; Immunohistochemistry; Levodopa; Male; Mesencephalon; Middle Aged; Motor Neurons; Nerve Tissue Proteins; Neurons; Oxidative Stress; Parkinson Disease; Reference Values; Substantia Nigra | 1996 |
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Cysteinyldopa; Humans; Levodopa; Malondialdehyde; Methoxyhydroxyphenylglycol; Middle Aged; Oxidative Stress; Parkinson Disease; Selegiline | 1996 |
Cortical inhibition in Parkinson's disease. A study with paired magnetic stimulation.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Differential Threshold; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Muscles; Neural Inhibition; Parkinson Disease; Reaction Time | 1996 |
[Parkinson disease. Early diagnosis and combined therapy for better prognosis].
Topics: Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Prognosis | 1993 |
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.
Topics: Adult; Amantadine; Antiparkinson Agents; Autopsy; Basal Ganglia; Brain Tissue Transplantation; Carbidopa; Cell Division; Cerebral Ventricles; Corpus Striatum; Embryo, Mammalian; Fetal Tissue Transplantation; Fetus; Gestational Age; Graft Survival; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Transplantation, Homologous | 1996 |
Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Topics: Aged; Antiparkinson Agents; Carbon Radioisotopes; Caudate Nucleus; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Putamen; Raclopride; Salicylamides; Synapses; Tomography, Emission-Computed | 1996 |
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
Topics: Aged; Antiparkinson Agents; Deglutition Disorders; Diagnosis, Differential; Diagnostic Errors; Diet Therapy; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Medical Records; Middle Aged; Parkinson Disease; Pneumonia, Aspiration; Supranuclear Palsy, Progressive; Survival Rate; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 1996 |
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Abnormalities of smooth eye and head movement control in Parkinson's disease.
Topics: Adult; Aged; Female; Head; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Pursuit, Smooth; Reaction Time; Reflex, Vestibulo-Ocular; Saccades | 1996 |
[Reversible esophageal dysfunction as a side effect of levodopa].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Esophageal Stenosis; Esophagoscopy; Humans; Levodopa; Male; Parkinson Disease; Radiography | 1996 |
A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales | 1995 |
Levodopa does not aggravate postural tremor in Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Tremor | 1995 |
Effects of levodopa and viscosity on the velocity and accuracy of visually guided tracking in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Data Interpretation, Statistical; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Neural Conduction; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Viscosity | 1996 |
Therapeutic dilemma: psychosis and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Risperidone | 1995 |
Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.
Topics: Aged; Antiparkinson Agents; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Sleep Wake Disorders; Sleep, REM | 1996 |
Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.
Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Densitometry; Electron Transport Complex IV; Female; Histocytochemistry; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary | 1996 |
[L-dopa and antiparkinson agents].
Topics: Antiparkinson Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 1996 |
[Urinary incontinence in patients with Parkinson syndrome].
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Urinary Incontinence; Urinary Incontinence, Stress; Urodynamics | 1996 |
[Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 1996 |
[Parkinsonism after lethargic encephalitis: possibly the first Spanish case in the second half of the century].
Topics: Adult; Age of Onset; Brain; Humans; Levodopa; Magnetic Resonance Imaging; Male; Meningoencephalitis; Parkinson Disease; Sleep Stages; Spain | 1996 |
Nursing care of patients undergoing pallidotomy.
Topics: Globus Pallidus; Humans; Levodopa; Neurosurgery; Parkinson Disease; Postoperative Care; Preoperative Care | 1996 |
[Daily defined doses of parkinsonian drugs in Alcoi].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Utilization; Humans; Levodopa; Parkinson Disease; Selegiline; Spain | 1996 |
Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients.
Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Dominance, Cerebral; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Thalamic Nuclei; Treatment Outcome | 1996 |
Clinical course of patients with idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cause of Death; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Survival Rate | 1996 |
Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catalase; Drug Therapy, Combination; Erythrocytes; Female; Free Radicals; Humans; Hydrogen Peroxide; Levodopa; Luminescent Measurements; Male; Middle Aged; Neutrophils; Nitric Oxide; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Superoxide Dismutase | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma.
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Brain; Diagnosis, Differential; Erectile Dysfunction; Humans; Levodopa; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Paraneoplastic Syndromes; Parkinson Disease; Urinary Incontinence; Verbal Behavior | 1996 |
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide | 1996 |
Does levodopa therapy delay death in Parkinson's disease?
Topics: Antiparkinson Agents; Humans; Levodopa; Minnesota; Parkinson Disease; Survival Analysis | 1996 |
Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Electromagnetic Fields; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1996 |
[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1995 |
Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome | 1996 |
Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease.
Topics: Aged; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors | 1995 |
Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording.
Topics: Antiparkinson Agents; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Cerebral Cortex; Chorea; Deoxyglucose; Dyskinesia, Drug-Induced; Electrodes, Implanted; Energy Metabolism; Fluorodeoxyglucose F18; Globus Pallidus; Humans; Levodopa; Motor Neurons; Neural Pathways; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, Emission-Computed; Tremor | 1995 |
Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Levodopa; Male; Parkinson Disease; Rats | 1995 |
Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Topics: Adult; Aged; Antiparkinson Agents; Benzamides; Case-Control Studies; Corpus Striatum; Dopamine Agents; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1995 |
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Case-Control Studies; Dopamine Agonists; Evoked Potentials, Somatosensory; Humans; Levodopa; Median Nerve; Middle Aged; Parkinson Disease; Psychotic Disorders; Reaction Time; Reference Values | 1995 |
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1995 |
Chronic anterior pallidal stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Monitoring, Intraoperative; Motor Skills; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted | 1995 |
Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dose-Response Relationship, Drug; Hypokinesia; Injections, Intraventricular; Levodopa; Male; Methylation; Motor Activity; Neostriatum; Parkinson Disease; Rats; Rats, Sprague-Dawley; S-Adenosylhomocysteine; S-Adenosylmethionine; Tremor | 1995 |
Zotepine in levodopa-induced Psychosis.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiepins; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1995 |
Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Seizures | 1995 |
Parkinson's disease affects automatic and spares intentional verbal learning. A stochastic approach to explicit learning processes.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Mental Recall; Middle Aged; Models, Psychological; Paired-Associate Learning; Parkinson Disease; Stochastic Processes; Verbal Learning | 1995 |
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbolines; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Parkinson Disease; Selegiline | 1995 |
Parkinson's disease epidemiology in the Northampton District, England, 1992.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Severity of Illness Index; Sex Factors | 1995 |
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Risk Factors; Selegiline | 1996 |
[Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations].
Topics: Aged; Antiparkinson Agents; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perceptual Disorders; Photic Stimulation | 1996 |
Sleep in older women with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Circadian Rhythm; Cross-Sectional Studies; Female; Humans; Levodopa; Middle Aged; Nursing Assessment; Parkinson Disease; Sleep Stages; Sleep Wake Disorders; Wakefulness | 1995 |
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Drug Stability; Drug Storage; Humans; Levodopa; Light; Parkinson Disease; Temperature; Time Factors | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Myoclonus; Neurologic Examination; Parkinson Disease; Verbal Behavior | 1996 |
Levodopa in pregnancy.
Topics: Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications; Risk Factors | 1996 |
Deprenyl's neuroprotective action remains unresolved.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Deprenyl and levodopa and Parkinson's disease progression.
Topics: Antiparkinson Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Selegiline | 1996 |
Deprenyl in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time; Severity of Illness Index; Treatment Outcome | 1996 |
Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease | 1995 |
Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Fluorine Radioisotopes; Levodopa; Macaca; Male; Parkinson Disease; Tomography, Emission-Computed | 1996 |
Muscle relaxation in Parkinson's disease: a reaction time study.
Topics: Aged; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscle Contraction; Muscle Relaxation; Parkinson Disease; Reaction Time; Recruitment, Neurophysiological | 1996 |
Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
Topics: Abdominal Muscles; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Biperiden; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Electromyography; Humans; Levodopa; Male; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease | 1996 |
Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene.
Topics: Cell Line; DNA Mutational Analysis; Escherichia coli; Exons; Female; Gene Expression; Genes; Humans; Infant; Kidney; Levodopa; Molecular Weight; Parkinson Disease; Point Mutation; Recombinant Fusion Proteins; RNA, Messenger; Transfection; Tyrosine 3-Monooxygenase | 1996 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Monoamines; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Efferent Pathways; Excitatory Amino Acid Antagonists; Levodopa; Locomotion; Male; Mice; Mice, Inbred Strains; Motor Neurons; Parkinson Disease; Phenethylamines; Piperidines; Receptors, Dopamine D1; Reserpine; Sympatholytics | 1996 |
Supplement: treatment for Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
Motor neuron disease with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Fatal Outcome; Female; Humans; Levodopa; Male; Medical Records; Middle Aged; Motor Neuron Disease; Parkinson Disease | 1996 |
Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Risk Factors; Time Factors | 1996 |
[Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
Topics: Adult; Age of Onset; Aged; Dystonia; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Smoking | 1996 |
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Topics: Dextrorphan; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Placebos; Severity of Illness Index | 1996 |
[Perioperative management of the patient with atypical Parkinson disease].
Topics: Amantadine; Anesthesia, General; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Intraoperative Complications; Levodopa; Male; Middle Aged; Neural Pathways; Neurologic Examination; Parkinson Disease; Postoperative Complications; Premedication; Preoperative Care; Substantia Nigra | 1996 |
Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease | 1996 |
Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.
Topics: Administration, Oral; Adult; Aged; Animals; Antiparkinson Agents; Bayes Theorem; Cats; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease | 1996 |
The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
Topics: Acoustic Stimulation; Antiparkinson Agents; Blinking; Brain Stem; Case-Control Studies; Dopamine Agents; Electromyography; Female; Habituation, Psychophysiologic; Humans; Levodopa; Male; Middle Aged; Oculomotor Muscles; Parkinson Disease; Reflex, Abnormal; Reflex, Acoustic | 1996 |
Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Benzazepines; Biotransformation; Corpus Striatum; Denervation; Dopamine Agonists; Dopamine Antagonists; Levodopa; Male; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Sulpiride | 1996 |
[A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study].
Topics: Adult; Age of Onset; Brain; Deoxyglucose; Dihydroxyphenylalanine; Dystonia; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed | 1996 |
[Malignant-like neuroleptic syndrome: a sign to call attention to].
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cephalosporins; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease | 1995 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.
Topics: Adult; Antiparkinson Agents; Brain; Humans; Hypertrophy; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Male; Pantothenate Kinase-Associated Neurodegeneration; Parkinson Disease; Substantia Nigra | 1996 |
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 1996 |
Pallidotomy in Parkinson's disease.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Globus Pallidus; Humans; Levodopa; Motor Skills; Neurons; Parkinson Disease; Patient Selection; Selegiline | 1996 |
The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning.
Topics: Aged; Aged, 80 and over; Aging; Disease Progression; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Retina; Space Perception; Time Perception; Visual Perception | 1996 |
Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Topics: Antiparkinson Agents; Benzamides; Brain; Case-Control Studies; Contrast Media; Dopamine Agonists; Dopamine Antagonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1996 |
Disordered axial movement in Parkinson's disease.
Topics: Adult; Aged; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Understanding Parkinson's disease.
Topics: Acetylcholine; Brain; Dopamine; Free Radicals; Heroin Dependence; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Reactive Oxygen Species; Substantia Nigra | 1997 |
Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Denervation; Electron Transport Complex IV; Enzyme Induction; Female; Globus Pallidus; Humans; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Nerve Tissue Proteins; Parkinson Disease; Parkinson Disease, Secondary; RNA, Messenger; Substantia Nigra | 1997 |
Measurement of rigidity in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Reproducibility of Results; Transducers | 1997 |
Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Topics: Animals; Antioxidants; Antiparkinson Agents; Apoptosis; Cell Count; Cell Survival; Cells, Cultured; Chick Embryo; Corpus Striatum; Cycloheximide; Dactinomycin; Flow Cytometry; Ganglia, Sympathetic; Humans; Levodopa; Microscopy, Fluorescence; Nerve Degeneration; Neurons; Parkinson Disease; Substantia Nigra | 1997 |
Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Topics: Aged; Antiparkinson Agents; Caudate Nucleus; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neural Pathways; Parkinson Disease; Putamen; Raclopride; Receptors, Dopamine D2; Salicylamides; Substantia Nigra; Tomography, Emission-Computed | 1997 |
Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prognosis; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 1997 |
New approaches to Parkinson's.
Topics: Aged; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Physician's Role; Time Factors | 1996 |
Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Corpus Striatum; Dextroamphetamine; Dopamine; Ion Channels; Levodopa; Male; Motor Activity; Nicotinic Agonists; Olfactory Pathways; Parkinson Disease; Pyridines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reserpine | 1997 |
Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, X-Ray Computed | 1996 |
Study design problems of DATATOP study analysis.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Selegiline; Vitamin E | 1996 |
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking | 1996 |
Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.
Topics: Aged; Female; Fingers; Humans; Learning; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time | 1996 |
Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
Topics: Aged; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Duodenum; Female; Half-Life; Humans; Intestinal Absorption; Levodopa; Liver; Male; Middle Aged; Models, Biological; Parkinson Disease | 1996 |
Current therapy of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Patient Selection; Selegiline | 1997 |
Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Prospective Studies; Retrospective Studies; Tremor | 1997 |
Sympathetic cardioneuropathy in dysautonomias.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Diagnosis, Differential; Dopamine; Fluorine Radioisotopes; Heart; Humans; Levodopa; Middle Aged; Myocardium; Norepinephrine; Parasympathetic Nervous System; Parkinson Disease; Reference Values; Shy-Drager Syndrome; Sympathetic Nervous System; Tomography, Emission-Computed | 1997 |
Usefulness of pallidotomy in advanced Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Female; Follow-Up Studies; Globus Pallidus; Humans; Intraoperative Complications; Levodopa; Lifting; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Pilot Projects; Prospective Studies; Reoperation; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome; Tremor; Video Recording | 1997 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combinations; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Syndrome | 1997 |
Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
Topics: Fixation, Ocular; Gait; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Supranuclear Palsy, Progressive | 1997 |
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients.
Topics: Brain Mapping; Cerebellum; Cerebrovascular Circulation; Hand; Humans; Levodopa; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 1997 |
N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach.
Topics: Aged; Apomorphine; Dopamine Agents; Dopamine Agonists; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Time Factors | 1996 |
An evaluation of the Alexander Technique for the management of disability in Parkinson's disease--a preliminary study.
Topics: Aged; Body Image; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Rehabilitation; Social Adjustment | 1997 |
Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Thalamus; Tomography, Emission-Computed | 1997 |
Further comments on swallowing in Parkinson's disease.
Topics: Deglutition; Deglutition Disorders; Humans; Levodopa; Parkinson Disease | 1997 |
Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
Topics: Antiparkinson Agents; Carbidopa; Demography; Drug Combinations; Drug Utilization; Humans; Levodopa; Linear Models; Parkinson Disease; United States | 1997 |
Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers.
Topics: Aged; Antiparkinson Agents; Arousal; Attention; Cues; Female; Gait; Humans; Levodopa; Locomotion; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postural Balance; Posture; Proprioception; Receptors, Dopamine | 1997 |
The nurse's role in clinical trials.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase IV as Topic; Drug Combinations; Humans; Job Description; Levodopa; Nursing Care; Parkinson Disease | 1996 |
Gallium-transferrin binding in treated and untreated Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Drug Therapy, Combination; Gallium; Humans; Levodopa; Middle Aged; Parkinson Disease; Protein Binding; Selegiline; Transferrin | 1997 |
Clinical correlates of sleep benefit in Parkinson's disease.
Topics: Animals; Antidepressive Agents; Cats; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sleep; Time Factors | 1997 |
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Kidney Failure, Chronic; Levodopa; Male; Mental Disorders; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Psychotic Disorders; Renal Dialysis | 1996 |
Motor evoked responses to paired cortical magnetic stimulation in Parkinson's disease.
Topics: Aged; Cerebral Cortex; Differential Threshold; Electric Stimulation; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Parkinson Disease | 1997 |
Parkinson's disease: the case for novel treatment strategies.
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurology; Parkinson Disease | 1997 |
L-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; COS Cells; DNA; DNA Transposable Elements; Dopamine; Genetic Therapy; Humans; Levodopa; Mutagenesis, Insertional; Parkinson Disease; Transfection; Tyrosine 3-Monooxygenase | 1997 |
Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
Topics: Adsorption; Aluminum Oxide; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Humans; Hydrogen-Ion Concentration; Hydrolysis; Levodopa; Parkinson Disease; Phenylacetates | 1997 |
[Parkinson disease: physiopathology and therapy. Differential diagnosis of Parkinson disease].
Topics: Diagnosis, Differential; Humans; Levodopa; Parkinson Disease | 1995 |
[Clinical aspects and therapy of Parkinson syndrome].
Topics: Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1996 |
Prolongation of QTc interval in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Autonomic Nervous System; Electrocardiography; Female; Humans; Levodopa; Long QT Syndrome; Male; Middle Aged; Parkinson Disease; Reference Values; Regression Analysis; Valsalva Maneuver | 1997 |
Atypical parkinsonism in a family of Portuguese ancestry: absence of CAG repeat expansion in the MJD1 gene.
Topics: Adult; Base Sequence; Eye Diseases; Female; Genes; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Mutation; Parkinson Disease; Pedigree; Portugal; Repetitive Sequences, Nucleic Acid; Spinocerebellar Degenerations | 1997 |
Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Severity of Illness Index | 1997 |
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Mitochondrial respiratory chain function in multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Atrophy; Blood Platelets; Brain; Citrate (si)-Synthase; Culture Techniques; Electron Transport; Humans; Levodopa; Middle Aged; Mitochondria; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1997 |
Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
Topics: Age of Onset; Antiparkinson Agents; Corpus Striatum; Dopamine; Dystonia; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed; Videotape Recording | 1997 |
[Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance Withdrawal Syndrome | 1997 |
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Kinetics; Levodopa; Microdialysis; Middle Aged; Parkinson Disease | 1997 |
Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; Disease Models, Animal; Enzyme Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Retrospective Studies; Treatment Outcome | 1997 |
Treatment of Parkinson's disease: disagreements.
Topics: Disease Progression; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
New treatment for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzophenones; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat.
Topics: Animals; Antiparkinson Agents; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme Inhibitors; Levodopa; Male; Motor Activity; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Thionucleotides | 1997 |
Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease.
Topics: Aged; Atrophy; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
[Depressive pseudodementia in early Parkinson's disease: lessons from a case with long-term follow-up].
Topics: Aged; Dementia; Depressive Disorder; Female; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 1997 |
Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1997 |
[Diagnosis and course (under treatment) of Parkinson disease].
Topics: Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease | 1997 |
[Mechanisms and treatments of Parkinson disease].
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Neurons; Parkinson Disease | 1997 |
[Parkinson "plus"].
Topics: Antiparkinson Agents; Humans; Levodopa; Nervous System Diseases; Parkinson Disease; Sensitivity and Specificity | 1997 |
Swallowing difficulty in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Barium Sulfate; Benserazide; Contrast Media; Deglutition Disorders; Drug Therapy, Combination; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Oropharynx; Parkinson Disease; Videotape Recording | 1997 |
Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease.
Topics: Antiparkinson Agents; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; Levodopa; Male; Methionine Adenosyltransferase; Middle Aged; Parkinson Disease; S-Adenosylhomocysteine; S-Adenosylmethionine | 1997 |
[L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
Topics: Adult; Animals; Antiparkinson Agents; Benserazide; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Pregnancy; Pregnancy Complications; Rabbits | 1997 |
Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine.
Topics: Adrenergic alpha-Agonists; Atrophy; Autonomic Nervous System Diseases; Clonidine; Diagnosis, Differential; Dopamine; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Levodopa; Middle Aged; Norepinephrine; Parkinson Disease | 1997 |
[From James Parkinson to modern Parkinson-therapy].
Topics: Dopamine Agonists; Drug Therapy, Combination; England; History, 19th Century; Humans; Levodopa; Parkinson Disease | 1994 |
The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Female; Frontal Lobe; Humans; Language Tests; Levodopa; Male; Memory; Parkinson Disease; Phonetics; Piribedil; Severity of Illness Index; Verbal Behavior | 1997 |
Cenesthetic hallucinations in a patient with Parkinson's disease.
Topics: Aged; Clozapine; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide | 1997 |
Levodopa-inhibiting effect of pallidal surgery.
Topics: Globus Pallidus; Humans; Levodopa; Parkinson Disease | 1997 |
Selection criteria for unilateral posteroventral pallidotomy.
Topics: Antiparkinson Agents; Blood Glucose; Dominance, Cerebral; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Patient Selection; Postoperative Complications; Stereotaxic Techniques; Tomography, Emission-Computed; Treatment Outcome | 1997 |
[Levodopa: controlled release or standard?].
Topics: Humans; Levodopa; Parkinson Disease | 1997 |
Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis?
Topics: Aged; Bilirubin; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 1997 |
Sleep benefit in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Sleep; Surveys and Questionnaires; Time Factors | 1997 |
The stability of carbidopa in solution.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Stability; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Solutions | 1997 |
Delirium in a 75-year-old woman receiving ECT and levodopa.
Topics: Aged; Delirium; Electroconvulsive Therapy; Female; Humans; Levodopa; Parkinson Disease | 1997 |
[Parkinson disease. Early diagnosis and combined therapy improve prognosis. Report from the Symposium: "New and successful attempts at the diagnosis and therapy of Parkinson disease"].
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Prognosis | 1993 |
A model of human aiming movements applied to Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Arm; Basal Ganglia; Case-Control Studies; Feedback; Humans; Levodopa; Linear Models; Models, Neurological; Movement; Parkinson Disease | 1997 |
A dynamic model of motor basal ganglia functions.
Topics: Antiparkinson Agents; Basal Ganglia; Bone and Bones; Brain; Dopamine; Forearm; Humans; Levodopa; Models, Neurological; Motor Activity; Motor Neurons; Movement; Muscle, Skeletal; Neurons; Parkinson Disease; Reference Values | 1997 |
Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
Topics: Administration, Oral; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Reproducibility of Results; Time Factors | 1997 |
Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism.
Topics: Adult; Brain; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease | 1997 |
Unexpected findings of study of selegiline have not been treated with caution its authors advised.
Topics: Antiparkinson Agents; Carboxy-Lyases; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
High prevalence of Parkinson's disease in the Faroe Islands.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Denmark; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Prevalence; Tremor | 1997 |
Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Antiparkinson Agents; Aspartic Acid; Choline; Creatine; Dopamine Agents; Humans; Levodopa; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease; Phosphocreatine; Protons; Putamen; Reference Values | 1997 |
Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy.
Topics: Adult; Age of Onset; Antiparkinson Agents; Female; Genes, Dominant; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedigree; Treatment Outcome | 1997 |
Clinical features of familial diffuse Lewy body disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Genes, Dominant; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree | 1997 |
Analyzer workshop on the treatment of Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Bromocriptine; Cerebrovascular Disorders; Computer Simulation; Diagnosis, Differential; Forecasting; Humans; Levodopa; Middle Aged; Parkinson Disease; Supranuclear Palsy, Progressive; Tablets | 1997 |
Natural history studies: their critical role.
Topics: Antiparkinson Agents; Deglutition Disorders; Humans; Levodopa; Parkinson Disease; Tissue Plasminogen Activator | 1997 |
In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Topics: Adult; Aged; Carbon Radioisotopes; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Raclopride; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 1997 |
Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.
Topics: Adult; Aged; Homovanillic Acid; Humans; Levodopa; Middle Aged; Parkinson Disease | 1997 |
Safety of long-term levodopa therapy in malignant melanoma.
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Humans; Levodopa; Male; Melanoma; Parkinson Disease | 1994 |
Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Dopamine; Glutathione; Glutathione Disulfide; Levodopa; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1994 |
High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases.
Topics: Adult; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Gait; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Speech Disorders; Stereotaxic Techniques; Thalamic Nuclei; Treatment Outcome; Tremor | 1997 |
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
Topics: Amidines; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Female; Levodopa; Macaca mulatta; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Pregnancy; Pyridones; Rats; Tolcapone | 1998 |
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Intestinal Absorption; Levodopa; Nitriles; Parkinson Disease; Tissue Distribution | 1998 |
[Parkinson disease--a movement disorder].
Topics: Dopamine Agonists; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1997 |
The long-duration action of levodopa may be due to a postsynaptic effect.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Time Factors | 1997 |
Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Aging; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Severity of Illness Index; Treatment Outcome | 1997 |
Preoperative indicators of clinical outcome following stereotaxic pallidotomy.
Topics: Aged; Antiparkinson Agents; Brain; Electrophysiology; Female; Fluorodeoxyglucose F18; Globus Pallidus; Glucose; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Postoperative Period; Stereotaxic Techniques; Tomography, Emission-Computed; Treatment Outcome | 1997 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell Transplantation; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Female; Fibroblasts; Genetic Therapy; GTP Cyclohydrolase; Homovanillic Acid; Levodopa; Microdialysis; Parkinson Disease; Rats; Rats, Inbred F344; Recombinant Proteins; Transfection; Tyrosine 3-Monooxygenase | 1997 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
[Parkinson's disease. The parkinsonian patient treated with L. Dopa, the 30th anniversary of a new disease].
Topics: Brain; Dopamine Agents; History, 20th Century; Humans; Levodopa; Neurons; Parkinson Disease | 1997 |
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Time Factors | 1997 |
[Driving licence renewal in persons with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Automobile Driving; Female; Humans; Levodopa; Licensure; Male; Middle Aged; Parkinson Disease; Self Disclosure | 1997 |
[A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pergolide; Retrospective Studies; Tremor | 1997 |
Is levodopa toxic to human substantia nigra?
Topics: Adult; Aged; Aged, 80 and over; Child; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Time Factors; Tomography, Emission-Computed; Tremor | 1997 |
Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients.
Topics: Activities of Daily Living; Age of Onset; Antiparkinson Agents; Drug Resistance; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Pilot Projects; Prospective Studies; Severity of Illness Index; Treatment Outcome | 1997 |
Effects of chronic levodopa therapy on dopa pharmacokinetics.
Topics: Aged; Antiparkinson Agents; Biological Availability; Dihydroxyphenylalanine; Female; Half-Life; Humans; Levodopa; Long-Term Care; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Aged; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electrochemistry; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1997 |
Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Topics: Adult; Aged; Antiparkinson Agents; Binding, Competitive; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Caudate Nucleus; Diprenorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Narcotic Antagonists; Occipital Lobe; Parkinson Disease; Putamen; Receptors, Opioid; Thalamic Nuclei | 1997 |
Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Circadian Rhythm; Combined Modality Therapy; Drug Combinations; Electromagnetic Fields; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[Body fat loss in patients with Parkinson's disease].
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antiparkinson Agents; Body Mass Index; Body Weight; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Topics: Aged; Antiparkinson Agents; Aspartic Acid; Atrophy; Cerebral Cortex; Choline; Corpus Striatum; Creatinine; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phosphocreatine; Protons; Putamen; Supranuclear Palsy, Progressive | 1997 |
[New methods in the pharmacotherapy of Parkinson disease].
Topics: Antiparkinson Agents; Benzophenones; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Tolcapone | 1996 |
Motor complications of chronic levodopa therapy in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Selegiline and excess mortality.
Topics: Antiparkinson Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
[COMT inhibition with tolcapone].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1996 |
Response of parkinsonian swallowing dysfunction to dopaminergic stimulation.
Topics: Aged; Apomorphine; Barium; Deglutition Disorders; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis.
Topics: Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tic Disorders; Treatment Outcome | 1997 |
Decreased beta-phenylethylamine in CSF in Parkinson's disease.
Topics: Aged; Chromatography, Gas; Female; Homovanillic Acid; Humans; Levodopa; Male; Mass Spectrometry; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Phenethylamines; Psychotropic Drugs; Severity of Illness Index | 1997 |
Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: is magnocellular function essential to reading motion-defined letters?
Topics: Contrast Sensitivity; Humans; Levodopa; Male; Middle Aged; Motion Perception; Neural Pathways; Parkinson Disease; Perceptual Distortion; Vision Tests; Visual Acuity | 1997 |
Parkinson's disease: clinical features.
Topics: Aging; Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Treatment Outcome | 1997 |
[Parkinson's disease: from pallidotomy to L-dopa and back to pallidotomy].
Topics: Antiparkinson Agents; Globus Pallidus; Humans; Levodopa; Parkinson Disease | 1997 |
Maintenance electroconvulsive therapy for Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Electroconvulsive Therapy; Female; Fluvoxamine; Functional Laterality; Humans; Informed Consent; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1997 |
[Parkinson disease--planning of long-term therapy].
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1997 |
Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interactions; Female; Humans; Levodopa; Mianserin; Mirtazapine; Parkinson Disease; Psychoses, Substance-Induced; Suicide, Attempted | 1997 |
Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Antioxidants; Cells, Cultured; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Synergism; Excitatory Amino Acid Antagonists; Levodopa; Mesencephalon; NAD(P)H Dehydrogenase (Quinone); Neurons; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents | 1997 |
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques | 1997 |
Abnormalities in the stride length-cadence relation in parkinsonian gait.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Female; Gait; Humans; Hypokinesia; Levodopa; Linear Models; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies | 1998 |
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Inappropriate ADH Syndrome; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Trihexyphenidyl | 1998 |
[Stereotactic surgery in Parkinson's disease].
Topics: Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Neural Pathways; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1997 |
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Female; Hallucinations; Humans; Infusions, Intravenous; Levodopa; Male; Parkinson Disease; Time Factors | 1998 |
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Humans; Levodopa; Motor Activity; Parkinson Disease | 1998 |
[Medial posteroventral pallidotomy for the treatment of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Brain; Electrocoagulation; Follow-Up Studies; Functional Laterality; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Motor Activity; Parkinson Disease; Postoperative Complications; Radio Waves; Stereotaxic Techniques | 1997 |
Parkinson's disease.
Topics: Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1998 |
Yawning as an aura for an L-dopa-induced "on" in Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Yawning | 1998 |
Adverse reactions to levodopa: drug toxicity or progression of disease?
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease | 1998 |
[Madopar: more than 20 years].
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; History, 20th Century; Humans; Levodopa; Parkinson Disease | 1997 |
Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes?
Topics: Aged; Antiparkinson Agents; Attention; Cerebral Cortex; Dopamine; Female; Humans; Learning; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Photic Stimulation; Visual Cortex | 1998 |
Costs of drug treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Costs and Cost Analysis; Dopamine Agonists; Drug Costs; Drug Therapy, Combination; Germany; Humans; Levodopa; National Health Programs; Neurologic Examination; Parkinson Disease | 1998 |
Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Blood Glucose; Brain Mapping; Dominance, Cerebral; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Levodopa; Male; Middle Aged; Motor Skills; Multiple System Atrophy; Neurologic Examination; Parkinson Disease; Tomography, Emission-Computed; Treatment Outcome | 1998 |
Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
Square-wave action dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dominance, Cerebral; Drug Combinations; Dystonia; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease; Postoperative Complications; Treatment Outcome | 1998 |
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease.
Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Thalamic Nuclei | 1998 |
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
Topics: Aged; Analysis of Variance; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Multivariate Analysis; Parkinson Disease; Reference Values; Tomography, Emission-Computed, Single-Photon | 1998 |
[Long-term strategy for the management of Parkinson patients].
Topics: Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1998 |
Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1998 |
Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
Topics: Antiparkinson Agents; Bromocriptine; Decision Making; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1998 |
Total and non-protein-bound fractions of 3,4-dihydroxyphenylalanine.
Topics: Antiparkinson Agents; Blood Proteins; Chromatography, High Pressure Liquid; Humans; Levodopa; Microdialysis; Parkinson Disease; Protein Binding | 1998 |
Poly(vinyl alcohol) synthetic polymer foams as scaffolds for cell encapsulation.
Topics: Animals; Cell Division; Cell Survival; Cell Transplantation; Cells, Cultured; Chitin; Chitosan; Corpus Striatum; Dopamine; Levodopa; Membranes, Artificial; Parkinson Disease; PC12 Cells; Polyvinyl Alcohol; Porosity; Rats; Rats, Sprague-Dawley | 1998 |
Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
Topics: Aged; Cyclic GMP; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1998 |
A frequency and correlation analysis of motor deficits in Parkinson patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prognosis; Psychomotor Disorders; Psychomotor Performance; Selegiline; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 1998 |
The co-ordination and phasing of a bilateral prehension task. The influence of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Functional Laterality; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time; Reference Values | 1998 |
[Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy].
Topics: Aged; Amylases; Diabetic Coma; Disseminated Intravascular Coagulation; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1998 |
Welcome news about levodopa, but uncertainty remains.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Melanoma and levodopa.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Melanoma; Parkinson Disease; Risk Factors; Skin Neoplasms | 1998 |
A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Circadian Rhythm; Female; Humans; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Parkinson Disease; Polysomnography; Psychomotor Performance; Sleep; Surveys and Questionnaires; Treatment Outcome | 1998 |
Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cognition; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance | 1998 |
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Chronotherapy; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps, Implantable; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.
Topics: Aged; Ambulatory Care; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurocognitive Disorders; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Patient Admission; Retrospective Studies; Treatment Outcome | 1998 |
Cortical myoclonus in levodopa-responsive parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Cerebral Cortex; Electroencephalography; Electromyography; Follow-Up Studies; Humans; Levodopa; Male; Myoclonus; Parkinson Disease | 1998 |
Quality of life and Parkinson's disease: the CR FIRST Study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Emotions; Humans; Levodopa; Parkinson Disease; Quality of Life; Social Isolation; Treatment Outcome | 1998 |
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Isoquinolines; Levodopa; Male; Parkinson Disease; Reference Values; Regression Analysis; Tyrosine | 1996 |
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Parkinson Disease; Reference Values | 1996 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline | 1995 |
Hereditary form of parkinsonism--dementia.
Topics: Adult; Antiparkinson Agents; Choline O-Acetyltransferase; Dementia; Dopamine; Family Health; Female; Genes, Dominant; Hippocampus; Homovanillic Acid; Humans; Levodopa; Lewy Bodies; Locus Coeruleus; Male; Middle Aged; Neostriatum; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Pedigree; Substantia Innominata; Substantia Nigra; Temporal Lobe; Tomography, Emission-Computed | 1998 |
Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Topics: Adult; Brain; Carrier Proteins; Child; Diagnosis, Differential; DNA Mutational Analysis; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dystonia; Exons; Family Health; Female; Gene Expression Regulation, Enzymologic; GTP Cyclohydrolase; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neopterin; Nerve Tissue Proteins; Parkinson Disease; Pedigree; Tomography, Emission-Computed, Single-Photon | 1998 |
Current and emerging drug therapies in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1998 |
History of levodopa and dopamine agonists in Parkinson's disease treatment.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; History, 19th Century; History, 20th Century; Humans; Levodopa; Parkinson Disease | 1998 |
Mood response to levodopa infusion in early Parkinson's disease.
Topics: Affect; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Self-Assessment | 1998 |
Levodopa in human breast milk: clinical implications.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Lactation; Levodopa; Milk, Human; Osmolar Concentration; Parkinson Disease | 1998 |
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Dysarthria; Female; Humans; Levodopa; Lip; Male; Middle Aged; Parkinson Disease | 1998 |
An unusual enhancement of motor performance during bimanual movement in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Hand; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 1998 |
Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Levodopa; Lisuride; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Skin; Treatment Outcome | 1998 |
Neural dynamics of short and medium-term motor control effects of levodopa therapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Computer Simulation; Dopamine; Humans; Levodopa; Male; Models, Neurological; Neural Networks, Computer; Neuropeptides; Parkinson Disease; Psychomotor Performance | 1998 |
Successful perioperative management of a patient with Parkinson's disease by enteral levodopa administration under propofol anesthesia.
Topics: Aged; Anesthetics, Intravenous; Anesthetics, Local; Antiparkinson Agents; Bupivacaine; Colonic Neoplasms; Fentanyl; Humans; Infusions, Intravenous; Injections, Spinal; Levodopa; Liver; Male; Neuromuscular Nondepolarizing Agents; Parkinson Disease; Propofol; Vecuronium Bromide | 1998 |
Dopaminergic influences on the P300 abnormality in Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Event-Related Potentials, P300; Female; Humans; Levodopa; Longitudinal Studies; Male; Mental Processes; Middle Aged; Parkinson Disease; Reaction Time; Severity of Illness Index | 1998 |
[Long chronic course of hemiparkinson-plus with l-dopa maintained response].
Topics: Aged; Antiparkinson Agents; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Dystonia; Functional Laterality; Humans; Levodopa; Male; Parkinson Disease | 1998 |
Early morning dystonia in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1998 |
Inhibition of levodopa effects by internal pallidal stimulation.
Topics: Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1998 |
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease | 1998 |
Gamma knife radiosurgery as a lesioning technique in movement disorder surgery.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Dopamine Agents; Dyskinesia, Drug-Induced; Electroencephalography; Female; Follow-Up Studies; Gait; Globus Pallidus; Hemianopsia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neuropsychological Tests; Parkinson Disease; Radiosurgery; Radiotherapy Dosage; Safety; Single-Blind Method; Thalamus; Tremor | 1998 |
New anti-parkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 1998 |
Levodopa monitoring by retrodialysis.
Topics: Antiparkinson Agents; Humans; Levodopa; Microdialysis; Parkinson Disease; Reference Values | 1998 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1998 |
Cognitive functioning after pallidotomy for refractory Parkinson's disease.
Topics: Activities of Daily Living; Aged; Cognition Disorders; Combined Modality Therapy; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Treatment Outcome | 1998 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver | 1998 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver | 1998 |
Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disabled Persons; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1998 |
Pallidotomy revisited. Analysis of posteroventral pallidotomy.
Topics: Aged; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; MMPI; Movement Disorders; Muscle Rigidity; Parkinson Disease; Postoperative Period; Stereotaxic Techniques; Thalamic Nuclei; Thalamus; Treatment Outcome; Tremor | 1997 |
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Confusion; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain; Dihydroxyphenylalanine; Encephalitis, Arbovirus; Female; Fluorine Radioisotopes; Follow-Up Studies; Humans; Levodopa; Memory Disorders; Neuropsychological Tests; Obsessive-Compulsive Disorder; Parkinson Disease; Phobic Disorders; Tomography, Emission-Computed | 1998 |
Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Blood Proteins; Copper; Dopamine Agonists; Female; Humans; Iron; Levodopa; Male; Manganese; Metals, Heavy; Middle Aged; Nutritional Status; Parkinson Disease; Reference Values; Selegiline; Spectrophotometry, Atomic; Trace Elements; Vitamin A; Zinc | 1998 |
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; Decarboxylation; Dopamine; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra; Trihexyphenidyl | 1998 |
Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1998 |
Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese and copper.
Topics: Animals; Cell Division; Cell Line; Copper; Cricetinae; Cysteine; Dopamine; Glutathione; Levodopa; Lung; Manganese; Melanins; Micronucleus Tests; Mutagens; Parkinson Disease | 1998 |
Early dopaminergic drug-induced hallucinations in parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1998 |
Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.
Topics: Adult; Aged; Carbidopa; Case-Control Studies; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Thalamus; Tomography, Emission-Computed | 1998 |
Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Combined Modality Therapy; Dihydroxyphenylalanine; Dominance, Cerebral; Female; Gait; Globus Pallidus; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Prolactin; Stereotaxic Techniques | 1998 |
New hope for Parkinson's disease.
Topics: Antiparkinson Agents; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease | 1998 |
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Thalamic Nuclei | 1998 |
Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index | 1998 |
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.
Topics: Aged; Algorithms; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Care Planning | 1998 |
Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease .
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Drug Monitoring; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Spatial Behavior; Time Factors; Treatment Outcome | 1998 |
Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.
Topics: Adult; Aged; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Movement; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 1998 |
Treating Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei | 1998 |
Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Antiparkinson Agents; Cause of Death; Chi-Square Distribution; Cognition Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Likelihood Functions; Male; Parkinson Disease; Poisson Distribution; Risk Factors | 1998 |
Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Statistics, Nonparametric | 1998 |
Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Parkinson Disease | 1998 |
Handwriting and speech changes across the levodopa cycle in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Administration Schedule; Handwriting; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Verbal Behavior | 1998 |
Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
Topics: Blood Platelets; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1998 |
Enhanced fatigue during motor performance in patients with Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Female; Forearm; Humans; Isometric Contraction; Levodopa; Male; Middle Aged; Muscle Fatigue; Parkinson Disease; Psychomotor Performance | 1998 |
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease | 1998 |
[L-dopa: a fascinating history].
Topics: Antiparkinson Agents; History, 20th Century; Humans; Levodopa; Parkinson Disease | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextrorphan; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1998 |
Cerebrospinal fluid from L-dopa-treated Parkinson's disease patients is dystrophic for various neural cell types ex vivo: effects of astroglia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Astrocytes; Cebus; Cerebral Cortex; Cerebrospinal Fluid Proteins; Chromaffin Cells; Humans; Levodopa; Mesencephalon; Middle Aged; Neostriatum; Neurons; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley | 1998 |
A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor.
Topics: Chromosome Mapping; Chromosomes, Human, Pair 4; Female; Genes, Dominant; Haplotypes; Humans; Levodopa; Lod Score; Male; Parkinson Disease; Pedigree; Phenotype; Posture; Tremor | 1999 |
Dopamine autoreceptor function is lost in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Autoreceptors; Brain Chemistry; Carbon Radioisotopes; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
Fluctuating penile erection related with levodopa therapy.
Topics: Aged; Antiparkinson Agents; Erectile Dysfunction; Humans; Levodopa; Male; Parkinson Disease | 1999 |
Intravenous levodopa in hallucinating PD patients.
Topics: Antiparkinson Agents; Hallucinations; Humans; Injections, Intravenous; Levodopa; Parkinson Disease | 1999 |
Clinical correlates of vascular parkinsonism.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Treatment Failure | 1999 |
Mortality cancer risk in parkinsonian patients: a population-based study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Neoplasms; Parkinson Disease; Poisson Distribution; Retrospective Studies; Rome; Selegiline | 1999 |
Yawning in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Yawning | 1999 |
Yawning in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Yawning | 1999 |
Yawning in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Yawning | 1999 |
Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dopamine; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 1999 |
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Disorders; Treatment Outcome | 1999 |
Loss of long-duration response to levodopa over time in PD: implications for wearing-off.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1999 |
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progression; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1999 |
The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Dopamine; Female; Fructose-Bisphosphate Aldolase; Humans; In Situ Hybridization; Levodopa; Male; Middle Aged; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Time Factors; Transcription, Genetic; Tubulin; Tyrosine 3-Monooxygenase | 1999 |
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
Topics: Analysis of Variance; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Problem Solving; Severity of Illness Index; Speech; Volition | 1999 |
[Event-related desynchronization and Parkinson disease. Importance in the analysis of the phase of preparation for movement].
Topics: Antiparkinson Agents; Case-Control Studies; Cortical Synchronization; Electroencephalography; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Volition | 1999 |
Stereotactic radiofrequency pallidotomy with microelectrode mapping for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Globus Pallidus; Humans; Levodopa; Microelectrodes; Outcome Assessment, Health Care; Parkinson Disease; Patient Selection; Radiosurgery; Technology Assessment, Biomedical | 1996 |
Non-drug therapies are highly beneficial in Parkinson's disease, but seldom prescribed.
Topics: Aged; Diet Therapy; Disease Management; Drug Interactions; Humans; Levodopa; Male; Managed Care Programs; Middle Aged; Parkinson Disease; Patient Participation; Prognosis; Social Support; United States | 1998 |
Ropinirole: new preparation. Wait for more convincing data.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; France; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Time Factors; Treatment Outcome | 1998 |
Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Thalamic Nuclei; Thalamus | 1999 |
Study of central motor functions using magnetic stimulation in Parkinson's disease.
Topics: Aged; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Parkinson Disease; Reaction Time | 1999 |
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.
Topics: Aged; Aged, 80 and over; Female; Gene Expression Regulation; Humans; Interferon-gamma; Interleukin-1; Levodopa; Male; Middle Aged; Neuroglia; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Parkinson Disease; Receptors, IgE; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Substantia Nigra; Tumor Necrosis Factor-alpha | 1999 |
SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD.
Topics: Aged; Carrier Proteins; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1999 |
[Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Patient Selection; Psychoses, Substance-Induced; Retrospective Studies; Risk Factors | 1999 |
[Treating Parkinson-patients with dopamine agonists. Role of the age at manifestation in the therapy].
Topics: Adult; Age Factors; Female; Humans; Levodopa; Male; Motor Skills Disorders; Parkinson Disease | 1999 |
Transient acute depression induced by high-frequency deep-brain stimulation.
Topics: Acute Disease; Aged; Antiparkinson Agents; Brain; Depression; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Thalamic Nuclei | 1999 |
L-dopa and cancer anorexia.
Topics: Anorexia; Carbidopa; Dopamine Agents; Humans; Levodopa; Male; Parkinson Disease; Urinary Bladder Neoplasms | 1999 |
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Ceruloplasmin; Copper; Enzyme Activation; Female; Humans; Iron; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 1999 |
Developmental stuttering and Parkinson's disease: the effects of levodopa treatment.
Topics: Adult; Humans; Levodopa; Male; Parkinson Disease; Stuttering | 1999 |
[Drug therapy in Parkinson's disease].
Topics: Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Netherlands; Parkinson Disease; Practice Guidelines as Topic; Psychosurgery | 1999 |
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Riluzole; Treatment Outcome | 1999 |
Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon.
Topics: Aged; Antineoplastic Agents; Brain; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Posture; Severity of Illness Index; Spinal Diseases; Tomography, X-Ray Computed | 1999 |
Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale.
Topics: Antiparkinson Agents; Dystonia; Female; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Time Factors | 1999 |
Protease inhibitors enhance levodopa effects in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Synergism; Dyskinesia, Drug-Induced; HIV Protease Inhibitors; Humans; Indinavir; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease.
Topics: Cell Division; Cytokines; Female; Humans; In Vitro Techniques; Interleukin-1; Interleukin-2; Interleukin-6; Interleukins; Leukocytes, Mononuclear; Levodopa; Male; Middle Aged; Mitogens; Parkinson Disease; Tumor Necrosis Factor-alpha | 1999 |
Decreased phagocytic function in patients with Parkinson's disease.
Topics: Female; Humans; In Vitro Techniques; Levodopa; Male; Microspheres; Middle Aged; Neutrophils; Parkinson Disease; Phagocytosis | 1999 |
Voluntary movement after pallidotomy in severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Cues; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Volition | 1999 |
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
Topics: Adult; Antiparkinson Agents; Chorea; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Thalamic Nuclei | 1999 |
L-dopa slows the progression of familial parkinsonism.
Topics: Adult; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Middle Aged; Parkinson Disease; Survival Analysis | 1999 |
[COMT inhibitors].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Gait consistency over a 7-day interval in people with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1999 |
Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence.
Topics: Aged; Aged, 80 and over; Diagnostic Errors; Female; Humans; Levodopa; Parkinson Disease; Tremor | 1999 |
Medication-induced hallucination and cerebral blood flow in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Female; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 1999 |
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carboxy-Lyases; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Vascular Diseases | 1999 |
Autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions.
Topics: Antiparkinson Agents; Brain; Cerebral Cortex; DNA, Mitochondrial; Female; Genes, Dominant; Humans; Levodopa; Middle Aged; Muscle, Skeletal; Ophthalmoplegia, Chronic Progressive External; Parkinson Disease; Repetitive Sequences, Nucleic Acid; Sequence Deletion | 1999 |
Objective assessment in Parkinson's disease: optoelectronic movement and force analysis in clinical routine and research.
Topics: Aging; Antiparkinson Agents; Dopamine Agonists; Electronics; Hand; Hand Strength; Humans; Levodopa; Methods; Movement; Optics and Photonics; Parkinson Disease; Posture; Reference Values; Tremor | 1999 |
Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 1999 |
Glottographic measures before and after levodopa treatment in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Electric Stimulation; Electronic Data Processing; Female; Glottis; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Software; Speech Acoustics; Speech Production Measurement; Tremor; Voice Disorders | 1999 |
Pharmacodynamics of the long-duration response to levodopa in PD.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1999 |
Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.
Topics: Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinson Disease; Thalamic Nuclei | 1999 |
Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism.
Topics: Antiparkinson Agents; Brain; Fatal Outcome; Female; Humans; Levodopa; Lewy Bodies; Middle Aged; Parkinson Disease; Substantia Nigra; Vagus Nerve | 1999 |
Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases.
Topics: Adult; Aged; Animals; Antiparkinson Agents; Contracture; Humans; Levodopa; Mice; Middle Aged; Parkinson Disease; Treatment Outcome | 1999 |
Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Selegiline; Thiamine; Thiamine Monophosphate; Thiamine Pyrophosphate | 1999 |
Parkinson's disease or Parkinson's diseases?
Topics: Humans; Levodopa; Lewy Bodies; Parkinson Disease; Parkinson Disease, Secondary | 1999 |
The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
Topics: Adult; Affect; Aged; Analysis of Variance; Case-Control Studies; Caudate Nucleus; Cognition; Dopamine Agents; Event-Related Potentials, P300; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Putamen; Tomography, Emission-Computed | 1999 |
[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Several classes of new drugs emerging for Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies.
Topics: Animals; Antiparkinson Agents; Brain; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Self-Assessment; Treatment Outcome | 1999 |
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Binding, Competitive; Brain; Cell Count; Dopamine Agonists; Female; Humans; Levodopa; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Radioligand Assay; Receptors, Dopamine; Sensitivity and Specificity; Treatment Outcome | 1999 |
Punding on L-dopa.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Parkinson Disease; Stereotypic Movement Disorder | 1999 |
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Parkinson Disease | 1999 |
Levodopa-induced dyskinesias treated by pallidotomy.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma.
Topics: Aged; Antiparkinson Agents; Benserazide; Female; Humans; Levodopa; Male; Melanoma; Microdialysis; Middle Aged; Parkinson Disease; Skin Neoplasms | 1999 |
Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa.
Topics: Antiparkinson Agents; Brain; Convergence, Ocular; Diplopia; Exotropia; Eye Movements; Fatal Outcome; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
Cerebral dopamine concentrations during levodopa treatment.
Topics: Brain; Dopamine; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed | 1999 |
Clinical investigation of medicinal products in the treatment of Parkinson's disease (CPMP note for guidance). European Agency for Evaluation of Medicinal Products.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Selection | 1999 |
[Parkinson disease. Evidence based medicine for Levodopa].
Topics: Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease | 1999 |
Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Articulation Disorders; Dopamine Agents; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Humans; Levodopa; Lip; Male; Middle Aged; Parkinson Disease; Pulse Therapy, Drug; Reaction Time; Subthalamic Nucleus; Tongue; Treatment Outcome | 1999 |
Burning mouth in Parkinson's disease sufferers.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Burning Mouth Syndrome; Dental Care for Chronically Ill; Female; Humans; Levodopa; Male; Middle Aged; Northern Ireland; Parkinson Disease; Prevalence; Sampling Studies | 1998 |
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Topics: Adult; Aged; Alleles; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Dyskinesias; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Tandem Repeat Sequences | 1999 |
Time course of frontal somatosensory evoked potentials. Relation to L-dopa plasma levels and motor performance in PD.
Topics: Aged; Brain; Dose-Response Relationship, Drug; Electric Stimulation; Evoked Potentials, Somatosensory; Frontal Lobe; Humans; Levodopa; Median Nerve; Middle Aged; Movement; Neural Conduction; Parkinson Disease; Reaction Time; Reference Values; Scalp; Time Factors | 1999 |
Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1 | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease.
Topics: Animals; Bone Marrow Cells; Brain; Cell Survival; Cell Transplantation; Cells, Cultured; Disease Models, Animal; Genetic Therapy; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Lew; Stromal Cells; Transduction, Genetic; Tyrosine 3-Monooxygenase | 1999 |
Inter-patient and intra-patient variations in the baseline tapping test in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Evaluation; Female; Fingers; Genetic Variation; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index | 1999 |
Clinical management of Parkinson's disease. Introduction.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopaminergic Neurons; Humans; Levodopa; Parkinson Disease | 1999 |
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Odds Ratio; Parkinson Disease | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |
Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Erythrocytes; Humans; Hydroxyl Radical; Levodopa; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pergolide; Severity of Illness Index; Statistics as Topic; Superoxide Dismutase; Time Factors | 1999 |
Neurodegenerative disease: a different view of diagnosis.
Topics: Alzheimer Disease; Dementia; Dopamine Agents; Humans; Levodopa; Lewy Bodies; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Prion Diseases; Synucleins; tau Proteins | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Vitiligo | 1999 |
Worsening of motor features of parkinsonism with olanzapine.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Olanzapine; Parkinson Disease; Parkinson Disease, Secondary; Pirenzepine; Psychoses, Substance-Induced; Risk Factors | 1999 |
Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Drug Combinations; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Raclopride; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
PET studies of parkinsonism associated with mutation in the alpha-synuclein gene.
Topics: Adult; alpha-Synuclein; Antiparkinson Agents; Brain Mapping; Caudate Nucleus; Chromosome Aberrations; Chromosome Disorders; Female; Gene Expression; Genes, Dominant; Greece; Humans; Levodopa; Male; Middle Aged; Mutation; Nerve Tissue Proteins; Parkinson Disease; Pedigree; Phosphoproteins; Putamen; Receptors, Dopamine; Synucleins; Tomography, Emission-Computed; United States | 1999 |
Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Parkinson Disease | 1999 |
Bilateral intracaudate cografting of fetal ventral mesencephalon and striatum in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Corpus Striatum; Disease Progression; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Motor Activity; Parkinson Disease; Time Factors; Tomography, X-Ray Computed | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease.
Topics: Depressive Disorder; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Time Factors | 2000 |
Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; RNA, Messenger; Tyrosine 3-Monooxygenase | 1999 |
Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
Topics: Animals; Corpus Striatum; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine D1 | 2000 |
The effect of pregnancy in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life | 2000 |
Severe off-period facial dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Dystonia; Humans; Levodopa; Male; Masseter Muscle; Middle Aged; Parkinson Disease; Spasm; Tooth Fractures | 2000 |
Broad bean (Vicia faba)--a natural source of L-dopa--prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations.
Topics: Adult; Antiparkinson Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Fabaceae; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plant Proteins; Plants, Medicinal; Seed Storage Proteins | 2000 |
Extradural motor cortex stimulation for advanced Parkinson's disease: case report.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Motor Cortex; Neurologic Examination; Parkinson Disease | 2000 |
Strategies of segmental stabilization during gait in Parkinson's disease.
Topics: Acceleration; Aged; Antiparkinson Agents; Child, Preschool; Female; Gait; Gait Disorders, Neurologic; Head Movements; Hip Joint; Humans; Infant; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Shoulder Joint | 1999 |
Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome.
Topics: Aged; Antiparkinson Agents; Chorea; Diagnosis, Differential; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed; Treatment Outcome; Trinucleotide Repeats | 2000 |
Breathing pattern in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Mechanics | 1999 |
Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons.
Topics: Animals; Benzophenones; Catechol O-Methyltransferase Inhibitors; Cells, Cultured; Dopamine; Dopamine Antagonists; Electrophysiology; Enzyme Inhibitors; GABA Antagonists; Glycine Agents; Levodopa; Male; Neurons; Nitrophenols; Organophosphorus Compounds; Parkinson Disease; Picrotoxin; Rats; Rats, Wistar; Strychnine; Substantia Nigra; Sulpiride; Synaptic Transmission; Tolcapone; Ventral Tegmental Area | 1999 |
Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Age of Onset; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Risk Factors; Survival Analysis; Time Factors | 1999 |
Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease.
Topics: Antiparkinson Agents; Globus Pallidus; Humans; Levodopa; Motor Activity; Motor Neurons; Parkinson Disease; Postoperative Care | 2000 |
High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei | 2000 |
Improvement of memory guided saccades in parkinsonian patients by high frequency subthalamic nucleus stimulation.
Topics: Electric Stimulation Therapy; Humans; Levodopa; Memory; Middle Aged; Parkinson Disease; Reaction Time; Saccades; Subthalamic Nucleus | 2000 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Idazoxan; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease | 2000 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change.
Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Research Design; Treatment Outcome | 2000 |
Is levodopa toxic?
Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 2000 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Levodopa; Male; Olanzapine; Parkinson Disease; Pirenzepine; Psychoses, Substance-Induced; Quetiapine Fumarate; Treatment Outcome | 2000 |
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Parkinson Disease | 2000 |
The initial treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2000 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2000 |
Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease.
Topics: Adult; Aged; Basal Ganglia; Brain; Cognition Disorders; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Preoperative Care; Subthalamic Nucleus; Surveys and Questionnaires | 2000 |
[Efficacy and safety of posteroventral pallidotomy for the treatment of advanced Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 2000 |
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Monitoring, Intraoperative; Movement; Parkinson Disease; Patient Care Planning; Radiology, Interventional; Red Nucleus; Safety; Stereotaxic Techniques; Subthalamic Nucleus; Tremor | 2000 |
Serotonergic decompensation in the akinetic expression of Parkinson's disease.
Topics: Brain; Chromatography, High Pressure Liquid; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Levodopa; Methoxyhydroxyphenylglycol; Norepinephrine; Parkinson Disease; Serotonin; Synaptic Transmission | 2000 |
Parkinson disease survival: a population-based study.
Topics: Age Distribution; Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Comorbidity; Female; Heart Diseases; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Pneumonia; Prevalence; Proportional Hazards Models; Sex Distribution; Sicily; Survival Analysis; Survival Rate | 2000 |
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
Topics: Adult; Aged; Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2000 |
Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Movement Disorders; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed | 2000 |
Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone | 2000 |
Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.
Topics: Age Distribution; Age of Onset; Aged; Antiparkinson Agents; Dementia; Depression; Disease Progression; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Prevalence; Psychotic Disorders; Risk Factors | 2000 |
Levodopa-treated Parkinson disease has better long-term outcome than previously predicted.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2000 |
Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Motor Skills; Neurologic Examination; Parkinson Disease | 2000 |
Parkinsonism, dystonia, and hemiatrophy.
Topics: Adolescent; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Child; Child, Preschool; Dominance, Cerebral; Drug Therapy, Combination; Dystonia; Humans; Infant; Infant, Newborn; Levodopa; Magnetic Resonance Imaging; Muscular Atrophy; Neurologic Examination; Parkinson Disease; Putamen; Treatment Outcome | 2000 |
[L-dopa effective parkinsonism appeared after shunt revision of the aqueductal stenosis: report of two cases].
Topics: Adult; Antiparkinson Agents; Cerebral Aqueduct; Constriction, Pathologic; Female; Humans; Hydrocephalus; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Ventriculoperitoneal Shunt | 2000 |
Monitoring of the levodopa concentration-response relationship in Parkinson's disease.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2000 |
Subthalamic stimulation in Parkinson's disease. Preliminary results.
Topics: Antiparkinson Agents; Brain Mapping; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Electrosurgery; Evaluation Studies as Topic; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Monitoring, Intraoperative; Parkinson Disease; Prospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 1999 |
Electrophysiological recordings in pallidotomy localized to 3D stereoscopic imaging.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Brain Mapping; Combined Modality Therapy; Electromyography; Electrosurgery; Evoked Potentials; Globus Pallidus; Humans; Image Processing, Computer-Assisted; Levodopa; Microelectrodes; Middle Aged; Monitoring, Intraoperative; Neurons; Online Systems; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1999 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, High Pressure Liquid; Corpus Striatum; Dialysis Solutions; Dopamine; Homovanillic Acid; Infusion Pumps; Levodopa; Male; Manganese; Manganese Compounds; Microdialysis; Movement; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Wistar; Time Factors; Uric Acid | 2000 |
Treatments for Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Clinical Trials, Phase II as Topic; Double-Blind Method; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Models, Theoretical; Multicenter Studies as Topic; Nitrophenols; Parkinson Disease; Population Surveillance; Randomized Controlled Trials as Topic; Tolcapone | 2000 |
Treatment of early Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Indoles; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
[Worsened orthostatic hypotension due to levodopa administration in a case of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Female; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease | 2000 |
Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
New dopaminergic neurons in Parkinson's disease striatum.
Topics: Aged; Carrier Proteins; Cell Count; Cell Differentiation; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Interneurons; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neurons; Parkinson Disease; Tyrosine 3-Monooxygenase | 2000 |
Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica.
Topics: Aged; Analgesics, Opioid; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Intervertebral Disc Displacement; Levodopa; Lumbar Vertebrae; Male; Middle Aged; Morphine; Parkinson Disease; Sciatica | 1999 |
Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Female; Gene Expression Regulation, Enzymologic; Humans; Levodopa; Male; Neurons; Organ Specificity; Parkinson Disease; Reference Values; RNA, Messenger; Transcription, Genetic; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2000 |
Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
Topics: Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Pyridines; Zolpidem | 2000 |
Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease.
Topics: Female; Humans; India; Levodopa; Male; Medicine, Ayurvedic; Middle Aged; Parkinson Disease; Plant Extracts; Prospective Studies; Recovery of Function; Treatment Outcome | 2000 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Folic Acid; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Point Mutation | 2000 |
A dynamical-systems model for Parkinson's disease.
Topics: Antiparkinson Agents; Gait; Humans; Hypokinesia; Levodopa; Models, Neurological; Movement; Parkinson Disease; Posture | 2000 |
Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2000 |
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Risperidone; Treatment Outcome | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agents; Excitatory Amino Acid Antagonists; Levodopa; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Piperidines | 2000 |
Cardiac sympathetic denervation in Parkinson disease.
Topics: Adult; Aged; Blood Pressure; Brain; Cardiac Catheterization; Diagnosis, Differential; Dopamine; Female; Fluorine Radioisotopes; Heart; Heart Rate; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Multiple System Atrophy; Myocardium; Norepinephrine; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tritium; Valsalva Maneuver | 2000 |
Levodopa toxicity in Parkinson disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2000 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Levodopa; Parkinson Disease; Pirenzepine; Psychoses, Substance-Induced | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Sleep | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Hallucinations; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life | 2000 |
N-methyl(R)salsolinol and a neutral N-methyltransferase as pathogenic factors in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Female; Homovanillic Acid; Humans; Levodopa; Lymphocytes; Male; Methyltransferases; Middle Aged; Parkinson Disease; Salsoline Alkaloids; Statistics, Nonparametric; Tetrahydroisoquinolines | 2000 |
Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Dementia; Depression; Diabetes Mellitus; Drug Tolerance; Fatigue; Female; Humans; Levodopa; Male; Movement Disorders; Neurologic Examination; Norway; Outpatients; Parkinson Disease; Prevalence; Psychomotor Performance; Quality of Life; Severity of Illness Index; Sleep Wake Disorders; Surveys and Questionnaires | 2000 |
Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Practice, Psychological; Psychomotor Performance; Sex Factors | 2000 |
Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?
Topics: Adult; Aged; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2000 |
Increased blink rate in advanced Parkinson's disease: a form of 'off'-period dystonia?
Topics: Adult; Aged; Antiparkinson Agents; Blinking; Case-Control Studies; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2000 |
Is there addiction to levodopa in patients with Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Behavior, Addictive; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Quadriplegia; Substance Withdrawal Syndrome | 2000 |
Motor performance after posteroventral pallidotomy and VIM-thalamotomy in Parkinson's disease: a 1-year follow-up study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Stereotaxic Techniques; Thalamus; Treatment Outcome | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Diagnosis, Computer-Assisted; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Postural Balance; Posture; Severity of Illness Index; Supranuclear Palsy, Progressive | 2000 |
Weighing the neurological complexities of long-term levodopa use.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2000 |
Dopamine agonists in early therapy for Parkinson disease: promise and problems.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Mesencephalon; Parkinson Disease | 2000 |
Development of an activity scale for individuals with advanced Parkinson disease: reliability and "on-off" variability.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Observer Variation; Parkinson Disease; Reproducibility of Results; Videotape Recording | 2000 |
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
Topics: Age of Onset; Aged; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Outpatients; Parkinson Disease; Prevalence; Quality of Life; Regression Analysis; Treatment Outcome | 2000 |
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric | 2000 |
Dopa-induced blood flow responses in nonhuman primates.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Arousal; Carbidopa; Cerebrovascular Circulation; Dopamine; Frontal Lobe; Gyrus Cinguli; Ketamine; Levodopa; Macaca nemestrina; Male; Papio; Parkinson Disease; Putamen; Temporal Lobe; Tomography, Emission-Computed | 2000 |
Choice reaction time after levodopa challenge in parkinsonian patients.
Topics: Adult; Aged; Domperidone; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Reaction Time; Treatment Outcome | 2000 |
Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Diagnosis, Computer-Assisted; Diagnosis, Differential; Dyskinesia, Drug-Induced; Feasibility Studies; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2000 |
An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice.
Topics: Adult; Aged; Antiparkinson Agents; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Speech Intelligibility; Subthalamic Nucleus; Treatment Outcome; Voice; Voice Disorders | 2000 |
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Thalamic Nuclei | 2000 |
Proteasomal function is impaired in substantia nigra in Parkinson's disease.
Topics: Acetylcysteine; Aged; Cysteine Endopeptidases; Dihydroxyphenylalanine; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Hydrolysis; Levodopa; Lewy Bodies; Male; Multienzyme Complexes; Parkinson Disease; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Substantia Nigra; Ubiquitins | 2001 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease | 2001 |
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Topics: Aged; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechols; Dihydroxyphenylalanine; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 2001 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
The L-DOPA story revisited. Further surprises to be expected?
Topics: Animals; Antiparkinson Agents; History, 20th Century; Humans; Japan; Levodopa; Parkinson Disease | 2000 |
Case report: successful use of rectally administered levodopa-carbidopa.
Topics: Administration, Oral; Administration, Rectal; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deglutition Disorders; Female; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2001 |
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Acceleration; Activities of Daily Living; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index | 2001 |
Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; Dopamine Agonists; Female; Humans; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 2000 |
Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2000 |
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa.
Topics: Aged; Brain Mapping; Cerebrovascular Circulation; Evoked Potentials; Female; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Psychomotor Performance | 2001 |
Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD.
Topics: Activities of Daily Living; Aged; Electric Stimulation; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Time Factors | 2001 |
Deep brain stimulation of the subthalamic nucleus: clinical effectiveness and safety.
Topics: Aged; Electric Stimulation; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2001 |
Nobel prize. Researcher overlooked for 2000 Nobel.
Topics: Austria; Brain; Dopamine; History, 20th Century; Humans; Levodopa; Nobel Prize; Parkinson Disease | 2001 |
Dopamine supports sentence comprehension in Parkinson's Disease.
Topics: Aged; Cognition; Dopamine; Dopamine Agents; Humans; Levodopa; Memory; Middle Aged; Parkinson Disease | 2001 |
Levodopa reversible loss of the Piper frequency oscillation component in Parkinson's disease.
Topics: Electromyography; Fingers; Humans; Levodopa; Middle Aged; Muscle Contraction; Muscles; Parkinson Disease | 2001 |
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease | 2001 |
The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Parkinson Disease | 2001 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline | 2001 |
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles | 2001 |
[A case of delusional jealousy in Parkinson disease ].
Topics: Antiparkinson Agents; Benserazide; Delusions; Dose-Response Relationship, Drug; Drug Combinations; Humans; Jealousy; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 2001 |
[Parkinson's disease].
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Catechols; Depressive Disorder; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Follow-Up Studies; Humans; Indoles; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders; Time Factors | 2001 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease | 2001 |
Task-related EEG-EEG coherence depends on dopaminergic activity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dopamine; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Psychomotor Performance; Reticular Formation | 2001 |
Effects of anterodorsal pallidal stimulation on gait freezing (Kinesia paradoxa) in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Double-Blind Method; Electric Stimulation Therapy; Electrodes, Implanted; Female; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Stereotaxic Techniques; Treatment Outcome | 2000 |
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Topics: Apomorphine; Corpus Striatum; Decision Making; Domperidone; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Guidelines as Topic; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Time Factors | 2001 |
Does stimulation of the GPi control dyskinesia by activating inhibitory axons?
Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Evoked Potentials, Visual; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Microelectrodes; Monitoring, Intraoperative; Neural Inhibition; Parkinson Disease; Periodicity | 2001 |
A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Cognition; Dopamine Agents; Dopamine Agonists; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Recurrence | 2001 |
Levodopa, ayurveda and Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Medicine, Ayurvedic; Parkinson Disease | 2001 |
Interruption of the MnO2 oxidative process on dopamine and L-dopa by the action of S2O3(2-).
Topics: Dopamine; Humans; In Vitro Techniques; Levodopa; Manganese Compounds; Models, Neurological; Neurons; Oxidation-Reduction; Oxides; Parkinson Disease; Spectrophotometry; Spectrum Analysis, Raman; Thiosulfates | 2001 |
Neurobiology. Dopamine receptors get a boost.
Topics: Animals; Brain-Derived Neurotrophic Factor; Dopamine; Frontal Lobe; Levodopa; Mice; Neurons; Nucleus Accumbens; Parkinson Disease; Rats; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2001 |
Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Extracellular Space; Fluoxetine; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2001 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Antiparkinson Agents; Bromocriptine; Creatine Kinase; Diagnosis, Differential; Diagnostic Errors; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2001 |
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Speech dysfluency exacerbated by levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Speech Disorders; Stuttering; Videotape Recording | 2001 |
Advances in managing Parkinson's disease.
Topics: Activities of Daily Living; Algorithms; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2001 |
[Parkinson disease. Directed use of modern therapy].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2001 |
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Wake Disorders | 2001 |
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Topics: Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; France; Health Care Costs; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Sex Distribution | 2001 |
Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; DNA Mutational Analysis; Female; Gene Frequency; Genetic Testing; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D1; Receptors, Dopamine D5; Risk Factors | 2001 |
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cardiovascular Diseases; Dopa Decarboxylase; Down-Regulation; Drug Interactions; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Up-Regulation | 2001 |
Effects of bilateral subthalamic nucleus stimulation on parkinsonian gait.
Topics: Antiparkinson Agents; Biomechanical Phenomena; Electric Stimulation Therapy; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2001 |
Initial treatment of Parkinson's disease: wait just a minute.
Topics: Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Time Factors | 2001 |
[Treatment of Parkinson patients].
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 2001 |
Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Caudate Nucleus; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agents; Female; Fluorine Radioisotopes; Half-Life; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Putamen; Severity of Illness Index; Tomography, Emission-Computed | 2001 |
Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain Infarction; Brain Ischemia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Substantia Nigra | 2001 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone | 2001 |
Daytime sleepiness improvement following bilateral chronic electrical stimulation of the subthalamic nucleus in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electric Stimulation Therapy; Humans; Levodopa; Male; Parkinson Disease; Sleep Wake Disorders; Subthalamic Nucleus | 2001 |
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Decarboxylation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Levodopa; Male; Microdialysis; Neostriatum; Parkinson Disease; Rats; Rats, Wistar | 2001 |
[Sleepiness attacks while driving: adverse effects of new antiparkinson drugs].
Topics: Antiparkinson Agents; Automobile Driving; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Sleep Wake Disorders | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Pergolide and Parkinson's disease: new preparation. No clear benefit.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Treatment Outcome | 2000 |
Acute effects of bilateral subthalamic nucleus stimulation on clinical and kinematic parameters in Parkinson's disease.
Topics: Aged; Combined Modality Therapy; Dominance, Cerebral; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2001 |
Focal myopathy as a cause of anterocollis in Parkinsonism.
Topics: Aged; Biopsy; Diagnosis, Differential; Dystonic Disorders; Female; Humans; Levodopa; Multiple System Atrophy; Neck Muscles; Neurologic Examination; Parkinson Disease | 2001 |
A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
Topics: Aged; Amantadine; Binding, Competitive; Carbon Radioisotopes; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Presynaptic Terminals; Putamen; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Tomography, Emission-Computed | 2001 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Malabsorption Syndromes; Middle Aged; Parkinson Disease | 2001 |
Entacapone: new preparation. Comparative data are lacking.
Topics: Antiparkinson Agents; Catechols; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 1999 |
Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro.
Topics: Animals; Bone Marrow Cells; Cell Division; Cells, Cultured; Clone Cells; Gene Expression; Genetic Therapy; Green Fluorescent Proteins; GTP Cyclohydrolase; Humans; Levodopa; Luminescent Proteins; Male; Parkinson Disease; Promoter Regions, Genetic; Rats; Rats, Inbred Lew; Retroviridae; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2001 |
[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].
Topics: Animals; Brain Tissue Transplantation; Cells, Cultured; Combined Modality Therapy; Cricetinae; Fetal Tissue Transplantation; Forecasting; France; Humans; Huntington Disease; Levodopa; Neurodegenerative Diseases; Neurons; Parkinson Disease; Rabbits; Rats; Species Specificity; Stem Cell Transplantation; Swine; Tissue and Organ Procurement; Transplantation, Heterologous; Transplantation, Homologous; Treatment Outcome | 2001 |
Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
Topics: Adult; Aged; Antiparkinson Agents; Brain Tissue Transplantation; Chorea; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Fetal Tissue Transplantation; Globus Pallidus; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease | 2001 |
Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Humans; Indoles; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic; Regression Analysis; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Clinical correlates of action tremor in Parkinson disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Arm; Female; Humans; Hypokinesia; Levodopa; Male; Mental Status Schedule; Middle Aged; Motor Activity; Movement; Muscle Rigidity; Parkinson Disease; Physical Examination; Posture; Rest; Tremor; Video Recording | 2001 |
Relation between changes in long-latency stretch reflexes and muscle stiffness in Parkinson's disease--comparison before and after unilateral pallidotomy.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Dementia; Electromyography; Female; Functional Laterality; Globus Pallidus; Hand; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscle Rigidity; Muscle, Skeletal; Parkinson Disease; Reaction Time; Reflex, Stretch; Wrist Joint | 2001 |
[A case of elderly onset Parkinson's disease complicated by dropped head syndrome].
Topics: Aged; Aged, 80 and over; Humans; Levodopa; Male; Neck; Parkinson Disease; Posture | 2001 |
Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications.
Topics: Acute Disease; Adult; Aged; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Somatosensory Disorders | 2001 |
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Binding Sites; Carbidopa; Crystallography, X-Ray; Dopa Decarboxylase; Drug Design; Humans; Kidney; Levodopa; Ligands; Models, Molecular; Parkinson Disease; Pliability; Protein Structure, Secondary; Swine | 2001 |
Relationship between lesion location and the outcome of pallidotomy for Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Globus Pallidus; Humans; Intelligence Tests; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2001 |
Parkinson's disease. Dopamine may sustain toxic protein.
Topics: Cytoplasm; Dopamine; Humans; Levodopa; Nerve Tissue Proteins; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Protein Conformation; Protein Folding; Synaptic Vesicles; Synucleins | 2001 |
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Topics: alpha-Synuclein; Animals; Antioxidants; Biopolymers; Catecholamines; Cytoplasm; Dopamine; Humans; Levodopa; Nerve Tissue Proteins; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Quinones; Spectrometry, Fluorescence; Synaptic Vesicles; Synucleins | 2001 |
Pharmacodynamic modeling of oral levodopa in Parkinson's disease.
Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Predictive Value of Tests; Psychomotor Performance; Raclopride; Tomography, Emission-Computed | 2001 |
Speech motor stability in IPD: effects of rate and loudness manipulations.
Topics: Aged; Aging; Antiparkinson Agents; Dysarthria; Female; Humans; Levodopa; Lip; Loudness Perception; Male; Mandible; Middle Aged; Parkinson Disease; Severity of Illness Index; Speech | 2001 |
Complete genomic screen in Parkinson disease: evidence for multiple genes.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Drug Resistance; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Ligases; Lod Score; Microsatellite Repeats; Middle Aged; Parkinson Disease; Risk Factors; Ubiquitin-Protein Ligases | 2001 |
Deep brain stimulation (DBS) attentional effects parallel those of l-dopa treatment.
Topics: Adult; Attention; Cognition; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Middle Aged; Neuropsychological Tests; Parkinson Disease; Speech Disorders; Subthalamic Nucleus | 2001 |
Interactions between deep brain stimulation and levodopa in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time; Subthalamic Nucleus; Walking | 2001 |
Prospective longitudinal assessment of hallucinations in Parkinson's disease.
Topics: Aged; Dementia; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Risk Factors | 2001 |
Metabolic correlates of levodopa response in Parkinson's disease.
Topics: Aged; Blood Glucose; Brain; Brain Mapping; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Reference Values; Tomography, Emission-Computed | 2001 |
Neuroleptic malignant syndrome in advanced Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Secondary Prevention; Severity of Illness Index; Substance Withdrawal Syndrome | 2001 |
Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.
Topics: Adult; Antiparkinson Agents; Case-Control Studies; Cerebral Cortex; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Glucose; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Radiopharmaceuticals; Severity of Illness Index; Tomography, Emission-Computed | 2001 |
Gastric emptying time and gastric motility in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Severity of Illness Index; Technetium Tc 99m Aggregated Albumin; Tomography, Emission-Computed | 2001 |
Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor.
Topics: Aged; Anti-Anxiety Agents; Antiparkinson Agents; Clonazepam; Electromyography; Female; Humans; Leg; Levodopa; Male; Parkinson Disease; Treatment Outcome; Tremor | 2001 |
Poetic talent unmasked by treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Creativity; Dopamine Agonists; Humans; Levodopa; Libido; Lisuride; Male; Middle Aged; Parkinson Disease; Poetry as Topic; Serotonin Receptor Agonists | 2001 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Bromocriptine; Disease Models, Animal; Drosophila melanogaster; Genotype; Levodopa; Motor Activity; Nerve Tissue Proteins; Neurons; Parkinson Disease; Pergolide; Postural Balance; Synapses; Synucleins | 2002 |
[Deep stimulation helps in advanced Parkinson's disease. Electrodes in the brain spare L-dopa].
Topics: Brain; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Parkinson Disease; Patient Selection | 2001 |
Professor Oleh Hornykiewicz on the occasion of his 75th birthday and the first L-DOPA treatment of Parkinson's disease 40 years ago.
Topics: Austria; History, 20th Century; Humans; Levodopa; Neurology; Parkinson Disease | 2001 |
How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago.
Topics: Antiparkinson Agents; Austria; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2001 |
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.
Topics: Antiparkinson Agents; Brain; Dopamine; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2001 |
Parkinson's disease. A half century of progress.
Topics: Animals; Antiparkinson Agents; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2001 |
[Relation between autonomic dysfunction and progression of Parkinson's disease].
Topics: Adult; Aged; Autonomic Nervous System Diseases; Baroreflex; Disease Progression; Humans; Levodopa; Middle Aged; Parkinson Disease; Valsalva Maneuver | 2001 |
Levodopa. Is toxicity a myth? 1998.
Topics: Animals; Antiparkinson Agents; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2001 |
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. 2000.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; History, 20th Century; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2001 |
Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease.
Topics: Adult; Antiparkinson Agents; Electromyography; Female; Humans; Larynx; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Phonation; Sound Spectrography; Voice Quality | 2001 |
PARK6-linked parkinsonism occurs in several European families.
Topics: Adult; Age of Onset; Antiparkinson Agents; Chromosomes, Human, Pair 1; Europe; Family Health; Female; Founder Effect; Genetic Linkage; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree; Phenotype | 2002 |
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Disease Progression; Female; Humans; Incidence; Levodopa; Lewy Bodies; Lewy Body Disease; Male; Middle Aged; Neurofibrillary Tangles; Parkinson Disease; Plaque, Amyloid; Prevalence; Retrospective Studies | 2002 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Disease Progression; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 2002 |
Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach.
Topics: Adult; Aged; Antiparkinson Agents; Drug Monitoring; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Motor Activity; Parkinson Disease | 2001 |
[A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1999 |
Interaction of levodopa and cues on voluntary reaching in Parkinson's disease.
Topics: Antiparkinson Agents; Cues; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2002 |
β-Adrenergics enhance brain extraction of levodopa.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Cerebrovascular Circulation; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar | 2002 |
Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Disability Evaluation; Electric Stimulation Therapy; Female; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Posture | 2002 |
Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients.
Topics: Antiparkinson Agents; Combined Modality Therapy; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Time | 2002 |
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome | 2002 |
Levodopa-induced ocular dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Parkinson Disease | 2002 |
The straight dope on addiction to dopamimetic drugs.
Topics: Humans; Levodopa; Parkinson Disease; Substance-Related Disorders | 2002 |
Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD.
Topics: Adult; Disorders of Excessive Somnolence; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Female; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Sleep, REM; Wakefulness | 2002 |
[High dose L-dopa infusion during general anesthesia for gastrectomy in a patient with parkinsonism].
Topics: Aged; Anesthesia, General; Antiparkinson Agents; Gastrectomy; Humans; Infusions, Intravenous; Levodopa; Male; Parkinson Disease; Stomach Neoplasms | 2002 |
Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
Topics: Adult; Aged; Benzamides; Corpus Striatum; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Synaptic Transmission; Tomography, Emission-Computed, Single-Photon | 2002 |
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dyskinesia, Drug-Induced; Enkephalins; Humans; In Situ Hybridization; Levodopa; Parkinson Disease; Protein Precursors; Putamen; RNA, Messenger; Statistics as Topic | 2002 |
The clinical profile of nonmotor fluctuations in Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dopamine Agents; Humans; Levodopa; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease; Sensation Disorders; Surveys and Questionnaires; Time Factors | 2002 |
Respiratory muscle performance and the Perception of dyspnea in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Dopamine Agents; Dyspnea; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Function Tests; Respiratory Muscles | 2002 |
Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients.
Topics: Adult; Aged; Antiparkinson Agents; Case-Control Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 2002 |
Juvenile Parkinson's disease.
Topics: Adult; Age Factors; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2001 |
Medical management of Parkinson's disease.
Topics: Amantadine; Cholinergic Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Humans; Levodopa; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 2002 |
Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa.
Topics: Adult; Aged; Anterior Horn Cells; Antiparkinson Agents; Basal Ganglia; Biological Clocks; Cortical Synchronization; Efferent Pathways; Electromyography; Female; Humans; Levodopa; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Muscle Contraction; Muscle, Skeletal; Parkinson Disease; Recovery of Function; Treatment Outcome | 2002 |
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
Topics: Brain; Cerebrovascular Circulation; Cognition; Cognition Disorders; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Parkinson Disease; Prefrontal Cortex; Psychomotor Performance; Tomography, Emission-Computed | 2002 |
Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Dopamine; Injections, Intraventricular; Kinetics; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar; Stereotyped Behavior | 2002 |
New guidelines help providers refine Parkinson's strategy.
Topics: Humans; Levodopa; Nutrition Disorders; Parkinson Disease; Practice Guidelines as Topic; Surgical Procedures, Operative; United States | 2002 |
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.
Topics: Antiparkinson Agents; Humans; Levodopa; Motor Activity; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2002 |
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2002 |
Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes.
Topics: Age Factors; Aged; Brain; Clinical Trials as Topic; Electric Stimulation Therapy; Epilepsy; Female; Hematologic Diseases; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motivation; Neurosurgical Procedures; Parkinson Disease; Patient Selection; Subthalamic Nucleus | 2002 |
Literature alert.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; Humans; Incidence; Indoles; Levodopa; Neurons; Parkinson Disease | 2001 |
Entacapone: adjunctive use in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Canada; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Technology Assessment, Biomedical | 2000 |
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time | 2001 |
Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Benzodiazepines; Drug Interactions; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2002 |
Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Hand Strength; Humans; Levodopa; Middle Aged; Movement; Muscle Contraction; Parkinson Disease; Weight-Bearing | 2002 |
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.
Topics: Animals; Corpus Striatum; Dependovirus; Female; Gene Transfer, Horizontal; Genetic Therapy; GTP Cyclohydrolase; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2002 |
Is it time to abandon functional imaging in the study of neuroprotection?
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Disease Progression; Humans; Indoles; Levodopa; Parkinson Disease; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Clinical-pathological study of levodopa complications.
Topics: Aged; Antiparkinson Agents; Brain; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2002 |
Antiparkinsonian treatment in pregnancy.
Topics: Adult; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pergolide; Pregnancy; Pregnancy Complications | 2002 |
Bruxism as presenting feature of Parkinson's disease.
Topics: Antiparkinson Agents; Bruxism; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
An MCASE approach to the search of a cure for Parkinson's Disease.
Topics: Antiparkinson Agents; Computer Simulation; Dopamine Agonists; Drug Design; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2002 |
Myopathic camptocormia in a patient with levodopa unresponsive parkinsonism.
Topics: Aged; Antiparkinson Agents; Drug Resistance; Humans; Levodopa; Male; Muscle, Skeletal; Muscular Diseases; Parkinson Disease; Posture; Tomography, X-Ray Computed | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
[Short history of L-Dopa].
Topics: Antiparkinson Agents; Antipsychotic Agents; History, 20th Century; Humans; Levodopa; Parkinson Disease; Reserpine | 2002 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Space; Kynurenic Acid; Levodopa; Male; Neostriatum; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Substantia Nigra | 2002 |
Restless legs syndrome in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Prospective Studies; Restless Legs Syndrome | 2002 |
[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Delusions; Female; France; Hallucinations; Health Surveys; Humans; Inpatients; Levodopa; Male; Middle Aged; Outpatients; Paranoid Disorders; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders | 2002 |
[Multiple system atrophy which had been treated as juvenile Parkinson's disease].
Topics: Adult; Antiparkinson Agents; Humans; Levodopa; Male; Multiple System Atrophy; Parkinson Disease; Pergolide | 2002 |
Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Cognition; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement; Neostriatum; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Reaction Time; Recovery of Function; Treatment Outcome; Visual Perception | 2002 |
Drugs can trigger pathological gambling.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Levodopa; Parkinson Disease | 2002 |
Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cholinergic Antagonists; Cohort Studies; Comorbidity; Cross-Sectional Studies; Data Collection; Dopamine Agents; Drug Prescriptions; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacoepidemiology | 2002 |
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole | 2001 |
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Biological Clocks; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Intraoperative; Movement; Neurons; Parkinson Disease; Subthalamic Nucleus | 2002 |
Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.
Topics: Aged; Analysis of Variance; Corpus Striatum; Dementia; Dopamine Agents; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 2002 |
Sleep disorders and their determinants in multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Depression; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders | 2002 |
Quantification of the dopaminergic response in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reference Values; Severity of Illness Index; Time Factors | 2002 |
Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.
Topics: Aged; Analysis of Variance; Disorders of Excessive Somnolence; Dopamine Agents; Humans; Levodopa; Linear Models; Middle Aged; Parkinson Disease; Severity of Illness Index | 2002 |
Modification of tyrosine hydroxylase activity by chloral derived beta-carbolines in vitro.
Topics: Animals; Carbolines; Chloral Hydrate; Chromatography, High Pressure Liquid; Enzyme Activation; Humans; Levodopa; Nucleus Accumbens; Parkinson Disease; Rats; Tyrosine 3-Monooxygenase | 2002 |
[Rush dyskinesia scale or Goetz scale].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2002 |
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa].
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Drug Interactions; Hallucinations; Levodopa; Parkinson Disease; Paroxetine | 2002 |
3-OMD and homocysteine plasma levels in parkinsonian patients.
Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2002 |
The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Topics: Aged; Brain; Catechol O-Methyltransferase; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Methyldopa; Middle Aged; Monoamine Oxidase; Parkinson Disease; Tyrosine 3-Monooxygenase | 1975 |
Drug therapy for Parkinsonism.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
How to achieve maximum benefit for the patient with Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Histamine H1 Antagonists; Humans; Levodopa; Nervous System Diseases; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Trihexyphenidyl | 1976 |
Physiological and pharmacological aids in the differential diagnosis of tremor.
Topics: Ataxia; Diagnosis, Differential; Ethanol; Humans; Isoproterenol; Levodopa; Methods; Parkinson Disease; Phenothiazines; Polyneuropathies; Propranolol; Tremor | 1976 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Carbidopa; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities | 1977 |
Update on drug treatment of Parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1977 |
[Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Topics: Administration, Oral; Adrenergic Agonists; Aged; Drug Therapy, Combination; Electromyography; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Receptors, Dopamine | 1977 |
[Treatment of parkinson's syndrome. New developments].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents; Benzodiazepines; Carboxy-Lyases; Humans; Hyperkinesis; Levodopa; Parasympatholytics; Parkinson Disease; Tranquilizing Agents | 1978 |
Dopaminephilic properties of ergot alkaloids.
Topics: Acetonitriles; Animals; Bromocriptine; Corpus Striatum; Ergolines; Ergot Alkaloids; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Spiperone; Substantia Nigra; Synaptosomes; Tremor; Tyrosine 3-Monooxygenase | 1978 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Physical Therapy Modalities; Speech Disorders | 1978 |
Renal effects in L-dopa treated parkinsonian patients [proceedings].
Topics: Kidney; Levodopa; Parkinson Disease | 1978 |
Treatment with L-dopa for 5 years of more in 85 parkinsonian patients [proceedings].
Topics: Humans; Levodopa; Long-Term Care; Parkinson Disease | 1978 |
Lergotrile in Parkinson disease: further studies.
Topics: Aged; Bromocriptine; Chemical Phenomena; Chemistry; Dopa Decarboxylase; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 1979 |
[Acute pharmacotoxic psychoses in patients with chronic cerebral disorders].
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Brain Diseases; Cerebrovascular Disorders; Dementia; Digitalis Glycosides; Diuretics; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Multiple Sclerosis; Parkinson Disease; Psychoses, Substance-Induced | 1979 |
Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
Topics: Aged; Behavior; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Parkinson Disease; Placebos; Prolactin; Time Factors | 1979 |
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induced; Epilepsy; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Limbic System; Neural Pathways; Neurons; Neurotransmitter Agents; Parkinson Disease; Psychopharmacology | 1979 |
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Sleep | 1978 |
Letter: Ascorbic acid in levodopa therapy.
Topics: Ascorbic Acid; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Letter: Diphasic dyskinesia during levodopa therapy.
Topics: Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1975 |
Letter: Extrapyramidal dementia and levodopa.
Topics: Aged; Basal Ganglia Diseases; Dementia; Female; Humans; Levodopa; Male; Parkinson Disease | 1975 |
Letter: Parkinsonism and dementia: effects of levodopa.
Topics: Dementia; Humans; Levodopa; Mental Processes; Parkinson Disease | 1975 |
Letter: Parkinsonism and dementia: effects of levodopa.
Topics: Dementia; Electroencephalography; Humans; Levodopa; Parkinson Disease | 1975 |
Letter: Dyskinesias during levodopa therapy.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1975 |
Letter: Do changes in blood levels of other aromatic aminoacids influence levodopa therapy?
Topics: Amino Acids; Blood-Brain Barrier; Histidine; Humans; Levodopa; Parkinson Disease; Phenylalanine; Tryptophan | 1976 |
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
Topics: Dose-Response Relationship, Drug; Half-Life; Levodopa; Long-Term Care; Movement Disorders; Muscle Rigidity; Parkinson Disease; Time Factors | 1976 |
Letter: Growth-hormone responses in Parkinson's disease.
Topics: Bromocriptine; Growth Hormone; Humans; Levodopa; Parkinson Disease | 1976 |
Letter: Peak-dose dysphonia in parkinsonism.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Disorders | 1976 |
Editorial: After dopa.
Topics: Apomorphine; Chemoreceptor Cells; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Stimulation, Chemical | 1976 |
Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
Topics: Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Schizophrenia, Paranoid | 1976 |
Success and problems of long-term levodopa therapy in Parkinson's disease.
Topics: Brain; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation; gamma-Aminobutyric Acid; Glutamate Dehydrogenase; Humans; Levodopa; Motor Neurons; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin; Time Factors | 1977 |
Long-term levodopa in Parkinson's disease.
Topics: Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Time Factors | 1977 |
[The "off-on" phenomenon during treatment of parkinson's disease with levodopa (author's transl)].
Topics: Aged; Carboxy-Lyases; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
EEG power spectral changes secondary to L-DOPA treatment in parkinsonian patients: a pilot study.
Topics: Electroencephalography; Humans; Levodopa; Parkinson Disease; Pilot Projects | 1977 |
Parkinson's disease, melanoma, and levodopa.
Topics: Aged; Humans; Levodopa; Male; Melanoma; Parkinson Disease; Skin Neoplasms | 1977 |
"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
Topics: Athetosis; Chorea; Dystonia Musculorum Deformans; Female; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1977 |
Long-term treatment of parkinsonism with bromocriptine.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Time Factors | 1978 |
Drugs for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Drug Evaluation; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Phenethylamines | 1978 |
Drugs for Parkinson's disease.
Topics: Age Factors; Aged; Humans; Levodopa; Parkinson Disease | 1978 |
Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study.
Topics: Aged; Bromocriptine; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Myoclonus; Parkinson Disease; Sleep | 1978 |
Unsuccessful treatment with levodopa of a parkinsonian patient with calcification of the basal ganglia.
Topics: Aged; Basal Ganglia; Brain Diseases; Calcinosis; Drug Resistance; Humans; Levodopa; Male; Parkinson Disease | 1978 |
Bromocriptine in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1978 |
Tiapride in Parkinson's disease.
Topics: Antiparkinson Agents; Benzamides; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Placebos | 1978 |
Cerebral atrophy and long-term response to levodopa in Parkinson's disease.
Topics: Adult; Aged; Atrophy; Brain; Cerebral Cortex; Cerebral Ventricles; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors; Tomography, X-Ray Computed | 1979 |
[Today's treatment of Parkinsonism].
Topics: Chronic Disease; Humans; Levodopa; Long-Term Care; Parkinson Disease | 1978 |
Dream phenomena induced by chronic levodopa therapy.
Topics: Adult; Aged; Carbidopa; Delusions; Dreams; Female; Hallucinations; Humans; Illusions; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1978 |
Plasmatic renin activity in patients treated with L-dopa and inhibitor of dopa decarboxylase (IDC).
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Dopamine; Humans; Levodopa; Middle Aged; Parkinson Disease; Physical Exertion; Renin; Sympathetic Nervous System | 1979 |
[Endocrinological studies on Parkinson's disease (author's transl)].
Topics: Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1979 |
Long-term effects of home-made levodopa in 43 cases of paralysis agitans.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
Diphenylhydantoin. Blocking of levodopa effects.
Topics: Adult; Aged; Dopamine; Female; Humans; Huntington Disease; Levodopa; Male; Manganese Poisoning; Middle Aged; Movement Disorders; Neurons; Parkinson Disease; Phenytoin; Receptors, Adrenergic | 1975 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1975 |
[The activity of aminotransferases in serum and cerebrospinal fluid in neurological diseases (author's transl)].
Topics: Alanine Transaminase; Amyotrophic Lateral Sclerosis; Aspartate Aminotransferases; Craniocerebral Trauma; Friedreich Ataxia; Guanidines; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Nervous System Diseases; Parkinson Disease; Penicillins; Phenylketonurias; Transaminases | 1975 |
Therapeutics of disordered movement.
Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1977 |
Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Huntington Disease; Levodopa; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synapses; Tranquilizing Agents | 1977 |
[Clinical picture and treatment of Parkinson-like syndromes of hereditary etiology].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Child; Diagnosis, Differential; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Pantothenate Kinase-Associated Neurodegeneration; Parkinson Disease | 1978 |
Standard values of the amplitude of jaw jerk action potential and differences due to age, sex and L-dopa treatment.
Topics: Action Potentials; Adult; Age Factors; Electromyography; Evoked Potentials; Female; Humans; Levodopa; Male; Mandible; Masticatory Muscles; Middle Aged; Muscle Spindles; Parkinson Disease; Reflex, Monosynaptic; Sex Factors | 1979 |
Editorial: Miracle cures in Parkinson's disease.
Topics: Chloramphenicol; Cyclic AMP; Depression; Electroconvulsive Therapy; Humans; Levodopa; Parkinson Disease | 1975 |
Circulating levels of corticotrophin and cortisol after infusions of L-DOPA, dopamine and noradrenaline, in man.
Topics: Adrenocorticotropic Hormone; Blood Pressure; Catheterization; Cosyntropin; Dihydroxyphenylalanine; Dopamine; Humans; Hydrocortisone; Infusions, Parenteral; Insulin; Lactates; Levodopa; Norepinephrine; Parkinson Disease; Pulse; Sodium Chloride | 1975 |
Effect of levodopa on urinary bladder.
Topics: Aged; Animals; Central Nervous System; Dogs; Dopamine; Ganglia, Autonomic; Humans; Levodopa; Male; Muscles; Neural Inhibition; Norepinephrine; Parkinson Disease; Synaptic Transmission; Urethra; Urinary Bladder | 1976 |
[Extrapyramidal and presenile dementia. Relation between symptoms of dementia and cerebral transmitters, particularly dopamine].
Topics: Acetylcholine; Brain; Dementia; Dopamine; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 1976 |
The effect of L-dopa and propranolol on human CSF cyclic nucleotides.
Topics: Adult; Aged; Cyclic AMP; Cyclic GMP; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propranolol; Schizophrenia | 1978 |
[Therapeutic use of tiapride in movement disorders].
Topics: Benzamides; Chorea; Chronic Disease; Drug Tolerance; Female; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease | 1978 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Angiotensin converting enzyme in the Parkinsonian brain.
Topics: Aged; Brain; Female; Humans; Levodopa; Male; Parkinson Disease; Peptidyl-Dipeptidase A | 1978 |
In practice. Parkinson's disease.
Topics: Amantadine; Basal Ganglia; Bromocriptine; Humans; Levodopa; Middle Aged; Movement; Parasympatholytics; Parkinson Disease; Prognosis; Synaptic Transmission | 1979 |
Cerebrospinal fluid cyclic AMP in parkinsonism [proceedings].
Topics: Adult; Carbidopa; Cyclic AMP; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Distinction between benign and malignant type of Parkinson's disease.
Topics: Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Prognosis | 1979 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; Carbon Radioisotopes; Depression, Chemical; Dopamine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H1 Antagonists; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Time Factors; Trihexyphenidyl | 1975 |
Parkinson's disease and its chemotherapy.
Topics: Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 1975 |
Individualization of drug therapy for the parkinsonian patient.
Topics: Antiparkinson Agents; Arrhythmia, Sinus; Blood-Brain Barrier; Deglutition Disorders; Drug Interactions; Histamine H1 Antagonists; Humans; Hypotension, Orthostatic; Levodopa; Parasympatholytics; Parkinson Disease | 1975 |
Treating parkinsonism in the era of levodopa.
Topics: Amantadine; Antidepressive Agents; Anxiety; Depression; Histamine H1 Antagonists; Humans; Levodopa; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Tranquilizing Agents | 1975 |
Diseases of the central nervous system. Pharmacological basis of treatment.
Topics: Amantadine; Analgesics, Opioid; Anticonvulsants; Blood-Brain Barrier; Central Nervous System Diseases; Cholinesterase Inhibitors; Edrophonium; Epilepsy; Headache; Humans; Levodopa; Methysergide; Migraine Disorders; Myasthenia Gravis; Parkinson Disease; Pyridostigmine Bromide; Serotonin Antagonists | 1975 |
[Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
Topics: Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle Aged; Neurotransmitter Agents; Parkinson Disease | 1975 |
Parkinson's disease--a review.
Topics: Levodopa; Parkinson Disease | 1975 |
Parkinson's disease.
Topics: Amantadine; Benztropine; Humans; Levodopa; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1977 |
The on-off effect - a side-effect of long-term levodopa treatment.
Topics: Emotions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine; Humans; Levodopa; Parkinson Disease | 1979 |
The relationship of the basic intellectual endowment of the Parkinson patient to the long-term effect of L-dopa.
Topics: Aged; Female; Humans; Intelligence; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
[Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
Topics: Dementia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1979 |
Levodopa in the treatment of Parkinson's disease.
Topics: Brain; Humans; Levodopa; Parkinson Disease | 1977 |
Psychiatric disturbances occurring during levodopa therapy of Parkinson's disease.
Topics: Humans; Levodopa; Mental Disorders; Parkinson Disease | 1977 |
Increased appetite (bulimia) in Parkinson's disease.
Topics: Aged; Amantadine; Feeding and Eating Disorders; Female; Humans; Hunger; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Bromocriptine and parkinsonism.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1978 |
The hypothalamus in Parkinson disease.
Topics: Aged; Cell Nucleus; Female; Growth Hormone-Releasing Hormone; Humans; Hypothalamus; Levodopa; Male; Melanocyte-Stimulating Hormones; Middle Aged; Parkinson Disease | 1978 |
George C. Cotzias 1918-1977.
Topics: Greece; History, 20th Century; Humans; Levodopa; Parkinson Disease; Pathology | 1978 |
Background to the levodopa treatment of Parkinson's disease.
Topics: History, 20th Century; Humans; Levodopa; Parkinson Disease | 1977 |
Dose-related levodopa-induced haemolytic anaemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Benserazide; Dose-Response Relationship, Drug; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 1977 |
Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
Topics: Adult; Age Factors; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Oral Manifestations; Parkinson Disease; Tranquilizing Agents | 1977 |
Pharmaceutical review: salbutamol - madopar - isocal.
Topics: Albuterol; Australia; Benserazide; Humans; Hydrazines; Levodopa; Lung Diseases; Parenteral Nutrition; Parkinson Disease | 1978 |
Parkinson's disease: search for better therapies.
Topics: Bromocriptine; Humans; Levodopa; Oligopeptides; Parkinson Disease; Receptors, Dopamine | 1979 |
Parkinsonism with 'on-off' phenomena. Intravenous treatment with levodopa after major abdominal surgery.
Topics: Abdomen; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Care; Rectal Neoplasms | 1979 |
Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor.
Topics: Aged; Basal Ganglia Diseases; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Torticollis; Tremor; Trihexyphenidyl | 1979 |
Long-term treatment of Parkinson's disease with bromocriptine.
Topics: Adult; Age Factors; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
[Risks of modern therapy for parkinsonism, and their consequences (author's transl)].
Topics: Cardiovascular System; Digestive System; Dopa Decarboxylase; Dopamine; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Models, Chemical; Parkinson Disease; Risk | 1979 |
Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease.
Topics: Adult; Dystonia; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1979 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Electroencephalographic change in Parkinsonian patients treated with levodopa-carbidopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Dopamine receptors and sleep induction in man.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Receptors, Dopamine; Sleep; Sleep Stages; Time Factors; Vomiting | 1979 |
Drug holidays for patients with parkinsonism.
Topics: Drug Administration Schedule; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1979 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1979 |
Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1979 |
Causes of pseudotumor cerebri and papilledema.
Topics: Aged; Carbidopa; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Levodopa; Papilledema; Parkinson Disease; Pseudotumor Cerebri | 1979 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Parkinson's disease.
Topics: Aged; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Trihexyphenidyl | 1979 |
Tiapride in levodopa-induced involuntary movements.
Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Reversible haemolytic anaemia after levodopa-carbidopa.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1979 |
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
Topics: Adolescent; Adult; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Hydrazines; Levodopa; Male; Micrococcus; Middle Aged; Nicotinamidase; Nicotinic Acids; Parkinson Disease; Tryptophan | 1979 |
The significance of cerebral atrophy for the symptomatology of Parkinson's disease.
Topics: Adult; Aged; Atrophy; Brain; Cerebral Cortex; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychological Tests; Tomography, X-Ray Computed | 1979 |
Administration of human somatotropin in levodopa-treated patients with Parkinsonism.
Topics: Aged; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1979 |
EEG sleep patterns in Parkinsonian patients treated with bromocryptine and L-dopa: a comparative study.
Topics: Aged; Bromocriptine; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Reticular Formation; Sleep | 1979 |
Conditioning of the H reflex by stimulation of the posterior tibial nerve in Parkinson's disease.
Topics: Aged; Carbidopa; Conditioning, Psychological; Drug Therapy, Combination; Electric Stimulation; Evoked Potentials; Female; H-Reflex; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Reflex, Monosynaptic; Tibial Nerve | 1979 |
Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.
Topics: Bromocriptine; Dopamine beta-Hydroxylase; Humans; Kinetics; Levodopa; Parkinson Disease | 1979 |
Electroretinographic changes in patients with parkinsonism treated with various classes of antiparkinsonian drugs.
Topics: Amantadine; Antiparkinson Agents; Electroretinography; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Retina | 1979 |
Orbicularis oculi reflex in parkinsonism [proceedings].
Topics: Facial Muscles; Habituation, Psychophysiologic; Humans; Levodopa; Parkinson Disease; Reflex, Abnormal; Thalamic Nuclei | 1979 |
Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.
Topics: Binding Sites; Butyrophenones; Caudate Nucleus; Cerebral Cortex; Frontal Lobe; Humans; Levodopa; Muscular Atrophy; Neuromuscular Diseases; Parkinson Disease; Receptors, Dopamine; Spiperone; Substantia Nigra; Syndrome | 1979 |
[Alphamethyldopa and levodopa interaction].
Topics: Aged; Drug Interactions; Female; Humans; Levodopa; Methyldopa; Parkinson Disease | 1979 |
An analysis of tremor--alteration of parkinsonian tremor by L-dopa and surgical treatment.
Topics: Electromyography; Female; Humans; Levodopa; Male; Parkinson Disease; Thalamus; Tremor | 1979 |
Chronic agonist-induced hypersensitivity and on-off hyperkinesis.
Topics: Animals; Drug Hypersensitivity; Humans; Hyperkinesis; Levodopa; Parkinson Disease | 1979 |
[Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
Topics: Basal Ganglia Diseases; Blood-Brain Barrier; Dopa Decarboxylase; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1979 |
[Long-term therapy of Parkinson's syndrome with L-dopa].
Topics: Carboxy-Lyases; Enzyme Inhibitors; Levodopa; Parkinson Disease; Physical Therapy Modalities | 1979 |
[Value of sulpiride and tiapride in geriatrics. Antagonism between Parkinson disease and chorea].
Topics: Aged; Benzamides; Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Sulpiride; Tiapamil Hydrochloride | 1979 |
["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Coombs Test; Female; Humans; Hydrazines; Levodopa; Parkinson Disease | 1979 |
Dementia in Parkinson Disease.
Topics: Aged; Dementia; Female; Humans; Levodopa; Male; Parkinson Disease | 1979 |
Antagonism by piperidine of levodopa effects in Parkinson disease.
Topics: Aged; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1977 |
Western equine encephalitis with rapid onset of parkinsonism.
Topics: Adult; Carbidopa; Encephalitis Virus, Western Equine; Encephalomyelitis, Equine; Female; Humans; Levodopa; Parkinson Disease; Trihexyphenidyl | 1977 |
Normal pressure hydrocephalus, parkinsonism, and primary empty sella--coincidence or cause-effect?
Topics: Aged; Carbidopa; Cerebrospinal Fluid Shunts; Drug Therapy, Combination; Empty Sella Syndrome; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Jugular Veins; Levodopa; Parkinson Disease | 1978 |
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
Topics: Adult; Aged; Cerebral Palsy; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle Aged; Movement Disorders; Multiple Sclerosis; Parkinson Disease; Phenylacetates | 1978 |
Need for uncombined carbidopa to treat parkinsonism.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1978 |
Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
Topics: Aged; Carbidopa; Dihydroxyphenylalanine; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Bromocriptine in Parkinson disease: further studies.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
The role of bromocriptine in the treatment of parkinsonism.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1979 |
Sinemet and thyroid function in Parkinson disease.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Thyroid Function Tests; Thyroid Gland; Thyrotropin | 1979 |
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.
Topics: Adolescent; Adult; Aged; Chorea; Encephalitis; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Rats; Serotonin | 1977 |
Treatment of Parkinson's disease with bromocriptine.
Topics: Bromocriptine; Ergolines; Humans; Levodopa; Parkinson Disease | 1977 |
L-dopa induced dyskinesias in asymmetrical parkinsonism.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Pathways; Parkinson Disease | 1979 |
Effects of levodopa on "frontal" signs in Parkinsonism.
Topics: Aged; Female; Frontal Lobe; Humans; Levodopa; Parkinson Disease | 1977 |
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Serotonin; Tetrabenazine; Torticollis | 1977 |
Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Choice of treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Humans; Levodopa; Parkinson Disease | 1977 |
Treating parkinsonism with L-dopa and carboxylase inhibitor.
Topics: Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Topics: Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
Topics: Dihydroxyphenylalanine; Dopamine; Epinephrine; Follow-Up Studies; Humans; Levodopa; Norepinephrine; Parkinson Disease; Time Factors | 1977 |
[Ambulatory care of Parkinson-disease patients in a general hospital].
Topics: Adult; Aged; Ambulatory Care; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Outpatient Clinics, Hospital; Parkinson Disease; Patient Compliance; Transportation of Patients | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
[On and off phenomenon].
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease | 1977 |
Effects of somatostatin in parkinsonism, growth hormone, and dopa metabolism.
Topics: Animals; Female; Growth Hormone; Levodopa; Male; Mice; Parkinson Disease; Rats; Somatostatin | 1977 |
[Acute psychotic status after sudden interruption of treatment of Parkinsonism with levodopa].
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1977 |
[Clinical experiences with Nacom in the treatment of Parkinsonism].
Topics: Carboxy-Lyases; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1978 |
Drug therapy for Parkinson's disease.
Topics: Diagnosis, Differential; Dopamine Antagonists; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Time Factors | 1978 |
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
Topics: Aged; Benzimidazoles; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1978 |
Update on Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1978 |
[Levodopa in combined chemotherapy. Clinical considerations].
Topics: Adult; Aged; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1978 |
Application of paired-ion high-pressure liquid column chromatography to the analysis of L-3,4-dihydroxyphenylalanine metabolites.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1978 |
Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease.
Topics: Acetylcholinesterase; Dopamine beta-Hydroxylase; Erythrocytes; Humans; Levodopa; Parkinson Disease | 1978 |
[Levodopa treatment of parkinsonism].
Topics: Humans; Levodopa; Parkinson Disease | 1978 |
Levodopa-induced psychosis: a kindling phenomenon.
Topics: Adult; Aged; Chronic Disease; Confusion; Corpus Striatum; Delusions; Dreams; Female; Hallucinations; Humans; Levodopa; Limbic System; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Dopamine; Stimulation, Chemical; Time Factors | 1978 |
Comparison between lergotrile and bromocriptine in parkinsonism.
Topics: Acetonitriles; Adult; Aged; Bromocriptine; Carbidopa; Chemical Phenomena; Chemistry; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
Paradoxial response to dopaminergic agents in parkinsonism.
Topics: Acetonitriles; Aged; Carbidopa; Ergolines; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Receptors, Dopamine | 1978 |
Bromocriptine in parkinsonism. A long-term study.
Topics: Anorexia; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Time Factors; Urinary Incontinence; Vasomotor System | 1978 |
Levodopa therapy and malignant melanoma.
Topics: Adult; Age Factors; Aged; Humans; Levodopa; Male; Melanoma; Middle Aged; Parkinson Disease; Skin Neoplasms | 1978 |
GABA receptor binding in the parkinsonian brain.
Topics: Aged; Aminobutyrates; Brain; Cerebellar Cortex; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Drug; Substantia Nigra | 1978 |
Parkinsonism. Clinical and neuropharmacologic aspects.
Topics: Animals; Humans; Levodopa; Middle Aged; Parkinson Disease; Rats | 1978 |
Breast cancer in a patient under levodopa treatment.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Prolactin | 1978 |
Photic EEG-driving responses in thalamotomized and medicated cases of Parkinson's disease.
Topics: Adult; Aged; Alpha Rhythm; Beta Rhythm; Carbidopa; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Spectrum Analysis; Thalamus; Theta Rhythm | 1978 |
[Drug therapy of parkinsonism].
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1978 |
Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Caudate Nucleus; Dopamine; Haloperidol; Homovanillic Acid; Humans; Levodopa; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Synaptic Membranes | 1978 |
[Induction of dreams by levodopa].
Topics: Dreams; Humans; Levodopa; Parkinson Disease | 1978 |
Identification and quantification of 3-methoxy-4-hydroxyphenyllactic acid (VLA) in cerebrospinal fluid and 3-methoxy-4-hydroxy phenylpyruvic acid (VPA) in the urine of Parkinsonian patients treated with L-DOPA.
Topics: Catechols; Chromatography, Gas; Gas Chromatography-Mass Spectrometry; Humans; Lactates; Levodopa; Mass Spectrometry; Parkinson Disease; Phenylpyruvic Acids | 1978 |
[Combined administration of cholinolytic metamizil and L-Dopa in vascular parkinsonism].
Topics: Aged; Benactyzine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Vascular Diseases | 1978 |
Changes of electrooculogram (EOG) in Parkinson's disease.
Topics: Electrooculography; Eye Movements; Humans; Levodopa; Parkinson Disease | 1978 |
Determination of 3-methoxy-4-hydroxyphenylpyruvic acid, 3,4-dihydroxyphenylethylene glycol, and 3,4-dihydroxyphenylmandelic acid in urine by mass fragmentography, with use of deuterium-labeled internal standards.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Catechols; Child; Child, Preschool; Deuterium; Dopamine; Ethylene Glycols; Gas Chromatography-Mass Spectrometry; Humans; Infant; Infant, Newborn; Levodopa; Mandelic Acids; Methoxyhydroxyphenylglycol; Middle Aged; Neuroblastoma; Parkinson Disease; Phenylpyruvic Acids; Pheochromocytoma; Reference Standards; Reference Values; Shock, Cardiogenic | 1978 |
Abnormal epinephrine urinary excretion in Parkinsonians: correction of the disorder by levodopa administration.
Topics: Adult; Age Factors; Aged; Epinephrine; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Vanilmandelic Acid | 1978 |
[Treatment of parkinsonism today. Disappointments and new hope].
Topics: Humans; Levodopa; Parkinson Disease | 1978 |
Sexual function and affect in parkinsonian men treated with L-dopa.
Topics: Affect; Aged; Humans; Hypothalamo-Hypophyseal System; Levodopa; Libido; Luteinizing Hormone; Male; Middle Aged; Parkinson Disease; Sexual Behavior; Testis | 1978 |
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Topics: Benserazide; Brain; Bromocriptine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
[Long-term prognostic factors in Parkinson's disease (author's transl)].
Topics: Age Factors; Aged; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Sex Factors; Time Factors; Tremor | 1978 |
Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Furosemide; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Parkinson Disease; Posture; Renin | 1978 |
Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Xenon Radioisotopes | 1978 |
Measurements of visual evoked potentials in Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Dominance, Cerebral; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time; Visual Cortex; Visual Pathways; Visual Perception | 1978 |
The L-dopa on-off effect in Parkinson disease: treatment by transient drug withdrawal and dopamine receptor resensitization.
Topics: Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 1978 |
Bromocriptine in Parkinson's disease.
Topics: Bromocriptine; Humans; Levodopa; Parkinson Disease | 1978 |
The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
Topics: Acetylcholine; Animals; Biogenic Amines; Biological Transport; Cats; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Muscle Contraction; Muscle, Smooth; Parkinson Disease; Phenethylamines; Rabbits; Rats; Selegiline | 1978 |
Overview of present day treatment of Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Receptors, Dopamine; Selegiline | 1978 |
Long term treatment with L-deprenyl.
Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1978 |
Recent observations on the clinical pharmacology of (-)deprenyl.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors; Tyramine | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
Bromocriptine in lieu of levodopa for Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Humans; Levodopa; Middle Aged; Parkinson Disease | 1978 |
Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak.
Topics: Adult; Aged; Biological Availability; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plants, Medicinal | 1978 |
Patterns of response to levodopa in Parkinson's disease.
Topics: Aged; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 1978 |
Electrical properties of motor units in Parkinsonism and a possible relationship with bradykinesia.
Topics: Action Potentials; Adult; Aged; Carbidopa; Electromyography; Forearm; Gait; Hand; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Contraction; Muscles; Neuromuscular Junction; Parkinson Disease; Recruitment, Neurophysiological | 1979 |
Levodopa and melanoma.
Topics: Humans; Levodopa; Melanoma; Parkinson Disease; Skin Neoplasms | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
[Permanence of indications of stereotaxic surgery in parkinsonian tremors and various persistent abnormal movements].
Topics: Humans; Levodopa; Methods; Movement Disorders; Parkinson Disease; Stereotaxic Techniques | 1975 |
[Stereotaxic surgery of tremors].
Topics: Humans; Levodopa; Neurosurgery; Parkinson Disease; Stereotaxic Techniques; Tremor | 1976 |
The influence of previous stereotactic thalamotomy on l-dopa therapy in Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1976 |
Speech changes in Parkinson's disease during treatment with L-dopa.
Topics: Levodopa; Parkinson Disease; Speech | 1975 |
[Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
Topics: Aged; Antiparkinson Agents; Arrhythmias, Cardiac; Blood Pressure; Blood Pressure Determination; Calcium; Carboxy-Lyases; Chlorides; Drug Combinations; Electrolytes; Female; Humans; Hypotension; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Potassium; Pulse; Sodium | 1975 |
Editorial: Is L-dopa the final answer?
Topics: Animals; Haplorhini; Humans; Levodopa; Parkinson Disease | 1975 |
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
Topics: Administration, Oral; Aged; Blood Pressure; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Female; Humans; Hyperkinesis; Infusions, Parenteral; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Parkinson Disease; Posture; Time Factors | 1975 |
Levodopa and psychometric test performance in parkinsonism-5 years later.
Topics: Age Factors; Aged; Female; Follow-Up Studies; Humans; Intelligence; Learning; Levodopa; Long-Term Care; Male; Memory; Mental Processes; Middle Aged; Motor Skills; Parkinson Disease; Psychometrics; Time Factors; Visual Perception | 1976 |
Six years of high-level levodopa therapy in severely akinetic parkinsonian patients.
Topics: Activities of Daily Living; Drug Evaluation; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Parkinson Disease; Patient Dropouts; Prognosis | 1976 |
Results of present-day therapy of Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1976 |
Role of manganese in dystonia.
Topics: Animals; Brain; Brain Chemistry; Dogs; Dystonia Musculorum Deformans; Functional Laterality; Gait; Haplorhini; Humans; Levodopa; Manganese; Manganese Poisoning; Movement Disorders; Parkinson Disease; Rabbits; Rats; Synapses; Syndrome | 1976 |
Weight loss in patients treated long-term with levodopa. Metabolic aspects.
Topics: Age Factors; Aged; Body Weight; Fatty Acids; Glucose; Growth Hormone; Humans; Hydrocortisone; Insulin; Levodopa; Long-Term Care; Middle Aged; Parkinson Disease | 1976 |
Parkinsonism: animal analogues of the human disorder.
Topics: Animals; Butyrophenones; Chlorpromazine; Disease Models, Animal; Haplorhini; Hydroxydopamines; Levodopa; Methyltyrosines; Mice; Parkinson Disease; Rats; Reserpine; Substantia Nigra; Tremor | 1976 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
Topics: Adult; Benserazide; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1976 |
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (6) Problems of long-term treatment of levodopa in parkinsoism].
Topics: Humans; Levodopa; Long-Term Care; Parkinson Disease; Time Factors | 1976 |
[Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
Topics: Animals; Carbidopa; Carboxy-Lyases; Dogs; Drug Therapy, Combination; Female; Haplorhini; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine; Rats; Tremor | 1976 |
The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Parkinson Disease | 1976 |
Serum dopamine-beta-hydroxylase in parkinsonism.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine beta-Hydroxylase; Humans; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease | 1977 |
Drug therapy of Parkinsonism dopaminergic drugs.
Topics: Carbidopa; Humans; Hydrazines; Levodopa; Parkinson Disease | 1977 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
Topics: Dose-Response Relationship, Drug; Humans; Levodopa; Muscle Tonus; Parkinson Disease | 1977 |
[Characteristics of regional cerebral circulation in parkinsonism patients according the 133Xe clearance findings].
Topics: Adult; Aged; Cerebral Cortex; Cerebrovascular Circulation; Cerebrovascular Disorders; Female; Frontal Lobe; Humans; Infant, Newborn; Levodopa; Male; Middle Aged; Occipital Lobe; Parietal Lobe; Parkinson Disease; Parkinson Disease, Secondary; Xenon Radioisotopes | 1977 |
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Juvenile parkinsonism treated with levodopa.
Topics: Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Parkinson Disease; Serotonin | 1977 |
Levodopa, parkinsonism, and recent memory.
Topics: Humans; Intelligence; Levodopa; Memory; Parkinson Disease; Time Factors | 1977 |
Reciprocal continuous inhibition in rigidity of Parkinsonism.
Topics: Adult; Aged; H-Reflex; Humans; Levodopa; Middle Aged; Muscle Rigidity; Muscles; Neural Inhibition; Parkinson Disease; Peroneal Nerve; Procaine | 1977 |
[Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
Topics: Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
Topics: Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1977 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Carboxy-Lyases; Drug Combinations; Evaluation Studies as Topic; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Thalamus | 1977 |
Kaliuretic effect of L-dopa treatment in parkinsonian patients.
Topics: Aged; Aldosterone; Blood Pressure; Carboxy-Lyases; Diuresis; Female; Glomerular Filtration Rate; Humans; Hypokalemia; Levodopa; Liver Circulation; Male; Middle Aged; Parkinson Disease; Potassium; Sodium | 1977 |
Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients.
Topics: Aged; Aphasia; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Speech; Thalamus; Vital Capacity | 1977 |
Effect of L-dopa on polycythemia.
Topics: Aged; Benserazide; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Polycythemia Vera | 1977 |
Levodopa in parkinsonism.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Time Factors | 1977 |
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Topics: Benserazide; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Time Factors | 1977 |
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Combined treatment of parkinsonism with L-dopa and Parkopan].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Trihexyphenidyl | 1977 |
The relationship between parkinsonism and tardive dyskinesia.
Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Methyltyrosines; Mouth; Parkinson Disease; Piperidines; Tranquilizing Agents | 1977 |
Response to lithium in a case of L-dopa-induced psychosis.
Topics: Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Personality; Psychoses, Substance-Induced | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; Middle Aged; Movement Disorders; Parkinson Disease; Phenylacetates; Tremor | 1977 |
Theophyllamine and the antiparkinsonian response to levodopa treatment.
Topics: Aged; Aminophylline; Drug Evaluation; Drug Synergism; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Xanthines | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Continuous drug delivery methods reflect progress in therapy for chronic diseases.
Topics: Aged; Chronic Disease; Cytarabine; Dosage Forms; Drug Implants; Glaucoma; Humans; Injections, Intravenous; Leukemia; Levodopa; Neoplasms; Parkinson Disease; Pilocarpine; Research | 1977 |
Ocular dyskinesias in patients with Parkinson's disease treated with levodopa.
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Oculomotor Muscles; Parkinson Disease; Syndrome | 1977 |
L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.
Topics: Aged; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tryptophan | 1977 |
["Beginning and end of dose" dyskinesias caused by L-DOPA].
Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Clinical and electromyographic examinations on the effect of hydrochloride (Viregyt-K) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1977 |
Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline.
Topics: Acute Disease; Amitriptyline; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypertension; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease | 1977 |
[Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)].
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets, Enteric-Coated | 1977 |
Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients.
Topics: Animals; Biotransformation; Brain; Carbidopa; Catechols; Humans; Levodopa; Mice; Papaverine; Parkinson Disease; Rats; Tetrahydropapaveroline | 1977 |
[Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
Topics: Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1977 |
Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.
Topics: Brain Chemistry; Glycols; Humans; Hypothalamus; Levodopa; Methoxyhydroxyphenylglycol; Norepinephrine; Nucleus Accumbens; Parkinson Disease; Red Nucleus; Thalamus | 1977 |
L-DOPA effect on blood pressure in man.
Topics: Blood Pressure; Humans; Levodopa; Parkinson Disease | 1977 |
[Striato-nigral degeneration. Clinical and anatomic study of a case which responded favorably to L-Dopa].
Topics: Aged; Brain Diseases; Cerebral Cortex; Corpus Striatum; Female; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 1977 |
Treatment of parkinsonism by dopaflex (L-DOPA).
Topics: Adult; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease | 1977 |
Problems in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Arteriosclerosis; Carbidopa; Diagnosis, Differential; Drug Combinations; Eye Manifestations; Humans; Levodopa; Mental Disorders; Movement Disorders; Parasympatholytics; Paresthesia; Parkinson Disease; Vision Disorders | 1977 |
The on-off effect in Parkinson's disease treated with levodopa with remarks concerning the effect of sleep.
Topics: Aged; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Parkinson Disease; Piperazines; Piribedil; Probenecid; Receptors, Dopamine | 1977 |
Failure of L-dopa to relieve activated rigidity in Parkinson's disease.
Topics: Adult; Amantadine; Extrapyramidal Tracts; Hepatolenticular Degeneration; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Penicillamine; Thalamus | 1977 |
Treatment of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Carbidopa; Dopamine; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1977 |
Sociopsychological factors influencing response to levodopa therapy for Parkinson's disease.
Topics: Adaptation, Psychological; Affect; Attitude to Health; Dependency, Psychological; Female; Humans; Levodopa; Male; Parkinson Disease; Personality; Psychometrics; Self Concept; Sick Role; Social Adjustment; Social Perception | 1976 |
Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
Topics: Adolescent; Adult; Aged; Dopamine beta-Hydroxylase; Dystonia Musculorum Deformans; Female; Growth Hormone; Handwriting; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Parkinson Disease; Pedigree; Prolactin; Reflex, Pupillary; Syndrome; Trihexyphenidyl | 1976 |
Calcification of the basal ganglia as a cause of levodopa-resistant parkinsonism.
Topics: Basal Ganglia; Brain Diseases; Calcinosis; Computers; Dopamine; Female; Humans; Hypoparathyroidism; Levodopa; Middle Aged; Parkinson Disease; Thyroidectomy; Tomography, X-Ray | 1976 |
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Patient Dropouts; Time Factors | 1976 |
Primary sensory symptoms in parkinsonism.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pain; Paresthesia; Parkinson Disease; Parkinson Disease, Postencephalitic; Restless Legs Syndrome; Sensation | 1976 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Movement Disorders; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1976 |
Studies with bromocriptine. Part 1. "On-off" phenomena.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
Thrombocytopenia associated with long-term levodopa therapy.
Topics: Administration, Oral; Autoimmune Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Thrombocytopenia; Time Factors | 1976 |
Letter: Urinary retention as complication of levodopa therapy.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Urination Disorders | 1976 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1976 |
Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Switzerland | 1976 |
[Is there anything new in the treatment of Parkinsonism?].
Topics: Drug Combinations; Humans; Levodopa; Parkinson Disease | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Interactions; Humans; Hydrazines; Levodopa; Parkinson Disease; Pyridoxine; Rats | 1976 |
Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.
Topics: Age Factors; Aged; California; Humans; Levodopa; Middle Aged; New York; Parkinson Disease; Quebec; Research Design; Time Factors; United States | 1976 |
Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
Topics: Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1976 |
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.
Topics: Age Factors; Aged; Biogenic Amines; Brain Chemistry; Circadian Rhythm; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Postmortem Changes; Serotonin; Temperature; Time Factors | 1976 |
Drug therapy of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior; Dopa Decarboxylase; Drug Interactions; Humans; Levodopa; Parkinson Disease; Trihexyphenidyl | 1976 |
Prolonged symptoms of brain dysfunction--adverse effect of levodopa.
Topics: Aged; Benserazide; Brain Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Time Factors | 1976 |
[Carbidopa-levodopa, growth hormone and parkinsonism].
Topics: Aged; Carbidopa; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1976 |
14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Topics: Aged; Brain; Carbidopa; Carboxy-Lyases; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Probenecid; Sensory Receptor Cells | 1976 |
[A case of mental change resulting from L-dopa treatment].
Topics: Aged; Diagnostic Errors; Humans; Levodopa; Male; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1976 |
Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Platelets; Child; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Sex Factors | 1976 |
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Topics: Adult; Aged; Benserazide; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Parkinson's disease and anosmia in monozygotic twin sisters (author's transl)].
Topics: Adult; Diseases in Twins; Dopamine; Female; Humans; Levodopa; Olfaction Disorders; Parkinson Disease; Pedigree; Pregnancy; Twins, Monozygotic | 1976 |
Comparison of reflex effects of levodopa and bromocriptine in Parkinsonism.
Topics: Bromocriptine; Ergolines; Humans; Levodopa; Parkinson Disease; Reflex | 1976 |
Treatment of parkinson's disease with bromocriptine.
Topics: Aged; Bromocriptine; Delusions; Dopa Decarboxylase; Drug Evaluation; Ergolines; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
Topics: Aged; Carboxy-Lyases; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1976 |
Drugs that reduce efficacy of levodopa.
Topics: Humans; Levodopa; Parkinson Disease; Psychotic Disorders; Tranquilizing Agents | 1976 |
[Interaction between L-dopa and other drugs].
Topics: Amantadine; Anti-Arrhythmia Agents; Apomorphine; Chlorpromazine; Drug Antagonism; Drug Interactions; Drug Synergism; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1976 |
Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Affect; Aged; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; MMPI; Parkinson Disease; Psychopathology | 1976 |
New drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Food; Humans; Levodopa; Parkinson Disease | 1976 |
Behavioral alterations in patients with basal ganglia lesions.
Topics: Basal Ganglia; Behavior; Brain Injuries; Drug Evaluation; Humans; Intelligence; Levodopa; Orientation; Parkinson Disease; Posture; Space Perception; Visual Perception | 1976 |
Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
Topics: Amantadine; Apomorphine; Growth Hormone; Humans; Levodopa; Parkinson Disease; Somatostatin | 1976 |
[Side-effects of levodopa therapy in the treatment of the Parkinsonian syndrome].
Topics: Humans; Levodopa; Parkinson Disease | 1976 |
[Current drug treatment of parkinsonism].
Topics: Adult; Aged; Amantadine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1976 |
alpha and beta Dopamine receptors?
Topics: Apomorphine; Chorea; Haloperidol; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Torticollis | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Trihexyphenidyl | 1976 |
[5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
Topics: Adult; Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 1976 |
Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
Topics: Animals; Apomorphine; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Piperazines; Rats; Receptors, Dopamine; Stereotyped Behavior; Stimulation, Chemical | 1976 |
Parkinsonism and neurogenic bladder. Experimental and clinical observations.
Topics: Animals; Antiparkinson Agents; Dogs; In Vitro Techniques; Levodopa; Male; Muscle, Smooth; Muscles; Parkinson Disease; Pressure; Reflex; Urethra; Urinary Bladder; Urinary Bladder, Neurogenic; Urination | 1976 |
[Effects and side effects of levodopa in parkinsonism- results of a collaborative study].
Topics: Humans; Levodopa; Parkinson Disease | 1976 |
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (2) The relationship between the age of the onset and therapeutic effects].
Topics: Adult; Age Factors; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease | 1976 |
[Effects and side effects of levodopa in parkinsonism-results of a collaborative study. (1) Therapeutic responses in relation to the etiology and clinical types].
Topics: Adult; Humans; Levodopa; Middle Aged; Parkinson Disease | 1976 |
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (3) Side effects of levodopa].
Topics: Female; Humans; Levodopa; Male; Parkinson Disease | 1976 |
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (4) Dyskinesia caused by levodopa].
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease | 1976 |
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Follow-Up Studies; Growth Hormone; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1976 |
[Current methods in treatment of parkinsonism].
Topics: Humans; Levodopa; Parkinson Disease | 1975 |
Do's and don'ts for the patient on levodopa therapy.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Diet; Dietary Proteins; Drug Antagonism; Ethanol; Humans; Levodopa; Parkinson Disease; Pyridoxine; Sodium Chloride | 1976 |
Parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease | 1976 |
The drug treatment of parkinsonism.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Levodopa; Male; Methysergide; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Propranolol; Serotonin; Serotonin Antagonists; Sleep; Trihexyphenidyl | 1975 |
Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases.
Topics: 5-Hydroxytryptophan; Aged; Amines; Brain Diseases; Female; Ganglia, Autonomic; Humans; Hydroxyindoleacetic Acid; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Spinal Cord; Substantia Nigra | 1975 |
[Effects of dopamine on the vestibulo-ocular reflex in parkinsonism].
Topics: Aged; Dopamine; Eye Movements; Humans; Levodopa; Middle Aged; Parkinson Disease; Reflex; Reflex, Oculocardiac; Time Factors; Vestibule, Labyrinth | 1975 |
L-dopa therapy and stereotaxic thalamotomy for parkinsonism.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1975 |
Letter: Miracle cures in Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1975 |
Protein intake and treatment of Parkinson's disease with levodopa.
Topics: Calcium; Calcium Radioisotopes; Dietary Proteins; Growth Hormone; Humans; Levodopa; Parkinson Disease; Time Factors | 1975 |
Management of parkinson's disease--combined therapy with levodopa and thalamotomy.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Thalamus | 1975 |
[Therapy of parkinsonism using L-Dopa (Brocadopa)].
Topics: Aged; Drug Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
[Long-term results of L-dopa treatment of parkinsonism].
Topics: Adult; Aged; Drug Evaluation; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1975 |
[Side effects in the treatment with L-dopa].
Topics: Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Diseases; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Letter: Ammonia and L-dopa: Parkinson's disease and hepatic encephalopathy.
Topics: Ammonia; Animals; Dietary Proteins; Hepatic Encephalopathy; Humans; Levodopa; Parkinson Disease | 1975 |
Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients.
Topics: Aged; Autopsy; Carboxy-Lyases; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylinositols; Phosphatidylserines; Phospholipids; Sphingomyelins; Substantia Nigra | 1975 |
Levodopa-induced postural hypotension. Treatment with fludrocortisone.
Topics: Aged; Blood Pressure; Female; Fludrocortisone; Humans; Hypotension, Orthostatic; Kidney; Levodopa; Natriuresis; Parkinson Disease; Pressoreceptors; Receptors, Adrenergic | 1975 |
Effects of L-dopa metabolites at a dopamine receptor suggest a basis for 'on-off' effect in Parkinson's disease.
Topics: Animals; Dopamine; Dopamine Antagonists; Evoked Potentials; Intestinal Mucosa; Isoquinolines; Levodopa; Mollusca; Muscle Contraction; Papaverine; Parkinson Disease; Receptors, Drug; Stereoisomerism | 1975 |
Letter: Electroconvulsive therapy in patients with parkinsonism.
Topics: Amantadine; Atropine; Depression; Diphenhydramine; Electroconvulsive Therapy; Female; Humans; Levodopa; Methohexital; Middle Aged; Parkinson Disease; Succinylcholine; Suicide | 1975 |
Clonidine in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Clonidine; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic | 1975 |
[Disturbance of the Histidine Reabsorption of the Renal Tubes in Patient with Cystine Lysinuria in Conjunction with Severe Cerebral Damage (author's transl)].
Topics: Amino Acid Metabolism, Inborn Errors; Brain Damage, Chronic; Child; Cystinuria; Histidine; Humans; Intellectual Disability; Kidney Tubules; Levodopa; Lysine; Male; Parkinson Disease | 1975 |
[Abnormal movements induced by L-dopa. New therapeutic possibilities].
Topics: Heartburn; Humans; Indenes; Levodopa; Movement Disorders; Nausea; Parkinson Disease; Pyridines; Time Factors | 1975 |
[Effect of L-dopa on EEG tracings in patients with parkinsonism].
Topics: Aged; Brain; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Persistent parkinsonism following neuroleptanalgesia.
Topics: Adolescent; Anesthesia, Inhalation; Anesthesia, Intravenous; Droperidol; Female; Fentanyl; Humans; Levodopa; Neuroleptanalgesia; Nitrous Oxide; Parkinson Disease; Parkinson Disease, Secondary; Propranolol; Tooth Extraction; Tooth, Impacted | 1975 |
[Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
Topics: Adrenal Glands; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Guinea Pigs; Intestinal Mucosa; Kidney; Levodopa; Liver; Myocardium; Parkinson Disease; Rabbits; Rats; Spleen | 1975 |
[Respiratory functions in parkinsonian patients with predominant akinesia during treatment with decarboxylase-blocked L-dopa (author's transl)].
Topics: Adult; Aged; Carboxy-Lyases; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration; Respiratory System; Spirometry; Vital Capacity | 1975 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic | 1975 |
3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.
Topics: Animals; Biological Availability; Biological Transport, Active; Blood-Brain Barrier; Brain; Cerebral Cortex; Corpus Striatum; Diffusion; Hypothalamus; Kinetics; Levodopa; Male; Mesencephalon; Methyldopa; Parkinson Disease; Rats | 1975 |
[Drug treatment of hyperkinesis and mental changes caused by levodopa].
Topics: Humans; Hyperkinesis; Levodopa; Mental Disorders; Parkinson Disease; Psychotropic Drugs | 1975 |
[Comparison between EEG-finding and clinical picture in patients with Parkinsonism under L-dopa].
Topics: Basal Ganglia Diseases; Brain; Electroencephalography; Humans; Levodopa; Parkinson Disease | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Reserpine; Substantia Nigra | 1975 |
Dopaminergic supersensitivity in parkinsonism.
Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Nerve Degeneration; Norepinephrine; Parkinson Disease; Psychoses, Substance-Induced; Serotonin; Tryptophan; Tyrosine | 1975 |
Dopaminergic mechanisms in patients with extrapyramidal disease.
Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combination; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil; Pituitary Gland, Anterior; Prolactin; Rats; Receptors, Drug; Stimulation, Chemical | 1975 |
Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
Topics: Aged; Carboxy-Lyases; Drug Combinations; Drug Evaluation; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Parkinson Disease; Tremor | 1975 |
Pallido-pyramidal syndrome treated with levodopa.
Topics: Adolescent; Adult; Age Factors; Diagnosis, Differential; Female; Humans; Levodopa; Male; Parkinson Disease; Pyramidal Tracts; Spinal Cord Diseases | 1975 |
Effects of levodopa on the bladder outlet.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Ureter; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination | 1975 |
Effect of L-DOPA on endogenous histamine metabolism.
Topics: Acetates; Adult; Aged; Animals; Carbidopa; Depression, Chemical; Female; Guinea Pigs; Histamine; Humans; Imidazoles; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; Rats; Species Specificity | 1975 |
Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
Topics: 3,4-Dihydroxyphenylacetic Acid; Chromatography, Gas; Dopamine; Homovanillic Acid; Levodopa; Parkinson Disease; Phenylacetates; Propionates | 1975 |
Brain monoamines and Parkinsonism.
Topics: Biogenic Amines; Brain Chemistry; Humans; Levodopa; Parkinson Disease | 1975 |
Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1975 |
L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Topics: Adult; Aged; Animals; Carbidopa; Carboxy-Lyases; Cats; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Injections, Intraperitoneal; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase.
Topics: Adult; Amino Acids; Blood Pressure; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Stimulation, Chemical; Time Factors; Tranylcypromine | 1975 |
Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
Topics: Adult; Aged; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1975 |
Effect of chronic levodopa treatment on pyridoxine metabolism.
Topics: Aged; Erythrocytes; Humans; Levodopa; Middle Aged; Parkinson Disease; Plasma; Pyridoxal Phosphate; Pyridoxine; Stimulation, Chemical; Time Factors | 1975 |
Deanol in the treatment of levodopa-induced dyskinesias.
Topics: Aged; Deanol; Drug Evaluation; Ethanolamines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Patterns of clinical response and plasma dopa levels in Parkinson's disease.
Topics: Adult; Aged; Brain; Carbidopa; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1975 |
Drug therapy for Parkinson's disease.
Topics: Carbidopa; Circadian Rhythm; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Parkinsonism: effects of levodopa treatment on concept formation.
Topics: Choice Behavior; Concept Formation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychological Tests; Wechsler Scales | 1975 |
Acute overdose with levodopa. Clinical and biochemical consequences.
Topics: Acute Disease; Heart Rate; Humans; Hypertension; Hypotension; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Sleep Initiation and Maintenance Disorders | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Humans; Levodopa; Male; Mice; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Motor unit control in Parkinson's disease and the influence of levodopa.
Topics: Aged; Humans; Levodopa; Motor Neurons; Muscle Contraction; Parkinson Disease; Physical Exertion; Tremor | 1975 |
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
Topics: Administration, Oral; Age Factors; Aged; Brain; Brain Chemistry; Circadian Rhythm; Dopamine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1975 |
Antagonism of levodopa by papaverine.
Topics: Aged; Corpus Striatum; Fatigue; Female; Headache; Humans; Hyperhidrosis; Intracranial Arteriosclerosis; Levodopa; Papaverine; Parkinson Disease; Receptors, Drug | 1975 |
Letter: antagonism of levodopa by papaverine.
Topics: Aged; Female; Humans; Levodopa; Papaverine; Parkinson Disease | 1975 |
Olfactory function in patients with Parkinson's disease.
Topics: Adult; Aged; Differential Threshold; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Olfaction Disorders; Olfactory Bulb; Parkinson Disease; Smoking | 1975 |
[Newest achievements in neurology: L-dopa treatment].
Topics: Chemical Phenomena; Chemistry; Humans; Levodopa; Parkinson Disease | 1975 |
Current therapy of Parkinson's disease.
Topics: Levodopa; Parkinson Disease | 1975 |
[L dopa and mental disorders].
Topics: Humans; Levodopa; Mental Disorders; Parkinson Disease | 1975 |
Neuropsychological findings in Parkinson's disease: a comparison between various tests during long-term levodopa therapy.
Topics: Humans; Levodopa; Mental Disorders; Parkinson Disease | 1975 |
Parkinsonism, levodopa, and intelligence.
Topics: Adult; Aged; Female; Humans; Intelligence; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1975 |
Proceedings: Late results of thalamotomy in Parkinsonism with and without the influence of levodopa.
Topics: Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Thalamus | 1975 |
Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings).
Topics: Brain; Brain Mapping; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1975 |
[Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
Topics: Adult; Aged; Carbidopa; Carboxy-Lyases; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Augmenting procedures during L-dopa therapy for Parkinsonism.
Topics: Antacids; Dextroamphetamine; Drug Synergism; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Parkinson Disease; Propranolol | 1975 |
The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
Topics: Administration, Oral; Aged; Chromatography, Gas; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Dopamine; Female; Humans; Infusions, Parenteral; Isomerism; Levodopa; Male; Mass Spectrometry; Middle Aged; Parkinson Disease; Sulfates; Tyramine | 1975 |
Letter: Fattening of parkinsonians: a hypothalamic side effect of L-dopa?
Topics: Body Weight; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stimulation, Chemical | 1975 |
[The deterioration of patients with parkinsonism treated with L-dopa].
Topics: Aged; Cognition Disorders; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Muscle Tonus; Parkinson Disease; Postural Balance; Recurrence; Tremor | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
Diseases of the central nervous system. Involuntary movements.
Topics: Athetosis; Central Nervous System Diseases; Chorea; Face; Humans; Levodopa; Movement Disorders; Myoclonus; Parkinson Disease; Spasm; Tic Disorders; Torticollis; Tremor | 1975 |
Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets, Enteric-Coated | 1975 |
[Treatment of parkinsonian syndrome with Ro 8-0576].
Topics: Aged; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Dopamine: a sensitive automated assay and examples of levodopa therapy.
Topics: Autoanalysis; Dopamine; Humans; Levodopa; Parkinson Disease; Spectrometry, Fluorescence | 1975 |
Enteric coated levo-dopa in clinical practice.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recurrence; Syndrome; Tablets, Enteric-Coated | 1975 |
[Long-term treatment of middle-aged and old patients with paralysis agitans and parkinsonism with levodopa].
Topics: Age Factors; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Metanephrine; Middle Aged; Normetanephrine; Parkinson Disease; Tyramine; Vanilmandelic Acid | 1975 |
The sixth year after L-dopa: quality of life and insights derived.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Parkinson Disease; Perceptual Disorders; Visual Perception | 1975 |
[Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
Topics: Carbidopa; Growth Hormone; Humans; Hydrazines; Levodopa; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1975 |
[Treatment of Parkinson's disease associated with psychosis].
Topics: Aged; Female; Haloperidol; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 1975 |
[Current medical treatment in the disorders of the extrapyramidal nervous system].
Topics: Basal Ganglia Diseases; Carboxy-Lyases; Humans; Levodopa; Parkinson Disease | 1975 |
[Levels of slow bioelectric organization of the human brain].
Topics: Brain; Brain Mapping; Contingent Negative Variation; Electrophysiology; Humans; Levodopa; Mental Processes; Pain; Parkinson Disease; Phantom Limb; Psychophysiology; Stanford-Binet Test | 1975 |
[Psychological changes in patients with Parkinson's disease during treatment with L-Dopa. Interpretation and comprehension of the observed phenomena].
Topics: Humans; Learning; Levodopa; Memory; Movement; Parkinson Disease; Perception; Problem Solving; Psychological Tests; Time Factors | 1975 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa].
Topics: Benserazide; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Time Factors | 1975 |
Tryptophan/nicotinic acid pathway during levodopa treatment of Parkinsonism.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Nicotinic Acids; Parkinson Disease; Tryptophan | 1975 |
Letter: Somatostatin, growth hormone and parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Growth Hormone; Humans; Levodopa; Mice; Parkinson Disease; Somatostatin | 1976 |
[Use of the preparation L-dopa in parkinsonism].
Topics: Adolescent; Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic | 1976 |
Letter: Effect of levodopa on Parkinsonian tremor.
Topics: Humans; Levodopa; Parkinson Disease; Tremor | 1976 |
Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man.
Topics: Administration, Oral; Adult; Aged; Animals; Atropine; Digestive System; Drug Interactions; Female; Humans; Injections, Intraperitoneal; Intestinal Absorption; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Rats; Time Factors; Trihexyphenidyl | 1976 |
[L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
Topics: Aged; Drug Combinations; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Nausea; Parkinson Disease; Psychoses, Substance-Induced; Vomiting | 1976 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hormone; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Psychotropic Drugs; Tyrosine | 1976 |
Reaction times in Parkinson disease.
Topics: Arousal; Humans; Levodopa; Motor Activity; Parkinson Disease; Reaction Time | 1976 |
L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloperidol; Humans; Levodopa; Models, Neurological; Movement Disorders; Parkinson Disease; Reserpine; Schizophrenia; Tranquilizing Agents; Trihexyphenidyl | 1976 |
Cardiovascular effects of levodopa in aged versus younger patients with Parkinson's disease.
Topics: Age Factors; Aged; Blood Pressure; Cardiovascular System; Heart Diseases; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine].
Topics: Adult; Aged; Drug Combinations; Drug Evaluation; Drug Synergism; Humans; Hydrazines; Levodopa; Methyldopa; Middle Aged; Parkinson Disease | 1976 |
Letter: Parkinson's disease and ascorbate.
Topics: Ascorbic Acid; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1976 |
Parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease | 1976 |
[Treatment of parkinsonism].
Topics: Amantadine; Benztropine; Biperiden; Humans; Levodopa; Orphenadrine; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1976 |
Editorial: Alternatives to levodopa.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease | 1976 |
Metal chelates of L-DOPA for improved replenishment of dopaminergic pools.
Topics: Animals; Chelating Agents; Chemical Phenomena; Chemistry; Cobalt; Copper; Levodopa; Magnesium; Metals; Parkinson Disease; Rats; Time Factors; Zinc | 1976 |
Gout induced by L-dopa and decarboxylase inhibitors.
Topics: Aged; Carbidopa; Carboxy-Lyases; Gout; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1976 |
[Results of L-dopa treatment in parkinsonism (author's transl)].
Topics: Adult; Age Factors; Aged; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease | 1976 |
[L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Parkinson Disease; Rats | 1976 |
Letter: Alternatives to levodopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease.
Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1976 |
Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1976 |
[Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease | 1992 |
[Influence of protein-restricted diet on motor response fluctuations in Parkinson's disease].
Topics: Adult; Aged; Brain; Dietary Proteins; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1992 |
Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon.
Topics: Aged; Electromagnetic Fields; Humans; Levodopa; Male; Parkinson Disease; Psychomotor Performance | 1992 |
Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease.
Topics: Brain Tissue Transplantation; Contingent Negative Variation; Corpus Striatum; Dopamine; Female; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Motor Activity; Nervous System; Neurons; Nomifensine; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 1992 |
Levodopa induced ON-OFF motor fluctuations in Parkinson's disease related to rhythmical masticatory jaw movements.
Topics: Administration, Oral; Aged; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mastication; Masticatory Muscles; Middle Aged; Neurologic Examination; Neurons; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synaptic Transmission | 1992 |
Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease.
Topics: Administration, Oral; Aged; Constipation; Dietary Fiber; Female; Gastrointestinal Motility; Humans; Intestinal Absorption; Levodopa; Male; Motor Activity; Movement Disorders; Parkinson Disease; Psychomotor Performance; Time Factors | 1992 |
Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland | 1992 |
Magnetic fields in the treatment of Parkinson's disease.
Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland | 1992 |
Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism.
Topics: Adult; Benserazide; Drug Combinations; Female; Hemiplegia; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Reflex, Abnormal; Syndrome | 1992 |
Levodopa.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Neurons; Parkinson Disease; Substantia Nigra; Time Factors | 1992 |
Levodopa challenge test in Parkinson's disease.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
"Wearing-off" and beta 2-adrenoceptor agonist in Parkinson's disease.
Topics: Aged; Albuterol; Brain; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Influence of Parkinson's disease on oral health.
Topics: Activities of Daily Living; Aged; Deglutition Disorders; Dental Caries; Dopamine Agents; Female; Humans; Levodopa; Male; Mandible; Motor Skills; Mouth Diseases; Oral Hygiene; Parkinson Disease; Saliva; Secretory Rate; Tooth Loss | 1992 |
Clozapine prevents recurrence of psychosis in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Clozapine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Sleep Stages | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Topics: Bromocriptine; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1992 |
Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.
Topics: Administration, Oral; Aged; Apomorphine; Female; Hip Fractures; Humans; Infusion Pumps; Injections, Subcutaneous; Intestinal Obstruction; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Therapy of Parkinson's disease: are we at the end of the road?
Topics: Antiparkinson Agents; Dopamine Agents; Humans; India; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E | 1992 |
The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.
Topics: Adult; Aged; Arousal; Attention; Choice Behavior; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Substance Withdrawal Syndrome | 1992 |
The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.
Topics: Aged; Amino Acids; Animals; Biogenic Monoamines; Corpus Striatum; Dialysis; Dopamine; Female; Humans; In Vitro Techniques; Kinetics; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; PC12 Cells; Rats; Tryptophan Hydroxylase; Tyrosine; Tyrosine 3-Monooxygenase | 1992 |
Low contrast stimuli enhance PERG sensitivity to the visual dysfunction in Parkinson's disease.
Topics: Aged; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Pilot Projects; Piperidines; Receptors, N-Methyl-D-Aspartate | 1992 |
Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Arylsulfotransferase; Brain; Dopamine; Humans; Kinetics; Levodopa; Middle Aged; Nerve Tissue Proteins; Parkinson Disease | 1992 |
Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
[Motor fluctuations in Parkinson disease: risk factors].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prevalence; Retrospective Studies; Risk Factors; Time Factors | 1992 |
Lid melanoma and parkinsonism.
Topics: Aged; Eyelid Neoplasms; Female; Humans; Levodopa; Melanoma; Parkinson Disease | 1992 |
[The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Topics: Aged; Benzamides; Brain; Color; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Protein Binding; Pyrrolidines; Receptors, Dopamine D2; Software; Tomography, Emission-Computed, Single-Photon | 1992 |
Postural inflexibility in parkinsonian subjects.
Topics: Adult; Aged; Aged, 80 and over; Aging; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscles; Parkinson Disease; Postural Balance; Posture; Reflex | 1992 |
The clinical use of apomorphine in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance | 1992 |
Parkinson's disease in Taiwan: an analysis of 215 patients.
Topics: ABO Blood-Group System; Adult; Aged; Disability Evaluation; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Taiwan | 1992 |
The effect of exercise on levodopa absorption.
Topics: Absorption; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion; Physical Fitness; Reproducibility of Results | 1992 |
[Physical therapy and speech therapy in Parkinson syndrome--a status assessment].
Topics: Aged; Combined Modality Therapy; Dementia; Disability Evaluation; Female; Humans; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Parkinson Disease, Secondary; Physical Therapy Modalities; Quality of Life; Speech Therapy | 1992 |
Motor impairments after methamphetamine-induced neurotoxicity in the rat.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopamine; Fenfluramine; Levodopa; Male; Methamphetamine; Motor Activity; Nervous System Diseases; Parkinson Disease; Rats; Serotonin | 1992 |
Bilateral fetal grafts for Parkinson's disease: 22 months' results.
Topics: Brain Tissue Transplantation; Diencephalon; Fetal Tissue Transplantation; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Time Factors | 1992 |
Phenelzine treatment of depression in Parkinson's disease.
Topics: Aged; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Phenelzine | 1992 |
ECT and delirium in Parkinson's disease.
Topics: Carbidopa; Combined Modality Therapy; Delirium; Depressive Disorder; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parkinson Disease | 1992 |
Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1992 |
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies | 1992 |
[The results of drug holiday in Parkinson's disease].
Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.
Topics: Adult; Aged; Brain; Child; Child, Preschool; Dihydroxyphenylalanine; Dystonia; Family; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree; Tomography, Emission-Computed | 1992 |
Hyperparathyroidism associated with parkinsonism.
Topics: Adenoma; Aged; Drug Resistance; Female; Humans; Hypercalcemia; Hyperparathyroidism; Levodopa; Olivopontocerebellar Atrophies; Parathyroid Neoplasms; Parathyroidectomy; Parkinson Disease | 1992 |
Combination therapy of parkinsonism with deprenyl.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; India; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Selegiline | 1992 |
[Clozapine, a valuable contribution for the treatment of psychoses in Parkinson disease].
Topics: Aged; Bromocriptine; Clozapine; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
Relationship between the immune system and the diseases of the central nervous system.
Topics: Age Factors; Aged; Aged, 80 and over; Evaluation Studies as Topic; Female; Humans; Killer Cells, Natural; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 1992 |
The dopaminergic response in multiple system atrophy.
Topics: Adult; Aged; Apomorphine; Atrophy; Brain Stem; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Terminology as Topic | 1992 |
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
Topics: Adult; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1992 |
The IMAO-B MDL 72.974 A in Parkinson's disease.
Topics: Allyl Compounds; Butylamines; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 1992 |
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Topics: Adult; Analysis of Variance; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Middle Aged; Movement; Parkinson Disease; Receptors, Dopamine | 1992 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
[Autopsied case of Parkinson disease with neuroleptic malignant-like syndrome and rhabdomyolysis].
Topics: Acute Kidney Injury; Aged; Brain; Humans; Kidney; Levodopa; Male; Muscles; Neuroleptic Malignant Syndrome; Parkinson Disease; Rhabdomyolysis | 1992 |
Ultrasensitive TSH assay and anti-parkinsonian treatment with levodopa.
Topics: Aged; Aged, 80 and over; Female; Humans; Hyperthyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Thyrotropin; Thyrotropin-Releasing Hormone | 1992 |
Gait in relation to ageing and idiopathic parkinsonism.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cognition; Diagnosis, Computer-Assisted; Evaluation Studies as Topic; Female; Gait; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Postural Balance; Range of Motion, Articular; Time Factors | 1992 |
Stapedial reflex in Parkinson's disease.
Topics: Acoustic Impedance Tests; Adult; Aged; Audiometry, Pure-Tone; Auditory Pathways; Auditory Threshold; Female; Hearing Disorders; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Reflex, Acoustic; Reflex, Stretch; Stapedius | 1992 |
Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease.
Topics: Aged; Brain; Cerebrovascular Circulation; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1992 |
Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment.
Topics: Aged; Anthropometry; Body Composition; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Nutrition Assessment; Parkinson Disease; Reference Values; Sex Characteristics; Weight Loss | 1992 |
Dream structure in Parkinson's patients.
Topics: Age Factors; Aged; Ambulatory Care; Cognition Disorders; Dose-Response Relationship, Drug; Dreams; Female; Humans; Language Tests; Levodopa; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Parkinson Disease; Time Factors | 1992 |
Fetal transplants show promise.
Topics: Aborted Fetus; Animal Experimentation; Animals; Astrocytes; Brain Tissue Transplantation; Fetal Tissue Transplantation; Fetus; Haplorhini; Humans; Internationality; Levodopa; Neurons; Parkinson Disease; Risk Assessment; Therapeutic Human Experimentation | 1992 |
Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
Exacerbation of parkinsonism by tacrine.
Topics: Aged; Alzheimer Disease; Electromyography; Female; Humans; Levodopa; Parkinson Disease; Tacrine | 1992 |
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
Topics: Adult; Age Factors; Benserazide; Biomarkers; Biopterins; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease | 1992 |
[Effect of apomorphine on the bladder of parkinsonian patients].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Urinary Bladder Diseases; Urodynamics | 1992 |
Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption.
Topics: Aged; Bromocriptine; Carbidopa; Combined Modality Therapy; Fabaceae; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1992 |
Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.
Topics: Animals; Corpus Striatum; Dialysis; Dopamine; Extracellular Space; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Substantia Nigra | 1992 |
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa.
Topics: Aged; Carbidopa; Cerebral Ventricles; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
Topics: Carbidopa; Drug Combinations; Hand; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychomotor Performance; Reaction Time | 1992 |
Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans.
Topics: Adult; Alcohol Drinking; Codeine; Humans; Levodopa; Male; Morphine; Pain; Parkinson Disease; Tetrahydropapaveroline | 1992 |
Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
Topics: Carbidopa; Circadian Rhythm; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Evaluation Studies as Topic; Humans; Levodopa; Parkinson Disease | 1992 |
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution | 1992 |
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1992 |
Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients.
Topics: Aged; Body Weight; Dietary Proteins; Energy Intake; Female; Humans; Levodopa; Male; Middle Aged; Nutritional Status; Parkinson Disease; Prealbumin; Serum Albumin; Surveys and Questionnaires | 1992 |
Core assessment program for intracerebral transplantations (CAPIT).
Topics: Activities of Daily Living; Brain; Brain Tissue Transplantation; Fetal Tissue Transplantation; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests; Parkinson Disease | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Short-term synchrony of motor unit discharge during weak isometric contraction in Parkinson's disease.
Topics: Adult; Aged; Arm; Cerebral Cortex; Female; Humans; Isometric Contraction; Leg; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Periodicity | 1992 |
Time estimation and reproduction is abnormal in Parkinson's disease.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Psychomotor Performance; Time Perception | 1992 |
[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
Topics: Depression; Female; Fluoxetine; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Relationship between levodopa-independent symptoms and central atrophy evaluated by magnetic resonance imaging in Parkinson's disease.
Topics: Aged; Atrophy; Female; Frontal Lobe; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinson Disease | 1992 |
Visual evoked cortical responses and electroretinograms following implantation of human fetal mesencephalon to the right caudate nucleus in Parkinson's disease.
Topics: Brain Tissue Transplantation; Caudate Nucleus; Electroretinography; Evoked Potentials, Visual; Female; Fetal Tissue Transplantation; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Transplantation, Heterotopic | 1992 |
[L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function].
Topics: Aged; Dopamine; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Shy-Drager Syndrome; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1992 |
Some new aspects of the effect of (-)deprenyl in Parkinson's disease--a retrospective study.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index | 1992 |
Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Topics: Aged; Brain; Corpus Striatum; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Nomifensine; Parkinson Disease; Radioligand Assay; Receptors, Dopamine; Tomography, Emission-Computed | 1992 |
Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants.
Topics: Combined Modality Therapy; Dopamine; Fetal Tissue Transplantation; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Putamen; Treatment Outcome | 1992 |
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Topics: Adult; Aged; Caudate Nucleus; Corpus Striatum; Humans; Levodopa; Middle Aged; Nerve Degeneration; Parkinson Disease; Putamen; Raclopride; Receptors, Dopamine; Salicylamides; Substantia Nigra; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Impaired levodopa response in Parkinson's disease during melanoma therapy.
Topics: Adult; Dacarbazine; Dopamine; Drug Interactions; Humans; Levodopa; Male; Melanins; Melanoma; Parkinson Disease; Skin Neoplasms | 1992 |
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide | 1992 |
A brief history of parkinsonism.
Topics: Corpus Striatum; History, 16th Century; History, 18th Century; History, 19th Century; History, 20th Century; History, Ancient; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1992 |
Long-term experience with selegiline and levodopa in Parkinson's disease.
Topics: Aged; Humans; Levodopa; Longitudinal Studies; Middle Aged; Parkinson Disease; Selegiline | 1992 |
Emerging perspectives in Parkinson's disease.
Topics: Animals; Humans; Levodopa; MPTP Poisoning; Neurology; Parkinson Disease; Parkinson Disease, Secondary; Selegiline | 1992 |
Chronic administration of L-dopa affects the movement-related cortical potentials of patients with Parkinson's disease.
Topics: Adult; Aged; Cerebral Cortex; Drug Administration Schedule; Electroencephalography; Female; Humans; Levodopa; Male; Membrane Potentials; Middle Aged; Movement; Parkinson Disease; Time Factors | 1992 |
Apomorphine in malignant syndrome due to levodopa withdrawal.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1992 |
Medications and their monitoring in Parkinson's disease in Dunedin.
Topics: Aged; Blood Pressure; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease | 1992 |
Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Vigabatrin | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
The locus coeruleus and dopaminergic function in rat brain: implications to parkinsonism.
Topics: Animals; Biogenic Amines; Corpus Striatum; Dopamine; Levodopa; Locus Coeruleus; Male; Neural Pathways; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Substantia Nigra | 1992 |
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Lactates; Lactic Acid; Levodopa; Lisuride; Male; Middle Aged; Mitochondria; Oxygen Consumption; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Topics: Adult; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time | 1992 |
Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases.
Topics: Aged; Female; Humans; Immunohistochemistry; Levodopa; Lewy Bodies; Locus Coeruleus; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1992 |
[Exogenous ochronosis after L-dopa treatment].
Topics: Aged; Aged, 80 and over; Cartilage; Female; Humans; Intervertebral Disc; Levodopa; Male; Ochronosis; Parkinson Disease; Ribs | 1992 |
Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR)
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease | 1992 |
A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Deoxyglucose; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Thalamic Nuclei | 1992 |
Performance of repetitive wrist movements in Parkinson's disease.
Topics: Acoustic Stimulation; Adult; Electromyography; Female; Forearm; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Muscles; Parkinson Disease; Wrist | 1992 |
A component analysis of the generation and release of isometric force in Parkinson's disease.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isometric Contraction; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Neurons; Muscles; Neurologic Examination; Parkinson Disease; Reaction Time; Trihexyphenidyl | 1992 |
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.
Topics: Adult; Aged; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture; Reference Values; Substantia Nigra; Tomography, Emission-Computed; Tremor | 1992 |
Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
Topics: Adult; Brain Tissue Transplantation; Bromocriptine; Caudate Nucleus; Down-Regulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Quinuclidinyl Benzilate; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Neurotransmitter; Spiperone | 1991 |
Cardiac beta-adrenoceptor sensitivity and Parkinson's disease.
Topics: Aged; Aging; Blood Pressure; Bromocriptine; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Isoproterenol; Levodopa; Male; Middle Aged; Myocardium; Parkinson Disease; Piribedil; Receptors, Adrenergic, beta | 1991 |
L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice.
Topics: Animals; Brain; Disease Models, Animal; Female; Inclusion Bodies; Levodopa; Mice; Mice, Inbred BALB C; Movement Disorders; Nocardia asteroides; Nocardia Infections; Parkinson Disease; Tyrosine 3-Monooxygenase | 1991 |
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
Topics: Adult; Aged; Aging; Antipsychotic Agents; Benzamides; Brain Diseases; Cerebellum; Corpus Striatum; Frontal Lobe; Humans; Huntington Disease; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Receptors, Dopamine D2; Stereoisomerism; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 1991 |
Parkinson's disease: progress and controversies.
Topics: Dopamine Agents; Humans; Levodopa; Parkinson Disease | 1991 |
Botulinum toxin A in orthopaedic surgery.
Topics: Botulinum Toxins; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Rupture; Shoulder Injuries; Shoulder Joint | 1991 |
Is levodopa harmful?
Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1991 |
Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.
Topics: Aged; Dopamine Agents; Dose-Response Relationship, Drug; Humans; Indoles; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Topics: Adult; Aged; Aged, 80 and over; Dopamine; Dynorphins; Endorphins; Enkephalin, Methionine; Female; Homovanillic Acid; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Peptide Fragments | 1991 |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Somatostatin | 1990 |
Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
Topics: Dystonia Musculorum Deformans; Enkephalin, Methionine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Neuropeptides; Neurotransmitter Agents; Parkinson Disease; Shy-Drager Syndrome; Somatostatin | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Selegiline | 1990 |
[Dopamine antibodies in the pathogenesis of parkinsonism].
Topics: Adult; Aged; Animals; Antibodies; Caudate Nucleus; Dopamine; Electroencephalography; gamma-Globulins; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Time Factors | 1991 |
Motor blocks in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Risk Factors | 1992 |
Periodic triphasic waves in levodopa-induced encephalopathy.
Topics: Aged; Brain Diseases; Electroencephalography; Female; Humans; Levodopa; Male; Parkinson Disease | 1992 |
Protein redistribution diet remains effective in patients with fluctuating parkinsonism.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
The apomorphine test in parkinsonian syndromes.
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Muscular Atrophy; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Prognosis; Supranuclear Palsy, Progressive | 1991 |
Epidemiology and out-patient care in Parkinson's disease--results from a pilot-study in northern Germany (Schleswig-Holstein).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Female; Germany; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prevalence; Surveys and Questionnaires | 1991 |
Levodopa-associated hemifacial dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dystonia; Facial Muscles; Female; Humans; Levodopa; Parkinson Disease; Putamen | 1991 |
Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
Topics: Administration, Oral; Aged; Carbidopa; Drug Therapy, Combination; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.
Topics: Administration, Oral; Adult; Age Factors; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Evaluation of how age modifies the risk for Parkinson's disease, based on stratified comparisons of descriptive data.
Topics: Age Factors; Aged; Cause of Death; Cross-Sectional Studies; Humans; Iceland; Incidence; Levodopa; Parkinson Disease; Risk Factors; Survival Rate; Sweden | 1991 |
Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
Topics: Humans; Levodopa; Lisuride; Nervous System; Parkinson Disease; Selegiline; Survival Analysis | 1991 |
Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments.
Topics: Aged; Epidemiologic Methods; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; United States | 1991 |
A computational model of levodopa pharmacodynamics in Parkinson's disease.
Topics: Basal Ganglia; Corpus Striatum; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease | 1991 |
The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease.
Topics: Aged; Bromocriptine; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Autologous adrenal medullary, fetal mesencephalic, and fetal adrenal brain transplantation in Parkinson's disease: a long-term postoperative follow-up.
Topics: Adrenal Glands; Adrenal Medulla; Adult; Brain Tissue Transplantation; Caudate Nucleus; Combined Modality Therapy; Evaluation Studies as Topic; Female; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Transplantation, Autologous | 1991 |
The immunological status in Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Humans; Immunoglobulins; Levodopa; Lymphocyte Activation; Middle Aged; Parkinson Disease | 1991 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Topics: Biogenic Monoamines; Biomarkers; Carbidopa; Humans; Levodopa; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
Topics: Drug Administration Schedule; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1991 |
A comparison between the effect of intentional modulations and the action of L-dopa on gait in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Experience with selegiline and levodopa in advanced Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1991 |
[A case of progressive systemic sclerosis and Sjögren's syndrome complicated by parkinsonism with special reference to the beneficial effect of corticosteroid].
Topics: Aged; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease; Prednisolone; Scleroderma, Systemic; Sjogren's Syndrome | 1991 |
[Juvenile parkinsonism. 18 cases].
Topics: Adolescent; Adult; Age Factors; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease | 1991 |
Autonomic involvement in extrapyramidal and cerebellar disorders.
Topics: Adult; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Cerebellar Diseases; Cognition Disorders; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex; Shy-Drager Syndrome; Supranuclear Palsy, Progressive; Valsalva Maneuver | 1991 |
[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy.
Topics: Aged; Brain; Dizocilpine Maleate; Humans; Kinetics; Levodopa; Organ Specificity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Reference Values; Supranuclear Palsy, Progressive | 1991 |
Exteroceptive suppression of the masseter and temporalis muscles and parkinsonian rigidity.
Topics: Adult; Aged; Amantadine; Basal Ganglia; Bromocriptine; Electric Stimulation; Electromyography; Female; Humans; Levodopa; Male; Masseter Muscle; Middle Aged; Muscle Rigidity; Muscle Spindles; Parkinson Disease; Temporal Muscle; Trigeminal Nerve; Trihexyphenidyl | 1991 |
[Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
Topics: Analysis of Variance; Bromocriptine; Female; Humans; Hypothalamo-Hypophyseal System; Levodopa; Male; Parkinson Disease; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone | 1991 |
Autologous adrenal medullary transplants in advanced Parkinson's disease with particular attention to the selective improvement in symptoms.
Topics: Adrenal Medulla; Adult; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors; Tomography, X-Ray Computed; Transplantation, Heterotopic | 1991 |
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 1991 |
Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. One-year follow-up.
Topics: Adrenal Medulla; Adrenalectomy; Adult; Caudate Nucleus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiography; Stereotaxic Techniques; Tissue Transplantation | 1991 |
Abbreviated rating score for Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Drug-induced koro in a non-Chinese man.
Topics: Aged; Cultural Characteristics; Delusions; Depersonalization; Humans; Levodopa; Male; Parkinson Disease; Self Mutilation; Urethra | 1991 |
Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Drug Resistance; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Statistics as Topic | 1991 |
A balanced carbohydrate: protein diet in the management of Parkinson's disease.
Topics: Amino Acids; Dietary Carbohydrates; Dietary Proteins; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Self Concept | 1991 |
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Topics: Animals; Benserazide; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone; Tomography, Emission-Computed | 1991 |
Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea.
Topics: Chorea; Delayed-Action Preparations; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Time Factors | 1991 |
High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.
Topics: Frontal Lobe; Humans; Levodopa; Memory Disorders; Memory, Short-Term; Mental Recall; Parkinson Disease; Psychological Tests; Receptors, Dopamine | 1991 |
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.
Topics: Adult; Aged; Aging; Corpus Striatum; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 1991 |
[Juvenile parkinsonism in monozygotic twins].
Topics: Adult; Age Factors; Basal Ganglia; Diseases in Twins; Female; Humans; Levodopa; Parkinson Disease; Tomography, X-Ray Computed; Twins, Monozygotic | 1991 |
Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cerebral Cortex; Cognition Disorders; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 1991 |
Sinemet CR for Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1991 |
Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease.
Topics: Adult; Aged; Brain Tissue Transplantation; Caudate Nucleus; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Middle Aged; Movement; Parkinson Disease | 1991 |
Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Selegiline (Eldepryl) for Parkinson's disease.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Rotation; Selegiline | 1991 |
Decrease in blood histamine in drug-treated parkinsonian patients.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Carbidopa; Female; Histamine; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1991 |
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Levodopa; Macaca fascicularis; Male; Nitriles; Parkinson Disease; Pentanones; Tyrosine | 1991 |
Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Thalamus; Tremor | 1991 |
[Changes in movement-related cortical potentials in Parkinson's patients before and after treatment with levodopa].
Topics: Adult; Aged; Aged, 80 and over; Cerebral Cortex; Electroencephalography; Electromyography; Evoked Potentials; Female; Hand; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1991 |
Absorption of apomorphine by various routes in parkinsonism.
Topics: Absorption; Administration, Cutaneous; Administration, Oral; Administration, Sublingual; Animals; Apomorphine; Biological Availability; Drug Therapy, Combination; Infusions, Parenteral; Levodopa; Parkinson Disease | 1991 |
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Topics: Carbidopa; Cerebral Ventricles; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Sulfates | 1991 |
L-dopa in Parkinson's disease.
Topics: Dopamine; Humans; Levodopa; Parkinson Disease | 1991 |
Effects of withdrawal of antiparkinson medication on gait and clinical score in the Parkinson patient.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Disability Evaluation; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Early therapy for Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
Parkinson's disease as community health problem: study in Norwegian nursing homes. The Norwegian Study Group of Parkinson's Disease in the Elderly.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Diagnosis, Differential; Diagnostic Errors; Female; Homes for the Aged; Humans; Levodopa; Male; Norway; Nursing Homes; Parkinson Disease; Prevalence; Quality of Life | 1991 |
Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Psychotic complications of long-term levodopa treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1991 |
Does ageing aggravate parkinsonian disability?
Topics: Age Factors; Aged; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscles; Neurologic Examination; Parkinson Disease; Retrospective Studies | 1991 |
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.
Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline | 1991 |
Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms.
Topics: Aged; Depression; Female; Humans; Intelligence Tests; Levodopa; Male; Mental Recall; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Reaction Time; Severity of Illness Index; Synaptic Transmission | 1990 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
Topics: Adult; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Psychomotor Performance | 1990 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |
Ropinirole without levodopa in Parkinson's disease.
Topics: Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.
Topics: Animals; Antipsychotic Agents; Benzophenones; Catalepsy; Catechol O-Methyltransferase; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Levodopa; Male; Mice; Motor Activity; Nitrophenols; Nomifensine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Tolcapone | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Fluphenazine; Levodopa; Male; Methamphetamine; Microinjections; Parkinson Disease; Rats; Sulpiride | 1990 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; DNA; Dopamine; Enzyme Induction; Graft Survival; Levodopa; Male; Neuroblastoma; Parkinson Disease; Rats; Rats, Inbred Strains; Recombinant Fusion Proteins; Transplantation, Heterotopic; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1990 |
Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson's disease: the Mexican experience.
Topics: Adrenal Medulla; Brain Tissue Transplantation; Caudate Nucleus; Combined Modality Therapy; Female; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Male; Mesencephalon; Mexico; Middle Aged; Neurotransmitter Agents; Outcome and Process Assessment, Health Care; Parkinson Disease; Substantia Nigra; Transplantation, Heterotopic | 1990 |
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
Topics: Adult; Aging; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Probability; Severity of Illness Index; Time Factors | 1991 |
Changing mortality from Parkinson's disease.
Topics: Death Certificates; Denmark; Female; Humans; Levodopa; Male; Norway; Parkinson Disease; United States | 1991 |
Diet therapy helps this drug work better.
Topics: Dietary Proteins; Humans; Levodopa; Parkinson Disease | 1991 |
Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Combinations; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1991 |
Early-onset Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced; Risk Factors | 1991 |
Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Crying; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1991 |
The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression.
Topics: Age Factors; Female; Forecasting; Humans; Levodopa; Male; Movement; Multivariate Analysis; Parkinson Disease; Risk Factors | 1991 |
Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validity.
Topics: Activities of Daily Living; Humans; Levodopa; Neurologic Examination; Observer Variation; Parkinson Disease | 1991 |
Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial.
Topics: Adrenal Medulla; Evoked Potentials; Female; Humans; Hyperkinesis; Levodopa; Middle Aged; Nerve Growth Factors; Parkinson Disease; Psychomotor Performance; Putamen; Transplantation, Autologous | 1991 |
Relations between on-off phenomena and cognitive functions in Parkinson disease.
Topics: Affect; Cognition; Humans; Levodopa; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance | 1991 |
Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability.
Topics: Adult; Aged; Biological Availability; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease; Statistics as Topic | 1991 |
Comparison of combination pergolide and levodopa to levodopa alone after 63 months of treatment.
Topics: Aged; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Statistics as Topic | 1991 |
Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.
Topics: Administration, Oral; Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
Topics: Aged; Analysis of Variance; Cohort Studies; Dementia; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1991 |
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Topics: Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1991 |
Intranasal apomorphine in Parkinson's disease.
Topics: Administration, Intranasal; Aged; Apomorphine; Female; Humans; Levodopa; Male; Parkinson Disease; Pilot Projects | 1991 |
Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians.
Topics: Aged; Blood Pressure; Bromocriptine; Epinephrine; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Posture | 1991 |
A 73-year-old woman with confusion, rigidity, and fever.
Topics: Aged; Carbidopa; Confusion; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Muscle Rigidity; Neuroleptic Malignant Syndrome; Parkinson Disease | 1991 |
Protein redistribution diet and antiparkinsonian response to levodopa.
Topics: Aged; Combined Modality Therapy; Dietary Proteins; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Topics: Adult; Autonomic Nervous System Diseases; Benserazide; Delayed-Action Preparations; Drug Combinations; Fever; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease | 1991 |
The motor response to sequential apomorphine in parkinsonian fluctuations.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Performance | 1991 |
Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease.
Topics: Administration, Sublingual; Antiparkinson Agents; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
Topics: Administration, Oral; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance-Related Disorders | 1991 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
Epidemiological assessment of levodopa use by populations.
Topics: Cross-Cultural Comparison; Cross-Sectional Studies; Drug Utilization; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies | 1991 |
Neuroleptic malignant syndrome complicating levodopa withdrawal.
Topics: Aged; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
[Headache, hypertension].
Topics: Adrenal Gland Neoplasms; Aged; Diagnosis, Differential; Female; Headache; Humans; Hypertension; Levodopa; Medical History Taking; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 1991 |
The motor response to repeated apomorphine administration in Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1991 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Psychomotor Performance; Selegiline | 1990 |
Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dystonia; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Early combination with deprenyl: a retrospective analysis.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Retrospective Studies; Selegiline | 1990 |
Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Serotonin | 1990 |
Small doses of levodopa for Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1990 |
Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Dopamine; Female; Humans; Levodopa; Ligands; Male; Middle Aged; Parkinson Disease; Piperazines; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Schizophrenia | 1990 |
[The prevalence of Parkinson disease in West Germany--are general practice data a suitable survey instrument?].
Topics: Cross-Sectional Studies; Drug Utilization; Family Practice; Germany, West; Humans; Incidence; Levodopa; Parkinson Disease; Pilot Projects; Referral and Consultation | 1990 |
A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
Topics: Chorea; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Parkinson Disease; Videotape Recording | 1990 |
New drugs for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline | 1990 |
Levodopa-responsive parkinsonism in a patient with Down's syndrome.
Topics: Activities of Daily Living; Carbidopa; Dose-Response Relationship, Drug; Down Syndrome; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
Topics: Aged; Dose-Response Relationship, Drug; Epinephrine; Fatty Acids, Nonesterified; Female; Heart Rate; Humans; Isoproterenol; Kinetics; Levodopa; Lymphocytes; Male; Middle Aged; Norepinephrine; Parkinson Disease; Radioligand Assay; Receptors, Adrenergic, beta | 1990 |
Stereotaxic thalamotomy--experiences from the levodopa era.
Topics: Aged; Disability Evaluation; Follow-Up Studies; Humans; Levodopa; Middle Aged; Multiple Sclerosis; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Thalamus; Tremor | 1990 |
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations.
Topics: Adrenal Medulla; Adult; Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Tomography, X-Ray Computed | 1990 |
A view from inside.
Topics: Accidental Falls; Antiparkinson Agents; Bromocriptine; Carbidopa; Dentists; Drug Combinations; Humans; Levodopa; Male; Northern Ireland; Parkinson Disease | 1990 |
Parkinsonism with neuroacanthocytosis.
Topics: Acanthocytes; Adult; Carbidopa; Erythrocytes; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1990 |
Apomorphine in the diagnosis and treatment of parkinsonian tremor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 1990 |
Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
Topics: Aged; Biogenic Monoamines; Blood Pressure; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination.
Topics: Carbidopa; Catecholamines; Catechols; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Levodopa; Parkinson Disease | 1990 |
Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
Topics: Afferent Pathways; Cholinergic Fibers; Cognition Disorders; Frontal Lobe; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Psychological Tests | 1990 |
[Orthostatic dysregulation in Parkinson syndrome. Results of a study of 250 patients].
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Sympathetic Nervous System | 1990 |
Conditioning transcranial cortical stimulation (TCCS) by exteroceptive stimulation in parkinsonian patients.
Topics: Adult; Aged; Arousal; Conditioning, Psychological; Electric Stimulation; Electromyography; Evoked Potentials; H-Reflex; Humans; Levodopa; Middle Aged; Motor Cortex; Motor Neurons; Muscles; Neural Inhibition; Neural Pathways; Parkinson Disease; Skin | 1990 |
Research diagnostic criteria for Parkinson's disease.
Topics: Diagnosis, Differential; Humans; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease; Research | 1990 |
Risk factors for dementia in Parkinson's disease.
Topics: Aged; Cardiovascular Diseases; Dementia; Diabetes Complications; Female; Humans; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Risk Factors; Smoking | 1990 |
Utilization of antiparkinsonian drugs in Sweden, 1974-1987.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Utilization; Humans; Incidence; Levodopa; Parkinson Disease; Risk Factors; Sweden | 1990 |
Longitudinal study of effects of early levodopa treatment on disability and mortality in Parkinson's disease.
Topics: Disability Evaluation; Drug Administration Schedule; Follow-Up Studies; Humans; Levodopa; Life Expectancy; Longitudinal Studies; Parkinson Disease; Survival Analysis; United States | 1990 |
The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.
Topics: Aged; Disability Evaluation; Humans; Infusions, Intravenous; Levodopa; Middle Aged; NAD; Neurologic Examination; Parkinson Disease | 1990 |
Decreased dopamine in the retinas of patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retina | 1990 |
Terguride in the treatment of Parkinson disease: preliminary experience.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1990 |
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Motor Activity; Muscle Rigidity; N-Methylaspartate; Parkinson Disease; Piperazines; Rats; Rats, Inbred Strains; Reserpine | 1990 |
Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cabergoline; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1990 |
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Topics: Carbidopa; Droxidopa; Humans; Levodopa; Middle Aged; Norepinephrine; Parkinson Disease | 1990 |
CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
Topics: Aged; Antiparkinson Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
Levodopa efficacy and pathological basis of Parkinson syndrome.
Topics: Female; Humans; Levodopa; Male; Parkinson Disease | 1990 |
Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Carbidopa; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Tranylcypromine; Tryptophan | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up.
Topics: Adrenal Medulla; Canada; Caudate Nucleus; Chicago; Combined Modality Therapy; Female; Follow-Up Studies; Forms and Records Control; Humans; Levodopa; Male; Outcome and Process Assessment, Health Care; Parkinson Disease; Registries; Severity of Illness Index; Transplantation, Heterotopic; United States | 1990 |
Autologous adrenal medulla to caudate nucleus transplantation in advanced Parkinson's disease: 18 month results.
Topics: Adrenal Medulla; Caudate Nucleus; Cerebral Hemorrhage; Cerebrospinal Fluid; Combined Modality Therapy; Florida; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
A year follow-up of autoimplants of perfused adrenal medulla into parkinsonian patients. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Perfusion; Severity of Illness Index; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Adrenal medulla autograft in 3 parkinsonian patients: results using two different approaches.
Topics: Adrenal Medulla; Caudate Nucleus; Combined Modality Therapy; Evaluation Studies as Topic; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Stereotactic implantation of foetal mesencephalon (STIM): the UK experience.
Topics: Adult; Brain Tissue Transplantation; Caudate Nucleus; Combined Modality Therapy; Female; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Stereotaxic Techniques; United Kingdom | 1990 |
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Drug Interactions; Female; Ferrous Compounds; Humans; Levodopa; Male; Middle Aged; Oxygen; Parkinson Disease | 1990 |
Depression in Parkinson's disease.
Topics: Cognition Disorders; Depression; Dose-Response Relationship, Drug; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales | 1990 |
A case of pure akinesia due to Lewy body parkinson's disease with pathology.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease | 1990 |
Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family.
Topics: Adult; Aged; Child; Child, Preschool; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; North America; Parkinson Disease; Pedigree | 1990 |
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Models, Biological; Parkinson Disease | 1990 |
Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Survival Analysis; Time Factors | 1990 |
Anxiety disorders in patients with Parkinson's disease.
Topics: Adult; Aged; Anxiety Disorders; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Topics: Aged; Central Nervous System; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1990 |
Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance; Reaction Time | 1990 |
[A new method of quantitative analysis of parkinsonian gait: report of 6 patients].
Topics: Aged; Aged, 80 and over; Female; Gait; Humans; Levodopa; Methods; Middle Aged; Parkinson Disease | 1990 |
Subcutaneous apomorphine in the treatment of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.
Topics: Activities of Daily Living; Adrenal Medulla; Adult; Caudate Nucleus; Cells, Cultured; Dopamine; Epinephrine; Follow-Up Studies; Homovanillic Acid; Humans; Hydrocortisone; Levodopa; Male; Middle Aged; Movement Disorders; Nerve Growth Factors; Norepinephrine; Parkinson Disease | 1990 |
Adrenal medulla transplantation into the putamen in Parkinson's disease.
Topics: Adrenal Medulla; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Putamen; Transplantation, Heterotopic | 1990 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1990 |
[Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.
Topics: Aged; Dose-Response Relationship, Drug; Dystonia; Facial Muscles; Humans; Levodopa; Middle Aged; Parkinson Disease | 1990 |
Evidence for the role of spinal cord systems in Parkinson's disease-associated pain.
Topics: Aged; Dystonia; Female; Humans; Levodopa; Pain; Parkinson Disease; Spinal Cord | 1990 |
Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status.
Topics: Adult; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1990 |
['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.
Topics: Aged; Blood Pressure; Cause of Death; Cerebral Hemorrhage; Female; Humans; Japan; Levodopa; Male; Parkinson Disease | 1990 |
Juvenile Parkinson's disease and its response to L-dopa therapy.
Topics: Adolescent; Adult; Female; Humans; Levodopa; Male; Parkinson Disease; Pedigree | 1990 |
MAO and L-dopa treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease | 1990 |
Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients.
Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex | 1990 |
Temporal arteritis presenting as an extrapyramidal disorder.
Topics: Aged; Arteritis; Cerebral Arterial Diseases; Diagnosis, Differential; Female; Humans; Levodopa; Parkinson Disease; Prednisone | 1990 |
The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
Topics: Aged; Apomorphine; Dopamine; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1990 |
[The treatment of Parkinson disease using the combination bromocriptine and levodopa].
Topics: Aged; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1990 |
Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography.
Topics: Aged; Carbidopa; Dyspnea; Humans; Levodopa; Lung Volume Measurements; Male; Middle Aged; Parkinson Disease; Plethysmography; Pulmonary Ventilation; Respiration Disorders | 1990 |
Clozapine for psychosis in Parkinson's disease.
Topics: Aged; Clozapine; Dibenzazepines; Dose-Response Relationship, Drug; Hallucinations; Humans; Levodopa; Male; Parkinson Disease | 1990 |
Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Drug Tolerance; Ergolines; Humans; Infusion Pumps; Levodopa; Lisuride; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Induction of dyskinesias.
Topics: Animals; Apomorphine; Delayed-Action Preparations; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1990 |
Response fluctuations in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Time Factors | 1990 |
Electron microscopy of red blood cells altered by auto-immunity-inducing drugs.
Topics: Anemia, Hemolytic, Autoimmune; Autoimmunity; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Formaldehyde; Humans; Immunoglobulin G; Immunoglobulin M; Levodopa; Microscopy, Electron; Parkinson Disease | 1990 |
Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise.
Topics: History, Ancient; India; Levodopa; Medicine, Ayurvedic; Parkinson Disease; Plants, Medicinal | 1990 |
Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual | 1985 |
Development of two malignant melanomas during administration of levodopa.
Topics: Aged; Humans; Levodopa; Male; Melanoma; Parkinson Disease; Time Factors | 1985 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Synergism; Hydroxyindoleacetic Acid; Levodopa; Male; Manganese Poisoning; Pargyline; Parkinson Disease; Rats; Serotonin | 1986 |
Clinical and biochemical features of depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Prolactin; Psychomotor Performance; Self Concept; Thyrotropin-Releasing Hormone | 1986 |
Parkinson disease: electrophysiological (CNV) analysis related to pharmacological treatment.
Topics: Bromocriptine; Contingent Negative Variation; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
The Bereitschaftspotential, L-DOPA and Parkinson's disease.
Topics: Adult; Electroencephalography; Evoked Potentials; Fingers; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease | 1987 |
Continuous levodopa infusions to treat complex dystonia in Parkinson's disease.
Topics: Aged; Duodenum; Dystonia; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Osmolar Concentration; Palliative Care; Parkinson Disease | 1989 |
Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Topics: Aged; Biomarkers; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Parkinson Disease | 1989 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Metabolic Clearance Rate; Middle Aged; Motor Skills; Parkinson Disease; Reaction Time | 1989 |
PET studies of parkinsonian patients treated with autologous adrenal implants.
Topics: Adrenal Medulla; Adult; Blood-Brain Barrier; Edetic Acid; Evaluation Studies as Topic; Female; Fluorine Radioisotopes; Gallium Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1989 |
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
New approaches in the use of selegiline for the treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Selegiline in the treatment of Parkinson's disease--long term experience.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Inhibitory action of L-dopa.
Topics: Animals; Humans; Levodopa; Mice; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Sulpiride | 1989 |
[Study of the immunologic status of persons with Parkinson disease with special reference to the effect of levodopa treatment. Preliminary report].
Topics: Adult; Aged; Female; Humans; Leukocyte Count; Levodopa; Lymphocyte Activation; Male; Middle Aged; Parkinson Disease; T-Lymphocytes; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory | 1989 |
Dopamine and memory function in Parkinson's disease.
Topics: Aged; Attention; Brain; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Mental Recall; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Receptors, Dopamine; Synaptic Transmission; Verbal Learning | 1989 |
Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Tyrosine hydroxylase and levodopa responsive dystonia.
Topics: Chromosome Mapping; Chromosomes, Human, Pair 11; DNA Probes; Dystonia; Genetic Linkage; Humans; Levodopa; Parkinson Disease; Pedigree; Polymorphism, Restriction Fragment Length; Tyrosine 3-Monooxygenase | 1989 |
Apomorphine test for dopaminergic responsiveness.
Topics: Apomorphine; Diagnosis, Differential; Double-Blind Method; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1989 |
Early dopamine agonist therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Receptors, Dopamine | 1989 |
[Antiparkinsonian drugs].
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1989 |
Jejunal delivery of levodopa methyl ester.
Topics: Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Agents; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phenanthridines; Pyridines | 1989 |
Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.
Topics: Animals; Cell Line; Disease Models, Animal; DNA; Fibroblasts; Genetic Vectors; Levodopa; Moloney murine leukemia virus; Parkinson Disease; Plasmids; Rats; Transfection; Tyrosine 3-Monooxygenase | 1989 |
Hypersexuality with antiparkinsonian therapy.
Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors; Sexual Behavior | 1989 |
[Current advances in neural transplantation].
Topics: Animals; Brain; Cloning, Molecular; Genetic Vectors; Humans; Levodopa; Neurons; Parkinson Disease; Plasmids; Transfection; Tyrosine 3-Monooxygenase | 1989 |
New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease.
Topics: Aged; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance | 1989 |
Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tablets | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Sleep tonus inversion: a feature of juvenile dystonic parkinsonism.
Topics: Adolescent; Female; Humans; Levodopa; Muscle Tonus; Parkinson Disease; Sleep | 1989 |
Darkening of white hair in Parkinson's disease.
Topics: Carbidopa; Hair Color; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
Topics: Aged; Aged, 80 and over; Benserazide; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; Levodopa; Male; Middle Aged; Parkinson Disease; Stereoisomerism | 1989 |
[Clinical characteristics of painful dystonic foot response in patients with Parkinson's disease].
Topics: Aged; Dystonia; Female; Foot; Humans; Levodopa; Male; Middle Aged; Pain; Parkinson Disease | 1989 |
Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains | 1989 |
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites.
Topics: Aged; Carbidopa; Drug Combinations; Homovanillic Acid; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1989 |
The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Aged; Bromocriptine; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction.
Topics: Aged; Attention; Drug Therapy, Combination; Female; Form Perception; Humans; Levodopa; Male; Middle Aged; Neurocognitive Disorders; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Psychomotor Performance; Reaction Time; Trihexyphenidyl | 1989 |
Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Humans; Levodopa; Male; Middle Aged; NAD; NADP; Parkinson Disease | 1989 |
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
Topics: Adult; Aged; Cognition Disorders; Dopamine; Frontal Lobe; Humans; Levodopa; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Receptors, Dopamine | 1989 |
Blink reflex in dyskinetic and nondyskinetic patients with Parkinson's disease.
Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Topics: Adult; Aged; Carbidopa; Disability Evaluation; Dominance, Cerebral; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1989 |
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Biological Availability; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Hallucinations; Humans; Hypotension, Orthostatic; Levodopa; Male; Movement Disorders; Parkinson Disease; Scotland; Time Factors | 1989 |
Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease. Initial clinical results in 18 patients.
Topics: Adrenal Medulla; Aged; Caudate Nucleus; Disability Evaluation; Humans; Levodopa; Middle Aged; Parkinson Disease; Pilot Projects; Time Factors; Transplantation, Autologous | 1989 |
Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
Topics: Aged; Aged, 80 and over; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Second interim report of the nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Estrogens and the pathophysiology of Parkinson's disease.
Topics: Estrogens; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Mathematics; Middle Aged; Models, Theoretical; Parkinson Disease | 1989 |
Falls and Parkinson's disease.
Topics: Accidental Falls; Accidents; Aged; Bromocriptine; Female; Humans; Levodopa; Male; Parkinson Disease; Physical Therapy Modalities; Posture; Risk Factors | 1989 |
Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test.
Topics: Adolescent; Adult; Aged; Cognition; Discrimination, Psychological; Humans; Levodopa; Middle Aged; Neuropsychological Tests; Parkinson Disease; Regression Analysis; Visual Perception | 1989 |
[Development of Parkinson's disease].
Topics: Humans; Levodopa; Life Expectancy; Mental Disorders; Movement Disorders; Parkinson Disease; Prognosis | 1989 |
[The mental state of parkinsonian patients].
Topics: Cognition Disorders; Dementia; Depression; Humans; Levodopa; Mental Disorders; Parkinson Disease | 1989 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1989 |
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Topics: Administration, Cutaneous; Adult; Antiparkinson Agents; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease.
Topics: Aged; Dyspnea; Humans; Levodopa; Male; Parkinson Disease; Pulmonary Ventilation | 1989 |
[The problems of L-dopa therapy in the course of Parkinson syndrome].
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1989 |
Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.
Topics: Adult; Aged; Amino Acids; Blood-Brain Barrier; Circadian Rhythm; Feeding Behavior; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1989 |
Subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Parkinsonism manifesting depression as the first sign.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
[Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease].
Topics: Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Topics: Aged; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carboxy-Lyases; Drug Combinations; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Pregnancy and parkinsonism. A case report without problem.
Topics: Adult; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications | 1989 |
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
L-tryptophan supplementation in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Tryptophan | 1989 |
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Palilalia as a symptom of levodopa induced hyperkinesia in Parkinson's disease.
Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echolalia; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease | 1989 |
One year treatment with lisuride delivery pump in Parkinson's disease.
Topics: Adult; Drug Therapy, Combination; Ergolines; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1989 |
[Parkinson disease and cognitive evoked potentials].
Topics: Age Factors; Cognition Disorders; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Reaction Time | 1989 |
Acute postoperative confusion and hallucinations in Parkinson disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Cognition Disorders; Confusion; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Risk | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Phenytoin; Time Factors; Tyrosine | 1989 |
[L-dopa, biperiden and sebum excretion in Parkinson disease].
Topics: Aged; Aged, 80 and over; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Sebum; Sex Factors | 1989 |
A community survey of Parkinson's disease.
Topics: Aged; British Columbia; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rural Population | 1989 |
A parkinsonian kindred.
Topics: Aged; Aged, 80 and over; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree | 1989 |
Effect of age at onset on progression and mortality in Parkinson's disease.
Topics: Aging; Athetosis; Chorea; Disability Evaluation; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Pathogenesis of dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Peripheral pharmacokinetics of apomorphine in humans.
Topics: Adult; Aged; Apomorphine; Dopamine; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.
Topics: Acetaminophen; Carbidopa; Cytochrome P-450 Enzyme System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
Topics: Diazepam; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Pilot Projects; Tropanes | 1989 |
Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up.
Topics: Contingent Negative Variation; Corpus Striatum; Dopamine; Female; Fetus; Follow-Up Studies; Humans; Levodopa; Methods; Middle Aged; Movement; Nerve Tissue; Neurologic Examination; Neurons; Neuropsychological Tests; Parkinson Disease; Self Concept; Tomography, Emission-Computed | 1989 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Swallowing abnormalities and their response to treatment in Parkinson's disease.
Topics: Aged; Barium; Deglutition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Observer Variation; Parkinson Disease; Single-Blind Method | 1989 |
Depression and cognitive impairment in Parkinson's disease.
Topics: Cognition; Cognition Disorders; Depression; Humans; Language Tests; Levodopa; Neuropsychological Tests; Parkinson Disease; Regression Analysis | 1989 |
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems.
Topics: Adult; Aged; Dopamine; Electrooculography; Eye Movements; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex, Vestibulo-Ocular; Severity of Illness Index | 1989 |
Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Topics: Aged; Apomorphine; Carbidopa; Drug Resistance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1989 |
Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson's disease.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Injections, Intravenous; Levodopa; Methyldopa; Parkinson Disease | 1989 |
Tremors in early Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor | 1989 |
[Two siblings of juvenile Parkinson's disease dystonic type (Yokochi type 3) and hereditary progressive dystonia with marked diurnal fluctuation (Segawa)].
Topics: Child; Circadian Rhythm; Dystonia; Family; Humans; Levodopa; Male; Parkinson Disease | 1989 |
ECT and Parkinson's disease revisited: a "naturalistic" study.
Topics: Aged; Carbidopa; Confusion; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1989 |
The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson's disease.
Topics: Adult; Aged; Droxidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscles; Parkinson Disease; Reference Values; Serine; Synapses; Synaptic Transmission | 1987 |
Clinical and neuropathological study of a familial case of juvenile parkinsonism.
Topics: Adult; Brain; Cerebral Cortex; Female; Humans; Inclusion Bodies; Levodopa; Locus Coeruleus; Microscopy, Electron; Nerve Degeneration; Neurons; Parkinson Disease; Substantia Nigra | 1988 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Induced; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Exertion | 1985 |
Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dipeptides; Drug Synergism; Drug Therapy, Combination; Levodopa; Motor Activity; MSH Release-Inhibiting Hormone; Neuropeptides; Parkinson Disease; Peptides, Cyclic; Rats; Structure-Activity Relationship | 1985 |
Fluctuating levodopa concentrations and Parkinson's disease.
Topics: Delayed-Action Preparations; Humans; Levodopa; Parkinson Disease | 1985 |
Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.
Topics: Aged; Antipsychotic Agents; Benserazide; Bromocriptine; Clozapine; Delusions; Dibenzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hallucinations; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Tryptophan | 1985 |
[Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Topics: Animals; Caudate Nucleus; Drug Synergism; Enkephalins; Levodopa; MSH Release-Inhibiting Hormone; Parkinson Disease; Rats | 1985 |
Rationale for early use of levodopa in parkinsonism.
Topics: Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Time Factors | 1986 |
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Topics: Animals; Callithrix; Carbidopa; Domperidone; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Oxazines; Parkinson Disease; Time Factors | 1986 |
Neurotransmitter precursors and brain function.
Topics: Aged; Aging; Alzheimer Disease; Animals; Biological Transport; Brain; Diet; Humans; Learning; Levodopa; Memory; Neurotransmitter Agents; Parkinson Disease; Phosphatidylcholines; Serotonin; Sleep; Tryptophan | 1986 |
When to use levodopa in parkinsonism.
Topics: Acute Disease; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
Lisuride infusion pump for Parkinson's disease.
Topics: Adult; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Ergolines; Female; Humans; Infusions, Parenteral; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1986 |
Psychosis and the lisuride pump.
Topics: Drug Therapy, Combination; Ergolines; Humans; Infusions, Parenteral; Levodopa; Lisuride; Parkinson Disease; Psychoses, Substance-Induced | 1986 |
Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease.
Topics: Aged; Cognition; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
When should levodopa be started?
Topics: Adult; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1986 |
[Depression and Parkinson syndrome].
Topics: Antidepressive Agents; Brain; Depressive Disorder; Drug Therapy, Combination; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Tryptophan | 1986 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Time Factors | 1987 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior | 1987 |
Apomorphine infusion for motor fluctuations in Parkinson's disease.
Topics: Apomorphine; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 1987 |
Changes in serum prolactin after electroconvulsive and epileptic seizures.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Epilepsy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Schizophrenia | 1987 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; Movement Disorders; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Reserpine; Stereotyped Behavior | 1987 |
The treatment of tremor.
Topics: Adrenergic beta-Antagonists; Alcoholic Beverages; Cerebellar Diseases; Humans; Isoniazid; Levodopa; Parkinson Disease; Primidone; Pyridoxine; Tremor | 1987 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Tetrabenazine | 1987 |
Subcutaneous apomorphine in parkinsonian on-off oscillations.
Topics: Adult; Aged; Apomorphine; Domperidone; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Parkinsonism: candidate disorder for implanted pumps?
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dopamine; Hallucinations; Humans; Infusion Pumps; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine | 1988 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease.
Topics: Adult; Aged; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies | 1988 |
Parkinson's disease, depression, and the on-off phenomenon.
Topics: Bromocriptine; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Optimization of symptomatic therapy in Parkinson's disease.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Computer-Assisted; Humans; Hydrazines; Levodopa; Models, Biological; Parkinson Disease; Reaction Time; Therapy, Computer-Assisted | 1989 |
Defective concept formation in parkinsonians is independent from mental deterioration.
Topics: Aged; Concept Formation; Dementia; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parasympatholytics; Parkinson Disease; Psychometrics | 1989 |
Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine.
Topics: Aged; Apomorphine; Drug Therapy, Combination; Eructation; Esophageal Motility Disorders; Esophagus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peristalsis | 1989 |
Dose-dependent memory impairment in Parkinson's disease.
Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Memory Disorders; Parkinson Disease | 1989 |
L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
Topics: Adult; Aged; Caudate Nucleus; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Receptors, Dopamine D2; Tissue Distribution | 1985 |
Dopamine D2 receptor density remains constant in treated Parkinson's disease.
Topics: Age Factors; Aged; Caudate Nucleus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Receptors, Dopamine D2; Time Factors | 1986 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Patient Care Planning; Patient Care Team; Tremor | 1986 |
Plasma beta-endorphin and beta-lipotropin in patients with Parkinson's disease.
Topics: Aged; beta-Endorphin; beta-Lipotropin; Dopamine; Endorphins; Female; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland | 1986 |
Pharmacokinetics of L-dopa in patients with Parkinson's disease.
Topics: Biotransformation; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kinetics; Levodopa; Methyldopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Tiapamil Hydrochloride | 1987 |
Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
Topics: Brain; Caudate Nucleus; Humans; Levodopa; Parkinson Disease; Putamen; Receptors, Dopamine; Receptors, Dopamine D2 | 1987 |
[Parkinson's disease 20 years later].
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Parkinson Disease; Time Factors | 1987 |
Treatment of Parkinson's disease with subcutaneous lisuride infusions.
Topics: Aged; Drug Eruptions; Drug Therapy, Combination; Ergolines; Female; Hematoma; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1988 |
Lisuride infusion pump in Parkinson's disease. A report of two cases.
Topics: Aged; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Lisuride; Mental Disorders; Parkinson Disease | 1988 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Corpus Striatum; Denervation; Dextroamphetamine; Ergolines; Female; Flunarizine; Functional Laterality; Haloperidol; Levodopa; Neural Pathways; Parkinson Disease; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Substantia Nigra | 1988 |
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea.
Topics: Adult; Aged; Carnosine; Dipeptides; Female; Friedreich Ataxia; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
[On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
Topics: Aged; Chronic Disease; Drug Evaluation; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1987 |
[An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
Topics: Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Problems in the contemporary treatment of parkinsonism.
Topics: Basal Ganglia; Dementia; Humans; Kinetics; Levodopa; Movement Disorders; Neuromuscular Junction; Parkinson Disease; Receptors, Dopamine; Synaptic Transmission | 1985 |
Pathophysiology of L-dopa-induced abnormal involuntary movements.
Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Spiperone; Substance Withdrawal Syndrome; Substantia Nigra; Synapses; Synaptic Transmission | 1985 |
Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Naloxone; Parkinson Disease; Receptors, Opioid | 1986 |
Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment.
Topics: Aged; Blood Platelets; Bromocriptine; Cell Membrane; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Platelet Aggregation; Receptors, Adrenergic, alpha; Yohimbine | 1985 |
[Thoughts on the neurobiological aspects of Parkinson syndrome].
Topics: Basal Ganglia; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Synapses; Synaptic Transmission | 1986 |
Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Topics: Adult; Aged; Brain; Carbidopa; Dopamine; Evoked Potentials, Visual; Female; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Synaptic Transmission; Visual Pathways | 1986 |
Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.
Topics: Adult; Aged; Brain; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Synaptic Transmission; Tomography, Emission-Computed | 1986 |
Familial Alzheimer's disease presenting as levodopa-responsive parkinsonism.
Topics: Aged; Alzheimer Disease; Brain; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Inclusion Bodies; Levodopa; Parkinson Disease; Pedigree | 1987 |
Function of dopamine receptors in Parkinson's disease: prolactin responses.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone; Time Factors | 1986 |
Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease.
Topics: Drug Tolerance; Humans; Levodopa; Long-Term Care; Parkinson Disease | 1986 |
Modification of Parkinson's disease by long-term levodopa treatment.
Topics: Humans; Levodopa; Long-Term Care; Parkinson Disease | 1986 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques | 1986 |
Effect of supplemental carbidopa on bioavailability of L-dopa.
Topics: Aged; Biological Availability; Carbidopa; Dihydroxyphenylalanine; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1986 |
Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
Topics: Aged; Dihydroxyphenylalanine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Retrospective Studies; Time Factors | 1986 |
Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
Topics: Adult; Aged; Benserazide; Dopamine; Drug Combinations; Female; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary-Adrenal System; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1986 |
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.
Topics: Aged; Carbimazole; Dyskinesia, Drug-Induced; Female; Humans; Hyperthyroidism; Levodopa; Movement Disorders; Parkinson Disease | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline | 1986 |
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Topics: Adult; Aged; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1986 |
Open pilot trial of ritanserin in parkinsonism.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pilot Projects; Piperidines; Ritanserin | 1986 |
[Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors | 1986 |
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Topics: Adult; Aged; Carboxy-Lyases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Critical role of MAO inhibition in Parkinson's disease.
Topics: Acetylcholine; Animals; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Structure-Activity Relationship | 1987 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
The visual system in Parkinson's disease.
Topics: Animals; Carbidopa; Drug Therapy, Combination; Evoked Potentials, Visual; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Reaction Time; Vision Disorders; Vision Tests; Visual Acuity | 1987 |
Parkinson's disease and long-term levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1987 |
Long-term effect of levodopa on progression of Parkinson's disease.
Topics: Disability Evaluation; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Motor Skills; Parkinson Disease; Psychomotor Performance | 1987 |
Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
Topics: Delayed-Action Preparations; Half-Life; Humans; Infusions, Intravenous; Levodopa; Long-Term Care; Parkinson Disease | 1987 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Dopamine agonists as primary treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Long-Term Care; Parkinson Disease; Pergolide; Receptors, Dopamine | 1987 |
Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Topics: Adult; Aged; Antiparkinson Agents; Droxidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Serine; Shy-Drager Syndrome | 1987 |
Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Parkinson Disease | 1987 |
Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.
Topics: Adult; Aged; Blood Glucose; Brain; Caudate Nucleus; Cerebellum; Deoxyglucose; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Levodopa; Middle Aged; Parkinson Disease; Putamen; Tomography, Emission-Computed | 1987 |
[Long-term problems of levodopa therapy in Parkinson disease].
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors | 1987 |
Management of Parkinson's disease.
Topics: Algorithms; Humans; Levodopa; Parkinson Disease | 1987 |
Parkinson's disease in the elderly: current management strategies.
Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1987 |
[Lisuride in the combination treatment of Parkinson disease].
Topics: Adult; Aged; Aged, 80 and over; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1987 |
Milestones in the development of modern Parkinson therapy.
Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan | 1987 |
R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Disability Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.
Topics: Absorption; Administration, Oral; Dihydroxyphenylalanine; Duodenum; Gastric Emptying; Humans; Intubation; Levodopa; Male; Middle Aged; Nose; Parkinson Disease | 1988 |
Tuberoinfundibular dopaminergic function in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Neuropeptides; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1988 |
[Determination of serum L-dopa in healthy people and patients with Parkinson's disease].
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values | 1988 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Acute exacerbation of Parkinson's disease with sulindac.
Topics: Back Pain; Carbidopa; Drug Combinations; Humans; Indenes; Levodopa; Male; Middle Aged; Parkinson Disease; Sulindac | 1985 |
The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems.
Topics: Adult; Aged; Apomorphine; Blood Pressure; Bromocriptine; Cardiovascular System; Catecholamines; Dopamine; Dopamine beta-Hydroxylase; Female; Heart Rate; Hemodynamics; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Pulse; Sympathetic Nervous System | 1985 |
[Clinical study of pergolide in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Pergolide | 1985 |
Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Topics: Administration, Oral; Adult; Drug Therapy, Combination; Ergolines; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Ketones; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Pentanones; Rats; Rats, Inbred Strains; Rotation | 1988 |
Treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1988 |
[Current methods of treating parkinsonism].
Topics: Antiparkinson Agents; Humans; Levodopa; Middle Aged; Parkinson Disease | 1988 |
A woman with dementia and parkinsonism unresponsive to levodopa.
Topics: Alzheimer Disease; Brain; Dementia; Female; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease | 1988 |
Spatial disorientation in Parkinson's disease: no effect of levodopa substitution therapy.
Topics: Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychological Tests; Spatial Behavior | 1988 |
Dementia and treatment with L-dopa in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cognition; Dementia; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 1988 |
Levodopa therapy and motor fluctuations in Parkinson's disease.
Topics: Humans; Levodopa; Motor Neurons; Parkinson Disease | 1988 |
Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
Topics: Adult; Drug Administration Schedule; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Motor Skills; Parkinson Disease | 1988 |
[Correlation of clinico-physiologic indices and the serotonin content of the blood of patients with parkinsonism].
Topics: Adult; Aged; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Serotonin | 1988 |
Role of dopamine receptors in neurological drug treatment.
Topics: Antiparkinson Agents; Brain; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine | 1988 |
Isoniazid therapy in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Isoniazid; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Relation of blood serotonin and benzylamine oxidase to clinical symptoms and prognosis in Parkinson's disease.
Topics: Adult; Benzylamine Oxidase; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Prognosis; Serotonin; Time Factors | 1988 |
Parkinsonian syndrome in the course of aqueductal stenosis hydrocephalus.
Topics: Adult; Cerebral Aqueduct; Cerebrospinal Fluid Shunts; Humans; Hydrocephalus; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease | 1988 |
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Topics: Adult; Aged; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1988 |
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
Serotonergic mechanisms in levodopa-induced "on-off" and sleep disorders in Parkinson's disease.
Topics: Amitriptyline; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Serotonin; Sleep Wake Disorders | 1988 |
Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
Topics: Carbidopa; Catecholamines; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Levodopa; Parkinson Disease; Spectrometry, Fluorescence | 1988 |
[Experience using veroshpiron in the combined therapy of parkinsonism].
Topics: Adrenal Glands; Adult; Aged; Antiparkinson Agents; Catecholamines; Drug Evaluation; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Spironolactone; Sympathetic Nervous System | 1988 |
Neuroleptic malignant syndrome in striatonigral degeneration.
Topics: Aged; Corpus Striatum; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Substantia Nigra | 1988 |
Serial cognitive profiles in levodopa-induced hypersexuality.
Topics: Cognition; Humans; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Sexual Behavior | 1988 |
Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
Topics: Adult; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Biochemical aspects of Parkinson-dementia complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dementia; Female; Humans; Levodopa; Male; Mice; Middle Aged; Oxygen; Parkinson Disease; Pyridines; Serotonin; Tryptophan Hydroxylase | 1988 |
Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1988 |
Brain dopaminergic system studied in patients with dystonia using positron emission tomography.
Topics: Adult; Brain; Dopamine; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Spiperone; Tomography, Emission-Computed; Torticollis | 1988 |
Transplantation to the brain--a new therapeutic principle or useless venture?
Topics: Adrenal Medulla; Animals; Brain; Forecasting; Humans; Levodopa; Muscle Rigidity; Neurosurgery; Parkinson Disease; Stereotaxic Techniques; Tomography, X-Ray Computed | 1987 |
Modification of Parkinson's disease by long-term levodopa treatment.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1988 |
Timing of levodopa in parkinsonism.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1988 |
Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa.
Topics: Adult; Aged; Amino Acids; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time | 1988 |
International symposium on early dopamine agonist therapy of Parkinson's disease.
Topics: Animals; Bromocriptine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease; Pergolide; Time Factors | 1988 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Piperidines | 1988 |
Dystonia in Parkinson's disease: clinical and pharmacological features.
Topics: Adult; Aged; Circadian Rhythm; Dose-Response Relationship, Drug; Dystonia; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1988 |
Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy.
Topics: Aged; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance-Related Disorders | 1988 |
Parkinson's disease in blacks. Observations on epidemiology in Natal.
Topics: Age Factors; Aged; Aged, 80 and over; Black People; Ethnicity; Humans; Levodopa; Middle Aged; Motor Neurons; Neuromuscular Diseases; Parkinson Disease; South Africa; White People | 1988 |
Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
Topics: Adult; Duodenum; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Lack of pharmacokinetic influence on levodopa by bromocriptine.
Topics: Bromocriptine; Carbidopa; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1988 |
Axial versus distal motor impairment in Parkinson's disease.
Topics: Aged; Female; Head; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Wrist | 1988 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1988 |
Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations.
Topics: Aged; Aging; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Time Factors | 1988 |
Neuropharmacological intervention with motor system aging.
Topics: Adult; Aged; Aging; Cognition; Gait; Humans; Levodopa; Middle Aged; Movement Disorders; Neuropharmacology; Neuropsychological Tests; Parkinson Disease; Posture; Reaction Time; Sympathomimetics | 1988 |
Human motor behavior and aging.
Topics: Aged; Aging; Brain; Extrapyramidal Tracts; Humans; Levodopa; Movement; Parkinson Disease; Reference Values | 1988 |
Undetectable thyrotropin levels using immunoradiometric assay in L-dopa-treated patients.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radioimmunoassay; Thyrotropin | 1988 |
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.
Topics: Aged; Cognition; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 1988 |
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1988 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1988 |
Practical application of a low-protein diet for Parkinson's disease.
Topics: Body Weight; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Serum Albumin | 1988 |
[Nursing homes patients with Parkinson disease: treatment].
Topics: Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease | 1988 |
Continuing problems in the treatment of Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1988 |
Lisuride in Parkinson's disease. 4-year follow-up.
Topics: Adult; Aged; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Isolated jejunal pouches for levodopa delivery in parkinsonian patients with "on-off". Successful experimental model in dogs.
Topics: Animals; Dietary Proteins; Dogs; Drug Implants; Jejunum; Levodopa; Parkinson Disease; Tablets | 1988 |
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.
Topics: Aged; Cyproheptadine; Humans; Levodopa; Male; Methysergide; Myoclonus; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1988 |
Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
Topics: Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa.
Topics: Adrenal Gland Neoplasms; Aged; Carbidopa; Diagnostic Errors; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 1988 |
Duodenal and gastric delivery of levodopa in parkinsonism.
Topics: Administration, Oral; Drug Administration Schedule; Duodenum; Gastric Emptying; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Stomach | 1988 |
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscular Diseases; Parkinson Disease; Personality; Substantia Nigra | 1988 |
Does levodopa aggravate Parkinson's disease?
Topics: Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Duodenum; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
[Cholestasis caused by Nakom].
Topics: Antiparkinson Agents; Carbidopa; Cholestasis; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients.
Topics: Adrenal Medulla; Adult; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications | 1988 |
Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.
Topics: Aged; Female; Food; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1987 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Brainstem auditory evoked potentials with and without increased stimulus rate as diagnostic tool in brainstem minor transient changes.
Topics: Adolescent; Adult; Aged; Brain Stem; Child; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Migraine Disorders; Parkinson Disease | 1987 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Parkinson's disease: further steps forward.
Topics: Adrenal Medulla; Adult; Animals; Dementia; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxazines; Parkinson Disease | 1987 |
[Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years].
Topics: Drug Evaluation; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Time Factors | 1987 |
Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
Topics: Aged; Aged, 80 and over; Bromocriptine; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Nosography of Parkinson's disease.
Topics: Cognition; Dementia; Humans; Levodopa; Movement; Parkinson Disease | 1986 |
Evaluation of chronic levodopa therapy in Parkinson's disease.
Topics: Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1986 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1986 |
Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
Topics: Aged; Carbidopa; Drug Antagonism; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Update on Parkinson disease.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Bilateral vocal cord paralysis due to laryngeal carcinoma in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carcinoma, Squamous Cell; Humans; Laryngeal Neoplasms; Levodopa; Male; Parkinson Disease; Vocal Cord Paralysis | 1987 |
Drug-induced myoclonus.
Topics: 5-Hydroxytryptophan; Anesthetics; Animals; Anti-Bacterial Agents; Antidepressive Agents; Bismuth; Carbidopa; Electroencephalography; Gasoline; Guinea Pigs; Humans; Hydrocarbons, Brominated; Imipramine; Levodopa; Methysergide; Models, Biological; Myoclonus; Parkinson Disease; Sleep | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
Topics: Aged; Dyskinesia, Drug-Induced; Eye Movements; Head; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Reflex, Abnormal; Vestibule, Labyrinth | 1986 |
Recent research advances in Parkinson's disease: Part I.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Levodopa; Parkinson Disease; Pyridines; Research; Substantia Nigra | 1986 |
Environmental and genetic factors in the etiology of Parkinson's disease.
Topics: Cross-Sectional Studies; Humans; Levodopa; Parkinson Disease; Pedigree; Quebec; Risk; Rural Population; Social Environment; Urban Population | 1987 |
Development of new pharmacological approaches in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cysteinyldopa; Delayed-Action Preparations; Dopamine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Structure-Activity Relationship | 1987 |
Exercise and the antiparkinsonian response to levodopa.
Topics: Adult; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion | 1987 |
Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1987 |
Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa.
Topics: Adult; Carbidopa; Clozapine; Dibenzazepines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Schizophrenia | 1987 |
Restless legs syndrome and Parkinson's disease: insights into pathophysiology.
Topics: Aged; Clonazepam; Codeine; Dopamine; Humans; Levodopa; Male; Parkinson Disease; Restless Legs Syndrome | 1987 |
Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Locus Coeruleus; Male; Parkinson Disease; Substantia Nigra | 1986 |
Tics in a patient with Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Tourette Syndrome | 1986 |
Parkinsonism following dystonia in three patients.
Topics: Adult; Dystonia; Handwriting; Humans; Levodopa; Male; Meige Syndrome; Middle Aged; Muscle Cramp; Parkinson Disease; Time Factors | 1986 |
Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy.
Topics: Aged; Brain; Female; Humans; Levodopa; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Spinocerebellar Degenerations; Tomography, X-Ray Computed | 1986 |
Individual manifestations of Parkinson's disease after ten or more years of levodopa.
Topics: Gait; Handwriting; Humans; Levodopa; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture; Prognosis; Speech; Time Factors; Tremor | 1986 |
Young onset Parkinson's disease.
Topics: Adult; Age Factors; Circadian Rhythm; Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedigree; Risk Factors; Tremor | 1987 |
Sudden confusion with levodopa withdrawal.
Topics: Cognition Disorders; Confusion; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1987 |
Corneal and blink reflexes in Parkinson's disease with "on-off" fluctuations.
Topics: Adult; Aged; Blinking; Brain; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Reaction Time; Receptors, Dopamine | 1987 |
Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
Topics: Administration, Oral; Aged; Bromocriptine; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Regional Blood Flow; Tomography, Emission-Computed | 1987 |
Simple and complex movements off and on treatment in patients with Parkinson's disease.
Topics: Adult; Aged; Electromyography; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Contraction; Parkinson Disease; Reaction Time | 1987 |
Juvenile Parkinsonism: clinical and metabolic characteristics.
Topics: Adult; Brain; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, X-Ray Computed | 1987 |
Tracers for paralysis agitans in epidemiological research. V. Prevalence of the disease in Swedish counties.
Topics: Adult; Age Factors; Aged; Drug Utilization; Epidemiologic Methods; Humans; Levodopa; Middle Aged; Parkinson Disease; Risk; Sweden | 1986 |
Progression of Parkinson's disease without levodopa.
Topics: Humans; Levodopa; Longitudinal Studies; Parkinson Disease | 1987 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levodopa; Lisuride; Male; Motor Activity; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
[Effect of L-dopa on P300 component--study in patients with juvenile parkinsonism having a wearing-off phenomenon].
Topics: Adult; Cognition; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1987 |
A case of normal pressure hydrocephalus presenting as levodopa responsive parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.
Topics: Bromocriptine; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1987 |
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Tyrosine | 1987 |
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1987 |
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
"Drug holiday" in Parkinson's disease.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Risk | 1987 |
Forms of dystonia in patients with Parkinson's disease.
Topics: Adult; Aged; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.
Topics: Aged; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Amantadine for levodopa resistant parkinsonism.
Topics: Aged; Amantadine; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease | 1987 |
Early morning headache of Parkinson's disease: a hitherto unrecognized symptom?
Topics: Adolescent; Adult; Circadian Rhythm; Female; Headache; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Remission, Spontaneous | 1987 |
Levodopa methyl ester treatment of Parkinson's disease.
Topics: Administration, Oral; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Diurnal responsiveness to apomorphine.
Topics: Aged; Apomorphine; Circadian Rhythm; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1987 |
3-O-methyldopa and the response to levodopa in Parkinson's disease.
Topics: Administration, Oral; Blood-Brain Barrier; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Tyrosine | 1987 |
Optimization of drug administration by a Tauberian approach.
Topics: Drug Administration Schedule; Humans; Levodopa; Metabolic Clearance Rate; Parkinson Disease; Pharmaceutical Preparations | 1987 |
Stridor during dystonic phases of Parkinson's disease.
Topics: Adult; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Sounds | 1987 |
Fluctuations in plasma dopamine level impair memory in Parkinson's disease.
Topics: Carbidopa; Dopamine; Humans; Levodopa; Memory; Parkinson Disease | 1987 |
Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease.
Topics: Electrooculography; Eye Movements; Humans; Levodopa; Middle Aged; Parkinson Disease; Pursuit, Smooth; Time Factors | 1987 |
Ganzfeld electroretinographic findings in parkinsonism: untreated patients and the effect of levodopa intravenous infusion.
Topics: Electroretinography; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Retina | 1987 |
Ocular motor and manual tracking in Parkinson's disease and the effect of treatment.
Topics: Adult; Aged; Bromocriptine; Eye Movements; Female; Hand; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time; Saccades | 1987 |
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?
Topics: Brain; Dopamine; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1987 |
Controlled-release Sinemet.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
To treat early or to treat late?
Topics: Humans; Levodopa; Parkinson Disease; Time Factors | 1987 |
Factors that influence the occurrence of response variations in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Carboxy-Lyases; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1987 |
Multi-center study of Parkinson mortality with early versus later dopa treatment.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1987 |
Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.
Topics: Amino Acids; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
Dietary influences on the antiparkinsonian response to levodopa.
Topics: Amino Acids; Carbidopa; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Paranoid Disorders; Parkinson Disease; Patient Acceptance of Health Care; Time Factors | 1987 |
[Psychiatric symptoms and plasma levodopa dynamics in Parkinson's disease].
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Reaction times and attention in Parkinson's disease.
Topics: Adult; Aged; Attention; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time | 1987 |
Readiness potential of cortical area 6 preceding self paced movement in Parkinson's disease.
Topics: Adult; Aged; Arousal; Attention; Corpus Striatum; Dominance, Cerebral; Electroencephalography; Electromyography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Psychomotor Performance | 1987 |
Effect of levodopa treatment on contrast sensitivity in Parkinson's disease.
Topics: Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Vision Tests; Vision, Ocular | 1987 |
Dietary therapy for motor fluctuations in Parkinson's disease.
Topics: Absorption; Amino Acids; Dietary Proteins; Drug Interactions; Humans; Levodopa; Parkinson Disease | 1987 |
Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
Topics: Aged; Bromocriptine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Continuous dopaminergic stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Lisuride; Parkinson Disease | 1987 |
Low dose lisuride in advanced Parkinson disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Follow-Up Studies; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1987 |
Turtle headaches and Parkinson's disease.
Topics: Headache; Humans; Hypoxia; Levodopa; Parkinson Disease | 1987 |
["Parkinson plus." Multisystem involvement in Parkinson disease].
Topics: Brain Ischemia; Dopamine; Humans; Levodopa; Muscle Rigidity; Neurocognitive Disorders; Parkinson Disease | 1986 |
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
The management of Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities; Referral and Consultation | 1986 |
[Experience with the use of parlodel in the treatment of Parkinson patients].
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Hypoxia, Brain; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1986 |
Long-term follow-up of early dopa treatment in Parkinson's disease.
Topics: Dementia; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
Bromocriptine: long-term low-dose therapy in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement; Muscle Rigidity; Parkinson Disease; Tremor | 1986 |
Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1986 |
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
Topics: Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease; Time Factors | 1986 |
Sinemet in Parkinson's disease: efficacy with and without food.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Diet; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
[L-dopa-induced psychoses and their treatment with L-tryptophan].
Topics: Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Tryptophan | 1986 |
L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Serotonin | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
Akinetic parkinsonism and the catatonic syndrome: an overview.
Topics: Adult; Akinetic Mutism; Benztropine; Carbidopa; Catatonia; Humans; Levodopa; Male; Parasympatholytics; Parkinson Disease; Syndrome | 1986 |
Dystonia in untreated parkinsonism.
Topics: Adult; Aged; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis | 1986 |
[Revision of the treatment strategy in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Care Planning | 1986 |
[An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
Topics: Adult; Aged; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease.
Topics: Affect; Aged; Attention; Cognition; Female; Humans; Levodopa; Male; Middle Aged; Movement; Orientation; Parkinson Disease; Reaction Time; Verbal Behavior | 1986 |
Effect of L-dopa on visual evoked potential in patients with Parkinson's disease.
Topics: Aged; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual | 1986 |
The drug treatment of parkinsonism.
Topics: Bromocriptine; Carboxy-Lyases; Dopamine; Humans; Levodopa; Parkinson Disease | 1986 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1986 |
An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?
Topics: Adult; Aged; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Prognosis; Receptors, Dopamine; Time Factors; Tremor | 1986 |
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Duodenum; Female; Gastric Emptying; Humans; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 1986 |
Hereditary dystonia-parkinsonism syndrome of juvenile onset.
Topics: Adult; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pedigree | 1986 |
Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study.
Topics: Aged; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.
Topics: Administration, Oral; Adult; Aged; Delayed-Action Preparations; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Effect of antacid on levodopa therapy.
Topics: Aluminum Hydroxide; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Interactions; Humans; Levodopa; Magnesium; Magnesium Hydroxide; Parkinson Disease | 1986 |
[Clinical subtypes of Parkinson disease].
Topics: Dementia; Diagnosis, Differential; Follow-Up Studies; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Tremor | 1986 |
Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease.
Topics: Adult; Aged; Electromyography; Humans; Levodopa; Middle Aged; Motor Activity; Muscles; Parkinson Disease; Wrist | 1986 |
Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.
Topics: Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1986 |
[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
Topics: Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis | 1986 |
A micro-system for measuring oxygen kinetic parameters of biopterin linked hydroxylations: L-dopa synthesis and Parkinson's disease.
Topics: Animals; Biopterins; Humans; Hydroxylation; Kinetics; Levodopa; Liver; Oxygen Consumption; Parkinson Disease; Phenylalanine Hydroxylase; Rats | 1986 |
[Early or late onset of L-dopa treatment in Parkinson disease?].
Topics: Adult; Age Factors; Aged; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1986 |
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Parkinson Disease | 1987 |
Depressive symptoms and the dexamethasone suppression test in parkinsonian patients.
Topics: Adult; Aged; Aged, 80 and over; Depression; Dexamethasone; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1987 |
Transdihydrolisuride in parkinsonism.
Topics: Aged; Blood Pressure; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1987 |
Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease.
Topics: Aged; Bone and Bones; Female; Growth Hormone; Humans; Levodopa; Menopause; Middle Aged; Parkinson Disease | 1987 |
Transient levodopa withdrawal in Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1987 |
Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
Topics: Affective Symptoms; Aged; Carbidopa; Dopamine; Drug Combinations; Emotions; Humans; Levodopa; Male; Parkinson Disease | 1987 |
Akathisia in idiopathic Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Agitation; Sensation | 1987 |
[Combination treatment in the early stages of Parkinson's disease].
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1987 |
Juvenile onset Parkinson's disease.
Topics: Adolescent; Adult; Carbidopa; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
Topics: Brain Damage, Chronic; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1987 |
Hereditary progressive dystonia with marked diurnal fluctuation: clinicopathophysiological identification in reference to juvenile Parkinson's disease.
Topics: Adolescent; Adult; Aged; Child; Circadian Rhythm; Dystonia; Female; Humans; Levodopa; Male; Parkinson Disease | 1987 |
Breathing in Parkinson's disease.
Topics: Aged; Autonomic Nervous System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Respiration Disorders; Respiratory Insufficiency | 1987 |
Quantitative study of "on-off" fluctuations in the ocular motor system in Parkinson's disease.
Topics: Aged; Eye Movements; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Pursuit, Smooth; Saccades | 1987 |
Sensorimotor disturbances in Parkinson's disease: index finger test.
Topics: Adult; Aged; Dominance, Cerebral; Female; Humans; Levodopa; Male; Middle Aged; Orientation; Parkinson Disease; Psychomotor Performance; Tomography, X-Ray Computed; Vestibular Function Tests | 1987 |
Clinical and radiographic features of scoliosis in Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Parkinson Disease; Radiography; Scoliosis; Spine | 1987 |
Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology.
Topics: Adult; Aged; Dystonia; Foot Deformities, Acquired; Humans; Levodopa; Parkinson Disease | 1987 |
Predictive factors for cognitive deterioration and dementia in Parkinson's disease.
Topics: Cognition Disorders; Dementia; Electroencephalography; Homovanillic Acid; Humans; Levodopa; Parkinson Disease; Prognosis | 1987 |
Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease.
Topics: Hallucinations; Humans; Levodopa; Middle Aged; MMPI; Parkinson Disease; Psychometrics; Risk | 1987 |
Dexamethasone suppression test in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortisone; Levodopa; Male; Parkinson Disease | 1987 |
Parkinson's disease: progression and mortality.
Topics: Carbidopa; Disability Evaluation; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems.
Topics: Aged; Dementia; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Posture | 1987 |
Pharmacokinetics of levodopa and motor fluctuations.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Kinetics; Levodopa; Methyldopa; Motor Skills; Parkinson Disease | 1987 |
Individual levodopa therapy in Parkinson's disease.
Topics: Benserazide; Chromatography, High Pressure Liquid; Drug Combinations; Gait; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1987 |
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Brain; Dopamine; Drug Administration Schedule; Drug Tolerance; Homovanillic Acid; Humans; Levodopa; Male; Parkinson Disease; Rats | 1987 |
Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
Topics: Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1987 |
Pergolide mesylate: four years experience in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1987 |
Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Motor Skills; Parkinson Disease | 1987 |
Therapeutic experiences with an abeorphine derivative in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1987 |
Influence of dietary protein on motor fluctuations in Parkinson's disease.
Topics: Aged; Combined Modality Therapy; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
[An autopsy case of progressive supranuclear palsy showing "pure akinesia without rigidity and tremor and with no effect by L-dopa therapy (Imai)"].
Topics: Aged; Brain; Bulbar Palsy, Progressive; Diagnosis, Differential; Female; Humans; Levodopa; Limbic System; Ophthalmoplegia; Parkinson Disease; Supranuclear Palsy, Progressive | 1987 |
Tracers for paralysis agitans in epidemiological research. III. Refinement of the model for estimation of the prevalence of the disease.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Demography; Drug Utilization; Epidemiologic Methods; Female; Humans; Iceland; Infant; Infant Mortality; Italy; Levodopa; Male; Middle Aged; Models, Theoretical; Parkinson Disease; Probability; Sex Factors; Sweden | 1985 |
Tracers for paralysis agitans in epidemiological research. IV. Trends in national drug policy and measurement of the prevalence of the disease in Sweden.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Antiparkinson Agents; Bromocriptine; Child; Child, Preschool; Drug Utilization; Epidemiologic Methods; Female; Humans; Infant; Infant Mortality; Levodopa; Male; Middle Aged; Parkinson Disease; Probability; Sweden; Time Factors | 1985 |
L-dopa-induced asterixis.
Topics: Aged; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 1985 |
[Research--the source of medical progress].
Topics: Animals; Antibodies, Monoclonal; Cell Line; DNA, Recombinant; Forecasting; Humans; Hybridization, Genetic; Levodopa; Parkinson Disease; Recombination, Genetic; Research Design | 1985 |
[L-Dopa].
Topics: Humans; Levodopa; Parkinson Disease | 1985 |
A simple algorithm for the solution of the multiple dosing problem.
Topics: Computers; Drug Administration Schedule; Humans; Kinetics; Levodopa; Parkinson Disease; Pharmaceutical Preparations; Software; Systems Theory | 1985 |
Controversies in the treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1985 |
Regional cerebral blood flow in hemiparkinsonian patients. Emission computerized tomography of inhaled 133Xenon before and after levodopa.
Topics: Adult; Aged; Cerebellum; Cerebral Cortex; Cerebrovascular Circulation; Corpus Striatum; Dominance, Cerebral; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Thalamus; Tomography, Emission-Computed; Xenon Radioisotopes | 1985 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Pyridines; Substance-Related Disorders; Substantia Nigra | 1985 |
Regional blood flow in hemiparkinsonism.
Topics: Adult; Aged; Autoradiography; Caudate Nucleus; Cerebral Cortex; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Thalamus; Tomography, Emission-Computed | 1985 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Ergot Alkaloids; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physician-Patient Relations; Social Support; Stereotaxic Techniques | 1985 |
Parkinson disease. Individualizing therapy.
Topics: Aged; Bromocriptine; Carbidopa; Central Nervous System Diseases; Diagnosis, Differential; Gait; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1985 |
[L-dopa therapy of parkinson syndrome].
Topics: Benserazide; Biotransformation; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine | 1985 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Practical therapeutics: advances in the management of Parkinson's disease.
Topics: Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Autonomic dysfunction in Parkinson's disease.
Topics: Adult; Aged; Autonomic Nervous System; Autonomic Nervous System Diseases; Body Temperature; Extremities; Female; Hemodynamics; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sweating; Valsalva Maneuver | 1986 |
Respiratory dyskinesia in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders; Tiapamil Hydrochloride | 1986 |
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
Topics: Adult; Aged; Domperidone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Injections, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Trihexyphenidyl | 1986 |
Efficacy of pergolide and mesulergine.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1986 |
Electroconvulsive shock and L-dopa reduce head-turning induced by electrical stimulation of the caudate nucleus in the rat.
Topics: Animals; Carboxymethylcellulose Sodium; Caudate Nucleus; Electric Stimulation; Electroshock; Head; Levodopa; Male; Movement; Parkinson Disease; Rats; Rats, Inbred Strains | 1986 |
Temporary levodopa withdrawal.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 1986 |
Timing of levodopa therapy.
Topics: Humans; Levodopa; Parkinson Disease | 1986 |
Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Blood Platelets; Chromatography, High Pressure Liquid; Deamination; Decarboxylation; Deuterium; Dopamine; Female; Humans; Kinetics; Levodopa; Liver; Male; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Placenta; Pregnancy; Rats; Rats, Inbred Strains; Stereoisomerism | 1986 |
[Dopaminergic agonists in Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Piribedil | 1986 |
L-dopa-induced respiratory disturbance in Parkinson's disease suppressed by tiapride.
Topics: Benzamides; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Respiration Disorders; Tiapamil Hydrochloride | 1985 |
Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
Topics: Body Temperature Regulation; Bromocriptine; Carbidopa; Drug Combinations; Female; Fever; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Receptors, Dopamine | 1985 |
Long-term study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Disability Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1985 |
Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System; Benserazide; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Heart; Heart Rate; Humans; Hydrazines; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease | 1985 |
The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.
Topics: Adult; Aged; Cerebral Cortex; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Oxygen Consumption; Parkinson Disease | 1985 |
Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
Levodopa during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications | 1985 |
[Dopamine agonists in the therapy of parkinson syndrome].
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Bromocriptine; Corpus Striatum; Dopamine; Humans; Levodopa; Lisuride; Neural Pathways; Parkinson Disease; Piribedil; Receptors, Dopamine; Substantia Nigra | 1985 |
Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
Topics: Aged; Carbidopa; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Receptors, Dopamine; Sleep Wake Disorders; Sleep, REM | 1985 |
Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1985 |
Idiopathic dystonia-parkinsonism with marked diurnal fluctuation of symptoms.
Topics: Adult; Bromocriptine; Electromyography; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Trihexyphenidyl | 1985 |
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Outcome and Process Assessment, Health Care; Parkinson Disease; Pergolide; Time Factors | 1985 |
Levodopa-induced dyskinesia: clinical observations.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk | 1985 |
Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
The symptoms of patients treated for Parkinson's disease.
Topics: Adult; Age Factors; Aged; Carboxy-Lyases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Surveys and Questionnaires | 1985 |
[Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tiapamil Hydrochloride | 1985 |
[Clinical significance of long-term treatment of L-dopa with bromocriptine in parkinsonian patients who showed declining efficacy during L-dopa therapy].
Topics: Adult; Aged; Bromocriptine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
Levodopa and melanoma: three cases and review of literature.
Topics: Aged; Female; Humans; Levodopa; Male; Melanoma; Parkinson Disease; Skin Neoplasms | 1985 |
Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature.
Topics: Female; Humans; Levodopa; Melanoma; Middle Aged; Nevus, Pigmented; Parkinson Disease; Skin Neoplasms | 1985 |
[Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Topics: Age Factors; Aged; Amantadine; Antidepressive Agents, Tricyclic; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1985 |
Combined bromocriptine-levodopa therapy early in Parkinson's disease.
Topics: Bromocriptine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1985 |
Audit of the drug treatment of Parkinson's disease in general practice.
Topics: Aged; Carbidopa; Family Practice; Humans; Levodopa; Medical Audit; Middle Aged; Parasympatholytics; Parkinson Disease | 1985 |
Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk | 1985 |
Nomifensine in advanced parkinsonism.
Topics: Aged; Humans; Levodopa; Male; Nomifensine; Parkinson Disease | 1985 |
The treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1985 |
Pain in Parkinson's disease.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Pain; Parkinson Disease | 1985 |
Controversies in the treatment of Parkinson's disease.
Topics: Bromocriptine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1985 |
[The L-dopa test in Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Drug Therapy, Combination; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Recurrence; Time Factors | 1985 |
A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.
Topics: Aged; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1985 |
Effects of lisuride on blink reflex habituation in Parkinson disease.
Topics: Adult; Aged; Amantadine; Blinking; Electrophysiology; Ergolines; Habituation, Psychophysiologic; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
Auditory and somatosensory evoked potentials (AEPs and SEPs) and ballistic movements in Parkinson disease.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
Induction of mania by L-dopa in a nonbipolar patient.
Topics: Adult; Bipolar Disorder; Dopamine; Female; Humans; Levodopa; Parkinson Disease | 1985 |
[Oral lisuride in Parkinson's disease].
Topics: Adult; Aged; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Combined therapy of carbidopa and levodopa in Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Tryptophan; Tyrosine | 1985 |
Micturition disturbance in Parkinson's disease.
Topics: Adult; Aged; Electromyography; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Urination Disorders; Urodynamics | 1985 |
Determination of m- and p-O-methylated products of L-3,4-dihydroxyphenylalanine using high-performance liquid chromatography and electrochemical detection.
Topics: Animals; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isomerism; Levodopa; Liver; Methylation; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1985 |
[A case of L-dopa induced autoimmune hemolytic anemida].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Humans; Levodopa; Male; Parkinson Disease | 1985 |
Treatment of parkinsonism with bromocriptine.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease | 1974 |
The "on-off" effect.
Topics: Dopa Decarboxylase; Humans; Levodopa; Movement Disorders; Parkinson Disease; Tyrosine 3-Monooxygenase | 1974 |
[Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
Topics: Aged; Antiparkinson Agents; Carboxy-Lyases; Drug Synergism; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Muscle Rigidity; Myography; Parkinson Disease | 1974 |
The effect of L-DOPA on the hypothalamic-pituitary-thyroid axis.
Topics: Aged; Female; Humans; Hydroxybutyrates; Hypothalamus; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Function Tests; Pituitary Gland; Pituitary Gland, Anterior; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Time Factors; Triiodothyronine | 1974 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal Lobe; Haloperidol; Haplorhini; Levodopa; Mesencephalon; Methyltyrosines; Mice; Movement Disorders; Parkinson Disease; Posture; Rats; Reserpine; Substantia Nigra; Tegmentum Mesencephali; Thalamic Nuclei; Tremor | 1974 |
Possible role of cerebellar circuits in parkinsonian symptoms.
Topics: Aged; Animals; Cats; Cerebellar Diseases; Cerebellum; Female; Haplorhini; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Neural Pathways; Parkinson Disease; Thalamic Nuclei; Tremor | 1974 |
[Problems in the administration of L-DOPA (author's transl)].
Topics: Cardiovascular Diseases; Drug Eruptions; Gastrointestinal Diseases; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Urologic Diseases; Vision Disorders | 1974 |
Exaggerated response to levodopa. A case of "contaminated parkinsonism".
Topics: Aged; Drug Synergism; Humans; Levodopa; Male; Parkinson Disease; Reserpine | 1974 |
Editorial: Levodopa after five years.
Topics: Humans; Levodopa; Parkinson Disease; Substantia Nigra | 1974 |
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzyl Compounds; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenols | 1974 |
Effects of levodopa therapy in patients with Parkinson's disease: statistical evidence for reduced tolerance to levodopa in the elderly.
Topics: Age Factors; Aged; Analysis of Variance; Blood Pressure; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Female; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pulse; Sex Factors | 1974 |
The effect of dopaflex on the clinical picture and reaction time of parkinsonian patients.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time | 1974 |
Letter: Brown urine, bleach, and L-dopa.
Topics: Chlorine; Color; Dopamine; Humans; Levodopa; Male; Parkinson Disease; Toilet Facilities; Urine | 1974 |
Clinical features, etiology and treatment of facial dyskinesias in the elderly.
Topics: Age Factors; Aged; Brain; Brain Damage, Chronic; Brain Stem; Chorea; Dementia; Dopamine; Face; Female; Haloperidol; Humans; Intracranial Arteriosclerosis; Levodopa; Lip; Male; Movement Disorders; Parasympathomimetics; Parkinson Disease; Phenothiazines; Tongue | 1974 |
Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dioxoles; Dopamine; Drug Evaluation; Haloperidol; Homovanillic Acid; Humans; Levodopa; Parkinson Disease; Piperidines; Probenecid; Pyrimidines | 1974 |
Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients.
Topics: Adult; Aged; Dopamine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sulfuric Acids | 1974 |
The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Apomorphine; Dioxoles; Drug Evaluation; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Piperazines; Pyrimidines; Time Factors | 1974 |
Editorial: Dopa decarboxylase inhibitors.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Drug Combinations; Humans; Levodopa; Nausea; Parkinson Disease; Vomiting | 1974 |
Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.
Topics: Aged; Analysis of Variance; Cognition; Drug Evaluation; Female; Follow-Up Studies; Handwriting; Humans; Intelligence Tests; Levodopa; Male; Memory; Middle Aged; Motor Skills; Parkinson Disease; Psychological Tests; Time Factors; Verbal Behavior | 1974 |
[Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
The effect of treatment with levodopa on Parkinson patients' social functioning and outlook on life.
Topics: Activities of Daily Living; Aged; Attitude to Health; Depression; Family; Female; Humans; Interview, Psychological; Leisure Activities; Levodopa; Life Style; Male; Parkinson Disease; Social Behavior; Social Environment; Work | 1974 |
Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nausea; Parasympatholytics; Parkinson Disease; Prognosis; Psychological Tests; Time Factors | 1974 |
Some anomalies in the L-DOPA response: recent biochemical studies.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Models, Biological; Papaverine; Parkinson Disease | 1974 |
Unexpected findings with apomorphine and their possible consequences.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Movement Disorders; Parkinson Disease; Structure-Activity Relationship; Uremia | 1974 |
Dihydroxyphenylacetic acid in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Movement Disorders; Parkinson Disease; Phenylacetates; Pyridoxine | 1974 |
3-O-Methyldopa in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Antagonism; Drug Therapy, Combination; Humans; Levodopa; Methyldopa; Parkinson Disease; Time Factors; Trihexyphenidyl | 1974 |
The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Confusion; Dietary Proteins; Enzyme Inhibitors; Female; Gait; Humans; Levodopa; Male; Methyldopa; Movement Disorders; Muscle Cramp; Parkinson Disease; Time Factors | 1974 |
Variations in the "on-off" phenomenon.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Enzyme Inhibitors; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substantia Nigra | 1974 |
Plasma levodopa and the "on-off" effect.
Topics: Aged; Female; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chlordiazepoxide; Chorea; Desipramine; Diazepam; Dietary Proteins; Enzyme Inhibitors; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Physical Exertion; Picolinic Acids; Prochlorperazine; Sex Factors; Stress, Psychological | 1974 |
Variations in the "on-off" effect.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Depression, Chemical; Dopa Decarboxylase; Drug Combinations; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Probenecid; Stimulation, Chemical; Time Factors | 1974 |
[A year of treatment with carbidopa and levodopa in Parkinsonian patients].
Topics: Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease; Tablets; Time Factors | 1974 |
Levodopa, manganese, and degenerations of the brain.
Topics: Administration, Oral; Animals; Apomorphine; Blood Urea Nitrogen; Brain Diseases; Carbon Radioisotopes; Chemical Phenomena; Chemistry; Chronic Disease; Dietary Proteins; Dopamine; Drug Therapy, Combination; Growth Hormone; Humans; Injections; Levodopa; Manganese Poisoning; Movement Disorders; Neutron Activation Analysis; Parkinson Disease; Psychoses, Substance-Induced; Radioisotopes | 1974 |
[Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Form Perception; Humans; Intelligence Tests; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Perceptual Disorders; Problem Solving; Space Perception; Thinking; Visual Perception; Wechsler Scales | 1974 |
[L-dopa therapy for Parkinsonism and its relationship to surgical methods of treatments].
Topics: Cardiovascular Diseases; Dyspepsia; Fear; Hallucinations; Humans; Hyperkinesis; Levodopa; Mental Disorders; Nausea; Parkinson Disease; Postoperative Care; Preoperative Care; Vomiting | 1974 |
Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
Topics: Administration, Oral; Aged; Carbon Radioisotopes; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylalanine; Stimulation, Chemical; Sulfates; Tyrosine | 1974 |
[Malignant melanoma and L-dopa. Review of literature on the problem of causal relationship].
Topics: Humans; Levodopa; Male; Melanins; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Parkinson Disease; Skin Neoplasms; Tryptophan | 1974 |
Review of parkinsonian patients treated surgically and by L-dopa.
Topics: Humans; Levodopa; Parkinson Disease | 1974 |
High-level levodopa therapy in Parkinson's disease: five years later.
Topics: Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1974 |
L-dopa, parkinsonism, and involuntary movements.
Topics: Electromyography; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1974 |
Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil | 1974 |
Treatment of blepharospasm with levodopa.
Topics: Aged; Blepharospasm; Depression; Eyelid Diseases; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease | 1974 |
[The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
Topics: Benserazide; Drug Combinations; Drug Evaluation; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Mental Processes; Parkinson Disease; Psychological Tests | 1974 |
Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
Topics: Dietary Proteins; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Movement Disorders; Parkinson Disease | 1974 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermia; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Reserpine; Structure-Activity Relationship; Tremor | 1974 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parasympatholytics; Parkinson Disease; Posture; Reflex; Remission, Spontaneous; Tremor | 1974 |
Decreased arginine-induced HGH response during L-dopa therapy in parkinsonian patients.
Topics: Adult; Arginine; Depression, Chemical; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radioimmunoassay; Stimulation, Chemical | 1974 |
Levodopa.
Topics: Humans; Levodopa; Parkinson Disease | 1974 |
Rehabilitation of the patient with Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease | 1974 |
Metoclopramide, gastric emptying and L-dopa absorption.
Topics: Biological Transport, Active; Biopharmaceutics; Female; Fluorometry; Gastrointestinal Motility; Humans; Intestinal Absorption; Intestine, Small; Levodopa; Male; Metoclopramide; Parkinson Disease; Stimulation, Chemical; Stomach; Time Factors | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |
Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
Topics: Aged; Carbidopa; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1974 |
Parkinsonism and its treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Stereotaxic Techniques | 1974 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopamine; Pargyline; Parkinson Disease; Rats; Time Factors; Tritium; Tryptamines; Tyramine; Tyrosine | 1974 |
Comparative study on the results of consecutive Dopaflex (L-DOPA) and stereotactic surgical treatments in Parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1974 |
Psychiatric aspects of L-dopa therapy of Parkinson's disease.
Topics: Adult; Aged; Delirium; Depression; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1972 |
[Hemodynamic response to prolonged treatment with L-dopa in cirrhotic patients].
Topics: Hemodynamics; Humans; Levodopa; Liver Cirrhosis; Parkinson Disease; Time Factors | 1973 |
[L-dopa treatment of Parkinson's disease].
Topics: Dopamine; Humans; Levodopa; Parkinson Disease | 1971 |
Levodopa for parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease | 1971 |
[Acute dopamine deficiency and malignant neuroleptic-like syndrome].
Topics: Antiparkinson Agents; Dopamine; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Organic Chemicals; Parkinson Disease | 1992 |